PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Georgeadis, AC; Brennan, DM; Barker, LM; Baron, CR				Georgeadis, AC; Brennan, DM; Barker, LM; Baron, CR			Telerehabilitation and its effect on story retelling by adults with neurogenic communication disorders	APHASIOLOGY			English	Article; Proceedings Paper	33rd Annual Clinical Aphasiology Conference	MAY, 2003	Orcas Isl, WA				TRAUMATIC BRAIN INJURY; COGNITIVE FUNCTION; SPEECH; TELEHEALTH; ATTENTION; PATHOLOGY	Background: Telerehabilitation (telerehab) is the method of using technology to provide rehabilitation services at a distance. The concept of delivering remote speech-language pathology (SLP) services using telerehab tools and techniques has been acknowledged for more than 25 years. While research has demonstrated videoconference-based telerehab to be a feasible, effective, and appropriate method for providing SLP services to a broad range of clients, studies have been primarily limited to technical feasibility or demonstration projects with relatively small sample sizes. There is an expressed need in the literature for controlled, randomised studies that track both quantitative outcomes of services delivered via telerehab as well as qualitative measures of satisfaction. Aims: The purpose of the study was to measure performance of adults with acquired brain injury on a standardised SLP assessment conducted in both face-to-face (FF) and videoconference-based telerehab (T) settings. The objective was to determine if performance on the assessment, or subjective feedback from the participants, differed between settings. Methods & Procedures: A total of 40 participants with a recent onset of brain injury--12 with traumatic brain injury (TBI), 14 with a left cerebrovascular accident (LCVA), and 14 with a right cerebrovascular accident (RCVA)--were enrolled in the study. Participants were asked to retell stories from the Story Retell Procedure (Doyle, McNeil, Spencer, Goda, Cotrell, & Lustig, 1998) in both FF and T settings. Responses from the stories were scored by the clinician using the percent information unit scoring metric (McNeil, Doyle, Fossett, Park, & Goda, 2001). Additionally, a survey tool was used to probe each participant's level of satisfaction and willingness to use telerehab services in the future. Outcomes & Results: Across all participants, and within the TBI, LCVA, and RCVA groups, no significant difference in performance between the FF and T settings was found. Feedback from survey data demonstrated a high level of acceptance of the T setting. When compared to participants with LCVA or RCVA, however, participants with TBI were significantly more likely to show a lack of interest in future videoconferencing use. Conclusions: Story-retelling performance by brain-injured adults was not affected by setting. Additionally, participants expressed a high level of interest in using videoconferencing in the future. These findings offer additional support for telerehab as a viable alternative mode of SLP treatment for survivors of stroke and TBI. Further research is needed to investigate the utility of telerehab for delivering services to clients with attention impairments as well as those with severe cognitive-communicative impairment, dysarthria, or aphasia.	Natl Rehabil Hosp, Speech Language Pathol Serv, Washington, DC 20010 USA		Georgeadis, AC (corresponding author), Natl Rehabil Hosp, Speech Language Pathol Serv, 102 Irving St NW, Washington, DC 20010 USA.	amy.c.georgeadis@medstar.net					APPEL PR, 2002, P STAT SCI C TEL APP, P23; Ball C, 1997, J Telemed Telecare, V3, P126, DOI 10.1258/1357633971931020; Ball C, 1998, J TELEMED TELECARE, V4, P36, DOI 10.1258/1357633981931362; BRENNAN D, IN PRESS TELEMEDICIN; Brennan David, 2002, Top Stroke Rehabil, V8, P71; Brookshire R. H., 1993, DISCOURSE COMPREHENS; BUCKLEY KM, 2002, P STAT SCI C TEL APP, P35; Burnham AK, 1999, ENERG FUEL, V13, P1, DOI 10.1021/ef9800765; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Doyle PJ, 1998, APHASIOLOGY, V12, P561, DOI 10.1080/02687039808249558; Duffy JR, 1997, MAYO CLIN PROC, V72, P1116, DOI 10.4065/72.12.1116; Goodglass H, 1983, ASSESSMENT APHASIA R; Halstead Lauro S, 2003, Adv Skin Wound Care, V16, P91, DOI 10.1097/00129334-200303000-00010; Hill A, 2002, J TELEMED TELECARE, V8, P187, DOI 10.1258/135763302320272158; Kully D, 2000, J TELEMED TELECARE, V6, P39, DOI 10.1258/1357633001935509; Mashima P A, 1999, J Healthc Inf Manag, V13, P71; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; McCullough A, 2001, INT J LANG COMM DIS, V36, P321, DOI 10.3109/13682820109177905; McNeil MR, 2001, APHASIOLOGY, V15, P991, DOI 10.1080/02687040143000348; Menon AS, 2001, J NERV MENT DIS, V189, P399, DOI 10.1097/00005053-200106000-00009; Savard L, 2003, NEUROREHABILITATION, V18, P93; SAVARD L, 2002, COMB SECT M AM PHYS; Schopp LH, 2000, J TELEMED TELECARE, V6, P146, DOI 10.1258/1357633001934474; TRAN BQ, 2003, COMB SECT M AM PHYS; TREPAGNIER C, 2002, P STAT SCI C TEL APP, P42; Vaughn G R, 1976, ASHA, V18, P13; Vesmarovich S, 1999, Adv Wound Care, V12, P264; Wertz R. T., 1987, CLIN APHASIOLOGY, V17, P117; WERTZ RT, 1992, APHASIOLOGY, V6, P195, DOI 10.1080/02687039208248591; WHITE MW, 2003, ANN C AM OCC THER AS	30	58	58	0	28	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology	MAY-JUL	2004	18	5-7					639	652		10.1080/02687030444000075			14	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	817NC	WOS:000221183200017					2022-02-06	
J	Sherman, JE; DeVinney, DJ; Sperling, KB				Sherman, JE; DeVinney, DJ; Sperling, KB			Social support and adjustment after spinal cord injury: Influence of past peer-mentoring experiences and current live-in partner	REHABILITATION PSYCHOLOGY			English	Article							QUALITY-OF-LIFE; TRAUMATIC BRAIN INJURY; HEALTH-STATUS; SATISFACTION; COMMUNITY; MORTALITY; OUTCOMES; HANDICAP; IMPACT; PEOPLE	Objective: To compare the impact of 2 types of social support, past peer-mentoring experience (PME) and current live-in partner (LIP), on adjustment after spinal cord injury (SCI). Participants: Sixty-two individuals with SCI (mean age = 42 years; 11.7 years since injury). Design: Cross-sectional survey. PME (yes vs. no) and LIP (yes vs. no) were nearly equally balanced, affording 2 X 2 factorial analyses. Outcome Measures: Craig Handicap Assessment and Reporting Technique, Brief Symptom Inventory, and Satisfaction With Life Scale. Results: PME, which typically concluded over 10 years ago, was associated with higher occupational activity and life satisfaction, whereas having an LIP was associated with greater mobility and economic self-sufficiency. Conclusion: PME positively complements more traditionally studied sources of social support, which is encouraging for the use of PME as a clinical intervention.	Univ Wisconsin Hosp & Clin, Dept Orthoped Surg & Rehabil Med, Madison, WI 53792 USA; Univ Wisconsin, Dept Rehabil Psychol, Madison, WI USA		Sherman, JE (corresponding author), Univ Wisconsin Hosp & Clin, Dept Orthoped Surg & Rehabil Med, 600 N Highland Ave, Madison, WI 53792 USA.	je.sherman@hosp.wisc.edu					ANSON CA, 1993, PARAPLEGIA, V31, P632, DOI 10.1038/sc.1993.102; BERKMAN LF, 1986, AM J EPIDEMIOL, V123, P559, DOI 10.1093/oxfordjournals.aje.a114276; BORKMAN T, 1976, SOC SERV REV, V50, P445, DOI 10.1086/643401; Brissette I, 2002, J PERS SOC PSYCHOL, V82, P102, DOI 10.1037//0022-3514.82.1.102; BROADHEAD WE, 1983, AM J EPIDEMIOL, V117, P521, DOI 10.1093/oxfordjournals.aje.a113575; Cohen J., 1975, APPL MULTIPLE REGRES; COYNE JC, 1986, J CONSULT CLIN PSYCH, V54, P454, DOI 10.1037/0022-006X.54.4.454; Crewe N M, 1992, J Am Paraplegia Soc, V15, P14; Derogatis L.R., 1993, BRIEF SYMPTOM INVENT; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers Marcel P., 1995, P185; Dijkers MPJM, 1999, ARCH PHYS MED REHAB, V80, P867, DOI 10.1016/S0003-9993(99)90076-X; Dowler R, 2001, J Spinal Cord Med, V24, P87; ELLIOTT TR, 1992, REHABIL PSYCHOL, V37, P241; Frankel H L, 1969, Paraplegia, V7, P179; Hall K., 1998, TOP SPINAL CORD INJ, V4, P16, DOI DOI 10.1310/V5RU-FRFE-50E6-E2NA; Hernandez B., 2001, SCI PSYCHOSOC PROCES, V14, P142; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Holicky R, 1999, DISABIL REHABIL, V21, P250; KRAUSE JS, 1991, ARCH PHYS MED REHAB, V72, P91; KRAUSE JS, 1987, REHABIL PSYCHOL, V32, P205; KRAUSE JS, 1992, ARCH PHYS MED REHAB, V73, P558; Krause JS, 1997, ARCH PHYS MED REHAB, V78, P815, DOI 10.1016/S0003-9993(97)90193-3; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; Kreuter M, 2000, SPINAL CORD, V38, P2, DOI 10.1038/sj.sc.3100933; Lutz CJ, 2001, J PERS SOC PSYCHOL, V81, P1070, DOI 10.1037/0022-3514.81.6.1070; MCCOLL MA, 1995, SOC SCI MED, V41, P395, DOI 10.1016/0277-9536(94)00338-T; Menter Robert R., 1995, P272; Miller GA, 2001, J ABNORM PSYCHOL, V110, P40, DOI 10.1037//0021-843X.110.1.40; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; Post MWM, 1999, PSYCHOL HEALTH, V14, P679, DOI 10.1080/08870449908410757; Putzke JD, 2002, ARCH PHYS MED REHAB, V83, P555, DOI 10.1053/apmr.2002.31173; Putzke JD, 2001, ARCH PHYS MED REHAB, V82, P949, DOI 10.1053/apmr.2001.23973; Putzke JD, 2001, J CLIN PSYCHOL MED S, V8, P101, DOI 10.1023/A:1009555910604; Ragins BR, 1999, J APPL PSYCHOL, V84, P529, DOI 10.1037/0021-9010.84.4.529; Richards JS, 1999, ARCH PHYS MED REHAB, V80, P1501; RINTALA DH, 1992, REHABIL PSYCHOL, V37, P155, DOI 10.1037/0090-5550.37.3.155; Scherer MJ, 2001, DISABIL REHABIL, V23, P387; SHERMAN JE, 2001, M AM ASS SPIN CORD I; TATE D, 1994, AM J PHYS MED REHAB, V73, P175, DOI 10.1097/00002060-199406000-00006; TATE DG, 1994, PARAPLEGIA, V32, P473, DOI 10.1038/sc.1994.75; THOITS PA, 1986, J CONSULT CLIN PSYCH, V54, P416, DOI 10.1037/0022-006X.54.4.416; Thoits PA, 2000, HEALTH PSYCHOL, V19, P264, DOI 10.1037//0278-6133.19.3.264; Vines CL., 2000, PSYCHOSOC PROCESS, V13, P185; Weinfurt KP., 1995, READING UNDERSTANDIN, P245; Whiteneck G, 1999, ARCH PHYS MED REHAB, V80, P1485, DOI 10.1016/S0003-9993(99)90262-9; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WHITENECK GG, 1992, PARAPLEGIA, V30, P617, DOI 10.1038/sc.1992.124; Whittemore R, 2000, QUAL HEALTH RES, V10, P260, DOI 10.1177/104973200129118408; Winer BJ, 1962, STAT PRINCIPLES EXPT; World Health Organization, 1980, INT CLASS IMP DIS HA; Young J M, 1999, Healthc Manage Forum, V12, P51; [No title captured]	53	58	60	0	9	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	MAY	2004	49	2					140	149		10.1037/0090-5550.49.2.140			10	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	819BS	WOS:000221288800008					2022-02-06	
J	Hecht, JS				Hecht, JS			Occipital nerve blocks in postconcussive headaches - A retrospective review and report of ten patients	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain concussion; brain injuries; cervicogenic headache; headache; bead injuries; occipital nerve block; occipital neuralgia; pain therapy; postconcussive syndrome; whiplash	BASILAR ARTERY MIGRAINE; TENSION-TYPE HEADACHE; CERVICOGENIC HEADACHE; POSTTRAUMATIC HEADACHE; CERVICAL-SPINE; ANESTHETIC BLOCKADES; DIAGNOSTIC-CRITERIA; HISTORICAL COHORT; WHIPLASH INJURIES; BOTULINUM-TOXIN	Headaches are common following traumatic brain injuries of all severities. Pain generators may be in the head itself or the neck. Headache assessment is discussed. Diagnosis and treatment of cervical headaches syndromes and, in particular, occipital neuralgia are reviewed. Finally, a retrospective study of 10 postconcussive patients with headaches who were treated with greater occipital nerve blocks is presented. Following the injection(s), 80% had a "good" response and 20% had a "partial" response. Occipital nerve block is a useful diagnostic and treatment modality in the setting of postconcussive headaches.	Univ Tennessee, Grad Sch Med, Div Surg Rehabil, Dept Surg, Knoxville, TN 37920 USA		Hecht, JS (corresponding author), Univ Tennessee, Grad Sch Med, Div Surg Rehabil, Dept Surg, 1932 Alcoa Highway,Suite C580, Knoxville, TN 37920 USA.	jhecht@tennessee.edu					Anthony KRN, 2000, CORAL REEFS, V19, P59, DOI 10.1007/s003380050227; Antonaci F, 1997, FUNCT NEUROL, V12, P11; Astin JA, 2002, CEPHALALGIA, V22, P617, DOI 10.1046/j.1468-2982.2002.00423.x; Barre J-A., 1926, REV NEUROL, V33, P1246; Becser N, 1998, SPINE, V23, P1435, DOI 10.1097/00007632-199807010-00001; BLUME HG, 1976, ADV PAIN RES THER, V7, P691; BOGDUK N, 1985, MED J AUSTRALIA, V143, P202, DOI 10.5694/j.1326-5377.1985.tb122915.x; BOGDUK N, 1986, J NEUROL NEUROSUR PS, V49, P775, DOI 10.1136/jnnp.49.7.775; BOGDUK N, 1985, CURRENT THERAPY NEUR, P175; Bono G, 2000, CLIN EXP RHEUMATOL, V18, pS23; BOVIM G, 1992, PAIN, V49, P315, DOI 10.1016/0304-3959(92)90237-6; BOVIM G, 1992, PAIN, V51, P43, DOI 10.1016/0304-3959(92)90007-X; Caputi CA, 1998, HEADACHE, V38, P57; Chouret E E, 1967, Headache, V7, P33, DOI 10.1111/j.1526-4610.1967.hed0701033.x; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Deyo RA, 1996, SPINE, V21, P2840, DOI 10.1097/00007632-199612150-00007; Diener H C, 2001, Curr Med Res Opin, V17 Suppl 1, ps17, DOI 10.1185/0300799039117003; DREYER SJ, 2000, PAIN PROCEDURES CLIN; DROZ J, 1985, SWISS ANN CHIROPRAC, V8; DUBUISSON D, 1995, J NEUROSURG, V82, P581, DOI 10.3171/jns.1995.82.4.0581; Dumas JP, 2001, CEPHALALGIA, V21, P884, DOI 10.1046/j.1468-2982.2001.00264.x; DUTTON CB, 1969, AM J MED, V47, P141, DOI 10.1016/0002-9343(69)90248-4; ELKIND AH, 1989, CLIN J PAIN, V5, P77, DOI 10.1097/00002508-198903000-00014; ERLINGTON G, 2002, J NEUROL NEURSURG S2, V72, P10; ETTLIN TM, 1992, J NEUROL NEUROSUR PS, V55, P943, DOI 10.1136/jnnp.55.10.943; EVANS RW, 1994, HEADACHE, V34, P268, DOI 10.1111/j.1526-4610.1994.hed3405268.x; Evers S, 2002, CEPHALALGIA, V22, P699, DOI 10.1046/j.1468-2982.2002.00390.x; Fredriksen TA, 2003, FUNCT NEUROL, V18, P17; Freund BJ, 2002, CLIN J PAIN, V18, pS163, DOI 10.1097/00002508-200211001-00008; Gilkey SJ, 1997, HEADACHE, V37, P583, DOI 10.1046/j.1526-4610.1997.3709583.x; Goadsby PJ, 2002, J NEUROL NEUROSUR PS, V72, P2; GREENE WB, 2001, ESSENTIALS MUSCULOSK, P478; GREENE WB, 2001, ESSENTIALS MUSCULOSK, P230; Hachinski V, 2000, ARCH NEUROL-CHICAGO, V57, P1780, DOI 10.1001/archneur.57.12.1780; Haldeman S, 2001, Spine J, V1, P31, DOI 10.1016/S1529-9430(01)00024-9; Hammond S R, 1978, Clin Exp Neurol, V15, P258; HORN LJ, 1992, REHABILTATION POSTCO, P69; HOROWITZ MB, 1993, CEPHALALGIA, V13, P354, DOI 10.1046/j.1468-2982.1993.1305354.x; HOWE DH, 1983, J ROY COLL GEN PRACT, V33, P574; HUNTER CR, 1949, AM J SURG, V78, P743, DOI 10.1016/0002-9610(49)90316-5; JACOME DE, 1986, HEADACHE, V26, P515, DOI 10.1111/j.1526-4610.1986.hed2610515.x; JENSEN OK, 1990, CEPHALALGIA, V10, P241, DOI 10.1046/j.1468-2982.1990.1005241.x; JOSEPH B, 1994, SPINE, V19, P454, DOI 10.1097/00007632-199402001-00013; JOSEY AI, 1949, JAMA-J AM MED ASSOC, V140, P944, DOI 10.1001/jama.1949.02900460014005; Keidel M, 2001, PAIN, V92, P319, DOI 10.1016/S0304-3959(01)00272-X; KOVACS A, 1955, ACTA RADIOL, V43, P1; KRANZLIN P, 1993, ANN POSTGRADUATE COU, V13; Lake AE, 2002, NEUROLOGY, V59, pS8, DOI 10.1212/WNL.59.5_suppl_2.S8; Lavin PJ, 2001, HEADACHE, V41, P902, DOI 10.1046/j.1526-4610.2001.041009902.x; Lennard T, 2000, PAIN PROCEDURES CLIN; Lewis DW, 2002, NEUROLOGY, V59, P490, DOI 10.1212/WNL.59.4.490; LEWIS RC, 1956, MISSOURI MED, V53, P1059; Limmroth V, 2002, NEUROLOGY, V59, P1011, DOI 10.1212/WNL.59.7.1011; Loder E, 2002, CLIN J PAIN, V18, pS169, DOI 10.1097/00002508-200211001-00009; LORD SM, 1994, J NEUROL NEUROSUR PS, V57, P1187, DOI 10.1136/jnnp.57.10.1187; MACNAB I, 1964, J BONE JOINT SURG AM, V46, P1797, DOI 10.2106/00004623-196446080-00021; Magnusson T, 1996, HEADACHE, V36, P32, DOI 10.1046/j.1526-4610.1996.3601032.x; MAGNUSSON T, 1994, CEPHALALGIA, V14, P223, DOI 10.1046/j.1468-2982.1994.014003223.x; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; May A, 2003, BRIT MED BULL, V65, P223, DOI 10.1093/bmb/65.1.223; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; Melchart D, 2003, J INTERN MED, V253, P181, DOI 10.1046/j.1365-2796.2003.01081.x; Merskey H, 1994, CERVICOGENIC HEADACH; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; Murphy J P, 1969, Md State Med J, V18, P62; Obelieniene D, 1998, CEPHALALGIA, V18, P559, DOI 10.1046/j.1468-2982.1998.1808559.x; OCONNOR AJ, 2003, CERVICOGENIC HEADACH; OH M, 1999, ACNS PAIN SECT N APR, P3; OKEDA Y, 2001, DJ ANESTHESIA, V18, P829; OLESEN J, INT HEADACHE CLASSIF; OMMAYA AK, 1984, BIOMECHANICS IMPACT; ONOFRIO BM, 1972, J NEUROSURG, V36, P751, DOI 10.3171/jns.1972.36.6.0751; PEARCE JMS, 1995, J NEUROL NEUROSUR PS, V58, P698, DOI 10.1136/jnnp.58.6.698; Peres MFP, 2002, CEPHALALGIA, V22, P520, DOI 10.1046/j.1468-2982.2002.00410.x; POLETTI CE, 1990, NEUROSURGERY, V27, P288, DOI 10.1227/00006123-199008000-00019; Pollmann W, 1997, CEPHALALGIA, V17, P801, DOI 10.1046/j.1468-2982.1997.1708801.x; Radanov BP, 1996, PAIN, V64, P429, DOI 10.1016/0304-3959(95)00148-4; ROHEN J, 2002, COLOR ATLAS ANATOMY, P227; Saper JR, 2002, HEADACHE, V42, P470, DOI 10.1046/j.1526-4610.2002.02122.x; Silverman Steven B, 2002, Curr Pain Headache Rep, V6, P308, DOI 10.1007/s11916-002-0052-3; SJAASTAD O, 1983, CEPHALALGIA, V3, P249, DOI 10.1046/j.1468-2982.1983.0304249.x; Sjaastad O, 1998, HEADACHE, V38, P442, DOI 10.1046/j.1526-4610.1998.3806442.x; Sjaastad O, 2002, CEPHALALGIA, V22, P667, DOI 10.1046/j.1468-2982.2002.00408.x; SJAASTAD O, 1990, HEADACHE, V30, P725, DOI 10.1111/j.1526-4610.1990.hed3011725.x; STECHISON MT, 1994, ACTA NEUROCHIR, V131, P236, DOI 10.1007/BF01808620; STEVANS JM, 1996, CHIROPRAC TECH, V8, P12; STURZENEGGER MH, 1985, HEADACHE, V25, P408; TOLLISON CD, 1992, PAINFUL CERVICAL TRA; Travell J.G., 1992, MYOFASCIAL PAIN DYSF, V1; Valenca MM, 2002, ARQ NEURO-PSIQUIAT, V60, P542, DOI 10.1590/S0004-282X2002000400005; Vincent M, 1998, FUNCT NEUROL, V13, P78; Vincent MB, 1998, ARQ NEURO-PSIQUIAT, V56, P720, DOI 10.1590/S0004-282X1998000500004; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x; ZASLER N, 1996, MED REHABILITATION T, P145; [No title captured]	95	58	60	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2004	19	1					58	71		10.1097/00001199-200401000-00006			14	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	768UT	WOS:000188554000006	14732831				2022-02-06	
J	Pelinka, LE; Harada, N; Szalay, L; Jafarmadar, M; Redl, H; Bahrami, S				Pelinka, LE; Harada, N; Szalay, L; Jafarmadar, M; Redl, H; Bahrami, S			Release of S100B differs during ischemia and reperfusion of the liver, the gut, and the kidney in rats	SHOCK			English	Article						S100 protein; astrocytes; blood brain barrier; non-neuronal damage; extracranial trauma	NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; S-100 PROTEIN RELEASE; HEMORRHAGIC-SHOCK; CARDIAC MYOCYTES; SKELETAL-MUSCLE; SERUM S100B; INDUCTION; MARKER; S100-BETA	S100B, an acknowledged marker of brain damage, is increased post-traumatically in plasma. The aim of this study was to investigate the diagnostic value of S100B release in experimental local extracranial ischemia and reperfusion. Anesthetized rats underwent laparotomy and ligation of the afferent blood vessels to the liver, gut, or kidney to achieve local ischemia in each organ separately. After 60 min of ischemia, ligatures were removed and resuscitation was performed for 3 h. S100B was determined in plasma by immunoluminometric assay 55, 65, and 240 min after the onset of ischemia (5 min before reperfusion and 5 min and 3 h after the onset of reperfusion). During ischemia of the liver, S100B increased before ligature removal and reperfusion, reaching significance early after the onset of reperfusion and remaining almost unchanged throughout reperfusion. In contrast, S100B did not increase during ischemia of the gut or kidney before ligature removal or during early reperfusion but increased significantly to similar levels as during reperfusion of the liver 240 min after the onset of ischemia (after 3 h of reperfusion). Our findings show for the first time that S100B increases during local extracranial ischemia and reperfusion. These experimental findings support the concept that brain damage is not necessarily the cause of increased S100B. Although S100B has been an acknowledged marker of brain damage for years, our experimental clinically relevant data indicate that S100B is, in fact, not specific as a marker of brain damage in the setting of local ischemia and reperfusion of the liver, gut, and kidney because local ischemia and reperfusion of these organs cause an S100B increase per se.	Ludwig Boltzmann Inst Expt & Clin Traumatol, A-1200 Vienna, Austria; Res Ctr Allgemeine Unfallversicherungsansalt, A-1200 Vienna, Austria; Fukuoka Univ, Inst Pharmacol, Fukuoka 81401, Japan; Univ Szeged, Inst Surg Res, H-6720 Szeged, Hungary		Pelinka, LE (corresponding author), Ludwig Boltzmann Inst Expt & Clin Traumatol, Donaueschingenstr 13, A-1200 Vienna, Austria.		Redl, Heinz/AAD-8157-2019	Bahrami, Soheyl/0000-0002-4563-6251			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Egerbacher M, 1997, EUR ARCH OTO-RHINO-L, V254, P449, DOI 10.1007/BF02439977; Egerbacher M, 1997, ARCH HISTOL CYTOL, V60, P121, DOI 10.1679/aohc.60.121; Grocott HP, 2001, BRAIN CARDIAC SURG, P113; HAIMOTO H, 1987, LAB INVEST, V57, P489; Harada N, 1999, CRIT CARE MED, V27, P1958, DOI 10.1097/00003246-199909000-00040; HomerVanniasinkam S, 1997, EUR J VASC ENDOVASC, V14, P195, DOI 10.1016/S1078-5884(97)80191-8; Horie Y, 1996, GASTROENTEROLOGY, V111, P666, DOI 10.1053/gast.1996.v111.pm8780571; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; KAHN HJ, 1983, AM J CLIN PATHOL, V79, P341, DOI 10.1093/ajcp/79.3.341; KAHN HJ, 1991, MODERN PATHOL, V4, P698; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Leonardi R, 2000, ARCH ORAL BIOL, V45, P411, DOI 10.1016/S0003-9969(99)00144-2; Missler U, 2002, CLIN CHIM ACTA, V321, P29, DOI 10.1016/S0009-8981(02)00061-X; Molina R, 2002, TUMOR BIOL, V23, P39, DOI 10.1159/000048687; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; NAKAMURA Y, 1983, ARCH PATHOL LAB MED, V107, P118; Novak L, 1999, J TRAUMA, V47, P834, DOI 10.1097/00005373-199911000-00003; Parker TG, 1998, CAN J APPL PHYSIOL, V23, P377, DOI 10.1139/h98-022; Pelinka LE, 2003, SHOCK, V19, P422, DOI 10.1097/01.shk.0000055345.58165.52; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Strauss GI, 2001, LIVER TRANSPLANT, V7, P964, DOI 10.1053/jlts.2001.28742; Sun ZW, 2000, SHOCK, V13, P209, DOI 10.1097/00024382-200003000-00007; SUZUKI F, 1985, BIOCHIM BIOPHYS ACTA, V845, P311, DOI 10.1016/0167-4889(85)90193-4; SUZUKI F, 1986, BIOCHIM BIOPHYS ACTA, V889, P84, DOI 10.1016/0167-4889(86)90011-X; Tsoporis JN, 2003, AM J PHYSIOL-HEART C, V284, pH193, DOI 10.1152/ajpheart.00161.2002; Tsoporis JN, 1997, J BIOL CHEM, V272, P31915, DOI 10.1074/jbc.272.50.31915; Wanner GA, 1996, SHOCK, V5, P34, DOI 10.1097/00024382-199601000-00008; Ytrebo LM, 2001, SCAND J CLIN LAB INV, V61, P217; ZIMMER DB, 1991, CELL MOTIL CYTOSKEL, V20, P325, DOI 10.1002/cm.970200408; ZIMMER DB, 1987, AM J PHYSIOL, V252, P285	34	58	62	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1073-2322			SHOCK	Shock	JAN	2004	21	1					72	76		10.1097/01.shk.0000101672.49265.14			5	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	756LD	WOS:000187465800012	14676687				2022-02-06	
J	Martin, LJ; Price, AC; McClendon, KB; Al-Abdulla, NA; Subramaniam, JR; Wong, PC; Liu, ZP				Martin, LJ; Price, AC; McClendon, KB; Al-Abdulla, NA; Subramaniam, JR; Wong, PC; Liu, ZP			Early events of target deprivation/axotomy-induced neuronal apoptosis in vivo: oxidative stress, DNA damage, p53 phosphorylation and subcellular redistribution of death proteins	JOURNAL OF NEUROCHEMISTRY			English	Article						Alzheimer's disease; amyotrophic lateral sclerosis; cell death; DNA damage; Parkinson's disease; traumatic brain injury	LATERAL GENICULATE-NUCLEUS; PROGRAMMED CELL-DEATH; SUPEROXIDE-DISMUTASE; CEREBRAL-ISCHEMIA; GANGLION-CELLS; BAX; BRAIN; DEGENERATION; MITOCHONDRIA; ACTIVATION	The mechanisms of injury- and disease-associated apoptosis of neurons within the CNS are not understood. We used a model of cortical injury in rat and mouse to induce retrograde neuronal apoptosis in thalamus. In this animal model, unilateral ablation of the occipital cortex induces apoptosis of corticopetal projection neurons in the dorsal lateral geniculate nucleus (LGN), by 7 days post-lesion, that is p53 modulated and Bax dependent. We tested the hypothesis that this degenerative process is initiated by oxidative stress and early formation of DNA damage and is accompanied by changes in the levels of pro-apoptotic mediators of cell death. Immunoblotting revealed that the protein profiles of Bax, Bak and Bad were different during the progression of neuronal apoptosis in the LGN. Bax underwent a subcellular redistribution by 1 day post-lesion, while Bak increased later. Bad showed an early sustained increase. Cleaved caspase-3 was elevated maximally at 5 and 6 days. Active caspase-3 underwent a subcellular translocation to the nucleus. A dramatic phosphorylation of p53 was detected at 4 days post-lesion. DNA damage was assessed immunocytochemically as hydroxyl radical adducts (8-hydroxy-2-deoxyguanosine) and single-stranded DNA. Both forms of DNA damage accumulated early in target-deprived LGN neurons. Transgenic overexpression of superoxide dismutase-1 provided significant protection against the apoptosis but antioxidant pharmacotreatments with trolox and ascorbate were ineffective. We conclude that overlapping and sequential signaling pathways are involved in the apoptosis of adult brain neurons and that DNA damage generated by superoxide derivatives is an upstream mechanism for p53-regulated, Bax-dependent apoptosis of target-deprived neurons.	Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ Hosp, Wilmer Eye Inst, Baltimore, MD 21287 USA		Martin, LJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, 558 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	martinl@jhmi.edu		Subramaniam, Jamuna/0000-0003-0343-2469	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG16282] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34100] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG016282] Funding Source: NIH RePORTER		Al-Abdulla NA, 1998, NEUROSCIENCE, V86, P191, DOI 10.1016/S0306-4522(98)00014-1; Al-Abdulla NA, 1998, AM J PATHOL, V153, P447, DOI 10.1016/S0002-9440(10)65588-5; Al-Abdulla NA, 2002, NEUROSCIENCE, V115, P7, DOI 10.1016/S0306-4522(02)00363-9; Anderson AJ, 1996, J NEUROSCI, V16, P1710, DOI 10.1523/jneurosci.16-05-01710.1996; Aust AE, 1999, P SOC EXP BIOL MED, V222, P246, DOI 10.1046/j.1525-1373.1999.d01-141.x; BARRON KD, 1967, J NEUROPATH EXP NEUR, V26, P300, DOI 10.1097/00005072-196704000-00007; BECKMAN JS, 1990, NATURE, V345, P27, DOI 10.1038/345027b0; Burke RE, 1998, ANN NEUROL, V44, pS126, DOI 10.1002/ana.410440719; Calhoun ME, 1996, J NEUROCYTOL, V25, P821, DOI 10.1007/BF02284844; Carr A, 1999, FASEB J, V13, P1007, DOI 10.1096/fasebj.13.9.1007; Castagna V, 1999, NEUROSCIENCE, V93, P313, DOI 10.1016/S0306-4522(99)00138-4; Coddington JW, 1999, J AM CHEM SOC, V121, P2438, DOI 10.1021/ja982887t; Conti AC, 1998, J NEUROSCI, V18, P5663; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; DEL PL, 1997, SCIENCE, V278, P687; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frankfurt OS, 1996, EXP CELL RES, V226, P387, DOI 10.1006/excr.1996.0240; GIOLLI RA, 1971, J COMP NEUROL, V142, P351, DOI 10.1002/cne.901420306; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kermer P, 1998, J NEUROSCI, V18, P4656; Kitamura Y, 1999, JPN J PHARMACOL, V79, P1, DOI 10.1254/jjp.79.1; Klocker N, 1998, J NEUROSCI, V18, P1038; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; KOHN KW, 1991, PHARMACOL THERAPEUT, V49, P55, DOI 10.1016/0163-7258(91)90022-E; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lashley KS, 1941, J COMP NEUROL, V75, P67, DOI 10.1002/cne.900750105; Lesuisse C, 2002, J CEREBR BLOOD F MET, V22, P935, DOI 10.1097/00004647-200208000-00005; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lok J, 2002, J NEUROTRAUM, V19, P815, DOI 10.1089/08977150260190410; MacManus JP, 1997, J CEREBR BLOOD F MET, V17, P815, DOI 10.1038/aj.jcbfm.9590266; Martin LJ, 1999, J NEUROBIOL, V40, P185, DOI 10.1002/(SICI)1097-4695(199908)40:2<185::AID-NEU5>3.3.CO;2-R; Martin LJ, 1999, J NEUROPATH EXP NEUR, V58, P459, DOI 10.1097/00005072-199905000-00005; Martin LJ, 2002, NEUROCHEM RES, V27, P1093, DOI 10.1023/A:1020961006216; Martin LJ, 2002, J NEUROBIOL, V50, P181, DOI 10.1002/neu.10026; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; Martin LJ, 2000, NEUROBIOL DIS, V7, P613, DOI 10.1006/nbdi.2000.0314; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; Mattacola CG, 1999, ATHLET THER TODAY, V4, P13; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MIYASHITA T, 1995, CELL, V80, P293; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; Natale JE, 2002, NEUROSCIENCE, V112, P665, DOI 10.1016/S0306-4522(02)00098-2; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Pohl U, 1999, CELL PHYSIOL BIOCHEM, V9, P29, DOI 10.1159/000016300; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Putcha GV, 2002, J CELL BIOL, V157, P441, DOI 10.1083/jcb.200110108; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Salgo MG, 1996, ARCH BIOCHEM BIOPHYS, V333, P482, DOI 10.1006/abbi.1996.0418; SHANGARY S, 2000, J BIOL CHEM, V275; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Usuki F, 2001, NEUROSCI LETT, V304, P199, DOI 10.1016/S0304-3940(01)01764-5; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536; [No title captured]	61	58	61	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	APR	2003	85	1					234	247		10.1046/j.1471-4159.2003.01659.x			14	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	657EF	WOS:000181651900024	12641745				2022-02-06	
J	Dimopoulou, I; Korfias, S; Dafni, U; Anthi, A; Psachoulia, C; Jullien, G; Sakas, DE; Roussos, C				Dimopoulou, I; Korfias, S; Dafni, U; Anthi, A; Psachoulia, C; Jullien, G; Sakas, DE; Roussos, C			Protein S-100b serum levels in trauma-induced brain death	NEUROLOGY			English	Article							SEVERE HEAD-INJURY; MARKERS; DAMAGE; TOMOGRAPHY; S-100-BETA; PATHOLOGY; ENOLASE	Objective: To analyze the time course of serum protein S-100b in patients with traumatic brain injury deteriorating to brain death and to investigate the predictive value of initial S-100b levels in relation to clinical and radiologic measures of injury severity with regard to brain death. Methods: Forty-seven patients who sustained severe head injury were studied. Blood samples for measurement of S-100b were drawn on admission in the intensive care unit and every 24 hours thereafter for a maximum of 6 consecutive days or until brain death occurred. Variables related to outcome were recorded, including age, sex, Glasgow Coma Scale (GCS), and brain CT findings on admission. Outcome was defined as deterioration to brain death or not. Results: Of the 47 patients studied, 17 deteriorated to brain death and 30 did not. On admission, patients who became brain dead had higher median serum S-100b levels compared with those who did not (2.32 mug/L vs 1.04 mug/L, p = 0.0028). Logistic regression analysis showed that initial S-100b was an independent predictor of brain death (p = 0.041), in the presence of advanced age (p = 0.043) and low GCS score (p = 0.013). The odds ratio of 2.09 (95% CI, 1.03 to 4.25) indicates a more than doubling of the probability of deteriorating to brain death per 1-mug/L increase in S-100b on admission. At clinical brain death, median S-100b was higher in patients with brain death compared with the peak S-100b value obtained over a 6-day period in those who did not become brain dead (6.58 mug/L vs 1.49 mug/L, p < 0.0001). Conclusions: Prediction of brain death after severe head injury can be improved by combining clinical and S-100b data; thus, serum S-100b determination deserves to be included in the neuromonitoring of patients with severe traumatic brain injury.	Natl & Kapodistrian Univ, Dept Crit Care Med, Athens, Greece; Natl & Kapodistrian Univ, Dept Neurosurg, Athens, Greece; Natl & Kapodistrian Univ, Dept Neurosurg, Athens, Greece; Natl & Kapodistrian Univ, Dept Biostat, Athens, Greece; Natl & Kapodistrian Univ, Dept Biochem, Athens, Greece; Natl & Kapodistrian Univ, Evangelismos Hosp, Med & Nursing Sch, Athens, Greece		Dimopoulou, I (corresponding author), 2 Pesmazoglou St, Athens 14561, Greece.		Dafni, Ourania/AAH-4453-2019	Dafni, Ourania/0000-0003-4367-4497			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ikeda Y, 2001, NEUROSURG QUART, V11, P173, DOI 10.1097/00013414-200109000-00001; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Marshall LF, 1991, J NEUROSURG S, V75, P14; McKeating EG, 1998, ACT NEUR S, V71, P117; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Regner A, 2001, NEUROREPORT, V12, P691, DOI 10.1097/00001756-200103260-00015; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Rothoerl RD, 2000, ACT NEUR S, V76, P97; SAKAS DE, 1995, J NEUROSURG, V82, P961, DOI 10.3171/jns.1995.82.6.0961; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7; Wiesmann M, 1998, CLIN CHEM, V44, P1056; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606; Wijdicks EFM, 2002, NEUROLOGY, V58, P20, DOI 10.1212/WNL.58.1.20; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	26	58	58	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	MAR 25	2003	60	6					947	951		10.1212/01.WNL.0000049931.77887.7F			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	679YB	WOS:000182948600012	12654958				2022-02-06	
J	Okonkwo, DO; Melon, DE; Pellicane, AJ; Mutlu, LK; Rubin, DG; Stone, JR; Helm, GA				Okonkwo, DO; Melon, DE; Pellicane, AJ; Mutlu, LK; Rubin, DG; Stone, JR; Helm, GA			Dose-response of cyclosporin A in attenuating traumatic axonal injury in rat	NEUROREPORT			English	Article						calcineurin; cyclosporin A; diffuse axonal injury; mitochondria; traumatic brain injury	POSTTRAUMATIC BRAIN INJURY; CYTOCHROME-C RELEASE; DAMAGE; PERMEABILITY; MITOCHONDRIA; INHIBITION	Cyclosporin A has emerged as a promising therapeutic agent in traumatic brain injury (TBI), although its precise neuroprotective mechanism is unclear. Cyclosporin A, given as a single-dose intrathecal bolus, has previously been shown to attenuate mitochondrial damage and reduce axonal injury in experimental TBI. We assessed the effect of a range of intravenous cyclosporin A doses upon axonal injury attenuation to determine the ideal dose. Rats were subjected to experimental TBI and given one of five intravenous doses of cyclosporin A. At 3 h post-injury, brains were processed for brain tissue cyclosporin A concentration. In a second set of animals, at 24 h postinjury, brains were processed for amyloid precursor protein immunoreactivity, a widely used marker of axonal injury. Intravenous administration produced therapeutic levels of cyclosporin A in brain parenchyma. Higher concentrations were achieved with equivalent doses given intrathecally; this is consistent with the reported poor blood-brain barrier permeability of cyclosporin A. Cyclosporin A 10 mg/kg i.v. produced the greatest degree of neuroprotection against diffuse axonal injury; cyclosporin A 50 mg/kg i.v. was toxic. Intravenous cyclosporin A administration achieves therapeutic levels in brain parenchyma and 10 mg/kg is the most effective dose in attenuating axonal damage after traumatic brain injury.	Univ Virginia, Dept Neurosci, Charlottesville, VA 22908 USA; Univ Virginia, Dept Neurol Surg, Charlottesville, VA 22908 USA		Okonkwo, DO (corresponding author), Univ Virginia, Dept Neurosci, POB 800212, Charlottesville, VA 22908 USA.						Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Movsesyan VA, 2001, EXP NEUROL, V167, P366, DOI 10.1006/exnr.2000.7567; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; SANGHVI A, 1988, CLIN CHEM, V34, P1904; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	22	58	61	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	MAR 3	2003	14	3					463	466		10.1097/01.wnr.0000058958.85541.d3			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	656ZW	WOS:000181641800033	12634504				2022-02-06	
J	Pan, WH; Kastin, AJ; Rigai, T; McLay, R; Pick, CG				Pan, WH; Kastin, AJ; Rigai, T; McLay, R; Pick, CG			Increased hippocampal uptake of tumor necrosis factor alpha and behavioral changes in mice	EXPERIMENTAL BRAIN RESEARCH			English	Article						traumatic brain injury; staircase test; blood-brain barrier; transport; TNF alpha; IL1 beta; behavior; hippocampus	BLOOD-BRAIN-BARRIER; SPINAL-CORD-INJURY; STAIRCASE TEST; MESSENGER-RNA; TNF-ALPHA; HEAD-INJURY; EXPRESSION; MOUSE; PERMEABILITY; TRANSPORT	Brain trauma may alter the function of the blood-brain barrier (BBB) and affect psychornotor activity. We have shown that the transport system for tumor necrosis factor a (TNFalpha) at the BBB undergoes regulatory changes after spinal cord injury. In this study, we show in CD I mice that mild trauma by weight-drop to the right temporal region specifically increases the uptake of blood-borne TNFalpha. This increase, measured by use of radiolabeled murine TNFalpha, occurred only in the right hippocampus 24 h after injury and returned to normal at 1 week. There was no increase in the uptake of the vascular marker albumin at I h, 24 h, or I week postinjury, indicating that the BBB remained relatively intact. Human interleukin-1beta, which does not cross the BBB by saturable transport, showed no significant changes in brain uptake after trauma. Therefore, the selective entry of TNFa in the injured right hippocampus may be explained by enhanced transport across the BBB. To explore the functional relevance of this transport regulation, we measured mouse behavior by the staircase test. The number of rearings, mainly reflective of exploratory behavior, decreased at I h and I day after injury but increased at 1 week after a 30-g weight-drop injury. The number of stairs ascended, mainly indicative of locomotor activity, was unchanged at all times tested. We conclude that mild, blunt brain trauma involving the hippocampus causes specific upregulation of TNFalpha transport and a selective change in exploratory behavior. Although no causal relationship can be established at this time, the behavioral changes might be related to the increased TNFalpha transport after trauma.	Tulane Univ, Sch Med, New Orleans, LA 70112 USA; VAMC, New Orleans, LA 70112 USA; Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; USN, Ctr Med, Dept Mental Hlth, San Diego, CA USA		Pan, WH (corresponding author), Tulane Univ, Sch Med, 1430 Tulane Ave, New Orleans, LA 70112 USA.	wpan@tulane.edu	Pick, Chaim/D-4789-2009				BANKS WA, 1992, PEPTIDES, V13, P1289, DOI 10.1016/0196-9781(92)90037-4; Banks WA, 2001, J PHARMACOL EXP THER, V299, P536; BANKS WA, 1991, J PHARMACOL EXP THER, V259, P988; BANKS WA, 1990, AM J PHYSIOL, V259, P1; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; EMMANOUIL DE, 1990, PSYCHOPHARMACOLOGY, V102, P95, DOI 10.1007/BF02245750; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Gabellec MM, 1999, NEUROSCI RES, V33, P251, DOI 10.1016/S0168-0102(99)00014-0; GUTIERREZ EG, 1993, J NEUROIMMUNOL, V47, P169, DOI 10.1016/0165-5728(93)90027-V; Hayashi M, 2000, J NEUROTRAUM, V17, P203, DOI 10.1089/neu.2000.17.203; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5; Pan WH, 1996, AM J PHYSIOL-ENDOC M, V271, pE636, DOI 10.1152/ajpendo.1996.271.4.E636; Pan WH, 1999, J NEUROSCI, V19, P3649; Pan WH, 1997, EXP NEUROL, V146, P367, DOI 10.1006/exnr.1997.6533; Pan WH, 1997, J NEUROIMMUNOL, V76, P105, DOI 10.1016/S0165-5728(97)00034-9; Pan WH, 2000, EXP NEUROL, V170, P357, DOI 10.1006/exnr.2001.7702; Pick CG, 1996, PSYCHOPHARMACOLOGY, V128, P61, DOI 10.1007/s002130050110; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SIMIAND J, 1984, PSYCHOPHARMACOLOGY, V84, P48, DOI 10.1007/BF00432023; SMITH RA, 1987, J BIOL CHEM, V262, P6951; Weizman R, 2001, PHARMACOL BIOCHEM BE, V68, P491, DOI 10.1016/S0091-3057(01)00450-6	25	58	59	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819			EXP BRAIN RES	Exp. Brain Res.	MAR	2003	149	2					195	199		10.1007/s00221-002-1355-7			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	660BH	WOS:000181813700008	12610687				2022-02-06	
J	Wehman, P; Kregel, J; Keyser-Marcus, L; Sherron-Targett, P; Campbell, L; West, M; Cifu, DX				Wehman, P; Kregel, J; Keyser-Marcus, L; Sherron-Targett, P; Campbell, L; West, M; Cifu, DX			Supported employment for persons with traumatic brain injury: A preliminary investigation of long-term follow-up costs and program efficiency	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; employment; supported; rehabilitation	RETURN; WORK; REHABILITATION; BENEFIT; DISABILITIES	Objective: To investigate the long-term follow-up costs of supported employment as well as the wage and employment characteristics for individuals with moderate to severe traumatic brain injury (TBI) who participated in supported employment services over a 14-year time period. Design: Longitudinal design with prospectively collected data. Setting: A university-based supported employment program that uses the individual placement model of supported employment. Participants: Fifty-nine individuals with moderate to severe TBI who were consecutively referred for supported employment services. The sample was restricted to individuals who were placed into a least 1 supported employment position during the study period. Interventions: Not applicable. Main Outcome Measures: Data. were collected on clients placed into at least 1 competitive supported employment position from 1985 to 1999. Analyses were performed to examine the costs of supported employment, employment characteristics (eg, wages, length of employment), and benefit-cost ratios of supported employment for individuals with TBI. Results: The average length of employment for the current sample was 42.58 months. Average gross earnings were $26,129.74 for individuals during their entire duration of employment. Billing charges accrued for employment services averaged $10,349.37. Individuals with TBI earned an average of $17,515 more than the costs associated with their supported employment. Conclusions: Our investigation provides additional support for the conclusion that supported employment is cost effective for individuals with disabilities, including individuals with TBI, and that the costs of supported employment decrease over time.	Virginia Commonwealth Univ, Med Coll Virginia, Rehabil Res & Training Ctr, Dept Phys Med & Rehabil, Richmond, VA 23284 USA; Virginia Commonwealth Univ, Sch Educ, Richmond, VA 23284 USA		Wehman, P (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Rehabil Res & Training Ctr, Dept Phys Med & Rehabil, Box 842011, Richmond, VA 23284 USA.	pwehman@atlas.vcu.edu		Cifu, David/0000-0003-1600-9387			Anthes M, 1999, LIBR COLLECT ACQUIS, V23, P1, DOI 10.1016/S1464-9055(98)00103-1; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Bell KR, 1998, ARCH PHYS MED REHAB, V79, pS21, DOI 10.1016/S0003-9993(98)90116-2; BOND GR, 1995, J VOCATIONAL REHABIL, V5, P75; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Cimera RE, 1998, MENT RETARD, V36, P280, DOI 10.1352/0047-6765(1998)036<0280:AIWSMR>2.0.CO;2; Clark RE, 1996, ADM POLICY MENT HLTH, V24, P63, DOI 10.1007/BF02106484; CRISP R, 1992, J REHABIL, V58, P27; Curl RM, 1996, J HEAD TRAUMA REHAB, V11, P75, DOI 10.1097/00001199-199602000-00009; DANLEY KS, 1994, REHABIL PSYCHOL, V39, P269, DOI 10.1037/0090-5550.39.4.269; HILL ML, 1987, RES DEV DISABIL, V8, P71, DOI 10.1016/0891-4222(87)90041-2; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kregel J., 2000, J VOCATIONAL REHABIL, V14, P153; KREUTZER JS, 1988, VOCATIONAL REHABILIT, P291; LUBUSKO AA, 1994, BRAIN INJURY, V8, P65, DOI 10.3109/02699059409150959; MCCAUGHRIN WB, 1993, MENT RETARD, V31, P41; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; O'Connell MJ, 2000, REHABIL PSYCHOL, V45, P212, DOI 10.1037/0090-5550.45.2.212; Rogers ES, 1997, PSYCHIATR REHABIL J, V20, P25, DOI 10.1037/h0095367; ROGERS ES, 1995, EVAL PROGRAM PLANN, V18, P105, DOI 10.1016/0149-7189(95)00002-S; SHAFER MS, 1990, AM J MENT RETARD, V95, P316; Shearn J, 2000, J APPL RES INTELLECT, V13, P29, DOI 10.1046/j.1468-3148.2000.00005.x; THOMPSON L, 1992, J ASSOC PERS SEVERE, V17, P87, DOI 10.1177/154079699201700203; Wall JR, 1998, NEUROREHABILITATION, V10, P39, DOI 10.3233/NRE-1998-10105; Wehman P, 1989, Brain Inj, V3, P397, DOI 10.3109/02699058909004563; WEHMAN P, 1994, AM J PHYS MED REHAB, V73, P280, DOI 10.1097/00002060-199407000-00010; WEHMAN P, 1998, AM REHABIL       SPR, P31; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WEST M, 1991, ARCH PHYS MED REHAB, V72, P127	31	58	59	0	17	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					192	196		10.1053/apmr.2003.50027			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	643QV	WOS:000180872700007	12601649	Green Published			2022-02-06	
J	Ruchholtz, S; Waydhas, C; Lewan, U; Piepenbrink, K; Stolke, D; Debatin, J; Schweiberer, L; Nast-Kolb, D				Ruchholtz, S; Waydhas, C; Lewan, U; Piepenbrink, K; Stolke, D; Debatin, J; Schweiberer, L; Nast-Kolb, D			A multidisciplinary quality management system for the early treatment of severely injured patients: implementation and results in two trauma centers	INTENSIVE CARE MEDICINE			English	Article						quality management; early clinical therapy; multiple injuries; severe blunt trauma; penetrating trauma; emergency operation	ACUTE SUBDURAL-HEMATOMA; MISSED INJURIES; PREVENTABLE DEATHS; COMATOSE PATIENTS; CARE; IMPROVEMENT; MORBIDITY; MORTALITY; DIRECTIONS; ALGORITHM	Objective: The impact of a multidisciplinary quality management system (MQMS) on the early treatment of severely injured patients was tested. Design and setting: Prospective clinical study in two level I trauma centers. Methods and materials: MQMS comprised a protocol for documentation, 20 assessment criteria, and the judgement of data by a quality circle. After implementation in Munich (1st period, n=90; 2nd period, n=77) the validation took place in Essen (1st period, n=175; 2nd period, n=150). Results: Improvements in diagnostics were shown by significant time savings in radiological diagnostics and before computed tomography in severe traumatic brain injury. In patients with hemorrhagic shock there was a reduction in time before transfusion (49 to 14 min in Munich; 31 to 22 min in Essen) and before emergency operation (74 to 43 min in Munich; 69 to 45 min in Essen). The time before craniotomy was reduced from 97 to 67 min in Munich. The incidence of delayed diagnosis of life-threatening lesions was diminished from 6% to 3% in Munich (not found in Essen). The TRISS technique showed a reduction in mortality in both hospitals in the second period (Munich: 15.4% TRISS vs. 9.1% observed mortality; Essen: 17.8% vs. 11.3%). Conclusions: MQMS improved early clinical treatment in severe injury with respect to therapeutic effectiveness and outcome. The effectiveness of the MQMS was shown at two different hospitals.	Univ Hosp Essen, Dept Trauma Surg, D-45122 Essen, Germany; Univ Hosp Essen, Dept Anesthesiol, D-45122 Essen, Germany; Univ Hosp Essen, Dept Neurosurg, D-45122 Essen, Germany; Univ Hosp Essen, Dept Radiol, D-45122 Essen, Germany; Univ Munich, Klinikum Innenstadt, Dept Surg, D-8000 Munich, Germany		Ruchholtz, S (corresponding author), Univ Hosp Essen, Dept Trauma Surg, Hufelandstr 55, D-45122 Essen, Germany.						*AM COLL SURG COMM, 1993, RES OPT CAR INJ PAT; BISHOP M, 1991, AM SURGEON, V57, P736; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CAMPBELL S, 1989, AM SURGEON, V55, P478; CAYTEN CG, 1991, ANN SURG, V214, P510, DOI 10.1097/00000658-199110000-00015; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; CHAMPION HR, 1992, ARCH SURG-CHICAGO, V127, P333; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; COPES WS, 1995, J TRAUMA, V38, P432, DOI 10.1097/00005373-199503000-00027; DAVIS JW, 1991, J TRAUMA, V31, P813, DOI 10.1097/00005373-199106000-00012; DEMING WE, 1985, OUT CRISIS; DRAAISMA JMT, 1989, J TRAUMA, V29, P1552; ESPOSITO TJ, 1995, ARCH SURG-CHICAGO, V130, P171; HIRSHBERG A, 1994, AM J SURG, V168, P299, DOI 10.1016/S0002-9610(05)80152-7; HOYT DB, 1992, J TRAUMA, V33, P586, DOI 10.1097/00005373-199210000-00016; HOYT DB, 1994, J TRAUMA, V36, P377, DOI 10.1097/00005373-199403000-00017; Ishikawa K, 1985, WHAT IS TOTAL QUALIT; Juran J.M., 1989, JURAN LEADERSHIP QUA; KREIS DJ, 1986, J TRAUMA, V26, P649, DOI 10.1097/00005373-198607000-00010; LIU M, 1988, CRIT CARE MED, V16, P1191, DOI 10.1097/00003246-198812000-00004; MACKENZIE EJ, 1992, J TRAUMA, V33, P292, DOI 10.1097/00005373-199208000-00021; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; McDermott FT, 1996, J TRAUMA, V40, P520, DOI 10.1097/00005373-199604000-00003; MUCKART DJJ, 1991, AM J SURG, V162, P457, DOI 10.1016/0002-9610(91)90260-K; NASTKOLB D, 1994, UNFALLCHIRURG, V97, P292; Robertson R, 1996, AM J SURG, V172, P564, DOI 10.1016/S0002-9610(96)00247-4; Ruchholtz S, 1998, INJURY, V29, P115, DOI 10.1016/S0020-1383(97)00150-2; SCHWARTZ ML, 1991, J TRAUMA, V31, P962, DOI 10.1097/00005373-199107000-00013; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SHACKFORD SR, 1987, J TRAUMA, V27, P866, DOI 10.1097/00005373-198708000-00004; STOCCHETTI N, 1994, J TRAUMA, V36, P401, DOI 10.1097/00005373-199403000-00022; STOTHERT JC, 1990, J TRAUMA, V30, P1021, DOI 10.1097/00005373-199008000-00012; Sung CK, 1996, J TRAUMA, V41, P276, DOI 10.1097/00005373-199608000-00013; TRUNKEY D, 1991, NEW ENGL J MED, V324, P1259; WENNEKER WW, 1990, AM J SURG, V160, P655, DOI 10.1016/S0002-9610(05)80768-8; WEST JG, 1979, ARCH SURG-CHICAGO, V114, P455; WILBERGER JE, 1990, J TRAUMA, V30, P733, DOI 10.1097/00005373-199006000-00014; WILSON DS, 1992, J TRAUMA, V32, P45, DOI 10.1097/00005373-199201000-00010; Zintl B, 1997, UNFALLCHIRURG, V100, P811, DOI 10.1007/s001130050198	39	58	62	0	2	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	OCT	2002	28	10					1395	1404		10.1007/s00134-002-1446-8			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	641PG	WOS:000180753500006	12373463				2022-02-06	
J	Braun, H; Schafer, K; Hollt, V				Braun, H; Schafer, K; Hollt, V			beta III tubulin-expressing neurons reveal enhanced neurogenesis in hippocampal and cortical structures after a contusion trauma in rats	JOURNAL OF NEUROTRAUMA			English	Article						beta III tubulin; cortex; hippocampus; neurogenesis; neurotrauma; neuronal cell death; tissue recovery	CENTRAL-NERVOUS-SYSTEM; ADULT MAMMALIAN BRAIN; DENTATE GYRUS; SUBVENTRICULAR ZONE; AXONAL REGENERATION; SENSORY NEURONS; STEM-CELLS; PROLIFERATION; STROKE; DIFFERENTIATION	Neurogenesis is not only restricted to embryonic development, but also occurs in adult mammalian brains, including human. In this study, evidence is provided, that neurogenesis is involved in the repair of hippocampal and cortical structures after CNS injury. Cortical contusion was induced in 8-week-old Wistar rats. This trauma resulted in a primary cortical lesion and ipsilateral distant remote hippocampal damage, involving primarily CA3-pyramidal cells. The progression of injury was followed over a time course of 7 days, using Nissl-staining and a monoclonal antibody against betaIII tubulin-a specific marker for neurogenic cells. Nissl staining showed a partial recovery of damaged cortical and hippocampal cells at day 7. This recovery was accompanied by an increase of neurogenic cells in these structures, particularly in the dentate gyrus and the neocortical areas. Taken together, these findings provide evidence for the involvement of neurogenesis in the repair processes after traumatic brain injury.	Univ Magdeburg, Inst Pharmakol & Toxikol, D-39106 Magdeburg, Germany		Hollt, V (corresponding author), Otto Von Guericke Univ, Inst Pharmakol & Toxikol, Leipziger Str 44, D-39120 Magdeburg, Germany.						Aldskogius H, 1998, PROG NEUROBIOL, V55, P1, DOI 10.1016/S0301-0082(97)00093-2; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; Cao Y, 1999, STROKE, V30, P2331, DOI 10.1161/01.STR.30.11.2331; Doetsch F, 1997, J NEUROSCI, V17, P5046; Fanarraga ML, 1999, EUR J NEUROSCI, V11, P517; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; Garcia-Verdugo J, 1998, J NEUROBIOL, V36, P234, DOI 10.1002/(SICI)1097-4695(199808)36:2<234::AID-NEU10>3.0.CO;2-E; GATES MA, 1995, J COMP NEUROL, V361, P249, DOI 10.1002/cne.903610205; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; Gu WG, 2000, J CEREBR BLOOD F MET, V20, P1166, DOI 10.1097/00004647-200008000-00002; Hailer NP, 1999, EUR J NEUROSCI, V11, P3359, DOI 10.1046/j.1460-9568.1999.00808.x; Johansson CB, 1999, EXP CELL RES, V253, P733, DOI 10.1006/excr.1999.4678; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; KAPLAN MS, 1985, ANN NY ACAD SCI, V457, P173, DOI 10.1111/j.1749-6632.1985.tb20805.x; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; LEE VM, 1994, DEV BRAIN RES, V83, P209, DOI 10.1016/0165-3806(94)00139-1; Liu JL, 1998, J NEUROSCI, V18, P7768; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Luskin MB, 1998, J NEUROBIOL, V36, P221; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; MOSKOWITZ PF, 1993, J NEUROSCI RES, V34, P129, DOI 10.1002/jnr.490340113; MOSKOWITZ PF, 1995, J NEUROSCI, V15, P1545; Parent JM, 1997, J NEUROSCI, V17, P3727; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Roskams AJI, 1998, NEUROSCIENCE, V83, P191, DOI 10.1016/S0306-4522(97)00344-8; Roy NS, 2000, NAT MED, V6, P271; Rumbach L, 2000, NEUROLOGY, V54, P350, DOI 10.1212/WNL.54.2.350; Schulz S, 1998, EUR J NEUROSCI, V10, P3700, DOI 10.1046/j.1460-9568.1998.00386.x; Weiller C, 1998, EXP BRAIN RES, V123, P13, DOI 10.1007/s002210050539; Weinstein DE, 1996, BRAIN RES, V743, P11, DOI 10.1016/S0006-8993(96)00979-1	35	58	59	1	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2002	19	8					975	983		10.1089/089771502320317122			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	585JC	WOS:000177520800007	12225657				2022-02-06	
J	Jackson, H; Philp, E; Nuttall, RL; Diller, L				Jackson, H; Philp, E; Nuttall, RL; Diller, L			Traumatic brain injury: A hidden consequence for battered women	PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE			English	Article							HEAD-INJURY; CONSCIOUSNESS; DISORDERS; VIOLENCE	The inability of substantial numbers of battered women to terminate or extricate themselves from violent relationships is of grave concern to clinical practitioners. Despite professional intervention, many victims of domestic violence return to the batterer and to repetitive battering, demonstrating that, for these women, traditional psychosocial interventions are ineffective. In a sample of 53 battered women, 92% reported having received blows to the head in the course of their battering; 40% reported loss of consciousness. Correlations between frequency of being hit in the head and severity of cognitive symptoms were significant, strongly suggesting that battered women should be routinely screened for traumatic brain injury and postconcussive syndrome. Development of treatment strategies to address the potentially damaging sequelae of head trauma in this population is essential.	Columbia Univ, Sch Social Work, New York, NY 10025 USA; Columbia Univ, New York, NY 10027 USA; Boston Coll, Lynch Sch Educ, Chestnut Hill, MA 02167 USA; NYU, Med Ctr, New York, NY USA		Jackson, H (corresponding author), Columbia Univ, Sch Social Work, 622 W 113th St, New York, NY 10025 USA.	maj3@columbia.edu					American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Barnett OW., 1997, FAMILY VIOLENCE LIFE; BOHNEN N, 1992, J NEUROL NEUROSUR PS, V55, P222, DOI 10.1136/jnnp.55.3.222; BROWNE A, 1993, AM PSYCHOL, V48, P1077, DOI 10.1037/0003-066X.48.10.1077; CLAERHOUT S, 1982, AM J COMMUN PSYCHOL, V10, P605, DOI 10.1007/BF00894147; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; DIKMEN SS, 1989, MILD HEAD INJURY, P229; DILLER L, 1992, NEUROPSYCHOLOGICAL R; FERRANT SL, 1992, DISS ABSTR INT B, V530, P6; GELLES RJ, 1990, PHYSICAL VIOLENCE AM; Gronwall D, 1989, MILD HEAD INJURY, P153; KAY R, 1992, NEUROPSYCHOLOGY, V4, P371; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KAY T, 1992, PACIF COAST BRAIN IN; KELLY R, 1975, Forensic Science, V6, P17, DOI 10.1016/0300-9432(75)90219-8; Kubzansky LD, 1997, CIRCULATION, V95, P818; Kyriacou DN, 1999, NEW ENGL J MED, V341, P1892, DOI 10.1056/NEJM199912163412505; Lawler KA, 1996, J HEAD TRAUMA REHAB, V11, P18, DOI 10.1097/00001199-199612000-00005; LOSEKE DR, 1992, BATTERED WOMAN SHELT; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Ochs HA, 1996, J AM DENT ASSOC, V127, P757, DOI 10.14219/jada.archive.1996.0311; Pelcovitz D, 1997, J TRAUMA STRESS, V10, P3, DOI 10.1023/A:1024800212070; Picard N., 1999, HELPS; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; ROSENBAUM A, 1994, J CONSULT CLIN PSYCH, V62, P1187, DOI 10.1037/0022-006X.62.6.1187; SATO RA, 1992, J FAM VIOLENCE, V7, P229, DOI 10.1007/BF00979030; Silver JM., 1994, NEUROPSYCHIATRY TRAU; SILVER JM, 1994, SYNOPSIS NEUROPSYCHI, P279; SLAGLE DA, 1990, INT J PSYCHIAT MED, V20, P1, DOI 10.2190/BE6W-DCY1-V71N-N7J7; SOUTHERN JP, 1990, LANCET, V336, P1425, DOI 10.1016/0140-6736(90)93114-5; STARK E, 1996, COMMUNICATION    JAN; Straus M, 1990, MANUAL CONFLICT TACT; STRAUS MA, 1986, J MARRIAGE FAM, V48, P465, DOI 10.2307/352033; Sutherland C, 1998, Womens Health, V4, P41; TEASDALE G, 1974, LANCET, V2, P81; WALKER LE, 1991, PSYCHOTHER, V28, P21, DOI 10.1037/0033-3204.28.1.21; WALKER LEA, 1994, CURRENT CONTROVERSIE, P133; Walker Leonore., 1977, VICTIMOLOGY INT J, V2, P525, DOI [DOI 10.1521/JSCP.23.4.445.40311, 10.1521/jscp.23.4.445.40311]; WILT SA, 1997, FEMALE HOMICIDE VICT; [No title captured]	42	58	58	0	12	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0735-7028	1939-1323		PROF PSYCHOL-RES PR	Prof. Psychol.-Res. Pract.	FEB	2002	33	1					39	45		10.1037//0735-7028.33.1.39			7	Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Psychology	514QJ	WOS:000173452300006					2022-02-06	
J	Machamer, J; Temkin, N; Dikmen, S				Machamer, J; Temkin, N; Dikmen, S			Significant other burden and factors related to it in traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							BLUNT HEAD-INJURY; DEPRESSIVE SYMPTOMS; RANDOMIZED TRIAL; CAREGIVER BURDEN; RELATIVES VIEW; DISTRESS; VALPROATE; SCALE	Feelings of burden and factors related to it were examined in a sample of 180 relatives of moderately to severely traumatically brain injured (TBI) subjects 6 months postinjury. Relatives were enrolled onto the study based on their family member's head injury and not on outcome. The results indicate that although both positive and negative experiences were common, the majority of the relatives reported an overall positive experience. The significant other's (SO's) experience was significantly and systematically related to many factors with overall negative experience associated with increased brain injury severity, worse neuropsychological functioning, increased dependency on others, SO's report of changes in the TBI subject, changes in the SO's life as a result of caregiving and SO depression.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA		Machamer, J (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.	machamer@u.washington.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD033677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD33677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS19643] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A980023] Funding Source: Medline		ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/0090-5550.39.1.29; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Chiu Wen-Ta, 1993, Journal of the Formosan Medical Association, V92, P255; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; JENNETT B, 1975, LANCET, V1, P480; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Panting A, 1972, REHABILITATION, V38, P33; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Reitan R.M., 1993, HALSTEADREITAN NEURO; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Teri L, 1997, J GERONTOL B-PSYCHOL, V52, pP159, DOI 10.1093/geronb/52B.4.P159; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; Wechsler D., 1955, MANUAL WECHSLER ADUL; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	37	58	58	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2002	24	4					420	433		10.1076/jcen.24.4.420.1040			14	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	568ZJ	WOS:000176574600002	12187456				2022-02-06	
J	Macmillan, PJ; Hart, RP; Martelli, MF; Zasler, ND				Macmillan, PJ; Hart, RP; Martelli, MF; Zasler, ND			Pre-injury status and adaptation following traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; IMPACT	There are an estimated two million traumatic brain injuries (TBI) each year in the US. Behavioural and psychosocial sequelae are the most disabling consequences of TBI, but relatively little empirical data exist that identify factors underlying the variability in patient outcomes. There is an increasing appreciation that pre-injury coping liabilities are likely to contribute to persistent disability and that outcome reflects the combined effects of pre-morbid, injury-related, and post-injury factors. Despite this, most outcome studies focus On the effects of injury-related and post-injury variables. The present study evaluated outcome in 45 adults who suffered a moderate or severe TBI at least 2 years earlier. It was hypothesized that severity of pre-morbid psychiatric and substance abuse problems and less social support following brain injury would be associated with poorer post-injury adaptation as measured by employment status, independent living status, and neurobehavioural symptomatology. The authors found that pre-injury psychiatric and substance abuse histories predicted employment status and that pre-injury substance abuse predicted independent living status. Social support following TBI predicted significant other's assessment of the patients' neurobehavioural status. None of the independent variables were found to predict patient assessment of his or her own neurobehavioural functioning. These findings support the premise that pre-morbid coping liabilities are related to the degree of post-injury disability.	Sheltering Arms Phys Rehabil, Richmond, VA USA; Coll William & Mary, Williamsburg, VA USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA; Concuss Care Ctr Virginia Ltd, Richmond, VA USA; Tree Life, Richmond, VA USA		Martelli, MF (corresponding author), Concuss Care Ctr Virginia, Rehabil Neuropsychol, 10120 W Broad St,Suite GH&I, Glen Allen, VA 23060 USA.	mikefm@erols.com					ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; Atkinson JS, 2000, AM J DRUG ALCOHOL AB, V26, P355, DOI 10.1081/ADA-100100249; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; Ettner SL, 1997, IND LABOR RELAT REV, V51, P64, DOI 10.1177/001979399705100105; Folkman S., 1984, STRESS; GANS J, 1983, SEMINARS NEUROLOGY, V3, P201; Hall KM, 1998, NEUROREHABILITATION, V10, P3, DOI 10.3233/NRE-1998-10102; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC2; KAY T, 1992, REHABILITATION POST, P109; KREUTZER J S, 1990, Brain Injury, V4, P1, DOI 10.3109/02699059009026142; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; LAZARUS RS, 1993, PSYCHOSOM MED, V55, P234, DOI 10.1097/00006842-199305000-00002; LAZARUS RS, 1976, PATTERNS ADJUSTMENT; Levin HS., 1982, NEUROBEHAVIORAL CONS; Lubben J. E., 1988, FAM COMMUNITY HEALTH; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; Martelli MF, 1998, NEUROREHABILITATION, V11, P51, DOI 10.1016/S1053-8135(98)00009-2; MARTELLI MF, 1996, NAT AC NEUR ANN M NE; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Rutherford WH, 1989, MILD HEAD INJURY, P229; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; *SPSS INC, 1999, SPSS WIND REL 10 0; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Zasler ND, 1997, ARCH PHYS MED REHAB, V78, pS12, DOI 10.1016/S0003-9993(97)90150-7; [No title captured], DOI DOI 10.1037/0894-4105.7.3.296	31	58	60	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2002	16	1					41	49		10.1080/0269905011008812			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	515BM	WOS:000173475600004	11796098				2022-02-06	
J	Mangels, JA; Craik, FIM; Levine, B; Schwartz, ML; Stuss, DT				Mangels, JA; Craik, FIM; Levine, B; Schwartz, ML; Stuss, DT			Effects of divided attention on episodic memory in chronic traumatic brain injury: A function of severity and strategy	NEUROPSYCHOLOGIA			English	Article; Proceedings Paper	Rotman-Research-Institute Conference on Traumatic Brain Injury	1999	TORONTO, CANADA	Rotman Res Inst		executive control; frontal-lobe; outcome; neuropsychology	CLOSED-HEAD-INJURY; DUAL-TASK PERFORMANCE; FRONTAL-LOBE LESIONS; TECHNETIUM-99M-HMPAO SPECT; AMNESIC PATIENTS; EXPLICIT MEMORY; PRACTICAL SCALE; FALSE RECALL; OLDER-ADULTS; MILD	Eleven patients with mild traumatic brain injury (MTBI) and 13 patients with moderate-to-severe TBI (STBI) were compared to 10 matched controls on episodic memory for pictorial scene-object associations (e.g. kitchen-bread) and a range of standardized neuropsychological tests of memory and frontal-lobe functions. We tested the hypothesis that deficits in episodic memory result from impaired attentional resources and/or strategic control by manipulating attentional load at encoding (focused versus divided attention) and environmental support at retrieval (free recall and recalled cued by scene versus recognition of object and scene). Patients with TBI were disproportionately affected by the divided attention manipulation, but this effect was modulated by injury severity and encoding strategy. Overall, MTBI patients were impaired only when items were encoded under divided attention, indicating memory deficits that were secondary to deficits in the executive control. STBI patients could be differentiated into two distinct functional subgroups based on whether they favored a strategy of attending to the encoding or digit-monitoring task. The subgroup favoring the digit-monitoring task demonstrated deficits in the focused attention condition, and disproportionate memory deficits in the divided attention condition. In contrast, the subgroup favoring the encoding task demonstrated intact performance across all memory Measures, regardless of attentional load, and despite remarkable similarity to the other STBI subgroup on demographic, neuropsychological, and acute injury severity measures. We discuss these outcome differences in terms of the relationship between strategy and executive control and highlight the need for more sensitive anatomical and behavioral measurement at both acute and chronic stages of injury. (C) 2002 Elsevier Science Ltd. All rights reserved.	Columbia Univ, Dept Psychol, New York, NY 10027 USA; Univ Toronto, Rotman Res Inst, Baycrest Ctr Geriatr Care, Toronto, ON, Canada; Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Neurosurg, Toronto, ON, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Med Neurol Rehabil Med, Toronto, ON, Canada		Mangels, JA (corresponding author), Columbia Univ, Dept Psychol, Schermerhorn Hall,1190 Amsterdam Ave, New York, NY 10027 USA.	mangels@psych.columbia.edu	Levine, Brian/O-2725-2019; Levine, Brian/G-4328-2010	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; Craik, Fergus/0000-0001-8073-3236			Alderman N, 1996, NEUROPSYCHOL REHABIL, V6, P161, DOI 10.1080/713755505; Anderson ND, 2000, J COGNITIVE NEUROSCI, V12, P775, DOI 10.1162/089892900562598; Anderson ND, 1998, PSYCHOL AGING, V13, P405, DOI 10.1037/0882-7974.13.3.405; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Baddeley A.D., 1986, WORKING MEMORY; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Campbell K. B., 1995, HDB NEUROPSYCHOLOGY, V10, P269; Craik FIM, 1996, J EXP PSYCHOL GEN, V125, P159, DOI 10.1037/0096-3445.125.2.159; DELIS DC, 1992, NEUROPSYCHOLOGIA, V30, P683, DOI 10.1016/0028-3932(92)90039-O; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Eslinger P. J, 1996, ATTENTION MEMORY EXE, P367; FLETCHER PC, 1995, BRAIN, V118, P401, DOI 10.1093/brain/118.2.401; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GERSHBERG FB, 1995, NEUROPSYCHOLOGIA, V33, P1305, DOI 10.1016/0028-3932(95)00103-A; GRAY BG, 1992, J NUCL MED, V33, P52; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Iidaka T, 2000, J COGNITIVE NEUROSCI, V12, P267, DOI 10.1162/089892900562093; JACOBS A, 1994, J NUCL MED, V35, P942; JANOWSKY JS, 1989, NEUROPSYCHOLOGIA, V27, P1043, DOI 10.1016/0028-3932(89)90184-X; Kaipio ML, 1999, NEUROREPORT, V10, P2125, DOI 10.1097/00001756-199907130-00024; Kaipio ML, 2000, NEUROREPORT, V11, P1463; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVINE B, 1995, J CLIN EXP NEUROPSYC, V17, P740, DOI 10.1080/01688639508405164; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; LEVINE B, IN PRESS NEUROSURGER; Mangels JA, 1997, NEUROPSYCHOLOGY, V11, P207, DOI 10.1037/0894-4105.11.2.207; Mangels JA, 2001, COGNITIVE BRAIN RES, V11, P77, DOI 10.1016/S0926-6410(00)00066-5; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Melo B, 1999, COGNITIVE NEUROPSYCH, V16, P343, DOI 10.1080/026432999380825; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Niemann H, 1996, NEUROPSYCHOL REV, V6, P11, DOI 10.1007/BF01875418; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; ROENKER DL, 1971, PSYCHOL BULL, V76, P45, DOI 10.1037/h0031355; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Santos ME, 1998, BRAIN INJURY, V12, P759, DOI 10.1080/026990598122151; SCHACTER DL, 1984, J VERB LEARN VERB BE, V23, P593, DOI 10.1016/S0022-5371(84)90373-6; Schacter DL, 1996, J MEM LANG, V35, P319, DOI 10.1006/jmla.1996.0018; SchmitterEdgecombe M, 1996, NEUROPSYCHOLOGY, V10, P155; SchmitterEdgecombe M, 1996, J HEAD TRAUMA REHAB, V11, P17, DOI 10.1097/00001199-199604000-00003; SHALLICE T, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P125; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SHIMAMURA AP, 1987, J EXP PSYCHOL LEARN, V13, P464, DOI 10.1037/0278-7393.13.3.464; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STERN Y, 2002, J CLIN EXPT NEURPSYC, V58, P1182; Stuss D.T., 1994, NEUROPSYCHOLOGY, V8, P355, DOI [https://doi.org/10.1037/0894-4105.8.3.355, DOI 10.1037/0894-4105.8.3.355]; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Stuss DT, 2000, NEUROLOGY, V54, P1337, DOI 10.1212/WNL.54.6.1337; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TEASDALE G, 1974, LANCET, V2, P81; Troyer AK, 1999, NEUROPSYCHOLOGY, V13, P467, DOI 10.1037/0894-4105.13.4.467; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; Watt S, 1999, NEUROPSYCHOLOGY, V13, P338, DOI 10.1037/0894-4105.13.3.338; Wheeler M A, 1995, J Int Neuropsychol Soc, V1, P525; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; [No title captured]	69	58	59	1	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2002	40	13					2369	2385	PII S0028-3932(02)00084-2	10.1016/S0028-3932(02)00084-2			17	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Behavioral Sciences; Neurosciences & Neurology; Psychology	623RH	WOS:000179716300016	12417466				2022-02-06	
J	McCauley, SR; Levin, HS; Vanier, M; Mazaux, JM; Boake, C; Goldfader, PR; Rockers, D; Butters, M; Kareken, DA; Lambert, J; Clifton, GL; Butters, M; Lambert, J				McCauley, SR; Levin, HS; Vanier, M; Mazaux, JM; Boake, C; Goldfader, PR; Rockers, D; Butters, M; Kareken, DA; Lambert, J; Clifton, GL; Butters, M; Lambert, J			The neurobehavioural rating scale-revised: sensitivity and validity in closed head injury assessment	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						outcome measures; head injury; randomised clinical trials; neurobehavioural sequelae	TRAUMATIC BRAIN INJURY; BEHAVIORAL DISTURBANCES; PSYCHIATRIC-SYMPTOMS; ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; TEST-PERFORMANCE; FOLLOW-UP; RECOVERY; SEQUELAE; RELIABILITY	Objectives-To investigate the factor structure and psychometric properties of the neurobehavioural rating scale-revised (NRS-R) and to determine its usefulness in clinical trials. Methods-A consecutive series of patients sustaining severe closed head injury were evacuated to one of 11 large regional North American trauma centres and entered into a randomised, phase III, multicentre clinical trial investigating the therapeutic use of moderate hypothermia. Acute care personnel were blinded to outcome and outcome personnel were blinded to treatment condition. The Glasgow outcome scale (GOS) was the primary outcome measure. Secondary outcome measures included the disability rating scale (DRS) and the NRS-R. Results-Exploratory factor analysis of NRS-R data collected at 6 months after injury (n=210) resulted in a five factor model including: (1) executive/cognition, (2) positive symptoms, (3) negative symptoms, (4) mood/affect, and (5) oral/motor. These factors showed acceptable internal consistency (0.62 to 0.88), low to moderate interfactor correlations (0.19 to 0.61), and discriminated well between GOS defined groups. Factor validity was demonstrated by significant correlations with specific neuropsychological domains. Significant change was measured from 3 to 6 months after injury for the total score (sum of all 29 item ratings) and all factor scores except mood/affect and positive symptoms. The total score and all factor scores correlated significantly with concurrent GOS and DRS scores. Conclusions-The NRS-R is weld suited as a secondary outcome measure for clinical trials as its completion rate exceeds that of neuropsychological assessment and it provides important neurobehavioural information complementary to that provided by global outcome and neuropsychological measures.	Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA; Univ Montreal, Ecole Readapt, Montreal, PQ, Canada; CHU Bordeaux, Bordeaux, France; Univ Texas, Hlth Sci Ctr, Dept Phys Med & Rehabil, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Dept Neurosurg, Houston, TX USA; St Louis Univ, Sch Med, Dept Neurol, St Louis, MO 63103 USA; St Louis Univ, Sch Med, Dept Neurosurg, St Louis, MO 63103 USA; Univ Calif Davis, Dept Neurol Surg, Sacramento, CA 95817 USA; Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA		Levin, HS (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 6560 Fannin,Ste 1144, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu	Butters, Meryl/AAR-2863-2021; Kareken, David/Z-1960-2019	Kareken, David/0000-0003-0855-8300	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889, NS-32786] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [49CCR612707-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS032786, R01NS021889] Funding Source: NIH RePORTER		ACHTE K, 1991, PSYCHOPATHOLOGY, V24, P309, DOI 10.1159/000284731; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BAYLESS JD, 1989, J CLIN EXP NEUROPSYC, V11, P913, DOI 10.1080/01688638908400944; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; BENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285; BENNETT B, 1979, NEUROSURGERY, V4, P283; BENNETT B, 1976, LANCET, V1, P1031; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; CORRIGAN J D, 1990, Brain Injury, V4, P215, DOI 10.3109/02699059009026170; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Foglia JP, 1997, PSYCHOPHARMACOL BULL, V33, P109; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; GASS CS, 1990, PSYCHOL REP, V67, P435, DOI 10.2466/PR0.67.6.435-438; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; GUALTIERI CT, 1991, J CLIN PSYCHOPHARM, V11, P280, DOI 10.1097/00004714-199108000-00027; Hamsher K., 1989, MULTILINGUAL APHASIA; HART RP, 1987, J CONSULT CLIN PSYCH, V55, P101, DOI 10.1037/0022-006X.55.1.101; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; HILLBOM E, 1951, ACTA PSYCHIAT NEUROL, V60, P36; Hilton G, 1990, J Neurosci Nurs, V22, P36; Jane J, 1996, NEUROTRAUMA, P793; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; KARLSSON C, 1968, J NEUROSURG, V29, P242; Kaszniak A. W., 1986, HDB CLIN MEMORY ASSE, P168, DOI 10.1037/10057-014; KAY T, 1988, J HEAD TRAUMA REHAB, V3, P65; KING DA, 1990, SUBCORTICAL DEMENTIA, P218; KIRK C, 1975, LANCET, V1, P1180; KLOVE H, 1973, MED CLIN N AM; Larrabee GJ, 1988, NEUROPSYCHOLOGY, V2, P173, DOI 10.1037//0894-4105.2.3-4.173; LEVIN H S, 1990, Annales de Readaptation et de Medecine Physique, V33, P35; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Luria A.R., 1966, HIGHER CORTICAL FUNC; Luria A.R., 1973, WORKING BRAIN; MATTHEWS CG, 1974, INSTRUCTION MANUAL A; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P336; Mulsant BH, 1997, INT J GERIATR PSYCH, V12, P537, DOI 10.1002/(SICI)1099-1166(199705)12:5<537::AID-GPS542>3.3.CO;2-Q; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; OVERALL JE, 1962, PSYCHOL REP, V10, P799; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Silver Jonathan M., 1994, P313; Smeltzer Donald J., 1994, P251; Smith A., 1982, SYMBOL DIGIT MODALIT; Smith A., 1968, LEARN DISORD, V3, P83, DOI 10.1080/13803390591004428; Stevens JP., 1996, APPL MULTIVARIATE ST; SULTZER DL, 1995, J NEUROPSYCH CLIN N, V7, P476; SULTZER DL, 1995, ARCH NEUROL-CHICAGO, V52, P773, DOI 10.1001/archneur.1995.00540320049012; SULTZER DL, 1993, AM J PSYCHIAT, V150, P1806; SULTZER DL, 1995, J PSYCHIATR RES, V29, P185, DOI 10.1016/0022-3956(95)00018-Z; SULTZER DL, 1992, J AM GERIATR SOC, V40, P549, DOI 10.1111/j.1532-5415.1992.tb02101.x; Tabachnick B. G., 1989, USING MULTIVARIATE S; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1016/S0003-9993(00)90114-X; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; VIOLON A, 1987, ACTA NEUROCHIR, V85, P96, DOI 10.1007/BF01456104; Weingartner H., 1986, HDB CLIN MEMORY ASSE, P218, DOI [10.1037/10057-018, DOI 10.1037/10057-018]	69	58	61	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	2001	71	5					643	651		10.1136/jnnp.71.5.643			9	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	486BM	WOS:000171798600017	11606677	Bronze, Green Published			2022-02-06	
J	Hamlin, GP; Cernak, I; Wixey, JA; Vink, R				Hamlin, GP; Cernak, I; Wixey, JA; Vink, R			Increased expression of neuronal glucose transporter 3 but not glial glucose transporter 1 following severe diffuse traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						cerebellum; glucose transport; Glut1; Glut3; neurotrauma	GLUCOSE-TRANSPORTER PROTEINS; GLUT1; ISCHEMIA; LOCALIZATION	Traumatic brain injury results in an increased brain energy demand that is associated with profound changes in brain glycolysis and energy metabolism. Increased glycolysis must be met by increasing glucose supply that, in brain, is primarily mediated by two members of the facilitative glucose transporter family, Glut1 and Glut3. Glut1 is expressed in endothelial cells of the blood-brain barrier (BBB) and also in glia, while Glut3 is the primary glucose transporter expressed in neurons. However, few studies have investigated the changes in glucose transporter expression following traumatic brain injury, and in particular, the neuronal and glial glucose transporter responses to injury. This study has therefore focussed on investigating the expression of the glial specific 45-kDa isoform of Glut1 and neuronal specific Glut3 following severe diffuse traumatic brain injury in rats. Following impact-acceleration injury, Glut3 expression was found to increase by at least 300% as early as 4 h after induction of injury and remained elevated for at least 48 h postinjury. The increase in Glut3 expression was clearly evident in both the cerebral cortex and cerebellum. In contrast, expression of the glial specific 45-kDa isoform of Glut1 did not significantly change in either the cerebral cortex or cerebellum following traumatic injury. We conclude that increased glucose uptake after traumatic brain injury is primarily accounted for by increased neuronal Glut 3 glucose transporter expression and that this increased expression after trauma is part of a neuronal stress response that may be involved in increasing neuronal glycolysis and associated energy metabolism to fuel repair processes.	James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia; Univ Adelaide, Dept Pathol, Adelaide, SA 5001, Australia		Hamlin, GP (corresponding author), James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia.		Wixey, Julie/C-7684-2011; Vink, Robert/S-5616-2019; Vink, Robert/J-7351-2012; Cernak, Ibolja/A-6399-2008	Wixey, Julie/0000-0002-9716-8170; Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X			ASANO T, 1991, J BIOL CHEM, V266, P24632; Bastian A., 1999, FUNDAMENTAL NEUROSCI, P973; BELL GI, 1993, J BIOL CHEM, V268, P19161; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BONDY CA, 1992, MOL CELL NEUROSCI, V3, P305, DOI 10.1016/1044-7431(92)90027-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruckner BA, 1999, METABOLISM, V48, P422, DOI 10.1016/S0026-0495(99)90098-7; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Cornford EM, 1996, J NEUROTRAUM, V13, P523, DOI 10.1089/neu.1996.13.523; Devaskar SU, 1999, BRAIN RES, V823, P113, DOI 10.1016/S0006-8993(99)01143-9; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; Duelli R, 1999, BRAIN RES, V831, P254, DOI 10.1016/S0006-8993(99)01463-8; GERHART DZ, 1995, NEUROSCIENCE, V66, P237, DOI 10.1016/0306-4522(94)00544-F; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; GOODMAN JC, 1997, J NEUROTRAUM, V14, P785; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; HOVDA DA, 1996, NEUROTRAUMA, P1450; KLIP A, 1994, FASEB J, V8, P43, DOI 10.1096/fasebj.8.1.8299889; Koehler-Stec EM, 2000, J CEREBR BLOOD F MET, V20, P192, DOI 10.1097/00004647-200001000-00024; Lee DH, 2000, DIABETES RES CLIN PR, V47, P15, DOI 10.1016/S0168-8227(99)00107-2; LEE WH, 1993, ENDOCRINOLOGY, V133, P2540, DOI 10.1210/en.133.6.2540; Leino RL, 1997, J NEUROSCI RES, V49, P617; MAHER F, 1993, J CEREBR BLOOD F MET, V13, P342, DOI 10.1038/jcbfm.1993.43; MAHER F, 1994, FASEB J, V8, P1003, DOI 10.1096/fasebj.8.13.7926364; MAHER F, 1995, J NEUROSCI RES, V42, P459, DOI 10.1002/jnr.490420404; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Massa SM, 1996, CEREBROVAS BRAIN MET, V8, P95; McCall AL, 1996, J CEREBR BLOOD F MET, V16, P69, DOI 10.1097/00004647-199601000-00008; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MURAKAMI T, 1992, J BIOL CHEM, V267, P9300; Thach WT, 1998, NEUROBIOL LEARN MEM, V70, P177, DOI 10.1006/nlme.1998.3846; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; Urabe T, 1996, J NEUROCHEM, V67, P265; Vannucci SJ, 1998, DEV BRAIN RES, V107, P255, DOI 10.1016/S0165-3806(98)00021-2; Vannucci SJ, 1997, GLIA, V21, P2, DOI 10.1002/(SICI)1098-1136(199709)21:1<2::AID-GLIA2>3.0.CO;2-C; VANNUCCI SJ, 1994, J NEUROCHEM, V62, P240; Vink R, 2000, FRONT BIOSCI, V5, pD656, DOI 10.2741/Vink; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	39	58	59	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2001	18	10					1011	1018		10.1089/08977150152693700			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	484NG	WOS:000171696000004	11686488				2022-02-06	
J	Bryant, RA; Marosszeky, JE; Crooks, J; Baguley, IJ; Gurka, JA				Bryant, RA; Marosszeky, JE; Crooks, J; Baguley, IJ; Gurka, JA			Posttraumatic stress disorder and psychosocial functioning after severe traumatic brain injury	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article							CLOSED-HEAD INJURY; PSYCHIATRIC-DISORDERS; SCALE; PSEUDOMEMORIES; DEFICITS	The aim of this study was to investigate the influence of posttraumatic stress disorder (PTSD) on rehabilitation after severe traumatic brain injury (TBI). Ninety-six patients with severe TBI patients were assessed 6 months after hospital discharge with the Posttraumatic Stress Disorder Interview, the Functional Assessment Measure (FAM), the Community Integration Questionnaire (CIQ), the Overt Aggression Scale (OAS), the General Health Questionnaire (GHQ), the Beck Depression inventory (BDI), and the Satisfaction with Life Scale (SWL). PTSD was diagnosed in 27% of patients. Patients with PTSD reported higher scores on the GHQ and BDI, and lower scores on the FAM, CIQ, GAS, and SWLS than those without PTSD. Effective rehabilitation after severe TBI may be enhanced by management of PTSD.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Westmead Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia		Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Bryant, Richard/AAA-6479-2019; Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Bryant, Richard/0000-0002-9607-819X; Baguley, Ian J/0000-0001-5650-3705; 			Barrett DH, 1996, J ABNORM PSYCHOL, V105, P575, DOI 10.1037/0021-843X.105.4.575; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BREMNER JD, 1993, AM J PSYCHIAT, V150, P1015; BRYAN S, 1995, HEALTH POLICY, V33, P31, DOI 10.1016/0168-8510(94)00699-F; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; Bryant RA, 1998, APPL COGNITIVE PSYCH, V12, P81, DOI 10.1002/(SICI)1099-0720(199802)12:1<81::AID-ACP507>3.0.CO;2-8; BRYANT RA, IN PRESS CLIN PSYCHO; Chemtob CM, 1997, J TRAUMA STRESS, V10, P17, DOI 10.1002/jts.2490100104; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Duncan-Jones P., 1981, NEUROSIS SOCIAL ENV; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Hall K, 1992, NEUROREHABILITATION, V2, P98, DOI DOI 10.3233/NRE-1992-2410; King LA, 1998, J PERS SOC PSYCHOL, V74, P420, DOI 10.1037/0022-3514.74.2.420; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; MILLER L, 1994, J OFFENDER REHABILIT, V21, P91, DOI DOI 10.1300/J076; Norris Fran H., 1997, P7; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P318; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Silver J M, 1991, J Neuropsychiatry Clin Neurosci, V3, pS22; Valentiner DP, 1996, J ABNORM PSYCHOL, V105, P455, DOI 10.1037/0021-843X.105.3.455; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Warda G, 1998, BEHAV RES THER, V36, P1177, DOI 10.1016/S0005-7967(98)00071-0; WATSON CG, 1991, J CLIN PSYCHOL, V47, P179, DOI 10.1002/1097-4679(199103)47:2<179::AID-JCLP2270470202>3.0.CO;2-P; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	36	58	59	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	FEB	2001	189	2					109	113		10.1097/00005053-200102000-00006			5	Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	402YK	WOS:000167015600006	11225683				2022-02-06	
J	Engberg, AW; Teasdale, TW				Engberg, AW; Teasdale, TW			Traumatic brain injury in Denmark 1979-1996. A national study of incidenceand mortality	EUROPEAN JOURNAL OF EPIDEMIOLOGY			English	Article						epidemiology; primary prevention; traumatic brain injury	HEAD-INJURY; EPIDEMIOLOGY; TRENDS	In order to describe and analyse the development of the incidence of traumatic brain injury (TBI) in Denmark for different age groups of the two genders from 1979 through 1993 (for fatal injuries through 1996), a computerised search corresponding to diagnoses ICD 8th ed., 800, 801, 803, 850-854 from 1979 through 1993 was carried through in the national hospital register. Each person was counted only once, according to the most serious injury during the study period. For fatal cases, the search was extended till 1996. From 1979-1981 to 1991-1993, the total age-adjusted incidence of persons hospitalised under diagnoses ICD 800, 801, 803, 850-854 decreased 41% from 265 to 157 per 100,000 of the population per year. Decreases were 42% for ICD 850, brain concussion, 56% for ICD 800, 801, 803, cranial fractures, and 16% for ICD 851-854, structural brain injury. The percentage of cases with ICD 851-854 increased from 8.4 to 11.7% of the total. From 1979-1981 to 1985-1987 there was a 2% decrease in fatal TBI in and outside hospital (from 14.68 to 14.35 per 100,000), against a total 27% decrease to 10.67 in 1994-1996. For diagnoses ICD 851-854 and for fatal cases, significantly accelerating decreases from 1985-1987 were found only for the younger age groups. Consequently, in the period from 1979 to 1993, the mean age at injury increased by 10 years for persons hospitalised under diagnoses ICD 851-854. Decreases may be explained partly by changing admission and other hospital practices, and partly by the effect of comprehensive national preventive programs launched at the middle of the study period, the effect of which seemed to vary by age group and gender.	Univ Copenhagen Hosp, Hvidovre Hosp, Div Neurol Rehabil 231, Ctr Med, DK-2650 Hvidovre, Denmark		Engberg, AW (corresponding author), Univ Copenhagen Hosp, Hvidovre Hosp, Div Neurol Rehabil 231, Ctr Med, DK-2650 Hvidovre, Denmark.						ALS E, 1958, Ugeskr Laeger, V120, P857; Andersen TF, 1999, DAN MED BULL, V46, P263; ANNEGERS JF, 1980, NEUROLOGY, V30, P186; Annoni J M, 1992, Disabil Rehabil, V14, P23; BAY NH, 1991, 1 EHLASS FORBR; *BORNS SIKK, 1988, CAMP ORG NAT CONS AG; Engberg A, 1998, EUR J EPIDEMIOL, V14, P165, DOI 10.1023/A:1007492025190; Engberg A W, 2001, Ugeskr Laeger, V163, P3755; Engberg A W, 2001, Ugeskr Laeger, V163, P3757; Engberg Aase, 1995, Acta Neurologica Scandinavica, V92, P1; *FAERDS, 1988, 1157 FAERDS; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MCKENZIE EJ, 1989, MARYLAND MED J, V38, P725; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; *NAT BUR HLTH, 1981, SUNDH DODS KONG DANM; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1996, WESTERN J MED, V165, P192; World Health Organization, INT CLASS DIS	23	58	58	0	1	KLUWER ACADEMIC PUBL	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0393-2990			EUR J EPIDEMIOL	Eur. J. Epidemiol.		2001	17	5					437	442		10.1023/A:1013733107520			6	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	510KZ	WOS:000173208400007	11855577				2022-02-06	
J	Graber, KD; Prince, DA				Graber, KD; Prince, DA			Tetrodotoxin prevents posttraumatic epileptogenesis in rats	ANNALS OF NEUROLOGY			English	Article							TEMPORAL-LOBE EPILEPSY; PROPHYLACTICALLY ADMINISTERED PHENYTOIN; POST-TRAUMATIC SEIZURES; DENTATE GRANULE; KINDLING MODEL; GROWTH-FACTOR; BRAIN INJURY; IN-VITRO; SYNAPTIC TRANSMISSION; NEUROTROPHIC FACTOR	Severe cortical trauma frequently causes epilepsy that develops after a long latency. We hypothesized that plastic changes in excitability during this latent period might be initiated or sustained by the level of neuronal activity in the injured cortex. We therefore studied effects of action potential blockade by application of tetrodotoxin (TTX) to areas of cortical injury in a model of chronic epileptogenesis. Partially isolated islands of sensorimotor cortex were made in 28- to 30-day-old male Sprague-Dawley rats and thin sheets of Elvax polymer containing TTX or control vehicle were implanted over lesions. Ten to 15 days later neocortical slices were obtained through isolates for electrophysiological studies. Slices from all animals (n = 12) with lesions contacted by control-Elvax (58% of 36 slices) exhibited evoked epileptiform field potentials, and those hom 4 rats had spontaneous epileptiform events. Only 2 of 11 lesioned animals and 6% of slices from cortex exposed to TTX in vivo exhibited evoked epileptiform potentials, and no spontaneous epileptiform events were observed. There was no evidence of residual TTX during recordings. TTX-Elvax was ineffective in reversing epileptogenesis when implanted 11 days after cortical injury. These data suggest that development of anti-epileptogenic drugs for humans may be possible.	Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA		Prince, DA (corresponding author), Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Room M016, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012151, P50NS012151] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12151, NS 06477] Funding Source: Medline		ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ASPRODINI EK, 1992, J PHARMACOL EXP THER, V262, P1011; Buhl EH, 1996, SCIENCE, V271, P369, DOI 10.1126/science.271.5247.369; Burack MA, 1995, EPILEPSY RES, V22, P115, DOI 10.1016/0920-1211(95)00030-5; BUSH PC, 1999, IN PRESS J NEUROPHYS; Carmignoto G, 1997, J PHYSIOL-LONDON, V498, P153, DOI 10.1113/jphysiol.1997.sp021848; CHIAIA NL, 1994, DEV BRAIN RES, V79, P301, DOI 10.1016/0165-3806(94)90136-8; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; DICHTER MA, 1987, SCIENCE, V237, P157, DOI 10.1126/science.3037700; DRAGUNOW M, 1992, MOL BRAIN RES, V13, P119, DOI 10.1016/0169-328X(92)90051-C; ECHLIN FA, 1963, ARCH NEUROL-CHICAGO, V9, P154, DOI 10.1001/archneur.1963.00460080064009; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FARIELLO RG, 1989, EPILEPSY RES, V3, P206, DOI 10.1016/0920-1211(89)90025-9; GALL CM, 1993, EXP NEUROL, V124, P150, DOI 10.1006/exnr.1993.1186; Gibbs JW, 1997, J NEUROPHYSIOL, V77, P1924, DOI 10.1152/jn.1997.77.4.1924; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; GODDARD GV, 1983, TRENDS NEUROSCI, V6, P275, DOI 10.1016/0166-2236(83)90118-2; Gold SJ, 1996, J COMP NEUROL, V365, P541; GOLDENSOHN ES, 1984, EPILEPSIA, V25, pS156, DOI 10.1111/j.1528-1157.1984.tb05648.x; GRIGONIS AM, 1994, DEV BRAIN RES, V77, P251, DOI 10.1016/0165-3806(94)90200-3; HALPERN LM, 1972, EXPT MODELS EPILEPSY, P197; Hernandez TD, 1997, NEUROLOGY, V48, P803, DOI 10.1212/WNL.48.4.803; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762, DOI 10.1152/jn.1994.71.5.1762; HOFFMAN WH, 1989, J NEUROSCI, V9, P206; HOLTZMAN DM, 1995, J NEUROSCI, V15, P7062; INNOCENTI G M, 1991, Journal of Neural Transplantation and Plasticity, V2, P29; Jacobs KM, 1996, CEREB CORTEX, V6, P514, DOI 10.1093/cercor/6.3.514; Jacobs KM, 1999, J NEUROPHYSIOL, V81, P159, DOI 10.1152/jn.1999.81.1.159; KRNJEVIC K, 1970, ELECTROEN CLIN NEURO, V29, P269, DOI 10.1016/0013-4694(70)90139-2; Liang FY, 1997, J NEUROSCI, V17, P2168; Lowenstein DH, 1996, NEUROSCIENCE, V74, P1197, DOI 10.1016/S0306-4522(96)00226-6; LYNCH JJ, 1995, J PHARMACOL EXP THER, V273, P554; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; McNamara J O, 1992, Adv Neurol, V57, P555; MCNAMARA JO, 1980, PROG NEUROBIOL, V15, P139, DOI 10.1016/0301-0082(80)90006-4; MCNAMARA RK, 1995, MOL BRAIN RES, V33, P22, DOI 10.1016/0169-328X(95)00083-5; MIKATI MA, 1994, ANN NEUROL, V36, P425, DOI 10.1002/ana.410360314; MODY I, 1987, NATURE, V326, P701, DOI 10.1038/326701a0; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; Niessen C. E., 1997, Society for Neuroscience Abstracts, V23, P1687; PATEL MN, 1995, NEUROSCIENCE, V69, P763, DOI 10.1016/0306-4522(95)00281-M; POLLARD H, 1994, NEUROSCIENCE, V61, P773, DOI 10.1016/0306-4522(94)90401-4; Prince D A, 1965, Epilepsia, V6, P226, DOI 10.1111/j.1528-1157.1965.tb03791.x; Prince D A, 1986, Adv Neurol, V44, P275; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276, DOI 10.1152/jn.1993.69.4.1276; PRINCE DA, IN PRESS BASIC MECHA; Prince David A., 1995, P3; PURPURA DP, 1972, EXPT MODELS EPILEPSY; Rice A, 1996, P NATL ACAD SCI USA, V93, P9665, DOI 10.1073/pnas.93.18.9665; Rice AC, 1998, BRAIN RES, V782, P240, DOI 10.1016/S0006-8993(97)01285-7; RUTLEDGE LT, 1967, ELECTROEN CLIN NEURO, V23, P256, DOI 10.1016/0013-4694(67)90122-8; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salin P, 1995, J NEUROSCI, V15, P8234; SATO M, 1990, ELECTROEN CLIN NEURO, V76, P459, DOI 10.1016/0013-4694(90)90099-6; Schwartzkroin Philip A., 1995, P276; Sharpless SK, 1969, BASIC MECH EPILEPSIE, P329; Shatz CJ, 1996, P NATL ACAD SCI USA, V93, P602, DOI 10.1073/pnas.93.2.602; SILBERSTEIN GB, 1982, DEV BIOL, V93, P272, DOI 10.1016/0012-1606(82)90259-7; SILVER JM, 1991, ANN NEUROL, V29, P356, DOI 10.1002/ana.410290404; STASHEFF SF, 1989, SCIENCE, V245, P648, DOI 10.1126/science.2569762; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; Sutula T, 1996, J NEUROSCI, V16, P7398; SUZUKI H, 1964, ELECTROEN CLIN NEURO, V17, P405, DOI 10.1016/0013-4694(64)90164-6; Temkin N R, 1998, Adv Neurol, V76, P179; Temkin Nancy R., 1997, Epilepsia, V38, P102; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; VANDERZEE CEE, 1995, J NEUROSCI, V15, P5316; WADA JA, 1976, ARCH NEUROL-CHICAGO, V33, P426, DOI 10.1001/archneur.1976.00500060032008; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, CHILD BRAIN, V10, P185	70	58	58	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0364-5134			ANN NEUROL	Ann. Neurol.	AUG	1999	46	2					234	242		10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	224BU	WOS:000081876900013	10443889				2022-02-06	
J	Truettner, J; Schmidt-Kastner, R; Busto, R; Alonso, OF; Loor, JY; Dietrich, WD; Ginsberg, MD				Truettner, J; Schmidt-Kastner, R; Busto, R; Alonso, OF; Loor, JY; Dietrich, WD; Ginsberg, MD			Expression of brain-derived neurotrophic factor, nerve growth factor, and heat shock protein HSP70 following fluid percussion brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						brain-derived neurotrophic factor; HSP70; in situ hybridization; nerve growth factor; traumatic brain injury	CORTICAL IMPACT INJURY; FOREBRAIN CHOLINERGIC NEURONS; FOCAL CEREBRAL-ISCHEMIA; FACTOR MESSENGER-RNA; C-FOS; GENE-EXPRESSION; GLUCOSE-UTILIZATION; HIPPOCAMPAL DAMAGE; RAPID INCREASE; TIME-COURSE	Traumatic brain injury can induce the expression of stress-related and neurotrophic genes both within the injury site and in distant regions, These genes may affect severity of damage and/or be neuroprotective. We used in situ hybridization to assess the alterations in expression of the heat shock protein HSP70, nerve growth factor (NGF), and brain-derived neurotrophic factor (BDNF) genes in rat brain following moderate fluid-percussion (F-P) injury at various survival times, HSP70 gene expression was induced at and surrounding the injury site as early as 30 min after trauma, This elevated signal spread ventrally and laterally through the ipsilateral cortex and into the underlying white matter over the next few hours. In addition, there was elevated expression in the temporal hippocampus. BDNF was strongly upregulated in the granular cells of the dentate gyrus and in the CA3 hippocampus 2-6 h after injury, Cortical regions at and near the injury site showed no response at the mRNA level. NGF mRNA increased over the granular cells of the dentate gyrus at early time points, There was also a weaker secondary induction of the NGF gene in the contralateral dentate gyrus of some animals, Cortical response was observed in the entorhinal cortex, bilaterally, but not at the injury site. All three of the studied genes responded quickly to injury, as early as 30 min, The induction of gene expression for neurotrophins in regions remote from areas with histopathology may reflect coupling of gene expression to neuronal excitation, which may be associated with neuroprotection and plasticity.	Univ Miami, Sch Med, Dept Neurol D4 5, Cerebral Vasc Dis Res Ctr, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Neurol, Neurotrauma Res Ctr, Miami, FL 33101 USA		Truettner, J (corresponding author), Univ Miami, Sch Med, Dept Neurol D4 5, Cerebral Vasc Dis Res Ctr, POB 016960, Miami, FL 33101 USA.	Jessie@stroke.med.miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS005820, P50NS005820, P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-30291, NS-05820] Funding Source: Medline		Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BALLARIN M, 1991, EXP NEUROL, V114, P35, DOI 10.1016/0014-4886(91)90082-N; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; BURES J, 1974, MORPHOLOGICAL DEV AS, P115; Busto R, 1997, J NEUROTRAUM, V14, P35, DOI 10.1089/neu.1997.14.35; CHOPP M, 1991, ACTA NEUROPATHOL, V83, P66, DOI 10.1007/BF00294432; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; COMELLI MC, 1993, NEUROSCIENCE, V55, P473, DOI 10.1016/0306-4522(93)90517-J; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dutcher SA, 1998, J NEUROTRAUM, V15, P411, DOI 10.1089/neu.1998.15.411; ERNFORS P, 1991, NEURON, V7, P165, DOI 10.1016/0896-6273(91)90084-D; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; GALL CM, 1993, EXP NEUROL, V124, P150, DOI 10.1006/exnr.1993.1186; Gingrich JR, 1998, ANNU REV NEUROSCI, V21, P377, DOI 10.1146/annurev.neuro.21.1.377; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; GONZALEZ MF, 1989, MOL BRAIN RES, V6, P93, DOI 10.1016/0169-328X(89)90033-8; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hoshino S, 1996, BRAIN RES, V711, P73, DOI 10.1016/0006-8993(95)01329-6; IKEDA J, 1994, MOL BRAIN RES, V26, P249, DOI 10.1016/0169-328X(94)90097-3; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KIESSLING M, 1994, BRAIN PATHOL, V4, P77; KINOUCHI H, 1993, J CEREBR BLOOD F MET, V13, P105, DOI 10.1038/jcbfm.1993.13; Klocker N, 1998, J NEUROSCI, V18, P1038; Kobayashi NR, 1996, EUR J NEUROSCI, V8, P1018, DOI 10.1111/j.1460-9568.1996.tb01588.x; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; KOKAIA Z, 1994, EUR J NEUROSCI, V6, P587, DOI 10.1111/j.1460-9568.1994.tb00303.x; KOKAIA Z, 1993, MOL BRAIN RES, V19, P277, DOI 10.1016/0169-328X(93)90126-A; KOKAIA Z, 1995, EXP NEUROL, V136, P73, DOI 10.1006/exnr.1995.1085; LAUTERBORN JC, 1994, EXP NEUROL, V125, P22, DOI 10.1006/exnr.1994.1003; Leonard JR, 1997, EXP NEUROL, V143, P177, DOI 10.1006/exnr.1996.6366; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LONGO FM, 1993, J NEUROSCI RES, V36, P325, DOI 10.1002/jnr.490360310; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Massa SM, 1996, CEREBROVAS BRAIN MET, V8, P95; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; METSIS M, 1993, P NATL ACAD SCI USA, V90, P8802, DOI 10.1073/pnas.90.19.8802; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Murray KD, 1996, NEUROSCIENCE, V70, P617, DOI 10.1016/S0306-4522(96)83002-8; NOWAK TS, 1993, PROG BRAIN RES, V96, P195; NOWAK TS, 1994, BRAIN PATHOL, V4, P67; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; Plumier JCL, 1997, J CEREBR BLOOD F MET, V17, P781; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; RINK A, 1995, AM J PATHOL, V147, P1575; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SchmidtKastner R, 1996, EXP BRAIN RES, V107, P331; SchmidtKastner R, 1996, NEUROSCIENCE, V74, P161, DOI 10.1016/0306-4522(96)00093-0; SIMON RP, 1991, J NEUROSCI, V11, P881; SINSON G, 1995, J NEUROCHEM, V65, P2209; SLOVITER RS, 1993, J COMP NEUROL, V330, P337, DOI 10.1002/cne.903300305; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; WHITTEMORE SR, 1988, J NEUROSCI RES, V20, P403, DOI 10.1002/jnr.490200402; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuen EC, 1996, ANN NEUROL, V40, P346, DOI 10.1002/ana.410400304	84	58	64	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1999	16	6					471	486		10.1089/neu.1999.16.471			16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	206LD	WOS:000080879800004	10391364				2022-02-06	
J	Chatzipanteli, K; Wada, K; Busto, R; Dietrich, WD				Chatzipanteli, K; Wada, K; Busto, R; Dietrich, WD			Effects of moderate hypothermia on constitutive and inducible nitric oxide synthase activities after traumatic brain injury in the rat	JOURNAL OF NEUROCHEMISTRY			English	Article						hypothermia; nitric oxide; constitutive nitric oxide synthase; inducible nitric oxide synthase; fluid-percussion brain injury	CEREBRAL BLOOD-FLOW; MILD HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; RADICAL PRODUCTION; NEUROTOXICITY; TEMPERATURE; PROTECTION; INHIBITION; ISCHEMIA; PHOSPHORYLATION	We investigated the effects of therapeutic hypothermia (30 degrees C) on alterations in constitutive (cNOS) and inducible (iNOS) nitric oxide synthase activities following traumatic brain injury (TBI). Male Sprague-Dawley rats were anesthetized with 0.5% halothane and underwent moderate (1.8-2.2 atm) parasagittal fluid-percussion (F-P) brain injury. In normothermic rats (37 degrees C) the enzymatic activity of cNOS was significantly increased at 5 min within the injured cerebral cortex compared with contralateral values (286.5 +/- 68.9% of contralateral value; mean +/- SEM). This rise in nitric oxide synthase activity was significantly reduced with pretraumatic hypothermia (138.8 +/- 17% of contralateral value; p < 0.05). At 3 and 7 days after normothermic TBI the enzymatic activity of cNOS was decreased significantly (30 +/- 8.4 and 28.6 +/- 20.9% of contralateral value, respectively; p < 0.05). However, immediate posttraumatic hypothermia (3 h at 30 degrees C) preserved cNOS activity at 3 and 7 days (69.5 +/- 23.3 and 78.6 +/- 7.6% of contralateral value, respectively; mean +/- SEM; p < 0.05). Posttraumatic hypothermia also significantly reduced iNOS activity at 7 days compared with normothermic rats (0.021 +/- 0.06 and 0.23 +/- 0.06 pmol/mg of protein/min, respectively; p < 0.05). The present results indicate that hypothermia (a) decreases early cNOS activation after TBI, (b) preserves cNOS activity at later periods, and (c) prevents the delayed induction of iNOS. Temperature-dependent alterations in cNOS and iNOS enzymatic activities may participate in the neuroprotective effect of hypothermia in this TBI model.	Univ Miami, Sch Med, Dept Neurol & Neurol Surg, Miami, FL 33101 USA		Chatzipanteli, K (corresponding author), Univ Miami, Sch Med, Dept Neurol D4 5, POB 016960, Miami, FL 33101 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30291] Funding Source: Medline		Alagarsamy S, 1998, J NEUROTRAUM, V15, P627, DOI 10.1089/neu.1998.15.627; ALBINA JE, 1993, J IMMUNOL, V150, P5080; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CORBETT D, 1990, BRAIN RES, V514, P300, DOI 10.1016/0006-8993(90)91424-F; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DAWSON TM, 1995, ANN NEUROL, V37, P115, DOI 10.1002/ana.410370122; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Dawson VL, 1996, J CHEM NEUROANAT, V10, P179, DOI 10.1016/0891-0618(96)00148-2; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1996, ADV NEUROL, V71, P177; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286, DOI 10.1152/ajpregu.1995.268.1.R286; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KADER A, 1994, NEUROSURGERY, V35, P272, DOI 10.1227/00006123-199408000-00013; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Lu YC, 1997, MOL CHEM NEUROPATHOL, V30, P125, DOI 10.1007/BF02815154; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; SUZUKI S, 1995, J NEUROSURG, V83, P862, DOI 10.3171/jns.1995.83.5.0862; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; Young W, 1988, J Neurotrauma, V5, P219, DOI 10.1089/neu.1988.5.219; ZILLES L, 1985, CORTEX BRAIN STEREOT	46	58	60	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	1999	72	5					2047	2052		10.1046/j.1471-4159.1999.0722047.x			6	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	186WJ	WOS:000079753400030	10217283	Bronze			2022-02-06	
J	Tarantino, CA; Dowd, MD; Murdock, TC				Tarantino, CA; Dowd, MD; Murdock, TC			Short vertical falls in infants	PEDIATRIC EMERGENCY CARE			English	Article						pediatric emergency medicine; emergency medicine; accidental falls; injuries; infants	CHILDREN FALL; INJURIES; BED	Objective: To define injuries from short vertical falls (SVF) in infants, and to compare those with minor or no injuries to those with significant injury. Design: Descriptive, retrospective chart review. Setting: Pediatric emergency department (PED) of an urban teaching hospital. Subjects: Infants less than or equal to 10 months treated between January 1990 and December 1992 presenting with a SVF (less than or equal to 4 feet). Results: 167 patients met the definition. The mean age was 5.2 months; 56% were male. The mechanisms of injury included rolling off a bed (55%), being dropped from a caretaker's arms (20%), rolling off a couch (16%), and falling from other objects (10%). The majority of patients (85%) had minor or no injury. Significant injuries were sustained by 15% (n = 25), including 16 with a closed head injury (12 with skull fractures), two with intracranial bleed, and seven with a long bone fracture. Subsequently, the two patients with intracranial hemorrhages were confirmed as being from child abuse. After excluding cases of suspected abuse, the only characteristic found to be independently associated with significant injury was being dropped by the caretaker (odds ratio: 6.4 vs rolling or falling from furniture, 95% CI: 2.0, 21.5). Conclusion: The most common mechanism of a SVF was rolling off a bed. Most patients sustained minor or no injury. No child sustained an intracranial hemorrhage from a SVF, The child with intracranial injury and/or multiple injuries warrants an investigation. Being dropped appears to be a greater risk for significant injury than rolling off or falling from furniture.	Childrens Mercy Hosp, Div Emergency Med, Dept Pediat, Kansas City, MO 64108 USA		Tarantino, CA (corresponding author), Childrens Mercy Hosp, Div Emergency Med, Dept Pediat, 2401 Gillham Rd, Kansas City, MO 64108 USA.						*CDC, 1994, EP INF VERS 6; CHADWICK DL, 1991, J TRAUMA, V31, P1353, DOI 10.1097/00005373-199110000-00006; CHIAVIELLO CT, 1994, PEDIATRICS, V94, P679; DUHAIME AC, 1992, PEDIATRICS, V90, P179; GUYER B, 1990, AM J DIS CHILD, V144, P649, DOI 10.1001/archpedi.1990.02150300047016; HALL JR, 1989, J TRAUMA, V29, P12723; HELFER RE, 1977, PEDIATRICS, V60, P533; JOFFE M, 1988, PEDIATRICS, V82, P457; LYONS TJ, 1993, PEDIATRICS, V92, P125; NIMITYONGSKUL P, 1987, J PEDIATR ORTHOPED, V7, P184, DOI 10.1097/01241398-198703000-00014; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; *STAT EP RES CORP, 1993, EGRET REV 4; WILLIAMS RA, 1991, J TRAUMA, V31, P1350, DOI 10.1097/00005373-199110000-00005	13	58	59	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-5161			PEDIATR EMERG CARE	Pediatr. Emerg. Care	FEB	1999	15	1					5	8		10.1097/00006565-199902000-00002			4	Emergency Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine; Pediatrics	168XJ	WOS:000078718200002	10069302				2022-02-06	
J	Armstead, WM				Armstead, WM			Superoxide generation links protein kinase C activation to impaired ATP-sensitive K+ channel function after brain injury	STROKE			English	Article						cerebral circulation; newborn; nitric oxide	PIAL ARTERY VASODILATION; CEREBRAL ARTERIOLES; SMOOTH-MUSCLE; HEAD-INJURY; RESPONSES; DISMUTASE; ISCHEMIA; NEWBORN; PIGLETS; OXYGEN	Background and Purpose-Endothelin-1, in concentrations similar to that present in cerebrospinal fluid after fluid percussion brain injury (FPI), increases superoxide anion (P-2(-)) production. Endothelin-l also contributes to altered cerebral hemodynamics after FPI through impairment of ATP-sensitive K+ (K-ATP) channel function through protein kinase C (PKC) activation. Generation of O-2(-) additionally occurs after FPI. Nitric oxide and cGMP elicit pial artery dilation through K-ATP channel activation. The present study was designed to determine whether PKC activation generates O-2(-), which, in turn, could link such activation to impaired K-ATP channel function after FPI. Methods-Injury of moderate severity (1.9 to 2.1 atm) was produced by the lateral FPI technique in anesthetized newborn pigs equipped with a closed cranial window. Superoxide dismutase-inhibitable nitroblue tetrazolium (NBT) reduction was determined as an index of O-2(-) generation. Results-Phorbol 12,13-dibutyrate (10(-6) mol/L), a PKC activator, increased superoxide dismutase-inhibitable NET reduction from 1+/-1 to 37+/-5 pmol/mm(2). Staurosporine (10(-7) mol/L), a PKC antagonist, blocked the NET reduction after phorbol 12,13-dibutyrate and blunted the NET reduction observed after FPI (1+/-1 to 15+/-2 versus 1+/-1 to 5+/-1 pmol/mm(2) after FPI in the absence versus presence of staurosporine). Exposure of the cerebral cortex to a xanthine oxidase O-2(-)-generating system increased NET reduction in a manner similar to FPI and blunted pial artery dilation to the K-ATP channel agonists cromakalim and calcitonin gene-related peptide, the nitric oxide releasers sodium nitroprusside and S-nitroso-N-acetylpenicillamine, and the cGMP analogue 8-bromo-cGMP (10+/-1% and 21+/-1% versus 4+/-1% and 9+/-1% for 10(-8) and 10(-6) mol/L cromakalim before and after activated oxygen-generating system exposure). Conclusions-These data show that PKC activation increases O-2(-) production and contributes to such production observed after FPI. These data also show that an activated system that generates an amount of O-2(-) similar to that observed with FPI blunted pial artery dilation to K-ATP channel agonists and nitric oxide/cGMP. These data suggest, therefore, that O-2(-) generation links PKC activation to impaired K-ATP channel function after FPI.	Childrens Hosp Philadelphia, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA		Armstead, WM (corresponding author), Childrens Hosp Philadelphia, Dept Anesthesia, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	armsteaw@mail.med.upenn.edu					Armstead WM, 1996, AM J PHYSIOL-HEART C, V270, pH1272; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1997, STROKE, V28, P2273, DOI 10.1161/01.STR.28.11.2273; Armstead WM, 1996, AM J PHYSIOL-HEART C, V270, pH423, DOI 10.1152/ajpheart.1996.270.2.H423; Bari F, 1996, STROKE, V27, P1874, DOI 10.1161/01.STR.27.10.1874; Bari F, 1996, J CEREBR BLOOD F MET, V16, P1158, DOI 10.1097/00004647-199611000-00010; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; IMAIZUMI S, 1990, STROKE, V21, P1312, DOI 10.1161/01.STR.21.9.1312; Kasemsri T, 1997, AM J PHYSIOL-HEART C, V273, pH2639; Kasemsri T, 1997, STROKE, V28, P190, DOI 10.1161/01.STR.28.1.190; KITAZONO T, 1995, STROKE, V26, P1713, DOI 10.1161/01.STR.26.9.1713; KITAZONO T, 1993, AM J PHYSIOL, V265, pH581, DOI 10.1152/ajpheart.1993.265.2.H581; KONTOS HA, 1985, CIRC RES, V57, P142, DOI 10.1161/01.RES.57.1.142; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kontos HA, 1996, AM J PHYSIOL-HEART C, V271, pH1498, DOI 10.1152/ajpheart.1996.271.4.H1498; Lange A, 1997, J BIOL CHEM, V272, P27345, DOI 10.1074/jbc.272.43.27345; LEFFLER CW, 1989, STROKE, V20, P541, DOI 10.1161/01.STR.20.4.541; LEFFLER CW, 1989, PEDIATR RES, V25, P180; LEFFLER CW, 1990, AM J PHYSIOL, V259, pH1230, DOI 10.1152/ajpheart.1990.259.4.H1230; LESCOHIER I, 1993, PEDIATRICS, V91, P721; MILLER JD, 1994, LANCET, V344, P421; MIYOSHI Y, 1992, CIRC RES, V70, P612, DOI 10.1161/01.RES.70.3.612; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; MURRAY MA, 1992, AM J PHYSIOL, V32, pH1643; Satoh H, 1995, GEN PHARMACOL, V26, P1549, DOI 10.1016/0306-3623(95)00046-1; SHANKAR V, 1995, AM J PHYSIOL-HEART C, V269, pH997, DOI 10.1152/ajpheart.1995.269.3.H997; SMITH NC, 1991, PARASITOL RES, V77, P521, DOI 10.1007/BF00928421; Thorogood MC, 1996, ANESTHESIOLOGY, V84, P614, DOI 10.1097/00000542-199603000-00017; THOROGOOD MC, 1995, AM J PHYSIOL-HEART C, V269, pH1776; WEI EP, 1986, AM J PHYSIOL, V251, pH693, DOI 10.1152/ajpheart.1986.251.4.H693; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1985, CIRC RES, V57, P781, DOI 10.1161/01.RES.57.5.781	33	58	60	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	JAN	1999	30	1					153	159		10.1161/01.STR.30.1.153			7	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	155EW	WOS:000077934200032	9880404	Bronze			2022-02-06	
J	Bernard, SA; Jones, BM; Buist, M				Bernard, SA; Jones, BM; Buist, M			Experience with prolonged induced hypothermia in severe head injury	CRITICAL CARE			English	Article						hypokalaemia; ileus; induced hypothermia; neutropenia; nosocomial pneumonia; septic shock; thrombocytopenia; traumatic brain injury	INTRACRANIAL HYPERTENSION; MODERATE HYPOTHERMIA; BRAIN INJURY; TRAUMA	Background: Recent prospective controlled trials of induced moderate hypothermia (32-34 degrees C) for relatively short periods (24-48 h) in patients with severe head injury have suggested improvement in intracranial pressure control and outcome. It is possible that increased benefit might be achieved if hypothermia was maintained for more periods longer than 48 h, but there is little in the literature on the effects of prolonged moderate hypothermia in adults with severe head injury. We used moderate induced hypothermia (30-33 degrees C) in 43 patients with severe head injury for prolonged periods (mean 8 days, range 2-19 days). Results: Although nosocomial pneumonia (defined in this study as both new chest radiograph changes and culture of a respiratory pathogen from tracheal aspirate) was quite common (45%), death from sepsis was rare (5%). Other findings included hypokalaemia on induction of hypothermia and a decreasing total white cell and platelet count over 10 days. There were no major cardiac arrhythmias. There was a satisfactory neurological outcome in 20 out of 43 patients (47%). Conclusion: Moderate hypothermia may be induced for more prolonged periods, and is a relatively safe and feasible therapeutic option in the treatment of selected patients with severe traumatic brain injury. Thus, further prospective controlled trials using induced hypothermia for longer periods than 48 h are warranted.	Dandenong Hosp, Intens Care Unit, Dandenong, Vic 3175, Australia		Bernard, SA (corresponding author), Dandenong Hosp, Intens Care Unit, David St, Dandenong, Vic 3175, Australia.						BIGGAR WD, 1983, INFECT IMMUN, V40, P708, DOI 10.1128/IAI.40.2.708-712.1983; BLOCH M, 1967, BRAIN, V90, P769, DOI 10.1093/brain/90.4.769; BOHN DJ, 1986, CRIT CARE MED, V14, P529, DOI 10.1097/00003246-198606000-00002; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BONTEN MJM, 1994, CRIT CARE MED, V22, P1683; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CANCIO LC, 1994, RESUSCITATION, V28, P9, DOI 10.1016/0300-9572(94)90049-3; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CURRY DL, 1970, ENDOCRINOLOGY, V87, P750, DOI 10.1210/endo-87-4-750; DARBY J M, 1992, Anesthesiology (Hagerstown), V77, pA295, DOI 10.1097/00000542-199209001-00295; DARBY JM, 1994, CRIT CARE MED, V22, pA71; DELANEY KA, 1989, ANN EMERG MED, V18, P72, DOI 10.1016/S0196-0644(89)80319-1; DEMARIA EJ, 1985, ANN SURG, V202, P248, DOI 10.1097/00000658-198508000-00017; EPSTEIN FM, 1987, HEAD INJURY, P391; FAY T, 1945, RES PUBL ASS NERV ME, V24, P611; FAY T, 1940, NY STATE J MED, V40, P1351; HENDRICK EB, 1959, ARCH SURG-CHICAGO, V79, P362; JURKOVICH GJ, 1987, J TRAUMA, V27, P1019, DOI 10.1097/00005373-198709000-00011; KOHT A, 1983, INTENS CARE MED, V9, P275, DOI 10.1007/BF01691254; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; LAZORTHES G, 1958, J NEUROSURG, V15, P162, DOI 10.3171/jns.1958.15.2.0162; LUNA GK, 1987, J TRAUMA, V27, P1014, DOI 10.1097/00005373-198709000-00010; MACLEAN D, 1974, BMJ-BRIT MED J, V2, P59; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MICHENFELDER JD, 1965, SURG CLIN N AM, V45, P889; ORLOWSKI JP, 1984, CRIT CARE MED, V12, P367, DOI 10.1097/00003246-198404000-00006; PATT A, 1988, SURG CLIN N AM, V68, P775; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; REULER JB, 1978, ANN INTERN MED, V89, P519, DOI 10.7326/0003-4819-89-4-519; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85, DOI 10.1152/ajplegacy.1954.179.1.85; SEDZIMIR CB, 1959, J NEUROSURG, V16, P407, DOI 10.3171/jns.1959.16.4.0407; SHAPIRO HM, 1974, J NEUROSURG, V40, P90, DOI 10.3171/jns.1974.40.1.0090; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SPRUNG J, 1991, CRIT CARE MED, V19, P1545, DOI 10.1097/00003246-199112000-00018; STEEN PA, 1979, STROKE, V10, P522, DOI 10.1161/01.STR.10.5.522; SWAIN JA, 1993, NEW ENGL J MED, V329, P1119, DOI 10.1056/NEJM199310073291511; VALERI CR, 1987, ANN SURG, V205, P175, DOI 10.1097/00000658-198702000-00012	38	58	61	0	4	CURRENT SCIENCE LTD	LONDON	34-42 CLEVELAND STREET, LONDON W1P 6LE, ENGLAND	1466-609X			CRIT CARE	Crit. Care		1999	3	6					167	172		10.1186/cc371			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	271JJ	WOS:000084590200009	11056742	Green Published, gold			2022-02-06	
J	Philips, MF; Muir, JK; Saatman, KE; Raghupathi, R; Lee, VMY; Trojanowski, JQ; McIntosh, TK				Philips, MF; Muir, JK; Saatman, KE; Raghupathi, R; Lee, VMY; Trojanowski, JQ; McIntosh, TK			Survival and integration of transplanted postmitotic human neurons following experimental brain injury in immunocompetent rats	JOURNAL OF NEUROSURGERY			English	Article; Proceedings Paper	Annual Meeting of the American-Association-of-Neurological-Surgeons	APR 25-30, 1998	PHILADELPHIA, PENNSYLVANIA	Amer Assoc Neurol Surgeons		traumatic brain injury; fluid-percussion injury; neuronal development; neural transplantation; inflammation; postmitotic human neuron cells; rat	NEURAL PROGENITOR CELLS; LONG-TERM SURVIVAL; REGION-SPECIFIC DIFFERENTIATION; FETAL MESENCEPHALIC TISSUE; EMBRYONAL CARCINOMA-CELLS; FLUID-PERCUSSION MODEL; CENTRAL-NERVOUS-SYSTEM; PARKINSONS-DISEASE; GROWTH-FACTOR; MOUSE-BRAIN	Object. Limitations regarding cell homogeneity and survivability do not affect neuronlike hNT cells, which are derived from a human teratocarcinoma cell line (Ntera2) that differentiates into postmitotic neurons with exposure to retinoic acid. Because NT2N neurons survive longer than 1 year after transplantation into nude mice brains, the authors grafted these cells into the brains of immunocompetent rats following lateral fluid-percussion brain injury to determine the long-term survivability of NT2N cell grafts in cortices damaged by traumatic brain injury (TBI) and the therapeutic effect of NT2N neurons on cognitive and motor deficits. Methods. Seventy-two adult male Sprague-Dawley rats. each weighing between 340 and 370 g, were given an anesthetic agent and subjected to lateral fluid percussion brain injury of moderate severity (2.2-2.5 atm in 46 rats) or to surgery without TBI (shamoperation, 26 rats). Twenty-four hours postinjury, 10(5) NT2N cells (24 injured animals) or 3 mu l of vehicle (22 injured and 14 control animals) was stereotactically implanted into the periinjured or control cerebral cortex. Motor function was assessed at weekly intervals and all animals were killed at 2 or 4 weeks after their posttraumatic learning ability was assessed using a Morris water maze paradigm. Viable NT2N grafts were routinely observed to extend human neural cell adhesion molecule-(MOC-1)immunoreactive processes into the periinjured cortex at 2 and 4 weeks posttransplantation, although no significant improvement in motor or cognitive function was noted. Inflammation identified around the transplant at both time points was assessed by immunohistochemical identification of macrophages (ED-1) and microglia (isolectin B4). Conclusions. Long-term survival and integration of NT2N cells in the periinjured cortex of immunocompetent rats provides the researcher with an important cellular system that can be used to study maturation, regulation, and neurite outgrowth of transplanted neurons following TBI.	Univ Penn, Dept Neurosurg, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA		McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, Sch Med, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.		Raghupathi, Ramesh/AAX-5538-2021		NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG09215] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, P01-NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS026818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG009215] Funding Source: NIH RePORTER		ANDREWS PW, 1984, LAB INVEST, V50, P147; Belkadi AM, 1997, EXP NEUROL, V144, P369, DOI 10.1006/exnr.1997.6414; Borlongan CV, 1998, EXP NEUROL, V149, P310, DOI 10.1006/exnr.1997.6730; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BRUNDIN P, 1988, EXP BRAIN RES, V70, P192; BRUNDIN P, 1985, EXP BRAIN RES, V60, P204; Butcher SP, 1997, J NEUROSCI, V17, P6939; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Drake M, 1996, ACTA PHYSIOL SCAND, V158, P155, DOI 10.1046/j.1365-201X.1996.535298000.x; Duan WM, 1996, BRAIN RES, V712, P199, DOI 10.1016/0006-8993(95)01409-8; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; FRODL EM, 1994, BRAIN RES, V647, P286, DOI 10.1016/0006-8993(94)91328-5; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Galpern WR, 1996, EXP NEUROL, V140, P1, DOI 10.1006/exnr.1996.0109; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GRABOWSKI M, 1993, ANN NEUROL, V34, P362, DOI 10.1002/ana.410340310; Gritti A, 1996, J NEUROSCI, V16, P1091; HADANI M, 1992, J NEUROTRAUM, V9, P107, DOI 10.1089/neu.1992.9.107; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Honey C R, 1990, Neuroreport, V1, P247, DOI 10.1097/00001756-199011000-00019; Iacovitti L, 1997, NEUROREPORT, V8, P1471, DOI 10.1097/00001756-199704140-00029; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; KLEPPNER SR, 1995, J COMP NEUROL, V357, P618, DOI 10.1002/cne.903570410; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Lacorazza HD, 1996, NAT MED, V2, P424, DOI 10.1038/nm0496-424; LEE VMY, 1986, J NEUROSCI, V6, P514; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; LINDVALL O, 1994, ANN NEUROL, V35, P172, DOI 10.1002/ana.410350208; LINDVALL O, 1997, NEUROREPORT, V8, P3; Lundberg C, 1996, NEUROBIOL DIS, V3, P33, DOI 10.1006/nbdi.1996.0004; Lundberg C, 1996, EXP NEUROL, V139, P39, DOI 10.1006/exnr.1996.0079; MANTIONE JR, 1995, BRAIN RES, V671, P333, DOI 10.1016/0006-8993(94)01400-C; MARTINEZSERRANO A, 1995, NEURON, V15, P473, DOI 10.1016/0896-6273(95)90051-9; MartinezSerrano A, 1997, TRENDS NEUROSCI, V20, P530, DOI 10.1016/S0166-2236(97)01119-3; MartinezSerrano A, 1996, J NEUROSCI, V16, P4604; MARTINEZSERRANO A, 1995, J NEUROSCI, V15, P5668; Mattsson B, 1997, STROKE, V28, P1225, DOI 10.1161/01.STR.28.6.1225; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIYAZONO M, 1995, LAB INVEST, V73, P273; Miyazono M, 1996, J COMP NEUROL, V376, P603, DOI 10.1002/(SICI)1096-9861(19961223)376:4<603::AID-CNE8>3.0.CO;2-5; MOLENAAR WM, 1991, ACTA NEUROPATHOL, V83, P46, DOI 10.1007/BF00294429; Munir M, 1996, J PHARMACOL EXP THER, V276, P819; Munir M, 1995, J NEUROSCI, V15, P7847; Onizuka K, 1996, EXP NEUROL, V137, P324, DOI 10.1006/exnr.1996.0033; Peschanski M, 1996, NEUROSCIENCE, V71, P899, DOI 10.1016/0306-4522(95)00575-7; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; Rothwell NJ, 1996, PHARMACOL THERAPEUT, V69, P85, DOI 10.1016/0163-7258(95)02033-0; Sah DWY, 1997, NAT BIOTECHNOL, V15, P574, DOI 10.1038/nbt0697-574; SAKAI K, 1991, BRAIN RES, V565, P167, DOI 10.1016/0006-8993(91)91750-U; SHIHABUDDIN LS, 1995, J NEUROSCI, V15, P6666; Shihabuddin LS, 1996, EXP NEUROL, V139, P61, DOI 10.1006/exnr.1996.0081; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Snyder Evan Y., 1994, Current Opinion in Neurobiology, V4, P742, DOI 10.1016/0959-4388(94)90018-3; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; SNYDER EY, 1995, NATURE, V374, P367, DOI 10.1038/374367a0; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Soares HD, 1995, J NEUROSCI, V15, P8223; Sorensen JC, 1996, EXP NEUROL, V138, P227, DOI 10.1006/exnr.1996.0061; SPENCER DD, 1992, NEW ENGL J MED, V327, P1541, DOI 10.1056/NEJM199211263272201; SPENCER L, 1996, SIGHT SOUND, V6, P47; TROJANOWSKI JQ, 1993, EXP NEUROL, V122, P283, DOI 10.1006/exnr.1993.1128; Trojanowski JQ, 1997, EXP NEUROL, V144, P92, DOI 10.1006/exnr.1996.6393; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Wenning GK, 1997, ANN NEUROL, V42, P95, DOI 10.1002/ana.410420115; Wu P, 1996, GENE THER, V3, P246; YOUNKIN DP, 1993, P NATL ACAD SCI USA, V90, P2174, DOI 10.1073/pnas.90.6.2174	76	58	60	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JAN	1999	90	1					116	124		10.3171/jns.1999.90.1.0116			9	Clinical Neurology; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	168TH	WOS:000078708400016	10413164				2022-02-06	
J	Mallinson, AI; Longridge, NS				Mallinson, AI; Longridge, NS			Dizziness from whiplash and head injury - Differences between whiplash and head injury	AMERICAN JOURNAL OF OTOLOGY			English	Article						posturography; compensation; whiplash; head injury; dizziness	POSTURAL CONTROL	Objective: Large discrepancies exist in the literature regarding incidence and types of symptomatology in whiplash. This is because of the evolution of whiplash injury over the years with the advent of head rests and seat belts. Previous authors have regarded symptoms of dizziness as a result of brainstem or cerebellar injury or both. it has been difficult in those studies to ascribe a mechanism of injury, as patients with whiplash injury only have been grouped with those who have incurred mild traumatic brain injury as a result of a significant blow to the head. The authors saw the need to delineate patients who had suffered whiplash injury from those who also had suffered mild head injury, as defined in the rehabilitation-neurosurgical literature, to attempt to define differences in symptoms. abnormalities, and mechanisms of recovery in these two groups. Study Design: The study design was a retrospective case review. Setting: The study was conducted at a tertiary-quaternary referral clinic. Patients: The records of 36 patients were reviewed. Nineteen of these patients suffered a whiplash-associated disorder and 17 suffered a mild head injury as well. These patients were referred for assessment of symptoms persisting for at least 2 years after their injury. Patients were excluded if they had not completed clinical assessment, including electronystagmography (ENG) and computerized dynamic posturography (CDP). Interventions: A Full history, otolaryngologic examination, including assessment of eye movements, corneal reflexes and gait, as well as an investigation, including ENG and CDP, and history taking and detailed recording of related complaints immediately before diagnostic work-up were performed. Main Outcome Measures: Symptoms reported by patients who had received either whiplash alone or whiplash plus mild head trauma as defined in thr literature were measured. Patients were classified according to type of accident, type of injury suffered, and degree and nature of posturographic abnormalities. Results: Patients often have similar complaints regardless of whether or not they had suffered a head injury. Although CDP showed abnormalities in both groups, standard ENG assessment, including caloric testing, showed abnormalities only in the head-injured group. The posturographic abnormalities also were analyzed in both groups, and it was found that there was a correlation between the type of posturographic abnormality and the type of injury suffered. Although ENG testing is done routinely, posturography is shown to be more sensitive in picking up abnormalities. In addition, the authors have shown that posturography can delineate the type of injury suffered by exhibiting the compensation strategy used as well as the efficacy of that compensation strategy. Conclusions: Because ENG abnormalities are limited to patients who have suffered a head injury, the inference is that these two groups of patients have suffered damage at different sites along the balance system pathways, but both of these lesions can lead to similar symptoms. Although the mechanisms of whiplash injury and how they affect the vestibular system are poorly understood, posturography testing is essential in inferring how a patient is recovering by measuring how and how well the patient is overcoming his or her deficit. This has important medical legal implications regarding legitimizing a patient's problem, prognostic factors, as well as rehabilitation plans, measures, and outcomes.	Univ British Columbia, Dept Surg, Div Otolaryngol, Vancouver, BC V5Z 1M9, Canada; Vancouver Gen Hosp, Neurotol Unit, Vancouver, BC, Canada		Longridge, NS (corresponding author), Univ British Columbia, Dept Surg, Div Otolaryngol, WP 4,805 W 12 Ave, Vancouver, BC V5Z 1M9, Canada.						BRONSTEIN AM, 1986, EXP BRAIN RES, V63, P655, DOI 10.1007/BF00237488; BRONSTEIN AM, 1990, BRAIN, V113, P767, DOI 10.1093/brain/113.3.767; CHESTER JB, 1991, SPINE, V16, P716, DOI 10.1097/00007632-199107000-00004; HINOKI M, 1985, ACTA OTOLARYNGOL S S, V419, P9; JANE JA, 1989, MILD MODERATE HEAD I, P1; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; MACNAB I, 1964, J BONE JOINT SURG AM, V46, P1797, DOI 10.2106/00004623-196446080-00021; MALLINSON AI, 1996, J MUSCULOSKELET PAIN, V4, P105, DOI DOI 10.1300/J094V04N04_10; MERTZ HJ, 1967, SAE T, V76, P2952; NASHNER LM, 1985, BEHAV BRAIN SCI, V8, P135, DOI 10.1017/S0140525X00020008; *NEUR INT INC, 1992, EQ INT MAN; Ommaya A.K., 1985, BIOMECHANICS TRAUMA, P245; OOSTERVELD WJ, 1991, ACTA OTO-LARYNGOL, V111, P201, DOI 10.3109/00016489109137375; Paige G D, 1992, J Vestib Res, V2, P133; Persson L, 1996, J VESTIBUL RES-EQUIL, V6, P439; REID SE, 1984, HEAD NECK INJURIES S, P24; RUBIN AM, 1995, AM J OTOL, V16, P216; Shupert CL, 1996, J VESTIBUL RES-EQUIL, V6, P423; STURZENEGGER M, 1994, NEUROLOGY, V44, P688, DOI 10.1212/WNL.44.4.688; Vitte E, 1992, POSTURE GAIT CONTROL, V2, P176	20	58	58	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0192-9763			AM J OTOL	Am. J. Otol.	NOV	1998	19	6					814	818					5	Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED)	Otorhinolaryngology	178BL	WOS:000079245700025	9831160				2022-02-06	
J	Donaghy, S; Wass, PJ				Donaghy, S; Wass, PJ			Interrater reliability of the functional assessment measure in a brain injury rehabilitation program	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							FIM+FAM	Objective: To examine the interrater reliability and completion time of the Functional Assessment Measure, which is the Functional Independence Measure (FIM(TM)) plus additional items (FIM +FAM). Design: Interrater reliability study. Setting: Inpatient rehabilitation units of a postacute care brain injury rehabilitation program. Patients: A convenience sample of 53 extremely severely impaired adult survivors of traumatic brain injuries (40 men, 13 women, mean age 38yrs). Main Outcome Measures: Treatment team members' ratings of the 30 FIM+FAM items, and time taken to complete the FIMS FAM. Results: Intraclass Correlation Coefficients (ICCs) were within the good to excellent range (ICC >.60) for 29 of 30 items and for all subscales except psychosocial adjustment. Higher mean ICC values were obtained for motor domain items than for cognitive/psychosocial domain items. Treatment teams became progressively faster over a 12-week period in completing the FIM+FAM. Conclusions: The generally good to excellent range interrater reliability found in this study helps support the use of the FIM+FAM in rehabilitation settings. Further support was obtained for the finding that motor items are more reliable than cognitive and psychosocial items. Administration of the FIM+FAM can be done in a timely manner in a rehabilitation setting. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Alberta Hosp Ponoka, Brain Injury Rehabil Program, Ponoka, AB T4J 1R8, Canada		Donaghy, S (corresponding author), Alberta Hosp Ponoka, Brain Injury Rehabil Program, POB 1000, Ponoka, AB T4J 1R8, Canada.						ADAMOVICH BLB, 1992, NEUROREHABILITATION, V2, P42; BARTKO JJ, 1976, J NERV MENT DIS, V163, P307, DOI 10.1097/00005053-197611000-00003; CICCHETTI DV, 1991, BEHAV BRAIN SCI, V14, P119, DOI 10.1017/S0140525X00065675; CICCHETTI DV, 1981, AM J MENT DEF, V86, P127; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pS10; HARVEY RF, 1981, ARCH PHYS MED REHAB, V74, P566; McPherson KM, 1996, DISABIL REHABIL, V18, P341, DOI 10.3109/09638289609165892; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Scherer M., 1995, PSYCHOL ASSESSMENT M, P101; *STAT U NY BUFF, 1993, GUID UN DAT SET MED; Wilson BA, 1997, J INT NEUROPSYCH SOC, V3, P487, DOI 10.1017/S1355617797004876	13	58	65	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1998	79	10					1231	1236		10.1016/S0003-9993(98)90267-2			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	128CC	WOS:000076386800007	9779676				2022-02-06	
J	Harrison-Felix, C; Zafonte, R; Mann, N; Dijkers, M; Englander, J; Kreutzer, J				Harrison-Felix, C; Zafonte, R; Mann, N; Dijkers, M; Englander, J; Kreutzer, J			Brain injury as a result of violence: Preliminary findings from the traumatic brain injury model systems	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							CIVILIAN GUNSHOT WOUNDS; SUBSTANCE-ABUSE; HEAD; COMA; MANAGEMENT; SCALE	Objectives: To identify possible risk factors that may predispose individuals to violent traumatic brain injury (TBI) and to determine the effect of etiology of injury on outcomes. Study Design: Prospective, longitudinal multicenter study. Setting: TBI Model Systems (TBIMS) located at Wayne State University/Rehabilitation Institute of Michigan, Detroit, MI; The Institute for Rehabilitation and Research, Houston, TX; Medical College of Virginia, Richmond, VA; and Santa Clara Valley Medical Center, San Jose, CA. Subjects: Individuals treated in the four TBIMS programs between 3/89 and 9/96 who met the criteria for inclusion in the TBIMS National Database and for whom the etiology was known (n = 812). Main Outcome Measures: Functional Independence Measure, Alcohol Quantity Frequency Variability Index, Community Integration Questionnaire. Results: Individuals who incur violence-related TBI tend to be male, nonwhite, unmarried, living alone, less educated, and unemployed at time of injury. They tend to have less severe brain injuries and better motor function at the time of admission to inpatient rehabilitation. At 1 year postinjury, they score lower on community integration measures; however, no difference exists in functional status. Etiology of injury was found to only play a minor role in the prediction of social and productive integration at 1 year postinjury. Conclusions: Survivors of violent and nonviolent TBI have similar functional outcomes; however, they differ in preinjury and postinjury socio-economic characteristics, injury severity, and postinjury community integration. Socio-economic factors appear to play a large role in the risk for violent injury and in community integration following injury. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Wayne State Univ, Rehabil Inst Michigan, Res Dept, Detroit, MI 48201 USA; Santa Clara Valley Med Ctr, San Jose, CA 95128 USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA		Harrison-Felix, C (corresponding author), Wayne State Univ, Rehabil Inst Michigan, Res Dept, 261 Mack Blvd, Detroit, MI 48201 USA.			Dijkers, Marcel/0000-0002-8362-5596			BENZEL EC, 1991, NEUROSURGERY, V29, P67, DOI 10.1227/00006123-199107000-00011; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; *COMM PROF HOSP AC, 1986, INT CLASS DIS; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; COTTON P, 1992, JAMA-J AM MED ASSOC, V267, P1171, DOI 10.1001/jama.267.9.1171; COWAN T, 1995, ARCH PHYS MED REHAB, V76, P797; ELOVIC E, 1996, MED REHABILITATION T, P1; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; JENNETT B, 1990, REHABILITATION ADULT, P3; KAUFMAN HH, 1993, NEUROSURGERY, V32, P962, DOI 10.1227/00006123-199306000-00013; Kraus JF, 1993, HEAD INJURY, P1; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; MERCY JA, 1993, HEALTH AFFAIR, V12, P7, DOI 10.1377/hlthaff.12.4.7; *NAT I DIS REH RES, 1996, J HEAD TRAUMA REHAB, V11, P1; RAMONDI A, 1970, J NEUROSURG, V32, P647; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenberg M. L., 1991, VIOLENCE AM PUBLIC H; SICCARDI D, 1991, SURG NEUROL, V35, P455, DOI 10.1016/0090-3019(91)90179-D; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; STONE JL, 1995, J TRAUMA, V38, P851, DOI 10.1097/00005373-199506000-00002; SUDDABY L, 1987, CAN J NEUROL SCI, V14, P268, DOI 10.1017/S0317167100026597; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; *TRAUM BRAIN INJ M, 1993, J HEAD TRAUMA REHAB, V8, P1; *UB FDN ACT INC, 1993, GUID UN DAT SET MED; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; Zafonte RD, 1997, BRAIN INJURY, V11, P403	34	58	58	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	1998	79	7					730	737		10.1016/S0003-9993(98)90348-3			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	ZZ388	WOS:000074724400002	9685083				2022-02-06	
J	Brauer, P; Kochs, E; Werner, C; Bloom, M; Policare, R; Pentheny, S; Yonas, H; Kofke, WA; Esch, JSA				Brauer, P; Kochs, E; Werner, C; Bloom, M; Policare, R; Pentheny, S; Yonas, H; Kofke, WA; Esch, JSA			Correlation of transcranial Doppler sonography mean flow velocity with cerebral blood flow in patients with intracranial pathology	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						brain; blood flow; blood flow velocity; measurement technique; transcranial Doppler ultrasonography; xenon-enhanced computed tomography; carbon dioxide reactivity; acetazolamide	ULTRASOUND; ACETAZOLAMIDE; ARTERY	Several studies suggest that relative changes in cerebral blood flow (CBF) may be assessed via transcranial Doppler sonography (TCD). The present study investigates the correlation between changes In TCD-mean now velocity (Vm) and changes in CBF in patients with a variety of types intracranial pathology undergoing cerebrovascular reactivity tests. After informed consent was obtained, 32 patients presenting with stenoses of brain-supplying arteries (n = 13), cerebral vascular malformations (n = 6), surgical decompression for subarachnoid hemorrhage (n = 2), brain edema after closed head injury (n = 8), or hepatic encephalopathy (n = 3) were studied. The patients were divided into mio groups for different reactivity tests. Patients in group 1 (awake or sedated, n = 18) received a 1-g dose of acetazolamide intravenously. In group 2 (n = 14), mechanical ventilation was adjusted to produce a 20% decrease in arterial CO2 tension compared with baseline. Regional CBF was measured using xenon-enhanced computed tomography (Xe-CT). Xe-CT scans at the levels of the basal ganglia and the lateral ventricles were performed during a 4.5-min xenon wash-in period. Bilateral flow velocity was measured in the middle cerebral artery using a 2-MHz pulsed TCD system. Mean arterial blood pressure, heart rate, and end-tidal CO2 were continuously recorded during the procedure. After baseline measurements and either alteration of CO2 or application of acetazolamide, the cerebrovascular reactivity was assessed at 20 min by a second measurement of CBF, TCD, and all other physiologic variables. The correlation coefficient for relative changes of MCA territory CBF versus Vm and for the overall population was r = 0.82. In groups 1 and 2, the values were 0.39 and 0.5, respectively. Correlation coefficients did not exceed r = 0.4 in any subgroup-classification based on diagnosis. The close correlation between changes in CBF and Vm (r = 0.82) in patients with heterogenous intracranial pathology seems to show that TCD is a measure of CBF. However, in groups 1 and 2, and in subgroups formed of patients classified according to diagnoses, data dispersion suggests that the actual correlation is weaker. Relation of changes in Vm to those in CBF may depend on the underlying diagnosis. These data indicate that the correlation between Vm and CBF may vary with intracranial pathology.	Univ Hamburg, Hosp Eppendorf, Dept Anesthesiol, D-20246 Hamburg, Germany; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol CCM, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15260 USA		Brauer, P (corresponding author), Univ Hamburg, Hosp Eppendorf, Dept Anesthesiol, Martinistr 52, D-20246 Hamburg, Germany.			Bloom, Marc/0000-0002-8268-3209			AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; ARNOLDS BJ, 1986, ULTRASOUND MED BIOL, V12, P115, DOI 10.1016/0301-5629(86)90016-5; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; GUR D, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P68; HARTMANN A, 1991, NEUROCHIRURGIA, V34, P6; Huber P, 1967, Invest Radiol, V2, P17, DOI 10.1097/00004424-196701000-00016; KIRKHAM FJ, 1986, ULTRASOUND MED BIOL, V12, P15, DOI 10.1016/0301-5629(86)90139-0; KOFKE WA, 1995, STROKE, V26, P1603, DOI 10.1161/01.STR.26.9.1603; KONTOS HA, 1989, STROKE, V20, P1; MARKWALDER TM, 1984, J CEREBR BLOOD F MET, V4, P368, DOI 10.1038/jcbfm.1984.54; MULLER M, 1995, STROKE, V26, P96, DOI 10.1161/01.STR.26.1.96; PIEPGRAS A, 1990, STROKE, V21, P1306, DOI 10.1161/01.STR.21.9.1306; TARR RW, 1990, AM J NEURORADIOL, V11, P441	13	58	60	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	APR	1998	10	2					80	85		10.1097/00008506-199804000-00003			6	Anesthesiology; Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology; Surgery	ZF382	WOS:000072891900004	9559765				2022-02-06	
J	Harvey, AG; Bryant, RA				Harvey, AG; Bryant, RA			Predictors of acute stress following mild traumatic brain injury	BRAIN INJURY			English	Article							MOTOR-VEHICLE ACCIDENTS; MINOR HEAD-INJURY; DISORDER; SURVIVORS; RESPONSES; EVENTS	The aim of this study was to investigate the predictors of acute stress disorder (ASD) following mild traumatic brain injury (MTBI). Patients who sustained MTBI following a motor vehicle accident (n = 48) were assessed with a structured interview within 18 days of the trauma for the presence of ASD and administered the Beck Depression Inventory (BDI), Coping Style Questionnaire, Dissociative Experiences Scale, and the Eysenck Personality Inventory. ASD was diagnosed in 14.6% of patients and 4.2% were diagnosed with sub-syndromal ASD. BDI scores and avoidant coping were significant predictors of ASD and acute stress severity. This study provides further evidence that traumatic stress reactions occur following MTBI and highlights the possibility of identifying those who may benefit from early intervention.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia		Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BECK AT, 1979, COGNITIVE THERAPY DE; Billings A G, 1981, J Behav Med, V4, P139, DOI 10.1007/BF00844267; Blanchard EB, 1996, BEHAV RES THER, V34, P1, DOI 10.1016/0005-7967(95)00058-6; Bohnen N., 1992, J NERV MENT DIS, V180, P183; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Bryant RA, 1996, J TRAUMA STRESS, V9, P223, DOI 10.1002/jts.2490090206; BRYANT RA, 1995, BEHAV RES THER, V33, P631, DOI 10.1016/0005-7967(94)00093-Y; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; BRYANT RA, 1997, UNPUB PSYCHOMETRIC P; CARLSON EB, 1992, UNPUB MANUAL DISSOCI; CREAMER M, 1992, J ABNORM PSYCHOL, V101, P452, DOI 10.1037/0021-843X.101.3.452; DAVIDOFF DA, 1988, COGNITIVE REHABILITA, V2, P8; DUNCANJONES P, 1983, UNPUB SHORT MEASURES; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; GRIGSBY JP, 1986, INT J CLIN NEUROPSYC, V8, P65; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; KOOPMAN C, 1994, AM J PSYCHIAT, V151, P888; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; MIDDELBOE T, 1991, Acta Neurologica Scandinavica, V85, P5; MILLER L, 1993, J COGNITIVE REHABILI, V11, P18; NORTH CS, 1994, AM J PSYCHIAT, V151, P82; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; RATTOCK J, 1993, J CLIN EXPT NEUROPSY, V6, P243; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SCHWARZ ED, 1992, J NERV MENT DIS, V180, P767, DOI 10.1097/00005053-199212000-00005; SHORE JH, 1989, J NERV MENT DIS, V177, P681, DOI 10.1097/00005053-198911000-00004; SOLOMON Z, 1988, J ABNORM PSYCHOL, V97, P302, DOI 10.1037/0021-843X.97.3.302; Tabachnick B. G., 1989, USING MULTIVARIATE S; Waller NG, 1996, PSYCHOL METHODS, V1, P300, DOI 10.1037/1082-989X.1.3.300	35	58	59	1	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	1998	12	2					147	154		10.1080/026990598122773			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	YV073	WOS:000071786900005	9492962				2022-02-06	
J	Roe, SY; McGowan, EM; Rothwell, NJ				Roe, SY; McGowan, EM; Rothwell, NJ			Evidence for the involvement of corticotrophin-releasing hormone in the pathogenesis of traumatic brain injury	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						amygdala; CRH antagonist; in situ hybridization; PVN; Sprague-Dawley rats	FOCAL CEREBRAL-ISCHEMIA; MESSENGER-RNA; RAT-BRAIN; ALZHEIMERS-DISEASE; FACTOR RECEPTORS; CRF; PHARMACOLOGY; PHYSIOLOGY; SECRETION; AMYGDALA	The aim of this study was to investigate the role of the neuropeptide corticotrophin-releasing hormone (CRH) in neurodegeneration induced by traumatic brain injury, using a well characterized model of lateral fluid percussion injury in male, Sprague-Dawley rats. In the first series of experiments, CRH gene expression was assessed by in situ hybridization after traumatic brain injury, A bilateral increase in CRH mRNA in the paraventricular nucleus was observed in rats subjected to traumatic brain injury compared with sham-operated controls, A maximal (40%) increase in hybridization signal was detected 2 h after trauma compared with control rat brains. In addition, marked induction of CRH transcripts was found in the ipsilateral amygdala after trauma, but no increase was detected in the ipsilateral cortex around the area of damage. In a separate experiment, the effects of the CRH antagonist, D-Phe CRH(12-41) (25 mu g total dose), or appropriate vehicle injected intracerebroventricularly, was tested on infarct volume caused by brain injury. Repeated intracerebroventricular injection of D-Phe CRH(12-41) significantly reduced, by 45%, the volume of cortical damage in injured rats compared with vehicle-treated, trauma animals. The rapid upregulation of CRH gene expression in the paraventricular nucleus and amygdala following lateral fluid percussion injury and the marked neuroprotection achieved by inhibiting CRH action suggest that CRH is involved directly in the pathogenesis of traumatic brain injury. This observation may have important implications for the development of novel therapeutic strategies for treating the neurological consequences of brain trauma and related conditions.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England		Rothwell, NJ (corresponding author), Univ Manchester, Sch Biol Sci, 1-124 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.				Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		BALDWIN HA, 1991, PSYCHOPHARMACOLOGY, V103, P227, DOI 10.1007/BF02244208; BEHAN DP, 1995, NATURE, V378, P284, DOI 10.1038/378284a0; BERKENBOSCH F, 1987, SCIENCE, V238, P524, DOI 10.1126/science.2443979; Chalmers DT, 1996, TRENDS PHARMACOL SCI, V17, P166, DOI 10.1016/0165-6147(96)81594-X; CHEUNG RTF, 1995, J COMP NEUROL, V360, P101, DOI 10.1002/cne.903600108; DeSouza EB, 1995, PSYCHONEUROENDOCRINO, V20, P789, DOI 10.1016/0306-4530(95)00011-9; DESOUZA EB, 1990, CORTICOTROPIN RELEAS, P335; EHLERS CL, 1983, BRAIN RES, V278, P332, DOI 10.1016/0006-8993(83)90266-4; FOX MW, 1993, STROKE, V24, P1072, DOI 10.1161/01.STR.24.7.1072; JINGAMI H, 1985, FEBS LETT, V191, P63, DOI 10.1016/0014-5793(85)80994-7; LIGHTMAN SL, 1987, J PHYSIOL-LONDON, V394, P23, DOI 10.1113/jphysiol.1987.sp016858; LIGHTMAN SL, 1993, ANN NY ACAD SCI, V697, P28, DOI 10.1111/j.1749-6632.1993.tb49920.x; LYONS MK, 1991, BRAIN RES, V545, P339, DOI 10.1016/0006-8993(91)91310-W; MARROSU F, 1988, EPILEPSIA, V29, P369, DOI 10.1111/j.1528-1157.1988.tb03733.x; MCDONALD AJ, 1987, J COMP NEUROL, V262, P59, DOI 10.1002/cne.902620106; MENZAGHI F, 1994, J PHARMACOL EXP THER, V269, P564; NELSON LR, 1982, HEAD INJURY BASIC CL, P117; OWENS MJ, 1991, PHARMACOL REV, V43, P425; Paxinos G, 1986, RAT BRAIN STEREOTAXI; RAADSHEER FC, 1995, AM J PSYCHIAT, V152, P1372; RAINNIE DG, 1992, J PHARMACOL EXP THER, V263, P846; RIVIER CL, 1986, ANNU REV PHYSIOL, V48, P475, DOI 10.1146/annurev.ph.48.030186.002355; Roe S. Y., 1995, Society for Neuroscience Abstracts, V21, P1731; ROTHWELL N, 1989, NEUROSCI BIOBEHAV R, V14, P263; ROTHWELL N, 1995, IMMUNE RESPONSES NER, P77; Sawchenko P. E., 1990, CORTICOTROPIN RELEAS, P29; SHARKEY J, 1989, SYNAPSE, V4, P80, DOI 10.1002/syn.890040109; STRIJBOS PJLM, 1994, BRAIN RES, V656, P405, DOI 10.1016/0006-8993(94)91485-0; SWANSON LW, 1983, NEUROENDOCRINOLOGY, V36, P165, DOI 10.1159/000123454; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0; WELSH FA, 1980, STROKE, V11, P355, DOI 10.1161/01.STR.11.4.355; WISDEN W, 1994, IN SITU HYBRIDIZATIO, P9; Wong M.-L., 1995, Society for Neuroscience Abstracts, V21, P230; WONG ML, 1995, NEUROREPORT, V6, P1785, DOI 10.1097/00001756-199509000-00019; YASUI Y, 1991, J COMP NEUROL, V303, P355, DOI 10.1002/cne.903030303	37	58	61	0	2	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	FEB	1998	10	2					553	559		10.1046/j.1460-9568.1998.00064.x			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	YY335	WOS:000072136800017	9749718				2022-02-06	
J	Al-Adawi, S; Powell, JH; Greenwood, RJ				Al-Adawi, S; Powell, JH; Greenwood, RJ			Motivational deficits after brain injury: A neuropsychological approach using new assessment techniques	NEUROPSYCHOLOGY			English	Article							HEAD-INJURY; BROMOCRIPTINE; BEHAVIOR; SCALE	Deficits of motivation art: recognized as a significant clinical problem following brain injury, and a neuropsychological model is postulated linking such deficits with cognitive deficits of a frontal type. However, few, if any, quantitative assessment measures exist; most descriptions in the literature are qualitative, and this has limited the scope and robustness of research into the problem. The authors in the present research have developed new tools for assessing patients' level of motivation in therapy (percent participation index) and their behavioral responsiveness to experimental incentive (the card-arranging reward responsivity objective test). Relationships among poor motivation, reward responsiveness, frontal lobe function, and mood were explored in a sample of 54 patients with nonfocal vascular or traumatic brain injury; the results were consistent with the neuropsychological model. Preliminary reliability and validation data on the new measures are reported.	Univ London Goldsmiths Coll, Dept Psychol, London SE14 6NW, England; Inst Psychiat, Dept Psychol, London SE5 8AF, England; Homerton Hosp, Reg Neurol Rehabil Unit, London, England		Powell, JH (corresponding author), Univ London Goldsmiths Coll, Dept Psychol, Lewisham Way, London SE14 6NW, England.	psa01jhp@gold.ac.uk	Al-Adawi, Samir/A-9663-2016	Al-Adawi, Samir/0000-0002-9858-5582			ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; ALADAWI S, IN PRESS ADDICTION; Ammons RB, 1962, QUICK TEST; BENTON AL, 1986, NEUROPSYCHOLOGIA, V6, P63; Black, 1992, MULTIVARIATE DATA AN; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; COLLIN C, 1988, J NEUROL NEUROSUR PS, V141, P68; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Frith C.D., 1992, COGN NEUROPSYCHOL; FRITH CD, 1983, PSYCHOL MED, V13, P779, DOI 10.1017/S0033291700051485; FRITH CD, 1992, J ROY SOC MED, V85, P222; GILES GM, 1993, BRAIN INJURY REHABIL; Hamilton BB, 1987, REHABILITATION OUTCO, P137; KATZMANN S, 1994, AM J OCCUP THER, V48, P259, DOI 10.5014/ajot.48.3.259; KLINE P, 1983, ADV BEHAV RES THER, V5, P141, DOI 10.1016/0146-6402(83)90017-6; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Liddle P F, 1993, Behav Neurol, V6, P5, DOI 10.3233/BEN-1993-6102; MULLER U, 1994, PROG NEURO-PSYCHOPH, V18, P1103, DOI 10.1016/0278-5846(94)90114-7; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Norman DA., 1986, CONSCIOUSNESS SELF R, P1, DOI [10.1007/978-1-4757-0629-1_1, DOI 10.1007/978-1-4757-0629-1_1]; PICKERING AD, IN PRESS SCI STUDY P; Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416; Raven J.C., 1965, GUIDE USING COLOURED; RICHARDS PM, 1989, J CONSULT CLIN PSYCH, V57, P396, DOI 10.1037/0022-006X.57.3.396; SALAMONE JD, 1994, BEHAV BRAIN RES, V61, P117, DOI 10.1016/0166-4328(94)90153-8; Savournin R, 1995, BRIT J MED PSYCHOL, V68, P353, DOI 10.1111/j.2044-8341.1995.tb01843.x; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; Seligman M., 1981, BEHAVIOR THERAPY DEP, P123; SHAKOW D, 1963, BEHAV SCI, V8, P275; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Vikki Juhani, 1994, Journal of Clinical and Experimental Neuropsychology, V16, P325; Wechsler, 1997, WECHSLER ADULT INTEL; WILLNER P, 1987, PSYCHOPHARMACOLOGY, V93, P358; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	38	58	59	1	4	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JAN	1998	12	1					115	124		10.1037/0894-4105.12.1.115			10	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	YR430	WOS:000071494500010	9460739				2022-02-06	
J	Gallily, R; Yamin, A; Waksmann, Y; Ovadia, H; Weidenfeld, J; BarJoseph, A; Biegon, A; Mechoulam, R; Shohami, E				Gallily, R; Yamin, A; Waksmann, Y; Ovadia, H; Weidenfeld, J; BarJoseph, A; Biegon, A; Mechoulam, R; Shohami, E			Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							CLOSED-HEAD INJURY; NONCOMPETITIVE NMDA ANTAGONIST; LETHAL TOXICITY; NERVOUS-SYSTEM; RAT-BRAIN; CYTOKINE; INHIBITORS; LIPOPOLYSACCHARIDE; ASTROCYTES; IMIDAZOLES	Dexanabinol, HU-211, a synthetic cannabinoid devoid of psychotropic effects, improves neurological outcome in models of brain trauma, ischemia and meningitis. Recently, HU-211 was found to inhibit brain tumor necrosis factor (TNF alpha) production after head injury. In the present study, we demonstrate the ability of HU-211 to suppress TNF alpha production and to rescue mice and rats from endotoxic shock after LPS (Escherichia coli 055:B5) inoculation. In BALB/c mice, a dose of 10 mg/kg LPS, injected i.p., caused 57% and 100% mortality, at 24 and 48 hr, respectively. HU-211, administered i.p. 30 min before lipopolysaccharide (LPS), reduced lethality to 9 and 67% at these time points (P < .05). When coinjected with D-galactoseamine (i.p.), LPS was 100% lethal within 24 hr, whereas eight hourly injections of HU-211 caused mortality of C57BL/6 mice to drop to 10% (P < .001). Administration of LPS to Sprague-Dawley rats resulted in a 30% reduction in the mean arterial blood pressure within 30 min, which persisted for 3 hr. HU-211, given 2 to 3 min before LPS, completely abolished the typical hypotensive response. Furthermore, the drug also markedly suppressed in vitro TNF alpha production and nitric oxide generation (by >90%) by both murine peritoneal macrophages and rat alveolar macrophage cell line exposed to LPS. HU-211 may, therefore, have therapeutic implications in the treatment of TNF alpha-mediated pathologies.	HEBREW UNIV JERUSALEM,SCH PHARM,DEPT PHARMACOL,FAC MED,IL-91120 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,DEPT IMMUNOL,FAC MED,IL-91120 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,DEPT NAT PROD,FAC MED,IL-91120 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,DEPT EXPT NEUROL,FAC MED,IL-91120 JERUSALEM,ISRAEL								AVRON A, 1995, J LEUKOCYTE BIOL, V57, P264, DOI 10.1002/jlb.57.2.264; BARJOSEPH A, 1994, MOL CHEM NEUROPATHOL, V23, P125, DOI 10.1007/BF02815406; Bass R, 1996, J INFECT DIS, V173, P735, DOI 10.1093/infdis/173.3.735; BAUSS F, 1987, INFECT IMMUN, V55, P1622, DOI 10.1128/IAI.55.7.1622-1625.1987; BELAYEV L, 1995, BRAIN RES, V702, P266, DOI 10.1016/0006-8993(95)01127-9; BELAYEV L, 1995, STROKE, V26, P2313, DOI 10.1161/01.STR.26.12.2313; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BRENNER T, 1993, BRAIN RES, V608, P273, DOI 10.1016/0006-8993(93)91468-8; BURNETTECURLEY D, 1995, P SOC EXP BIOL MED, V209, P205; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANTZER R, 1996, INT SOC PSYCH 27 C M, P43; DOHERTY GM, 1991, SURGERY, V110, P192; ELDRIDGE JC, 1990, BRAIN RES, V534, P135; ESHHAR N, 1993, NEUROREPORT, V5, P37; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; GLAUSER MP, 1994, CLIN INFECT DIS, V18, pS205, DOI 10.1093/clinids/18.Supplement_2.S205; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; KLEIN TW, 1995, P SOC EXP BIOL MED, V209, P205; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEHMANN V, 1987, J EXP MED, V165, P657, DOI 10.1084/jem.165.3.657; MIER JW, 1992, TUMOR NECROSIS FACTO, P221; MOREIRA AL, 1993, J EXP MED, V177, P1675, DOI 10.1084/jem.177.6.1675; NADLER V, 1993, NEUROSCI LETT, V162, P43, DOI 10.1016/0304-3940(93)90555-Y; NADLER V, 1993, BRAIN RES, V622, P79, DOI 10.1016/0006-8993(93)90804-V; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; REDDY MP, 1994, INT J IMMUNOPHARMACO, V16, P795, DOI 10.1016/0192-0561(94)90053-1; REMICK DG, 1987, LAB INVEST, V56, P583; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SHOHAMI E, 1996, CNS DRUG REV, V2, P429; SPANGELO BL, 1990, ENDOCRINOLOGY, V127, P779; TEALE DM, 1992, J ANTIMICROB CHEMOTH, V30, P839, DOI 10.1093/jac/30.6.839; TERASHITA ZI, 1992, J PHARMACOL EXP THER, V260, P748; TRACEY KJ, 1991, CIRC SHOCK, V35, P123; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; WAAGE A, 1992, TUMOR NECROSIS FACTO, P275; WATKINS LR, 1995, LIFE SCI, V57, P1011, DOI 10.1016/0024-3205(95)02047-M; WEIDENFELD J, 1989, NEUROENDOCRINOLOGY, V50, P132, DOI 10.1159/000125212; WOLFE TA, 1995, ANN PHARMACOTHER, V29, P36, DOI 10.1177/106002809502900108; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; XU T, 1992, LIFE SCI, V51, P1817, DOI 10.1016/0024-3205(92)90053-R	47	58	58	0	3	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	NOV	1997	283	2					918	924					7	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	YF254	WOS:A1997YF25400062	9353414				2022-02-06	
J	LeRoux, PD; Newell, DW; Lam, AM; Grady, MS; Winn, HR				LeRoux, PD; Newell, DW; Lam, AM; Grady, MS; Winn, HR			Cerebral arteriovenous oxygen difference: A predictor of cerebral infarction and outcome in patients with severe head injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; arteriovenous oxygen difference; intracranial pressure; cerebral ischemia; outcome	EXCITATORY AMINO-ACIDS; TRAUMATIC BRAIN INJURY; ACUTE SUBDURAL-HEMATOMA; BLOOD-FLOW; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; COMATOSE PATIENTS; METABOLISM; SATURATION; CIRCULATION	Jugular bulb oxygen monitoring can be used to estimate the adequacy of cerebral blood flow to support cerebral metabolism after severe head injury. In the present study, the authors studied the cerebral arteriovenous oxygen difference (AVDO(2)) before and after treatment in 32 head-injured patients (Glasgow Coma Scale scores less than or equal to 8) to examine the relationships among AVDO(2) and cerebral perfusion pressure (CPP), delayed cerebral infarction, and outcome. Fifteen patients (Group A) underwent craniotomy for hematoma evacuation and 17 (Group B) received mannitol for sustained intracranial hypertension (intracranial pressure > 20 mm Hg, > 10 minutes). Radiographic evidence of delayed cerebral infarction was observed in 14 patients. Overall, 17 patients died or were severely disabled. Cerebral AVDO(2) was elevated before craniotomy or mannitol administration; the mean AVDO(2) for all patients before treatment was 8.6 +/- 1.8 vol%. Following craniotomy or mannitol administration, the AVDO(2) decreased in 27 patients and increased in five patients (mean AVDO(2) 6.2 +/- 2.1 vol% in all patients; 6 +/- 1.9 vol% in Group A; and 6.4 +/- 2.4 vol% in Group B). The mean CPP was 75 +/- 9.8 mm Hg and no relationship with AVDO(2) was demonstrated. Before treatment, the AVDO was not associated with delayed cerebral infarction or outcome. B; contrast, a limited improvement in elevated AVDO(2) after craniotomy or mannitol administration was significantly associated with delayed cerebral infarction (Group A: p < 0.001; Group B: p < 0.01). Similarly, a limited improvement in elevated AVDO(2) after treatment was significantly associated with an unfavorable outcome (Group A: p < 0.01; Group B: p < 0.001). In conclusion, these findings strongly indicate that, despite adequate cerebral perfusion, limited improvement in elevated cerebral AVDO(2) after treatment consisting of either craniotomy or mannitol administration may be used to help predict delayed cerebral infarction and poor outcome after traumatic brain injury.	UNIV WASHINGTON,DEPT NEUROSURG,HARBORVIEW MED CTR,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT ANESTHESIOL,HARBORVIEW MED CTR,SEATTLE,WA 98195								BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P270, DOI 10.1111/j.1399-6576.1978.tb01301.x; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; CRUZ J, 1992, J TRAUMA, V32, P629, DOI 10.1097/00005373-199205000-00015; DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; GIBBS EL, 1945, AM J PSYCHIAT, V102, P184, DOI 10.1176/ajp.102.2.184; Gibbs FA, 1934, ARCH NEURO PSYCHIATR, V32, P257, DOI 10.1001/archneurpsyc.1934.02250080003001; GOETTING MG, 1991, INTENS CARE MED, V17, P195, DOI 10.1007/BF01709876; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JAKOBSEN M, 1989, J CEREBR BLOOD F MET, V9, P717, DOI 10.1038/jcbfm.1989.101; JENNETT B, 1975, LANCET, V1, P480; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; KURODA Y, 1992, NEUROSURGERY, V30, P687; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARTIN NA, 1995, N JEUROTRAUMA, V12, P879; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MOULTON RJ, 1994, CLIN INVEST MED, V17, P187; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1981, J NEUROSURG, V55, P63, DOI 10.3171/jns.1981.55.1.0063; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SHENKIN HA, 1948, ARCH NEURO PSYCHIATR, V60, P240, DOI 10.1001/archneurpsyc.1948.02310030021002; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; SUTTON LN, 1987, J NEUROSURG, V67, P381, DOI 10.3171/jns.1987.67.3.0381; SUTTON LN, 1990, J NEUROSURG, V73, P927, DOI 10.3171/jns.1990.73.6.0927; TEASDALE G, 1974, LANCET, V2, P81	51	58	60	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	1997	87	1					1	8		10.3171/jns.1997.87.1.0001			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	XF331	WOS:A1997XF33100001	9202258				2022-02-06	
J	Priebe, MM; Sherwood, AM; Graves, DE; Mueller, M; Olson, WH				Priebe, MM; Sherwood, AM; Graves, DE; Mueller, M; Olson, WH			Effectiveness of gabapentin in controlling spasticity: A quantitative study	SPINAL CORD			English	Article						surface electromyography; spasticity; gabapentin; Neurontin; spinal cord injury; assessment		The purpose of this investigation was to study the effectiveness of gabapentin in controlling spasticity in persons with spinal cord injury (SCI) using a surface EMG-based quantitative assessment technique called the brain motor control assessment (BMCA). Six men from a Veterans Affairs Medical Center with spasticity due to traumatic SCI were studied as part of a multi-center, placebo-controlled, cross-over, clinical trial of gabapentin. Spasticity was evaluated using multi-channel surface EMG recordings of muscles in the lower extremities, abdomen and low back before and during treatment with oral gabapentin or placebo. Gabapentin or placebo was given orally in doses 400 mg three times daily for 48 h. Following a 10 day wash-out period subjects were crossed-over to receive the medication not received the first time. This was followed by an elective open-label extension. Group results during the controlled trial did not reach statistical significance at the dosage used. One subject demonstrated a dramatic improvement in spasticity that was apparent both clinically and with the BMCA. Other subjects demonstrated modest improvements which were seen in the BMCA but not recognized clinically. During the open label extension, the four subjects who participated experienced important clinical improvements with higher doses (to 3600 mg/day). These improvements were often in components of spasticity in which the BMCA had detected subclinical changes during the cross-over trial. A seventh subject was studied using the BMCA at doses of 1200 mg T.I.D. gabapentin, off gabapentin and 800 mg T.I.D. gabapentin and demonstrated quantitatively a dose-related effect with higher doses of gabapentin which matched clinical observations. Gabapentin at doses of 400 mg T.I.D. may be effective in controlling some features of spasticity in persons with SCI. Higher doses provide greater control of spasticity, and controlled studies using higher doses are needed to evaluate gabapentin's efficacy.	VET AFFAIRS MED CTR, SPINAL CORD INJURY SERV, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV RESTORAT NEUROL & HUMAN NEUROBIOL, HOUSTON, TX 77030 USA; UNIV KENTUCKY, DEPT PHYS MED & REHABIL, LEXINGTON, KY USA; UNIV LOUISVILLE, DEPT NEUROL, LOUISVILLE, KY 40292 USA		Priebe, MM (corresponding author), BAYLOR COLL MED, DEPT PHYS MED & REHABIL, HOUSTON, TX 77030 USA.			Graves, Daniel/0000-0002-1389-5216; Sherwood, Arthur/0000-0002-0110-4317			DITUNNO JF, 1994, PARAPLEGIA, V32, P70, DOI 10.1038/sc.1994.13; KATZ RT, 1989, ARCH PHYS MED REHAB, V70, P144; Petroff OAC, 1996, ANN NEUROL, V39, P95, DOI 10.1002/ana.410390114; Sherwood AM, 1996, MUSCLE NERVE, V19, P966, DOI 10.1002/(SICI)1097-4598(199608)19:8<966::AID-MUS5>3.0.CO;2-6; SHERWOOD AM, 1996, IN PRESS J ELECTROPH; YOUNG RR, 1994, NEUROLOGY, V44, P12	6	58	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393	1476-5624		SPINAL CORD	Spinal Cord	MAR	1997	35	3					171	175		10.1038/sj.sc.3100366			5	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	WM369	WOS:A1997WM36900008	9076868	Bronze			2022-02-06	
J	McMillan, TM				McMillan, TM			Post-traumatic stress disorder following minor and severe closed head injury: 10 single cases	BRAIN INJURY			English	Article							DISASTER; SCALE	Post-traumatic stress disorder (PTSD) was found to occur after minor or severe closed head injury in 10 single cases which are reported in detail. They were drawn from 312 cases of closed head injury who were referred for neuropsychological assessment or neurorehabilitation. All cases which had been given both diagnoses are presented. Information was collected retrospectively from case notes and reports. It is argued that a continuum of experience, which represents the entirety of an event, is not necessary for PTSD to occur, but that a 'window' of real or imagined experience which results from loss of consciousness and post-traumatic amnesia after closed head injury need not prevent the symptoms of PTSD from arising, although they may make them less likely and the phenomenon of the dual diagnoses relatively rare. The issue of whether PTSD found following closed head injury is a subclassification of PTSD is raised.	ST GEORGES HEALTHCARE, ATKINSON MORLEYS HOSP, LONDON SW20 0NE, ENGLAND		McMillan, TM (corresponding author), ST GEORGES HEALTHCARE, WOLFSON MED REHABIL CTR, COPSE HILL, LONDON SW20 0NE, ENGLAND.						*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P424; *AM PSYCH ASS, 1987, DIAGN STAT MAN MENT, P247; ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; Baddeley A., 1992, SPEED CAPACITY LANGU; Beck AT, 1987, BECK DEPRESSION INVE; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; DAVIDOFF DA, 1988, COGNITIVE REHABILITA, V6, P8; DAVIDSON JRT, 1991, PSYCHOL MED, V21, P713, DOI 10.1017/S0033291700022352; EVERLY GS, 1989, PERCEPT MOTOR SKILL, V68, P807, DOI 10.2466/pms.1989.68.3.807; GERSONS BPR, 1992, BRIT J PSYCHIAT, V161, P742, DOI 10.1192/bjp.161.6.742; GREENWOOD RJ, 1994, BRIT MED J, V308, P1199, DOI 10.1136/bmj.308.6938.1199; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; HORTON AM, 1993, PERCEPT MOTOR SKILL, V76, P243, DOI 10.2466/pms.1993.76.1.243; HORTON AM, 1988, ARCH CLIN NEUROPSYCH, V6, P8; Jennett B, 1981, MANAGEMENT HEAD INJU; JOSEPH S, 1993, BRIT J CLIN PSYCHOL, V32, P327, DOI 10.1111/j.2044-8260.1993.tb01063.x; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KOLB LC, 1987, AM J PSYCHIAT, V144, P989; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; Middelboe T., 1992, European Psychiatry, V7, P183; Nelson H. E., 1991, NATIONAL ADULT READI; Peterson L G, 1986, Adv Psychosom Med, V16, P84; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SBORDONE RJ, 1992, NEUROLAW LETT, V3; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; THOMPSON J, 1994, BRIT J CLIN PSYCHOL, V33, P75, DOI 10.1111/j.2044-8260.1994.tb01096.x; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WATSON IPB, 1988, BRIT J PSYCHIAT, V152, P164, DOI 10.1192/bjp.152.2.164; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; [No title captured]	33	58	59	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	1996	10	10					749	758		10.1080/026990596124016			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	VH730	WOS:A1996VH73000005	8879665				2022-02-06	
J	Tepper, S; Beatty, P; DeJong, G				Tepper, S; Beatty, P; DeJong, G			Outcomes in traumatic brain injury: Self-report versus report of significant others	BRAIN INJURY			English	Article							FUNCTIONAL INDEPENDENCE MEASURE; HEAD-INJURY; PSYCHOSOCIAL RECOVERY; DISABILITY; STABILITY; RETURN; WORK	This paper examines the inter-rater reliability of 148 persons with traumatic brain injury (PwTBI) and their significant others (SO) on the Functional Independence Measure (FIM), and the Community Integration Questionnaire (CIQ). Results reveal that agreement differs across instruments and subscales, with greatest response comparability on the productivity CIQ subscale, followed by the motor FIM, social integration CIQ, cognitive FIM, and home integration CIQ. These findings have important implications for the future of TBI outcomes studies.			Tepper, S (corresponding author), NATL REHABIL HOSP RES CTR,WASHINGTON,DC 20010, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR304550] Funding Source: Medline		BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; BURTON LA, 1993, J REHABILITATION OCT, P34; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Data Management Service of the Uniform Data System for Medical Rehabilitation and the Center for Functional Assessment Research, 1990, GUIDE USE UNIFORM DA; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; Hamilton BB, 1987, REHABILITATION OUTCO, P137; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Helmstadter G.C., 1964, PRINCIPLES PSYCHOL M; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; Kreutzer JS, 1990, COMMUNITY INTEGRATIO; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MAGAZINER J, 1988, J CLIN EPIDEMIOL, V41, P1065, DOI 10.1016/0895-4356(88)90076-5; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Nunnally JC., 1978, PSYCHOMETRIC THEORY, V2; OTTENBACHER KJ, 1994, ARCH PHYS MED REHAB, V75, P1297; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; WARE JE, 1993, SF36 HLTH SURV MAN I; Willer B, 1994, BRAIN INJURY REHABIL, P355; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009	27	58	58	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	AUG	1996	10	8					575	581		10.1080/026990596124142			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	UZ656	WOS:A1996UZ65600003	8836514				2022-02-06	
J	Wahl, M; Whalley, ET; Unterberg, A; Schilling, L; Parsons, AA; Baethmann, A; Young, AR				Wahl, M; Whalley, ET; Unterberg, A; Schilling, L; Parsons, AA; Baethmann, A; Young, AR			Vasomotor and permeability effects of bradykinin in the cerebral microcirculation	IMMUNOPHARMACOLOGY			English	Article; Proceedings Paper	14th International Symposium on Bradykinin and Related Kinins (KININ 95)	SEP 10-15, 1995	DENVER, CO			kallikrein-kinin; blood-brain barrier; cerebral microcirculation; brain oedema; Autacoids	VASOGENIC BRAIN EDEMA; KALLIKREIN-KININ SYSTEM; ANGIOTENSIN-CONVERTING ENZYME; HUMAN BASILAR ARTERY; PIAL-ARTERIES; CEREBROVASCULAR REACTIVITY; VASCULAR REACTIVITY; NITRIC-OXIDE; SUBSTANCE-P; RAT-BRAIN	All components of an intracerebral kallikrein-kinin system have been described. Thus, bradykinin (BK) acting from the parenchymal site as well as from the blood site may influence cerebral microcirculation. BK is a potent dilator of extra- and intraparenchymal cerebral arteries when acting from the perivascular site. The vasomotor effect of BK is mediated by B-2 receptors which appear to be located at the abluminal membrane of the endothelial cell. The effect of BK is mediated by NO, prostanoids, free radicals, H2O2 or leukotrienes depending on the animal species and on the location of the artery. Selective opening of the blood-brain barrier for small tracers (Na+-fluorescein; MW, 376) has been found in cats during cortical superfusion or intraarterial application of BK. This leakage is mediated by B-2 receptors located at the luminal and abluminal membrane of the endothelial cells. Formation of brain edema has been found after ventriculo-cisternal perfusion or interstitial infusion of BK. This can be explained by increase of vascular permeability and cerebral blood flow due to arterial dilatation thus enhancing driving forces for the extravasation. An increase of the BK concentration in the interstitial space of the brain up to concentrations which induce extravasation, dilatation and oedema formation has been found under several pathological conditions, Thus, BK may be involved in oedema formation after cold lesion, concussive brain injury, traumatic spinal cord and ischemic brain injury. The mediator role of BK in brain edema is further supported by therapeutic results. Brain swelling due to cold lesion or ischemia could be diminished by treatment with kallikrein-inhibitors. Similarly, dilatation of cerebral arterioles after concussive brain injury was reduced by blockade of B-2 receptors. Thus, all criteria favour BK as one mediator of vasogenic oedema.	CORTECH,DENVER,CO; DEPT NEUROSURG,BERLIN,GERMANY; DEPT NEUROSURG,MANNHEIM,GERMANY; SMITHKLINE BEECHAM,HARLOW,ESSEX,ENGLAND; INST EXPT SURG,MUNICH,GERMANY; CYCERON,CAEN,FRANCE		Wahl, M (corresponding author), UNIV MUNICH,DEPT PHYSIOL,PETTENKOFERSTR 12,D-8000 MUNICH,GERMANY.						ALMENOFF J, 1981, BIOCHEM BIOPH RES CO, V102, P206, DOI 10.1016/0006-291X(81)91508-4; Baethmann A, 1980, Adv Neurol, V28, P171; BUTT AM, 1990, J PHYSIOL-LONDON, V429, P47, DOI 10.1113/jphysiol.1990.sp018243; CHAO J, 1983, J BIOL CHEM, V258, P5173; CORREA FMA, 1986, BRAIN RES, V375, P259, DOI 10.1016/0006-8993(86)90746-8; DACEY RG, 1988, J CEREBR BLOOD F MET, V8, P254, DOI 10.1038/jcbfm.1988.56; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; ELLIS EF, 1988, AM J PHYSIOL, V255, pH397, DOI 10.1152/ajpheart.1988.255.2.H397; ELLIS EF, 1987, STROKE, V18, P792, DOI 10.1161/01.STR.18.4.792; FUXE K, 1980, ACTA PHYSIOL SCAND, V110, P321, DOI 10.1111/j.1748-1716.1980.tb06670.x; GUILLOT FL, 1990, J CEREBR BLOOD F MET, V10, P827, DOI 10.1038/jcbfm.1990.139; INAMURA T, 1994, J CEREBR BLOOD F MET, V14, P862, DOI 10.1038/jcbfm.1994.108; KAMITANI T, 1985, CIRC RES, V57, P545, DOI 10.1161/01.RES.57.4.545; KAMIYA T, 1989, J CEREB BLOOD FLO S1, V9, pS73; KARIYA K, 1981, J NEUROCHEM, V36, P2086, DOI 10.1111/j.1471-4159.1981.tb10838.x; KARIYA K, 1984, JPN J PHARMACOL, V34, P203, DOI 10.1254/jjp.34.203; KATUSIC ZS, 1989, AM J PHYSIOL, V257, pH1235, DOI 10.1152/ajpheart.1989.257.4.H1235; KATUSIC ZS, 1986, J PHARMACOL EXP THER, V236, P166; KONTOS HA, 1990, AM J PHYSIOL, V258, pH1261; KONTOS HA, 1984, CIRC RES, V55, P295, DOI 10.1161/01.RES.55.3.295; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; MAYHAN WG, 1990, AM J PHYSIOL, V259, pH1455, DOI 10.1152/ajpheart.1990.259.5.H1455; MAYHAN WG, 1990, AM J PHYSIOL, V258, pH1138, DOI 10.1152/ajpheart.1990.258.4.H1138; OLESEN SP, 1986, ACTA PHYSIOL SCAND, V127, P233, DOI 10.1111/j.1748-1716.1986.tb07898.x; OLESEN SP, 1987, J PHYSIOL-LONDON, V387, P59, DOI 10.1113/jphysiol.1987.sp016562; PARSONS AA, 1991, PFLUG ARCH EUR J PHY, V419, pR112; PERRY DC, 1984, J NEUROCHEM, V43, P1072, DOI 10.1111/j.1471-4159.1984.tb12846.x; Phillis J. W., 1993, REGULATION CEREBRAL, P315; RAYMOND JJ, 1986, CAN J NEUROL SCI, V13, P214, DOI 10.1017/S0317167100036301; REGOLI D, 1984, J CARDIOVASC PHARM, V6, pS401, DOI 10.1097/00005344-198406002-00015; REGOLI D, 1980, PHARMACOL REV, V32, P1; ROSENBLUM WI, 1987, CIRC RES, V61, P601, DOI 10.1161/01.RES.61.4.601; SARIA A, 1983, N-S ARCH PHARMACOL, V324, P212, DOI 10.1007/BF00503897; SCHILLING L, 1993, REGULATION CEREBRAL, P113; SCHURER L, 1989, ACTA NEUROPATHOL, V77, P576, DOI 10.1007/BF00687884; SHISHEVA A, 1983, FED PROC, V43, P1021; TODA N, 1977, AM J PHYSIOL, V232, pH267, DOI 10.1152/ajpheart.1977.232.3.H267; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; UNTERBERG A, 1987, ACTA NEUROPATHOL, V73, P209, DOI 10.1007/BF00686613; UNTERBERG A, 1988, ACTA NEUROPATHOL, V76, P238, DOI 10.1007/BF00687770; UNTERBERG A, 1984, J CEREBR BLOOD F MET, V4, P574, DOI 10.1038/jcbfm.1984.82; UNTERBERG A, 1984, J NEUROSURG, V61, P87, DOI 10.3171/jns.1984.61.1.0087; UNTERBERG A, 1983, CEREBRAL BLOOD FLOW, P174; UNTERBERG A, 1987, THESIS MUNCHEN; UNTERBERG A, 1985, ADV NEUROSURG, V13, P326; WAHL M, 1983, J CEREBR BLOOD F MET, V3, P231, DOI 10.1038/jcbfm.1983.31; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109; WAHL M, 1979, CIRC RES, V44, P161, DOI 10.1161/01.RES.44.2.161; WAHL M, 1976, PFLUG ARCH EUR J PHY, V362, P55, DOI 10.1007/BF00588681; WAHL M, 1987, BRAIN RES, V411, P72, DOI 10.1016/0006-8993(87)90682-2; WHALLEY ET, 1983, PFLUG ARCH EUR J PHY, V398, P175, DOI 10.1007/BF00581069; WHALLEY ET, 1987, N-S ARCH PHARMACOL, V335, P551; WHALLEY ET, 1983, N-S ARCH PHARMACOL, V324, P296, DOI 10.1007/BF00502627; WHALLEY ET, 1987, N-S ARCH PHARMACOL, V336, P430, DOI 10.1007/BF00164878; WHALLEY ET, 1988, BRAIN RES, V438, P1, DOI 10.1016/0006-8993(88)91318-2; WHALLEY ET, 1983, N-S ARCH PHARMACOL, V323, P66, DOI 10.1007/BF00498830; WHALLEY ET, 1987, N-S ARCH PHARMACOL, V335, P433, DOI 10.1007/BF00165559; WHALLEY ET, 1983, HYPERTENSION, V5, pV34, DOI 10.1161/01.HYP.5.6_Pt_3.V34; WHITTLE IR, 1992, ACTA NEUROCHIR, V115, P53, DOI 10.1007/BF01400591; WIEMER G, 1994, BRAIN RES, V638, P261, DOI 10.1016/0006-8993(94)90658-0; XU J, 1991, J NEUROCHEM, V57, P975, DOI 10.1111/j.1471-4159.1991.tb08246.x; YANG ST, 1991, STROKE, V22, P1177, DOI 10.1161/01.STR.22.9.1177	62	58	59	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0162-3109			IMMUNOPHARMACOLOGY	Immunopharmacology	JUN	1996	33	1-3					257	263		10.1016/0162-3109(96)00068-9			7	Immunology; Pharmacology & Pharmacy	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Pharmacology & Pharmacy	VA298	WOS:A1996VA29800053	8856159				2022-02-06	
J	Heath, DL; Vink, R				Heath, DL; Vink, R			Impact acceleration-induced severe diffuse axonal injury in rats: Characterization of phosphate metabolism and neurologic outcome	JOURNAL OF NEUROTRAUMA			English	Article						magnetic resonance; trauma; magnesium; bioenergetics	TRAUMATIC BRAIN INJURY; MAGNETIC-RESONANCE SPECTROSCOPY; EXPERIMENTAL HEAD-INJURY; VOLTAGE-DEPENDENT BLOCK; MAGNESIUM; PH; DAMAGE; MG-2+; POTASSIUM; RESPONSES	Diffuse axonal injury (DAI) occurs in over half of all severe cases of traumatic brain injury and has been associated with the development of a persistent vegetative state. Although a number of studies have examined the biochemical and physiological events following brain trauma, none of these has concentrated on events associated with the occurrence of severe DAI, The present study has used phosphorus magnetic resonance spectroscopy (MRS) and the rotarod motor test to characterize metabolic and neurologic consequences of severe diffuse axonal injury in rats induced by impact acceleration. Traumatic brain injury was induced in male rats by dropping a 450-g brass weight a distance of 2 m onto a 10-mm stainless-steel disc (3 mm wide) attached to the closed skull, Changes in brain intracellular pH, free magnesium concentration, cytosolic phosphorylation ratio, and mitochondrial oxidative metabolism after injury were monitored by phosphorus MRS while neurologic motor outcome over 1 week was assessed using the rotarod test, Impact acceleration-induced injury resulted in a highly significant decline in free magnesium concentration, cytosolic phosphorylation ratio, and an increased rate of mitochondrial oxidative phosphorylation, but no significant change in pH, These changes were associated with the occurrence of a significant neurologic deficit over 1 week postinjury, The similarity in metabolic events associated with production of neurologic deficits in this and other models of traumatic brain injury suggests that these bioenergetic changes may be common to all models of brain trauma.	JAMES COOK UNIV N QUEENSLAND,DIV BIOCHEM & HUMAN PHYSIOL,TOWNSVILLE,QLD 4811,AUSTRALIA				Vink, Robert/J-7351-2012; Vink, Robert/S-5616-2019	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667			ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Bara M., 1984, MAGNESIUM, V3, P212; BRAUGHLER JM, 1992, 1991 MA LIEB INC CEN, P1; BROWN AM, 1991, MG2 PLUS EXCITABLE M, P21; CHANCE B, 1986, P NATL ACAD SCI USA, V83, P9458, DOI 10.1073/pnas.83.24.9458; COHN M, 1962, J BIOL CHEM, V237, P176; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; EMERSON CS, 1992, NEUROREPORT, V11, P957; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GUNTHER T, 1986, MAGNESIUM, V5, P53; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HAYES RL, 1992, 1991 CENTR NERV SYST, P173; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; HOVDA DA, 1990, ACT NEUR S, V51, P331; HUBSCHMANN OR, 1985, J NEUROSURG, V62, P698, DOI 10.3171/jns.1985.62.5.0698; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; JOHNSON JW, 1990, BIOPHYS J, V57, P1085, DOI 10.1016/S0006-3495(90)82626-6; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KRAMER RS, 1979, 1979 CENTR NERV SYST, P70; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1992, EXCITATORY AMINO ACI, P247; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; Povlishock J.T., 1994, NEUROBIOLOGY CENTRAL, P109; SALZMAN SK, 1987, J NEUROSURG, V66, P431, DOI 10.3171/jns.1987.66.3.0431; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, J NEUROTRAUMA, V5, P365; WONG PP, 1994, BRAIN INJURY, V8, P509, DOI 10.3109/02699059409151003; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOUNG W, 1994, NEUROBIOLOGY CENTRAL, P123	51	58	60	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1995	12	6					1027	1034		10.1089/neu.1995.12.1027			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	TU518	WOS:A1995TU51800003	8742131				2022-02-06	
J	BAVARIA, JE; WOO, YJ; HALL, RA; CARPENTER, JP; GARDNER, TJ				BAVARIA, JE; WOO, YJ; HALL, RA; CARPENTER, JP; GARDNER, TJ			RETROGRADE CEREBRAL AND DISTAL AORTIC PERFUSION DURING ASCENDING AND THORACOABDOMINAL AORTIC OPERATIONS	ANNALS OF THORACIC SURGERY			English	Article							CIRCULATORY ARREST; SURGICAL-TREATMENT; ARCH ANEURYSM; REPLACEMENT; EXPERIENCE; DISSECTION; PREVENTION; SURGERY; BYPASS; BRAIN	Background. Several alternative circulatory management techniques during thoracic aortic reconstruction have been implemented at this institution. This study was performed to assess whether retrograde cerebral perfusion during proximal aortic operations and distal aortic perfusion during thoracoabdominal aortic operations have improved outcomes. Methods. A retrospective review of 156 patients undergoing elective and emergent operations of the thoracic aorta over the past 7 years was performed. Seventy-five patients underwent proximal aortic procedures: 22 with ascending aneurysms, 45 with type A dissections, and 8 with arch reconstructions. Eighty-one patients underwent descending thoracic or thoracoabdominal procedures: 26 with Crawford type I aneurysms, 18 with type II, 8 with type III, 8 with type IV, 11 with traumatic transections, and 10 with type B dissections. Outcomes measured were neurologic injury, renal failure, and mortality. Results. For proximal aortic procedures, the stroke rate was 12% using cardiopulmonary bypass and 48% using hypothermic circulatory arrest. The addition of retrograde cerebral perfusion decreased the stroke rate to 0% (p < 0.01) and the mortality rate to 7.1% compared with 37% for hypothermic circulatory arrest (p < 0.05). For thoracic and thoracoabdominal aortic operations, straight cross-clamping resulted in a 27% rate of spinal cord injury and a 24% rate of renal failure, whereas the addition of distal aortic bypass resulted in a statistically significant reduction (p < 0.01) in neurologic injury to 7% and a notable, but not statistically significant, decrease in renal failure to 13%. Distal aortic bypass also reduced the mortality rate from 22% to 7% (p < 0.05). Conclusions. Retrograde cerebral perfusion decreases the stroke rate and mortality rate in proximal aortic operations and distal aortic perfusion decreases the rates of neurologic injury, renal failure, and mortality in thoracoabdominal aortic operations.			BAVARIA, JE (corresponding author), HOSP UNIV PENN,DEPT SURG,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.						BORST HG, 1994, J THORAC CARDIOV SUR, V107, P126; BORST HG, 1991, SEMIN THORAC CARDIOV, V3, P334; CABROL CE, 1990, SEMIN THORAC CARDIOV, V3, P177; COOLEY DA, 1981, ANN THORAC SURG, V32, P260, DOI 10.1016/S0003-4975(10)61048-X; CRAWFORD ES, 1989, J THORAC CARDIOV SUR, V98, P659; CRAWFORD ES, 1981, ANN SURG, V194, P180, DOI 10.1097/00000658-198108000-00012; CRAWFORD ES, 1990, SEMIN TTHORAC CARDIO, V3, P194; DAVIS EA, 1992, ANN THORAC SURG, V53, P402, DOI 10.1016/0003-4975(92)90258-6; FEHRENBACHER JW, 1993, J VASC SURG, V18, P366, DOI 10.1016/0741-5214(93)90253-I; GRIEPP RB, 1975, J THORAC CARDIOV SUR, V70, P1051; GRIEPP RB, 1990, SEMIN THORAC CARDIOV, V3, P188; HIGGINS RSD, 1992, ARCH SURG-CHICAGO, V127, P516; HOLLIER LH, 1992, AM J SURG, V164, P210, DOI 10.1016/S0002-9610(05)81072-4; KAZUI T, 1992, ANN THORAC SURG, V53, P190; LIVESAY JJ, 1982, CIRCULATION, V66, P122; MASSIMO CG, 1993, ANN THORAC SURG, V56, P1110, DOI 10.1016/0003-4975(95)90026-8; MILLS NL, 1980, J THORAC CARDIOV SUR, V80, P708; NOJIMA T, 1994, AORTIC SURGERY S, V4; SAFI HJ, 1993, ANN THORAC SURG, V56, P270, DOI 10.1016/0003-4975(93)91158-J; SAFI HJ, 1994, AORTIC SURGERY S, V4; SVENSSON LG, 1993, J THORAC CARDIOV SUR, V106, P19, DOI 10.1016/S0022-5223(19)33737-7; UEDA U, 1988, J JPN ASS THOR SURG, V36, P161; UEDA Y, 1992, EUR J CARDIO-THORAC, V6, P36, DOI 10.1016/1010-7940(92)90096-G; USUI A, 1994, J THORAC CARDIOV SUR, V107, P1228, DOI 10.1016/S0022-5223(94)70042-7; USUI A, 1994, J THORAC CARDIOV SUR, V107, P300; USUI A, 1992, ANN THORAC SURG, V53, P47, DOI 10.1016/0003-4975(92)90756-T; VERDANT A, 1992, CAN J SURG, V35, P493; WADOUH F, 1992, THORAC CARDIOV SURG, V40, P26, DOI 10.1055/s-2007-1020106; YASUURA K, 1992, ANN THORAC SURG, V53, P655, DOI 10.1016/0003-4975(92)90328-2; YASUURA K, 1994, J THORAC CARDIOV SUR, V107, P1237, DOI 10.1016/S0022-5223(94)70043-5	30	58	59	0	2	ELSEVIER SCIENCE PUBL CO INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	0003-4975			ANN THORAC SURG	Ann. Thorac. Surg.	AUG	1995	60	2					345	353		10.1016/0003-4975(95)00447-S			9	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology; Respiratory System; Surgery	RQ583	WOS:A1995RQ58300018	7646094				2022-02-06	
J	SAKAS, DE; BULLOCK, MR; PATTERSON, J; HADLEY, D; WYPER, DJ; TEASDALE, GM				SAKAS, DE; BULLOCK, MR; PATTERSON, J; HADLEY, D; WYPER, DJ; TEASDALE, GM			FOCAL CEREBRAL HYPEREMIA AFTER FOCAL HEAD-INJURY IN HUMANS - A BENIGN PHENOMENON	JOURNAL OF NEUROSURGERY			English	Article						HYPEREMIA; CEREBRAL BLOOD FLOW; ISCHEMIA; INFARCTION; SUBDURAL HEMATOMA; HEAD INJURY; SINGLE-PHOTON EMISSION COMPUTERIZED TOMOGRAPHY	ACUTE SUBDURAL-HEMATOMA; BLOOD-FLOW; INTRAVENTRICULAR PRESSURE; GLUCOSE HYPERMETABOLISM; SPECT; METABOLISM; MECHANISMS; CHILDREN; RAT; AUTOREGULATION	To assess the relationship between posttraumatic cerebral hyperemia and focal cerebral damage, the authors performed cerebral blood flow mapping studies by single-photon emission computerized tomography (SPECT)) in 53 patients within 3 weeks of brain injury. Focal zones of hyperemia were present in 38% of patients. Hyperemia was correlated with clinical features and early computerized tomography (CT) and magnetic resonance (MR) imaging performed within 48 hours of the SPECT study and late CT and MR studies at 3 months. The hyperemia was observed primarily in structurally normal brain tissue (both gray and white matter), as revealed by CT and MR imaging, immediately adjacent to intraparenchymal or extracerebral focal lesions; it persisted for up to 10 days, but was never seen within the edematous pericontusional zones. The percentage of patients in the hyperemic group having brief (< 30 minutes) or no loss of consciousness was significantly higher than in the nonhyperemic group (twice as high, p < 0.05). Other clinical parameters were not significantly more common in the hyperemic group. The mortality of patients with focal hyperemia was lower than that of individuals without it, and the outcome of survivors with hyperemia was slightly better than patients without hyperemia. These results differ from the literature, which suggests that global post traumatic hyperemia is primarily an acute, malignant phenomenon associated with increased intracranial pressure, profound unconsciousness, and poor outcome. The current results agree with more recent studies which show that post traumatic hyperemia may occur across a wide spectrum of head injury severity and may be associated with favorable outcome.	SO GEN HOSP, INST NEUROL SCI, GLASGOW G51 4TF, LANARK, SCOTLAND; UNIV GLASGOW, DEPT NEUROSURG, GLASGOW, LANARK, SCOTLAND						Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		ANDERSEN A R, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P288; ANDERSON WF, 1988, BIOESSAYS, V8, P69, DOI 10.1002/bies.950080206; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1979, CHILD BRAIN, V5, P174; BULLOCK R, 1991, STROKE, V22, P1284, DOI 10.1161/01.STR.22.10.1284; Bullock R, 1994, INTRACRANIAL PRESSUR, P264; BULLOCK R, 1995, IN PRESS J NEUROTRAU; BULLOCK R, 1989, INTRACRANIAL PRESSUR, V7, P637; ENDOH K, 1991, AM J PHYSIOL, V261, pG1037, DOI 10.1152/ajpgi.1991.261.6.G1037; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; Eriksson L, 1986, Acta Radiol Suppl, V369, P453; FARACI FM, 1991, HYPERTENSION, V17, P917, DOI 10.1161/01.HYP.17.6.917; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; FUMEYA H, 1990, ACT NEUR S, V51, P283; GEMMELL HG, 1990, J NUCL MED, V31, P1595; HEISS WD, 1990, J CEREBR BLOOD F MET, V10, P687, DOI 10.1038/jcbfm.1990.122; INGLIS F, 1992, J NEUROTRAUM, V9, P75, DOI 10.1089/neu.1992.9.75; JENNETT B, 1975, LANCET, V1, P480; KUHL DE, 1980, J NEUROSURG, V52, P309, DOI 10.3171/jns.1980.52.3.0309; KURODA Y, 1992, NEUROSURGERY, V31, P1062, DOI 10.1227/00006123-199212000-00012; KURODA Y, 1992, J NEUROSURG, V76, P471, DOI 10.3171/jns.1992.76.3.0471; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; MACFARLANE R, 1991, J NEUROSURG, V75, P845, DOI 10.3171/jns.1991.75.6.0845; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; MARSHALL WJ, 1969, ARCH NEUROL-CHICAGO, V21, P545, DOI 10.1001/archneur.1969.00480170117012; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; MOSKOWITZ MA, 1989, AM J PHYSIOL, V257, pH1736, DOI 10.1152/ajpheart.1989.257.5.H1736; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; NEIRINCKX RD, 1987, J NUCL MED, V28, P191; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; OVERGAARD J, 1976, J NEUROSURG, V45, P292, DOI 10.3171/jns.1976.45.3.0292; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; PAULSON OB, 1972, NEUROLOGY, V22, P286, DOI 10.1212/WNL.22.3.286; PELLIGRINO DA, 1992, AM J PHYSIOL, V262, pE447, DOI 10.1152/ajpendo.1992.262.4.E447; POHL U, 1991, AM J PHYSIOL, V261, pH2016, DOI 10.1152/ajpheart.1991.261.6.H2016; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; SAKAS DE, 1989, P NATL ACAD SCI USA, V86, P1401, DOI 10.1073/pnas.86.4.1401; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SCHUTTA HS, 1968, BRAIN, V91, P281, DOI 10.1093/brain/91.2.281; SPERLING B, 1993, STROKE, V24, P193, DOI 10.1161/01.STR.24.2.193; TEASDALE G, 1974, LANCET, V2, P81; TSUDA Y, 1988, EUR J NUCL MED, V14, P546; WALDEMAR G, 1989, BRIT J CLIN PHARMACO, V28, pS177, DOI 10.1111/j.1365-2125.1989.tb03593.x; ZUPPING R, 1970, J NEUROSURG, V33, P498, DOI 10.3171/jns.1970.33.5.0498	50	58	58	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	1995	83	2					277	284		10.3171/jns.1995.83.2.0277			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	RL110	WOS:A1995RL11000015	7616274				2022-02-06	
J	ZINK, BJ; FEUSTEL, PJ				ZINK, BJ; FEUSTEL, PJ			EFFECTS OF ETHANOL ON RESPIRATORY-FUNCTION IN TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROSURGERY			English	Article						TRAUMATIC BRAIN INJURY; RESPIRATORY FUNCTION; VENTILATION; ETHANOL; PIG	NERVOUS-SYSTEM TRAUMA; ALCOHOL-INTOXICATION; HEAD-INJURY; NALOXONE; POTENTIATION; DEPRESSION; RESPONSES; OXYGEN; DAMAGE; CAT	It has been observed that traumatic brain injury (TBI) increases the susceptibility of the brain to subsequent hypoxia, and prolonged apnea occurs in ethanol (EtOH)-treated animals following brain injury. This investigation tests the hypothesis that EtOH suppresses ventilation and hypercapnic respiratory drive following TBI. Immature pigs were anesthetized with halothane and received a 2 to 3 atm fluid-percussion brain injury. Respiratory parameters, including tidal volume, frequency, ventilation (V-E), and arterial blood gases were measured on 100% O-2 and on 5% to 6% inspired CO2 in O-2 prior to and at 1O, 60, 120, and 180 minutes after TBI. Hypercapnic response sensitivity (S) was measured as the change in V-E per mm Hg increase in PaCO2. Intracranial pressure, mean arterial blood pressure, heart rate, brain temperature, glucose, and EtOH levels were also monitored. Three groups were studied: the first group of six received EtOH (3.5 gm/kg, intragastrically) without brain injury; the second group of six received TBI without EtOH; the third group of eight received EtOH and TBI. Ethanol levels were 121 +/- 13 (standard error of the mean) mg/dl in the EtOH/TBI group (136 +/- 25 in the EtOH group) at the time of injury, and 175 +/- 12 mg/dl in the EtOH/TBI group (200 +/- 20 mg/dl in the EtOH group) at 120 minutes after injury. The EtOH/TBI animals had significantly lower V-E and S, and higher PaCO2 following brain injury (p < 0.05, repeated-measures analysis of variance). No significant differences were identified between groups for pH, PaCO2, intracranial pressure, heart rate, brain temperature, or glucose levels. Ethanol intoxication leads to significant impairment of respiratory control following traumatic brain injury and may contribute to brain injury in intoxicated trauma victims.	ALBANY MED COLL,DEPT SURG,ALBANY,NY		ZINK, BJ (corresponding author), UNIV MICHIGAN,MED CTR,DEPT SURG,EMERGENCY SURG SECT,UH B1C255,1500 E MED CTR DR,ANN ARBOR,MI 48109, USA.		Feustel, Paul/AAW-5157-2021	Feustel, Paul/0000-0002-6963-4349			ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; BAZOR D, 1982, NEW ENGL J MED, V306, P1363; BRISMAR B, 1983, ACTA CHIR SCAND, V149, P11; BUNEGIN L, 1986, CRIT CARE MED, V14, P387, DOI 10.1097/00003246-198604000-00151; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DILUZIO NR, 1969, EXP MOL PATHOL, V11, P38, DOI 10.1016/0014-4800(69)90069-0; EDNA TH, 1982, ACTA CHIR SCAND, V148, P209; EVANS L, 1993, J STUD ALCOHOL, V54, P441, DOI 10.15288/jsa.1993.54.441; FELL JC, 1990, 34 ANN P ASS ADV AUT, P69; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FRANCO CD, 1988, J NATL MED ASSOC, V80, P63; GORDIS E, 1989, ALCOHOL ALERT NAT I, V3, P1; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JEFFCOATE WJ, 1979, LANCET, V2, P1157; JEFFERYS DB, 1980, LANCET, V1, P308; JOHNSTONE RE, 1973, CLIN PHARMACOL THER, V14, P501; KAZEMI H, 1991, J APPL PHYSIOL, V70, P1, DOI 10.1152/jappl.1991.70.1.1; KIM HJ, 1989, J NEUROSURG, V71, P565, DOI 10.3171/jns.1989.71.4.0565; LOVINGER DM, 1993, ALCOHOL CLIN EXP RES, V17, P19, DOI 10.1111/j.1530-0277.1993.tb00720.x; MARSHALL BE, 1985, PHARMACOL BASIS THER, P276; MELTON JE, 1990, J APPL PHYSIOL, V69, P1296, DOI 10.1152/jappl.1990.69.4.1296; MICHIELS TM, 1983, J APPL PHYSIOL, V55, P929, DOI 10.1152/jappl.1983.55.3.929; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MOSS IR, 1981, J APPL PHYSIOL, V50, P1011, DOI 10.1152/jappl.1981.50.5.1011; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; SAHN SA, 1975, CLIN SCI MOL MED, V49, P33, DOI 10.1042/cs0490033; SANTIAGO TV, 1985, J APPL PHYSIOL, V59, P1675, DOI 10.1152/jappl.1985.59.6.1675; SELIGMAN ML, 1977, LIPIDS, V12, P945, DOI 10.1007/BF02533316; STEWART JR, 1988, 32 ANN P ASS ADV AUT, P319; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275; ZINK BJ, 1988, CIRC SHOCK, V24, P19	38	58	59	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	1995	82	5					822	828		10.3171/jns.1995.82.5.0822			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	QU325	WOS:A1995QU32500016	7714608				2022-02-06	
J	FAKHOURY, T; ABOUKHALIL, B; PEGUERO, E				FAKHOURY, T; ABOUKHALIL, B; PEGUERO, E			DIFFERENTIATING CLINICAL-FEATURES OF RIGHT AND LEFT TEMPORAL-LOBE SEIZURES	EPILEPSIA			English	Article						TEMPORAL LOBE EPILEPSY; SEIZURE SEMIOLOGY; COMPLEX PARTIAL SEIZURES; ELECTROENCEPHALOGRAPHY CLOSED-CIRCUIT VIDEO MONITORING	COMPLEX PARTIAL SEIZURES; EPILEPTIC SEIZURES; LOCALIZING VALUE; HEAD-INJURY; LATERALIZATION; CONSCIOUSNESS; SPEECH; AURAS	We reviewed 127 seizures in 19 consecutive patients with temporal lobe epilepsy (TLE) documented by EEG/closed-circuit TV (EEG-CCTV) monitoring. Ten patients had seizure onset in the right temporal lobe (RTL, 54 seizures), and 9 had seizure onset in the left temporal lobe (LTL, 73 seizures). We compared the clinical characteristics in the two groups and analyzed the seizures for frequency of auras, seizures secondarily generalized, automatisms, tonic head deviation, focal posturing and jerking, ictal speech, and postical manifestations. Automatisms overall were more common in the RTL group, but individual categories (extremity, head and trunk, oroalimentary) were comparable among the two groups. Contralateral focal jerking and tonic head deviation were more common in LTL lobe seizures, as were secondarily generalized seizures. In addition to focal motor symptoms, three features were most statistically significant in distinguishing the two groups: Postictal aphasia occurred exclusively in the LTL group, whereas well-formed ictal speech and rapid return to baseline postictally were noted only in RTL seizures.	VANDERBILT UNIV,MED CTR,DEPT NEUROL,NASHVILLE,TN 37212								ALBERT ML, 1976, ARCH NEUROL-CHICAGO, V33, P453, DOI 10.1001/archneur.1976.00500060059013; BERKOVIC SF, 1991, ANN NEUROL, V29, P175, DOI 10.1002/ana.410290210; CURRIE S, 1971, BRAIN, V94, P173, DOI 10.1093/brain/94.1.173; Engel, 1987, SURG TREATMENT EPILE, P553; Engel J., 1987, SURGICAL TREATMENT E, P75; GABR M, 1989, ANN NEUROL, V25, P82, DOI 10.1002/ana.410250113; GUPTA AK, 1983, J NEUROL NEUROSUR PS, V46, P1079, DOI 10.1136/jnnp.46.12.1079; JACKSON JH, 1931, SELECTED WRITINGS J, V1, P464; KING DW, 1977, ANN NEUROL, V2, P138, DOI 10.1002/ana.410020209; KOERNER M, 1988, NEUROLOGY, V38, P634, DOI 10.1212/WNL.38.4.634; KOTAGAL P, 1992, EPILEPSY SURGERY, P143; KOTAGAL P, 1989, NEUROLOGY, V39, P196, DOI 10.1212/WNL.39.2.196; KRAMER RE, 1988, NEUROLOGY, V38, P1048, DOI 10.1212/WNL.38.7.1048; LEVIN HS, 1989, LANCET, V1, P1001; LUDERS H, 1991, BRAIN, V114, P743, DOI 10.1093/brain/114.2.743; MALDONADO HM, 1988, EPILEPSIA, V29, P420, DOI 10.1111/j.1528-1157.1988.tb03741.x; MCLACHLAN RS, 1987, NEUROLOGY, V37, P1617, DOI 10.1212/WNL.37.10.1617; MITCHELL WG, 1983, ARCH NEUROL-CHICAGO, V40, P251, DOI 10.1001/archneur.1983.04050040081017; OCHS R, 1984, NEUROLOGY, V34, P884, DOI 10.1212/WNL.34.7.884; PALMINI A, 1992, NEUROLOGY, V42, P801, DOI 10.1212/WNL.42.4.801; PRIVITERA MD, 1991, ANN NEUROL, V30, P391, DOI 10.1002/ana.410300311; QUESNEY LF, 1986, EPILEPSIA, V27, pS27, DOI 10.1111/j.1528-1157.1986.tb05738.x; ROBILLARD A, 1983, NEUROLOGY, V33, P1241, DOI 10.1212/WNL.33.9.1241; ROSADINI G, 1967, BRAIN, V90, P101, DOI 10.1093/brain/90.1.101; SALAZAR AM, 1986, NEUROLOGY, V36, P178, DOI 10.1212/WNL.36.2.178; SCHWARTZ B, 1967, ACTA NEUROL SCAND, V43, P513, DOI 10.1111/j.1600-0404.1967.tb05757.x; SERAFETINIDES EA, 1963, BRAIN, V86, P333, DOI 10.1093/brain/86.2.333; SERAFETINIDES EA, 1965, BRAIN, V88, P107, DOI 10.1093/brain/88.1.107; TAYLOR DC, 1987, J NEUROL NEUROSUR PS, V50, P673, DOI 10.1136/jnnp.50.6.673; THEODORE WH, 1983, NEUROLOGY, V53, P1115; WADA JA, 1982, ADV EPILEPTOL, P365; Wieser HG, 1986, RECENT ADV EPILEPSY, P57; WYLLIE E, 1986, NEUROLOGY, V36, P606, DOI 10.1212/WNL.36.5.606	33	58	59	0	2	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0013-9580			EPILEPSIA	Epilepsia	SEP-OCT	1994	35	5					1038	1044		10.1111/j.1528-1157.1994.tb02552.x			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PP612	WOS:A1994PP61200020	7925149				2022-02-06	
J	VINK, R; GOLDING, EM; HEADRICK, JP				VINK, R; GOLDING, EM; HEADRICK, JP			BIOENERGETIC ANALYSIS OF OXIDATIVE-METABOLISM FOLLOWING TRAUMATIC BRAIN INJURY IN RATS	JOURNAL OF NEUROTRAUMA			English	Article							NUCLEAR-MAGNETIC-RESONANCE; CEREBRAL BLOOD-FLOW; EXPERIMENTAL HEAD-INJURY; ENERGY-METABOLISM; FREE MAGNESIUM; FLUID; PH; SPECTROSCOPY; P-31-NMR; ACIDOSIS	Studies of fluid percussion-induced traumatic brain injury have shown that moderate trauma results in ionic imbalances, with resultant increases in energy demand to restore these ion gradients. Because there are also increased rates of glucose metabolism during periods of focal decline in blood flow, it has been suggested that the mitochondria may be incapable of sufficient oxidative metabolism to cope with this increased energy demand after injury and that ATP derived from substrate level phosphorylation must meet this demand. In the present study, we used phosphorus magnetic resonance spectroscopy to determine the:mitochondrial capacity for oxidative phosphorylation after moderate brain trauma. Before injury, mean oxidative capacity was 54% +/- 1%. After injury, mean capacity increased significantly (p < 0.001) to a maximum of 61% +/- 1%, indicating that mitochondrial oxidative metabolism was enhanced after trauma. Increased oxidative capacity was accompanied by increases in ADP, AMP, and inorganic phosphate concentrations and was correlated to decreases in cytosolic phosphorylation ratio. We conclude that moderate brain trauma increases mitochondrial rate of ATP synthesis over the first 4 h posttrauma, and that during this time of increased- ATP turnover, positive feedback regulation of glycolysis by increased concentrations of ADP, AMP, and inorganic phosphate contributes to maintenance of metabolic steady state.			VINK, R (corresponding author), JAMES COOK UNIV N QUEENSLAND, DIV BIOCHEM & HUMAN PHYSIOL, TOWNSVILLE, QLD 4811, AUSTRALIA.		Vink, Robert/S-5616-2019; Vink, Robert/J-7351-2012	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667			ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; BOCK JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P8, DOI 10.1016/0167-4889(87)90079-6; CHANCE B, 1955, J BIOL CHEM, V217, P383; CHANCE B, 1986, FED PROC, V45, P2915; CHANCE B, 1986, P NATL ACAD SCI USA, V83, P9458, DOI 10.1073/pnas.83.24.9458; COHN M, 1962, J BIOL CHEM, V237, P176; CUNNINGHAM CC, 1986, BIOCHIM BIOPHYS ACTA, V885, P12, DOI 10.1016/0167-4889(86)90033-9; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; EMERSON CS, 1992, NEUROREPORT, V3, P957, DOI 10.1097/00001756-199211000-00002; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HILLERED L, 1985, J CEREBR BLOOD F MET, V5, P259, DOI 10.1038/jcbfm.1985.33; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HOVDA DA, 1992, CENTRAL NERVOUS SYST, P47; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; JANE JA, 1992, CENTRAL NERVOUS SYST; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KOCHER M, 1990, J CEREBR BLOOD F MET, V10, P564, DOI 10.1038/jcbfm.1990.99; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEYER JS, 1970, J NEUROSURG, V32, P304, DOI 10.3171/jns.1970.32.3.0304; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NIOKA S, 1990, J APPL PHYSIOL, V68, P2527, DOI 10.1152/jappl.1990.68.6.2527; NIOKA S, 1991, Neurological Research, V13, P25; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; SHAH KR, 1983, NEUROSCI LETT, V40, P287, DOI 10.1016/0304-3940(83)90053-8; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; SUGANO T, 1974, BIOCHIM BIOPHYS ACTA, V347, P340, DOI 10.1016/0005-2728(74)90074-7; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	39	58	61	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1994	11	3					265	274		10.1089/neu.1994.11.265			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	PF221	WOS:A1994PF22100003	7996581				2022-02-06	
J	LEVIN, HS				LEVIN, HS			TREATMENT OF POSTCONCUSSIONAL SYMPTOMS WITH CDP-CHOLINE	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article; Proceedings Paper	MEETING ON PHARMACOLOGY OF TRAUMATIC BRAIN INJURY	JUN 22-23, 1990	TOLEDO, SPAIN	WORLD FEDERAT NEUROL				To evaluate the efficacy of cytidine diphosphoryl choline (CDP-choline) in treating postconcussional symptoms for one month after mild to moderate closed head injury (CHI), we completed a preliminary double blind placebo-controlled study. Fourteen young men admitted to the neurosurgery service after sustaining mild to moderate CHI were randomized to oral CDP-choline (1 g) and placebo control groupswhich were matched for age, education and severity of impaired consciousness. Baseline (prior to discharge) and one month examinations consisted of a structured postconcussional symptom interview and neuropsychological tests. Results (Wilcoxon test) showed that CDP-choline produced a greater reduction of postconcussional symptoms than placebo (P < 0.005). Analysis of the neuropsychological findings revealed a significantly greater improvement in recognition memory for designs in the CDP-choline treated patients (P < 0.02) whereas other changes in test performance did not differ for the two groups. Pending replication in a larger series of patients, our findings suggest that CDP-choline may be effective in treating sequelae of mild to moderate CHI.			LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550, USA.							0	58	61	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	JUL	1991	103			S			S39	S42					4	Clinical Neurology; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GF379	WOS:A1991GF37900007	1940965				2022-02-06	
J	MONTGOMERY, EA; FENTON, GW; MCCLELLAND, RJ; MACFLYNN, G; RUTHERFORD, WH				MONTGOMERY, EA; FENTON, GW; MCCLELLAND, RJ; MACFLYNN, G; RUTHERFORD, WH			THE PSYCHOBIOLOGY OF MINOR HEAD-INJURY	PSYCHOLOGICAL MEDICINE			English	Article							AUDITORY EVOKED-RESPONSES; CONCUSSION; SEQUELAE; COMPENSATION; POTENTIALS; NEUROSIS; MILD	Twenty-six consecutive admissions to an accident and emergency unit with minor head injury were examined. This was defined as a head injury warranting brief in-patient overnight stay but with a post-traumatic amnesia of less than 12 hours. Each patient had a neurological examination, a post-traumatic symptom check list completed, EEG power spectra analysis and auditory brain stem-evoked potential recordings, and a four-choice reaction-time measurement. These assessments were repeated six weeks later. Six months after the head injury a symptom check list was completed and four-choice reaction time measured again. Post-traumatic symptoms are persistent in half of all patients at six weeks and six months follow-up. The EEG power spectra showed a significant change in theta power between the first recording and the second one at six weeks, with relative reduction being noted. Approximately half of all the patients had significant delays in brain stem conduction time at day 0. There was a trend towards a decrease in brain stem conduction time at six weeks, though in almost half the brain stem conduction time still remained abnormal at six weeks. Head-injured patients had prolonged choice reaction times at day 0 with serial improvement between then and six months, though the values at six weeks were still significantly longer than health controls. It is suggested that these findings reflect both cortical and brain stem damage following minor head injury, the brain stem damage being more persistent. There appear to be three patterns of recovery, half recovering within six weeks, a minority persisting over six months with persisting brain stem dysfunction and less than a third showing an exacerbation of symptoms with no evidence of brain stem dysfunction, the exacerbation being possibly a consequence of psychological and social factors.	UNIV DUNDEE,DEPT PSYCHIAT,DUNDEE DD1 4HN,SCOTLAND; QUEENS UNIV BELFAST,DEPT MENTAL HLTH,BELFAST BT7 1NN,ANTRIM,NORTH IRELAND; HOLYWELL HOSP,ANTRIM,NORTH IRELAND; MATER INFIRMORIUM HOSP,BELFAST,NORTH IRELAND; ROYAL VICTORIA HOSP,BELFAST BT12 6BA,NORTH IRELAND								ALEXANDER MP, 1982, PSYCHIATRIC ASPECTS, V2, P219; Brown G. W., 1978, SOCIAL ORIGINS DEPRE; BROWN RH, 1981, ELECTROEN CLIN NEURO, V51, pP38; CARTLIDGE NEF, 1981, HEAD INJURY, P203; CHIAPPA KH, 1983, EVOKED POTENTIALS CL; COBB WA, 1963, ELECTROENCEPHALOGRAP, P232; COOPER R, 1965, ELECTROEN CLIN NEURO, V18, P217, DOI 10.1016/0013-4694(65)90088-X; Dow RS, 1944, AM J PSYCHIAT, V101, P174, DOI 10.1176/ajp.101.2.174; ERICKSEN JD, 1866, CONCUSSION SPINE NER; GRONWALL D, 1974, LANCET, V2, P605; HARRISON MS, 1956, BRAIN, V79, P474, DOI 10.1093/brain/79.3.474; HENDERSON S, 1981, NEUROSIS SOCIAL ENV, P279; HOUSTON HG, 1985, BIOL PSYCHIAT, V20, P419, DOI 10.1016/0006-3223(85)90044-7; JOHNSON LC, 1975, BEHAVIOR BRAIN ELECT, P1; KAY DWK, 1971, LANCET, V2, P1052; KUNKEL H, 1977, EEG INFORMATICS DIDA, P9; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; NOSEWORTHY JH, 1981, ARCH NEUROL-CHICAGO, V38, P275, DOI 10.1001/archneur.1981.00510050041004; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; RIZZO PA, 1983, NEUROPSYCHOBIOLOGY, V9, P78, DOI 10.1159/000117941; ROWE MJ, 1980, ARCH NEUROL-CHICAGO, V37, P679, DOI 10.1001/archneur.1980.00500600027002; Ruff R. M., 1989, MILD HEAD INJURY, P176; RUTHERFORD WH, 1977, LANCET, V1, P1; Schoenhuber R, 1983, J Neurosurg Sci, V27, P157; Strauss I, 1934, ARCH NEURO PSYCHIATR, V31, P893, DOI 10.1001/archneurpsyc.1934.02250050011001; TARSH MJ, 1985, BRIT J PSYCHIAT, V146, P18, DOI 10.1192/bjp.146.1.18; TAYLOR AR, 1967, BRIT MED J, V3, P67, DOI 10.1136/bmj.3.5557.67; Trimble M.R., 1981, POSTTRAUMATIC NEUROS; WEIGHILL VE, 1983, J PSYCHOSOM RES, V27, P97, DOI 10.1016/0022-3999(83)90085-5; WEINER RD, 1983, EEG EVOKED POTENTIAL, P1; WILKINSON RT, 1975, BEHAV RES METH INSTR, V7, P441, DOI 10.3758/BF03201557; Wing JK, 1974, MEASUREMENT CLASSIFI, P233	40	58	58	0	7	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211	0033-2917			PSYCHOL MED	Psychol. Med.	MAY	1991	21	2					375	384		10.1017/S0033291700020481			10	Psychology, Clinical; Psychiatry; Psychology	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Psychiatry	FR873	WOS:A1991FR87300013	1876643				2022-02-06	
J	PRATAPCHAND, R; SINNIAH, M; SALEM, FA				PRATAPCHAND, R; SINNIAH, M; SALEM, FA			COGNITIVE EVOKED-POTENTIAL P300 - A METRIC FOR CEREBRAL CONCUSSION	ACTA NEUROLOGICA SCANDINAVICA			English	Article											PRATAPCHAND, R (corresponding author), UNIV HOSP MALAYSIA,DEPT MED,KUBANG KERIAN 15990,MALAYSIA.						BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; CALLAWAY E, 1984, BIOL PSYCHIAT, V19, P649; Donchin E., 1979, EVOKED BRAIN POTENTI, P13, DOI DOI 10.1007/978-1-4684-3462-0_2; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GOODIN DS, 1978, ELECTROEN CLIN NEURO, V44, P447, DOI 10.1016/0013-4694(78)90029-9; GOODIN DS, 1979, BRAIN, V101, P635; GRONWALL D, 1974, LANCET, V2, P605; HAMMOND EJ, 1987, NEUROLOGY, V37, P346, DOI 10.1212/WNL.37.2.346; HILLYARD SA, 1983, ANNU REV PSYCHOL, V34, P33, DOI 10.1146/annurev.ps.34.020183.000341; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; MULLIS RJ, 1985, ELECTROEN CLIN NEURO, V62, P141, DOI 10.1016/0168-5597(85)90026-7; OKADA YC, 1983, ELECTROEN CLIN NEURO, V55, P417, DOI 10.1016/0013-4694(83)90130-X; OLBRICH HM, 1986, ACTA NEUROCHIR, V80, P116, DOI 10.1007/BF01812285; OLBRICH HM, 1986, SURG NEUROL, V26, P112, DOI 10.1016/0090-3019(86)90362-9; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PAPANICOLAOU AC, 1984, NEUROSURGERY, V6, P676; PICTON TW, 1984, PSYCHOPHYSIOLOGY, V21, P312, DOI 10.1111/j.1469-8986.1984.tb02941.x; ROHRBAUGH JW, 1974, PERCEPT PSYCHOPHYS, V15, P368, DOI 10.3758/BF03213960; ROWE MJ, 1980, ARCH NEUROL-CHICAGO, V37, P679, DOI 10.1001/archneur.1980.00500600027002; Schoenhuber R, 1983, J Neurosurg Sci, V27, P157; SIMSON R, 1976, ELECTROEN CLIN NEURO, V40, P33, DOI 10.1016/0013-4694(76)90177-2; TEASDALE G, 1974, LANCET, V2, P81; VAUGHAN HG, 1970, ELECTROEN CLIN NEURO, V28, P360, DOI 10.1016/0013-4694(70)90228-2; WARD AA, 1966, HEAD INJURY C P, P203; Wood C C, 1980, Prog Brain Res, V54, P51, DOI 10.1016/S0079-6123(08)61605-2	25	58	61	0	4	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-6314			ACTA NEUROL SCAND	Acta Neurol. Scand.	SEP	1988	78	3					185	189		10.1111/j.1600-0404.1988.tb03643.x			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	Q4555	WOS:A1988Q455500005	3227804				2022-02-06	
J	STOKX, LC; GAILLARD, AWK				STOKX, LC; GAILLARD, AWK			TASK AND DRIVING PERFORMANCE OF PATIENTS WITH A SEVERE CONCUSSION OF THE BRAIN	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article											STOKX, LC (corresponding author), TNO SOESTERBERG,INST PERCEPT,POB 23,3769 ZG SOESTERBERG,NETHERLANDS.						Frowein H.W., 1981, SELECTIVE DRUG EFFEC; HOUTMANS MJM, 1981, ACTA PSYCHOL, V55, P143; JENNETT B, 1984, CLOSED HEAD INJURY P, P37; MORAAL J, 1982, 26TH P ANN M HUM FAC; Sanders A. F., 1980, TUTORIALS MOTOR BEHA, P331, DOI DOI 10.1016/S0166-4115(08)61955-X; Sanders A. F., 1977, ATTENTION PERFORM, P3; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; Sternberg S, 1969, ACTA PSYCHOL, V30, P276, DOI 10.1016/0001-6918(69)90055-9; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1984, PSYCHOL SOCIAL FAMIL, P74; VELING IH, 1981, IZF1981M26 I PERC TN; WELFORD AT, 1980, HUMAN FACTORS, V23, P97	13	58	58	0	7	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG	1986	8	4					421	436		10.1080/01688638608401332			16	Psychology, Clinical; Clinical Neurology; Psychology	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Neurosciences & Neurology	D6021	WOS:A1986D602100009	3745415				2022-02-06	
J	ROSENBLUM, WI; GREENBERG, RP; SEELIG, JM; BECKER, DP				ROSENBLUM, WI; GREENBERG, RP; SEELIG, JM; BECKER, DP			MIDBRAIN LESIONS - FREQUENT AND SIGNIFICANT PROGNOSTIC FEATURE IN CLOSED HEAD-INJURY	NEUROSURGERY			English	Article									VIRGINIA COMMONWEALTH UNIV, DEPT SURG NEUROSURG, RICHMOND, VA 23298 USA		ROSENBLUM, WI (corresponding author), VIRGINIA COMMONWEALTH UNIV, DEPT PATHOL NEUROPATHOL, RICHMOND, VA 23298 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K07-NS346-03] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [124587] Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; Adams JH, 1975, HDB CLIN NEUROLOGY, V23, P35; BUDZILOVICH GN, 1976, HEAD INJURIES 2ND CH, P39; GREENBERG RP, 1977, J NEUROSURG, V47, P150, DOI 10.3171/jns.1977.47.2.0150; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; GREENBERG RP, 1964, CLIN NEUROSURG, V12, P129; MITCHELL DE, 1973, LANCET, V2, P215; NARAYAN RK, J NEUROSURG; NAUMENKO J, 1963, ACTA NEUROPATHOL BER, V2, P402; NEWLON P, REHABILITATION TRAUM; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; STRICH SJ, GREENFIELDS NEUROPAT, P327; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154	13	58	58	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery		1981	9	6					613	620		10.1227/00006123-198112000-00001			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	MT893	WOS:A1981MT89300001	7322325				2022-02-06	
J	Manek, R; Moghieb, A; Yang, ZH; Kumar, D; Kobessiy, F; Sarkis, GA; Raghavan, V; Wang, KKW				Manek, Rachna; Moghieb, Ahmed; Yang, Zhihui; Kumar, Dhwani; Kobessiy, Firas; Sarkis, George Anis; Raghavan, Vijaya; Wang, Kevin K. W.			Protein Biomarkers and Neuroproteomics Characterization of Microvesicles/Exosomes from Human Cerebrospinal Fluid Following Traumatic Brain Injury	MOLECULAR NEUROBIOLOGY			English	Article						Traumatic brain injury; Biomarkers; Neuronal injury; Glial injury; Systems biology; Exosome; Microvesicles	GLUTAMATE TRANSPORTERS; STROMAL CELLS; SERUM-LEVELS; EXOSOMES; MILD; MECHANISMS; BREAKDOWN; RECOVERY; TAU	Recently, there have been emerging interests in the area of microvesicles and exosome (MV/E) released from brain cells in relation to neurodegenerative diseases. However, only limited studies focused on MV/E released post-traumatic brain injury (TBI) as they highlight on the mechanistic roles of released proteins. This study sought to examine if CSF samples from severe TBI patients contain MV/E with unique protein contents. First, nanoparticle tracking analysis determined MV/E from TBI have a mode of 74-98 nm in diameter, while control CSF MV/E have a mode of 99-104 nm. Also, there are more MV/E were isolated from TBI CSF (27.8-33.6 x 10(8)/mL) than from control CSF (13.1-18.5 x 10(8)/mL). Transmission electron microscopy (TEM) visualization also confirmed characteristic MV/E morphology. Using targeted immunoblotting approach, we observed the presence of several known TBI biomarkers such as alpha II-spectrin breakdown products (BDPs), GFAP, and its BDPs and UCH-L1 in higher concentrations in MV/E from TBI CSF than their counterparts from control CSF. Furthermore, we found presynaptic terminal protein synaptophysin and known exosome marker Alix enriched in MV/E from human TBI CSF. In parallel, we conducted nRPLC-tandem mass spectrometry-based proteomic analysis of two control and two TBI CSF samples. Ninety-one proteins were identified with high confidence in MV/E from control CSF, whereas 466 proteins were identified in the counterpart from TBI CSF. MV/E isolated from human CSF contain cytoskeletal proteins, neurite-outgrowth related proteins, and synaptic proteins, extracellular matrix proteins, and complement protein C1q subcomponent subunit B. Taken together, following severe TBI, the injured human brain released increased number of extracellular microvesicles/exosomes (MV/E) into CSF. These TBI MV/E contain several known TBI biomarkers and previously undescribed brain protein markers. It is also possible that such TBI-specific MV/E might contain cell to cell communication factors related to both cell death signaling a well as neurodegeneration pathways.	[Manek, Rachna; Moghieb, Ahmed; Yang, Zhihui; Kumar, Dhwani; Kobessiy, Firas; Sarkis, George Anis; Raghavan, Vijaya; Wang, Kevin K. W.] Univ Florida, Dept Emergency Med, Program Neurotrauma Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA; [Manek, Rachna; Moghieb, Ahmed; Yang, Zhihui; Kumar, Dhwani; Kobessiy, Firas; Sarkis, George Anis; Raghavan, Vijaya; Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Moghieb, Ahmed] Pacific Northwest Natl Lab, 902 Battelle Blvd, Richland, WA 99352 USA; [Kobessiy, Firas] Amer Univ Beirut, Bliss St,POB 11-0236, Beirut, Lebanon; [Sarkis, George Anis] Alexandria Univ, Dept Chem, POB 426, Alexandria 21321, Egypt; [Raghavan, Vijaya] Schizophrenia Res Fdn, R-7A,North Main Rd, Madras 600101, Tamil Nadu, India; [Wang, Kevin K. W.] Univ Florida, Dept Neurosci, Gainesville, FL 32611 USA; [Wang, Kevin K. W.] Univ Florida, Dept Chem, Gainesville, FL 32603 USA		Wang, KKW (corresponding author), Univ Florida, Dept Emergency Med, Program Neurotrauma Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA.; Wang, KKW (corresponding author), Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA.; Wang, KKW (corresponding author), Univ Florida, Dept Neurosci, Gainesville, FL 32611 USA.; Wang, KKW (corresponding author), Univ Florida, Dept Chem, Gainesville, FL 32603 USA.	kwang@ufl.edu		Wang, Kevin/0000-0002-9343-6473	UF Psychiatry Department development fund; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 NS085455-01, 1U01 NS086090-01]; DOD grant [W81XWH-14-2-0176]; Fogarty International Training Program in Chronic Non-Communicable Diseases and Disorders at the University of Florida [1D43TW009120]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090] Funding Source: NIH RePORTER	This study is in part funded by UF Psychiatry Department development fund. This study is supported in part by NIH grant R21 NS085455-01 (KKW), NIH 1U01 NS086090-01), and DOD grant (W81XWH-14-2-0176) (KKW; G. Manley of UCSF). Post-Doctoral support is by the Fogarty International Training Program in Chronic Non-Communicable Diseases and Disorders at the University of Florida, Grant # 1D43TW009120 (L. Cottler, PI) (VR). We want to thank Dr. Linda Cottler for her support.	[Anonymous], TBI GET FACTS CONC T; Bernath E, 2006, NEUROBIOL AGING, V27, P624, DOI 10.1016/j.neurobiolaging.2005.02.013; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Foran E, 2009, ANTIOXID REDOX SIGN, V11, P1587, DOI 10.1089/ars.2009.2444; Fruhbeis C, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001604; Gisslen M, 2016, EBIOMEDICINE, V3, P135, DOI 10.1016/j.ebiom.2015.11.036; Haneklaus M, 2013, CURR OPIN IMMUNOL, V25, P40, DOI 10.1016/j.coi.2012.12.004; Kalani A, 2014, MOL NEUROBIOL, V49, P590, DOI 10.1007/s12035-013-8544-1; Kobeissy FH, 2009, METHODS MOL BIOL, V566, P217, DOI 10.1007/978-1-59745-562-6_15; Kobeissy FH, 2015, MOL NEUROBIOL, V52, P696, DOI 10.1007/s12035-014-8898-z; Kumar D, 2017, MOL NEUROBIOL, P1; Laskowitz D., 2016, TRANSLATIONAL RES TR; Lei J, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1081-8; Moghieb A, 2016, MOL CELL PROTEOMICS, V15, P2379, DOI 10.1074/mcp.M116.058115; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Nekludov M, 2014, J NEUROTRAUM, V31, P1927, DOI 10.1089/neu.2013.3168; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Reilly P, 2017, NEUROBIOL DIS; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Russo Isabella, 2012, Am J Neurodegener Dis, V1, P217; Stern RA, 2016, J ALZHEIMERS DIS, V51, P1099, DOI 10.3233/JAD-151028; Taylor DD, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0503; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Vaccari JPD, 2016, J NEUROCHEM, V136, P39, DOI 10.1111/jnc.13036; Vella LJ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020173; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang Y, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-016-0143-y; Xin HQ, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00377; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Xiong Y, 2017, NEURAL REGEN RES, V12, P19, DOI 10.4103/1673-5374.198966; Yang YX, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00055; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Yousefzadeh-Chabok S, 2015, ARCH TRAUMA RES, V4, DOI 10.5812/atr.18357; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhang ZQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092698; Zoltewicz JS, 2013, J NEUROTRAUM, V30, P1161, DOI 10.1089/neu.2012.2762	45	57	60	0	24	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	JUL	2018	55	7					6112	6128		10.1007/s12035-017-0821-y			17	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GI8VY	WOS:000434805100051	29188495	Green Accepted			2022-02-06	
J	Asken, BM; Bauer, RM; Guskiewicz, KM; McCrea, MA; Schmidt, JD; Giza, CC; Snyder, AR; Houck, ZM; Kontos, AP; McAllister, TW; Broglio, SP; Clugston, JR				Asken, Breton M.; Bauer, Russell M.; Guskiewicz, Kevin M.; McCrea, Michael A.; Schmidt, Julianne D.; Giza, Christopher C.; Snyder, Aliyah R.; Houck, Zachary M.; Kontos, Anthony P.; McAllister, Thomas W.; Broglio, Steven P.; Clugston, James R.		CARE Consortium Investigators	Immediate Removal From Activity After Sport-Related Concussion Is Associated With Shorter Clinical Recovery and Less Severe Symptoms in Collegiate Student-Athletes	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						brain injury; concussion reporting; CARE Consortium; mTBI	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; FOOTBALL PLAYERS; VOLUNTARY EXERCISE; PROLONGED RECOVERY; MILD CONCUSSION; NCAA CONCUSSION; UP-REGULATION; HEAD-INJURY; MANAGEMENT	Background: Timely removal from activity after concussion symptoms remains problematic despite heightened awareness. Previous studies indicated potential adverse effects of continuing to participate in physical activity immediately after sustaining a concussion. Hypothesis/Purpose: The purpose was to determine the effect of timing of removal from play after concussion on clinical outcomes. It was hypothesized that immediate removal from activity after sport-related concussion (SRC) would be associated with less time missed from sport, a shorter symptomatic period, and better outcomes on acute clinical measures. Study Design: Cohort study; Level of evidence, 3. Methods: Data were reported from the National Collegiate Athletic Association and Department of Defense Grand Alliance: Concussion Awareness, Research, and Education (CARE) Consortium. Participants with 506 diagnosed SRCs from 18 sports and 25 institutions and military service academies were analyzed and classified as either immediate removal from activity (I-RFA) or delayed removal from activity (D-RFA). Outcomes of interest included time missed from sport attributed to their SRC, symptom duration, and clinical assessment scores. Results: There were 322 participants (63.6%) characterized as D-RFA. I-RFA status was associated with significantly less time missed from sport (R-2 change = .022-.024, P < .001 to P = .001) and shorter symptom duration (R-2 change = .044-.046, P < .001 [all imputations]) while controlling for other SRC recovery modifiers. These athletes missed approximately 3 fewer days from sport participation. I-RFA athletes had significantly less severe acute SRC symptoms and were at lower risk of recovery taking >= 14 days (relative risk = .614, P < .001, small-medium effect size) and >= 21 days (relative risk = .534, P = .010, small effect size). Conclusion: I-RFA is a protective factor associated with less severe acute symptoms and shorter recovery after SRC. Conveying this message to athletes, coaches, and others involved in the care of athletes may promote timely injury reporting.	[Asken, Breton M.; Bauer, Russell M.; Guskiewicz, Kevin M.; McCrea, Michael A.; Schmidt, Julianne D.; Giza, Christopher C.; Snyder, Aliyah R.; Houck, Zachary M.; Kontos, Anthony P.; McAllister, Thomas W.; Broglio, Steven P.; Clugston, James R.; CARE Consortium Investigators] Univ Florida, Gainesville, FL USA		Asken, BM (corresponding author), Univ Florida, Dept Clin & Hlth Psychol, POB 100165, Gainesville, FL 32610 USA.	basken8@phhp.ufl.edu	Rowson, Steven/B-1270-2012; Snyder, Aliyah/AAT-6250-2020	Rowson, Steven/0000-0002-3227-0596; Chrisman, Sara/0000-0001-5373-7223; Asken, Breton/0000-0001-8419-142X; Snyder, Aliyah/0000-0003-1185-7424; Clugston, James/0000-0002-2103-1039	Grand Alliance Concussion Assessment, Research, and Education Consortium; National Collegiate Athletic Association; Department of DefenseUnited States Department of Defense; Office of the Assistant Secretary of Defense for Health Affairs through Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]; National Center for Advancing Translational SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 RR029890]; Veterans Health Administration Office of Research and Development [1 I21 RX001730]; Veterans AffairsUS Department of Veterans Affairs [I21RX001730] Funding Source: NIH RePORTER	This publication was supported in part by the Grand Alliance Concussion Assessment, Research, and Education Consortium, which receives funding from the National Collegiate Athletic Association and the Department of Defense. The US Army Medical Research Acquisition Activity is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program (award W81XWH-14-2-0151). The study was also supported by National Center for Advancing Translational Sciences (UL1 RR029890) and Veterans Health Administration Office of Research and Development (1 I21 RX001730; R.M.B.).	Asken BM, 2017, ARCH CLIN NEUROPSYCH, V32, P963, DOI 10.1093/arclin/acx018; Asken BM, 2017, CLIN NEUROPSYCHOL, V31, P138, DOI 10.1080/13854046.2016.1246672; Asken BM, 2016, J ATHL TRAINING, V51, P329, DOI 10.4085/1062-6050-51.5.02; Baugh CM, 2014, J LAW MED ETHICS, V42, P314, DOI 10.1111/jlme.12148; Broglio SP, 2017, SPORTS MED, V47, P1437, DOI 10.1007/s40279-017-0707-1; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, pe333; Collins MW, 2016, NEUROSURGERY, V79, P912, DOI 10.1227/NEU.0000000000001447; Derogatis LR., 2001, BSI 18 BRIEF SYMPTOM; Dvorak J, 2007, BRIT J SPORT MED, V41, pI44, DOI 10.1136/bjsm.2007.037960; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Elbin RJ, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0910; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Graham JW, 2007, PREV SCI, V8, P206, DOI 10.1007/s11121-007-0070-9; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Heyer GL, 2016, J PEDIATR-US, V174, P33, DOI 10.1016/j.jpeds.2016.03.014; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Kamins J, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097464; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mychasiuk R, 2016, EUR J NEUROSCI, V44, P2407, DOI 10.1111/ejn.13360; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Sakurai A, 2012, J NEUROTRAUM, V29, P313, DOI 10.1089/neu.2011.2152; Schneider KJ, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097475; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Terwilliger VK, 2016, J NEUROTRAUM, V33, P761, DOI 10.1089/neu.2015.4082; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Titus DJ, 2015, EXP NEUROL, V263, P254, DOI 10.1016/j.expneurol.2014.10.020; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339	50	57	56	2	12	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAY	2018	46	6					1465	1474		10.1177/0363546518757984			10	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Sport Sciences	GF7IB	WOS:000432140700024	29558195	Green Accepted			2022-02-06	
J	Li, HL; Wang, P; Huang, F; Jin, JM; Wu, H; Zhang, BB; Wang, ZF; Shi, HL; Wu, XJ				Li, Hongli; Wang, Ping; Huang, Fei; Jin, Jinmei; Wu, Hui; Zhang, Beibei; Wang, Zhifei; Shi, Hailian; Wu, Xiaojun			Astragaloside IV protects blood-brain barrier integrity from LPS-induced disruption via activating Nrf2 antioxidant signaling pathway in mice	TOXICOLOGY AND APPLIED PHARMACOLOGY			English	Article						Astragaloside IV; Blood-brain barrier; ROS; Nrf2; Tight junction	CEREBRAL ISCHEMIA-REPERFUSION; TRANSCRIPTION FACTOR NRF2; OXIDATIVE STRESS; ENDOTHELIAL-CELLS; COGNITIVE IMPAIRMENTS; PRIMARY CULTURES; DYSFUNCTION; DISEASE; STROKE; INJURY	Endothelial cells of cerebral microvessels are one of the components of blood-brain-barrier (BBB), which are connected by tight junctions (TJs). BBB disruption in cerebral diseases such as ischemic stroke, Alzhemer's disease, multiple sclerosis and traumatic brain injury is implicated to exacerbate the disease progression. Astragaloside IV (ASIV) isolated from Astragalus membranaceus prevents BBB breakdown in rodents induced with cerebral edema and experimental autoimmune encephalomyelitis. However, its underlying molecular mechanism has not been elucidated yet. In present study, ASIV was found to prevent the leakage of BBB in LPS-induced mice, which was accompanied with increased zo-1 and occludin but reduced VCAM-1 in brain micro vessels. Similarly, in brain endothelial cell line bEnd.3 cells, ASIV mitigated the increased permeability induced by LPS, as evidenced by increased TEER and reduced sodium fluorescein extravasation. ASIV also enhanced the expression of TJ proteins such as zo-1, occludin and claudin-5 in LPS stimulated bEnd.3 cells. Meanwhile, it inhibited the inflammatory responses and prevented the monocyte adhesion onto bEnd.3 cells upon LPS stimulation. Further study disclosed that ASIV could alleviate ROS level and activate Nrf2 antioxidant pathway in bEnd.3 cells. When Nrf2 was silenced, the protective effect of ASIV was abolished. In brain microvessels of LPS-induced mice, ASIV also enhanced the expression of Nrf2 antioxidant pathway related proteins. Collectively, our results demonstrated that ASIV protected the integrity of BBB in LPS-induced mice, the mechanism of which might be mediated via activating Nrf2 signaling pathway. The findings suggested that ASIV might be a potential neuroprotective drug acting on BBB.	[Li, Hongli; Wang, Ping; Huang, Fei; Jin, Jinmei; Wu, Hui; Zhang, Beibei; Wang, Zhifei; Shi, Hailian; Wu, Xiaojun] Shanghai Univ Tradit Chinese Med, Inst Chinese Mat Med, Shanghai Key Lab Compound Chinese Med, Minist Educ MOE,Key Lab Standardizat Chinese Med, Shanghai 201203, Peoples R China		Shi, HL; Wu, XJ (corresponding author), Shanghai Univ Tradit Chinese Med, Inst Chinese Mat Med, 1200 Cailun Rd,Zhangjiang Hitech Pk, Shanghai 201203, Peoples R China.	shihailian2003@163.com; xiaojunwu320@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81673626, 81603354]; Shanghai Eastern Scholar Program [2013-59]; Shanghai E-research Institute of Bioactive Constituent in TCM plan;  [QD2015037]	This work was supported by the National Natural Science Foundation of China (81673626, 81603354), Shanghai Eastern Scholar Program (2013-59), Shanghai Youth Eastern Scholar (QD2015037) and Shanghai E-research Institute of Bioactive Constituent in TCM plan.	Alfieri A, 2013, FREE RADICAL BIO MED, V65, P1012, DOI 10.1016/j.freeradbiomed.2013.08.190; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Cai Y, 2017, ADV EXP MED BIOL, V964, P163, DOI 10.1007/978-3-319-50174-1_12; Carrano A, 2011, ANTIOXID REDOX SIGN, V15, P1167, DOI 10.1089/ars.2011.3895; Chang R, 2017, MOL PHARMACEUT, V14, P2340, DOI 10.1021/acs.molpharmaceut.7b00200; Chen ZW, 2015, NEUROCHEM RES, V40, P186, DOI 10.1007/s11064-014-1483-z; Choi BY, 2016, NEUROBIOL DIS, V94, P205, DOI 10.1016/j.nbd.2016.06.018; De Oliveira PA, 2017, BRAIN RES, V1663, P78, DOI 10.1016/j.brainres.2017.03.002; Fukuda S, 2016, J MOL NEUROSCI, V59, P211, DOI 10.1007/s12031-015-0696-1; Gu DM, 2015, BIOCHEM BIOPH RES CO, V457, P391, DOI 10.1016/j.bbrc.2015.01.002; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; He YX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076495; Huang XP, 2014, PHARMACOGN MAG, V10, P402, DOI 10.4103/0973-1296.141765; Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005; Imai T, 2016, NEUROBIOL DIS, V89, P136, DOI 10.1016/j.nbd.2016.02.001; Jung Y. S., 2016, J BIOMED SCI, V2016, P23; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Khan M, 2012, J NEUROCHEM, V123, P86, DOI 10.1111/j.1471-4159.2012.07947.x; Li M, 2017, NEUROSCI LETT, V639, P114, DOI 10.1016/j.neulet.2016.12.046; Li M, 2013, EUR J PHARMACOL, V715, P189, DOI 10.1016/j.ejphar.2013.05.022; Li W, 2016, MICROVASC RES, V106, P117, DOI 10.1016/j.mvr.2015.12.008; Liu CL, 2016, INVEST OPHTH VIS SCI, V57, P2319, DOI 10.1167/iovs.16-19097; Liu GY, 2013, BEHAV BRAIN FUNCT, V9, DOI 10.1186/1744-9081-9-36; Liu H., 2016, SCI REP, V6; McSweeney SR, 2016, HYPERTENSION, V67, P20, DOI 10.1161/HYPERTENSIONAHA.115.06146; Nakagawa S, 2007, CELL MOL NEUROBIOL, V27, P687, DOI 10.1007/s10571-007-9195-4; Patabendige A, 2013, BRAIN RES, V1521, P1, DOI 10.1016/j.brainres.2012.06.057; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Qu YZ, 2009, EUR J PHARMACOL, V606, P137, DOI 10.1016/j.ejphar.2009.01.022; Reynolds A, 2007, INT REV NEUROBIOL, V82, P297, DOI 10.1016/S0074-7742(07)82016-2; Shang Y, 2017, TOXICOL IN VITRO, V44, P66, DOI 10.1016/j.tiv.2017.06.017; Tan S, 2017, CLIN SCI, V131, P1499, DOI 10.1042/CS20170984; Tebay LE, 2015, FREE RADICAL BIO MED, V88, P108, DOI 10.1016/j.freeradbiomed.2015.06.021; Wan WB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113126; Wang B, 2012, FREE RADICAL BIO MED, V52, P928, DOI 10.1016/j.freeradbiomed.2011.12.006; Wang H. L., 2017, OXID MED CELL LONGEV, V2017; WANG Qiang, 2016, J INTERATION TECHNOL, V2, P1, DOI DOI 10.1016/j.sandf.2016.02.001; Wang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep37098; Wei YH, 2015, P NATL ACAD SCI USA, V112, pE6927, DOI 10.1073/pnas.1512683112; Wolburg H, 2009, CELL TISSUE RES, V335, P75, DOI 10.1007/s00441-008-0658-9; Xu CH, 2016, INT IMMUNOPHARMACOL, V33, P119, DOI 10.1016/j.intimp.2016.02.009; Yang ST, 2014, AM J CHINESE MED, V42, P1357, DOI 10.1142/S0192415X14500852; Yu CH, 2007, EXP NEUROL, V203, P116, DOI 10.1016/j.expneurol.2006.07.023; Zehendner CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082823; Zhang M, 2017, CELL PHYSIOL BIOCHEM, V41, P2255, DOI 10.1159/000475640; Zhang WJ, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/274314; Zhao Y, 2015, J ETHNOPHARMACOL, V169, P210, DOI 10.1016/j.jep.2015.04.030	47	57	61	2	66	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0041-008X	1096-0333		TOXICOL APPL PHARM	Toxicol. Appl. Pharmacol.	FEB 1	2018	340						58	66		10.1016/j.taap.2017.12.019			9	Pharmacology & Pharmacy; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy; Toxicology	FV1JO	WOS:000424317600007	29294303				2022-02-06	
J	Webber, TA; Soble, JR				Webber, Troy A.; Soble, Jason R.			Utility of various WAIS-IV Digit Span indices for identifying noncredible performance validity among cognitively impaired and unimpaired examinees	CLINICAL NEUROPSYCHOLOGIST			English	Article						Assessment; malingering/symptom validity testing; elderly/geriatrics/aging	MEMORY MALINGERING TOMM; ADULT INTELLIGENCE SCALE; TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; INSUFFICIENT EFFORT; SCREENING MEASURE; AMERICAN-ACADEMY; EDITION; TESTS; SPECIFICITY	Objective: Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) Reliable Digit Span (RDS), RDS-revised (RDS-R), and age-corrected scaled score (ACSS) are validated and commonly used embedded performance validity tests (PVTs), though existing validation studies have largely examined younger (approximate ages 19-35) patients with mild traumatic brain injury or those without cognitive impairment. This study compared the classification accuracy of RDS, RDS-R, and ACSS in a mixed clinical sample of relatively older (M age=54.61) veterans with and without neurocognitive impairment. Method: During a comprehensive neuropsychological evaluation, 113 clinically-referred veterans completed the WAIS-IV Digit Span subtest and the following criterion PVTs: Dot Counting Test, Word Choice Test, and Test of Memory Malingering. Those with <= 1 criterion PVT failure were classified as valid (n=87), whereas those with >= 2 failures were classified as noncredible (n=26). Among valid participants, 49% were cognitively impaired. Results: RDS, RDS-R, and ACSS all significantly predicted validity group membership with respective areas under the curve (AUCs) of .79, .81, and .85, and optimal cut scores of RDS <= 5, RDS-R <= 9, and ACSS <= 5. Lower accuracy and AUCs were observed for the valid-cognitively impaired subsample across indices, but to a greater degree for traditional RDS. ACSS evidenced maximal sensitivity/specificity for the total sample (<= 5; .62/.87), cognitively unimpaired subsample (<= 5; .62/.95), and cognitively impaired subsample (<= 4; .39/.86). Conclusions: ACSS yielded better classification accuracy and sensitivity/specificity than RDS and RDS-R. While all three indices have utility as embedded PVTs, ACSS <= 5 may be most robust to cognitive impairment while identifying noncredible performance.	[Webber, Troy A.; Soble, Jason R.] South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX 78229 USA; [Soble, Jason R.] Univ Illinois, Dept Psychiat, Coll Med, Chicago, IL 60612 USA; [Soble, Jason R.] Univ Illinois, Coll Med, Dept Neurol, Chicago, IL USA		Webber, TA (corresponding author), South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX 78229 USA.	Troy.Webber@va.gov					American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Bain KM, 2019, ASSESSMENT, V26, P1320, DOI 10.1177/1073191117725172; Barhon LI, 2015, APPL NEUROPSYCH-ADUL, V22, P114, DOI 10.1080/23279095.2013.863775; Boone K., 2002, DOT COUNTING TEST; Boone K.B., 2007, ASSESSMENT FEIGNED C; Boone KB, 2002, ARCH CLIN NEUROPSYCH, V17, P625, DOI 10.1016/S0887-6177(01)00166-4; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Denning J., 2012, ARCH CLIN NEUROPSYCH, V27, P576; Dorociak KE, 2018, CLIN NEUROPSYCHOL, V32, P81, DOI 10.1080/13854046.2017.1339830; Fischer JE, 2003, INTENS CARE MED, V29, P1043, DOI 10.1007/s00134-003-1761-8; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2003, GREENS WORD MEMORY T; Green P, 2011, APPL NEUROPSYCHOL, V18, P86, DOI 10.1080/09084282.2010.523389; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hilsabeck RC, 2011, CLIN NEUROPSYCHOL, V25, P1228, DOI 10.1080/13854046.2011.589409; Jasinski LJ, 2011, J CLIN EXP NEUROPSYC, V33, P300, DOI 10.1080/13803395.2010.516743; Kiewel NA, 2012, CLIN NEUROPSYCHOL, V26, P965, DOI 10.1080/13854046.2012.694478; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Loring DW, 2016, ARCH CLIN NEUROPSYCH, V31, P313, DOI 10.1093/arclin/acw014; Miele AS, 2012, ARCH CLIN NEUROPSYCH, V27, P10, DOI 10.1093/arclin/acr084; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; O'Bryant SE, 2007, CLIN NEUROPSYCHOL, V21, P511, DOI 10.1080/13854040600611368; Pearson, 2009, ADV CLIN SOL WAIS 4; Reese CS, 2012, ARCH CLIN NEUROPSYCH, V27, P176, DOI 10.1093/arclin/acr117; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Roman GC, 2002, LANCET NEUROL, V1, P426, DOI 10.1016/S1474-4422(02)00190-4; Schroeder RW, 2012, ASSESSMENT, V19, P21, DOI 10.1177/1073191111428764; Schutte C., 2013, MILD TRAUMATIC BRAIN; Spencer RJ, 2017, BRAIN INJURY, V31, P32, DOI 10.1080/02699052.2016.1218546; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Suhr J. A., 2007, ASSESSMENT MALINGERE; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Wechsler, 2008, WAIS 4 ADM SCORING M; Wechsler D., 1997, WAIS 3 ADM SCORING M WAIS 3 ADM SCORING M; Whitney KA, 2013, APPL NEUROPSYCH-ADUL, V20, P83, DOI 10.1080/09084282.2012.670167; Young JC, 2012, CLIN NEUROPSYCHOL, V26, P147, DOI 10.1080/13854046.2011.647083; Zenisek R, 2016, ARCH CLIN NEUROPSYCH, V31, P426, DOI 10.1093/arclin/acw025	44	57	57	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2018	32	4					657	670		10.1080/13854046.2017.1415374			14	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	GD3XQ	WOS:000430437500002	29256334				2022-02-06	
J	Raoof, R; Jimenez-Mateos, EM; Bauer, S; Tackenberg, B; Rosenow, F; Lang, J; Onugoren, MD; Hamer, H; Huchtemann, T; Kortvelyessy, P; Connolly, NMC; Pfeiffer, S; Prehn, JHM; Farrell, MA; O'Brien, DF; Henshall, DC; Mooney, C				Raoof, Rana; Jimenez-Mateos, Eva M.; Bauer, Sebastian; Tackenberg, Bjoern; Rosenow, Felix; Lang, Johannes; Onugoren, Muejgan Dogan; Hamer, Hajo; Huchtemann, Tessa; Koertvelyessy, Peter; Connolly, Niamh M. C.; Pfeiffer, Shona; Prehn, Jochen H. M.; Farrell, Michael A.; O'Brien, Donncha F.; Henshall, David C.; Mooney, Catherine			Cerebrospinal fluid microRNAs are potential biomarkers of temporal lobe epilepsy and status epilepticus	SCIENTIFIC REPORTS			English	Article							NONCONVULSIVE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; DIFFERENTIAL EXPRESSION; CIRCULATING MICRORNAS; HIPPOCAMPAL SCLEROSIS; ALZHEIMERS-DISEASE; MIRNA; PROFILES; PROTEIN; BLOOD	There is a need for diagnostic biomarkers of epilepsy and status epilepticus to support clinical examination, electroencephalography and neuroimaging. Extracellular microRNAs may be potentially ideal biomarkers since some are expressed uniquely within specific brain regions and cell types. Cerebrospinal fluid offers a source of microRNA biomarkers with the advantage of being in close contact with the target tissue and sites of pathology. Here we profiled microRNA levels in cerebrospinal fluid from patients with temporal lobe epilepsy or status epilepticus, and compared findings to matched controls. Differential expression of 20 microRNAs was detected between patient groups and controls. A validation phase included an expanded cohort and samples from patients with other neurological diseases. This identified lower levels of miR-19b in temporal lobe epilepsy compared to controls, status epilepticus and other neurological diseases. Levels of miR-451a were higher in status epilepticus compared to other groups whereas miR-21-5p differed in status epilepticus compared to temporal lobe epilepsy but not to other neurological diseases. Targets of these microRNAs include proteins regulating neuronal death, tissue remodelling, gliosis and inflammation. The present study indicates cerebrospinal fluid contains microRNAs that can support differential diagnosis of temporal lobe epilepsy and status epilepticus from other neurological and non-neurological diseases.	[Raoof, Rana; Jimenez-Mateos, Eva M.; Connolly, Niamh M. C.; Pfeiffer, Shona; Prehn, Jochen H. M.; Henshall, David C.; Mooney, Catherine] Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, 123 St Stephens Green, Dublin 2, Ireland; [Raoof, Rana] Univ Mosul, Dept Anat, Mosul Med Coll, Mosul, Iraq; [Bauer, Sebastian; Tackenberg, Bjoern; Rosenow, Felix] Epilepsy Ctr Hessen, Dept Neurol, Baldingerstr, D-35043 Marburg, Germany; [Bauer, Sebastian; Rosenow, Felix] Goethe Univ, Epilepsy Ctr Frankfurt Rhine Main, Neuroctr, Schleusenweg 2-16,Haus 95, D-60528 Frankfurt, Germany; [Lang, Johannes; Onugoren, Muejgan Dogan; Hamer, Hajo] Univ Hosp Erlangen, Schwabachanlage 6, D-91054 Erlangen, Germany; [Huchtemann, Tessa; Koertvelyessy, Peter] Univ Hosp Magdeburg, Dept Neurol, Leipziger Str 44, D-39120 Magdeburg, Germany; [Farrell, Michael A.; O'Brien, Donncha F.] Beaumont Hosp, Beaumont Rd, Dublin 9, Ireland		Henshall, DC (corresponding author), Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, 123 St Stephens Green, Dublin 2, Ireland.	dhenshall@rcsi.ie	Raoof, Rana Mumtaz/J-9316-2019; Jimenez-Mateos, Eva/AAG-8072-2019; Prehn, Jochen HM/A-3928-2010; Raoof, Rana/F-8562-2019; Connolly, Niamh M. C./U-6083-2019	Raoof, Rana Mumtaz/0000-0001-5418-1407; Prehn, Jochen HM/0000-0003-3479-7794; Raoof, Rana/0000-0001-5418-1407; Connolly, Niamh M. C./0000-0002-6005-1307; Jimenez-Mateos, Eva/0000-0001-6417-6580; Mooney, Catherine/0000-0002-7696-1364; Hamer, Hajo/0000-0003-1709-8617; Pfeiffer, Shona/0000-0002-8728-1620	European Union's 'Seventh Framework' Programme (FP7) [602130]; Science Foundation Ireland (SFI)Science Foundation Ireland [SFI/13/IA/1891, SFI/14/ADV/RC2721, 13/SIRG/2114, SFI/12/COEN/18, SFI/12/RC/2272]; Detlev-Wrobel-Fonds for Epilepsy Research Frankfurt; Iraqi Ministry of Higher Education and Scientific Research	We thank all the members of the EpimiRNA consortium. We also thank Petra M~ller, Dr. Susanne Knake, Dr. Ilka Immisch and the teams from the epilepsy monitoring unit and neurological intensive care unit for their support in sample acquisition. Also, we thank Kerstin Kaiser and Jeanette Witzke for technical assistance with neurochemistry aspects. This publication has emanated from research conducted with the financial support of the European Union's 'Seventh Framework' Programme (FP7) under Grant Agreement no. 602130. Additional funding was from Science Foundation Ireland (SFI) under grants SFI/13/IA/1891, SFI/14/ADV/RC2721, 13/SIRG/2114, SFI/12/COEN/18 and SFI/12/RC/2272, the Detlev-Wrobel-Fonds for Epilepsy Research Frankfurt and a fellowship from the Iraqi Ministry of Higher Education and Scientific Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahlbrecht J, 2016, MULT SCLER J, V22, P1202, DOI 10.1177/1352458515613641; Aronica E, 2003, NEUROSCIENCE, V118, P417, DOI 10.1016/S0306-4522(02)00992-2; Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Azzouzi I, 2015, EXP HEMATOL, V43, P382, DOI 10.1016/j.exphem.2015.01.007; Baraniskin A, 2011, BLOOD, V117, P3140, DOI 10.1182/blood-2010-09-308684; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bauer G, 2010, EPILEPSIA, V51, P177, DOI 10.1111/j.1528-1167.2009.02297.x; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bleazard T, 2015, BIOINFORMATICS, V31, P1592, DOI 10.1093/bioinformatics/btv023; Bot AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076051; Buller B, 2010, FEBS J, V277, P4299, DOI 10.1111/j.1742-4658.2010.07818.x; Burgos KL, 2013, RNA, V19, P712, DOI 10.1261/rna.036863.112; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Chang BS, 2003, NEW ENGL J MED, V349, P1257, DOI 10.1056/NEJMra022308; Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282; Cheng HH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064795; Chou CH, 2016, NUCLEIC ACIDS RES, V44, pD239, DOI 10.1093/nar/gkv1258; Czech B, 2011, NAT REV GENET, V12, P19, DOI 10.1038/nrg2916; Dvinge H, 2009, BIOINFORMATICS, V25, P3325, DOI 10.1093/bioinformatics/btp578; Engel T, 2007, EPILEPSY RES, V77, P151, DOI 10.1016/j.eplepsyres.2007.09.001; Freischmidt A, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-42; Fromm B, 2015, ANNU REV GENET, V49, P213, DOI 10.1146/annurev-genet-120213-092023; Gallego JA, 2012, J MOL NEUROSCI, V47, P243, DOI 10.1007/s12031-012-9731-7; Gallo A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030679; Godard P, 2015, NUCLEIC ACIDS RES, V43, P3490, DOI 10.1093/nar/gkv249; Gorter JA, 2014, NEUROBIOL DIS, V62, P508, DOI 10.1016/j.nbd.2013.10.026; Gross C, 2016, CELL REP, V17, P37, DOI 10.1016/j.celrep.2016.08.074; Haghikia A, 2012, NEUROLOGY, V79, P2166, DOI 10.1212/WNL.0b013e3182759621; Hegde M, 2014, BIOMARK MED, V8, P413, DOI [10.2217/BMM.13.142, 10.2217/bmm.13.142]; Henshall DC, 2016, LANCET NEUROL, V15, P1368, DOI 10.1016/S1474-4422(16)30246-0; Henshall DC, 2002, J NEUROSCI, V22, P8458; Henshall DC, 2000, NEUROLOGY, V55, P250, DOI 10.1212/WNL.55.2.250; Henshall DC, 2001, CELL DEATH DIFFER, V8, P1169, DOI 10.1038/sj.cdd.4400921; Holm A, 2014, J NEUROL SCI, V347, P199, DOI 10.1016/j.jns.2014.09.047; Huber W, 2015, NAT METHODS, V12, P115, DOI [10.1038/NMETH.3252, 10.1038/nmeth.3252]; Hunter MP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003694; Ivens S, 2007, BRAIN, V130, P535, DOI 10.1093/brain/awl317; Jeffries CD, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.148; Jimenez-Mateos EM, 2012, NAT MED, V18, P1087, DOI 10.1038/nm.2834; Jimenez-Mateos EM, 2011, AM J PATHOL, V179, P2519, DOI 10.1016/j.ajpath.2011.07.036; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Jovicic A, 2013, J NEUROSCI, V33, P5127, DOI 10.1523/JNEUROSCI.0600-12.2013; Kaalund SS, 2014, EPILEPSIA, V55, P2017, DOI 10.1111/epi.12839; Kan AA, 2012, CELL MOL LIFE SCI, V69, P3127, DOI 10.1007/s00018-012-0992-7; Kirschner MB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024145; Knake S, 2001, EPILEPSIA, V42, P714, DOI 10.1046/j.1528-1157.2001.01101.x; Kretschmann A, 2015, J MOL NEUROSCI, V55, P466, DOI 10.1007/s12031-014-0368-6; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lee SM, 2016, MOL NEUROBIOL; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Liu CG, 2014, INT J MOL MED, V34, P160, DOI 10.3892/ijmm.2014.1780; Liu DZ, 2010, J CEREBR BLOOD F MET, V30, P92, DOI 10.1038/jcbfm.2009.186; Lobb RJ, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27031; Maroso M, 2010, NAT MED, V16, P413, DOI 10.1038/nm.2127; McCall MN, 2014, BIOINFORMATICS, V30, P2310, DOI 10.1093/bioinformatics/btu239; McClelland S, 2014, ELIFE, V3, DOI 10.7554/eLife.01267; Meierkord H, 2007, LANCET NEUROL, V6, P329, DOI 10.1016/S1474-4422(07)70074-1; Mestdagh P, 2014, NAT METHODS, V11, P809, DOI [10.1038/NMETH.3014, 10.1038/nmeth.3014]; Mi HY, 2016, NUCLEIC ACIDS RES, V44, pD336, DOI 10.1093/nar/gkv1194; Miller-Delaney SFC, 2015, BRAIN, V138, P616, DOI 10.1093/brain/awu373; Mishra MK, 2016, NAT REV NEUROL, V12, P539, DOI 10.1038/nrneurol.2016.110; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Mooney C, 2016, BIOINFORMATICS, V32, P1436, DOI 10.1093/bioinformatics/btw008; Mooney C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145316; Muller M, 2014, NEUROBIOL AGING, V35, P152, DOI 10.1016/j.neurobiolaging.2013.07.005; Peng J, 2013, J MOL NEUROSCI, V50, P291, DOI 10.1007/s12031-013-9953-3; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Petkar S, 2012, EUROPACE, V14, P1653, DOI 10.1093/europace/eus185; Pitkanen A, 2016, LANCET NEUROL, V15, P843, DOI 10.1016/S1474-4422(16)00112-5; Pitkanen A, 2016, LANCET NEUROL, V15, P185, DOI 10.1016/S1474-4422(15)00248-3; Pitkanen A, 2011, BIOMARK MED, V5, P629, DOI [10.2217/BMM.11.67, 10.2217/bmm.11.67]; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Prehn J. H., 2016, BIOINFORMATICS; Pritchard CC, 2012, NAT REV GENET, V13, P358, DOI 10.1038/nrg3198; Qureshi IA, 2012, NAT REV NEUROSCI, V13, P528, DOI 10.1038/nrn3234; Risbud RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053464; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Roncon P, 2015, SCI REP-UK, V5, DOI 10.1038/srep14143; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shavit L, 2012, EUR J INTERN MED, V23, P701, DOI 10.1016/j.ejim.2012.06.015; Shinoda S, 2004, J CLIN INVEST, V113, P1059, DOI 10.1172/JCI200419971; Sorensen SS, 2016, TRANSL NEURODEGENER, V5, DOI 10.1186/s40035-016-0053-5; Spain E, 2015, RSC ADV, V5, P90071, DOI 10.1039/c5ra16352h; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Tan NCK, 2010, EPILEPSIA, V51, P686, DOI 10.1111/j.1528-1167.2009.02423.x; Team RCR, 2016, LANG ENV STAT COMP; Teplyuk NM, 2012, NEURO-ONCOLOGY, V14, P689, DOI 10.1093/neuonc/nos074; Trinka E, 2015, EPILEPSIA, V56, P1515, DOI 10.1111/epi.13121; Truettner JS, 2011, J CEREBR BLOOD F MET, V31, P1897, DOI 10.1038/jcbfm.2011.33; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van Donselaar CA, 2006, EPILEPSIA, V47, P9, DOI 10.1111/j.1528-1167.2006.00653.x; Wang J, 2015, SCI REP-UK, V5, DOI 10.1038/srep10201; Wang J, 2015, SCI REP-UK, V5, DOI 10.1038/srep09522; Zaidi A, 2000, J AM COLL CARDIOL, V36, P181, DOI 10.1016/S0735-1097(00)00700-2	97	57	59	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 12	2017	7								3328	10.1038/s41598-017-02969-6			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EX2UJ	WOS:000403082700013	28607431	Green Published, gold			2022-02-06	
J	Dixon, KJ				Dixon, Kirsty J.			Pathophysiology of Traumatic Brain Injury	PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; TBI; Pathophysiology; Symptoms; Mild TBI; Concussion; Blast TBI	DIFFUSE AXONAL INJURY; CEREBRAL-BLOOD-FLOW; HEAD-INJURY; NEURONAL LOSS; POSTTRAUMATIC HYPOTHERMIA; OXIDATIVE STRESS; VASCULAR INJURY; BLAST INJURIES; MILD; ENCEPHALOPATHY	Traumatic brain injury (TBI) has become the signature injury of the military conflict in Iraq and Afghanistan and also has a high rate of occurrence in civilian populations in the United States. Although the effects of a moderate to severe brain injury have been investigated for decades, the chronic effects of single and repetitive mild TBI are just beginning to be investigated. Data suggest that the different types and severities of TBI have unique long-term outcomes and thus may represent different types of diseases. Therefore, this review outlines the causes, incidence, symptoms, and pathophysiology of mild, moderate, and severe TBI.	[Dixon, Kirsty J.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, 1223 East Marshall St, Richmond, VA 23298 USA		Dixon, KJ (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, 1223 East Marshall St, Richmond, VA 23298 USA.	Kirsty.dixon@vcuhealth.org					Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; [Anonymous], 2015, C TRAUM BRAIN INJ US; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Baranova AI, 2008, J NEUROSURG, V109, P502, DOI 10.3171/JNS/2008/109/9/0502; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; *CDCP NAT CTR INJ, 1999, TRAUM BRAIN INJ US R; CELANDER H, 1955, ACTA PHYSIOL SCAND, V33, P14, DOI 10.1111/j.1748-1716.1955.tb01189.x; Centers for Disease Control and Prevention National Center for Injury Prevention and Control, 2016, BLAST INJ FACT SHEET; Centers for Disease Control and Prevention National Center for Injury Prevention and Control, 2016, EXPL BLAST INJ PRIM; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Chu SJ, 2005, CRIT CARE MED, V33, P2056, DOI 10.1097/01.CCM.0000178175.54354.EA; Courtney A, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00221; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Department of Veterans Affairs and Department of Defense, 2010, VA DOD CLIN PRACT GU; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Ditillo M, 2011, J TRAUMA, V71, P373; Divani AA, 2015, J NEUROTRAUM, V32, P1109, DOI 10.1089/neu.2014.3686; Dore-Duffy P, 2011, NEUROL RES, V33, P176, DOI 10.1179/016164111X12881719352372; Ekmark-Lewen S, 2010, RESTOR NEUROL NEUROS, V28, P311, DOI 10.3233/RNN-2010-0529; Eskridge SL, 2013, J REHABIL RES DEV, V50, P7, DOI 10.1682/JRRD.2012.01.0004; Faul M, 2010, TRAUMATIC BRAIN INJU; Gao GY, 2010, J CEREBR BLOOD F MET, V30, P628, DOI 10.1038/jcbfm.2009.235; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Gilmore CS, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.454; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Hayward NMEA, 2011, J CEREBR BLOOD F MET, V31, P166, DOI 10.1038/jcbfm.2010.67; Hill CS, 2016, TRENDS NEUROSCI, V39, P311, DOI 10.1016/j.tins.2016.03.002; Hoiland RL, 2016, AM J PHYSIOL-REG I, V310, pR398, DOI 10.1152/ajpregu.00270.2015; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Hotta H, 2016, PROG BRAIN RES, V225, P3, DOI 10.1016/bs.pbr.2016.03.001; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jullienne A, 2016, J NEUROSCI RES, V94, P609, DOI 10.1002/jnr.23732; Kanaan NM, 2016, J NEUROPATH EXP NEUR, V75, P19, DOI 10.1093/jnen/nlv001; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Lafrenaye AD, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0405-6; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lossinsky AS, 2004, HISTOL HISTOPATHOL, V19, P535, DOI 10.14670/HH-19.535; Lotocki G, 2011, NEUROSCI LETT, V499, P143, DOI 10.1016/j.neulet.2011.05.056; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Lucas S, 2016, HEADACHE, V56, P323, DOI 10.1111/head.12762; Lucca JJD, 2012, J NEUROL SCI, V318, P146, DOI 10.1016/j.jns.2012.02.002; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McQuire JC, 1998, J NEUROSURG, V89, P526, DOI 10.3171/jns.1998.89.4.0526; Meabon JS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaa9585; Mishra V, 2016, SCI REP-UK, V6, DOI 10.1038/srep26992; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Moro N, 2016, BRAIN RES, V1642, P270, DOI 10.1016/j.brainres.2016.04.005; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; O'Connor CA, 2006, ACTA NEUROCHIR SUPPL, V96, P121; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Petkus V, 2016, MEDICINA-LITHUANIA, V52, P46, DOI 10.1016/j.medici.2016.01.004; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rickards CA, 2015, COMPR PHYSIOL, V5, P1585, DOI 10.1002/cphy.c140058; Ritenour AE, 2010, ANN SURG, V251, P1140, DOI 10.1097/SLA.0b013e3181e01270; Rossle R, 1950, GERMAN AVIATION MED, V2; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Scalfani MT, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.10.008; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Stein DM, 2011, J TRAUMA, V71, P364, DOI 10.1097/TA.0b013e31822820da; Stein TD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0522-z; Stemper BD, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00031; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Taupin Philippe, 2008, Int J Med Sci, V5, P127; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Tumer N, 2013, NEUROSCI LETT, V544, P62, DOI 10.1016/j.neulet.2013.03.042; Ueda Y, 2003, J NEUROSURG, V99, P899, DOI 10.3171/jns.2003.99.5.0899; Villalba N, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001474; Wang JY, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0631-6; Wei EP, 2009, J NEUROTRAUM, V26, P527, DOI 10.1089/neu.2008.0797; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Yang SH, 2013, SHOCK, V40, P471, DOI 10.1097/SHK.0000000000000037; Zhang YM, 2014, NEUROCHEM RES, V39, P950, DOI 10.1007/s11064-014-1292-4; Zuckerman A, 2017, J NEUROTRAUM, V34, P145, DOI 10.1089/neu.2015.4310	91	57	65	5	27	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1047-9651	1558-1381		PHYS MED REH CLIN N	Phys. Med. Rehabil. Clin. N. Am.	MAY	2017	28	2					215	+		10.1016/j.pmr.2016.12.001			12	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	EU5AJ	WOS:000401043700003	28390509				2022-02-06	
J	Raffiz, M; Abdullah, JM				Raffiz, Mohd; Abdullah, Jafri M.			Optic nerve sheath diameter measurement: a means of detecting raised ICP in adult traumatic and non-traumatic neurosurgical patients	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							INTRACRANIAL-PRESSURE; BRAIN-INJURY; HEAD-INJURY; SONOGRAPHY	Introduction: Bedside ultrasound measurement of optic nerve sheath diameter (ONSD) is emerging as a non-invasive technique to evaluate and predict raised intracranial pressure (ICP). It has been shown in previous literature that ONSD measurement has good correlation with surrogate findings of raised ICP such as clinical and radiological findings suggestive of raised ICP. Objectives: The objective of the study is to find a correlation between sonographic measurements of ONSD value with ICP value measured via the gold standard invasive intracranial ICP catheter, and to find the cut-off value of ONSD measurement in predicting raised ICP, along with its sensitivity and specificity value. Methods: A prospective observational study was performed using convenience sample of 41 adult neurosurgical patients treated in neurosurgical intensive care unit with invasive intracranial pressure monitoring placed in-situ as part of their clinical care. Portable SonoSite ultrasound machine with 7MHz linear probe were used to measure optic nerve sheath diameter using the standard technique. Simultaneous ICP readings were obtained directly from the invasive monitoring. Results: Seventy-five measurements were performed on 41 patients. The non-parametric Spearman correlation test revealed a significant correlation at the 0.01 level between the ICP and ONSD value, with correlation coefficient of 0.820. The receiver operating characteristic curve generated an area under the curve with the value of 0.964, and with standard error of 0.22. From the receiver operating characteristic curve, we found that the ONSD value of 5.205 mm is 95.8% sensitive and 80.4% specific in detecting raised ICP. Conclusions: ONSD value of 5.205 is sensitive and specific in detecting raised ICP. Bedside ultrasound measurement of ONSD is readily learned, and is reproducible and reliable in predicting raised ICP. This non-invasive technique can be a useful adjunct to the current invasive intracranial catheter monitoring, and has wide potential clinical applications in district hospitals, emergency departments and intensive care units. (C) 2016 Elsevier Inc. All rights reserved.	[Raffiz, Mohd] Kuala Lumpur Hosp, Jalan Pahang, Kuala Lumpur 50586, Malaysia; [Abdullah, Jafri M.] Univ Sains Malaysia, Ctr Neurosci Serv & Res, Jalan Sultanah Zainab 2, Kota Baharu, Kelantan, Malaysia; [Abdullah, Jafri M.] Hosp Univ Sains Malaysia, Dept Neurosci, Jalan Hosp USM, Kubang Kerian 16150, Kelantan, Malaysia		Raffiz, M (corresponding author), Kuala Lumpur Hosp, Jalan Pahang, Kuala Lumpur 50586, Malaysia.	raffiz_dr@yahoo.co.uk	Abdullah, J/C-2828-2011	Abdullah, J/0000-0002-0258-7410			Ballantynea S A, 2012, EUROPEAN J ULTRASOUN, V5, P145; Blaivas M, 2003, ACAD EMERG MED, V10, P376, DOI 10.1197/aemj.10.4.376; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Czosnyka M, 2006, ACTA NEUROCHIR SUPPL, V96, P114; Friedman DI, 2002, NEUROLOGY, V59, P1492, DOI 10.1212/01.WNL.0000029570.69134.1B; Geeraerts T, 2008, INTENS CARE MED, V34, P2062, DOI 10.1007/s00134-008-1149-x; Hartl R, 2013, WORLD NEUROSURG, V79, P599, DOI 10.1016/j.wneu.2013.03.046; Kimberly HH, 2008, ACAD EMERG MED, V15, P201, DOI 10.1111/j.1553-2712.2007.00031.x; Levitt MR, 2013, WORLD NEUROSURG, V79, P600, DOI 10.1016/j.wneu.2013.03.047; LIU D, 1993, AM J OPHTHALMOL, V116, P548, DOI 10.1016/S0002-9394(14)73195-2; Mattei TA, 2013, WORLD NEUROSURG, V79, P602, DOI 10.1016/j.wneu.2013.03.048; Newman WD, 2002, BRIT J OPHTHALMOL, V86, P1109, DOI 10.1136/bjo.86.10.1109; Soldatos T, 2009, EMERG MED J, V26, P630, DOI 10.1136/emj.2008.058453; Strumwasser A, 2011, J SURG RES, V170, P265, DOI 10.1016/j.jss.2011.03.009; Tayal VS, 2007, ANN EMERG MED, V49, P508, DOI 10.1016/j.annemergmed.2006.06.040	15	57	60	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	JAN	2017	35	1					150	153		10.1016/j.ajem.2016.09.044			4	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	EP5KE	WOS:000397416600030	27852525				2022-02-06	
J	Russo, R; Varano, GP; Adornetto, A; Nucci, C; Corasaniti, MT; Bagetta, G; Morrone, LA				Russo, Rossella; Varano, Giuseppe Pasquale; Adornetto, Annagrazia; Nucci, Carlo; Corasaniti, Maria Tiziana; Bagetta, Giacinto; Morrone, Luigi Antonio			Retinal ganglion cell death in glaucoma: Exploring the role of neuroinflammation	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Glaucoma; Retinal ganglion cells; Neuroinflammation; Glial cells; Neurodegeneration; Neuroprotection; Antiinflammatory	OPTIC-NERVE HEAD; NECROSIS-FACTOR-ALPHA; OPEN-ANGLE GLAUCOMA; NITRIC-OXIDE SYNTHASE; MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; TRABECULAR MESHWORK CELLS; HIGH INTRAOCULAR-PRESSURE; TRAUMATIC BRAIN-INJURY; DBA/2J MOUSE MODEL; GROWTH-FACTOR-BETA	In clinical glaucoma, as well as in experimental models, the loss of retinal ganglion cells occurs by apoptosis. This final event is preceded by inflammatory responses involving the activation of innate and adaptive immunity, with retinal and optic nerve resident glial cells acting as major players. Here we review the current literature on the role of neuroinflammation in neurodegeneration, focusing on the inflammatory molecular mechanisms involved in the pathogenesis and progression of the optic neuropathy. (C) 2016 Elsevier B.V. All rights reserved.	[Russo, Rossella; Varano, Giuseppe Pasquale; Adornetto, Annagrazia; Bagetta, Giacinto; Morrone, Luigi Antonio] Univ Calabria, Dept Pharm Nutr & Hlth Sci, Arcavacata Di Rende, Italy; [Bagetta, Giacinto; Morrone, Luigi Antonio] Univ Calabria, Sect Neuiopharmacol Normal & Pathol Neuronal Plas, Univ Ctr Adapt Disorders & Head Pain, Arcavacata Di Rende, Italy; [Nucci, Carlo] Univ Roma Tor Vergata, Dept Expt Med & Surg, Ophthalmol Unit, Rome, Italy; [Corasaniti, Maria Tiziana] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy		Russo, R (corresponding author), Univ Calabria, Dept Pharm Nutr & Hlth Sci, Arcavacata Di Rende, Italy.	rossella.russo@unical.it	Bagetta, Giacinto/N-9716-2018; Corasaniti, Maria Tiziana/N-1332-2015; Adornetto, Annagrazia/AAG-5467-2020	Bagetta, Giacinto/0000-0001-8540-6218; Corasaniti, Maria Tiziana/0000-0001-6472-0697; Adornetto, Annagrazia/0000-0003-1869-2642; Russo, Rossella/0000-0001-8758-6523	PRINMinistry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN) [20109MXHMR_008]; University of Calabria	Partial financial support from PRIN (Project protocol 20109MXHMR_008) and from University of Calabria (ex quota 60%) are gratefully acknowledged.	Abcouwer SF, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-149; Agrawal A, 2008, CHEMMEDCHEM, V3, P812, DOI 10.1002/cmdc.200700290; Alano CC, 2006, P NATL ACAD SCI USA, V103, P9685, DOI 10.1073/pnas.0600554103; Amin AR, 1996, P NATL ACAD SCI USA, V93, P14014, DOI 10.1073/pnas.93.24.14014; Amin AR, 1997, FEBS LETT, V410, P259, DOI 10.1016/S0014-5793(97)00605-4; Amor S, 2014, IMMUNOLOGY, V142, P151, DOI 10.1111/imm.12233; Bakalash S, 2002, INVEST OPHTH VIS SCI, V43, P2648; Balaiya S, 2011, CLIN OPHTHALMOL, V5, P553, DOI 10.2147/OPTH.S19453; Baptiste DC, 2005, NEUROSCIENCE, V134, P575, DOI 10.1016/j.neuroscience.2005.04.011; Barnett NL, 2001, NEUROCHEM INT, V39, P291, DOI 10.1016/S0197-0186(01)00033-X; Benhar I, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00296; Beynon SB, 2012, NEUROSCIENCE, V225, P162, DOI 10.1016/j.neuroscience.2012.07.029; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bolz S, 2008, GRAEF ARCH CLIN EXP, V246, P1249, DOI 10.1007/s00417-008-0872-x; Bonelli RM, 2004, INT CLIN PSYCHOPHARM, V19, P337, DOI 10.1097/00004850-200411000-00004; Borkenstein A, 2013, MOL VIS, V19, P2306; Bosco A, 2008, INVEST OPHTH VIS SCI, V49, P1437, DOI 10.1167/iovs.07-1337; Bosco A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043602; Bosco A, 2011, J COMP NEUROL, V519, P599, DOI 10.1002/cne.22516; Bozkurt B, 2012, CLIN EXP OPHTHALMOL, V40, pE156, DOI 10.1111/j.1442-9071.2011.02595.x; Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003; Bringmann A, 2009, PROG RETIN EYE RES, V28, P423, DOI 10.1016/j.preteyeres.2009.07.001; Bucolo C, 2013, CURR OPIN PHARMACOL, V13, P50, DOI 10.1016/j.coph.2012.09.012; Butt AM, 2004, EYE, V18, P1110, DOI 10.1038/sj.eye.6701595; Cagnin A, 2006, ACTA NEUROL SCAND, V114, P107, DOI 10.1111/j.1600-0404.2006.00694.x; Carter SF, 2012, J NUCL MED, V53, P37, DOI 10.2967/jnumed.110.087031; Chang ZY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055291; Chen C, 2013, J MOL NEUROSCI, V51, P47, DOI 10.1007/s12031-012-9943-x; Cheng JW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046632; Chiu K, 2010, CELL MOL IMMUNOL, V7, P61, DOI 10.1038/cmi.2009.110; Das S, 2008, J NEUROSCI RES, V86, P1199, DOI 10.1002/jnr.21585; de Hoz R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083733; Denoyer A., 2012, PLOS ONE, V7; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Dvoriantchikova G, 2014, EUR J NEUROSCI, V40, P3171, DOI 10.1111/ejn.12710; Ebneter A, 2010, INVEST OPHTH VIS SCI, V51, P6448, DOI 10.1167/iovs.10-5284; Ergorul C, 2010, J MOL NEUROSCI, V42, P183, DOI 10.1007/s12031-010-9343-z; Fingert JH, 1999, HUM MOL GENET, V8, P899, DOI 10.1093/hmg/8.5.899; Fisher J, 2001, J NEUROSCI, V21, P136, DOI 10.1523/JNEUROSCI.21-01-00136.2001; Fleenor DL, 2006, INVEST OPHTH VIS SCI, V47, P226, DOI 10.1167/iovs.05-1060; Fontaine V, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-07-j0001.2002; Formichella C. R., 2014, J CLIN CELL IMMUNOL, V5; Foxton RH, 2013, AM J PATHOL, V182, P1379, DOI 10.1016/j.ajpath.2012.12.032; Franceschi C, 2000, ANN NY ACAD SCI, V908, P244; Frank MG, 2006, NEUROBIOL AGING, V27, P717, DOI 10.1016/j.neurobiolaging.2005.03.013; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Fu QL, 2008, CELL MOL NEUROBIOL, V28, P317, DOI 10.1007/s10571-007-9155-z; Fuchshofer R, 2011, EXP EYE RES, V93, P165, DOI 10.1016/j.exer.2010.07.014; Galindo-Romero C, 2013, INVEST OPHTH VIS SCI, V54, P974, DOI 10.1167/iovs.12-11207; Gallego BI, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-92; Geissmann F, 2008, IMMUNOL CELL BIOL, V86, P398, DOI 10.1038/icb.2008.19; GOLUB LM, 1987, J DENT RES, V66, P1310, DOI 10.1177/00220345870660080401; Gordon PH, 2007, LANCET NEUROL, V6, P1045, DOI 10.1016/S1474-4422(07)70270-3; Gramlich OW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057557; Griffiths M, 2007, INT REV NEUROBIOL, V82, P29, DOI 10.1016/S0074-7742(07)82002-2; Gronert K, 2010, EXP EYE RES, V91, P478, DOI 10.1016/j.exer.2010.07.004; HANGAI M, 1995, INVEST OPHTH VIS SCI, V36, P571; Harada T, 1998, P NATL ACAD SCI USA, V95, P4663, DOI 10.1073/pnas.95.8.4663; Hernandez MR, 2008, PROG BRAIN RES, V173, P353, DOI 10.1016/S0079-6123(08)01125-4; Hernandez MR, 2000, GLIA, V32, P122, DOI 10.1002/1098-1136(200011)32:2<122::AID-GLIA20>3.0.CO;2-J; Hernandez MR, 2000, PROG RETIN EYE RES, V19, P297, DOI 10.1016/S1350-9462(99)00017-8; Hickey WF, 1999, SEMIN IMMUNOL, V11, P125, DOI 10.1006/smim.1999.0168; Hirrlinger PG, 2010, NEUROSCI LETT, V472, P73, DOI 10.1016/j.neulet.2010.01.062; Howell GR, 2012, J CLIN INVEST, V122, P1246, DOI 10.1172/JCI61135; Howell GR, 2011, J CLIN INVEST, V121, P1429, DOI 10.1172/JCI44646; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Inatani M, 2001, GRAEF ARCH CLIN EXP, V239, P109, DOI 10.1007/s004170000241; Inman DM, 2007, GLIA, V55, P942, DOI 10.1002/glia.20516; Itakura T, 2015, MOL VIS, V21, P1071; Joachim SC, 2008, GRAEF ARCH CLIN EXP, V246, P573, DOI 10.1007/s00417-007-0737-8; Joachim SC, 2009, INVEST OPHTH VIS SCI, V50, P4734, DOI 10.1167/iovs.08-3144; Joe MK, 2003, BIOCHEM BIOPH RES CO, V312, P592, DOI 10.1016/j.bbrc.2003.10.162; Johnson EC, 2007, INVEST OPHTH VIS SCI, V48, P3161, DOI 10.1167/iovs.06-1282; Johnson EC, 2011, INVEST OPHTH VIS SCI, V52, P504, DOI 10.1167/iovs.10-5317; Johnson EC, 2009, J GLAUCOMA, V18, P341, DOI 10.1097/IJG.0b013e31818c6ef6; Kanamori A, 2005, EXP EYE RES, V81, P48, DOI 10.1016/j.exer.2005.01.012; Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004; Kieburtz K, 2008, CLIN NEUROPHARMACOL, V31, P141, DOI 10.1097/WNF.0b013e3181342f32; Kim HS, 2009, BEHAV BRAIN RES, V196, P168, DOI 10.1016/j.bbr.2008.09.040; Kim JH, 2006, J BIOCHEM MOL BIOL, V39, P339; King CE, 2007, EXP NEUROL, V205, P48, DOI 10.1016/j.expneurol.2007.01.017; Kipnis J, 2001, J NEUROSCI, V21, P4564, DOI 10.1523/JNEUROSCI.21-13-04564.2001; Kreutz MR, 2004, EUR J NEUROSCI, V19, P247, DOI 10.1111/j.1460-9568.2004.03087.x; Kuchtey J, 2014, INVEST OPHTH VIS SCI, V55, P5291, DOI 10.1167/iovs.14-14578; Lam D, 2009, MOL VIS, V15, P2217; Lampl Y, 2007, NEUROLOGY, V69, P1404, DOI 10.1212/01.wnl.0000277487.04281.db; Leske MC, 2007, OPHTHALMOLOGY, V114, P1965, DOI 10.1016/j.ophtha.2007.03.016; Levkovitch-Verbin H, 2006, ARCH OPHTHALMOL-CHIC, V124, P520, DOI 10.1001/archopht.124.4.520; Liu YH, 2004, HUM MOL GENET, V13, P1193, DOI 10.1093/hmg/ddh128; London A, 2011, J EXP MED, V208, P23, DOI 10.1084/jem.20101202; Lopez-Herrera MPL, 2002, EXP NEUROL, V178, P243, DOI 10.1006/exnr.2002.8043; Lorber B, 2005, EUR J NEUROSCI, V21, P2029, DOI 10.1111/j.1460-9568.2005.04034.x; Lorber B, 2009, J NEUROSCI RES, V87, P2645, DOI 10.1002/jnr.22095; Lye-Barthel M, 2013, INVEST OPHTH VIS SCI, V54, P909, DOI 10.1167/iovs.12-10109; Ma WX, 2013, NEUROBIOL AGING, V34, P2310, DOI 10.1016/j.neurobiolaging.2013.03.022; Mac Nair CE, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0194-3; Machado LS, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-56; Maruyama I, 2000, INVEST OPHTH VIS SCI, V41, P1657; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Nadal-Nicolas FM, 2015, INVEST OPHTH VIS SCI, V56, P6095, DOI 10.1167/iovs.15-17195; Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885; Nakazawa T, 2006, J NEUROSCI, V26, P12633, DOI 10.1523/JNEUROSCI.2801-06.2006; Naskar R, 2002, INVEST OPHTH VIS SCI, V43, P2962; Neufeld AH, 1999, P NATL ACAD SCI USA, V96, P9944, DOI 10.1073/pnas.96.17.9944; Nguyen JV, 2011, P NATL ACAD SCI USA, V108, P1176, DOI 10.1073/pnas.1013965108; Niederkorn JY, 2010, OCUL IMMUNOL INFLAMM, V18, P19, DOI 10.3109/09273940903564766; Nikodemova M, 2006, J NEUROCHEM, V96, P314, DOI 10.1111/j.1471-4159.2005.03520.x; Nucci C, 2005, NEUROTOXICOLOGY, V26, P935, DOI 10.1016/j.neuro.2005.06.002; O'Reilly AM, 2010, MOL NEUROBIOL, V42, P124, DOI 10.1007/s12035-010-8143-3; Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6; Park SH, 2007, VISION RES, V47, P2732, DOI 10.1016/j.visres.2007.07.011; Pepe G, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0211-6; Picht G, 2001, GRAEF ARCH CLIN EXP, V239, P199, DOI 10.1007/s004170000252; Pisanu A, 2014, NEUROBIOL DIS, V71, P280, DOI 10.1016/j.nbd.2014.08.011; Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191; Prendes MA, 2013, BRIT J OPHTHALMOL, V97, P680, DOI 10.1136/bjophthalmol-2011-301132; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Prokop Stefan, 2013, Acta Neuropathol, V126, P461; Qu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067094; Qu J, 2010, EXP EYE RES, V91, P48, DOI 10.1016/j.exer.2010.04.002; Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7; Ramirez AI, 2015, PROG BRAIN RES, V220, P155, DOI 10.1016/bs.pbr.2015.05.003; Ramirez AI, 2010, INVEST OPHTH VIS SCI, V51, P5690, DOI 10.1167/iovs.10-5248; Reichelt J, 2008, CURR EYE RES, V33, P253, DOI 10.1080/02713680701871157; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Roh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040065; Rojas B, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-133; Russo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069250; Russo R, 2009, INT REV NEUROBIOL, V85, P407, DOI 10.1016/S0074-7742(09)85028-9; Sappington RM, 2008, INVEST OPHTH VIS SCI, V49, P3004, DOI 10.1167/iovs.07-1355; Sappington RM, 2006, INVEST OPHTH VIS SCI, V47, P2932, DOI 10.1167/iovs.05-1407; Sawada H, 2010, INVEST OPHTH VIS SCI, V51, P903, DOI 10.1167/iovs.09-4247; Schneider M., 2015, EXP EYE RES; Schori H, 2001, P NATL ACAD SCI USA, V98, P3398, DOI 10.1073/pnas.041609498; Schuetz E, 2004, BRAIN RES BULL, V62, P391, DOI 10.1016/j.brainresbull.2003.10.008; Schwartz Michal, 2009, J Ocul Biol Dis Infor, V2, P104; Seitz R, 2013, CELL TISSUE RES, V353, P339, DOI 10.1007/s00441-013-1666-y; SellesNavarro I, 1996, INVEST OPHTH VIS SCI, V37, P2002; Sheng JG, 1998, ACTA NEUROPATHOL, V95, P229, DOI 10.1007/s004010050792; Shepard AR, 2010, INVEST OPHTH VIS SCI, V51, P2067, DOI 10.1167/iovs.09-4567; Shimazawa M, 2005, BRAIN RES, V1053, P185, DOI 10.1016/j.brainres.2005.06.053; Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468; Sobrado-Calvo P, 2007, J COMP NEUROL, V501, P866, DOI 10.1002/cne.21279; Soto I, 2014, COLD SPRING HARB PER, V4; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; Stein-Streilein J, 2008, TRENDS IMMUNOL, V29, P548, DOI 10.1016/j.it.2008.08.002; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; Sullivan TA, 2012, EXP EYE RES, V96, P36, DOI 10.1016/j.exer.2012.01.006; Sun D, 2013, GLIA, V61, P1218, DOI 10.1002/glia.22507; Takai Y, 2012, INVEST OPHTH VIS SCI, V53, P241, DOI 10.1167/iovs.11-8434; Tang Y, 2014, CELL DEATH DIFFER, V21, P369, DOI 10.1038/cdd.2013.159; Tansey MG, 2007, EXP NEUROL, V208, P1, DOI 10.1016/j.expneurol.2007.07.004; Taupin J L, 1998, Int Rev Immunol, V16, P397, DOI 10.3109/08830189809043003; Taylor S, 2003, MOL BRAIN RES, V111, P189, DOI 10.1016/S0169-328X(03)00030-5; Taylor S, 2011, EXP EYE RES, V92, P338, DOI 10.1016/j.exer.2011.01.012; Tezel G, 2004, ARCH OPHTHALMOL-CHIC, V122, P1348, DOI 10.1001/archopht.122.9.1348; Tezel G, 1998, INVEST OPHTH VIS SCI, V39, P2277; Tezel G, 2000, ARCH OPHTHALMOL-CHIC, V118, P511, DOI 10.1001/archopht.118.4.511; Tezel G, 2003, INVEST OPHTH VIS SCI, V44, P3025, DOI 10.1167/iovs.02-1136; Tezel G, 2001, GLIA, V34, P178, DOI 10.1002/glia.1052; Tezel G, 2001, INVEST OPHTH VIS SCI, V42, P1787; Tezel G, 2000, J NEUROSCI, V20, P3552, DOI 10.1523/JNEUROSCI.20-10-03552.2000; Tezel G, 2013, CURR OPIN PHARMACOL, V13, P23, DOI 10.1016/j.coph.2012.09.013; Tezel G, 2008, PROG BRAIN RES, V173, P409, DOI 10.1016/S0079-6123(08)01128-X; Tezel Gulgun, 2004, Curr Opin Ophthalmol, V15, P80, DOI 10.1097/00055735-200404000-00003; Trost A, 2015, EXP EYE RES, V136, P59, DOI 10.1016/j.exer.2015.05.010; van Noort JM, 2009, PROG BRAIN RES, V175, P139, DOI 10.1016/S0079-6123(09)17509-X; Vargas JLC, 2015, J NEUROSCI, V35, P12088, DOI 10.1523/JNEUROSCI.1273-15.2015; Vecino E., 2015, PROG RETIN EYE RES; Vidal L, 2006, BRAIN RES BULL, V70, P406, DOI 10.1016/j.brainresbull.2006.07.009; Vivekanantham S, 2015, INT J NEUROSCI, V125, P717, DOI 10.3109/00207454.2014.982795; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang L, 2002, INVEST OPHTH VIS SCI, V43, P1088; Wang N, 2001, NAT MED, V7, P304, DOI 10.1038/85446; Wang X, 2000, EXP BRAIN RES, V132, P476, DOI 10.1007/s002210000360; Wang Zhe, 2013, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V38, P113, DOI 10.3969/j.issn.1672-7347.2013.02.001; Wax MB, 2008, J NEUROSCI, V28, P12085, DOI 10.1523/JNEUROSCI.3200-08.2008; Wax MB, 2001, J GLAUCOMA, V10, pS22, DOI 10.1097/00061198-200110001-00009; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Wilson GN, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0399-0; Xin XY, 2013, MOL VIS, V19, P526; Yam GHF, 2007, AM J PATHOL, V170, P100, DOI 10.2353/ajpath.2007.060806; Yang BB, 2010, J OCUL PHARMACOL TH, V26, P11, DOI 10.1089/jop.2009.0037; Ye SM, 2001, NEUROIMMUNOMODULAT, V9, P183, DOI 10.1159/000049025; Yin YQ, 2006, NAT NEUROSCI, V9, P843, DOI 10.1038/nn1701; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001; Yoneda S, 2001, EXP EYE RES, V73, P661, DOI 10.1006/exer.2001.1072; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Yuan LY, 2001, J NEUROSCI RES, V64, P523, DOI 10.1002/jnr.1104; Zhang C, 2003, J NEUROSCI RES, V73, P840, DOI 10.1002/jnr.10713; Zhang SSM, 2005, EXP EYE RES, V81, P103, DOI 10.1016/j.exer.2005.01.016; Zhang X, 2004, INVEST OPHTH VIS SCI, V45, P2374, DOI 10.1167/iovs.03-1239; Zhang X, 2004, EXP EYE RES, V78, P849, DOI 10.1016/j.exer.2003.10.018; Zhang X, 2004, NEUROSCI LETT, V356, P140, DOI 10.1016/j.neulet.2003.10.084; Zhong LC, 2007, INVEST OPHTH VIS SCI, V48, P1212, DOI 10.1167/iovs.06-0757; Zhou X, 2013, MOL CELL NEUROSCI, V54, P1, DOI 10.1016/j.mcn.2012.12.001	197	57	58	1	24	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	SEP 15	2016	787				SI		134	142		10.1016/j.ejphar.2016.03.064			9	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	DW0EX	WOS:000383314800016	27044433				2022-02-06	
J	Mishra, V; Skotak, M; Schuetz, H; Heller, A; Haorah, J; Chandra, N				Mishra, Vikas; Skotak, Maciej; Schuetz, Heather; Heller, Abi; Haorah, James; Chandra, Namas			Primary blast causes mild, moderate, severe and lethal TBI with increasing blast overpressures: Experimental rat injury model	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; ACETYL-L-CARNITINE; OXIDATIVE STRESS; SHOCK-WAVE; BARRIER DYSFUNCTION; INDUCED NEUROTRAUMA; ANESTHETIZED RAT; COMBAT VETERANS; NERVOUS-SYSTEM; SHELL SHOCK	Injury severity in blast induced Traumatic Brain Injury (bTBI) increases with blast overpressure (BOP) and impulse in dose-dependent manner. Pure primary blast waves were simulated in compressed gas shock-tubes in discrete increments. Present work demonstrates 24 hour survival of rats in 0-450 kPa (0-800 Pa.s impulse) range at 10 discrete levels (60, 100, 130, 160, 190, 230, 250, 290, 350 and 420 kPa) and determines the mortality rate as a non-linear function of BOP. Using logistic regression model, predicted mortality rate (PMR) function was calculated, and used to establish TBI severities. We determined a BOP of 145 kPa as upper mild TBI threshold (5% PMR). Also we determined 146-220 kPa and 221-290 kPa levels as moderate and severe TBI based on 35%, and 70% PMR, respectively, while BOP above 290 kPa is lethal. Since there are no standards for animal bTBI injury severity, these thresholds need further refinements using histopathology, immunohistochemistry and behavior. Further, we specifically investigated mild TBI range (0-145 kPa) using physiological (heart rate), pathological (lung injury), immuno-histochemical (oxidative/nitrosative and blood-brain barrier markers) as well as blood borne biomarkers. With these additional data, we conclude that mild bTBI occurs in rats when the BOP is in the range of 85-145 kPa.	[Mishra, Vikas; Skotak, Maciej; Haorah, James; Chandra, Namas] New Jersey Inst Technol, Dept Biomed Engn, Ctr Injury Biomech Mat & Med CIBM3, Newark, NJ 07102 USA; [Schuetz, Heather; Heller, Abi] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA		Haorah, J; Chandra, N (corresponding author), New Jersey Inst Technol, Dept Biomed Engn, Ctr Injury Biomech Mat & Med CIBM3, Newark, NJ 07102 USA.	james.haorah@njit.edu; namas.chandra@njit.edu	Skotak, Maciej/H-4769-2019	Skotak, Maciej/0000-0003-2584-7294	NIH/NIAAAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [1R21AA022734-01A1]; U.S. Army Medical Research and Materiel Command grantU.S. Army Medical Research & Materiel Command (USAMRMC) [14059001 (W81XWH-15-1-0303)]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R21AA022734] Funding Source: NIH RePORTER	This work was supported by NIH/NIAAA grants 1R21AA022734-01A1 to JH, and the U.S. Army Medical Research and Materiel Command grant Log No. 14059001 (W81XWH-15-1-0303) to NC. Authors declare no conflicts of interest.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Alikunju S, 2011, BRAIN BEHAV IMMUN, V25, pS129, DOI 10.1016/j.bbi.2011.01.007; Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; Borkholder D. A., 2014, INT STAT OF THE SCI; Budde MD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00154; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chandra N, 2012, SHOCK WAVES, V22, P403, DOI 10.1007/s00193-012-0399-2; Chandra N., 2015, BRAIN NEUROTRAUMA MO, P199; Chandra N., 2011, U.S. provisional patent application, Patent No. 61542354; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Chen Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039353; Chen Y, 2011, BRAIN INJURY, V25, P641, DOI 10.3109/02699052.2011.580313; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Clifton G. L., 2007, J CEREB BLOOD FLOW M, V11, P114; Courtney MW, 2010, REV SCI INSTRUM, V81, DOI 10.1063/1.3518970; DePalma R. G., 2011, P NATO RTO MP HFM 20; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goeller J, 2012, J NEUROTRAUM, V29, P1970, DOI 10.1089/neu.2011.2224; Guy RJ, 1998, J TRAUMA, V45, P983, DOI 10.1097/00005373-199812000-00001; Haorah J, 2011, FREE RADICAL BIO MED, V51, P1601, DOI 10.1016/j.freeradbiomed.2011.06.020; Haorah J, 2008, FREE RADICAL BIO MED, V45, P1542, DOI 10.1016/j.freeradbiomed.2008.08.030; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Hue CD, 2013, J NEUROTRAUM, V30, P1652, DOI 10.1089/neu.2012.2773; Hyde D, 2004, CONVENTIONAL WEAPONS; Irwin RJ, 1999, J TRAUMA, V47, P105, DOI 10.1097/00005373-199907000-00023; Jean A, 2014, P NATL ACAD SCI USA, V111, P15310, DOI 10.1073/pnas.1415743111; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kinney G. F., 1985, EXPLOSIVE SHOCKS AIR, V1; Knoferl MW, 2003, SHOCK, V19, P519, DOI 10.1097/01.shk.0000070739.34700.f6; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lucke-Wold BP, 2015, MOL NEUROBIOL, V52, P1119, DOI 10.1007/s12035-014-8902-7; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moore DF, 2010, NEUROREHABILITATION, V26, P179, DOI 10.3233/NRE-2010-0553; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Muneer PMA, 2012, ARTERIOSCL THROM VAS, V32, P1167, DOI 10.1161/ATVBAHA.112.247668; Ohnishi M, 2001, EXP PHYSIOL, V86, P357, DOI 10.1113/eph8602145; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Otis JD, 2011, J CLIN PSYCHOL MED S, V18, P145, DOI 10.1007/s10880-011-9239-2; Panzer MB, 2014, EXP NEUROL, V261, P120, DOI 10.1016/j.expneurol.2014.07.002; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; RICHMOND DR, 1968, ANN NY ACAD SCI, V152, P103, DOI 10.1111/j.1749-6632.1968.tb11970.x; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Rump TJ, 2010, FREE RADICAL BIO MED, V49, P1494, DOI 10.1016/j.freeradbiomed.2010.08.011; Sajja VSSS, 2012, NMR BIOMED, V25, P1331, DOI 10.1002/nbm.2805; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Santiago PN, 2010, PSYCHIAT SERV, V61, P575, DOI 10.1176/ps.2010.61.6.575; Sawdon M, 2002, EXP PHYSIOL, V87, P683, DOI 10.1113/eph8702432; Selvan V, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4024132; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Skotak M, 2013, J NEUROTRAUM, V30, P1147, DOI 10.1089/neu.2012.2652; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Southard E. E., 1919, CASE HIST SERIES, V905-982; Stuhmiller JH, 1996, J BIOMECH, V29, P227, DOI 10.1016/0021-9290(95)00039-9; Sundaramurthy A, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00253; Sundaramurthy A, 2012, J NEUROTRAUM, V29, P2352, DOI 10.1089/neu.2012.2413; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Wilk JE, 2010, DRUG ALCOHOL DEPEN, V108, P115, DOI 10.1016/j.drugalcdep.2009.12.003; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yattoo Gh, 2008, J Trauma Manag Outcomes, V2, P5, DOI 10.1186/1752-2897-2-5; Yelverton JT, 1996, J TRAUMA, V40, pS111, DOI 10.1097/00005373-199603001-00025; Zhang JK, 1996, J TRAUMA, V40, pS77	89	57	61	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 7	2016	6								26992	10.1038/srep26992			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DO1QF	WOS:000377552500001	27270403	Green Published, gold			2022-02-06	
J	Ren, CH; Kobeissy, F; Alawieh, A; Li, N; Li, N; Zibara, K; Zoltewicz, S; Guingab-Cagmat, J; Larner, SF; Ding, YC; Hayes, RL; Ji, XM; Mondello, S				Ren, Changhong; Kobeissy, Firas; Alawieh, Ali; Li, Na; Li, Ning; Zibara, Kazem; Zoltewicz, Susie; Guingab-Cagmat, Joy; Larner, Stephen F.; Ding, Yuchuan; Hayes, Ronald L.; Ji, Xunming; Mondello, Stefania			Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE-L1; HEALTH-CARE PROFESSIONALS; ACUTE ISCHEMIC-STROKE; INTRACEREBRAL HEMORRHAGE; NEUROSURGICAL INTERVENTION; INTRACRANIAL LESIONS; COMPUTED-TOMOGRAPHY; BIOMARKERS	A rapid and reliable diagnostic test to distinguish ischemic from hemorrhagic stroke in patients presenting with stroke-like symptoms is essential to optimize management and triage for thrombolytic therapy. The present study measured serum concentrations of ubiquitin C-terminal hydrolase (UCH-L1) and glial fibrillary astrocytic protein (GFAP) in acute stroke patients and healthy controls and investigated their relation to stroke severity and patient characteristics. We also assessed the diagnostic performance of these markers for the differentiation of intracerebral hemorrhage (ICH) from ischemic stroke (IS). Both UCH-L1 and GFAP concentrations were significantly greater in ICH patients than in controls (p < 0.0001). However, exclusively GFAP differed in ICH compared with IS (p < 0.0001). GFAP yielded an AUC of 0.86 for differentiating between ICH and IS within 4.5hrs of symptom onset with a sensitivity of 61% and a specificity of 96% using a cut-off of 0.34ng/ml. Higher GFAP levels were associated with stroke severity and history of prior stroke. Our results demonstrate that blood UCH-L1 and GFAP are increased early after stroke and distinct biomarker-specific release profiles are associated with stroke characteristics and type. We also confirmed the potential of GFAP as a tool for early rule-in of ICH, while UCH-L1 was not clinically useful.	[Ren, Changhong; Li, Na; Li, Ning; Ji, Xunming] Capital Med Univ, Inst Hypoxia Med, Xuanwu Hosp, Beijing 100053, Peoples R China; [Ren, Changhong; Ji, Xunming] Beijing Key Lab Hypoxia Conditioning Translat Med, Beijing 100053, Peoples R China; [Ren, Changhong; Ji, Xunming] Beijing Inst Brain Disorder, Ctr Stroke, Beijing 100069, Peoples R China; [Kobeissy, Firas] Univ Florida, Dept Psychiat, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA; [Kobeissy, Firas] Amer Univ Beirut, Med Ctr, Fac Med, Dept Biochem & Mol Genet, Beirut, Lebanon; [Alawieh, Ali] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA; [Zibara, Kazem] Amer Univ Beirut, Med Ctr, Fac Med, Beirut, Lebanon; [Zibara, Kazem] Lebanese Univ, Dept Biol, Fac Sci, Beirut, Lebanon; [Zoltewicz, Susie; Guingab-Cagmat, Joy; Larner, Stephen F.; Hayes, Ronald L.] Banyan Biomarkers Inc, Banyan Labs, Alachua, FL USA; [Ding, Yuchuan] Wayne State Univ, Sch Med, Dept Neurosurg, Detroit, MI 48201 USA; [Mondello, Stefania] Univ Messina, Dept Biomed Dent & Morphol & Funct Imaging Sci, Messina, Italy		Ji, XM (corresponding author), Capital Med Univ, Inst Hypoxia Med, Xuanwu Hosp, Beijing 100053, Peoples R China.; Ji, XM (corresponding author), Beijing Key Lab Hypoxia Conditioning Translat Med, Beijing 100053, Peoples R China.; Ji, XM (corresponding author), Beijing Inst Brain Disorder, Ctr Stroke, Beijing 100069, Peoples R China.; Mondello, S (corresponding author), Univ Messina, Dept Biomed Dent & Morphol & Funct Imaging Sci, Messina, Italy.	jixm@ccmu.edu.cn; stm_mondello@hotmail.com	Alawieh, Ali/AAM-1898-2020; Ji, Xunming/AAN-3370-2021; Mondello, Stefania/A-1813-2012; Alawieh, Ali/AAM-1420-2020; Kobeissy, Firas/E-7042-2017	Alawieh, Ali/0000-0003-2601-8850; Mondello, Stefania/0000-0002-8587-3614; Kobeissy, Firas/0000-0002-5008-6944; Zibara, Kazem/0000-0002-9887-072X	Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81573867]; Scientific Special Funding of Capital Health Development [2011-1001-03]; China National Funds for Distinguished Youth Scientist [81325007]; Distinguished Professor of cheung kong scholars programme [T2014251]; 12th Five Year Plan of National Science and Technology [2013BAI07B00]	This work was partially supported by the program of Natural Science Foundation of China (No. 81573867), Scientific Special Funding of Capital Health Development (No. 2011-1001-03), China National Funds for Distinguished Youth Scientist (No. 81325007, Distinguished Professor of cheung kong scholars programme (No, T2014251) and The 12th Five Year Plan of National Science and Technology (No, 2013BAI07B00).	Barber M, 2004, STROKE, V35, P1421, DOI 10.1161/01.STR.0000126890.63512.41; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Brouns R, 2010, CLIN CHEM, V56, P451, DOI 10.1373/clinchem.2009.134122; Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475; Cano Climaco P, 2003, Am J Ther, V10, P473, DOI 10.1097/00045391-200311000-00018; Chalela JA, 2007, LANCET, V369, P293, DOI 10.1016/S0140-6736(07)60151-2; Dambinova SA, 2002, STROKE, V33, P1181, DOI 10.1161/01.STR.0000014922.83673.86; Danton GH, 2002, STROKE, V33, P1113, DOI 10.1161/hs0402.105554; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Dvorak F, 2009, CEREBROVASC DIS, V27, P37, DOI 10.1159/000172632; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Foerch C, 2006, J NEUROL NEUROSUR PS, V77, P181, DOI 10.1136/jnnp.2005.074823; Foerch C, 2009, NEUROLOGY, V73, P393, DOI 10.1212/WNL.0b013e3181b05ef9; Foerch C, 2012, CLIN CHEM, V58, P237, DOI 10.1373/clinchem.2011.172676; Furie KL, 2011, STROKE, V42, P227, DOI 10.1161/STR.0b013e3181f7d043; George PM, 2015, INT J STROKE, V10, P1204, DOI 10.1111/ijs.12603; JACKSON P, 1981, J NEUROL SCI, V49, P429, DOI 10.1016/0022-510X(81)90032-0; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Mondello S, 2014, PARKINSONISM RELAT D, V20, P382, DOI 10.1016/j.parkreldis.2014.01.011; Mondello S, 2014, MED RES REV, V34, P503, DOI 10.1002/med.21295; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mouhieddine TH, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-014-0505-1; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Olivot JM, 2004, STROKE, V35, P1946, DOI 10.1161/01.STR.0000133340.37712.9b; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Ren CH, 2013, BRAIN RES, V1540, P84, DOI 10.1016/j.brainres.2013.09.051; Rodriguez-Yanez M, 2008, CURR OPIN NEUROL, V21, P353, DOI 10.1097/WCO.0b013e3282ffafbf; Rojo DR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023111; Sato Mika, 2006, J Stroke Cerebrovasc Dis, V15, P1, DOI 10.1016/j.jstrokecerebrovasdis.2005.09.005; Schiff L, 2012, MOL DIAGN THER, V16, P79, DOI 10.2165/11631580-000000000-00000; Tombul T, 2005, J CLIN NEUROSCI, V12, P429, DOI 10.1016/j.jocn.2004.06.013; Tso AWK, 2011, NEUROLOGY, V76, P1968, DOI 10.1212/WNL.0b013e31821e54b3; Unden J, 2009, J NEUROL, V256, P72, DOI 10.1007/s00415-009-0054-8; Vos PE, 2006, EUR J NEUROL, V13, P632, DOI 10.1111/j.1468-1331.2006.01332.x; Whiteley W, 2011, J ROY COLL PHYS EDIN, V41, P152, DOI 10.4997/JRCPE.2011.207; Zoltewicz JS, 2013, J NEUROTRAUM, V30, P1161, DOI 10.1089/neu.2012.2762	44	57	61	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	APR 14	2016	6								24588	10.1038/srep24588			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ2OK	WOS:000374044100001	27074724	Green Published, gold			2022-02-06	
J	Jutzeler, CR; Huber, E; Callaghan, MF; Luechinger, R; Curt, A; Kramer, JLK; Freund, P				Jutzeler, Catherine R.; Huber, Eveline; Callaghan, Martina F.; Luechinger, Roger; Curt, Armin; Kramer, John L. K.; Freund, Patrick			Association of pain and CNS structural changes after spinal cord injury	SCIENTIFIC REPORTS			English	Article							VOXEL-BASED MORPHOMETRY; GRAY-MATTER CHANGES; CHRONIC BACK-PAIN; NEUROPATHIC PAIN; CORTICAL REORGANIZATION; MOTOR CORTEX; NEUROLOGICAL CLASSIFICATION; INTERNATIONAL STANDARDS; SOMATOSENSORY CORTEX; THALAMIC NEURONS	Traumatic spinal cord injury (SCI) has been shown to trigger structural atrophic changes within the spinal cord and brain. However, the relationship between structural changes and magnitude of neuropathic pain (NP) remains incompletely understood. Voxel-wise analysis of anatomical magnetic resonance imaging data provided information on cross-sectional cervical cord area and volumetric brain changes in 30 individuals with chronic traumatic SCI and 31 healthy controls. Participants were clinically assessed including neurological examination and pain questionnaire. Compared to controls, individuals with SCI exhibited decreased cord area, reduced grey matter (GM) volumes in anterior cingulate cortex (ACC), left insula, left secondary somatosensory cortex, bilateral thalamus, and decreased white matter volumes in pyramids and left internal capsule. The presence of NP was related with smaller cord area, increased GM in left ACC and right M1, and decreased GM in right primary somatosensory cortex and thalamus. Greater GM volume in M1 was associated with amount of NP. Below-level NP-associated structural changes in the spinal cord and brain can be discerned from trauma-induced consequences of SCI. The directionality of these relationships reveals specific changes across the neuroaxis (i.e., atrophic changes versus increases in volume) and may provide substrates of underlying neural mechanisms in the development of NP.	[Jutzeler, Catherine R.; Huber, Eveline; Curt, Armin; Kramer, John L. K.; Freund, Patrick] Univ Zurich, Univ Hosp Balgrist, Spinal Cord Injury Ctr, Zurich, Switzerland; [Kramer, John L. K.] Univ British Columbia, ICORD, Sch Kinesiol, Fac Educ, Vancouver, BC V5Z 1M9, Canada; [Luechinger, Roger] Univ Zurich, Inst Biomed Engn, Zurich, Switzerland; [Luechinger, Roger] ETH, Zurich, Switzerland; [Freund, Patrick] UCL, UCL Inst Neurol, Dept Brain Repair & Rehabil, London, England; [Callaghan, Martina F.; Freund, Patrick] UCL, UCL Inst Neurol, Wellcome Trust Ctr Neuroimaging, London, England; [Freund, Patrick] Max Planck Inst Human Cognit & Brain Sci, Dept Neurophys, Leipzig, Germany		Jutzeler, CR (corresponding author), Univ Zurich, Univ Hosp Balgrist, Spinal Cord Injury Ctr, Zurich, Switzerland.	cjutzeler@paralab.balgrist.ch	Luechinger, Roger/AAD-5192-2019; Freund, Patrick/D-4193-2013; Callaghan, Martina F/H-5297-2019	Luechinger, Roger/0000-0002-7365-0421; Freund, Patrick/0000-0002-4851-2246; Callaghan, Martina F/0000-0003-0374-1659	Swiss National Science Foundation (SNF)Swiss National Science Foundation (SNSF); Clinical Research Priority Program "Neurorehab" of the University of Zurich, Switzerland; International Foundation for Paraplegia - Zurich	We would like to thank all of the subjects participating in our study, and Jenny Haefeli and Alexandra Schaettin for their support in collecting data. The study was supported by the Swiss National Science Foundation (SNF) and the Clinical Research Priority Program "Neurorehab" of the University of Zurich, Switzerland. John Kramer was supported by postdoctoral funding from the International Foundation for Paraplegia - Zurich.	Apkarian AV, 2004, J NEUROSCI, V24, P10410, DOI 10.1523/JNEUROSCI.2541-04.2004; Ashburner J, 2003, LANCET NEUROL, V2, P79, DOI 10.1016/S1474-4422(03)00304-1; Barnes J, 2010, NEUROIMAGE, V53, P1244, DOI 10.1016/j.neuroimage.2010.06.025; Callaghan MF, 2014, NEUROBIOL AGING, V35, P1862, DOI 10.1016/j.neurobiolaging.2014.02.008; Davis KD, 2008, NEUROLOGY, V70, P153, DOI 10.1212/01.wnl.0000295509.30630.10; Derbyshire SWG, 1999, BIOETHICS, V13, P1, DOI 10.1111/1467-8519.00129; Dietz V, 2004, J APPL PHYSIOL, V96, P1954, DOI 10.1152/japplphysiol.00942.2003; DIPIERO V, 1991, PAIN, V46, P9, DOI 10.1016/0304-3959(91)90026-T; Draganski B, 2006, NEUROIMAGE, V31, P951, DOI 10.1016/j.neuroimage.2006.01.018; Draganski B, 2004, NATURE, V427, P311, DOI 10.1038/427311a; Finnerup NB, 2007, FUND CLIN PHARMACOL, V21, P129, DOI 10.1111/j.1472-8206.2007.00474.x; Finnerup NB, 2004, EUR J NEUROL, V11, P73, DOI 10.1046/j.1351-5101.2003.00725.x; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; Freund P, 2013, LANCET NEUROL, V12, P873, DOI 10.1016/S1474-4422(13)70146-7; Freund P, 2013, NEUROSCIENTIST, V19, P116, DOI 10.1177/1073858412449192; Freund P, 2011, BRAIN, V134, P1610, DOI 10.1093/brain/awr093; Freund PAB, 2010, J MAGN RESON IMAGING, V32, P1242, DOI 10.1002/jmri.22340; Garcia-Larrea L, 2013, PAIN, V154, pS29, DOI 10.1016/j.pain.2013.09.001; Ghosh A, 2009, J NEUROSCI, V29, P12210, DOI 10.1523/JNEUROSCI.1828-09.2009; Gomez-Pinilla F, 2002, J NEUROPHYSIOL, V88, P2187, DOI 10.1152/jn.00152.2002; Gustin SM, 2010, CEREB CORTEX, V20, P1409, DOI 10.1093/cercor/bhp205; Hains BC, 2003, J COMP NEUROL, V462, P328, DOI 10.1002/cne.10733; HARDY TL, 1979, APPL NEUROPHYSIOL, V42, P160; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Hutton C, 2009, NEUROIMAGE, V48, P371, DOI 10.1016/j.neuroimage.2009.06.043; Jain N, 1997, NATURE, V386, P495, DOI 10.1038/386495a0; Kim BG, 2006, EXP NEUROL, V198, P401, DOI 10.1016/j.expneurol.2005.12.010; Kirshblum SC, 2011, J SPINAL CORD MED, V34, P547, DOI 10.1179/107902611X13186000420242; Knikou M, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/254948; Kuchinad A, 2007, J NEUROSCI, V27, P4004, DOI 10.1523/JNEUROSCI.0098-07.2007; LATERRE EC, 1988, J NEUROL NEUROSUR PS, V51, P427, DOI 10.1136/jnnp.51.3.427; Lee BH, 2004, BRAIN RES, V1020, P37, DOI 10.1016/j.brainres.2004.05.113; Lemon RN, 2008, ANNU REV NEUROSCI, V31, P195, DOI 10.1146/annurev.neuro.31.060407.125547; Llinas R, 2005, TRENDS NEUROSCI, V28, P325, DOI 10.1016/j.tins.2005.04.006; LLINAS R, 1982, NATURE, V297, P406, DOI 10.1038/297406a0; Llinas RR, 2006, J NEUROPHYSIOL, V95, P3297, DOI 10.1152/jn.00166.2006; Lotze M, 1999, NAT NEUROSCI, V2, P501, DOI 10.1038/9145; Lundell H, 2011, SPINAL CORD, V49, P70, DOI 10.1038/sc.2010.87; Lundell H, 2011, NEUROIMAGE, V54, P1254, DOI 10.1016/j.neuroimage.2010.09.009; Lynskey JV, 2008, J REHABIL RES DEV, V45, P229, DOI 10.1682/JRRD.2007.03.0047; Makin TR, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2571; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Maldjian JA, 2004, NEUROIMAGE, V21, P450, DOI 10.1016/j.neuroimage.2003.09.032; Marino RJ, 2008, J SPINAL CORD MED, V31, P166, DOI 10.1080/10790268.2008.11760707; May A, 2008, PAIN, V137, P7, DOI 10.1016/j.pain.2008.02.034; Mole TB, 2014, NEUROIMAGE-CLIN, V5, P28, DOI 10.1016/j.nicl.2014.05.014; Moore KA, 2002, J NEUROSCI, V22, P6724, DOI 10.1523/jneurosci.22-15-06724.2002; Papinutto N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118576; Paus T, 2001, NAT REV NEUROSCI, V2, P417, DOI 10.1038/35077500; Preissler S, 2013, CEREB CORTEX, V23, P1038, DOI 10.1093/cercor/bhs063; Reulen JPH, 2003, CLIN NEUROPHYSIOL, V114, P556, DOI 10.1016/S1388-2457(02)00405-4; Rocca MA, 2006, STROKE, V37, P1765, DOI 10.1161/01.STR.0000226589.00599.4d; Sarnthein J, 2006, BRAIN, V129, P55, DOI 10.1093/brain/awh631; Schmidt-Wilcke T, 2007, PAIN, V132, pS109, DOI 10.1016/j.pain.2007.05.010; Schmidt-Wilcke T, 2006, PAIN, V125, P89, DOI 10.1016/j.pain.2006.05.004; Schmidt-Wilcke T, 2005, NEUROLOGY, V65, P1483, DOI 10.1212/01.wnl.0000183067.94400.80; Schnitzler A, 2000, J CLIN NEUROPHYSIOL, V17, P592, DOI 10.1097/00004691-200011000-00005; Siddall PJ, 2001, SPINAL CORD, V39, P63, DOI 10.1038/sj.sc.3101116; Siddall PJ, 1997, SPINAL CORD, V35, P69, DOI 10.1038/sj.sc.3100365; Valfre W, 2008, HEADACHE, V48, P109, DOI 10.1111/j.1526-4610.2007.00723.x; van den Berg-Emons RJ, 2007, EUR J PAIN, V11, P587, DOI 10.1016/j.ejpain.2006.09.003; Villiger M, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00254; Villiger M, 2013, NEUROREHAB NEURAL RE, V27, P675, DOI 10.1177/1545968313490999; Wang GX, 2008, J NEUROSCI, V28, P11959, DOI 10.1523/JNEUROSCI.3296-08.2008; WANG T, 1995, J NEUROSCI, V15, P4796; Warden P, 2001, EXP NEUROL, V168, P213, DOI 10.1006/exnr.2000.7622; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; Wrigley PJ, 2009, PAIN, V141, P52, DOI 10.1016/j.pain.2008.10.007; Wrigley PJ, 2009, CEREB CORTEX, V19, P224, DOI 10.1093/cercor/bhn072; Wu G, 2002, J NEUROSCI, V22, P7746; Wydenkeller S, 2009, EUR J NEUROSCI, V30, P91, DOI 10.1111/j.1460-9568.2009.06801.x; Yoon EJ, 2013, BRAIN RES, V1540, P64, DOI 10.1016/j.brainres.2013.10.007	72	57	61	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JAN 6	2016	6									10.1038/srep18534			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB1AQ	WOS:000368240800001	26732942	Green Published, Green Submitted, Green Accepted, gold			2022-02-06	
J	Baulac, M; de Boer, H; Elger, C; Glynn, M; Kalviainen, R; Little, A; Mifsud, J; Perucca, E; Pitkanen, A; Ryvlin, P				Baulac, Michel; de Boer, Hanneke; Elger, Christian; Glynn, Mike; Kalviainen, Reetta; Little, Ann; Mifsud, Janet; Perucca, Emilio; Pitkanen, Asla; Ryvlin, Philippe			Epilepsy priorities in Europe: A report of the ILAE-IBE Epilepsy Advocacy Europe Task Force	EPILEPSIA			English	Article						Advocacy; Biomarkers; Cure; Epileptogenesis; Epilepsy; European Commission; Horizon 2020; Research; Treatment	PSYCHIATRIC COMORBIDITY; ANTIEPILEPTIC DRUGS; GENE-THERAPY; SEIZURES; CHILDREN; CARE; EPIDEMIOLOGY; HEALTH; MECHANISMS; DEPRESSION	The European Forum on Epilepsy Research (ERF2013), which took place in Dublin, Ireland, on May 26-29, 2013, was designed to appraise epilepsy research priorities in Europe through consultation with clinical and basic scientists as well as representatives of lay organizations and health care providers. The ultimate goal was to provide a platform to improve the lives of persons with epilepsy by influencing the political agenda of the EU. The Forum highlighted the epidemiologic, medical, and social importance of epilepsy in Europe, and addressed three separate but closely related concepts. First, possibilities were explored as to how the stigma and social burden associated with epilepsy could be reduced through targeted initiatives at EU national and regional levels. Second, ways to ensure optimal standards of care throughout Europe were specifically discussed. Finally, a need for further funding in epilepsy research within the European Horizon 2020 funding programme was communicated to politicians and policymakers participating to the forum. Research topics discussed specifically included (1) epilepsy in the developing brain; (2) novel targets for innovative diagnostics and treatment of epilepsy; (3) what is required for prevention and cure of epilepsy; and (4) epilepsy and comorbidities, with a special focus on aging and mental health. This report provides a summary of recommendations that emerged at ERF2013 about how to (1) strengthen epilepsy research, (2) reduce the treatment gap, and (3) reduce the burden and stigma associated with epilepsy. Half of the 6 million European citizens with epilepsy feel stigmatized and experience social exclusion, stressing the need for funding trans-European awareness campaigns and monitoring their impact on stigma, in line with the global commitment of the European Commission and with the recommendations made in the 2011 Written Declaration on Epilepsy. Epilepsy care has high rates of misdiagnosis and considerable variability in organization and quality across European countries, translating into huge societal cost (0.2% GDP) and stressing the need for cost-effective programs of harmonization and optimization of epilepsy care throughout Europe. There is currently no cure or prevention for epilepsy, and 30% of affected persons are not controlled by current treatments, stressing the need for pursuing research efforts in the field within Horizon 2020. Priorities should include (1) development of innovative biomarkers and therapeutic targets and strategies, from gene and cell-based therapies to technologically advanced surgical treatment; (2) addressing issues raised by pediatric and aging populations, as well as by specific etiologies and comorbidities such as traumatic brain injury (TBI) and cognitive dysfunction, toward more personalized medicine and prevention; and (3) translational studies and clinical trials built upon well-established European consortia.	[Baulac, Michel] Salpetriere Hosp, Dept Neurol, Paris, France; [Baulac, Michel] Salpetriere Hosp, ICM A IHU, Paris, France; [de Boer, Hanneke] SEIN Epilepsy Inst Netherlands, Heemstede, Netherlands; [Elger, Christian] Univ Bonn, Dept Epileptol, Bonn, Germany; [Glynn, Mike] Epilepsy Ireland, Dublin, Ireland; [Kalviainen, Reetta] Kuopio Univ Hosp, Kuopio Epilepsy Ctr, SF-70210 Kuopio, Finland; [Kalviainen, Reetta] Univ Eastern Finland, Dept Neurol, Kuopio, Finland; [Little, Ann] Int Bur Epilepsy, Dublin, Ireland; [Mifsud, Janet] Univ Malta, Dept Clin Pharmacol & Therapeut, Msida, Malta; [Perucca, Emilio] Univ Pavia, Dept Internal Med & Therapeut, C Mondino Natl Neurol Inst, I-27100 Pavia, Italy; [Pitkanen, Asla] Univ Eastern Finland, Dept Neurol, AI Virtanen Inst Mol Sci, Kuopio, Finland; [Ryvlin, Philippe] CHU Vaudois, Dept Clin Neurosci, CH-1011 Lausanne, Switzerland		Ryvlin, P (corresponding author), CHU Vaudois, Dept Clin Neurosci, BH-10-137,Rue Bugnon 46, CH-1011 Lausanne, Switzerland.	philipperyvlin@gmail.com	Ryvlin, Philippe/O-5214-2016; Mifsud, Janet/AAP-3121-2021; Perucca, Emilio/Q-7308-2019; Ryvlin, Philippe/K-7402-2019	Ryvlin, Philippe/0000-0001-7775-6576; Mifsud, Janet/0000-0002-7047-6827	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [Health-F1-2012-306020]	The ERF 2013 was made possible through a grant from the European Commission, within the 7th Framework Program; Grant Agreement No.: Health-F1-2012-306020.	ANNEGERS JF, 1988, NEUROLOGY, V38, P1407, DOI 10.1212/WNL.38.9.1407; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], 2012, EP SPECTR; Baker GA, 2000, EPILEPSIA, V41, P98, DOI 10.1111/j.1528-1157.2000.tb01512.x; Baulac M, 2012, SEIZURE-EUR J EPILEP, V21, P75, DOI 10.1016/j.seizure.2011.11.001; Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; Brodie MJ, 2012, NEUROLOGY, V78, P1548, DOI 10.1212/WNL.0b013e3182563b19; Brodie MJ, 1997, EPILEPSIA, V38, P1245, DOI 10.1111/j.1528-1157.1997.tb01224.x; Burn J, 1997, BRIT MED J, V315, P1582, DOI 10.1136/bmj.315.7122.1582; Catena-Dell'Osso M, 2013, CURR MED CHEM, V20, P2861; Cleaver A, CALL CHARITIES CHALL; Cowan LD, 2002, MENT RETARD DEV D R, V8, P171, DOI 10.1002/mrdd.10035; Curry DJ, 2012, EPILEPSY BEHAV, V24, P408, DOI 10.1016/j.yebeh.2012.04.135; de Boer HM, 2008, EPILEPSY BEHAV, V12, P540, DOI 10.1016/j.yebeh.2007.12.019; de Curtis M, 2009, EPILEPSIA, V50, P2514, DOI 10.1111/j.1528-1167.2009.02249.x; Devinsky O, 2013, TRENDS NEUROSCI, V36, P174, DOI 10.1016/j.tins.2012.11.008; Engel J, 2013, EPILEPSIA, V54, P61, DOI 10.1111/epi.12299; England MJ, 2012, EPILEPSY BEHAV, V25, P266, DOI 10.1016/j.yebeh.2012.06.016; EUCARE, 2003, Epilepsia, V44 Suppl 6, P1; Fitzsimons M, 2012, EPILEPSY BEHAV, V23, P1, DOI 10.1016/j.yebeh.2011.10.019; Forsgren L, 2005, EUR J NEUROL, V12, P245, DOI 10.1111/j.1468-1331.2004.00992.x; Gaitatzis A, 2004, EPILEPSIA, V45, P1613, DOI 10.1111/j.0013-9580.2004.17504.x; Galanopoulou AS, 2012, EPILEPSIA, V53, P571, DOI 10.1111/j.1528-1167.2011.03391.x; Guerrini R, 2006, LANCET, V367, P499, DOI 10.1016/S0140-6736(06)68182-8; Helmstaedter Christoph, 2012, Handb Clin Neurol, V107, P437, DOI 10.1016/B978-0-444-52898-8.00036-7; Hermann B, 2006, BRAIN, V129, P2609, DOI 10.1093/brain/awl196; Hesdorffer DC, 2006, ANN NEUROL, V59, P35, DOI 10.1002/ana.20685; Hunt RF, 2013, NAT NEUROSCI, V16, P692, DOI 10.1038/nn.3392; Jacoby A, 2004, EPILEPSIA, V45, P1405, DOI 10.1111/j.0013-9580.2004.02904.x; Jedrzejczak J, 2013, SEIZURE-EUR J EPILEP, V22, P452, DOI 10.1016/j.seizure.2013.03.001; Jimenez-Mateos EM, 2013, NEUROSCIENCE, V238, P218, DOI 10.1016/j.neuroscience.2013.02.027; Jones JE, 2007, EPILEPSIA, V48, P2357; Jones JE, 2007, DEV MED CHILD NEUROL, V49, P493, DOI 10.1111/j.1469-8749.2007.00493.x; Kaindl AM, 2006, CELL MOL LIFE SCI, V63, P399, DOI 10.1007/s00018-005-5348-0; Kerr MP, 2012, ACTA NEUROL SCAND, V126, P1, DOI 10.1111/ane.12014; Kokaia M, 2013, NEUROPHARMACOLOGY, V69, P89, DOI 10.1016/j.neuropharm.2012.05.049; Lin JJ, 2012, LANCET, V380, P1180, DOI 10.1016/S0140-6736(12)61455-X; Lombroso CT, 2007, EPILEPSIA, V48, P83, DOI 10.1111/j.1528-1167.2007.01070.x; Luoni C, 2011, EPILEPSIA, V52, P2181, DOI 10.1111/j.1528-1167.2011.03325.x; Malmgren K, 2003, EPILEPSIA, V44, P727, DOI 10.1046/j.1528-1157.2003.58402.x; Marsh ED, 2006, EPILEPSIA, V47, P1999, DOI 10.1111/j.1528-1167.2006.00894.x; Nikolas H, 2007, EPILEPSY BEHAV, V10, P363, DOI 10.1016/j.yebeh.2007.01.005; Noe FM, 2012, JASPERS BASIC MECH E, P1; Ortinski P, 2004, EPILEPSY BEHAV, V5, pS60, DOI 10.1016/j.yebeh.2003.11.008; Pahl K, 2005, ATLAS EPILEPSY CARE ATLAS EPILEPSY CARE; Perucca E, 2011, CNS DRUGS, V25, P907, DOI 10.2165/11587900-000000000-00000; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Potschka H, 2012, ADV DRUG DELIVER REV, V64, P943, DOI 10.1016/j.addr.2011.12.007; Rai D, 2012, EPILEPSIA, V53, P1095, DOI 10.1111/j.1528-1167.2012.03500.x; Ryvlin P, 2014, LANCET NEUROL, V13, P1114, DOI 10.1016/S1474-4422(14)70156-5; Simonato M, 2014, EPILEPSY BEHAV, V38, P125, DOI 10.1016/j.yebeh.2013.09.013; Sun FT, 2014, NEUROTHERAPEUTICS, V11, P553, DOI 10.1007/s13311-014-0280-3; Taylor D, 2013, HAND CLINIC, V111, P697, DOI 10.1016/B978-0-444-52891-9.00072-5; Tomson T, 2005, EPILEPSIA, V46, P54, DOI 10.1111/j.1528-1167.2005.00411.x; Tovar-Spinoza Z, 2013, CHILD NERV SYST, V29, P2089, DOI 10.1007/s00381-013-2169-6; Vezzani Annamaria, 2012, Handb Clin Neurol, V107, P163, DOI 10.1016/B978-0-444-52898-8.00010-0; Walker MC, 2013, EPILEPSIA, V54, P43, DOI 10.1111/epi.12275; Wilcox KS, 2014, ADV EXP MED BIOL, V813, P169, DOI 10.1007/978-94-017-8914-1_14; Witt JA, 2012, J NEUROL, V259, P1727, DOI 10.1007/s00415-012-6526-2; Wykes RC, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004190	60	57	57	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	NOV	2015	56	11					1687	1695		10.1111/epi.13201			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CU9RZ	WOS:000363884100009	26415919	hybrid, Green Published			2022-02-06	
J	Buckley, TA; Burdette, G; Kelly, K				Buckley, Thomas A.; Burdette, Glenn; Kelly, Kassandra			Concussion-Management Practice Patterns of National Collegiate Athletic Association Division II and III Athletic Trainers: How the Other Half Lives	JOURNAL OF ATHLETIC TRAINING			English	Article						mild traumatic brain injury; return to play; baseline testing	SPORT-RELATED CONCUSSION; MEDICINE PROFESSIONALS; POSITION STATEMENT; CLINICAL PRACTICES; FOOTBALL PLAYERS; BASE	Context: The National Collegiate Athletic Association (NCAA) has published concussion-management practice guidelines consistent with recent position and consensus statements. Whereas NCAA Division I athletic trainers appear highly compliant, little is known about the concussion-management practice patterns of athletic trainers at smaller institutions where staffing and resources may be limited. Objective: To descriptively define the concussion-management practice patterns of NCAA Division II and III athletic trainers. Design: Cross-sectional study. Setting: Web-based questionnaire. Patients or Other Participants: A total of 755 respondents (response rate = 40.2%) from NCAA Division II and Division III institutions. Main Outcome Measure(s): The primary outcome measures were the rate of multifaceted concussion-assessment techniques, defined as 3 or more assessments; the specific practice patterns of each assessment battery; and tests used during a clinical examination. Results: Most respondents indicated using a multifaceted assessment during acute assessment (Division II = 76.9%, n = 473; Division III = 76.0%, n = 467) and determination of recovery (Division II = 65.0%, n = 194; Division III = 63.1%, n = 288) but not at baseline (Division II = 43.1%, n = 122; Division III = 41.0%, n = 176). Typically, when a postconcussion assessment was initiated, testing occurred daily until baseline values were achieved, and most respondents (80.6% [244/278]) reported using a graded exercise protocol before return to participation. Conclusions: We found limited use of the multifaceted assessment battery at baseline but higher rates at both acute assessment and return-to-participation time points. A primary reason cited for not using test-battery components was a lack of staffing or funding for the assessments. We observed limited use of neuropsychologists to interpret neuropsychological testing. Otherwise, most respondents reported concussion-management protocols consistent with recommendations, including a high level of use of objective measures and incorporation of a progressive return-to-participation protocol.	[Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE 19716 USA; [Burdette, Glenn] Georgia So Univ, Sch Hlth & Kinesiol, Statesboro, GA 30460 USA; [Kelly, Kassandra] Georgia So Univ, Dept Intercollegiate Athlet, Statesboro, GA 30460 USA		Buckley, TA (corresponding author), Univ Delaware, Dept Kinesiol & Appl Physiol, Human Performance Lab 144, 541 South Coll Ave, Newark, DE 19716 USA.	tbuckley@udel.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150			Baugh CM, 2015, AM J SPORT MED, V43, P47, DOI 10.1177/0363546514553090; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Burk JM, 2013, CLIN J SPORT MED, V23, P312, DOI 10.1097/JSM.0b013e318285633f; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Diamond D., 2012, ARIZONA JUST BROKE N; Ferrara Michael S., 2001, J Athl Train, V36, P145; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Fulks DL, 2013, 2004 2012 NCAA DIVIS, P11; Fulks DL, 2013, 2004 2012 NCAA DIVIS, P9; Fulks DL, 2013, 2004 2012 NCAA DIVIS, P13; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Kelly KC, 2014, J ATHL TRAINING, V49, P665, DOI 10.4085/1062-6050-49.3.25; Kilcoyne KG, 2014, SPORTS HEALTH, V6, P402, DOI 10.1177/1941738113491545; Klossner D, 2013, 2013 14 NCAA SPORTS, P56; Klossner D, 2010, 2010 2011 NCAA SPORT, P52; Lebrun CM, 2013, BRIT J SPORT MED, V47, P54, DOI 10.1136/bjsports-2012-091480; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Lynall RC, 2013, J ATHL TRAINING, V48, P844, DOI 10.4085/1062-6050-48.6.04; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Murray N, 2014, J ATHL TRAINING, V49, P540, DOI 10.4085/1062-6050-49.3.32; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Rigby J, 2013, J ATHL TRAINING, V48, P636, DOI 10.4085/1062-6050-48.3.10; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Schwarz A, 2011, NY TIMES, pB16; Williams RM, 2014, SPORTS HEALTH, V6, P434, DOI 10.1177/1941738114545612; Wolverton B, 2013, CHRONICLE HIGHER ED	32	57	57	0	8	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	AUG	2015	50	8					879	888		10.4085/1062-6050-50.7.04			10	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	CW7MO	WOS:000365183500014	26196701	Green Published, Bronze			2022-02-06	
J	Nigrovic, LE; Stack, AM; Mannix, RC; Lyons, TW; Samnaliev, M; Bachur, RG; Proctor, MR				Nigrovic, Lise E.; Stack, Anne M.; Mannix, Rebekah C.; Lyons, Todd W.; Samnaliev, Mihail; Bachur, Richard G.; Proctor, Mark R.			Quality Improvement Effort to Reduce Cranial CTs for Children With Minor Blunt Head Trauma	PEDIATRICS			English	Article							COMPUTED-TOMOGRAPHY UTILIZATION; CLINICAL DECISION-SUPPORT; EMERGENCY-DEPARTMENT; UNITED-STATES; ADHERENCE; TRENDS; MODEL	OBJECTIVE: Blunt head trauma is a common injury in children, although it rarely requires surgical intervention. Cranial computed tomography (CT) is the reference standard for the diagnosis of traumatic brain injury but has been associated with increased lifetime malignancy risk. We implemented a multifaceted quality improvement initiative to decrease the use of cranial CT for children with minor head injuries. METHODS: We designed and implemented a quality improvement effort that included an evidence-based guideline as well as individual feedback for children aged 0 to 21 years who present to the emergency department (ED) for evaluation of minor blunt head trauma. Our primary outcome was cranial CT rate, and our balancing measure was any return to the ED within 72 hours that required hospitalization. We used statistical process control methodology to measure cranial CT rates over time. RESULTS: We included 6851 ED visits of which 4242 (62%) occurred in the post-guideline implementation period. From a baseline CT rate of 21%, we observed an absolute reduction of 6% in cranial CT rate (95% confidence interval 3% to 9%) after initial guideline implementation and an additional absolute reduction of 6% (95% confidence interval 4% to 8%) after initiation of individual provider feedback. No children discharged from the ED required admission within 72 hours of initial evaluation. CONCLUSIONS: An ED quality improvement effort that included an evidence-based guideline as well as individual provider feedback was associated with a reduction in cranial CT rates without an increase in missed significant head injuries.	[Nigrovic, Lise E.; Stack, Anne M.; Mannix, Rebekah C.; Lyons, Todd W.; Bachur, Richard G.] Boston Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; [Samnaliev, Mihail] Boston Childrens Hosp, Clin Res Ctr, Boston, MA 02115 USA; [Proctor, Mark R.] Boston Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA		Nigrovic, LE (corresponding author), Boston Childrens Hosp, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	Lise.nigrovic@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020	Lyons, Todd/0000-0002-7033-1070; Nigrovic, Lise/0000-0002-6369-3997; Bachur, Richard/0000-0001-8831-014X	Provider Payor Quality Initiative foundation (Boston, MA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER	This project was supported by a grant from the Provider Payor Quality Initiative foundation (Boston, MA).	American Academy of Pediatrics, CHOOS WIS; [Anonymous], 2012, PASW STAT 21 COMUTER; [Anonymous], 2013, CHARTRUNNER LEAN COM; Axon RN, 2011, JAMA-J AM MED ASSOC, V305, P504, DOI 10.1001/jama.2011.72; Back SE, 2011, ACAD PSYCHIATR, V35, P40, DOI 10.1176/appi.ap.35.1.40; Benneyan JC, 2003, QUAL SAF HEALTH CARE, V12, P458, DOI 10.1136/qhc.12.6.458; Bischoff K, 2013, BMJ QUAL SAF, V22, P768, DOI 10.1136/bmjqs-2012-001671; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Bourgeois FT, 2014, PEDIATRICS, V134, P539, DOI 10.1542/peds.2014-1278; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Chumpitazi CE, 2011, CLIN PEDIATR EMERG M, V12, P113, DOI 10.1016/j.cpem.2011.05.001; Easter JS, 2014, ANN EMERG MED, V64, P145, DOI 10.1016/j.annemergmed.2014.01.030; Ferguson J, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-76; Forrest CB, 2013, PEDIATRICS, V131, pE1071, DOI 10.1542/peds.2012-1988; Frush DP, 2008, NEW ENGL J MED, V358, P851; Gagliardi AR, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-26; Institute of Medicine of the National Academies, 2007, EM CAR CHILDR GROW P; Jamtvedt G, 2006, QUAL SAF HEALTH CARE, V15, P433, DOI 10.1136/qshc.2006.018549; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Mannix R, 2012, J PEDIATR-US, V160, P136, DOI 10.1016/j.jpeds.2011.06.024; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; Menoch MJA, 2012, PEDIATRICS, V129, pE690, DOI 10.1542/peds.2011-2548; Nigrovic LE, 2011, PEDIATRICS, V127, P1067, DOI 10.1542/peds.2010-3373; Pathman DE, 1996, MED CARE, V34, P873, DOI 10.1097/00005650-199609000-00002; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Schonfeld D, 2014, ARCH DIS CHILD, V99, P427, DOI 10.1136/archdischild-2013-305004; Schonfeld D, 2013, ANN EMERG MED, V62, P597, DOI 10.1016/j.annemergmed.2013.06.020; Sheehan B, 2013, J BIOMED INFORM, V46, P905, DOI 10.1016/j.jbi.2013.07.005	28	57	58	0	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUL	2015	136	1					E227	E233		10.1542/peds.2014-3588			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	CL9KB	WOS:000357296000026	26101363	Green Accepted			2022-02-06	
J	Alberts, JL; Hirsch, JR; Koop, MM; Schindler, DD; Kana, DE; Linder, SM; Campbell, S; Thota, AK				Alberts, Jay L.; Hirsch, Joshua R.; Koop, Mandy Miller; Schindler, David D.; Kana, Daniel E.; Linder, Susan M.; Campbell, Scott; Thota, Anil K.			Using Accelerometer and Gyroscopic Measures to Quantify Postural Stability	JOURNAL OF ATHLETIC TRAINING			English	Article						concussions; motor function; motor control; biomechanics	TRAUMATIC BRAIN-INJURY; DWELLING OLDER-ADULTS; PARKINSONS-DISEASE; CEREBRAL CONCUSSION; MULTIPLE-SCLEROSIS; STANDING BALANCE; HEAD-INJURY; BASE-LINE; INSTABILITY; GAIT	Context: Force platforms and 3-dimensional motion-capture systems provide an accurate method of quantifying postural stability. Substantial cost, space, time to administer, and need for trained personnel limit widespread use of biomechanical techniques in the assessment of postural stability in clinical or field environments. Objective: To determine whether accelerometer and gyroscope data sampled from a consumer electronics device (iPad2) provide sufficient resolution of center-of-gravity (COG) movements to accurately quantify postural stability in healthy young people. Design: Controlled laboratory study. Setting: Research laboratory in an academic medical center. Patients or Other Participants: A total of 49 healthy individuals (age = 19.5 +/- 3.1 years, height = 167.7 +/- 13.2 cm, mass = 68.5 +/- 17.5 kg). Intervention(s): Participants completed the NeuroCom Sensory Organization Test (SOT) with an iPad2 affixed at the sacral level. Main Outcome Measure(s): Primary outcomes were equilibrium scores from both systems and the time series of the angular displacement of the anteroposterior COG sway during each trial. A Bland-Altman assessment for agreement was used to compare equilibrium scores produced by the NeuroCom and iPad2 devices. Limits of agreement was defined as the mean bias (NeuroCom - iPad) +/- 2 standard deviations. Mean absolute percentage error and median difference between the NeuroCom and iPad2 measurements were used to evaluate how closely the real-time COG sway measured by the 2 systems tracked each other. Results: The limits between the 2 devices ranged from -0.5 degrees to 0.5 degrees in SOT condition 1 to -2.9 degrees to 1.3 degrees in SOT condition 5. The largest absolute value of the measurement error within the 95% confidence intervals for all conditions was 2.9 degrees. The mean absolute percentage error analysis indicated that the iPad2 tracked NeuroCom COG with an average error ranging from 5.87% to 10.42% of the NeuroCom measurement across SOT conditions. Conclusions: The iPad2 hardware provided data of sufficient precision and accuracy to quantify postural stability. Accuracy, portability, and affordability make using the iPad2 a reasonable approach for assessing postural stability in clinical and field environments.	[Alberts, Jay L.; Hirsch, Joshua R.; Koop, Mandy Miller; Schindler, David D.; Kana, Daniel E.; Linder, Susan M.; Campbell, Scott; Thota, Anil K.] Cleveland Clin, Dept Biomed Engn, Cleveland, OH 44195 USA; [Alberts, Jay L.; Thota, Anil K.] Cleveland Clin, Ctr Neurol Restorat, Cleveland, OH 44195 USA; [Alberts, Jay L.; Hirsch, Joshua R.; Schindler, David D.; Linder, Susan M.; Campbell, Scott] Cleveland Clin, Concuss Ctr, Cleveland, OH 44195 USA; [Alberts, Jay L.] L Stokes Cleveland VA Med Ctr, Cleveland Funct Elect Stimulat Ctr, Cleveland, OH USA		Alberts, JL (corresponding author), Cleveland Clin, Concuss Ctr, 9500 Euclid Ave, Cleveland, OH 44195 USA.	albertj@ccf.org	Thota, Anil/J-3305-2019	Thota, Anil/0000-0003-0605-2269	Lincy Foundation; Edward F. and Barbara S. Bell Family Endowed Chair	This study was supported by the Lincy Foundation and Edward F. and Barbara S. Bell Family Endowed Chair (Dr Alberts). We thank Patrick Cummings, PTA, ATC, for participating in initial discussions about the clinical utility of this approach and Sarah Ozinga and Emma Phillips for assisting in data collection.	Adlerton Anna-Karin, 2003, Physiother Res Int, V8, P187, DOI 10.1002/pri.289; Alberts JL, 2015, MED SCI SPORT EXER, V47, P2233, DOI 10.1249/MSS.0000000000000656; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Blum L, 2008, PHYS THER, V88, P559, DOI 10.2522/ptj.20070205; Borah Diganta, 2007, Indian J Physiol Pharmacol, V51, P395; Boulgarides LK, 2003, PHYS THER, V83, P328, DOI 10.1093/ptj/83.4.328; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; Frzovic D, 2000, ARCH PHYS MED REHAB, V81, P215, DOI 10.1053/apmr.2000.0810215; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hamilton J, 1994, TIME SERIES ANAL, P435; Horak FB, 2006, AGE AGEING, V35, P7, DOI 10.1093/ageing/afl077; Horak FB, 1996, J NEUROPHYSIOL, V75, P2380, DOI 10.1152/jn.1996.75.6.2380; Horak FB, 2005, EXP NEUROL, V193, P504, DOI 10.1016/j.expneurol.2004.12.008; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; JANKOVIC J, 1990, NEUROLOGY, V40, P1529, DOI 10.1212/WNL.40.10.1529; Mancini M, 2011, PARKINSONISM RELAT D, V17, P557, DOI 10.1016/j.parkreldis.2011.05.010; Martin CL, 2006, MULT SCLER J, V12, P620, DOI 10.1177/1352458506070658; Martinez-Ramirez A, 2011, J BIOMECH, V44, P2213, DOI 10.1016/j.jbiomech.2011.06.007; Mathie MJ, 2004, J TELEMED TELECARE, V10, P144, DOI 10.1258/135763304323070788; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Melzer I, 2004, AGE AGEING, V33, P602, DOI 10.1093/ageing/afh218; Menz HB, 2003, AGE AGEING, V32, P137, DOI 10.1093/ageing/32.2.137; Morris M, 2000, GAIT POSTURE, V12, P205, DOI 10.1016/S0966-6362(00)00076-X; Morris ME, 2002, J NEUROL NEUROSUR PS, V72, P361, DOI 10.1136/jnnp.72.3.361; Nashner L.M., 1993, HDB BALANCE FUNCTION, P280; O'Sullivan M, 2009, AGE AGEING, V38, P308, DOI 10.1093/ageing/afp009; Pardasaney PK, 2012, PHYS THER, V92, P388, DOI 10.2522/ptj.20100398; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; PRINCE F, 1994, GAIT POSTURE, V2, P19, DOI 10.1016/0966-6362(94)90013-2; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Slobounov S, 2006, CYBERPSYCHOL BEHAV, V9, P188, DOI 10.1089/cpb.2006.9.188; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Tarantola J, 1997, NEUROSCI LETT, V228, P75, DOI 10.1016/S0304-3940(97)00370-4; Teasdale N, 2001, GAIT POSTURE, V14, P203, DOI 10.1016/S0966-6362(01)00134-5; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Whitney SL, 2011, GAIT POSTURE, V33, P594, DOI 10.1016/j.gaitpost.2011.01.015; Whitney SL, 2006, ARCH PHYS MED REHAB, V87, P402, DOI 10.1016/j.apmr.2005.11.002; Wrisley DM, 2007, ARCH PHYS MED REHAB, V88, P1049, DOI 10.1016/j.apmr.2007.05.003	53	57	58	0	31	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUN	2015	50	6					578	588		10.4085/1062-6050-50.2.01			11	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	CW7MK	WOS:000365183100003	25844853	Green Published, Bronze			2022-02-06	
J	Saxena, M; Young, P; Pilcher, D; Bailey, M; Harrison, D; Bellomo, R; Finfer, S; Beasley, R; Hyam, J; Menon, D; Rowan, K; Myburgh, J				Saxena, Manoj; Young, Paul; Pilcher, David; Bailey, Michael; Harrison, David; Bellomo, Rinaldo; Finfer, Simon; Beasley, Richard; Hyam, Jonathan; Menon, David; Rowan, Kathryn; Myburgh, John			Early temperature and mortality in critically ill patients with acute neurological diseases: trauma and stroke differ from infection	INTENSIVE CARE MEDICINE			English	Article						Temperature; Mortality; Stroke; Traumatic brain injury; Meningitis; Encephalitis	BODY-TEMPERATURE; BACTERIAL-MENINGITIS; RISK PREDICTION; BRAIN-INJURY; FEVER; HYPERTHERMIA; CARE; NORMOTHERMIA; MANAGEMENT; SEVERITY	Fever suppression may be beneficial for patients with traumatic brain injury (TBI) and stroke, but for patients with meningitis or encephalitis [central nervous system (CNS) infection], the febrile response may be advantageous. To evaluate the relationship between peak temperature in the first 24 h of intensive care unit (ICU) admission and all-cause hospital mortality for acute neurological diseases. Retrospective cohort design from 2005 to 2013, including 934,159 admissions to 148 ICUs in Australia and New Zealand (ANZ) and 908,775 admissions to 236 ICUs in the UK. There were 53,942 (5.8 %) patients in ANZ and 56,696 (6.2 %) patients in the UK with a diagnosis of TBI, stroke or CNS infection. For both the ANZ (P = 0.02) and UK (P < 0.0001) cohorts there was a significant interaction between early peak temperature and CNS infection, indicating that the nature of the relationship between in-hospital mortality and peak temperature differed between TBI/stroke and CNS infection. For patients with CNS infection, elevated peak temperature was not associated with an increased risk of death, relative to the risk at 37-37.4 A degrees C (normothermia). For patients with stroke and TBI, peak temperature below 37 A degrees C and above 39 A degrees C was associated with an increased risk of death, compared to normothermia. The relationship between peak temperature in the first 24 h after ICU admission and in-hospital mortality differs for TBI/stroke compared to CNS infection. For CNS infection, increased temperature is not associated with increased risk of death.	[Saxena, Manoj; Finfer, Simon; Myburgh, John] George Inst Global Hlth, Crit Care & Trauma Div, Sydney, NSW, Australia; [Saxena, Manoj; Myburgh, John] Univ New S Wales, St George Hosp Clin Sch, Sydney, NSW, Australia; [Young, Paul] Wellington Reg Hosp, Intens Care Unit, Capital & Coast Dist Hlth Board, Wellington, New Zealand; [Young, Paul; Beasley, Richard] Med Res Inst New Zealand, Wellington, New Zealand; [Pilcher, David; Bailey, Michael; Bellomo, Rinaldo] Australian & New Zealand Intens Care Soc Ctr Outc, Melbourne, Vic, Australia; [Pilcher, David] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia; [Pilcher, David] Alfred Hosp, Dept Intens Care, Prahran, Vic 3181, Australia; [Harrison, David; Rowan, Kathryn] Intens Care Natl Audit & Res Ctr, London, England; [Finfer, Simon] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia; [Hyam, Jonathan] Natl Hosp Neurol & Neurosurg, Victor Horsely Dept Neurosurg, London WC1N 3BG, England; [Menon, David] Univ Cambridge, Div Anaesthesia, Cambridge, England		Saxena, M (corresponding author), George Inst Global Hlth, Crit Care & Trauma Div, Sydney, NSW, Australia.	m.saxena@unsw.edu.au	Beasley, Richard/AAH-3908-2019; Harrison, David A/O-4355-2018; Bailey, Michael J/A-4499-2012	Beasley, Richard/0000-0003-0337-406X; Harrison, David A/0000-0002-9002-9098; Bailey, Michael J/0000-0002-5551-1401; Saxena, Manoj/0000-0002-0385-6731; Bellomo, Rinaldo/0000-0002-1650-8939; Finfer, Simon/0000-0002-2785-5864; Rowan, Kathryn/0000-0001-8217-5602; Pilcher, David/0000-0002-8939-7985; Young, Paul/0000-0002-3428-3083			Alyagari V, 2007, J NEUROL SCI, V261, P39, DOI 10.1016/j.jns.2007.04.030; Arons MM, 1999, CRIT CARE MED, V27, P699, DOI 10.1097/00003246-199904000-00020; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; Blanford S, 1998, ECOL ENTOMOL, V23, P9, DOI 10.1046/j.1365-2311.1998.00104.x; BUSTO R, 1989, STROKE, V20, P1113, DOI 10.1161/01.STR.20.8.1113; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; Chaudhuri A, 2008, EUR J NEUROL, V15, P649, DOI 10.1111/j.1468-1331.2008.02193.x; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; de Jonge RCJ, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-232; den Hertog HM, 2011, J NEUROL, V258, P302, DOI 10.1007/s00415-010-5756-4; den Hertog HM, 2009, LANCET NEUROL, V8, P434, DOI 10.1016/S1474-4422(09)70051-1; Den Hertog HM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001247.pub2; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; Diringer MN, 2004, CRIT CARE MED, V32, P2170; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Frank B, 2013, ACTA NEUROL SCAND, V128, P172, DOI 10.1111/ane.12094; Frank SM, 1997, JAMA-J AM MED ASSOC, V277, P1127, DOI 10.1001/jama.277.14.1127; Greer DM, 2008, STROKE, V39, P3029, DOI 10.1161/STROKEAHA.108.521583; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Harrison DA, 2005, CRIT CARE, V9; Harrison DA, 2007, CRIT CARE MED, V35, P1091, DOI 10.1097/01.CCM.0000259468.24532.44; Hensch PS, 1935, JAMA-J AM MED ASSOC, V104, P1779; Jorgensen HS, 2001, CEREBROVASC DIS, V11, P207, DOI 10.1159/000047640; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; KLUGER MJ, 1979, AM ZOOL, V19, P295; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Kushimoto S, 2013, CRIT CARE, V17, DOI 10.1186/cc13106; Lee BH, 2012, CRIT CARE, V16, DOI 10.1186/cc11211; Li J, 2012, J NEUROTRAUM, V29, P96, DOI 10.1089/neu.2011.1753; Mackowiak PA, 1998, ARCH INTERN MED, V158, P1870, DOI 10.1001/archinte.158.17.1870; Marion DW, 2004, CRIT CARE MED, V32, pS43, DOI 10.1097/01.CCM.0000110731.69637.16; Moench M., 1926, J LAB CLIN MED, V57, P665; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Paul E, 2013, J CRIT CARE, V28, P935, DOI 10.1016/j.jcrc.2013.07.058; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Sacho RH, 2008, BRIT J NEUROSURG, V22, P497, DOI 10.1080/02688690802245558; Saxena M, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006811.pub3; Saxena M, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006811.pub2; Saxena MK, 2013, CRIT CARE RESUSC, V15, P110; Seguin P, 2012, CRIT CARE, V16, DOI 10.1186/cc11465; Starks PT, 2000, NATURWISSENSCHAFTEN, V87, P229, DOI 10.1007/s001140050709; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; Stow PJ, 2006, J CRIT CARE, V21, P133, DOI 10.1016/j.jcrc.2005.11.010; SYDENHAM E, 2009, COCHRANE DATABASE SY; Tunkel AR, 2004, CLIN INFECT DIS, V39, P1267, DOI 10.1086/425368; W.H. Organization, 2006, NEUR DIS PUBL HLTH C; Young PJ, 2011, MED J AUSTRALIA, V195, P458, DOI 10.5694/mja11.10502; Young PJ, 2012, INTENS CARE MED, V38, P437, DOI 10.1007/s00134-012-2478-3	52	57	59	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAY	2015	41	5					823	832		10.1007/s00134-015-3676-6			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CH2FR	WOS:000353841600008	25643903	hybrid, Green Published, Green Submitted			2022-02-06	
J	Yang, JZ; Peek-Asa, C; Covassin, T; Torner, JC				Yang, Jingzhen; Peek-Asa, Corinne; Covassin, Tracey; Torner, James C.			Post-Concussion Symptoms of Depression and Anxiety in Division I Collegiate Athletes	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							PSYCHOLOGY; STATEMENT; SPORTS	This study examined the effect of baseline psychological symptoms on post-concussion symptoms among 67 concussed collegiate athletes. Depression at baseline was the strongest predictor of post-concussion depression and anxiety. Post-concussion depression and anxiety were significantly associated. These results support the importance of baseline screenings for risk of post-concussion psychological symptoms.	[Yang, Jingzhen; Peek-Asa, Corinne; Torner, James C.] Univ Iowa, Injury Prevent Res Ctr, Iowa City, IA USA; [Yang, Jingzhen] Ohio State Univ, Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; [Peek-Asa, Corinne] Univ Iowa, Dept Occupat & Environm Hlth, Iowa City, IA USA; [Covassin, Tracey] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; [Torner, James C.] Univ Iowa, Dept Epidemiol, Iowa City, IA USA		Yang, JZ (corresponding author), Ohio State Univ, Coll Med, Ctr Injury Res & Policy, Res Inst,Nationwide Childrens Hosp,Dept Pediat, 700 Childrens Dr, Columbus, OH 43205 USA.	ginger.yang@nationwidechildrens.org			University of Iowa Injury Prevention Research Center; Centers for Disease Control and Prevention (CDC)/National Center for Injury Prevention and Control [R49 CD001167-01]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001167] Funding Source: NIH RePORTER	This research work was supported by the University of Iowa Injury Prevention Research Center, and funded by grant # R49 CD001167-01 of the Centers for Disease Control and Prevention (CDC)/National Center for Injury Prevention and Control.	Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; Hootman JM, 2007, J ATHL TRAINING, V42, P311; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; RADLOFF LS, 1991, J YOUTH ADOLESCENCE, V20, P149, DOI 10.1007/BF01537606; Spielberger CD, 1989, MANUAL STATE TRAIT A, V2nd; Wiese-Bjornstal DM, 2010, SCAND J MED SCI SPOR, V20, P103, DOI 10.1111/j.1600-0838.2010.01195.x	10	57	57	0	35	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	JAN 2	2015	40	1			SI		18	23		10.1080/87565641.2014.973499			6	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	CA6IR	WOS:000349015800004	25649775				2022-02-06	
J	Narayana, PA; Yu, XT; Hasan, KM; Wilde, EA; Levin, HS; Hunter, JV; Miller, ER; Patel, VKS; Robertson, CS; McCarthy, JJ				Narayana, Ponnada A.; Yu, Xintian; Hasan, Khader M.; Wilde, Elisabeth A.; Levin, Harvey S.; Hunter, Jill V.; Miller, Emmy R.; Patel, Vipul Kumar S.; Robertson, Claudia S.; McCarthy, James J.			Multi-modal MRI of mild traumatic brain injury	NEUROIMAGE-CLINICAL			English	Article						Mild traumatic brain injury; Orthopedic injury; Magnetic resonance imaging; Diffusion tensor imaging; Magnetic resonance spectroscopic imaging; Magnetization transfer ratio; Tensor based morphometry	MAGNETIC-RESONANCE-SPECTROSCOPY; TENSOR-BASED MORPHOMETRY; WHITE-MATTER INTEGRITY; MULTIPLE-SCLEROSIS; AXONAL INJURY; CORPUS-CALLOSUM; HEAD-INJURY; CONCUSSION; ABNORMALITIES; MODERATE	Multi-modal magnetic resonance imaging (MRI) that included high resolution structural imaging, diffusion tensor imaging (DTI), magnetization transfer ratio (MTR) imaging, and magnetic resonance spectroscopic imaging (MRSI) were performed in mild traumatic brain injury (mTBI) patients with negative computed tomographic scans and in an orthopedic-injured (OI) group without concomitant injury to the brain. The OI group served as a comparison group tot mTBI. MRI scans were performed both in the acute phase of injury (similar to 24 h) and at follow-up (similar to 90 days). DTI data was analyzed using tract based spatial statistics (TBSS). Global and regional atrophies were calculated using tensor-based morphometry (TBM). MTR values were calculated using the standard method. MRSI was analyzed using LC Model. At the initial scan, the mean diffusivity (MD) was significantly higher in the mTBI cohort relative to the comparison group in several white matter (WM) regions that included internal capsule, external capsule, superior corona radiata, anterior corona radiata, posterior corona radiata, inferior fronto-occipital fasciculus, inferior longitudinal fasciculus, forceps major and forceps minor of the corpus callosum, superior longitudinal fasciculus, and corticospinal tract in the right hemisphere. TBSS analysis failed to detect significant differences in any DTI measures between the initial and follow-up scans either in the mTBI or OI group. No significant differences were found in MRSI, MTR or morphometry between the mTBI and OI cohorts either at the initial or follow-up scans with or without family wise error (ME) correction. Our study suggests that a number of WM tracts are affected in mTBI in the acute phase of injury and that these changes disappear by 90 clays. This study also suggests that none of the MRI-modalities used in this study, with the exception of DTI, is sensitive in detecting changes in the acute phase of mTBI. (C) 2014 The Authors. Published by Elsevier Inc.	[Narayana, Ponnada A.; Yu, Xintian; Hasan, Khader M.; Patel, Vipul Kumar S.] Univ Texas Hlth Sci Ctr Houston, Diagnost & Intervent Imaging, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Phys Med & Rehabil, Houston, TX 77030 USA; [Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Wilde, Elisabeth A.; Hunter, Jill V.] Baylor Coll Med, Radiol, Houston, TX 77030 USA; [Miller, Emmy R.; Robertson, Claudia S.] Baylor Coll Med, Neurosurg, Houston, TX 77030 USA; [McCarthy, James J.] Univ Texas Hlth Sci Ctr Houston, Emergency Med, Houston, TX 77030 USA		Narayana, PA (corresponding author), Univ Texas Hlth Sci Ctr Houston, Diagnost & Intervent Imaging, Houston, TX 77030 USA.	ponnada.a.narayana@uth.tmc.edu	Hasan, Khader M./ABB-5767-2020		Congressionally Directed Medical Research Program of the Department of Defense [W81XWH-08-2-0133, W81XWH-08-2-0135, W81XWH-08-2-0138, W81XWH-08-2-0132, W81XWH-08-2-0149, W81XWH-08-2-0142, W81XWH-08-2-0140, W81XWH-08-2-0131]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000371] Funding Source: NIH RePORTER	This study was funded by the Congressionally Directed Medical Research Program of the Department of Defense (W81XWH-08-2-0133, W81XWH-08-2-0135, W81XWH-08-2-0138, W81XWH-08-2-0132, W81XWH-08-2-0149, W81XWH-08-2-0142, W81XWH-08-2-0140, and W81XWH-08-2-0131). The funding agency played no role in the study design, data collection, analysis and interpretation of data, writing of this manuscript and its submission for publication. The funding agency is not responsible for the contents of this article. One of the authors (PAN) gratefully acknowledges the support by the endowment provided by the Chair in Biomedical Engineering.	Assistant Secretary of Defense for Health Affairs, 2007, TRAUM BRAIN INJ DEF; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; CDC, 2010, INJ PREV CONTR TRAUM; Chenevert TL, 2011, J MAGN RESON IMAGING, V34, P983, DOI 10.1002/jmri.22363; Chumbley JR, 2009, NEUROIMAGE, V44, P62, DOI 10.1016/j.neuroimage.2008.05.021; Cimatti M, 2006, J Neurosurg Sci, V50, P83; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Faul M, 2010, TRAUMATIC BRAIN INJU; Fox WC, 2013, NEUROL RES, V35, P223, DOI 10.1179/1743132813Y.0000000162; Garcia M, 2012, NEUROIMAGE, V59, P202, DOI 10.1016/j.neuroimage.2011.07.038; Gardner A, 2014, J NEUROTRAUM, V31, P1, DOI 10.1089/neu.2013.3079; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Giza CC, 2001, J ATHL TRAINING, V36, P228; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Hasan KM, 2007, MAGN RESON IMAGING, V25, P1196, DOI 10.1016/j.mri.2007.02.011; Hasan KM, 2014, J NEUROTRAUM, V31, P466, DOI [10.1089/NEU.2013.3085, 10.1089/neu.2013.3085]; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Hunsche S, 2001, RADIOLOGY, V221, P550, DOI 10.1148/radiol.2212001823; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Johnson B, 2012, NEUROSCI LETT, V509, P5, DOI 10.1016/j.neulet.2011.11.013; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kim N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059382; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lannsjo M, 2013, J REHABIL MED, V45, P721, DOI 10.2340/16501977-1169; Leow AD, 2006, NEUROIMAGE, V31, P627, DOI 10.1016/j.neuroimage.2005.12.013; Levin HS, 2013, J NEUROTRAUM, V30, P625, DOI 10.1089/neu.2012.2627; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Ling JM, 2013, NEUROLOGY, V81, P2121, DOI 10.1212/01.wnl.0000437302.36064.b1; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McGowan JC, 1999, NEUROLOGY, V53, pS3; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Mottershead JP, 2003, J NEUROL, V250, P1293, DOI 10.1007/s00415-003-0192-3; Narayana PA, 2005, J NEUROIMAGING, V15, p46S, DOI 10.1177/1051228405284200; Narayana PA, 2013, NEUROIMAGE-CLIN, V2, P120, DOI 10.1016/j.nicl.2012.11.009; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Oishi K., 2010, ATLAS HUMAN WHITE MA; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Pike GB, 2000, RADIOLOGY, V215, P824, DOI 10.1148/radiology.215.3.r00jn02824; Ross DE, 2012, BRAIN INJURY, V26, P1500, DOI 10.3109/02699052.2012.694570; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Sajja BR, 2009, NEUROIMAG CLIN N AM, V19, P45, DOI 10.1016/j.nic.2008.08.002; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Tao GZ, 2009, J NEUROL SCI, V282, P39, DOI 10.1016/j.jns.2008.12.035; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2013, J HEAD TRAUMA REHAB, V28, P284, DOI 10.1097/HTR.0b013e3182795045; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Yarnykh VL, 2012, MAGN RESON MED, V68, P166, DOI 10.1002/mrm.23224; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	76	57	58	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2015	7						87	97		10.1016/j.nicl.2014.07.010			11	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DI0GE	WOS:000373172600011	25610770	Green Published, gold			2022-02-06	
J	Dutca, LM; Stasheff, SF; Hedberg-Buenz, A; Rudd, DS; Batra, N; Blodi, FR; Yorek, MS; Yin, T; Shankar, M; Herlein, JA; Naidoo, J; Morlock, L; Williams, N; Kardon, RH; Anderson, MG; Pieper, AA; Harper, MM				Dutca, Laura M.; Stasheff, Steven F.; Hedberg-Buenz, Adam; Rudd, Danielle S.; Batra, Nikhil; Blodi, Frederick R.; Yorek, Matthew S.; Yin, Terry; Shankar, Malini; Herlein, Judith A.; Naidoo, Jacinth; Morlock, Lorraine; Williams, Noelle; Kardon, Randy H.; Anderson, Michael G.; Pieper, Andrew A.; Harper, Matthew M.			Early Detection of Subclinical Visual Damage After Blast-Mediated TBI Enables Prevention of Chronic Visual Deficit by Treatment With P7C3-S243	INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE			English	Article						multielectrode array; retinal ganglion cell; pattern ERG; blast injury; neuroprotection	NEUROPROTECTIVE EFFICACY; MOUSE MODEL; AMINOPROPYL CARBAZOLES; DYSFUNCTION; DEGENERATION; DISCOVERY; CELLS; FIELD; EYE	PURPOSE. Traumatic brain injury (TBI) frequently leads to chronic visual dysfunction. The purpose of this study was to investigate the effect of TBI on retinal ganglion cells (RGCs), and to test whether treatment with the novel neuroprotective compound P7C3-S243 could prevent in vivo functional deficits in the visual system. METHODS. Blast-mediated TBI was modeled using an enclosed over-pressure blast chamber. The RGC physiology was evaluated using a multielectrode array and pattern electroretinogram (PERG). Histological analysis of RGC dendritic field and cell number were evaluated at the end of the study. Visual outcome measures also were evaluated based on treatment of mice with P7C3-S243 or vehicle control. RESULTS. We show that deficits in neutral position PERG after blast-mediated TBI occur in a temporally bimodal fashion, with temporary recovery 4 weeks after injury followed by chronically persistent dysfunction 12 weeks later. This later time point is associated with development of dendritic abnormalities and irreversible death of RGCs. We also demonstrate that ongoing pathologic processes during the temporary recovery latent period (including abnormalities of RGC physiology) lead to future dysfunction of the visual system. We report that modification of PERG to provocative postural tilt testing elicits changes in PERG measurements that correlate with a key in vitro measures of damage: the spontaneous and light-evoked activity of RGCs. Treatment with P7C3-S243 immediately after injury and throughout the temporary recovery latent period protects mice from developing chronic visual system dysfunction. CONCLUSIONS. Provocative PERG testing serves as a noninvasive test in the living organism to identify early damage to the visual system, which may reflect corresponding damage in the brain that is not otherwise detectable by noninvasive means. This provides the basis for developing an earlier diagnostic test to identify patients at risk for developing chronic CNS and visual system damage after TBI at an earlier stage when treatments may be more effective in preventing these sequelae. In addition, treatment with the neuroprotective agent P7C3-S243 after TBI protects from visual system dysfunction after TBI.	[Dutca, Laura M.; Hedberg-Buenz, Adam; Rudd, Danielle S.; Batra, Nikhil; Yorek, Matthew S.; Herlein, Judith A.; Kardon, Randy H.; Anderson, Michael G.; Pieper, Andrew A.; Harper, Matthew M.] Iowa City Dept Vet Affairs, Ctr Prevent & Treatment Visual Loss, Iowa City, IA USA; [Dutca, Laura M.; Stasheff, Steven F.; Kardon, Randy H.; Anderson, Michael G.; Harper, Matthew M.] Univ Iowa, Dept Ophthalmol, Iowa City, IA 52242 USA; [Dutca, Laura M.; Stasheff, Steven F.; Kardon, Randy H.; Anderson, Michael G.; Harper, Matthew M.] Univ Iowa, Dept Visual Sci, Iowa City, IA 52242 USA; [Stasheff, Steven F.; Blodi, Frederick R.; Shankar, Malini] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; [Stasheff, Steven F.; Pieper, Andrew A.] Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA; [Hedberg-Buenz, Adam; Anderson, Michael G.] Univ Iowa, Dept Physiol & Mol Biophys, Iowa City, IA 52242 USA; [Yin, Terry; Pieper, Andrew A.] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; [Naidoo, Jacinth; Morlock, Lorraine; Williams, Noelle] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA		Harper, MM (corresponding author), Univ Iowa, Ctr Prevent & Treatment Visual Loss, Dept Vet Affairs, 601 Highway 6 W, Iowa City, IA 52242 USA.	andrew-pieper@uiowa.edu; matthew-harper@uiowa.edu	Pieper, Andrew A/R-5552-2016; Anderson, Michael/B-4580-2009	Anderson, Michael/0000-0001-5730-6105; Harper, Matthew/0000-0003-3395-2406; Kardon, Randy/0000-0002-3173-7123; Pieper, Andrew/0000-0001-6299-6577	Department of Veterans Affairs, Veterans Health Administration, Office of Research and [1I01RX000427-01]; University of Iowa Carver College of Medicine; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY017673, ZIAEY000545] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000427] Funding Source: NIH RePORTER	Supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Center for Prevention and Treatment of Visual Loss, a Rehabilitation Research and Development Career Development Award (MMH), an RR&D Merit Study Award (1I01RX000427-01), and funds from the University of Iowa Carver College of Medicine (AAP). The authors alone are responsible for the content and writing of thse paper.	Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Chichilnisky EJ, 2001, NETWORK-COMP NEURAL, V12, P199, DOI 10.1088/0954-898X/12/2/306; Cockerham GC, 2011, NEW ENGL J MED, V364, P2172, DOI 10.1056/NEJMc1010683; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; CONNOLLY SE, 1988, MICROVASC RES, V36, P275, DOI 10.1016/0026-2862(88)90028-3; De Jesus-Cortes H, 2012, P NATL ACAD SCI USA, V109, P17010, DOI 10.1073/pnas.1213956109; Della Santina L, 2013, J NEUROSCI, V33, P17444, DOI 10.1523/JNEUROSCI.5461-12.2013; Dougherty AL, 2011, BRAIN INJURY, V25, P8, DOI 10.3109/02699052.2010.536195; Feng L, 2013, INVEST OPHTH VIS SCI, V54, P1106, DOI 10.1167/iovs.12-10791; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Kemp SWP, 2015, NEUROSCIENCE, V284, P202, DOI 10.1016/j.neuroscience.2014.10.005; Lemke S, 2013, JAMA OPHTHALMOL, V131, P1602, DOI 10.1001/jamaophthalmol.2013.5028; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Luo XD, 2011, INVEST OPHTH VIS SCI, V52, P8571, DOI 10.1167/iovs.11-8376; MacMillan KS, 2011, J AM CHEM SOC, V133, P1428, DOI 10.1021/ja108211m; Magone MT, 2014, J REHABIL RES DEV, V51, P71, DOI 10.1682/JRRD.2013.01.0008; MAUNSELL JHR, 1992, J NEUROPHYSIOL, V68, P1332, DOI 10.1152/jn.1992.68.4.1332; Miura G, 2009, EXP EYE RES, V89, P49, DOI 10.1016/j.exer.2009.02.009; Mohan K, 2013, INVEST OPHTH VIS SCI, V54, P3440, DOI 10.1167/iovs.12-11522; Mohan K, 2012, VET OPHTHALMOL, V15, P94, DOI 10.1111/j.1463-5224.2012.01034.x; Nagaraju M, 2007, INVEST OPHTH VIS SCI, V48, P4573, DOI 10.1167/iovs.07-0582; Naidoo J, 2014, J MED CHEM, V57, P3746, DOI 10.1021/jm401919s; Pieper AA, 2014, CHEM SOC REV, V43, P6716, DOI 10.1039/c3cs60448a; Pieper AA, 2010, CELL, V142, P39, DOI 10.1016/j.cell.2010.06.018; Reid RC, 1997, VISUAL NEUROSCI, V14, P1015, DOI 10.1017/S0952523800011743; SOTA, 2008, STAT ART 9 TRAUM BRA; Tesla R, 2012, P NATL ACAD SCI USA, V109, P17016, DOI 10.1073/pnas.1213960109; Thompson S, 2014, INVEST OPHTH VIS SCI, V55, P1859, DOI 10.1167/iovs.13-13661; Ventura LM, 2013, J GLAUCOMA, V22, P255, DOI 10.1097/IJG.0b013e318232973b; Viswanathan S, 2000, INVEST OPHTH VIS SCI, V41, P2797; Walker AK, 2014, MOL PSYCHIAT; Wang G, 2014, CELL, V158, P1324, DOI 10.1016/j.cell.2014.07.040; Williams PA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072282; Yin TC, 2014, CELL REP, V8, P1731, DOI 10.1016/j.celrep.2014.08.030	34	57	57	0	10	ASSOC RESEARCH VISION OPHTHALMOLOGY INC	ROCKVILLE	12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA	0146-0404	1552-5783		INVEST OPHTH VIS SCI	Invest. Ophthalmol. Vis. Sci.	DEC	2014	55	12					8330	8341		10.1167/iovs.14-15468			12	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	AX9KR	WOS:000347222300071	25468886	Green Published			2022-02-06	
J	Loane, D; Stoica, B; Tchantchou, F; Kumar, A; Barrett, J; Akintola, T; Xue, F; Conn, P; Faden, A				Loane, David J.; Stoica, Bogdan A.; Tchantchou, Flaubert; Kumar, Alok; Barrett, James P.; Akintola, Titilola; Xue, Fengtian; Conn, P. Jeffrey; Faden, Alan I.			Novel mGluR5 Positive Allosteric Modulator Improves Functional Recovery, Attenuates Neurodegeneration, and Alters Microglial Polarization after Experimental Traumatic Brain Injury	NEUROTHERAPEUTICS			English	Article						Traumatic brain injury; Metabotropic glutamate receptor 5; Positive allosteric modulator; Neuroprotection; Functional recovery; Microglial activation	METABOTROPIC GLUTAMATE RECEPTORS; IN-VIVO ACTIVITY; ALTERNATIVE ACTIVATION; CELL-DEATH; NEURONAL APOPTOSIS; SUBTYPE 5; INFLAMMATION; ANTAGONISTS; INHIBITION; TARGETS	Traumatic brain injury (TBI) causes microglial activation and related neurotoxicity that contributes to chronic neurodegeneration and loss of neurological function. Selective activation of metabotropic glutamate receptor 5 (mGluR5) by the orthosteric agonist (RS)-2-chloro-5-hydroxyphenylglycine (CHPG), is neuroprotective in experimental models of TBI, and has potent anti-inflammatory effects in vitro. However, the therapeutic potential of CHPG is limited due to its relatively weak potency and brain permeability. Highly potent, selective and brain penetrant mGluR5 positive allosteric modulators (PAMs) have been developed and show promise as therapeutic agents. We evaluated the therapeutic potential of a novel mGluR5 PAM, VU0360172, after controlled cortical impact (CCI) in mice. Vehicle, VU0360172, or VU0360172 plus mGluR5 antagonist (MTEP), were administered systemically to CCI mice at 3 h post-injury; lesion volume, hippocampal neurodegeneration, microglial activation, and functional recovery were assessed through 28 days post-injury. Anti-inflammatory effects of VU0360172 were also examined in vitro using BV2 and primary microglia. VU0360172 treatment significantly reduced the lesion, attenuated hippocampal neurodegeneration, and improved motor function recovery after CCI. Effects were mediated by mGluR5 as co-administration of MTEP blocked the protective effects of VU0360172. VU0360172 significantly reduced CD68 and NOX2 expression in activated microglia in the cortex at 28 days post-injury, and also suppressed pro-inflammatory signaling pathways in BV2 and primary microglia. In addition, VU0360172 treatment shifted the balance between M1/M2 microglial activation states towards an M2 pro-repair phenotype. This study demonstrates that VU0360172 confers neuroprotection after experimental TBI, and suggests that mGluR5 PAMs may be promising therapeutic agents for head injury.	[Loane, David J.; Stoica, Bogdan A.; Tchantchou, Flaubert; Kumar, Alok; Barrett, James P.; Akintola, Titilola; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Hlth Sci Facil HSFII 2, Baltimore, MD 21201 USA; [Loane, David J.; Stoica, Bogdan A.; Tchantchou, Flaubert; Kumar, Alok; Barrett, James P.; Akintola, Titilola; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA; [Xue, Fengtian] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; [Conn, P. Jeffrey] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; [Conn, P. Jeffrey] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA		Faden, A (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, Hlth Sci Facil HSFII 2, S247,20 Penn St, Baltimore, MD 21201 USA.	afaden@anes.umm.edu	STOICA, BOGDAN/H-9782-2013; Loane, David/ABD-5177-2021	STOICA, BOGDAN/0000-0002-2501-6434; Loane, David/0000-0003-0393-3503; Faden, Alan I./0000-0003-0128-2348; Barrett, James/0000-0002-0924-9449	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5R01NS037313]; UMB Pilot & Exploratory Interdisciplinary Research (IDR) Award; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH062646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313, R37NS031373] Funding Source: NIH RePORTER	We thank Marie Hanscom for expert technical assistance. This work was supported by a grant from the NIH/NINDS to AIF (5R01NS037313), and by a 2013 UMB Pilot & Exploratory Interdisciplinary Research (IDR) Award to B.S. and F.X.	Allen JW, 1999, NEUROPHARMACOLOGY, V38, P1243, DOI 10.1016/S0028-3908(99)00044-1; Allen JW, 2000, CELL DEATH DIFFER, V7, P470, DOI 10.1038/sj.cdd.4400678; Ayala JE, 2009, NEUROPSYCHOPHARMACOL, V34, P2057, DOI 10.1038/npp.2009.30; Bao WL, 2001, BRAIN RES, V922, P173, DOI 10.1016/S0006-8993(01)03062-1; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Byrnes KR, 2009, ANN NEUROL, V66, P63, DOI 10.1002/ana.21673; Byrnes KR, 2009, NEUROTHERAPEUTICS, V6, P94, DOI 10.1016/j.nurt.2008.10.038; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Chen T, 2012, INT J MOL MED, V29, P630, DOI 10.3892/ijmm.2011.870; Colton CA, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-27; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Conn PJ, 2009, NAT REV DRUG DISCOV, V8, P41, DOI 10.1038/nrd2760; de Paulis T, 2006, J MED CHEM, V49, P3332, DOI 10.1021/jm051252j; Fei Z, 2006, J CLIN NEUROSCI, V13, P1023, DOI 10.1016/j.jocn.2005.11.042; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gass JT, 2009, BIOL PSYCHIAT, V65, P717, DOI 10.1016/j.biopsych.2008.11.001; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gravius A, 2008, J NEURAL TRANSM, V115, P1609, DOI 10.1007/s00702-008-0098-4; Homayoun H, 2004, NEUROPSYCHOPHARMACOL, V29, P1259, DOI 10.1038/sj.npp.1300417; Homayoun H, 2010, EUR J PHARMACOL, V639, P33, DOI 10.1016/j.ejphar.2009.12.042; Kinney GG, 2005, J PHARMACOL EXP THER, V313, P199, DOI 10.1124/jpet.104.079244; Kinney GG, 2003, J PHARMACOL EXP THER, V306, P116, DOI 10.1124/jpet.103.048702; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Lecourtier L, 2007, BIOL PSYCHIAT, V62, P739, DOI 10.1016/j.biopsych.2006.12.003; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane David J, 2012, Wiley Interdiscip Rev Membr Transp Signal, V1, P136; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014; Lynch MA, 2009, MOL NEUROBIOL, V40, P139, DOI 10.1007/s12035-009-8077-9; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Movsesyan VA, 2004, J NEUROCHEM, V89, P1528, DOI 10.1111/j.1471-4159.2004.02451.x; Nickols HH, 2014, NEUROBIOL DIS, V61, P55, DOI 10.1016/j.nbd.2013.09.013; Nicoletti E, 2011, NEUROPHARMACOLOGY, V60, P1017, DOI 10.1016/j.neuropharm.2010.10.022; Noetzel MJ, 2012, MOL PHARMACOL, V81, P120, DOI 10.1124/mol.111.075184; Olive MF, 2010, EUR J PHARMACOL, V639, P47, DOI 10.1016/j.ejphar.2010.01.029; Piers TM, 2011, NEUROSCI LETT, V505, P140, DOI 10.1016/j.neulet.2011.10.007; Ponomarev ED, 2007, J NEUROSCI, V27, P10714, DOI 10.1523/JNEUROSCI.1922-07.2007; Rodriguez AL, 2010, MOL PHARMACOL, V78, P1105, DOI 10.1124/mol.110.067207; Szydlowska K, 2007, EUR J PHARMACOL, V554, P18, DOI 10.1016/j.ejphar.2006.09.061; Vincent AM, 1999, EXP NEUROL, V155, P79, DOI 10.1006/exnr.1998.6966; Wang JW, 2013, BIOCHEM BIOPH RES CO, V430, P1016, DOI 10.1016/j.bbrc.2012.12.046; Xue FT, 2014, CNS NEUROL DISORD-DR, V13, P558, DOI 10.2174/18715273113126660199; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511; Zhu PM, 2004, J NEUROSCI RES, V77, P525, DOI 10.1002/jnr.20175	46	57	59	1	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	OCT	2014	11	4					857	869		10.1007/s13311-014-0298-6			13	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	AS3AI	WOS:000344147100015	25096154	Green Published			2022-02-06	
J	Honeybul, S; Ho, KM				Honeybul, Stephen; Ho, Kwok M.			Decompressive craniectomy for severe traumatic brain injury: The relationship between surgical complications and the prediction of an unfavourable outcome	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Decompressive craniectomy; Complications; Injury severity	NEUROSURGICAL SITE INFECTIONS; SEVERE HEAD-INJURY; RISK-FACTORS; DELAYED CRANIOPLASTY; SUBDURAL HYGROMA; CEREBRAL EDEMA; HEMICRANIECTOMY; HYDROCEPHALUS; BONE; CRANIOTOMY	Object: To assess the impact that injury severity has on complications in patients who have had a decompressive craniectomy for severe traumatic brain injury (TBI). Methods: This prospective observational cohort study included all patients who underwent a decompressive craniectomy following severe TBI at the two major trauma hospitals in Western Australia from 2004 to 2012. All complications were recorded during this period. The clinical and radiological data of the patients on initial presentation were entered into a web-based model prognostic model, the CRASH (Corticosteroid Randomization After Significant Head injury) collaborators prediction model, to obtain the predicted risk of an unfavourable outcome which was used as a measure of injury severity. Results: Complications after decompressive craniectomy for severe TBI were common. The predicted risk of unfavourable outcome was strongly associated with the development of neurological complications such as herniation of the brain outside the skull bone defects (median predicted risk of unfavourable outcome for herniation 72% vs. 57% without herniation, p = 0.001), subdural effusion (median predicted risk of unfavourable outcome 67% with an effusion vs. 57% for those without an effusion, p = 0.03), hydrocephalus requiring ventriculo-peritoneal shunt (median predicted risk of unfavourable outcome 86% for those with hydrocephalus vs. 59% for those without hydrocephalus, p = 0.001), but not infection (p = 0.251) or resorption of bone flap (p = 0.697) and seizures (0.987). We did not observe any associations between timing of cranioplasty and risk of infection or resorption of bone flap after cranioplasty. Conclusions: Mechanical complications after decompressive craniectomy including herniation of the brain outside the skull bone defects, subdural effusion, and hydrocephalus requiring ventriculoperitoneal shunt were more common in patients with a more severe form of TBI when quantified by the CRASH predicted risk of unfavourable outcome. The CRASH predicted risk of unfavourable outcome represents a useful baseline characteristic of patients in observational and interventional trials involving patients with severe TBI requiring decompressive craniectomy. (C) 2014 Elsevier Ltd. All rights reserved.	[Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Nedlands, WA 6009, Australia; [Honeybul, Stephen] Royal Perth Hosp, Perth, WA, Australia; [Ho, Kwok M.] Univ Western Australia, Dept Intens Care Med, Nedlands, WA 6009, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Nedlands, WA 6009, Australia		Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Hosp Ave, Nedlands, WA 6009, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Aarabi B, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0947; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Bratton S.L., 2007, J NEUROTRAUMA S1, V24; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cooper P R, 1976, Surg Neurol, V5, P25; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; De Bonis P, 2010, J NEUROTRAUM, V27, P1965, DOI 10.1089/neu.2010.1425; FOSTER R.D., 2000, SCHMIDEK SWEET OPERA, P29; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hlatky R, 2002, J NEUROSURG, V97, P1054, DOI 10.3171/jns.2002.97.5.1054; Honeybul S, 2009, J CLIN NEUROSCI, V16, P727, DOI 10.1016/j.jocn.2008.06.015; Honeybul S, 2014, J NEUROSURG; Honeybul S, 2013, BRAIN INJURY, V27, P1732, DOI 10.3109/02699052.2013.830194; Honeybul S, 2013, BRIT J NEUROSURG, V27, P636, DOI 10.3109/02688697.2013.817532; Honeybul S, 2013, WORLD NEUROSURG, V79, P159, DOI 10.1016/j.wneu.2012.08.012; Honeybul S, 2012, PLAST RECONSTR SURG, V130, P1110, DOI 10.1097/PRS.0b013e318267d4de; Honeybul S, 2012, J NEUROTRAUM, V29, P1872, DOI 10.1089/neu.2012.2356; Honeybul S, 2011, J NEUROTRAUM, V28, P2199, DOI 10.1089/neu.2011.1907; Honeybul S, 2011, BRIT J NEUROSURG, V25, P343, DOI 10.3109/02688697.2011.568643; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Hutchinson PJ, 2011, BRIT J NEUROSURG, V25, P441, DOI 10.3109/02688697.2011.583366; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; JENNETT B, 1975, LANCET, V1, P480; Jiao Qing-fang, 2007, Chin J Traumatol, V10, P159; Kaen A, 2010, J NEUROSURG, V113, P1287, DOI 10.3171/2010.4.JNS10132; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kelly AG, 2010, NEUROLOGY, V75, P682, DOI 10.1212/WNL.0b013e3181eee273; Korinek AM, 2005, BRIT J NEUROSURG, V19, P155, DOI 10.1080/02688690500145639; Korinek AM, 1997, NEUROSURGERY, V41, P1073, DOI 10.1097/00006123-199711000-00010; Lavinio A, 2008, EUR J ANAESTH, V25, P137, DOI 10.1017/S0265021507003298; Lee KS, 1998, BRAIN INJURY, V12, P595, DOI 10.1080/026990598122359; Marion DW, 2011, LANCET NEUROL, V10, P497, DOI 10.1016/S1474-4422(11)70098-9; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; PROLO D.J, 1996, NEUROSURGERY, V2nd, P2783; RANSOHOFF J, 1971, J NEUROL NEUROSUR PS, V34, P106, DOI 10.1136/jnnp.34.1.106-a; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; SUZUKI N, 1993, ACTA NEUROCHIR, V122, P49, DOI 10.1007/BF01446986; Timmons SD, 2011, NEW ENGL J MED, V365, P373, DOI 10.1056/NEJMc1106421; Vashu R, 2011, ACTA NEUROCHIR, V153, P2065, DOI 10.1007/s00701-011-1101-7; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Wen L, 2007, J CRANIOFAC SURG, V18, P526, DOI 10.1097/scs.0b013e3180534348; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	53	57	64	0	20	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2014	45	9					1332	1339		10.1016/j.injury.2014.03.007			8	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	AN0NI	WOS:000340280900009	24704150				2022-02-06	
J	Carlson, SW; Madathil, SK; Sama, DM; Gao, X; Chen, JH; Saatman, KE				Carlson, Shaun W.; Madathil, Sindhu K.; Sama, Diana M.; Gao, Xiang; Chen, Jinhui; Saatman, Kathryn E.			Conditional Overexpression of Insulin-Like Growth Factor-1 Enhances Hippocampal Neurogenesis and Restores Immature Neuron Dendritic Processes After Traumatic Brain Injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Cellular proliferation; Controlled cortical impact; Dendrites; Doublecortin; Hippocampus; IGF-1; Neuronal differentiation; Traumatic brain injury	CONTROLLED CORTICAL IMPACT; DENTATE GYRUS; ADULT NEUROGENESIS; COGNITIVE RECOVERY; CELL-PROLIFERATION; IGF-I; PATTERN SEPARATION; GRANULE CELLS; MICE; RATS	Traumatic brain injury (TBI) is associated with neuronal damage or neuronal death in the hippocampus, a region critical for cognitive function. Immature neurons within the hippocampal neurogenic niche are particularly susceptible to TBI. Therapeutic strategies that protect immature hippocampal neurons or enhance posttraumatic neurogenesis may be advantageous for promoting functional recovery after TBI. Insulin-like growth factor-1 (IGF-1) promotes neurogenesis in the adult brain, but its effects on neurogenesis after TBI are unknown. We used an astrocyte-specific conditional IGF-1-overexpressing mouse model to supplement IGF-1 in regions of neuronal damage and reactive astrocytosis after controlled cortical impact injury. Although early loss of immature neurons was not significantly attenuated, overexpression of IGF-1 resulted in a marked increase in immature neuron density in the subgranular zone at 10 days after injury. This delayed increase seemed to be driven by enhanced neuron differentiation rather than by increased cellular proliferation. In wild-type mice, dendrites of immature neurons exhibited significant decreases in total length and number of bifurcations at 10 days after injury versus neurons in sham-injured mice. In contrast, the morphology of immature neuron dendrites in brain-injured IGF1-overexpressing mice was equivalent to that in sham controls. These data provide compelling evidence that IGF-1 promotes neurogenesis after TBI.	[Carlson, Shaun W.; Madathil, Sindhu K.; Sama, Diana M.; Saatman, Kathryn E.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA; [Carlson, Shaun W.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Gao, Xiang; Chen, Jinhui] Indiana Univ, Dept Neurol Surg, Stark Neurosci Res Inst, Indianapolis, IN 46204 USA		Saatman, KE (corresponding author), Spinal Cord & Brain Injury Res Ctr, B473 Biomed & Biol Res Bldg,741 S Limestone St, Lexington, KY 40536 USA.	k.saatman@uky.edu	Madathil, Sindhu K/E-9407-2012	Carlson, Shaun/0000-0002-1413-5075	Kentucky Spinal Cord and Head Injury Research Trust [KSCHIRT 7-20]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS072302, P30 NS051220, R21 NS072631]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS083182, R01NS072302, P30NS051220, R21NS072631] Funding Source: NIH RePORTER	This study was supported by Kentucky Spinal Cord and Head Injury Research Trust Grant No. KSCHIRT 7-20 (Kathryn E. Saatman) and National Institutes of Health Grant Nos. R01 NS072302 (Kathryn E. Saatman), P30 NS051220 (Kathryn E. Saatman), and R21 NS072631 (Jinhui Chen).	Aberg MAI, 2000, J NEUROSCI, V20, P2896; Aberg ND, 2006, THESCIENTIFICWORLDJO, V6, P53, DOI 10.1100/tsw.2006.22; Aberg ND, 2003, J NEUROSCI RES, V74, P12, DOI 10.1002/jnr.10734; Aimone JB, 2010, TRENDS COGN SCI, V14, P325, DOI 10.1016/j.tics.2010.04.003; Amiri A, 2012, J NEUROSCI, V32, P5880, DOI 10.1523/JNEUROSCI.5462-11.2012; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Arsenijevic Y, 1998, J NEUROSCI, V18, P2118; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Bondy CA, 2004, EUR J PHARMACOL, V490, P25, DOI 10.1016/j.ejphar.2004.02.042; Brooker GJF, 2000, J NEUROSCI RES, V59, P332, DOI 10.1002/(SICI)1097-4547(20000201)59:3<332::AID-JNR6>3.0.CO;2-2; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; Cai WK, 2012, J NEUROSCI, V32, P9887, DOI 10.1523/JNEUROSCI.0375-12.2012; Cheng CM, 2003, J NEUROSCI RES, V73, P1, DOI 10.1002/jnr.10634; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dempsey RJ, 2003, J NEUROCHEM, V87, P586, DOI 10.1046/j.1471-4159.2003.02022.x; Deng W, 2009, J NEUROSCI, V29, P13532, DOI 10.1523/JNEUROSCI.3362-09.2009; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Jessberger S, 2009, LEARN MEMORY, V16, P147, DOI 10.1101/lm.1172609; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Lichtenwalner RJ, 2001, NEUROSCIENCE, V107, P603, DOI 10.1016/S0306-4522(01)00378-5; Liquitaya-Montiel A, 2012, CNS NEUROL DISORD-DR, V11, P818, DOI 10.2174/1871527311201070818; LLorens-Martin M, 2010, MOL CELL NEUROSCI, V44, P109, DOI 10.1016/j.mcn.2010.02.006; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; Madathil SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067204; Madathil SK, 2010, J NEUROTRAUM, V27, P95, DOI 10.1089/neu.2009.1002; Madsen TM, 2003, NEUROSCIENCE, V119, P635, DOI 10.1016/S0306-4522(03)00199-4; McCurdy RD, 2005, EUR J NEUROSCI, V22, P1581, DOI 10.1111/j.1460-9568.2005.04355.x; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Niblock MM, 2000, J NEUROSCI, V20, P4165; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; Paxinos GFK., 2001, MOUSE BRAIN STEREOTA, V2nd ed.; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; TORRESALEMAN I, 1989, INT J DEV NEUROSCI, V7, P195, DOI 10.1016/0736-5748(89)90069-5; Trejo JL, 2008, MOL CELL NEUROSCI, V37, P402, DOI 10.1016/j.mcn.2007.10.016; Trejo JL, 2001, J NEUROSCI, V21, P1628, DOI 10.1523/JNEUROSCI.21-05-01628.2001; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Wang YG, 2011, J NEUROTRAUM, V28, P259, DOI 10.1089/neu.2010.1648; Xiong Y, 2012, J NEUROSURG, V116, P1081, DOI 10.3171/2012.1.JNS111729; Ye P, 2004, J NEUROSCI RES, V78, P472, DOI 10.1002/jnr.20288; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078; Zhu W, 2008, STROKE, V39, P1254, DOI 10.1161/STROKEAHA.107.500801	78	57	61	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	AUG	2014	73	8					734	746		10.1097/NEN.0000000000000092			13	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	AL8KF	WOS:000339386600001	25003234	Bronze, Green Accepted			2022-02-06	
J	Romine, J; Gao, X; Chen, JH				Romine, Jennifer; Gao, Xiang; Chen, Jinhui			Controlled Cortical Impact Model for Traumatic Brain Injury	JOVE-JOURNAL OF VISUALIZED EXPERIMENTS			English	Article						Medicine; Issue 90; controlled cortical impact; traumatic brain injury; cortical contusion	NEURONAL DEATH; RATS; EXPRESSION; DEFICITS	Every year over a million Americans suffer a traumatic brain injury (TBI). Combined with the incidence of TBIs worldwide, the physical, emotional, social, and economical effects are staggering. Therefore, further research into the effects of TBI and effective treatments is necessary. The controlled cortical impact (CCI) model induces traumatic brain injuries ranging from mild to severe. This method uses a rigid impactor to deliver mechanical energy to an intact dura exposed following a craniectomy. Impact is made under precise parameters at a set velocity to achieve a pre-determined deformation depth. Although other TBI models, such as weight drop and fluid percussion, exist, CCI is more accurate, easier to control, and most importantly, produces traumatic brain injuries similar to those seen in humans. However, no TBI model is currently able to reproduce pathological changes identical to those seen in human patients. The CCI model allows investigation into the short-term and long-term effects of TBI, such as neuronal death, memory deficits, and cerebral edema, as well as potential therapeutic treatments for TBI.	[Romine, Jennifer; Gao, Xiang; Chen, Jinhui] Indiana Univ Sch Med, Dept Neurol Surg, Stark Neurosci Res Inst, Spinal Cord & Brain Injury Res Grp, Indianapolis, IN 46202 USA		Chen, JH (corresponding author), Indiana Univ Sch Med, Dept Neurol Surg, Stark Neurosci Res Inst, Spinal Cord & Brain Injury Res Grp, Indianapolis, IN 46202 USA.	chen204@iupui.edu			Indiana Spinal Cord & Brain Injury Research Grants [SCBI 200-12]; Ralph W. and Grace M. Showalter Research Award; Indiana University Biological Research Grant; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RR025761, 1R21NS072631-01A]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072631] Funding Source: NIH RePORTER	This work was supported by funding from the Indiana Spinal Cord & Brain Injury Research Grants (SCBI 200-12), the Ralph W. and Grace M. Showalter Research Award, Indiana University Biological Research Grant, NIH grants RR025761 and 1R21NS072631-01A.	Anderson RWG, 2003, J NEUROTRAUM, V20, P961, DOI 10.1089/089771503770195812; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Gao X, 2013, EXP NEUROL, V239, P38, DOI 10.1016/j.expneurol.2012.09.012; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131	16	57	59	1	11	JOURNAL OF VISUALIZED EXPERIMENTS	CAMBRIDGE	1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA	1940-087X			JOVE-J VIS EXP	J. Vis. Exp.	AUG	2014		90							e51781	10.3791/51781			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CB0EV	WOS:000349299200053	25145417	Green Published			2022-02-06	
J	Ditillo, M; Pandit, V; Rhee, P; Aziz, H; Hadeed, S; Bhattacharya, B; Friese, RS; Davis, K; Joseph, B				Ditillo, Michael; Pandit, Viraj; Rhee, Peter; Aziz, Hassan; Hadeed, Steven; Bhattacharya, Bishwajit; Friese, Randall S.; Davis, Kimberly; Joseph, Bellal			Morbid obesity predisposes trauma patients to worse outcomes: A National Trauma Data Bank analysis	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	72nd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 18-23, 2013	San Francisco, CA	Amer Assoc Surg Trauma		Obesity; trauma; adverse outcomes in obese patients; mortality in obese patients; obesity and trauma	INDEPENDENT RISK-FACTOR; BLUNT TRAUMA; INJURED PATIENTS; MORTALITY	BACKGROUND: One third of US adults are obese. The impact of obesity on outcomes after blunt traumatic injury has been studied with discrepant results. The aim of our study was to evaluate outcomes in morbidly obese patients after blunt trauma. We hypothesized that morbidly obese patients have adverse outcomes as compared with nonobese patients after blunt traumatic injury. METHODS: We performed a retrospective analysis of all blunt trauma patients (>= 18 years) using the National Trauma Data Bank for years 2007 to 2010. Patients with recorded comorbidity of morbid obesity (body mass index >= 40) were identified. Patients transferred, dead on arrival, and with isolated traumatic brain injury were excluded. Propensity score matching was used to match morbidly obese patients to non-morbidly obese patients (body mass index < 40) in a 1: 1 ratio based on age, sex, Injury Severity Score (ISS), Glasgow Coma Scale (GCS), and systolic blood pressure on presentation. The primary outcome was mortality, and the secondary outcome was hospital complications. RESULTS: A total of 32,780 patients (morbidly obese, 16,390; nonobese, 16,390) were included in the study. Morbidly obese patients were more likely to have in-hospital complications (odds ratio [OR], 1.8, 95% confidence interval [CI], 1.6-1.9), longer hospital stay (OR, 1.2; 95% CI, 1.1-1.3), and longer intensive care unit stay (OR, 1.15; 95% CI, 1.09-1.2). The overall mortality rate was 2.8% (n = 851). Mortality was higher in morbidly obese patients compared with the nonobese patients (3.0 vs. 2.2; OR, 1.4; 95% CI, 1.1-1.5). CONCLUSION: In a cohort of matched patients, morbid obesity is a risk factor for the development of in-hospital complications and mortality after blunt traumatic injury. The results of our study call for attention through focused injury prevention efforts. Future studies are needed to help define the consequences of obesity that influence outcomes. Copyright (C) 2014 by Lippincott Williams & Wilkins	[Pandit, Viraj; Rhee, Peter; Aziz, Hassan; Hadeed, Steven; Friese, Randall S.; Joseph, Bellal] Univ Arizona, Dept Surg, Div Trauma Crit Care Burns & Emergency Surg, Tucson, AZ 85724 USA; [Ditillo, Michael; Bhattacharya, Bishwajit; Davis, Kimberly] Yale New Haven Med Ctr, Dept Surg, Div Trauma Crit Care Burns & Emergency Surg, New Haven, CT 06504 USA		Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care Burns & Emergency Surg, 1501 N Campbell Ave,Room 5411,POB 245063, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu	Aziz, Hassan/ABA-5681-2021; Ditillo, Michael/AAI-6259-2020	Aziz, Hassan/0000-0003-0406-1946; Bhattacharya, Bishwajit/0000-0002-7118-7621			Arbabi S, 2003, J TRAUMA, V54, P1090, DOI 10.1097/01.TA.0000064449.11809.48; BOULANGER BR, 1994, CRIT CARE CLIN, V10, P613, DOI 10.1016/S0749-0704(18)30121-0; Brown Carlos V R, 2006, World J Emerg Surg, V1, P27, DOI 10.1186/1749-7922-1-27; Brown CVR, 2005, J TRAUMA, V59, P1048, DOI 10.1097/01.ta.0000189047.65630.c5; Byrnes MC, 2005, J TRAUMA, V58, P232, DOI 10.1097/01.TA.0000152081.67588.10; CHOBAN PS, 1991, J TRAUMA, V31, P1253, DOI 10.1097/00005373-199109000-00009; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Fryar CD., PREVALENCE OVERWEIGH; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; Kisat M, 2013, SURG INFECT, V14, P62, DOI 10.1089/sur.2012.009; Neville AL, 2004, ARCH SURG-CHICAGO, V139, P983, DOI 10.1001/archsurg.139.9.983; Winfield RD, 2013, J AM COLL SURGEONS, V216, P1193, DOI 10.1016/j.jamcollsurg.2013.01.055	12	57	57	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JAN	2014	76	1					176	179		10.1097/TA.0b013e3182ab0d7c			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	AH8JN	WOS:000336384200033	24368375				2022-02-06	
J	Dunkley, BT; Doesburg, SM; Sedge, PA; Grodecki, RJ; Shek, PN; Pang, EW; Taylor, MJ				Dunkley, B. T.; Doesburg, S. M.; Sedge, P. A.; Grodecki, R. J.; Shek, P. N.; Pang, E. W.; Taylor, M. J.			Resting-state hippocampal connectivity correlates with symptom severity in post-traumatic stress disorder	NEUROIMAGE-CLINICAL			English	Article						Post-traumatic stress disorder; Magnetoencephalography (MEG); Resting-state; Functional connectivity; Neural network	MEDIAL PREFRONTAL CORTEX; CEREBRAL-BLOOD-FLOW; FUNCTIONAL CONNECTIVITY; VIETNAM VETERANS; PREVALENCE; NETWORKS; DYNAMICS; IMAGERY; TRAUMA; INDEX	Post-traumatic stress disorder (PTSD) is a serious mental health injury which can manifest after experiencing a traumatic life event. The disorder is characterized by symptoms of re-experiencing, avoidance, emotional numbing and hyper-arousal. Whilst its aetiology and resultant symptomology are better understood, relatively little is known about the underlying cortical pathophysiology, and in particular whether changes in functional connectivity may be linked to the disorder. Here, we used non-invasive neuroimaging with magnetoencephalography to examine functional connectivity in a resting-state protocol in the combat-related PTSD group (n = 23), and a military control group (n = 21). We identify atypical long-range hyperconnectivity in the high-gamma-band resting-state networks in a combat-related PTSD population compared to soldiers who underwent comparable environmental exposure but did not develop PTSD. Using graph analysis, we demonstrate that apparent network connectivity of relevant brain regions is associated with cognitive-behavioural outcomes. We also show that left hippocampal connectivity in the PTSD group correlates with scores on the well-established PTSD Checklist (PCL). These findings indicate that atypical synchronous neural interactions may underlie the psychological symptoms of PTSD, whilst also having utility as a potential biomarker to aid in the diagnosis and monitoring of the disorder. (C) 2014 The Authors. Published by Elsevier Inc.	[Dunkley, B. T.; Doesburg, S. M.; Taylor, M. J.] Hosp Sick Children, Dept Diagnost Imaging, Toronto, ON M5G 1X8, Canada; [Dunkley, B. T.; Doesburg, S. M.; Pang, E. W.; Taylor, M. J.] Hosp Sick Children, Res Inst, Neurosci & Mental Hlth Program, Toronto, ON M5G 1X8, Canada; [Doesburg, S. M.; Taylor, M. J.] Univ Toronto, Dept Med Imaging, Toronto, ON, Canada; [Doesburg, S. M.; Taylor, M. J.] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Sedge, P. A.] Canadian Forces Hlth Serv, Directorate Mental Hlth, Ottawa, ON, Canada; [Grodecki, R. J.] Canadian Forces Environm Med Estab, Toronto, ON, Canada; [Shek, P. N.] Def Res & Dev Canada, Toronto, ON, Canada; [Pang, E. W.] Hosp Sick Children, Div Neurol, Toronto, ON M5G 1X8, Canada		Dunkley, BT (corresponding author), Dept Diagnost Imaging, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	ben.dunkley@sickkids.ca		Dunkley, Ben/0000-0001-6173-1171	Defence Research and Development Canada (DRDC) [W7719-135182/001/TOR]; Canadian Forces Health Services	The authors would like to thank Amanda Robertson and Marc Lalancette for help in the data collection, and Daniel Cassel for help with the data analysis pipeline. This work was supported by funding from Defence Research and Development Canada (DRDC) (contract # W7719-135182/001/TOR) and the Canadian Forces Health Services to MJT and EWP.	American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, DOI 10.1176/appi.books.9780890425596; American Psychiatric Association, 2000, DIAGNOSTIC STAT MANU DIAGNOSTIC STAT MANU; Bluhm RL, 2009, J PSYCHIATR NEUROSCI, V34, P187; Bremner JD, 2003, AM J PSYCHIAT, V160, P924, DOI 10.1176/appi.ajp.160.5.924; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; Engdahl B, 2010, J NEURAL ENG, V7, DOI 10.1088/1741-2560/7/6/066005; Engel AK, 2013, NEURON, V80, P867, DOI 10.1016/j.neuron.2013.09.038; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; Fell J, 2001, NAT NEUROSCI, V4, P1259, DOI 10.1038/nn759; Fries P., 2012, TRENDS COGN SCI, V9, P356; Garber BG, 2012, CAN J PSYCHIAT, V57, P736, DOI 10.1177/070674371205701205; Georgopoulos AP, 2010, J NEURAL ENG, V7, DOI 10.1088/1741-2560/7/1/016011; Gold AL, 2011, PSYCHOL MED, V41, P2563, DOI 10.1017/S0033291711000730; Hall E.L., 2013, NEUROIMAGE; Hari R, 2012, NEUROIMAGE, V61, P386, DOI 10.1016/j.neuroimage.2011.11.074; Hiltunen T, 2014, J NEUROSCI, V34, P356, DOI 10.1523/JNEUROSCI.0276-13.2014; Hull AM, 2002, BRIT J PSYCHIAT, V181, P102; James LM, 2013, JAMA PSYCHIAT, V70, P410, DOI 10.1001/jamapsychiatry.2013.878; Jin C, 2014, PSYCHOL MED, V44, P1927, DOI 10.1017/S003329171300250X; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kolassa IT, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-56; Lau TM, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-47; Llinas RR, 2006, J NEUROPHYSIOL, V95, P3297, DOI 10.1152/jn.00166.2006; Luo Q, 2009, CEREB CORTEX, V19, P1896, DOI 10.1093/cercor/bhn216; Mukamel R, 2005, SCIENCE, V309, P951, DOI 10.1126/science.1110913; Muthukumaraswamy SD, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00138; Nir Y, 2007, CURR BIOL, V17, P1275, DOI 10.1016/j.cub.2007.06.066; Pagani M, 2010, EUR PSYCHIAT, V25; Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339; Quraan MA, 2010, NEUROIMAGE, V49, P2387, DOI 10.1016/j.neuroimage.2009.10.012; Rabinak Christine A, 2011, Front Psychiatry, V2, P62, DOI 10.3389/fpsyt.2011.00062; Richardson LK, 2010, AUST NZ J PSYCHIAT, V44, P4, DOI 10.3109/00048670903393597; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Shin LM, 2011, AM J PSYCHIAT, V168, P979, DOI 10.1176/appi.ajp.2011.09121812; Shin LM, 2004, ARCH GEN PSYCHIAT, V61, P168, DOI 10.1001/archpsyc.61.2.168; Sripada RK, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00672; Tagliazucchi E, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00339; Tewarie P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069318; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Vinck M, 2011, NEUROIMAGE, V55, P1548, DOI 10.1016/j.neuroimage.2011.01.055; Wang L, 2012, NEURON, V76, P1010, DOI 10.1016/j.neuron.2012.09.033; Wang XJ, 2010, PHYSIOL REV, V90, P1195, DOI 10.1152/physrev.00035.2008; Xia MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068910; Yin Y, 2011, BRAIN RES, V1411, P98, DOI 10.1016/j.brainres.2011.07.016; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041	46	57	57	0	10	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2014	5						377	384		10.1016/j.nicl.2014.07.017			8	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CB5LF	WOS:000349667800041	25180157	Green Published, gold			2022-02-06	
J	Srinivasan, VM; O'Neill, BR; Jho, D; Whiting, DM; Oh, MY				Srinivasan, Visish M.; O'Neill, Brent R.; Jho, Diana; Whiting, Donald M.; Oh, Michael Y.			The history of external ventricular drainage	JOURNAL OF NEUROSURGERY			English	Article						external ventricular drainage; intracranial pressure monitoring; ventriculostomy; history	CATHETER PLACEMENT; VIRTUAL-REALITY; PRESSURE; HYDROCEPHALUS; ANTIBIOTICS; INFECTIONS; ACCURACY; EFFICACY; MONITOR	External ventricular drainage (EVD) is one of the most commonly performed neurosurgical procedures. It was first performed as early as 1744 by Claude-Nicholas Le Cat. Since then, there have been numerous changes in technique, materials used, indications for the procedure, and safety. The history of EVD is best appreciated in 4 eras of progress: development of the technique (1850-1908), technological advancements (1927-1950), expansion of indications (1960-1995), and accuracy, training, and infection control (1995 present). While EVD was first attempted in he 18th century, it was not until 1890 that the first thorough report of EVD technique and outcomes was published by William Williams Keen. He was followed by H. Tillmanns, who described the technique that would be used for many years. Following this, many improvements were made to the EVD apparatus itself, including the addition of manometry by Adson and Lillie in 1927, and continued experimentation in cannulation/drainage materials. Technological advancements allowed a great expansion of indications for EVD, sparked by Nils Lundberg, who published a thorough analysis of the use of intracranial pressure (ICP) monitoring in patients with brain tumors in 1960. This led to the application of EVD and ICP monitoring in subarachnoid hemorrhage, Reye syndrome, and traumatic brain injury. Recent research in EVD has focused on improving the overall safety of the procedure, which has included the development of guidance-based systems, virtual reality simulators for trainees, and antibiotic-impregnated catheters.	[Srinivasan, Visish M.; Whiting, Donald M.; Oh, Michael Y.] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA; [Srinivasan, Visish M.; Jho, Diana; Whiting, Donald M.; Oh, Michael Y.] Allegheny Gen Hosp, Dept Neurosurg, Pittsburgh, PA 15212 USA; [O'Neill, Brent R.] Univ Colorado, Sch Med, Div Pediat Neurosurg, Aurora, CO USA		Srinivasan, VM (corresponding author), Baylor Coll Med, Dept Neurosurg, 1709 Dryden Rd,Ste 750, Houston, TX 77030 USA.	visishs@glink.drexel.edu	Srinivasan, Visish M./H-9811-2019	Srinivasan, Visish M./0000-0001-7673-6805			Adson AW, 1927, T AM ACAD OPHTHALMOL, V30, P138; Aschoff A, 1999, NEUROSURG REV, V22, P67, DOI 10.1007/s101430050035; Banerjee PP, 2007, J NEUROSURG, V107, P515, DOI 10.3171/JNS-07/09/0515; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BERING EA, 1951, J NEUROSURG, V8, P450, DOI 10.3171/jns.1951.8.4.0450; BINGHAM WF, 1986, J NEUROSURG, V64, P705, DOI 10.3171/jns.1986.64.5.0705; BRUNORI A, 1993, J NEUROSURG, V78, P515, DOI 10.3171/jns.1993.78.3.0515; Bullock MR, 1996, J NEUROTRAUM, V13, P685; CHAN KH, 1988, NEUROSURGERY, V23, P436, DOI 10.1227/00006123-198810000-00005; Crawford AS, 1943, ANN SURG, V117, P798, DOI 10.1097/00000658-194305000-00021; Dandy WE, 1922, B JOHNS HOPKINS HOSP, V33, P189; Dandy WE, 1918, ANN SURG, V68, P5, DOI 10.1097/00000658-191807000-00002; FRIEDMAN WA, 1980, J NEUROSURG, V53, P662, DOI 10.3171/jns.1980.53.5.0662; Greenberg MS., 2010, HDB NEUROSURGERY, V7th; Greer B, 2009, MONT MATH ENTHUS MON, V6, P3, DOI 10.1016/B978-141602908-3.50004-2; Haynes IS, 1913, ANN SURG, V57, P449, DOI 10.1097/00000658-191304000-00001; Hill BL, 1866, LECT AM ECLECTIC SYS; Huyette DR, 2008, J NEUROSURG, V108, P88, DOI 10.3171/JNS/2008/108/01/0088; INGRAHAM FD, 1947, JAMA-J AM MED ASSOC, V135, P82, DOI 10.1001/jama.1947.02890020012005; Ingraham FD, 1941, ANN SURG, V114, P1096, DOI 10.1097/00000658-194112000-00017; Kakarla UK, 2008, NEUROSURGERY S1, V63; KAUFMANN GE, 1970, J NEUROSURG, V33, P226, DOI 10.3171/jns.1970.33.2.0226; Keen, 1890, LANCET, V136, P553, DOI DOI 10.1016/S0140-6736(00)48676-9; Keong NCH, 2012, NEUROSURGERY, V71, P394, DOI 10.1227/NEU.0b013e318257bebb; Kompanje EJO, 2003, PEDIATR NEUROSURG, V39, P10, DOI 10.1159/000070872; Krombach G, 2000, MINIM INVAS NEUROSUR, V43, P171, DOI 10.1055/s-2000-11376; KUSSKE JA, 1973, J NEUROSURG, V38, P591, DOI 10.3171/jns.1973.38.5.0591; Lemole GM, 2007, NEUROSURGERY, V61, P142, DOI 10.1227/01.neu.0000279734.22931.21; Lifshutz JI, 2001, NEUROSURG FOCUS, V11, pE1, DOI DOI 10.3171/F0C.2001.11.2.2; Lozier AP, 2002, NEUROSURGERY, V51, P170, DOI 10.1097/00006123-200207000-00024; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MATSON DD, 1966, J NEUROSURG, V24, P945; McCarthy PJ, 2010, NEUROCRIT CARE, V12, P220, DOI 10.1007/s12028-009-9284-y; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; O'Leary ST, 2000, J NEUROSURG, V92, P801, DOI 10.3171/jns.2000.92.5.0801; O'Neill BR, 2008, SURG NEUROL, V70, P268, DOI 10.1016/j.surneu.2007.05.007; PIZZI FJ, 1976, CHILD BRAIN, V2, P59; Pople I, 2012, NEUROSURGERY, V71, P6, DOI 10.1227/NEU.0b013e3182544e31; Poppen JL, 1943, ARCH NEURO PSYCHIATR, V50, P587, DOI 10.1001/archneurpsyc.1943.02290230099011; RAJSHEKHAR V, 1992, ACTA NEUROCHIR, V115, P8, DOI 10.1007/BF01400584; Rengachary SS, 2005, PRINCIPLES NEUROSURG; Retzius MG, 1875, STUDIEN ANATOMIE NER; ROBINSON F, 1948, J NEUROSURG, V5, P320, DOI 10.3171/jns.1948.5.3.0320; ROSEGAY H, 1992, J NEUROSURG, V76, P1032, DOI 10.3171/jns.1992.76.6.1032; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SAUNDERS RL, 1978, NEUROSURGERY, V3, P130, DOI 10.1097/00006123-197807000-00021; SAUNDERS RL, 1979, CRIT CARE MED, V7, P556, DOI 10.1097/00003246-197912000-00010; Schultke E, 2009, NEUROSURGERY, V64, P1001, DOI 10.1227/01.NEU.0000344003.72056.7F; Sekula RF, 2008, BRIT J NEUROSURG, V22, P213, DOI 10.1080/02688690701832084; Selden NR, 2012, NEUROSURGERY, V70, P971, DOI 10.1227/NEU.0b013e31823d7a45; SHAPIRO HM, 1972, J NEUROSURG, V36, P798, DOI 10.3171/jns.1972.36.6.0798; SMITH RW, 1976, J NEUROSURG, V44, P567, DOI 10.3171/jns.1976.44.5.0567; Sonabend AM, 2011, NEUROSURGERY, V68, P996, DOI 10.1227/NEU.0b013e3182096d84; STONE JL, 1985, NEUROSURGERY, V17, P997, DOI 10.1227/00006123-198512000-00024; Tillmanns H, 1908, BRIT MED J, V1908, P983; Walker ML, 2001, NEUROSURG CLIN N AM, V12, P101, DOI 10.1016/S1042-3680(18)30070-6; WHITE RJ, 1969, J NEUROSURG, V30, P264, DOI 10.3171/jns.1969.30.3part1.0264; Whytt R, 1768, OBSERVATIONS DROPSY; WILKINS RH, 1964, J NEUROSURG, V21, P240, DOI 10.3171/jns.1964.21.3.0240; WYLER AR, 1972, J NEUROSURG, V37, P185, DOI 10.3171/jns.1972.37.2.0185; Zabramski JM, 2003, J NEUROSURG, V98, P725, DOI 10.3171/jns.2003.98.4.0725	63	57	58	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2014	120	1					228	236		10.3171/2013.6.JNS121577			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	281GL	WOS:000329087900033	23889138				2022-02-06	
J	Izzy, S; Compton, R; Carandang, R; Hall, W; Muehlschlegel, S				Izzy, Saef; Compton, Rebecca; Carandang, Raphael; Hall, Wiley; Muehlschlegel, Susanne			Self-Fulfilling Prophecies Through Withdrawal of Care: Do They Exist in Traumatic Brain Injury, Too?	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Withdrawal of care; Prognostication; Self-fulfilling prophecies	PROGNOSTICATION; SUPPORT; IMPACT	We examined factors associated with withdrawal of care (WOC) in moderate-severe traumatic brain injury (msTBI) patients, and how WOC may affect short-term mortality and receipt of neurosurgery. Variability in msTBI-related outcome prognostication by clinicians from different specialties was also assessed. Rates of WOC, factors associated with WOC, and the relation between WOC and in-hospital case-fatality rate (CFR) and neurosurgery were determined in 232 prospectively enrolled msTBI patients in the ongoing OPTIMISM Study at a level-1 trauma center. In a concomitant web-based survey with clinical vignettes, outcome prognostication comfort, treatment aggressiveness, and WOC recommendations were examined among 106 respondents from neurology, neurocritical care, neurosurgery, trauma and anesthesia/critical care. The average age of the study sample was 53 years, with a median Glasgow Coma Scale of 6. The in-hospital CFR was 36 and 68 % of patients had WOC. Factors independently associated with WOC were advanced age, pupillary reactivity, lower intensive care unit-length-of-stay, pre- and in-hospital cardiac arrest, herniation, intracranial pressure crisis, and pre-existing endocrine disease. Inclusion of WOC in our multivariable regression model predicting in-hospital CFRs negated all other variables. Survey results suggested that in younger patients, some clinicians prognosticated overly pessimistically based upon data available at the time of presentation. In our msTBI cohort, WOC was the most important predictor of in-hospital mortality. We identified several important independent predictors of WOC. Large within-center variability in msTBI outcome prognostication with varying levels of possible clinical nihilism exists, which may form the basis of self-fulfilling prophecies.	[Izzy, Saef; Compton, Rebecca; Carandang, Raphael; Hall, Wiley] Univ Massachusetts, Sch Med, Dept Neurol Neurocrit Care, Worcester, MA 01655 USA; [Carandang, Raphael; Hall, Wiley] Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA USA; [Muehlschlegel, Susanne] Univ Massachusetts, Sch Med, Dept Anesthesia Crit Care, Worcester, MA 01655 USA; [Muehlschlegel, Susanne] Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA 01655 USA		Muehlschlegel, S (corresponding author), Univ Massachusetts, Sch Med, Dept Neurol Neurocrit Care, 55 Lake Ave North, Worcester, MA 01655 USA.	susanne.muehlschlegel@umassmemorial.org			University of Massachusetts Medical School Faculty Scholar Award; National Institute of Health Clinical Translational Science Award [5UL1TR000161]; Worcester Research Foundation	This study was funded in part by the University of Massachusetts Medical School Faculty Scholar Award (S. M.) (funded by the National Institute of Health Clinical Translational Science Award (5UL1TR000161) to the University of Massachusetts Medical School). Funding was also provided by the Worcester Research Foundation (S. M. and R.C.).	[Anonymous], 2013, TRAUM BRAIN INJ STAT; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Garland A, 2013, CHEST, V143, P214, DOI 10.1378/chest.12-1531; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hemphill JC, 2009, EMERG MED CLIN N AM, V27, P27, DOI 10.1016/j.emc.2008.08.009; Johnston SC, 2000, MUSCLE NERVE, V23, P839, DOI 10.1002/(SICI)1097-4598(200006)23:6<839::AID-MUS1>3.3.CO;2-M; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Mayor SA, 1999, NEUROLOGY, V52, P1602, DOI 10.1212/WNL.52.8.1602; Muehlschlegel S, 2013, NEUROCRIT CARE, V18, P318, DOI 10.1007/s12028-013-9817-2; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Rabinstein AA, 2010, NEUROLOGY, V74, P1086, DOI 10.1212/WNL.0b013e3181d7d928; Sheth KN, 2012, NEUROLOGY, V78, P1793, DOI 10.1212/WNL.0b013e3182583034; Stacey D, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001431.pub4, 10.1002/14651858.CD001431.pub3, 10.1002/14651858.CD001431.pub2]; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Turgeon AF, 2013, CRIT CARE MED, V41, P1086, DOI 10.1097/CCM.0b013e318275d046; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Wilson ME, 2013, INTENS CARE MED, V39, P1009, DOI 10.1007/s00134-013-2896-x	17	57	59	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2013	19	3					347	363		10.1007/s12028-013-9925-z			17	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	257OB	WOS:000327393200014	24132565				2022-02-06	
J	Rachmany, L; Tweedie, D; Rubovitch, V; Yu, QS; Li, YZ; Wang, JY; Pick, CG; Greig, NH				Rachmany, Lital; Tweedie, David; Rubovitch, Vardit; Yu, Qian-Sheng; Li, Yazhou; Wang, Jia-Yi; Pick, Chaim G.; Greig, Nigel H.			Cognitive Impairments Accompanying Rodent Mild Traumatic Brain Injury Involve p53-Dependent Neuronal Cell Death and Are Ameliorated by the Tetrahydrobenzothiazole PFT-alpha	PLOS ONE			English	Article							GLUCAGON-LIKE PEPTIDE-1; OBJECT RECOGNITION MEMORY; FLUORO-JADE-B; CEREBRAL-ISCHEMIA; P53-INDUCED APOPTOSIS; FUNCTIONAL OUTCOMES; GENE-EXPRESSION; HEAD-INJURY; P53; MECHANISMS	With parallels to concussive mild traumatic brain injury (mTBI) occurring in humans, anesthetized mice subjected to a single 30 g weight drop mTBI event to the right parietal cortex exhibited significant diffuse neuronal degeneration that was accompanied by delayed impairments in recognition and spatial memory. To elucidate the involvement of reversible p53-dependent apoptosis in this neuronal loss and associated cognitive deficits, mice were subjected to experimental mTBI followed by the systemic administration of the tetrahydrobenzothiazole p53 inactivator, PFT-alpha, or vehicle. Neuronal loss was quantified immunohistochemically at 72 hr. post-injury by the use of fluoro-Jade B and NeuN within the dentate gyrus on both sides of the brain, and recognition and spatial memory were assessed by novel object recognition and Y-maze paradigms at 7 and 30 days post injury. Systemic administration of a single dose of PFT-alpha 1 hr. post-injury significantly ameliorated both neuronal cell death and cognitive impairments, which were no different from sham control animals. Cellular studies on human SH-SY5Y cells and rat primary neurons challenged with glutamate excitotoxicity and H2O2 induced oxidative stress, confirmed the ability of PFT-alpha and a close analog to protect against these TBI associated mechanisms mediating neuronal loss. These studies suggest that p53-dependent apoptotic mechanisms underpin the neuronal and cognitive losses accompanying mTBI, and that these are potentially reversible by p53 inactivation.	[Rachmany, Lital; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Rachmany, Lital; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel; [Tweedie, David; Yu, Qian-Sheng; Li, Yazhou; Greig, Nigel H.] NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA; [Wang, Jia-Yi] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan		Pick, CG (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel.	pickc@post.tau.ac.il; Greign@grc.nia.nih.gov		Wang, Jia-Yi/0000-0002-9106-3351	Intramural Research Program of the National Institute on Aging, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); National Science Council, TaiwanMinistry of Science and Technology, Taiwan [NSC 101-2321-B-038-003, NSC 102-2321-B-038-003]; Sackler School of Medicine, Tel-Aviv University; Israeli Science FoundationIsrael Science Foundation [108/09]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000311] Funding Source: NIH RePORTER	This research was supported in part by (i) the Intramural Research Program of the National Institute on Aging, National Institutes of Health (DT,QSY,NHG); (ii) grants from the National Science Council (NSC 101-2321-B-038-003 and NSC 102-2321-B-038-003), Taiwan (JYW); (iii) by the Sackler School of Medicine, Tel-Aviv University, and, in part, by a grant from the Israeli Science Foundation (grant no. 108/09) (LR,VR,CGP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AGGLETON JP, 1986, BEHAV BRAIN RES, V19, P133, DOI 10.1016/0166-4328(86)90011-2; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Bae BI, 2005, NEURON, V47, P29, DOI 10.1016/j.neuron.2005.06.005; Bailey JA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021954; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Broadbent NJ, 2010, LEARN MEMORY, V17, P794, DOI 10.1101/lm.1650110; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; CHOI DW, 1987, J NEUROSCI, V7, P357; Chuah YML, 2004, BRAIN COGNITION, V56, P304, DOI 10.1016/j.bandc.2004.08.002; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Culmsee C, 2003, J NEUROSCI, V23, P8586; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; Das M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-148; Davenport CM, 2010, J NEUROCHEM, V112, P552, DOI 10.1111/j.1471-4159.2009.06485.x; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; Duan WZ, 2002, ANN NEUROL, V52, P597, DOI 10.1002/ana.10350; Edut S, 2011, PSYCHOPHARMACOLOGY, V214, P877, DOI 10.1007/s00213-010-2098-y; Endo H, 2006, J NEUROSCI, V26, P7974, DOI 10.1523/JNEUROSCI.0897-06.2006; Eve DJ, 2007, BRAIN RES, V1150, P174, DOI 10.1016/j.brainres.2007.02.088; Floyd CL, 2005, GLIA, V51, P35, DOI 10.1002/glia.20183; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Greig NH, 2004, ANN NY ACAD SCI, V1035, P290, DOI 10.1196/annals.1332.018; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Gudkov AV, 2007, HUM MOL GENET, V16, pR67, DOI 10.1093/hmg/ddm052; Gudkov AV, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001180; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Hatic H, 2012, J NEUROTRAUM, V29, P1188, DOI 10.1089/neu.2011.1806; Hellmich HL, 2007, BRAIN RES, V1127, P119, DOI 10.1016/j.brainres.2006.09.094; Herculano-Houzel S, 2005, J NEUROSCI, V25, P2518, DOI 10.1523/JNEUROSCI.4526-04.2005; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hong MY, 2012, CHINESE MED J-PEKING, V125, P2019, DOI 10.3760/cma.j.issn.0366-6999.2012.11.032; HOSSMANN KA, 1994, BRAIN PATHOL, V4, P23; Howard DB, 2008, VIROLOGY, V372, P24, DOI 10.1016/j.virol.2007.10.007; Jessberger S, 2009, LEARN MEMORY, V16, P147, DOI 10.1101/lm.1172609; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Lea PM, 2001, MENT RETARD DEV D R, V7, P235, DOI 10.1002/mrdd.1033; Lee C, 2009, EXP NEUROL, V220, P400, DOI 10.1016/j.expneurol.2009.08.019; Leker RR, 2004, EXP NEUROL, V187, P478, DOI 10.1016/j.expneurol.2004.01.030; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Luo Y, 2009, ANN NEUROL, V65, P520, DOI 10.1002/ana.21592; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mehta A, 2013, EUR J PHARMACOL, V698, P6, DOI 10.1016/j.ejphar.2012.10.032; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Muir JK, 1999, EXP NEUROL, V159, P584, DOI 10.1006/exnr.1999.7187; Nakajima Y, 2010, TOHOKU J EXP MED, V221, P229, DOI 10.1620/tjem.221.229; Nayak SK, 2009, CURR MED CHEM, V16, P2627, DOI 10.2174/092986709788681976; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Rachmany L, 2013, AGE, V35, P1621, DOI 10.1007/s11357-012-9464-0; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Salcedo I, 2012, BRIT J PHARMACOL, V166, P1586, DOI 10.1111/j.1476-5381.2012.01971.x; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Saykally JN, 2012, NEUROSCIENCE, V223, P305, DOI 10.1016/j.neuroscience.2012.07.070; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schober ME, 2010, J NEUROTRAUM, V27, P2011, DOI 10.1089/neu.2009.1226; Schultz BA, 2011, NEUROREHABILITATION, V28, P309, DOI 10.3233/NRE-2011-0659; Squire LR, 2007, NAT REV NEUROSCI, V8, P872, DOI 10.1038/nrn2154; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Watanabe H, 1999, BRAIN RES, V837, P38, DOI 10.1016/S0006-8993(99)01652-2; Winters BD, 2008, NEUROSCI BIOBEHAV R, V32, P1055, DOI 10.1016/j.neubiorev.2008.04.004; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zhu XX, 2002, J MED CHEM, V45, P5090, DOI 10.1021/jm020044d; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	87	57	57	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2013	8	11							e79837	10.1371/journal.pone.0079837			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261IJ	WOS:000327657900003	24312187	Green Published, gold, Green Submitted			2022-02-06	
J	Yu, FS; Wang, ZF; Tanaka, M; Chiu, CT; Leeds, P; Zhang, YM; Chuang, DM				Yu, Fengshan; Wang, Zhifei; Tanaka, Mikiei; Chiu, Chi-Tso; Leeds, Peter; Zhang, Yumin; Chuang, De-Maw			Posttrauma cotreatment with lithium and valproate: reduction of lesion volume, attenuation of blood-brain barrier disruption, and improvement in motor coordination in mice with traumatic brain injury Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; lithium; valproate; neuroprotection; acetylhistone H3; mouse	MOOD STABILIZERS LITHIUM; BIPOLAR DISORDER; MOUSE MODEL; ACID; INHIBITION; NEURODEGENERATION; DEFICITS; DISEASE; ROLES; HDAC	Object. Although traumatic brain injury (TBI) is the leading cause of death and morbidity in young adults, no effective pharmaceutical treatment is available. By inhibiting glycogen synthase kinase-3 (GSK-3) and histone deacetylases (HDACs), respectively, lithium and valproate (VPA) have beneficial effects in diverse neurodegenerative diseases. Furthermore, in an excitotoxic neuronal model and in animal models of amyotrophic lateral sclerosis, Huntington disease, and stroke, combined treatment with lithium and VPA produces more robust neuroprotective effects than treatment with either agent alone. Building on previous work that establishes that therapeutic doses of either lithium or VPA have beneficial effects in mouse models of TBI, this study evaluated the effects of combined treatment with subeffective doses of lithium and VPA in a mouse model of TBI. Methods. Male C57BL/6 mice underwent TBI and were subsequently treated with lithium, VPA, or a combination of lithium and VPA 15 minutes post-TBI and once daily thereafter for up to 3 weeks; all doses were subeffective (1 mEq/kg of lithium and 200 mg/kg of VPA). Assessed parameters included lesion volume via H & E staining; blood-brain bather (BBB) integrity via immunoglobulin G extravasation; neurodegeneration via Fluoro-Jade B staining; motor coordination via a beam-walk test; and protein levels of acetylhistone H3, phospho-GSK-3 beta, and beta-catenin via Western blotting. Results. Posttrauma treatment with combined subeffective doses of lithium and VPA significantly reduced lesion volume, attenuated BBB disruption, and mitigated hippocampal neurodegeneration 3 days after TBI. As expected, subeffective doses of lithium or VPA alone did not have these beneficial effects. Combined treatment also improved motor coordination starting from Day 7 and persisting at least 21 days after TBI. Acetylation of histone H3, an index of HDAC inhibition, was robustly increased by the combined treatment 3 days after TBI. Conclusions. Cotreatment with subeffective doses of lithium and VPA significantly attenuated TBI-induced brain lesion, BBB disruption, and neurodegeneration, and robustly improved long-term functional recovery. These findings suggest that potentiating histone acetylation by HDAC inhibition is probably part of the mechanism underlying the beneficial effects associated with this combined treatment for TBI. Because both lithium and VPA have a long history of safe clinical use, the results suggest that using a combination of these 2 agents at subtherapeutic doses to treat patients with TBI may also reduce side effects and enhance tolerability.	[Yu, Fengshan; Wang, Zhifei; Chiu, Chi-Tso; Leeds, Peter; Chuang, De-Maw] NIMH, Mol Neurobiol Sect, NIH, Bethesda, MD 20892 USA; [Yu, Fengshan; Zhang, Yumin; Chuang, De-Maw] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Yu, Fengshan; Tanaka, Mikiei; Zhang, Yumin] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA		Chuang, DM (corresponding author), NIMH, Mol Neurobiol Sect, NIH, 10 Ctr Dr,MSC 1363, Bethesda, MD 20892 USA.	chuang@mail.nih.gov		Yu, Fengshan/0000-0001-8620-3084	Center for Neuroscience and Regenerative Medicine of the Department of Defense; Blast Lethality Injury and Research Program; Intramural Research Program of the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH); NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [ZIAMH002468] Funding Source: NIH RePORTER	This work was funded in part by the Center for Neuroscience and Regenerative Medicine of the Department of Defense, the Blast Lethality Injury and Research Program, and the Intramural Research Program of the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH). The authors have no conflicts of interest to disclose, financial or otherwise.	Autry AE, 2012, PHARMACOL REV, V64, P238, DOI 10.1124/pr.111.005108; Chiu CT, 2013, PHARMACOL REV, V65, P105, DOI 10.1124/pr.111.005512; Chiu CT, 2011, NEUROPSYCHOPHARMACOL, V36, P2406, DOI 10.1038/npp.2011.128; Chiu CT, 2010, PHARMACOL THERAPEUT, V128, P281, DOI 10.1016/j.pharmthera.2010.07.006; Chuang DM, 2009, TRENDS NEUROSCI, V32, P591, DOI 10.1016/j.tins.2009.06.002; Dash PK, 2009, NEUROSCIENCE, V163, P1, DOI 10.1016/j.neuroscience.2009.06.028; Dash PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024648; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Faul M, 2010, TRAUMATIC BRAIN INJU; Feng HL, 2008, NEUROSCIENCE, V155, P567, DOI 10.1016/j.neuroscience.2008.06.040; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Leng Y, 2008, J NEUROSCI, V28, P2576, DOI 10.1523/JNEUROSCI.5467-07.2008; Lin D, 2006, CNS DRUGS, V20, P29, DOI 10.2165/00023210-200620010-00003; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; Tsai LK, 2011, STROKE, V42, P2932, DOI 10.1161/STROKEAHA.110.612788; Tsai LK, 2010, NEUROPSYCHOPHARMACOL, V35, P2225, DOI 10.1038/npp.2010.97; Wang ZF, 2011, ACTA PHARMACOL SIN, V32, P1433, DOI 10.1038/aps.2011.140; Wang ZF, 2011, J CEREBR BLOOD F MET, V31, P52, DOI 10.1038/jcbfm.2010.195; Yu F, 2012, J NEUROTRAUM, V29, P2342; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085; Zhu ZF, 2010, BRAIN RES BULL, V83, P272, DOI 10.1016/j.brainresbull.2010.07.008	28	57	58	1	18	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	2013	119	3					766	773		10.3171/2013.6.JNS13135			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	204IJ	WOS:000323358700029	23848820	Green Accepted			2022-02-06	
J	Fait, P; Swaine, B; Cantin, JF; Leblond, J; McFadyen, BJ				Fait, Philippe; Swaine, Bonnie; Cantin, Jean-Francois; Leblond, Jean; McFadyen, Bradford J.			Altered Integrated Locomotor and Cognitive Function in Elite Athletes 30 Days Postconcussion: A Preliminary Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						athletes; clinical testing; concussion; divided attention; neuropsychological tests; return to play	TRAUMATIC BRAIN-INJURY; CONTROL FOLLOWING CONCUSSION; COLLEGIATE FOOTBALL PLAYERS; SPORT-RELATED CONCUSSION; CLOSED-HEAD INJURY; POSTURAL STABILITY; NCAA CONCUSSION; ATTENTION; RECOVERY; DEFICITS	Objective: To begin to understand changes in locomotor navigation in elite athletes following concussion. Methods: Clinical measures and gait analysis were undertaken on average 37.33 days (SD = 4.8) postconcussion for 6 athletes as well as for a control group of athletes matched for age, sex, and team. The locomotor task consisted of walking at a self-selected speed along an unobstructed or obstructed path with and without a visual interference task. The trends for 4 dependent variables were described (2 for gait behavior and 2 for cognitive behavior). A principal component analysis was used to reduce data to root sources of variance among these variables. General group differences were tested with Wilcoxon matched-pairs tests on factorial scores. Results: Athletes with concussion were symptom free at the time of testing and their neuropsychological test results were not different from those of athletes in the control group. However, when the laboratory data between paired groups were compared, descriptive analyses suggested potential group differences in navigating the obstacle. The simultaneous Stroop task appeared to present difficulty for both groups. A significant group effect was found on the component of the factorial analysis that was highly loaded with both gait and cognitive variables (minimum clearance, Stroop task errors, and cognitive dual-task costs), generally supporting the descriptive analyses by suggesting that athletes with concussion do not navigate the targeted complex environments like the control group. Conclusions: Athletes with concussion appear to still show navigational deficits in environments well after being considered fully recovered according to current return-to-play protocols. Although still preliminary and requiring further study, the present findings suggest that functional assessment within complex environment contexts could be considered before sending athletes back to play following a concussion, even in the absence of postconcussion symptoms or with normal clinical outcomes.	[Fait, Philippe; McFadyen, Bradford J.] Univ Laval, Quebec City, PQ, Canada; [Cantin, Jean-Francois] Quebec Rehabil Inst, Quebec City, PQ, Canada; [Fait, Philippe; Leblond, Jean; McFadyen, Bradford J.] Ctr Interdisciplinary Res Rehabil & Social Integr, Quebec City, PQ G1M 2S8, Canada; [Swaine, Bonnie] Univ Montreal, Montreal, PQ, Canada		McFadyen, BJ (corresponding author), Ctr Interdisciplinary Res Rehabil & Social Integr, 525 Boul Hamel, Quebec City, PQ G1M 2S8, Canada.	brad.mcfadyen@rea.ulaval.ca		Fait, Philippe/0000-0002-2554-9273; McFadyen, Bradford/0000-0003-1992-4927	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR; Ontario Neurotrauma Foundation-Quebec Rehabilitation Network	The authors thank Guy St-Vincent for his technical assistance, Eric Huard and Janick Bisson for their consultation and development of the Stroop presentation program, and the TBI unit of the IRDPQ, This study was partially funded by the Canadian Institutes of Health Research and the Natural Sciences and Engineering Research Council of Canada (to Dr McFadyen) and partial Ontario Neurotrauma Foundation-Quebec Rehabilitation Network stipend (to Dr Fait).	Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-8; Catena RD, 2009, EXP BRAIN RES, V194, P67, DOI 10.1007/s00221-008-1669-1; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; Delis DC, 2004, J INT NEUROPSYCH SOC, V10, P301, DOI 10.1017/S1355617704102191; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Fait P, 2009, BRAIN INJURY, V23, P362, DOI 10.1080/02699050902788485; Gerin-Lajoie M, 2005, MOTOR CONTROL, V9, P242, DOI 10.1123/mcj.9.3.242; Gerin-Lajoie M, 2006, GAIT POSTURE, V24, P364, DOI 10.1016/j.gaitpost.2005.11.001; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Golden CJ, 1978, STROOP COLOR WORD TE; Green P, 2001, CLIN NEUROPSYCHOL, V15, P492, DOI 10.1076/clin.15.4.492.1887; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Lahat E, 1996, PEDIATR NEUROL, V15, P299, DOI 10.1016/S0887-8994(96)00221-4; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Miller E, 2002, CALCAP CALIFORNIA CO; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Randolph C, 2001, J ATHL TRAINING, V36, P288; Robertson I., 1994, TEST EVERYDAY ATTENT; SLOBOUNOV S, 2006, FDN SPORT RELATED BR; Smith A., 1982, SYMBOL DIGIT MODALIT; Standaert CJ, 2007, ARCH PHYS MED REHAB, V88, P1077, DOI 10.1016/j.apmr.2007.06.002; Thompson JWG, 2006, FDN SPORT RELATED BR; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Wai-Hang JL, 2002, ARE YOU LEFT HANDED; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	45	57	58	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2013	28	4					293	301		10.1097/HTR.0b013e3182407ace			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	298ZO	WOS:000330363900007	22495102				2022-02-06	
J	Prichep, LS; McCrea, M; Barr, W; Powell, M; Chabot, RJ				Prichep, Leslie S.; McCrea, Michael; Barr, William; Powell, Matthew; Chabot, Robert J.			Time Course of Clinical and Electrophysiological Recovery After Sport-Related Concussion	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						electroencephalography; mTBI; neuroimaging; sports concussion; TBI Index	TRAUMATIC BRAIN-INJURY; SYMPTOMS; SEVERITY; MODERATE	Background and Purpose: Recent neuroimaging studies suggest that abnormalities in brain function after concussion exist beyond the point of observed clinical recovery. This study investigated the relationship between an index of brain dysfunction (traumatic brain injury [TBI] Index), concussion severity, and outcome. Methods: EEG was collected from forehead locations in 65 male athletes with concussion within 24 hours of concussion, with follow-up at 8 and 45 days postinjury. Neurocognitive and symptom assessments were also performed and used to classify subjects in mild or moderate concussion categories. Time to return to play was recorded. Results: The TBI Index was higher in the moderate than mild concussion group at injury, day 8, and day 45. The moderate group had increased symptoms and decreased cognitive performance only at the time of injury. At the time of injury, only the TBI Index was significantly associated with the length of time to return to play. Conclusions: Recovery of brain function after sport-related concussion may extend well beyond the time course of clinical recovery and be related to clinical severity. An index of brain dysfunction may be an objective indicator of injury, recovery, and readiness to return to play. The relatively small sample indicates the need for further study on the time course of physiological recovery.	[Prichep, Leslie S.; Chabot, Robert J.] NYU, Sch Med, Dept Psychiat, Brain Res Labs, New York, NY 10016 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Barr, William] NYU, Langone Med Ctr, Dept Neurol, New York, NY 10016 USA; [Barr, William] NYU, Langone Med Ctr, Dept Psychiat, New York, NY USA; [Powell, Matthew] Marshfield Clin Fdn Med Res & Educ, Dept Neuropsychol, Minocqua, WI USA		Prichep, LS (corresponding author), NYU, Sch Med, Dept Psychiat, Brain Res Labs, 550 First Ave, New York, NY 10016 USA.	leslie.prichep@nyumc.org		Barr, William/0000-0001-7711-7758	BrainScope, Inc	This research was supported by a clinical research grant from BrainScope, Inc, as an investigator-initiated study. Drs Prichep, Barr, and Chabot serve as consultants to BrainScope, Inc, and Dr Prichep and NYU School of Medicine hold financial interest in BrainScope, Inc, through patented technology. Aside from the author investigators, representatives from BrainScope, Inc, had no role in the conduct of the studies, analysis of the data, or preparation of manuscripts.	Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Faux S, 2011, BRAIN INJURY, V25, P14, DOI 10.3109/02699052.2010.531686; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2001, J ATHL TRAINING, V2, P24; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; JOHN ER, 1988, SCIENCE, V239, P162, DOI 10.1126/science.3336779; Kabat MH, 2001, CLIN NEUROPSYCHOL, V15, P498, DOI 10.1076/clin.15.4.498.1882; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Kohavi R., 1995, INT JOINT C ART INT; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Malloy, 1998, Semin Clin Neuropsychiatry, V3, P186; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; Naunheim RS, 2010, BRAIN INJURY, V24, P1324, DOI 10.3109/02699052.2010.506862; Pardini JE, 2010, NEUROSURGERY, V67, P1020, DOI 10.1227/NEU.0b013e3181ee33e2; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004	40	57	57	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2013	28	4					266	273		10.1097/HTR.0b013e318247b54e			8	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	298ZO	WOS:000330363900004	22588360				2022-02-06	
J	Silverberg, ND; Hallam, BJ; Rose, A; Underwood, H; Whitfield, K; Thornton, AE; Whittal, ML				Silverberg, Noah D.; Hallam, Bradley J.; Rose, Alice; Underwood, Heather; Whitfield, Kevin; Thornton, Allen E.; Whittal, Maureen L.			Cognitive-Behavioral Prevention of Postconcussion Syndrome in At-Risk Patients: A Pilot Randomized Controlled Trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain concussion; cognitive-behavioral therapy; postconcussion syndrome; randomized controlled trial; traumatic brain injury	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; WHIPLASH-ASSOCIATED DISORDERS; POST-CONCUSSION SYMPTOMS; TASK-FORCE; HOSPITAL ANXIETY; QUESTIONNAIRE; THERAPY; RULE	Objective: To examine the tolerability and estimate the treatment effect of cognitive-behavioral therapy (CBT) delivered soon after mild traumatic brain injury to patients at risk for chronic postconcussion syndrome (PCS). Setting: Tertiary rehabilitation center. Participants: Twenty-eight patients with uncomplicated mild traumatic brain injury, determined to be at risk for chronic PCS based on a published algorithm that incorporates subacute postconcussion symptoms and maladaptive illness beliefs (recovery expectations and perceived consequences). They were enrolled within 6 weeks postinjury. Design: Open-label, parallel-group, randomized controlled trial, with masked outcome assessment 3 months after enrolment. Interventions were (1) treatment as usual (education, reassurance, and symptom management strategies) from an occupational therapist, or (2) treatment as usual plus CBT delivered by a psychologist. Main Measures: Rivermead Postconcussion Symptoms Questionnaire. Results: Four participants (2:2) withdrew. Treatment credibility and satisfaction ratings were high in the CBT group. Treatment effect sizes were moderate for postconcussion symptoms (Cohen d = 0.74) and moderate-large for most secondary outcome measures (Cohen d = 0.62-1.61). Fewer participants receiving CBT had a diagnosis of PCS at follow-up (54% vs 91%, P < .05). Conclusion: Our preliminary data suggest that CBT delivered soon after mild traumatic brain injury is well tolerated and may facilitate recovery in patients who are at risk for chronic PCS. A definitive clinical trial is warranted.	[Silverberg, Noah D.; Hallam, Bradley J.; Rose, Alice] GF Strong Rehab Ctr, Vancouver, BC V5Z 2G9, Canada; [Silverberg, Noah D.; Underwood, Heather] Univ British Columbia, Div Phys Med & Rehabil, Vancouver, BC V5Z 1M9, Canada; [Silverberg, Noah D.; Hallam, Bradley J.] Univ British Columbia, Div Neurol, Vancouver, BC V5Z 1M9, Canada; [Whittal, Maureen L.] Univ British Columbia, Fac Med, Vancouver, BC, Canada; [Whittal, Maureen L.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Whitfield, Kevin; Thornton, Allen E.] Simon Fraser Univ, Human Neuropsychol Lab, Burnaby, BC V5A 1S6, Canada		Silverberg, ND (corresponding author), GF Strong Rehab Ctr, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada.	noah.silverberg@vch.ca		Thornton, Allen/0000-0002-9942-0122	BC Rehab Foundation; Vancouver Coastal Health Research Institute	A William G. Fraser Rehabilitation Research Award from the BC Rehab Foundation provided operational funds for this study. The principal investigator (N.D.S) received salary support from the Vancouver Coastal Health Research Institute.	Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Barsky A, 2003, MANAGING MED SYMPTOM; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; BORKOVEC TD, 1972, J BEHAV THER EXP PSY, V3, P257, DOI 10.1016/0005-7916(72)90045-6; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Butler AC, 2006, CLIN PSYCHOL REV, V26, P17, DOI 10.1016/j.cpr.2005.07.003; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cote P, 2011, SPINE, V36, pS275, DOI 10.1097/BRS.0b013e3182388d32; Devilly GJ, 2000, J BEHAV THER EXP PSY, V31, P73, DOI 10.1016/S0005-7916(00)00012-4; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Greenberg RP, 2006, CLIN PSYCHOL REV, V26, P657, DOI 10.1016/j.cpr.2005.03.002; HOLDEN G, 1991, SOC WORK HEALTH CARE, V16, P53; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Julious SA, 2005, PHARM STAT, V4, P287, DOI 10.1002/pst.185; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Kirsch NL, 2010, ARCH PHYS MED REHAB, V91, P35, DOI 10.1016/j.apmr.2009.09.019; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Malec JF, 2004, ARCH PHYS MED REHAB, V85, P1989, DOI 10.1016/j.apmr.2004.01.032; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Marshall S, 2012, CAN FAM PHYSICIAN, V58, P257; Marshall S, 2012, CAN FAM PHYSICIAN, V58, pE128; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Moss-Morris R, 2002, PSYCHOL HEALTH, V17, P1, DOI 10.1080/08870440290001494; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; NSW Government Motor Accidents Authority, 2008, GUID MILD TRAUM BRAI; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Potter S, 2012, NEUROPSYCHOL REHABIL, V22, P1, DOI 10.1080/09602011.2011.630883; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Silverberg ND, 2013, 41 ANN M INT NEUR SO; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Snell DL, 2010, BRAIN INJURY, V24, P1595, DOI 10.3109/02699052.2010.523048; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; SPITZER WO, 1995, SPINE, V20, pS1; Stallard N, 2012, STAT MED, V31, P1031, DOI 10.1002/sim.4357; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Taylor S, 2004, TREATING HLTH ANXIET; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	48	57	57	1	36	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2013	28	4					313	322		10.1097/HTR.0b013e3182915cb5			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	298ZO	WOS:000330363900009	23640544				2022-02-06	
J	Bryan, CJ				Bryan, Craig J.			Repetitive Traumatic Brain Injury (or Concussion) Increases Severity of Sleep Disturbance among Deployed Military Personnel	SLEEP			English	Article						Insomnia; military; multiple TBI; sleep; TBI; traumatic brain injury	INSOMNIA; PREVALENCE; DISORDERS; COMPLAINTS; SOLDIERS; CONTEXT; IRAQ	Study Objectives: Considerable research indicates that sleep disturbances and insomnia are more common and severe among individuals following a traumatic brain injury (TBI). It remains unclear, however, how the experience of multiple TBIs affect sleep disturbances and insomnia. The current study investigated the incidence and severity of insomnia and sleep complaints among active-duty military personnel who have sustained multiple TBIs. Design and Setting: Upon intake at a military TBI clinic located in Iraq, 150 male military patients completed standardized self-report measures and clinical interviews. Measurements and Results: Patients were categorized into three groups according to history of TBI: zero TBIs (n = 18), single TBI (n = 54), multiple TBIs (n = 78). Rates of clinical insomnia significantly increased across TBI groups (P < 0.001): 5.6% for no TBIs, 20.4% for single TBI, and 50.0% for multiple TBIs. Insomnia severity significantly increased across TBI groups even when controlling for depression, posttraumatic stress disorder, and concussion symptom severity (B = 1.134, standard error = 0.577, P = 0.049). Conclusions: Multiple TBIs are associated with increased risk for and severity of sleep disturbance among male military personnel.	Natl Ctr Vet Studies, Salt Lake City, UT 84112 USA		Bryan, CJ (corresponding author), Natl Ctr Vet Studies, 260 S Cent Campus Dr,Room 205, Salt Lake City, UT 84112 USA.	craig.bryan@utah.edu	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; Bryan, Craig/0000-0002-9714-0733			[Anonymous], 2005, SLEEP, V28, P1049; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Blount TH, 2010, ANN M ASS BEH COGN T; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; CelestHealth Solutions, 2008, CLIN REP MAN COLL CO; Def. Veterans Brain Inj. Cent, 2007, MIL AC CONC EV MACE; Department of Veterans Affairs Department of Defense, 2009, CLIN PRACT GUID MAN; DOD/VA Traumatic Brain Injury Task Force, 2008, REP SURG GEN TRAUM B; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Luxton DD, 2011, SLEEP, V34, P1189, DOI 10.5665/SLEEP.1236; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Medical Surveillance Monthly Report, 2010, MED SURV MONTHLY REP, V17, P12; Morin CM, 1993, INSOMNIA PSYCHOL ASS; Ohayon MM, 2002, SLEEP MED REV, V6, P97, DOI 10.1053/smrv.2002.0186; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Taylor DJ, 2007, HDB PSYCHOL ASSESSME, V1, P674; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weathers F.W., 1993, ANN CONV INT SOC TRA; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	28	57	57	0	14	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA		1550-9109		SLEEP	Sleep	JUN 1	2013	36	6					941	946		10.5665/sleep.2730			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	155HX	WOS:000319739700021	23729938	Green Published, Bronze			2022-02-06	
J	Harrison, DA; Prabhu, G; Grieve, R; Harvey, SE; Sadique, MZ; Gomes, M; Griggs, KA; Walmsley, E; Smith, M; Yeoman, P; Lecky, FE; Hutchinson, PJA; Menon, DK; Rowan, KM				Harrison, D. A.; Prabhu, G.; Grieve, R.; Harvey, S. E.; Sadique, M. Z.; Gomes, M.; Griggs, K. A.; Walmsley, E.; Smith, M.; Yeoman, P.; Lecky, F. E.; Hutchinson, P. J. A.; Menon, D. K.; Rowan, K. M.			Risk Adjustment In Neurocritical care (RAIN) - prospective validation of risk prediction models for adult patients with acute traumatic brain injury to use to evaluate the optimum location and comparative costs of neurocritical care: a cohort study	HEALTH TECHNOLOGY ASSESSMENT			English	Article							ACUTE SUBDURAL-HEMATOMA; SEVERE HEAD-INJURY; QUALITY-OF-LIFE; CHRONIC HEALTH EVALUATION; LONG-TERM OUTCOMES; SOCIETY APACHE-II; INTENSIVE-CARE; MULTIPLE IMPUTATION; POSTAL QUESTIONNAIRES; FUNCTIONAL RECOVERY	Objectives: To validate risk prediction models for acute traumatic brain injury (TBI) and to use the best model to evaluate the optimum location and comparative costs of neurocritical care in the NHS. Design: Cohort study. Setting: Sixty-seven adult critical care units. Participants: Adult patients admitted to critical care following actual/suspected TBI with a Glasgow Coma Scale (GCS) score of < 15. Interventions: Critical care delivered in a dedicated neurocritical care unit, a combined neuro/general critical care unit within a neuroscience centre or a general critical care unit outside a neuroscience centre. Main outcome measures: Mortality, Glasgow Outcome Scale - Extended (GOSE) questionnaire and European Quality of Life-5 Dimensions, 3-level version (EQ-5D-3L) questionnaire at 6 months following TBI. Results: The final Risk Adjustment In Neurocritical care (RAIN) study data set contained 3626 admissions. After exclusions, 3210 patients with acute TBI were included. Overall follow-up rate at 6 months was 81%. Of 3210 patients, 101 (3.1%) had no GCS score recorded and 134 (4.2%) had a last pre-sedation GCS score of 15, resulting in 2975 patients for analysis. The most common causes of TBI were road traffic accidents (RTAs) (33%), falls (47%) and assault (12%). Patients were predominantly young (mean age 45 years overall) and male (76% overall). Six-month mortality was 22% for RTAs, 32% for falls and 17% for assault. Of survivors at 6 months with a known GOSE category, 44% had severe disability, 30% moderate disability and 26% made a good recovery. Overall, 61% of patients with known outcome had an unfavourable outcome (death or severe disability) at 6 months. Between 35% and 70% of survivors reported problems across the five domains of the EQ-5D-3L. Of the 10 risk models selected for validation, the best discrimination overall was from the International Mission for Prognosis and Analysis of Clinical Trials in TBI Lab model (IMPACT) (c-index 0.779 for mortality, 0.713 for unfavourable outcome). The model was well calibrated for 6-month mortality but substantially underpredicted the risk of unfavourable outcome at 6 months. Baseline patient characteristics were similar between dedicated neurocritical care units and combined neuro/general critical care units. In lifetime cost-effectiveness analysis, dedicated neurocritical care units had higher mean lifetime quality-adjusted life-years (QALYs) at small additional mean costs with an incremental cost-effectiveness ratio (ICER) of 14,000 pound per QALY and incremental net monetary benefit (INB) of 17,000 pound. The cost-effectiveness acceptability curve suggested that the probability that dedicated compared with combined neurocritical care units are cost-effective is around 60%. There were substantial differences in case mix between the 'early' (within 18 hours of presentation) and 'no or late' (after 24 hours) transfer groups. After adjustment, the 'early' transfer group reported higher lifetime QALYs at an additional cost with an ICER of 11,000 pound and INB of 17,000 pound. Conclusions: The risk models demonstrated sufficient statistical performance to support their use in research but fell below the level required to guide individual patient decision-making. The results suggest that management in a dedicated neurocritical care unit may be cost-effective compared with a combined neuro/general critical care unit (although there is considerable statistical uncertainty) and support current recommendations that all patients with severe TBI would benefit from transfer to a neurosciences centre, regardless of the need for surgery. We recommend further research to improve risk prediction models; consider alternative approaches for handling unobserved confounding; better understand long-term outcomes and alternative pathways of care; and explore equity of access to postcritical care support for patients following acute TBI.	[Harrison, D. A.; Prabhu, G.; Harvey, S. E.; Griggs, K. A.; Walmsley, E.; Rowan, K. M.] Intens Care Natl Audit & Res Ctr, London, England; [Grieve, R.; Sadique, M. Z.; Gomes, M.] London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London WC1, England; [Smith, M.] Univ Coll London Hosp NHS Fdn Trust, Natl Hosp Neurol & Neurosurg, London, England; [Yeoman, P.] Nottingham Univ Hosp NHS Trust, Queens Med Ctr, Nottingham, England; [Lecky, F. E.] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England; [Hutchinson, P. J. A.; Menon, D. K.] Univ Cambridge, Cambridge, England		Harrison, DA (corresponding author), Intens Care Natl Audit & Res Ctr, London, England.		Harrison, David A/O-4355-2018	Harrison, David A/0000-0002-9002-9098; Gomes, Manuel/0000-0002-1428-1232; Harvey, Sheila/0000-0001-7604-8607; Grieve, Richard/0000-0001-8899-1301; Rowan, Kathryn/0000-0001-8217-5602; Sadique, Zia/0000-0001-5814-0258	National Institute for Health Research Health Technology Assessment programmeNational Institute for Health Research (NIHR); National Institute for Health ResearchNational Institute for Health Research (NIHR) [07/37/29, NF-SI-0512-10090] Funding Source: researchfish	The National Institute for Health Research Health Technology Assessment programme.	Abadie A, 2011, J BUS ECON STAT, V29, P1, DOI 10.1198/jbes.2009.07333; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Baguley IJ, 2012, MED J AUSTRALIA, V196, P40, DOI 10.5694/mja11.10090; Barber Julie, 2004, J Health Serv Res Policy, V9, P197, DOI 10.1258/1355819042250249; Barratt H, 2010, EMERG MED J, V27, P173, DOI 10.1136/emj.2009.075382; Black N, 1996, BRIT MED J, V312, P1215; Brier GW, 1950, MON WEATHER REV, V78, P1, DOI DOI 10.1175/1520-0493(1950)078<0001:VOFEIT>2.0.CO;2; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock M Ross, 2006, Neurosurgery, V58, pS7; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Carpenter JR, 2011, J STAT SOFTW, V45, P1; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Centers for Disease Control and Prevention  National Center for Injury Prevention and Control, 2010, TRAUMATIC BRAIN INJU; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P418, DOI 10.1016/j.apmr.2007.01.010; COX DR, 1958, BIOMETRIKA, V45, P562, DOI 10.1093/biomet/45.3-4.562; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Curtis L, 2011, UNIT COSTS HLTH SOCI; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Department for Communities and Local Government, 2011, ENGL IND DEPR 2010; Department of Health (DoH), 2011, NHS REF COSTS 2010 1; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Dolan P, 1999, 138 CHE U YORK; DONNER A, 1992, STAT MED, V11, P1511, DOI 10.1002/sim.4780111109; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Edwards P, 2005, LANCET, V365, P1957; Edwards P, 2002, BRIT MED J, V324, P1183, DOI 10.1136/bmj.324.7347.1183; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Feiz-Erfan I, 2007, J NEUROSURG, V107, P364, DOI 10.3171/JNS-07/08/0364; Field D, 2005, PEDIATRICS, V115, P926, DOI 10.1542/peds.2004-1209; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Fuller G, 2011, BRIT J NEUROSURG, V25, P414, DOI 10.3109/02688697.2011.570882; Fuller G, 2011, J NEUROSURG ANESTH, V23, P198, DOI 10.1097/ANA.0b013e3182161816; Gabbe BJ, 2011, ANN SURG, V253, P138, DOI 10.1097/SLA.0b013e3181f6685b; GENTLEMAN D, 1981, LANCET, V2, P853; Gomes M, 2012, MED DECIS MAKING, V32, P350, DOI 10.1177/0272989X11418372; Greene WH., 2003, ECONOMETRIC ANAL; Grieve R, 2010, MED DECIS MAKING, V30, P163, DOI 10.1177/0272989X09341752; HANLEY JA, 1988, MED DECIS MAKING, V8, P197, DOI 10.1177/0272989X8800800308; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Harrison DA, 2006, CRIT CARE MED, V34, P1378, DOI 10.1097/01.CCM.0000216702.94014.75; Harrison DA, 2007, CRIT CARE MED, V35, P1091, DOI 10.1097/01.CCM.0000259468.24532.44; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Hayes JA, 2000, HLTH TECHNOL ASSESS, V4; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Ho KM, 2010, CRIT CARE MED, V38, P1562, DOI 10.1097/CCM.0b013e3181e2ccd8; Hollingworth W, 2007, PEDIATR CRIT CARE ME, V8, P348, DOI 10.1097/01.PCC.0000270837.66217.3B; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; Hsiao KY, 2008, EMERG MED J, V25, P670, DOI 10.1136/emj.2007.053405; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Hyam JA, 2006, CRIT CARE, V10, DOI 10.1186/cc5066; Ibrahim MI, 2007, ASIAN J SURG, V30, P261, DOI 10.1016/S1015-9584(08)60036-6; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; Johnson P, 2006, BRAIN COGNITION, V60, P205; Kenward MG, 2007, STAT METHODS MED RES, V16, P199, DOI 10.1177/0962280206075304; Kim KH, 2009, J KOREAN NEUROSURG S, V45, P143, DOI 10.3340/jkns.2009.45.3.143; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Kochanek PM, 2001, CRIT CARE MED, V29, P692, DOI 10.1097/00003246-200103000-00053; Kramer AA, 2007, CRIT CARE MED, V35, P2052, DOI 10.1097/01.CCM.0000275267.64078.B0; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Latimer N, 2011, NICE DSU TECHNICAL S; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; Liao CC, 2007, J TRAUMA, V63, P827, DOI 10.1097/TA.0b013e31814b9466; Livingston BM, 2000, CRIT CARE MED, V28, P389, DOI 10.1097/00003246-200002000-00017; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Mauritz W, 2007, WIEN KLIN WOCHENSCHR, V119, P46, DOI 10.1007/s00508-006-0763-2; McCullagh P., 1989, GEN LINEAR MODELS 2, V2; McMillan TM, 2007, BRAIN, V130, P2520, DOI 10.1093/brain/awm185; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Menon D, 2008, BMJ-BRIT MED J, V336, P397, DOI 10.1136/bmj.39461.616991.80; Menon David, 2004, Curr Opin Crit Care, V10, P91, DOI 10.1097/00075198-200404000-00002; Menon DK, 2009, CURR OPIN CRIT CARE, V15, P437, DOI 10.1097/MCC.0b013e3283307a26; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; National Collaborating Centre for Acute Care (UK), 2007, HEAD INJ TRIAG ASS I; National Institute for Health and Care Excellence (NICE), 2008, GUID METH TECHN APPR; Neurocritical Care Stakeholder Group, 2006, NEUR CAR CAP DEM; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; Noah MA, 2011, JAMA-J AM MED ASSOC, V306, P1659, DOI 10.1001/jama.2011.1471; Oh Hyun Soo, 2006, Taehan Kanho Hakhoe Chi, V36, P621; ONS, 2011, INT LIF TABL 2008 20; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Pang BC, 2007, J NEUROTRAUM, V24, P136, DOI 10.1089/neu.2006.0113; Pape TLB, 2006, BRAIN INJURY, V20, P743, DOI 10.1080/02699050600676933; Park CA, 2001, AM SURGEON, V67, P665; Patel HC, 2010, ACTA NEUROCHIR, V152, P1353, DOI 10.1007/s00701-010-0666-x; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Pirracchio R, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-132; Reichenheim ME, 2004, STATA J, V4, P421, DOI 10.1177/1536867X0400400404; Rocker GM, 2006, CAN J ANAESTH, V53, P814, DOI 10.1007/BF03022799; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Rosenbaum PR, 2002, STAT SCI, V17, P286; Rowan K, 2007, EVALUATION OUTREACH; ROWAN KM, 1993, BRIT MED J, V307, P977, DOI 10.1136/bmj.307.6910.977; ROWAN KM, 1993, BRIT MED J, V307, P972, DOI 10.1136/bmj.307.6910.972; Rubin D.B., 1987, MULTIPLE IMPUTATION; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Salorio CF, 2008, PEDIATR CRIT CARE ME, V9, P47, DOI 10.1097/01.PCC.0000298638.66240.0E; Schafer J., 1997, ANAL INCOMPLETE MULT, DOI [10.1201/9781439821862, DOI 10.1201/9781439821862]; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Smith M, 2004, BRIT J ANAESTH, V93, P753, DOI 10.1093/bja/aeh275; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Statistics for Wales, 2011, WELSH IND MULT DEPR; Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Teig M, 2010, J NEUROSURG ANESTH, V22, P357, DOI 10.1097/ANA.0b013e3181f0dada; The CRASH trial management group, 2001, BMC Emerg Med, V1, P1; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A; Thompson SG, 2000, BRIT MED J, V320, P1197, DOI 10.1136/bmj.320.7243.1197; Tian HL, 2008, CHINESE MED J-PEKING, V121, P1080, DOI 10.1097/00029330-200806020-00007; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577; van Buuren S, 2011, J STAT SOFTW, V45, P1; van Leeuwen N, 2012, NEUROSURGERY, V70, P811, DOI 10.1227/NEU.0b013e318235d640; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; Xu XY, 2007, BRAIN INJURY, V21, P575, DOI 10.1080/02699050701426881; Yeoman P, 2011, J TRAUMA, V71, P387, DOI 10.1097/TA.0b013e31820ceadd; Zheng WB, 2007, NEURORADIOLOGY, V49, P271, DOI 10.1007/s00234-006-0187-8; Zou GY, 2004, BIOMETRICS, V60, P807, DOI 10.1111/j.0006-341X.2004.00232.x	153	57	59	0	9	NIHR JOURNALS LIBRARY	SOUTHAMPTON	UNIV SOUTHAMPTON, EVALUATION, TRIALS & STUDIES COORDINATING CENTRE, ALPHA HOUSE, ENTERPRISE RD, SOUTHAMPTON, SO16 7NS, ENGLAND	1366-5278	2046-4924		HEALTH TECHNOL ASSES	Health Technol. Assess.	JUN	2013	17	23					1	+		10.3310/hta17230			351	Health Care Sciences & Services	Science Citation Index Expanded (SCI-EXPANDED)	Health Care Sciences & Services	164AG	WOS:000320380500001	23763763	Green Accepted, Green Published, gold			2022-02-06	
J	Lincoln, AE; Caswell, SV; Almquist, JL; Dunn, RE; Hinton, RY				Lincoln, Andrew E.; Caswell, Shane V.; Almquist, Jon L.; Dunn, Reginald E.; Hinton, Richard Y.			Video Incident Analysis of Concussions in Boys' High School Lacrosse	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						high school; head injury; concussion; sports; boys' lacrosse; video analysis	TRAUMATIC BRAIN-INJURY; HEAD-INJURIES; SPORTS; GAME; MECHANISMS; FOOTBALL; EPIDEMIOLOGY; GIRLS	Background: Boys' lacrosse has one of the highest rates of concussion among boys' high school sports. A thorough understanding of injury mechanisms and game situations associated with concussions in boys' high school lacrosse is necessary to target injury prevention efforts. Purpose: To characterize common game-play scenarios and mechanisms of injury associated with concussions in boys' high school lacrosse using game video. Study Design: Descriptive epidemiological study. Methods: In 25 public high schools of a single school system, 518 boys' lacrosse games were videotaped by trained videographers during the 2008 and 2009 seasons. Video of concussion incidents was examined to identify game characteristics and injury mechanisms using a lacrosse-specific coding instrument. Results: A total of 34 concussions were captured on video. All concussions resulted from player-to-player bodily contact. Players were most often injured when contact was unanticipated or players were defenseless (n = 19; 56%), attempting to pick up a loose ball (n = 16; 47%), and/or ball handling (n = 14; 41%). Most frequently, the striking player's head (n = 27; 79%) was involved in the collision, and the struck player's head was the initial point of impact in 20 incidents (59%). In 68% (n = 23) of cases, a subsequent impact with the playing surface occurred immediately after the initial impact. A penalty was called in 26% (n = 9) of collisions. Conclusion: Player-to-player contact was the mechanism for all concussions. Most commonly, injured players were unaware of the pending contact, and the striking player used his head to initiate contact. Further investigation of preventive measures such as education of coaches and officials and enforcement of rules designed to prevent intentional head-to-head contact is warranted to reduce the incidence of concussions in boys' lacrosse.	[Lincoln, Andrew E.; Caswell, Shane V.; Almquist, Jon L.; Dunn, Reginald E.; Hinton, Richard Y.] MedStar Sports Med Res Ctr, Baltimore, MD USA		Lincoln, AE (corresponding author), Care of Camire L, MedStar Union Mem Orthopaed, 3333 North Calvert St,Suite 400, Baltimore, MD 21218 USA.	lyn.camire@medstar.net			National Operating Committee on Standards for Athletic Equipment (NOCSAE); US Lacrosse Sports Science & Safety Committee	One or more of the authors has declared the following potential conflict of interest or source of funding: Funded in part by a grant from the National Operating Committee on Standards for Athletic Equipment (NOCSAE) and from the US Lacrosse Sports Science & Safety Committee.	Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; Appleby B, 2002, J SCI MED SPORT, V5, P129, DOI 10.1016/S1440-2440(02)80034-2; Arnason A, 2004, AM J SPORT MED, V32, P1459, DOI 10.1177/0363546504262973; Carter EA, 2010, INT J INJ CONTROL SA, V17, P111, DOI 10.1080/17457300903524888; Caswell SV, 2012, AM J SPORT MED, V40, P756, DOI 10.1177/0363546512436647; Caswell SV, 2010, MED SCI SPORT EXER, V42, P813, DOI 10.1249/01.MSS.0000386513.75340.cb; Crisco JJ, 2011, CURR SPORT MED REP, V10, P7, DOI 10.1249/JSR.0b013e318205e063; ESPN, OUTS LIN; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2012, INJURY RES THEORIES, P397; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Mcintosh AS, 2010, MED SCI SPORT EXER, V42, P977, DOI 10.1249/MSS.0b013e3181c07b5b; McIntosh AS, 2005, BRIT J SPORT MED, V39, P2, DOI 10.1136/bjsm.2004.016188; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; National Federation of State High School Associations, 2012 BOYS LACR RUL C; National Football League, DEF DEF PLAYER; National Hockey League, BOARD GOV APPR CHANG; NCAA Men's Lacrosse Rules Committee, 2011 2012 APPR RUL C; Olsen E., 1997, SCI FOOTBALL, P209; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; US Lacrosse, 2012 RUL BOYS YOUTH; US Lacrosse, 2010, 2010 PART SURV	29	57	57	0	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	APR	2013	41	4					756	761		10.1177/0363546513476265			6	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	135NR	WOS:000318295500014	23413274				2022-02-06	
J	Piazza-Gardner, AK; Gaffud, TJB; Barry, AE				Piazza-Gardner, Anna K.; Gaffud, Timothy J. B.; Barry, Adam E.			The impact of alcohol on Alzheimer's disease: A systematic review	AGING & MENTAL HEALTH			English	Article						Alzheimer's disease; alcohol; drinking; dementia	TRAUMATIC BRAIN-INJURY; RISK-FACTORS; COGNITIVE DECLINE; BEVERAGE PREFERENCE; TOBACCO CONSUMPTION; METABOLIC SYNDROME; VASCULAR DEMENTIA; WHITE WINE; DRINKING; HEALTH	Currently, there is discrepancy regarding alcohol's impact on Alzheimer's disease (AD). Consequently, the purpose of this systematic review was to determine whether alcohol serves as a protective agent against the development of AD, as well as whether protective effects are influenced by quantity and/or frequency of drinking. Adapted versions of the Matrix Method and PRISMA guidelines were used in order to identify, organize, and synthesize relevant research. Overall, there is no consensus regarding alcohol's impact on AD. Specifically, seven articles suggested drinking alcohol decreases the risk of AD, three studies found drinking led to an increased risk of AD, and yet another nine reported alcohol had no impact on AD. Validity and consistency of both alcohol and AD measures across studies represents a severe limitation. Prior to the development of standards and/or clinical recommendations, more investigations into the association between alcohol and AD are necessary. Considering the current evidence base, alcohol should not be used as a means to decrease risk of developing AD.	[Piazza-Gardner, Anna K.; Gaffud, Timothy J. B.; Barry, Adam E.] Univ Florida, Dept Hlth Educ & Behav, Gainesville, FL 32611 USA		Barry, AE (corresponding author), Univ Florida, Dept Hlth Educ & Behav, Gainesville, FL 32611 USA.	aebarry@ufl.edu		Barry, Adam/0000-0001-6527-6866			Alzheimers Assoc, 2012, ALZHEIMERS DEMENT, V8, P131, DOI 10.1016/j.jalz.2012.02.001; American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Angevaren M, 2008, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD005381.pub2, 10.1002/14651858.CD005381.pub3]; Anstey KJ, 2007, AM J EPIDEMIOL, V166, P367, DOI 10.1093/aje/kwm116; Anstey KJ, 2009, AM J GERIAT PSYCHIAT, V17, P542, DOI 10.1097/JGP.0b013e3181a2fd07; Bachman DL, 2003, NEUROLOGY, V60, P1372, DOI 10.1212/01.WNL.0000058751.43033.4D; Broe GA, 1998, AUST NZ J PUBL HEAL, V22, P621, DOI 10.1111/j.1467-842X.1998.tb01449.x; Brookmeyer R, 1998, AM J PUBLIC HEALTH, V88, P1337, DOI 10.2105/AJPH.88.9.1337; Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381; Chiu E, 2008, AGE AGEING, V37, P493, DOI 10.1093/ageing/afn157; Corrao G, 2000, ADDICTION, V95, P1505, DOI 10.1046/j.1360-0443.2000.951015056.x; Del Boca FK, 2003, ADDICTION, V98, P1, DOI 10.1046/j.1359-6357.2003.00586.x; Deng J, 2006, CLIN NEUROL NEUROSUR, V108, P378, DOI 10.1016/j.clineuro.2005.06.005; Dubois B, 2007, LANCET NEUROL, V6, P734, DOI 10.1016/S1474-4422(07)70178-3; Fillmore KM, 2007, ANN EPIDEMIOL, V17, pS16, DOI 10.1016/j.annepidem.2007.01.005; Flesch M, 1998, AM J PHYSIOL-HEART C, V275, pH1183, DOI 10.1152/ajpheart.1998.275.4.H1183; Folstein M, 1988, NEUROPSY NEUROPSY BE, V1, P111; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; Gao S, 1998, ARCH GEN PSYCHIAT, V55, P809, DOI 10.1001/archpsyc.55.9.809; Garcia AM, 2010, J ALZHEIMERS DIS, V20, P577, DOI 10.3233/JAD-2010-1399; Garrard J, 1999, HLTH SCI LIT REV MAD; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; GRAVES AB, 1991, INT J EPIDEMIOL, V20, pS48, DOI 10.1093/ije/20.Supplement_2.S48; Green RC, 2002, JAMA-J AM MED ASSOC, V287, P329, DOI 10.1001/jama.287.3.329; Gronbaek M, 2009, J INTERN MED, V265, P407, DOI 10.1111/j.1365-2796.2009.02082.x; Grossberg GT, 2003, J CLIN PSYCHIAT, V64, P3; Hall W, 2012, DRUG ALCOHOL REV, V31, P194, DOI 10.1111/j.1465-3362.2011.00345.x; Harwood DG, 1999, NEUROLOGY, V52, P551, DOI 10.1212/WNL.52.3.551; Harwood DG, 2010, INT J GERIATR PSYCH, V25, P511, DOI 10.1002/gps.2372; HEBERT LE, 1992, AM J EPIDEMIOL, V135, P347, DOI 10.1093/oxfordjournals.aje.a116296; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Holland D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042325; Huang WY, 2002, J CLIN EPIDEMIOL, V55, P959, DOI 10.1016/S0895-4356(02)00462-6; Jensen MK, 2002, EPIDEMIOLOGY, V13, P127, DOI 10.1097/00001648-200203000-00005; Khachaturian Zaven S, 2005, Alzheimers Dement, V1, P93, DOI 10.1016/j.jalz.2005.09.001; Klatsky AL, 1997, AM J CARDIOL, V80, P416, DOI 10.1016/S0002-9149(97)00388-3; Kochanek SL, 2012, NATL VITAL STAT REP, V60, P1; Kramer AF, 2006, J APPL PHYSIOL, V101, P1237, DOI 10.1152/japplphysiol.00500.2006; Kuntsche E, 2006, ALCOHOL ALCOHOLISM, V41, P566, DOI 10.1093/alcalc/agl046; Lautenschlager NT, 2008, JAMA-J AM MED ASSOC, V300, P1027, DOI 10.1001/jama.300.9.1027; Lautenschlager NT, 1996, NEUROLOGY, V46, P641, DOI 10.1212/WNL.46.3.641; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Lopez OL, 2000, NEUROLOGY, V55, P1854, DOI 10.1212/WNL.55.12.1854; Luchsinger JA, 2004, J AM GERIATR SOC, V52, P540, DOI 10.1111/j.1532-5415.2004.52159.x; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Mitchell AJ, 2009, J PSYCHIATR RES, V43, P411, DOI 10.1016/j.jpsychires.2008.04.014; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b2535, 10.1371/journal.pmed.1000217, 10.1016/j.ijsu.2010.02.007]; Naimi TS, 2007, AM J PREV MED, V33, P188, DOI 10.1016/j.amepre.2007.04.026; National Institute on Alcohol Abuse and Alcoholism, 2003, NAT COUNC ALC AB ALC; Neafsey EJ, 2011, NEUROPSYCH DIS TREAT, V7, P465, DOI 10.2147/NDT.S23159; Ogunniyi A, 2006, METAB BRAIN DIS, V21, P235, DOI 10.1007/s11011-006-9017-2; Panza F, 2009, J ALZHEIMERS DIS, V17, P7, DOI 10.3233/JAD-2009-1009; Peele S, 2000, DRUG ALCOHOL DEPEN, V60, P221, DOI 10.1016/S0376-8716(00)00112-5; Peters R, 2008, AGE AGEING, V37, P505, DOI 10.1093/ageing/afn095; Piazza-Gardner AK, 2012, DRUG ALCOHOL REV, V31, P198, DOI 10.1111/j.1465-3362.2011.00415.x; Pinder RM, 2004, J PSYCHOPHARMACOL, V18, P449, DOI 10.1177/0269881104047272; Puddey IB, 2006, CLIN EXP PHARMACOL P, V33, P847, DOI 10.1111/j.1440-1681.2006.04452.x; Rehm J, 2003, ADDICTION, V98, P1209, DOI 10.1046/j.1360-0443.2003.00467.x; Richard F, 2012, J ALZHEIMERS DIS, V32, P765, DOI 10.3233/JAD-2012-121012; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; ROSEN J, 1993, BRIT J PSYCHIAT, V163, P358, DOI 10.1192/bjp.163.3.358; Ruitenberg A, 2002, LANCET, V359, P281, DOI 10.1016/S0140-6736(02)07493-7; Rusanen M, 2011, ARCH INTERN MED, V171, P333, DOI 10.1001/archinternmed.2010.393; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Siegel MB, 2011, AM J PREV MED, V40, P419, DOI 10.1016/j.amepre.2010.12.011; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Solomon A, 2009, DEMENT GERIATR COGN, V28, P75, DOI 10.1159/000231980; Thakker KD, 1998, ALCOHOL CLIN EXP RES, V22, p285S, DOI 10.1111/j.1530-0277.1998.tb04381.x; Tsolaki M, 1997, Int Psychogeriatr, V9, P327, DOI 10.1017/S104161029700447X; Tyas SL, 2000, STAT MED, V19, P1685, DOI 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1685::AID-SIM454>3.0.CO;2-#; Vogel RA, 2003, J AM COLL CARDIOL, V41, P479, DOI 10.1016/S0735-1097(02)02825-5; Weyerer S, 2011, AGE AGEING, V40, P456, DOI 10.1093/ageing/afr007; Whitmer RA, 2008, NEUROLOGY, V71, P1057, DOI 10.1212/01.wnl.0000306313.89165.ef; Yaffe K, 2007, CURR ALZHEIMER RES, V4, P123, DOI 10.2174/156720507780362191; Yaffe K, 2007, ALZ DIS ASSOC DIS, V21, P167, DOI 10.1097/WAD.0b013e318065bfd6; YOSHITAKE T, 1995, NEUROLOGY, V45, P1161, DOI 10.1212/WNL.45.6.1161	77	57	58	2	49	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1360-7863	1364-6915		AGING MENT HEALTH	Aging Ment. Health	MAR 1	2013	17	2					133	146		10.1080/13607863.2012.742488			14	Geriatrics & Gerontology; Gerontology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Geriatrics & Gerontology; Psychiatry	100ED	WOS:000315677700001	23171229				2022-02-06	
J	Carroll, CP; Cochran, JA; Guse, CE; Wang, MC				Carroll, Christopher P.; Cochran, Joseph A.; Guse, Clare E.; Wang, Marjorie C.			Are We Underestimating the Burden of Traumatic Brain Injury? Surveillance of Severe Traumatic Brain Injury Using Centers for Disease Control International Classification of Disease, Ninth Revision, Clinical Modification, Traumatic Brain Injury Codes	NEUROSURGERY			English	Article						Accuracy; Centers for Disease Control; Epidemiology; Sensitivity; Traumatic brain injury: International Classification of Diseases; ninth revision; clinical modification	ACCURACY; TRENDS	BACKGROUND: The epidemiology of traumatic brain injury (TBI) is often studied through the use of International Classification of Disease, ninth revision, clinical modification (ICD-9-CM), diagnosis codes from the Centers for Disease Control and Prevention TBI Surveillance System. Recent studies suggest that these codes may underestimate the burden of TBI because of inaccuracies and low sensitivity. OBJECTIVE: To determine the sensitivity and specificity of ICD-9-CM codes in a severe TBI population. METHODS: We retrospectively reviewed medical records of all hospital admissions including computed tomography of the head at a single center to identify severe blunt TBI patients, their injuries, and the neurosurgical procedures performed. We calculated sensitivity and specificity by comparing ICD-9-CM diagnosis and procedure codes assigned by hospital coders with medical records, the gold standard. RESULTS: In 2008, there were 148 qualifying admissions. These codes were 89% sensitive for the presence of any severe TBI. However, one-fifth of these cases were identified only with a code defining a nonspecific head injury. Next, we studied types of TBI by categories defined by the Centers for Disease Control and Prevention (morbidity groups) and by ICD-9-CM codes for types of injury (any skull fracture, intracranial contusion, intracranial hemorrhage, concussion/loss of consciousness) and found widely varying sensitivity and specificity for both. In general, these codes had higher specificity than sensitivity. Both sensitivity and specificity were > 80% for only 2 categories: any skull fracture and intracranial hemorrhage. In contrast, we found high sensitivity and specificity for neurosurgical procedures (97% and 94%). CONCLUSION: ICD-9-CM codes were sensitive for the presence of any severe TBI, but further classification of specific types of TBI was limited by variable sensitivity/specificity. Use of these codes should be supplemented by other methodology.	[Cochran, Joseph A.; Wang, Marjorie C.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Guse, Clare E.] Med Coll Wisconsin, Injury Res Ctr, Dept Family & Community Med, Milwaukee, WI 53226 USA; [Carroll, Christopher P.] Univ Cincinnati, Dept Neurosurg, Cincinnati, OH USA		Wang, MC (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	mwang@mcw.edu	Carroll, Christopher P./AAK-5502-2020	Carroll, Christopher P./0000-0001-5833-7405	Department of Neurosurgery, Medical College of Wisconsin; Centers for Disease ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE001175]	This project was supported by the Department of Neurosurgery, Medical College of Wisconsin. C.E. Guse is partially supported by Centers for Disease Control grant R49/CE001175. The other authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Ahmed S, 2000, BRAIN INJURY, V14, P765; Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P201; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Buck CJ, 2008, 2008 ICD 9 CM, V2; Buck CJ, 2008, 2008 ICD 9 CM, V3; Buck CJ, 2008, 2008 ICD 9 CM, V1; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; Centers for Disease Control and Prevention (CDC), 2004, CENTR NERV SYST INJ; Elkin PL, 2001, J AM MED INFORM ASSN, P159; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; Golomb MR, 2006, NEUROLOGY, V67, P2053, DOI 10.1212/01.wnl.0000247281.98094.e2; Hagen EM, 2009, SPINAL CORD, V47, P367, DOI 10.1038/sc.2008.118; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kalanithi P, 2011, J NEUROSURG, V115, P1013, DOI 10.3171/2011.6.JNS101989; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Lorence Daniel P, 2003, J Health Care Finance, V29, P29; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; O'Malley KJ, 2005, HEALTH SERV RES, V40, P1620, DOI 10.1111/j.1475-6773.2005.00444.x; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Shore AD, 2005, BRAIN INJURY, V19, P613, DOI 10.1080/02699050400013568; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Trent R, 2001, 129 ANN M AM PUBL HL; Woodworth GF, 2009, NEUROSURGERY, V65, P251, DOI 10.1227/01.NEU.0000347003.35690.7A	27	57	57	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2012	71	6					1064	1070		10.1227/NEU.0b013e31826f7c16			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	040RC	WOS:000311339600017	22922677				2022-02-06	
J	McMillan, TM; Teasdale, GM; Stewart, E				McMillan, Thomas M.; Teasdale, Graham M.; Stewart, Elaine			Disability in young people and adults after head injury: 12-14 year follow-up of a prospective cohort	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; STRUCTURED INTERVIEWS; REHABILITATION; PREDICTORS; SEVERITY	Background There is a need to establish how long term outcome evolves after head injury (HI) and factors related to this, to inform opportunities for intervention. Objective To determine late outcome in adults 12-14 years after hospital admission for HI and to examine relationships between injury, early and late factors, and disability. Methods A prospective cohort with HI, whose outcome was reported previously at 1 and 5-7 years after injury, were followed up after 12-14 years. Participants were assessed using structured and validated measures of disability (Glasgow Outcome Scale-Extended), psychological well being, alcohol use and health status. Results Of 219 survivors followed-up at 5-7 years, 34 (15.5%) had died by 12-14 years. Disability remained common in survivors at 12-14 years (51%), as found at 1 and 5-7 years (53%). For those disabled at 1 year, outcome was poor, with 80% dead or disabled at 12-14 years. Older age at injury, a premorbid history of brain illness or physical disability and post-injury low self-esteem and stress were associated with disability at 12-14 years. Disability changed between 5-7 and 12-14 years in 55% of survivors, improving in 23%. Late changes in disability between 5-7 and 12-14 years were associated with self-perceptions of locus of control as being 'powerful others' at 5-7 years. Conclusions Disability is common 12-14 years after hospital admission with a HI. For some there is a dynamic process of change in disability over time that is associated with self-perceptions of control that could be a target for intervention based research.	[McMillan, Thomas M.; Teasdale, Graham M.; Stewart, Elaine] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow G12 0XH, Lanark, Scotland		McMillan, TM (corresponding author), Univ Glasgow, Gartnavel Royal Hosp, Inst Hlth & Wellbeing, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.	thomas.mcmillan@glasgow.ac.uk					Arbuthnott John, 2000, FAIR SHAR ALL FIN RE; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Brown AW, 2011, J NEUROTRAUM, V28, P167, DOI 10.1089/neu.2010.1400; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Grant M., 1992, AUDIT ALCOHOL USE DI; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; Judge TA, 2002, J PERS SOC PSYCHOL, V83, P693, DOI 10.1037//0022-3514.83.3.693; McMillan TM, 2007, BRAIN, V130, P2520, DOI 10.1093/brain/awm185; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Rosenberg M, 1989, SOC ADOLESCENT SELF; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Snaith R., 1994, HOSP ANXIETY DEPRESS; Svendsen HA, 2006, BRAIN INJURY, V20, P1295, DOI 10.1080/02699050601082123; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Turner-Stokes L, 2005, COCHRANE DB SYST REV, V3, DOI DOI 10.1016/S0079-6123(09)17707-5; Walker J, 2001, CONTROL PSYCHOL HLTH; WALLSTON KA, 1978, RES LOCUS CONTROL CO, V1; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670	28	57	57	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	2012	83	11					1086	1091		10.1136/jnnp-2012-302746			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	020MG	WOS:000309813600011	22645256	Bronze			2022-02-06	
J	Starkey, ML; Bleul, C; Zorner, B; Lindau, NT; Mueggler, T; Rudin, M; Schwab, ME				Starkey, Michelle Louise; Bleul, Christiane; Zoerner, Bjoern; Lindau, Nicolas Thomas; Mueggler, Thomas; Rudin, Markus; Schwab, Martin Ernst			Back seat driving: hindlimb corticospinal neurons assume forelimb control following ischaemic stroke	BRAIN			English	Article						stroke; functional recovery; plasticity; sprouting; movement control	INDUCED MOVEMENT THERAPY; FOCAL CEREBRAL-ISCHEMIA; PRIMARY MOTOR CORTEX; SPINAL-CORD INJURY; IN-VIVO; FUNCTIONAL REORGANIZATION; SOMATOSENSORY STIMULATION; CORTICAL REORGANIZATION; ELECTRICAL-STIMULATION; BRAIN REORGANIZATION	Whereas large injuries to the brain lead to considerable irreversible functional impairments, smaller strokes or traumatic lesions are often associated with good recovery. This recovery occurs spontaneously, and there is ample evidence from preclinical studies to suggest that adjacent undamaged areas (also known as peri-infarct regions) of the cortex 'take over' control of the disrupted functions. In rodents, sprouting of axons and dendrites has been observed in this region following stroke, while reduced inhibition from horizontal or callosal connections, or plastic changes in subcortical connections, could also occur. The exact mechanisms underlying functional recovery after small- to medium-sized strokes remain undetermined but are of utmost importance for understanding the human situation and for designing effective treatments and rehabilitation strategies. In the present study, we selectively destroyed large parts of the forelimb motor and premotor cortex of adult rats with an ischaemic injury. A behavioural test requiring highly skilled, cortically controlled forelimb movements showed that some animals recovered well from this lesion whereas others did not. To investigate the reasons behind these differences, we used anterograde and retrograde tracing techniques and intracortical microstimulation. Retrograde tracing from the cervical spinal cord showed a correlation between the number of cervically projecting corticospinal neurons present in the hindlimb sensory-motor cortex and good behavioural recovery. Anterograde tracing from the hindlimb sensory-motor cortex also showed a positive correlation between the degree of functional recovery and the sprouting of neurons from this region into the cervical spinal cord. Finally, intracortical microstimulation confirmed the positive correlation between rewiring of the hindlimb sensory-motor cortex and the degree of forelimb motor recovery. In conclusion, these experiments suggest that following stroke to the forelimb motor cortex, cells in the hindlimb sensory-motor area reorganize and become functionally connected to the cervical spinal cord. These new connections, probably in collaboration with surviving forelimb neurons and more complex indirect connections via the brainstem, play an important role for the recovery of cortically controlled behaviours like skilled forelimb reaching.	[Starkey, Michelle Louise; Bleul, Christiane; Zoerner, Bjoern; Lindau, Nicolas Thomas; Schwab, Martin Ernst] Univ Zurich, Brain Res Inst, Dept Hlth Sci & Technol, CH-8057 Zurich, Switzerland; [Mueggler, Thomas; Rudin, Markus] ETH, Anim Imaging Ctr, CH-8093 Zurich, Switzerland		Starkey, ML (corresponding author), Balgrist Univ Hosp, Forchstr 340, CH-8008 Zurich, Switzerland.	mstarkey@paralab.balgrist.ch	Schwab, Martin E/B-6818-2016; Mueggler, Thomas/AAC-7998-2020		Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [3100AO-122527/1]; National Centre for Competence in Research 'Neural Plasticity and Repair' of the Swiss National Science Foundation; European UnionEuropean Commission [201024, 202213]; European CommissionEuropean CommissionEuropean Commission Joint Research Centre [223524]; Spinal Cord Consortium of the Christopher and Dana Reeve Foundation	Swiss National Science Foundation (Grant number 3100AO-122527/1); the National Centre for Competence in Research 'Neural Plasticity and Repair' of the Swiss National Science Foundation; The European Union's Seventh Framework Programme FP7/2007-2013 (Grant numbers 201024 and 202213) (European Stroke Network, www.europeanstrokenetwork.info/); The European Commission under the 7th Framework Programme-HEALTH-Collaborative Project Plasticise (www.plasticise.eu) (Grant number 223524) and The Spinal Cord Consortium of the Christopher and Dana Reeve Foundation.	Adesnik H, 2010, NATURE, V464, P1155, DOI 10.1038/nature08935; Adkins DL, 2006, J APPL PHYSIOL, V101, P1776, DOI 10.1152/japplphysiol.00515.2006; Adkins DL, 2004, NEUROSCIENCE, V128, P473, DOI 10.1016/j.neuroscience.2004.07.019; ASANUMA H, 1967, J NEUROPHYSIOL, V30, P35, DOI 10.1152/jn.1967.30.1.35; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Brown AW, 2010, SEMIN NEUROL, V30, P511, DOI 10.1055/s-0030-1268867; Brown CE, 2007, J NEUROSCI, V27, P4101, DOI 10.1523/JNEUROSCI.4295-06.2007; Brown CE, 2010, J CEREBR BLOOD F MET, V30, P783, DOI 10.1038/jcbfm.2009.241; Brown CE, 2009, J NEUROSCI, V29, P1719, DOI 10.1523/JNEUROSCI.4249-08.2009; Brus-Ramer M, 2007, J NEUROSCI, V27, P13793, DOI 10.1523/JNEUROSCI.3489-07.2007; Carmel JB, 2010, J NEUROSCI, V30, P10918, DOI 10.1523/JNEUROSCI.1435-10.2010; CASTROALAMANCOS MA, 1992, EUR J NEUROSCI, V4, P853, DOI 10.1111/j.1460-9568.1992.tb00195.x; CASTROALAMANCOS MA, 1995, NEUROSCIENCE, V68, P793, DOI 10.1016/0306-4522(95)00178-L; Cicinelli P, 1997, MUSCLE NERVE, V20, P535, DOI 10.1002/(SICI)1097-4598(199705)20:5<535::AID-MUS1>3.0.CO;2-A; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Dancause N, 2011, PROG BRAIN RES, V192, P273, DOI 10.1016/B978-0-444-53355-5.00015-4; Dijkhuizen RM, 2001, P NATL ACAD SCI USA, V98, P12766, DOI 10.1073/pnas.231235598; Dijkhuizen RM, 2003, J NEUROSCI, V23, P510, DOI 10.1523/JNEUROSCI.23-02-00510.2003; DONOGHUE JP, 1988, J NEUROSCI, V8, P3221; DONOGHUE JP, 1982, J COMP NEUROL, V212, P76, DOI 10.1002/cne.902120106; Emerick AJ, 2003, J NEUROSCI, V23, P4826; Enright LE, 2007, J CEREBR BLOOD F MET, V27, P1185, DOI 10.1038/sj.jcbfm.9600428; Feydy A, 2002, STROKE, V33, P1610, DOI 10.1161/01.STR.0000017100.68294.52; Fouad K, 2001, CURR BIOL, V11, P1766, DOI 10.1016/S0960-9822(01)00535-8; Gharbawie OA, 2005, NEUROSCIENCE, V130, P601, DOI 10.1016/j.neuroscience.2004.10.010; Ghosh A, 2010, NAT NEUROSCI, V13, P97, DOI 10.1038/nn.2448; Gilmour G, 2004, BEHAV BRAIN RES, V150, P171, DOI 10.1016/j.bbr.2003.07.006; Green JB, 1999, NEUROLOGY, V53, P736, DOI 10.1212/WNL.53.4.736; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Herzog A, 1997, J NEUROSCI METH, V72, P57, DOI 10.1016/S0165-0270(96)00156-2; Hewlett KA, 2006, NEUROSCIENCE, V141, P27, DOI 10.1016/j.neuroscience.2006.03.071; Hoffman LR, 2007, PHYS THER, V87, P208, DOI 10.2522/ptj.20050365; Kaas JH, 2008, EXP NEUROL, V209, P407, DOI 10.1016/j.expneurol.2007.06.014; Keyvani K, 2002, J CEREBR BLOOD F MET, V22, P153, DOI 10.1097/00004647-200202000-00003; Kleim JA, 2004, J NEUROSCI, V24, P628, DOI 10.1523/JNEUROSCI.3440-03.2004; Kleim JA, 1998, J NEUROPHYSIOL, V80, P3321, DOI 10.1152/jn.1998.80.6.3321; KLINE J, 1984, PHYSIOL BEHAV, V33, P301, DOI 10.1016/0031-9384(84)90116-1; Langer N, 2012, NEUROLOGY, V78, P182, DOI 10.1212/WNL.0b013e31823fcd9c; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Li SL, 2006, NEUROBIOL DIS, V23, P362, DOI 10.1016/j.nbd.2006.03.011; Li SL, 2010, NAT NEUROSCI, V13, P1496, DOI 10.1038/nn.2674; Liepert J, 1998, NEUROSCI LETT, V250, P5, DOI 10.1016/S0304-3940(98)00386-3; Liepert J, 2000, ACTA NEUROL SCAND, V101, P321, DOI 10.1034/j.1600-0404.2000.90337a.x; Lu AG, 2003, J CEREBR BLOOD F MET, V23, P786, DOI 10.1097/01.WCB.0000062340.80057.06; Maier IC, 2008, J NEUROSCI, V28, P9386, DOI 10.1523/JNEUROSCI.1697-08.2008; Markus TM, 2005, ANN NEUROL, V58, P950, DOI 10.1002/ana.20676; Marshall RS, 2000, STROKE, V31, P656, DOI 10.1161/01.STR.31.3.656; Martin JH, 1999, EXP BRAIN RES, V125, P184, DOI 10.1007/s002210050673; Martin JH, 2004, J NEUROSCI, V24, P2122, DOI 10.1523/JNEUROSCI.4616-03.2004; Mostany R, 2011, J NEUROSCI, V31, P1734, DOI 10.1523/JNEUROSCI.4386-10.2011; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; NEAFSEY EJ, 1986, BRAIN RES REV, V11, P77, DOI 10.1016/0165-0173(86)90011-1; NEAFSEY EJ, 1982, BRAIN RES, V232, P151, DOI 10.1016/0006-8993(82)90617-5; Schaechter JD, 2012, NEUROREHAB NEURAL RE, V26, P325, DOI 10.1177/1545968311421613; Starkey ML, 2011, EXP NEUROL, V232, P81, DOI 10.1016/j.expneurol.2011.08.006; Stinear C, 2010, LANCET NEUROL, V9, P1228, DOI 10.1016/S1474-4422(10)70247-7; STROEMER RP, 1993, NEUROSCI LETT, V162, P51, DOI 10.1016/0304-3940(93)90557-2; Traversa R, 1997, STROKE, V28, P110, DOI 10.1161/01.STR.28.1.110; Wang L, 2011, P NATL ACAD SCI USA, V108, P2545, DOI 10.1073/pnas.1014335108; Ward NS, 2007, EUR J NEUROSCI, V25, P1865, DOI 10.1111/j.1460-9568.2007.05434.x; Ward NS, 2006, BRAIN, V129, P809, DOI 10.1093/brain/awl002; Weishaupt N, 2010, J NEUROTRAUM, V27, P1387, DOI 10.1089/neu.2010.1346; Werhahn KJ, 2003, ANN NEUROL, V54, P464, DOI 10.1002/ana.10686; Whishaw IQ, 2000, NEUROPHARMACOLOGY, V39, P788, DOI 10.1016/S0028-3908(99)00259-2; WHISHAW IQ, 1990, BEHAV BRAIN RES, V41, P49, DOI 10.1016/0166-4328(90)90053-H; WHISHAW IQ, 1993, BEHAV BRAIN RES, V56, P59, DOI 10.1016/0166-4328(93)90022-I; Winship IR, 2008, J NEUROSCI, V28, P6592, DOI 10.1523/JNEUROSCI.0622-08.2008; Wu CWH, 1999, J NEUROSCI, V19, P7679, DOI 10.1523/JNEUROSCI.19-17-07679.1999; Xerri C, 1998, J NEUROPHYSIOL, V79, P2119, DOI 10.1152/jn.1998.79.4.2119; Z'Graggen WJ, 2000, J NEUROSCI, V20, P6561, DOI 10.1523/JNEUROSCI.20-17-06561.2000; Zhang SX, 2007, PLOS BIOL, V5, P1152, DOI 10.1371/journal.pbio.0050119; Zhang SX, 2005, J NEUROSCI, V25, P5333, DOI 10.1523/JNEUROSCI.1085-05.2005; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387; Zorner B, 2010, NAT METHODS, V7, P701, DOI 10.1038/nmeth.1484	75	57	59	0	13	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	NOV	2012	135		11				3265	3281		10.1093/brain/aws270			17	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	044SV	WOS:000311644800014	23169918	Green Published, Bronze, Green Accepted			2022-02-06	
J	Budohoski, KP; Reinhard, M; Aries, MJH; Czosnyka, Z; Smielewski, P; Pickard, JD; Kirkpatrick, PJ; Czosnyka, M				Budohoski, Karol P.; Reinhard, Matthias; Aries, Marcel J. H.; Czosnyka, Zofia; Smielewski, Peter; Pickard, John D.; Kirkpatrick, Peter J.; Czosnyka, Marek			Monitoring cerebral autoregulation after head injury. Which component of transcranial Doppler flow velocity is optimal?	NEUROCRITICAL CARE			English	Article						Cerebral autoregulation; Traumatic brain injury; Flow velocity; Transcranial Doppler	TRAUMATIC BRAIN-INJURY; CAROTID-ARTERY STENOSIS; HYPEREMIC RESPONSE TEST; PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; BLOOD-FLOW; ULTRASOUND; INDEX; IMPAIRMENT; SONOGRAPHY	Cerebral autoregulation assessed using transcranial Doppler (TCD) mean flow velocity (FV) in response to various physiological challenges is predictive of outcome after traumatic brain injury (TBI). Systolic and diastolic FV have been explored in other diseases. This study aims to evaluate the systolic, mean and diastolic FV for monitoring autoregulation and predicting outcome after TBI. 300 head-injured patients with blood pressure (ABP), intracranial pressure (ICP), cerebral perfusion pressure (CPP), and FV recordings were studied. Autoregulation was calculated as a correlation of slow changes in diastolic, mean and systolic components of FV with CPP (Dx, Mx, Sx, respectively) and ABP (Dxa, Mxa, Sxa, respectively) from 30 consecutive 10 s averaged values. The relationship with age, severity of injury, and dichotomized 6 months outcome was examined. Association with outcome was significant for Mx and Sx. For favorable/unfavorable and death/survival outcomes Sx showed the strongest association (F = 20.11; P = 0.00001 and F = 13.10; P = 0.0003, respectively). Similarly, indices derived from ABP demonstrated the highest discriminatory value when systolic FV was used (F = 12.49; P = 0.0005 and F = 5.32; P = 0.02, respectively). Indices derived from diastolic FV demonstrated significant differences (when calculated using CPP) only when comparing between fatal and non-fatal outcome. Systolic flow indices (Sx and Sxa) demonstrated a stronger association with outcome than the mean flow indices (Mx and Mxa), irrespective of whether CPP or ABP was used for calculation.	[Budohoski, Karol P.; Czosnyka, Zofia; Smielewski, Peter; Pickard, John D.; Kirkpatrick, Peter J.; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 0QQ, England; [Reinhard, Matthias] Univ Freiburg, Dept Neurol, Neuroctr, D-79095 Freiburg, Germany; [Aries, Marcel J. H.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9713 GZ Groningen, Netherlands; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland		Budohoski, KP (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Hills Rd, Cambridge CB2 0QQ, England.	kpb26@cam.ac.uk		Smielewski, Peter/0000-0001-5096-3938	National Institute of Health Research Brain Repair Centre (Cambridge University Hospitals Foundation Trust) Neuroscience Theme; Fearnside Trust, UK; Marry and Clifford Corbridge Trust of Robinson College, UK; European Federation of Neurological Societies; Netherlands Organisation for Health Research and DevelopmentNetherlands Organization for Health Research and Development; National Institute of Health Research Senior Investigator Award; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G0001237, G9439390] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	This project was supported by the National Institute of Health Research Brain Repair Centre (Cambridge University Hospitals Foundation Trust) Neuroscience Theme. KPB received a scholarship from the Fearnside Trust, UK and Marry and Clifford Corbridge Trust of Robinson College, UK. MJHA received a travel grant from the European Federation of Neurological Societies and is supported by the Netherlands Organisation for Health Research and Development. JDP is a recipient of a National Institute of Health Research Senior Investigator Award.	AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; Bokkers RPH, 2010, RADIOLOGY, V256, P201, DOI 10.1148/radiol.10091262; Bouzat P, 2011, NEUROSURGERY; Brandi G, 2010, ACTA NEUROCHIR, V152, P965, DOI 10.1007/s00701-010-0643-4; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; CZOSNYKA M, 1994, NEUROSURGERY, V35, P287, DOI 10.1227/00006123-199408000-00015; CZOSNYKA M, 1994, ACTA NEUROCHIR, P468; GILLER CA, 1991, ACTA NEUROCHIR, V108, P7, DOI 10.1007/BF01407660; HOMBURG AM, 1993, ACTA NEUROL SCAND, V87, P488; Lang EW, 2003, J NEUROTRAUM, V20, P69, DOI 10.1089/08977150360517191; LASSEN NA, 1959, PHYSIOL REV, V39, P183, DOI 10.1152/physrev.1959.39.2.183; Lewis SB, 1999, J CLIN NEUROSCI, V6, P42, DOI 10.1016/S0967-5868(99)90602-1; MENDELOW AD, 1987, J NEUROSURG, V66, P755, DOI 10.3171/jns.1987.66.5.0755; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; OBoyle MK, 1996, AM J ROENTGENOL, V166, P197, DOI 10.2214/ajr.166.1.8571875; Panerai RB, 2004, BRIT J NEUROSURG, V18, P471, DOI 10.1080/02688690400012343; Prevention CfDCa Services UDoHaH, 2010, TRAUMATIC BRAIN INJU; Ract C, 2007, INTENS CARE MED, V33, P645, DOI 10.1007/s00134-007-0558-6; Reinhard M, 2004, STROKE, V35, P1381, DOI 10.1161/01.STR.0000127533.46914.31; Reinhard M, 2003, STROKE, V34, P2138, DOI 10.1161/01.STR.0000087788.65566.AC; Rosengarten B, 2002, CEREBROVASC DIS, V13, P230, DOI 10.1159/000057848; Schmidt EA, 2000, ACT NEUR S, V76, P451; Smielewski P, 1997, J NEUROSURG, V86, P773, DOI 10.3171/jns.1997.86.5.0773; SMIELEWSKI P, 1995, ULTRASOUND MED BIOL, V21, P599, DOI 10.1016/0301-5629(94)00154-6; Sorrentino E, 2011, NEUROCRIT CARE, V14, P188, DOI 10.1007/s12028-010-9492-5; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; White H, 2006, INTENS CARE MED, V32, P981, DOI 10.1007/s00134-006-0173-y	29	57	57	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	OCT	2012	17	2					211	218		10.1007/s12028-011-9572-1			8	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	002QU	WOS:000308548800009	21691895				2022-02-06	
J	Bao, F; Shultz, SR; Hepburn, JD; Omana, V; Weaver, LC; Cain, DP; Brown, A				Bao, Feng; Shultz, Sandy R.; Hepburn, Jeff D.; Omana, Vanessa; Weaver, Lynne C.; Cain, Donald P.; Brown, Arthur			A CD11d Monoclonal Antibody Treatment Reduces Tissue Injury and Improves Neurological Outcome after Fluid Percussion Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; behavioral assessments; inflammation; oxidative stress; traumatic brain injury	SPINAL-CORD-INJURY; AMYLOID PRECURSOR PROTEIN; LONG-EVANS RAT; HEAD-INJURY; SYNAPTIC PLASTICITY; REACTIVE ASTROCYTES; ADHESION MOLECULES; LIPID-PEROXIDATION; DNA OXIDATION; INFLAMMATION	Traumatic brain injury (TBI) is an international health concern often resulting in chronic neurological abnormalities, including cognitive deficits, emotional disturbances, and motor impairments. An anti-CD11d monoclonal antibody that blocks the CD11d/CD18 integrin and vascular cell adhesion molecule (VCAM)-1 interaction following experimental spinal cord injury improves functional recovery, while reducing the intraspinal number of neutrophils and macrophages, oxidative activity, and tissue damage. Since the mechanisms of secondary injury in the brain and spinal cord are similar, we designed a study to evaluate fully the effects of anti-CD11d treatment after a moderate lateral fluid percussion TBI in the rat. Rats were treated at 2 h after TBI with either the anti-CD11d antibody or an isotype-matched control antibody 1B7, and both short (24- to 72-h) and long (4-week) recovery periods were examined. The anti-CD11d integrin treatment reduced neutrophil and macrophage levels in the injured brain, with concomitant reductions in lipid peroxidation, astrocyte activation, amyloid precursor protein accumulation, and neuronal loss. The reduced neuroinflammation seen in anti-CD11d-treated rats correlated with improved performance on a number of behavioral tests. At 24 h, the anti-CD11d group performed significantly better than the 1B7 controls on several water maze measures of spatial cognition. At 4 weeks post-injury the anti-CD11d-treated rats had better sensorimotor function as assessed by the beam task, and reduced anxiety-like behaviors, as evidenced by elevated-plus maze testing, compared to 1B7 controls. These findings suggest that neuroinflammation is associated with behavioral deficits after TBI, and that anti-CD11d antibody treatment is a viable strategy to improve neurological outcomes after TBI.	[Brown, Arthur] Univ Western Ontario, Robarts Res Inst, Schulich Sch Med, London, ON N6A 5K8, Canada; [Shultz, Sandy R.; Weaver, Lynne C.; Cain, Donald P.; Brown, Arthur] Univ Western Ontario, Dept Psychol, London, ON N6A 5K8, Canada; [Shultz, Sandy R.; Weaver, Lynne C.; Cain, Donald P.; Brown, Arthur] Univ Western Ontario, Grad Program Neurosci, London, ON N6A 5K8, Canada; [Hepburn, Jeff D.; Brown, Arthur] Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5K8, Canada		Brown, A (corresponding author), Univ Western Ontario, Robarts Res Inst, Schulich Sch Med, 100 Perth Dr, London, ON N6A 5K8, Canada.	abrown@robarts.ca	Weaver, Lynne C/K-8491-2013; Brown, Arthur/K-8328-2013; Brown, Arthur/K-6837-2013	Brown, Arthur/0000-0002-8725-3195; Shultz, Sandy/0000-0002-2525-8775	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR	This work was supported the Canadian Institutes of Health Research (L.C.W. and A. B.), and the Natural Sciences and Engineering Research Council of Canada (D.P.C.).	Atif F, 2009, MOL MED, V15, P328, DOI 10.2119/molmed.2009.00016; Bao F, 2005, J NEUROCHEM, V94, P1361, DOI 10.1111/j.1471-4159.2005.03280.x; Bao F, 2004, J NEUROCHEM, V90, P1194, DOI 10.1111/j.1471-4159.2004.02580.x; Bao F, 2004, J NEUROCHEM, V88, P1335, DOI 10.1046/j.1471-4159.2003.02240.x; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.immunol.11.1.767; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Cain P, 1993, Nurs Times, V89, P36; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Dringen R, 2005, ANTIOXID REDOX SIGN, V7, P1223, DOI 10.1089/ars.2005.7.1223; Farkas I, 1998, J PHYSIOL-LONDON, V507, P679, DOI 10.1111/j.1469-7793.1998.679bs.x; Fleming JC, 2008, EXP NEUROL, V214, P147, DOI 10.1016/j.expneurol.2008.04.024; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Grady MS, 1999, J NEUROTRAUM, V16, P13, DOI 10.1089/neu.1999.16.13; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; Hogg N, 2001, J LEUKOCYTE BIOL, V69, P893; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; KOLB B, 1985, BEHAV BRAIN RES, V17, P25, DOI 10.1016/0166-4328(85)90005-1; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Leski ML, 2001, FREE RADICAL BIO MED, V30, P613, DOI 10.1016/S0891-5849(00)00500-1; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Maas Andrew I.R., 2000, Curr Opin Crit Care, V6, P281, DOI 10.1097/00075198-200008000-00008; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Oatway MA, 2005, J NEUROSCI, V25, P637, DOI 10.1523/JNEUROSCI.3960-04.2005; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Saucier DM, 2008, ANIM COGN, V11, P129, DOI 10.1007/s10071-007-0096-1; Saville LR, 2004, J NEUROIMMUNOL, V156, P42, DOI 10.1016/j.jneuroim.2004.07.002; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Shultz SR, 2009, BEHAV BRAIN RES, V200, P33, DOI 10.1016/j.bbr.2008.12.023; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Steimer T, 2003, STRESS, V6, P87, DOI 10.1080/1025389031000111320; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tan AA, 2009, J NEUROTRAUM, V26, P539, DOI 10.1089/neu.2008.0611; Taoka Y, 1998, PROG NEUROBIOL, V56, P341, DOI 10.1016/S0301-0082(98)00049-5; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Utagawa A, 2008, BRAIN RES, V1207, P155, DOI 10.1016/j.brainres.2008.02.057; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Whishaw IQ, 1995, HIPPOCAMPUS, V5, P595, DOI 10.1002/hipo.450050610; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; Zhu SW, 2006, BEHAV BRAIN RES, V169, P10, DOI 10.1016/j.bbr.2005.11.024; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	67	57	57	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2012	29	14					2375	2392		10.1089/neu.2012.2408			18	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	004SM	WOS:000308701400002	22676851	Green Accepted			2022-02-06	
J	Crowe, LM; Catroppa, C; Babl, FE; Rosenfeld, JV; Anderson, V				Crowe, Louise M.; Catroppa, Cathy; Babl, Franz E.; Rosenfeld, Jeffrey V.; Anderson, Vicki			Timing of Traumatic Brain Injury in Childhood and Intellectual Outcome	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						children; IQ; outcome; plasticity; traumatic brain injury	CLOSED HEAD-INJURY; DEVELOPMENTAL-CHANGES; YOUNG-CHILDREN; FUNCTIONAL RECOVERY; FRONTAL-CORTEX; PLASTICITY; AGE; LANGUAGE; INFANTS; PERFORMANCE	Objective Typically, studies on outcomes after traumatic brain injury (TBI) have investigated whether a younger age at injury is associated with poorer recovery by comparing 2 age groups rather than participants injured across childhood. This study extended previous research by examining whether the influence of age on recovery fits an early vulnerability or critical developmental periods model. Methods Children with a TBI (n = 181) were categorized into 4 age-at-injury groups-infant, preschool, middle childhood, and late childhood-and were evaluated at least 2-years post-TBI on IQ. Results Overall, the middle childhood group had lower IQ scores across all domains. Infant and preschool groups performed below the late childhood group on nonverbal and processing speed domains. Conclusions Contrary to expectations, children injured in middle childhood demonstrated the poorest outcomes; this age potentially coincides with a critical period of brain and cognitive development.	[Crowe, Louise M.] Royal Childrens Hosp, Dept Child Neuropsychol Crit Care & Neurosci, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Crowe, Louise M.; Catroppa, Cathy; Anderson, Vicki] Univ Melbourne, Melbourne, Vic 3010, Australia; [Anderson, Vicki] Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; [Babl, Franz E.] Royal Childrens Hosp, Emergency Dept, Parkville, Vic 3052, Australia; [Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia		Crowe, LM (corresponding author), Royal Childrens Hosp, Dept Child Neuropsychol Crit Care & Neurosci, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	louise.crowe@mcri.edu.au	Catroppa, Cathy/AAX-9458-2021; Rosenfeld, Jeffrey V/B-7249-2011	Catroppa, Cathy/0000-0002-9750-0436; Crowe, Louise/0000-0003-4619-9708			Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Ballantyne AO, 2008, BRAIN, V131, P2975, DOI 10.1093/brain/awn176; Case ME, 2008, BRAIN PATHOL, V18, P562, DOI 10.1111/j.1750-3639.2008.00202.x; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Daniel A., 1983, POWER PRESTIGE OCCUP; DENNIS M, 1976, BRAIN LANG, V3, P404, DOI 10.1016/0093-934X(76)90036-5; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Ennis Elaine, 2004, Pediatr Rehabil, V7, P205, DOI 10.1080/13638490410001703316; ESCALONA SK, 1982, PEDIATRICS, V70, P670; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Gerring J., 2012, J NEUROTRAUMA; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Greenham M, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00022; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HEBB D. O., 1942, PROC AMER PHIL SOC, V85, P275; Hertz-Pannier L, 2002, BRAIN, V125, P361, DOI 10.1093/brain/awf020; HUDSPETH WJ, 1990, J EDUC PSYCHOL, V82, P881, DOI 10.1037/0022-0663.82.4.881; HUTTENLOCHER PR, 1979, BRAIN RES, V163, P195; HUTTENLOCHER PR, 1997, DEV PREFRONTAL CORTE, P69; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Kennard MA, 1936, AM J PHYSIOL, V115, P138, DOI 10.1152/ajplegacy.1936.115.1.138; Klenberg L, 2001, DEV NEUROPSYCHOL, V20, P407, DOI 10.1207/S15326942DN2001_6; Kolb B, 2004, BRAIN COGNITION, V55, P104, DOI 10.1016/s0278-2626(03)00278-1; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; NOLLER P, 1992, J ADOLESCENCE, V15, P101, DOI 10.1016/0140-1971(92)90041-3; Noller P., 1988, ICPS FAMILY FUNCTION; Paul R., 2006, LANGUAGE DISORDERS I; Rebok GW, 1997, CHILD NEUROPSYCHOL, V3, P28, DOI 10.1080/09297049708401366; REILLY PL, 1988, CHILD NERV SYST, V4, P30; Spencer-Smith M, 2009, DEV NEUROREHABIL, V12, P279, DOI 10.3109/17518420903090701; Stiles J, 2000, DEV NEUROPSYCHOL, V18, P237, DOI 10.1207/S15326942DN1802_5; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; TEASDALE G, 1974, LANCET, V2, P81; Teuber H., 1971, NEUROPSYCHOLOGIA, V17, P557; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wechsler D., 2002, WECHSLER PRESCHOOL P; Wechsler D., 1989, MANUAL PRESCHOOL PRI; YULE W, 1982, PERS INDIV DIFFER, V3, P65, DOI 10.1016/0191-8869(82)90075-7; [No title captured]	56	57	58	1	26	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	AUG	2012	37	7					745	754		10.1093/jpepsy/jss070			10	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	981KC	WOS:000306965500005	22669504	Bronze			2022-02-06	
J	Elliott, MB; Oshinsky, ML; Amenta, PS; Awe, OO; Jallo, JI				Elliott, Melanie B.; Oshinsky, Michael L.; Amenta, Peter S.; Awe, Olatilewa O.; Jallo, Jack I.			Nociceptive Neuropeptide Increases and Periorbital Allodynia in a Model of Traumatic Brain Injury	HEADACHE			English	Article						post-traumatic headache; traumatic brain injury; calcitonin gene-related peptide; trigeminal; allodynia; central sensitization	POSTTRAUMATIC-STRESS-DISORDER; US SOLDIERS; HEADACHE; COMBAT; IRAQ; VETERANS; FREEDOM; AFGHANISTAN; PREVALENCE; HEALTH	Objective.-This study tests the hypothesis that injury to the somatosensory cortex is associated with periorbital allodynia and increases in nociceptive neuropeptides in the brainstem in a mouse model of controlled cortical impact (CCI) injury. Methods.-Male C57BL/6 mice received either CCI or craniotomy-only followed by weekly periorbital von Frey (mechanical) sensory testing for up to 28 days post-injury. Mice receiving an incision only and na ve mice were included as control groups. Changes in calcitonin gene-related peptide (CGRP) and substance P (SP) within the brainstem were determined using enzyme-linked immunosorbent assay and immunohistochemistry, respectively. Activation of ionized calcium-binding adaptor molecule-1-labeled macrophages/microglia and glial fibrillary acidic protein (GFAP)-positive astrocytes were evaluated using immunohistochemistry because of their potential involvement in nociceptor sensitization. Results.-Incision-only control mice showed no changes from baseline periorbital von Frey mechanical thresholds. CCI significantly reduced mean periorbital von Frey thresholds (periorbital allodynia) compared with baseline and craniotomy-only at each endpoint, analysis of variance P <.0001. Craniotomy significantly reduced periorbital threshold at 14 days but not 7, 21, or 28 days compared with baseline threshold, P <.01. CCI significantly increased SP immunoreactivity in the brainstem at 7 and 14 days but not 28 days compared with craniotomy-only and controls, P <.001. CGRP levels in brainstem tissues were significantly increased in CCI groups compared with controls (incision-only and na ve mice) or craniotomy-only mice at each endpoint examined, P <.0001. There was a significant correlation between CGRP and periorbital allodynia (P <.0001, r = -0.65) but not for SP (r = 0.20). CCI significantly increased the number of macrophage/microglia in the injured cortex at each endpoint up to 28 days, although cell numbers declined over weeks post-injury, P <.001. GFAP+ immunoreactivity was significantly increased at 7 but not 14 or 28 days after CCI, P <.001. Craniotomy resulted in transient periorbital allodynia accompanied by transient increases in SP, CGRP, and GFAP immunoreactivity compared with control mice. There was no increase in the number of macrophage/microglia cells compared with controls after craniotomy. Conclusion.-Injury to the somatosensory cortex results in persistent periorbital allodynia and increases in brainstem nociceptive neuropeptides. Findings suggest that persistent allodynia and increased neuropeptides are maintained by mechanisms other than activation of macrophage/microglia or astrocyte in the injured somatosensory cortex.	[Elliott, Melanie B.; Amenta, Peter S.; Awe, Olatilewa O.; Jallo, Jack I.] Thomas Jefferson Univ, Dept Neurol Surg, Philadelphia, PA 19107 USA; [Oshinsky, Michael L.] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA		Elliott, MB (corresponding author), Thomas Jefferson Univ, Dept Neurosurg, 1025Walnut St,Suite 516 Coll, Philadelphia, PA 19107 USA.	Melanie.elliott@jefferson.edu		Oshinsky, Michael/0000-0002-0976-1047; Jallo, Jack/0000-0002-5512-1729	 [R01-NS061571]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS058695, R01NS061571] Funding Source: NIH RePORTER	Experiments were conducted by Dr. Melanie B. Elliott, Dr. Peter S. Amenta, Olatilewa O. Awe, and Karena Browne. Data interpretation and manuscript preparation were done by Drs. Melanie Elliott, Michael L. Oshinsky (support by R01-NS061571), and Jack I. Jallo. Thank you to Dr. Elisabeth Van Bockstaele for contributing microscopy equipment for our histological analyses and Karena Browne for contributing to the behavioral testing. We would also like to thank Dr. Mary Barbe for reviewing and providing valuable feedback on this manuscript.	Afari N, 2009, HEADACHE, V49, P1267, DOI 10.1111/j.1526-4610.2009.01517.x; Amin MM, 2010, MIL MED, V175, P155; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2011, CLIN NEUROPSYCHOL, V1, P1; Bryan CJ, 2011, HEADACHE, V51, P945, DOI 10.1111/j.1526-4610.2011.01887.x; Couch JR, 2007, NEUROLOGY, V69, P1169, DOI 10.1212/01.wnl.0000276985.07981.0a; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Evans RW, 2010, HEADACHE, V50, P716, DOI 10.1111/j.1526-4610.2010.01645.x; Finkel A, 2009, 24 INT HEAD C PHIL P; Ford S, 2008, HEADACHE, V48, P523, DOI 10.1111/j.1526-4610.2008.00859.x; Gladstone J, 2009, HEADACHE, V49, P1097, DOI 10.1111/j.1526-4610.2009.01461.x; Grosberg Brian M, 2007, Curr Pain Headache Rep, V11, P310, DOI 10.1007/s11916-007-0209-1; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2010, ARCH PHYS MED REHAB, V91, P963, DOI 10.1016/j.apmr.2010.02.005; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Neely ET, 2009, HEADACHE, V49, P1089, DOI 10.1111/j.1526-4610.2009.001460.x; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Scher AI, 2011, 63 ANN M AM AC NEUR; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Theeler BJ, 2008, HEADACHE, V48, P876, DOI 10.1111/j.1526-4610.2008.01159.x; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Theeler BJ, 2010, HEADACHE, V50, P790, DOI 10.1111/j.1526-4610.2009.01571.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Vargas BB, 2009, CURR PAIN HEADACHE R, V13, P64, DOI 10.1007/s11916-009-0013-1; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158	32	57	59	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	JUN	2012	52	6					966	984		10.1111/j.1526-4610.2012.02160.x			19	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	952OA	WOS:000304800600005	22568499	Green Published, Green Accepted			2022-02-06	
J	Rosenbloom, MH; Schmahmann, JD; Price, BH				Rosenbloom, Michael H.; Schmahmann, Jeremy D.; Price, Bruce H.			The Functional Neuroanatomy of Decision-Making	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							MEDIAL PREFRONTAL CORTEX; ORBITOFRONTAL CORTEX; MORAL JUDGMENT; ARCHITECTONIC SUBDIVISION; NEURONAL-ACTIVITY; NEURAL BASIS; EMOTION; DAMAGE; BEHAVIOR; REWARD	Decision-making is a complex executive function that draws on past experience, present goals, and anticipation of outcome, and which is influenced by prevailing and predicted emotional tone and cultural context. Functional imaging investigations and focal lesion studies identify the orbitofrontal, anterior cingulate, and dorsolateral prefrontal cortices as critical to decision-making. The authors review the connections of these prefrontal regions with the neocortex, limbic system, basal ganglia, and cerebellum, highlight current ideas regarding the cognitive processes of decision-making that these networks subserve, and present a novel integrated neuroanatomical model for decision-making. Finally, clinical relevance of this circuitry is illustrated through a discussion of frontotemporal dementia, traumatic brain injury, and sociopathy. (The Journal of Neuropsychiatry and Clinical Neurosciences 2012; 24:266-277)	[Rosenbloom, Michael H.] HealthPartners, Dept Neurol, Ctr Dementia & Alzheimers Care, St Paul, MN USA; [Schmahmann, Jeremy D.] Massachusetts Gen Hosp, Dept Neurol, Cognit Behav Neurol Unit, Ataxia Unit, Boston, MA 02114 USA; [Schmahmann, Jeremy D.; Price, Bruce H.] Harvard Univ, Sch Med, Boston, MA USA; [Price, Bruce H.] McLean Hosp, Dept Neurol, Belmont, MA 02178 USA; [Price, Bruce H.] Massachusetts Gen Hosp, Ctr Law Brain & Behav, Boston, MA 02114 USA		Rosenbloom, MH (corresponding author), HealthPartners, Dept Neurol, Ctr Dementia & Alzheimers Care, St Paul, MN USA.	Michael.H.Rosenbloom@HealthPartners.com	Schmahmann, Jeremy/ABF-1215-2021	Schmahmann, Jeremy/0000-0003-0706-5125	Birmingham Foundation; MINDlink Foundation; Sydney R. Baer Jr. Foundation	This work was supported in part by the Birmingham, MINDlink, and Sydney R. Baer Jr. Foundations. We also acknowledge the Massachusetts General Hospital Center for Law, Brain, and Behavior.	Adolphs R, 1998, NATURE, V393, P470, DOI 10.1038/30982; ALBERT ML, 1974, J NEUROL NEUROSUR PS, V37, P121, DOI 10.1136/jnnp.37.2.121; Alexander MP, 2007, NEUROLOGY, V68, P1515, DOI 10.1212/01.wnl.0000261482.99569.fb; Barbas H, 2000, ADV NEUROL, V84, P87; Barbas H, 2007, ANN NY ACAD SCI, V1121, P10, DOI 10.1196/annals.1401.015; Barbas H, 2007, J ANAT, V211, P237, DOI 10.1111/j.1469-7580.2007.00777.x; Baskin JH, 2007, AM J LAW MED, V33, P239, DOI 10.1177/009885880703300205; Bechara A, 2004, BRAIN COGNITION, V55, P30, DOI 10.1016/j.bandc.2003.04.001; Bechara A, 2004, INT REV NEUROBIOL, V62, P159, DOI 10.1016/S0074-7742(04)62006-X; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; Beer JS, 2003, J PERS SOC PSYCHOL, V85, P594, DOI 10.1037/0022-3514.85.4.594; BLAKE PY, 1995, NEUROLOGY, V45, P1641, DOI 10.1212/WNL.45.9.1641; BOGOUSSLAVSKY J, 1988, NEUROLOGY, V38, P837, DOI 10.1212/WNL.38.6.837; Brower MC, 2001, J NEUROL NEUROSUR PS, V71, P720, DOI 10.1136/jnnp.71.6.720; Buckholtz JW, 2008, NEURON, V60, P930, DOI 10.1016/j.neuron.2008.10.016; Buckner RL, 2005, J NEUROSCI, V25, P7709, DOI 10.1523/JNEUROSCI.2177-05.2005; Camille N, 2004, SCIENCE, V304, P1167, DOI 10.1126/science.1094550; Cardinal RN, 2004, ANN NY ACAD SCI, V1021, P33, DOI 10.1196/annals.1308.004; CARMICHAEL ST, 1994, J COMP NEUROL, V346, P366, DOI 10.1002/cne.903460305; Carmichael ST, 1995, J COMP NEUROL, V363, P642, DOI 10.1002/cne.903630409; Carmichael ST, 1995, J COMP NEUROL, V363, P615, DOI 10.1002/cne.903630408; Cella M, 2010, J AFFECT DISORDERS, V124, P207, DOI 10.1016/j.jad.2009.11.013; Chukwudelunzu FE, 2001, J NEUROL NEUROSUR PS, V71, P658, DOI 10.1136/jnnp.71.5.658; Clark L, 2008, BRAIN, V131, P1311, DOI 10.1093/brain/awn066; Clark L, 2004, NEUROCASE, V10, P398, DOI 10.1080/13554790490882799; Critchley HD, 2000, BIOL PSYCHIAT, V47, P928, DOI 10.1016/S0006-3223(00)00231-6; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; Decety Jean, 2004, Behav Cogn Neurosci Rev, V3, P71, DOI 10.1177/1534582304267187; Delgado MR, 2007, ANN NY ACAD SCI, V1104, P70, DOI 10.1196/annals.1390.002; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Fishbein DH, 2005, COGNITIVE BRAIN RES, V23, P119, DOI 10.1016/j.cogbrainres.2004.12.010; Floden D, 2008, NEUROPSYCHOLOGIA, V46, P213, DOI 10.1016/j.neuropsychologia.2007.07.020; Floresco SB, 2008, COGN AFFECT BEHAV NE, V8, P375, DOI 10.3758/CABN.8.4.375; Ghashghaei HT, 2002, NEUROSCIENCE, V115, P1261, DOI 10.1016/S0306-4522(02)00446-3; Ghika J, 1999, J NEUROSURG, V91, P313, DOI 10.3171/jns.1999.91.2.0313; Goel V, 2000, COGN NEUROPSYCHOL, V17, P415, DOI 10.1080/026432900410775; GOLDMANRAKIC PS, 1985, J COMP NEUROL, V242, P535, DOI 10.1002/cne.902420406; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Graybiel AM, 2008, ANNU REV NEUROSCI, V31, P359, DOI 10.1146/annurev.neuro.29.051605.112851; Greene JD, 2007, TRENDS COGN SCI, V11, P322, DOI 10.1016/j.tics.2007.06.004; Harenski CL, 2006, NEUROIMAGE, V30, P313, DOI 10.1016/j.neuroimage.2005.09.034; Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168; Hsu M, 2005, SCIENCE, V310, P1680, DOI 10.1126/science.1115327; Jones CL, J NEUROL NEUROSURG P, V81, P611; Kelly RM, 2003, J NEUROSCI, V23, P8432; Koenigs M, 2007, NATURE, V446, P908, DOI 10.1038/nature05631; Krawczyk DC, 2002, NEUROSCI BIOBEHAV R, V26, P631, DOI 10.1016/S0149-7634(02)00021-0; Kuhnen CM, 2005, NEURON, V47, P763, DOI 10.1016/j.neuron.2005.08.008; Kuruoglu AC, 1996, BRIT J PSYCHIAT, V169, P348, DOI 10.1192/bjp.169.3.348; Labudda K, 2010, NEUROCASE, V16, P59, DOI 10.1080/13554790903329125; Levenston GK, 2000, J ABNORM PSYCHOL, V109, P373, DOI 10.1037//0021-843X.109.3.373; Levisohn L, 2000, BRAIN, V123, P1041, DOI 10.1093/brain/123.5.1041; LEWIS DO, 1988, AM J PSYCHIAT, V145, P584; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; Mayberg HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; Mendez MF, 2009, CNS SPECTRUMS, V14, P608, DOI 10.1017/S1092852900023853; Mendez MF, 2005, COGN BEHAV NEUROL, V18, P193, DOI 10.1097/01.wnn.0000191292.17964.bb; Mendez MF, 2005, DEMENT GERIATR COGN, V20, P99, DOI 10.1159/000086474; Middleton FA, 2001, J NEUROSCI, V21, P700, DOI 10.1523/JNEUROSCI.21-02-00700.2001; Miller B.L., 2007, HUMAN FRONTAL LOBES, V2nd; MILLER BL, 1993, DEMENTIA, V4, P204, DOI 10.1159/000107324; Moll J, 2007, TRENDS COGN SCI, V11, P319, DOI 10.1016/j.tics.2007.06.001; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; O'Doherty J, 2001, NAT NEUROSCI, V4, P95, DOI 10.1038/82959; O'Reilly JX, 2010, CEREB CORTEX, V20, P953, DOI 10.1093/cercor/bhp157; Ongur D, 2003, J COMP NEUROL, V460, P425, DOI 10.1002/cne.10609; Pandya DN, 1996, PHILOS T ROY SOC B, V351, P1423, DOI 10.1098/rstb.1996.0127; Petrides M, 2002, EUR J NEUROSCI, V16, P291, DOI 10.1046/j.1460-9568.2001.02090.x; Prehn K, 2008, SOC COGN AFFECT NEUR, V3, P33, DOI 10.1093/scan/nsm037; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; Raine A, 1998, NEUROPSY NEUROPSY BE, V11, P1; Raine A, 1997, BIOL PSYCHIAT, V42, P495, DOI 10.1016/S0006-3223(96)00362-9; Raine A, 1998, BEHAV SCI LAW, V16, P319, DOI 10.1002/(SICI)1099-0798(199822)16:3<319::AID-BSL311>3.0.CO;2-G; Roesch MR, 2005, J NEUROPHYSIOL, V94, P2457, DOI 10.1152/jn.00373.2005; Roesch MR, 2004, SCIENCE, V304, P307, DOI 10.1126/science.1093223; Rogers RD, 1999, J NEUROSCI, V19, P9029, DOI 10.1523/JNEUROSCI.19-20-09029.1999; Rolls ET, 2004, BRAIN COGNITION, V55, P11, DOI 10.1016/s0278-2626(03)00277-x; Schmahmann J.D., 2006, FIBER PATHWAYS BRAIN; SCHMAHMANN JD, 1995, NEUROSCI LETT, V199, P175, DOI 10.1016/0304-3940(95)12056-A; Schmahmann JD, 1997, INT REV NEUROBIOL, V41, P31, DOI 10.1016/S0074-7742(08)60346-3; Schmahmann JD, 1998, BRAIN, V121, P561, DOI 10.1093/brain/121.4.561; Schmahmann JD, 1997, J NEUROSCI, V17, P438, DOI 10.1523/JNEUROSCI.17-01-00438.1997; Schmahmann JD, 2008, ANN NY ACAD SCI, V1142, P266, DOI 10.1196/annals.1444.017; Schmahmann JD, 2008, CORTEX, V44, P1037, DOI 10.1016/j.cortex.2008.04.004; Schroeder SA, 2007, NEW ENGL J MED, V357, P1221, DOI 10.1056/NEJMsa073350; Seeley WW, 2009, NEURON, V62, P42, DOI 10.1016/j.neuron.2009.03.024; Shima K, 1998, SCIENCE, V282, P1335, DOI 10.1126/science.282.5392.1335; Soderstrom H, 2000, PSYCHIAT RES-NEUROIM, V98, P29, DOI 10.1016/S0925-4927(99)00049-9; Stoodley CJ, 2009, NEUROIMAGE, V44, P489, DOI 10.1016/j.neuroimage.2008.08.039; TATEMICHI TK, 1992, NEUROLOGY, V42, P1966, DOI 10.1212/WNL.42.10.1966; Ullsperger M, 2003, J NEUROSCI, V23, P4308, DOI 10.1523/jneurosci.23-10-04308.2003; Volkow ND, 2010, NEUROIMAGE, V49, P2536, DOI 10.1016/j.neuroimage.2009.10.088; Wallis JD, 2007, ANNU REV NEUROSCI, V30, P31, DOI 10.1146/annurev.neuro.30.051606.094334; Weller JA, 2009, SOC NEUROSCI-UK, V4, P347, DOI 10.1080/17470910902934400; Willis ML, 2010, NEUROPSYCHOLOGIA, V48, P2182, DOI 10.1016/j.neuropsychologia.2010.04.010; Yang YL, 2009, PSYCHIAT RES-NEUROIM, V174, P81, DOI 10.1016/j.pscychresns.2009.03.012; Yechiam E, 2008, PSYCHON B REV, V15, P44, DOI 10.3758/PBR.15.1.44; Yeterian EH, 1998, J COMP NEUROL, V399, P384; Zahn R, 2009, BRAIN, V132, P604, DOI 10.1093/brain/awn343	100	57	60	1	48	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	2012	24	3					266	277		10.1176/appi.neuropsych.11060139			12	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	057VS	WOS:000312592800037	23037641				2022-02-06	
J	Barwick, F; Arnett, P; Slobounov, S				Barwick, Fiona; Arnett, Peter; Slobounov, Semyon			EEG correlates of fatigue during administration of a neuropsychological test battery	CLINICAL NEUROPHYSIOLOGY			English	Article						Mental fatigue; EEG; Stroop Interference Test	EVENT-RELATED POTENTIALS; TRAUMATIC BRAIN-INJURY; SLEEP-DEPRIVATION; MULTIPLE-SCLEROSIS; DRIVER FATIGUE; WAKING EEG; PERFORMANCE; CONCUSSION; ALERTNESS; INDEXES	Objective: Mental fatigue, a poorly understood symptom of sports-related concussion, ideally requires assessment across multiple modalities. Our study aimed to examine mental fatigue effects among 10 neurologically normal, athletically active students undergoing typical concussion testing. It is our intention to ultimately address the question whether fatigue effects due to mild traumatic brain injury (mTBI) may become confounded with fatigue effects due to testing effort. Methods: Fourteen athletically active and neurologically normal volunteers were initially recruited from Penn State University. Self-reported fatigue, neuropsychological performance, and electroencephalographic (EEG) activity were measured throughout the whole testing duration. EEG measures in frequency domain (e. g., relative power of theta, alpha, and beta bands) were examined over the course of neuropsychological (NP) test administration. Results: Predicted fatigue effects over the course of testing included: (a) increased self-reported fatigue; (b) increased errors on the Stroop Interference Test; (c) significantly increased relative power of theta activity during the Stroop Interference Test in frontal-central and parietal regions; and (d) migration of alpha activation from the occipital to anterior (left parietal and pre-central) regions during the Stroop Interference task administered at the beginning compared with the end of testing. Conclusions: Results supported predictions related to subjective fatigue and cognitive performance and offered partial support for predictions related to EEG activation patterns over the course of administering the NP testing. Significance: Neurologically intact and athletically active college students demonstrate effects related to fatigue after undergoing a typical sports concussion assessment battery, including an increase in subjectively experienced fatigue, a decrease in cognitive task performance accuracy and associated modulations in EEG activity. This finding should be considered by clinical practitioners while evaluating the symptoms of concussion and making a decision regarding the return-to-sport participation. (C) 2011 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Barwick, Fiona; Arnett, Peter] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; [Slobounov, Semyon] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA		Slobounov, S (corresponding author), 19 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu			NIH, NINDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS056227-02]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056227] Funding Source: NIH RePORTER	We would like to thank Dr. Cao Cheng for EEG data analysis. This research was partly supported by NIH, NIND Grant R01 NS056227-02 "Identification of Athletes at Risk for Traumatic Brain Injury'', awarded to Dr. Slobounov.	Beebe DW, 2003, SLEEP, V26, P298, DOI 10.1093/sleep/26.3.298; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Buzsaki G., 2006, RHYTHMS BRAIN CYCLE, P341; Cajochen C, 1995, SLEEP, V18, P890, DOI 10.1093/sleep/18.10.890; CHAPMAN LJ, 1987, BRAIN COGNITION, V6, P175, DOI 10.1016/0278-2626(87)90118-7; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Corsi-Cabrera M, 2003, INT J PSYCHOPHYSIOL, V50, P213, DOI 10.1016/S0167-8760(03)00168-5; De Gennaro L, 2007, NEUROIMAGE, V36, P1277, DOI 10.1016/j.neuroimage.2007.04.013; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; DeLuca J, 2007, NAT AC NEUR 27 ANN C; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Durmer JS, 2005, SEMIN NEUROL, V25, P117, DOI 10.1055/s-0029-1237117; FISK JD, 1994, CAN J NEUROL SCI, V21, P9, DOI 10.1017/S0317167100048691; Gevins A, 1997, CEREB CORTEX, V7, P374, DOI 10.1093/cercor/7.4.374; Gioia G, 2008, 3 INT C CONC SPORT Z; GRANDJEAN EP, 1970, AM IND HYG ASSOC J, V31, P401, DOI 10.1080/0002889708506267; HORVATH M, 1976, ACTIV NERV SUPER, V18, P207; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Jones K, 2001, SLEEP MED REV, V5, P463, DOI 10.1053/smrv.2001.0203; Karni A, 1998, P NATL ACAD SCI USA, V95, P861, DOI 10.1073/pnas.95.3.861; Kiroy VN, 1996, INT J NEUROSCI, V85, P31, DOI 10.3109/00207459608986349; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Lal SKL, 2002, PSYCHOPHYSIOLOGY, V39, P313, DOI 10.1017/S0048577201393095; Lal SKL, 2001, BIOL PSYCHOL, V55, P173, DOI 10.1016/S0301-0511(00)00085-5; Lim JL, 2008, ANN NY ACAD SCI, V1129, P305, DOI 10.1196/annals.1417.002; Loomis AL, 1937, J EXP PSYCHOL, V21, P127, DOI 10.1037/h0057431; Makeig S, 1995, NEUROREPORT, V7, P213, DOI 10.1097/00001756-199512000-00051; MAKEIG S, 1993, ELECTROEN CLIN NEURO, V86, P23, DOI 10.1016/0013-4694(93)90064-3; MATOUSEK M, 1983, ELECTROEN CLIN NEURO, V55, P108, DOI 10.1016/0013-4694(83)90154-2; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; OKEN BS, 1986, ANN NEUROL, V19, P493, DOI 10.1002/ana.410190511; Papadelis C, 2007, CLIN NEUROPHYSIOL, V118, P1906, DOI 10.1016/j.clinph.2007.04.031; *PSYCH CORP, 2001, WECHSL TEST AD READ; Rosenbaum AM, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P137, DOI 10.1007/0-387-32565-4_7; SANTAMARIA J, 1987, J CLIN NEUROPHYSIOL, V4, P327, DOI 10.1097/00004691-198710000-00002; Shen KQ, 2008, CLIN NEUROPHYSIOL, V119, P1524, DOI 10.1016/j.clinph.2008.03.012; Slobounov SM, 2000, COGNITIVE BRAIN RES, V9, P287, DOI 10.1016/S0926-6410(00)00009-4; Smith ME, 1999, COGNITIVE BRAIN RES, V7, P389, DOI 10.1016/S0926-6410(98)00043-3; Stein KD, 2001, CANCER PRACT, V6, P143; Stern R., 2000, PSYCHOPHYSIOLOGICAL; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Thompson J, 2007, THESIS PENN STATE U, V68, P3000; Tinguely G, 2006, NEUROIMAGE, V32, P283, DOI 10.1016/j.neuroimage.2006.03.017; TORSVALL L, 1987, ELECTROEN CLIN NEURO, V66, P502, DOI 10.1016/0013-4694(87)90096-4; TREJO LJ, 1995, BIOL PSYCHOL, V40, P33, DOI 10.1016/0301-0511(95)05103-1; Trenerry MR, 1989, STROOP NEUROPSYCHOLO; Whitehead L, 2009, J PAIN SYMPTOM MANAG, V37, P107, DOI 10.1016/j.jpainsymman.2007.08.019	52	57	59	8	66	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	FEB	2012	123	2					278	284		10.1016/j.clinph.2011.06.027			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	876PB	WOS:000299118600014	21798799	Green Accepted			2022-02-06	
J	Corrigan, JD; Bogner, J; Holloman, C				Corrigan, John D.; Bogner, Jennifer; Holloman, Christopher			Lifetime history of traumatic brain injury among persons with substance use disorders	BRAIN INJURY			English	Article						Craniocerebral trauma; substance-related disorder; speed of information processing	SICKNESS IMPACT PROFILE; YOUNG-ADULTS; SOCIALIZATION SCALE; ABUSE; RELIABILITY; CHILDREN; VALIDITY; TBI; IDENTIFICATION; PREVALENCE	Objective: Determine (a) if there are sub-groups of individuals with substance use disorders distinguished by their pattern of sustaining traumatic brain injury (TBI) over the lifetime and (b) whether sub-group membership affects current functioning. Design: Secondary analysis. Settings: Outpatient substance abuse treatment programme and state prison. Participants: Two hundred and fifty-seven participants with lifetime histories of both TBI and substance used disorder drawn from two previous studies of (a) persons in substance abuse treatment and (b) prison inmates. Main outcome measures: Ohio State University TBI Identification Method, speed of information processing, working memory, disinhibition, cognitive complaints, sociopathy and substance use disorder severity. Results: Seven clusters of lifetime history of TBI were characterized by the severity of injuries, age at occurrence and presence of a period of time when multiple mild injuries were incurred, often receiving no medical attention. Cluster membership contributed to the prediction of cognitive performance (i.e. processing speed), self-reported cognitive problems and alcohol and other drug severity. Conclusions: In addition to injury severity, age at injury and periods of repeated injury may be distinguishing aspects of a lifetime history of TBI for persons with substance use disorders. Results suggest that clinicians would benefit from knowledge of a person's full history of TBI.	[Corrigan, John D.; Bogner, Jennifer] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Holloman, Christopher] Ohio State Univ, Stat Consulting Serv, Columbus, OH 43210 USA		Corrigan, JD (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, 480 Med Ctr Dr, Columbus, OH 43210 USA.	corrigan.1@osu.edu	Bogner, Jennifer/E-2773-2011; Corrigan, John D./E-2921-2011		National Institute on Disability and Rehabilitation Research [H133A970032]; Ohio Department of Alcohol and Drug Addiction Services [99-08315-00-DISC-T-0263]; National Center for Injury Prevention and Control at the Centers for Disease Control and Prevention [U49/CE000359-01]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U49CE000359] Funding Source: NIH RePORTER	Collection of data reported in this study was supported in part by grants from the National Institute on Disability and Rehabilitation Research to the Ohio Regional TBI Model System at the Ohio State University (H133A970032); the Ohio Department of Alcohol and Drug Addiction Services grant 99-08315-00-DISC-T-0263 and the National Center for Injury Prevention and Control at the Centers for Disease Control and Prevention grant U49/CE000359-01. The contents do not necessarily represent the policy of the Department of Education, the Centers for Disease Control and Prevention nor the Ohio Department of Alcohol and Drug Addiction Services, and the reader should not assume endorsement	Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bjork JM, 2009, J NEUROTRAUM, V26, P1077, DOI [10.1089/neu.2008.0849, 10.1089/neu.2008-0849]; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Chapman S.B., 2006, BRAIN INJ PROF, V3, P10; Chapman SB, 2001, J HEAD TRAUMA REHAB, V16, P441, DOI 10.1097/00001199-200110000-00004; CORRIGAN JD, 1995, BRAIN INJURY, V9, P221, DOI 10.3109/02699059509008195; Corrigan JD, 2005, PSYCHOL ADDICT BEHAV, V19, P131, DOI 10.1037/0893-164X.19.2.131; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2008, BRAIN INJURY, V22, P223, DOI 10.1080/02699050801938967; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Corrigan JD, 2007, BRAIN INJURY, V21, P343, DOI 10.1080/02699050701253103; DEFRANCESCO JJ, 1993, J PSYCHOPATHOL BEHAV, V15, P53, DOI 10.1007/BF00964323; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Felde AB, 2006, BRAIN INJURY, V20, P41, DOI 10.1080/02699050500309718; Gough H. G., 1957, MANUAL CALIFORNIA PS; GOUGH HG, 1992, J CLIN PSYCHOL, V48, P298, DOI 10.1002/1097-4679(199205)48:3<298::AID-JCLP2270480306>3.0.CO;2-X; GOUGH HG, 1994, PSYCHOL REP, V75, P651, DOI 10.2466/pr0.1994.75.1.651; Gough HG, 1987, MANUAL CALIFORNIA PS; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; Graham DP, 2008, ANN NY ACAD SCI, V1141, P148, DOI 10.1196/annals.1441.029; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; JURKOVICH G, 1995, J TRAUMA, V39, P625, DOI 10.1097/00005373-199510000-00001; Kadden RM, 1996, PSYCHOL ADDICT BEHAV, V10, P131, DOI 10.1037/0893-164X.10.3.131; Malloy P.F., 2001, FRONTAL SYSTEMS BEHA; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McKinlay A, 2010, INJURY PREV, V16, P31, DOI 10.1136/ip.2009.022483; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005; Megargee EI, 1972, CALIFORNIA PSYCHOL I; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; *PSYCH CORP, 1997, WAIS 3 WMS 3 TECHN M; R Development Core Team, 2008, R LANG ENV STAT COMP; Sacks AL, 2009, J DUAL DIAGN, V5, P404, DOI 10.1080/15504260903182755; Savola O, 2005, ALCOHOL ALCOHOLISM, V40, P269, DOI 10.1093/alcalc/agh159; Schofield P, 2011, BRAIN INJURY, V25, P74, DOI 10.3109/02699052.2010.531690; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Stout JC, 2003, ASSESSMENT, V10, P79, DOI 10.1177/1073191102250339; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Walker R, 2007, J HEAD TRAUMA REHAB, V22, P360, DOI 10.1097/01.HTR.0000300231.90619.50; Warner M, 2005, INJURY PREV, V11, P282, DOI 10.1136/ip.2004.006965; Warner M., 2000, VITAL HLTH STAT, V10, P1; Whiteneck G, 2001, COLORADO TRAUMATIC B; Winqvist S, 2006, J ADOLESC HLTH, V39, p275e1, DOI DOI 10.1016/J.JADOHEALTH.2005.12.019; Winqvist S, 2008, BRAIN INJURY, V22, P780, DOI 10.1080/02699050802339397; Winqvist S, 2007, NEUROEPIDEMIOLOGY, V29, P136, DOI 10.1159/000110741; Winqvist S, 2007, BRAIN INJURY, V21, P1079, DOI 10.1080/02699050701553221	51	57	57	0	24	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2012	26	2					139	150		10.3109/02699052.2011.648705			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	897NP	WOS:000300658200003	22360520				2022-02-06	
J	Toblin, RL; Riviere, LA; Thomas, JL; Adler, AB; Kok, BC; Hoge, CW				Toblin, Robin L.; Riviere, Lyndon A.; Thomas, Jeffrey L.; Adler, Amy B.; Kok, Brian C.; Hoge, Charles W.			Grief and physical health outcomes in US soldiers returning from combat	JOURNAL OF AFFECTIVE DISORDERS			English	Article						Military; Grief; Epidemiology; Somatic symptoms; Occupational functioning	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; SELF-REPORTED SYMPTOMS; COMPLICATED GRIEF; GULF-WAR; IRAQ WAR; DEPRESSION; COMORBIDITY; PREVALENCE; PERSONNEL	Background: Few studies have measured the burden of physical health problems after Iraq/Afghanistan deployment, except in association with post-traumatic stress disorder (PTSD) or mild traumatic brain injury (mTBI). Grief, a correlate of health problems in the general population, has not been systematically examined. We aimed to identify the prevalence of post-deployment physical health problems and their association with difficulty coping with grief. Methods: Infantry soldiers (n=1522) completed anonymous surveys using validated instruments six months following deployment in November-December 2008. Multiple logistic regression was used to assess the association of difficulty coping with grief and physical health. Results: The most frequent physical health symptoms reported were: sleep problems (32.8%), musculoskeletal pain (32.7%), fatigue (32.3%), and back pain (28.1%). Difficulty coping with grief over the death of someone close affected 21.3%. There was a dose-response relationship between level of difficulty coping with grief and principal physical health outcomes (ps<.002). Controlling for demographics, combat experiences, injuries, PTSD, depression, and other factors, grief significantly and uniquely contributed to a high somatic symptom score (adjusted odds ratio (AOR)=3.6), poor general health (AOR=2.0), missed work (AOR=1.7), medical utilization (AOR=1.5), difficulty carrying a heavy load (AOR=1.7), and difficulty performing physical training (AOR=1.6; all 95% confidence intervals > 1). Limitations: Data are cross-sectional and grief was measured with one item. Conclusions: Over 20% of soldiers reported difficulty coping with grief. This difficulty was significantly associated with physical health outcomes and occupational impairment Clinicians should be aware of the unique role grief plays in post-deployment physical health when treating patients. Published by Elsevier B.V.	[Toblin, Robin L.; Riviere, Lyndon A.; Thomas, Jeffrey L.; Kok, Brian C.; Hoge, Charles W.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Mil Psychiat Branch, Silver Spring, MD 20910 USA; [Adler, Amy B.] US Army Med Res Unit Europe, D-69126 Heidelberg, Germany		Toblin, RL (corresponding author), Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Mil Psychiat Branch, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	robin.l.toblin@us.army.mil			U.S. Army Medical Research and Materiel Command (MRMC)U.S. Army Medical Research & Materiel Command (USAMRMC)	We accomplished this work entirely using internal funding supplied by the U.S. Army Medical Research and Materiel Command (MRMC). MRMC's Research Area Directorate III: Interventions to Enhance Psychological Resilience and Prevent Psychiatric Casualties is the funding mechanism. MRMC did not have any role in writing the manuscript or the decision to submit it for publication and did not pay us to write the article.	Adler AB, 2008, MIL MED, V173, P10, DOI 10.7205/MILMED.173.1.10; Bartone P. T., 1990, J TRAUMA STRESS, V3, P523; Boelen PA, 2010, J AFFECT DISORDERS, V125, P374, DOI 10.1016/j.jad.2010.01.076; Bonanno GA, 2007, J ABNORM PSYCHOL, V116, P342, DOI 10.1037/0021-843X.116.2.342; Brown R L, 2001, J Am Board Fam Pract, V14, P95; Cabrera OA, 2007, AM J PREV MED, V33, P77, DOI 10.1016/j.amepre.2007.03.019; Committee on Gulf War and Health Institute of Medicine, 2010, GULF WAR HLTH, V8; Engel CC, 1999, J OCCUP ENVIRON MED, V41, P384, DOI 10.1097/00043764-199905000-00006; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Gray GC, 2002, AM J EPIDEMIOL, V155, P1033, DOI 10.1093/aje/155.11.1033; Hardison Heather Gaines, 2005, Behav Sleep Med, V3, P99, DOI 10.1207/s15402010bsm0302_4; Hoge C., 2010, ONCE WARRIOR ALWAYS; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hotopf M, 2006, LANCET, V367, P1731, DOI 10.1016/S0140-6736(06)68662-5; Hyams KC, 1996, ANN INTERN MED, V125, P398, DOI 10.7326/0003-4819-125-5-199609010-00007; Jones E, 2002, BMJ-BRIT MED J, V324, P321, DOI 10.1136/bmj.324.7333.321; Kroenke K, 2002, PSYCHOSOM MED, V64, P258, DOI 10.1097/00006842-200203000-00008; Maciejewski PK, 2007, JAMA-J AM MED ASSOC, V297, P716, DOI 10.1001/jama.297.7.716; Mancini AD, 2011, RESILIENCE MENTAL HL, P189; Neria Y, 2007, J TRAUMA STRESS, V20, P251, DOI 10.1002/jts.20223; Papa A, 2008, PSYCHIAT ANN, V38, P686, DOI 10.3928/00485713-20081001-07; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Proctor SP, 1998, INT J EPIDEMIOL, V27, P1000, DOI 10.1093/ije/27.6.1000; Santiago PN, 2010, PSYCHIAT SERV, V61, P575, DOI 10.1176/ps.2010.61.6.575; Stroebe M, 2007, LANCET, V370, P1960, DOI 10.1016/S0140-6736(07)61816-9; Sung SC, 2011, J AFFECT DISORDERS, V134, P453, DOI 10.1016/j.jad.2011.05.017; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; U.S. Department of Defense, 2011, CAS STAT REP SIT; Wittouck C, 2011, CLIN PSYCHOL REV, V31, P69, DOI 10.1016/j.cpr.2010.09.005	32	57	58	0	26	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0327	1573-2517		J AFFECT DISORDERS	J. Affect. Disord.	FEB	2012	136	3					469	475		10.1016/j.jad.2011.10.048			7	Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	915AT	WOS:000301996000035	22154707				2022-02-06	
J	Guo, QX; Li, HM; Gaddam, SSK; Justice, NJ; Robertson, CS; Zheng, H				Guo, Qinxi; Li, Hongmei; Gaddam, Samson S. K.; Justice, Nicholas J.; Robertson, Claudia S.; Zheng, Hui			Amyloid Precursor Protein Revisited NEURON-SPECIFIC EXPRESSION AND HIGHLY STABLE NATURE OF SOLUBLE DERIVATIVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; MESSENGER-RNAS; DYSTROPHIC NEURITES; HIPPOCAMPAL-NEURONS; REACTIVE ASTROCYTES; ASTROGLIAL CELLS; SENILE PLAQUES; GLIAL-CELLS; IN-VIVO	APP processing and amyloid-beta production play a central role in Alzheimer disease pathogenesis. APP has been considered a ubiquitously expressed protein. In addition to amyloid-beta, alpha- or beta-secretase-dependent cleavage of APP also generates soluble secreted APP (APPs alpha or APPs beta, respectively). Interestingly, APPs beta has been shown to be subject to further cleavage to create an N-APP fragment that binds to the DR6 death receptor and mediates axon pruning and degeneration under trophic factor withdrawal conditions. By performing APP immunocytochemical staining, we found that, unexpectedly, many antibodies yielded nonspecific staining in APP-null samples. Screening of a series of antibodies allowed us to identify a rabbit monoclonal antibody Y188 that is highly specific for APP and prompted us to re-examine the expression, localization, and stability of endogenous APP and APPs beta in wild-type and in APPs beta knock-in mice, respectively. In contrast to earlier studies, we found that APP is specifically expressed in neurons and that its expression cannot be detected in major types of glial cells under basal or neuroinflammatory conditions. Both APPs alpha and APPs beta are highly stable in the central nervous system (CNS) and do not undergo further cleavage with or without trophic factor support. Our results clarify several key questions with regard to the fundamental properties of APP and offer critical cellular insights into the pathophysiology of APP.	[Guo, Qinxi; Li, Hongmei; Justice, Nicholas J.; Zheng, Hui] Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA; [Guo, Qinxi] Baylor Coll Med, Interdept Program Translat Biol & Mol Med, Houston, TX 77030 USA; [Gaddam, Samson S. K.; Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA		Zheng, H (corresponding author), Baylor Coll Med, Huffington Ctr Aging, BCM230,1 Baylor Plaza, Houston, TX 77030 USA.	huiz@bcm.edu	Li, Hongmei/L-2595-2013	Li, Hongmei/0000-0002-4952-1734; Guo, Qinxi/0000-0003-4320-6757	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 NS38660, R01 AG032051, AG033467, NS076117]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660, R01NS076117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG032051, R01AG033467, R01AG020670] Funding Source: NIH RePORTER	This work was supported, in whole or in part, by National Institutes of Health Grants P01 NS38660 (to C. S. R.) and R01 AG032051, AG033467, and NS076117 (to H. Z.).	Bai Y, 2008, MOL CELL PROTEOMICS, V7, P15, DOI 10.1074/mcp.M700077-MCP200; BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; BERKENBOSCH F, 1990, J NEUROSCI RES, V25, P431, DOI 10.1002/jnr.490250321; Bitner BR, 2010, J CEREBR BLOOD F MET, V30, P1105, DOI 10.1038/jcbfm.2010.47; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; Chauvet N, 1997, J COMP NEUROL, V377, P550; Clarner T, 2011, J MOL NEUROSCI, V43, P268, DOI 10.1007/s12031-010-9419-9; CRAS P, 1991, P NATL ACAD SCI USA, V88, P7552, DOI 10.1073/pnas.88.17.7552; CUMMINGS BJ, 1992, NEUROSCIENCE, V48, P763, DOI 10.1016/0306-4522(92)90265-4; deSilva HAR, 1997, MOL BRAIN RES, V47, P147; FORLONI G, 1992, MOL BRAIN RES, V16, P128, DOI 10.1016/0169-328X(92)90202-M; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; Hoshino T, 2007, BIOCHEM J, V402, P581, DOI 10.1042/BJ20061318; Hsu WC, 2008, J NEURAL TRANSM, V115, P1537, DOI 10.1007/s00702-008-0117-5; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; Kaden D, 2009, J CELL SCI, V122, P368, DOI 10.1242/jcs.034058; Kohler C, 2005, NEUROBIOL DIS, V20, P528, DOI 10.1016/j.nbd.2005.04.009; LeBlanc AC, 1997, J NEUROCHEM, V68, P1183; Li HM, 2010, P NATL ACAD SCI USA, V107, P17362, DOI 10.1073/pnas.1012568107; Li HM, 2010, J BIOL CHEM, V285, P30598, DOI 10.1074/jbc.M110.137729; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Martins RN, 2001, NEUROSCIENCE, V106, P557, DOI 10.1016/S0306-4522(01)00289-5; Matsui T, 2007, BRAIN RES, V1161, P116, DOI 10.1016/j.brainres.2007.05.050; Moreno-Flores MT, 1998, J NEUROSCI RES, V52, P661, DOI 10.1002/(SICI)1097-4547(19980615)52:6<661::AID-JNR5>3.0.CO;2-6; Ni M, 2011, BIOCHEM J, V434, P181, DOI 10.1042/BJ20101569; Nihashi T, 2001, ACTA NEUROCHIR, V143, P287, DOI 10.1007/s007010170109; Nikolaev A, 2009, NATURE, V457, P981, DOI 10.1038/nature07767; Norstrom EM, 2010, J NEUROSCI, V30, P15677, DOI 10.1523/JNEUROSCI.4464-10.2010; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; PALACIOS G, 1995, EUR J NEUROSCI, V7, P501, DOI 10.1111/j.1460-9568.1995.tb00346.x; PALACIOS G, 1992, MOL BRAIN RES, V15, P195, DOI 10.1016/0169-328X(92)90109-O; Palmert M R, 1989, Prog Clin Biol Res, V317, P971; PALMERT MR, 1988, BIOCHEM BIOPH RES CO, V156, P432, DOI 10.1016/S0006-291X(88)80859-3; Pierce JES, 1996, J NEUROSCI, V16, P1083; Shim DJ, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-42; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SHOJI M, 1990, BRAIN RES, V512, P164, DOI 10.1016/0006-8993(90)91187-L; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SOLA C, 1993, MOL BRAIN RES, V17, P41, DOI 10.1016/0169-328X(93)90071-V; Szczygielski J, 2005, J NEURAL TRANSM, V112, P1547, DOI 10.1007/s00702-005-0326-0; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tran MD, 2011, NEUROSCI LETT, V492, P155, DOI 10.1016/j.neulet.2011.01.078; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Yang YN, 1998, J BIOL CHEM, V273, P25552, DOI 10.1074/jbc.273.40.25552; Yasuoka K, 2004, J ANAT, V205, P135, DOI 10.1111/j.0021-8782.2004.00320.x; Young MJ, 1999, BRAIN RES BULL, V50, P27, DOI 10.1016/S0361-9230(99)00084-2; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X; Zheng H, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-27; Zink BJ, 2010, PSYCHIAT CLIN N AM, V33, P741, DOI 10.1016/j.psc.2010.08.005	49	57	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2012	287	4					2437	2445		10.1074/jbc.M111.315051			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	892NG	WOS:000300292300018	22144675	hybrid, Green Published			2022-02-06	
J	Kurtz, P; Fitts, V; Sumer, Z; Jalon, H; Cooke, J; Kvetan, V; Mayer, SA				Kurtz, Pedro; Fitts, Vincent; Sumer, Zeynep; Jalon, Hillary; Cooke, Joseph; Kvetan, Vladimir; Mayer, Stephan A.			How Does Care Differ for Neurological Patients Admitted to a Neurocritical Care Unit Versus a General ICU?	NEUROCRITICAL CARE			English	Article						Neurocritical care; Outcomes research	ILL PATIENTS; IMPACT; MORTALITY; OUTCOMES; NEUROINTENSIVIST; TRACHEOSTOMY; PROTOCOL	Neurological patients have lower mortality and better outcomes when cared for in specialized neurointensive care units than in general ICUs. However, little is known about how the process of care differs between these types of units. The Greater New York Hospital Association conducted a city-wide 24-h ICU prevalence survey on March 15th, 2007. Data was collected on all patients admitted to 143 ICUs in 69 different hospitals. Of 1,906 ICU patients surveyed, 231 had a primary neurological diagnosis. Of these, 52 (22%) were admitted to one of 9 neuro-ICU's in NY and 179 (78%) to a medical or surgical ICU. Neurological patients in neuro-ICUs were more likely to have been transferred from an outside hospital (37% vs. 11%, P < 0.0001). Hemorrhagic stroke was more frequent in neuro-ICUs (46% vs. 16%, P < 0.0001), whereas traumatic brain injury (2% vs. 24%, P < 0.0001) and ischemic stroke (0% vs. 19%, P = 0.001) were less common. Despite a lower rate of mechanical ventilation (39% vs. 50%, P = 0.15), ICU length of stay was longer in neuro-ICU patients (a parts per thousand yen10 days, 40% vs. 17%, P < 0.0001). More neuro-ICU patients had undergone tracheostomy (35% vs. 15%, P = 0.04), invasive hemodynamic monitoring (40% vs. 20%, P = 0.002), and invasive intracranial pressure monitoring (29% vs. 9%, P < 0.001) than patients cared for in general ICUs. Intravenous sedation was less prevalent in neuro-ICUs (12% vs. 30%, P = 0.009) and more patients were receiving nutritional support compared to general ICUs (67% vs. 39%, P < 0.001). Neurological patients cared for in specialty neuro-ICUs underwent more invasive intracranial and hemodynamic monitoring, tracheostomy, and nutritional support, and received less IV sedation than patients in general ICUs. These differences in care may explain previously observed disparities in outcome between neurocritical care and general ICUs.	[Mayer, Stephan A.] Neurol Inst, Div Neurocrit Care, New York, NY 10032 USA; [Kurtz, Pedro; Mayer, Stephan A.] Columbia Univ, Dept Neurol, New York, NY USA; [Kurtz, Pedro; Mayer, Stephan A.] Columbia Univ, Dept Neurosurg, New York, NY USA; [Fitts, Vincent; Sumer, Zeynep; Jalon, Hillary] GNYHA, New York, NY USA; [Cooke, Joseph] Weill Cornell Med Ctr, Dept Med, New York, NY USA; [Kvetan, Vladimir] Montefiore Med Ctr, Div Crit Care Med, Bronx, NY USA; [Fitts, Vincent; Sumer, Zeynep; Jalon, Hillary] UHF, New York, NY USA		Mayer, SA (corresponding author), Neurol Inst, Div Neurocrit Care, Milstein Hosp Bldg,Suite 8-300 Ctr,177 Ft Washing, New York, NY 10032 USA.	sam14@columbia.edu			Greater New York Hospital Association/United Hospital	The authors wish to thank the many physicians and nurses who participated in the Greater New York Hospital Association/United Hospital Fund ICU Survey. GNYHA, a trade association representing 150 hospitals throughout New York State, New Jersey, Connecticut, Pennsylvania, and Rhode Island, and UHF, a private not-for-profit health services research and philanthropic organization, formed a partnership in 2005 to support hospitals' quality improvement efforts. This survey was part of the initiatives they partner on in the area of critical care.	Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Bouderka MA, 2004, J TRAUMA, V57, P251, DOI 10.1097/01.TA.0000087646.68382.9A; Clarke J, 2005, LANCET, V365, P764, DOI 10.1016/S0140-6736(05)17983-5; Clayton TJ, 2004, BRIT J ANAESTH, V93, P761, DOI 10.1093/bja/aeh249; Diringer MN, 2001, CRIT CARE MED, V29, P635, DOI 10.1097/00003246-200103000-00031; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hemphill JC, 2004, STROKE, V35, P1130, DOI 10.1161/01.STR.0000125858.71051.ca; Koh WY, 1997, ANAESTH INTENS CARE, V25, P365, DOI 10.1177/0310057X9702500407; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Mirski MA, 2001, J NEUROSURG ANESTH, V13, P83, DOI 10.1097/00008506-200104000-00004; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Rincon F, 2007, CURR OPIN CRIT CARE, V13, P115, DOI 10.1097/MCC.0b013e32808255c6; Suarez JI, 2004, CRIT CARE MED, V32, P2311, DOI 10.1097/01.CCM.0000146132.29042.4c; Varelas PN, 2006, J NEUROSURG, V104, P713, DOI 10.3171/jns.2006.104.5.713; Varelas PN, 2004, CRIT CARE MED, V32, P2191, DOI 10.1097/01.CCM.0000146131.03578.21	17	57	60	2	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2011	15	3					477	480		10.1007/s12028-011-9539-2			4	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	852NT	WOS:000297365400018	21519958				2022-02-06	
J	de Lanerolle, NC; Bandak, F; Kang, DW; Li, AY; Swauger, P; Parks, S; Ling, G; Kim, JH				de Lanerolle, Nihal C.; Bandak, Faris; Kang, Dewey; Li, Alexander Y.; Swauger, Peter; Parks, Steven; Ling, Geoffrey; Kim, Jung H.			Characteristics of an Explosive Blast-Induced Brain Injury in an Experimental Model	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Astrogliosis; Axonal injury; Blast injury; Blast pressure; Mild traumatic brain injury; Neurotrauma	DIFFUSE AXONAL INJURY; HEAD-INJURY; PRECURSOR; PROTEIN; DAMAGE	Mild traumatic brain injury resulting from exposure to an explosive blast is associated with significant neurobehavioral outcomes in soldiers. Little is known about the neuropathologic consequences of such an insult to the human brain. This study is an attempt to understand the effects of an explosive blast in a large animal gyrencephalic brain blast injury model. Anesthetized Yorkshire swine were exposed to measured explosive blast levels in 3 operationally relevant scenarios: simulated free field (blast tube), high-mobility multipurpose wheeled vehicle surrogate, and building (4-walled structure). Histologic changes in exposed animals up to 2 weeks after blast were compared to a group of naive and sham controls. The overall pathologic changes in all 3 blast scenarios were limited, with very little neuronal injury, fiber tract demyelination, or intracranial hemorrhage observed. However, there were 2 distinct neuropathologic changes observed: increased astrocyte activation and proliferation and periventricular axonal injury detected with beta-amyloid precursor protein immunohistochemistry. We postulate that the increased astrogliosis observed may have a longer-term potential for the exacerbation of brain injury and that the pattern of periventricular axonal injury may be related to a potential for cognitive and mood disorders.	[de Lanerolle, Nihal C.; Kang, Dewey; Li, Alexander Y.] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06520 USA; [Kim, Jung H.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; [Bandak, Faris; Ling, Geoffrey] Uniformed Serv Univ Hlth Sci, Dept Neurol, F Edward Hebert Sch Med, Bethesda, MD 20814 USA; FD Neurotechnol Inc, Baltimore, MD USA; [Swauger, Peter; Parks, Steven] ORA Inc, Fredericksburg, VA USA; [Bandak, Faris] Integrated Serv Grp Inc, Potomac, MD USA		de Lanerolle, NC (corresponding author), Yale Univ, Sch Med, Dept Neurosurg, FMB 414,333 Cedar St, New Haven, CT 06520 USA.	nihal.delanerolle@yale.edu			Defense Advanced Research Projects AgencyUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA)	This study was supported by funds from the Defense Advanced Research Projects Agency.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALTSHULER LL, 1995, AM J PSYCHIAT, V152, P1139; BANDAK FA, 1996, TRAUMATIC BRAIN INJU; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; de Lanerolle NC, 2010, NEUROTHERAPEUTICS, V7, P424, DOI 10.1016/j.nurt.2010.08.002; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Ferri A, 2004, FASEB J, V18, P1261, DOI 10.1096/fj.03-1199fje; Friedman A, 2009, EPILEPSY RES, V85, P142, DOI 10.1016/j.eplepsyres.2009.03.005; GANNARELLI TA, 1997, NEUROPATHOL APPL NEU, V22, P509; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; HERRMANN LL, 2010, J NEUROL NEUROSUR PS, V79, P619; KAWARABAYASHI T, 1991, BRAIN RES, V552, P1, DOI 10.1016/0006-8993(91)90651-B; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lycke JN, 1998, J NEUROL NEUROSUR PS, V64, P402, DOI 10.1136/jnnp.64.3.402; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; STEFANINI M, 1967, NATURE, V216, P173, DOI 10.1038/216173a0; Warden DL, 2005, NEW ENGL J MED, V353, P633; Zhang D, 2010, MOL NEUROBIOL, V41, P232, DOI 10.1007/s12035-010-8098-4; Zhu Z, 2007, GLIA, V55, P546, DOI 10.1002/glia.20476	28	57	57	1	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	NOV	2011	70	11					1046	1057		10.1097/NEN.0b013e318235bef2			12	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	842DB	WOS:000296567800009	22002430	Bronze			2022-02-06	
J	Pleasant, JM; Carlson, SW; Mao, HJ; Scheff, SW; Yang, KH; Saatman, KE				Pleasant, Jennifer M.; Carlson, Shaun W.; Mao, Haojie; Scheff, Stephen W.; Yang, King H.; Saatman, Kathryn E.			Rate of Neurodegeneration in the Mouse Controlled Cortical Impact Model Is Influenced by Impactor Tip Shape: Implications for Mechanistic and Therapeutic Studies	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; behavior; contusion; finite element modeling; neuronal death; traumatic brain injury	TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; HEAD-INJURY; AXONAL INJURY; COGNITIVE DEFICITS; DEPENDENT CHANGES; CLINICAL-TRIALS; FLUORO-JADE; MICE; CLASSIFICATION	Controlled cortical impact (CCI), one of the most common models of traumatic brain injury, is being increasingly used with mice for exploration of cell injury mechanisms and pre-clinical evaluation of therapeutic strategies. Although CCI brain injury was originally effected using an impactor with a rounded tip, the majority of studies with mouse CCI use a flat or beveled tip. Recent finite element modeling analyses demonstrate that tip geometry is a significant determinant of predicted cortical tissue strains in rat CCI, and that cell death is proportional to predicted tissue strains. In the current study, a three-dimensional finite element model of a C57BL/6J mouse brain predicted higher maximum principal strains during a simulated 1.0-mm, 3.5-m/s CCI injury with a flat tip when compared to a rounded tip. Consistent with this prediction, experimental CCI with a flat-tip impactor resulted in greater acute cortical hemorrhage and neuron loss in adult male C57BL/6J mice. The amount of neocortical tissue damage was equivalent for the two tip geometries at 9 days following injury, but the rate of neocortical neurodegeneration was markedly slower following CCI with a rounded-tip impactor, with damage reaching a plateau after 24 h as opposed to after 4 h for the flat tip. The flat-tip impactor was associated in general with more regional hippocampal neurodegeneration, especially at early time points such as 4 h. Impactor tip geometry did not have a notable effect on blood-brain barrier breakdown, traumatic axonal injury, or motor and cognitive dysfunction. Execution of CCI injury with a rounded-tip impactor is posited to provide a substantially enhanced temporal window for the study of cellular injury mechanisms and therapeutic intervention while maintaining critical aspects of the pathophysiological response to contusion brain injury.	[Pleasant, Jennifer M.; Carlson, Shaun W.; Saatman, Kathryn E.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Coll Med, Lexington, KY 40536 USA; [Pleasant, Jennifer M.; Carlson, Shaun W.; Saatman, Kathryn E.] Univ Kentucky, Dept Physiol, Coll Med, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Coll Med, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Dept Anat & Neurobiol, Coll Med, Lexington, KY 40536 USA; [Mao, Haojie; Yang, King H.] Wayne State Univ, Ctr Bioengn, Detroit, MI USA		Saatman, KE (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Coll Med, B473 Biomed & Biol Sci Res Bldg BBSRB,741 S Limes, Lexington, KY 40536 USA.	k.saatman@uky.edu	Mao, Haojie/Q-7514-2018	Mao, Haojie/0000-0002-7563-9234; Carlson, Shaun/0000-0002-1413-5075	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 NS058484, P30 NS051220]; KSCHIRT [6-12, 7-20, 8-15A]; Injury Control Research Center at University of Alabama at Birmingham	This work was funded by NIH P01 NS058484, P30 NS051220 and KSCHIRT 6-12 and 7-20 (K. E. S.), KSCHIRT 8-15A (S. W. S.), and by the Injury Control Research Center at University of Alabama at Birmingham (K.Y.).	Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Elkin BS, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000164; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; Jin Xin, 2006, Stapp Car Crash J, V50, P637; Kilinc D, 2009, EXP NEUROL, V219, P553, DOI 10.1016/j.expneurol.2009.07.014; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Ma Y, 2005, NEUROSCIENCE, V135, P1203, DOI 10.1016/j.neuroscience.2005.07.014; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Mao HJ, 2010, BIOMECH MODEL MECHAN, V9, P763, DOI 10.1007/s10237-010-0212-z; Mao HJ, 2010, J NEUROTRAUM, V27, P877, DOI 10.1089/neu.2008.0616; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Monson KL, 2003, J BIOMECH ENG-T ASME, V125, P288, DOI 10.1115/1.1554412; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Paxinos GFK., 2001, MOUSE BRAIN STEREOTA, V2nd ed.; Prins ML, 2001, J NEUROTRAUM, V18, P31, DOI 10.1089/089771501750055758; Royo NC, 2006, EUR J NEUROSCI, V23, P1089, DOI 10.1111/j.1460-9568.2006.04642.x; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SAATMAN KE, 2009, HDB NEUROCHEMISTRY M, V15, P343; Sandhir R, 2010, NEUROCHEM INT, V56, P188, DOI 10.1016/j.neuint.2009.10.002; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067	65	57	59	0	1	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2011	28	11			SI		2245	2262		10.1089/neu.2010.1499			18	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	849VY	WOS:000297154600005	21341976	Green Published			2022-02-06	
J	Larson, MJ; Forrer, TJ; Clayson, PE				Larson, Michael J.; Forrer, Thomas J.; Clayson, Peter E.			Cognitive control in mild traumatic brain injury: Conflict monitoring and conflict adaptation	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						N450; Conflict SP; Concussion; Mild TBI; Event-related potential; Sequential trial	ANTERIOR CINGULATE CORTEX; POST-CONCUSSION SYMPTOMS; ERROR-RELATED NEGATIVITY; EVENT-RELATED POTENTIALS; STROOP TASK; DIFFUSION-TENSOR; HEAD-INJURY; PERSISTENT SYMPTOMS; SEVERE TBI; DYSFUNCTION	Recent studies suggest that individuals who have experienced a concussion or mild traumatic brain injury (TBI) show deficits in cognitive control. We tested the hypothesis that behavioral (response time [RT] and error rate) and electrophysiological (N450 and conflict SP components of the event-related potential [ERP]) reflections of conflict monitoring and conflict adaptation would be attenuated in 29 individuals with mild TBI compared to 36 control participants. Groups did not differ in age, sex, years of education, or neuropsychological test performance. Conflict monitoring and conflict adaptation can be seen when behavioral and ERP indices are reduced following high-conflict trials relative to low-conflict trials. Participants completed a Stroop task with 50% congruent and 50% incongruent trials. Behaviorally, both groups showed statistically significant conflict adaptation effects for RTs and error rates; these effects did not differ as a function of group. For ERPs, both groups showed more negative N450 and more positive conflict SP amplitudes on incongruent trials relative to congruent trials. Groups significantly differed in level of conflict adaptation for the conflict SP; controls showed significant conflict adaptation, whereas individuals with mild TBI did not. ERP amplitudes did not correlate with indices of injury severity or time since injury. Findings replicate and extend previous work that suggests the conflict SP is sensitive to conflict adaptation in healthy individuals, but is decreased in individuals across the range of TB! severity. Findings also suggest that mild TBI is associated with intact conflict monitoring, but altered conflict adaptation and adjustment processes. (C) 2011 Elsevier B.V. All rights reserved.	[Larson, Michael J.; Forrer, Thomas J.; Clayson, Peter E.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Larson, Michael J.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA		Larson, MJ (corresponding author), Brigham Young Univ, Dept Psychol, 244 TLRB, Provo, UT 84602 USA.	michael_larson@byu.edu	Clayson, Peter E/F-5438-2011; Larson, Michael J/C-8543-2012; Clayson, Peter/AAC-9207-2019; Clayson, Peter/AAC-4028-2022	Clayson, Peter E/0000-0003-4437-6598; Larson, Michael J/0000-0002-8199-8065; Clayson, Peter/0000-0003-4437-6598; Farrer, Thomas J./0000-0001-8092-6214			Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benton A., 1976, MULTILINGUAL APHASIA; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Botvinick M, 1999, NATURE, V402, P179, DOI 10.1038/46035; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Carroll JFX., 2001, MENTAL HLTH SCREENIN; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carter CS, 2007, COGN AFFECT BEHAV NE, V7, P367, DOI 10.3758/CABN.7.4.367; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Dai Q, 2011, CLIN NEUROPHYSIOL, V122, P52, DOI 10.1016/j.clinph.2010.05.025; Danielmeier C, 2009, PSYCHOPHYSIOLOGY, V46, P1288, DOI 10.1111/j.1469-8986.2009.00860.x; di Pellegrino G, 2007, J COGNITIVE NEUROSCI, V19, P275, DOI 10.1162/jocn.2007.19.2.275; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Folstein JR, 2008, PSYCHOPHYSIOLOGY, V45, P152, DOI 10.1111/j.1469-8986.2007.00602.x; Forster SE, 2011, J COGNITIVE NEUROSCI, V23, P923, DOI 10.1162/jocn.2010.21458; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; GRATTON G, 1992, J EXP PSYCHOL GEN, V121, P480, DOI 10.1037/0096-3445.121.4.480; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Hanslmayr S, 2008, J COGNITIVE NEUROSCI, V20, P215, DOI 10.1162/jocn.2008.20020; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Holmes AJ, 2008, NEUROPSYCHOLOGIA, V46, P2904, DOI 10.1016/j.neuropsychologia.2008.05.028; Hommel B, 2004, PSYCHOL RES-PSYCH FO, V68, P1, DOI 10.1007/s00426-003-0132-y; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Keren O, 1998, J HEAD TRAUMA REHAB, V13, P15; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; Larson MJ, 2009, J INT NEUROPSYCH SOC, V15, P927, DOI 10.1017/S1355617709990701; Larson MJ, 2009, NEUROPSYCHOLOGIA, V47, P663, DOI 10.1016/j.neuropsychologia.2008.11.013; Liotti M, 2000, NEUROPSYCHOLOGIA, V38, P701, DOI 10.1016/S0028-3932(99)00106-2; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Mayr U, 2003, NAT NEUROSCI, V6, P450, DOI 10.1038/nn1051; Mayr U, 2009, PSYCHOL RES-PSYCH FO, V73, P794, DOI 10.1007/s00426-008-0191-1; Meyer MJ, 2010, BRAIN INJURY, V24, P706, DOI 10.3109/02699051003692126; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Moore DW, 2010, NEUROPSYCHOL REHABIL, V20, P340, DOI 10.1080/09602010903250928; Nieuwenhuis S, 2003, COGN AFFECT BEHAV NE, V3, P17, DOI 10.3758/CABN.3.1.17; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A., 1964, EXAMEN CLIN PSYCHOL; Ridderinkhof KR, 2002, SCIENCE, V298, P2209, DOI 10.1126/science.1076929; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sarno S, 2006, FUNCT NEUROL, V21, P21; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Sivak S, 2008, BRAIN INJURY, V22, P193, DOI 10.1080/02699050801895431; Slewa-Younan S, 2008, BRAIN INJURY, V22, P183, DOI 10.1080/02699050801888808; Speilberger CD., 1970, MANUAL STATE TRAIT A, DOI DOI 10.1017/S0033291701005141; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Swick D, 2002, P NATL ACAD SCI USA, V99, P16354, DOI 10.1073/pnas.252521499; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Ullsperger M, 2005, COGN AFFECT BEHAV NE, V5, P467, DOI 10.3758/CABN.5.4.467; Vanderhasselt MA, 2009, BIOL PSYCHOL, V81, P169, DOI 10.1016/j.biopsycho.2009.03.009; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; West R, 1999, COGNITIVE BRAIN RES, V8, P157, DOI 10.1016/S0926-6410(99)00017-8; West R, 2000, BRAIN RES, V873, P102, DOI 10.1016/S0006-8993(00)02530-0; West R, 2005, CORTEX, V41, P570, DOI 10.1016/S0010-9452(08)70197-7; West R, 2003, NEUROPSYCHOLOGIA, V41, P1122, DOI 10.1016/S0028-3932(02)00297-X; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Yeung N, 2006, PSYCHOL SCI, V17, P164, DOI 10.1111/j.1467-9280.2006.01680.x; Yeung N, 2004, PSYCHOL REV, V111, P931, DOI [10.1037/0033-295X.111.4.931, 10.1037/0033-295x.111.4.931]; Yeung N, 2007, COGN AFFECT BEHAV NE, V7, P347, DOI 10.3758/CABN.7.4.347	82	57	61	1	25	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	OCT	2011	82	1			SI		69	78		10.1016/j.ijpsycho.2011.02.018			10	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology; Physiology	859PZ	WOS:000297889600008	21392543				2022-02-06	
J	Snell, DL; Siegert, RJ; Hay-Smith, EJC; Surgenor, LJ				Snell, Deborah L.; Siegert, Richard J.; Hay-Smith, E. Jean C.; Surgenor, Lois J.			Associations between illness perceptions, coping styles and outcome after mild traumatic brain injury: Preliminary results from a cohort study	BRAIN INJURY			English	Article						Mild traumatic brain injury; MTBI; illness perceptions; outcome	POST-CONCUSSION SYMPTOMS; HEAD-INJURY; HEALTH PSYCHOLOGY; HOSPITAL ANXIETY; CLUSTER-ANALYSIS; NECK-CANCER; QUESTIONNAIRE; RECOVERY; DEPRESSION; PREDICTION	Purpose: The objective of this study was to examine associations between injury perceptions, coping, distress and outcome after mild traumatic brain injury (MTBI). Design: A prospective observational study with repeated measures. This study reports results from the first of two study visits. Participants: Participants (n = 147) were recruited within 3 months following presentation to a concussion clinic or an emergency department setting. Methods: Clinical and demographic information was collected and participants completed a range of questionnaires (Revised Illness Perceptions Questionnaire, Brief COPE, Rivermead Post-Concussion Symptoms Questionnaire, Rivermead Follow-Up Questionnaire and HADS). Associations between independent variables and outcome were examined using odds ratios and 95% confidence intervals. Results: Preliminary results suggested participants endorsing stronger beliefs about the injury identity (p < 0.05) and emotional impact (p < 0.01) had significantly greater odds of poor outcome at 3 months. There were also associations between higher educational attainment (p < 0.05), using active coping strategies (p < 0.06) and poor outcome. Conclusions: These variables appeared important determinants of outcome early after MTBI and may help identify those at risk for slow recovery. Current reassurance-based interventions may be improved by targeting such variables.	[Snell, Deborah L.] Burwood Hosp, Brain Injury Rehabil Serv, Canterbury Dist Hlth Board, Concuss Clin, Christchurch, New Zealand; [Snell, Deborah L.; Hay-Smith, E. Jean C.] Univ Otago, Rehabil Teaching & Res Unit, Wellington, New Zealand; [Siegert, Richard J.] Kings Coll London, Dept Palliat Care Policy & Rehabil, Sch Med Guys, London WC2R 2LS, England; [Siegert, Richard J.] St Thomas Hosp, London, England; [Surgenor, Lois J.] Univ Otago, Dept Psychol Med, Christchurch, New Zealand		Snell, DL (corresponding author), Burwood Hosp, Brain Injury Rehabil Serv, Canterbury Dist Hlth Board, Concuss Clin, Private Bag 4708, Christchurch, New Zealand.	deborah.snell@cdhb.govt.nz	Siegert, Richard J./K-2030-2019	Siegert, Richard/0000-0002-3074-0929	Neurological Foundation of New Zealand [0728-SPG]	This research has been supported by a Small Project Grant from the Neurological Foundation of New Zealand (Grant no: 0728-SPG).	American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Cicerone KD, 2004, J HEAD TRAUMA REHAB, V19, P494, DOI 10.1097/00001199-200411000-00006; Clatworthy J, 2005, BRIT J HEALTH PSYCH, V10, P329, DOI 10.1348/135910705X25697; Clatworthy J, 2007, PSYCHOL HEALTH, V22, P123, DOI 10.1080/14768320600774496; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Foster NE, 2008, PAIN, V136, P177, DOI 10.1016/j.pain.2007.12.007; French DP, 2006, J PSYCHOSOM RES, V61, P757, DOI 10.1016/j.jpsychores.2006.07.029; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Leventhal H, 2001, HANDBOOK OF HEALTH PSYCHOLOGY, P19; Leventhal H, 2008, ANNU REV PSYCHOL, V59, P477, DOI 10.1146/annurev.psych.59.103006.093643; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Llewellyn CD, 2008, J PSYCHOSOM RES, V65, P525, DOI 10.1016/j.jpsychores.2008.03.014; Llewellyn CD, 2007, J PSYCHOSOM RES, V63, P17, DOI 10.1016/j.jpsychores.2007.01.013; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Macleod AD, 2010, MED HYPOTHESES, V74, P1033, DOI 10.1016/j.mehy.2010.01.002; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V41, P611; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Moss-Morris R, 2002, PSYCHOL HEALTH, V17, P1, DOI 10.1080/08870440290001494; Mulhern S, 2006, J PSYCHOSOM RES, V61, P439, DOI 10.1016/j.jpsychores.2006.03.004; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; PETRIE K, 1995, J PSYCHOSOM RES, V39, P31, DOI 10.1016/0022-3999(94)00071-C; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Ptacek JT, 2008, ANXIETY STRESS COPIN, V21, P155, DOI 10.1080/10615800701466467; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Rose JM, 2005, BRAIN INJURY, V19, P29, DOI 10.1080/02699050310001617361; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; SNELL D, 2011, PREDICTING IN PRESS; SNELL D, 2011, J HEAD TRAUMA REHABI; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; SNELL DL, 2006, NZ MED J, V119, P1231; Stanton AL, 2007, ANNU REV PSYCHOL, V58, P565, DOI 10.1146/annurev.psych.58.110405.085615; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Taylor SE, 2007, ANNU REV CLIN PSYCHO, V3, P377, DOI 10.1146/annurev.clinpsy.3.022806.091520; TEASDALE G, 1974, LANCET, V2, P81; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Van Ittersum MW, 2009, PATIENT EDUC COUNS, V74, P53, DOI 10.1016/j.pec.2008.07.041; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organization, 1992, ICD 10 CLASSIFICATIO; World Health Organization, 2007, INT CLASS FUNCT DIS; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	64	57	57	1	18	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2011	25	11					1126	1138		10.3109/02699052.2011.607786			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	829WC	WOS:000295614900011	21870903				2022-02-06	
J	Itoh, T; Imano, M; Nishida, S; Tsubaki, M; Hashimoto, S; Ito, A; Satou, T				Itoh, Tatsuki; Imano, Motohiro; Nishida, Shozo; Tsubaki, Masahiro; Hashimoto, Shigeo; Ito, Akihiko; Satou, Takao			Exercise inhibits neuronal apoptosis and improves cerebral function following rat traumatic brain injury	JOURNAL OF NEURAL TRANSMISSION			English	Article						Cerebral dysfunction; Neuroprotection; Apoptotic cell death; Neuronal degeneration	CENTRAL-NERVOUS-SYSTEM; CELL-DEATH; GROWTH-FACTOR; ISCHEMIA; ACTIVATION; PROTECTS; MICE; NEUROPROTECTION; HIPPOCAMPUS; RECEPTOR	Exercise is reported to inhibit neuronal apoptotic cell death in the hippocampus and improve learning and memory. However, the effect of exercise on inhibition of neuronal apoptosis surrounding the area of damage after traumatic brain injury (TBI) and the improvement of cerebral dysfunction following TBI are unknown. Here, we investigate the effect of exercise on morphology and cerebral function following TBI in rats. Wistar rats received TBI by a pneumatic controlled injury device were randomly divided into two groups: (1) non-exercise group and (2) exercise group. The exercise group ran on a treadmill for 30 min/day at 22 m/min for seven consecutive days. Immunohistochemical and behavioral studies were performed following TBI. The number of single-stranded DNA (ssDNA)-positive cells around the damaged area early after TBI was significantly reduced in the exercise group compared with the non-exercise group (P < 0.05). Furthermore, most ssDNA-positive cells in the non-exercise group co-localized with neuronal cells. However, in the exercise group, a few ssDNA-positive cells co-localized with neurons. In addition, there was a significant increase in neuronal cell number and improvement in cerebral dysfunction after TBI in the exercise group compared with the non-exercise group (P < 0.05). These results indicate that exercise following TBI inhibits neuronal degeneration and apoptotic cell death around the damaged area, which results in improvement of cerebral dysfunction. In summary, treadmill running improved cerebral dysfunction following TBI, indicating its potential as an effective clinical therapy. Therefore, exercise therapy (rehabilitation) in the early phase following TBI is important for recuperation from cerebral dysfunction.	[Itoh, Tatsuki; Ito, Akihiko; Satou, Takao] Kinki Univ, Sch Med, Dept Pathol, Osaka 5898511, Japan; [Imano, Motohiro] Kinki Univ, Sch Med, Dept Surg, Osaka 5898511, Japan; [Nishida, Shozo; Tsubaki, Masahiro] Kinki Univ, Sch Pharmaceut Sci, Osaka 5898511, Japan; [Hashimoto, Shigeo] PL Hosp, Div Pathol, Osaka, Japan; [Satou, Takao] Kinki Univ Hosp, Sch Med, Div Hosp Pathol, Osaka, Japan; [Satou, Takao] Kinki Univ, Inst Life Sci, Div Sports Med, Osaka 5898511, Japan		Itoh, T (corresponding author), Kinki Univ, Sch Med, Dept Pathol, 377-2 Ohno Higashi, Osaka 5898511, Japan.	tatsuki@med.kindai.ac.jp		Itoh, Tatsuki/0000-0003-2015-7788	ZENRYOKEN;  [20500472];  [21500803]	This work was supported by Grant-in-Aid for Scientific Research (20500472 and 21500803) and ZENRYOKEN. The authors thank Mari Yachi for technical assistance.	Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Blackmore DG, 2009, STEM CELLS, V27, P2044, DOI 10.1002/stem.120; Cechetti F, 2008, BRAIN RES, V1188, P182, DOI 10.1016/j.brainres.2007.10.012; Chae CH, 2009, NEUROCHEM INT, V55, P208, DOI 10.1016/j.neuint.2009.02.024; CHAN PH, 1985, PROG BRAIN RES, V63, P227; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Dressler Jan, 2009, Leg Med (Tokyo), V11 Suppl 1, pS54, DOI 10.1016/j.legalmed.2009.02.024; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Hata R, 1999, METAB BRAIN DIS, V14, P117, DOI 10.1023/A:1020709814456; Hayes K, 2008, ACTA NEUROPATHOL, V115, P289, DOI 10.1007/s00401-008-0340-z; Hennigan A, 2007, BIOCHEM SOC T, V35, P424, DOI 10.1042/BST0350424; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsuan SL, 2006, J NEUROSCI, V26, P4481, DOI 10.1523/JNEUROSCI.4922-05.2006; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Itoh T, 2007, NEUROL RES, V29, P734, DOI 10.1179/016164107X208086; Itoh T, 2011, J NEURAL TRANSM, V118, P193, DOI 10.1007/s00702-010-0495-3; Itoh T, 2010, NEUROCHEM RES, V35, P348, DOI 10.1007/s11064-009-0061-2; Itoh T, 2009, MOL CELL BIOCHEM, V324, P191, DOI 10.1007/s11010-008-0013-1; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kim DH, 2004, J NEUROSURG, V100, P79, DOI 10.3171/jns.2004.100.1.0079; Lee EJ, 2005, J PINEAL RES, V38, P42, DOI 10.1111/j.1600-079X.2004.00173.x; Liebelt B, 2010, NEUROSCIENCE, V166, P1091, DOI 10.1016/j.neuroscience.2009.12.067; LLorens-Martin M, 2010, MOL CELL NEUROSCI, V44, P109, DOI 10.1016/j.mcn.2010.02.006; Lyden P, 2000, J Stroke Cerebrovasc Dis, V9, P9; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Nguyen TLX, 2010, EXP MOL MED, V42, P583, DOI 10.3858/emm.2010.42.8.060; Ou-Yang W, 2000, ACTA PHARMACOL SIN, V21, P296; Radak Z, 2001, NEUROCHEM INT, V38, P17, DOI 10.1016/S0197-0186(00)00063-2; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rizk NN, 2007, ENDOCRINE, V31, P66, DOI 10.1007/s12020-007-0012-0; Sahin S, 2010, J CLIN NEUROSCI, V17, P227, DOI 10.1016/j.jocn.2009.05.016; Shin DH, 2004, NEUROSCI LETT, V354, P64, DOI 10.1016/j.neulet.2003.09.070; Sim YJ, 2005, PHYSIOL BEHAV, V84, P733, DOI 10.1016/j.physbeh.2005.02.019; Sugawara T, 2002, J NEUROSCI, V22, P209, DOI 10.1523/JNEUROSCI.22-01-00209.2002; Sun X, 2010, TOXICOLOGY, V271, P5, DOI 10.1016/j.tox.2010.01.001; Uda M, 2006, BRAIN RES, V1104, P64, DOI 10.1016/j.brainres.2006.05.066; Uysal N, 2005, NEUROSCI LETT, V383, P241, DOI 10.1016/j.neulet.2005.04.054; Wine RN, 2009, NEUROTOX RES, V16, P280, DOI 10.1007/s12640-009-9060-y; Wu CW, 2007, J NEUROCHEM, V103, P2471, DOI 10.1111/j.1471-4159.2007.04987.x; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Zhang CY, 2002, NEUROSCI LETT, V328, P265, DOI 10.1016/S0304-3940(02)00543-8	45	57	58	1	19	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0300-9564	1435-1463		J NEURAL TRANSM	J. Neural Transm.	SEP	2011	118	9					1263	1272		10.1007/s00702-011-0629-2			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	813HB	WOS:000294356300001	21442353				2022-02-06	
J	Guo, W; Wang, H; Zou, SP; Gu, M; Watanabe, M; Wei, F; Dubner, R; Huang, GTJ; Ren, K				Guo, Wei; Wang, Hu; Zou, Shiping; Gu, Ming; Watanabe, Mineo; Wei, Feng; Dubner, Ronald; Huang, George T. -J.; Ren, Ke			Bone Marrow Stromal Cells Produce Long-Term Pain Relief in Rat Models of Persistent Pain	STEM CELLS			English	Article						Adult stem cells; Bone marrow stromal cells; Cellular therapy; Neuropathy; Rat model; Stem cell transplantation	MESENCHYMAL STEM-CELLS; SCIATIC-NERVE CONSTRICTION; TRIGEMINAL NEUROPATHIC PAIN; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; THERAPEUTIC BENEFIT; CEREBRAL-ISCHEMIA; RHEUMATOID-ARTHRITIS; GROWTH-FACTORS; TRANSPLANTATION	Chronic pain conditions are difficult to treat and are major health problems. Bone marrow stromal cells (BMSCs) have generated considerable interest as a candidate for cell-based therapy. BMSCs are readily accessible and are easy to isolate and expand ex vivo. Clinical studies show that direct injection of BMSCs does not produce unwanted side effects and is well tolerated and safe. Here, we show that a single systemic (intravenous) or local injection (into the lesion site) of rat primary BMSCs reversed pain hypersensitivity in rats after injury and that the effect lasted until the conclusion of the study at 22 weeks. The pain hypersensitivity was rekindled by naloxone hydrochloride, an opioid receptor antagonist that acts peripherally and centrally, when tested at 1-5 weeks after BMSC infusion. In contrast, naloxone methiodide, a peripherally acting opioid receptor antagonist, only rekindled hyperalgesia in the first 3 weeks of BMSC treatment. Focal downregulation of brainstem mu opioid receptors by RNA interference (RNAi) reversed the effect of BMSCs, when RNAi was introduced at 5-but not 1-week after BMSC transplantation. Thus, BMSCs produced long-term relief of pain and this effect involved activation of peripheral and central opioid receptors in distinct time domains. The findings prompt studies to elucidate the cellular mechanisms of the BMSC-induced pain relieving effect and translate these observations into clinical settings. STEM CELLS 2011; 29: 1294-1303	[Huang, George T. -J.] Boston Univ, Dept Endodont, Henry M Goldman Sch Dent Med, Boston, MA 02118 USA; [Huang, George T. -J.] Boston Univ, Dept Mol & Cell Biol, Henry M Goldman Sch Dent Med, Boston, MA 02118 USA; [Watanabe, Mineo] Hiroshima Univ, Grad Sch Biomed Sci, Dept Oral Biol, Div Mol Med Sci, Hiroshima, Japan; [Guo, Wei; Wang, Hu; Zou, Shiping; Gu, Ming; Wei, Feng; Dubner, Ronald; Ren, Ke] Univ Maryland, Sch Dent, Dept Neural & Pain Sci, Baltimore, MD 21201 USA; [Guo, Wei; Wang, Hu; Zou, Shiping; Gu, Ming; Wei, Feng; Dubner, Ronald; Ren, Ke] Univ Maryland, Program Neurosci, Baltimore, MD 21201 USA		Huang, GTJ (corresponding author), Boston Univ, Dept Endodont, Henry M Goldman Sch Dent Med, 100 E Newton St G-705, Boston, MA 02118 USA.	gtjhuang@bu.edu; kren@umaryland.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DE11964, DE018573, NS060735, NS059028, DE019156]; Japanese Ministry of Education, Science and CultureMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [22592039]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01DE019156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01DE018573, R01DE011964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS059028, R01NS060735] Funding Source: NIH RePORTER	This work was supported by Grants DE11964, DE018573, NS060735, NS059028, and DE019156 from the NIH. M.W. is supported by Grant-in-Aid for Scientific Research (22592039) from the Japanese Ministry of Education, Science and Culture.	Abrams MB, 2009, RESTOR NEUROL NEUROS, V27, P307, DOI 10.3233/RNN-2009-0480; Andrews EM, 2008, EXP NEUROL, V211, P588, DOI 10.1016/j.expneurol.2008.02.027; Bai LH, 2009, GLIA, V57, P1192, DOI 10.1002/glia.20841; Barbash IM, 2003, CIRCULATION, V108, P863, DOI 10.1161/01.CIR.0000084828.50310.6A; Bouffi C, 2009, RHEUMATOLOGY, V48, P1185, DOI 10.1093/rheumatology/kep162; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Carr CA, 2008, AM J PHYSIOL-HEART C, V295, pH533, DOI 10.1152/ajpheart.00094.2008; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Christensen D, 1999, PAIN, V83, P433, DOI 10.1016/S0304-3959(99)00126-8; Coronel MF, 2009, NEUROPEPTIDES, V43, P125, DOI 10.1016/j.npep.2008.12.003; Coronel MF, 2006, NEUROSCI LETT, V405, P5, DOI 10.1016/j.neulet.2006.06.018; Crisostomo PR, 2008, AM J PHYSIOL-CELL PH, V294, pC675, DOI 10.1152/ajpcell.00437.2007; Diatchenko L, 2005, HUM MOL GENET, V14, P135, DOI 10.1093/hmg/ddi013; DiGirolamo CM, 1999, BRIT J HAEMATOL, V107, P275, DOI 10.1046/j.1365-2141.1999.01715.x; Djouad F, 2009, NAT REV RHEUMATOL, V5, P392, DOI 10.1038/nrrheum.2009.104; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Guo W, 2006, J NEUROSCI, V26, P126, DOI 10.1523/JNEUROSCI.3686-05.2006; Guo W, 2004, J NEUROSCI, V24, P9161, DOI 10.1523/JNEUROSCI.3422-04.2004; Guo W, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-40; Harden RN, 2004, ANESTH ANALG, V99, P1478, DOI 10.1213/01.ANE.0000132549.25154.ED; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Holzer U, 2010, SCAND J RHEUMATOL, V39, P88, DOI 10.3109/03009740903096622; Horwitz EM, 2009, ISR MED ASSOC J, V11, P209; Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399; Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867; Jessop DS, 2010, ANN NY ACAD SCI, V1193, P117, DOI 10.1111/j.1749-6632.2009.05294.x; Kajii TS, 2005, J OROFAC PAIN, V19, P41; Klass M, 2007, ANESTH ANALG, V104, P944, DOI 10.1213/01.ane.0000258021.03211.d0; LAZARUS HM, 1995, BONE MARROW TRANSPL, V16, P557; LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X; Liechty KW, 2000, NAT MED, V6, P1282, DOI 10.1038/81395; Machelska H, 2007, NEUROPEPTIDES, V41, P355, DOI 10.1016/j.npep.2007.06.001; Macias MY, 2006, EXP NEUROL, V201, P335, DOI 10.1016/j.expneurol.2006.04.035; Maestroni GJM, 1998, EXP HEMATOL, V26, P1172; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mao F, 2010, INFLAMM RES, V59, P219, DOI 10.1007/s00011-009-0090-y; Mazzini L, 2006, NEUROL RES, V28, P523, DOI 10.1179/016164106X116791; Meunier A, 2005, MOL THER, V11, P608, DOI 10.1016/j.ymthe.2004.12.011; Musolino PL, 2007, NEUROSCI LETT, V418, P97, DOI 10.1016/j.neulet.2007.03.001; Niikura K, 2010, TRENDS PHARMACOL SCI, V31, P299, DOI 10.1016/j.tips.2010.04.003; Noel D, 2007, LEUKEMIA LYMPHOMA, V48, P1283, DOI 10.1080/10428190701361869; Pavlichenko N, 2008, BRAIN RES, V1233, P203, DOI 10.1016/j.brainres.2008.06.123; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V400; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Ren K, 1999, PHYSIOL BEHAV, V67, P711, DOI 10.1016/S0031-9384(99)00136-5; REN K, 2008, SENSES COMPREHENSIVE, V5, P723; Ren K, 2010, NAT MED, V16, P1267, DOI 10.1038/nm.2234; Salem HK, 2010, STEM CELLS, V28, P585, DOI 10.1002/stem.269; Shen LH, 2006, NEUROSCIENCE, V137, P393, DOI 10.1016/j.neuroscience.2005.08.092; Shen LH, 2007, J CEREBR BLOOD F MET, V27, P6, DOI 10.1038/sj.jcbfm.9600311; Shibata T, 2008, DIABETES, V57, P3099, DOI 10.2337/db08-0031; Siniscalco D, 2010, CELL MOL LIFE SCI, V67, P655, DOI 10.1007/s00018-009-0202-4; Stein C, 2009, CURR OPIN PHARMACOL, V9, P3, DOI 10.1016/j.coph.2008.12.009; Wakabayashi K, 2010, J NEUROSCI RES, V88, P1017, DOI 10.1002/jnr.22279; Wang J, 2009, BRAIN RES, V1262, P7, DOI 10.1016/j.brainres.2009.01.056; Wei F, 2008, J NEUROSCI, V28, P10482, DOI 10.1523/JNEUROSCI.3593-08.2008; Wei F, 2010, J NEUROSCI, V30, P8624, DOI 10.1523/JNEUROSCI.5389-09.2010; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126	60	57	61	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	AUG	2011	29	8					1294	1303		10.1002/stem.667			10	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	797NF	WOS:000293133900013	21630378	Green Accepted			2022-02-06	
J	Matter, AM; Folweiler, KA; Curatolo, LM; Kline, AE				Matter, Ashley M.; Folweiler, Kaitlin A.; Curatolo, Lauren M.; Kline, Anthony E.			Temporal Effects of Environmental Enrichment-Mediated Functional Improvement After Experimental Traumatic Brain Injury in Rats	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						beam-walking; controlled cortical impact; functional recovery; learning and memory; Morris water maze; neurobehavior; traumatic brain injury	CONTROLLED CORTICAL IMPACT; COGNITIVE DEFICITS; RECOVERY; HISTOPATHOLOGY; HIPPOCAMPUS; COMPLEXITY; EXPERIENCE; 8-OH-DPAT; SURVIVAL; EXERCISE	Background. Environmental enrichment (EE) enhances motor and cognitive performance after traumatic brain injury (TBI). However, whether the EE-mediated benefits are time dependent and task specific is unclear. A preliminary study, in which only half of the possible temporal manipulations were evaluated, revealed that the beneficial effects of enrichment were only observed when provided concurrently with specific training (ie, motor or cognitive), suggesting task-specific dependence. Objective. To further assess the effects of time of initiation and duration of EE on neurobehavioral recovery after TBI by evaluating and directly comparing all the temporal permutations. Methods. Anesthetized adult male rats received either a cortical impact or sham injury and were then randomly assigned to 8 groups receiving continuous or early and delayed EE with either 1 or 2 weeks of exposure. Functional outcome was assessed with established motor (beam-balance/walk) and cognitive (Morris water maze) tests on postinjury days 1 to 5 and 14 to 18, respectively. Results. Motor ability was enhanced in the TBI groups that received early EE (ie, during testing) versus standard housing. In contrast, acquisition of spatial learning was facilitated in the groups receiving delayed EE (ie, during training). Conclusions. These data support the conclusion from the previous study that EE-mediated functional improvement after TBI is contingent on task-specific neurobehavioral experience and extends those preliminary findings by demonstrating that the duration of enriched exposure is also important for functional recovery.	[Matter, Ashley M.; Folweiler, Kaitlin A.; Curatolo, Lauren M.; Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA		Kline, AE (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD046700, NS060005]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research and/or authorship of this article: This work was supported, in part, by National Institutes of Health grants HD046700 and NS060005 awarded to AEK.	Charney DS, 2004, AM J PSYCHIAT, V161, P1, DOI 10.1176/appi.ajp.161.1.1; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Dixon CE, 2003, CRIT CARE MED, V31, P2222, DOI 10.1097/01.CCM.0000080493.04978.73; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Frick KM, 2003, NEUROBIOL AGING, V24, P615, DOI 10.1016/S0197-4580(02)00138-0; Gaulke LJ, 2005, MOL BRAIN RES, V141, P138, DOI 10.1016/j.molbrainres.2005.08.011; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Kokiko ON, 2007, BRAIN INJURY, V21, P259, DOI 10.1080/02699050701209964; KRECH D, 1960, J COMP PHYSIOL PSYCH, V53, P509, DOI 10.1037/h0045402; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Parton A, 2005, CURR OPIN NEUROL, V18, P675, DOI 10.1097/01.wco.0000189872.54245.13; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Reid WM, 2008, J NEUROTRAUM, V25, P248, DOI 10.1089/neu.2007.0389; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318	32	57	57	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JUL-AUG	2011	25	6					558	564		10.1177/1545968310397206			7	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	774KL	WOS:000291384200008	21436387	Green Accepted			2022-02-06	
J	Bogner, JA; Whiteneck, GG; Corrigan, JD; Lai, JS; Dijkers, MP; Heinemann, AW				Bogner, Jennifer A.; Whiteneck, Gale G.; Corrigan, John D.; Lai, Jin-Shei; Dijkers, Marcel P.; Heinemann, Allen W.			Comparison of Scoring Methods for the Participation Assessment With Recombined Tools-Objective	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Social participation; Psychometrics; Rehabilitation	QUALITY-OF-LIFE; DISABILITY; SATISFACTION; CONFLICT; ISSUES; HEALTH	Bogner JA, Whiteneck GG, Corrigan JD, Lai J-S, Dijkers MP, Heinemann AW. Comparison of scoring methods for the Participation Assessment with Recombined Tools Objective. Arch Phys Med Rehabil 2011;92:552-63. Objective: To develop and compare 2 scoring algorithms for a measure of participation, the Participation Assessment with Recombined Tools Objective (PART-O) based on the assumption that more participation is better versus an alternative that reflects balance in domains of participation. Design: Survey. Setting: Community settings. Participants: Three groups of participants under the age of 65 years were included: (1) persons with spinal cord injury, traumatic brain injury, stroke, and other disorders who are commonly treated in acute rehabilitation settings (n=220), and (2) participants from the general population who did (n=366) or (3) did not (n=284) self-report limitations indicative of a disability who participated in the 2006 Colorado Behavioral Risk Factor Surveillance System (N=870). Interventions: Not applicable. Main Outcome Measure: PART-O. Results: We developed PART-O subscores using a consensus process and then evaluated them empirically. We combined subscores using 2 contrasting algorithms, one using average scores and the other reflecting the amount of participation and variation in participation across 3 domains. The algorithms for the total scores yielded normal distributions in all 3 samples and were equally sensitive to the impact of disability. While strongly correlated, about 30% of the variance of the 2 total scores was not shared. Conclusions: Two scoring algorithms for the PART-O illustrate contrasting perspectives of the construct of participation. The 2 algorithms may be used in future studies to expand our understanding of the construct of participation.	[Bogner, Jennifer A.; Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Whiteneck, Gale G.] Craig Hosp, Res Dept, Englewood, CO USA; [Lai, Jin-Shei] Northwestern Univ, Dept Med Social Sci, Feinberg Sch Med, Chicago, IL 60611 USA; [Heinemann, Allen W.] Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Chicago, IL 60611 USA; [Heinemann, Allen W.] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Dijkers, Marcel P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA		Bogner, JA (corresponding author), 480 Med Ctr Dr, Columbus, OH 43210 USA.	bogner.1@osu.edu	Heinemann, Allen W/K-6283-2012; Heinemann, Allen W./AAI-2790-2021; Corrigan, John D./E-2921-2011	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596	National Institute on Disability and Rehabilitation Research through a Rehabilitation Research and Training Center [H133B040032]; Traumatic Brain Injury Model System [H133A070029]; Craig Hospital [H133A070022]; Mount Sinai School of Medicine [H133A070033]	Supported by National Institute on Disability and Rehabilitation Research through a Rehabilitation Research and Training Center on Measuring Rehabilitation Outcomes and Effectiveness grant awarded to the Rehabilitation Institute of Chicago (H133B040032) and Traumatic Brain Injury Model System grants awarded to Ohio State University (H133A070029), Craig Hospital (H133A070022), and Mount Sinai School of Medicine (H133A070033).	Bohle P, 2004, REV SAUDE PUBL, V38, P19, DOI 10.1590/S0034-89102004000700004; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Brown M, 2009, ARCH PHYS MED REHAB, V90, pS36, DOI 10.1016/j.apmr.2009.04.024; *CDCP, 2006, BEH RISK FACT SURV S; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P711; Dijkers MP, 2010, ARCH PHYS MED REHAB, V91, pS5, DOI 10.1016/j.apmr.2009.10.036; Dijkers MPJM, 2000, ARCH PHYS MED REHAB, V81, pS63, DOI 10.1053/apmr.2000.20627; Hammig O, 2009, INT J PUBLIC HEALTH, V54, P88, DOI 10.1007/s00038-009-8031-7; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Levasseur M, 2010, QUAL LIFE RES, V19, P665, DOI 10.1007/s11136-010-9633-5; Lund ML, 2009, DISABIL REHABIL, V31, P1592, DOI 10.1080/09638280802638881; Magasi S, 2010, ARCH PHYS MED REHAB, V91, pS17, DOI 10.1016/j.apmr.2010.07.011; Magasi S, 2009, J REHABIL MED, V41, P936, DOI 10.2340/16501977-0450; Mortenson WB, 2010, SPINAL CORD, V48, P73, DOI 10.1038/sc.2009.92; Noonan VK, 2009, SPINAL CORD, V47, P435, DOI 10.1038/sc.2008.171; Noonan VK, 2009, DISABIL REHABIL, V31, P1883, DOI 10.1080/09638280902846947; Roos E, 2007, PUBLIC HEALTH NUTR, V10, P222, DOI 10.1017/S1368980007248487; *US BUR CENS, 2006 2008 AM COMM SU; van Campen C, 2007, QUAL LIFE RES, V16, P635, DOI 10.1007/s11136-006-9147-3; Wang JL, 2007, AM J IND MED, V50, P143, DOI 10.1002/ajim.20428; Whiteneck G, 2009, ARCH PHYS MED REHAB, V90, pS22, DOI 10.1016/j.apmr.2009.06.009; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; World Health Organization, 2010, INT CLASS FUNCT DIS	25	57	57	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2011	92	4					552	563		10.1016/j.apmr.2010.11.014			12	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	743VT	WOS:000289047500005	21367397				2022-02-06	
J	Krajewska, M; Xu, L; Xu, WJ; Krajewski, S; Kress, CL; Cui, JK; Yang, L; Irie, F; Yamaguchi, Y; Lipton, SA; Reed, JC				Krajewska, Maryla; Xu, Lucy; Xu, Wenjie; Krajewski, Stan; Kress, Christina L.; Cui, Jiankun; Yang, Li; Irie, Fumitoshi; Yamaguchi, Yu; Lipton, Stuart A.; Reed, John C.			Endoplasmic reticulum protein BI-1 modulates unfolded protein response signaling and protects against stroke and traumatic brain injury	BRAIN RESEARCH			English	Article						Neuroprotection; Unfolded protein response; Brain injury	BAX-DEPENDENT APOPTOSIS; NEURONAL CELL-DEATH; ER STRESS; NITRIC-OXIDE; PHOSPHORYLATION; INHIBITOR-1; MICE; ACTIVATION; JNK; IRE1-ALPHA	Bax-Inhibitor-1 (BI-1) is an evolutionarily conserved cytoprotective protein that resides in membranes of the endoplasmic reticulum (ER). BI-1's cytoprotective activity is manifested in the context of ER stress, with previous studies showing that BI-1 modulates several ER-associated functions, including Unfolded Protein Response (UPR) signaling. Here we investigated the role of BM in neuroprotection by generating transgenic mice in which BI-1 was constitutively expressed from a neuronal-specific promoter. Cultured primary cortical neurons from BI-1 transgenic mouse embryos exhibited greater resistance to cell death induced by agents known to cause ER stress compared to their non-transgenic counterparts. While brain morphology and vasculature of BI-1 mice appeared to be unchanged from normal non-transgenic mice, BI-1 transgenic mice showed reduced brain lesion volumes and better performance in motoric tests, compared with non-transgenic littermates, in two models of acute brain injury: stroke caused by middle cerebral artery occlusion (MCAO) and traumatic brain injury (TBI) caused by controlled cortical impact. Furthermore, brain tissue from BI-1 transgenic mice showed reduced levels of apoptotic cells and reduced induction of markers of ER stress after brain injury, including CHOP protein expression. In summary, our findings demonstrate that enforced neuronal expression of BI-1 reduces ER stress and provides protection from acute brain injury, suggesting that strategies for enhancing BI-1 expression or activity should be considered for development of new therapies for counteracting the consequences of stroke and acute brain trauma. (C) 2010 Elsevier B.V. All rights reserved.	[Krajewska, Maryla; Xu, Lucy; Xu, Wenjie; Krajewski, Stan; Kress, Christina L.; Cui, Jiankun; Yang, Li; Irie, Fumitoshi; Yamaguchi, Yu; Lipton, Stuart A.; Reed, John C.] Sanford Burnham Med Res Inst, La Jolla, CA 92037 USA		Reed, JC (corresponding author), Sanford Burnham Med Res Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	reedoffice@burnham.org			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG015393-10, R01 AG015393, AG-15393] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG015393] Funding Source: NIH RePORTER		Ahlemeyer B, 2005, J NEUROSCI METH, V149, P110, DOI 10.1016/j.jneumeth.2005.05.022; Bailly-Maitre B, 2006, P NATL ACAD SCI USA, V103, P2809, DOI 10.1073/pnas.0506854103; Bailly-Maitre B, 2010, J BIOL CHEM, V285, P6198, DOI 10.1074/jbc.M109.056648; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; Chae HJ, 2003, GENE, V323, P101, DOI 10.1016/j.gene.2003.09.011; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Gotoh T, 2006, ARTERIOSCL THROM VAS, V26, P1439, DOI 10.1161/01.ATV.0000223900.67024.15; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; Hetz C, 2006, SCIENCE, V312, P572, DOI 10.1126/science.1123480; Iadecola C, 1997, J NEUROSCI, V17, P9157; Kadoya K, 2008, J HISTOCHEM CYTOCHEM, V56, P295, DOI 10.1369/jhc.7A7349.2007; Kang KW, 2005, ANTIOXID REDOX SIGN, V7, P1664, DOI 10.1089/ars.2005.7.1664; Kermer P, 2003, BRAIN PATHOL, V13, P495; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Krajewska M, 2009, J HISTOCHEM CYTOCHEM, V57, P649, DOI 10.1369/jhc.2009.952812; Lee GH, 2007, J BIOL CHEM, V282, P21618, DOI 10.1074/jbc.M700053200; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Lisbona F, 2009, MOL CELL, V33, P679, DOI 10.1016/j.molcel.2009.02.017; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Nakanishi N, 2009, J NEUROSCI, V29, P5260, DOI 10.1523/JNEUROSCI.1067-09.2009; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Paxinos A, 2001, SPORTS MED, V31, P819, DOI 10.2165/00007256-200131110-00004; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Rao RV, 2004, CURR OPIN CELL BIOL, V16, P653, DOI 10.1016/j.ceb.2004.09.012; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rong YP, 2008, MOL CELL, V31, P255, DOI 10.1016/j.molcel.2008.06.014; ROSEN GD, 1990, J NEUROSCI METH, V35, P115, DOI 10.1016/0165-0270(90)90101-K; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Shen XH, 2004, J CHEM NEUROANAT, V28, P79, DOI 10.1016/j.jchemneu.2004.02.006; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tajiri S, 2004, CELL DEATH DIFFER, V11, P403, DOI 10.1038/sj.cdd.4401365; Uehara T, 2006, NATURE, V441, P513, DOI 10.1038/nature04782; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788; Westphalen BC, 2005, CELL DEATH DIFFER, V12, P304, DOI 10.1038/sj.cdd.4401547; Xu CY, 2008, J BIOL CHEM, V283, P11477, DOI 10.1074/jbc.M708385200; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Xu QL, 2000, METHOD ENZYMOL, V322, P283; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zou W, 2008, CANCER RES, V68, P7484, DOI 10.1158/0008-5472.CAN-08-1318	49	57	67	1	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 25	2011	1370						227	237		10.1016/j.brainres.2010.11.015			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	717RU	WOS:000287065900022	21075086	Green Accepted			2022-02-06	
J	Xiong, Y; Mahmood, A; Meng, YL; Zhang, YL; Zhang, ZG; Morris, DC; Chopp, M				Xiong, Ye; Mahmood, Asim; Meng, Yuling; Zhang, Yanlu; Zhang, Zheng Gang; Morris, Daniel C.; Chopp, Michael			Treatment of traumatic brain injury with thymosin beta(4) in rats Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						angiogenesis; neurogenesis; rat; oligodendrogenesis; thymosin beta(4); traumatic brain injury	FUNCTIONAL RECOVERY; CELL MIGRATION; SPATIAL MEMORY; MESSENGER-RNA; HAIR-GROWTH; NEUROGENESIS; STROKE; ERYTHROPOIETIN; BETA-4; ANGIOGENESIS	Object. This study was designed to investigate the efficacy of delayed thymosin beta(4) (T beta(4)) treatment of traumatic brain injury (TBI) in rats. Methods. Young adult male Wistar rats were divided into the following groups: 1) sham group (6 rats); 2) TBI + saline group (9 rats); 3) and TBI + T beta(4) group (10 rats). Traumatic brain injury was induced by controlled cortical impact over the left parietal cortex. Thymosin beta(4) (6 mg/kg) or saline was administered intraperitoneally starting at Day 1 and then every 3 days for an additional 4 doses. Neurological function was assessed using a modified neurological severity score (mNSS), foot fault, and Morris water maze tests. Animals were killed 35 days after injury, and brain sections were stained for immunohistochemistry to assess angiogenesis, neurogenesis, and oligodendrogenesis after T beta(4) treatment. Results. Compared with the saline treatment, delayed T beta(4) treatment did not affect lesion volume but significantly reduced hippocampal cell loss, enhanced angiogenesis and neurogenesis in the injured cortex and hippocampus, increased oligodendrogenesis in the CA3 region, and significantly improved sensorimotor functional recovery and spatial learning. Conclusions. These data for the first time demonstrate that delayed administration of T beta(4) significantly improves histological and functional outcomes in rats with TBI, indicating that T beta(4) has considerable therapeutic potential for patients with TBI. (DOI: 10.3171/2010.4.JNS10118)	[Xiong, Ye; Mahmood, Asim; Meng, Yuling; Zhang, Yanlu] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Zhang, Zheng Gang; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Morris, Daniel C.] Henry Ford Hlth Syst, Dept Emergency Med, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA		Xiong, Y (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	nsxye@neuro.hfh.edu	Zhang, Yanlu/H-1275-2011	Xiong, Ye/0000-0001-9770-6031	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS62002, P01 NS42345]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS062002, P01NS042345] Funding Source: NIH RePORTER	This work was supported by NIH Grant Nos. R01 NS62002 (to Dr. Xiong) and P01 NS42345 (to Drs. Mahmood and Chopp). Drs. Z. G. Zhang, Morris, and Chopp have applied for a patent for the use of T beta<INF>4</INF> as a treatment of stroke, neurological disease, and injury.	BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Bednarek R, 2008, J BIOL CHEM, V283, P1534, DOI 10.1074/jbc.M707539200; Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000; Boncela J, 2006, J BIOL CHEM, V281, P1066, DOI 10.1074/jbc.M506303200; Cavasin Maria A, 2006, Am J Cardiovasc Drugs, V6, P305, DOI 10.2165/00129784-200606050-00003; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Choi SY, 2007, BIOCHEM BIOPH RES CO, V362, P587, DOI 10.1016/j.bbrc.2007.08.031; Chopp M, 2007, STROKE, V38, P827, DOI 10.1161/01.STR.0000250235.80253.e9; Crockford D, 2007, ANN NY ACAD SCI, V1112, P385, DOI 10.1196/annals.1415.051; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dong JH, 2005, NEUROREPORT, V16, P1629, DOI 10.1097/01.wnr.0000183326.21241.48; Fine JD, 2007, ANN NY ACAD SCI, V1112, P396, DOI 10.1196/annals.1415.017; Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com; Guarnera G, 2007, ANN NY ACAD SCI, V1112, P407, DOI 10.1196/annals.1415.003; Hartley CE, 2008, J NEUROSURG, V109, P708, DOI 10.3171/JNS/2008/109/10/0708; Hinkel R, 2008, CIRCULATION, V117, P2232, DOI 10.1161/CIRCULATIONAHA.107.758904; Ho JHC, 2008, BRIT J OPHTHALMOL, V92, P992, DOI 10.1136/bjo.2007.136747; Ho JHC, 2007, INVEST OPHTH VIS SCI, V48, P27, DOI 10.1167/iovs.06-0826; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; Kupatt C, 2008, TRENDS CARDIOVAS MED, V18, P205, DOI 10.1016/j.tcm.2008.10.002; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mora CA, 1997, INT J IMMUNOPHARMACO, V19, P1, DOI 10.1016/S0192-0561(97)00005-2; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Paulussen M, 2009, PEPTIDES, V30, P1822, DOI 10.1016/j.peptides.2009.07.010; Petraglia AL, 2010, NEUROSURGERY, V66, P165, DOI 10.1227/01.NEU.0000363148.49779.68; Philp D, 2003, FASEB J, V17, P385, DOI 10.1096/fj.03-0244fje; Philp D, 2004, MECH AGEING DEV, V125, P113, DOI 10.1016/j.mad.2003.11.005; Philp D, 2007, ANN NY ACAD SCI, V1112, P95, DOI 10.1196/annals.1415.009; Popoli P, 2007, ANN NY ACAD SCI, V1112, P219, DOI 10.1196/annals.1415.033; Qiu FY, 2009, J CARDIOVASC PHARM, V53, P209, DOI 10.1097/FJC.0b013e318199f326; Reti R, 2008, EUR J ORAL SCI, V116, P424, DOI 10.1111/j.1600-0722.2008.00569.x; Riley PR, 2009, BIOCHEM SOC T, V37, P1218, DOI 10.1042/BST0371218; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Smart Nicola, 2007, Angiogenesis, V10, P229, DOI 10.1007/s10456-007-9077-x; Smart N, 2007, ANN NY ACAD SCI, V1112, P171, DOI 10.1196/annals.1415.000; Smart N, 2007, NATURE, V445, P177, DOI 10.1038/nature05383; Sosne G, 2007, ANN NY ACAD SCI, V1112, P114, DOI 10.1196/annals.1415.004; Srivastava D, 2007, ANN NY ACAD SCI, V1112, P161, DOI 10.1196/annals.1415.048; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Sun W, 2007, ANN NY ACAD SCI, V1112, P210, DOI 10.1196/annals.1415.013; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Vartiainen N, 1996, NEUROREPORT, V7, P1613, DOI 10.1097/00001756-199607080-00017; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yang H, 2008, NEUROCHEM RES, V33, P2269, DOI 10.1007/s11064-008-9712-y; Yarmola EG, 2007, ANN NY ACAD SCI, V1112, P76, DOI 10.1196/annals.1415.008; Zhang J, 2009, NEUROSCIENCE, V164, P1887, DOI 10.1016/j.neuroscience.2009.09.054; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2004, J NEUROSCI, V24, P5810, DOI 10.1523/JNEUROSCI.1109-04.2004; Zhang RL, 2008, NEUROPHARMACOLOGY, V55, P345, DOI 10.1016/j.neuropharm.2008.05.027; Zhang RL, 2007, J NEUROSCI, V27, P3157, DOI 10.1523/JNEUROSCI.4969-06.2007; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	70	57	58	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2011	114	1					102	115		10.3171/2010.4.JNS10118			14	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	699NG	WOS:000285669500022	20486893	Green Accepted			2022-02-06	
J	Chen, HW; Epstein, J; Stern, E				Chen, Haiwen; Epstein, Jane; Stern, Emily			Neural Plasticity After Acquired Brain Injury: Evidence from Functional Neuroimaging	PM&R			English	Article							ACTIVATION	The reorganization of the adult central nervous system after damage is a relatively new area of investigation. Neuroimaging methods, such as functional magnetic resonance imaging, diffusion tensor imaging, and positron emission tomography, have the ability to identify, in vivo, some of the processes involved in these neuroplastic changes and can help with diagnosis, prognosis, and potentially treatment approaches. In this article, traumatic brain injury and stroke are used as examples in which neural plasticity plays an important role in recovery. Basic concepts related to brain remodeling, including spontaneous reorganization and training-induced recovery, as well as characteristics of reorganization in successful recovery, are reviewed. The microscopic and molecular mechanisms that underlie neural plasticity and neurogenesis are briefly described. Finally, exciting future directions for the evaluation, diagnosis, and treatment of severe brain injury are explored, with an emphasis on how neuroimaging can help to inform these new approaches. PM R 2010;2:S306-S312	[Chen, Haiwen; Epstein, Jane; Stern, Emily] Harvard Univ, Funct Neuroimaging Lab, Brigham & Womens Hosp, Sch Med, Chestnut Hill, MA 02467 USA; [Chen, Haiwen] Univ Maryland, Sch Med, Baltimore, MD 21201 USA		Stern, E (corresponding author), Harvard Univ, Funct Neuroimaging Lab, Brigham & Womens Hosp, Sch Med, 824 Boylston St, Chestnut Hill, MA 02467 USA.	estern3@partners.org	Stern, Emily/E-6035-2011				Bolognini N, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-8; Butelisch CM, 2001, J PHYSIOL-PARIS, V99, P437; Calautti C, 2001, NEUROREPORT, V12, P3883, DOI 10.1097/00001756-200112210-00005; Calautti C, 2007, NEUROIMAGE, V34, P322, DOI 10.1016/j.neuroimage.2006.08.026; Carey LM, 2007, INT J STROKE, V2, P245, DOI 10.1111/j.1747-4949.2007.00164.x; Carey LM, 2001, NEUROREHAB NEURAL RE, V20, P24; Carmichael ST, 2006, ANN NEUROL, V59, P735, DOI 10.1002/ana.20845; Chanraud S, 2010, NEUROPSYCHOL REV, V20, P209, DOI 10.1007/s11065-010-9129-7; Coleman MR, 2009, BRAIN, V132, P2541, DOI 10.1093/brain/awp183; Corbetta M, 2005, NAT NEUROSCI, V8, P1603, DOI 10.1038/nn1574; Dobkin BH, 2005, NEW ENGL J MED, V352, P1677, DOI 10.1056/NEJMcp043511; Draganski B, 2004, NATURE, V427, P311, DOI 10.1038/427311a; Duffau H, 2006, J CLIN NEUROSCI, V13, P885, DOI 10.1016/j.jocn.2005.11.045; Engelien A, 1995, BRAIN, V118, P1395, DOI 10.1093/brain/118.6.1395; Epstein J, 2006, AM J PSYCHIAT, V163, P1784, DOI 10.1176/appi.ajp.163.10.1784; Fields RD, 2002, SCIENCE, V298, P556, DOI 10.1126/science.298.5593.556; Fregni F, 2007, NAT CLIN PRACT NEURO, V3, P383, DOI 10.1038/ncpneuro0530; Fregni F, 2006, STROKE, V37, P2115, DOI 10.1161/01.STR.0000231390.58967.6b; Frewen P, 2001, CLIN PSYCHOL REV, V28, P228; Ganasen KA, 2010, PSYCHIAT CLIN N AM, V33, P687, DOI 10.1016/j.psc.2010.04.008; Giacino JT, 2006, ARCH PHYS MED REHAB, V87, pS67, DOI 10.1016/j.apmr.2006.07.272; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Hodics T, 2006, ARCH PHYS MED REHAB, V87, pS36, DOI 10.1016/j.apmr.2006.09.005; Hummel FC, 2006, LANCET NEUROL, V5, P708, DOI 10.1016/S1474-4422(06)70525-7; Ji YY, 2010, NAT NEUROSCI, V13, P302, DOI 10.1038/nn.2505; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kim YH, 2006, NEUROLOGY, V67, P330, DOI 10.1212/01.wnl.0000225178.85833.0d; Kim YH, 2004, YONSEI MED J, V45, P241, DOI 10.3349/ymj.2004.45.2.241; Kubicki M, 2002, HARVARD REV PSYCHIAT, V10, P324, DOI 10.1080/10673220216231; Kwakkel G, 2006, STROKE, V37, P2348, DOI 10.1161/01.STR.0000238594.91938.1e; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; Lauterbach EC, 2010, J NEUROPSYCH CLIN N, V22, P8, DOI 10.1176/appi.neuropsych.22.1.8; Leger A, 2002, NEUROIMAGE, V17, P174, DOI 10.1006/nimg.2002.1238; Levin HS, 2001, BRAIN INJURY, V17, P665; Luft AR, 2004, JAMA-J AM MED ASSOC, V292, P1853, DOI 10.1001/jama.292.15.1853; Maguire EA, 2000, P NATL ACAD SCI USA, V97, P4398, DOI 10.1073/pnas.070039597; Marino S, 2011, NEUROCRIT CARE, V2010, P25; Marr RA, 2010, FUTUR NEUROL, V5, P527, DOI 10.2217/FNL.10.33; Meinzer M, 2007, NEUROREHABILITATION, V22, P311; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Munoz-Cespedes JM, 2005, NEUROPSYCHOL REV, V15, P169, DOI 10.1007/s11065-005-9178-5; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Nighoghossian N, 2001, STROKE, V38, P303; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; Pineiro R, 2001, STROKE, V32, P1134, DOI 10.1161/01.STR.32.5.1134; PRICE CJ, 2001, HDB FUNCTIONAL NEURO, P379; Price CJ, 2001, STROKE, V37, P1749; Protopopescu X, 2008, HIPPOCAMPUS, V18, P985, DOI 10.1002/hipo.20468; Richter M, 2008, BRAIN, V131, P1391, DOI 10.1093/brain/awn043; Root JC, 2009, NEUROREPORT, V20, P429, DOI 10.1097/WNR.0b013e328326a031; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Saur D, 2006, BRAIN, V129, P1371, DOI 10.1093/brain/awl090; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Seitz RJ, 1999, RESTOR NEUROL NEUROS, V14, P25; Seitz RJ, 2004, RESTOR NEUROL NEUROS, V22, P207; Stern E, 2001, J CLIN EXP NEUROPSYC, V23, P3, DOI 10.1076/jcen.23.1.3.1222; Strangman G, 2005, AM J PHYS MED REHAB, V84, P62, DOI 10.1097/01.PHM.0000150787.26860.12; Takahashi CD, 2008, BRAIN, V131, P425, DOI 10.1093/brain/awm311; Taub E, 2002, NAT REV NEUROSCI, V3, P228, DOI 10.1038/nrn754; Triggs WJ, 1999, BIOL PSYCHIAT, V45, P1440, DOI 10.1016/S0006-3223(99)00031-1; Ungerleider LG, 2002, NEUROBIOL LEARN MEM, V78, P553, DOI 10.1006/nlme.2002.4091; van der Graaf M, 2001, EUR BIOPHYS J, V39, P527; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Ween JE, 2008, J NEUROIMAGING, V18, P227, DOI 10.1111/j.1552-6569.2007.00180.x; Werring DJ, 1991, J NEUROL NEUROSUR PS, V65, P863; Winward CE, 2007, DISABIL REHABIL, V29, P293, DOI 10.1080/09638280600756489; Yang YH, 2000, NEUROIMAGE, V12, P287, DOI 10.1006/nimg.2000.0625; Zahn R, 2004, COGNITIVE BRAIN RES, V18, P322, DOI 10.1016/j.cogbrainres.2003.10.021	69	57	59	1	26	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	DEC	2010	2	12		2			S306	S312		10.1016/j.pmrj.2010.10.006			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	V24LT	WOS:000208412600011	21172692				2022-02-06	
J	Rao, V; Bertrand, M; Rosenberg, P; Makley, M; Schretlen, DJ; Brandt, J; Mielke, MM				Rao, Vani; Bertrand, Melaine; Rosenberg, Paul; Makley, Michael; Schretlen, David J.; Brandt, Jason; Mielke, Michelle M.			Predictors of New-Onset Depression After Mild Traumatic Brain Injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							MAJOR DEPRESSION; CONCUSSION; LIFE	Mild traumatic brain injury (TBI) is the most common form of TBI. Most people recover after mild TBI, but a small percentage continues to have persistent problems, predominantly depression. There is, however, minimal literature on the risk factors associated with mild TBI depression. In a sample of 43 mild TBI patients, followed longitudinally for 1 year, the prevalence of new-onset depression was found to be 18%. Older age and presence of frontal subdural hemorrhage were the only two significant findings noted in the depressed group compared with the nondepressed group. Identifying risk factors for mild TBI depression can aid in early diagnosis and treatment. (The Journal of Neuropsychiatry and Clinical Neurosciences 2010; 22:100-104)	[Rao, Vani; Bertrand, Melaine; Rosenberg, Paul; Mielke, Michelle M.] Johns Hopkins Univ, Div Geriatr Psychiat & Neuropsychiat, Dept Psychiat, Johns Hopkins Sch Med, Baltimore, MD 21224 USA; [Makley, Michael] Univ Maryland, Dept Neurol, Baltimore, MD 21201 USA; [Schretlen, David J.; Brandt, Jason] Johns Hopkins Sch Med, Div Med Psychol, Dept Psychiat, Baltimore, MD USA; [Brandt, Jason] Johns Hopkins Sch Med, Div Med Psychol, Dept Neurol, Baltimore, MD USA		Rao, V (corresponding author), Johns Hopkins Univ, Div Geriatr Psychiat & Neuropsychiat, Dept Psychiat, Johns Hopkins Sch Med, 5300 Alpha Commons Dr,4th Floor,444, Baltimore, MD 21224 USA.	vrao@jhmi.edu		Mielke, Michelle/0000-0001-7177-1185; Brandt, Jason/0000-0001-7381-6244	NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH 066894]; Forest; PfizerPfizer; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH066894] Funding Source: NIH RePORTER	This study was supported by grant K23 MH 066894 from the NIMH. The abstract was presented at the 2008 annual neuropsychiatry conference in Savannah, Ga. Dr. Rao has a grant from Forest to conduct a clinical trial in post-TBI depression and a grant from Pfizer to conduct a clinical trial in poststroke anxiety. Dr. Jason Brandt receives royalties from Psychological Assessment Resources, Inc., on sales of Hopkins Verbal Learning Test and Dr. David Schretlen on sales of Brief Test of Attention. There are no conflicts of interest to declare by other authors on this paper.	Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Beekman ATF, 1997, PSYCHOL MED, V27, P1397, DOI 10.1017/S0033291797005734; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	15	57	57	0	8	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2010	22	1					100	104		10.1176/jnp.2010.22.1.100			5	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	555VO	WOS:000274544500013	20160216	Green Accepted			2022-02-06	
J	Signoretti, S; Vagnozzi, R; Tavazzi, B; Lazzarino, G				Signoretti, Stefano; Vagnozzi, Roberto; Tavazzi, Barbara; Lazzarino, Giuseppe			Biochemical and neurochemical sequelae following mild traumatic brain injury: summary of experimental data and clinical implications	NEUROSURGICAL FOCUS			English	Article						mild traumatic brain injury; N-acetylaspartate; concussion; brain energy; metabolism; oxidative stress	MAGNETIC-RESONANCE-SPECTROSCOPY; INCOMPLETE CEREBRAL-ISCHEMIA; CONTROLLED CORTICAL IMPACT; FLUID-PERCUSSION MODEL; NITRIC-OXIDE SYNTHASE; L-ASPARTIC ACID; OXIDATIVE STRESS; LIPID-PEROXIDATION; N-ACETYLASPARTATE; HEAD-INJURY	Although numerous studies have been carried out to investigate the pathophysiology of mild traumatic brain injury (mTBI), there are still no standard criteria for the diagnosis and treatment of this peculiar condition. The dominant theory that diffuse axonal injury is the main neuropathological process behind mTBI is being revealed as weak at best or inconclusive, given the current literature and the fact that neuronal injury inherent to mTBI improves, with few lasting clinical sequelae in the vast majority of patients. Clinical and experimental evidence suggests that such a course, rather than being due to cell death, is based on temporal neuronal dysfunction, the inevitable consequence of complex biochemical and neurochemical cascade mechanisms directly and immediately triggered by the traumatic insult. This report is an attempt to summarize data from a long series of experiments conducted in the authors' laboratories and published during the past 12 years, together with an extensive analysis of the available literature, focused on understanding the biochemical damage produced by an mTBI. The overall clinical implications, as well as the metabolic nature of the post-mTBI brain vulnerability, are discussed. Finally, the application of proton MR spectroscopy as a possible tool to monitor the full recovery of brain metabolic functions is emphasized. (DOI: 10.3171/2010.9.FOCUS10183)	[Signoretti, Stefano] San Camillo Hosp, Dept Neurosci Head & Neck Surg, Div Neurosurg, I-00100 Rome, Italy; [Vagnozzi, Roberto] Univ Roma Tor Vergata, Dept Neurosci, Rome, Italy; [Tavazzi, Barbara] Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; [Lazzarino, Giuseppe] Univ Catania, Div Biochem & Mol Biol, Dept Chem Sci, I-95124 Catania, Italy		Signoretti, S (corresponding author), San Camillo Hosp, Dept Neurosci Head & Neck Surg, Div Neurosurg, Circonvallaz Gianicolense 183, I-00100 Rome, Italy.	stefano.signoretti@tiscali.it	Signoretti, stefano/AAL-5631-2020; TAVAZZI, BARBARA/AAB-9830-2019; lazzarino, giuseppe/K-2277-2015	Signoretti, stefano/0000-0002-8086-1622; TAVAZZI, BARBARA/0000-0001-8743-0895; lazzarino, giuseppe/0000-0002-5917-7279	Italian Ministry of University and ResearchMinistry of Education, Universities and Research (MIUR) [2007JBHZ5F]	The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. This study was funded by PRIN 2007JBHZ5F grant from the Italian Ministry of University and Research.	Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.0741951.x; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BARTLETT D, 1995, FREE RADICAL BIO MED, V18, P85, DOI 10.1016/0891-5849(94)E0133-4; Baslow MH, 2006, DRUG NEWS PERSPECT, V19, P145, DOI 10.1358/dnp.2006.19.3.985930; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 1998, CLIN SPORT MED, V17, pXI, DOI 10.1016/S0278-5919(05)70055-7; Cantu RC, 2007, NEUROSURGERY, V60, P963, DOI 10.1227/01.NEU.0000255430.62291.7B; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOBERSTEIN CE, 1993, ANN EMERG MED, V22, P993, DOI 10.1016/S0196-0644(05)82740-4; Donzelli S, 2006, FREE RADICAL BIO MED, V40, P1056, DOI 10.1016/j.freeradbiomed.2005.10.058; Donzelli S, 2006, ANTIOXID REDOX SIGN, V8, P1363, DOI 10.1089/ars.2006.8.1363; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Fabbri A, 2010, INJURY, V41, P913, DOI 10.1016/j.injury.2010.03.002; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Giza CC, 2001, J ATHL TRAINING, V36, P228; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; HOVDA DA, 1983, INTRACRANIAL PRESSUR, V8, P469; HUMPHREY SM, 1987, BASIC RES CARDIOL, V82, P304, DOI 10.1007/BF01906863; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; JANERO DR, 1993, AM J PHYSIOL, V264, pC1401; Kaminski KA, 2002, INT J CARDIOL, V86, P41, DOI 10.1016/S0167-5273(02)00189-4; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Kikugawa K, 2004, BIOL PHARM BULL, V27, P17, DOI 10.1248/bpb.27.17; Kirsch M, 2000, J BIOL CHEM, V275, P16702, DOI 10.1074/jbc.M909228199; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LAUTIER D, 1994, BBA-MOL CELL RES, V1221, P215, DOI 10.1016/0167-4889(94)90243-7; Lazzarino G, 2003, ANAL BIOCHEM, V322, P51, DOI 10.1016/j.ab.2003.07.013; LAZZARINO G, 1992, FREE RADICAL BIO MED, V13, P489, DOI 10.1016/0891-5849(92)90143-5; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; Mendez DR, 2004, J TRAUMA, V56, P1235, DOI 10.1097/01.TA.0000130759.62286.0E; MIYAKE M, 1981, J NEUROCHEM, V36, P804, DOI 10.1111/j.1471-4159.1981.tb01665.x; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; MORGAN WA, 1995, BIOCHEM PHARMACOL, V49, P1179, DOI 10.1016/0006-2952(95)00034-W; Movsesyan VA, 2006, J NEUROTRAUM, V23, P117, DOI 10.1089/neu.2006.23.117; Nanavaty UB, 2002, EXP LUNG RES, V28, P591, DOI 10.1080/01902140260426715; Neale JH, 2005, TRENDS PHARMACOL SCI, V26, P477, DOI 10.1016/j.tips.2005.07.004; Nojiri H, 2006, J BIOL CHEM, V281, P33789, DOI 10.1074/jbc.M602118200; Pacher P, 2002, J AM COLL CARDIOL, V40, P1006, DOI 10.1016/S0735-1097(02)02062-4; PALOZZA P, 1992, FREE RADICAL BIO MED, V13, P127, DOI 10.1016/0891-5849(92)90074-Q; PATEL TB, 1979, BIOCHEM J, V184, P539, DOI 10.1042/bj1840539; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Sawa T, 2006, NITRIC OXIDE-BIOL CH, V14, P91, DOI 10.1016/j.niox.2005.06.005; Schinder AF, 1996, J NEUROSCI, V16, P6125; Schrammel A, 2003, FREE RADICAL BIO MED, V34, P1078, DOI 10.1016/S0891-5849(03)00038-8; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P288; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Solaroglu I, 2005, J CLIN NEUROSCI, V12, P273, DOI 10.1016/j.jocn.2004.12.002; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TALLAN HH, 1957, J BIOL CHEM, V224, P41; Tavazzi B, 1998, FREE RADICAL RES, V28, P25, DOI 10.3109/10715769809097873; Tavazzi B, 2000, ANAL BIOCHEM, V277, P104, DOI 10.1006/abio.1999.4386; Tavazzi B, 2000, FREE RADICAL RES, V33, P1, DOI 10.1080/10715760000300561; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; THIES RL, 1991, ARCH BIOCHEM BIOPHYS, V286, P353, DOI 10.1016/0003-9861(91)90051-J; TRUCKENMILLER ME, 1985, J NEUROCHEM, V45, P1658, DOI 10.1111/j.1471-4159.1985.tb07240.x; Vagnozzi R, 1997, EXP BRAIN RES, V117, P411, DOI 10.1007/s002210050235; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wilson JX, 2002, J NEUROSURG ANESTH, V14, P66, DOI 10.1097/00008506-200201000-00014; Wroblewska B, 2006, ADV EXP MED BIOL, V576, P317; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhong CL, 2005, J NEUROTRAUM, V22, P266, DOI 10.1089/neu.2005.22.266; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	97	57	58	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	NOV	2010	29	5							E1	10.3171/2010.9.FOCUS10183			12	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	675CE	WOS:000283801900002	21039135				2022-02-06	
J	Naylor, JC; Kilts, JD; Hulette, CM; Steffens, DC; Blazer, DG; Ervin, JF; Strauss, JL; Allen, TB; Massing, MW; Payne, VM; Youssef, NA; Shampine, LJ; Marx, CE				Naylor, Jennifer C.; Kilts, Jason D.; Hulette, Christine M.; Steffens, David C.; Blazer, Dan G.; Ervin, John F.; Strauss, Jennifer L.; Allen, Trina B.; Massing, Mark W.; Payne, Victoria M.; Youssef, Nagy A.; Shampine, Lawrence J.; Marx, Christine E.			Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS			English	Article						Alzheimer's disease; temporal cortex; allopregnanolone; DHEA; pregnenolone; neurosteroid; postmortem	TRAUMATIC BRAIN-INJURY; RAT HIPPOCAMPAL-NEURONS; NEUROACTIVE STEROIDS; CELL-DEATH; NEUROSTEROID ALLOPREGNANOLONE; DEHYDROEPIANDROSTERONE DHEA; PROGESTERONE METABOLITE; RECEPTOR AGONISTS; OXIDATIVE STRESS; APOLIPOPROTEIN-E	The neurosteroid allopregnanolone has pronounced neuroprotective actions, increases myelination, and enhances neurogenesis. Evidence suggests that allopregnanolone dysregulation may play a role in the pathophysiology of Alzheimer's disease (AD) and other neurodegenerative disorders. Our prior data demonstrate that allopregnanolone is reduced in prefrontal cortex in male patients with AD compared to male cognitively intact control subjects, and inversely correlated with neuropathological disease stage (Braak and Braak). We therefore determined if allopregnanolone levels are also reduced in AD patients compared to control subjects in temporal cortex, utilizing a larger set of samples from both male and female patients. In addition, we investigated if neurosteroids are altered in subjects who are APOE4 allele carriers. Allopregnanolone, dehydroepiandrosterone (DHEA), and pregnenolone levels were determined in temporal cortex postmortem samples by gas chromatography/mass spectrometry, preceded by high performance liquid chromatography (40 subjects with AD/41 cognitively intact control subjects). Allopregnanolone levels are reduced in temporal cortex in patients with AD (median 2.68 ng/g, n = 40) compared to control subjects (median 5.64 ng/g, n = 41), Mann-Whitney p = 0.0002, and inversely correlated with Braak and Braak neuropathological disease stage (Spearman r = -0.38, p = 0.0004). DHEA and pregnenolone are increased in patients with AD compared to control subjects. Patients carrying an APOE4 allele demonstrate reduced allopregnanolone levels in temporal cortex (Mann-Whitney p = 0.04). In summary, our findings indicate that neurosteroids are altered in temporal cortex in patients with AD and related to neuropathological disease stage. In addition, the APOE4 allele is associated with reduced allopregnanolone levels. Neurosteroids may be relevant to the neurobiology and therapeutics of AD. Published by Elsevier B.V.	[Naylor, Jennifer C.; Kilts, Jason D.; Strauss, Jennifer L.; Allen, Trina B.; Payne, Victoria M.; Youssef, Nagy A.; Shampine, Lawrence J.; Marx, Christine E.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham VA Med Ctr, Durham, NC 27705 USA; [Naylor, Jennifer C.; Kilts, Jason D.; Strauss, Jennifer L.; Allen, Trina B.; Payne, Victoria M.; Youssef, Nagy A.; Shampine, Lawrence J.; Marx, Christine E.] Res & Clin Ctr MIRECC, VA Midatlantic Mental Illness, Durham, NC USA; [Hulette, Christine M.; Ervin, John F.] Duke Univ, Med Ctr, Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Durham, NC 27705 USA		Marx, CE (corresponding author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham VA Med Ctr, 508 Fulton St,MHSL 116A, Durham, NC 27705 USA.	marx0001@mc.duke.edu	Youssef, Nagy A/F-5869-2019	Youssef, Nagy A/0000-0002-1922-9396	VA Advanced Research Career Development Award; VA Mid-Atlantic Mental Illness, Research, Education, and Clinical Center (MIRECC); National Institute of Mental Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH 65080]; National Institute on Aging (NIA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50 AG05128, P30: AG028377]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH065080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028377, P50AG005128] Funding Source: NIH RePORTER	This work was supported by the following sources: VA Advanced Research Career Development Award (C.E.M.), VA Mid-Atlantic Mental Illness, Research, Education, and Clinical Center (MIRECC), and the National Institute of Mental Health (NIH), K23 MH 65080 (C.E.M.), National Institute on Aging (NIA) P50 AG05128 (C.M.H.), and NIA P30: AG028377 (C.M.H.). Dr. Marx discloses that she is a co-applicant on pending U.S. patent applications for the use of neurosteroids and derivatives for the treatment of central nervous system disorders and for lowering cholesterol. The remaining authors have no potential conflicts of interest to disclose. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the National Institutes of Health.	Ahmad I, 2005, J NEUROSCI RES, V82, P811, DOI 10.1002/jnr.20685; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; AZIZI H, 2009, STEM CELLS DEV; BALES KR, NEUROPHARMA IN PRESS; Barbaccia ML, 2001, NEUROPSYCHOPHARMACOL, V25, P489, DOI 10.1016/S0893-133X(01)00254-8; Bartzokis G, 2004, NEUROBIOL AGING, V25, P49, DOI 10.1016/j.neurobiolaging.2003.08.001; Bartzokis G, 2004, NEUROBIOL AGING, V25, P5, DOI 10.1016/j.neurobiolaging.2003.03.001; Benes FM, 2004, NEUROBIOL AGING, V25, P41, DOI 10.1016/j.neurobiolaging.2003.06.003; Bergeron R, 1996, J NEUROSCI, V16, P1193; Bernardi F, 2000, EUR J ENDOCRINOL, V142, P466, DOI 10.1530/eje.0.1420466; Bjorkhem I, 2004, ARTERIOSCL THROM VAS, V24, P806, DOI 10.1161/01.ATV.0000120374.59826.1b; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; Brown RC, 2000, J NEUROCHEM, V74, P847, DOI 10.1046/j.1471-4159.2000.740847.x; Brown RC, 2003, NEUROBIOL AGING, V24, P57, DOI 10.1016/S0197-4580(02)00048-9; Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620; Calissano P, 2009, Commun Integr Biol, V2, P163; Cardounel A, 1999, P SOC EXP BIOL MED, V222, P145, DOI 10.1046/j.1525-1373.1999.d01-124.x; Charalampopoulos I, 2006, ANN NY ACAD SCI, V1088, P139, DOI 10.1196/annals.1366.003; Charalampopoulos L, 2004, P NATL ACAD SCI USA, V101, P8209, DOI 10.1073/pnas.0306631101; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Compagnone NA, 1998, P NATL ACAD SCI USA, V95, P4678, DOI 10.1073/pnas.95.8.4678; COSTA E, 1994, J STEROID BIOCHEM, V49, P385, DOI 10.1016/0960-0760(94)90284-4; Debonnel G, 1996, J ENDOCRINOL, V150, pS33; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; FLOOD JF, 1992, P NATL ACAD SCI USA, V89, P1567, DOI 10.1073/pnas.89.5.1567; Fontaine-Lenoir V, 2006, P NATL ACAD SCI USA, V103, P4711, DOI 10.1073/pnas.0600113103; Francis PT, 2005, CNS SPECTRUMS, V10, P6, DOI 10.1017/S1092852900014164; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Girdler SS, 2001, BIOL PSYCHIAT, V49, P788, DOI 10.1016/S0006-3223(00)01044-1; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Gursoy E, 2001, NEUROCHEM RES, V26, P15, DOI 10.1023/A:1007668213330; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Hsu HJ, 2006, NATURE, V439, P480, DOI 10.1038/nature04436; Hulette CM, 1997, ARCH PATHOL LAB MED, V121, P615; Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007; Imamura M, 1998, BIOCHEM BIOPH RES CO, V243, P771, DOI 10.1006/bbrc.1998.8177; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P511; Jin LW, 2004, AM J PATHOL, V164, P975, DOI 10.1016/S0002-9440(10)63185-9; Karishma KK, 2002, EUR J NEUROSCI, V16, P445, DOI 10.1046/j.1460-9568.2002.02099.x; Kato-Negishi Midori, 2008, Neuropsychiatr Dis Treat, V4, P209; Kaufman KR, 2010, NEUROSCIENCE, V166, P5, DOI 10.1016/j.neuroscience.2009.11.075; Kim SB, 2003, J CLIN ENDOCR METAB, V88, P5199, DOI 10.1210/jc.2003-030646; Kimonides VG, 1999, NEUROSCIENCE, V89, P429, DOI 10.1016/S0306-4522(98)00347-9; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Kokate TG, 1999, J PHARMACOL EXP THER, V288, P679; Kurata K, 2004, J PHARMACOL EXP THER, V311, P237, DOI 10.1124/jpet.104.067629; Leskiewicz M, 2008, J PHYSIOL PHARMACOL, V59, P457; Liao GH, 2009, BRAIN RES, V1270, P140, DOI 10.1016/j.brainres.2009.03.027; Lipton Stuart A., 2005, Current Alzheimer Research, V2, P155, DOI 10.2174/1567205053585846; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; LUCHETTI S, 2009, NEUROBIOL AGING; Martins IJ, 2009, J NEUROCHEM, V111, P1275, DOI 10.1111/j.1471-4159.2009.06408.x; Marx CE, 2000, BRAIN RES, V871, P104, DOI 10.1016/S0006-8993(00)02452-5; MARX CE, 2005, P 44 ANN M AM COLL N, pS79; Marx CE, 2006, PHARMACOL BIOCHEM BE, V84, P598, DOI 10.1016/j.pbb.2006.07.026; Marx CE, 2006, PHARMACOL BIOCHEM BE, V84, P609, DOI 10.1016/j.pbb.2006.07.032; Marx CE, 2006, PSYCHOPHARMACOLOGY, V186, P462, DOI 10.1007/s00213-005-0226-x; Marx CE, 2006, NEUROPSYCHOPHARMACOL, V31, P1249, DOI 10.1038/sj.npp.1300952; Marx CE, 2006, BIOL PSYCHIAT, V60, P1287, DOI 10.1016/j.biopsych.2006.06.017; Maurice T, 1998, NEUROSCIENCE, V83, P413, DOI 10.1016/S0306-4522(97)00405-3; Mellon SH, 2008, BRAIN RES REV, V57, P410, DOI 10.1016/j.brainresrev.2007.05.012; Mendelson JH, 2005, NEUROPSYCHOPHARMACOL, V30, P1751, DOI 10.1038/sj.npp.1300753; Meunier J, 2004, NEUROTOXICOL TERATOL, V26, P783, DOI 10.1016/j.ntt.2004.07.003; MORROW AL, 1990, MOL PHARMACOL, V37, P263; Naylor JC, 2008, J CLIN ENDOCR METAB, V93, P3173, DOI 10.1210/jc.2007-1229; Papadopoulos V, 1997, STEROIDS, V62, P21, DOI 10.1016/S0039-128X(96)00154-7; Papassotiropoulos A, 2005, J CLIN PSYCHIAT, V66, P940, DOI 10.4088/JCP.v66n0720; Pinna G, 2004, P NATL ACAD SCI USA, V101, P6222, DOI 10.1073/pnas.0401479101; Pinna G, 2003, P NATL ACAD SCI USA, V100, P2035, DOI 10.1073/pnas.0337642100; Puglielli L, 2003, NAT NEUROSCI, V6, P345, DOI 10.1038/nn0403-345; PURDY RH, 1990, J MED CHEM, V33, P1572, DOI 10.1021/jm00168a008; Rohn T.T., 2010, APOPTOSIS; Romeo E, 1998, AM J PSYCHIAT, V155, P910, DOI 10.1176/ajp.155.7.910; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Serra M, 2001, PSYCHOPHARMACOLOGY, V158, P48, DOI 10.1007/s002130100853; Shobab LA, 2005, LANCET NEUROL, V4, P841, DOI 10.1016/S1474-4422(05)70248-9; Sliwinski A, 2004, J NEUROSCI RES, V78, P691, DOI 10.1002/jnr.20332; Smith CD, 2006, PSYCHOPHARMACOLOGY, V186, P481, DOI 10.1007/s00213-005-0186-1; Steckelbroeck S, 2004, J BIOL CHEM, V279, P10784, DOI 10.1074/jbc.M313308200; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Suzuki M, 2004, P NATL ACAD SCI USA, V101, P3202, DOI 10.1073/pnas.0307325101; Tamagno E, 2003, NEUROBIOL DIS, V14, P291, DOI 10.1016/S0969-9961(03)00131-1; Treiber-Held S, 2003, J PATHOL, V200, P95, DOI 10.1002/path.1345; Uzunov DP, 1996, P NATL ACAD SCI USA, V93, P12599, DOI 10.1073/pnas.93.22.12599; Uzunova V, 1998, P NATL ACAD SCI USA, V95, P3239, DOI 10.1073/pnas.95.6.3239; Vallee M, 2001, BRAIN RES REV, V37, P301, DOI 10.1016/S0165-0173(01)00135-7; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Weill-Engerer S, 2002, J CLIN ENDOCR METAB, V87, P5138, DOI 10.1210/jc.2002-020878; Wenk GL, 2006, BEHAV PHARMACOL, V17, P411, DOI 10.1097/00008877-200609000-00007; Wolozin B, 2004, NEURON, V41, P7, DOI 10.1016/S0896-6273(03)00840-7; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xilouri M, 2006, EUR J NEUROSCI, V23, P43, DOI 10.1111/j.1460-9568.2005.04548.x; Yu WX, 2005, J BIOL CHEM, V280, P27296, DOI 10.1074/jbc.M503922200; Zotova E, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt24	100	57	61	0	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1388-1981	1879-2618		BBA-MOL CELL BIOL L	Biochim. Biophys. Acta Mol. Cell Biol. Lipids	AUG	2010	1801	8			SI		951	959		10.1016/j.bbalip.2010.05.006			9	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics; Cell Biology	620CG	WOS:000279476000027	20488256	Green Accepted			2022-02-06	
J	Bonneh-Barkay, D; Zagadailov, P; Zou, HC; Niyonkuru, C; Figley, M; Starkey, A; Wang, GJ; Bissel, SJ; Wiley, CA; Wagner, AK				Bonneh-Barkay, Dafna; Zagadailov, Pavel; Zou, Huichao; Niyonkuru, Christian; Figley, Matthew; Starkey, Adam; Wang, Guoji; Bissel, Stephanie J.; Wiley, Clayton A.; Wagner, Amy K.			YKL-40 Expression in Traumatic Brain Injury: An Initial Analysis	JOURNAL OF NEUROTRAUMA			English	Article						chitinase; controlled cortical impact; cytokine; gliosis; neuroinflammation; traumatic brain injury; YKL-40	CEREBROSPINAL-FLUID; GROWTH-FACTOR; MODERATE HYPOTHERMIA; HEAD-INJURY; CHILDREN; INTERLEUKIN-10; IL-6; CYTOKINE; MARKER; TISSUE	YKL-40 (chitinase 3-like protein 1) is expressed in a broad spectrum of inflammatory conditions and cancers. We have previously reported that YKL-40 levels are elevated in the cerebrospinal fluid (CSF) of macaques and humans with lentiviral encephalitis, as well as multiple sclerosis (MS). The current study assessed temporal CSF YKL-40 levels in subjects with severe traumatic brain injury (TBI; Glasgow Coma Scale [GCS] score <= 8). We also evaluated temporal expression of YKL-40 after parasagittal controlled cortical impact (CCI) injury over the parietal cortex (2.8 mm deep, 4 m/sec). We demonstrate that CSF YKL-40 levels are elevated after acute TBI, and that YKL-40 levels are higher in patients who died following injury than in patients who survived. YKL-40 levels significantly correlate with CSF levels of inflammatory cytokines such as interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha), as well as the inflammatory marker C-reactive protein (CRP). After CCI, in situ hybridization (ISH) showed that YKL-40 transcription is primarily associated with reactive astrocytes in peri-contusional cortex. Tissue YKL-40 transcription time course analysis after CCI showed that YKL40 transcription in astrocytes began 1 day after injury, remained elevated for several days, and then declined by day 12. Similarly to our temporal CSF measurements in humans, YKL-40 induction after CCI is coincident with IL-1 beta expression. Taken together these findings demonstrate that YKL-40 is induced in astrocytes during acute neuroinflammation, is temporally related to inflammatory mediator expression, and may be a useful biomarker for understanding secondary injury and for patient prognosis.	[Bonneh-Barkay, Dafna; Figley, Matthew; Starkey, Adam; Wang, Guoji; Bissel, Stephanie J.; Wiley, Clayton A.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA; [Zagadailov, Pavel; Zou, Huichao; Niyonkuru, Christian; Wagner, Amy K.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Zagadailov, Pavel; Zou, Huichao; Wagner, Amy K.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA		Bonneh-Barkay, D (corresponding author), Univ Pittsburgh, Dept Pathol, 200 Lothrop St, Pittsburgh, PA 15213 USA.	bonnehbarkayd@upmc.edu	Zou, Huichao/D-4094-2011	Zagadailov, Pavel/0000-0002-5433-1118; Figley, Matthew/0000-0003-2125-829X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5P01NS030318-16]; Pittsburgh Foundation;  [DODW81XWH-071-0701];  [CDCR 49 CCR323155-03];  [K24 MH01717];  [RO1 MH071151]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K24MH001717, R01MH071151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318] Funding Source: NIH RePORTER	We thank Arlene Carbone-Wiley, Jonette Werley, and Mark Stauffer for valuable technical assistance. We thank the Brain Trauma Research Center (National Institutes of Health grant no. 5P01NS030318-16) for assistance with subject recruitment and sample collection. This work was supported by grants DODW81XWH-071-0701 and CDCR 49 CCR323155-03 to A. K. W.; K24 MH01717 and RO1 MH071151 to C. A. W.; and Pittsburgh Foundation Emmerling funds to D.B.-B.	Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bonneh-Barkay D, 2008, AM J PATHOL, V173, P130, DOI 10.2353/ajpath.2008.080045; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Chiaretti A, 2008, EUR J PAEDIATR NEURO, V12, P195, DOI 10.1016/j.ejpn.2007.07.016; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hergenroeder G, 2008, J NEUROTRAUM, V25, P79, DOI 10.1089/neu.2007.0386; JENNETT B, 1975, LANCET, V1, P480; Johansen JS, 2006, DAN MED BULL, V53, P172; Kirchhoff C, 2008, EUR J MED RES, V13, P464; Kirkpatrick RB, 1997, EXP CELL RES, V237, P46, DOI 10.1006/excr.1997.3764; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lee CG, 2009, J EXP MED, V206, P1149, DOI 10.1084/jem.20081271; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Rehli M, 2003, J BIOL CHEM, V278, P44058, DOI 10.1074/jbc.M306792200; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Waje-Andreassen U, 2005, ACTA NEUROL SCAND, V111, P360, DOI 10.1111/j.1600-0404.2005.00416.x; Zhou ZG, 2009, EXP NEUROL, V220, P183, DOI 10.1016/j.expneurol.2009.08.018; Zhou ZG, 2009, J NEUROCHEM, V110, P1617, DOI 10.1111/j.1471-4159.2009.06263.x	25	57	59	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1215	1223		10.1089/neu.2010.1310			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100006	20486806	Green Published			2022-02-06	
J	Tian, HL; Chen, H; Wu, BS; Cao, HL; Xu, T; Hu, J; Wang, G; Gao, WW; Lin, ZK; Chen, SW				Tian, Heng-Li; Chen, Hao; Wu, Bing-Shan; Cao, He-Li; Xu, Tao; Hu, Jin; Wang, Gan; Gao, Wen-Wei; Lin, Zai-Kai; Chen, Shi-Wen			D-dimer as a predictor of progressive hemorrhagic injury in patients with traumatic brain injury: analysis of 194 cases	NEUROSURGICAL REVIEW			English	Article						Coagulation; D-dimer; Fibrinolysis; Progressive hemorrhagic injury; Traumatic brain injury	POSTTRAUMATIC CEREBRAL INFARCTION; RECOMBINANT FACTOR-VIIA; HEAD TRAUMA; COMPUTED-TOMOGRAPHY; COAGULOPATHY; BLUNT; THROMBOCYTOPENIA; MODERATE; UTILITY; LESIONS	This study sought to describe and evaluate any relationship between D-dimer values and progressive hemorrhagic injury (PHI) after traumatic brain injury (TBI). In patients with TBI, plasma D-dimer was measured while a computed tomography (CT) scan was conducted as soon as the patient was admitted to the emergency department. A series of other clinical and laboratory parameters were also measured and recorded. A logistic multiple regression analysis was used to identify risk factors for PHI. A cohort of 194 patients with TBI was evaluated in this clinical study. Eighty-one (41.8%) patients suffered PHI as determined by a second CT scan. The plasma D-dimer level was higher in patients who demonstrated PHI compared with those who did not (P < 0.001. Using a receiver-operator characteristic curve to predict the possibility by measuring the D-dimer level, a value of 5.00 mg/L was considered the cutoff point, with a sensitivity of 72.8% and a specificity of 78.8%. Eight-four patients had D-dimer levels higher than the cut point value (5.0 mg/L); PHI was seen in 71.4% of these patients and in 19.1% of the other patients (P < 0.01). Factors with P < 0.2 on bivariate analysis were included in a stepwise logistic regression analysis to identify independent risk factors for TBI coagulopathy. Logistic regression analysis showed that the D-dimer value was a predictor of PHI, and the odds ratio (OR) was 1.341 with per milligram per liter (P = 0.020). The stepwise logistic regression also identified that time from injury to the first CT shorter than 2 h (OR = 2.118, P = 0.047), PLT counts lesser than 100 x 109/L (OR = 7.853, P = 0.018), and Fg lower than 2.0 g/L (OR = 3.001, P = 0.012) were risk factors for the development of PHI. When D-dimer values were dichotomized at 5 mg/L, time from injury to the first CT scan was no longer a risk factor statistically while the OR value of D-dimer to the occurrence of PHI elevated to 11.850(P < 0.001). The level of plasma D-dimer after TBI can be a useful prognostic factor for PHI and should be considered in the clinical management of patients in combination with neuroimaging and other data.	[Tian, Heng-Li; Chen, Hao; Wu, Bing-Shan; Cao, He-Li; Xu, Tao; Hu, Jin; Wang, Gan; Gao, Wen-Wei; Lin, Zai-Kai] Shanghai Jiao Tong Univ, Shanghai People Hosp 6, Dept Neurosurg, Shanghai 200233, Peoples R China; [Chen, Shi-Wen] Shanghai Jiao Tong Univ, Shanghai People Hosp 6, Dept Radiol, Shanghai 200233, Peoples R China		Wu, BS (corresponding author), Shanghai Jiao Tong Univ, Shanghai People Hosp 6, Dept Neurosurg, 600 Yishan Rd, Shanghai 200233, Peoples R China.	wubingshan@gmail.com					Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; Barber M, 2004, STROKE, V35, P1421, DOI 10.1161/01.STR.0000126890.63512.41; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; Delgado P, 2006, NEUROLOGY, V67, P94, DOI 10.1212/01.wnl.0000223349.97278.e0; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; Juvela S, 2006, STROKE, V37, P1451, DOI 10.1161/01.STR.0000221710.55467.33; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Kuo JR, 2007, EUR J NEUROL, V14, P1073, DOI 10.1111/j.1468-1331.2007.01908.x; Kuo JR, 2004, J CLIN NEUROSCI, V11, P710, DOI 10.1016/j.jocn.2003.10.011; Lee KR, 1997, J NEUROSURG, V86, P272, DOI 10.3171/jns.1997.86.2.0272; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; MIRVIS SE, 1990, AM J ROENTGENOL, V154, P1293, DOI 10.2214/ajr.154.6.2110744; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Rathbun SW, 2004, CHEST, V125, P851, DOI 10.1378/chest.125.3.851; ROBSON SC, 1994, BRIT J HAEMATOL, V86, P322, DOI 10.1111/j.1365-2141.1994.tb04733.x; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sanus GZ, 2004, NEUROSURG QUART, V14, P97, DOI 10.1097/01.wnq.0000127718.06183.12; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Stein DM, 2009, J TRAUMA, V66, P63, DOI 10.1097/TA.0b013e318191bc8a; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TALVING P, 2008, J TRAUMA, V66, P61; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Tian HL, 2008, NEUROSURG REV, V31, P431, DOI 10.1007/s10143-008-0153-5; Wells PS, 2003, NEW ENGL J MED, V349, P1227, DOI 10.1056/NEJMoa023153; Williams MT, 2003, CRIT CARE CLIN, V19, P185, DOI 10.1016/S0749-0704(02)00048-9; Zaaroor M, 2008, ACTA NEUROCHIR, V150, P663, DOI 10.1007/s00701-008-1593-y	32	57	67	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5607	1437-2320		NEUROSURG REV	Neurosurg. Rev.	JUL	2010	33	3					359	365		10.1007/s10143-010-0251-z			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	612MN	WOS:000278902900021	20349100				2022-02-06	
J	Bansal, V; Costantini, T; Ryu, SY; Peterson, C; Loomis, W; Putnam, J; Elicieri, B; Baird, A; Coimbra, R				Bansal, Vishal; Costantini, Todd; Ryu, Seok Yong; Peterson, Carrie; Loomis, William; Putnam, James; Elicieri, Brian; Baird, Andrew; Coimbra, Raul			Stimulating the Central Nervous System to Prevent Intestinal Dysfunction After Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	68th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST)	OCT 01-03, 2009	Pittsburgh, PA	Amer Assoc Surg Trauma (AAST)		Traumatic brain injury; Intestinal permeability; Vagus nerve; TNF-alpha	INFLAMMATORY RESPONSE; SEVERITY; SURVIVAL; ALPHA; BLOOD; RATS; GUT	Background: Traumatic brain injury (TBI) causes gastrointestinal dysfunction and increased intestinal permeability. Regulation of the gut barrier may involve the central nervous system. We hypothesize that vagal nerve stimulation prevents an increase in intestinal permeability after TBI. Methods: Balb/c mice underwent a weight drop TBI. Selected mice had electrical stimulation of the cervical vagus nerve before TBI. Intestinal permeability to 4.4 kDa FITC-Dextran was measured 6 hours after injury. Ileum was harvested and intestinal tumor necrosis factor-alpha and glial fibrillary acidic protein (GFAP), a marker of glial activity, were measured. Results: TBI increased intestinal permeability compared with sham, 6 hours after injury (98.5 mu g/mL +/- 12.5 vs. 29.5 mu g/mL +/- 5.9 mu g/mL; p < 0.01). Vagal stimulation prevented TBI-induced intestinal permeability (55.8 +/- 4.8 mu g/mL vs. 98.49 mu g/mL +/- 12.5; p < 0.02). TBI animals had an increase in intestinal tumor necrosis factor-alpha 6 hours after injury compared with vagal stimulation + TBI (45.6 +/- 8.6 pg/mL vs. 24.1 +/- 1.4 pg/mL; p < 0.001). TBI increased intestinal GFAP 6.2-fold higher than sham at 2 hours and 11.5-fold higher at 4 hours after injury (p < 0.05). Intestinal GFAP in vagal stimulation + TBI animals was also 6.7-fold higher than sham at 2 hours, however, intestinal GFAP was 18.0-fold higher at 4 hours compared with sham and 1.6-fold higher than TBI alone (p < 0.05). Conclusion: In a mouse model of TBI, vagal stimulation prevented TBI-induced intestinal permeability. Furthermore, vagal stimulation increased enteric glial activity and may represent the pathway for central nervous system regulation of intestinal permeability.	[Bansal, Vishal; Costantini, Todd; Peterson, Carrie; Loomis, William; Putnam, James; Elicieri, Brian; Baird, Andrew; Coimbra, Raul] Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, San Diego, CA 92103 USA; [Ryu, Seok Yong] Inje Univ, Sanggye Paik Hosp, Dept Emergency Med, Gyeongnam, South Korea		Coimbra, R (corresponding author), Dept Surg, Div Trauma, San Diego, CA 92103 USA.	rcoimbra@ucsd.edu	Peterson, Carrie/AAF-8586-2021; Coimbra, Raul/AAP-3019-2020	Peterson, Carrie/0000-0002-8448-4633; Coimbra, Raul/0000-0002-3759-6851; Baird, Andrew/0000-0003-0027-9905	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20 GM078421-05, P20 GM078421] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM078421] Funding Source: NIH RePORTER		Ammori JB, 2008, SURGERY, V144, P159, DOI 10.1016/j.surg.2008.03.008; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; BANSAL V, 2009, J NEUROTRAUMA   0406; BEAL AL, 1994, JAMA-J AM MED ASSOC, V271, P226, DOI 10.1001/jama.271.3.226; Berthoud HR, 2004, NEUROGASTROENT MOTIL, V16, P28, DOI 10.1111/j.1743-3150.2004.00471.x; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Bush TG, 1998, CELL, V93, P189, DOI 10.1016/S0092-8674(00)81571-8; Costantini TW, 2009, SHOCK, V31, P416, DOI 10.1097/SHK.0b013e3181863080; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Cuzzocrea S, 2002, SHOCK, V18, P169, DOI 10.1097/00024382-200208000-00014; Enderson BL, 2007, J TRAUMA, V62, P33; Feighery L, 2008, J TRAUMA, V64, P131, DOI 10.1097/TA.0b013e3181568d9f; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2007, J SURG RES, V137, P53, DOI 10.1016/j.jss.2006.06.026; Kemp CD, 2008, AM SURGEON, V74, P866; Luyer MD, 2005, J EXP MED, V202, P1023, DOI 10.1084/jem.20042397; Ma B, 2007, ANAT HISTOL EMBRYOL, V36, P62, DOI 10.1111/j.1439-0264.2006.00741.x; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; Todd SR, 2008, CURR OPIN CRIT CARE, V14, P690, DOI 10.1097/MCC.0b013e3283196562; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Zolotarevsky Y, 2002, GASTROENTEROLOGY, V123, P163, DOI 10.1053/gast.2002.34235	26	57	60	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2010	68	5					1059	1064		10.1097/TA.0b013e3181d87373			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	595MQ	WOS:000277615200007	20453760	Green Accepted			2022-02-06	
J	Ragel, BT; Klimo, P; Martin, JE; Teff, RJ; Bakken, HE; Armonda, RA				Ragel, Brian T.; Klimo, Paul, Jr.; Martin, Jonathan E.; Teff, Richard J.; Bakken, Hans E.; Armonda, Rocco A.			Wartime decompressive craniectomy: technique and lessons learned	NEUROSURGICAL FOCUS			English	Article						battlefield; decompressive craniectomy; military	PENETRATING CRANIOCEREBRAL INJURIES; MIDDLE CEREBRAL-ARTERY; SEVERE HEAD-INJURY; INTRACRANIAL HYPERTENSION; NEUROSURGICAL EXPERIENCE; TRAUMATIC BRAIN; BULLET VELOCITY; INFARCTION; LEBANON; WOUNDS	Object. Decompressive craniectomy (DC) with dural expansion is a life-saving neurosurgical procedure performed for recalcitrant intracranial hypertension due to trauma, stroke, and a multitude of other etiologies. Illustratively, we describe technique and lessons learned using DC for battlefield trauma. Methods. Neurosurgical operative logs from service (October 2007 to September 2009) in Afghanistan that detail DC cases for trauma were analyzed. Illustrative examples of frontotemporoparietal and bifrontal DC that depict battlefield experience performing these procedures are presented with attention drawn to the L. G. Kempe hemispherectomy incision, brainstem decompression techniques, and dural onlay substitutes. Results. Ninety craniotomies were performed for trauma over the time period analyzed. Of these, 28 (31%) were DCs. Of the 28 DCs, 24 (86%) were frontotemporoparietal DCs, 7 (25%) were bifrontal DCs, and 2 (7%) were suboccipital DCs. Decompressive craniectomies were performed for 19 penetrating head injuries (13 gunshot wounds and 6 explosions) and 9 severe closed head injuries (6 war-related explosions and 3 others). Conclusions. Thirty-one percent of craniotomies performed for trauma were DCs. Battlefield neurosurgeons use DC to allow for safe transfer of neurologically ill patients to tertiary military hospitals, which can be located 8-18 hours from a war zone. The authors recommend the L. G. Kempe incision for blood supply preservation, large craniectomies to prevent brain strangulation over bone edges, minimal brain debridement, adequate brainstem decompression, and dural onlay substitutes for dural closure. (DOI: 10.3171/2010.3.FOCUS1028)	[Ragel, Brian T.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97239 USA; [Klimo, Paul, Jr.] Neurosurg Serv, Wright Patterson AFB, OH USA; [Martin, Jonathan E.] Connecticut Childrens Med Ctr, Div Neurosurg, Hartford, CT USA; [Teff, Richard J.] Brooke Army Med Ctr, Dept Neurosurg, Ft Sam Houston, TX 78234 USA; [Bakken, Hans E.] Madigan Army Med Ctr, Dept Neurosurg, Ft Lewis, WA USA; [Armonda, Rocco A.] Walter Reed Army Med Ctr, Dept Neurosurg, Washington, DC 20307 USA		Ragel, BT (corresponding author), Oregon Hlth & Sci Univ, Dept Neurol Surg, Mail Code CH8N,3303 SW Bond Ave, Portland, OR 97239 USA.	brian.ragel@gmail.com		Martin, Jonathan/0000-0003-3180-2084			Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; BATES M, 2008, AIRMAN OFFICAL MAGAZ, V42, P4; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; Chen CC, 2007, J CLIN NEUROSCI, V14, P317, DOI 10.1016/j.jocn.2005.05.024; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cushing H, 1918, BRIT J SURG, V5, P558; Cushing H, 1908, ANN SURG, V47, P641, DOI 10.1097/00000658-190805000-00001; Day JD, 1998, NEUROSURGERY, V42, P198, DOI 10.1097/00006123-199801000-00045; DEMUTH WE, 1969, J TRAUM, V9, P27, DOI 10.1097/00005373-196901000-00003; DEMUTH WE, 1966, J TRAUM, V6, P222, DOI 10.1097/00005373-196606020-00008; HAMMON WM, 1971, J NEUROSURG, V34, P142, DOI 10.3171/jns.1971.34.2part1.0142; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Kempke LG, 1968, OPERATIVE NEUROSURGE, V1, P179; KLIMO PK, 2009, AANS YOUNG NEUROSURG, P2; LEVI L, 1990, ISRAEL J MED SCI, V26, P548; LEVI L, 1990, ISRAEL J MED SCI, V26, P555; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; MATSON DD, 1958, SURGERY WORLD WAR 2, V1, P123; MOORES L, 2008, C Q, V9, P31; Schirmer CM, 2008, NEUROCRIT CARE, V8, P456, DOI 10.1007/s12028-008-9082-y; TRUNKEY D, 1993, ARCH SURG-CHICAGO, V128, P261; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012	26	57	59	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	MAY	2010	28	5							E2	10.3171/2010.3.FOCUS1028			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	589ZU	WOS:000277193600002	20568936				2022-02-06	
J	Meric, E; Gunduz, A; Turedi, S; Cakir, E; Yandi, M				Meric, Emine; Gunduz, Abdulkadir; Turedi, Suleyman; Cakir, Ertugrul; Yandi, Mustafa			THE PROGNOSTIC VALUE OF NEURON-SPECIFIC ENOLASE IN HEAD TRAUMA PATIENTS	JOURNAL OF EMERGENCY MEDICINE			English	Article						head trauma; neuron-specific enolase; prognosis	SERUM; BRAIN; MARKER; INJURY	In recent years, in addition to neurological examination and neuroradiologic examinations, attempts have been made to assess the severity of post-traumatic brain injury and to obtain an early idea of patient prognosis using biochemical markers with a high degree of brain tissue specificity. One such enzyme is neuron-specific enolase (NSE). This study investigates the correlation between serum NSE levels, Glasgow Coma Score, and prognosis measured by Glasgow Outcome Scores in head trauma patients. This was a prospective study conducted with 80 trauma patients presenting to the Emergency Department. Patients were divided into four groups. The first group consisted of patients with general body trauma, but no head trauma. The second group had minor head trauma. The third group had moderate head trauma, and the fourth group had severe head trauma. The relationship between subjects' admission NSE levels and admission and discharge Glasgow Coma Scores (GCS) and Glasgow Outcome Scores (GOS) 1 month later was examined. A receiver operating characteristic (ROC) analysis was performed using a serum NSE cutoff level of 20.52 ng/mL and a GOS of 3 or less as the definition of poor neurologic outcome. There was a significant difference in the NSE levels between group 1 (general trauma) and group 3 (moderate head trauma). There was also a statistically significant difference in NSE levels between group 1 (general trauma) and group 4 (severe head trauma) (p < 0.05). There was a statistically significant inverse relationship between NSE levels and GOS as determined within groups 3 (moderate) and 4 (severe head trauma) (p < 0.05). When NSE levels were compared with admission GCS, it was found that GCS fell as NSE levels rose. There was no significant correlation between NSE and GCS within groups 3 (moderate) or 4 (severe). There was a statistically significant correlation within group 2 (mild) (p < 0.05). By ROC analysis, serum NSE was 87% sensitive and 82.1% specific in predicting poor neurologic outcome in the study patients. The area under the curve was 0.931. This study shows that initial serum NSE levels in moderate and severe head trauma patients correlate inversely with GOS 1 month later, but only within the moderate and severe head trauma groups. However, serum NSE was 87% sensitive and 82.1% specific in predicting poor neurologic outcome in all of the study patients. This derived cutoff value now needs to be prospectively validated. (C) 2010 Elsevier Inc.	[Gunduz, Abdulkadir; Turedi, Suleyman] Karadeniz Tech Univ, Fac Med, Dept Emergency Med, TR-61080 Trabzon, Turkey; [Meric, Emine] Ordu Gen Hosp, Dept Emergency Med, Ordu, Turkey; [Cakir, Ertugrul] Karadeniz Tech Univ, Fac Med, Dept Neurosurg, TR-61080 Trabzon, Turkey; [Yandi, Mustafa] Karadeniz Tech Univ, Fac Med, Dept Gen Surg, TR-61080 Trabzon, Turkey		Turedi, S (corresponding author), Karadeniz Tech Univ, Tip Fak, Farabi Hastanesi, Acil Tip Anabilim Dali, TR-61080 Trabzon, Turkey.		Turedi, Suleyman/AAW-5507-2021; Gunduz, Abdulkadir/AAW-7072-2020; Cakir, Ertugrul/AAW-1783-2021	Turedi, Suleyman/0000-0002-6500-3961			BAKAY RA, 1996, NEUROSURGERY, V18, P376; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; DeGiorgio CM, 1996, EPILEPSIA, V37, P606, DOI 10.1111/j.1528-1157.1996.tb00623.x; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; HECK CN, 1996, EPILEPSY Q, V37, P606; Hermann DM, 1999, RESTOR NEUROL NEUROS, V14, P103; Kukacka J, 2006, NEUROENDOCRINOL LETT, V27, P116; KUROIWA T, 1993, SHINKEI GEKA, V21, P1021; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6	15	57	66	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	APR	2010	38	3					297	301		10.1016/j.jemermed.2007.11.032			5	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	581ZI	WOS:000276564200004	18499387				2022-02-06	
J	Hunt, RF; Scheff, SW; Smith, BN				Hunt, Robert F.; Scheff, Stephen W.; Smith, Bret N.			Regionally Localized Recurrent Excitation in the Dentate Gyrus of a Cortical Contusion Model of Posttraumatic Epilepsy	JOURNAL OF NEUROPHYSIOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; KAINATE-TREATED RATS; GRANULE CELLS; SYNAPTIC REORGANIZATION; HIPPOCAMPAL SLICES; STATUS EPILEPTICUS; PYRAMIDAL CELLS; MOSSY FIBERS; SEIZURES	Hunt RF, Scheff SW, Smith BN. Regionally localized recurrent excitation in the dentate gyrus of a cortical contusion model of posttraumatic epilepsy. J Neurophysiol 103: 1490-1500, 2010. First published January 20, 2010; doi: 10.1152/jn.00957.2009. Posttraumatic epilepsy is a frequent consequence of brain trauma, but relatively little is known about how neuronal circuits are chronically altered after closed head injury. We examined whether local recurrent excitatory synaptic connections form between dentate granule cells in mice 8-12 wk after cortical contusion injury. Mice were monitored for behavioral seizures shortly after brain injury and <= 10 wk postinjury. Injury-induced seizures were observed in 15% of mice, and spontaneous seizures were observed weeks later in 40% of mice. Timm's staining revealed mossy fiber sprouting into the inner molecular layer of the dorsal dentate gyrus ipsilateral to the injury in 95% of mice but not contralateral to the injury or in uninjured controls. Whole cell patch-clamp recordings were made from granule cells in isolated hippocampal brain slices. Cells in slices with posttraumatic mossy fiber sprouting had an increased excitatory postsynaptic current (EPSC) frequency compared with cells in slices without sprouting from injured and control animals (P < 0.001). When perfused with Mg2+-free artificial cerebrospinal fluid containing 100 mu M picrotoxin, these cells had spontaneous bursts of EPSCs and action potentials. Focal glutamate photostimulation of the granule cell layer evoked a burst of EPSCs and action potentials indicative of recurrent excitatory connections in granule cells of slices with mossy fiber sprouting. In granule cells of slices without sprouting from injured animals and controls, spontaneous or photostimulation-evoked epileptiform activity was never observed. These results suggest that a new regionally localized excitatory network forms between dentate granule cells near the injury site within weeks after cortical contusion head injury.	[Hunt, Robert F.; Smith, Bret N.] Univ Kentucky, Dept Physiol, Chandler Med Ctr MS 508, Lexington, KY 40536 USA; [Scheff, Stephen W.; Smith, Bret N.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA		Smith, BN (corresponding author), Univ Kentucky, Dept Physiol, Chandler Med Ctr MS 508, 800 Rose St, Lexington, KY 40536 USA.	bret.smith@uky.edu		Hunt, Robert/0000-0003-4490-8718	Epilepsy Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG-21981, NS-052302]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS052302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER	This work was supported by an Epilepsy Foundation training fellowship to R. F. Hunt and National Institutes of Health Grants AG-21981 to S. W. Scheff and NS-052302 to B. N. Smith.	ALVAREZBUYLLA A, 1990, J NEUROSCI METH, V33, P129, DOI 10.1016/0165-0270(90)90016-9; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BUCKMASTER PS, 1992, HIPPOCAMPUS, V2, P349, DOI 10.1002/hipo.450020403; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Buckmaster PS, 2002, J NEUROSCI, V22, P6650; CALLAWAY EM, 1993, P NATL ACAD SCI USA, V90, P7661, DOI 10.1073/pnas.90.16.7661; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; CRONIN J, 1988, BRAIN RES, V474, P181, DOI 10.1016/0006-8993(88)90681-6; CRONIN J, 1992, BRAIN RES, V573, P305, DOI 10.1016/0006-8993(92)90777-7; Dudek FE, 1997, J CLIN NEUROPHYSIOL, V14, P90, DOI 10.1097/00004691-199703000-00002; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; FRICKE RA, 1984, J NEUROPHYSIOL, V51, P195, DOI 10.1152/jn.1984.51.2.195; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HOUSER CR, 1990, BRAIN RES, V535, P195, DOI 10.1016/0006-8993(90)91601-C; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; KELLER BU, 1991, J PHYSIOL-LONDON, V435, P275, DOI 10.1113/jphysiol.1991.sp018510; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Kotti T, 1997, EXP NEUROL, V146, P323, DOI 10.1006/exnr.1997.6553; Lynch M, 2000, J NEUROPHYSIOL, V83, P693, DOI 10.1152/jn.2000.83.2.693; Meldrum BS, 1999, EPILEPSY RES, V36, P189, DOI 10.1016/S0920-1211(99)00051-0; MILES R, 1984, NEUROSCIENCE, V12, P1179, DOI 10.1016/0306-4522(84)90012-5; MILES R, 1987, J PHYSIOL-LONDON, V388, P611, DOI 10.1113/jphysiol.1987.sp016634; Patrylo PR, 1998, J NEUROPHYSIOL, V79, P418, DOI 10.1152/jn.1998.79.1.418; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Racine R. J., 1979, CLIN NEUROPHYSIOL, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Salin P, 1995, J NEUROSCI, V15, P8234; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; SCHARFMAN HE, 1995, J NEUROPHYSIOL, V74, P179, DOI 10.1152/jn.1995.74.1.179; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schubert D, 2001, J NEUROSCI, V21, P3580, DOI 10.1523/JNEUROSCI.21-10-03580.2001; Shibley H, 2002, EPILEPSY RES, V49, P109, DOI 10.1016/S0920-1211(02)00012-8; Shumate Melissa, 1995, Epilepsia, V36, P118; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1992, NEUROSCI LETT, V137, P91, DOI 10.1016/0304-3940(92)90306-R; Smith BN, 2002, J NEUROPHYSIOL, V87, P1655, DOI 10.1152/jn.00581.2001; Smith BN, 2001, J NEUROPHYSIOL, V85, P1, DOI 10.1152/jn.2001.85.1.1; STALEY KJ, 1992, J NEUROPHYSIOL, V67, P1346, DOI 10.1152/jn.1992.67.5.1346; STALEY KJ, 1992, SYNAPSE, V9, P219; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; Steinlein OK, 2004, NAT REV NEUROSCI, V5, P400, DOI 10.1038/nrn1388; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; TRAUB RD, 1982, SCIENCE, V216, P745, DOI 10.1126/science.7079735; TRAUB RD, 1981, NEUROSCIENCE, V6, P223, DOI 10.1016/0306-4522(81)90058-0; Winokur RS, 2004, EPILEPSY RES, V58, P93, DOI 10.1016/j.eplepsyres.2004.01.002; Wong RKS, 1983, NATURE, V306, P397; Wuarin JP, 1996, J NEUROSCI, V16, P4438; Wuarin JP, 2001, J NEUROPHYSIOL, V85, P1067, DOI 10.1152/jn.2001.85.3.1067	58	57	57	0	8	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077			J NEUROPHYSIOL	J. Neurophysiol.	MAR	2010	103	3					1490	1500		10.1152/jn.00957.2009			11	Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Physiology	570EY	WOS:000275656200033	20089815	Green Published			2022-02-06	
J	White, BD; Nathe, RJ; Maris, DO; Nguyen, NK; Goodson, JM; Moon, RT; Horner, PJ				White, Bryan D.; Nathe, Ryan J.; Maris, Don O.; Nguyen, Nghi K.; Goodson, Jamie M.; Moon, Randall T.; Horner, Philip J.			beta-Catenin Signaling Increases in Proliferating NG2+Progenitors and Astrocytes during Post-Traumatic Gliogenesis in the Adult Brain	STEM CELLS			English	Article						Wnt; Neural stem cell; Gliosis; Brain injury; Spinal cord injury	SPINAL-CORD-INJURY; EMBRYONIC STEM-CELLS; UP-REGULATES STAT3; NG2 PROTEOGLYCAN; SELF-RENEWAL; STEM/PROGENITOR CELLS; SUBVENTRICULAR ZONE; REACTIVE GLIOSIS; PROGENITOR CELLS; NERVOUS-SYSTEM	Wnt/beta-catenin signaling can influence the proliferation and differentiation of progenitor populations in the hippocampus and subventricular zone, known germinal centers in the adult mouse brain. It is not known whether beta-catenin signaling occurs in quiescent glial progenitors in cortex or spinal cord, nor is it known whether beta-catenin is involved in the activation of glial progenitor populations after injury. Using a beta-catenin reporter mouse (BATGAL mouse), we show that beta-catenin signaling occurs in NG2 chondroitin sulfate proteoglycan+ (NG2) progenitors in the cortex, in subcallosal zone (SCZ) progenitors, and in subependymal cells surrounding the central canal. Interestingly, cells with beta-catenin signaling increased in the cortex and SCZ following traumatic brain injury (TBI) but did not following spinal cord injury. Initially after TBI, beta-catenin signaling was predominantly increased in a subset of NG2+ progenitors in the cortex. One week following injury, the majority of beta-catenin signaling appeared in reactive astrocytes but not oligodendrocytes. Bromodeoxyuridine (BrdU) paradigms and Ki-67 staining showed that the increase in beta-catenin signaling occurred in newly born cells and was sustained after cell division. Dividing cells with beta-catenin signaling were initially NG21; however, by four days after a single injection of BrdU, they were predominantly astrocytes. Infusing animals with the mitotic inhibitor cytosine arabinoside prevented the increase of beta-catenin signaling in the cortex, confirming that the majority of beta-catenin signaling after TBI occurs in newly born cells. These data argue for manipulating the Wnt/beta-catenin pathway after TBI as a way to modify post-traumatic gliogenesis. STEM CELLS 2010;28:297-307	[Nathe, Ryan J.; Maris, Don O.; Horner, Philip J.] Univ Washington, Sch Med, Dept Neurosurg, Seattle, WA 98109 USA; [White, Bryan D.] Univ Washington, Sch Med, Program Neurobiol & Behav, Seattle, WA 98109 USA; [White, Bryan D.; Moon, Randall T.] Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98109 USA; [White, Bryan D.; Nguyen, Nghi K.; Goodson, Jamie M.; Moon, Randall T.] Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98109 USA		Horner, PJ (corresponding author), Univ Washington, Sch Med, Dept Neurol Surg, Inst Stem Cell & Regenerat Med, Box 358056,815 Mercer St, Seattle, WA 98109 USA.	rtmoon@u.washington.edu; phorner@u.washington.edu	Horner, Philip J./AAF-7012-2021; Moon, Randall T/B-1743-2014; Moon, Randall/M-5605-2019	Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408; Goodson, Jamie/0000-0002-9091-8362	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 GM073887, NSO46724, NIG5 T32GM07108]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM073887, T32GM007108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046724] Funding Source: NIH RePORTER	We wish to thank Denise Inman, Kathy Davidson, Andy Chien, Richard James, and Nathan Camp for helpful comments on the manuscript; Ramona Hicks and Andy Fink for initial discussions and assistance with TBI procedure; William Stallcup for the gift of anti-NG2 antibody. This work was supported by NIH RO1 GM073887 (R. T. M.), NIH NSO46724 (P. J. H.), and NIH NIG5 T32GM07108 (B. D. W). R. T. M is an Investigator of the HHMI.	Adachi K, 2007, STEM CELLS, V25, P2827, DOI 10.1634/stemcells.2007-0177; Alonso G, 2005, GLIA, V49, P318, DOI 10.1002/glia.20121; Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; Bikkavilli Rama Kamesh, 2009, Commun Integr Biol, V2, P46; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Burns KA, 2009, GLIA, V57, P1115, DOI 10.1002/glia.20835; Butt AM, 2002, J NEUROCYTOL, V31, P551, DOI 10.1023/A:1025751900356; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Chittajallu R, 2004, J PHYSIOL-LONDON, V561, P109, DOI 10.1113/jphysiol.2004.074252; Dravid G, 2005, STEM CELLS, V23, P1489, DOI 10.1634/stemcells.2005-0034; Fancy SPJ, 2009, GENE DEV, V23, P1571, DOI 10.1101/gad.1806309; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Goessling W, 2008, DEV BIOL, V320, P161, DOI 10.1016/j.ydbio.2008.05.526; Gulacsi AA, 2008, NAT NEUROSCI, V11, P1383, DOI 10.1038/nn.2226; Hampton DW, 2004, NEUROSCIENCE, V127, P813, DOI 10.1016/j.neuroscience.2004.05.028; Hao J, 2006, DEV BIOL, V290, P81, DOI 10.1016/j.ydbio.2005.11.011; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Horner PJ, 2002, J NEUROCYTOL, V31, P469, DOI 10.1023/A:1025739630398; Ito M, 2007, NATURE, V447, P316, DOI 10.1038/nature05766; Ito M, 2009, J NEUROTRAUM, V26, P41, DOI 10.1089/neu.2008.0646; Kalani MYS, 2008, P NATL ACAD SCI USA, V105, P16970, DOI 10.1073/pnas.0808616105; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Liebner S, 2008, J CELL BIOL, V183, P409, DOI 10.1083/jcb.200806024; Lytle JM, 2009, GLIA, V57, P270, DOI 10.1002/glia.20755; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Mothe AJ, 2005, NEUROSCIENCE, V131, P177, DOI 10.1016/j.neuroscience.2004.10.011; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; Osakada F, 2007, J NEUROSCI, V27, P4210, DOI 10.1523/JNEUROSCI.4193-06.2007; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Rivers LE, 2008, NAT NEUROSCI, V11, P1392, DOI 10.1038/nn.2220; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Sellers DL, 2009, J NEUROSCI, V29, P6722, DOI 10.1523/JNEUROSCI.4538-08.2009; Seri B, 2006, CEREB CORTEX, V16, pI103, DOI 10.1093/cercor/bhk027; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Shimizu T, 2005, DEV BIOL, V282, P397, DOI 10.1016/j.ydbio.2005.03.020; Stoick-Cooper CL, 2007, DEVELOPMENT, V134, P479, DOI 10.1242/dev.001123; Yamashita S, 2002, DEV CELL, V2, P363, DOI 10.1016/S1534-5807(02)00126-0; Yan S, 2008, CANCER LETT, V271, P85, DOI 10.1016/j.canlet.2008.05.035; YE F, 2009, NATURE NEUROSCI; Zechner D, 2003, DEV BIOL, V258, P406, DOI 10.1016/S0012-1606(03)00123-4; Zhao JW, 2009, EUR J NEUROSCI, V29, P1853, DOI 10.1111/j.1460-9568.2009.06736.x; Zhu XQ, 2008, DEVELOPMENT, V135, P145, DOI 10.1242/dev.004895; Zhu XQ, 2008, NEURON GLIA BIOL, V4, P19, DOI 10.1017/S1740925X09000015	51	57	60	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	FEB	2010	28	2					297	307		10.1002/stem.268			11	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	562NK	WOS:000275058400014	19960516	Bronze, Green Accepted			2022-02-06	
J	Walker, WC; Ketchum, JM; Marwitz, JH; Chen, T; Hammond, F; Sherer, M; Meythaler, J				Walker, W. C.; Ketchum, J. M.; Marwitz, J. H.; Chen, T.; Hammond, F.; Sherer, M.; Meythaler, J.			A multicentre study on the clinical utility of post-traumatic amnesia duration in predicting global outcome after moderate-severe traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							GLASGOW COMA SCALE; HEAD-INJURY; GALVESTON ORIENTATION; PRACTICAL SCALE; REHABILITATION; LOG	Background: Past research shows that post-traumatic amnesia (PTA) duration is a particularly robust traumatic brain injury (TBI) outcome predictor, but low specificity limits its clinical utility. Objectives: The current study assessed the relationship between PTA duration and probability thresholds for Glasgow Outcome Scale (GOS) levels. Methods: Data were prospectively collected in this multicentre observational study. The cohort was a consecutive sample of rehabilitation patients enrolled in the National Institute on Disability and Rehabilitation Research funded TBI Model Systems (n=1332) that had documented finite PTA duration greater than 24 h, and 1-year and 2-year GOS. Results: The cohort had proportionally more Good Recovery (44% vs 39%) and less Severe Disability (19% vs 23%) at year 2 than at year 1. Longer PTA resulted in an incremental decline in probability of Good Recovery and a corresponding increase in probability of Severe Disability. When PTA ended within 4 weeks, Severe Disability was unlikely (< 15% chance) at year 1, and Good Recovery was the most likely GOS at year 2. When PTA lasted beyond 8 weeks, Good Recovery was highly unlikely (< 10% chance) at year 1, and Severe Disability was equal to or more likely than Moderate Disability at year 2. Conclusions: Two PTA durations, 4 weeks and 8 weeks, emerged as particularly salient GOS probability thresholds that may aid prognostication after TBI.	[Walker, W. C.; Marwitz, J. H.; Chen, T.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Ketchum, J. M.] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23298 USA; [Hammond, F.] Carolinas Rehabil, Charlotte, NC USA; [Sherer, M.] TIRR Mem Hermann, Houston, TX USA; [Meythaler, J.] Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI USA		Walker, WC (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Box 980661, Richmond, VA 23298 USA.	wwalker@mcvh-vcu.edu	Ketchum, Jessica/AAE-8200-2020; Walker, William C/N-3162-2014	Ketchum, Jessica/0000-0002-5566-3691	National Institute on Disability and Rehabilitation Research, United States Department of EducationUS Department of Education [H133A070036, H133A070042, H133A070043]	Supported by grants H133A070036 (VCU TBI Model System), H133A070042 (Carolinas TBI Model System), H133A070043 (Texas TBI Model System of TIRR) from the National Institute on Disability and Rehabilitation Research, United States Department of Education.	Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; JENNETT B, 1975, LANCET, V1, P480; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kothari S., 2006, BRAIN INJURY MED PRI, P529; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2001, CURR PHARM DESIGN, V7, P1537, DOI 10.2174/1381612013397276	15	57	57	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JAN 10	2010	81	1					87	89		10.1136/jnnp.2008.161570			3	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	533WF	WOS:000272855400021	20019222				2022-02-06	
S	Bruce, ML		Barchas, JD; Difede, J		Bruce, Martha L.			Suicide risk and prevention in veteran populations	PSYCHIATRIC AND NEUROLOGIC ASPECTS OF WAR	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	89th Annual Conference of the Association for Research in Nervous and Mental Disease	DEC 16, 2009	Rockefeller Univ, New York, NY		Rockefeller Univ	suicide; veterans; military	TRAUMATIC BRAIN-INJURY; VIETNAM VETERANS; INTEGRATED CARE; VA PATIENTS; FOLLOW-UP; PRISM-E; DEPRESSION; MORTALITY; OUTCOMES; PERIODS	Rates of suicide among veterans of Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) rose significantly from 2005 to 2007, adding to existing concerns about veteran suicide risk by the Department of Veterans Affairs. This paper summarizes the available data about risk and rates of suicide in veterans, including the choice of appropriate comparison groups and the identification of risk factors. The data suggest that taking into account the selection bias of who enters the military (known as the healthy soldier effect), rates of suicide in veterans are higher than expected, especially among activity duty OEF/OIF veterans and even more so among those who experienced injuries and trauma. Thus, the experiences of war and the downstream sequelae, in particular the individuals' psychological reactions and societal responses, lead to suicide risk. This paper describes the VA's response to these data in developing and implementing suicide prevention interventions.	Weill Cornell Med Coll, Dept Psychiat, Westchester Div, White Plains, NY 10605 USA		Bruce, ML (corresponding author), Weill Cornell Med Coll, Dept Psychiat, Westchester Div, 21 Bloomingdale Rd, White Plains, NY 10605 USA.	mbruce@med.cornell.edu					Blue Ribbon Work Group on Suicide Prevention in the Veteran Population, 2008, REP BLUE RIBB WORK G; Boehmer TKC, 2004, ARCH INTERN MED, V164, P1908, DOI 10.1001/archinte.164.17.1908; Breiding MJ, 2006, INJURY PREV, V12, P49, DOI 10.1136/ip.2006.012591; Brenner LA, 2009, REHABIL PSYCHOL, V54, P390, DOI 10.1037/a0017802; Bruce ML, 2004, JAMA-J AM MED ASSOC, V291, P1081, DOI 10.1001/jama.291.9.1081; Bullman TA, 1996, AM J PUBLIC HEALTH, V86, P662, DOI 10.2105/AJPH.86.5.662; CLIFTON E, 2010, SUICIDE RATE SURGED; Cukor J, 2009, CLIN PSYCHOL REV, V29, P715, DOI 10.1016/j.cpr.2009.09.001; Desai RA, 2008, MIL MED, V173, P721, DOI 10.7205/MILMED.173.8.721; Difede J, 2009, INT REV PSYCHIATR, V21, P559, DOI 10.3109/09540260903344081; Gibbons RD, 2007, AM J PSYCHIAT, V164, P1044, DOI 10.1176/appi.ajp.164.7.1044; Gutierrez PM, 2008, ARCH SUICIDE RES, V12, P336, DOI 10.1080/13811110802324961; HEFLING K, 2010, HUFFINGTON POST 0111, P18; *I MED, 1994, RED RISKS MENT DIS F; Kang HK, 2008, JAMA-J AM MED ASSOC, V300, P652, DOI 10.1001/jama.300.6.652; Kang HK, 2009, ANN EPIDEMIOL, V19, P757, DOI 10.1016/j.annepidem.2009.05.004; Kaplan MS, 2007, J EPIDEMIOL COMMUN H, V61, P619, DOI 10.1136/jech.2006.054346; Krahn DD, 2006, PSYCHIAT SERV, V57, P946, DOI 10.1176/appi.ps.57.7.946; Matthieu MM, 2009, MIL MED, V174, P1123, DOI 10.7205/MILMED-D-00-1109; Matthieu MM, 2008, ARCH SUICIDE RES, V12, P148, DOI 10.1080/13811110701857491; McAllister TW, 2009, CLIN NEUROPSYCHOL, V23, P1338, DOI 10.1080/13854040903277289; McLaughlin R, 2008, ANN EPIDEMIOL, V18, P928, DOI 10.1016/j.annepidem.2008.09.002; Mills PD, 2008, JT COMM J QUAL PATIE, V34, P482, DOI 10.1016/S1553-7250(08)34061-6; National Institute of Mental Health, 2006, SUIC US STAT PREV; Oslin DW, 2006, PSYCHIAT SERV, V57, P954, DOI 10.1176/appi.ps.57.7.954; Pietrzak RH, 2010, J AFFECT DISORDERS, V123, P102, DOI 10.1016/j.jad.2009.08.001; Pietrzak RH, 2009, PSYCHIAT SERV, V60, P1118, DOI 10.1176/ps.2009.60.8.1118; *US DEP HHS, 2001, NAT STRAT SUIC PREV; *US DEP VET AFF, 2010, SUIC PREV; Valenstein M, 2009, PSYCHIAT SERV, V60, P439, DOI 10.1176/appi.ps.60.4.439; Valenstein M, 2009, J AFFECT DISORDERS, V112, P50, DOI 10.1016/j.jad.2008.08.020; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004	32	57	57	0	15	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND	0077-8923		978-1-57331-804-4	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2010	1208						98	103		10.1111/j.1749-6632.2010.05697.x			6	Neurosciences; Psychiatry	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	BSK28	WOS:000284742000013	20955331				2022-02-06	
J	Larson, EB; Zollman, FS				Larson, Eric B.; Zollman, Felise S.			The Effect of Sleep Medications on Cognitive Recovery From Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; cognition disorders; hypnotics and sedatives; sleep initiation and maintenance disorders	DOSE-RESPONSE; ZOLPIDEM; TRAZODONE; INSOMNIA; MEMORY; TRIAZOLAM; EFFICACY; DRUGS; IMPAIRMENT; ZOPICLONE	Objective: To summarize the literature on the available pharmacotherapy for insomnia and the adverse cognitive effects of those options in persons with traumatic brain injury (TBI). Design: Ovid/MEDLINE databases were searched by using the following key words: "brain injury," "sleep initiation and maintenance disorders," "hypnotics and sedatives," "benzodiazepines," "trazodone," and "neuronal plasticity." Results: The reviewed literature consistently reported that benzodiazepines and atypical gamma-aminobutyric acid (GABA) agonists result in cognitive impairment when plasma levels are at their peak. Evidence of residual effects on cognition was reported for benzodiazepines but was seen less often in atypical GABA agonists. However, evidence has also been presented that GABA agonists have adverse effects on neuroplasticity, raising concerns about their use in patients recovering from TBI. Conclusions: Use of benzodiazepines in TBI has been discouraged and some authors also advocate caution in prescribingatypical GABA agonists. Alternate treatments including trazodone and a newer class of agents, melatonin agonists, are highlighted, along with the limited data available addressing the use of these medications in TBI. Finally, suggestions are offered for further research, especially on topic related to neural plasticity and functional recovery.	[Larson, Eric B.; Zollman, Felise S.] Rehabil Inst Chicago, Brain Injury Rehabil & Med Program, Chicago, IL 60611 USA; [Larson, Eric B.; Zollman, Felise S.] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Zollman, Felise S.] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA		Larson, EB (corresponding author), Rehabil Inst Chicago, Brain Injury Rehabil & Med Program, 345 E Super St, Chicago, IL 60611 USA.	elarson@ric.org	Sanguansri, Luz/B-6630-2011; Larson, Eric/AAD-9567-2021	Sanguansri, Luz/0000-0003-1908-7604; 	US Department of Education, National Institute on Disability and Rehabilitation ResearchUS Department of Education [HI33N060014]	This study was supported by the US Department of Education, National Institute on Disability and Rehabilitation Research, grant HI33N060014 through the Midwest Regional Traumatic Brain Injury Model System: Innovative Approaches to Improve Cognition, Function, and Community Living. We thank Laura Wasek for her assistance in this project.	ALLEN D, 1993, EUR J CLIN PHARMACOL, V45, P313; Barker MJ, 2005, J INT NEUROPSYCH SOC, V11, P281, DOI 10.1017/S1355617705050332; Barker MJ, 2004, ARCH CLIN NEUROPSYCH, V19, P437, DOI 10.1016/S0887-6177(03)00096-9; BARRON J, 1985, AM J MENT DEF, V90, P124; BEER B, 1994, J CLIN PHARMACOL, V34, P335, DOI 10.1002/j.1552-4604.1994.tb02002.x; BILLIARD M, 1987, SLEEP, V10, P27, DOI 10.1093/sleep/10.suppl_1.27; BOYESON MG, 1993, AM J PHYS MED REHAB, V72, P286, DOI 10.1097/00002060-199310000-00007; Buscemi N, 2005, J GEN INTERN MED, V20, P1151, DOI 10.1111/j.1525-1497.2005.0243.x; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; CUNNINGHAM LA, 1994, J CLIN PSYCHOPHARM, V14, P99; CURRAN HV, 1988, PSYCHOPHARMACOLOGY, V95, P520; Danjou P, 1999, BRIT J CLIN PHARMACO, V48, P367; Dujardin K, 1998, PHARMACOPSYCHIATRY, V31, P14, DOI 10.1055/s-2007-979289; Erman M, 2006, SLEEP MED, V7, P17, DOI 10.1016/j.sleep.2005.09.004; Flanagan SR, 2007, J HEAD TRAUMA REHAB, V22, P67, DOI 10.1097/00001199-200701000-00009; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FUDGE JL, 1990, J AFFECT DISORDERS, V18, P275, DOI 10.1016/0165-0327(90)90079-N; GOLDSTEIN LB, 1993, J NEURAL TRANSP PLAS, V4, P175, DOI 10.1155/NP.1993.175; Goldstein LB, 2003, BRAIN INJURY, V17, P685, DOI 10.1080/0269905031000107179; GOLDSTEIN LB, 1995, J NEUROL NEUROSUR PS, V58, P753, DOI 10.1136/jnnp.58.6.753; Greenblatt DJ, 2004, CLIN PHARMACOL THER, V76, P467, DOI 10.1016/j.clpt.2004.07.009; Greenblatt DJ, 1998, CLIN PHARMACOL THER, V64, P553, DOI 10.1016/S0009-9236(98)90139-4; GREENBLATT DJ, 1989, J CLIN PHARMACOL, V29, P866, DOI 10.1002/j.1552-4604.1989.tb03246.x; GREENBLATT DJ, 1993, CLIN PHARMACOKINET, V24, P453, DOI 10.2165/00003088-199324060-00003; Isawa S, 2000, Nihon Shinkei Seishin Yakurigaku Zasshi, V20, P61; Lee HCB, 2003, INT REV PSYCHIATR, V15, P359, DOI 10.1080/09540260310001606746; Lenhart SE, 2001, ANN PHARMACOTHER, V35, P1449; MALEC JF, 1991, PSYCHOL ASSESSMENT J, V3, P82; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Mendelson WB, 2004, SLEEP MED REV, V8, P7, DOI 10.1016/S1087-0792(03)00042-X; Meythaler J. M., 2006, BRAIN INJURY MED PRI, P1023; MONTGOMERY I, 1983, BRIT J CLIN PHARMACO, V16, P139, DOI 10.1111/j.1365-2125.1983.tb04977.x; Mort JR, 2002, CNS DRUGS, V16, P99, DOI 10.2165/00023210-200216020-00003; MOSKOWITZ RW, 1986, SEMIN ARTHRITIS RHEU, V15, P1, DOI 10.1016/S0049-0172(86)80001-4; MOURET J, 1988, PSYCHOPHARMACOLOGY, V95, pS37; Mysiw WJ, 2006, BRAIN INJURY, V20, P905, DOI 10.1080/02699050600743972; NIERENBERG AA, 1994, AM J PSYCHIAT, V151, P1069; Nudo RJ, 2003, J REHABIL MED, V35, P7, DOI 10.1080/16501960310010070; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Paparrigopoulos T, 2006, BRAIN INJURY, V20, P873, DOI 10.1080/02699050600832114; Pompeia S, 2004, PSYCHOPHARMACOLOGY, V174, P327, DOI 10.1007/s00213-003-1760-z; RAKEL RE, 1987, PSYCHOPATHOLOGY, V20, P57, DOI 10.1159/000284524; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rush CR, 1996, J CLIN PSYCHOPHARM, V16, P146, DOI 10.1097/00004714-199604000-00007; Saletu-Zyhlarz GM, 2002, PROG NEURO-PSYCHOPH, V26, P249, DOI 10.1016/S0278-5846(01)00262-7; Saletu-Zyhlarz GM, 2001, NEUROPSYCHOBIOLOGY, V44, P139, DOI 10.1159/000054934; Sanger DJ, 1999, PHARMACOL BIOCHEM BE, V64, P269, DOI 10.1016/S0091-3057(99)00081-7; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; SCHARF MB, 1990, J CLIN PSYCHIAT, V51, P13; Seibi J, 2008, SLEEP, V31, P1381; Shan RSLP, 2004, AM J PHYS MED REHAB, V83, P421, DOI 10.1097/00002060-200406000-00003; Stewart SA, 2005, J CLIN PSYCHIAT, V66, P9; TATA PR, 1994, PSYCHOL MED, V24, P203, DOI 10.1017/S0033291700026969; Terzano MG, 2003, DRUG SAFETY, V26, P261, DOI 10.2165/00002018-200326040-00004; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; Troy SM, 2000, J CLIN PSYCHOPHARM, V20, P328, DOI 10.1097/00004714-200006000-00007; VANBEMMEL AL, 1992, PSYCHOPHARMACOLOGY, V107, P569, DOI 10.1007/BF02245272; Vermeeren A, 1998, HUM PSYCHOPHARM CLIN, V13, pS98, DOI 10.1002/(SICI)1099-1077(1998110)13:2+<S98::AID-HUP54>3.0.CO;2-1; Verster JC, 2004, CNS DRUG REV, V10, P45; Waldron-Perrine B, 2008, REHABIL PSYCHOL, V53, P426, DOI 10.1037/a0013530; Walsh JK, 1998, HUM PSYCHOPHARM CLIN, V13, P191, DOI 10.1002/(SICI)1099-1077(199804)13:3<191::AID-HUP972>3.0.CO;2-X; WALSH KW, 1985, UNDERSTANDING BRAIN, P234; Wan H, 2004, EUR J NEUROSCI, V20, P2214, DOI 10.1111/j.1460-9568.2004.03688.x; Wang-Weigand S, 2007, SLEEP, V30, pA244; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D., 1955, WAIS MANUAL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WESENSTEN NJ, 1995, PSYCHOPHARMACOLOGY, V121, P242, DOI 10.1007/BF02245635; WESENSTEN NJ, 1995, EUR J CLIN PHARMACOL, V48, P115; Wiegand MH, 2008, DRUGS, V68, P2411, DOI 10.2165/0003495-200868170-00001; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012	74	57	59	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2010	25	1					61	67		10.1097/HTR.0b013e3181c1d1e1			7	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	550XC	WOS:000274165800008	20051895				2022-02-06	
J	Moore, EM; Bellomo, R; Nichol, A; Harley, N; MacIsaac, C; Cooper, DJ				Moore, Elizabeth M.; Bellomo, Rinaldo; Nichol, Alistair; Harley, Nerina; MacIsaac, Christopher; Cooper, D. James			The incidence of acute kidney injury in patients with traumatic brain injury	RENAL FAILURE			English	Article						kidney failure, acute; renal insufficiency, acute, brain injuries, craniocerebral trauma; acute kidney injury; traumatic brain injury	ACUTE-RENAL-FAILURE; CRITICALLY-ILL PATIENTS; CARDIAC-SURGERY; RIFLE CRITERIA; MULTICENTER EVALUATION; HOSPITALIZED-PATIENTS; REPLACEMENT THERAPY; CLINICAL-OUTCOMES; ORGAN DYSFUNCTION; FLUID THERAPY	There is limited information on the incidence of acute kidney injury (AKI) in patients with traumatic brain injury (TBI) although AKI may contribute to morbidity and mortality. We investigated the incidence of AKI in patients with moderate and severe TBI and the association of AKI with risk factors and outcomes in these patients. We studied all TBI patients over 16 years of age admitted to the two designated trauma hospitals in the state of Victoria, Australia from 1 January to 31 December 2008. Patients were included if they had head trauma and presented with a Glasgow coma scale (GCS) < 13. Prospectively collected data from the hospital trauma registries, ICUs, and pathology databases were analyzed retrospectively. Risk injury failure loss end (RIFLE) criteria were used to categorize renal function. The incidence of AKI was 9.2% (19/207). Patients who developed AKI were older, had higher severity of illness scores, and a lower GCS. Overall 42.1% of these patients died in hospital compared with 18.1% in patients without AKI. In univariable linear regression analysis, age, severity of illness, and admitting hospital were associated with AKI. After multivariable logistic regression, the occurrence of AKI was associated with age (p < 0.001) and higher APACHE III scores (p = 0.016). AKI is relatively common even in patients with TBI. Its association with age and APACHE III scores helps identify patients at higher risk of AKI.	[Moore, Elizabeth M.; Bellomo, Rinaldo; Nichol, Alistair; Cooper, D. James] Monash Univ, Australian & New Zealand Intens Care ANZIC Res Ct, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Nichol, Alistair; Cooper, D. James] Alfred Hosp, Intens Care Unit, Melbourne, Vic, Australia; [Harley, Nerina; MacIsaac, Christopher] Royal Melbourne Hosp, Intens Care Unit, Parkville, Vic 3050, Australia		Moore, EM (corresponding author), Monash Univ, Australian & New Zealand Intens Care ANZIC Res Ct, Dept Epidemiol & Prevent Med, 99 Commercial Rd, Melbourne, Vic 3004, Australia.	Elizabeth.Moore@med.monash.edu.au	Moore, Elizabeth/W-1687-2019; Cooper, D. James/G-7961-2013	Moore, Elizabeth/0000-0002-3881-6000; Cooper, D. James/0000-0002-5872-9051; Nichol, Alistair Dualta/0000-0002-4771-5615; Bellomo, Rinaldo/0000-0002-1650-8939; Nichol, Alistair/0000-0002-4689-1238	Erythropoietin in TBI [NCT00987454]	RB, AN and DJC are investigators of a National Health and Medical Research Council/Victorian Neurotrauma Initiative funded clinical trial of Erythropoietin in TBI (NCT00987454).	Bagshaw SM, 2008, RENAL FAILURE, V30, P581, DOI 10.1080/08860220802134649; Bagshaw SM, 2008, NEPHROL DIAL TRANSPL, V23, P1203, DOI 10.1093/ndt/gfm744; Bagshaw SM, 2009, NEPHROL DIAL TRANSPL, V24, P2739, DOI 10.1093/ndt/gfp159; Bagshaw SM, 2009, INTENS CARE MED, V35, P871, DOI 10.1007/s00134-008-1367-2; Bagshaw SM, 2009, J CRIT CARE, V24, P129, DOI 10.1016/j.jcrc.2007.12.017; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Chertow GM, 2005, J AM SOC NEPHROL, V16, P3365, DOI 10.1681/ASN.2004090740; Cooper WA, 2006, CIRCULATION, V113, P1063, DOI 10.1161/CIRCULATIONAHA.105.580084; Dasta JF, 2008, NEPHROL DIAL TRANSPL, V23, P1970, DOI 10.1093/ndt/gfm908; Davenport A, 2001, AM J KIDNEY DIS, V37, P457, DOI 10.1053/ajkd.2001.22068; Guitard J, 2006, CLIN NEPHROL, V65, P103; Heringlake M, 2006, MINERVA ANESTESIOL, V72, P645; Hillis GS, 2006, CIRCULATION, V113, P1056, DOI 10.1161/CIRCULATIONAHA.105.591990; Kuitunen A, 2006, ANN THORAC SURG, V81, P542, DOI 10.1016/j.athoracsur.2005.07.047; Mathew TH, 2007, MED J AUSTRALIA, V187, P459, DOI 10.5694/j.1326-5377.2007.tb01357.x; Nijboer WN, 2010, CRIT CARE MED, V38, P1155, DOI 10.1097/CCM.0b013e3181cf6e78; Ostermann M, 2007, CRIT CARE MED, V35, P1837, DOI 10.1097/01.CCM.0000277041.13090.0A; Ricci Z, 2008, KIDNEY INT, V73, P538, DOI 10.1038/sj.ki.5002743; Ricci Z, 2009, BLOOD PURIFICAT, V27, P127, DOI 10.1159/000167019; Uchino S, 2006, CRIT CARE MED, V34, P1913, DOI 10.1097/01.CCM.0000224227.70642.4F; Wahlstrom MR, 2009, ACTA ANAESTH SCAND, V53, P18, DOI 10.1111/j.1399-6576.2008.01798.x; Wetzels JFM, 2007, KIDNEY INT, V72, P632, DOI 10.1038/sj.ki.5002374; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54; Zygun DA, 2003, J CRIT CARE, V18, P238, DOI 10.1016/j.jcrc.2003.10.007	25	57	59	0	3	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0886-022X			RENAL FAILURE	Ren. Fail.		2010	32	9					1060	1065		10.3109/0886022X.2010.510234			6	Urology & Nephrology	Science Citation Index Expanded (SCI-EXPANDED)	Urology & Nephrology	666NI	WOS:000283121700007	20863210	Bronze			2022-02-06	
J	Broglio, SP; Zhu, WM; Sopiarz, K; Park, Y				Broglio, Steven P.; Zhu, Weimo; Sopiarz, Kay; Park, Youngsik			Generalizability Theory Analysis of Balance Error Scoring System Reliability in Healthy Young Adults	JOURNAL OF ATHLETIC TRAINING			English	Article						learning effects; concussions; postural control	COLLEGIATE FOOTBALL PLAYERS; SPORTS-RELATED CONCUSSION; MILD HEAD-INJURY; HIGH-SCHOOL; POSTURAL STABILITY; RECOVERY; IMPACT; SEX; AGE	Context: An assessment of postural control is commonly included in the clinical concussion evaluation. Previous investigators have demonstrated learning effects that may mask concussion-induced balance decrements. Objective: To establish the test-retest reliability of the Balance Error Scoring System (BESS) and to provide recommendations that account for known learning effects. Design: Test-retest generalizability study. Setting: Balance research laboratory. Patients or Other Participants: Young adults (n = 48) free from injuries and illnesses known to affect balance. Intervention(s): Each participant completed 5 BESS trials on each of the assessment dates, which were separated by 50 days. Main Outcome Measure(s): Total score of the BESS was used in a generalizability theory analysis to estimate the overall reliability of the BESS and that of each facet. A decision study was completed to estimate the number of days and trials needed to establish clinical reliability. Results: The overall reliability of the BESS was G = 0.64. The test-retest reliability was improved when male (0.92) and female (0.91) participants were examined independently. Clinically acceptable reliability (greater than 0.80) was established when 3 BESS trials were administered in a single day or 2 trials were administered at different time points. Conclusions: Learning effects have been noted in individuals with no previous exposure to the BESS. Our findings indicate that clinicians should consider interpreting the mean score from 3 BESS administrations on a given occasion for both normative data comparison and pretest and posttest design. The multiple assessment technique yields clinically reliable scores and provides the sports medicine practitioner with accurate data for clinical decision making.	[Broglio, Steven P.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA		Broglio, SP (corresponding author), Univ Illinois, Dept Kinesiol & Community Hlth, 906 S Goodwin Ave, Urbana, IL 61801 USA.	broglio@illinois.edu					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BRENNAN RL, 2001, GENERALIZABILITY THE, P1; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Cronbach L.J., 1972, DEPENDABILITY BEHAV, P1; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; HIRABAYASHI S, 1995, BRAIN DEV-JPN, V17, P111, DOI 10.1016/0387-7604(95)00009-Z; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Morrow JR, 1989, MEASUREMENT CONCEPTS, P73; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; PORTNEY LG, 1993, FDN CLIN RES APPL PR, P63; Riemann BL, 2000, PROPRIOCEPTION AND NEUROMUSCULAR CONTROL IN JOINT STABILITY, P37; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Safrit MJ, 1995, INTRO MEASUREMENT PH, P159; Steindl R, 2006, DEV MED CHILD NEUROL, V48, P477, DOI 10.1017/S0012162206001022; Tjernstrom F, 2002, GAIT POSTURE, V15, P75, DOI 10.1016/S0966-6362(01)00175-8; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Wade MG, 1997, PHYS THER, V77, P619, DOI 10.1093/ptj/77.6.619; [No title captured]	30	57	58	2	9	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	SEP-OCT	2009	44	5					497	502		10.4085/1062-6050-44.5.497			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	499SP	WOS:000270246100008	19771288	Green Published, Bronze			2022-02-06	
J	Jiang, C; Wang, JP; Li, X; Liu, CL; Chen, NN; Hao, YJ				Jiang, Chao; Wang, Jianping; Li, Xin; Liu, Chunling; Chen, Ningning; Hao, Yujin			Progesterone exerts neuroprotective effects by inhibiting inflammatory response after stroke	INFLAMMATION RESEARCH			English	Article						Progesterone; Tumor necrosis factor-alpha; Claudin5; Blood-brain barrier	TRAUMATIC BRAIN-INJURY; SPONTANEOUSLY HYPERTENSIVE-RATS; TUMOR-NECROSIS-FACTOR; CEREBRAL-ARTERY OCCLUSION; FACTOR-ALPHA; ISCHEMIA; EXPRESSION; BARRIER; EDEMA; CYTOKINES	We evaluated the inhibitory effects of progesterone (PROG) on inflammatory response and its influence on the structure of blood-brain barrier in a permanent model of stroke. One hundred and twenty adult male Sprague-Dawley rats were used in this study. PROG was dissolved in 22.5% 2-hydroxypropyl-bcyclodextrin and given in a dose of 15 mg/kg by intraperitoneal injection 1 h after permanent occlusion of middle cerebral artery (pMCAO). Additional injections of 15 mg/kg were administered subcutaneously 6, 24, and 48 h after pMCAO. The expression of tumor necrosis factor-alpha (TNF-alpha) and claudin5 was measured by immunohistochemistry and western blot technique. Brain water content was determined by the dry-wet weight method. TNF-alpha were increased, but claudin5 were reduced in vehicle-treated rats after pMCAO. PROG-treated rats showed a substantial reduction in the expression of TNF-alpha compared to vehicle controls. In addition, there was significant increase in the expression of claudin5 in the pMCAO rats treated with PROG compared to vehicle. Examination of the water content of the brain also revealed that administration of PROG significantly attenuated the amount of water compared to vehicle in the ipsilateral hemispheres. These data indicate that PROG is beneficial in this animal model, and may warrant further test in future clinical trials for human stroke.	[Jiang, Chao; Wang, Jianping; Li, Xin; Liu, Chunling; Chen, Ningning; Hao, Yujin] Zhengzhou Univ, Dept Neurol, Affiliated Hosp 2, Zhengzhou 450014, Henan, Peoples R China		Wang, JP (corresponding author), Zhengzhou Univ, Dept Neurol, Affiliated Hosp 2, Zhengzhou 450014, Henan, Peoples R China.	jcmd666@126.com					Begley DJ, 2003, PROG DRUG RES, V61, P39; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Cai WY, 2008, NEUROPHARMACOLOGY, V55, P127, DOI 10.1016/j.neuropharm.2008.04.023; Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Dziewulska D, 2003, CLIN NEUROPATHOL, V22, P35; Fisher Mark, 2008, Rev Neurol Dis, V5 Suppl 1, pS4; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; GOTTSCHALL PE, 1995, J NEUROCHEM, V64, P1513; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Hatashita S, 1990, Adv Neurol, V52, P327; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Kniesel U, 2000, CELL MOL NEUROBIOL, V20, P57, DOI 10.1023/A:1006995910836; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Manicone AM, 2008, SEMIN CELL DEV BIOL, V19, P34, DOI 10.1016/j.semcdb.2007.07.003; Meistrell ME, 1997, SHOCK, V8, P341; Nawashiro H, 1997, BRAIN RES, V778, P265, DOI 10.1016/S0006-8993(97)00981-5; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Svedin P, 2007, J NEUROSCI, V27, P1511, DOI 10.1523/JNEUROSCI.4391-06.2007; Takaba H, 2004, CELL MOL NEUROBIOL, V24, P589, DOI 10.1023/B:CEMN.0000036400.55503.5e; Tsukita S, 1998, GENES CELLS, V3, P569, DOI 10.1046/j.1365-2443.1998.00212.x; Ueno M, 2004, HISTOCHEM CELL BIOL, V122, P131, DOI 10.1007/s00418-004-0684-y; Vagnerova K, 2008, ANESTH ANALG, V107, P201, DOI 10.1213/ane.0b013e31817326a5; Vandromme M, 2008, CRIT CARE, V12, DOI 10.1186/cc6899; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	31	57	62	0	7	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1023-3830	1420-908X		INFLAMM RES	Inflamm. Res.	SEP	2009	58	9					619	624		10.1007/s00011-009-0032-8			6	Cell Biology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Immunology	475AJ	WOS:000268326500010	19333725				2022-02-06	
J	Wei, HH; Lu, XCM; Shear, DA; Waghray, A; Yao, CP; Tortella, FC; Dave, JR				Wei, Hans H.; Lu, Xi-Chun M.; Shear, Deborah A.; Waghray, Anu; Yao, Changping; Tortella, Frank C.; Dave, Jitendra R.			NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats	JOURNAL OF NEUROINFLAMMATION			English	Article							GROWTH-FACTOR-I; GLYCINE-PROLINE-GLUTAMATE; N-TERMINAL TRIPEPTIDE; NECROSIS-FACTOR-ALPHA; CLOSED-HEAD INJURY; GENE-EXPRESSION; IGF-I; TISSUE-DAMAGE; ANIMAL-MODEL; CELL-DEATH	Background: Inflammatory cytokines play a crucial role in the pathophysiology of traumatic brain injury (TBI), exerting either deleterious effects on the progression of tissue damage or beneficial roles during recovery and repair. NNZ-2566, a synthetic analogue of the neuroprotective tripeptide Glypromate (R), has been shown to be neuroprotective in animal models of brain injury. The goal of this study was to determine the effects of NNZ-2566 on inflammatory cytokine expression and neuroinflammation induced by penetrating ballistic-like brain injury (PBBI) in rats. Methods: NNZ-2566 or vehicle (saline) was administered intravenously as a bolus injection (10 mg/kg) at 30 min post-injury, immediately followed by a continuous infusion of NNZ-2566 (3 mg/kg/h), or equal volume of vehicle, for various durations. Inflammatory cytokine gene expression from the brain tissue of rats exposed to PBBI was evaluated using microarray, quantitative real time PCR (QRT-PCR), and enzyme-linked immunosorbent assay (ELISA) array. Histopathology of the injured brains was examined using hematoxylin and eosin (H&E) and immunocytochemistry of inflammatory cytokine IL-1 beta. Results: NNZ-2566 treatment significantly reduced injury-mediated up-regulation of IL-1 beta, TNF-alpha, E-selectin and IL-6 mRNA during the acute injury phase. ELISA cytokine array showed that NZ-2566 treatment significantly reduced levels of the pro-inflammatory cytokines IL-1 beta, TNF-alpha and IFN-gamma in the injured brain, but did not affect anti-inflammatory cytokine IL- 6 levels. Conclusion: Collectively, these results suggest that the neuroprotective effects of NNZ-2566 may, in part, be functionally attributed to the compound's ability to modulate expression of multiple neuroinflammatory mediators in the injured brain.	[Wei, Hans H.; Lu, Xi-Chun M.; Shear, Deborah A.; Waghray, Anu; Yao, Changping; Tortella, Frank C.; Dave, Jitendra R.] Walter Reed Army Inst Res, Dept Appl Neurobiol, Div Psychiat & Neurosci, Silver Spring, MD 20910 USA		Wei, HH (corresponding author), Walter Reed Army Inst Res, Dept Appl Neurobiol, Div Psychiat & Neurosci, Silver Spring, MD 20910 USA.	hans.wei@us.army.mil; may.lu@amedd.army.mil; deborah.shear@amedd.army.mil; anu.waghray@amedd.army.mi; changping.yao@amedd.army.mil; frank.tortella@amedd.army.mil; jit.dave@amedd.army.mil	Shear, Deborah/B-3607-2011; Dave, Jitendra R/A-8940-2011		Neuren Pharmaceuticals Ltd. [W81XWH-05-0074]	We would like to thank SPC. Monika Torres and SPC. Katie Phillips for their excellent technical assistance and Ms. Christine Gallo for her help in manuscript preparation. These studies were supported in part by a cooperative research and development agreement with Neuren Pharmaceuticals Ltd. (W81XWH-05-0074).	Alexi T, 1999, EXP NEUROL, V159, P84, DOI 10.1006/exnr.1999.7168; Amantea D, 2009, FEBS J, V276, P13, DOI 10.1111/j.1742-4658.2008.06766.x; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Asirvatham AJ, 2009, CYTOKINE, V45, P58, DOI 10.1016/j.cyto.2008.11.010; Balasingam V, 1996, J NEUROSCI, V16, P2945; Batchelor DC, 2003, ANAL BIOCHEM, V323, P156, DOI 10.1016/j.ab.2003.08.032; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; Berti R, 2003, NEUROTOX RES, V5, P505, DOI 10.1007/BF03033160; Berti R, 2002, J CEREBR BLOOD F MET, V22, P1068, DOI 10.1097/00004647-200209000-00004; Bian ZM, 2001, EXP EYE RES, V73, P111, DOI 10.1006/exer.2001.1019; Bourguignon JP, 1999, BRAIN RES, V847, P247, DOI 10.1016/S0006-8993(99)02051-X; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; CARLSSONSKWIRUT C, 1989, BIOCHIM BIOPHYS ACTA, V1011, P192, DOI 10.1016/0167-4889(89)90209-7; CLARK RK, 1993, BRAIN RES BULL, V31, P565, DOI 10.1016/0361-9230(93)90124-T; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; ELNER SG, 1991, LAB INVEST, V64, P819; ELNER VM, 1990, AM J PATHOL, V136, P745; Eugster HP, 1998, EUR J IMMUNOL, V28, P2178, DOI 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Guan J, 2004, NEUROPHARMACOLOGY, V47, P892, DOI 10.1016/j.neuropharm.2004.07.002; Guan Jian, 2008, Recent Pat CNS Drug Discov, V3, P112, DOI 10.2174/157488908784534630; Haraldsen G, 1996, J IMMUNOL, V156, P2558; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Koprich JB, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-8; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; LU XC, J NEUROTRAUMA, V26, P141; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Modur V, 1997, J CLIN INVEST, V100, P2752, DOI 10.1172/JCI119821; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Opal SM, 2000, CHEST, V117, P1162, DOI 10.1378/chest.117.4.1162; Ray KP, 1997, BIOCHEM J, V328, P707; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SARA VR, 1993, ANN NY ACAD SCI, V692, P183; SARA VR, 1989, BIOCHEM BIOPH RES CO, V165, P766, DOI 10.1016/S0006-291X(89)80032-4; Saura J, 1999, NEUROREPORT, V10, P161, DOI 10.1097/00001756-199901180-00031; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Thurman D, 1999, TRAUMATIC BRAIN INJU, DOI http://www.cdc.gov/ncipc/tbi/tbi_congress/TBI_in_the_US.PDF; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Williams AJ, 2006, NEUROCHEM INT, V49, P106, DOI 10.1016/j.neuint.2006.03.018; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; YAMAMOTO H, 1995, J ENDOCRINOL, V146, P141, DOI 10.1677/joe.0.1460141; YAMAMOTO H, 1994, ENDOCRINOLOGY, V135, P2432, DOI 10.1210/en.135.6.2432	62	57	57	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	AUG 5	2009	6								19	10.1186/1742-2094-6-19			10	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	495DB	WOS:000269869000001	19656406	gold, Green Published			2022-02-06	
J	Guo, XB; Liu, L; Zhang, M; Bergeron, A; Cui, Z; Dong, JF; Zhang, JN				Guo, Xinbin; Liu, Li; Zhang, Ming; Bergeron, Angela; Cui, Zhuang; Dong, Jing-Fei; Zhang, Jianning			Correlation of CD34(+) Cells with Tissue Angiogenesis after Traumatic Brain Injury in a Rat Model	JOURNAL OF NEUROTRAUMA			English	Article						angiogenesis; CD34(+) cells; endothelial progenitor cells; traumatic brain injury	ENDOTHELIAL PROGENITOR CELLS; FOCAL CEREBRAL-ISCHEMIA; ACUTE MYOCARDIAL-INFARCTION; PERIPHERAL-BLOOD; THERAPEUTIC NEOVASCULARIZATION; MONONUCLEAR-CELLS; MOUSE MODEL; STROKE; TRANSPLANTATION; NEUROGENESIS	Increasing evidence suggests that circulating endothelial progenitor cells, which are a subpopulation of hematopoietic progenitor CD34(+) cells, play a critical role in neovascularization and tissue repair. We have tested the hypothesis that traumatic brain injury (TBI) could mobilize CD34(+) cells to peripheral blood and brain tissue, a process critical for vascular repair, in a rat model of TBI. Male Wistar rats were subjected to controlled fluid percussion. Blood and brain tissue were collected before and after TBI to measure the levels of CD34(+) cells in peripheral blood and to detect their accumulation in the damaged cerebral tissue. Compared with surgery controls, CD34(+) cells significantly increased in the peripheral blood and accumulated in the brain tissue of TBI rats. Immunohistochemistry detected new vessels with incomplete CD34(+) endothelial-like cell lining and an increased number of microvessels in the injured and surrounding tissue. The results demonstrate a close correlation between an increase in circulating CD34(+) cells in response to traumatic injury and angiogenesis in TBI rat brain. They also suggest that transplantation of CD34(+) cells or augmentation of endogenous CD34(+) cells may be a novel therapeutic approach for patients with TBI.	[Guo, Xinbin; Liu, Li; Cui, Zhuang; Zhang, Jianning] Tianjin Med Univ, Dept Neurosurg, Tianjin Neurol Inst, Lab TJIVR, Tianjin 300052, Peoples R China; [Zhang, Ming] Temple Univ, Dept Physiol, Sch Med, Philadelphia, PA 19122 USA; [Bergeron, Angela; Dong, Jing-Fei] Baylor Coll Med, Dept Med, Thrombosis Res Sect, Houston, TX 77030 USA		Zhang, JN (corresponding author), Tianjin Med Univ, Dept Neurosurg, Tianjin Neurol Inst, Lab TJIVR, 154 Anshan Rd, Tianjin 300052, Peoples R China.	Jianning_zhang@sina.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30772229]; National 973 ProjectNational Basic Research Program of China [2005CB522600]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL71895]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL071895] Funding Source: NIH RePORTER	This work was supported by the National Natural Science Foundation of China (30772229), the National 973 Project (2005CB522600), and an NIH grant (HL71895).	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Assmus B, 2006, NEW ENGL J MED, V355, P1222, DOI 10.1056/NEJMoa051779; Beck H, 2003, J CEREBR BLOOD F MET, V23, P709, DOI 10.1097/01.WCB.0000065940.18332.8D; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Cho SW, 2007, CIRCULATION, V116, P2409, DOI 10.1161/CIRCULATIONAHA.106.687038; del Zoppo GJ, 2006, NEW ENGL J MED, V354, P553, DOI 10.1056/NEJMp058312; Fujiyama S, 2003, CIRC RES, V93, P980, DOI 10.1161/01.RES.0000099245.08637.CE; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kawamoto A, 2006, CIRCULATION, V114, P2163, DOI 10.1161/CIRCULATIONAHA.106.644518; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Krupinski J, 2003, NEUROREPORT, V14, P1171, DOI 10.1097/00001756-200306110-00014; Ladeby R, 2005, GLIA, V50, P121, DOI 10.1002/glia.20159; Liu L, 2007, J NEUROTRAUM, V24, P936, DOI 10.1089/neu.2006.0250; Machalinski B, 2006, FOLIA HISTOCHEM CYTO, V44, P97; Morris DC, 2003, BRAIN RES, V972, P31, DOI 10.1016/S0006-8993(03)02433-8; Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323-06.2006; Ohta T, 2006, NEUROSURGERY, V59, P679, DOI 10.1227/01.NEU.0000229058.08706.88; Okada S, 2008, DIABETES CARE, V31, P157, DOI 10.2337/dc07-1125; Paczkowska E, 2005, EUR J HAEMATOL, V75, P461, DOI 10.1111/j.1600-0609.2005.00536.x; Rookmaaker MB, 2005, ARTERIO THROMB VASC, V25, P1; Salven P, 2003, BLOOD, V101, P168, DOI 10.1182/blood-2002-03-0755; Shen FX, 2006, STROKE, V37, P2601, DOI 10.1161/01.STR.0000240407.14765.e8; Shyu WC, 2006, J NEUROSCI, V26, P3444, DOI 10.1523/JNEUROSCI.5165-05.2006; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Tei K, 2008, STEM CELLS, V26, P819, DOI 10.1634/stemcells.2007-0671; Wei L, 2001, STROKE, V32, P2179, DOI 10.1161/hs0901.094282; Wojakowski W, 2004, CIRCULATION, V110, P3213, DOI 10.1161/01.CIR.0000147609.39780.02; Xu Qing-Bo, 2005, Shengli Xuebao, V57, P1; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460	30	57	66	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2009	26	8					1337	1344		10.1089/neu.2008.0733			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	479AF	WOS:000268629900016	19226208	Green Published			2022-02-06	
J	Xu, G; Bayly, PV; Taber, LA				Xu, Gang; Bayly, Philip V.; Taber, Larry A.			Residual stress in the adult mouse brain	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Biomechanics; Morphogenesis; Cortical folding; Axon; Stiffness	IN-VIVO; MECHANICAL-PROPERTIES; WHITE-MATTER; TISSUE; GROWTH; MODEL; NEURONS; TENSION; CYTOMECHANICS; HYDROCEPHALUS	This work provides direct evidence that sustained tensile stress exists in white matter of the mature mouse brain. This finding has important implications for the mechanisms of brain development, as tension in neural axons has been hypothesized to drive cortical folding in the human brain. In addition, knowledge of residual stress is required to fully understand the mechanisms behind traumatic brain injury and changes in mechanical properties due to aging and disease. To estimate residual stress in the brain, we performed serial dissection experiments on 500-mum thick coronal slices from fresh adult mouse brains and developed finite element models for these experiments. Radial cuts were made either into cortical gray matter, or through the cortex and the underlying white matter tract composed of parallel neural axons. Cuts into cortical gray matter did not open, but cuts through both layers consistently opened at the point where the cut crossed the white matter. We infer that the cerebral white matter is under considerable tension in the circumferential direction in the coronal cerebral plane, parallel to most of the neural fibers, while the cerebral cortical gray matter is in compression. The models show that the observed deformation after cutting can be caused by more growth in the gray matter than in the white matter, with the estimated tensile stress in the white matter being on the order of 100-1,000 Pa.	[Xu, Gang; Bayly, Philip V.; Taber, Larry A.] Washington Univ, Dept Biomed Engn, St Louis, MO 63130 USA; [Bayly, Philip V.] Washington Univ, Dept Mech Aerosp & Struct Engn, St Louis, MO 63130 USA		Taber, LA (corresponding author), Washington Univ, Dept Biomed Engn, 1 Brookings Dr,Campus Box 1097, St Louis, MO 63130 USA.	lat@wustl.edu	Xu, Gang/C-7118-2013	Bayly, Philip/0000-0003-4303-0704	National Science FoundationNational Science Foundation (NSF) [DMS-0540701]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R21EB005834] Funding Source: NIH RePORTER	We gratefully acknowledge technical assistance from Edward Kim, William McCarran, and Christine McDonald in harvesting the mouse brains used in this work. We also thank Paul Bridgman, Krikor Dikranian, Jeffrey Neil, and David Van Essen for their helpful discussions and suggestions. This work was supported by the National Science Foundation ( grant #DMS-0540701).	Alexander GM, 2000, J NEUROCHEM, V74, P1666, DOI 10.1046/j.1471-4159.2000.0741666.x; Chada S, 1997, J CELL SCI, V110, P1179; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; DENNERLL TJ, 1989, J CELL BIOL, V109, P3073, DOI 10.1083/jcb.109.6.3073; Drapaca CS, 2006, J ELASTICITY, V85, P65, DOI 10.1007/s10659-006-9071-3; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Faisal AA, 2005, CURR BIOL, V15, P1143, DOI 10.1016/j.cub.2005.05.056; Fung Y. C., 1993, BIOMECHANICS MECH PR; FUNG YC, 1998, BIOMECHANICS MOTION; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Georges PC, 2006, BIOPHYS J, V90, P3012, DOI 10.1529/biophysj.105.073114; Hilgetag CC, 2005, ANAT EMBRYOL, V210, P411, DOI 10.1007/s00429-005-0041-5; Hilgetag CC, 2006, PLOS COMPUT BIOL, V2, P146, DOI 10.1371/journal.pcbi.0020022; Hrapko M, 2006, BIORHEOLOGY, V43, P623; Kingsbury MA, 2003, NAT NEUROSCI, V6, P1292, DOI 10.1038/nn1157; Kioussi C, 2007, BRAIN RES BULL, V74, P439, DOI 10.1016/j.brainresbull.2007.07.024; Kyriacou SK, 2002, BIOMECH MODEL MECHAN, V1, P151, DOI 10.1007/s10237-002-0013-0; Lamoureux P, 2002, J CELL BIOL, V159, P499, DOI 10.1083/jcb.200207174; LAMOUREUX P, 1989, Nature (London), V340, P159, DOI 10.1038/340159a0; Larvaron P, 2007, NMR BIOMED, V20, P413, DOI 10.1002/nbm.1082; Miller K, 1999, J BIOMECH, V32, P531, DOI 10.1016/S0021-9290(99)00010-X; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Miller K, 2000, J BIOMECH, V33, P1369, DOI 10.1016/S0021-9290(00)00120-2; MILLER M, 1992, NEURON, V8, P25, DOI 10.1016/0896-6273(92)90106-N; Neil J, 2002, NMR BIOMED, V15, P543, DOI 10.1002/nbm.784; Nordahl CW, 2007, J NEUROSCI, V27, P11725, DOI 10.1523/JNEUROSCI.0777-07.2007; Olivares R, 2001, BRAIN BEHAV EVOLUT, V57, P98, DOI 10.1159/000047229; Porter BE, 2002, ARCH NEUROL-CHICAGO, V59, P361, DOI 10.1001/archneur.59.3.361; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; RICHMAN DP, 1975, SCIENCE, V189, P18; RODRIGUEZ EK, 1994, J BIOMECH, V27, P455, DOI 10.1016/0021-9290(94)90021-3; Sallet PC, 2003, AM J PSYCHIAT, V160, P1606, DOI 10.1176/appi.ajp.160.9.1606; Taber LA, 2001, ANNU REV BIOMED ENG, V3, P1, DOI 10.1146/annurev.bioeng.3.1.1; Taber LA, 2000, J ELASTICITY, V61, P165, DOI 10.1023/A:1011082712497; Taber LA, 2008, BIOMECH MODEL MECHAN, V7, P427, DOI 10.1007/s10237-007-0106-x; Taylor Z, 2004, J BIOMECH, V37, P1263, DOI 10.1016/j.jbiomech.2003.11.027; Tekkok SB, 2001, J NEUROSCI, V21, P4237, DOI 10.1523/JNEUROSCI.21-12-04237.2001; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; TODD PH, 1982, J THEOR BIOL, V97, P529, DOI 10.1016/0022-5193(82)90380-0; Toro R, 2005, CEREB CORTEX, V15, P1900, DOI 10.1093/cercor/bhi068; VALVERDE F, 2004, GOLGI ATLAS POSTNATA; VanEssen DC, 1997, NATURE, V385, P313, DOI 10.1038/385313a0; Zamir EA, 2004, J BIOMECH ENG-T ASME, V126, P276, DOI 10.1115/1.1695573; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488; [No title captured], DOI DOI 10.1007/978-1-4615-3824-0	48	57	57	0	18	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	AUG	2009	8	4					253	262		10.1007/s10237-008-0131-4			10	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	476XF	WOS:000268479400001	18651186	Green Accepted			2022-02-06	
J	Linares, G; Mayer, SA				Linares, Guillermo; Mayer, Stephan A.			Hypothermia for the treatment of ischemic and hemorrhagic stroke	CRITICAL CARE MEDICINE			English	Article						therapeutic hypothermia; stroke; ischemia; hypothermia; temperature control; neuroprotection	TRANSIENT CEREBRAL-ISCHEMIA; DAMAGE COOL AID; MILD HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; MODERATE HYPOTHERMIA; CARDIAC-ARREST; CLINICAL-TRIAL; AWAKE PATIENTS; FOCAL MODEL; FEASIBILITY	Hypothermia is considered nature's "gold standard" for neuroprotection, and its efficacy for improving outcome in patients with hypoxic-ischemic brain injury as a result of cardiac arrest is well-established. Hypothermia reduces brain edema and intracranial pressure in patients with traumatic brain injury. By contrast, only a few small pilot studies have evaluated hypothermia as a treatment for acute ischemic stroke, and no controlled trials of hypothermia for hemorrhagic stroke have been performed. Logistic challenges present an important barrier to the widespread application of hypothermia for stroke, most importantly the need for high-quality critical care to start immediately in the emergency department. Rapid induction of hypothermia within 3 to 6 hrs of onset has been hampered by slow cooling rates, but is feasible. Delayed cooling for the treatment of cytotoxic brain edema does not provide definitive or lasting treatment for intra-cranial mass effect, and should not be used as an alternative to hemicraniectomy. Sustained fever control is feasible in patients with intracerebral and subarachnoid hemorrhage, but has yet to be tested in a phase III study. Important observations from studies investigating the use of hypothermia for stroke to date include the necessity for proactive antishivering therapy for successful cooling, the importance of slow controlled rewarming to avoid rebound brain edema, and the high risk for infectious and cardiovascular complications in this patient population. More research is clearly needed to bring us closer to the successful application of hypothermia in the treatment for stroke. (Crit Care Med 2009; 37[Suppl.]:S243-S249)	[Linares, Guillermo; Mayer, Stephan A.] Columbia Univ, Coll Phys & Surg, Dept Neurol, Div Neurocrit Care, New York, NY 10027 USA; [Linares, Guillermo] Columbia Univ, Coll Phys & Surg, Dept Neurol, Div Stroke, New York, NY USA; [Mayer, Stephan A.] Columbia Univ, Coll Phys & Surg, Dept Neurol Surg, New York, NY USA		Mayer, SA (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Neurol, Div Neurocrit Care, New York, NY 10027 USA.	sam14@columbia.edu					Alyagari V, 2007, J NEUROL SCI, V261, P39, DOI 10.1016/j.jns.2007.04.030; Bath P, 2002, STROKE, V33, P639; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; CAMARATA PJ, 1994, NEUROSURGERY, V34, P144, DOI 10.1227/00006123-199401000-00021; Colbourne F, 1999, J CEREBR BLOOD F MET, V19, P742, DOI 10.1097/00004647-199907000-00003; Corbett D, 2000, BRAIN PATHOL, V10, P145; De Georgia MA, 2004, NEUROLOGY, V63, P312, DOI 10.1212/01.WNL.0000129840.66938.75; Doufas AG, 2003, STROKE, V34, P1218, DOI 10.1161/01.STR.0000068787.76670.A4; Els T, 2006, CEREBROVASC DIS, V21, P79, DOI 10.1159/000090007; Feigin VL, 2002, J CLIN NEUROSCI, V9, P502, DOI 10.1054/jocn.2001.1072; Feng Honglin, 2002, Zhonghua Yi Xue Za Zhi, V82, P1622; Fingas M, 2007, EXP NEUROL, V208, P277, DOI 10.1016/j.expneurol.2007.08.018; Gasser S, 2003, J NEUROSURG ANESTH, V15, P240, DOI 10.1097/00008506-200307000-00012; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GINSBERG MD, 2004, THERAPEUTIC HYPOTHER; Guluma KZ, 2008, NEUROCRIT CARE, V8, P42, DOI 10.1007/s12028-007-9009-z; Guluma KZ, 2006, ACAD EMERG MED, V13, P820, DOI 10.1197/j.aem.2006.03.559; Hemmen TM, 2007, STROKE, V38, P794, DOI 10.1161/01.STR.0000247920.15708.fa; HOWELL D A, 1956, Can Med Assoc J, V75, P388; Ji XM, 2007, FRONT BIOSCI, V12, P1737, DOI 10.2741/2185; Jiang JY, 2006, J NEUROTRAUM, V23, P1847, DOI 10.1089/neu.2006.23.1847; Kammersgaard LP, 2000, STROKE, V31, P2251, DOI 10.1161/01.STR.31.9.2251; Kim F, 2007, CIRCULATION, V115, P3064, DOI 10.1161/CIRCULATIONAHA.106.655480; Kliegel A, 2005, RESUSCITATION, V64, P347, DOI 10.1016/j.resuscitation.2004.09.002; Kollmar R, 2002, STROKE, V33, P1899, DOI 10.1161/01.STR.0000019603.29818.9C; Komotar RJ, 2008, NEUROSURGERY, V62, P396, DOI 10.1227/01.neu.0000316006.26635.b0; Krieger DW, 2004, STROKE, V35, P1482, DOI 10.1161/01.STR.0000126118.44249.5c; Krieger DW, 2001, STROKE, V32, P1847, DOI 10.1161/01.STR.32.8.1847; KURZ M, 1993, ANESTHESIOLOGY, V79, P1193, DOI 10.1097/00000542-199312000-00009; Lyden Patrick D, 2005, J Stroke Cerebrovasc Dis, V14, P107, DOI 10.1016/j.jstrokecerebrovasdis.2005.01.001; MAHER J, 1993, CEREBROVAS BRAIN MET, V5, P277; Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; Mokhtarani M, 2001, ANESTH ANALG, V93, P1233, DOI 10.1097/00000539-200111000-00038; Moran JL, 2007, CRIT CARE MED, V35, P155, DOI 10.1097/01.CCM.0000250318.31453.CB; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; Nolan JP, 2003, CIRCULATION, V108, P118, DOI 10.1161/01.CIR.0000079019.02601.90; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; Steiner T, 2001, STROKE, V32, P2833, DOI 10.1161/hs1201.99511; Theard MA, 1997, J NEUROSURG ANESTH, V9, P250; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; XUE D, 1992, BRAIN RES, V587, P66, DOI 10.1016/0006-8993(92)91428-H; Yanamoto H, 1999, STROKE, V30, P2720, DOI 10.1161/01.STR.30.12.2720; YOUNG RSK, 1980, JAMA-J AM MED ASSOC, V244, P1233, DOI 10.1001/jama.244.11.1233; Zweifler Richard M, 2003, J Stroke Cerebrovasc Dis, V12, P237, DOI 10.1016/j.jstrokecerebrovasdis.2003.09.006	48	57	63	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUL	2009	37	7		S			S243	S249		10.1097/CCM.0b013e3181aa5de1			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	461DT	WOS:000267245500009	19535954				2022-02-06	
J	Kern, RS; Green, MF; Fiske, AP; Kee, KS; Lee, J; Sergi, MJ; Horan, WP; Subotnik, KL; Sugar, CA; Nuechterlein, KH				Kern, R. S.; Green, M. F.; Fiske, A. P.; Kee, K. S.; Lee, J.; Sergi, M. J.; Horan, W. P.; Subotnik, K. L.; Sugar, C. A.; Nuechterlein, K. H.			Theory of mind deficits for processing counterfactual information in persons with chronic schizophrenia	PSYCHOLOGICAL MEDICINE			English	Article						Counterfactual information; deception; sarcasm; schizophrenia; theory of mind	TRAUMATIC BRAIN-INJURY; SOCIAL-PERCEPTION; MENTALIZING ABILITY; PEOPLE; COMPREHENSION; REMISSION; COMMUNICATION; PRAGMATICS; INFERENCE; VALIDITY	Background. Interpersonal communication problems are common among persons with schizophrenia and may be linked, in part, to deficits in theory of mind (ToM), the ability to accurately perceive the attitudes, beliefs and intentions of others. Particular difficulties might be expected in the processing of counterfactual information such as sarcasm or lies. Method. The present study included 50 schizophrenia or schizo-affective out-patients and 44 demographically comparable healthy adults who were administered Part III of The Awareness of Social Inference Test (TASIT; a measure assessing comprehension of sarcasm Versus lies) as well as measures of positive and negative symptoms and community functioning. Results. TASIT data were analyzed using a 2 (group: patients versus healthy adults) x 2 (condition: sarcasm versus lie) repeated-measures ANOVA. The results show significant effects for group, condition, and the group x condition interaction. Compared to controls, patients performed significantly worse on sarcasm but not lie scenes. Within-group contrasts showed that patients performed significantly worse on sarcasm versus lie scenes; controls performed comparably on both. In patients, performance on TASIT showed a significant correlation with positive, but not negative, symptoms. The group and interaction effects remained significant when rerun with a subset of patients with low-level positive symptoms. The findings for a relationship between TASIT performance and community functioning were essentially negative. Conclusions. The findings replicate a prior demonstration of difficulty in the comprehension of sarcasm using a different test, but are not consistent with previous studies showing global ToM deficits in schizophrenia.	[Kern, R. S.; Green, M. F.; Kee, K. S.; Lee, J.; Sergi, M. J.; Horan, W. P.; Subotnik, K. L.; Nuechterlein, K. H.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Geffen Sch Med, Los Angeles, CA 90024 USA; [Kern, R. S.; Green, M. F.; Kee, K. S.; Lee, J.; Sergi, M. J.; Horan, W. P.] Mental Illness Res Educ & Clin Ctr, Dept Vet Affairs, VISN 22, Los Angeles, CA USA; [Fiske, A. P.] Univ Calif Los Angeles, Dept Anthropol, Ctr Culture Brain & Dev, Los Angeles, CA 90024 USA; [Fiske, A. P.] Univ Calif Los Angeles, Ctr Behav Evolut & Culture, Los Angeles, CA 90024 USA; [Kee, K. S.] Calif State Univ, Channel Isl, CA USA; [Sergi, M. J.] Calif State Univ Northridge, Northridge, CA 91330 USA; [Nuechterlein, K. H.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Psychol, Los Angeles, CA 90024 USA		Kern, RS (corresponding author), VA Greater Los Angeles Healthcare Syst MIRECC 210, Bldg 210,Room 116,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	rkern@ucla.edu	Nuechterlein, Keith H/K-8654-2012; Lee, Junghee/C-5226-2014; Lee, Junghee/AAX-6124-2021; Horan, William/V-7495-2019	Lee, Junghee/0000-0001-9567-8700; Lee, Junghee/0000-0001-9567-8700; 	NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P50 MH 66586]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P50MH066286] Funding Source: NIH RePORTER	We thank the patients for their participation in the project, and Mike DeGroot, Robin Kite, Jeff Nishii, and Samantha Swain for their help in the data collection. The project was supported by an NIMH Center grant to K.H.N. (P50 MH 66586).	Andreasen N.C., 1984, SCALE ASSESSMENT POS; Andreasen NC, 1984, SCALE ASSESSMENT NEG; AUTHER AM, 2006, GLOBAL FUNCTIIONING; Baron-Cohen S., 1995, MINDBLINDNESS ESSAY; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Blanchard JJ, 2006, SCHIZOPHRENIA BULL, V32, P238, DOI 10.1093/schbul/sbj013; Brune M, 2005, SCHIZOPHRENIA BULL, V31, P21, DOI 10.1093/schbul/sbi002; Brune M, 2003, SCHIZOPHR RES, V60, P57, DOI 10.1016/s0920-9964(02)00162-7; CHAPMAN LJ, 1978, J PSYCHIAT RES, V14, P303, DOI 10.1016/0022-3956(78)90034-1; Corcoran R, 1997, SCHIZOPHR RES, V24, P319, DOI 10.1016/S0920-9964(96)00117-X; CORCORAN R, 1995, SCHIZOPHR RES, V17, P5, DOI 10.1016/0920-9964(95)00024-G; CORCORAN R, 2001, SOCIAL COGNITION SCH, P149, DOI DOI 10.1037/10407-005; Cornblatt BA, 2007, SCHIZOPHRENIA BULL, V33, P688, DOI 10.1093/schbul/sbm029; Couture SM, 2006, SCHIZOPHRENIA BULL, V32, pS44, DOI 10.1093/schbul/sbl029; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; DONAHOE CP, 1990, PSYCHIATRY, V53, P329; Doody GA, 1998, PSYCHOL MED, V28, P397, DOI 10.1017/S003329179700648X; Ekman P., 1976, PICTURES FACIAL AFFE; First M.B., 1996, STRUCTURED CLIN INTE; Frith C.D., 1992, COGN NEUROPSYCHOL; Frith CD, 1996, PSYCHOL MED, V26, P521, DOI 10.1017/S0033291700035601; HAPPE FGE, 1993, COGNITION, V48, P101, DOI 10.1016/0010-0277(93)90026-R; Harrington Leigh, 2005, Cogn Neuropsychiatry, V10, P249, DOI 10.1080/13546800444000056; Herold R, 2002, PSYCHOL MED, V32, P1125, DOI 10.1017/S0033291702005433; Inoue Y, 2006, EUR ARCH PSY CLIN N, V256, P326, DOI 10.1007/s00406-006-0608-z; Jahshan CS, 2007, SCHIZOPHR RES, V89, P278, DOI 10.1016/j.schres.2006.09.004; Janssen I, 2003, ACTA PSYCHIAT SCAND, V108, P110, DOI 10.1034/j.1600-0447.2003.00092.x; Langdon R, 2002, PSYCHOL MED, V32, P1273, DOI 10.1017/S0033291702006396; Leitman DI, 2006, PSYCHOL MED, V36, P1075, DOI 10.1017/S0033291706007653; Leslie AM, 2004, TRENDS COGN SCI, V8, P528, DOI 10.1016/j.tics.2004.10.001; LESLIE AM, 1987, PSYCHOL REV, V94, P412, DOI 10.1037/0033-295X.94.4.412; Marjoram Dominic, 2005, Cogn Neuropsychiatry, V10, P347, DOI 10.1080/13546800444000092; Marjoram D, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-12; Mazza M, 2001, SCHIZOPHR RES, V47, P299, DOI 10.1016/S0920-9964(00)00157-2; McCabe R, 2004, PSYCHOL MED, V34, P401, DOI 10.1017/S0033291703001338; McDonald, 2000, METAPHOR SYMBOL, V15, P85, DOI DOI 10.1080/10926488.2000.9678866; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; MCPHEETERS HL, 1984, COMMUNITY MENT HLT J, V20, P44; Mitchley N.J., 1998, COGNITIVE NEUROPSYCH, V3, P127, DOI [10.1080/135468098396206, DOI 10.1080/135468098396206]; Mo SL, 2008, PSYCHIAT RES, V157, P21, DOI 10.1016/j.psychres.2006.04.002; Niendam T.A., 2006, GLOBAL FUNCTIONING S; Orbelo DM, 2005, J GERIATR PSYCH NEUR, V18, P25, DOI 10.1177/0891988704272214; Pilowsky T, 2000, SCHIZOPHR RES, V42, P145, DOI 10.1016/S0920-9964(99)00101-2; Pollice R, 2002, PSYCHOPATHOLOGY, V35, P280, DOI 10.1159/000067062; PREMACK D, 1978, BEHAV BRAIN SCI, V0001, DOI DOI 10.1017/S0140525X00076512; Randall Fiona, 2003, Cogn Neuropsychiatry, V8, P287, DOI 10.1080/135468000057; Reichenberg A, 2002, AM J PSYCHIAT, V159, P2027, DOI 10.1176/appi.ajp.159.12.2027; Sperber D, 2002, MIND LANG, V17, P3, DOI 10.1111/1468-0017.00186; Sprong M, 2007, BRIT J PSYCHIAT, V191, P5, DOI 10.1192/bjp.bp.107.035899; STEIN LI, 1980, ARCH GEN PSYCHIAT, V37, P392; WechslerD, 2001, WECHSLER TEST ADULT; Weiser M, 2007, J NERV MENT DIS, V195, P883, DOI 10.1097/NMD.0b013e31815928b0	56	57	57	0	17	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0033-2917			PSYCHOL MED	Psychol. Med.	APR	2009	39	4					645	654		10.1017/S0033291708003966			10	Psychology, Clinical; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	426EO	WOS:000264691000011	18694537	Green Accepted			2022-02-06	
J	Xiong, Y; Qu, CS; Mahmood, A; Liu, ZW; Ning, RZ; Li, Y; Kaplan, DL; Schallert, T; Chopp, M				Xiong, Ye; Qu, Changsheng; Mahmood, Asim; Liu, Zhongwu; Ning, Ruizhuo; Li, Yi; Kaplan, David L.; Schallert, Timothy; Chopp, Michael			Delayed transplantation of human marrow stromal cell-seeded scaffolds increases transcallosal neural fiber length, angiogenesis, and hippocampal neuronal survival and improves functional outcome after traumatic brain injury in rats	BRAIN RESEARCH			English	Article						Angiogenesis; Neural fiber length; Human bone marrow stromal cell; Scaffold; Sensorimotor; Spatial learning; Traumatic brain injury	SPINAL-CORD-INJURY; SPATIAL MEMORY; STEM-CELLS; STROKE; NEUROGENESIS; MICE; ERYTHROPOIETIN; RECOVERY; THERAPY; PROLIFERATION	Traumatic brain injury (TBI) is a major cause of death and disability worldwide; however, no effective treatment has been clinically identified. Our recent studies show that the combination of Collagen scaffolds with human bone morrow stromal cells (hMSCs) for treatment of TBI improves functional outcome and reduces the lesion volume when this combination was applied at day 4 after TBI in rats. The mechanisms underlying these benefits remain unclear. Whether further delayed treatment with this combination will provide benefits has not been investigated. In the present study, we investigated whether the delayed (7 days post injury) transplantation would have beneficial effects on functional and histological outcome and sought to elucidate underlying mechanisms of therapeutic action. Collagen scaffolds seeded with 3 x 106 hMSCs, scaffolds alone, 3 x 106 hMSCs alone, or saline were transplanted into the lesion cavity of the injured cortex 7 days after TBI. Sensorimotor function and spatial learning were measured. Corticocortical labeling with 1, 1 ''-dioleyl-3, 3, 3 '', 3 ''-tetramethylindocarbocyanine methanesulfonate (DiI) was performed at day 36 after TBI. The rats were sacrificed 43 days after TBI, and the brain tissue was processed for DiI-labeling fiber and immunohistochemical analyses. The present data show that delayed transplantation of hMSCs or scaffolds seeded with hMSCs improved spatial learning and sensorimotor function, enhanced angiogenesis in the injured cortex and the ipsilateral hippocampus and increased DiI-labeled neural fiber length in the injured cortex. hMSC-seeded scaffolds may be a new and effective way to improve neurological function after TBI. (C) 2009 Elsevier B.V. All rights reserved.	[Xiong, Ye; Qu, Changsheng; Mahmood, Asim; Ning, Ruizhuo] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Liu, Zhongwu; Li, Yi; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Kaplan, David L.] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA; [Schallert, Timothy] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Schallert, Timothy] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI 48309 USA		Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, E&R Bldg,Room 3056,2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu	ning, ruizhuo/E-6401-2012	Xiong, Ye/0000-0001-9770-6031	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS042259, RO1 NS 062002, PO1 NS42345, P41 EB002520]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB002520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS042345, R01NS042259, R01NS062002] Funding Source: NIH RePORTER	This work was supported by NIH grants RO1 NS042259, RO1 NS 062002, PO1 NS42345 and P41 EB002520.	Bakshi A, 2004, J NEUROSURG-SPINE, V1, P322, DOI 10.3171/spi.2004.1.3.0322; Chen Jieli, 2006, NeuroRx, V3, P466, DOI 10.1016/j.nurx.2006.07.007; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2004, BRAIN RES, V1005, P21, DOI 10.1016/j.brainres.2003.11.080; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Liu ZW, 2007, BRAIN RES, V1149, P172, DOI 10.1016/j.brainres.2007.02.047; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Paxinos G, 1986, RAT BRAIN STEREOTACT; Potter W, 2008, FRONT BIOSCI-LANDMRK, V13, P806, DOI 10.2741/2721; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Shen CF, 2007, IET OPTOELECTRON, V1, P27, DOI 10.1049/iet-opt:20060003; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Urdzikova L, 2006, J NEUROTRAUM, V23, P1379, DOI 10.1089/neu.2006.23.1379; Wright KT, 2007, BIOCHEM BIOPH RES CO, V354, P559, DOI 10.1016/j.bbrc.2007.01.013; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126; Zhang C, 2006, NEUROSCIENCE, V141, P687, DOI 10.1016/j.neuroscience.2006.04.054; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; NIH CONSENS STATEMEN, V16, P1	35	57	58	0	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 31	2009	1263						183	191		10.1016/j.brainres.2009.01.032			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	431CV	WOS:000265039800020	19368838	Green Accepted			2022-02-06	
J	Bowman, SM; Aitken, ME; Helmkamp, JC; Maham, SA; Graham, CJ				Bowman, S. M.; Aitken, M. E.; Helmkamp, J. C.; Maham, S. A.; Graham, C. J.			Impact of helmets on injuries to riders of all-terrain vehicles	INJURY PREVENTION			English	Article							UNITED-STATES; DEATH RATES; TRAUMA; CHILDREN; SEVERITY; CRASHES; KIDS	Background: Although helmet use has been shown to be effective in reducing traumatic brain injuries (TBIs) due to motorcycle and bicycle crashes, it is unknown whether helmet use is associated with different injury patterns and severity for users of all-terrain vehicles (ATVs). Objectives: To compare likelihood of injury and death between helmeted and unhelmeted riders of ATVs. Methods: The National Trauma Data Bank for years 2002-2006 was used to examine the records of 11 589 patients hospitalized for injuries resulting from ATV use. The likelihood of receiving a TBI diagnosis or a significant injury to other body regions and differences in injury severity and in-hospital mortality between helmeted and unhelmeted ATV riders were compared. Results: After multivariable adjustment, compared with helmeted riders, unhelmeted riders were significantly more likely to sustain any TBI (OR 1.62, 95% CI 1.49 to 1.76, p, 0.001) and major/severe TBI (OR 3.19, 95% CI 2.39 to 4.25, p, 0.001). Unhelmeted riders were significantly more likely to die while in hospital than were helmeted riders (OR 2.58, 95% CI 1.79 to 3.71, p, 0.001). Significant injuries to the neck and face regions were also significantly more likely in unhelmeted riders (OR 3.53, 95% CI 1.28 to 9.71, p = 0.015, and OR 1.94, 95% CI 1.32 to 2.84, p = 0.001, respectively). Conclusions: ATV riders who do not wear helmets are more likely to receive significant injuries to the head, face, and neck. Prevention strategies and enforceable policy interventions to increase helmet use among ATV riders appear warranted.	[Bowman, S. M.; Aitken, M. E.; Maham, S. A.; Graham, C. J.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA; [Helmkamp, J. C.] W Virginia Univ, Morgantown, WV 26506 USA		Bowman, SM (corresponding author), Arkansas Childrens Hosp, 800 Marshall St,Slot 512-26, Little Rock, AR 72202 USA.	bowmanstephenm@uams.edu	Aitken, Mary/ABG-6119-2021; Bowman, Stephen/AAF-2154-2019	Aitken, Mary/0000-0002-8318-9755			Acosta JA, 2003, J TRAUMA, V55, P282, DOI 10.1097/01.TA.0000080525.77566.ED; Aitken ME, 2004, INJURY PREV, V10, P303, DOI 10.1136/ip.2003.004176; American College of Surgeons, NAT TRAUM DAT BANK 2; *AR LEG FUND CONC, 2007, DEATH INJ RES ATV BI; Balthrop PM, 2007, J TRAUMA, V62, P1163, DOI 10.1097/01.ta.0000229814.08289.9a; BALTHROP PM, 2007, J EMERG MED     1012; Brandenburg Mark A, 2005, J Okla State Med Assoc, V98, P194; Brown RL, 2002, J PEDIATR SURG, V37, P375, DOI 10.1053/jpsu.2002.30826; Carr AM, 2004, NEUROSURGERY, V54, P861, DOI 10.1227/01.NEU.0000114922.46342.38; Charles A, 2007, AM SURGEON, V73, P1; Clark DE, 2007, J TRAUMA, V62, P592, DOI 10.1097/01.ta.0000257239.15436.29; Fonseca AH, 2005, AM SURGEON, V71, P937; Gennarelli T. A, 2007, ABBREVIATED INJURY S; Gittelman MA, 2006, PEDIATRICS, V117, P2190, DOI 10.1542/peds.2005-2603; Helmkamp JC, 2008, AM J PREV MED, V34, P39, DOI 10.1016/j.amepre.2007.09.016; Helmkamp JC, 2001, AM J PUBLIC HEALTH, V91, P1792, DOI 10.2105/AJPH.91.11.1792; Helmkamp J, 2007, PEDIATRICS, V119, P223, DOI 10.1542/peds.2006-2890; *J HOPK U TRI AN, 1997, ICDMAP 90 INJ SEV CO; Jones CS, 2005, J RURAL HEALTH, V21, P70, DOI 10.1111/j.1748-0361.2005.tb00064.x; Keenan HT, 2004, PEDIATRICS, V113, pE330, DOI 10.1542/peds.113.4.e330; Kelleher CM, 2005, J PEDIATR SURG, V40, P929, DOI 10.1016/j.jpedsurg.2005.03.007; Killingsworth JB, 2005, PEDIATRICS, V115, pE316, DOI 10.1542/peds.2004-1585; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Liu BC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004333.pub3; Mullins RJ, 2007, J AM COLL SURGEONS, V204, P216, DOI 10.1016/j.jamcollsurg.2006.10.025; Murphy N, 2004, J TRAUMA, V56, P1185, DOI 10.1097/01.TA.0000123038.94864.E2; RODGERS GB, 1990, ACCIDENT ANAL PREV, V22, P47, DOI 10.1016/0001-4575(90)90006-7; Rodgers GB, 1999, ACCIDENT ANAL PREV, V31, P409, DOI 10.1016/S0001-4575(98)00080-3; Roudsari B, 2008, INJURY PREV, V14, P96, DOI 10.1136/ip.2007.017129; *SPEC VEH I AM, 2005, STAT ALL TERR VEH RE; *US CONS PROD SAF, 2008, 2006 ANN REP ATV REL; *US CONS PROD SAF, ATV STAT LEG	32	57	57	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047			INJURY PREV	Inj. Prev.	FEB	2009	15	1					3	7		10.1136/ip.2008.019372			5	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	403GO	WOS:000263071300003	19190268				2022-02-06	
J	Su, TM; Lee, TH; Chen, WF; Lee, TC; Cheng, CH				Su, Thung-Ming; Lee, Tsung-Han; Chen, Wu-Fu; Lee, Tao-Chen; Cheng, Ching-Hsiao			Contralateral Acute Epidural Hematoma After Decompressive Surgery of Acute Subdural Hematoma: Clinical Features and Outcome	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Acute epidural hematoma; Acute subdural hematoma; Decompressive surgery	EXTRADURAL HEMATOMA; CT-SCAN; EVACUATION	Background. Delayed contralateral epidural hematoma (EDH) after decompressive surgery for acute subdural hematoma (SDH) is uncommon. If unrecognized, this delayed hematoma can cause devastating consequences. We present our experience with this group of patients and discuss the diagnosis and management of this dangerous condition. Methods: This study included 12 traumatic patients with acute SDH who developed delayed contralateral EDH after acute SDH evacuation. Clinical and radiographic information was obtained through a retrospective review of the medical records and the radiographs. Results: There were seven males and five females. Nine patients had severe head injury (Glasgow Coma Scale (GCS) score <= 8). Ten patients underwent acute SDH evacuation within 4 hours after the trauma. Intraoperative brain swelling during SDH evacuation was noted in 10 patients. A skull fracture at the site of the EDH on computed tomography (CT) was noted only in 10 patients. However, a skull fracture overlying the EDH was found during EDH evacuation in all patients. Only three patients with less severe head injury (GCS > 8) had good recovery. Other patients with severe bead injury (GCS <= 58) had poor outcome. Conclusions: Severe head injury, a skull fracture contralateral to the original hematoma, intraoperative brain protrusion, and a poor outcome are typical clinical findings in this disorder. In patients with acute SDH and a contralateral skull fracture, immediate postoperative CT scan is indicated to evaluate this rare but potentially lethal complication. According to the findings of the postoperative CT scan, the neurosurgeon can make an appropriate strategy of treatment promptly. Early detection and prompt treatment may improve the poor outcome in this group of patients.	[Su, Thung-Ming; Lee, Tsung-Han; Chen, Wu-Fu; Lee, Tao-Chen; Cheng, Ching-Hsiao] Chang Gung Univ Coll Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Neurosurg, Niao Sung Hsiang, Kaohsiung Hsien, Taiwan		Cheng, CH (corresponding author), Chang Gung Univ Coll Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Neurosurg, 123 Ta Pei Rd, Niao Sung Hsiang, Kaohsiung Hsien, Taiwan.	ma4200@adm.cgmh.org.tw					BOROVICH B, 1985, J NEUROSURG, V63, P30, DOI 10.3171/jns.1985.63.1.0030; CORDOBES F, 1981, J NEUROSURG, V54, P179, DOI 10.3171/jns.1981.54.2.0179; FEUERMAN T, 1988, NEUROSURGERY, V23, P480, DOI 10.1227/00006123-198810000-00013; JENNETT B, 1975, LANCET, V1, P480; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; Matsuno A, 2003, SURG NEUROL, V60, P23, DOI 10.1016/S0090-3019(03)00023-5; MEGURO K, 1987, NEUROSURGERY, V20, P326, DOI 10.1227/00006123-198702000-00023; Mohindra S, 2005, BRIT J NEUROSURG, V19, P490, DOI 10.1080/02688690500495216; PETERSEN OF, 1984, NEURORADIOLOGY, V26, P363, DOI 10.1007/BF00327488; PIEPMEIER JM, 1982, J TRAUMA, V22, P455, DOI 10.1097/00005373-198206000-00003; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; THIBODEAU M, 1987, J CAN ASSOC RADIOL, V38, P52; Yague L G, 1991, J Neurosurg Sci, V35, P107	14	57	70	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2008	65	6					1298	1302		10.1097/TA.0b013e31815885d9			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	383WV	WOS:000261706000020	19077617				2022-02-06	
J	Topal, NB; Hakyemez, B; Erdogan, C; Bulut, M; Koksal, O; Akkose, S; Dogan, S; Parlak, M; Ozguc, H; Korfali, E				Topal, Naile Bolca; Hakyemez, Bahattin; Erdogan, Cuneyt; Bulut, Mehtap; Koksal, Ozlem; Akkose, Sule; Dogan, Seref; Parlak, Mufit; Ozguc, Halil; Korfali, Ender			MR imaging in the detection of diffuse axonal injury with mild traumatic brain injury	NEUROLOGICAL RESEARCH			English	Article						Brain injury; axonal injury; magnetic resonance	CLOSED-HEAD INJURY; GRADIENT-RECALLED ECHO; CONCUSSION; DAMAGE; CT	Purpose: To evaluate the occurrence and distribution of mild traumatic brain injury MTBI) caused by diffuse axonal injury DAI) using magnetic resonance MR) imaging and to attempt to correlate MR findings with post-concussion symptoms PCS). Patients and methods: Forty MTBI patients mean age: 32.5 years) with normal cranial computed tomography CT) findings were examined with standard MR protocol including T1-weighted, T(2)-weighted, fluid attenuated inversion recovery FLAIR), gradient echo GRE) and diffusion-weighted DW) sequences. MR imaging was performed within 24 hours of injury. The lesions were classified as DAI based on their location and morphologic appearance. Results: In MR imaging of five 12.5%) of the patients, the lesions compatible with DAI were observed. Four patients 10%) had the foci of low signal intensity compatible with hemorrhagic shear injury on the GRE sequence, and five 12.5%) patients had high signal intensity on FLAIR and DW sequence. Conclusion: MR imaging can be helpful in revealing DAI lesions in patients with normal CT scan findings after MTBI. FLAIR, GRE and DW sequences are superior to conventional spin-echo images in detecting DAI lesions. [Neurol Res 2008; 30: 974-978]	[Topal, Naile Bolca; Hakyemez, Bahattin; Erdogan, Cuneyt; Parlak, Mufit] Uludag Univ, Sch Med, Dept Radiol, TR-16059 Gorukle, Bursa, Turkey; [Bulut, Mehtap; Koksal, Ozlem; Akkose, Sule] Uludag Univ, Sch Med, Dept Emergency Med, TR-16059 Gorukle, Bursa, Turkey; [Dogan, Seref; Korfali, Ender] Uludag Univ, Sch Med, Dept Neurosurg, TR-16059 Gorukle, Bursa, Turkey; [Ozguc, Halil] Uludag Univ, Sch Med, Dept Gen Surg, TR-16059 Gorukle, Bursa, Turkey		Topal, NB (corresponding author), Uludag Univ, Sch Med, Dept Radiol, TR-16059 Gorukle, Bursa, Turkey.	nailebolca@yahoo.com	dogan, seref/AAI-6531-2021; Parlak, Mufit/AAG-8521-2021; Topal, Naile Bolca/AAI-2327-2021; koksal, ozlem/AAK-8332-2020; bulut, mehtap/AAX-5571-2021; Hakyemez, Bahattin/AAI-2318-2021	koksal, ozlem/0000-0003-2271-5659; Hakyemez, Bahattin/0000-0002-3425-0740			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Ezaki Y, 2006, ACTA NEUROCHIR, V148, P547, DOI 10.1007/s00701-005-0692-2; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Giugni E, 2005, RADIOL MED, V109, P563; Giugni E, 2005, AM J NEURORADIOL, V26, P1140; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kinoshita T, 2005, EUR J RADIOL, V56, P5, DOI 10.1016/j.ejrad.2005.04.001; Kushner D, 2002, AM J NEURORADIOL, V23, P1442; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Neumar RW, 2002, ANN EMERG MED, V39, P342, DOI 10.1067/mem.2002.122007; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Sklar EM, 2000, AM J NEURORADIOL, V21, P808; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Zheng WB, 2007, NEURORADIOLOGY, V49, P271, DOI 10.1007/s00234-006-0187-8	30	57	60	0	13	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	NOV	2008	30	9					974	978		10.1179/016164108X323799			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	378LT	WOS:000261323000016	18691451				2022-02-06	
J	Mazzeo, AT; Alves, OL; Gilman, CB; Hayes, RL; Tolias, C; Kunene, KN; Bullock, MR				Mazzeo, Anna Teresa; Alves, Oscar Luis; Gilman, Charlotte B.; Hayes, Ronald L.; Tolias, Christos; Kunene, K. Niki; Bullock, M. Ross			Brain metabolic and hemodynamic effects of cyclosporin A after human severe traumatic brain injury: a microdialysis study	ACTA NEUROCHIRURGICA			English	Article						Cyclosporin A; Neuroprotection; Traumatic brain injury; Cerebral microdialysis; Cerebral hemodynamics	MITOCHONDRIAL PERMEABILITY TRANSITION; POSITRON-EMISSION-TOMOGRAPHY; HUMAN HEAD-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; CEREBRAL PERFUSION-PRESSURE; NITRIC-OXIDE SYNTHASE; INDUCED AXONAL DAMAGE; AMINO-ACID RELEASE; INTRACEREBRAL MICRODIALYSIS; CELL-DEATH	Background Mitochondrial dysfunction is a major limiting factor in neuronal recovery following traumatic brain injury. Cyclosporin A (CsA) has been recently proposed for use in the early phase after severe head injury, for its ability to preserve mitochondrial bioenergetic state, potentially exerting a neuroprotective effect. The aim of this study was, therefore, to evaluate the effect of CsA on brain energy metabolism, as measured by cerebral microdialysis, and on cerebral hemodynamics, in a group of severely head injured patients. Methods Fifty adult patients with a severe head injury were enrolled in this randomized, double-blind, placebo-controlled study. Patients received 5 mg/kg of CsA over 24 h, or placebo, within 12 h of the injury. A microdialysis probe was placed in all patients, who were managed according to standard protocols for the treatment of severe head injury. Findings The most robust result of this study was that, over most of the monitoring period, brain dialysate glucose was significantly higher in the CsA treated patients than in placebo. Both lactate and pyruvate were also significantly higher in the CsA group. Glutamate concentration and lactate/pyruvate ratio were significantly higher in the placebo group than in CsA treated patients, respectively 1 to 2 days, and 2 to 3 days after the end of the 24-h drug infusion. The administration of CsA was also associated with a significant increase in mean arterial pressure (MAP) and cerebral perfusion pressure (CPP). Conclusions The administration of CsA in the early phase after head injury resulted in significantly higher extracellular fluid glucose and pyruvate, which may be evidence of a beneficial effect. The early administration of CsA was also associated with a significant increase in MAP and CPP and such a potentially beneficial hemodynamic effect might contribute to a neuroprotective effect.	[Mazzeo, Anna Teresa] Univ Messina, Dept Neurosci Psychiat & Anesthesiol Sci, I-98121 Messina, Italy; [Mazzeo, Anna Teresa; Gilman, Charlotte B.] Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; [Alves, Oscar Luis] Univ Porto, Fac Med, Ctr Hosp Vila Nova Gaia, Serv Neurocirurgia, P-4100 Oporto, Portugal; [Hayes, Ronald L.] Univ Florida, Dept Anesthesiol, Gainesville, FL USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL USA; [Tolias, Christos] Kings Coll Hosp London, Dept Neurosurg, London, England; [Kunene, K. Niki] Univ Louisville, Dept Comp Informat Syst, Louisville, KY 40292 USA; [Bullock, M. Ross] Univ Miami, Miller Sch Med, Lois Pope LIFE Ctr, Dept Neurosurg, Miami, FL 33136 USA		Mazzeo, AT (corresponding author), Univ Messina, Dept Neurosci Psychiat & Anesthesiol Sci, Viale Regina Margherita 59, I-98121 Messina, Italy.	annateresamazzeo@unime.it; oscar.luis.alves@clix.pt; cbgilman@vcu.edu; rhayes@banyanbio.com; Christos.Tolias@kch.nhs.uk; niki.kunene@gmail.com; rbullock@med.miami.edu		Mazzeo, Anna Teresa/0000-0002-8454-7243	NIH NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS 12587-27]; Reynolds; Lind-Lawrence Foundations; Fundacao para a Ciencia e TecnologiaPortuguese Foundation for Science and TechnologyEuropean Commission [SFRH/BD/3421/2000]; Fulbright Fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587] Funding Source: NIH RePORTER	Funding for this study was provided by NIH NINDS grant N. P50 NS 12587-27, and Ross Bullock was supported by the Reynolds, and Lind-Lawrence Foundations.; Oscar L Alves was supported by grant no. SFRH/BD/3421/2000 from Fundacao para a Ciencia e Tecnologia, and by a Fulbright Fellowship.	Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Alves OL, 2003, ANN NY ACAD SCI, V993, P25, DOI 10.1111/j.1749-6632.2003.tb07508.x; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; BENVENISTE H, 1989, J NEUROCHEM, V52, P1667, DOI 10.1111/j.1471-4159.1989.tb07243.x; Brain Trauma Foundation: American association of Neurological surgeons, 2007, J NEUROTRAUMA S1, V24, pS59; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cesarini KG, 2002, ACTA NEUROCHIR, V144, P1121, DOI 10.1007/s00701-002-1011-9; Chaurasia CS, 1999, BIOMED CHROMATOGR, V13, P317, DOI 10.1002/(SICI)1099-0801(199908)13:5<317::AID-BMC891>3.0.CO;2-I; Christians U, 2004, BRIT J PHARMACOL, V143, P388, DOI 10.1038/sj.bjp.0705939; Danovitch GM, 2005, HDB KIDNEY TRANSPLAN, P72; Domanska-Janik K, 2004, MOL BRAIN RES, V121, P50, DOI 10.1016/j.molbrainres.2003.11.006; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; Enblad P, 2001, STROKE, V32, P1574, DOI 10.1161/01.STR.32.7.1574; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; Gardiner SM, 2004, BRIT J PHARMACOL, V141, P634, DOI 10.1038/sj.bjp.0705659; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; KATSURA K, 1992, J CEREBR BLOOD F MET, V12, P270, DOI 10.1038/jcbfm.1992.37; Kett-White R, 2002, NEUROSURGERY, V50, P1213, DOI 10.1097/00006123-200206000-00008; Kosch M, 2003, TRANSPLANTATION, V76, P1516, DOI 10.1097/01.TP.0000092521.57633.BD; Koura SS, 1998, ACT NEUR S, V71, P244; LANGEMANN H, 1995, CLIN NEUROL NEUROSUR, V97, P149, DOI 10.1016/0303-8467(94)00067-G; Langemann H, 2001, NEUROL RES, V23, P531, DOI 10.1179/016164101101198785; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lungu AO, 2004, J BIOL CHEM, V279, P48794, DOI 10.1074/jbc.M313897200; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Marrif H, 1999, J NEUROSCI RES, V57, P255; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Mazzeo AT, 2006, J NEUROTRAUM, V23, P962, DOI 10.1089/neu.2006.23.962; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MEYERSON BA, 1990, LIFE SCI, V46, P301, DOI 10.1016/0024-3205(90)90037-R; Nishiyama A, 2003, HYPERTENSION, V42, P754, DOI 10.1161/01.HYP.0000085195.38870.44; Okonkwo DO, 2003, NEUROREPORT, V14, P463, DOI 10.1097/01.wnr.0000058958.85541.d3; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Peerdeman SM, 2003, INTENS CARE MED, V29, P1825, DOI 10.1007/s00134-003-1850-8; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Povlishock JT, 1996, ACT NEUR S, V66, P81; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; ROULLET JB, 1994, J CLIN INVEST, V93, P2244, DOI 10.1172/JCI117222; Sanchez-Lozada LG, 2000, HYPERTENSION, V36, P642, DOI 10.1161/01.HYP.36.4.642; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schneweis S, 2001, STROKE, V32, P1863, DOI 10.1161/01.STR.32.8.1863; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Shaltout HA, 2003, J PHARMACOL EXP THER, V305, P966, DOI 10.1124/jpet.102.048447; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Skjoth-Rasmussen J, 2004, J NEUROSURG, V100, P8, DOI 10.3171/jns.2004.100.1.0008; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Starkov AA, 2004, CELL CALCIUM, V36, P257, DOI 10.1016/j.ceca.2004.02.012; Staub F, 2000, NEUROSURGERY, V47, P1106, DOI 10.1097/00006123-200011000-00016; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Ungerstedt U, 2004, CURR PHARM DESIGN, V10, P2145, DOI 10.2174/1381612043384105; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Valtysson J, 1998, ACTA NEUROCHIR, V140, P387, DOI 10.1007/s007010050113; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wang XD, 2001, GENE DEV, V15, P2922; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Yu GL, 2004, BRAIN RES, V1018, P32, DOI 10.1016/j.brainres.2004.05.056; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547	83	57	59	0	7	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	OCT	2008	150	10					1019	1031		10.1007/s00701-008-0021-7			13	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	363ZP	WOS:000260306300001	18781275				2022-02-06	
J	Cooper, DJ; Rosenfeld, JV; Murray, L; Wolfe, R; Ponsford, J; Davies, A; D'Urso, P; Pellegrino, V; Malham, G; Kossmann, T				Cooper, D. James; Rosenfeld, Jeffrey V.; Murray, Lynnette; Wolfe, Rory; Ponsford, Jennie; Davies, Andrew; D'Urso, Paul; Pellegrino, Vincent; Malham, Gregory; Kossmann, Thomas			Early decompressive craniectomy for patients with severe traumatic brain injury and refractory intracranial hypertension - A pilot randomized trial	JOURNAL OF CRITICAL CARE			English	Article						decompressive craniectomy; diffuse traumatic brain injury; intracranial hypertension	SEVERE HEAD-INJURY; GLASGOW OUTCOME SCALE; STRUCTURED INTERVIEWS; CEREBRAL EDEMA; MANAGEMENT; PROPHYLAXIS; CRANIOTOMY; GUIDELINES; CHILDREN	Purpose: The aims of this study were to test the feasibility and to assess potential recruitment rates in a pilot study preliminary to a phase III randomized trial of decompressive craniectomy surgery in patients with diffuse traumatic brain injury (TBI) and refractory intracranial hypertension. Materials and Methods:. A Study protocol was developed, inclusion and exclusion criteria were defined, and a standardized surgical technique was established. Neurologic outcomes were assessed 6 months after injury with a validated, structured questionnaire and a single trained assessor blind to treatment group. Results: During the 8-month pilot study at a level 1 trauma center in Melbourne, Australia, 69 intensive care patients with severe TBI were assessed for inclusion. Six patients were eligible, and 5 (8%) were randomized. Six months after injury, 100% of patients received outcome assessments. Key improvements to the multicenter Decompressive Craniectomy study protocol were enabled by the pilot study. Conclusions: In patients with severe TBI and refractory intracranial hypertension, the frequency of favorable neurologic outcomes (independent living) was low and similar to predicted values (40% favorable). A future multicenter phase III trial involving IS neurotrauma centers with most sites conservatively recruiting at just 25% of the pilot study rate would require at least 5 years to achieve an estimated 210-patient sample size. Collaboration With neurotrauma centers in countries other than Australia and New Zealand would be required for such a phase III trial to be successful. (c) 2008 Elsevier Inc. All rights reserved.	[Cooper, D. James; Murray, Lynnette; Davies, Andrew; Pellegrino, Vincent] Monash Univ, Alfred Hosp, Dept Intens Care, Melbourne, Vic 3004, Australia; [Rosenfeld, Jeffrey V.; Malham, Gregory] Monash Univ, Alfred Hosp, Dept Neurosurg, Melbourne, Vic 3004, Australia; [Kossmann, Thomas] Monash Univ, Alfred Hosp, Dept Trauma Surg, Melbourne, Vic 3004, Australia; [Cooper, D. James; Rosenfeld, Jeffrey V.; Malham, Gregory] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia; [Cooper, D. James; Wolfe, Rory] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Ponsford, Jennie] Monash Univ, Dept Psychol, Melbourne, Vic 3004, Australia; [Cooper, D. James; Rosenfeld, Jeffrey V.; Murray, Lynnette; D'Urso, Paul; Malham, Gregory; Kossmann, Thomas] Natl Trauma Res Inst, Melbourne, Vic 3004, Australia		Cooper, DJ (corresponding author), Natl Trauma Res Inst, Melbourne, Vic 3004, Australia.	j.cooper@alfred.org.au	Rosenfeld, Jeffrey V/B-7249-2011; Cooper, D. James/G-7961-2013	Cooper, D. James/0000-0002-5872-9051; Wolfe, Rory/0000-0002-2126-1045	Victorian Trauma Foundation (Melbourne, Victoria, Australia); Australian and New Zealand Intensive Care Research Foundation	The DECRA Pilot Study was funded by the Victorian Trauma Foundation (Melbourne, Victoria, Australia) and the Australian and New Zealand Intensive Care Research Foundation. We are grateful to our colleagues in Intensive Care and Neurosurgery at the Alfred Hospital for facilitating this Study, to the Australian and New Zealand Intensive Care Society Clinical Trials Group for input into trial design and for planning, coordination, and endorsement of the phase III trial, and to Cristina Morganti-Kossmann for reviewing the manuscript. Dr Cooper is a National Health and Medical Research Council practitioner fellow.	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Cook D, 2001, INTENS CARE MED, V27, P347, DOI 10.1007/s001340000828; Cook DJ, 2005, J CRIT CARE, V20, P364, DOI 10.1016/j.jcrc.2005.09.010; COOPER D, 2002, CURRENT OUTCOMES P 1, P1; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P643, DOI 10.3109/02688699308995093; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; GAAB MR, 1990, ACT NEUR S, V51, P326; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Kunze E, 1998, ACT NEUR S, V71, P16; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MENON D, 2000, NEUROANESTHESIA NEUR, P301; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Messing-Junger AM, 2003, ZBL NEUROCHIR, V64, P171; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; MYBURGH J, 2007, J TRAUMA; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2001, CURR PHARM DESIGN, V7, P1537, DOI 10.2174/1381612013397276; Yang Xue-Jun, 2003, Chin J Traumatol, V6, P99; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	35	57	60	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	SEP	2008	23	3					387	393		10.1016/j.jcrc.2007.05.002			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347EW	WOS:000259124400017	18725045				2022-02-06	
J	Guseva, MV; Hopkins, DM; Scheff, SW; Pauly, JR				Guseva, Maria V.; Hopkins, Deann M.; Scheff, Stephen W.; Pauly, James R.			Dietary choline supplementation improves behavioral, histological, and neurochemical outcomes in a rat model of traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						acetylcholine; alpha 7 nAChR; bungarotoxin; dietary supplementation; Morris water maze; neuroprotection; nicotinic	RECEPTOR ALPHA-7 SUBUNIT; NICOTINIC RECEPTORS; PERIPHERAL BENZODIAZEPINE; BINDING-SITES; ACETYLCHOLINE-RECEPTORS; MICROGLIAL ACTIVATION; HIPPOCAMPAL ALPHA-7; SELECTIVE AGONIST; EVOKED RELEASE; NEURODEGENERATION	Novel pharmacological approaches that safely and effectively lessen the degree of neurological impairment following traumatic brain injury (TBI) are sorely needed. Non-invasive approaches that could be used over an extended periods of time might be particularly useful. Previous studies from our lab have hypothesized that TBI-induced decreases in hippocampal and cortical alpha 7 neuronal nicotinic cholinergic receptor (nAChR) expression might contribute to cognitive impairment that follows brain injury. The purpose of this study was to determine whether the low-potency, but selective alpha 7 nAChR agonist choline might be a useful treatment for improvement of neurological outcome in a rat model of TBI. Male Sprague-Dawley rats were exposed to control or choline-supplemented diets for 2 weeks prior to experimental brain injury (1.5-mm cortical contusion injury) and throughout the recovery phase. Dietary choline supplementation resulted in a modest degree of improvement in spatial memory as assessed in the Morris water maze test. In addition, choline treatment resulted in significant cortical tissue sparing, reduced brain inflammation, and normalized some TBI-induced deficits in nAChR expression. The results of this study suggest that alpha 7 nAChR agonists may be useful drugs to enhance recovery following brain injury.	[Guseva, Maria V.; Hopkins, Deann M.; Pauly, James R.] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA; [Guseva, Maria V.; Hopkins, Deann M.; Scheff, Stephen W.; Pauly, James R.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA		Pauly, JR (corresponding author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.	jpauly@uky.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS42196, NS39828]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828, R01NS042196] Funding Source: NIH RePORTER	This research was supported by the National Institutes of Health (grant NS42196 to J.R.P. and grant NS39828 to S.W.S.).	Albuquerque EX, 1998, J PHYSIOLOGY-PARIS, V92, P309, DOI 10.1016/S0928-4257(98)80039-9; Alkondon M, 1997, EUR J NEUROSCI, V9, P2734, DOI 10.1111/j.1460-9568.1997.tb01702.x; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; Banati RB, 1997, J NEUROCYTOL, V26, P77, DOI 10.1023/A:1018567510105; Bazan NG, 2005, ANN NY ACAD SCI, V1053, P137, DOI 10.1196/annals.1344.011; Berg DK, 2002, J NEUROBIOL, V53, P512, DOI 10.1002/neu.10116; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Blusztajn JK, 1998, SCIENCE, V281, P794, DOI 10.1126/science.281.5378.794; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Buccafusco JJ, 2005, TRENDS PHARMACOL SCI, V26, P352, DOI 10.1016/j.tips.2005.05.007; Cacabelos R, 1996, ANN NY ACAD SCI, V777, P399, DOI 10.1111/j.1749-6632.1996.tb34452.x; Casellas P, 2002, NEUROCHEM INT, V40, P475, DOI 10.1016/S0197-0186(01)00118-8; Clark WM, 1997, NEUROLOGY, V49, P671, DOI 10.1212/WNL.49.3.671; COUTCHER JB, 1992, J PHARMACOL EXP THER, V262, P1128; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DIXON CE, 1995, NEUROSCI LETT, V198, P111, DOI 10.1016/0304-3940(95)11979-7; Fayuk D, 2004, MOL PHARMACOL, V66, P658, DOI 10.1124/mol.104.000042; FREEDMAN R, 1994, HARVARD REV PSYCHIAT, V2, P179, DOI 10.3109/10673229409017136; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Guan ZZ, 1999, NEUROREPORT, V10, P1779, DOI 10.1097/00001756-199906030-00028; Guan ZZ, 2000, J NEUROCHEM, V74, P237, DOI 10.1046/j.1471-4159.2000.0740237.x; Guseva MV, 2006, PHARMACOL BIOCHEM BE, V84, P26, DOI 10.1016/j.pbb.2006.04.002; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hazell AS, 1999, NEUROSCI LETT, V271, P5, DOI 10.1016/S0304-3940(99)00489-9; Jonnala RR, 2003, SYNAPSE, V47, P262, DOI 10.1002/syn.10176; Kihara T, 2001, J BIOL CHEM, V276, P13541, DOI 10.1074/jbc.M008035200; Kuhlmann AC, 1999, TOXICOL SCI, V48, P107, DOI 10.1093/toxsci/48.1.107; Leon-Carrion J, 2000, NEUROREHABILITATION, V14, P33; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Levin ED, 2006, PSYCHOPHARMACOLOGY, V184, P523, DOI 10.1007/s00213-005-0164-7; MARKS MJ, 1986, MOL PHARMACOL, V30, P427; Marrero MB, 2004, J PHARMACOL EXP THER, V309, P16, DOI 10.1124/jpet.103.061655; McIntosh TK, 1996, LAB INVEST, V74, P315; MORLEY BJ, 1977, NATURE, V266, P848, DOI 10.1038/266848a0; Mulholland PJ, 2004, DEV BRAIN RES, V153, P203, DOI 10.1016/j.devbrainres.2004.08.008; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; MYERS R, 1991, NEUROSCI LETT, V133, P20, DOI 10.1016/0304-3940(91)90047-W; Nott A, 2006, BRAIN RES, V1081, P72, DOI 10.1016/j.brainres.2006.01.052; Park CH, 1996, GLIA, V16, P65, DOI 10.1002/(SICI)1098-1136(199601)16:1<65::AID-GLIA7>3.0.CO;2-A; Parnetti L, 2007, J NEUROL SCI, V257, P264, DOI 10.1016/j.jns.2007.01.043; PERRY DC, 1995, J PHARMACOL EXP THER, V275, P1030; RINNE JO, 1991, BRAIN RES, V547, P167; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Shytle RD, 2004, J NEUROCHEM, V89, P337, DOI 10.1046/j.1471-4159.2004.02347.x; Sparks JA, 1999, PSYCHOPHARMACOLOGY, V141, P145, DOI 10.1007/s002130050818; Starkstein SE, 2005, INT PSYCHOGERIATR, V17, pS93, DOI 10.1017/S1041610205001973; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Town T, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-24; Tribollet E, 2004, NEUROSCIENCE, V124, P405, DOI 10.1016/j.neuroscience.2003.09.028; van Kampen M, 2004, PSYCHOPHARMACOLOGY, V172, P375, DOI 10.1007/s00213-003-1668-7; Verbois SL, 2000, J NEUROTRAUM, V17, P1001, DOI 10.1089/neu.2000.17.1001; Verbois SL, 2003, NEUROPHARMACOLOGY, V44, P224, DOI 10.1016/S0028-3908(02)00366-0; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Zeisel SH, 2006, NUTR REV, V64, P197, DOI [10.1301/nr.2006.janr.197-203, 10.1111/j.1753-4887.2006.tb00202.x]	56	57	65	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2008	25	8					975	983		10.1089/neu.2008.0516			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	343ZT	WOS:000258895700003	18665805	Green Published			2022-02-06	
J	Mauritz, W; Steltzer, H; Bauer, P; Dolanski-Aghamanoukjan, L; Metnitz, P				Mauritz, Walter; Steltzer, Heinz; Bauer, Peter; Dolanski-Aghamanoukjan, Lorenz; Metnitz, Philipp			Monitoring of intracranial pressure in patients with severe traumatic brain injury: an Austrian prospective multicenter study	INTENSIVE CARE MEDICINE			English	Article						traumatic brain injury; intracranial pressure; mortality; Glasgow Coma Scale; Abbreviated Injury Score	INTENSIVE-CARE; HEAD-INJURY; OUTCOMES; EPIDEMIOLOGY; MANAGEMENT; MORTALITY; EFFICACY; SYSTEM; SCORE; AGE	Objective: The goals of this study were to elucidate reasons why patients did or did not receive intracranial pressure (ICP) monitoring and to describe factors influencing hospital mortality after severe traumatic brain injury (TBI). Design: Prospective multicenter cohort study. Patients and participants: 88,274 patients consecutively admitted to 32 medical, surgical and mixed Austrian ICUs between 1998 and 2004. Interventions: None. Measurements and results: 1,856 patients (2.1% of all ICU admissions) exhibited severe TBI (GCS < 9); of these, 1,031 (56%) had ICP monitoring. The "worst" and the "best" cases were both less likely to receive ICP monitoring. Younger patients, female patients, and patients with isolated TBI were more likely to receive ICP monitoring. Compared with large centers ICP was monitored more frequently [odds ratio (OR) 3.09, CI 2.42-3.94] in medium-sized centers. The 20% of patients with the highest likelihood to receive ICP monitoring were monitored in 91% of cases, and had the lowest hospital mortality (31%, OR 0.78, CI 0.37-1.64). Multivariate analysis revealed that severity of illness, TBI severity, isolated TBI, and the number of cases treated per year were associated with hospital outcome. Compared with the large centers, ORs for hospital mortality were 1.85 (CI 1.42-2.40) for patients from medium-sized centers and 1.91 (CI 1.24-2.93) for patients from small centers. Conclusions: ICP monitoring may possibly have some beneficial effects, but this needs further evaluation. Patients with severe TBI should be admitted to experienced centers with high patient volumes since this might improve hospital mortality rates.	[Mauritz, Walter] Trauma Hosp Lorenz Boehler, Dept Anaesthesia & Crit Care Med, A-1200 Vienna, Austria; [Steltzer, Heinz] Trauma Hosp Meidling, Dept Anaesthesia & Crit Care Med, A-1120 Vienna, Austria; [Bauer, Peter; Dolanski-Aghamanoukjan, Lorenz] Med Univ Vienna, Dept Med Stat, A-1090 Vienna, Austria; [Metnitz, Philipp] Med Univ Vienna, Dept Anaesthesia & Gen Intens Care Med, A-1090 Vienna, Austria		Mauritz, W (corresponding author), Trauma Hosp Lorenz Boehler, Dept Anaesthesia & Crit Care Med, Donaueschingenstr 13, A-1200 Vienna, Austria.	walter.mauritz@auva.nt		Mauritz, Walter/0000-0001-9043-3712			*AM ASS SURG TRAUM, 2003, J TRAUMA S, V24, P235; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; Firsching R, 2001, WORLD J SURG, V25, P1221; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hyam JA, 2006, CRIT CARE, V10, DOI 10.1186/cc5066; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Lane PL, 2000, CAN J SURG, V43, P442; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lu J, 2005, ACT NEUR S, V95, P281; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mauritz W, 2007, WIEN KLIN WOCHENSCHR, V119, P46, DOI 10.1007/s00508-006-0763-2; Metnitz PGH, 1999, CRIT CARE MED, V27, P1486, DOI 10.1097/00003246-199908000-00014; Metnitz PGH, 1997, WIEN KLIN WOCHENSCHR, V109, P132; Miranda DR, 1996, CRIT CARE MED, V24, P64, DOI 10.1097/00003246-199601000-00012; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Procaccio F, 2000, J Neurosurg Sci, V44, P1; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P23, DOI 10.1007/s00508-006-0760-5; Sahjpaul R, 2000, CAN J NEUROL SCI, V27, P143; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A	29	57	60	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	JUL	2008	34	7					1208	1215		10.1007/s00134-008-1079-7			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	318WL	WOS:000257123400007	18365169				2022-02-06	
J	Turkstra, LS				Turkstra, Lyn S.			(Conversation-based assessment of social cognition in adults with traumatic brain injury	BRAIN INJURY			English	Article						social cognition; theory of mind; brain injury; pragmatic language; inference	CLOSED-HEAD-INJURY; WORKING-MEMORY CAPACITY; FALSE-BELIEF TASK; INDIVIDUAL-DIFFERENCES; LOBE CONTRIBUTIONS; ASPERGER-SYNDROME; ELICITATION TASK; MIND; DISCOURSE; CHILDREN	Primary objective: The purpose of this study was to characterize performance of individuals with traumatic brain injury (TBI) on a novel video-based test, the Video Social Inference Test (VSIT). The VSIT was designed to capture social inference processes that would be engaged in daily conversations. The test required both initial social inferences and also predictions or explanations of subsequent behaviours. Research design: Between-groups comparison. Methods: Adults with TBI (n=19) and typical controls matched for age and sex (n=19) completed the VSIT, as well as a working memory test and the Eyes Test, a widely-used picture-based test of social cognition. Results: VSIT scores were lower in the TBI group and higher than on the Eyes Test. Participants in both groups had lower scores when required to predict or explain future behaviours based on an initial social inference. Conclusions and implications: The results suggest that conversation-based stimuli may yield unique and useful information about social cognition beyond the laboratory.	[Turkstra, Lyn S.] Univ Wisconsin, Dept Communicat Disorders, Madison, WI 53706 USA		Turkstra, LS (corresponding author), Univ Wisconsin, Dept Communicat Disorders, 1975 Willow Dr, Madison, WI 53706 USA.	lsturkstra@wisc.edu	Turkstra, Lyn/ABC-5831-2021	Turkstra, Lyn/0000-0002-6948-6921			Apperly IA, 2004, J COGNITIVE NEUROSCI, V16, P1773, DOI 10.1162/0898929042947928; Apperly IA, 2007, COGNITION, V103, P300, DOI 10.1016/j.cognition.2006.04.012; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; Baron-Cohen S., 2001, J DEV LEARN DISORD, V5, P47, DOI [10.1177/1362361303007002005, DOI 10.1177/1362361303007002005]; Baron-Cohen S., 1995, MIND BLINDNESS ESSAY; Barrett L, 2007, PHILOS T R SOC B, V362, P561, DOI 10.1098/rstb.2006.1995; Beaumont RB, 2008, J AUTISM DEV DISORD, V38, P249, DOI 10.1007/s10803-007-0384-2; Beer JS, 2006, BRAIN RES, V1079, P98, DOI 10.1016/j.brainres.2006.01.002; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bosacki SL, 2000, J EDUC PSYCHOL, V92, P709, DOI 10.1037//0022-0663.92.4.709; Bowie CR, 2005, PSYCHIAT CLIN N AM, V28, P613, DOI 10.1016/j.psc.2005.05.004; Brune M, 2006, NEUROSCI BIOBEHAV R, V30, P437, DOI 10.1016/j.neubiorev.2005.08.001; Campbell T, 1997, J SPEECH LANG HEAR R, V40, P519, DOI 10.1044/jslhr.4003.519; Canadian Institute for Health Information, 2006, HEAD INJ CAN DEC CHA; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Channon Shelley, 2003, Cogn Neuropsychiatry, V8, P243, DOI 10.1080/135468000344000002; Coelho C., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Daneman M, 1996, PSYCHON B REV, V3, P422, DOI 10.3758/BF03214546; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; DODGE KA, 1986, MONOGR SOC RES CHILD, V51, P1; DODGE KA, 1994, CHILD DEV, V65, P1385, DOI 10.2307/1131505; Dziobek I, 2006, J AUTISM DEV DISORD, V36, P623, DOI 10.1007/s10803-006-0107-0; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; FOLDI NS, 1987, BRAIN LANG, V31, P88, DOI 10.1016/0093-934X(87)90062-9; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; GAULIN CA, 1994, PERCEPT MOTOR SKILL, V79, P55, DOI 10.2466/pms.1994.79.1.55; Gordon ACL, 1998, J EXP CHILD PSYCHOL, V68, P70, DOI 10.1006/jecp.1997.2423; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Heavey L, 2000, J AUTISM DEV DISORD, V30, P225, DOI 10.1023/A:1005544518785; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Hill RW, 1998, ASSESSMENT, V5, P67, DOI 10.1177/107319119800500109; Kendall E, 1997, J HEAD TRAUMA REHAB, V12, P68, DOI 10.1097/00001199-199706000-00007; Knickmeyer R, 2006, HORM BEHAV, V49, P282, DOI 10.1016/j.yhbeh.2005.08.010; Langlois J. A., 2006, TRAUMATIC BRAIN INJU, P1; Lehman MT, 1998, APHASIOLOGY, V12, P771, DOI 10.1080/02687039808249572; MACCOBY EE, 1988, DEV PSYCHOL, V24, P755, DOI 10.1037/0012-1649.24.6.755; Martin I, 2005, APHASIOLOGY, V19, P712, DOI 10.1080/02687030500172203; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 1999, BRAIN LANG, V68, P486, DOI 10.1006/brln.1999.2124; MCDONALD S, 2005, BRAIN IMPAIR, V6, P58; McDonald S., 2002, AWARENESS SOCIAL INF; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; McKinnon MC, 2007, COGNITION, V102, P179, DOI 10.1016/j.cognition.2005.12.011; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Mutter B, 2006, PERCEPT MOTOR SKILL, V102, P819, DOI 10.2466/PMS.102.3.819-835; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Rath JF, 2000, J HEAD TRAUMA REHAB, V15, P724, DOI 10.1097/00001199-200002000-00010; Roeyers H, 2001, J CHILD PSYCHOL PSYC, V42, P271, DOI 10.1111/1469-7610.00718; Saltzman-Benaiah J, 2007, CLIN NEUROPSYCHOL, V21, P294, DOI 10.1080/13854040500473760; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; Simon JA, 2001, COGNITIVE NEUROPSYCH, V18, P1, DOI 10.1080/02643290126042; Snodgrass C, 2006, BRAIN INJURY, V20, P825, DOI 10.1080/02699050600832585; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; STRONACH ST, 2007, IN PRESS APHASIOLOGY; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; TOMPKINS CA, 1994, J SPEECH HEAR RES, V37, P896, DOI 10.1044/jshr.3704.896; Tranel D, 2005, BRAIN, V128, P2872, DOI 10.1093/brain/awh643; Turkstra L.S., 2006, BRAIN IMPAIR, V7, P234, DOI [DOI 10.1375/BRIM.7.3.234, 10.1375/brim.7.3.234]; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Turkstra LS, 1998, APHASIOLOGY, V12, P421, DOI 10.1080/02687039808249541; Turkstra LS, 2000, APHASIOLOGY, V14, P349, DOI 10.1080/026870300401405; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; VANLEER E, 1999, J COMMUNICATIION DIS, V32, P348; Walker S, 2005, J GENET PSYCHOL, V166, P297, DOI 10.3200/GNTP.166.3.297-312; Warschausky S, 2003, REHABIL PSYCHOL, V48, P250, DOI 10.1037/0090-5550.48.4.250; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Weismer SE, 1999, J SPEECH LANG HEAR R, V42, P1249, DOI 10.1044/jslhr.4205.1249; WIIG EH, 1974, PERCEPT MOTOR SKILL, V38, P239, DOI 10.2466/pms.1974.38.1.239; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	80	57	58	0	18	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2008	22	5					397	409		10.1080/02699050802027059			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	302RH	WOS:000255986500005	18415720				2022-02-06	
J	Colantonio, A; Escobar, MD; Chipman, M; McLellan, B; Austin, PC; Mirabella, G; Ratcliff, G				Colantonio, Angela; Escobar, Michael D.; Chipman, Mary; McLellan, Barry; Austin, Peter C.; Mirabella, Giuseppe; Ratcliff, Graham			Predictors of postacute mortality following traumatic brain injury in a seriously injured population	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						brain injury; mortality; trauma	LONG-TERM SURVIVAL; LIFE EXPECTANCY; DEATH; VETERANS; TRENDS	Background: Traumatic brain injury (TBI) is a primary cause of injury mortality in developed countries but less is known about the impact of TBI on postacute mortality in large study populations. This study investigates the rate and predictors of postacute mortality (1-9 years after the initial injury) of severely injured persons with TBI in the Province of Ontario from April 1, 1993 to March 31, 1995. Method: Cases were identified (n = 2,721) from the Ontario Trauma Registry Comprehensive Data Set based on lead trauma hospitals in the province which also provided data on predictors. Severely injured patients (n = 557) who had lower extremity injuries during the sample time period formed a control population. Results: Poisson regression modeling showed that having a TBI was a significant predictor of premature death controlling for age and injury severity. Age, the number of comorbidities, injury severity, mechanism of injury, and discharge destination were significant predictors in the multivariate analyses for the TBI population. Conclusions: This research quantifies the elevated risk of premature death in the postacute period for seriously injured adults with TBI and identifies factors most associated with highest mortality rates in this population.	[Colantonio, Angela; Escobar, Michael D.; Chipman, Mary; McLellan, Barry; Austin, Peter C.] Univ Toronto, Toronto Rehab Inst, Toronto, ON M5G 1V7, Canada; [McLellan, Barry] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Mirabella, Giuseppe] Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Ratcliff, Graham] Clin Neuropsychol Serv, Pittsburgh, PA USA		Colantonio, A (corresponding author), Univ Toronto, Toronto Rehab Inst, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca		Colantonio, Angela/0000-0003-2094-4765; Austin, Peter/0000-0003-3337-233X; Escobar, Michael/0000-0001-9055-4709			Baguley I, 2000, BRAIN INJURY, V14, P505; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; COPES WS, 1989, P ANN C ASS, P205; CORKIN S, 1984, ARCH NEUROL-CHICAGO, V41, P975, DOI 10.1001/archneur.1984.04050200081022; FAHY TJ, 1967, LANCET, V2, P475; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Kim H, 2006, CAN J NEUROL SCI, V33, P48, DOI 10.1017/S0317167100004686; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; *ONT BRAIN INJ ASS, 2001, EST INC TRAUM BRAIN; *ONT TRAUM REG REP, 2003, INJ HOSP INCL 2000 2; Pickett William, 2004, Chronic Dis Can, V25, P32; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shavelle R, 2000, J Insur Med, V32, P163; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WALKER AE, 1989, ARCH NEUROL-CHICAGO, V46, P23, DOI 10.1001/archneur.1989.00520370025013; WEISS GH, 1982, ARCH NEUROL-CHICAGO, V39, P741, DOI 10.1001/archneur.1982.00510240003001	24	57	57	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2008	64	4					876	882		10.1097/TA.0b013e31804d493e			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	287UN	WOS:000254942100006	18404051				2022-02-06	
J	Bornhofen, C; McDonald, S				Bornhofen, Cristina; McDonald, Skye			Comparing strategies for treating emotion perception deficits in traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive rehabilitation; emotions; social perception; teaching methods; traumatic brain injury	ANXIETY STRESS SCALES; PSYCHOMETRIC PROPERTIES; FACIAL EXPRESSION; HEAD TRAUMA; SOCIAL-BEHAVIOR; RECOGNITION; REHABILITATION; COMMUNITY; COMMUNICATION; ADJUSTMENT	Objective: To compare the efficacy of 2 strategies, errorless learning (EL) and self-instruction training (SIT), for remediating emotion perception deficits in individuals with traumatic brain injury (TBI). Design: Randomized controlled trial comparing groups receiving 25 hours (across 10 weeks) of treatment with either EL or SIT with waitlist control. Setting and Participants: Eighteen adult outpatient volunteers with severe TBI who were at least 6 months postinjury. Main Outcomes Measures: Photograph-based emotion recognition tasks, The Awareness of Social Inferences Test, and questionnaire measures, for example, the Sydney Psychosocial Reintegration Scale. Results: Both treatment groups showed modest improvement in emotion perception ability. Limited evidence suggests that SIT may be a favorable approach for this type of remediation. Conclusions: Although further research is needed, there are reasons for optimism regarding rehabilitation of emotion perception following TBI.	[Bornhofen, Cristina; McDonald, Skye] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia		Bornhofen, C (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	cristinab@iinet.net.au	McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			Adolphs Ralph, 2002, Behav Cogn Neurosci Rev, V1, P21, DOI 10.1177/1534582302001001003; Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; BIRD K, 2001, PROGRAM CONTRAST ANA; Bornhofen C, 2008, NEUROPSYCHOL REHABIL, V18, P22, DOI 10.1080/09602010601061213; Braun C M, 1989, Brain Inj, V3, P5, DOI 10.3109/02699058909008068; BRAUNLINGMCMORROW D, 1986, J REHABIL, V52, P39; BROTHERTON FA, 1988, ARCH PHYS MED REHAB, V69, P827; Browder DM, 2000, EDUC TRAIN MENT RET, V35, P78; Brown TA, 1997, BEHAV RES THER, V35, P79, DOI 10.1016/S0005-7967(96)00068-X; BURKE W H, 1991, Brain Injury, V5, P241, DOI 10.3109/02699059109008095; Cardinal RN, 2002, NEUROSCI BIOBEHAV R, V26, P321, DOI 10.1016/S0149-7634(02)00007-6; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; Critchley H, 2000, HUM BRAIN MAPP, V9, P93, DOI 10.1002/(SICI)1097-0193(200002)9:2<93::AID-HBM4>3.0.CO;2-Z; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Duchaine BC, 2003, PERCEPTION, V32, P827, DOI 10.1068/p5067; Ekman P., 1975, UNMASKING FACE GUIDE; Ekman P., 1976, PICTURES FACIAL AFFE; Elfenbein HA, 2002, PSYCHOL BULL, V128, P203, DOI 10.1037//0033-2909.128.2.203; GAJAR A, 1984, J APPL BEHAV ANAL, V17, P353, DOI 10.1901/jaba.1984.17-353; Giles G M, 1988, Brain Inj, V2, P75, DOI 10.3109/02699058809150933; GRATTAN LM, 2002, REHABILITATION NEURR; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Hughes C, 1996, AM J MENT RETARD, V100, P565; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; JOHNSON DA, 1987, BRIT J CLIN PSYCHOL, V26, P289, DOI 10.1111/j.2044-8260.1987.tb01362.x; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; Keane J, 2002, NEUROPSYCHOLOGIA, V40, P655, DOI 10.1016/S0028-3932(01)00156-7; Kern RS, 2005, AM J PSYCHIAT, V162, P513, DOI 10.1176/appi.ajp.162.3.513; Kern RS, 2003, PSYCHOL MED, V33, P433, DOI 10.1017/S0033291702007298; Kubu CS, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P451; Kuipers P, 2004, BRAIN INJURY, V18, P161, DOI 10.1080/0269905031000149524; LAWSON MJ, 1989, J CLIN EXP NEUROPSYC, V11, P842, DOI 10.1080/01688638908400939; Ley P., 1972, QUANTITATIVE ASPECTS; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; LOWE MR, 1978, BEHAV THER, V9, P535, DOI 10.1016/S0005-7894(78)80126-9; McClelland JL, 2002, PHYSIOL BEHAV, V77, P657, DOI 10.1016/S0031-9384(02)00916-2; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; McDonald S, 2000, APHASIOLOGY, V14, P339, DOI 10.1080/026870300401397; McDonald S., 2003, BRAIN IMPAIR, V4, P36, DOI [10.1375/brim.4.1.36.27032, DOI 10.1375/BRIM.4.1.36.27032, DOI 10.1375/brim.4.1.36.27032]; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; MEICHENBAUM D, 1973, BEHAV THER, V4, P515, DOI 10.1016/S0005-7894(73)80003-6; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; O'Carroll RE, 1999, PSYCHOL MED, V29, P105, DOI 10.1017/S0033291798007673; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Phillips ML, 2003, BRIT J PSYCHIAT, V182, P190, DOI 10.1192/bjp.182.3.190; Pope JW, 2006, J CLIN EXP NEUROPSYC, V28, P101, DOI 10.1080/13803390490918138; PRIGATANO GP, 1982, PERCEPT MOTOR SKILL, V54, P859, DOI 10.2466/pms.1982.54.3.859; PRIGATANO GP, 1999, PRINCIPLES NEUROPSCH; *PSYCH CORP, 1997, WECHSL MEM SCAL 3 ED; *PSYCH CORP, 1997, WECHS AD INT SCAL 3; *PSYCH CORP, 2001, WECHS TEST ADULT REA; Roudier M, 1998, J NEUROL SCI, V154, P151, DOI 10.1016/S0022-510X(97)00222-0; SCHLOSS PJ, 1985, APPL RES MENT RETARD, V6, P269, DOI 10.1016/0270-3092(85)90001-3; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Squires EJ, 1997, NEUROPSYCHOLOGIA, V35, P1103, DOI 10.1016/S0028-3932(97)00039-0; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; TATE R, 2002, 4 SYDN U; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Winter J, 1999, INT J GERIATR PSYCH, V14, P987; Yates PJ, 2003, NEUROPSYCHOL REHABIL, V13, P291, DOI 10.1080/09602010244000408	73	57	58	0	28	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2008	23	2					103	115		10.1097/01.HTR.0000314529.22777.43			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	280KW	WOS:000254426700005	18362764				2022-02-06	
J	Schneider, M; Schneider, HJ; Yassouridis, A; Saller, B; von Rosen, F; Stalla, GK				Schneider, M.; Schneider, H. J.; Yassouridis, A.; Saller, B.; von Rosen, F.; Stalla, G. K.			Predictors of anterior pituitary insufficiency after traumatic brain injury	CLINICAL ENDOCRINOLOGY			English	Article							DIFFUSE AXONAL INJURY; SUBARACHNOID HEMORRHAGE; HEAD-INJURY; HYPOPITUITARISM; DYSFUNCTION; MULTICENTER; PREVALENCE; SECONDARY; LESIONS; MEN	Background Several studies have reported a high prevalence of hypopituitarism after traumatic brain injury (TBI). Risk stratification is a prerequisite for cost-effective hormonal screening of these patients. However, it is still unclear which risk factors predispose patients to develop anterior hypopituitarism after TBI. Objective To assess clinical and radiological risk factors for post-traumatic hypopituitarism. Patients and methods Seventy-eight consecutive patients (52 men, 26 women; mean age 36.0 years, range 18-65 years) with mild, moderate or severe TBI were studied. Endocrine and clinical parameters were assessed 3 and 12 months after TBI. Results We found diffuse axonal injury, basal skull fracture and older age to be major risk factors of post-traumatic hypopituitarism. Conclusions We have defined specific risk factors for the development of post-traumatic hypopituitarism that are consistent with pathophysiological considerations. These findings might help to identify at-risk patients.	[Schneider, H. J.; Yassouridis, A.; Stalla, G. K.] Max Planck Inst Psychiat, D-80804 Munich, Germany; [Schneider, M.; von Rosen, F.] Neurol Clin Bad Aibling, Bad Aibling, Germany		Schneider, HJ (corresponding author), Max Planck Inst Psychiat Internal Med Endocrinol, Kraepelinstr 10, D-80804 Munich, Germany.	schneider@mpipsykl.mpg.de					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Brabant G, 2003, HORM RES, V60, P53, DOI 10.1159/000071871; Ceballos R, 1966, Ala J Med Sci, V3, P185; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Cryan E., 1918, DTSCH MED WOCHENSCHR, V44, P1261; DANIEL PM, 1959, LANCET, V2, P927; Feldman HA, 2002, J CLIN ENDOCR METAB, V87, P589, DOI 10.1210/jc.87.2.589; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; GREENWOOD R, 2002, J NEUROLOGICAL NEURO, V73, P18; Hassan A, 2002, CLIN EXP OPHTHALMOL, V30, P273, DOI 10.1046/j.1442-9071.2002.00534.x; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; LOSA M, 1983, KLIN WOCHENSCHR, V61, P1249, DOI 10.1007/BF01540473; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Schneider HJ, 2006, ACTA NEUROCHIR, V148, P449, DOI 10.1007/s00701-005-0724-y; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2005, J NEUROTRAUM, V22, P937, DOI 10.1089/neu.2005.22.937; Song JK, 1999, J NEUROSURG, V90, P1141, DOI 10.3171/jns.1999.90.6.1141; Struffert T, 2003, RADIOLOGE, V43, P1001, DOI 10.1007/s00117-003-0962-z; TEASDALE G, 1974, LANCET, V2, P81; Toyama Yoshihiro, 2005, Radiat Med, V23, P309; Van den Berghe G, 2001, J CLIN ENDOCR METAB, V86, P3217, DOI 10.1210/jc.86.7.3217; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604	32	57	59	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664			CLIN ENDOCRINOL	Clin. Endocrinol.	FEB	2008	68	2					206	212		10.1111/j.1365-2265.2007.03020.x			7	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	250SD	WOS:000252319800007	17803694				2022-02-06	
J	Kraus, MF; Little, DM; Donnell, AJ; Reilly, JL; Simonian, N; Sweeney, JA				Kraus, Marilyn F.; Little, Deborah M.; Donnell, Alison J.; Reilly, James L.; Simonian, Narina; Sweeney, John A.			Oculomotor function in chronic traumatic brain injury	COGNITIVE AND BEHAVIORAL NEUROLOGY			English	Article						traumatic brain injury; visually guided saccades; antisaccades; executive function; prefrontal cortex	SACCADIC EYE-MOVEMENTS; CLOSED-HEAD-INJURY; EXECUTIVE FUNCTION; PREFRONTAL CORTEX; WORKING-MEMORY; AXONAL INJURY; MILD; TASK; SCHIZOPHRENIA; CONCUSSION	Objective: To characterize oculomotor function using visually guided saccade and antisaccade (AS) tasks in chronic traumatic brain injury (TBI) and assess the relationship to neuropsychologic testing. Background: TBI causes dysfunction of prefrontal cortex, in part by disrupting cortical and subcortical pathways, resulting in specific cognitive impairments. Oculomotor function tests provide a method of assessing the integrity of these pathways. Methods: Twenty mild TBI (MTBI), 17 moderate to severe TBI (M/STBI), and 19 healthy controls underwent oculomotor and neuropsychologic testing. Results: On the visually guided saccade task, the M/STBI showed longer latencies and reduced accuracy. On the AS task, which is more dependent on prefrontal cortex function, both patient groups committed more prosaccade errors than controls. On neuropsychologic testing, only the M/STBI patients were significantly impaired. Correlations were found between AS and neuropsychologic performance. Conclusions: The M/STBI group was impaired on both oculomotor tasks and neuropsychologic testing, consistent with more global neuropathology. The MTBI group showed impaired performance primarily on the AS task, consistent with prefrontal system dysfunction. Hence, oculomotor testing is sensitive to the range of neuropathology in chronic TBI. and importantly, may be more sensitive to neuropathology in MTBI.	Univ Illinois, Coll Med, Ctr Cognit Med, Dept Psychiat, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Neurol, Chicago, IL 60612 USA; Univ Illinois, Dept Ophthalmol & Psychol, Chicago, IL 60612 USA		Kraus, MF (corresponding author), Univ Illinois, Coll Med, Ctr Cognit Med, Dept Psychiat, Chicago, IL 60612 USA.	mkraus@psych.uic.edu		Sweeney, John/0000-0003-1752-2828	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH068787] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH068787] Funding Source: Medline		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Basso MR, 2003, J CLIN EXP NEUROPSYC, V25, P893, DOI 10.1076/jcen.25.7.893.16489; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bearden CE, 2004, AM J PSYCHIAT, V161, P1700, DOI 10.1176/appi.ajp.161.9.1700; Benedict R., 1997, BRIEF VISUOSPATIAL M; Benton A., 1976, MULTILINGUAL APHASIA; Berman RA, 1999, HUM BRAIN MAPP, V8, P209, DOI 10.1002/(SICI)1097-0193(1999)8:4<209::AID-HBM5>3.0.CO;2-0; Bozikas VP, 2004, COMPR PSYCHIAT, V45, P392, DOI 10.1016/j.comppsych.2004.03.006; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control, 2001, TRAUM BRAIN INJ US R; Chey J, 2002, PSYCHIAT RES, V110, P259, DOI 10.1016/S0165-1781(02)00105-1; CONNERS D, 2000, CONNERS CONTINOUS PE; Crevits L, 2005, NEUROPSYCHOBIOLOGY, V51, P39, DOI 10.1159/000082854; Crevits L, 2000, J NEUROL, V247, P179, DOI 10.1007/s004150050559; Culbertson WC., 2001, TOWER LONDON DREXEL; Delis D.C., 2000, CALIFORNIA VERBAL LE; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GLASS I, 1995, BRAIN INJURY, V9, P769, DOI 10.3109/02699059509008233; Godefroy O, 2003, J NEUROL, V250, P1, DOI 10.1007/s00415-003-0918-2; Golden CJ., 2002, STROOP COLOR WORD TE; Gronwall D, 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; GUITTON D, 1985, EXP BRAIN RES, V58, P455; Hamsher K., 1989, MULTILINGUAL APHASIA; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Jefferson AL, 2006, ARCH CLIN NEUROPSYCH, V21, P311, DOI 10.1016/j.acn.2006.03.007; JENSEN AR, 1966, ACTA PSYCHOL, V25, P36, DOI 10.1016/0001-6918(66)90004-7; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KLOVE H, 1964, CLIN NEUROPSYCHOLOGY; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Little DM, 2000, PSYCHOL AGING, V15, P9, DOI 10.1037//0882-7974.15.1.9; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Luna B, 1998, CEREB CORTEX, V8, P40, DOI 10.1093/cercor/8.1.40; Matthews CG., 1964, INSTRUCTION MANUAL A; Metrics Becker W., 1989, NEUROBIOLOGY SACCADI, P13; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; MIRANDA M, 2007, IN PRESS J ATTEN DIS; Munoz DP, 2004, NAT REV NEUROSCI, V5, P218, DOI 10.1038/nrn1345; Newman SD, 2003, NEUROPSYCHOLOGIA, V41, P1668, DOI 10.1016/S0028-3932(03)00091-5; Pierrot-Deseilligny C, 2005, ANN NY ACAD SCI, V1039, P239, DOI 10.1196/annals.1325.023; Ploner CJ, 2005, BIOL PSYCHIAT, V57, P1159, DOI 10.1016/j.biopsych.2005.02.017; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; PSYCHOLOGICAL C, 2001, WECHSLER TEST ADULT; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Ruff RM, 1988, RUFF FIGURAL FLUENCY; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Snitz BE, 2006, SCHIZOPHRENIA BULL, V32, P179, DOI 10.1093/schbul/sbi048; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TOMBAUCH T, 1996, TEST MEMORY MALINGER; TOMBAUCH T, 1997, TEST MEMORY MALINGER; Van der Elst W, 2006, ASSESSMENT, V13, P62, DOI 10.1177/1073191105283427; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wechsler D, 1997, WMS 3 ADM SCORING MA	59	57	57	0	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1543-3633	1543-3641		COGN BEHAV NEUROL	Cogn. Behav. Neurol.	SEP	2007	20	3					170	178		10.1097/WNN.0b013e318142badb			9	Behavioral Sciences; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	214NQ	WOS:000249745600006	17846516				2022-02-06	
J	Register-Mihalik, J; Guskiewicz, KM; Mann, JD; Shields, EW				Register-Mihalik, Johna; Guskiewicz, Kevin M.; Mann, John Douglas; Shields, Edgar W.			The effects of headache on clinical measures of neurocognitive function	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						headache; concussion; balance; cognition	SPORT-RELATED CONCUSSION; POSTURAL STABILITY; FOOTBALL PLAYERS; MANAGEMENT; COLLEGIATE; MIGRAINE	Objective: To examine effects of preseason baseline headache and posttraumatic headache (PTH) on neurocognitive function. Design: Retrospective repeated measures study with headache groups formed regarding baseline headache score (0 = negative headache; 1-6 = positive headache) and day I postinjury headache score (0 = no headache; 1-2 = mild headache; 3-6 = moderate-severe headache). Setting: Clinical athletic training setting and sports medicine research laboratory. Participants: High-school and collegiate athletes with a concussion. Independent Variables: Preseason baseline headache, PTH, test-day. Main Outcome Measures: A Graded Symptom Checklist (GSC) was used to assess symptoms. The Automated Neuropsychological Assessment Metrics (ANAM) and the Standardized Assessment of Concussion (SAC) were used to assess neuropsychological function and mental status. The Balance Error Scoring System (BESS) was used to assess postural stability. Results: Both baseline headache groups displayed a higher symptom endorsement and higher symptom severity at day I postinjury and improved by day 7 postinjury. The positive headache group reported an even greater increase in symptom severity and presence (P < 0.05). ANAM revealed deficits in both groups I day postinjury. All PTH headache groups displayed a difference in symptom number and severity with the increase being magnified by headache severity (P < 0.05). Individuals reporting moderate-severe PTH displayed increased deficits subacutely but improved by 5-7 days postinjury on overall neuropsychological performance, reaction time, and working memory (P < 0.05). Deficits were observed for all ANAM measures except simple reaction time I (SRT 1) and match to sample subacutely and improved over time (P < 0.05). The SAC yielded an interaction (P < 0.05) for baseline headache. The BESS yielded no significant findings. Conclusions: Clinicians should consider headache when assessing concussion and during preseason baseline assessments because headache may affect symptom presence and other clinical measures of concussion.	Univ N Carolina, Sports Med Res Lab, Dept Exercise & Sports Sci, Chapel Hill, NC 27599 USA; Univ N Carolina Hosp, Dept Neurol, Chapel Hill, NC USA		Register-Mihalik, J (corresponding author), Univ N Carolina, Sports Med Res Lab, Dept Exercise & Sports Sci, CB 8700,Fetzer Gymnasium,S Rd, Chapel Hill, NC 27599 USA.	johnakay@email.unc.edu		Guskiewicz, Kevin/0000-0002-8682-2130; Register-Mihalik, Johna/0000-0002-4229-4743			Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HOOKER WD, 1986, ARCH NEUROL-CHICAGO, V43, P709, DOI 10.1001/archneur.1986.00520070065020; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; MCCREA M, 2000, STANDARD ASSESSMENT; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Nicholson K, 2001, NEUROREHABILITATION, V16, P225; Piland SG, 2003, J ATHL TRAINING, V38, P104; Randolph C, 2005, J ATHL TRAINING, V40, P139; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19	18	57	58	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2007	17	4					282	288		10.1097/JSM.0b013e31804ca68a			7	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	188VX	WOS:000247948500009	17620782				2022-02-06	
J	Buss, A; Pech, K; Kakulas, BA; Martin, D; Schoenen, J; Noth, J; Brook, GA				Buss, Armin; Pech, Katrin; Kakulas, Byron A.; Martin, Didier; Schoenen, Jean; Noth, Johannes; Brook, Gary A.			Matrix metalloproteinases and their inhibitors in human traumatic spinal cord injury	BMC NEUROLOGY			English	Article							MULTIPLE-SCLEROSIS LESIONS; HUMAN BRAIN-TUMORS; FUNCTIONAL RECOVERY; TISSUE INHIBITORS; NERVOUS-SYSTEM; FOCAL ISCHEMIA; GELATINASE-A; EXPRESSION; MATRIX-METALLOPROTEINASE-9; REGENERATION	Background: Matrix metalloproteinases (MMPs) are a family of extracellular endopeptidases that degrade the extracellular matrix and other extracellular proteins. Studies in experimental animals demonstrate that MMPs play a number of roles in the detrimental as well as in the beneficial events after spinal cord injury (SCI). In the present correlative investigation, the expression pattern of several MMPs and their inhibitors has been investigated in the human spinal cord. Methods: An immunohistochemical investigation in post mortem samples of control and lesioned human spinal cords was performed. All patients with traumatic SCI had been clinically diagnosed as having " complete" injuries and presented lesions of the maceration type. Results: In the unlesioned human spinal cord, MMP and TIMP immunoreactivity was scarce. After traumatic SCI, a lesion- induced bi- phasic pattern of raised MMP- 1 levels could be found with an early up- regulation in macrophages within the lesion epicentre and a later induction in peri- lesional activated astrocytes. There was an early and brief induction of MMP- 2 at the lesion core in macrophages. MMP- 9 and - 12 expression peaked at 24 days after injury and both molecules were mostly expressed in macrophages at the lesion epicentre. Whereas MMP- 9 levels rose progressively from 1 week to 3 weeks, there was an isolated peak of MMP- 12 expression at 24 days. The post- traumatic distribution of the MMP inhibitors TIMP- 1, - 2 and - 3 was limited. Only occasional TIMP immuno- positive macrophages could be detected at short survival times. The only clear induction was detected for TIMP- 3 at survival times of 8 months and 1 year in peri- lesional activated astrocytes. Conclusion: The involvement of MMP- 1, - 2, - 9 and - 12 has been demonstrated in the post- traumatic events after human SCI. With an expression pattern corresponding largely to prior experimental studies, they were mainly expressed during the first weeks after injury and were most likely involved in the destructive inflammatory events of protein breakdown and phagocytosis carried out by infiltrating neutrophils and macrophages, as well as being involved in enhanced permeability of the blood spinal cord barrier. Similar to animal investigations, the strong induction of MMPs was not accompanied by an expression of their inhibitors, allowing these proteins to exert their effects in the lesioned spinal cord.	Aachen Univ Hosp, Dept Neurol, Aachen, Germany; Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Perth, WA 6009, Australia; Univ Liege, Sart Tilman Hosp, Dept Neurosurg, Liege, Belgium; Univ Liege, Dept Neurol & Neuropathol, Liege, Belgium; Aachen Univ Hosp, Dept Neuropathol, Aachen, Germany		Buss, A (corresponding author), Aachen Univ Hosp, Dept Neurol, Aachen, Germany.	abuss@ukaachen.de; pech13@gmx.de; bkakulas@cyllene.uwa.edu.au; didier.martin@chu.ulg.ac.be; jschoenen@ulg.ac.be; jnoth@ukaachen.de; gary.brook@rwth-aachen.de		MARTIN, Didier/0000-0001-7325-4958			Ahmed Z, 2005, MOL CELL NEUROSCI, V28, P64, DOI 10.1016/j.mcn.2004.08.013; Anthony DC, 1997, NEUROPATH APPL NEURO, V23, P406, DOI 10.1111/j.1365-2990.1997.tb01315.x; Asahina M, 2001, CLIN NEUROPATHOL, V20, P60; BACKSTROM JR, 1992, J NEUROCHEM, V58, P983, DOI 10.1111/j.1471-4159.1992.tb09352.x; BUSS A, 2007, BRAIN; Clark AW, 1997, NEUROSCI LETT, V238, P53, DOI 10.1016/S0304-3940(97)00859-8; Cossins JA, 1997, ACTA NEUROPATHOL, V94, P590, DOI 10.1007/s004010050754; Dang CM, 2003, PLAST RECONSTR SURG, V111, P2273, DOI 10.1097/01.PRS.0000060102.57809.DA; de Castro R, 2000, NEUROREPORT, V11, P3551, DOI 10.1097/00001756-200011090-00029; Duchossoy Y, 2001, MOL CELL NEUROSCI, V17, P945, DOI 10.1006/mcne.2001.0986; Dzwonek J, 2004, FEBS LETT, V567, P129, DOI 10.1016/j.febslet.2004.03.070; FLEMING JC, 2006, BRAIN; GOTTSCHALL PE, 1995, J NEUROCHEM, V64, P1513; Hsu JYC, 2006, J NEUROSCI, V26, P9841, DOI 10.1523/JNEUROSCI.1993-06.2006; Lampert K, 1998, AM J PATHOL, V153, P429, DOI 10.1016/S0002-9440(10)65586-1; Lim GP, 1996, J NEUROCHEM, V67, P251; Lorenzl S, 2004, J NEUROL SCI, V218, P39, DOI 10.1016/j.jns.2003.10.015; Lorenzl S, 2002, EXP NEUROL, V178, P13, DOI 10.1006/exnr.2002.8019; Maeda A, 1996, J NEUROPATH EXP NEUR, V55, P300, DOI 10.1097/00005072-199603000-00005; NAKAGAWA T, 1994, J NEUROSURG, V81, P69, DOI 10.3171/jns.1994.81.1.0069; Noble LJ, 2002, J NEUROSCI, V22, P7526; Peled ZM, 2002, PLAST RECONSTR SURG, V110, P801, DOI 10.1097/01.PRS.0000019915.20203.EC; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Rosenberg GA, 2001, STROKE, V32, P1162, DOI 10.1161/01.STR.32.5.1162; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Vos CMP, 2003, J NEUROIMMUNOL, V138, P106, DOI 10.1016/S0165-5728(03)00036-5; Vos CMP, 2000, EXP NEUROL, V163, P324, DOI 10.1006/exnr.2000.7388; Wells JEA, 2003, J NEUROSCI, V23, P10107, DOI 10.1523/jneurosci.23-31-10107.2003; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571	33	57	61	0	3	BIOMED CENTRAL LTD	LONDON	MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	JUN 26	2007	7								7	10.1186/1471-2377-7-17			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	190XE	WOS:000248093200001	17594482	Green Published, gold			2022-02-06	
J	Hillman, J; Aneman, O; Persson, M; Andersson, C; Dabrosin, C; Mellergard, P				Hillman, Jan; Aneman, Oscar; Persson, Mikael; Andersson, Chris; Dabrosin, Charlotte; Mellergard, Pekka			Variations in the response of interleukins in neurosurgical intensive care patients monitored using intracerebral microdialysis	JOURNAL OF NEUROSURGERY			English	Article						intensive care; microdialysis; interleukin; vascular endothelial growth factor; cathepsin-D	TRAUMATIC BRAIN-INJURY; MOLECULAR DIAGNOSTICS; INFLAMMATION; CONTUSION	Object The aim of this study was to make a preliminary evaluation of whether microdialysis monitoring of cytokines and other proteins in severely diseased neurosurgical patients has the potential of adding significant information to optimize care, thus broadening the understanding of the function of these molecules in brain injury. Methods. Paired intracerebral microdialysis catheters with high-cutoff membranes were inserted in 14 comatose patients who had been treated in a neurosurgical intensive care unit following subarachnoidal hemorrhage or traumatic brain injury. Samples were collected every 6 hours (for up to 7 days) and were analyzed at bedside for routine metabolites and later in the laboratory for interleukin (IL)-1 and IL-6; in two patients, vascular endothelial growth factor and cathepsin-D were also checked. Aggregated microprobe data gave rough estimations of profound focal cytokine responses related to morphological tissue injury and to anaerobic metabolism that were not evident from the concomitantly collected cerebrospinal fluid data. Data regarding tissue with no macroscopic evidence of injury demonstrated that IL release not only is elicited in severely compromised tissue but also may be a general phenomenon in brains subjected to stress. Macroscopic tissue injury was strongly linked to IL-6 but not IL-1b activation. Furthermore, IL release seems to be stimulated by local ischemia. The basal tissue concentration level of IL-1b was estimated in the range of 10 to 150 pg/ml; for IL-6, the corresponding figure was 1000 to 20,000 pg/ml. Conclusions. Data in the present study indicate that catheters with high-cutoff membranes have the potential of expanding microdialysis to the study of protein chemistry as a routine bedside method in neurointensive care.	Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden; Univ Hosp, Dept Dermatol, Linkoping, Sweden; Univ Hosp, Dept Gynecol, Linkoping, Sweden		Hillman, J (corresponding author), Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden.	pekka.mellergard@lio.se					Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E; Ferrari M, 2003, CLIN CHEM LAB MED, V41, P462, DOI 10.1515/CCLM.2003.069; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hillman J, 2006, ACTA NEUROCHIR, V148, P319, DOI 10.1007/s00701-005-0670-8; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; McGlennen RC, 2001, CLIN CHEM, V47, P393; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Perry VH, 2004, BRAIN BEHAV IMMUN, V18, P407, DOI 10.1016/j.bbi.2004.01.004; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Sjogren S, 2002, BRIT J DERMATOL, V146, P375, DOI 10.1046/j.1365-2133.2002.04621.x; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039	19	57	57	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2007	106	5					820	825		10.3171/jns.2007.106.5.820			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	161WQ	WOS:000246047800003	17542525				2022-02-06	
J	Choi, YS; Lin, SL; Lee, B; Kurup, P; Cho, HY; Naegele, JR; Lombroso, PJ; Obrietan, K				Choi, Yun-Sik; Lin, Stanley L.; Lee, Boyoung; Kurup, Pradeep; Cho, Hee-Yeon; Naegele, Janice R.; Lombroso, Paul J.; Obrietan, Karl			Status epilepticus-induced somatostatinergic hilar interneuron degeneration is regulated by striatal enriched protein tyrosine phosphatase	JOURNAL OF NEUROSCIENCE			English	Article						STEP; ERK/MAPK; cell death; apoptosis; hippocampus; seizure; somatostatin	TEMPORAL-LOBE EPILEPSY; DENTATE GRANULE CELLS; TRAUMATIC BRAIN-INJURY; ADULT-RAT HIPPOCAMPUS; MOLECULAR CHARACTERIZATION; NEUROTROPHIC FACTOR; PILOCARPINE MODEL; INDUCED SEIZURES; KINASE PATHWAYS; SELECTIVE LOSS	Excitotoxic cell death is one of the precipitating events in the development of temporal lobe epilepsy. Of particular prominence is the loss of GABAergic hilar neurons. Although the molecular mechanisms responsible for the selective vulnerability of these cells are not well understood, activation of the extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) pathway has been implicated in neuroprotective responses to excitotoxicity in other neuronal populations. Here, we report that high levels of the striatal-enriched protein tyrosine phosphatase (STEP), a key regulator of ERK/MAPK signaling, are found in vulnerable somatostatin-immunoreactive hilar interneurons. Under both control conditions and after pilocarpine-induced status epilepticus (SE), ERK/MAPK activation was repressed in STEP-immunoreactive hilar neurons. This contrasts with robust SE-induced ERK/MAPK activation in the granule cell layer of the dentate gyrus, a cell region that does not express STEP. During pilocarpine-induced SE, in vivo disruption of STEP activity allowed activation of the MAPK pathway, leading to immediate-early gene expression and significant rescue from cell death. Thus, STEP increases the sensitivity of neurons to SE-induced excitotoxicity by specifically blocking a latent neuroprotective response initiated by the MAPK pathway. These findings identify a key set of signaling events that render somatostat-inergic hilar interneurons vulnerable to SE-induced cell death.	Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; Wesleyan Univ, Dept Biol, Middletown, CT 06459 USA; Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06520 USA		Obrietan, K (corresponding author), Ohio State Univ, Dept Neurosci, Graves Hall,Room 4118,333 W 10th Ave, Columbus, OH 43210 USA.	obrietan.1@osu.edu	Kurup, Pradeep/F-1291-2010; Lee, Boyoung/AAV-8719-2021	Lee, Boyoung/0000-0001-9445-510X; Naegele, Janice/0000-0001-5151-0543	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R29MH052711, R01MH052711, R01MH062335, K02MH001527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042826, P30NS045758, R01NS047176] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K02 MH001527-08, K02 MH001527, MH62335, MH52711, R01 MH052711-13, MH01527, R01 MH052711, R01 MH062335] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS42826, R01 NS047176, R01 NS042826-05, P30 NS045758, 5P30NS045758, R01 NS042826, NS47176] Funding Source: Medline		Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Acsady L, 1998, J NEUROSCI, V18, P3386; Borges K, 2003, EXP NEUROL, V182, P21, DOI 10.1016/S0014-4886(03)00086-4; BOULANGER LM, 1995, J NEUROSCI, V15, P1532; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Buckmaster PS, 2002, EPILEPSY RES, V48, P43, DOI 10.1016/S0920-1211(01)00318-7; Buckmaster PS, 1999, J NEUROSCI, V19, P9519; BUCKMASTER PS, 1995, EUR J NEUROSCI, V7, P1393, DOI 10.1111/j.1460-9568.1995.tb01131.x; Butcher SP, 1997, J NEUROSCI, V17, P6939; Chung HY, 1999, CELL SIGNAL, V11, P575, DOI 10.1016/S0898-6568(99)00033-9; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; COFFER P, 1994, ONCOGENE, V9, P911; Cossart R, 2005, TRENDS NEUROSCI, V28, P108, DOI 10.1016/j.tins.2004.11.011; Criswell T, 2005, J BIOL CHEM, V280, P14212, DOI 10.1074/jbc.M412569200; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; El Bahh B, 1999, EPILEPSIA, V40, P1393; ESCLAPEZ M, 1995, NEUROSCIENCE, V64, P339, DOI 10.1016/0306-4522(94)00406-U; Ford Sr, 1998, METH MOL B, V102, P3; Furuichi Y, 2003, BRAIN RES, V965, P137, DOI 10.1016/S0006-8993(02)04151-3; Goodman LJ, 1996, MOL CELL NEUROSCI, V7, P222, DOI 10.1006/mcne.1996.0017; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Haas KZ, 1996, J NEUROSCI, V16, P4250; HAGLUND L, 1984, J COMP NEUROL, V229, P171, DOI 10.1002/cne.902290204; HAN ZS, 1993, EUR J NEUROSCI, V5, P395, DOI 10.1111/j.1460-9568.1993.tb00507.x; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hetman M, 2000, ACTA NEUROBIOL EXP, V60, P531; Houser CR, 1996, EPILEPSY RES, V26, P207, DOI 10.1016/S0920-1211(96)00054-X; Howard EM, 1998, BRAIN RES, V798, P109, DOI 10.1016/S0006-8993(98)00403-X; Inoue D, 2004, J BIOL CHEM, V279, P49795, DOI 10.1074/jbc.M404096200; Jeon SH, 2000, EXP MOL MED, V32, P227, DOI 10.1038/emm.2000.37; Jiang W, 2005, J NEUROSCI RES, V81, P581, DOI 10.1002/jnr.20566; Kobayashi M, 2003, J NEUROSCI, V23, P2440; KOHLER C, 1985, NEUROSCIENCE, V16, P85, DOI 10.1016/0306-4522(85)90049-1; Kondratyev A, 2001, NEUROSCI LETT, V310, P13, DOI 10.1016/S0304-3940(01)02055-9; Lee B, 2005, J NEUROSCI, V25, P1137, DOI 10.1523/JNEUROSCI.4288-04.2005; Lein ES, 2004, J NEUROSCI, V24, P3879, DOI 10.1523/JNEUROSCI.4710-03.2004; LERANTH C, 1990, J COMP NEUROL, V295, P111, DOI 10.1002/cne.902950110; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MATSUYAMA T, 1993, J CEREBR BLOOD F MET, V13, P229, DOI 10.1038/jcbfm.1993.28; McDonald DR, 1998, J NEUROSCI, V18, P4451; Moriwaki A, 1998, NEUROSCIENCE, V86, P855, DOI 10.1016/S0306-4522(98)00071-2; Noto T, 2004, MOL BRAIN RES, V128, P30, DOI 10.1016/j.molbrainres.2004.06.003; OBENAUS A, 1993, J NEUROSCI, V13, P4470; Ochiishi T, 1999, NEUROSCIENCE, V93, P955, DOI 10.1016/S0306-4522(99)00179-7; Paul S, 2003, NAT NEUROSCI, V6, P34, DOI 10.1038/nn989; PAUL S, 2007, IN PRESS BIOL PSYCHI; Pelkey KA, 2002, NEURON, V34, P127, DOI 10.1016/S0896-6273(02)00633-5; Prendergast MA, 2002, BRAIN RES, V954, P300, DOI 10.1016/S0006-8993(02)03360-7; QUIRK GJ, 1992, J NEUROSCI, V12, P1945; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Ribak C.E., 2005, PROG BRAIN RES, V136, P319; ROBBINS RJ, 1991, ANN NEUROL, V29, P325, DOI 10.1002/ana.410290316; Roux PP, 1999, J NEUROSCI, V19, P6887, DOI 10.1523/JNEUROSCI.19-16-06887.1999; Scharfman HE, 2000, ANN NY ACAD SCI, V911, P305; Schwartzkroin PA, 1997, EPILEPSIA, V38, P853, DOI 10.1111/j.1528-1157.1997.tb01250.x; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; Sloviter RS, 1996, J COMP NEUROL, V366, P516, DOI 10.1002/(SICI)1096-9861(19960311)366:3<516::AID-CNE10>3.0.CO;2-N; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TUCKER MS, 1993, BRAIN RES, V631, P65, DOI 10.1016/0006-8993(93)91187-W; TUFF LP, 1983, BRAIN RES, V277, P79, DOI 10.1016/0006-8993(83)90909-5; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Vogt KE, 2001, J NEUROSCI, V21, P75, DOI 10.1523/JNEUROSCI.21-01-00075.2001; Williamson A, 1999, ANN NEUROL, V45, P92, DOI 10.1002/1531-8249(199901)45:1<92::AID-ART15>3.0.CO;2-N; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhang XA, 1997, EUR J NEUROSCI, V9, P760, DOI 10.1111/j.1460-9568.1997.tb01424.x	71	57	60	0	1	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 14	2007	27	11					2999	3009		10.1523/JNEUROSCI.4913-06.2007			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	148VB	WOS:000245103600030	17360923	Bronze, Green Accepted, Green Published			2022-02-06	
J	Holtslag, HR; Post, MW; Lindeman, E; Van der Werken, C				Holtslag, H. R.; Post, M. W.; Lindeman, E.; Van der Werken, Chr.			Long-term functional health status of severely injured patients	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						functional health status; long-term consequences; polytrauma; severely injured patients; sickness impact profile; SIP-136; co-morbidity; major trauma	SICKNESS IMPACT PROFILE; QUALITY-OF-LIFE; LOWER-EXTREMITY FRACTURE; TRAUMA RECOVERY PROJECT; SHORT GENERIC VERSION; MAJOR TRAUMA; MULTIPLE TRAUMA; HEAD-INJURY; WORK STATUS; DETERMINANTS	Background: Studies of the consequences of major trauma have traditionally focused on mortality rates. The aims of this study were, firstly, to investigate the long-term functional health status in a large, unselected group of severely injured patients and to compare this with normative data, and secondly, to explore relations between functional health status and personal and injury characteristics. Methods: A prospective cohort study was performed at the University Medical Centre Utrecht (a level-1 trauma centre) in The Netherlands. Consecutive survivors of major trauma (ISS >= 16; > 16 years of age) were included from January 1999 until December 2000. After an average of 15 months (range 12-18 months), 335 of the 359 eligible persons (response rate 93%) participated. Demographic and injury characteristics were retrieved from a hospital-based registration system. Functional health status was measured using the 136-item Sickness impact profile (SIP). Co-morbidity was assessed at the follow-up examination using a standard list of 26 conditions. Results: Subjects were 249 men and 86 women, mean age 37.7 years, mean ISS was 24.9 (S.D. = 10.6). Almost, three quarters were traffic victims. Mean hospital stay was 25 days (S. D. = 23.4). Discharge destination was home in 70% of all subjects. At follow-up, the mean overall SIP score was 9.3 (S.D. = 10.1), which means mild to moderate disability. The mean score on the physical function dimension was 7.2 (S.D. = 9.8) and that on psychosocial function was 8.7 (S.D. = 12.0). Most problems were experienced in the categories of Work, Ambulation, Home Management, Recreation and Pastimes, and Alertness Behaviour. Scores of younger subjects deviated more strongly from the norm scores than those of elderly patients. Type of injury, especially lesions of traumatic brain and spinal cord and extremity injuries, was a predictor of both psychosocial and physical functioning after more than 1 year. The most important predictors, however, were age and co-morbidity. (C) 2006 Elsevier Ltd. All rights reserved.	Rehabil Ctr Hoogstr, Utrecht, Netherlands; Univ Med Ctr, Dept Rehabil, Rudolf Magnus Inst Neurosci, NL-3508 GA Utrecht, Netherlands; Univ Med Ctr, Dept Surg, NL-3508 GA Utrecht, Netherlands		Holtslag, HR (corresponding author), Univ Med Ctr, Dept Rehabil, Rudolf Magnus Inst Neurosci, POB 85500,HP F00-810, NL-3508 GA Utrecht, Netherlands.	h.r.holtslag@umcutrecht.nl; m.post@dehoogstraat.nl; e.lindeman@umcutrecht.nl; c.werken@chir.umcutrecht.nl	Post, Marcel/AAS-2502-2021				Anke AGW, 1997, J TRAUMA, V42, P54, DOI 10.1097/00005373-199701000-00010; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bardenheuer M, 2000, UNFALLCHIRURG, V103, P355, DOI 10.1007/s001130050550; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bosse MJ, 2002, NEW ENGL J MED, V347, P1924, DOI 10.1056/NEJMoa012604; Butcher JL, 1996, J TRAUMA, V41, P4, DOI 10.1097/00005373-199607000-00002; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; DEBRUIN AF, 1994, J CLIN EPIDEMIOL, V47, P863, DOI 10.1016/0895-4356(94)90189-9; DEBRUIN AF, 1994, J CLIN EPIDEMIOL, V47, P407, DOI 10.1016/0895-4356(94)90162-7; DEBRUIN AF, 1992, SOC SCI MED, V35, P1003, DOI 10.1016/0277-9536(92)90240-Q; DePalma Judith A, 2003, AACN Clin Issues, V14, P54; Erli HJ, 2000, CHIRURG, V71, P1132, DOI 10.1007/s001040051190; Faergemann C, 1998, J TRAUMA, V45, P123, DOI 10.1097/00005373-199807000-00026; GERETY MB, 1994, J GERONTOL, V49, pM2, DOI 10.1093/geronj/49.1.M2; GRUEN GS, 1995, J TRAUMA, V39, P838, DOI 10.1097/00005373-199511000-00006; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; HOLBROOK TL, 1994, J TRAUMA, V36, P74, DOI 10.1097/00005373-199401000-00011; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Jacobs H M, 1990, Ned Tijdschr Geneeskd, V134, P1950; JURKOVICH G, 1995, J TRAUMA, V39, P625, DOI 10.1097/00005373-199510000-00001; Lew HL, 2002, AM J PHYS MED REHAB, V81, P830, DOI 10.1097/00002060-200211000-00005; Lipsett PA, 2000, J TRAUMA, V49, P737, DOI 10.1097/00005373-200010000-00024; LUNDQVIST C, 1991, SPINE, V16, P78, DOI 10.1097/00007632-199101000-00014; MACKENZIE EJ, 1993, J TRAUMA, V34, P528, DOI 10.1097/00005373-199304000-00009; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; MacKenzie EJ, 2002, QUAL LIFE RES, V11, P797, DOI 10.1023/A:1020820017658; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Meerding WJ, 2004, J TRAUMA, V56, P150, DOI 10.1097/01.TA.0000062969.65847.8B; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Mock C, 2000, J TRAUMA, V49, P1002, DOI 10.1097/00005373-200012000-00005; Morris S, 2000, J TRAUMA, V49, P461, DOI 10.1097/00005373-200009000-00013; Post MWM, 1996, ARCH PHYS MED REHAB, V77, P440, DOI 10.1016/S0003-9993(96)90031-3; Riemsma R P, 2001, Health Technol Assess, V5, P1; SACCO WJ, 1993, J TRAUMA, V35, P538, DOI 10.1097/00005373-199310000-00007; Smith JJ, 2005, J ORTHOP TRAUMA, V19, P249, DOI 10.1097/01.bot.0000151813.10046.e4; Stalp M, 2002, J TRAUMA, V52, P1160, DOI 10.1097/00005373-200206000-00023; SULLIVAN M, 1993, J RHEUMATOL, V20, P1500; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; TEMKIN NR, 1989, MED CARE, V27, pS44, DOI 10.1097/00005650-198903001-00004; Van de Port IGL, 2004, DISABIL REHABIL, V26, P635, DOI 10.1080/09638280410001672481; VANDERSLUIS CK, 1995, J TRAUMA, V38, P681, DOI 10.1097/00005373-199505000-00001; vanRoijen L, 1996, INT J TECHNOL ASSESS, V12, P405, DOI 10.1017/S0266462300009764; vanStraten A, 1997, STROKE, V28, P2155, DOI 10.1161/01.STR.28.11.2155; Vles WJ, 2005, J TRAUMA, V58, P126, DOI 10.1097/01.TA.0000112342.40296.1F; Zahavi A, 2004, J NEUROL NEUROSUR PS, V75, P1553, DOI 10.1136/jnnp.2003.014282	46	57	57	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	MAR	2007	38	3					280	289		10.1016/j.injury.2006.10.026			10	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	147CA	WOS:000244979800004	17250834				2022-02-06	
J	Maruishi, M; Miyatani, M; Nakao, T; Muranaka, H				Maruishi, M.; Miyatani, M.; Nakao, T.; Muranaka, H.			Compensatory cortical activation during performance of an attention task by patients with diffuse axonal injury: a functional magnetic resonance imaging study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; MULTIPLE-SCLEROSIS; EARLIEST STAGE; HEAD-INJURY; FMRI; MS; REORGANIZATION; IMPAIRMENT; SEQUELAE	Objective: To determine how cortical compensation occurs in higher cognitive systems during the recovery phase of diffuse axonal injury (DAI). Design: 12 right-handed patients with a magnetic resonance imaging (MRI) lesion pattern compatible with pure DAI were identified. Pure DAI was defined as finding of traumatic microbleeds on T2*-weighted gradient-echo images in the absence of otherwise traumatic or non-traumatic MRI abnormalities. 12 matched healthy controls were also enrolled. Functional magnetic resonance imaging (fMRI) was used to assess brain activation during a working memory test (Paced Visual Serial Attention Test (PVSAT)). Results: No significant group differences were observed in reaction times for the PVSAT. Although patients with pure DAI committed a few errors during the PVSAT, controls respond correctly to each probe. Controls showed activations in the left frontal gyrus, left parietal gyrus and right inferior parietal gyrus. Patients with pure DAI showed activations in the left inferior frontal gyrus, right inferior frontal gyrus and right middle frontal gyrus. Between-group analysis of the PVSAT task showed significantly greater activation of the right inferior frontal gyrus (BA 45) and right middle frontal gyrus (BA 9) in patient with pure DAI versus controls. Conclusions: Patients with pure DAI require compensatory activation of the contralateral (right) prefrontal region to carry out activities similar to healthy controls. These findings provide further evidence for the adaptive capacity of neuronal systems and brain plasticity during the recovery stages of DAI.	Hiroshima Prefectural Rehabil Ctr, Higher Brain Funct Ctr, Higashihiroshima 7390036, Japan; Hiroshima Univ, Grad Sch Educ, Psychol Lab, Higashihiroshima 724, Japan		Maruishi, M (corresponding author), Hiroshima Prefectural Rehabil Ctr, Higher Brain Funct Ctr, 295-3 Taguchi, Higashihiroshima 7390036, Japan.	maruishi@rehab-hiroshima.gr.jp	nakao, takashi/U-7188-2017	nakao, takashi/0000-0002-2227-4526			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Ashburner J, 1997, NEUROIMAGE, V6, P209, DOI 10.1006/nimg.1997.0290; Audoin B, 2005, HUM BRAIN MAPP, V24, P216, DOI 10.1002/hbm.20083; Audoin B, 2003, HUM BRAIN MAPP, V20, P51, DOI 10.1002/hbm.10128; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Chang L, 2001, NEUROLOGY, V57, P1001, DOI 10.1212/WNL.57.6.1001; Chein J. M., 2003, HDB NEUROPSYCHOLOGY, V9, P299; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; D'Esposito M, 2000, EXP BRAIN RES, V133, P3, DOI 10.1007/s002210000395; Diamond BJ, 1997, J CLIN EXP NEUROPSYC, V19, P34, DOI 10.1080/01688639708403834; Ernst T, 2002, NEUROLOGY, V59, P1343, DOI 10.1212/01.WNL.0000031811.45569.B0; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; FOS LA, 2000, APPL NEUROPSYCHOL, V9, P97; FRISTON KJ, 1995, NEUROIMAGE, V2, P166, DOI 10.1006/nimg.1995.1019; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Hillary FG, 2003, J CLIN EXP NEUROPSYC, V25, P965, DOI 10.1076/jcen.25.7.965.16490; Inoue Y, 2005, J NEUROTRAUM, V22, P1411, DOI 10.1089/neu.2005.22.1411; JENKINS IH, 1994, J NEUROSCI, V14, P3775; Mainero C, 2004, NEUROIMAGE, V21, P858, DOI 10.1016/j.neuroimage.2003.10.004; Maruishi M, 2004, NEUROIMAGE, V21, P1604, DOI 10.1016/j.neuroimage.2003.12.001; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Nagels G, 2005, CLIN NEUROL NEUROSUR, V107, P218, DOI 10.1016/j.clineuro.2004.11.016; Olfield R. C., 1971, NEUROPSYCHOLOGIA, V9, P97; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; Penner IK, 2003, J NEUROL, V250, P461, DOI 10.1007/s00415-003-1025-0; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Staffen W, 2002, BRAIN, V125, P1275, DOI 10.1093/brain/awf125; TALAIRACH J, 1998, CO PLANAR STEREOTAXI; Wishart HA, 2004, NEUROLOGY, V62, P234, DOI 10.1212/01.WNL.0000103238.91536.5F; Yamaki T, 1996, J TRAUMA, V40, P50, DOI 10.1097/00005373-199601000-00010; [No title captured]	36	57	57	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	2007	78	2					168	173		10.1136/jnnp.2006.097345			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	126NY	WOS:000243520800015	16952916	Green Published			2022-02-06	
J	Amirjamshidi, A; Abouzari, M; Eftekhar, B; Rashidi, A; Rezaii, J; Esfandiari, K; Shirani, A; Asadollahi, M; Aleali, H				Amirjamshidi, A.; Abouzari, M.; Eftekhar, B.; Rashidi, A.; Rezaii, J.; Esfandiari, K.; Shirani, A.; Asadollahi, M.; Aleali, H.			Outcomes and recurrence rates in chronic subdural haematoma	BRITISH JOURNAL OF NEUROSURGERY			English	Article						chronic subdural haematoma; Glasgow Coma Scale; Glasgow Outcome Scale; recurrence	CLOSED-SYSTEM DRAINAGE; POSTOPERATIVE RECURRENCE; SURGICAL-TREATMENT; TRIAL	The object of this study was to determine the relationship between outcome (assessed by Glasgow Outcome Scale) and recurrence in chronic subdural haematoma (CSDH). Eighty-two consecutive patients who underwent surgery for CSDH were included in this study. The relationship between the following variables and CSDH recurrence was studied: sex; age; history of trauma; Glasgow Coma Scale (GCS) at the time of admission (stage 1: GCS > 12, stage 2: GCS: 8-12, stage 3: GCS < 8); interval between head injury ( when a history of trauma was present) and surgery; presence of a midline shift on CT scans; presence of intracranial air 7 days after surgery; haematoma density; haematoma width; presence of brain atrophy; and Glasgow Outcome Scale (GOS, both quantitative and non-quantitative) at the time of discharge. Throughout the analysis, p < 0.05 was considered statistically significant. The results showed lower GCS (p50.001), higher GOS ( p50.001), presence of intracranial air 7 days after surgery (p = 0.002), and a high density haematoma (p50.001) were significantly associated with recurrence of CSDH. It was concluded that GOS is related with recurrence in CSDH.	Univ Tehran Med Sci, Sinai Hosp, Tehran, Iran; Amir Alam Hosp, Tehran, Iran; Shahid Beheshti Univ Med Sci, Tehran, Iran		Abouzari, M (corresponding author), 17 Allaei Alley,Ard E Iran St, Tehran, Iran.	maboozari@yahoo.com		Rashidi, Armin/0000-0002-9384-272X; Abouzari, Mehdi/0000-0002-3585-698X			AMIRJAMSHIDI A, 2007, IN PRESS J CLIN NEUR; Amirjamshidi A, 2007, CLIN NEUROL NEUROSUR, V109, P152, DOI 10.1016/j.clineuro.2006.07.007; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; CAMERON MM, 1978, J NEUROL NEUROSUR PS, V41, P834, DOI 10.1136/jnnp.41.9.834; El-Kadi H, 2000, NEUROSURG CLIN N AM, V11, P553, DOI 10.1016/S1042-3680(18)30122-0; Ernestus RI, 1997, SURG NEUROL, V48, P220, DOI 10.1016/S0090-3019(97)80031-6; FOELHOLM R, 1975, J NEUROSURG, V42, P43; FOGELHOLM R, 1975, ACTA NEUROCHIR, V32, P247, DOI 10.1007/BF01405457; Frati A, 2004, J NEUROSURG, V100, P24, DOI 10.3171/jns.2004.100.1.0024; Fukuhara T, 1996, SURG NEUROL, V45, P570, DOI 10.1016/0090-3019(95)00471-8; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; KOTWICA Z, 1991, British Journal of Neurosurgery, V5, P461, DOI 10.3109/02688699108998474; KRUPP WF, 1995, BRIT J NEUROSURG, V9, P619, DOI 10.1080/02688699550040909; LABADIE EL, 1976, J NEUROSURG, V45, P382, DOI 10.3171/jns.1976.45.4.0382; MARKWALDER TM, 1981, J NEUROSURG, V54, P637, DOI 10.3171/jns.1981.54.5.0637; Mori K, 2001, NEUROL MED-CHIR, V41, P371, DOI 10.2176/nmc.41.371; Nakaguchi H, 2000, J NEUROSURG, V93, P791, DOI 10.3171/jns.2000.93.5.0791; Nakaguchi H, 2001, J NEUROSURG, V95, P256, DOI 10.3171/jns.2001.95.2.0256; Nakajima H, 2002, SURG NEUROL, V58, P385, DOI 10.1016/S0090-3019(02)00921-7; Oishi M, 2001, NEUROL MED-CHIR, V41, P382, DOI 10.2176/nmc.41.382; OKU Y, 1984, J NEUROSURG, V61, P269, DOI 10.3171/jns.1984.61.2.0269; PROBST C, 1988, J NEUROSURG, V68, P908, DOI 10.3171/jns.1988.68.6.0908; ROBINSON RG, 1984, J NEUROSURG, V61, P263, DOI 10.3171/jns.1984.61.2.0263; Tsutsumi K, 1997, J NEUROSURG, V87, P870, DOI 10.3171/jns.1997.87.6.0870; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; WAKAI S, 1990, NEUROSURGERY, V26, P771, DOI 10.1227/00006123-199005000-00006; Weigel R, 2003, J NEUROL NEUROSUR PS, V74, P937, DOI 10.1136/jnnp.74.7.937; Yamamoto H, 2003, J NEUROSURG, V98, P1217, DOI 10.3171/jns.2003.98.6.1217	29	57	58	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.		2007	21	3					272	275		10.1080/02688690701272232			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	191QS	WOS:000248146700008	17612917				2022-02-06	
J	Huber, M; Kirchler, E; Karner, M; Pycha, R				Huber, M.; Kirchler, E.; Karner, M.; Pycha, R.			Delusional parasitosis and the dopamine transporter. A new insight of etiology?	MEDICAL HYPOTHESES			English	Article							BASAL GANGLIA; IN-VIVO; COCAINE; BRAIN; RAT; EXPRESSION; DISEASE; SYSTEM; HALLUCINATIONS; TRANSMISSION	Delusional parasitosis (DP) is a psychotic condition in which a person has the unshakeable and mistaken belief (delusion) and/or aberrant perception (hallucination) of being infested with parasites. The disorder will be usually classified in a primary DP-group without a detectable cause (so-called pure forms), while secondary DP-groups are associated with general organic conditions, psychiatric illnesses and drugs (substance induced). Etiology and pathophysiology of DP remain however unknown. In the present paper we hypothesize for the first time a decreased striatal. dopamine transporter (DAT)-functioning (corresponding with an increased extracellular dopamine-level) as etiologic condition for DP (primary and secondary groups). The DAT as key regulator of the dopamine-reuptake in the human brain is well known (regulation of the extracellular dopamine concentration). It is a presynaptic plasma membrane protein highly dense represented in the striatum. The hypothesis of a decreased DAT-functioning as etiologic condition by DP is revealed in case reports which show that DAT-inhibitors, such as cocaine, pemoline, methylphenidate and other amphetamine-derivatives can induce the clinical expression of DP. Several other associated causes of secondary DP-groups (medications, parkinson, chorea huntington, multiple system atrophy, diabetes, cerebrovascular diseases, alcoholism, traumatic brain injury, hyperuricemia, human immunodeficiency virus, iron deficiency, schizophrenia, depression) suggest that the clinical expression of DID may be related to a decreased striatal DAT-functioning (blocking, reduced ligand binding, reduced density, reduced activity). Our examined DP-cases (2-females) show means of magnetic resonance imaging a structurally damaged striatum. Furthermore, we presume that by the primary DP-group, the physiologically age-related decline of the DAT-density is pathologically elevated. Based on this hypothesis we show in the present paper the relation between DP and decreased striatal DAT-functioning, trying to give a new insight into the pathophysiologically mechanism involved. The hypothesis provides supporting evidence that increased levels of extracellular dopamine in the striatum of DP-patients is likely to be the result of decreased DAT-functioning and not increased rates of release. The hypothesis can be investigated simply by dopamine transporter imaging in patients with DP. (C) 2006 Elsevier Ltd. AR rights reserved.	Gen Hosp SB Bruneck, Dept Psychiat, I-39031 Brunico, Italy; Gen Hosp SB Bruneck, Dept Radiol, I-39031 Brunico, Italy		Huber, M (corresponding author), Gen Hosp SB Bruneck, Dept Psychiat, Spitalstr 4, I-39031 Brunico, Italy.	markus.huber@sb-bruneck.it			Austrian Science Fund FWFAustrian Science Fund (FWF) [P 19925] Funding Source: Medline		Abi-Dargham A, 2004, INT J NEUROPSYCHOPH, V7, pS1, DOI 10.1017/S1461145704004110; Amancio EJ, 2002, ARQ NEURO-PSIQUIAT, V60, P155, DOI 10.1590/S0004-282X2002000100029; ANDREWS E, 1986, J CLIN PSYCHIAT, V47, P188; Baker Glen B., 1992, Journal of Psychiatry and Neuroscience, V17, P206; Bannon MJ, 2005, TOXICOL APPL PHARM, V204, P355, DOI 10.1016/j.taap.2004.08.013; Czyrak A, 2003, POL J PHARMACOL, V55, P667; DAMIANI JT, 1990, J AM ACAD DERMATOL, V22, P312, DOI 10.1016/S0190-9622(08)80767-0; Demaria JE, 2000, ENDOCRINOLOGY, V141, P366, DOI 10.1210/en.141.1.366; Eisenhofer G, 2001, PHARMACOL THERAPEUT, V91, P35, DOI 10.1016/S0163-7258(01)00144-9; El Fakhri G, 2006, EUR J NUCL MED MOL I, V33, P87, DOI 10.1007/s00259-005-1920-y; Elliott JM, 2005, CURR OPIN PHARMACOL, V5, P94, DOI 10.1016/j.coph.2004.09.005; Elmer MKB, 2000, J AM ACAD DERMATOL, V43, P683, DOI 10.1067/mjd.2000.106510; ELPERN DJ, 1988, CUTIS, V42, P273; Erikson KM, 2000, J NUTR, V130, P2831, DOI 10.1093/jn/130.11.2831; Erixon-Lindroth N, 2005, PSYCHIAT RES-NEUROIM, V138, P1, DOI 10.1016/j.pscychresns.2004.09.005; Figlewicz DP, 1996, BRAIN RES, V736, P54, DOI 10.1016/0006-8993(96)00727-5; Freudenmann RW, 2002, FORTSCHR NEUROL PSYC, V70, P531, DOI 10.1055/s-2002-34666; Fujita M, 1996, J NUCL MED, V37, P1214; Geng Yu, 2005, J Zhejiang Univ Sci B, V6, P22, DOI 10.1631/jzus.2005.B0022; Gorelick DA, 2004, DRUGS, V64, P1547, DOI 10.2165/00003495-200464140-00004; Gross-Tsur V, 2004, NEUROLOGY, V63, P753, DOI 10.1212/01.WNL.0000134656.93147.F1; Hernandez-Albujar S, 1996, An Med Interna, V13, P549; Ichikawa H, 2001, Rinsho Shinkeigaku, V41, P423; Izzo E, 2005, PHARMACOL BIOCHEM BE, V81, P701, DOI 10.1016/j.pbb.2005.04.017; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; Kahlig KM, 2003, EUR J PHARMACOL, V479, P153, DOI 10.1016/j.ejphar.2003.08.065; Kapur Shitij, 2006, NeuroRx, V3, P10, DOI 10.1016/j.nurx.2005.12.003; KING BH, 1990, PHARMACOPSYCHIATRY, V23, P85, DOI 10.1055/s-2007-1014488; Krauseneck T, 2005, PSYCHOPATHOLOGY, V38, P103, DOI 10.1159/000085352; Laakso A, 2001, SCHIZOPHR RES, V52, P115, DOI 10.1016/S0920-9964(00)00095-5; Lanczik M, 1999, PSYCHOPATHOLOGY, V32, P277, DOI 10.1159/000029100; Laruelle M, 1998, Q J NUCL MED, V42, P211; Laruelle M, 1999, BIOL PSYCHIAT, V46, P56, DOI 10.1016/S0006-3223(99)00067-0; Lorberboym M, 2004, J NUCL MED, V45, P1688; Lorenzo CR, 2004, AM J CLIN DERMATOL, V5, P339, DOI 10.2165/00128071-200405050-00007; LYNCH PJ, 1993, SEMIN DERMATOL, V12, P39; MARNEROS A, 1988, PSYCHOPATHOLOGY, V21, P267, DOI 10.1159/000284569; MARSCHALL MA, 1991, PLAST RECONSTR SURG, V88, P328, DOI 10.1097/00006534-199108000-00027; Mateos JJ, 2005, PSYCHOPHARMACOLOGY, V181, P401, DOI 10.1007/s00213-005-2250-2; Meehan WJ, 2006, ARCH DERMATOL, V142, P352, DOI 10.1001/archderm.142.3.352; Melikian HE, 1999, J NEUROSCI, V19, P7699; MELTZER HY, 1983, PSYCHIAT RES, V9, P285, DOI 10.1016/0165-1781(83)90002-1; Mendez I, 2004, LUPUS, V13, P45, DOI 10.1191/0961203304lu487oa; Meng SZ, 2000, PEDIATR NEUROL, V22, P115, DOI 10.1016/S0887-8994(99)00126-5; Meng SZ, 1999, BRAIN RES, V843, P136, DOI 10.1016/S0006-8993(99)01933-2; Meyer JH, 2001, NEUROREPORT, V12, P4121, DOI 10.1097/00001756-200112210-00052; MITCHELL J, 1991, J PSYCHOL, V125, P301, DOI 10.1080/00223980.1991.10543294; MOLINA VA, 1981, ARCH INT PHARMACOD T, V251, P66; Mozley PD, 1996, J NUCL MED, V37, P1965; Narumoto J, 2006, PROG NEURO-PSYCHOPH, V30, P737, DOI 10.1016/j.pnpbp.2005.11.029; Ngai LY, 2005, J NEUROENDOCRINOL, V17, P424, DOI 10.1111/j.1365-2826.2005.01321.x; OLIANAS MC, 1988, EUR J PHARMACOL, V150, P389, DOI 10.1016/0014-2999(88)90025-8; Owens WA, 2005, J NEUROCHEM, V94, P1402, DOI 10.1111/j.1471-4159.2005.03289.x; Petrisic MS, 1997, J NEUROCHEM, V68, P2435; Raasch W, 1999, ANN NY ACAD SCI, V881, P313, DOI 10.1111/j.1749-6632.1999.tb09376.x; Repo E, 1999, PSYCHOPHARMACOLOGY, V147, P314, DOI 10.1007/s002130051173; Robinson DL, 2005, ALCOHOL CLIN EXP RES, V29, P746, DOI 10.1097/01.ALC.0000164362.21484.14; Schenk James O, 2002, Prog Drug Res, V59, P111; Silkis IG, 2005, ZH VYSSH NERV DEYAT+, V55, P592; Slaughter JR, 1998, PSYCHOSOMATICS, V39, P491, DOI 10.1016/S0033-3182(98)71281-2; Smagin GN, 2004, PSYCHONEUROENDOCRINO, V29, P1223, DOI 10.1016/j.psyneuen.2004.02.004; Suzuki M, 2001, SYNAPSE, V41, P329, DOI 10.1002/syn.1089; TAKEDA M, 1985, ACTA PSYCHIAT SCAND, V72, P470, DOI 10.1111/j.1600-0447.1985.tb02641.x; TRABERT W, 1995, PSYCHOPATHOLOGY, V28, P238, DOI 10.1159/000284934; van den Buuse M, 2005, NEUROSCI LETT, V380, P6, DOI 10.1016/j.neulet.2005.01.009; van Dyck CH, 2002, AM J GERIAT PSYCHIAT, V10, P36, DOI 10.1176/appi.ajgp.10.1.36; Volkow ND, 1998, AM J PSYCHIAT, V155, P1325, DOI 10.1176/ajp.155.10.1325; Volkow ND, 1996, J NUCL MED, V37, P554; VOLKOW ND, 1995, ARCH GEN PSYCHIAT, V52, P456; Vollenweider FX, 1999, NEUROPSYCHOPHARMACOL, V20, P424, DOI 10.1016/S0893-133X(98)00108-0; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Wang GJ, 2004, BRAIN, V127, P2452, DOI 10.1093/brain/awh269; Weintraub D, 2005, J NUCL MED, V46, P227; Wong DF, 1996, P NATL ACAD SCI USA, V93, P5539, DOI 10.1073/pnas.93.11.5539; Zhou CY, 2006, J PHARMACOL EXP THER, V317, P1155, DOI 10.1124/jpet.106.101923	76	57	58	0	9	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses		2007	68	6					1351	1358		10.1016/j.mehy.2006.07.061			8	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Research & Experimental Medicine	168QV	WOS:000246540000028	17134847				2022-02-06	
J	Jackson, JC; Obremskey, W; Bauer, R; Greevy, R; Cotton, BA; Anderson, V; Song, YN; Ely, EW				Jackson, James C.; Obremskey, William; Bauer, Rebecca; Greevy, Robert; Cotton, Bryan A.; Anderson, Venice; Song, Yanna; Ely, E. Wesley			Long-term cognitive, emotional, and functional outcomes in trauma intensive care unit survivors without intracranial hemorrhage	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						cognitive impairment; critical care; depression; neuropsychological assessment; PTSD; trauma	POSTTRAUMATIC-STRESS-DISORDER; MINI-MENTAL-STATE; BRAIN-INJURY; IMPAIRMENT; DEPRESSION; SEQUELAE; ANXIETY; QUESTIONNAIRE; DEFICITS; DISEASE	Background: Trauma patients without intracranial hemorrhage or focal neurologic deficits are typically considered low risk for lasting neuropsychological and emotional deficits, and such sequela may be overlooked, especially in those with skull fractures and concussions. We undertook this study to determine the prevalence of and risk factors for persistent cognitive impairment and emotional and functional difficulties in a sample of adult trauma intensive care unit survivors without intracranial hemorrhage. Methods: We queried the Vander-bilt University Trauma Registry for all patients admitted during 2003 with an Injury Severity Score > 25 and a head computed tomography scan showing no intracranial hemorrhage. Of the 97 patients identified, 58 were evaluated, in person between 12 to 24 months after hospital discharge, with a comprehensive battery of cognitive, emotional, and functional instruments. The Informant Questionnaire of Cognitive Decline in the Elderly-Short Form (IQCODE-SF) was used to evaluate for pre-existing cognitive deficits in patients suspected of having cognitive impairment before their trauma. Results: A total of 33 (57%) patients were determined to have cognitive impairment, which was most pronounced in the domains of attention and executive functioning/verbal fluency. Of these patients, one (3%) was determined by the IQCODE-SF to be cognitively impaired before trauma intensive care unit hospitalization. Of the 58 patients studied, 21 (36.2%) had a concussion or skull fracture and 37 (63.8%) had neither. Cognitive impairment was significantly more likely to occur in patients who sustained a concussion or skull fracture than in trauma patients who did not (81% versus 43%; p = 0.006). Patients reported significant depressive symptoms (56%), significant symptoms of posttraumatic stress disorder (38%), and significant symptoms of anxiety (29%). Quality of life scores were lower than in the general United States population and employment difficulties were widespread. A total of 34% of patients reported being unemployed at follow-up, and cognitive impairment was more common among these patients compared with patients in the workforce (p = 0.03). Neither cognitive impairment nor emotional dysfunction was associated with age, sex, race, Injury Severity Score, blood loss, ventilatory days, or intramedullary nailing of long-bone fractures. Conclusions: The majority of trauma survivors without intracranial hemorrhage display persistent cognitive impairment, which is nearly twice as likely in those with skull fractures or concussions. This cognitive impairment was associated with functional defects, poor quality of life, and an inability to return to work. Future research must delineate modifiable risk factors for these poor outcomes, especially in patients with skull fractures and concussions, to help improve long-term cognitive and functional status.	Vanderbilt Univ, Med Ctr, Div Allergy Pulm Crit Care Med, Ctr Hlth Serv Res,Dept Psychiat,Sch Med, Nashville, TN USA; Vanderbilt Univ, Sch Med, Dept Biostat, Div Trauma & Surg Crit Care, Nashville, TN USA; VA Tennessee Valley Hlth Care Syst, Clin Res Ctr Excellence, Nashville, TN USA; Middle Tennessee VA Med Ctr, GRECC, Nashville, TN USA; Trevecca Nazarene Univ, Grad Psychol Dept, Nashville, TN USA		Jackson, JC (corresponding author), Vanderbilt Univ, Med Ctr, Div Allergy Pulm Crit Care Med, Ctr Hlth Serv Res,Dept Psychiat,Sch Med, 6th Floor,Med Ctr 6109, Nashville, TN USA.	james.c.jackson@vanderbilt.edu	Cotton, Bryan/A-7107-2009; Ely, E. Wesley/Z-2018-2019	Ely, E. Wesley/0000-0003-3957-2172	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG027472-01A1] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG027472] Funding Source: NIH RePORTER		Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; AVIDSON JRT, 1996, DAVIDSON TRAUMS SCAL, P1; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Blostein P, 2003, J TRAUMA, V55, P450, DOI 10.1097/01.TA.0000038545.24879.4D; Breslau N, 1997, ARCH GEN PSYCHIAT, V54, P81; Bromet E, 1998, AM J EPIDEMIOL, V147, P353; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Chan RCK, 2005, CLIN REHABIL, V19, P188, DOI 10.1191/0269215505cr838oa; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; De Monte VE, 2005, J CLIN EXP NEUROPSYC, V27, P224, DOI 10.1080/13803390490515766; DISCHINGER PC, 1993, J TRAUMA, V35, P454, DOI 10.1097/00005373-199309000-00020; ECK AT, 1996, BDI 2 DEPRESSION INV; Feinstein A, 2000, BRAIN COGNITION, V44, P78; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Heaton RK, 2004, GRANT 1 REVISED COMP; Hedayati SS, 2004, AM J KIDNEY DIS, V44, P207, DOI 10.1053/j.ajkd.2004.04.025; Hilsabeck RC, 2002, HEPATOLOGY, V35, P440, DOI 10.1053/jhep.2002.31257; Hitzl M, 2001, PHARMACOGENETICS, V11, P293, DOI 10.1097/00008571-200106000-00003; Hopkins RO, 2005, AM J RESP CRIT CARE, V171, P340, DOI 10.1164/rccm.200406-763OC; Hopkins RO, 1999, AM J RESP CRIT CARE, V160, P50, DOI 10.1164/ajrccm.160.1.9708059; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jackson JC, 2004, INTENS CARE MED, V30, P2009, DOI 10.1007/s00134-004-2422-2; Jackson JC, 2003, CRIT CARE MED, V31, P1226, DOI 10.1097/01.CCM.0000059996.30263.94; JORM AF, 1994, PSYCHOL MED, V24, P145, DOI 10.1017/S003329170002691X; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Laforce R, 2001, PERCEPT MOTOR SKILL, V93, P281, DOI 10.2466/PMS.93.5.281-288; Mamelak M, 2000, NEUROPSY NEUROPSY BE, V13, P125; MARQUIS K, 2000, AM J RESP CRIT CARE, V161, pA383; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Mathiesen HK, 2006, ARCH NEUROL-CHICAGO, V63, P533, DOI 10.1001/archneur.63.4.533; Mikkelsen RL, 2004, NORD J PSYCHIAT, V58, P65, DOI 10.1080/08039480310000824; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; *NAT CTR INJ PREV, 2005, CDC AC INJ CAR RES A; Nirula R, 2003, ACCIDENT ANAL PREV, V35, P201, DOI 10.1016/S0001-4575(01)00104-X; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P68, DOI 10.1097/00001199-200601000-00007; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Patten SB, 2003, NEUROLOGY, V61, P1524, DOI 10.1212/01.WNL.0000095964.34294.B4; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; POKORNY AD, 1972, AM J PSYCHIAT, V129, P118; Reitan R, 1985, HALSTEAD REITAN NEUR; Rey A, 1958, LEXAMEN CLINIQUE PSY; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Rothenhausler HB, 2001, GEN HOSP PSYCHIAT, V23, P88, DOI 10.1016/S0163-8343(01)00123-2; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Spreen O., 1969, NEUROSENSORY CTR COM; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Sukantarat KT, 2005, ANAESTHESIA, V60, P847, DOI 10.1111/j.1365-2044.2005.04148.x; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; VARDY J, 2006, IN PRESS SUPPORT CAR; Ware J.E., 1994, SF 36 PHYS MENTAL SU; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Weinert C, 2005, CURR OPIN CRIT CARE, V11, P376, DOI 10.1097/01.ccx.0000168529.23078.64	55	57	60	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2007	62	1					80	88		10.1097/TA.0b013e31802ce9bd			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Surgery	126CP	WOS:000243490100018	17215737				2022-02-06	
J	Bianchini, KJ; Curtis, KL; Greve, KW				Bianchini, Kevin J.; Curtis, Kelly L.; Greve, Kevin W.			Compensation and malingering in traumatic brain injury: A dose-response relationship?	CLINICAL NEUROPSYCHOLOGIST			English	Article; Proceedings Paper	23rd Annual Meeting of the National-Academy-of-Neuropsychology	2003	Dallas, TX	Natl Acad Neuropsychol			FAKE-BAD SCALE; RELIABLE DIGIT SPAN; MILD HEAD-INJURY; LABORATORY-INDUCED PAIN; NEUROCOGNITIVE DYSFUNCTION; SYMPTOM EXAGGERATION; COGNITIVELY INTACT; NORMATIVE DATA; CLINICAL-USE; MMPI-2	The purpose of this study was to determine if there is a dose-response relationship between potential monetary compensation and failure on psychological indicators of malingering in traumatic brain injury. 332 traumatic brain injury patients were divided into three groups based on incentive to perform poorly on neuropsychological testing: no incentive; limited incentive as provided by State law; high incentive as provided by Federal law. The rate of failure on five well-validated malingering indicators across these groups was examined. Cases handled under Federal workers compensation laws showed considerably higher rates of failure and diagnosable malingering than cases handled under State law. The findings indicate that monetary compensation associated with workers compensation claims is a major motive for exaggeration and malingering of problems attributed to work-related brain injuries. The clinician's index of suspicion regarding exaggeration and malingering of symptoms and deficits should be much higher in the context of Federal workers compensation claims, particularly in patients who have suffered only mild traumatic brain injury.	Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA; Jefferson Neurobehav Grp, Metairie, LA USA		Greve, KW (corresponding author), Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Bianchini K, 2005, ARCH CLIN NEUROPSYCH, V20, P365, DOI 10.1016/j.acn.2004.09.003; Bianchini K. J., 2004, J FORENSIC NEUROPSYC, V4, P65; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Bianchini KJ, 2003, CLIN NEUROPSYCHOL, V17, P574, DOI 10.1076/clin.17.4.574.27946; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P461, DOI 10.1076/clin.15.4.461.1890; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; BINDER LM, 1993, PORTLAND DIGIT RECOG; Boone KB, 2003, CLIN NEUROPSYCHOL, V17, P244, DOI 10.1076/clin.17.2.244.16497; BUTCHER JN, 1989, MMPI2 MANUAL ADM SCO; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cato MA, 2002, CLIN NEUROPSYCHOL, V16, P524, DOI 10.1076/clin.16.4.524.13901; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; Denney RL, 1996, ARCH CLIN NEUROPSYCH, V11, P589, DOI 10.1016/0887-6177(95)00042-9; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Eaton D. L., 2001, CASARETT DOULLS TOXI, P11; Etherton J, 2005, ASSESSMENT, V12, P130, DOI 10.1177/1073191105274859; Etherton JL, 2005, ARCH CLIN NEUROPSYCH, V20, P375, DOI 10.1016/j.acn.2004.09.007; Etherton JL, 2005, ASSESSMENT, V12, P101, DOI 10.1177/1073191104270789; GRAHAM JR, 1990, MMPI2 ASSESSING PERS; Green P, 2003, BRAIN INJURY, V17, P479, DOI 10.1080/0269905031000070242; Greiffenstein MF, 2002, J CLIN PSYCHOL, V58, P1591, DOI 10.1002/jclp.10077; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; HENNEKENS CH, 1987, EPIDEMIOLOGY MED; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Iverson GL, 2002, PSYCHOL REP, V90, P131, DOI 10.2466/PR0.90.1.131-136; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 2003, J FORENSIC NEUROPSYC, V3, P167, DOI DOI 10.1300/J151V03N01_01; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Price J R, 1997, Appl Neuropsychol, V4, P75, DOI 10.1207/s15324826an0401_10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Ross SR, 2004, J CLIN EXP NEUROPSYC, V26, P115, DOI 10.1076/jcen.26.1.115.23933; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; TOMBAUGH TN, 2003, J FORENSIC NEUROPSYC, V2, P69, DOI DOI 10.1300/J151V02N03_04; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593; [No title captured]	66	57	57	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	DEC	2006	20	4					831	847		10.1080/13854040600875203			17	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Conference Proceedings Citation Index - Science (CPCI-S)	Psychology; Neurosciences & Neurology	085IE	WOS:000240597000017	16980265				2022-02-06	
J	Lotocki, G; Vaccari, JPD; Perez, ER; Alonso, OF; Curbelo, K; Keane, RW; Dietrich, WD				Lotocki, George; de Rivero Vaccari, Juan Pablo; Perez, Enrique R.; Alonso, Ofelia F.; Curbelo, Karell; Keane, Robert W.; Dietrich, W. Dalton			Therapeutic hypothermia modulates TNFR1 signaling in the traumatized brain via early transient activation of the JNK pathway and suppression of XIAP cleavage	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						apoptosis; inflammation; intracellular signaling; preconditioning; traumatic brain injury; tumor necrosis factor	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; AMYLOID PRECURSOR PROTEIN; CLOSED-HEAD INJURY; FACTOR-ALPHA; ISCHEMIC TOLERANCE; CASPASE-3 ACTIVATION; MODERATE HYPOTHERMIA; FACTOR RECEPTOR-1; GENE-EXPRESSION	Tumor necrosis factor (TNF) plays a critical role in pathomechanisms associated with secondary damage after traumatic brain injury (TBI). The TNF ligand-receptor system stimulates inflammation by activation of gene transcription through the I kappa B kinase (IKK)-NF-kappa B and c-Jun NH2-terminal kinase (JNK)-AP-1 signaling cascades. TNF signaling following TBI involves both cell survival and apoptotic pathways, but the mechanism that accounts for the dual role of TNF remains unclear. Multiple studies have reported hypothermia to be protective following TBI, but the precise mechanism has not been clearly defined. Here, TNFR1 signaling pathways were investigated in the cerebral cortex of adult male Sprague-Dawley rats subjected to moderate fluid-percussion TBI and of naive controls. Another group was subjected to moderate TBI with 30 min of pre- and post-traumatic hypothermia (33 degrees C). Rapid and marked increases in protein expression of TNFR1 and signaling intermediates in both the IKK-NF-kappa B and JNK pathways were induced in traumatized cortices. Hypothermia decreased TNFR1 protein expression acutely in traumatized cortices and stimulated early activation of signaling intermediates in the JNK, but not the IKK-NF-kappa B, signaling pathways. Hypothermia promoted a rapid activation of caspase-3 acutely after injury but suppressed caspase-3 activation at later time points. Moreover, hypothermia treatment suppressed cleavage of X-linked inhibitor of apoptosis protein (XIAP) into fragments induced by TBI. These data suggest that hypothermia may regulate both the JNK signaling cascade via XIAP and the preconditioning pathways that activate caspases. Thus, hypothermia mediates TNFR1 responses via early activation of the JNK signaling pathway and caspase-3, leading to endogenous neuroprotective events.	Univ Miami, Miller Sch Med, Dept Neurol Sci, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA		Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Sci, 1095 NW 14th Terrace, Miami, FL 33136 USA.	ddietrich@miami.edu	de Rivero Vaccari, Juan Pablo/ABE-3248-2020; de Rivero Vaccari, Juan Pablo/H-5718-2019	de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834; 	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291, NS42133] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, P50NS030291] Funding Source: NIH RePORTER		Bozyczko-Coyne D, 2002, CNS NEUROL DISORD-DR, V1, P31, DOI 10.2174/1568007023339472; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Clark WM, 2001, EXPERT OPIN BIOL TH, V1, P227, DOI 10.1517/14712598.1.2.227; Clem RJ, 2001, CELL DEATH DIFFER, V8, P137, DOI 10.1038/sj.cdd.4400821; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Colbourne F, 1997, MOL NEUROBIOL, V14, P171, DOI 10.1007/BF02740655; Conte D, 2001, P NATL ACAD SCI USA, V98, P5049, DOI 10.1073/pnas.081547998; Dawson VL, 2000, TRENDS PHARMACOL SCI, V21, P423, DOI 10.1016/S0165-6147(00)01560-1; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1996, ADV NEUROL, V71, P177; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Keane RW, 1997, J NEUROSCI RES, V48, P168, DOI 10.1002/(SICI)1097-4547(19970415)48:2<168::AID-JNR9>3.0.CO;2-A; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kirino T, 2002, J CEREBR BLOOD F MET, V22, P1283, DOI 10.1097/01.WCB.0000040942.89393.88; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kogel D, 2005, CELL DEATH DIFFER, V12, P1, DOI 10.1038/sj.cdd.4401495; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Lou J, 2001, CLIN MICROBIOL REV, V14, P810, DOI 10.1128/CMR.14.4.810-820.2001; Luo JJ, 2001, J NEUROSCI RES, V63, P410, DOI 10.1002/1097-4547(20010301)63:5<410::AID-JNR1036>3.0.CO;2-B; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Matsuda S, 2001, J NEUROSCI, V21, P6597; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McLaughlin B, 2003, P NATL ACAD SCI USA, V100, P715, DOI 10.1073/pnas.0232966100; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Noguchi K, 2001, BIOCHEM BIOPH RES CO, V281, P1313, DOI 10.1006/bbrc.2001.4498; Papa S, 2006, CELL DEATH DIFFER, V13, P712, DOI 10.1038/sj.cdd.4401865; Perez-Pinzon MA, 1999, NEUROREPORT, V10, P2951, DOI 10.1097/00001756-199909290-00014; Perez-Pinzon MA, 1997, ADV EXP MED BIOL, V428, P155; Perry RT, 2001, NEUROBIOL AGING, V22, P873, DOI 10.1016/S0197-4580(01)00291-3; Probert L, 2001, GLIA, V36, P212, DOI 10.1002/glia.1110; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Schermanz K, 2002, CATALY SCI, V2, P1, DOI 10.1142/9781860949654_0001; Shinoda S, 2003, EUR J NEUROSCI, V17, P2065, DOI 10.1046/j.1460-9568.2003.02655.x; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Tanaka H, 2004, J NEUROSCI, V24, P2750, DOI 10.1523/JNEUROSCI.5475-03.2004; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Taru H, 2002, J BIOL CHEM, V277, P27567, DOI 10.1074/jbc.M203713200; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TYOR WR, 1995, J ACQ IMMUN DEF SYND, V9, P379; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Ventura JJ, 2006, MOL CELL, V21, P701, DOI 10.1016/j.molcel.2006.01.018; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuan HB, 2004, ANESTHESIOLOGY, V100, P331, DOI 10.1097/00000542-200402000-00023; Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005	65	57	59	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	OCT	2006	24	8					2283	2290		10.1111/j.1460-9568.2006.05123.x			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	098FL	WOS:000241506300018	17074049				2022-02-06	
J	Hang, CH; Chen, G; Shi, JX; Zhang, X; Li, JS				Hang, Chun-Hua; Chen, Gang; Shi, Ji-Xin; Zhang, Xin; Li, Jing-Song			Cortical expression of nuclear factor kappa B after human brain contusion	BRAIN RESEARCH			English	Article						traumatic brain injury; NF-kappa B; cerebral inflammation; human	TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; RAT-BRAIN; UP-REGULATION; FACTOR-ALPHA; INJURY; ACTIVATION; NEURONS; NEUROPROTECTION; INFLAMMATION	The aim of current study was to analyze the binding activity and the temporal and cellular expression of nuclear factor kappa B (NF-kappa B) in human contused brain. Eighteen contused brain samples were obtained from 17 patients undergoing surgery for brain contusions 5-80 h after trauma. NF-kappa B binding activity was detected by electrophoretic mobility shift assay (EMSA), and temporal and cellular expression of NF-kappa B subunits p65 and p50 was analyzed by immunohistochemistry. The results showed that a progressive upregulation of NF-kappa B activity occurred in the area surrounding the injured brain with the time from brain trauma to operation. The maximal expression of NF-kappa B was detected after 48 h postinjury. The expression of NF-kappa B p65 was mainly located at glial and vascular endothelial cells without expression at neurons. The expression of NF-kappa B p50 was mainly located at glial cells, a little at neurons and no expression at vascular endothelial cells. Within 24 h postinjury, both NF-kappa B p65 and p50 immunoreactivity was mainly observed in the nucleus of cells. After 24 h postinjury, NF-kappa B p65 labeling was found in the both nucleus and cytoplasm of glial and endothelial cells; otherwise, p50 labeling was primarily found in the nucleus of glial cells and in the nucleus, cytoplasm and process of neurons. It is concluded that NF-kappa B could be highly upregulated at human contused brain and the cellular pattern of p65 and p50 expression might be closely associated with the cell functions. (c) 2006 Elsevier B.V. All rights reserved.	Nanjing Univ, Dept Neurosurg, Jinling Hosp, Sch Med, Nanjing 210002, Jiangsu Prov, Peoples R China		Hang, CH (corresponding author), Nanjing Univ, Dept Neurosurg, Jinling Hosp, Sch Med, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Prov, Peoples R China.	hang1965@public1.ptt.js.cn		Chen, Gang/0000-0002-0758-1907			Arvin B, 1995, ANN NY ACAD SCI, V765, P62, DOI 10.1111/j.1749-6632.1995.tb16561.x; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bales KR, 1998, MOL BRAIN RES, V57, P63, DOI 10.1016/S0169-328X(98)00066-7; Beauparlant Pierre, 1996, Cytokine and Growth Factor Reviews, V7, P175, DOI 10.1016/1359-6101(96)00020-2; Bonetti B, 1999, AM J PATHOL, V155, P1433, DOI 10.1016/S0002-9440(10)65456-9; Clemens JA, 1997, STROKE, V28, P1073, DOI 10.1161/01.STR.28.5.1073; Gabriel C, 1999, MOL BRAIN RES, V65, P61, DOI 10.1016/S0169-328X(98)00330-1; Grilli M, 1999, BIOCHEM PHARMACOL, V57, P1, DOI 10.1016/S0006-2952(98)00214-7; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Hang CH, 2005, NEUROL INDIA, V53, P312, DOI 10.4103/0028-3886.16930; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Isaksson J, 1997, ACTA NEUROPATHOL, V94, P16, DOI 10.1007/s004010050666; KALTSCHMIDT C, 1994, J NEUROIMMUNOL, V55, P99, DOI 10.1016/0165-5728(94)90151-1; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Lipton SA, 1997, NAT MED, V3, P20, DOI 10.1038/nm0197-20; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Meberg PJ, 1996, MOL BRAIN RES, V38, P179, DOI 10.1016/0169-328X(95)00229-L; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Nomoto Y, 2001, NEUROSURGERY, V48, P158, DOI 10.1097/00006123-200101000-00027; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Pennypacker KR, 2001, EXP NEUROL, V172, P307, DOI 10.1006/exnr.2001.7817; SALMINEN A, 1995, BIOCHEM BIOPH RES CO, V212, P939, DOI 10.1006/bbrc.1995.2060; Sanz O, 2002, J NEUROSCI RES, V67, P772, DOI 10.1002/jnr.10140; SELMAJ KW, 1990, J IMMUNOL, V144, P129; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Taglialatela G, 1997, J NEUROSCI RES, V47, P155; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N	32	57	58	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 13	2006	1109						14	21		10.1016/j.brainres.2006.06.045			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	086ZP	WOS:000240712100002	16857176				2022-02-06	
J	Byrnes, KR; Garay, J; Di Giovanni, S; De Biase, A; Knoblach, SM; Hoffman, EP; Movsesyan, V; Faden, AI				Byrnes, KR; Garay, J; Di Giovanni, S; De Biase, A; Knoblach, SM; Hoffman, EP; Movsesyan, V; Faden, AI			Expression of two temporally distinct microglia-related gene clusters after spinal cord injury	GLIA			English	Article						C1qB; chemokine; contusion; cytokine; Galectin-3; inflammation; microarray; p22(phox)	BLOOD-BRAIN-BARRIER; ACUTE INFLAMMATORY RESPONSE; CHEMOKINE MESSENGER-RNA; NITRIC-OXIDE SYNTHASE; NADPH OXIDASE; IN-VITRO; TRAUMATIC INJURY; BONE-MARROW; ADULT RATS; TNF-ALPHA	The dual role of microglia in cytotoxicity and neuroprotection is believed to depend on the specific, temporal expression of microglial-related genes. To better clarify this issue, we used high-density oligonucleotide microarrays to examine microglial gene expression after spinal cord injury (SCI) in rats. We compared expression changes at the lesion site, as well as in rostral and caudal regions after mild, moderate, or severe SCI. Using microglial-associated anchor genes, we identified two clusters with different temporal profiles. The first, induced by 4 h postinjury to peak between 4 and 24 h, included interieukin-1 beta, interleukin-6, osteopontin, and calgranulin, among others. The second was induced 24 h after SCI, and peaked between 72 h and 7 days; it included C1qB, Galectin-3, and p22(phox). These two clusters showed similar expression profiles regardless of injury severity, albeit with slight decreases in expression in mild or severe injury vs. moderate injury. Expression was also decreased rostral and caudal to the lesion site. We validated the expression of selected cluster members at the mRNA and protein levels. In addition, we demonstrated that stimulation of purified microglia in culture induces expression of C1qB, Galectin-3, and p22(phox). Finally, inhibition of P22(phox) activity within microglial cultures significantly suppressed proliferation in response to stimulation, confirming that this gene is involved in microglial activation. Because microglial-related factors have been implicated both in secondary injury and recovery, identification of temporally distinct clusters of genes related to microglial activation may suggest distinct roles for these groups of factors. (c) 2005 Wiley-Liss, Inc.	Georgetown Univ, Dept Neurosci, Med Ctr, Washington, DC 20057 USA; Childrens Natl Med Ctr, Ctr Genet Med, Washington, DC 20010 USA		Byrnes, KR (corresponding author), Georgetown Univ, Dept Neurosci, Med Ctr, Room EP16A,New Res Bldg,3790 Reservoir Rd NW, Washington, DC 20057 USA.	krb27@georgetown.edu		Hoffman, Eric/0000-0001-6470-5139; Byrnes, Kimberly/0000-0002-7501-7734	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD040677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS041218] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30 HD40677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5T32NS041218-04, NS-1-2339] Funding Source: Medline		Aimone JB, 2004, EXP NEUROL, V189, P204, DOI 10.1016/j.expneurol.2004.05.042; Albright AV, 2004, J NEUROIMMUNOL, V157, P27, DOI 10.1016/j.jneuroim.2004.09.007; ANDERSSON PB, 1992, NEUROSCIENCE, V48, P169, DOI 10.1016/0306-4522(92)90347-5; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Bellander BM, 2004, J NEUROTRAUM, V21, P605, DOI 10.1089/089771504774129937; Blamire AM, 2000, J NEUROSCI, V20, P8153; Bonmann E, 1997, NEUROSCI LETT, V230, P109, DOI 10.1016/S0304-3940(97)00485-0; Brandes RP, 2001, THROMB HAEMOSTASIS, V85, P1104; Brar SS, 2002, AM J PHYSIOL-LUNG C, V282, pL782, DOI 10.1152/ajplung.00206.2001; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Carmel JB, 2001, PHYSIOL GENOMICS, V7, P201, DOI 10.1152/physiolgenomics.00074.2001; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; De Biase A, 2005, PHYSIOL GENOMICS, V22, P368, DOI 10.1152/physiolgenomics.00081.2005; Dehghani F, 2004, EXP NEUROL, V189, P241, DOI 10.1016/j.expneurol.2004.06.010; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; Delves PJ, 2000, NEW ENGL J MED, V343, P37, DOI 10.1056/NEJM200007063430107; Demjen D, 2004, NAT MED, V10, P389, DOI 10.1038/nm1007; Di Giovanni S, 2004, FASEB J, V18, P153, DOI 10.1096/fj.04-2694fje; Di Giovanni S, 2005, J BIOL CHEM, V280, P2084, DOI 10.1074/jbc.M411975200; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Enose Y, 2005, GLIA, V51, P161, DOI 10.1002/glia.20193; Fernandez GC, 2005, GLYCOBIOLOGY, V15, P519, DOI 10.1093/glycob/cwi026; Fitch MT, 1999, J NEUROSCI, V19, P8182; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; Fonseca MI, 2004, J NEUROSCI, V24, P6457, DOI 10.1523/JNEUROSCI.0901-04.2004; Gomes-Leal W, 2004, EXP NEUROL, V190, P456, DOI 10.1016/j.expneurol.2004.06.028; Grewal RP, 1999, NEUROSCI LETT, V271, P65, DOI 10.1016/S0304-3940(99)00496-6; Hashimoto M, 2005, ACTA NEUROPATHOL, V109, P165, DOI 10.1007/s00401-004-0926-z; HWANG S, 1994, J BIOL CHEM, V269, P711; Jiang H, 1996, CELL IMMUNOL, V167, P293, DOI 10.1006/cimm.1996.0038; Kim HRC, 1999, CANCER RES, V59, P4148; Kim TG, 1995, BIBL SHAMAN, V1, P1; Lin HM, 2002, ONCOGENE, V21, P8001, DOI 10.1038/sj.onc.1205820; Lynch NJ, 2004, MOL IMMUNOL, V40, P709, DOI 10.1016/j.molimm.2003.08.009; Ma MH, 2002, J NEUROSCI RES, V68, P691, DOI 10.1002/jnr.10269; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; Moran LB, 2004, NEUROGENETICS, V5, P95, DOI 10.1007/s10048-004-0172-5; Pan JZ, 2002, J NEUROSCI RES, V68, P315, DOI 10.1002/jnr.10215; Pawate S, 2004, J NEUROSCI RES, V77, P540, DOI 10.1002/jnr.20180; Peng TQ, 2004, FASEB J, V18, P293, DOI 10.1096/fj.04-2289fje; Pesheva P, 1998, J NEUROSCI RES, V51, P49, DOI 10.1002/(SICI)1097-4547(19980101)51:1<49::AID-JNR5>3.3.CO;2-2; Popovich PG, 2003, EXP NEUROL, V182, P275, DOI 10.1016/S0014-4886(03)00120-1; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 2001, J NEUROPATH EXP NEUR, V60, P676, DOI 10.1093/jnen/60.7.676; Popovich PG, 2002, J NEUROPATH EXP NEUR, V61, P623, DOI 10.1093/jnen/61.7.623; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Reichert F, 1996, J NEUROIMMUNOL, V70, P153, DOI 10.1016/S0165-5728(96)00112-9; Reichert F, 1999, EXP NEUROL, V160, P508, DOI 10.1006/exnr.1999.7229; Sano H, 2000, J IMMUNOL, V165, P2156, DOI 10.4049/jimmunol.165.4.2156; Schwartz M, 1999, NEUROSURGERY, V44, P1041, DOI 10.1097/00006123-199905000-00057; Shaked I, 2005, J NEUROCHEM, V92, P997, DOI 10.1111/j.1471-4159.2004.02954.x; Shin T, 2005, BRAIN RES, V1041, P95, DOI 10.1016/j.brainres.2005.02.019; Smith ME, 1998, J NEUROSCI RES, V54, P68, DOI 10.1002/(SICI)1097-4547(19981001)54:1<68::AID-JNR8>3.0.CO;2-F; Spranger M, 1996, NEUROSCIENTIST, V2, P293, DOI 10.1177/107385849600200515; Stern EL, 2000, J NEUROIMMUNOL, V106, P114, DOI 10.1016/S0165-5728(00)00194-6; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Sugita Y, 1997, J NEUROSCI RES, V49, P710, DOI 10.1002/(SICI)1097-4547(19970915)49:6<710::AID-JNR5>3.0.CO;2-A; Suh HS, 2005, J IMMUNOL, V174, P2712, DOI 10.4049/jimmunol.174.5.2712; Tachibana T, 2002, NEUROSCI LETT, V327, P133, DOI 10.1016/S0304-3940(02)00375-0; Tator C H, 1996, J Spinal Cord Med, V19, P206; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Tsan MF, 2001, AM J PHYSIOL-CELL PH, V280, pC1422; Wang CX, 1997, BRAIN RES, V759, P190, DOI 10.1016/S0006-8993(97)00254-0; Watanabe T, 1999, J NEUROTRAUM, V16, P255, DOI 10.1089/neu.1999.16.255; Weber GF, 2002, J LEUKOCYTE BIOL, V72, P752; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; YAO JB, 1992, BRAIN RES, V591, P88, DOI 10.1016/0006-8993(92)90981-E; Zhang KH, 2004, NEUROSCIENCE, V128, P375, DOI 10.1016/j.neuroscience.2004.07.008	76	57	61	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	MAR	2006	53	4					420	433		10.1002/glia.20295			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	020CV	WOS:000235886400010	16345062				2022-02-06	
J	Shein, NA; Horowitz, M; Alexandrovich, AG; Tsenter, J; Shohami, E				Shein, NA; Horowitz, M; Alexandrovich, AG; Tsenter, J; Shohami, E			Heat acclimation increases hypoxia-inducible factor 1 alpha and erythropoietin receptor expression: implication for neuroprotection after closed head injury in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						erythropoietin; heat acclimation; hypoxia-inducible factor 1; neuroprotection; traumatic brain injury	RECOMBINANT-HUMAN-ERYTHROPOIETIN; PERMANENT CEREBRAL-ISCHEMIA; TARGET GENES; BRAIN; RAT; TOLERANCE; NEURONS; ASSOCIATION; PROTECTS; RECOVERY	Experimental evidence indicates that long-term exposure to moderately high ambient temperature (heat acclimation, HA) mediates cross-tolerance to various types of subsequently applied stress. The transcriptional activator hypoxia-inducible factor 1 (HIF-1) has been implicated in playing a critical role in HA. It also regulates the expression of Erythropoietin (Epo), whose neuroprotective effects have been shown in a variety of brain injuries. The aim of the present study was to examine whether HA exerts a beneficial effect on the outcome of closed head injury (CHI) in mice and to explore the possible involvement of HIF-1 and Epo in this process. Heat acclimated mice and matched normothermic controls were subjected to CHI or sham surgery. Postinjury motor and cognitive parameters of acclimated mice were compared with those of controls. Mice were killed at various time points after injury or sham surgery and brain levels of HIF-1 alpha, the inducible subunit of HIF-1 alpha Epo, and the specific erythropoietin receptor (EpoR) were analyzed by Western immunoblotting. Motor and cognitive functions of acclimated mice were significantly better than those of controls. Heat acclimation was found to induce a significant increase in expression of nuclear HIF-1 alpha and EpoR. The EpoR/Epo ratio was also significantly higher in acclimated mice as compared with controls. Nuclear HIF-1 alpha and EpoR were higher in the acclimated group at 4 h after injury as well. The improved outcome of acclimated mice taken together with the basal and postinjury upregulation of. the examined proteins suggests the involvement of this pathway in HA-induced neuroprotection.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Fac Med Dent, Environm Physiol Lab, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Physiol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Ctr, Rehabil Ctr, IL-91120 Jerusalem, Israel		Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	horowitz@cc.huji.ac.il; esty@cc.huji.ac.il					Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; Arieli Y, 2003, BRAIN RES, V962, P15, DOI 10.1016/S0006-8993(02)03681-8; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bernaudin M, 2000, GLIA, V30, P271, DOI 10.1002/(SICI)1098-1136(200005)30:3<271::AID-GLIA6>3.0.CO;2-H; Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393, DOI 10.1097/00004647-200204000-00003; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bromberg Z, 2004, P 1 INT M PHYS PHARM, P198; Buemi M, 2002, CLIN SCI, V103, P275, DOI 10.1042/cs1030275; Cai ZQ, 2003, CIRCULATION, V108, P79, DOI 10.1161/01.CIR.0000078635.89229.8A; Catania MA, 2002, EUR J PHARMACOL, V437, P147, DOI 10.1016/S0014-2999(02)01292-X; Chang EF, 2003, J NEUROSCI, V23, P3689; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chong ZZ, 2002, J CEREBR BLOOD F MET, V22, P503, DOI 10.1097/00004647-200205000-00001; Chun YS, 2002, J KOREAN MED SCI, V17, P581, DOI 10.3346/jkms.2002.17.5.581; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Eynan M, 2002, J APPL PHYSIOL, V93, P2095, DOI 10.1152/japplphysiol.00304.2002; Genc S, 2004, RESTOR NEUROL NEUROS, V22, P105; Genc S, 2004, BRAIN RES, V1000, P19, DOI 10.1016/j.brainres.2003.12.037; Glantz L, 2005, EXP NEUROL, V192, P117, DOI 10.1016/j.expneurol.2004.11.012; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Grasso G, 2002, P NATL ACAD SCI USA, V99, P5627, DOI 10.1073/pnas.082097299; Horowitz M, 2004, J APPL PHYSIOL, V97, P1496, DOI 10.1152/japplphysiol.00306.2004; Horowitz M, 2002, COMP BIOCHEM PHYS A, V131, P475, DOI 10.1016/S1095-6433(01)00500-1; Horowitz M, 2001, J THERM BIOL, V26, P357, DOI 10.1016/S0306-4565(01)00044-4; HOROWITZ M, 2005, EXP BIOL 35 INT C PH; Iwasaki Y, 2002, NEUROL RES, V24, P643, DOI 10.1179/016164102101200681; Jones NM, 2001, J CEREBR BLOOD F MET, V21, P1105, DOI 10.1097/00004647-200109000-00008; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Koshimura K, 1999, J NEUROCHEM, V72, P2565, DOI 10.1046/j.1471-4159.1999.0722565.x; LEVI E, 1993, J APPL PHYSIOL, V75, P833, DOI 10.1152/jappl.1993.75.2.833; Maloyan A, 2001, J MOL CELL CARDIOL, V33, pA72, DOI 10.1016/S0022-2828(01)90285-8; MALOYAN A, 1999, AM J PHYSIOL, V26, pR1506; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; SCHMIDTNIELSEN K, 1964, ANIMAL PHYSL, P13; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1994, RESTOR NEUROL NEUROS, V6, P107, DOI 10.3233/RNN-1994-6204; Siren AL, 2001, ACTA NEUROPATHOL, V101, P271, DOI 10.1007/s004010000297; Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092; Treinin M, 2003, PHYSIOL GENOMICS, V14, P17, DOI 10.1152/physiolgenomics.00179.2002; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; YATSIV I, 2002, NEURAL PLAST, V9, P119	48	57	58	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2005	25	11					1456	1465		10.1038/sj.jcbfm.9600142			10	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	977PF	WOS:000232815000006	15902197	Bronze			2022-02-06	
J	King, JT; Carlier, PM; Marion, DW				King, JT; Carlier, PM; Marion, DW			Early Glasgow Outcome Scale scores predict long-term functional outcome in patients with severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						Glasgow Outcome Scale; head injuries closed; outcomes; prognosis; trauma	SEVERE HEAD-INJURY; DISABILITY RATING-SCALE; ACUTE SUBDURAL-HEMATOMA; MODERATE HYPOTHERMIA; ANALYSIS RPA; METASTASES; MANAGEMENT; PROGRAM; SURGERY	Patients sustaining severe traumatic brain injury (TBI) have variable long-term outcomes. We examined the association between Glasgow Outcome Scale (GOS) assessed at 3 months and long-term outcomes at 12 months after TBI. We studied 159 patients with severe, closed traumatic brain injuries (Glasgow Coma Scale [GCS] <= 8) who were treated at an academic medical center and survived for a minimum of 3 months after TBI. Demographics and admission clinical data and GOS at 3 and 12 months were analyzed. Multivariate logistic regression was used to asses the relationship between 3-month GOS, demographics, and clinical data and a poor outcome, defined as GOS 1-3 assessed at 12 months after injury. The patient population was predominantly male (77%), with a median age of 30 years and a median admission GCS of 6. The logistic regression model showed that the GOS at 3 months was the best predictor of 12-month outcomes (odds ratio = 15.22, p < 0.001). The presence of prolonged hypotension, diffuse axonal injury (DAI), and fixed and dilated pupils on admission were also significant independent predictors of poor 12-month outcome (for all, p <= 0.047). The adjusted logistic model showed a steep gradient of long-term recovery potential depending upon GOS at 3 months, ranging from an 89.4% chance of poor outcome for patients with a GOS of 2, to a 0.11% chance of poor outcome for those with a GOS of 5. The 3-month GOS is a powerful independent predictor of long-term outcome for patients with severe TBI. Prolonged hypotension, DAI, and the presence of fixed and dilated pupils were also independent predictors of poor outcome.	VA Connecticut Healthcare Syst 112, Neurosurg Sect, West Haven, CT 06516 USA; Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Brain Trauma Fdn, New York, NY USA		King, JT (corresponding author), VA Connecticut Healthcare Syst 112, Neurosurg Sect, 950 Campbell Ave, West Haven, CT 06516 USA.	Joseph.KingJr@med.va.gov	Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS002169] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1K23 NS02169-06] Funding Source: Medline		Agboola O, 1998, INT J RADIAT ONCOL, V42, P155, DOI 10.1016/S0360-3016(98)00198-9; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Bullock MR, 1996, J NEUROTRAUM, V13, P643; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Gaspar LE, 2000, INT J RADIAT ONCOL, V47, P1001, DOI 10.1016/S0360-3016(00)00547-2; HAGEN C, 1972, RANCHO AMIGOS HOSP L; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; JENNETT B, 1975, LANCET, V1, P480; Karnofsky D.A., 1949, EVALUATION CHEMOTHER, P191; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; MURRAY GD, 1986, STAT MED, V5, P403, DOI 10.1002/sim.4780050504; Nissen JJ, 1999, J NEUROL NEUROSUR PS, V67, P796, DOI 10.1136/jnnp.67.6.796; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; RaeGrant AD, 1996, J TRAUMA, V40, P401, DOI 10.1097/00005373-199603000-00013; RANKIN J, 1957, Scott Med J, V2, P200; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; [No title captured]	30	57	58	0	7	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2005	22	9					947	954		10.1089/neu.2005.22.947			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	967HP	WOS:000232082600002	16156710				2022-02-06	
J	Adani, R; Tarallo, L; Marcoccio, I; Cipriani, R; Gelati, C; Innocenti, M				Adani, R; Tarallo, L; Marcoccio, I; Cipriani, R; Gelati, C; Innocenti, M			Hand reconstruction using the thin anterolateral thigh flap	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article; Proceedings Paper	2nd Congress of the World-Society-for-Reconstructive-Microsurgery	JUN 11-14, 2003	HEIDELBERG, GERMANY	World Soc Reconstruct Microsurg			FOREARM ISLAND FLAP; SOFT-TISSUE DEFECTS; PERFORATOR FLAP; RADIAL ARTERY; CLINICAL-APPLICATIONS; NECK DEFECTS; DONOR-SITE; EXPERIENCE; HEAD; PRESERVATION	Background: Perforator flaps have been introduced for various kinds of reconstruction and resurfacing; in particular, the free thin anterolateral thigh flap is becoming one of the most preferred options for reconstruction of soft-tissue defects. Methods: Between 1999 and 2002, the authors used this flap as a free flap for nine cases for covering hand defects after burn, crushing injuries, or severe scar contracture release. There were eight men and one woman, the mean age of the patients was 31 years, and the size of the flaps ranged from 7 X 3.5 cm to 15 X 9 cm; thinning was performed in all flaps. Results: All flaps survived completely, and the donor site was closed directly in seven cases; in two cases, the exposed muscle was covered with split thickness skin graft. Conclusions: The anterolaterul thigh flap was thin enough for defects on the dorsum and/ or palm of the hand and for first web reconstruction after scar contracture release. It has many advantages in free flap surgery including a long pedicle with a suitable vessel diameter, and the donor-site morbidity is acceptable. The thin anterolateral thigh flap is a versatile soft tissue flap that achieves good hand contour with low donor-site morbidity.	St Orsola Marcello Malpighi Hosp, Clin Ortoped & Traumatol, Plast Surg Unit, I-41100 Modena, Italy; Univ Modena & Reggio Emilia, Dept Orthoped Surg, Modena, Italy; Orthopaed Traumatol Ctr, Hand & Microsurg Unit, Florence, Italy		Adani, R (corresponding author), St Orsola Marcello Malpighi Hosp, Clin Ortoped & Traumatol, Plast Surg Unit, Largo Pozzo 71, I-41100 Modena, Italy.	adani.roberto@unimo.it		Tarallo, Luigi/0000-0002-7999-8154			Alkureishi LWT, 2003, BRIT J PLAST SURG, V56, P401, DOI 10.1016/S0007-1226(03)00125-5; ANGRIGIANI C, 1993, PLAST RECONSTR SURG, V92, P285, DOI 10.1097/00006534-199308000-00014; Blondeel PN, 2003, PLAST RECONSTR SURG, V112, P1378, DOI 10.1097/01.PRS.0000081071.83805.B6; Brunelli F, 2001, ANN PLAS SURG, V47, P25, DOI 10.1097/00000637-200107000-00005; Celik N, 2002, PLAST RECONSTR SURG, V109, P2211, DOI 10.1097/00006534-200206000-00005; Chang SM, 2003, MICROSURG, V23, P328, DOI 10.1002/micr.10155; Chen HC, 1997, PLAST RECONSTR SURG, V99, P454, DOI 10.1097/00006534-199702000-00021; Chen HC, 1999, HAND CLIN, V15, P541; Giunta R, 2002, PLAST RECONSTR SURG, V109, P1460, DOI 10.1097/00006534-200204010-00045; Hsieh CH, 2003, PLAST RECONSTR SURG, V112, P976, DOI 10.1097/01.PRS.0000076221.25738.66; Javaid M, 2003, J HAND SURG-BRIT EUR, V28B, P21, DOI 10.1054/jhsb.2002.0863; Jeng SF, 1998, PLAST RECONSTR SURG, V102, P400, DOI 10.1097/00006534-199808000-00017; Kim KS, 2003, ANN PLAS SURG, V50, P77, DOI 10.1097/00000637-200301000-00013; Kimata Y, 1997, ARCH OTOLARYNGOL, V123, P1325; Kimata Y, 1998, PLAST RECONSTR SURG, V102, P1517, DOI 10.1097/00006534-199810000-00026; Kimata Y, 2000, PLAST RECONSTR SURG, V106, P584, DOI 10.1097/00006534-200009030-00009; Kimura N, 1996, PLAST RECONSTR SURG, V97, P985, DOI 10.1097/00006534-199604001-00016; Kimura N, 2001, PLAST RECONSTR SURG, V108, P1197, DOI 10.1097/00006534-200110000-00015; KOSHIMA I, 1995, PLAST RECONSTR SURG, V95, P252, DOI 10.1097/00006534-199502000-00004; KOSHIMA I, 1993, PLAST RECONSTR SURG, V92, P411, DOI 10.1097/00006534-199309000-00004; KOSHIMA I, 1993, PLAST RECONSTR SURG, V92, P421, DOI 10.1097/00006534-199309000-00005; Kuo YR, 2002, ANN PLAS SURG, V48, P161, DOI 10.1097/00000637-200202000-00008; Kuo YR, 2001, PLAST RECONSTR SURG, V107, P1766, DOI 10.1097/00006534-200106000-00019; Luo SK, 1999, MICROSURG, V19, P232, DOI 10.1002/(SICI)1098-2752(1999)19:5<232::AID-MICR5>3.3.CO;2-J; Muneuchi G, 2002, ANN PLAS SURG, V49, P312, DOI 10.1097/00000637-200209000-00013; Rajacic N, 2002, ANN PLAS SURG, V48, P252, DOI 10.1097/00000637-200203000-00004; Ross GL, 2003, BRIT J PLAST SURG, V56, P409, DOI 10.1016/S0007-1226(03)00126-7; Rui YJ, 2004, MICROSURG, V24, P59, DOI 10.1002/micr.10204; SCHEKER LR, 1988, J HAND SURG-BRIT EUR, V13B, P146, DOI 10.1016/0266-7681(88)90123-4; SONG YG, 1984, BRIT J PLAST SURG, V37, P149, DOI 10.1016/0007-1226(84)90002-X; Wei FC, 2002, PLAST RECONSTR SURG, V109, P2219, DOI 10.1097/00006534-200206000-00007; Wei FC, 2001, PLAST RECONSTR SURG, V107, P874, DOI 10.1097/00006534-200103000-00037; WEINZWEIG N, 1994, PLAST RECONSTR SURG, V94, P675, DOI 10.1097/00006534-199410000-00016; XU DC, 1988, PLAST RECONSTR SURG, V82, P305; Yang DP, 2003, PLAST RECONSTR SURG, V112, P1012, DOI 10.1097/01.PRS.0000076192.14536.90; Yang JY, 2002, PLAST RECONSTR SURG, V110, P39, DOI 10.1097/00006534-200207000-00009; Yidirim S, 2003, ANN PLAS SURG, V51, P37, DOI 10.1097/01.SAP.0000054179.04469.8C; ZANCOLLI EA, 1988, J HAND SURG-BRIT EUR, V13B, P130, DOI 10.1016/0266-7681(88)90121-0; ZHOU G, 1991, BRIT J PLAST SURG, V44, P91, DOI 10.1016/0007-1226(91)90038-L	39	57	67	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0032-1052	1529-4242		PLAST RECONSTR SURG	Plast. Reconstr. Surg.	AUG	2005	116	2					467	473		10.1097/01.prs.0000173059.73982.50			7	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	951NM	WOS:000230937400020	16079675				2022-02-06	
J	Petzold, GC; Windmuller, O; Haack, S; Major, S; Buchheim, K; Megow, D; Gabriel, S; Lehmann, TN; Drenckhahn, C; Peters, O; Meierkord, H; Heinemann, U; Dirnagl, U; Dreier, JP				Petzold, GC; Windmuller, O; Haack, S; Major, S; Buchheim, K; Megow, D; Gabriel, S; Lehmann, TN; Drenckhahn, C; Peters, O; Meierkord, H; Heinemann, U; Dirnagl, U; Dreier, JP			Increased extracellular K+ concentration reduces the efficacy of N-methyl-D-aspartate receptor antagonists to block spreading depression-like depolarizations and spreading ischemia	STROKE			English	Article						brain injuries; N-methyl-D-aspartate; spreading cortical depression; stroke; subarachnoid hemorrhage; trauma	FOCAL CEREBRAL-ISCHEMIA; SUBARACHNOID SPACE; PERIINFARCT DEPOLARIZATIONS; ANOXIC DEPOLARIZATION; INTRACRANIAL-PRESSURE; RATS; INJURY; BRAIN; HEMORRHAGE; CORTEX	Background and Purpose - Spreading depression (SD)-like depolarizations may augment neuronal damage in neurovascular disorders such as stroke and traumatic brain injury. Spreading ischemia ( SI), a particularly malignant variant of SD-like depolarization, is characterized by inverse coupling between the spreading depolarization wave and cerebral blood flow. SI has been implicated in particular in the pathophysiology of subarachnoid hemorrhage. Under physiological conditions, SD is blocked by N-methyl-D-aspartate receptor ( NMDAR) antagonists. However, because both SD-like depolarizations and SI occur in presence of an increased extracellular K+ concentration ([K+](o)), we tested whether this increase in baseline [K+](o) would reduce the efficacy of NMDAR antagonists. Methods - Cranial window preparations, laser Doppler flowmetry, and K+-sensitive/reference microelectrodes were used to record SD, SD-like depolarizations, and SI in rats in vivo; microelectrodes and intrinsic optical signal measurements were used to record SD and SD-like depolarizations in human and rat brain slices. Results - In vivo, the noncompetitive NMDAR antagonist dizocilpine (MK-801) blocked SD propagation under physiological conditions, but did not block SD-like depolarizations or SI under high baseline [K+](o). Similar results were found in human and rat neocortical slices with both MK-801 and the competitive NMDAR antagonist D-2-amino-5-phosphonovaleric acid. Conclusions - Our data suggest that elevated baseline [K+](o) reduces the efficacy of NMDAR antagonists on SD-like depolarizations and SI. In conditions of moderate energy depletion, as in the ischemic penumbra, or after subarachnoid hemorrhage, NMDAR inhibition may not be sufficient to block these depolarizations.	Charite Univ Med Berlin, Dept Neurol, D-10117 Berlin, Germany; Charite Univ Med Berlin, Dept Expt Neurol, Berlin, Germany; Charite Univ Med Berlin, Johannes Muller Inst Physiol, Berlin, Germany; Charite Univ Med Berlin, Dept Neurosurg, Berlin, Germany; Charite Univ Med Berlin, Dept Psychiat, Berlin, Germany		Dreier, JP (corresponding author), Charite Univ Med Berlin, Dept Neurol, Schumannstr 20-21, D-10117 Berlin, Germany.	jens.dreier@charite.de	Major, Sebastian/I-1838-2019	Major, Sebastian/0000-0003-0970-1308; Dirnagl, Ulrich/0000-0003-0755-6119; Dreier, Jens/0000-0001-7459-2828; Megow, Dirk/0000-0002-7659-0524; Peters, Oliver/0000-0003-0568-2998			Anderson TR, 2002, J NEUROPHYSIOL, V88, P2713, DOI 10.1152/jn.00321.2002; AVOLI M, 1991, ANN NEUROL, V30, P589, DOI 10.1002/ana.410300412; AYATA C, 2004, MK 801 PREVENTS EXPA; Busch E, 1998, STROKE, V29, P2155, DOI 10.1161/01.STR.29.10.2155; Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; CHI OZ, 1991, CIRC RES, V69, P414, DOI 10.1161/01.RES.69.2.414; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dreier JP, 1998, J CEREBR BLOOD F MET, V18, P978, DOI 10.1097/00004647-199809000-00007; Dreier JP, 2002, NEUROSURGERY, V51, P1457, DOI 10.1097/00006123-200212000-00017; Dreier JP, 2002, ANN NEUROL, V52, P825, DOI 10.1002/ana.10383; Dreier JP, 2000, J NEUROSURG, V93, P658, DOI 10.3171/jns.2000.93.4.0658; Gabriel S, 1998, NEUROSCI LETT, V249, P91, DOI 10.1016/S0304-3940(98)00420-0; Hartings JA, 2003, J NEUROSCI, V23, P11602; HERNANDEZCACERES J, 1987, BRAIN RES, V437, P360, DOI 10.1016/0006-8993(87)91652-0; IIJIMA T, 1992, J CEREBR BLOOD F MET, V12, P727, DOI 10.1038/jcbfm.1992.103; LAURITZEN M, 1988, BRAIN RES, V475, P317, DOI 10.1016/0006-8993(88)90620-8; LAURITZEN M, 1992, J CEREBR BLOOD F MET, V12, P223, DOI 10.1038/jcbfm.1992.32; MIES G, 1994, J CEREBR BLOOD F MET, V14, P802, DOI 10.1038/jcbfm.1994.100; Muller M, 2000, J NEUROPHYSIOL, V84, P1869, DOI 10.1152/jn.2000.84.4.1869; NEDERGAARD M, 1988, BRAIN RES, V449, P395, DOI 10.1016/0006-8993(88)91062-1; NEDERGAARD M, 1993, J CEREBR BLOOD F MET, V13, P568, DOI 10.1038/jcbfm.1993.74; Ohta O., 1983, VASCULAR NEUROEFFECT, P353; Petzold GC, 2003, ANN NEUROL, V54, P591, DOI 10.1002/ana.10723; Reinert M, 2000, J NEUROSURG, V93, P800, DOI 10.3171/jns.2000.93.5.0800; Rogatsky GG, 2003, J NEUROTRAUM, V20, P1315, DOI 10.1089/089771503322686111; Somjen GG, 2001, PHYSIOL REV, V81, P1065, DOI 10.1152/physrev.2001.81.3.1065; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Strong AJ, 2000, STROKE, V31, P214, DOI 10.1161/01.STR.31.1.214	28	57	58	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	JUN	2005	36	6					1270	1277		10.1161/01.STR.0000166023.51307.e0			8	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	929EL	WOS:000229324800038	15879337	Bronze			2022-02-06	
J	Thompson, J; Sebastianelli, W; Slobounov, S				Thompson, J; Sebastianelli, W; Slobounov, S			EEG and postural correlates of mild traumatic brain injury in athletes	NEUROSCIENCE LETTERS			English	Article						electroencephalogram (EEG); mild traumatic brain injury (MTBI); posture; balance	PERFORMANCE; COLLEGIATE; MRI	Mild traumatic brain injury (MTBI), or concussion, is one of the least understood injuries facing the neuroscience and sports medicine community today. The notion of transient dysfunction and rapid symptom resolution is misleading since symptom resolution is not indicative of injury resolution. Our working hypothesis is that there are residual postural and EEG abnormalities in concussed individuals that could be reliably assessed using appropriate research methodology. This paper presents combined postural and electroencephalographic (EEG) findings suggesting the persistent functional deficits in athletes suffering from MTBI. Twelve concussed athletes and twelve normal controls participated in the study. There was a decrease in EEG power in all bandwidths studied in concussed subjects, especially in standing postures. This was accompanied by sustained postural instability especially under the no vision testing condition. Overall, this study demonstrated the presence of long-term functional abnormalities in individuals suffering from mild traumatic brain injury. (c) 2004 Published by Elsevier Ireland Ltd.	Penn State Univ, University Pk, PA 16802 USA		Slobounov, S (corresponding author), Penn State Univ, 19 Recreat Hall,Univ Pk, University Pk, PA 16802 USA.	sms18@psu.edu					Barth JT, 2001, J ATHL TRAINING, V36, P253; BEATTY J, 1974, SCIENCE, V183, P871, DOI 10.1126/science.183.4127.871; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; COLLINS D, 1999, J SPORT EXEC PSY, V12, P223; CREWS DJ, 1993, MED SCI SPORT EXER, V25, P116, DOI 10.1249/00005768-199301000-00016; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; GEVINS AS, 1979, SCIENCE, V203, P665, DOI 10.1126/science.760212; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; HOFFMAN DA, 1995, J NEUROTHERAPY, V2, P149; HOOVEY ZB, 1972, ELECTROEN CLIN NEURO, V32, P337, DOI 10.1016/0013-4694(72)90001-6; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Madeleine P, 2004, ARCH PHYS MED REHAB, V85, P432, DOI 10.1016/j.apmr.2003.03.003; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; Ouchi Y, 1999, BRAIN, V122, P329, DOI 10.1093/brain/122.2.329; Randolph C, 2001, J ATHL TRAINING, V36, P288; Saitou K, 1996, ELECTROEN CLIN NEURO, V98, P449, DOI 10.1016/0013-4694(96)95004-X; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Slobounov SM, 1997, J MOTOR BEHAV, V29, P263, DOI 10.1080/00222899709600841; SLOBUNOV S, IN PRESS CLIN NEUROP; Stuss D., 2002, PR FRONTAL LOBE FUNC, P392, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0025; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; Thatcher RW, 2001, CLIN NEUROPHYSIOL, V112, P1729, DOI 10.1016/S1388-2457(01)00609-5; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; VOLLER B, 1999, BRAIN INJURY, V15, P95	29	57	58	0	12	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	APR 4	2005	377	3					158	163		10.1016/j.neulet.2004.11.090			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	907WY	WOS:000227750000004	15755518				2022-02-06	
J	Jafarian-Tehrani, M; Louin, G; Royo, NC; Besson, VC; Bohme, GA; Plotkine, M; Marchand-Verrecchia, CM				Jafarian-Tehrani, M; Louin, G; Royo, NC; Besson, VC; Bohme, GA; Plotkine, M; Marchand-Verrecchia, CM			1400W, a potent selective inducible NOS inhibitor, improves hi stop atholo gical outcome following traumatic brain injury in rats	NITRIC OXIDE-BIOLOGY AND CHEMISTRY			English	Article						nitric oxide synthases; fluid percussion brain injury; 1400W; RT-PCR; western blots; brain lesion volumes; neuroprotection rat	NITRIC-OXIDE SYNTHASE; FOCAL CEREBRAL-ISCHEMIA; AMINOGUANIDINE TREATMENT; PROTEIN INHIBITOR; L-ARGININE; EXPRESSION; BINDING; MICE; PHOSPHORYLATION; NEUROPROTECTION	There are conflicting data regarding the role of nitric oxide (NO) produced by inducible NO synthase (iNOS) in the pathophysiology of traumatic brain injury (TBI). In this report, we evaluated the effect of a potent selective (iNOS) inhibitor, 1400W, on histopathological outcome following TBI in a rat model of lateral fluid percussion brain injury. First, to design an appropriate treatment protocol, the parallel time courses of iNOS and neuronal NOS (nNOS) gene expression, protein synthesis, and activity were investigated. Early induction of iNOS gene was observed in the cortex of injured rats, from 6 to 72 h with a peak at 24 H. Similarly, iNOS protein was detected from 24 to 72 h and de novo synthesized iNOS was functionally active, as measured by Ca2+ -independent NOS activity. The kinetic studies of nNOS showed discrepancies, since nNOS gene expression and protein synthesis were constant in the cortex of injured rats from 24 to 72 h, while Ca2+ -dependent constitutive NOS activity was markedly decreased at 24 11, persisting up to 72 h. Second, treatment with 1400W, started as a bolus of 20 mg kg(-1) (s.c.) at 18 h post-TBI, followed by s.c.-infusion at a rate of 2.2 mg kg(-1) h(-1) between 18 and 72 h, reduced by 64% the brain lesion volume at 72 h. However, THE same treatment paradigm initiated 24 It post-TBI did not have any effect. In conclusion, administration of a selective iNOS inhibitor, 1400W, even delayed by 18 It improves histopathological outcome Supporting a detrimental role for iNOS induction after TBI. (c) 2004 Elsevier Inc. All rights reserved.	Univ Paris 05, Pharmacol Lab, UPRES EA 2510, F-75270 Paris, France; Aventis Pharma SA, Ctr Rech Paris, Vitry Sur Seine, France		Jafarian-Tehrani, M (corresponding author), Univ Paris 05, Pharmacol Lab, UPRES EA 2510, 4 Ave Obser, F-75270 Paris, France.	mehranz.jafarian@univ-paris5.fr	MARCHAND-LEROUX, Catherine/L-7453-2017; BESSON, VALERIE/AAZ-9989-2020; besson, valerie C/L-7388-2017	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; BESSON, VALERIE/0000-0002-1491-2380; besson, valerie C/0000-0002-1491-2380; Jafarian-Tehrani, Mehrnaz/0000-0001-6895-5856			Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Armengou A, 2003, J CEREBR BLOOD F MET, V23, P978, DOI 10.1097/01.WCB.0000080651.64357.C6; Bagetta G, 2004, NEUROSCI LETT, V356, P183, DOI 10.1016/j.neulet.2003.11.065; Bal-Price A, 2001, J NEUROSCI, V21, P6480; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Cardenas A, 1998, EUR J PHARMACOL, V354, P161, DOI 10.1016/S0014-2999(98)00458-0; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Chatzipanteli K, 2002, J NEUROTRAUM, V19, P639, DOI 10.1089/089771502753754109; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171, DOI 10.1152/jn.2000.83.4.2171; CHORNCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; Colasanti M, 1999, J BIOL CHEM, V274, P9915, DOI 10.1074/jbc.274.15.9915; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gahm C, 2000, NEUROSURGERY, V46, P169, DOI 10.1093/neurosurgery/46.1.169; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; GOLANOV EV, 1995, J CEREBR BLOOD F MET, V15, P172, DOI 10.1038/jcbfm.1995.19; Grandati M, 1997, BRIT J PHARMACOL, V122, P625, DOI 10.1038/sj.bjp.0701427; Greenwood MT, 1997, BIOCHEM BIOPH RES CO, V238, P617, DOI 10.1006/bbrc.1997.7361; Hayashi Y, 1999, J BIOL CHEM, V274, P20597, DOI 10.1074/jbc.274.29.20597; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P52, DOI 10.1038/jcbfm.1995.6; Ivanova S, 1998, J EXP MED, V188, P327, DOI 10.1084/jem.188.2.327; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Law A, 2001, BRIT J PHARMACOL, V133, P1114, DOI 10.1038/sj.bjp.0704179; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Louin G, 2004, J NEUROSCI METH, V138, P73, DOI 10.1016/j.jneumeth.2004.03.010; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; Lu YC, 1997, MOL CHEM NEUROPATHOL, V30, P125, DOI 10.1007/BF02815154; Madrigal JLM, 2002, BRAIN RES, V938, P87, DOI 10.1016/S0006-8993(02)02467-8; Mattson DL, 2000, HYPERTENSION, V35, P337, DOI 10.1161/01.HYP.35.1.337; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nogawa S, 1998, P NATL ACAD SCI USA, V95, P10966, DOI 10.1073/pnas.95.18.10966; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Parmentier S, 1999, BRIT J PHARMACOL, V127, P546, DOI 10.1038/sj.bjp.0702549; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; RENGASAMY A, 1993, MOL PHARMACOL, V44, P124; ROGERS NE, 1992, BIOCHEM BIOPH RES CO, V189, P242, DOI 10.1016/0006-291X(92)91550-A; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; SMITH FS, 1998, DETECTION NOS ISOFOR; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3	50	57	61	2	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1089-8603	1089-8611		NITRIC OXIDE-BIOL CH	Nitric Oxide-Biol. Chem.	MAR	2005	12	2					61	69		10.1016/j.niox.2004.12.001			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	906DO	WOS:000227620900001	15740979				2022-02-06	
J	Amantini, A; Grippo, A; Fossi, S; Cesaretti, C; Piccioli, A; Peris, A; Ragazzoni, A; Pinto, F				Amantini, A; Grippo, A; Fossi, S; Cesaretti, C; Piccioli, A; Peris, A; Ragazzoni, A; Pinto, F			Prediction of 'awakening' and outcome in prolonged acute coma from severe traumatic brain injury: evidence for validity of short latency SEPs	CLINICAL NEUROPHYSIOLOGY			English	Article						somatosensory evoked potentials; coma; traumatic brain injury; outcome prediction; EEG; GCS	SOMATOSENSORY-EVOKED-POTENTIALS; SEVERE HEAD-INJURY; EVENT-RELATED POTENTIALS; PROGNOSTIC VALUE; COMPONENTS; RESPONSES; DAMAGE; EEG	Objective: To evaluate the prognostic value of somatosensory evoked potentials (SEP's) in severe traumatic brain injury (TBI) considering both 'awakening' and disability. Methods: SEPs were recorded in 60 severe TBI with duration of acute coma> 7 days. N20-P25 amplitudes, their side-to-side asymmetry and CCT were measured. SEPs on each hemisphere were classified as normal (N), pathological (P) or absent (A). 'Awakening' and disability were assessed after at least 12 months using Glasgow Outcome Scale (GOS). SEP predictive value was compared with GCS and EEG reactivity. Results: Seventy-five percent regained consciousness. 29/60 had a good outcome (GOS 4-5) and 31/60 had a bad outcome (GOS 1-3). According to the ROC curve, SEP findings were classified in 3 grades. Grade I (NN, NP) had PPV of 93.1% for 'awakening' and 86.2% for good outcome. Grade III (AA) had PPV of 100% forbad outcome and 72.7 % for 'awakening'. Grade II (PP, NA, PA) was associated with the wider range of outcome. A multivariate analysis including SEP grading, GCS and EEG reactivity did not increase the percentage of cases prognosticated by SEP alone. Conclusions: We confirm the high predictive value of SEPs in TBI, which is greater than GCS and EEG reactivity. Indeed, SEP grades I and III were able to predict the correct prognosis in more than 80% of severe TBI. Therefore, SEPs should be used more widely in the prognosis of severe TBI. Significance: Differently from post-anoxic, in post-traumatic coma the presence of normal SEPs has a favourable predictive value both for 'awakening' and disability. We think that in literature enough attention has still not been paid to this finding. (C) 2004 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	Univ Florence, Dept Neurol & Psychiat Sci, Az Osped Careggi, I-50134 Florence, Italy; Az Osped Careggi, Intens Care Unit 1, Florence, Italy; Osped S Giovanni di Dio, Serv Neurol, Florence, Italy		Amantini, A (corresponding author), Univ Florence, Dept Neurol & Psychiat Sci, Az Osped Careggi, Vle Morgagni 85, I-50134 Florence, Italy.	amantini@unifi.it	grippo, antonello/AAP-6926-2020	Grippo, Antonello/0000-0002-9997-8564			ANDERSON DC, 1984, ARCH NEUROL-CHICAGO, V41, P369, DOI 10.1001/archneur.1984.04050160031011; Attia J, 1998, CRIT CARE CLIN, V14, P497, DOI 10.1016/S0749-0704(05)70013-0; Brown JIM, 1998, NEUROSURGERY, V42, P1057, DOI 10.1097/00006123-199805000-00060; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; Carter BG, 2001, CRIT CARE MED, V29, P178, DOI 10.1097/00003246-200101000-00036; Claassen J, 2001, CRIT CARE MED, V29, P494, DOI 10.1097/00003246-200103000-00005; Facco E, 2000, INTENS CARE MED, V26, P998, DOI 10.1007/s001340051294; FACCO E, 1990, ELECTROEN CLIN NEURO, P330; FACCO E, 2002, EPIDEMIOLOGIA GESTIO; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; Fletcher R.H., 1996, CLIN EPIDEMIOLOGY ES; FSICHER C, 2002, NEUROPHYSIOL DATA AN, V45, P448; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; Guerit J. M., 1993, Neurophysiologie Clinique, V23, P209, DOI 10.1016/S0987-7053(05)80231-X; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; Guerit JM, 1999, NEUROPHYSIOL CLIN, V29, P301, DOI 10.1016/S0987-7053(99)90044-8; GUTLING E, 1994, ELECTROEN CLIN NEURO, V92, P568, DOI 10.1016/0168-5597(94)90141-4; GUTLING E, 1993, ELECTROEN CLIN NEURO, V88, P369, DOI 10.1016/0168-5597(93)90013-F; GUTLING E, 1995, NEUROLOGY, V45, P915, DOI 10.1212/WNL.45.5.915; HUTCHINSON DO, 1991, ELECTROEN CLIN NEURO, V78, P228, DOI 10.1016/0013-4694(91)90037-5; JENNETT B, 1975, LANCET, V1, P480; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI [10.1097/00002060-200301000-00009, 10.1097/01.PHM.0000043771.90606.81]; Logi F, 2003, CLIN NEUROPHYSIOL, V114, P1615, DOI 10.1016/S1388-2457(03)00086-5; PohlmannEden B, 1997, INTENS CARE MED, V23, P301, DOI 10.1007/s001340050332; Robinson LR, 2003, CRIT CARE MED, V31, P960, DOI 10.1097/01.CCM.0000053643.21751.3B; Rothstein TL, 2000, J CLIN NEUROPHYSIOL, V17, P486, DOI 10.1097/00004691-200009000-00007; RUMPL E, 1983, ELECTROEN CLIN NEURO, V56, P583, DOI 10.1016/0013-4694(83)90026-3; Sleigh JW, 1999, J NEUROSURG, V91, P577, DOI 10.3171/jns.1999.91.4.0577; Soldner F, 2001, ACTA NEUROCHIR, V143, P873, DOI 10.1007/s007010170017; Tozzi F, 1990, Minerva Anestesiol, V56, P1311	32	57	67	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	JAN	2005	116	1					229	235		10.1016/j.clinph.2004.07.008			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	885KW	WOS:000226156500026	15589201				2022-02-06	
J	Lotocki, G; Alonso, OF; Dietrich, WD; Keane, RW				Lotocki, G; Alonso, OF; Dietrich, WD; Keane, RW			Tumor necrosis factor receptor 1 and its signaling intermediates are recruited to lipid rafts in the traumatized brain	JOURNAL OF NEUROSCIENCE			English	Article						tumor necrosis factor; apoptosis; traumatic brain injury; lipid rafts; intracellular signaling; inflammation	NF-KAPPA-B; CLOSED-HEAD INJURY; SPINAL-CORD-INJURY; CELL-DEATH; TRANSDUCTION PATHWAYS; MEDIATED APOPTOSIS; TNF RECEPTOR-1; RAT-BRAIN; ACTIVATION; EXPRESSION	The tumor necrosis factor (TNF) ligand-receptor system plays an essential role in apoptosis that contributes to secondary damage after traumatic brain injury (TBI). TNF also stimulates inflammation by activation of gene transcription through the IkappaB kinase (IKK)/NF-kappaB and JNK (c-Jun N-terminal protein kinase)/AP-1 signaling cascades. The mechanism by which TNF signals between cell death and survival and the role of receptor localization in the activation of downstream signaling events are not fully understood. Here, TNF receptor 1 (TNFR1) signaling complexes in lipid rafts were investigated in the cerebral cortex of adult male Sprague Dawley rats subjected to moderate (1.8-2.2 atmospheres) fluid-percussion TBI and naive controls. In the normal rat cortex, a portion of TNFR1 was present in lipid raft microdomains, where it associated with the adaptor proteins TRADD ( TNF receptor-associated death domain), TNF receptor-associated factor-2 (TRAF-2), the Ser/Thr kinase RIP (receptor-interacting protein), TRAF1, and cIAP-1 ( cellular inhibitor of apoptosis protein-1), forming a survival signaling complex. Moderate TBI resulted in rapid recruitment of TNFR1, but not TNFR2 or Fas, to lipid rafts and induced alterations in the composition of signaling intermediates. TNFR1 and TRAF1 were polyubiquitinated in lipid rafts after TBI. Subsequently, the signaling complex contained activated caspase-8, thus initiating apoptosis. In addition, TBI caused a transient activation of NF-kappaB, but receptor signaling interacting proteins IKKalpha and IKKbeta were not detected in raft-containing fractions. Thus, redistribution of TNFR1 in lipid rafts and nonraft regions of the plasma membrane may regulate the diversity of signaling responses initiated by these receptors in the normal brain and after TBI.	Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA		Keane, RW (corresponding author), Univ Miami, Sch Med, Dept Physiol & Biophys, 1600 NW 10th Ave, Miami, FL 33136 USA.	rkeane@miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS042133] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS030291, NS42133, R01 NS042133, NS30291] Funding Source: Medline		Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Choi C, 2004, BRAIN RES REV, V44, P65, DOI 10.1016/j.brainresrev.2003.08.007; Clark WM, 2001, EXPERT OPIN BIOL TH, V1, P227, DOI 10.1517/14712598.1.2.227; Cottin V, 2002, J IMMUNOL, V168, P4095, DOI 10.4049/jimmunol.168.8.4095; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Doan JES, 2004, J IMMUNOL, V172, P7654, DOI 10.4049/jimmunol.172.12.7654; Dopp JM, 1997, J NEUROIMMUNOL, V75, P104, DOI 10.1016/S0165-5728(97)00009-X; EKLLIHER MA, 1998, IMMUNITY, V8, P297; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Keane RW, 1997, J NEUROSCI RES, V48, P168, DOI 10.1002/(SICI)1097-4547(19970415)48:2<168::AID-JNR9>3.0.CO;2-A; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kim GM, 2001, J NEUROSCI, V21, P6617, DOI 10.1523/JNEUROSCI.21-17-06617.2001; Ko YG, 1999, J IMMUNOL, V162, P7217; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lou J, 2001, CLIN MICROBIOL REV, V14, P810, DOI 10.1128/CMR.14.4.810-820.2001; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Muppidi JR, 2004, NAT IMMUNOL, V5, P182, DOI 10.1038/ni1024; Nawashiro H, 1997, BRAIN RES, V778, P265, DOI 10.1016/S0006-8993(97)00981-5; Perry RT, 2001, NEUROBIOL AGING, V22, P873, DOI 10.1016/S0197-4580(01)00291-3; Probert L, 2001, GLIA, V36, P212, DOI 10.1002/glia.1110; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Shinoda S, 2003, EUR J NEUROSCI, V17, P2065, DOI 10.1046/j.1460-9568.2003.02655.x; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; TYOR WR, 1995, J ACQ IMMUN DEF SYND, V9, P379; Veldman RJ, 2001, BIOCHEM J, V355, P859, DOI 10.1042/bj3550859; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yan P, 2003, EXP NEUROL, V183, P286, DOI 10.1016/S0014-4886(03)00135-3; Yang LB, 2002, J NEUROSCI, V22, P3025, DOI 10.1523/JNEUROSCI.22-08-03025.2002	48	57	62	0	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	DEC 8	2004	24	49					11010	11016		10.1523/JNEUROSCI.3823-04.2004			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	878AI	WOS:000225618300002	15590916	Green Published, Bronze			2022-02-06	
J	Massucci, JL; Kline, AE; Ma, XC; Zafonte, RD; Dixon, CE				Massucci, JL; Kline, AE; Ma, XC; Zafonte, RD; Dixon, CE			Time dependent alterations in dopamine tissue levels and metabolism after experimental traumatic brain injury in rats	NEUROSCIENCE LETTERS			English	Article						catecholamine; CCI; DOPAC; dopamine; TBI	WATER MAZE PERFORMANCE; METHYLPHENIDATE TREATMENT; TYROSINE-HYDROXYLASE; PREFRONTAL CORTEX; WORKING-MEMORY; FRONTAL-CORTEX; TRANSPORTER; EXPRESSION; AGONIST	Several studies have demonstrated alterations in the dopamine (DA) system after traumatic brain injury (TBI). The present study investigated the temporal changes in DA tissue levels and metabolism at 1-h or 1, 7, 14, and 28 days after cortical impact or sham injury in rats. DA and DOPAC levels were measured by HPLC in the frontal cortex (FC) and striatum. DA levels were significantly increased at 1 h in the contralateral FC and at 1 day in the ipsilateral FC versus respective sham groups. DA and DOPAC levels were significantly increased bilaterally at 1 h in the striatum versus sham. These data indicate that TBI induces an early increase in DA and DOPAC, which returns to sham levels over time. (C) 2004 Elsevier Ireland Ltd. All rights reserved.	Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA		Dixon, CE (corresponding author), Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA.	dixonec@upmc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD043851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040125] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD043851] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS303180, NS40125] Funding Source: Medline		BERGER B, 1991, TRENDS NEUROSCI, V14, P21, DOI 10.1016/0166-2236(91)90179-X; BJORKLUND A, 1984, HDB CHEM NEUROANATOM, P00055; BLANCHARD V, 1995, J NEUROCHEM, V64, P1669; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; GAMACHE P, 1993, J CHROMATOGR-BIOMED, V614, P213, DOI 10.1016/0378-4347(93)80311-Q; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; HUGER F, 1979, J NEUROCHEM, V33, P89, DOI 10.1111/j.1471-4159.1979.tb11710.x; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; KLINE AE, IN PRESS J NEUROTRAU; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Phillips JP, 2003, J HEAD TRAUMA REHAB, V18, P342, DOI 10.1097/00001199-200307000-00005; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009	23	57	58	0	12	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	NOV 30	2004	372	1-2					127	131		10.1016/j.neulet.2004.09.026			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	873BT	WOS:000225254500026	15531102				2022-02-06	
J	Hoshizaki, TB; Brien, SE				Hoshizaki, TB; Brien, SE			The science and design of head protection in sport	NEUROSURGERY			English	Article						brain injury criteria; brain trauma; concussion; head protection; helmet; helmet standards; sport; standard testing	FOOTBALL; CONCUSSION; IMPACTS	WE REVIEW THE relationship between science, testing standards, and helmet design to provide an understanding of how helmets protect the brain. Research describing the mechanisms of injury, resulting types of brain injuries, and characteristics of helmet protection are reviewed. The article is designed to describe the state of the relationship between science and helmet performance.	Univ Ottawa, Fac Human Kinet, Ottawa, ON, Canada; Hotel Dieu Grace Hosp, Dept Neurosurg, Windsor, ON, Canada		Hoshizaki, TB (corresponding author), 225 Hemlock Rd, Rockcliffe, ON K1M 1K4, Canada.	bhoshizaki@hotmail.com		Kaye, Andrew Henry/0000-0001-5049-8861			*AM ASS AUT MED, 1980, ABBR INJ SCAL AIS 80; *AM NAT STAND I, 1971, SPEC PROT HEADG VEH; AYA RH, 1965, BOOK MOTORCYCLES TRA; Bennett T., 1977, NFLS OFFICIAL ENCY H NFLS OFFICIAL ENCY H; *BRIT STAND I, 1958, 18691960 BS BRIT STA; Cairns H, 1941, BRIT MED J, V1941, P465, DOI 10.1136/bmj.2.4213.465; Cantu R., 2000, NEUROLOGIC ATHLETIC; CANTU RC, 2000, NEUROLOGIC ATHLETIC, P76; CANTU RC, 2000, NEUROLOGIC ATHLETIC, P124; CLEMENT L, 1989, SAFETY HOCKEY, P164; GADD CW, 1966, P 10 STAPP CAR CRASH, P146; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1985, NEUROSURGERY, P1531; GENNARELLI TA, 1972, P 16 STAPP CAR CRASH, P146; Giza CC, 2000, NEUROLOGIC ATHLETIC, P80; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; GURDJIAN ES, 1955, SURG GYNECOL OBSTET, V101, P680; GURDJIAN ES, 1975, IMPACT HEAD INJURY, P305; HODGSON V, 1973, FINAL REPORT NATL OP; Hodgson V. R., 1972, P 16 STAPP CAR CRASH; HODGSON VR, 1975, MED SCI SPORT EXER, V7, P225; HODGSON VR, 1968, P 12 STAPP CAR CRASH, P280; HODGSON VR, 1982, ATHLETIC INJURIES HE, P27; HODGSON VR, 1985, UTILITY HEAD INJURY; HODGSON VR, 1983, P 9 C INT SOC BIOM W, P23; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; HOSHIZAKI TB, 1995, IIHF INT S MED SCI I, P90; KING AI, 1975, AIRCRAFT CRASHWORTHI, P83; KING AI, 2003, 2003 INT IRCOBI C BI; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; LOMBARD CHARLES F., 1951, JOUR AVIATION MED, V22, P109; McIntosh A, 1998, ACCIDENT ANAL PREV, V30, P161, DOI 10.1016/S0001-4575(97)00089-4; MERTZ HJ, 1982, P 9 INT TECHN C EXP; Mills NJ, 1996, INT J CRASHWORTHINES, V2, P7; Mueller FO, 1998, CLIN SPORT MED, V17, P169, DOI 10.1016/S0278-5919(05)70071-5; *NAT OP COMM STAND, 1982, STAND METH IMP TEST; Newman J, 2000, P 44 STAPP CAR CRASH; NEWMAN JA, 1993, ACCIDENTAL INJURY BI, P292; NEWMAN JA, 1999, P INT IRCOBI C BIOM; Odelgard B., 1989, SAFETY ICE HOCKEY, P220; PATRICK LM, 1970, IMPACT INJURY CRASH, P444; Pearsall DJ, 2000, AM SOC TEST MATER, V1341, P78, DOI 10.1520/STP15229S; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Roper WW, 1927, FOOTBALL TODAY TOMOR, P155; Sano K, 1972, Scand J Rehabil Med, V4, P47; SPYROU E, 2001, MAT SCI SPORTS, P199; Spyrou E, 2000, SPORTS ENG, V3, P25; SWART R, 2003, HIST BICYCLE HELMETS; THIBAULT KL, 1997, 1997 ADV BIOENGINEER, V36, P137; YOGANANDAN N, 1998, FRONTIERS HEAD NECK, P113; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	52	57	57	1	34	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2004	55	4					956	966		10.1227/01.NEU.0000137275.50246.0B			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	860AI	WOS:000224309100052	15458605				2022-02-06	
J	Signoretti, S; Marmarou, A; Tavazzi, B; Dunbar, J; Amorini, AM; Lazzarino, G; Vagnozzi, R				Signoretti, S; Marmarou, A; Tavazzi, B; Dunbar, J; Amorini, AM; Lazzarino, G; Vagnozzi, R			The protective effect of Cyclosporin A upon N-acetylaspartate and mitochondrial dysfunction following experimental diffuse traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						energetic metabolism; high-performance liquid chromatography; magnetic resonance spectroscopy; mitochondrial dysfunction; N-acetylaspartate; traumatic brain injury	MAGNETIC-RESONANCE-SPECTROSCOPY; PERMEABILITY TRANSITION PORE; EXCITATORY AMINO-ACIDS; INDUCED AXONAL INJURY; RAT-BRAIN; ACETYL-ASPARTATE; P-GLYCOPROTEIN; CELL-DEATH; NERVOUS-SYSTEM; IN-VIVO	Pre- and post-injury Cyclosporin A (CsA) administration has shown neuroprotective properties by ameliorating mitochondrial damage. The aim of this study was to assess the effect of CsA upon N-acetylaspartate (NAA) reduction and ATP loss, two sensitive markers of mitochondrial dysfunction and bioenergetic impairment. Adult male Sprague-Dawley rats were exposed to impact acceleration traumatic brain injury (2 m/450 g) and randomized into the following experimental groups: intrathecal CsA/vehicle treated (n = 12), intravenous CsA/vehicle treated (n = 18) and sham (n = 12). Intrathecal treatment consisted of post-injury (30 min) cisternal bolus of CsA or Vehicle (0.15 mL, 10 mg/kg). Intravenous administration consisted of 30 min post-injury continuous 1hour infusion of either 20 or 35 mg/kg CsA or Vehicle. Quantitative HPLC analysis of whole brain samples was performed 6 h post-injury for levels of NAA and ATP. Following intrathecal delivery CsA demonstrated significant neuroprotection blunting a 30% NAA reduction (p < 0.001) and restoring 26% of the ATP loss (p < 0.005). The 20 mg/kg intravenous dose failed to ameliorate the biochemical damages while the 35 mg/kg dosage showed 36% NAA recovery and 39% ATP restoration (P < 0.001). In conclusion, CsA is capable of restoring ATP and blunting NAA reduction. Intravenous infusion of 35 mg/kg appears to be the optimal therapeutic strategy in this model. These findings contribute to the notion that CsA achieves neuroprotection, preserving mitochondrial function, and provides a rationale for the assessment of CsA in the clinical setting where MR spectroscopy can monitor NAA and ATP in brain-injured patients.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; Univ Catania, Div Biochem Mol Biol & Pharmacol, Dept Chem Sci, I-95124 Catania, Italy; Univ Roma Tor Vergata, Dept Neurosci, I-00173 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00173 Rome, Italy		Marmarou, A (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA.	marmarou@abic.vcu.edu	TAVAZZI, BARBARA/AAB-9830-2019; Signoretti, stefano/AAL-5631-2020; lazzarino, giuseppe/K-2277-2015	TAVAZZI, BARBARA/0000-0001-8743-0895; Signoretti, stefano/0000-0002-8086-1622; AMORINI, Angela Maria/0000-0003-3525-9955; lazzarino, giuseppe/0000-0002-5917-7279	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2R01 NS 19235, P50 NS 12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019235, P50NS012587] Funding Source: NIH RePORTER		Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Bart J, 2000, CANCER TREAT REV, V26, P449, DOI 10.1053/ctrv.2000.0194; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BRENNER RE, 1993, MAGNET RESON MED, V29, P737, DOI 10.1002/mrm.1910290605; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Capano M, 2002, BIOCHEM J, V363, P29, DOI 10.1042/bj3630029; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CEFALU WT, 1985, J NEUROCHEM, V45, P1954, DOI 10.1111/j.1471-4159.1985.tb10557.x; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; Davie CA, 1997, J NEUROL NEUROSUR PS, V63, P736, DOI 10.1136/jnnp.63.6.736; de Perrot M, 2000, TRANSPLANTATION, V70, P1259, DOI 10.1097/00007890-200010270-00025; DESHPANDE JK, 1987, J CEREBR BLOOD F MET, V7, P89, DOI 10.1038/jcbfm.1987.13; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; Dohgu S, 2000, CELL MOL NEUROBIOL, V20, P781, DOI 10.1023/A:1007015228318; Dubinsky JM, 1998, J NEUROSCI RES, V53, P728, DOI 10.1002/(SICI)1097-4547(19980915)53:6<728::AID-JNR10>3.0.CO;2-U; DUX E, 1987, NEUROSCI LETT, V78, P295, DOI 10.1016/0304-3940(87)90376-4; EBISU T, 1994, J CEREBR BLOOD F MET, V14, P373, DOI 10.1038/jcbfm.1994.48; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Falini A, 1998, AM J NEURORADIOL, V19, P648; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; HEALES SJR, 1995, NEUROCHEM RES, V20, P31; Jenkins BG, 1996, J CEREBR BLOOD F MET, V16, P450, DOI 10.1097/00004647-199605000-00011; Kalra S, 1998, NEUROREPORT, V9, P1757, DOI 10.1097/00001756-199806010-00016; Khodorov B, 1996, FEBS LETT, V393, P135, DOI 10.1016/0014-5793(96)00873-3; Kochi S, 2000, LIFE SCI, V66, P2255, DOI 10.1016/S0024-3205(00)00554-3; Kristal BS, 2000, DEV NEUROSCI-BASEL, V22, P376, DOI 10.1159/000017463; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; LAZZARINO G, 1991, ANAL BIOCHEM, V197, P191, DOI 10.1016/0003-2697(91)90378-7; Lemaire M, 1996, CANCER CHEMOTH PHARM, V38, P481, DOI 10.1007/s002800050515; Li PA, 2000, EXP NEUROL, V165, P153, DOI 10.1006/exnr.2000.7459; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Maxwell WL, 1997, J NEUROTRAUM, V14, P755; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MEIJER AJ, 1974, BIOCHIM BIOPHYS ACTA, V346, P213, DOI 10.1016/0304-4173(74)90001-9; MIYAMOTO S, 1998, J ARTIF ORGANS, V1, P10; MOFFETT JR, 1993, J HISTOCHEM CYTOCHEM, V41, P559, DOI 10.1177/41.4.8450195; MOFFETT JR, 1991, NEUROREPORT, V2, P131, DOI 10.1097/00001756-199103000-00005; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PATEL TB, 1979, BIOCHEM J, V184, P539, DOI 10.1042/bj1840539; Patt S, 1999, EXP TOXICOL PATHOL, V51, P119, DOI 10.1016/S0940-2993(99)80084-0; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Regina A, 1999, J NEUROCHEM, V73, P1954; Reynolds IJ, 1999, ANN NY ACAD SCI, V893, P33, DOI 10.1111/j.1749-6632.1999.tb07816.x; Rooney WD, 1998, NEUROLOGY, V50, P1800, DOI 10.1212/WNL.50.6.1800; Sager TN, 1999, J CEREBR BLOOD F MET, V19, P164, DOI 10.1097/00004647-199902000-00008; SAGER TN, 1995, J CEREBR BLOOD F MET, V15, P639, DOI 10.1038/jcbfm.1995.79; SAKATA A, 1994, BIOCHEM PHARMACOL, V48, P1989, DOI 10.1016/0006-2952(94)90601-7; SARAGEA M, 1965, MED PHARMACOL EXP, V13, P74; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schinder AF, 1996, J NEUROSCI, V16, P6125; SCIAMANNA MA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P223, DOI 10.1016/0167-4889(92)90180-J; SHIINO A, 1993, SURG NEUROL, V39, P143, DOI 10.1016/0090-3019(93)90093-G; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; SIMMONS ML, 1991, NEUROSCIENCE, V45, P37, DOI 10.1016/0306-4522(91)90101-S; SIMS NR, 1987, J NEUROCHEM, V49, P1367, DOI 10.1111/j.1471-4159.1987.tb01001.x; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; SZABO I, 1991, J BIOL CHEM, V266, P3376; Tasch E, 1999, ANN NEUROL, V45, P568, DOI 10.1002/1531-8249(199905)45:5<568::AID-ANA4>3.0.CO;2-P; Tavazzi B, 2000, ANAL BIOCHEM, V277, P104, DOI 10.1006/abio.1999.4386; TRUCKENMILLER ME, 1985, J NEUROCHEM, V45, P1658, DOI 10.1111/j.1471-4159.1985.tb07240.x; TSUJI A, 1993, BIOCHEM PHARMACOL, V46, P1096, DOI 10.1016/0006-2952(93)90677-O; Tymianski Michael, 1996, Neurosurgery (Baltimore), V38, P1176, DOI 10.1097/00006123-199606000-00028; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Warren KE, 2000, CANCER CHEMOTH PHARM, V45, P207, DOI 10.1007/s002800050031; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yamamoto T, 1999, ACT NEUR S, V75, P17; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Zaidan E, 1999, J NEUROCHEM, V73, P2214; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	95	57	59	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2004	21	9					1154	1167		10.1089/neu.2004.21.1154			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	855HC	WOS:000223962900005	15453986				2022-02-06	
J	Powell, MR; Gfeller, JD; Hendricks, BL; Sharland, M				Powell, MR; Gfeller, JD; Hendricks, BL; Sharland, M			Detecting symptom- and test-coached simulators with the Test of Memory Malingering	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	22nd Annual Meeting of the National-Academy-of-Neuropsychology	OCT   10, 2002	MIAMI, FL	Natl Acad Neuropsychol		symptom validity; effortful; malingering; coaching; assessment; forensics	FEIGNED COGNITIVE IMPAIRMENT; HEAD-INJURY; INCENTIVES; TOMM	The ability of the Test of Memory Malingering (TOMM; Tombaugh, 1996) to detect feigned-memory impairment was explored. The TOMM was administered to three groups: (a) a control group instructed to perform optimally, (b) a symptom-coached group instructed to feign memory problems after being educated about traumatic brain injury symptomatology, and (c) a test-coached group instructed to feign memory problems after being educated about test-taking strategies to avoid detection. The recommended cutoff scores (Tombaugh, 1996) on Trial 2 and the Retention Trial produced overall classification accuracy rates of 96%, with high levels of sensitivity and specificity. Although the symptom-coached group performed more poorly on the TOMM relative to the test-coached group, the test was equally sensitive in detecting suboptimal effort across the different coaching paradigms. (C) 2004 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Mayo Clin & Mayo Fdn, Dept Psychiat & Psychol W 11 B, Rochester, MN 55905 USA; St Louis Univ, St Louis, MO 63103 USA; Univ Wisconsin Marathon Cty, Wausau, WI USA		Powell, MR (corresponding author), Mayo Clin & Mayo Fdn, Dept Psychiat & Psychol W 11 B, 200 1st St SW, Rochester, MN 55905 USA.	powell.matthew@mayo.edu					BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; DiCarlo MA, 2000, ARCH CLIN NEUROPSYCH, V15, P399, DOI 10.1016/S0887-6177(99)00031-1; Faust D, 1998, CRIT ISS NE, P1; FELDSTEIN S, 2000, AM J FORESNIC PSYCHO, V18, P57; Frederick R. I., 1991, PSYCHOL ASSESSMENT J, V3, P596, DOI DOI 10.1037/1040-3590.3.4.596; Gervais RO, 2001, J RHEUMATOL, V28, P1892; GERVAIS RO, 2001, J FORENSIC NEUROPSYC, V2, DOI DOI 10.1300/J151V02N02_01; Gfeller JD, 2001, ARCH CLIN NEUROPSYCH, V16, P848; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Haines ME, 2001, CLIN NEUROPSYCHOL, V15, P171, DOI 10.1076/clin.15.2.171.1891; Langeluddecke PM, 2003, ARCH CLIN NEUROPSYCH, V18, P181, DOI 10.1016/S0887-6177(01)00195-0; LeesHaley PR, 1997, ASSESSMENT, V4, P321, DOI 10.1177/107319119700400402; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Rey A., 1964, EXAMEN CLIN PSYCHOL; REYNOLD CR, 1998, DETECTION MALINGERIN; Rohling ML, 2002, ARCH CLIN NEUROPSYCH, V17, P205, DOI 10.1016/S0887-6177(01)00109-3; Rose FE, 1998, ARCH CLIN NEUROPSYCH, V13, P349, DOI 10.1016/S0887-6177(97)00025-5; Smith G.E., 2003, CLIN INTERPRETATION, P273; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Spreen O., 1989, CLIN NEUROPSYCHOL, V3, P129, DOI [10.1080/13854048908403285, DOI 10.1080/13854048908403285]; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Williams JM, 1998, CRIT ISS NE, P105; Wolfson, 1992, HALSTEAD REITAN NEUR; Youngjohn, 1995, ASSESSMENT, V2, DOI [https://doi.org/10.1177/1073191195002003007, DOI 10.1177/1073191195002003007]	30	57	58	0	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2004	19	5					693	702		10.1016/j.acn.2004.04.001			10	Psychology, Clinical; Psychology	Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	845PT	WOS:000223257500007	15271412	Bronze			2022-02-06	
J	Kennepohl, S; Shore, D; Nabors, N; Hanks, R				Kennepohl, S; Shore, D; Nabors, N; Hanks, R			African American acculturation and neuropsychological test performance following traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article; Proceedings Paper	111th Annual Convention of the American-Psychological-Association	AUG 07-10, 2003	Toronto, CANADA	Amer Psychol Assoc		culture; neuropsychology; acculturation; assessment	COGNITIVE-ABILITY; SPANISH-SPEAKING; ENGLISH-SPEAKING; RACE; ETHNICITY; EDUCATION	The present study examined the influence of African American acculturation on the performance of neuropsychological tests following traumatic brain injury (TBI). Seventy one participants already enrolled in a larger-scale study assessing the impact of TBI (i.e., the South Eastern Michigan Traumatic Brain Injury Model Systems project) completed a self-report measure of African American acculturation (African American Acculturation Scale-Short Form; Landrine & Klonoff, 1995) in addition to a standardized battery of neuropsychological tests. Hierarchical regression analyses were conducted to evaluate the relationship between level of acculturation and test performance after controlling for injury-related (initial Glasgow Coma Scale score, time since injury) and demographic variables (age, sex, years of education, and socioeconomic status). Lower levels of acculturation were associated with significantly poorer performances on the Galveston Orientation & Amnesia Test, MAE Tokens test, WAIS-R Block Design, Rey Auditory Verbal Learning Test, and Symbol Digit Modalities Test. Decreased levels of acculturation were also significantly related to lower scores on a composite indicator of overall neuropsychological test performance. In addition, the examiner's ethnicity (Black or White) was related with scores on a few of the tests (i.e., Block Design, Trail Making Test), but was not significantly associated with the overall neuropsychological test performance. Overall, these findings suggest that differences in cultural experience may be an important factor in the neuropsychological assessment of African Americans following TBI, and provide additional support for the hypothesis that cultural factors may partially account for the differences among ethnic/cultural groups on neuropsychological tests.	Hotel Dieu CHUM, Psychol Serv, Montreal, PQ H2W 1T8, Canada; Univ Windsor, Dept Psychol, Windsor, ON N9B 3P4, Canada; Eastern Michigan Univ, Dept Psychol, Ypsilanti, MI 48197 USA; Rehabil Inst Michigan, Detroit, MI USA; Wayne State Univ, Detroit, MI USA		Kennepohl, S (corresponding author), Hotel Dieu CHUM, Psychol Serv, 3840 Rue St Urbain, Montreal, PQ H2W 1T8, Canada.	stephan.kennepohl.chum@ssss.gouv.qc.ca					Arnold B. R., 1994, ASSESSMENT, V1, P239, DOI DOI 10.1177/107319119400100303; BENTON AL, 1994, MULTILINGUAL APHASI; BENTON AL, 1983, CONTRIBUTIONS NEURO; Berry J W, 1989, Nebr Symp Motiv, V37, P201; BETANCOURT H, 1993, AM PSYCHOL, V48, P629, DOI 10.1037/0003-066X.48.6.629; Bowman ML, 1996, CLIN NEUROPSYCHOL, V10, P382, DOI 10.1080/13854049608406699; Cuellar I., 1980, HISPANIC J BEHAV SCI, V2, P199; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DEVIVO MJ, 1992, ARCH PHYS MED REHAB, V73, P424; Flynn JR, 1999, AM PSYCHOL, V54, P5, DOI 10.1037/0003-066X.54.1.5; GILES WH, 1995, ARCH INTERN MED, V155, P1319, DOI 10.1001/archinte.155.12.1319; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heaton RK, 1991, COMPREHENSIVE NORMS; Heaton RK, 1996, NEUROPSYCHOLOGICAL A, P141; HELMS JE, 1992, AM PSYCHOL, V47, P1083, DOI 10.1037/0003-066X.47.9.1083; Helms JE, 1997, CONT INTELLECTUAL AS, P517; Hollingshead A. B., 1957, 2 FACTOR INDEX SOCIA; Jacobs DM, 1997, J CLIN EXP NEUROPSYC, V19, P331, DOI 10.1080/01688639708403862; Johnson-Selfridge MT, 1998, ARCH CLIN NEUROPSYCH, V13, P319, DOI 10.1016/S0887-6177(97)00003-6; KAUFMAN AS, 1988, J CLIN PSYCHOL, V44, P231, DOI 10.1002/1097-4679(198803)44:2<231::AID-JCLP2270440224>3.0.CO;2-J; Kennepohl S, 1999, BRAIN COGNITION, V41, P365, DOI 10.1006/brcg.1999.1138; Kraus P, 1999, J HIGH ENERGY PHYS; LANDRINE H, 1996, AFRICAN AM ACCULTURA; LANDRINE H, 1994, J BLACK PSYCHOL, V20, P104, DOI DOI 10.1177/00957984940202002; Landrine Hope, 1995, J BLACK PSYCHOL, V21, P124, DOI DOI 10.1177/00957984950212003; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LOEWENSTEIN DA, 1995, ARCH CLIN NEUROPSYCH, V10, P75, DOI 10.1016/0887-6177(93)E0005-V; LOEWENSTEIN DA, 1993, J GERONTOL, V48, P389; MAJ M, 1993, ARCH CLIN NEUROPSYCH, V8, P123, DOI 10.1016/0887-6177(93)90030-5; MANLY J, 2000, J INT NEUROPSYCH SOC, V6, P245; Manly JJ, 1998, J INT NEUROPSYCH SOC, V4, P291, DOI 10.1017/S1355617798002914; Manly JJ, 1998, NEUROLOGY, V50, P1238, DOI 10.1212/WNL.50.5.1238; Manly JJ, 2002, STUD NEUROPSYCHOL DE, P79; MARCOPOULOS BA, 1997, J CLIN EXPT NEUROPSY, P112; MILLER EN, 1993, J CLIN EXP NEUROPSYC, V15, P66; Miller LS, 2001, NEUROPSYCHOL REV, V11, P143, DOI 10.1023/A:1016602708066; Myerson J, 1998, PSYCHOL SCI, V9, P139, DOI 10.1111/1467-9280.00026; Nabors NA, 2000, CRIT ISS NE, P31; Neisser U, 1996, AM PSYCHOL, V51, P77, DOI 10.1037/0003-066X.51.2.77; Nobles W. W., 1972, BLACK PSYCHOL, P18; REITAN RM, 1995, CLIN NEUROPSYCHOL, V9, P151, DOI 10.1080/13854049508401597; REYNOLDS CR, 1987, J SCHOOL PSYCHOL, V25, P323, DOI 10.1016/0022-4405(87)90035-5; Reynolds CR, 2000, CRIT ISS NE, P249; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; Smith A., 1991, SYMBOL DIGIT MODALIT; Spreen O, 1998, COMPENDIUM NEUROPSY; Steele CM, 1997, AM PSYCHOL, V52, P613, DOI 10.1037/0003-066X.52.6.613; Tabachnick B. G., 1989, USING MULTIVARIATE S; TEASDALE G, 1974, LANCET, V2, P81; TERRELL F, 1981, J CONSULT CLIN PSYCH, V49, P750, DOI 10.1037/0022-006X.49.5.750; Veiel HOF, 1997, J CLIN EXP NEUROPSYC, V19, P587, DOI 10.1080/01688639708403745; VINCENT KR, 1991, J CLIN PSYCHOL, V47, P266, DOI 10.1002/1097-4679(199103)47:2<266::AID-JCLP2270470213>3.0.CO;2-S; Wechsler D, 1987, MEMORY SCALE REVISED; Welsh KA, 1995, NEUROLOGY, V45, P2207, DOI 10.1212/WNL.45.12.2207; Willis M.G., 1989, J BLACK PSYCHOL, V16, P47, DOI 10.1177/009579848901600105; Wong TM, 2000, CRIT ISS NE, P3; [No title captured]; [No title captured]	59	57	57	0	5	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2004	10	4					566	577		10.1017/S1355617704104128			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Psychiatry; Psychology	833VA	WOS:000222367200010	15327735				2022-02-06	
J	Wisniewski, JF; Guskiewicz, K; Trope, M; Sigurdsson, A				Wisniewski, JF; Guskiewicz, K; Trope, M; Sigurdsson, A			Incidence of cerebral concussions associated with type of mouthguard used in college football	DENTAL TRAUMATOLOGY			English	Article						cerebral; brain concussions; concussions; college football; American football; football		Controversy exists among sports dentists as to whether or not a 'custom made' mouthguard is more effective in reducing the incidence of cerebral concussion than the boil-and-bite 'non-custom made' mouthguard. While members on each side remain steadfast in their opinion, not a single epidemiological study has been conducted to investigate the effect of type of mouthguard worn on the incidence of cerebral concussion. The aim of this study was to determine if there was a difference between the type of mouthguard worn and the incidence of cerebral concussions among National Collegiate Athletic Association (NCAA) Division I-A football players. During the 15-week 2001 college football season, trainers entered, via an interactive web site, weekly data for each game and practice sessions for the preceding week. Eighty-seven (76%) out of a possible 114 Division I teams participated. A total of 506 297 athletic exposures were recorded; 369 brain concussions were reported. The incidence of cerebral concussions per 1000 exposures was 0.73. Utilizing a risk ratio with a 95% confidence interval, no statistical difference occurred in the incidence of cerebral concussions between football players wearing custom made versus non-custom made mouthguards (0.990,1.750). In this study, there was no advantage of wearing a custom made mouthguard over a boil-and-bite mouthguard to reduce the risk of cerebral concussion in football players.	Univ N Carolina, Sch Dent, Dept Endodont, Chapel Hill, NC 27599 USA; Dent Hlth Associates, Cary, NC USA; Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA		Trope, M (corresponding author), Univ N Carolina, Sch Dent, Dept Endodont, Chapel Hill, NC 27599 USA.	martin_trope@dentistry.unc.edu	Sigurdsson, Asgeir/ABA-8829-2021	Guskiewicz, Kevin/0000-0002-8682-2130			Blignaut J B, 1987, Br J Sports Med, V21, P5; Booher MA, 2003, CLIN J SPORT MED, V13, P93, DOI 10.1097/00042752-200303000-00005; FINKBEINER BL, 1995, COMPREHENSIVE DENT A, P1035; Guskiewicz KM, 2001, ATHLET THER TODAY, V6, P18, DOI 10.1123/att.6.1.18; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HICKEY JC, 1967, J AM DENT ASSOC, V74, P735, DOI 10.14219/jada.archive.1967.0145; Kerr L, 1983, Clin Sports Med, V2, P115; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; PADILLA R, 1996, J CALIF DENT ASSOC, V24, P346; STENGER JM, 1964, J AM DENT ASSOC, V69, P273, DOI 10.14219/jada.archive.1964.0290; Sturmi JE, 1998, SPORTS MED, V25, P351, DOI 10.2165/00007256-199825060-00001; WINTERS JE, 2002, J ATHL TRAINING, V36, P339; WOODMANSEY KF, 1999, GEN DENT, V1, P64	13	57	59	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-4469	1600-9657		DENT TRAUMATOL	Dent. Traumatol.	JUN	2004	20	3					143	149		10.1111/j.1600-4469.2004.00259.x			7	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine	821CF	WOS:000221436600004	15144445				2022-02-06	
J	Petzold, A; Keir, G; Green, AJE; Giovannoni, G; Thompson, EJ				Petzold, A; Keir, G; Green, AJE; Giovannoni, G; Thompson, EJ			An ELISA for glial fibrillary acidic protein	JOURNAL OF IMMUNOLOGICAL METHODS			English	Article						Alzheimer's disease; CSF; ELISA GFAP; GFAP(SM126); normal pressure hydrocephalus; subarachnoid hemorrhage; traumatic brain injury	CEREBROSPINAL-FLUID; MONOCLONAL-ANTIBODIES; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; SENSITIVE ELISA; S-100 PROTEIN; GFAP; CSF; PRESSURE; CHILDREN	Glial fibrillary acidic protein (GFAP) is the major intermediate filament protein of the astrocyte, and body fluid levels of GFAP are an important tool for estimating astrogliosis and astrocytic activation in vivo. This paper presents a new sandwich ELISA allowing quantification of GFAP(SM126) from the cerebrospinal fluid (CSF). The sensitivity of the GFAP(SM126) ELISA is 5 pg/ml with a recovery of 94% and a mean within- and between-batch precision of 6% and 10%, respectively. The upper reference value for CSF GFAP(SM126) levels (9 pg/ml) was defined as the 95% cumulative frequency from 315 CSF samples. Based on this cut-off, a significantly higher proportion of patients with subarachnoid hemorrhage (100%), traumatic brain injury (100%), dementia (76%) and normal pressure hydrocephalus (85%) had pathologically elevated CSF GFAP(SM126) levels compared to patients with peripheral nervous system disorders (0%). In a critical review of the literature, we compare the analytical and clinical sensitivity of previous GFAP ELISA methods with particular reference to patients with dementia. (C) 2004 Elsevier B.V. All rights reserved.	UCL, Neurol Inst, Dept Neuroimmunol, London WC1N 3BG, England		Petzold, A (corresponding author), UCL, Neurol Inst, Dept Neuroimmunol, Queen Sq, London WC1N 3BG, England.	a.petzold@ion.ucl.ac.uk	Green, Alison/O-7356-2019; Petzold, Axel/C-1090-2009	Petzold, Axel/0000-0002-0344-9749			AHLSEN G, 1993, BIOL PSYCHIAT, V33, P734, DOI 10.1016/0006-3223(93)90124-V; ALBRECHTSEN M, 1984, PRENATAL DIAG, V4, P405, DOI 10.1002/pd.1970040603; ALBRECHTSEN M, 1984, J NEUROCHEM, V42, P86, DOI 10.1111/j.1471-4159.1984.tb09702.x; ALBRECHTSEN M, 1985, J NEUROIMMUNOL, V8, P301, DOI 10.1016/S0165-5728(85)80069-2; ALBRECHTSEN M, 1985, J NEUROL SCI, V70, P269, DOI 10.1016/0022-510X(85)90168-6; Cody R P, 1997, APPL STAT SAS PROGRA; CROLS R, 1986, J NEUROL, V233, P157, DOI 10.1007/BF00314423; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; EHLERS S, 1994, NEUROPEDIATRICS, V25, P129, DOI 10.1055/s-2008-1071599; ENG LF, 1976, ANAL BIOCHEM, V71, P243, DOI 10.1016/0003-2697(76)90033-6; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; ENG LF, 1970, T AM SOC NEUROCHEM, V1, P42; Fukuyama R, 2001, EUR NEUROL, V46, P35, DOI 10.1159/000050753; HIDAKA H, 1983, J BIOL CHEM, V258, P2705; Jackson RGM, 2001, BRIT J ANAESTH, V86, P601; MCLENDON RE, 1986, J NEUROPATH EXP NEUR, V45, P692, DOI 10.1097/00005072-198611000-00007; MICHETTI F, 1985, CELL TISSUE RES, V240, P137; Missler U, 1999, CLIN CHEM, V45, P138; NOPPE M, 1979, J IMMUNOL METHODS, V27, P75, DOI 10.1016/0022-1759(79)90240-0; PEGRAM CN, 1985, NEUROCHEM PATHOL, V3, P119; Petzold A, 2003, J IMMUNOL METHODS, V278, P179, DOI 10.1016/S0022-1759(03)00189-3; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Petzold A, 2002, BRAIN, V125, P1462, DOI 10.1093/brain/awf165; PETZOLD A, 2000, REV NEUROL PARIS, V156, pS140; REEVES SA, 1989, P NATL ACAD SCI USA, V86, P5178, DOI 10.1073/pnas.86.13.5178; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; ROSENGREN LE, 1995, J NEUROL SCI, V133, P61, DOI 10.1016/0022-510X(95)00152-R; ROSENGREN LE, 1985, SCAND J WORK ENV HEA, V11, P447, DOI 10.5271/sjweh.2201; ROSENGREN LE, 1992, J NEUROSCI METH, V44, P113, DOI 10.1016/0165-0270(92)90004-W; TAKAHASHI K, 1984, VIRCHOWS ARCH B, V45, P385, DOI 10.1007/BF02889881; Tullberg M, 1998, NEUROLOGY, V50, P1122, DOI 10.1212/WNL.50.4.1122; van Geel WJA, 2002, CLIN CHIM ACTA, V326, P151, DOI 10.1016/S0009-8981(02)00330-3; VICK WW, 1987, ACTA CYTOL, V31, P815; Wallin A, 1996, DEMENTIA, V7, P267, DOI 10.1159/000106891	35	57	61	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0022-1759	1872-7905		J IMMUNOL METHODS	J. Immunol. Methods	APR	2004	287	1-2					169	177		10.1016/j.jim.2004.01.015			9	Biochemical Research Methods; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Immunology	816ZW	WOS:000221148800015	15099765				2022-02-06	
J	Wilde, EA; Bigler, ED; Gandhi, PV; Lowry, CM; Blatter, DD; Brooks, J; Ryser, DK				Wilde, EA; Bigler, ED; Gandhi, PV; Lowry, CM; Blatter, DD; Brooks, J; Ryser, DK			Alcohol abuse and traumatic brain injury: Quantitative magnetic resonance imaging and neuropsychological outcome	JOURNAL OF NEUROTRAUMA			English	Article						alcohol; magnetic resonance imaging; neuropsychological outcome; substance abuse; traumatic brain injury	CEREBRAL BLOOD-FLOW; ACUTE ETHANOL INTOXICATION; POSITRON-EMISSION-TOMOGRAPHY; CENTRAL-NERVOUS-SYSTEM; COGNITIVE DEFICITS; HEAD-INJURY; DETOXIFIED ALCOHOLICS; ABSTINENT ALCOHOLICS; GLUCOSE-METABOLISM; HEMORRHAGIC-SHOCK	Prior or concurrent alcohol use at the time of traumatic brain injury (TBI) was examined in terms of post-injury atrophic changes measured by quantitative analysis of magnetic resonance imaging (MRI) and neuropsychological outcome. Two groups of TBI subjects were examined: those with a clinically significant blood alcohol level (BAL) present at the time of injury (TBI+BAL) and those without a significant BAL (TBI-only). To explore the potential impact of both acute and chronic alcohol use, subjects in both groups were further clustered into one of four subgroups (NONE, MILD, MODERATE or HEAVY) based upon available information regarding their pre-injury alcohol use. One-way analysis of covariance (ANCOVA) and multiple analysis of covariance (MANCOVA) were used with subject grouping as the main factor. Age, injury severity as measured by Glasgow Coma Scale (GCS) score, years of education, total intracranial volume (TICV), and the number of days post-injury were included as covariates where appropriate. Increased general atrophy was observed in patients with (a) a positive BAL and/or (b) a history of moderate to heavy pre-injury alcohol use. In addition, performance on neuropsychological outcome variables (WAIS-R and WMS-R Index scores) was generally worse in the subgroups of patients with positive BAL and a history of pre-injury alcohol use, as compared to the other TBI groups though not statistically significant. Implications of alcohol use, at the time of brain injury, are discussed.	Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; LDS Hosp, Salt Lake City, UT USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Brigham Young Univ, Dept Psychol, Rexburg, ID USA; Univ Utah, Dept Radiol, Salt Lake City, UT 84132 USA; Univ Utah, Dept Psychiat, Salt Lake City, UT 84132 USA		Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 SWKT, Provo, UT 84602 USA.	erin_bigler@byu.edu					AASLY J, 1993, ACTA NEUROL SCAND, V87, P210; ADAMS KM, 1993, ALCOHOL CLIN EXP RES, V17, P205, DOI 10.1111/j.1530-0277.1993.tb00750.x; ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; *AM PSYCH ASS, 1994, DSM4 DIAGN STAT MAN; BADSBERGJENSEN G, 1990, HISTOL HISTOPATHOL, V5, P349; Baguley IJ, 1997, ARCH PHYS MED REHAB, V78, P1248, DOI 10.1016/S0003-9993(97)90339-7; Barker LH, 1999, J INT NEUROPSYCH SOC, V5, P593, DOI 10.1017/S1355617799577023; Beresford T, 1999, J STUD ALCOHOL, V60, P586, DOI 10.15288/jsa.1999.60.586; BERGLUND M, 1987, ACTA PSYCHIAT SCAND, V75, P202, DOI 10.1111/j.1600-0447.1987.tb02775.x; Bigler E D, 1989, J Neuropsychiatry Clin Neurosci, V1, P341; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Brown SA, 2000, ALCOHOL CLIN EXP RES, V24, P164, DOI 10.1111/j.1530-0277.2000.tb04586.x; BULLOCK R, 1990, ALCOHOL CLIN EXP RES, V24, P164; CASPARI D, 1993, ACTA PSYCHIAT SCAND, V87, P414, DOI 10.1111/j.1600-0447.1993.tb03397.x; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DALLY S, 1988, BRIT J ADDICT, V83, P105; De Bellis MD, 2000, AM J PSYCHIAT, V157, P737, DOI 10.1176/appi.ajp.157.5.737; DEWIT H, 1990, ALCOHOL CLIN EXP RES, V14, P482; DISCLAFANI V, 1995, ALCOHOL CLIN EXP RES, V19, P1121; Dupont RM, 1996, PSYCHIAT RES-NEUROIM, V67, P99, DOI 10.1016/0925-4927(96)02769-2; ELMER O, 1984, HAEMOSTASIS, V14, P223; Emsley R, 1996, ALCOHOL ALCOHOLISM, V31, P479; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FULLER MG, 1994, J NEUROPSYCH CLIN N, V6, P143; Gilman S, 1996, ALCOHOL CLIN EXP RES, V20, P1456, DOI 10.1111/j.1530-0277.1996.tb01149.x; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HATA T, 1987, J CEREBR BLOOD F MET, V7, P35, DOI 10.1038/jcbfm.1987.6; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; KELLY DF, 1995, CRIT CARE MED, V23, pA245; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Mann K, 1999, ALCOHOL ALCOHOLISM, V34, P567, DOI 10.1093/alcalc/34.4.567; MANN K, 1995, J NEURAL TRANSM-GEN, V99, P145, DOI 10.1007/BF01271475; Masse J, 2000, J NEUROTRAUM, V17, P421, DOI 10.1089/neu.2000.17.421; McCann UD, 1997, NEUROSCIENTIST, V3, P399, DOI 10.1177/107385849700300613; McQueen J D, 1975, Surg Neurol, V4, P375; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; Netrakom P, 1999, PSYCHIAT CLIN N AM, V22, P313, DOI 10.1016/S0193-953X(05)70079-4; Nicolas JM, 1997, ANN NEUROL, V41, P590, DOI 10.1002/ana.410410507; Nutt D, 1999, BRIT J PSYCHIAT, V175, P114, DOI 10.1192/bjp.175.2.114; PARSONS OA, 1993, NEUROL CLIN, V11, P205, DOI 10.1016/S0733-8619(18)30178-6; PARSONS OA, 1986, ALCOHOL ALCOHOLISM, V21, P137; Parsons OA, 1998, J STUD ALCOHOL, V59, P180, DOI 10.15288/jsa.1998.59.180; PERSSON L, 1977, ACTA NEUROL SCAND, V56, P7; PERSSON LI, 1978, ACTA NEUROL SCAND, V57, P405; Pfefferbaum A, 1998, ARCH GEN PSYCHIAT, V55, P905, DOI 10.1001/archpsyc.55.10.905; Ridderinkhof KR, 2002, SCIENCE, V298, P2209, DOI 10.1126/science.1076929; RIDKER PM, 1994, JAMA-J AM MED ASSOC, V272, P929, DOI 10.1001/jama.272.12.929; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Robb RA, 2001, IEEE T MED IMAGING, V20, P854, DOI 10.1109/42.952724; ROBB RA, 1995, 3 DIMENSIONAL BIOMED; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; Sabhesan S, 1988, Indian J Psychiatry, V30, P345; Sall JM, 1996, EXP NEUROL, V139, P257, DOI 10.1006/exnr.1996.0099; SCHWARTZ JA, 1993, ALCOHOL CLIN EXP RES, V17, P1119, DOI 10.1111/j.1530-0277.1993.tb05217.x; Selby MJ, 1998, DRUG ALCOHOL DEPEN, V50, P39, DOI 10.1016/S0376-8716(98)00002-7; SHEAR PK, 1992, ALCOHOL, V9, P247, DOI 10.1016/0741-8329(92)90061-E; Shear PK, 1996, ALCOHOL CLIN EXP RES, V20, P1489, DOI 10.1111/j.1530-0277.1996.tb01153.x; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Tate PS, 1999, BRAIN INJURY, V13, P767; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; TEASDALE G, 1974, LANCET, V2, P81; VOLKOW ND, 1990, PSYCHIAT RES-NEUROIM, V35, P39, DOI 10.1016/S0165-1781(06)80006-5; VOLKOW ND, 1994, AM J PSYCHIAT, V151, P178; WANG GJ, 1993, RADIOLOGY, V186, P59, DOI 10.1148/radiology.186.1.8416587; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; White AM, 2000, HIPPOCAMPUS, V10, P88, DOI 10.1002/(SICI)1098-1063(2000)10:1<88::AID-HIPO10>3.0.CO;2-L; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P205, DOI 10.1111/j.1530-0277.1990.tb00473.x; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; Zink BJ, 1999, BRAIN RES, V837, P1, DOI 10.1016/S0006-8993(99)01646-7; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983; ZINK BJ, 1993, J NEUROTRAUM, P3; [No title captured], DOI DOI 10.1037/0894-4105.7.3.296	82	57	57	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2004	21	2					137	147		10.1089/089771504322778604			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	774WB	WOS:000189008200002	15000755				2022-02-06	
J	Lee, Y; Aono, M; Laskowitz, D; Warner, DS; Pearlstein, RD				Lee, Y; Aono, M; Laskowitz, D; Warner, DS; Pearlstein, RD			Apolipoprotein E protects against oxidative stress in mixed neuronal-glial cell cultures by reducing glutamate toxicity	NEUROCHEMISTRY INTERNATIONAL			English	Article						apolipoprotein E; neuronal-glial cell culture; lactate dehydrogenase	E-DEFICIENT MICE; CENTRAL-NERVOUS-SYSTEM; DENSITY-LIPOPROTEIN RECEPTOR; AMYLOID PRECURSOR PROTEIN; CLOSED-HEAD INJURY; E MESSENGER-RNA; ALZHEIMERS-DISEASE; LIPID-PEROXIDATION; CEREBRAL-ISCHEMIA; E IMMUNOREACTIVITY	Apolipoprotein E (ApoE) deficiency has been shown to adversely affect outcome after transient cerebral ischemia and head trauma. Since oxidative stress contributes to these injuries, the ability of ApoE to reduce irreversible oxidative damage was studied in primary mixed neuronal-glial cell cultures. Cells (13-16 days in vitro) were exposed to 50 muM hydrogen peroxide (H2O2) for 30 min, and toxicity was determined by the release of lactate dehydrogenase (LDH) 24 h after exposure. The presence of recombinant human ApoE2 (100, 300, or 1000 nM) in the culture media partially protected against oxidative injury. This protection was not reversed by pre-treatment with receptor associated protein. The NMDA receptor antagonist, MK-801, also provided partial protection against H2O2 toxicity. The degree of protection was similar to that conferred by ApoE treatment. The protective effects of ApoE and MK-801 were not additive; no ApoE protection was observed in cultures treated with MK-801 prior to H2O2 exposure. ApoE treatment had no effect on H2O2 stimulated glutamate release, but did increase the rate of glutamate uptake via the high affinity glutamate transporter in H2O2 treated cultures. Pre-treatment with ApoE also conferred partial protection against glutamate-induced LDH release. Taken together, these findings suggest that ApoE protects mixed neuronal-glial cell cultures against irreversible oxidative injury from H2O2 by reducing secondary glutamate excitotoxicity. (C) 2003 Elsevier Science Ltd. All rights reserved.	Duke Univ, Med Ctr, Dept Surg, Multidisciplinary Neuroprotect Labs, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Multidisciplinary Neuroprotect Labs, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Multidisciplinary Neuroprotect Labs, Durham, NC 27710 USA		Pearlstein, RD (corresponding author), Duke Univ, Med Ctr, Dept Surg, Multidisciplinary Neuroprotect Labs, Durham, NC 27710 USA.				NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01 HL4244-12] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS01949] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001949] Funding Source: NIH RePORTER		AAMAR S, 1992, J NEUROCHEM, V59, P1287, DOI 10.1111/j.1471-4159.1992.tb08439.x; ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Ali SM, 1996, MOL BRAIN RES, V38, P37, DOI 10.1016/0169-328X(95)00301-8; AMADOR E, 1963, CLIN CHEM, V9, P391; Amaratunga A, 1996, J BIOL CHEM, V271, P5628, DOI 10.1074/jbc.271.10.5628; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Beffert U, 1998, BRAIN RES REV, V27, P119, DOI 10.1016/S0165-0173(98)00008-3; Bellomo G, 1987, Mol Toxicol, V1, P281; BOYLES JK, 1990, J BIOL CHEM, V265, P17805; CARLSSON J, 1991, CLIN CHIM ACTA, V196, P167, DOI 10.1016/0009-8981(91)90070-S; Chapman S, 1998, J NEUROCHEM, V70, P708; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Fitzpatrick MO, 1998, BRIT J NEUROSURG, V12, P313; Gordon I, 1996, NEUROSCI LETT, V206, P212, DOI 10.1016/S0304-3940(96)12470-8; Gordon I, 1996, MOL CHEM NEUROPATHOL, V28, P97, DOI 10.1007/BF02815210; Gutman CR, 1997, J NEUROSCI, V17, P6114; HALL ED, 1995, EXP NEUROL, V135, P17, DOI 10.1006/exnr.1995.1062; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HAYEK T, 1994, BIOCHEM BIOPH RES CO, V201, P1567, DOI 10.1006/bbrc.1994.1883; HINSHAW DB, 1993, BRAIN RES, V615, P13, DOI 10.1016/0006-8993(93)91110-E; Horsburgh K, 1997, BRAIN RES, V763, P103, DOI 10.1016/S0006-8993(97)00411-3; Horsburgh K, 1999, J NEUROPATH EXP NEUR, V58, P227, DOI 10.1097/00005072-199903000-00002; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Horsburgh K, 1999, NEUROREPORT, V10, P837, DOI 10.1097/00001756-199903170-00031; Hu JR, 1998, J NEUROCHEM, V71, P1626; Igbavboa U, 1997, J NEUROCHEM, V69, P1661; Iwata E, 1997, MOL BRAIN RES, V50, P213, DOI 10.1016/S0169-328X(97)00190-3; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KIDA E, 1995, BRAIN RES, V674, P341, DOI 10.1016/0006-8993(94)01467-V; Kleifeld O, 1998, INT J DEV NEUROSCI, V16, P755, DOI 10.1016/S0736-5748(98)00084-7; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 1998, NEUROREPORT, V9, P615, DOI 10.1097/00001756-199803090-00010; Lei BP, 1997, NEUROSCI LETT, V222, P91, DOI 10.1016/S0304-3940(97)13349-3; Lei BP, 1998, BRAIN RES PROTOC, V3, P33, DOI 10.1016/S1385-299X(98)00018-X; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Mahley Robert W., 1995, Current Opinion in Lipidology, V6, P86, DOI 10.1097/00041433-199504000-00005; Mailly F, 1999, J NEUROCHEM, V73, P1181, DOI 10.1046/j.1471-4159.1999.0731181.x; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; Matthews RT, 1996, BRAIN RES, V718, P181, DOI 10.1016/0006-8993(95)01576-0; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; Metzger RE, 1996, J NEUROPATH EXP NEUR, V55, P372, DOI 10.1097/00005072-199603000-00013; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Montine TJ, 1999, EXP NEUROL, V158, P234, DOI 10.1006/exnr.1999.7067; Pearlstein RD, 1998, J NEUROCHEM, V70, P2012; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; POIRIER J, 1991, MOL BRAIN RES, V9, P191, DOI 10.1016/0169-328X(91)90002-F; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; Pratico D, 1999, J NEUROCHEM, V73, P736, DOI 10.1046/j.1471-4159.1999.0730736.x; RAGHU G, 1986, BRIT J EXP PATHOL, V67, P105; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; STARKE PE, 1985, J BIOL CHEM, V260, P99; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Veinbergs I, 1999, PROG NEURO-PSYCHOPH, V23, P519, DOI 10.1016/S0278-5846(99)00013-5; WEI EP, 1987, PHYSIOLOGIST, V30, P122; Williams KR, 1998, NEUROBIOL DIS, V5, P271, DOI 10.1006/nbdi.1998.0198; Yamauchi K, 1999, CLIN CHEM, V45, P497	67	57	60	0	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186			NEUROCHEM INT	Neurochem. Int.	JAN	2004	44	2					107	118		10.1016/S0197-0186(03)00112-8			12	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	725RN	WOS:000185556300006	12971913				2022-02-06	
J	Rao, KVR; Chen, M; Simard, JM; Norenberg, MD				Rao, KVR; Chen, M; Simard, JM; Norenberg, MD			Suppression of ammonia-induced astrocyte swelling by cyclosporin A	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						aquaporin 4; ammonia toxicity; astrocytes; brain edema; cyclosporin A; cell swelling; fulminant hepatic failure; hepatic encephalopathy; mitochondrial permeability transition	MITOCHONDRIAL PERMEABILITY TRANSITION; CEREBRAL CORTICAL SLICES; TRAUMATIC BRAIN-INJURY; ACETYL-L-CARNITINE; HEPATIC-ENCEPHALOPATHY; CULTURED ASTROCYTES; RAT ASTROCYTES; LIVER-FAILURE; INTRACRANIAL HYPERTENSION; NONSYNAPTIC MITOCHONDRIA	Brain edema is a serious complication of hepatic encephalopathy associated with fulminant hepatic failure (FHF). A major component of the edema seems to be cytotoxic, involving astrocyte swelling. Although the mechanism of brain edema in FHF is incompletely understood, it is generally believed that ammonia is involved critically in this process. Recent studies have shown that exposure of cultured astrocytes to ammonia results in the mitochondrial permeability transition (MPT), a phenomenon associated with mitochondrial failure and subsequent cellular dysfunction. The present study examined the potential role of the MPT in the astrocyte swelling associated with ammonia toxicity. Treatment of cultured astrocytes with ammonia (5 mM) caused a time-dependent increase in astrocyte cell volume (swelling), which was completely inhibited by the MPT inhibitor cyclosporin A (CsA). In this study, CsA also inhibited the ammonia-induced aquaporin 4 (AQP4) upregulation, which had been shown previously to be increased in cultured astrocytes by ammonia treatment. These findings suggest that the MPT plays a significant role in the ammonia-induced astrocyte swelling and may contribute to the brain edema associated with FHF. (C) 2003 Wiley-Liss, Inc.	Univ Miami, Sch Med, Dept Pathol, Miami, FL 33101 USA; Vet Affairs Med Ctr, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA		Norenberg, MD (corresponding author), Univ Miami, Sch Med, Dept Pathol, POB 016960, Miami, FL 33101 USA.	mnorenbe@med.miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS034951] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34951, NS30291] Funding Source: Medline		Allert N, 1998, BRAIN RES, V782, P261, DOI 10.1016/S0006-8993(97)01288-2; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Bai G, 2001, J NEUROSCI RES, V66, P981, DOI 10.1002/jnr.10056; BENDER AS, 1993, J NEUROCHEM, V61, P1506, DOI 10.1111/j.1471-4159.1993.tb13646.x; Bender AS, 1998, J NEUROSCI RES, V54, P673, DOI 10.1002/(SICI)1097-4547(19981201)54:5<673::AID-JNR12>3.0.CO;2-P; BENJAMIN AM, 1978, J NEUROCHEM, V30, P131, DOI 10.1111/j.1471-4159.1978.tb07044.x; BLEI AT, 1994, HEPATOLOGY, V19, P1437, DOI 10.1002/hep.1840190619; Blei AT, 1999, J HEPATOL, V31, P771, DOI 10.1016/S0168-8278(99)80361-4; BLEI AT, 1991, HEPATOLOGY, V13, P376, DOI 10.1016/0270-9139(91)92455-H; BRUSILOW SW, 1986, NEW ENGL J MED, V314, P786; CLEMMESEN JO, 1999, HEPATOLOGY, V19, P1437; Cordoba J, 1996, SEMIN LIVER DIS, V16, P271, DOI 10.1055/s-2007-1007240; Desjardins P, 2002, NEUROCHEM INT, V41, P109, DOI 10.1016/S0197-0186(02)00031-1; DUCIS I, 1990, BRAIN RES, V531, P318, DOI 10.1016/0006-8993(90)90793-B; FAFFMICHALAK L, 1991, METAB BRAIN DIS, V6, P187, DOI 10.1007/BF00996918; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; GANZ R, 1989, METAB BRAIN DIS, V4, P213, DOI 10.1007/BF01000297; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HINDFELT B, 1977, J CLIN INVEST, V59, P386, DOI 10.1172/JCI108651; Kimelberg H., 1993, ASTROCYTES PHARM FUN, P193; Kimelberg HK, 1998, CONTRIB NEPHROL, V123, P240, DOI 10.1159/000059916; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KIMELBERG HK, 1988, NEUROMETHODS NEUROAN, V9, P129; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; Kosenko E, 1997, METAB BRAIN DIS, V12, P69, DOI 10.1007/BF02676355; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Murthy CRK, 2002, NEUROCHEM INT, V41, P171, DOI 10.1016/S0197-0186(02)00039-6; Nielsen S, 1997, J NEUROSCI, V17, P171; Norenberg MD, 1997, GLIA, V21, P124; NORENBERG MD, 1991, NEUROCHEM RES, V16, P833, DOI 10.1007/BF00965694; NORENBERG MD, 1994, ACTA NEUROCHIR, P24; NORENBERG MD, 1977, LAB INVEST, V36, P618; NORENBERG MD, 2001, ASTROCYTES AGING BRA, P477; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; OLSON JE, 1992, CAN J PHYSIOL PHARM, V70, pS350, DOI 10.1139/y92-282; Perillan PR, 2002, J BIOL CHEM, V277, P1974, DOI 10.1074/jbc.M107984200; Pfeuffer J, 1998, BBA-MOL CELL RES, V1448, P27, DOI 10.1016/S0167-4889(98)00111-6; PILBEAM CM, 1983, J PATHOL, V140, P347, DOI 10.1002/path.1711400404; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; Qureshi K, 1998, NEUROCHEM RES, V23, P855, DOI 10.1023/A:1022406911604; Rao KVR, 1997, NEUROSCI LETT, V224, P83; Rao KVR, 2003, NEUROCHEM INT, V43, P517, DOI 10.1016/S0197-0186(03)00042-1; Rao KVR, 2002, J NEUROCHEM, V81, P19; Rao KVR, 2001, METAB BRAIN DIS, V16, P67, DOI 10.1023/A:1011666612822; Rao KVR, 2001, J NEUROCHEM, V78, P25; RAO KVR, 2002, INCREASED EXPRESSION; RATNAKUMARI L, 1989, NEUROCHEM RES, V14, P221, DOI 10.1007/BF00971314; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SWAIN M, 1992, HEPATOLOGY, V15, P449, DOI 10.1002/hep.1840150316; TAKAHASHI H, 1991, AM J PHYSIOL, V261, pH825, DOI 10.1152/ajpheart.1991.261.3.H825; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; TRABER P, 1989, GASTROENTEROLOGY, V96, P885; Trost LC, 1997, TOXICOL APPL PHARM, V147, P431, DOI 10.1006/taap.1997.8313; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; VOORHIES TM, 1983, PEDIATR RES, V17, P970, DOI 10.1203/00006450-198312000-00009; White RJ, 1996, J NEUROSCI, V16, P5688; WillardMack CL, 1996, NEUROSCIENCE, V71, P589, DOI 10.1016/0306-4522(95)00462-9; Yamamoto N, 2001, MOL BRAIN RES, V90, P26, DOI 10.1016/S0169-328X(01)00064-X; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572; Zielinska M, 2003, NEUROCHEM INT, V43, P299, DOI 10.1016/S0197-0186(03)00015-9; Zieminska E, 2000, NEUROTOXICOLOGY, V21, P295; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; Zwingmann C, 2000, DEV NEUROSCI-BASEL, V22, P463, DOI 10.1159/000017476	65	57	57	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	DEC 15	2003	74	6					891	897		10.1002/jnr.10755			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	750KW	WOS:000186990700011	14648594				2022-02-06	
J	Brown, M; Gordon, WA; Spielman, L				Brown, M; Gordon, WA; Spielman, L			Participation in social and recreational activity in the community by individuals with traumatic brain injury	REHABILITATION PSYCHOLOGY			English	Article							SPINAL-CORD-INJURY; QUALITY-OF-LIFE; CLOSED HEAD-INJURY; REHABILITATION; SATISFACTION; OUTCOMES; SUPPORT; INTEGRATION; HANDICAP; HEALTH	Objective: To compare the extent of engagement in social-recreational activity in individuals with traumatic brain injury (TBI) and with no disability (ND). Study Design: Between- and within-group comparisons. Participants: Samples (TBI, N = 279; ND, N = 224) recruited from community sources. Outcome Measures: A social-recreational measure based on items drawn from 3 measures of community integration. Results: The ND group was more active than the TBI group. For the latter, greater social-recreational activity was associated with being single, higher income, less depression, more vocational hours, and greater time since injury. Conclusions: Addressing depression, fatigue, and vocational engagement may promote entree to a fuller social-recreational life for individuals with TBI.	CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA		Gordon, WA (corresponding author), CUNY Mt Sinai Sch Med, Dept Rehabil Med, Box 1240,1 Gustave L Levy Pl, New York, NY 10029 USA.						Abreu BC, 2001, ARCH PHYS MED REHAB, V82, P49, DOI 10.1053/apmr.2001.9167; Bassuk SS, 1999, ANN INTERN MED, V131, P165, DOI 10.7326/0003-4819-131-3-199908030-00002; Baum FE, 2000, J EPIDEMIOL COMMUN H, V54, P414, DOI 10.1136/jech.54.6.414; Beck AT, 1987, BECK DEPRESSION INVE; BIGELOW D, 1992, PSYCHOL REHABIL J, V14, P94; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; BROWN M, 1998, UNPUB FLANAGAN QUALI; BROWN MM, 1983, DISS ABSTR INT B, V43, P2314; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Crespo CJ, 1999, MED SCI SPORT EXER, V31, P1821, DOI 10.1097/00005768-199912000-00019; Dalgard OS, 1998, J EPIDEMIOL COMMUN H, V52, P476, DOI 10.1136/jech.52.8.476; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Dijkers M., 2002, QUAL LIFE RES, V11, P672; Dijkers MPJM, 1999, ARCH PHYS MED REHAB, V80, P867, DOI 10.1016/S0003-9993(99)90076-X; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Eckert JK, 1999, MED CLIN N AM, V83, P1151, DOI 10.1016/S0025-7125(05)70156-5; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; GORDON WA, 1998, J HEAD TRAUMA REHAB, V13, P17; GOTTLIEB BH, 1985, HEALTH EDUC QUART, V12, P5, DOI 10.1177/109019818501200102; Hall K., 1998, TOP SPINAL CORD INJ, V4, P16, DOI DOI 10.1310/V5RU-FRFE-50E6-E2NA; Harlow RE, 1996, J PERS SOC PSYCHOL, V71, P1235, DOI 10.1037/0022-3514.71.6.1235; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Helminen A, 1997, J BIOSOC SCI, V29, P129, DOI 10.1017/S0021932097001296; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; Hughes C., 1996, QUALITY LIFE, V1, P51; Kannisto M, 1997, SPINAL CORD, V35, P747, DOI 10.1038/sj.sc.3100542; Lawton MP, 1999, J AGING HEALTH, V11, P169, DOI 10.1177/089826439901100203; Lehmkuhl D, 1988, TIRR SYMPTOM CHECKLI; LEZAK MD, 1990, TRAUMATIC BRAIN INJU, P365; Lin N, 1999, J HEALTH SOC BEHAV, V40, P344, DOI 10.2307/2676330; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; *MED OUTC TRUST, 1992, SF 36 HLTH SURV; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Noreau L, 2000, DISABIL REHABIL, V22, P170; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Prince MJ, 1998, PSYCHOL MED, V28, P337, DOI 10.1017/S0033291797006478; Ren XS, 1999, SOC SCI MED, V48, P1721, DOI 10.1016/S0277-9536(99)00069-6; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; *SPSS INC, 1999, SPSS WIND REL 10 0 0; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Steptoe A, 1996, LANCET, V347, P1789, DOI 10.1016/S0140-6736(96)91616-5; Veenstra G, 2000, SOC SCI MED, V50, P619, DOI 10.1016/S0277-9536(99)00307-X; Vogel LC, 1998, ARCH PHYS MED REHAB, V79, P1496, DOI 10.1016/S0003-9993(98)90409-9; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Whiteneck G, 1999, ARCH PHYS MED REHAB, V80, P1485, DOI 10.1016/S0003-9993(99)90262-9; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WHITENECK GG, 1992, UNPUB COMMUNITY REEN; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1980, INT CLASS IMP DIS HA; World Health Organization, 1997, ICIDH 2 INT CLASS IM; Zencius AH, 1999, BRAIN INJURY, V13, P723	57	57	57	0	10	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2003	48	4					266	274		10.1037/0090-5550.48.4.266			9	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	741ER	WOS:000186446200006					2022-02-06	
J	Pelinka, LE; Szalay, L; Jafarmadar, M; Schmidhammer, R; Redl, H; Bahrami, S				Pelinka, LE; Szalay, L; Jafarmadar, M; Schmidhammer, R; Redl, H; Bahrami, S			Circulating S100B is increased after bilateral femur fracture without brain injury in the rat	BRITISH JOURNAL OF ANAESTHESIA			English	Article						blood, protein S100; brain, traumatic injury; complications, long bone injury	CARDIAC-SURGERY; CEREBRAL-DAMAGE; SERUM S100B; PROTEIN; MARKER; TRAUMA	Background. S100B is an acknowledged marker of brain damage. However, trauma without brain damage also causes an increase in S100B. S100B concentrations are highest in multiple trauma patients with long bone fractures. Clinically, extensive long bone fractures are associated with haemorrhagic shock and haemorrhagic shock per se is associated with increased S100B. The aim of our experimental study was to verify the S100B increase in long bone fracture without haemorrhagic shock. Methods and results. Bilateral femur fracture was carried out in 10 anaesthetized rats. Blood samples were drawn for immuno-luminometrical S100B measurement 5, 15, 30, 120, and 240 min after fracture. Mean arterial pressure (MAP), heart rate, and body temperature were monitored continuously. S100B increased after bilateral femur fracture and reached a peak 30-120 min after fracture (P<0.001). MAP remained at a level which is not associated with shock in rats. Heart rate and body temperature remained unchanged. Autopsy verified open bilateral femur fracture surrounded only by small zones of clotted blood. Conclusions. S100B is increased in bilateral femur fracture without haemorrhagic shock in rats. This finding suggests that bone marrow is a potential extracerebral source of S100B.	Workers Compensat Board AUVA, Ludwig Boltzman Inst Expt & Clin Traumatol, A-1200 Vienna, Austria; Workers Compensat Board AUVA, Res Unit, A-1200 Vienna, Austria; Szent Gyorgyi Univ, Inst Expt Surg, H-6721 Szeged, Hungary		Pelinka, LE (corresponding author), Workers Compensat Board AUVA, Ludwig Boltzman Inst Expt & Clin Traumatol, Donaueschingenstr 13, A-1200 Vienna, Austria.		Redl, Heinz/AAD-8157-2019	Bahrami, Soheyl/0000-0002-4563-6251			Ali MS, 2000, BRIT J ANAESTH, V85, P287, DOI 10.1093/bja/85.2.287; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Kuzumi E, 2000, BRIT J ANAESTH, V85, P936; Missler U, 2002, CLIN CHIM ACTA, V321, P29, DOI 10.1016/S0009-8981(02)00061-X; Pelinka LE, 2003, SHOCK, V19, P422, DOI 10.1097/01.shk.0000055345.58165.52; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Raabe A, 2001, NEUROSURGERY, V49, P1491, DOI 10.1097/00006123-200112000-00055	8	57	60	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	OCT	2003	91	4					595	597		10.1093/bja/aeg225			3	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	726JT	WOS:000185596500024	14504167	Bronze			2022-02-06	
J	Vitaz, TW; Jenks, J; Raque, GH; Shields, CB; Ullman, JS; Andrews, BT				Vitaz, TW; Jenks, J; Raque, GH; Shields, CB; Ullman, JS; Andrews, BT			Outcome following moderate traumatic brain injury	SURGICAL NEUROLOGY			English	Article						moderate traumatic brain injury; outcome; neurologic recovery; clinical pathway	HEAD-INJURY; TRACHEOSTOMY; GASTROSTOMY	BACKGROUND Little is known about the outcome following moderate traumatic brain injury (TBI) (GCS 9-12). Most patients regain consciousness; however, the full magnitude of long-term cognitive and functional deficits is unknown. METHODS We conducted a prospective observational study evaluating the outcome of patients suffering moderate TBI between October 1995 and March 1998. Long-term outcome was assessed by telephone interviews. RESULTS A total of 79 consecutive patients were included. Average length of ICU and total hospital stay was 9.1 and 15.8 days respectively. The median GCS at 24 hours was 10 with 67% improving to GCS 15 by time of discharge. The presence of multisystem trauma did not affect outcome; however, age, greater than or equal to45, initiation of enteral feeding after postinjury day 4 and the presence of pneumonia were all associated with longer lengths of stay and increased complication rates. Fifty-six (71%) patients were contacted for follow-up at an average of 27.5 months. GOS scores were 5 in 44%, 4 in 41%, 3 in 9%, 1 in 6%. Seventy-four percent of patients employed premorbidly returned to full-time work. Questions regarding cognitive and functional status revealed significant problems in the majority of patients. CONCLUSIONS Pneumonia, age greater than or equal to45 years and a delay in initiation of enteral feeding all increased the duration of acute care hospital stay following moderate TBI. In addition, cognitive, emotional, and functional problems following such injuries are extensive and long lasting. Physicians must be knowledgeable of these long-term sequela so they can provide the appropriate support and treatment to these patients. (C) 2003 Elsevier Inc. All rights reserved.	Univ Louisville, Sch Med, Dept Neurol Surg, Louisville, KY 40292 USA; Univ Hlth Care, Louisville, KY USA		Vitaz, TW (corresponding author), 210 E Gray St,Suite 1102, Louisville, KY USA.		Ullman, Jamie/AAP-5983-2020				Armstrong PA, 1998, SURGERY, V124, P763, DOI 10.1067/msy.1998.91224; Aronson B, 1996, J Contin Educ Nurs, V27, P215; BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; DAMELIO LF, 1994, AM SURGEON, V60, P180; ELOVIC E, 1996, MED REHABILITATION T, P133; FRANKOWSKI RF, 1985, EPIDEMIOLOGICAL DE 1, P33; IBARRA VA, 1997, SPINE, V22, P353; JENNETT B, 1975, LANCET, V1, P480; JOHNSON SB, 1992, J TRAUMA, V33, P95, DOI 10.1097/00005373-199207000-00018; Kitchiner D, 1996, ARCH DIS CHILD, V75, P166, DOI 10.1136/adc.75.2.166; MOORE FA, 1992, J TRAUMA, V33, P435, DOI 10.1097/00005373-199209000-00017; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Ross BJ, 1996, AM SURGEON, V62, P19; Spain DA, 1995, J TRAUMA, V39, P1100, DOI 10.1097/00005373-199512000-00015; Spatt J, 1997, ACTA NEUROL SCAND, V95, P173, DOI 10.1111/j.1600-0404.1997.tb00091.x; Zevola D R, 1997, Crit Care Nurse, V17, P20	16	57	62	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	OCT	2003	60	4					285	291		10.1016/S0090-3019(03)00378-1			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	724DT	WOS:000185472400004	14505837				2022-02-06	
J	Sarrafzadeh, AS; Kiening, KL; Callsen, TA; Unterberg, AW				Sarrafzadeh, AS; Kiening, KL; Callsen, TA; Unterberg, AW			Metabolic changes during impending and manifest cerebral hypoxia in traumatic brain injury	BRITISH JOURNAL OF NEUROSURGERY			English	Article						brain tissue-PO2; cerebral metabolism; cerebral oxygenation; hypoxia; ischaemia; microdialysis; multimodal monitoring; severe head injury	SEVERE HEAD-INJURY; SUBSTRATE DELIVERY; TISSUE PO2; BLOOD-FLOW; MICRODIALYSIS; HYPERVENTILATION; RELEASE; LACTATE	The objective was to measure metabolic changes monitored by bedside microdialysis during impending and manifest hypoxia in traumatic brain injury. In 41 patients, a PtiO(2)-catheter (Licox; 1/min) was placed into non-lesioned frontal white matter together with a microdialysis catheter (CMA, hourly). Data were analysed for identification of episodes of impending (PtiO(2) <10 - 15 mmHg >5 min) and manifest cerebral hypoxia (PtiO(2) <10 mmHg, >5 min). In 69% of patients hypoxic episodes occurred, most frequently associated with hyperventilation ( p<0.001). During impending hypoxia, glutamate was increased ( p = 0.03), while the energy metabolites remained stable. Manifest hypoxia was reflected by significant increases of glutamate ( p = 0.007) and lactate ( p = 0.044), but normal lactate-pyruvate ratios. We conclude that hyperventilation had a potential adverse effect on cerebral metabolism and was most frequently associated with cerebral hypoxia. A PtiO(2) <10 mmHg can induce metabolic changes with increase of glutamate and lactate. The presence of anaerobic cerebral metabolism probably depends on duration and severity of the hypoxic episode.	Humboldt Univ, Virchow Med Ctr, Charite, Dept Neurosurg, D-13353 Berlin, Germany; Heidelberg Univ, Dept Neurosurg, D-6900 Heidelberg, Germany		Sarrafzadeh, AS (corresponding author), Humboldt Univ, Virchow Med Ctr, Charite, Dept Neurosurg, Augustenburger Pl 1, D-13353 Berlin, Germany.	asita.sarrafzadeh@charite.de					Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P597; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cesarini KG, 2002, ACTA NEUROCHIR, V144, P1121, DOI 10.1007/s00701-002-1011-9; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Dings J, 1997, NEUROL RES, V19, P241, DOI 10.1080/01616412.1997.11740806; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Magistretti PJ, 2000, BRAIN RES, V886, P108, DOI 10.1016/S0006-8993(00)02945-0; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P58; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Robertson CS, 1998, NEUROL RES, V20, pS91; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Schneider GH, 1998, ACT NEUR S, V71, P62; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; UNGERSTEDT U, 1987, LIFE SCI, V41, P861, DOI 10.1016/0024-3205(87)90181-0; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; Zauner A, 1996, ACT NEUR S, V67, P40	25	57	57	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	AUG	2003	17	4					340	346		10.1080/02688690310001601234			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	722FC	WOS:000185363900007	14579900				2022-02-06	
J	Meythaler, JM; Roper, JF; Brunner, RC				Meythaler, JM; Roper, JF; Brunner, RC			Cyproheptadine for intrathecal baclofen withdrawal	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						baclofen; cyproheptadine; hyperpyrexia; malignant; infusion pumps; implantable; muscle spasticity; neuroleptic malignant syndrome; receptors, GABA-B; rehabilitation; serotonin; serotonin syndrome; withdrawal symptoms	TRAUMATIC BRAIN INJURY; SPASTIC HYPERTONIA; SEROTONIN SYNDROME; SPINAL ORIGIN; MANAGEMENT; ECSTASY; DEATH	Objective: To evaluate the efficacy of cyproheptadine in the management of acute intrathecal baclofen (ITB) withdrawal. Design: Descriptive case series. Setting: University hospital with a comprehensive in- and outpatient rehabilitation center. Participants: Four patients (3 with spinal cord injury, 1 with cerebral palsy) with implanted ITB infusion pumps for treatment of severe spasticity, who had ITB withdrawal syndrome because of interruption of ITB infusion. Interventions: Patients were treated with 4 to 8mg of cyproheptadine by mouth every 6 to 8 hours, 5 to 10mg of diazeparn by mouth every 6 to 12 hours, 10 to 20mg of baclofen by mouth every 6 hours, and ITB boluses in some cases. Main Outcome Measures:' Clinical signs and symptoms of ITB withdrawal of varying severity were assessed by vital signs (temperature, heart rate), physical examination (reflexes, tone, clonus), and patient report of symptoms (itching, nausea, headache, malaise). Results: The patients in our series improved significantly when the serotonin antagonist cyproheptadine was added to their regimens. Fever dropped at least 1.5degreesC, and heart rate dropped from rates of 120 to 140 to less than 100bpm. Reflexes, tone, and myoclonus also decreased. Patients reported dramatic reduction in itching after cyproheptadine. These changes were associated temporally with cyproheptadine dosing. Discussion: Acute ITB withdrawal syndrome occurs frequently in cases of malfunctioning intrathecal infusion pumps or catheters. The syndrome commonly presents with pruritus and increased muscle tone. It can progress rapidly to high fever, altered mental status, seizures, profound muscle rigidity, rhabdomyolysis, brain injury, and death. Current therapy with oral baclofen and benzodiazepines is, useful but has variable success, particularly in severe cases. We note that ITB withdrawal is similar to serotonergic syndromes, such as in overdoses of selective serotonin reuptake inhibitors or the popular drug of abuse 3,4-methylenedioxymethamphetamine (Ecstasy). We postulate that ITB withdrawal may be a form of serotonergic syndrome that occurs from loss of gamma-aminobutyric acid B receptor-mediated presynaptic inhibition of serotonin. Conclusion: Cyproheptadine may be a useful adjunct to baclofen and benzodiazepines in the management of acute ITB withdrawal syndrome.	Univ Alabama, Sch Med, Dept Phys Med & Rehabil, Birmingham, AL 35249 USA; Univ Alabama, Spain Rehabil Ctr, Birmingham, AL 35249 USA		Meythaler, JM (corresponding author), Univ Alabama, Sch Med, Dept Phys Med & Rehabil, R157,619 6th Ave S, Birmingham, AL 35249 USA.						Al-Khodairy AT, 1999, AM J PHYS MED REHAB, V78, P272, DOI 10.1097/00002060-199905000-00018; ASHWORTH B, 1964, PRACTITIONER, V192, P540; BARKER I, 1982, LANCET, V2, P556; BOSE P, 2002, J NEUROTRAUM, V19, P1305; Burns AS, 2001, SPINAL CORD, V39, P413, DOI 10.1038/sj.sc.3101178; Carbone JR, 2000, EMERG MED CLIN N AM, V18, P317, DOI 10.1016/S0733-8627(05)70127-9; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; Coffey RJ, 2001, NEUROMODULATION, V4, P142, DOI 10.1046/j.1525-1403.2001.00142.x; Coffey RJ, 2002, ARCH PHYS MED REHAB, V83, P735, DOI 10.1053/apmr.2002.32820; David WS, 2000, NEUROL CLIN, V18, P215, DOI 10.1016/S0733-8619(05)70187-0; GARABEDIANRUFFALO SM, 1985, DRUG INTEL CLIN PHAR, V19, P304, DOI 10.1177/106002808501900415; Green LB, 1999, ARCH PHYS MED REHAB, V80, P1600, DOI 10.1016/S0003-9993(99)90337-4; Grenier B, 1996, ANN FR ANESTH, V15, P659, DOI 10.1016/0750-7658(96)82130-7; HARRISON SA, 1985, DRUG INTEL CLIN PHAR, V19, P747, DOI 10.1177/106002808501901012; McRae AL, 2001, MED CLIN N AM, V85, P779, DOI 10.1016/S0025-7125(05)70340-0; *MED EC, 2001, PHYS DESK REF, P1993; Meythaler J M, 2001, Phys Med Rehabil Clin N Am, V12, P725; Meythaler JM, 1999, ARCH PHYS MED REHAB, V80, P13, DOI 10.1016/S0003-9993(99)90301-5; MEYTHALER JM, 1992, AM J PHYS MED REHAB, V71, P321, DOI 10.1097/00002060-199212000-00003; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; Meythaler JM, 1997, J NEUROSURG, V87, P415, DOI 10.3171/jns.1997.87.3.0415; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P155, DOI 10.1053/apmr.2001.19246; Meythaler JM, 1999, SPINAL DRUG DELIVERY, P513; Meythaler JM, 2001, STROKE, V32, P2099, DOI 10.1161/hs0901.095682; Mills KC, 1997, CRIT CARE CLIN, V13, P763, DOI 10.1016/S0749-0704(05)70368-7; Mueller PD, 1998, ANN EMERG MED, V32, P377, DOI 10.1016/S0196-0644(98)70018-6; Nance P, 1999, Phys Med Rehabil Clin N Am, V10, P385; Nance P W, 2001, Phys Med Rehabil Clin N Am, V12, P889; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; Ramcharan S, 1998, J TOXICOL-CLIN TOXIC, V36, P727, DOI 10.3109/15563659809162623; Wilkinson R, 1999, BRAIN INJURY, V13, P1025	31	57	58	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2003	84	5					638	642		10.1016/S0003-9993(03)00105-9			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	675NF	WOS:000182700900003	12736874				2022-02-06	
J	Long, Y; Zou, LL; Liu, H; Lu, H; Yuan, XQ; Robertson, CS; Yang, KY				Long, Y; Zou, LL; Liu, H; Lu, H; Yuan, XQ; Robertson, CS; Yang, KY			Altered expression of randomly selected genes in mouse hippocampus after traumatic brain injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						microarray; hippocampus; gene expression; brain; trauma	CORTICAL IMPACT INJURY; SERINE-PROTEASE INHIBITORS; PLATELET-ACTIVATING-FACTOR; CENTRAL-NERVOUS-SYSTEM; MESSENGER-RNA; CELL-DEATH; RAT-BRAIN; MICROARRAY ANALYSIS; KINASE-C; UTEROGLOBIN	Using a cDNA microarray method, we analyzed gene expression profiles in mouse hippocampus after traumatic brain injury (TBI). Of 6,400 randomly selected arrayed genes and expressed sequence tags from a mouse cDNA library, 253 were found to be differentially expressed (106 increased and 147 decreased). Genes involved in cell homeostasis and calcium signaling were primarily up-regulated while those encoding mitochondrial enzymes, metabolic molecules, and structural proteins were predominantly down-regulated. Equal numbers of genes related to inflammatory reactions showed increased or decreased expression. Importantly, a large proportion of the dysregulated genes we identified have not been reported as differentially expressed in TBI models. Semiquantitative reverse-transcriptase polymerase chain reaction (RT-PCR) analyses of representative genes confirmed the validity of the corresponding microarray findings. Thus, our microarray-based evaluation of gene expression in traumatically injured hippocampus identified both known and novel genes that respond to TBI. Further investigation of these candidate molecules may suggest new ways to attenuate the traumatic effects of brain injury. (C) 2002 Wiley-Liss, Inc.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; PADRECC, Neurol Care Line, VA Med Ctr, Houston, TX USA		Yang, KY (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS35502-04, P01-NS38660] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035502, P01NS038660] Funding Source: NIH RePORTER		Almeida A, 2001, J NEUROCHEM, V77, P676, DOI 10.1046/j.1471-4159.2001.00276.x; Bazan NG, 1998, PROG BRAIN RES, V118, P281; Berger P, 1999, MOL CELL NEUROSCI, V14, P455, DOI 10.1006/mcne.1999.0804; Cirelli C, 1999, J SLEEP RES, V8, P44; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; Garbett EA, 1999, J CLIN PATHOL-MOL PA, V52, P140, DOI 10.1136/mp.52.3.140; Ginsberg SD, 2000, ANN NEUROL, V48, P77, DOI 10.1002/1531-8249(200007)48:1<77::AID-ANA12>3.0.CO;2-A; He XP, 2001, NEUROSCI RES, V39, P455, DOI 10.1016/S0168-0102(01)00200-0; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hirschberg DL, 1998, J NEUROIMMUNOL, V89, P88, DOI 10.1016/S0165-5728(98)00118-0; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Larson RA, 2000, J VASC SURG, V32, P1111, DOI 10.1067/mva.2000.111282; Li MD, 2000, J NEUROSCI, V20, P1318; Llanos S, 1998, J NEUROCHEM, V70, P2315; MANTILE G, 1993, J BIOL CHEM, V268, P20343; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Merched A, 1998, FEBS LETT, V425, P225, DOI 10.1016/S0014-5793(98)00234-8; Mirnics K, 2001, TRENDS NEUROSCI, V24, P479, DOI 10.1016/S0166-2236(00)01862-2; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Movsesyan VA, 2001, EXP NEUROL, V167, P366, DOI 10.1006/exnr.2000.7567; Mukherjee AB, 1999, CELL MOL LIFE SCI, V55, P771, DOI 10.1007/s000180050331; Nakaya N, 1998, NEUROSCI RES, V32, P221, DOI 10.1016/S0168-0102(98)00091-1; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Oh YJ, 1997, MOL BRAIN RES, V51, P133, DOI 10.1016/S0169-328X(97)00229-5; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Raivich Gennadij, 1996, Keio Journal of Medicine, V45, P239; RINA S, 2001, BRAIN RES, V911, P1; Sapirstein A, 2000, NEUROCHEM RES, V25, P745, DOI 10.1023/A:1007583708713; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Stephenson D, 1999, GLIA, V27, P110, DOI 10.1002/(SICI)1098-1136(199908)27:2<110::AID-GLIA2>3.0.CO;2-C; Takeshi K, 1999, J CLIN MICROBIOL, V37, P4093, DOI 10.1128/JCM.37.12.4093-4098.1999; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; Ueda T, 1999, J NEUROCHEM, V73, P2119; Uhl E, 1999, STROKE, V30, P880, DOI 10.1161/01.STR.30.4.880; Velazquez I, 2001, ARCH BIOCHEM BIOPHYS, V389, P7, DOI 10.1006/abbi.2001.2293; Vivien D, 2000, J CEREBR BLOOD F MET, V20, P755, DOI 10.1097/00004647-200005000-00001; WEKERLE H, 1993, INTERVIROLOGY, V35, P95, DOI 10.1159/000150299; Whitney LW, 2001, J NEUROIMMUNOL, V121, P40, DOI 10.1016/S0165-5728(01)00438-6; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; Zhang KZ, 2000, P NATL ACAD SCI USA, V97, P3637, DOI 10.1073/pnas.070045897; Zou LL, 1998, J NEUROCHEM, V71, P887	48	57	62	0	2	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	MAR 1	2003	71	5					710	720		10.1002/jnr.10524			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	650CK	WOS:000181244700010	12584729				2022-02-06	
J	Brenner, T; Freier, MC; Holshouser, BA; Burley, T; Ashwal, S				Brenner, T; Freier, MC; Holshouser, BA; Burley, T; Ashwal, S			Predicting neuropsychologic outcome after traumatic brain injury in children	PEDIATRIC NEUROLOGY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; CLOSED HEAD-INJURY; MR SPECTROSCOPY; PROTON; PERFORMANCE; SEVERITY; INFANTS; MEMORY; CHILDHOOD; AGE	The ability to predict long-term neurologic and neuropsychologic outcomes in 22 children, ages 1 week to 14 years at the time of traumatic brain injury, was investigated using proton magnetic resonance spectroscopy acquired post injury and compared with standardized neurologic, intellectual, and neuropsychologic testing done 1-7 years later. Clinical indicators of acute injury severity including age at injury, electroencephalography, spectroscopy metabolite ratio variables (N-acetyl aspartate/choline, choline/creatine) and lactate presence accurately classified children as functioning above or below the average range for most intellectual and neuropsychologic outcome measures. Combined clinical and spectroscopy variables accounted for approximately 50% of the variance in cognitive and neuropsychologic outcome confirming the validity of their predictive use. Of the injury severity indictors, presence of lactate is a particularly important prognostic marker of poor long-term intellectual and neuropsychologic functioning. Our findings indicate the potential for providing accurate estimates of long-term intellectual and neuropsychologic function after traumatic brain injury in infants and children using proton magnetic resonance spectroscopy in combination with clinical variables. (C) 2003 by Elsevier Inc. All rights reserved.	Loma Linda Univ, Sch Med, Dept Pediat, Div Child Neurol, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Psychol, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Radiol, Loma Linda, CA 92350 USA		Ashwal, S (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, Div Child Neurol, Coleman Pavill,11175 Campus St, Loma Linda, CA 92350 USA.						Ashwal S, 1996, J THORAC CARDIOV SUR, V112, P403, DOI 10.1016/S0022-5223(96)70268-4; Ashwal S, 1997, ANN NEUROL, V41, P470, DOI 10.1002/ana.410410410; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; AULD KL, 1995, PEDIATR NEUROL, V12, P323, DOI 10.1016/0887-8994(95)00062-K; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; CHOI SC, 1996, NEUROTRAUMA, P779; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1995, J HEAD TRAUMA REHAB, V10, P13, DOI 10.1097/00001199-199510000-00004; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; Fletcher JM, 1987, NEUROBEHAVIORAL RECO, P279; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Golden CJ, 1985, LURIA NEBRASKA NEURO; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JENNETT B, 1975, LANCET, V1, P480; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Kemp, 1998, NEPSY DEV NEUROPSYCH; KIMURA H, 1995, RADIOLOGY, V194, P483, DOI 10.1148/radiology.194.2.7529934; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Kreis R, 1996, J CLIN INVEST, V97, P1142, DOI 10.1172/JCI118528; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; Levin HS, 1996, CORTEX, V32, P461, DOI 10.1016/S0010-9452(96)80004-9; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; MINER ME, 1986, NEURAL TRAUMA TREATM, P233; Shevell M I, 1999, Semin Pediatr Neurol, V6, P68, DOI 10.1016/S1071-9091(99)80033-3; *US CENS BUR, 2000, POP PROJ PROGR POP D; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; VANDERKNAAP MS, 1990, RADIOLOGY, V176, P509, DOI 10.1148/radiology.176.2.2164237; Wechsler D, 1989, MANUAL WECHSLER PRES; Wechsler D., 1997, MANUAL WECHSLER ADUL; Wechsler D., 1991, MANUAL WECHSLER INTE, V3rd; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92	43	57	59	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	FEB	2003	28	2					104	114	PII S0887-8994(02)00491-5	10.1016/S0887-8994(02)00491-5			11	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pediatrics	670NU	WOS:000182415600004	12699860				2022-02-06	
J	Schatz, P; Zillmer, EA				Schatz, P; Zillmer, EA			Computer-based assessment of sports-related concussion	APPLIED NEUROPSYCHOLOGY			English	Article						sports-related concussion; mild traumatic brain injury; neuropsychology; computerized neuropsychological assessment	COGNITIVE ASSESSMENT; RELIABILITY; PERFORMANCE; MACINTOSH; TESTS	Sports-related concussion has received considerable attention from neuropsychologists, athletic trainers, team coaches, physicians, families, and athletes. In this context, researchers have recently developed computer programs for the assessment of sports-related concussion. Computer-based assessment of sports-related concussion saves time, allows for team baseline testing, and can be easily incorporated into the sports medicine environment. This article reviews the advantages and limitations of computer-based assessment of sports-related concussion. Within a well-coordinated concussion management program that includes input from a neuropsychologist, computer-based assessment of sports-related concussion will soon be the most common approach for assessing concussion in athletes.	St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA; Drexel Univ, Dept Athlet, Philadelphia, PA 19104 USA		Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, Post Hall 222, Philadelphia, PA 19131 USA.	pschatz@sju.edu		Schatz, Philip/0000-0002-6222-6545			American Psychological Association, 1986, GUID COMP BAS TEST I; Barak A, 1999, APPL PREV PSYCHOL, V8, P231, DOI 10.1016/S0962-1849(05)80038-1; Barth JT, 1989, MILD HEAD INJURY, P257; Bennett R. E., 1999, ED MEASUREMENT ISSUE, V18, P5, DOI DOI 10.1111/J.1745-3992.1999.TB00266.X; BROOKS J, 1998, EPIREMIOLOGY PREVENT; Campbell KA, 1999, ASSESSMENT, V6, P21, DOI 10.1177/107319119900600103; *COGSTATE, 1999, COGSPORT COMP SOFTW; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; COLLINS M, 2001, 21 ANN C NAT AC NEUR; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; ECHEMENDIA RJ, 2001, 21 C NAT AC NEUR SAN; ELWOOD DL, 1972, J CONSULT CLIN PSYCH, V38, P9, DOI 10.1037/h0032416; Erlanger D, 2001, J ATHL TRAINING, V36, P280; ERLANGER DM, IN PRESS ARCH CLIN N; Erlanger DM, 1999, CONCUSSION RESOLUTIO; FRENCH CC, 1987, BRIT J CLIN PSYCHOL, V26, P267, DOI 10.1111/j.2044-8260.1987.tb01360.x; Gur RC, 2001, NEUROPSYCHOPHARMACOL, V25, P766, DOI 10.1016/S0893-133X(01)00278-0; Gur RC, 2000, BRAIN LANG, V74, P157, DOI 10.1006/brln.2000.2325; HONAKER LM, 1988, CLIN PSYCHOL REV, V8, P561, DOI 10.1016/0272-7358(88)90081-5; Lovell M, 2000, IMPACT IMMEDIATE POS; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; MARION DW, R01HD42386; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; MEAD AD, 1993, PSYCHOL BULL, V114, P449, DOI 10.1037/0033-2909.114.3.449; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; REED AV, 1979, BEHAV RES METH INSTR, V11, P572, DOI 10.3758/BF03201384; Reeves DL., 1997, NEUROPSYCHOLOGY HDB, V1, P423; SPACE LG, 1981, BEHAV RES METH INSTR, V13, P595, DOI 10.3758/BF03202072; WESTALL R, 1986, BEHAV RES METH INSTR, V18, P307, DOI 10.3758/BF03204405; WESTALL RF, 1989, BEHAV RES METH INSTR, V21, P540, DOI 10.3758/BF03202886; WILSON SL, 1991, MICROCOMPUTERS CLIN, P79; ZILLMER EA, 1991, J PERS ASSESS, V57, P381, DOI 10.1207/s15327752jpa5702_15; ZILLMER EA, 1987, J FAMILY MED, V115, P107; ZILLMER ES, 2001, PRINCIPLES CLIN NEUR	39	57	57	3	13	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2003	10	1					42	47		10.1207/S15324826AN1001_6			6	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	780NF	WOS:000189386900006	12734074				2022-02-06	
J	Bein, T; Kuhr, LP; Bele, S; Ploner, F; Keyl, C; Taeger, K				Bein, T; Kuhr, LP; Bele, S; Ploner, F; Keyl, C; Taeger, K			Lung recruitment maneuver in patients with cerebral injury: effects on intracranial pressure and cerebral metabolism	INTENSIVE CARE MEDICINE			English	Article						volume recruitment; brain injury; jugular venous oxygen saturation	SEVERE HEAD-INJURY; CONTINUOUS ROTATIONAL THERAPY; TRAUMATIC BRAIN INJURY; UNILATERAL MEASUREMENTS; OXYGEN-METABOLISM; JUGULAR BULB; VENTILATION; ARDS	Objective: To investigate the effects of a lung recruitment maneuver on intracranial pressure (ICP) and cerebral metabolism in patients with acute cerebral injury and respiratory failure. Design: Prospective investigation. Setting: Ten-bed intensive care unit of a university hospital. Patients: Eleven patients with acute traumatic or non-traumatic cerebral lesions, who were on mechanical ventilation with acute lung injury. Interventions: Hemodynamics, ICP, cerebral perfusion pressure (CPP), jugular venous oxygen saturation (SJO(2)), and arterial minus jugular venous lactate content difference (AJDL) were measured before, during and after a volume recruitment maneuver (VRM), which included a 30-s progressive increase in peak pressure up to 60 cmH(2)O and a sustained pressure at the same level for the next 30 s. Results: At the end of VRM, ICP was elevated (16+/-5 mmHg vs 13+/-5 mmHg before VRM, P<0.05) and mean arterial pressure was reduced (75+/-10 vs 86+/-9 mmHg, P<0.01), which resulted in a decrease of CPP (60+/-10 vs 72+/-8 mmHg, P<0.01). SJO(2) deteriorated at the end of the procedure (59+/-7 vs 69+/-6%, P<0.05), AJDL was not altered. In the following period all parameters returned to normal values. An improvement in arterial oxygenation was observed at the end, but not in the period after the maneuver. Conclusions: Our VRM reduced cerebral hemodynamics and metabolism. We conclude that our VRM with high peak pressure effects only a marginal improvement in oxygenation but causes deterioration of cerebral hemodynamics. We therefore cannot recommend this technique for the ventilatory management of brain-injured patients.	Univ Hosp, Dept Anesthesia, D-93042 Regensburg, Germany; Univ Hosp, Dept Neurosurg, D-93042 Regensburg, Germany		Bein, T (corresponding author), Univ Hosp, Dept Anesthesia, D-93042 Regensburg, Germany.						Albert RK, 2000, CLIN CHEST MED, V21, P511, DOI 10.1016/S0272-5231(05)70162-3; Bein T, 1998, INTENS CARE MED, V24, P132, DOI 10.1007/s001340050534; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bohm SH, 1998, YB INTENSIVE CARE EM, P430; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRATTON SL, 1997, NEUROSURGERY, V41, P1214; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; Foti G, 2000, INTENS CARE MED, V26, P501, DOI 10.1007/s001340051196; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gibbs EL, 1942, J BIOL CHEM, V144, P325; Lapinsky SE, 1999, INTENS CARE MED, V25, P1297, DOI 10.1007/s001340051061; Mascia L, 1998, INTENS CARE MED, V24, P1115, DOI 10.1007/s001340050727; McGuire G, 1997, CRIT CARE MED, V25, P1059, DOI 10.1097/00003246-199706000-00025; Metz C, 1998, ACT NEUR S, V71, P324; Metz C, 1998, J CEREBR BLOOD F MET, V18, P332, DOI 10.1097/00004647-199803000-00012; Paolin A, 1998, J TRAUMA, V44, P495, DOI 10.1097/00005373-199803000-00012; ROGERS FB, 1995, J TRAUMA, V39, P860, DOI 10.1097/00005373-199511000-00009; TILLETT JM, 1993, CRIT CARE MED, V21, P1005, DOI 10.1097/00003246-199307000-00014; Vigue B, 1999, INTENS CARE MED, V25, P445, DOI 10.1007/s001340050878	20	57	69	0	2	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	MAY	2002	28	5					554	558		10.1007/s00134-002-1273-y			5	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558XP	WOS:000175993300005	12029401				2022-02-06	
J	Cannon, ML; Glazier, SS; Bauman, LA				Cannon, ML; Glazier, SS; Bauman, LA			Metabolic acidosis, rhabdomyolysis, and cardiovascular collapse after prolonged propofol infusion - Case report	JOURNAL OF NEUROSURGERY			English	Article						propofol; head injury; metabolic acidosis; rhabdomyolysis; multiorgan system failure	FATAL MYOCARDIAL FAILURE; INTENSIVE-CARE UNIT; MIDAZOLAM; SEDATION; CHILDREN; PATIENT; EFFICACY	The authors present the hospital course of a 13-year-old girl with a closed head injury who received a prolonged infusion of propofol for sedation and, subsequently, died as a result of severe metabolic acidosis, rhabdomyolysis, and cardiovascular collapse. The patient had been treated for 4 days at a referring hospital for a severe closed head injury sustained in a fall from a bicycle. During treatment for elevations of intracranial pressure, she received a continuous propofol infusion (100 mug/kg/min). The patient began to exhibit severe high anion gap/low lactate metabolic acidosis, and was transferred to the pediatric intensive care unit at the authors' institution. On arrival there, the patient's Glasgow Coma Scale score was 3 and this remained unchanged during her brief stay. The severe metabolic acidosis was unresponsive to maximum therapy. Acute renal failure ensued as a result of rhabdomyolysis, and myocardial dysfunction with bizarre, wide QRS complexes developed without hyperkalemia. The patient died of myocardial collapse with severe metabolic acidosis and multisystem organ failure (involving renal, hepatic, and cardiac systems) approximately 15 hours after admission to the authors' institution. This patient represents another case of severe metabolic acidosis, rhabdomyolysis, and cardiovascular collapse observed after a prolonged propofol infusion in a pediatric patient. The authors suggest selection of other pharmacological agents for long-term sedation in pediatric patients.	Wake Forest Univ, Sch Med, Sect Pediat Anesthesiol & Crit Care, Dept Anesthesiol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Neurosurg, Winston Salem, NC 27157 USA		Cannon, ML (corresponding author), Wake Forest Univ, Sch Med, Sect Pediat Anesthesiol & Crit Care, Dept Anesthesiol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	mlcannon@wfubmc.edu					AITKENHEAD AR, 1989, LANCET, V2, P704, DOI 10.1016/S0140-6736(89)90770-8; BRAY RJ, 1995, ANAESTHESIA, V50, P94, DOI 10.1111/j.1365-2044.1995.tb04544.x; BRUSSEL T, 1989, ANESTH ANALG, V69, P35; Canivet J L, 1994, Acta Anaesthesiol Belg, V45, P19; Cray SH, 1998, CRIT CARE MED, V26, P2087, DOI 10.1097/00003246-199812000-00046; DEARLOVE O, 1995, ANAESTHESIA, V50, P916, DOI 10.1111/j.1365-2044.1995.tb05874.x; FULTON B, 1995, DRUGS, V50, P636, DOI 10.2165/00003495-199550040-00006; GROUNDS RM, 1987, BRIT MED J, V294, P397, DOI 10.1136/bmj.294.6569.397; Hanna JP, 1998, NEUROLOGY, V50, P301, DOI 10.1212/WNL.50.1.301; HAWKINS WJ, 1995, ANAESTHESIA, V50, P564, DOI 10.1111/j.1365-2044.1995.tb06056.x; HIGGINS TL, 1994, CRIT CARE MED, V22, P1415, DOI 10.1097/00003246-199409000-00011; Ito H, 1999, ACTA ANAESTH SCAND, V43, P153, DOI 10.1034/j.1399-6576.1999.430206.x; KANTO J, 1989, CLIN PHARMACOKINET, V17, P308, DOI 10.2165/00003088-198917050-00002; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; KENNEDY TL, 1997, 5 MINUTE PEDIAT CONS, P660; PARKE TJ, 1992, BRIT MED J, V305, P613, DOI 10.1136/bmj.305.6854.613; Perrier ND, 2000, CRIT CARE MED, V28, P3071, DOI 10.1097/00003246-200008000-00066; Plotz FB, 1996, ANAESTH INTENS CARE, V24, P724; Reed MD, 1996, CRIT CARE MED, V24, P175, DOI 10.1097/00003246-199601000-00030; Sanchez-Izquierdo-Riera JA, 1998, ANESTH ANALG, V86, P1219, DOI 10.1097/00000539-199806000-00016; Sitar SM, 1999, ANESTHESIOLOGY, V90, P1446, DOI 10.1097/00000542-199905000-00030; STRICKLAND RA, 1995, CRIT CARE MED, V23, P405, DOI 10.1097/00003246-199502000-00029; Susla GM, 1998, CRIT CARE MED, V26, P1959, DOI 10.1097/00003246-199812000-00019; vanStraaten EA, 1996, INTENS CARE MED, V22, P997, DOI 10.1007/BF02044132; Zhou WG, 1997, ANESTHESIOLOGY, V86, P670, DOI 10.1097/00000542-199703000-00020; Zhou WG, 1999, ANESTH ANALG, V89, P604, DOI 10.1097/00000539-199909000-00011	26	57	59	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2001	95	6					1053	1056		10.3171/jns.2001.95.6.1053			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	499HA	WOS:000172564600022	11765823				2022-02-06	
J	Igarashi, T; Huang, TT; Noble, LJ				Igarashi, T; Huang, TT; Noble, LJ			Regional vulnerability after traumatic brain injury: Gender differences in mice that overexpress human copper, zinc superoxide dismutase	EXPERIMENTAL NEUROLOGY			English	Article						controlled cortical impact; human copper, zinc superoxide dismutase; regional neuronal vulnerability; gender difference	CONTROLLED CORTICAL IMPACT; SEVERE HEAD-INJURY; TRANSGENIC MICE; POSTTRAUMATIC HYPOTHERMIA; CONTUSION INJURY; RATS; PEGORGOTEIN; APOPTOSIS; DEFICITS; STROKE	Neuronal loss was quantified in both cortical and subcortical brain regions after traumatic brain injury in male and female nontransgenic (nTg) and transgenic (Tg) mice that overexpress human copper, zinc superoxide dismutase. Mice were euthanized at 7 days after a controlled cortical impact injury. Sections of brain were processed for immunolocalization of NeuN, a neuronal nuclear antigen, and the complement type 3 receptor, a marker of microglia/macrophages, and stained for iron. Cortical lesion volume and neuronal loss in the medial and/or lateral ventroposterior thalamic nuclei were significantly less in the nTg female compared to the nTg male (P = 0.0373 and P = 0.0023, respectively). In contrast, in CA3 of the hippocampus and laterodorsal thalamic nucleus (LD), there were no gender differences in neuronal loss between these nTg groups. Cortical lesion volume was significantly reduced in Tg males compared to nTg males (P = 0.0137) and was unchanged in the Tg females compared to the nTg females. Neuronal loss was attenuated in the CA3 and LD in the Tg females compared to the nTg females (P = 0.0252 and P = 0.0244, respectively). A similar protection was not observed in the Tg males. Microglial activation paralleled the pattern of neuronal loss and was most consistently aligned with iron deposition in the cortex and hippocampus. No overt differences were found in the pattern of microglial activation or iron staining between nTg and Tg mice nor between genders. Our findings demonstrate that neuroprotection, afforded by overexpression of copper, zinc superoxide dismutase, exhibits both regional and gender specificity. (C) 2001 Elsevier Science.	Univ Calif San Francisco, Dept Neurol Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA		Igarashi, T (corresponding author), Univ Calif San Francisco, Dept Neurol Sci, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS014543, P01NS014543] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14543] Funding Source: Medline		Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; DeWitt D S, 1995, New Horiz, V3, P376; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; Fabian RH, 1998, J NEUROTRAUM, V15, P433, DOI 10.1089/neu.1998.15.433; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; FUKUHARA T, 1994, BRAIN RES, V657, P333, DOI 10.1016/0006-8993(94)90987-3; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1998, ABSTR SOC NEUROSCI, V24, P496; Hamm RJ, 1996, J NEUROTRAUM, V13, P325, DOI 10.1089/neu.1996.13.325; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HILL JM, 1984, NEUROSCIENCE, V11, P595, DOI 10.1016/0306-4522(84)90046-0; HUANG TT, 2001, IN PRESS METHODS ENZ; Kinouchi H, 1998, CELL MOL NEUROBIOL, V18, P609, DOI 10.1023/A:1020213717336; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; Posmantur RM, 2000, EXP NEUROL, V161, P15, DOI 10.1006/exnr.1999.7244; PRZEDBORSKI S, 1992, J NEUROCHEM, V58, P1760, DOI 10.1111/j.1471-4159.1992.tb10051.x; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; SATO M, 1998, J NEUROTRAUM, V15, P895; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Vegeto E, 2001, J NEUROSCI, V21, P1809, DOI 10.1523/JNEUROSCI.21-06-01809.2001; Yamaki T, 1997, BRAIN RES, V752, P151, DOI 10.1016/S0006-8993(96)01469-2; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; Yunoki M, 1997, J NEUROTRAUM, V14, P739, DOI 10.1089/neu.1997.14.739	44	57	57	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	DEC	2001	172	2					332	341		10.1006/exnr.2001.7820			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	510QK	WOS:000173218600008	11716557				2022-02-06	
J	Chan, L; Doctor, J; Temkin, N; MacLehose, RF; Esselman, P; Bell, K; Dikmen, S				Chan, L; Doctor, J; Temkin, N; MacLehose, RF; Esselman, P; Bell, K; Dikmen, S			Discharge disposition from acute care after traumatic brain injury: The effect of insurance type	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; health care economics and organizations; health maintenance organizations; Medicaid; patient discharge; rehabilitation; skilled nursing facilities	REHABILITATION; OUTCOMES; STROKE	Objective: To determine if persons with traumatic brain injury (TBI) who are insured by Medicaid or health maintenance organizations (HMOs) are more likely to receive postacute care in skilled nursing facilities (SNFs) than in rehabilitation facilities, compared with persons insured by commercial fee-for-service (FFS) plans. Design: Retrospective cohort study. Setting: County hospital admitting 30% of all Washington State TBI patients. Patients: Patients with moderate to severe TBI discharged to rehabilitation facilities or SNFs between 1992 and 1997 (n = 1271); 56.3% were insured by Medicaid, 26.1% by FFS plans, and 17.6% by HMOs. Interventions: Not applicable. Main Outcome Measures: Disposition on discharge from acute care (rehabilitation facilities vs SNF); adjusted relative risk (RR) and confidence interval (CI) for different insurance types. Results: After accounting for confounding factors, Medicaid patients were 68% more likely (RR = 1.68, 95% CI 1.34-2.11) and HMO patients were 23% more likely (RR = 1.23, 95% CI = .90-1.68) to go to a SNF than FFS patients. However, the latter difference was not statistically significant. Conclusions: An association exists between insurance type and postacute care site. Efforts should be made to determine the effect this relationship has on the cost and outcomes for TBI patients.	Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Behav Sci, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biostat, Seattle, WA 98195 USA; Hlth Care Financing Adm, Div Clin Stan & Qual, Reg 10, Seattle, WA USA		Chan, L (corresponding author), Univ Washington, Sch Med, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.			Bell, Kathleen/0000-0002-0928-2046			Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; Chan L, 2000, ARCH PHYS MED REHAB, V81, P715, DOI 10.1016/S0003-9993(00)90098-4; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; *HLTH CAR FIN ADM, 1998, HCFA PUBL; Kramer AM, 1997, JAMA-J AM MED ASSOC, V277, P396, DOI 10.1001/jama.277.5.396; Retchin SM, 1997, JAMA-J AM MED ASSOC, V278, P119; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954	8	57	57	0	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2001	82	9					1151	1154		10.1053/apmr.2001.24892			4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	470LR	WOS:000170873900001	11552183				2022-02-06	
J	Wright, P; Rogers, N; Hall, C; Wilson, B; Evans, J; Emslie, H; Bartram, C				Wright, P; Rogers, N; Hall, C; Wilson, B; Evans, J; Emslie, H; Bartram, C			Comparison of pocket-computer memory aids for people with brain injury	BRAIN INJURY			English	Article								Two styles of pocket computer memory aid were compared as support for people who had sustained non-progressive, closed-head brain injury. A purpose-designed interface provided a diary with auditory alarms, a notebook and links between diary entries and specific notepages. One computer had a physical keyboard, the other did not. Twelve adult volunteers were loaned each computer for 2 months, with a 1 month gap between, in counterbalanced order. It was found that all participants could use the memory aids, and most (83%) found them useful. Little customizing was needed, but amount of use varied widely. Predictors of usage included use of other reminding systems before joining the project, and speed in calculator addition which may reflect working memory. High users preferred the computer with a physical keyboard; low users made more entries with the palm-size computer. These data highlight the need to distinguish ability to use from willingness to use.	Cardiff Univ, Sch Psychol, Cardiff CF10 3YG, S Glam, Wales; Addenbrookes Hosp, MRC, Cognit & Brain Sci Unit, Cambridge, England; Oliver Zangwill Ctr, Ely, Cambs, England		Wright, P (corresponding author), Cardiff Univ, Sch Psychol, POB 901, Cardiff CF10 3YG, S Glam, Wales.	WrightP1@cardiff.ac.uk					Baddeley A., 1992, SPEED CAPACITY LANGU; Burgess P, 1996, BEHAV ASSESSMENT DYS; EVANS JJ, 1999, ANN C SOC COGN REH B; KAPUR N, 1995, HDB MEMORY DISORDERS; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; *LIGHTH LOW VIS PR, LIGHTH NEAR VIS AC T; McDaniel M.A., 1996, PROSPECT MEM THEORY, P115; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; SMITH AD, 1996, PERSPECTIVES COGNITI, P192; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 1996, MEMORY, V4, P465, DOI 10.1080/741940776; Wright P, 2000, J EXP PSYCHOL-APPL, V6, P158; Wright P, 2000, ERGONOMICS, V43, P702, DOI 10.1080/001401300404689; [No title captured]; [No title captured]	16	57	57	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2001	15	9					787	800		10.1080/02699050110045161			14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	462ZM	WOS:000170452400004	11516347				2022-02-06	
J	Hammond, FM; Grattan, KD; Sasser, H; Corrigan, JD; Bushnik, T; Zafonte, RD				Hammond, FM; Grattan, KD; Sasser, H; Corrigan, JD; Bushnik, T; Zafonte, RD			Long-term recovery course after traumatic brain injury: A comparison of the functional independence measure and disability rating scale	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; Disability Rating Scale; Functional Independence Measure; outcome	SPINAL-CORD INJURY; GLASGOW OUTCOME SCALE; SEVERE HEAD-INJURY; REHABILITATION; VALIDITY; DYSFUNCTION; RELIABILITY; PREDICTION; RETURN; TESTS	Objectives: To study group changes over time after traumatic brain injury (TBI). Design: Prospective cohort. Setting and Participants: TBI Model System Database with 1160 subjects using cohort with complete data. Main Outcome Measures: Functional Independence Measure (FIM (TM)) and Disability Rating Scale (DRS) at rehabilitation discharge and annually after injury. Results: Statistically significant differences existed between FIM (TM) -Total, FIM (TM) -Motor. FIM (TM) -Cognitive subscales, and DRS at rehabilitation discharge and year 1. Comparisons of year-to-year intervals. years I and 3, 1 and 5, and 3 and 5, revealed no statistically significant differences except between years I and 3 and I and 5 with DRS. and years I and 5 with FIM (TM). Including only those more dependent at year I revealed statistically significant differences between years 1 and 2 and I and 5 on FIM (TM) -Cognitive and DRS, but not the FIM (TM) -Motor. The proportion of change for FIM (TM) and DRS items from year I to years 2 and 5 revealed DRS Level of Functioning and Employability items accounted for most DRS change, whereas FIM (TM) change was more spread across its components. Conclusions: DRS is more sensitive to changes during a shorter time period than FIM (TM) and seems to he more appropriate for detecting long-term deficits. However, research studies aimed at detecting meaningful changes year to year after TBI may need to use other tools or consider changes among individuals instead of group changes, DRS Level of Function and Employability Items represent complex functions expected to recover later than the more basic DRS items. Sole use of these two DRS items might provide an efficient means of measuring long-term recovery when resources are limited. whereas expansion of these two items might allow greater sensitivity and detail.	Charlotte Inst Rehabil, Dept Phys Med & Rehabil, Carolinas Healthcare Syst, Charlotte, NC 28203 USA; R Stuart Dickson Inst Hlth Stat, Carolinas Healthcare Syst, Charlotte, NC USA; Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Univ Pittsburgh, Coll Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA		Hammond, FM (corresponding author), Charlotte Inst Rehabil, Dept Phys Med & Rehabil, Carolinas Healthcare Syst, 1100 Blythe Blvd, Charlotte, NC 28203 USA.		Corrigan, John D./E-2921-2011	Bushnik, Tamara/0000-0003-3328-257X			Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; DAVIDOFF GN, 1990, ARCH PHYS MED REHAB, V71, P326; DITUNNO JF, 1995, SPINAL CORD INJURY C; ELIASON MR, 1984, PHYS THER, V64, P1357, DOI 10.1093/ptj/64.9.1357; Fiedler R., 1996, FUNCTIONAL ELEVATION, P75; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hall KM, 1999, ARCH PHYS MED REHAB, V80, P1471, DOI 10.1016/S0003-9993(99)90260-5; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; Heinemann Allen W, 1994, Top Stroke Rehabil, V1, P1; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; Heinemann AW, 1997, ARCH PHYS MED REHAB, V78, P143, DOI 10.1016/S0003-9993(97)90255-0; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SmithKnapp K, 1996, BRAIN INJURY, V10, P651, DOI 10.1080/026990596124070; Stineman Margaret G, 1994, Top Stroke Rehabil, V1, P40; Stineman MG, 1996, AM J PHYS MED REHAB, V75, P68, DOI 10.1097/00002060-199601000-00018; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; TEASDALE G, 1974, LANCET, V2, P81; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; World Health Organization, 1980, INT CLASS IMP DIS HA	41	57	59	0	4	ASPEN PUBL INC	GAITHERSBURG	200 ORCHARD RIDGE DR, STE 200, GAITHERSBURG, MD 20878 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	2001	16	4					318	329		10.1097/00001199-200108000-00003			12	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	459YA	WOS:000170278000003	11461655				2022-02-06	
J	Hanna-Pladdy, B; Berry, ZM; Bennett, T; Phillips, HL; Gouvier, WD				Hanna-Pladdy, B; Berry, ZM; Bennett, T; Phillips, HL; Gouvier, WD			Stress as a diagnostic challenge for postconcussive symptoms: Sequelae of mild traumatic brain injury or physiological stress response	CLINICAL NEUROPSYCHOLOGIST			English	Article; Proceedings Paper	Annual Meeting of the American-Psychological-Association	AUG 14-18, 1998	SAN FRANCISCO, CA	Amer Psychol Assoc			MINOR HEAD-INJURY; NEUROPSYCHOLOGICAL DEFICITS; RECOVERY; REHABILITATION; CONCUSSION; TASK	There is considerable controversy regarding whether persistent postconcussive symptoms (PCS) are injury-specific, in a subgroup of individuals after mild traumatic brain injury (TBI). The following findings have contributed to this controversy: (1) The base rate of PCS in mild TBI is comparable to uninjured controls; and (2) The severity of PCS covary with daily stress levels (Gouvier, Cubic, Jones, Brantley, & Cutlip, 1992). We examined this relationship further by evaluating the effects of experimental conditions of stress or relaxation on individuals with TBI and uninjured control subjects, with low and high PCS endorsement. We evaluated psychophysiological parameters, neuropsychological performance, and changes in PCS and stress perception. In our study, subjects with TBI increased PCS after engaging in cognitively challenging tasks, and demonstrated significant autonomic changes in the stress condition. Symptomatic TBI subjects exposed to high stress had increases in PCS complaints, decreased speed of information processing, and subtle memory deficits. Our results suggest that PCS are injury-specific and that individuals with a history of TBI are susceptible to the effects of stress. Relaxation training including breathing retraining may be an effective means of decreasing PCS and cognitive complaints in subjects with mild TBI.	Univ Florida, Hlth Sci Ctr, Dept Neurol, Gainesville, FL 32610 USA; Louisiana State Univ, Dept Psychol, Baton Rouge, LA 70803 USA		Hanna-Pladdy, B (corresponding author), Univ Florida, Hlth Sci Ctr, Dept Neurol, 100 S Newell Dr Room L3-100 Box 100236 UFBI, Gainesville, FL 32610 USA.	pladdybh@neurology.ufl.edu		Hanna-Pladdy, Brenda/0000-0001-7806-3843			ALBUS M, 1987, STRESS MEDICINE, V3, P233, DOI 10.1002/smi.2460030314; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; [Anonymous], 1942, Proc R Soc Med, V35, P601; BARTEL PL, 1993, CLONTECHNIQUES, V8, P1; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BINDER LM, 1989, FRONTIERS CLIN NEURO, P37; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; Cernak I, 1999, BRAIN INJURY, V13, P1005; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S, 1992, Brain Inj, V6, P477, DOI 10.3109/02699059209008143; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; Galea LAM, 1997, NEUROSCIENCE, V81, P689, DOI 10.1016/S0306-4522(97)00233-9; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; Gronwall D, 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P74, DOI [DOI 10.1097/00001199-199309000-00009, 10.1097/00001199-199309000-00009]; LEGEWIEPERTZBORN H, 1977, PSYCHIAT PRAX, V4, P223; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LONG CJ, 1984, J REHABIL, V50, P39; LONG CJ, 1986, SOUTHERN MED J, V79, P728, DOI 10.1097/00007611-198606000-00020; Lupien SJ, 1997, BRAIN RES REV, V24, P1, DOI 10.1016/S0165-0173(97)00004-0; LYSAGHT R, 1990, AM J OCCUP THER, V44, P797, DOI 10.5014/ajot.44.9.797; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; McEwen BS, 2000, NEUROCHEM RES, V25, P1219, DOI 10.1023/A:1007687911139; MCEWEN BS, 1995, CURR OPIN NEUROBIOL, V5, P205, DOI 10.1016/0959-4388(95)80028-X; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MCMORDIE WR, 1988, CLIN NEUROPSYCHOL, V2, P198; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MIZOGUCHI K, 1992, NEUROSCI LETT, V138, P157, DOI 10.1016/0304-3940(92)90495-S; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; NOVACK TA, 1988, REHABIL COUNS BULL, V31, P313; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Raber J, 2000, J NEUROSCI, V20, P2064; RAO SL, 1985, NIMHANS J, V2, P141; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Shohami E, 1995, J NEUROTRAUM, V12, P1069, DOI 10.1089/neu.1995.12.1069; Smith A., 1991, SYMBOL DIGIT MODALIT; STOZ P, 1998, BRAIN INJURY, V12, P537; TREMONT G, 1994, 14 M NAT AC NEUR ORL; UNO T, 1989, J NEUROSCI, V9, P1709; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; Wilken JA, 2000, INT J PSYCHOPHYSIOL, V37, P233, DOI 10.1016/S0167-8760(00)00082-9; Zachary R. A., 1986, SHIPLEY I LIVING SCA; [No title captured]; [No title captured]	76	57	57	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG	2001	15	3					289	304		10.1076/clin.15.3.289.10272			16	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Conference Proceedings Citation Index - Science (CPCI-S)	Psychology; Neurosciences & Neurology	482NA	WOS:000171581200001	11778766				2022-02-06	
J	Friedland, JF; Dawson, DR				Friedland, JF; Dawson, DR			Function after motor vehicle accidents: A prospective study of mild head injury and posttraumatic stress	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article							TRAUMATIC BRAIN INJURY; SICKNESS IMPACT PROFILE; PROSPECTIVE FOLLOW-UP; TRAFFIC ACCIDENTS; EVENT SCALE; DISORDER; VICTIMS; PREDICTORS; MORBIDITY; CONSCIOUSNESS	Relationships among mild traumatic brain injury (MTBI), posttraumatic stress (PTS), and function were examined in 99 motor vehicle accident (MVA) admissions: 64 in an MTBI group and 35 in a no-MTBI comparison group. Assessments occurred within the first month and at 6 to 9 months. At follow-up, the sample was moderately disabled on the Sickness Impact Profile (SIP), 71% satisfied on the Reintegration of Normal Living Index (RNL), and 42% had returned to work. Only the SIP Psychosocial score was significantly different for MTBI groups; 24% of the sample showed definite symptoms of PTS. This group was significantly more disabled on the SIP, less satisfied on the RNL, and less likely to return to work. The proportion of variance in outcome explained in each model ranged from 32% (Physical SIP) to 44% (RNL). Results suggest the need for clinicians to be more aware of the strong influence of PTS on functional outcomes.	Univ Toronto, Fac Med, Dept Occupat Therapy, Toronto, ON M5T 1W5, Canada		Friedland, JF (corresponding author), Univ Toronto, Fac Med, Dept Occupat Therapy, 256 McCaul St, Toronto, ON M5T 1W5, Canada.		Dawson, Deirdre R/I-8882-2014	Dawson, Deirdre R/0000-0001-7517-6121			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; ANDERSSON AL, 1994, SCAND J SOC MED, V22, P299, DOI 10.1177/140349489402200409; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Blanchard EB, 1996, BEHAV RES THER, V34, P775, DOI 10.1016/0005-7967(96)00038-1; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; BLANCHARD EB, 1994, BEHAV RES THER, V32, P283, DOI 10.1016/0005-7967(94)90123-6; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BROM D, 1993, J CLIN PSYCHOL, V49, P131, DOI 10.1002/1097-4679(199303)49:2<131::AID-JCLP2270490202>3.0.CO;2-2; Bryant RA, 1999, AM J PSYCHIAT, V156, P1780; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; BRYANT RA, 1995, BEHAV RES THER, V33, P631, DOI 10.1016/0005-7967(94)00093-Y; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Butler DJ, 1999, AM FAM PHYSICIAN, V60, P524; Carlier IVE, 2000, BRIT J MED PSYCHOL, V73, P87, DOI 10.1348/000711200160327; Chemtob CM, 1998, J NERV MENT DIS, V186, P701, DOI 10.1097/00005053-199811000-00007; DAVIDOFF DA, 1988, COGNITIVE REHABI MAR, P8; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; FEINSTEIN A, 1991, PSYCHOL MED, V21, P85, DOI 10.1017/S0033291700014689; Fern KT, 1998, J TRAUMA, V45, P489, DOI 10.1097/00005373-199809000-00010; Goldberg D., 1972, DETECTION PSYCHIAT I; GREEN MM, 1993, MED J AUSTRALIA, V159, P529, DOI 10.5694/j.1326-5377.1993.tb138006.x; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; JURKOVICH G, 1995, J TRAUMA, V39, P625, DOI 10.1097/00005373-199510000-00001; Koren D, 1999, AM J PSYCHIAT, V156, P367; Kuch K, 1996, CAN J PSYCHIAT, V41, P429, DOI 10.1177/070674379604100707; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; McDowell I., 1996, MEASURING HLTH OUTCO; MCFARLANE AC, 1988, J NERV MENT DIS, V176, P30, DOI 10.1097/00005053-198801000-00004; MCFARLANE AC, 1992, J NERV MENT DIS, V180, P439, DOI 10.1097/00005053-199207000-00006; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; McMillan TM, 1997, CURR OPIN NEUROL, V10, P479, DOI 10.1097/00019052-199712000-00008; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Naugle RI, 1990, TRAUMATIC BRAIN INJU, P69; O'Brien M, 1998, BRIT J PSYCHIAT, V173, P102, DOI 10.1192/bjp.173.2.102; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; TEASDALE G, 1974, LANCET, V2, P81; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tyndel M, 1997, CAN J PSYCHIAT, V42, P210, DOI 10.1177/070674379704200219; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; WATTS R, 1995, AUST NZ J PSYCHIAT, V29, P75, DOI 10.3109/00048679509075895; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583; Wrightson P, 1998, NEW ZEAL MED J, V111, P99; ZILBERG NJ, 1982, J CONSULT CLIN PSYCH, V50, P407, DOI 10.1037/0022-006X.50.3.407; 1995, STAT CANADA; [No title captured]	50	57	59	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	JUL	2001	189	7					426	434		10.1097/00005053-200107000-00003			9	Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	459ED	WOS:000170237300003	11504319				2022-02-06	
J	Harris, MB; Kronlage, SC; Carboni, PA; Robert, KQ; Menmuir, B; Ricciardi, JE; Chutkan, NB				Harris, MB; Kronlage, SC; Carboni, PA; Robert, KQ; Menmuir, B; Ricciardi, JE; Chutkan, NB			Evaluation of the cervical spine in the polytrauma patient	SPINE			English	Article; Proceedings Paper	27th Annual Meeting of the Cervical-Spine-Research-Society	DEC 17, 1999	SEATTLE, WA	Cervical Spine Res Soc			TRAUMA PATIENTS; BLUNT TRAUMA; FRACTURES; DIAGNOSIS; INJURIES; FLUOROSCOPY; RADIOGRAPHY; EMERGENCY; EFFICACY; VICTIMS	Study Design. Two-part study. Part One: the analysis of surveys distributed to members of the Orthopaedic Trauma Association (OTA) and 1000 surgeon members of NASS. Part Two:a prospective clinical study evaluating a new algorithm to evaluate the cerivcal spine in polytrauma patients. Objectives. To determine if there is a consensus of the optimal method for "clearing the cervical spine"; to assess the safety and efficacy of a newly proposed algorithm. Summary of Background Data. There is no uniformly accepted algorithm for "clearing the cervical spine" in the polytrauma patient or those patients with altered mental status secondary to the influence of alcohol, drugs or a closed head injury. Methods. All members of the OTA and 1000 surgeon members of NASS were sent questionnaires to assess their methods of "clearing the cervical spine" in the polytrauma patient. Their answers were collated, analyzed and compared to standard ATLS protocol guidelines. A new protocol, which includes a surgeon, controlled stretch test and flouroscopically visualized flexion-extension views, was initiated and evaluated for safety and efficacy. Results. Survey: Fifty-five percent of the members of the OTA and 31% of the NASS surgeons responded to the questionnaire. Among the responses from the NASS members, the ratio of orthopaedic spine surgeons to neurosurgeons accurately parallels the society's membership (77% ortho, 23% neuro). Sixty-nine of the OTA and 54% of the NASS responders : replied that they followed ATLS guidelines. Analysis of their responses showed only 40% compliance. Eighty-one percent of the OTA respondents utilize the standard three view cervical spine trauma services, only 31% of the NASS members adhere to this guidelines. Nearly 90% of ail respondents identified the presence of neck pain or retropharygeal soft tissue swelling as an indicator to expand their initial radiographic evaluation. There was no consensus as to management of the polytrauma patient with a closed head injury. Eighty-two percent of all respondents has seen or treated a purely ligamentous injury of the c-spine. Spective Study: Prospective clinical protocol. 35-monthperiod: enrolled 153 patients, 12,000 patients seen in trauma unit. Completed data 149/153. 8/153 unable to be cleared due to poor visualization of cervical-thoracic junction. 3/153 positive findings identified during fluoro examination. All three instability patterns verified in surgery (true positives). No untoward events to date. Conclusions. A standardized protocol to safely and effectively clear the cervical spine has yet to be established. Preliminary results of a new protocol to safely evaluate the cervical spine in the polytrauma patient are promising.	Louisiana State Univ, Hlth Sci Ctr, Sch Med, Dept Orthopaed Surg, New Orleans, LA USA; Tulane Univ, Sch Med, Dept Orthopaed Surg, New Orleans, LA 70112 USA		Harris, MB (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Orthopaed & Rehabil, Med Ctr Blvd, Winston Salem, NC 27157 USA.	miharris@wfubmc.edu					BACHULIS BL, 1987, AM J SURG, V153, P473, DOI 10.1016/0002-9610(87)90796-3; BLACKSIN MF, 1995, AM J ROENTGENOL, V165, P1201, DOI 10.2214/ajr.165.5.7572503; Chendrasekhar A, 1998, AM SURGEON, V64, P604; DAVIS JW, 1995, J TRAUMA, V39, P435; DAVIS JW, 1993, J TRAUMA, V34, P342, DOI 10.1097/00005373-199303000-00006; Emery S E, 1989, J Spinal Disord, V2, P229; FAZL M, 1990, NEUROSURGERY, V26, P674, DOI 10.1227/00006123-199004000-00019; FISCHER RP, 1984, ANN EMERG MED, V13, P905, DOI 10.1016/S0196-0644(84)80667-8; GERRELTS BD, 1991, J TRAUMA, V31, P1622, DOI 10.1097/00005373-199112000-00010; GISBERT VL, 1989, SURGERY, V106, P702; Harris MB, 1997, ORTHOPEDICS, V20, P903; Herr CH, 1998, AM J EMERG MED, V16, P346, DOI 10.1016/S0735-6757(98)90124-3; LINDSEY RW, 1993, SOUTHERN MED J, V86, P1253, DOI 10.1097/00007611-199311000-00013; MACDONALD RL, 1990, J TRAUMA, V30, P392, DOI 10.1097/00005373-199030040-00004; MILES KA, 1988, INJURY, V19, P177, DOI 10.1016/0020-1383(88)90010-1; *NAT CTR HLTH STAT, 1994, NAT HSOP AMB MED CAR; PLAISIER B, 1994, J TRAUMA, V37, P714, DOI 10.1097/00005373-199411000-00004; REID DC, 1988, J TRAUMA, V28, P1188, DOI 10.1097/00005373-198808000-00009; RINGENBERG BJ, 1988, ANN EMERG MED, V17, P792, DOI 10.1016/S0196-0644(88)80555-9; ROBERGE RJ, 1988, J TRAUMA, V28, P784, DOI 10.1097/00005373-198806000-00010; ROSS S, 1987, ANN EMERG MED, V165, P498; SCHLEEHAUF K, 1989, ANN EMERG MED, V18, P815, DOI 10.1016/S0196-0644(89)80202-1; Sees DW, 1998, J TRAUMA, V45, P768, DOI 10.1097/00005373-199810000-00026; SHAFFER MA, 1981, ANN EMERG MED, V10, P508, DOI 10.1016/S0196-0644(81)80004-2; Stiell IG, 1997, CAN MED ASSOC J, V156, P1537; TEHRANZADEH J, 1994, SKELETAL RADIOL, V23, P349, DOI 10.1007/BF02416991; WEBB JK, 1976, J BONE JOINT SURG BR, V58, P674; White A A 3rd, 1987, Instr Course Lect, V36, P513	28	57	57	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	NOV 15	2000	25	22					2884	2891		10.1097/00007632-200011150-00008			8	Clinical Neurology; Orthopedics	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Orthopedics	374ZA	WOS:000165373800007	11074674				2022-02-06	
J	Gray, DS; Burnham, RS				Gray, DS; Burnham, RS			Preliminary outcome analysis of a long-term rehabilitation program for severe acquired brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; length of stay; outcome assessment (health care); rehabilitation	SEVERE HEAD-INJURY; FUNCTIONAL INDEPENDENCE MEASURE; DISABILITY RATING-SCALE; FOLLOW-UP; EARLY INTERVENTION; OLDER ADULTS; RECOVERY; TRAUMA; COMA; RELIABILITY	Objectives: To describe the general characteristics and functional outcomes of individuals treated in a publicly funded, long-term, acquired brain injury rehabilitation program and investigate variables affecting functional outcomes in this patient population. Design: Retrospective database review of demographic, descriptive, and functional outcome assessment data. Setting: Publicly funded, comprehensive, multidisciplinary, long-term, residential brain injury rehabilitation program in Alberta, Canada (64 beds). Patients: All rehabilitation patients admitted to and discharged from the brain injury program from February 1991 to March 1999 (n = 349). Interventions: Multidisciplinary rehabilitation program. Main Outcome Measures: Demographic and descriptive information included sex, age at admission, type and severity of injury, time from injury to long-term program admission, and length of stay (LOS). Functional outcome information included level of care required at admission and discharge, admission and discharge Rappaport disability rating scale scores, and admission and discharge FIM(TM) instrument and Functional Assessment Measure scores for a subset of patients. Results: Fifty-nine percent of the subjects had severe traumatic brain injuries (TBI) and 41% had severe nontraumatic brain injuries (NTBI) of various causes. Mean age at admission was older and LOS was longer for NTBI compared with TBI; there were no other differences between the groups in demographic or descriptive measures. The TBI group had significantly lower admission motor subscale scores than the NTBI group, but the groups did not differ on cognitive scores. All functional assessment measures showed statistically significant improvement from admission to discharge, and 85.6% of patients were discharged to community living after a mean LOS of 359.5 days. Functional status at admission, age at admission, length of time between injury and admission, and LOS in the rehabilitation program significantly correlated with functional improvement. Conclusions: Patients with severe TBI and NTBI who were not candidates for other more conventional forms of rehabilitation showed significant improvement in functional outcomes after extended program admissions. Consideration was also given to the potential insensitivity of commonly used outcome assessment measures in this population.	Univ Alberta, Div Phys Med & Rehabil, Edmonton, AB, Canada; Alberta Hosp Ponoka, Brain Injury Rehabil Program, Alberta Mental Hlth Board, Edmonton, AB, Canada		Gray, DS (corresponding author), Univ Alberta, Glenrose Rehabil Hosp, Div Phys Med & Rehabil, 10230 111 Ave, Edmonton, AB T5G 0B7, Canada.	gray@telusplanet.net					ANDIEL C, 1995, CAN J REHABIL, V9, P17; BATES D, 1991, J NEUROL NEUROSUR PS, V54, P569, DOI 10.1136/jnnp.54.7.569; BELL KR, 1995, BRAIN INJURY, V9, P315, DOI 10.3109/02699059509008201; Bontke C. F., 1993, J HEAD TRAUMA REHAB, V8, P34; BURKE DC, 1995, BRAIN INJURY, V9, P735, DOI 10.3109/02699059509008229; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Clinchot DM, 1997, ARCH PHYS MED REHAB, V78, P346, DOI 10.1016/S0003-9993(97)90223-9; COPE D N, 1991, Brain Injury, V5, P127, DOI 10.3109/02699059109008084; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Donaghy S, 1998, ARCH PHYS MED REHAB, V79, P1231, DOI 10.1016/S0003-9993(98)90267-2; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; FINSET A, 1992, SCAND J REHABIL MED, P25; FLEMING JM, 1994, ARCH PHYS MED REHAB, V75, P156; GOLDSTEIN FC, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199502000-00007; Good DC, 1998, J NEUROL REHABIL, V12, P153; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Granger CV, 1998, ARCH PHYS MED REHAB, V79, P235, DOI 10.1016/S0003-9993(98)90000-4; Hal KM, 1997, J REHABILITATION OUT, V1, P63; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; HEDRICK WP, 1995, BRAIN INJURY, V9, P563, DOI 10.3109/02699059509008215; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P399, DOI 10.1016/S0003-9993(95)80567-2; Kraus JF, 1987, HEAD INJURY, V2, P1; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; LYLE DM, 1986, J NEUROSURG, V65, P15, DOI 10.3171/jns.1986.65.1.0015; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; Marks I, 1996, PSYCHIAT SERV, V47, P811; Ogden JA, 1997, NEUROSURGERY, V41, P25, DOI 10.1097/00006123-199707000-00008; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; Semlyen JK, 1998, ARCH PHYS MED REHAB, V79, P678, DOI 10.1016/S0003-9993(98)90044-2; SILVERSTEIN B, 1992, ARCH PHYS MED REHAB, V73, P507; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; SPIVACK G, 1992, Brain Injury, V6, P419, DOI 10.3109/02699059209008138; Stewart DG, 1998, NEUROREHABILITATION, V10, P13, DOI 10.3233/NRE-1998-10103; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TUEL S M, 1992, Brain Injury, V6, P363, DOI 10.3109/02699059209034951; Walker WC, 1996, BRAIN INJURY, V10, P65; Walpoth BH, 1997, NEW ENGL J MED, V337, P1500, DOI 10.1056/NEJM199711203372103; WHITENECK GG, 1994, ARCH PHYS MED REHAB, V75, P1073, DOI 10.1016/0003-9993(94)90080-9; WHITLOCK J A JR, 1992, Brain Injury, V6, P447, DOI 10.3109/02699059209008140; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; Willer B, 1999, ARCH PHYS MED REHAB, V80, P399, DOI 10.1016/S0003-9993(99)90276-9; WILSON BA, 1997, J REHABILITATION OUT, V1, P60	64	57	58	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2000	81	11					1447	1456		10.1053/apmr.2000.16343			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	369YT	WOS:000165095900001	11083347				2022-02-06	
J	Stern, SA; Zink, BJ; Mertz, M; Wang, X; Dronen, SC				Stern, SA; Zink, BJ; Mertz, M; Wang, X; Dronen, SC			Effect of initially limited resuscitation in a combined model of fluid-percussion brain injury and severe uncontrolled hemorrhagic shock	JOURNAL OF NEUROSURGERY			English	Article						brain injury; hemorrhage; shock; resuscitation; cerebral blood flow; pig	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; VASCULAR INJURY; VOLUME; ISOFLURANE; EPIDEMIOLOGY; MANAGEMENT; DISABILITY	Object. Studies of isolated uncontrolled hemorrhage have indicated that initial limited resuscitation improves survival. Limited rt suscitation has not been studied in combined traumatic brain injury and uncontrolled hemorrhage. In this study the authors evaluated the effects of limited resuscitation on outcome in combined fluid-percussion injury (FPI) and uncontrolled hemorrhage. Methods. Twenty-four swine weighing 17 to 24 kg each underwent FPI (3 arm) and hemorrhage to a mean arterial pressure (MAP) of 30 mm Hg in the presence of a 4-mm aortic tear. Group I (nine animals) was initially resuscitated to a goal MAP of 60 mm Hg; Group II (nine animals) was resuscitated to a goal MAP of 80 mm Hg; and Group III (control; six animals) was not resuscitated. After 60 minutes, the aortic hemorrhage was controlled and the animals were resuscitated to baseline physiological parameters and observed for 150 minutes. Mortality rates were 11%, 50%, and 100% for Groups I, TT, and III, respectively (Fisher's exact test; p = 0.002). The total hemorrhage volume was greater in Group II (69 +/- 32 ml/kg), as compared with Group I (41 +/- 18 ml/kg) and Group III (37 +/- 3 ml/kg) according to analysis of variance (p < 0.05). In surviving animals, cerebral perfusion pressure, cerebral blood flow (CBF), cerebral venous O-2 saturation (ScvO(2)), and cerebral metabolic rate of O-2 did not differ among groups. Although CBF was approximately 50% of baseline during the period of limited resuscitation in Group I, ScvO(2) remained greater than 60%, and arteriovenous O-2 differences remained within normal limits. Conclusions. In this model of FPI and uncontrolled hemorrhage, early aggressive resuscitation, which is currently recommended, resulted in increased hemorrhage and failure to optimize cerebrovascular parameters. In addition, a 60-minute period of moderate hypotension (MAP = 60 mm Hg) was well tolerated and did not compromise cerebrovascular hemodynamics, as evidenced by physiological parameters that remained within the limits of cerebral autoregulation.	Univ Michigan, Med Ctr, Dept Emergency Med, Ann Arbor, MI 48109 USA		Stern, SA (corresponding author), Univ Michigan, Med Ctr, Dept Emergency Med, TC-B1354-0303,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.						BATTISTELLA FD, 1991, J TRAUMA, V31, P182, DOI 10.1097/00005373-199131020-00005; BICKELL WH, 1991, SURGERY, V110, P529; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chestnut R. M., 1996, NEUROTRAUMA, P445; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276, DOI 10.1152/ajpheart.1992.263.4.H1276; Dixon CE, 1996, NEUROTRAUMA, P1337; DRONEN SC, 1993, AM J EMERG MED, V11, P331, DOI 10.1016/0735-6757(93)90162-5; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GROSS D, 1989, J TRAUMA, V29, P79, DOI 10.1097/00005373-198901000-00016; GROSSLIGHT K, 1985, ANESTHESIOLOGY, V63, P533, DOI 10.1097/00000542-198511000-00011; GUNNAR W, 1988, SURGERY, V103, P398; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; *JOINT SECT TRAUM, 1995, GUID MAN SEV HEAD IN; JONES RR, 1993, WORLD WATCH, V6, P4; Kelly DF, 1996, NEUROTRAUMA, P71; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LYONS C, 1964, ANN SURG, V160, P561, DOI 10.1097/00000658-196410000-00001; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MURR R, 1993, ANESTH ANALG, V77, P898; *NAT SAF COUNC, 1984, ACC FACTS; Prough DS, 1997, J TRAUMA, V42, pS10, DOI 10.1097/00005373-199705001-00003; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SCHELLER MS, 1987, ANESTHESIOLOGY, V67, P507, DOI 10.1097/00000542-198710000-00011; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; Sheikh AA, 1996, CRIT CARE MED, V24, P1226, DOI 10.1097/00003246-199607000-00027; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; STERN SA, 1993, ANN EMERG MED, V22, P155, DOI 10.1016/S0196-0644(05)80195-7; STERN SA, 1995, ACAD EMERG MED, V2, P89, DOI 10.1111/j.1553-2712.1995.tb03167.x; TRANMER BI, 1989, NEUROSURGERY, V25, P173, DOI 10.1227/00006123-198908000-00004; Unterberg AW, 1997, J TRAUMA, V42, pS32, DOI 10.1097/00005373-199705001-00006; *US DEP HHS, 1992, MONTHL VIT STAT REP, V43, P1; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WISNER D, 1989, J SURG RES, V46, P49, DOI 10.1016/0022-4804(89)90181-9; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983; Zink BJ, 1998, ACAD EMERG MED, V5, P9, DOI 10.1111/j.1553-2712.1998.tb02568.x; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011; [No title captured]	51	57	65	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	AUG	2000	93	2					305	314		10.3171/jns.2000.93.2.0305			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	338HY	WOS:000088414500019	10930018				2022-02-06	
J	Cernak, I; Savic, V; Kotur, J; Prokic, V; Kuljic, B; Grbovic, D; Veljovic, M				Cernak, I; Savic, V; Kotur, J; Prokic, V; Kuljic, B; Grbovic, D; Veljovic, M			Alterations in magnesium and oxidative status during chronic emotional stress	MAGNESIUM RESEARCH			English	Article						magnesium; oxidative stress; antioxidant system; chronic emotional stress	TRAUMATIC BRAIN INJURY; RATS; HOMEOSTASIS; TRANSITION; DEFICIENCY; RADICALS; SYSTEM	Magnesium and oxidative status were investigated in young volunteers exposed to chronic stress (political intolerance, awareness of potential military attacks, permanent stand-by duty and reduced holidays more than 10 years) or subchronic stress consisting of everyday mortal danger in military actions lasting more than 3 months. Significant decreases in plasma ionized Mg2+, total Mg and ionized Ca2+ concentrations were found in both groups. Similarly, both study groups exhibited oxidative stress as assessed by increased plasma superoxide anions and malondialdehyde and modified antioxidant defense. There were no significant differences between the two stress groups. A negative correlation between magnesium balance and oxidative stress was observed suggesting that the same etiological factor (chronic stress) initiate decreases in both free and total magnesium concentrations and simultaneously increase oxidative stress intensity. These findings support the need for magnesium supplementation with antioxidant vitamins for people living in conditions of chronic stress.	Mil Med Acad, YU-11002 Belgrade, Serbia		Cernak, I (corresponding author), James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia.	Ibolja.Cernak@jcu.edu.au	Cernak, Ibolja/A-6399-2008	Ibolja, Cernak/0000-0003-3214-698X			Auclair C., 1985, HDB METHODS OXYGEN R, P123; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; BIRCH NJ, 1993, MAGNESTUM CELL; Burke WJ, 1998, BRAIN RES, V787, P328, DOI 10.1016/S0006-8993(97)01488-1; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244; CHROUSOS GP, 1988, MECH PHYSICAL EMOTIO; CLASSEN HG, 1981, ARTERY, V9, P182; CLASSEN HG, 1990, MET IONS BIOL SYST, V26, P321; DarleyUsmar V, 1996, PHARM RES-DORDR, V13, P649, DOI 10.1023/A:1016079012214; DEGROOT H, 1994, HEPATO-GASTROENTEROL, V41, P328; DESOUZA EB, 1986, BRAIN RES, V367, P77, DOI 10.1016/0006-8993(86)91581-7; Durlach J., 1994, Magnesium Research, V7, P313; Durlach J., 1988, MAGNESIUM CLIN MED, P140; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Favier A, 1997, ANN BIOL CLIN-PARIS, V55, P9; GIROTTI MJ, 1991, J TRAUMA, V31, P32, DOI 10.1097/00005373-199101000-00007; Halliwell B., 1989, FREE RADICALS BIOL M, VSecond; Heath DL, 1998, SCAND J CLIN LAB INV, V58, P161, DOI 10.1080/00365519850186751; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Henrotte Jean-Georges, 1993, Magnesium Research, V6, P21; Henrotte JG, 1997, PHYSIOL BEHAV, V61, P653, DOI 10.1016/S0031-9384(96)00506-9; Konig D, 1998, EXERC IMMUNOL REV, V4, P2; Malpuech-Brugere C, 1998, LIFE SCI, V63, P1815, DOI 10.1016/S0024-3205(98)00455-X; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; Memon ZI, 1995, SCAND J CLIN LAB INV, V55, P671, DOI 10.3109/00365519509075397; MISRA HP, 1972, J BIOL CHEM, V247, P3170; MORI A, 1994, NEUROCHEM INT, V24, P201, DOI 10.1016/0197-0186(94)90076-0; Muir KW, 1998, MAGNESIUM RES, V11, P43; Oldham KM, 1998, J AM DIET ASSOC, V98, P1001, DOI 10.1016/S0002-8223(98)00230-2; Planas M, 1997, Nutr Hosp, V12, P233; PLANCER ZA, 1966, ANAL BIOCHEM, V16, P359; PORTA S, 1994, LIFE SCI, V55, pPL327, DOI 10.1016/0024-3205(94)00772-1; Regan RF, 1998, J NEUROCHEM, V70, P77; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Siemkowicz E, 1997, RESUSCITATION, V35, P53, DOI 10.1016/S0300-9572(97)00028-2; SUN M, 1978, ANAL BIOCHEM, V90, P81, DOI 10.1016/0003-2697(78)90010-6; Vigas M, 1996, Bratisl Lek Listy, V97, P63; WEGLICKI WB, 1992, AM J PHYSIOL, V263, pR734	38	57	62	0	5	JOHN LIBBEY EUROTEXT LTD	MONTROUGE	127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE	0953-1424	1952-4021		MAGNESIUM RES	Magnes. Res.	MAR	2000	13	1					29	36					8	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	298GE	WOS:000086130300004	10761188				2022-02-06	
J	Bramlett, HM; Green, EJ; Dietrich, WD				Bramlett, HM; Green, EJ; Dietrich, WD			Exacerbation of cortical and hippocampal CA1 damage due to posttraumatic hypoxia following moderate fluid-percussion brain injury in rats	JOURNAL OF NEUROSURGERY			English	Article						brain injury; hypoxia; secondary injury; fluid-percussion injury; rat	CEREBRAL BLOOD-FLOW; AMINO-ACIDS; IMPACT INJURY; HEAD-INJURY; ISCHEMIA; HYPOTHERMIA; MILD; VULNERABILITY; EXPRESSION; DISRUPTION	Object. Patients with head injuries often experience respiratory distress that results in a secondary hypoxic insult. The present experiment was designed to assess the 'histopathological consequences of a secondary hypoxic insult by using an established rodent model of traumatic brain injury (TBI). Methods. Intubated anesthetized rats were subjected to moderate (1.94-2.18 atm) parasagittal fluid-percussion injury (FPI) to the brain. Following the TBI, the animals were maintained for 30 minutes by using either hypoxic (TBI-HY group, nine animals) or normoxic (TBI-NO, 10 animals) gas levels. Sham-operated animals also underwent ail manipulations except for the FPI (sham-HY group, seven animals, and sham-NO group, seven animals). Three days after TBI the rats were killed, and quantitative histopathological evaluation was undertaken. Cortical contusion volumes were dramatically increased in the TBI-HY group compared with the TBI-NO group (p < 0.03). Qualitative assessment of cortical and subcortical structures demonstrated significant damage within the hippocampal areas, CAI and CA2, of TBI-HY animals compared with the TBI-NO animals (both p < 0.03). There was also a significant increase in the frequency of damaged neuronal profiles within the middle and medial sectors of the CA1 hippocampus (p < 0.03) due to the hypoxic insult. Conclusions. The results of this study demonstrate that a secondary hypoxic insult following parasagittal FPI exacerbates contusion and neuronal pathological conditions. These findings emphasize the need to control for secondary hypoxic insults after experimental and human head injury.	Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33101 USA; Univ Miami, Dept Psychol, Miami, FL 33101 USA; Univ Miami, Neurotrauma Res Ctr, Miami, FL 33101 USA		Dietrich, WD (corresponding author), Univ Miami, Sch Med, Dept Neurol Surg, POB 016960,Mail Locator R-48, Miami, FL 33101 USA.	ddietrich@miamiproject.med.miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291] Funding Source: Medline		Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Brown JIM, 1998, NEUROSURGERY, V42, P1057, DOI 10.1097/00006123-199805000-00060; Chen MZ, 1998, J NEUROTRAUM, V15, P171, DOI 10.1089/neu.1998.15.171; Chesnut R M, 1995, New Horiz, V3, P366; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dave JR, 1997, NEUROREPORT, V8, P395, DOI 10.1097/00001756-199701200-00002; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276, DOI 10.1152/ajpheart.1992.263.4.H1276; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Dings J, 1998, NEUROL RES, V20, pS71; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Graham DI, 1997, GREENFIELDS NEUROPAT, P197; GUTTERIDGE JMC, 1986, FEBS LETT, V201, P291, DOI 10.1016/0014-5793(86)80626-3; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PHILLIS JW, 1993, REGULATION CEREBRAL, P249; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Zilles K., 1985, CORTEX RAT STEREOTAX	35	57	57	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	1999	91	4					653	659		10.3171/jns.1999.91.4.0653			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	239HV	WOS:000082763400018	10507388				2022-02-06	
J	Van Leer, E; Turkstra, L				Van Leer, E; Turkstra, L			The effect of elicitation task on discourse coherence and cohesion in adolescents with brain injury	JOURNAL OF COMMUNICATION DISORDERS			English	Article						narrative structure; discourse analysis; head injury; communication assessment	CLOSED HEAD-INJURY; ADULTS; SKILLS; PERFORMANCE; CHILDREN; DEFICITS	Six adolescents with traumatic brain injury and six adolescents who had been hospitalized for an illness or injury not affecting the brain were administered two narrative tasks designed to vary in their demand for spontaneous organization of information and minimize the requirement for new learning. The discourse topics-a description of each subject's injury and hospitalization, and a re-telling of a current event-were chosen to be representative of discourse in adolescent daily living. Narratives produced by subjects in each group were compared between the two tasks on measures of coherence and cohesion. Subjects in both groups produced significantly more coherent and cohesive narratives in the personal event task than in the current event task, and there was no significant difference between groups. The results are discussed in relation to face validity of language tasks for adolescents, and the multiple factors contributing to adolescent social discourse. (C) 1999 by Elsevier Science Inc.	Univ Arizona, Tucson, AZ 85721 USA		Turkstra, L (corresponding author), Case Western Reserve Univ, Dept Commun Sci, 11206 Euclid Ave, Cleveland, OH 44106 USA.		Turkstra, Lyn/ABC-5831-2021	Turkstra, Lyn/0000-0002-6948-6921	NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC 01409] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [P60DC001409] Funding Source: NIH RePORTER		Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; Brownell, 1990, DISCOURSE ABILITY BR, P69, DOI 10.1007/978-1-4612-3262-9_4; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; CSIKSZENTMIHALY.M, 1984, BEING ADOLESCENT CON; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; GLOSSER G, 1987, UNPUB GUIDELINES RAT; Glosser G., 1990, BRAIN LANG, V40, P67; Halliday M. K., 1976, COHESION ENGLISH; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; Hartley L. L, 1995, COGNITIVE COMMUNICAT; HOLLAND A, 1982, CLIN APH C P MINN; JENNETT B, 1975, LANCET, V1, P480; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; KINTSCH W, 1978, PSYCHOL REV, V85, P363, DOI 10.1037/0033-295X.85.5.363; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1985, J SPEECH HEAR RES, V28, P123, DOI 10.1044/jshr.2801.123; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Patry R., 1990, DISCOURSE ABILITY BR, P3, DOI 10.1007/978-1-4612-3262-9_1; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; Scott CherylM., 1988, LATER LANGUAGE DEV A, P49; SEMEL W, 1995, CLIN EVALUATION LANG; Turkstra LS, 1998, J SPEECH LANG HEAR R, V41, P137, DOI 10.1044/jslhr.4101.137	27	57	57	0	6	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA	0021-9924			J COMMUN DISORD	J. Commun. Disord.	SEP-OCT	1999	32	5					327	349		10.1016/S0021-9924(99)00008-8			23	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	234DD	WOS:000082468500004	10498013				2022-02-06	
J	Marketos, SG; Skiadas, P				Marketos, SG; Skiadas, P			Hippocrates - The father of spine surgery	SPINE			English	Article						history of ancient medicine; Hippocrates; spine; spinal curvatures		Hippocrates (5th-4th century B.C.), the founder of scientific medicine, left a valuable heritage of knowledge and methodology, which extends to almost all branches of modern medicine. Among the many fields of medicine he explored, he devoted much of his scientific interest to the study of orthopedics In fact, some of the principles found in the Hippocratic treatises On Fractures and On Joints are still valid today. This great physician also was the first to deal with the anatomy and the pathology of human spine. In his books, he provides a precise description of the segments and the normal curves of the spine, the structure of the vertebrae, the tendons attached to them, the blood supply to the spine, and even its anatomic relations to adjacent vessels. The Hippocratic list of spinal diseases includes tuberculous spondylitis, post-traumatic kyphosis, scoliosis, concussion, dislocations of the vertebrae, and fractures of the spinous processes. Hippocrates devised two apparatuses, known as the Hippocratic ladder and the Hippocratic board, to reduce displaced vertebrae. Those pioneer methods are deemed to be the precursors to the sophisticated techniques used in spine surgery today. Because of his thorough study of spinal diseases and their management, which was the first such study in orthopedics in the history of medicine, Hippocrates should be regarded as the father of spine surgery.	Univ Athens, Sch Med, Dept Hist Med, GR-11527 Athens, Greece		Marketos, SG (corresponding author), 20 Patriarchou Ioakim St, Athens 10675, Greece.						Adams F, 1849, GENUINE WORKS HIPPOC; BURY RG, 1929, PLATO LONDON CLASSIC, P1; CAPPS E, 1927, HIPPOCRATES LOEB CLA, V3, P200; CAPPS E, 1923, HIPPOCRATES LOEB CLA, V2, P127; CAPPS E, 1927, HIPPOCRATES LOEB CLA, V3, P398; CAPPS E, 1923, HIPPOCRATES LOEB CLA, V2, P185; Edelstein L, 1967, ANCIENT MED SELECTED, P247; GOOLD GP, 1994, HIPPOCRATES LOEB CLA, V7, P18; GOOLD GP, 1995, HIPPOCRATES LOEB CLA, V8, P13; HANEVELD GT, 1980, NETH J SURG, V32, P2; HARTOFIL.G, 1972, CLIN ORTHOP RELAT R, P308; KOLLESCH J, 1965, CORPUS MEDICORUM GRA, V11, P1; KUHN CG, 1965, C GALENI OPERA OMN 1, V18, P300; Kumar K, 1996, SPINE, V21, P653, DOI 10.1097/00007632-199603010-00024; LITTRE PE, 1982, OEUVRES COMPLETES HI, V9, P162; MARKETOS SG, 1996, P 1 INT MED OL KOS I, P59; MARKETOS SG, 1993, ILLUSTRATED HIST MED, P53; Michler M, 1968, Bull Hist Med, V42, P297; PAGE TE, 1937, ARISTOTLE LOEB CLASS, P1; PETREQUIN JE, 1877, CHIRURGIE HIPPOCRATE; Sigerist HE, 1961, HIST MED, VII, P260	21	57	60	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436			SPINE	SPINE	JUL 1	1999	24	13					1381	1387		10.1097/00007632-199907010-00018			7	Clinical Neurology; Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics	211QH	WOS:000081171300021	10404583				2022-02-06	
J	Knerlich, F; Schilling, L; Gorlach, C; Wahl, M; Ehrenreich, H; Siren, AL				Knerlich, F; Schilling, L; Gorlach, C; Wahl, M; Ehrenreich, H; Siren, AL			Temporal profile of expression and cellular localization of inducible nitric oxide synthase, interleukin-1 beta and interleukin converting enzyme after cryogenic lesion of the rat parietal cortex	MOLECULAR BRAIN RESEARCH			English	Article						neurotrauma; iNOS; ICE; IL-1 beta; mRNA expression; immunoreactivity	ISCHEMIC BRAIN INJURY; NECROSIS-FACTOR-ALPHA; CEREBRAL-ARTERY OCCLUSION; GENE-EXPRESSION; MESSENGER-RNA; RECEPTOR ANTAGONIST; NEURONAL DAMAGE; HEAD-INJURY; EDEMA; ACTIVATION	We used in situ hybridization, RT PCR and immunohistochemistry to study the time course of expression and the cellular localization of inducible nitric oxide synthase (iNOS) and interleukin-1 beta (IL-1 beta) during the first 7 days after induction of a standardized cryogenic lesion on the right parietal cortex in male rats. Cryogenic lesion induced iNOS mRNA in the lesioned hemisphere after 6 to 72 h with a maximum (15 +/- 2 cells/mm(2), n = 4, p < 0.01 vs. sham) at 24 h. Microglia, invading monocytes and granulocytes in and around the lesion expressed iNOS immunoreactivity starting at 12 h and peaking (29 +/- 10 cells/mm(2), n = 4, p < 0.05 vs. sham) at 24 h after lesion. Induction of IL-1 beta mRNA expression was immediate with a peak (29 +/- 1 cells/mm2, It = 4, p < 0.01 vs. sham) at 24 h after cryogenic lesion. The number of round cells with IL-1 beta immunoreactivity around the lesion was maximal (8 +/- 2 cells/0.1 mm(2), n = 3, p < 0.01 vs, sham) at 24 h. A weak astrocytic expression of IL-lp-immunoreactivity was seen in sham animal brains. Astrocytic IL-lp-expression was significantly increased in the lesion hemisphere and both hippocampi. Interleukin converting enzyme (ICE) was expressed in astrocytes and microglia around the lesion 6 h after injury. The number of ICE immunoreactive cells (8 +/- 2 cells/0.1 mm2, n = 3, p < 0.05 vs, sham) peaked at 72 h after lesion. Neuronal expression of ICE and IL-1 beta was seen in the lesion periphery 72 h and 7 days after injury. At this time, morphological features of apoptosis were evident in cells in the lesion periphery. The data indicate an early activation of microglia and monocyte invasion into the lesion hemisphere leading to multicellular expression of iNOS, ICE, and IL-1 beta. These events may contribute to the expansion of neuronal damage after brain injury. (C) 1999 Elsevier Science B.V. All rights reserved.	Univ Gottingen, Dept Psychiat, D-3400 Gottingen, Germany; Univ Gottingen, Dept Neurol, D-3400 Gottingen, Germany; Max Planck Inst Expt Med, D-37075 Gottingen, Germany; Univ Hosp Mannheim, Dept Neurosurg, D-68167 Mannheim, Germany; Univ Munich, Dept Physiol, D-80366 Munich, Germany		Siren, AL (corresponding author), Univ Gottingen, Dept Psychiat, D-3400 Gottingen, Germany.	siren@exmax1.mpiem.gwdg.de	Knerlich-Lukoschus, Friederike F/J-2895-2016; Knerlich-Lukoschus, Friederike/A-3233-2011; Siren, Anna-Leena/AAE-1374-2019	Knerlich-Lukoschus, Friederike F/0000-0002-6284-0449; Siren, Anna-Leena/0000-0002-2217-0081; Knerlich-Lukoschus, Friederike/0000-0003-4907-015X; Ehrenreich, Hannelore/0000-0001-8371-5711			BERGER SL, 1989, METHOD ENZYMOL, V180, P3; Berker E, 1996, INT J NEUROSCI, V85, P195, DOI 10.3109/00207459608986683; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Cook JL, 1998, BRAIN RES PROTOC, V3, P1, DOI 10.1016/S1385-299X(98)00012-9; EHRENREICH H, 1993, BRAIN RES, V600, P201, DOI 10.1016/0006-8993(93)91374-2; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Endres M, 1998, NEUROSCI LETT, V248, P41, DOI 10.1016/S0304-3940(98)00224-9; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; ERISKAT J, 1994, ACTA NEUROCHIR, P425; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Gorlach C, 1998, J CEREBR BLOOD F MET, V18, P1357; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Hallenbeck JM, 1997, NEUROLOGY, V49, pS5, DOI 10.1212/WNL.49.5_Suppl_4.S5; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hayashi T, 1998, STROKE, V29, P1007, DOI 10.1161/01.STR.29.5.1007; Hermann DM, 1998, NEUROREPORT, V9, P1249, DOI 10.1097/00001756-199804200-00053; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P378, DOI 10.1038/jcbfm.1995.47; Iadecola C, 1997, J NEUROSCI, V17, P9157; Iadecola C, 1996, STROKE, V27, P1373, DOI 10.1161/01.STR.27.8.1373; Kitagawa H, 1998, STROKE, V29, P1417, DOI 10.1161/01.STR.29.7.1417; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Loddick SA, 1997, BIOCHEM BIOPH RES CO, V234, P211, DOI 10.1006/bbrc.1997.6436; Loddick SA, 1996, NEUROREPORT, V7, P1465, DOI 10.1097/00001756-199606170-00004; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; Murakami K, 1998, J NEUROTRAUM, V15, P825, DOI 10.1089/neu.1998.15.825; Murakami K, 1997, NEUROSCIENCE, V81, P231, DOI 10.1016/S0306-4522(97)00197-8; Murakami K, 1997, ACT NEUR S, V70, P234; Pasinelli P, 1998, P NATL ACAD SCI USA, V95, P15763, DOI 10.1073/pnas.95.26.15763; Sairanen TR, 1997, J CEREBR BLOOD F MET, V17, P1107, DOI 10.1097/00004647-199710000-00013; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; SCHILLING L, 1994, ACTA NEUROCHIR, P79; Stoffel M, 1997, J NEUROTRAUM, V14, P339, DOI 10.1089/neu.1997.14.339; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhang FY, 1996, STROKE, V27, P317, DOI 10.1161/01.STR.27.2.317	47	57	57	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	MAY 7	1999	68	1-2					73	87		10.1016/S0169-328X(99)00064-9			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	197JB	WOS:000080360700008	10320785				2022-02-06	
J	Radanov, BP; Bicik, I; Dvorak, J; Antinnes, J; von Schulthess, GK; Buck, A				Radanov, BP; Bicik, I; Dvorak, J; Antinnes, J; von Schulthess, GK; Buck, A			Relation between neuropsychological and neuroimaging findings in patients with late whiplash syndrome	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						brain damage; neuroimaging; neuropsychological testing; whiplash injury; working memory	POSITRON EMISSION TOMOGRAPHY; TRAUMATIC BRAIN INJURY; FOLLOW-UP; TECHNETIUM-99M-HMPAO SPECT; CEREBRAL SYMPTOMS; COMMON WHIPLASH; WORKING-MEMORY; DEFICITS; NECK	Objectives-The interpretation of long term cognitive impairment after whiplash injury is still a problem for many physicians. On the grounds of nuclear medicine findings previous research speculated that brain damage is responsible for cognitive problems of patients with whiplash. To test this hypothesis the relation between neuroimaging and neuropsychological findings was analysed. Methods-Twenty one patients (11 women, 10 men, mean age 42.2 (SD 8.6) years) with the late whiplash syndrome (average interval of trauma 26.1 (SD 20.7) months) referred for diagnostic action to the Department of Neurology were investigated. Assessment included computer assisted assessment of working memory and divided attention, neuroimaging (by the means of [Tc-99m]-HMPAO-SPECT, [O-15]-H2O-PET and [F-18]-FDG-PET), testing of emotional functioning (depression and anxiety ratings), and pain intensity at the time of testing. Results-On average, scoring on tests of cognitive functioning was very low. However, no significant correlations were found between regional perfusion or metabolism in any brain area and the scores of divided attention or working memory. By contrast, significant relations were found between indices of impaired emotional functioning (state anxiety) and divided attention. In addition, low scoring in divided attention was significantly correlated with pain intensity at the time of testing. Conclusions-The present data do not provide evidence of a significant relation between detectable morphological or functional brain damage and impaired cognitive performance in the late whiplash syndrome. Results indicate triggering of emotional and cognitive symptoms on the basis of initial injury of the cervical spine.	Univ Bern, Inselspital, Dept Psychiat, CH-3010 Bern, Switzerland; Univ Zurich Hosp, Div Nucl Med, CH-8091 Zurich, Switzerland; Wilhelm Schulthess Hosp, Dept Neurol, CH-8008 Zurich, Switzerland; Ochsner Fdn Hosp, Dept Orthoped Surg, New Orleans, LA 70121 USA		Radanov, BP (corresponding author), Univ Bern, Inselspital, Dept Psychiat, CH-3010 Bern, Switzerland.	radanov@pupk.unibe.ch					Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; BALLA JI, 1980, AUST NZ J SURG, V50, P610, DOI 10.1111/j.1445-2197.1980.tb04207.x; Beck AT, 1987, BECK DEPRESSION INVE; Bicik I, 1998, NEUROLOGY, V51, P345, DOI 10.1212/WNL.51.2.345; BLUM B, 1997, THESIS U ZUERICH ZUE; CAINE ED, 1986, NEUROPSYCHOLOGICAL A, P221; CASEY KL, 1994, J NEUROPHYSIOL, V71, P802, DOI 10.1152/jn.1994.71.2.802; COSTA PT, 1987, J PERS, V55, P299, DOI 10.1111/j.1467-6494.1987.tb00438.x; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; ETTLIN TM, 1992, J NEUROL NEUROSUR PS, V55, P943, DOI 10.1136/jnnp.55.10.943; EYSENCK MW, 1988, HDB LIFE STRESS COGN, P467; Fiez JA, 1996, J NEUROSCI, V16, P808; FRACKOWIAK RSJ, 1994, J ANAT, V184, P211; Goldman-Rakic P. S., 1994, MOTOR COGNITIVE FUNC, P112; HAUTZINGER M, 1992, BECK DEPRESSIONS INV; HIRSCH SA, 1988, ORTHOP CLIN N AM, V19, P791; ICHISE M, 1994, J NUCL MED, V35, P217; JACOBS A, 1994, J NUCL MED, V35, P942; KEIDEL M, 1992, NERVENARZT, V63, P731; KISCHKA U, 1991, EUR NEUROL, V31, P136, DOI 10.1159/000116663; Laux LG., 1981, STATE TRAIT ANGSTINV; Mayou R, 1996, J PSYCHOSOM RES, V40, P461, DOI 10.1016/0022-3999(95)00586-2; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; OMMAYA K, 1995, HDB CLIN NEUROLOGY, P67; Otte A, 1996, EUR J NUCL MED, V23, P72, DOI 10.1007/BF01736993; Otte A, 1997, J NEUROL NEUROSUR PS, V63, P368, DOI 10.1136/jnnp.63.3.368; Otte A, 1997, J NUCL MED, V38, P1002; RADANOV BP, 1994, J NEUROL NEUROSUR PS, V57, P486, DOI 10.1136/jnnp.57.4.486; RADANOV BP, 1995, MEDICINE, V74, P281, DOI 10.1097/00005792-199509000-00005; Radanov BP, 1996, PAIN, V64, P429, DOI 10.1016/0304-3959(95)00148-4; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; RADANOV BP, 1993, ARCH NEUROL-CHICAGO, V50, P87, DOI 10.1001/archneur.1993.00540010081022; Spielberger CD., 1970, STATE TRAIT ANXIETY; SPITZER WO, 1995, SPINE, V20, pS1; TALARAICH J, 1988, COPLANAR STEREOTACTI; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; Zimmermann P., 1993, DEV ASSESSMENT REHAB, P3	37	57	59	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	1999	66	4					485	489		10.1136/jnnp.66.4.485			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	181TA	WOS:000079457400013	10201421	Green Published, Bronze			2022-02-06	
J	Moore, AN; Kampfl, AW; Zhao, X; Hayes, RL; Dash, PK				Moore, AN; Kampfl, AW; Zhao, X; Hayes, RL; Dash, PK			Sphingosine-1-phosphate induces apoptosis of cultured hippocampal neurons that requires protein phosphatases and activator protein-1 complexes	NEUROSCIENCE			English	Article						phosphatases; calcineurin; TRE sequence; c-Fos; caspase; AP-1 complexes	PROGRAMMED CELL-DEATH; TRAUMATIC BRAIN INJURY; ICE-LIKE PROTEASE; C-JUN; THYMOCYTE APOPTOSIS; CALPAIN INHIBITORS; GENE-EXPRESSION; NERVOUS-SYSTEM; KINASE-C; CERAMIDE	In this study, we report that mobilization of internal Ca2+ by sphingosine-1-phosphate, a metabolite of ceramide, induces apoptosis in cultured hippocampal neurons. This sphingosine 1-phosphate-induced apoptosis is dependent upon the activation of protein phosphatases, possibly calcineurin and phosphatase 2A (or a related phosphatase). In addition, pretreatment of neurons with double-stranded oligonucleotides containing the metallothionein phorbol-12-myristate-13-acetate response element sequence as transcription factor decoys suppressed apoptosis. In contrast, double-stranded oligonucleotides containing either the c-jun or SV40 phorbol 12-myristate-13-acetate response element sequences were ineffective. Electrophoretic mobility shift assays and supershift assays revealed that c-Fos-containing activator protein-1 complexes preferentially bound the metallothionein phorbol-12-myristate-13-acetate response element sequence-containing oligonucleotides. Furthermore, antisense oligonucleotides to c-fos and c-jun were also protective. The apoptotic death of hippocampal neurons has been hypothesized to contribute to the cognitive impairments observed following insults to the brain. While increases in intracellular calcium are thought to be key mediators of neuronal apoptosis, the biochemical cascade(s) activated as a result of increased Ca2+ which mediates apoptosis of hippocampal neurons is (are) not well understood. The findings presented in this study suggest that mobilization of internal calcium via prolonged exposure of sphingosine-1-phosphate induces apoptosis of hippocampal neurons in culture. Sustained increases in intracellular calcium activate a phosphatase cascade that includes calcineurin and a phosphatase 2A-like phosphatase, and leads to the expression of genes containing metallothionein phorbol-12-myristate-13-acetate response element (TGAGTCA)-type enhancer sequences. The expression of genes containing TGAGTCA-type enhancer sequences appears to be essential for sphingosine-1-phosphate-induced apoptosis of hippocampal neurons. (C) 1999 IBRO. Published by Elsevier Science Ltd.	Univ Texas, Sch Med, Dept Neurobiol & Anat, WM Keck Ctr Neurobiol Learning & Memory, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Neurosurg, Houston, TX 77225 USA; Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria		Dash, PK (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, WM Keck Ctr Neurobiol Learning & Memory, POB 20708, Houston, TX 77225 USA.	pdash@nba19.med.uth.tmc.edu			NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH49662] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35457] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH049662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035457] Funding Source: NIH RePORTER		ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; BREWER GJ, 1989, BRAIN RES, V494, P6; CABELL L, 1993, INT J DEV NEUROSCI, V11, P357, DOI 10.1016/0736-5748(93)90007-Z; CHIASSON BJ, 1992, EUR J PHARM-MOLEC PH, V227, P451, DOI 10.1016/0922-4106(92)90167-T; Choi Dennis W., 1995, Trends in Neurosciences, V18, P58, DOI 10.1016/0166-2236(95)93870-4; COHEN P, 1988, METHOD ENZYMOL, V159, P427; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; GENESTIER L, 1994, CELL IMMUNOL, V155, P283, DOI 10.1006/cimm.1994.1122; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Irie F, 1998, J NEUROSCI RES, V54, P475, DOI 10.1002/(SICI)1097-4547(19981115)54:4<475::AID-JNR5>3.0.CO;2-P; JARVIS WD, 1994, CANCER RES, V54, P1707; Kampfl A, 1996, EUR J NEUROSCI, V8, P344, DOI 10.1111/j.1460-9568.1996.tb01218.x; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LEVLAM V, 1997, NEURON, V18, P1025; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MCCONKEY DJ, 1994, IMMUNOL REV, V142, P343, DOI 10.1111/j.1600-065X.1994.tb00896.x; McIntosh TK, 1996, EUR J ANAESTH, V13, P291, DOI 10.1046/j.1365-2346.1996.00981.x; Mitoma J, 1998, J NEUROSCI RES, V51, P712, DOI 10.1002/(SICI)1097-4547(19980315)51:6<712::AID-JNR5>3.3.CO;2-Q; Moore AN, 1996, J BIOL CHEM, V271, P14214, DOI 10.1074/jbc.271.24.14214; MORGAN JI, 1991, REV NEUROSCI, V14, P421; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; Neary JT, 1996, NEUROREPORT, V7, P2893, DOI 10.1097/00001756-199611250-00017; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; SCHLINGENSIEPEN KH, 1993, DEV GENET, V14, P305, DOI 10.1002/dvg.1020140408; Schwarz A, 1997, J NEUROSCI, V17, P2929; SHEN H, 1995, NEUROSCI LETT, V185, P115, DOI 10.1016/0304-3940(94)11238-E; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SONNENBERG JL, 1989, NEURON, V4, P477; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Squier MKT, 1997, J IMMUNOL, V158, P3690; SQUIRE LR, 1995, CURR OPIN NEUROBIOL, V5, P169, DOI 10.1016/0959-4388(95)80023-9; THOMBERRY NA, 1992, NATURE, V356, P768; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Waxham MN, 1996, J CEREBR BLOOD F MET, V16, P1, DOI 10.1097/00004647-199601000-00001; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	62	57	57	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		1999	94	2					405	415		10.1016/S0306-4522(99)00288-2			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	245YE	WOS:000083135600007	10579204				2022-02-06	
J	Morris, GF; Juul, N; Marshall, SB; Benedict, B; Marshall, LF				Morris, GF; Juul, N; Marshall, SB; Benedict, B; Marshall, LF		Executive Comm Int Selfotel Trial	Neurological deterioration as a potential alternative endpoint in human clinical trials of experimental pharmacological agents for treatment of severe traumatic brain injuries	NEUROSURGERY			English	Article						Glasgow Outcome Scale; human clinical trials; outcome measures; pupillary abnormality; severe head injury; traumatic brain injury	SEVERE HEAD-INJURY	OBJECTIVE: A recently improved understanding of the pathophysiological features of head injuries has led to the development of new drug therapies. Accurate human clinical trials remain necessary to document the efficacy and safety of new agents. It would be helpful to decrease the time from drug development to clinical use and general availability for drugs found to be effective. Conversely, ineffective agents could be abandoned in a timely fashion. RATIONALE: A new endpoint measure, defined as neuroworsening (NW), is an objective observable event that is identifiable during hospitalization. This may enable the efficacy of drugs to be demonstrated or disproved much earlier than with 6-month outcome assessments. The prospective, double-blind, multicenter trial of the N-methyl-D-aspartate receptor antagonist Selfotel was used to acquire data on the efficacy of NW in predicting neurological outcomes. The 6-month Glasgow Outcome Scale scores, which were the primary endpoints of that trial, were compared with the frequency of NW. NW was an observable event that could be objectively defined after head injuries. Patients who suffered one or more episodes of NW demonstrated significantly higher morbidity and mortality rates than did patients who did not. CONCLUSION: Future trials should consider the use of NW as an outcome measure that can be included with more traditional measures in the study design. If the strong correlation demonstrated between NW and 6-month Glasgow Outcome Scale scores can be prospectively demonstrated in a successful trial, the time to approval of future agents could be decreased.	Univ Calif San Diego, Ctr Med, Div Neurosurg, San Diego, CA 92103 USA; Aalborg Hosp, Dept Neuroanesthesia & Neurointens Care, Aalborg, Denmark		Marshall, LF (corresponding author), Univ Calif San Diego, Ctr Med, Div Neurosurg, 200 W Arbor Dr, San Diego, CA 92103 USA.						CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; HALL ED, 1993, RES P ARNMD, V71, P81; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1989, J NEUROSURG S, V75, pS28; MCINTOSH TK, 1992, EXCITATORY AMINO ACI, P247; Myseros JS, 1995, ANN NY ACAD SCI, V765, P262, DOI 10.1111/j.1749-6632.1995.tb16583.x; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538	11	57	58	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	1998	43	6					1369	1372		10.1097/00006123-199812000-00063			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	141LP	WOS:000077145700056	9848851				2022-02-06	
J	Whalen, MJ; Carlos, TM; Kochanek, PM; Wisniewski, SR; Bell, MJ; Carcillo, JA; Clark, RSB; DeKosky, ST; Adelson, PD				Whalen, MJ; Carlos, TM; Kochanek, PM; Wisniewski, SR; Bell, MJ; Carcillo, JA; Clark, RSB; DeKosky, ST; Adelson, PD			Soluble adhesion molecules in CSF are increased in children with severe head injury	JOURNAL OF NEUROTRAUMA			English	Article						ICAM-1; inflammation; meningitis; neutrophils; P-selectin; traumatic brain injury	TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL BACTERIAL-MENINGITIS; CEREBRAL-ARTERY OCCLUSION; NECROSIS-FACTOR-ALPHA; CEREBROSPINAL-FLUID; ENDOTHELIAL-CELLS; NEUTROPHIL ADHESION; MULTIPLE-SCLEROSIS; ICAM-1 EXPRESSION	Leukocyte-endothelial adhesion molecules, critical to the development of acute inflammation, are expressed in brain as part of the acute inflammatory response to traumatic brain injury (TBI), We measured the concentrations of the adhesion molecules P-selectin, ICAM-1, E-selectin, L-selectin, and VCAM-1 in ventricular cerebrospinal fluid (CSF) from children with severe TBI (Glasgow coma score < 8) and compared these findings with those from children with bacterial meningitis, P-selectin, an adhesion molecule associated with ischemia/reperfusion, was increased in children with TBI versus meningitis and control, Univariate and multivariate regression analyses demonstrated associations between CSF P-selectin and child abuse and age of <4 years, and a significant, independent association between CSF intercellular adhesion molecule-1 (ICAM-1) and child abuse. These results are consistent with a specific acute inflammatory component to TBI in children. Future studies of secondary injury mechanisms and therapy after TBI should assess on the roles of P-selectin and ICAM-1 in injury and repair processes in brain after TBI.	Univ Pittsburgh, Safar Ctr Resuscitat, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat, Dept Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat, Dept Epidemiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat, Dept Anesthesiol & Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.		Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758; Wisniewski, Stephen/0000-0002-3877-9860	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [KO8 NS01809-01, KO8 NS01946-01, NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, K08NS001946, P50NS030318, K08NS001809] Funding Source: NIH RePORTER		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Adelson PD, 1998, ACT NEUR S, V71, P104; AKIYAMA H, 1993, ACTA NEUROPATHOL, V85, P628, DOI 10.1007/BF00334673; Azuma H, 1997, J PEDIATR-US, V131, P463, DOI 10.1016/S0022-3476(97)80079-0; Barnett CC, 1996, J SURG RES, V63, P6; BELL M, 1998, CRIT CARE MED, V26, pA86; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BERG EL, 1989, IMMUNOL REV, V108, P5, DOI 10.1111/j.1600-065X.1989.tb00010.x; BIRDSALL HH, 1991, AM J PATHOL, V139, P1341; Buhrer C, 1996, ARCH DIS CHILD, V74, P288, DOI 10.1136/adc.74.4.288; CANNELLA B, 1991, LAB INVEST, V65, P23; CARLOS TM, 1994, BLOOD, V84, P2068; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; Chopp M, 1996, J CEREBR BLOOD F MET, V16, P578, DOI 10.1097/00004647-199607000-00007; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLARK WM, 1993, J NEUROIMMUNOL, V44, P123, DOI 10.1016/0165-5728(93)90275-4; CODY R, 1995, J NEUROTRAUM, V12, P976; DOREDUFFY P, 1995, ANN NEUROL, V37, P55, DOI 10.1002/ana.410370111; FABRY Z, 1992, J NEUROIMMUNOL, V36, P1, DOI 10.1016/0165-5728(92)90026-H; FASSBENDER K, 1995, STROKE, V26, P1361, DOI 10.1161/01.STR.26.8.1361; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; FROHMAN EM, 1989, J NEUROIMMUNOL, V23, P117, DOI 10.1016/0165-5728(89)90030-1; GAMBLE JR, 1990, SCIENCE, V249, P414; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Gupta AK, 1995, J CEREB BLOOD FLOW M, V15, pS33; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; HINES D, 1993, SOC NEUR ABSTR, V18, P1875; Ishiguro A, 1996, PEDIATR RES, V40, P610, DOI 10.1203/00006450-199610000-00016; JANDER S, 1993, NEUROLOGY, V43, P1809, DOI 10.1212/WNL.43.9.1809; Kochanek PM, 1998, CRIT CARE MED, V26, P1788, DOI 10.1097/00003246-199811000-00013; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Lindsberg PJ, 1996, CIRCULATION, V94, P939, DOI 10.1161/01.CIR.94.5.939; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; LopezCortes LF, 1997, ANN CLIN BIOCHEM, V34, P165, DOI 10.1177/000456329703400206; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; PFISTER HW, 1990, J CEREBR BLOOD F MET, V10, P914, DOI 10.1038/jcbfm.1990.148; PIGOTT R, 1992, BIOCHEM BIOPH RES CO, V187, P584, DOI 10.1016/0006-291X(92)91234-H; RIECKMANN P, 1995, NEUROSCI LETT, V186, P61, DOI 10.1016/0304-3940(95)11282-2; RIECKMANN P, 1993, J NEUROIMMUNOL, V47, P133, DOI 10.1016/0165-5728(93)90023-R; ROSNER B, 1984, BIOMETRICS, V40, P1025, DOI 10.2307/2531153; ROTHWELL NJ, 1995, INT J DEV NEUROSCI, V13, P179, DOI 10.1016/0736-5748(95)00018-C; SATOH JI, 1991, J NEUROPATH EXP NEUR, V50, P215, DOI 10.1097/00005072-199105000-00004; SCHURER L, 1990, ACT NEUR S, V51, P49; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHARIEF MK, 1993, J NEUROIMMUNOL, V43, P15, DOI 10.1016/0165-5728(93)90070-F; SHERMAN DG, 1995, STROKE, V26, P164; SHIGA Y, 1991, NEUROSCI LETT, V125, P110, DOI 10.1016/0304-3940(91)90003-C; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; SOBEL RA, 1990, AM J PATHOL, V136, P1309; Tang T, 1996, J CLIN INVEST, V97, P2485, DOI 10.1172/JCI118695; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; VORA AJ, 1995, J IMMUNOL METHODS, V180, P165, DOI 10.1016/0022-1759(94)00312-K; Weber JR, 1995, J NEUROIMMUNOL, V63, P63; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Whalen MJ, 1998, ACT NEUR S, V71, P212; Wong D, 1996, J NEUROPATH EXP NEUR, V55, P225, DOI 10.1097/00005072-199602000-00011; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767	64	57	61	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	1998	15	10					777	787		10.1089/neu.1998.15.777			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	132LW	WOS:000076632400003	9814634				2022-02-06	
J	Nahas, Z; Arlinghaus, KA; Kotrla, KJ; Clearman, RR; George, MS				Nahas, Z; Arlinghaus, KA; Kotrla, KJ; Clearman, RR; George, MS			Rapid response of emotional incontinence to selective serotonin reuptake inhibitors	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							DAMAGE; STROKE	Emotional incontinence (EI) is a perturbing condition characterized by uncontrollable outbursts of exaggerated, involuntary facial expressions and pathological crying or laughter. There is increasing evidence that serotonergic neurotransmission may be damaged in EI. The authors report 4 pathological crying cases (3 poststroke and 1 with multiple sclerosis) and 1 case of pathological laughter after traumatic brain injury. EI improved dramatically with three different selective serotonin reuptake inhibitors (fluoxetine, sertraline, and paroxetine) in the context of these different CNS diseases.	Baylor Coll Med, Houston, TX 77030 USA					George, Mark/0000-0003-1767-1815; Nahas, Ziad/0000-0002-8391-5673			ANDERSEN G, 1994, STROKE, V25, P1050, DOI 10.1161/01.STR.25.5.1050; ANDERSEN G, 1993, LANCET, V342, P837, DOI 10.1016/0140-6736(93)92696-Q; ANDERSEN G, 1995, DRUG AGING, V6, P105, DOI 10.2165/00002512-199506020-00003; BENEDEK DM, 1995, AM J PSYCHIAT, V152, P953; Derex L, 1997, STROKE, V28, P1464, DOI 10.1161/01.STR.28.7.1464; Iannaccone S, 1996, CLIN NEUROPHARMACOL, V19, P532, DOI 10.1097/00002826-199619060-00008; RASMUSSEN K, 1990, SYNAPSE, V5, P324, DOI 10.1002/syn.890050409; Robinson RG, 1997, ANNU REV MED, V48, P217; ROSS ED, 1987, J NERV MENT DIS, V175, P165, DOI 10.1097/00005053-198703000-00007; SANDYK R, 1985, CLIN NEUROPHARMACOL, V8, P377, DOI 10.1097/00002826-198512000-00009; SCHIFFER RB, 1985, NEW ENGL J MED, V312, P1480, DOI 10.1056/NEJM198506063122303; Szczudlik A, 1995, Neurol Neurochir Pol, V29, P663; TORK I, 1990, ANN NY ACAD SCI, V600, P194; UDAKA F, 1984, ARCH NEUROL-CHICAGO, V41, P1095, DOI 10.1001/archneur.1984.04050210093023; VANHILTEN JJ, 1988, ARCH NEUROL-CHICAGO, V45, P936, DOI 10.1001/archneur.1988.00520330010001	15	57	58	0	2	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	1998	10	4					453	455		10.1176/jnp.10.4.453			3	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	135CR	WOS:000076783200011	9813792				2022-02-06	
J	Hibbard, MR; Uysal, S; Sliwinski, M; Gordon, WA				Hibbard, MR; Uysal, S; Sliwinski, M; Gordon, WA			Undiagnosed health issues in individuals with traumatic brain injury living in the community	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							HEAD-INJURY; REHABILITATION; EPILEPSY	Objectives: To examine the self-reported prevalence of long-term health issues in individuals with traumatic brain injury (TBI) living in the community. Design: A structured health interview. For individuals with TBI, the presence of a specific health-related issue with onset post-TBI and currently a problem at the time of the interview was explored. For individuals without disability, a specific health-related issue was evaluated at time of interview. For each health issue, the proportion of individuals with TBI experiencing post-TBI onset but current symptoms was contrasted with symptom reports of individuals without disability. Chi-square statistical analyses were used to determine significance. For individuals with TBI, logistic regressions were used to model the probability of having a particular health difficulty when four covariates were examined, such as age, gender, rime since onset of TBI, and duration of loss of consciousness (LOC). Setting: Urban, suburban, and rural New York State. Participants: 338 individuals with TBI and 273 individuals without disability between the ages of 18 and 65 years. Individuals with TBI were, on average, 10 years post-onset at the time of interview. Main Outcome Measures: Self-reported health issues reflective of neuroendocrine, neurological, immunosuppression, and other hearth issues. Results: Chronic health issues suggestive of ongoing neuroendocrine dysfunctions (ie, changes in hair/skin texture, body temperature changes), neurologic difficulties (ie, headaches, seizures, balance difficulties, spasticity, sleep disturbances, loss of urinary control), and arthritic complaints were significantly more common in individuals with TBI. The prevalence of many of these health-related difficulties was related to duration of LOC but not to time since injury. Age and gender effects were found, with older women with TBI more Likely to report thyroid conditions, sleep disturbances, loss of urinary control, and arthritic changes. Women also reported greater frequency of headaches, colds, weight changes, and temperature changes post TBI. Conclusion: Health issues reflective of neuroendocrine, neurological, and arthritic difficulties are common long-term health issues for individuals with TBI. Proactive patient education, ongoing health screening with appropriate medical follow-up, and timely interventions for individuals with TBI are indicated. Longitudinal studies are necessary to examine the natural course of post-TBI health difficulties.	Mt Sinai Med Ctr, Dept Rehabil Med, New York, NY 10029 USA; Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA		Hibbard, MR (corresponding author), Mt Sinai Med Ctr, Dept Rehabil Med, 1 Gustave Levy Pl,Box 1240, New York, NY 10029 USA.						ALEXANDRE L, 1979, ACTA NEUROSURG S, V28, P188; ALTMAN R, 1961, ANN INTERN MED, V55, P149, DOI 10.7326/0003-4819-55-1-149; BARRECA T, 1980, J CLIN ENDOCR METAB, V51, P1279, DOI 10.1210/jcem-51-6-1279; Beck AT, 1987, BECK DEPRESSION INVE; BINDER L, 1986, J CLIN EXP NEUROPSYC, V1, P323; CHIOLERO RL, 1988, ACTA ENDOCRINOL-COP, V117, P80, DOI 10.1530/acta.0.1170080; CICCONE CD, 1990, PHARM REHABILITATION; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; COHEN B, 1993, J NEUROL NEUROSUR PS, V55, P313; DUNGER DB, 1980, LANCET, V1, P1277; Eames P, 1989, Brain Inj, V3, P319, DOI 10.3109/02699058909029645; GUALTIERI T, 1991, NEUROPSYCHIATRY BEHA; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; HARPER CG, 1986, J CLIN PATHOL, V39, P769, DOI 10.1136/jcp.39.7.769; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HEALY GB, 1982, NEW ENGL J MED, V306, P1029, DOI 10.1056/NEJM198204293061705; HERZOG AG, 1982, ARCH NEUROL-CHICAGO, V39, P133, DOI 10.1001/archneur.1982.00510150003001; HORN LJ, 1988, J HEAD TRAUMA REHAB, V3, P87; HORN LJ, 1988, J HEAD TRAUMA REHABI, V3, P86; KALISKY Z, 1985, ARCH PHYS MED REHAB, V66, P25; KLINGBEIL GEG, 1985, ARCH PHYS MED REHAB, V66, P44; Kowatch R A, 1989, Psychiatr Med, V7, P37; LABI M L C, 1990, Brain Injury, V4, P365, DOI 10.3109/02699059009026189; LABI MIC, 1996, MED REHABILITATION T; MANN NR, 1996, MED REHABILITATION T; MAYER NH, 1996, MED REHABILITATION T; MENDELSON L, 1975, SCAND J REHABIL MED, V7, P141; OTT LG, 1985, NEUROSURGERY, V16, P725; PENROD L, 1991, Archives of Physical Medicine and Rehabilitation, V72, P793; QUATTROCHI KB, 1990, J NEUROSURG, V75, P766; SHEPARD NT, 1993, ANN OTO RHINOL LARYN, V102, P198, DOI 10.1177/000348949310200306; STEWARD DG, 1997, PHYS MED REHABIL CLI, V8, P827; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022; VARGHESE G, 1992, PHYS MED REH CLIN N, V3, P407; WHYTE J, 1993, REHABILITATION MED P; ZASLER ND, 1996, MED REHABILITATION T; ZASLER ND, 1990, J HEAD TRAUMA REHAB, V5, P14, DOI DOI 10.1097/00001199-199005020-00004	38	57	59	1	4	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1998	13	4					47	57		10.1097/00001199-199808000-00005			11	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	110DZ	WOS:000075366000005	9651239				2022-02-06	
J	Inci, S; Ozcan, OE; Kilinc, K				Inci, S; Ozcan, OE; Kilinc, K			Time-level relationship for lipid peroxidation and the protective effect of alpha-tocopherol in experimental mild and severe brain injury	NEUROSURGERY			English	Article						brain injury; lipid peroxidation; alpha-tocopherol	CENTRAL-NERVOUS-SYSTEM; OXYGEN FREE-RADICALS; DIETARY VITAMIN-E; BLOOD-FLOW; EDEMA; RAT; ANTIOXIDANT; DAMAGE; SUPPLEMENTATION; MALONALDEHYDE	OBJECTIVE: Oxygen free radical-mediated lipid peroxidation has been proposed to be one of the major mechanisms of secondary damage in traumatic brain injury. The first purpose of this study was to establish the time-level relationship for lipid peroxidation in injured brain tissue. The second purpose was to examine the protective effect of alpha-tocopherol against lipid peroxidation. METHODS: For this study, 65 guinea pigs in five groups were studied. Five of the animals were identified as a control group, and the remaining 60 animals were divided equally into four groups (Groups A, B, C, and D). Mild injury (200 g x cm) (Groups A and C) and severe injury (1000 g x cm) (Croups B and D) were produced by the method of Feeney et al. alpha-Tocopherol (100 mg/kg) was administered intraperitoneally before brain injury in Groups C and D, Five animals from each group were killed immediately after trauma, five after 1 hour, and the remaining five animals after 36 hours. Lipid peroxidation in traumatized brain tissues was assessed using the thiobarbituric acid method. RESULTS: In all groups with traumatic brain injuries, levels of malondialdehyde, a lipid peroxidation product, were higher than in the control group. The amount of lipid peroxidation was increased by the severity of the trauma. alpha-Tocopherol significantly suppressed the rise in lipid peroxide levels in traumatized brain tissues. CONCLUSION: This study demonstrates that lipid peroxidation is increased by the severity of trauma and that cy-tocopherol has a protective effect against oxygen free radical-mediated lipid peroxidation in mild and severe brain injury.	Univ Hacettepe, Sch Med, Dept Neurosurg, TR-06100 Ankara, Turkey; Univ Hacettepe, Sch Med, Dept Biochem, TR-06100 Ankara, Turkey		Inci, S (corresponding author), Emek Mahallesi 4,Cadde 70-8, TR-06510 Ankara, Turkey.						ACOSTA D, 1987, EXP NEUROL, V97, P607, DOI 10.1016/0014-4886(87)90117-8; BARUT S, 1993, NEUROSURG REV, V16, P53, DOI 10.1007/BF00308614; BAST A, 1991, AM J MED, V91, pS2, DOI 10.1016/0002-9343(91)90278-6; BURTON GW, 1980, J AM CHEM SOC, V102, P7791, DOI 10.1021/ja00546a032; BURTON GW, 1981, J AM CHEM SOC, V103, P6472, DOI 10.1021/ja00411a035; BUSTO R, 1984, ANN NEUROL, V15, P441, DOI 10.1002/ana.410150507; CADET JL, 1988, INT J NEUROSCI, V40, P13, DOI 10.3109/00207458808985722; CHAN PH, 1978, SCIENCE, V201, P358, DOI 10.1126/science.663662; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; CHAN PH, 1980, J NEUROCHEM, V35, P1004, DOI 10.1111/j.1471-4159.1980.tb07100.x; COHEN G, 1984, NEUROTOXICOLOGY, V5, P77; DEAN RT, 1987, BIOCHEM BIOPH RES CO, V148, P1277, DOI 10.1016/S0006-291X(87)80271-1; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; ESTERBAUER H, 1993, BRIT MED BULL, V49, P566, DOI 10.1093/oxfordjournals.bmb.a072631; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; FAND J, 1981, ARCH INT PHARMACOD T, V250, P4; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; GOSSSAMPSON MA, 1987, NEUROPATH APPL NEURO, V13, P289, DOI 10.1111/j.1365-2990.1987.tb00068.x; GRISAR JM, 1995, J MED CHEM, V38, P453, DOI 10.1021/jm00003a008; GUYTON KZ, 1993, BRIT MED BULL, V49, P523, DOI 10.1093/oxfordjournals.bmb.a072628; HALL ED, 1993, RES P ARNMD, V71, P81; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P201; HARA H, 1990, BRAIN RES, V510, P335, DOI 10.1016/0006-8993(90)91386-U; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HOLLEY AE, 1993, BRIT MED BULL, V49, P494, DOI 10.1093/oxfordjournals.bmb.a072626; IKEDA Y, 1990, ACT NEUR S, V51, P74; IKEDA Y, 1989, Neurological Research, V11, P213; IKEDA Y, 1990, NEUROSURGERY, V27, P1; IKEDA Y, 1989, NEUROSURGERY, V24, P679, DOI 10.1227/00006123-198905000-00004; KANTOS HA, 1986, CENT NERV SYST TRAUM, V3, P257; KANTOS HA, 1986, J NEUROSURG, V64, P803; KUWASHIMA J, 1976, BRAIN RES, V110, P547, DOI 10.1016/0006-8993(76)90865-9; Long DM, 1972, STEROIDS BRAIN EDEMA, P87; LUCY JA, 1972, ANN NY ACAD SCI, V203, P4, DOI 10.1111/j.1749-6632.1972.tb27849.x; MCCAY PB, 1985, ANNU REV NUTR, V5, P323, DOI 10.1146/annurev.nu.05.070185.001543; MEYDANI M, 1988, LIPIDS, V23, P405, DOI 10.1007/BF02535510; MEYDANI M, 1995, LANCET, V345, P170, DOI 10.1016/S0140-6736(95)90172-8; MEYDANI SN, 1990, AM J CLIN NUTR, V52, P557, DOI 10.1093/ajcn/52.3.557; MIKI M, 1987, ARCH BIOCHEM BIOPHYS, V258, P373, DOI 10.1016/0003-9861(87)90358-4; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; ORTEGA BD, 1972, STEROIDS BRAIN EDEMA, P167; SHIN SM, 1994, BRAIN RES, V653, P45, DOI 10.1016/0006-8993(94)90370-0; SUZUKI R, 1983, ACTA NEUROPATHOL, V60, P207, DOI 10.1007/BF00691868; TAKENAKA Y, 1991, ARCH BIOCHEM BIOPHYS, V285, P344, DOI 10.1016/0003-9861(91)90370-X; Tappel A L, 1978, Adv Exp Med Biol, V97, P111; TAPPEL AL, 1968, GERIATRICS, V23, P97; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; VATASSERY GT, 1984, J NEUROCHEM, V43, P409, DOI 10.1111/j.1471-4159.1984.tb00916.x; WINROW VR, 1993, BRIT MED BULL, V49, P506, DOI 10.1093/oxfordjournals.bmb.a072627; WITTING LA, 1980, FREE RADICAL BIO MED, V4, P295; YAO T, 1994, AM J PHYSIOL, V267, pG476, DOI 10.1152/ajpgi.1994.267.3.G476; YOSHIDA S, 1983, NEUROLOGY, V33, P166, DOI 10.1212/WNL.33.2.166; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; ZELESKA MM, 1985, NEUROCHEM RES, V10, P397	57	57	59	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	AUG	1998	43	2					330	335		10.1097/00006123-199808000-00095			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	103VX	WOS:000074979500086	9696087				2022-02-06	
J	Levine, JM; Enquist, LW; Card, JP				Levine, JM; Enquist, LW; Card, JP			Reactions of oligodendrocyte precursor cells to alpha herpesvirus infection of the central nervous system	GLIA			English	Article						O-2A progenitor cell; reactive glia; neuropathology; pseudorabies virus; vagus nerve	CHONDROITIN-SULFATE PROTEOGLYCAN; O-2A PROGENITOR CELLS; RAT OPTIC-NERVE; PSEUDORABIES VIRUS; NG2 PROTEOGLYCAN; BRAIN INJURY; ASTROCYTES; EXPRESSION; DIFFERENTIATION; PROLIFERATION	Adult animals harbor an abundant population of oligodendrocyte precursor cells (OPCs) whose functions, other than providing a pool of precursors for oligodendrocytes, are unknown. Previous studies have demonstrated that these unusual glial cells, which can be identified by virtue of their expression of the NG2 chondroitin sulfate proteoglycan, react to traumatic brain injury. To determine the generality of the ability of OPCs to react to neuropathological insults, we have examined the reactions of OPCs to infection of the brainstem with virulent and attenuated strains pseudorabies virus (PRV). When motor neurons within the dorsal vagal complex are infected with PRV, OPCs immediately adjacent to the infected neurons display dramatic reactive changes. These changes are characterized by (1) cell bodies that stain more heavily with antibodies against NG2 than do non-reactive OPCs, (2) an increased density of processes, and (3) the appearance of fine filopodia on the cell body and processes. The onset of these morphological changes was rapid, and they occurred simultaneously with the appearance of viral antigens in motor neurons. At late stages of infection, the soma of OPCs elaborated fewer processes. A small number of the reactive OPCs contain viral antigens. These findings extend the range of neuropathological situations to which OPCs react indicating that this cell population is extremely dynamic. They also suggest that the reaction of OPCs and the consequences of these reactions to brain function must be considered in any procedure, either experimental or clinical, in which viruses are introduced into the central nervous system. (C) 1998 Wiley-Liss, Inc.	SUNY Stony Brook, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA		Levine, JM (corresponding author), SUNY Stony Brook, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA.	jlevine@neurobio.sunysb.edu	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Card, John/0000-0002-6148-7364	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021198] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH53574] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21198] Funding Source: Medline; DS NIH HHS [NINDS33506] Funding Source: Medline		Bartha A., 1961, Magyar Allatorvosok Lapja, V16, P42; BECKER CH, 1967, EXPERIENTIA, V23, P209, DOI 10.1007/BF02136291; BIRDSALL HH, 1992, J IMMUNOL, V148, P2717; CALDER VL, 1988, EUR J IMMUNOL, V18, P1195, DOI 10.1002/eji.1830180808; Card J. Patrick, 1995, P319, DOI 10.1016/B978-012397570-6/50020-4; CARD JP, 1995, CRIT REV NEUROBIOL, V9, P137; CARD JP, 1990, J NEUROSCI, V10, P1974; CARD JP, 1993, J NEUROSCI, V13, P2515, DOI 10.1523/JNEUROSCI.13-06-02515.1993; CARD JP, 1994, METH MOL G, V4, P363; CAVANAGH JB, 1970, J ANAT, V106, P471; DOU CL, 1994, J NEUROSCI, V14, P7616; Enquist L.W., 1996, PROTOCOLS GENE TRANS, P333; FULTON BP, 1992, J NEUROSCI, V12, P4816; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GRAKO KA, 1995, EXP CELL RES, V221, P231, DOI 10.1006/excr.1995.1371; Ho Dora Y., 1995, P133, DOI 10.1016/B978-012397570-6/50011-3; JORGENSEN MB, 1993, EXP NEUROL, V120, P70, DOI 10.1006/exnr.1993.1041; Keirstead HS, 1998, GLIA, V22, P161, DOI 10.1002/(SICI)1098-1136(199802)22:2<161::AID-GLIA7>3.0.CO;2-A; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; LEVINE JM, 1987, J NEUROSCI, V7, P2711; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Levine JM, 1996, PERSPECT DEV NEUROBI, V3, P245; LEVINE JM, 1993, GLIA, V7, P307, DOI 10.1002/glia.440070406; LEVINE JM, 1987, J NEUROSCI, V7, P2721; Loewy Arthur D., 1995, P349, DOI 10.1016/B978-012397570-6/50021-6; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; METTENLEITER TC, 1995, VIRAL VECTORS GENE T, P333; MILNER R, 1994, DEVELOPMENT, V120, P3497; MIYAKE T, 1988, BRAIN RES, V451, P133, DOI 10.1016/0006-8993(88)90757-3; NISHIYAMA A, 1995, MOL BIOL CELL, V6, P1819, DOI 10.1091/mbc.6.12.1819; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; Nishiyama A, 1997, J NEUROSCI RES, V48, P299, DOI 10.1002/(SICI)1097-4547(19970515)48:4<299::AID-JNR2>3.0.CO;2-6; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; OKAMOTO M, 1994, BRAIN RES, V637, P57, DOI 10.1016/0006-8993(94)91217-3; OKAMOTO M, 1994, NEUROSCI LETT, V172, P51, DOI 10.1016/0304-3940(94)90660-2; ONG WY, 1997, NEUR ABS, V23, P64; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; Reynolds R, 1997, J NEUROSCI RES, V47, P455, DOI 10.1002/(SICI)1097-4547(19970301)47:5<455::AID-JNR1>3.0.CO;2-G; RINAMAN L, 1993, J NEUROSCI, V13, P685; ROIZMAN B, 1990, VIROLOGY, P1787; STALLCUP WB, 1983, COLD SPRING HARB SYM, V48, P761, DOI 10.1101/SQB.1983.048.01.078; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; SUGIURA M, 1994, DEV BIOL, V164, P102, DOI 10.1006/dbio.1994.1183; SUR M, 1988, J NEUROSCI, V8, P874; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; TOPP KS, 1989, GLIA, V2, P201, DOI 10.1002/glia.440020309; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ugolini Gabriella, 1995, P293, DOI 10.1016/B978-012397570-6/50019-8; WILSON SS, 1981, DEV BIOL, V83, P146, DOI 10.1016/S0012-1606(81)80017-6; Wittmann G., 1989, HERPESVIRUS DIS CATT, P230	53	57	57	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	AUG	1998	23	4					316	328		10.1002/(SICI)1098-1136(199808)23:4<316::AID-GLIA4>3.3.CO;2-V			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZX335	WOS:000074505200004	9671962				2022-02-06	
J	Hertel, R; Pisan, M; Lambert, S; Ballmer, FT				Hertel, R; Pisan, M; Lambert, S; Ballmer, FT			Plate osteosynthesis of diaphyseal fractures of the radius and ulna	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article							BONE	Between January 1980 and December 1989, 133 consecutive patients were treated for a fracture of the shaft of one or both forearm bones (134 forearms in total). All fractures were stabilized with AO/ASIF 3.5 mm stainless-steel dynamic compression plates. The 1 year follow-up rate was 99 per cent; the long-term follow-up rate was 92 per cent (the mean long-term follow-up was 10.2 years (range, 2.7-15.2)) so there were 96 men and 35 women, with an average age of 37.5 years (range, 16-63). Twenty-two per cent of the forearms had open fractures, 26 per cent of patients had sustained multiple injuries and 19 per cent had a head injury. One hundred and twenty-seven of 132 forearms (96.2 per cent) underwent problem-free consolidation before 6 months. Two delayed unions and two non-unions required reoperation. There was one superficial infection in a patient with a closed fracture. Plates were removed from 70 patients (53 percent) at a mean of 33.1 months (range, 8-122) after the first operation. In this group, there were three refractures (4.3 per cent) occurring at a mean of 8.7 months (range, 0-14) after plate removal. This study confirms the safety and efficacy of plate osteosynthesis in forearm shaft fractures: a high union rate and low complication rate can be anticipated. The data presented form the most reliable information on this subject currently available with the longest and highest rate of follow up of a sufficient number of patients using a single implant system in a single institution. Copyright (C) 1996 Elsevier Science Ltd.			Hertel, R (corresponding author), UNIV BERN,INSELSPITAL,DEPT ORTHOPAED SURG,CH-3010 BERN,SWITZERLAND.						ANDERSON LD, 1975, J BONE JOINT SURG AM, VA 57, P287, DOI 10.2106/00004623-197557030-00001; CHAPMAN MW, 1989, J BONE JOINT SURG AM, V71A, P159, DOI 10.2106/00004623-198971020-00001; DELUCA PA, 1988, J BONE JOINT SURG AM, V70A, P1372, DOI 10.2106/00004623-198870090-00015; DODGE HS, 1972, J BONE JOINT SURG AM, V54, P1167, DOI 10.2106/00004623-197254060-00003; GRACE TG, 1980, J BONE JOINT SURG AM, V62, P433, DOI 10.2106/00004623-198062030-00013; GUSTILO RB, 1976, J BONE JOINT SURG AM, V58, P453, DOI 10.2106/00004623-197658040-00004; HIDAKA S, 1984, J BONE JOINT SURG AM, V66A, P1241, DOI 10.2106/00004623-198466080-00012; MOED BR, 1986, J BONE JOINT SURG AM, V68A, P1008, DOI 10.2106/00004623-198668070-00007; Muller M., 1990, COMPREHENSIVE CLASSI; Muller ME, 1991, MANUAL INTERNAL FIXA; PAAVOLAINEN P, 1978, CLIN ORTHOP RELAT R, V136, P287; PERREN SM, 1988, CLIN ORTHOP RELAT R, V232, P139; ROSSON JW, 1991, J BONE JOINT SURG BR, V73, P65, DOI 10.1302/0301-620X.73B1.1991777; Rumball K, 1990, J Orthop Trauma, V4, P124, DOI 10.1097/00005131-199004020-00004; UHTHOFF HK, 1983, J BONE JOINT SURG BR, V65, P66, DOI 10.1302/0301-620X.65B1.6822605	15	57	60	0	0	BUTTERWORTH-HEINEMANN LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB	0020-1383			INJURY	Injury-Int. J. Care Inj.	OCT	1996	27	8					545	548		10.1016/S0020-1383(96)00091-5			4	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	VV305	WOS:A1996VV30500004	8994558				2022-02-06	
J	Girard, D; Brown, J; BurnettStolnack, M; Hashimoto, N; HierWellmer, S; Perlman, OZ; Seigerman, C				Girard, D; Brown, J; BurnettStolnack, M; Hashimoto, N; HierWellmer, S; Perlman, OZ; Seigerman, C			The relationship of neuropsychological status and productive outcomes following traumatic brain injury	BRAIN INJURY			English	Article							EMPLOYMENT	Neuropsychological assessment is a standard component of traumatic brain injury rehabilitation programmes; however, the relationship between neuropsychological test scores and functional abilities is not clear. The current study compared serial neuropsychological test data with functional outcomes for 152 subjects. Outcome was operationally defined for three activity settings (home, school, work) with six levels of productivity for each. Productivity was defined as one's ability to function at increasing levels of independence. Demographic and caseload variables were analysed utilizing correlation and stepwise multiple regression analyses. Significant relationships to outcome were found between certain neuropsychological test scores, and certain demographic variables. Positive outcomes were related in part to patient's speed of information processing, memory skills, and simultaneous processing abilities. Also related to positive outcomes were mechanism of injury, level of insurance funding, premorbid educational level, and negative history of substance abuse. The activity setting influenced outcome such that it appeared to be most difficult to return to work, suggesting the necessity of adequate vocational assistance. However, cognitive and demographic variables accounted for less than 30% of the total variance in outcome. Therefore, brain injury rehabilitation must be multifaceted.	ST JOSEPH MERCY HOSP,DEPT PHYS MED & REHABIL,TBI SERV,ANN ARBOR,MI 48106; UNIV MICHIGAN,MED CTR,ANN ARBOR,MI								Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CICERONE K, 1989, 8 NAT S NAT HEAD INJ; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; HEATON RK, 1978, J NERV MENT DIS, V166, P408, DOI 10.1097/00005053-197806000-00004; MACCIOCCHI S, 1988, J HEAD TRAUMA REHABI, V3, P1; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; Vogenthaler D R, 1989, Brain Inj, V3, P355, DOI 10.3109/02699058909004560; WEHMAN P, 1989, ARCH PHYS MED REHAB, V70, P109	10	57	58	0	7	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	SEP	1996	10	9					663	676		10.1080/026990596124089			14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	VB635	WOS:A1996VB63500004	8853869				2022-02-06	
J	Nag, S				Nag, S			Cold-injury of the cerebral cortex: Immunolocalization of cellular proteins and blood-brain barrier permeability studies	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						angiogenesis; blood-brain barrier; c-fos; c-jun; glucose transporter; cold-injury	FIBRILLARY ACIDIC PROTEIN; CENTRAL NERVOUS-SYSTEM; C-FOS EXPRESSION; GLUCOSE-TRANSPORTER; FREEZE-INJURY; MESSENGER-RNA; RAT-BRAIN; MOUSE; EDEMA; LOCALIZATION	The occurrence of blood-brain barrier (BBB) permeability alterations and neovascularization are well documented in the cerebral cortical cold-injury model. This model was used to determine whether the glucose transporter (glut1) protein was present in endothelium of cerebral vessels with breakdown of BBB to protein and when regenerating endothelial cells become immunoreactive for glut1 protein. Secondly, the protein products of c-fos and c-jun were localized to determine whether these early immediate genes are activated in this model. Observations were made over a period of 12 hours to 14 days after the cold-injury. Blood-brain barrier permeability was assessed using horseradish peroxidase (HRP) as a tracer. Since HRP may not be able to enter thrombosed vessels within the cold lesion, immunohistochemistry was used to detect extravasation of endogenous serum proteins using antisera to rat serum proteins. The proteins-glut1, GFAP, c-fos and c-jun-were localized by immunohistochemistry. Endothelium of vessels which were permeable to protein, whether in the cold-injury site or in the perilesional area, all contained glut1 protein; hence, the presence of glut1 did not appear to correlate with an intact BBB to protein. An interesting point is that in the process of neovascularization, regenerating endothelial cells become immunoreactive for glut1 at 5 days and this coincides with the presence of tight junctions in these cells. Immunoreactivity for c-fos was observed in regenerating endothelium within the lesion site, in astrocytes, and to a lesser extent in endothelial cells and neurons in the perilesional area. Few astrocytes showed immunoreactivity for c-jun at 4 and 5 days. Possibly, the growth factors generated to promote angiogenesis and repair led to activation of the c-fos gene with deposition of c-fos protein. The results suggest that during nervous system development or endothelial regeneration, the presence of glut1 in cerebral endothelium coincides with the presence of an intact BBB to protein and protein tracers. However, in pathological states presence of glut1 in cerebral endothelium does not appear to correlate with an intact BBB to protein. This model lends itself to the study of angiogenesis and repair processes in the cerebral cortex in an environment unaffected by ischemia and thus the findings may be relevant to traumatic injuries of the human cerebral cortex.	UNIV TORONTO,DEPT PATHOL,DIV NEUROPATHOL,TORONTO,ON,CANADA; TORONTO HOSP,PLAYFAIR NEUROSCI UNIT,TORONTO,ON M5T 2S8,CANADA								AMADUCCI L, 1981, NEUROSCI LETT, V21, P27, DOI 10.1016/0304-3940(81)90052-5; AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; BAKER RN, 1971, J NEUROPATH EXP NEUR, V30, P668, DOI 10.1097/00005072-197110000-00010; BAUER H, 1995, DEV BRAIN RES, V86, P317, DOI 10.1016/0165-3806(95)00044-E; CANCILLA PA, 1979, LAB INVEST, V40, P74; CANCILLA PA, 1992, J NEUROPATH EXP NEUR, V51, P560, DOI 10.1097/00005072-199209000-00011; CORNFORD EM, 1995, J NEUROPATH EXP NEUR, V54, P842, DOI 10.1097/00005072-199511000-00011; DICK APK, 1984, P NATL ACAD SCI-BIOL, V81, P7233, DOI 10.1073/pnas.81.22.7233; DRAGUNOW M, 1990, BRAIN RES, V527, P41, DOI 10.1016/0006-8993(90)91058-O; FARRELL CL, 1991, P NATL ACAD SCI USA, V88, P5779, DOI 10.1073/pnas.88.13.5779; GERHART DZ, 1989, J NEUROSCI RES, V22, P464, DOI 10.1002/jnr.490220413; GUERIN C, 1990, ANN NEUROL, V28, P758, DOI 10.1002/ana.410280606; HARIK SI, 1990, P NATL ACAD SCI USA, V87, P4261, DOI 10.1073/pnas.87.11.4261; HARIK SI, 1990, J NEUROSCI, V10, P3862, DOI 10.1523/JNEUROSCI.10-12-03862.1990; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; KALARIA RN, 1988, ANN NEUROL, V24, P757, DOI 10.1002/ana.410240610; KOHMURA E, 1995, MOL BRAIN RES, V28, P117, DOI 10.1016/0169-328X(94)00198-N; LIU HM, 1994, J NEUROPATH EXP NEUR, V53, P118, DOI 10.1097/00005072-199403000-00002; LIU HM, 1994, J NEUROPATH EXP NEUR, V53, P598, DOI 10.1097/00005072-199411000-00007; MAXWELL K, 1993, BRAIN RES, V41, P309; MITCHELL J, 1979, ACTA NEUROPATHOL, V46, P45, DOI 10.1007/BF00684803; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NAG S, 1988, ACTA NEUROPATHOL, V75, P547, DOI 10.1007/BF00686198; NAG S, 1984, ACTA NEUROPATHOL, V62, P178, DOI 10.1007/BF00691850; OLSON JJ, 1987, J NEUROPATH EXP NEUR, V46, P682, DOI 10.1097/00005072-198711000-00007; ORITA T, 1989, ACTA NEUROPATHOL, V77, P397, DOI 10.1007/BF00687374; ORITA T, 1988, J NEUROSURG, V68, P608, DOI 10.3171/jns.1988.68.4.0608; TAOCHENG JH, 1987, J NEUROSCI, V7, P3293; TENGVAR C, 1986, ACTA NEUROPATHOL, V71, P177, DOI 10.1007/BF00688038; UEMURA Y, 1991, BRAIN RES, V552, P99, DOI 10.1016/0006-8993(91)90665-I; VORBRODT AW, 1993, HISTOL HISTOPATHOL, V8, P51; VORBRODT AW, 1985, ACTA NEUROPATHOL, V66, P265, DOI 10.1007/BF00690958	33	57	57	0	1	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	AUG	1996	55	8					880	888		10.1097/00005072-199608000-00003			9	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	VA570	WOS:A1996VA57000003	8759777	Bronze			2022-02-06	
J	CORRIGAN, JD; RUST, E; LAMBHART, GL				CORRIGAN, JD; RUST, E; LAMBHART, GL			THE NATURE AND EXTENT OF SUBSTANCE-ABUSE PROBLEMS IN PERSONS WITH TRAUMATIC BRAIN INJURY	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							ALCOHOL; TESTS	Objective: Describe the pre- and postinjury patterns of alcohol and other drug use among persons who have incurred traumatic brain injury (TBI). Injury-related characteristics and negative consequences are also reported, as well as preliminary outcomes of treatment. Design: Descriptive analysis of a consecutive sample of persons referred during an 18-month period to a treatment program for substance abuse after TBI. Setting: A community-based demonstration project affiliated with an acute rehabilitation hospital in a large midwestern academic medical center. Patients: The first 211 persons screened by the program, including all 97 receiving comprehensive assessments and 68 who dropped out prior to assessment. Preliminary outcomes were based on the first 37 clients monitored 6 months after entering into treatment. Intervention: Screening for appropriateness of referral; comprehensive, holistic assessment; and resource and service coordination provided by an interdisciplinary staff that facilitates treatment by local providers. Main Outcome Measures: Alcohol use measured by the Quantity-Frequency-Variability Index, completed by client and significant other; productivity measured by the Employability Rating Scale; multiple sociodemographic indicators. Results: More than 60% of injuries were use related; this included 71% of assaults. Alcohol was the preferred drug for 83%, and more than half used some marijuana. Prior to injury, the study sample consumed significantly greater amounts of alcohol than national averages; after injury, consumption was consistent with national averages. Approximately 20% of individuals who abstained or were light drinkers before injury showed high volume use after injury. Conclusions: There are multiple reasons why the harmful effects of alcohol and other drug use after TBI are underestimated, including cultural acceptance of beer and the subtle sequelae of marijuana use. It is recommended that the extent of use of same-aged peers not be used as the criterion for acceptable use by persons who have experienced TBI. Further study is needed regarding the utility of assessment devices, the effectiveness of referrals made during rehabilitation, and the efficacy of intervention techniques.			CORRIGAN, JD (corresponding author), OHIO STATE UNIV,DEPT PHYS MED & REHABIL,TBI SA,COLUMBUS,OH 43210, USA.		Corrigan, John D./E-2921-2011				Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Blackerby W.F., 1990, J HEAD TRAUMA REHAB, V5, P47; CALLAHAN D, 1968, Q J STUD ALCOHOL, V29, P130; Cervantes, 1994, Assessment, V1, P23, DOI 10.1177/1073191194001001004; CHARNESS ME, 1993, NIH933549 NAT I ALC; Corrigan J D, 1994, NeuroRehabilitation, V4, P109, DOI 10.3233/NRE-1994-4207; CORRIGAN JD, IN PRESS ARCH PHYS M; CORRIGAN JD, 1994, 102ND ANN CONV AM PS; CORRIGAN JD, IN PRESS BRAIN INJUR; Drubach D A, 1993, Md Med J, V42, P989; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P27; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Gualtieri T, 1990, J HEAD TRAUMA REHAB, V5, P32; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; JENSEN GB, 1993, LANCET, V342, P1201; Jones G.A., 1992, NEUROREHABILITATION, V2, P27; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; KREUTZER JS, 1991, J HEAD TRAUMA REHAB, V6, P12; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LANGLEY MJ, 1994, MAY INT SUBST AB INT; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; MILLER JD, 1983, DHHS ADM831263 PUBL; *OH REH SERV COMM, 1992, OH HEAD INJ PROGR NE; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SKINNER HA, 1984, ANN INTERN MED, V101, P847, DOI 10.7326/0003-4819-101-6-847; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; VERMA NP, 1992, CLIN ELECTROENCEPHAL, V23, P147, DOI 10.1177/155005949202300310; WILLIAMS GD, 1992, BRIT J ADDICT, V87, P643; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955	32	57	57	0	6	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1995	10	3					29	46					18	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	RC717	WOS:A1995RC71700004					2022-02-06	
J	BRUDER, N; LASSEGUE, D; PELISSIER, D; GRAZIANI, N; FRANCOIS, G				BRUDER, N; LASSEGUE, D; PELISSIER, D; GRAZIANI, N; FRANCOIS, G			ENERGY-EXPENDITURE AND WITHDRAWAL OF SEDATION IN SEVERE HEAD-INJURED PATIENTS	CRITICAL CARE MEDICINE			English	Article						HEAD INJURY; ENERGY EXPENDITURE; OXYGEN CONSUMPTION; SEDATION; INDIRECT CALORIMETRY; METABOLISM; RECOVERY; MECHANICAL VENTILATION; INTENSIVE CARE UNIT; CRITICAL ILLNESS; NEUROLOGIC EMERGENCIES	RESTING METABOLIC-RATE; GAS-EXCHANGE; SYMPATHOADRENAL RESPONSES; NUTRITIONAL-REQUIREMENTS; PLASMA-CATECHOLAMINE; GENERAL-ANESTHESIA; OXYGEN-CONSUMPTION; VENTILATION; NOREPINEPHRINE; VALIDATION	Objectives: To determine the outcome of oxygen consumption (Vo(2)) and energy expenditure after cessation of sedation in severe head-injured patients and to assess its usefulness as a predictor of neurologic severity. Design: Prospective, descriptive study. Setting: Neurosurgical intensive care unit (ICU) in a university hospital. Patients: Fifteen severe head-injured patients with tracheostomies and who were mechanically ventilated and sedated at the time of the study. Interventions: None. Measurements and Main Results: Vo(2) and energy expenditure were measured, using indirect calorimetry during and after discontinuation of sedation. After the measurement period, the patients were divided into two groups. Group 1 included patients who were completely weaned from sedation; group 2 included patients who had to be sedated again using predetermined criteria. In both groups, energy expenditure was close to basal energy expenditure during sedation, and increased to 150% of basal energy expenditure during the recovery period, with maximum hourly values 80% above basal energy expenditure. In group 1, Vo(2) and energy expenditure changed from 284 +/- 44 mL/min and 1833 +/- 261 kcal/day during sedation to 390 +/- 85 mL/min and 2512 +/- 486 kcal/day for the period without sedation. During this period, there was a significant correlation between Vo(2) and mean arterial pressure. For the recovery period, there was no difference in mean or maximum Vo(2) between the two groups of patients. At 24 and 48 hrs after cessation of sedation, Vo(2) and energy expenditure decreased to 30% above basal energy expenditure. These changes may be due to the recovery of muscular activity, weaning from mechanical ventilation, or an increase in the amount of circulating catecholamines. Conclusion: In severe head-injured patients, during the first 12 hrs after the discontinuation of sedation, the patients experienced a large increase in Vo(2), energy expenditure, and mean arterial pressure. Although these changes have no prognostic value in our study, they have potential deleterious effects in head-injured patients. Methods that blunt these changes which have proven efficacious in anesthesia may be effective for intensive care patients.	CHU TIMONE, SERV NEUROCHIRURG, MARSEILLE, FRANCE		BRUDER, N (corresponding author), CHU TIMONE, DEPT ANESTHESIE REANIMAT, MARSEILLE, FRANCE.						ASKANAZI J, 1981, SURGERY, V89, P478; BOREL C, 1990, CHEST, V98, P180, DOI 10.1378/chest.98.1.180; BREDBACKA S, 1984, ACTA ANAESTH SCAND, V28, P462, DOI 10.1111/j.1399-6576.1984.tb02099.x; BRUDER N, 1991, CRIT CARE MED, V19, P43, DOI 10.1097/00003246-199101000-00013; CHIOLERO R, 1989, JPEN-PARENTER ENTER, V13, P5, DOI 10.1177/014860718901300105; CHIOLERO RL, 1989, CRIT CARE MED, V17, P328, DOI 10.1097/00003246-198904000-00006; CIOFOLO MJ, 1989, ANESTHESIOLOGY, V70, P737; CLIFTON GL, 1986, J NEUROSURG, V64, P895, DOI 10.3171/jns.1986.64.6.0895; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; DAMASK MC, 1982, ANESTHESIOLOGY, V57, P213, DOI 10.1097/00000542-198209000-00011; DELAUNAY L, 1991, BRIT J ANAESTH, V67, P397, DOI 10.1093/bja/67.4.397; DEMPSEY DT, 1985, SURG GYNECOL OBSTET, V160, P128; DERBYSHIRE DR, 1984, BRIT J ANAESTH, V56, P725, DOI 10.1093/bja/56.7.725; DEUTSCHMAN CS, 1986, J NEUROSURG, V64, P89, DOI 10.3171/jns.1986.64.1.0089; ELWYN DH, 1980, CRIT CARE MED, V8, P9, DOI 10.1097/00003246-198001000-00003; ENSINGER H, 1992, CRIT CARE MED, V20, P1250, DOI 10.1097/00003246-199209000-00011; FELLOWS IW, 1985, CLIN SCI, V69, P215, DOI 10.1042/cs0690215; GADISSEUX P, 1984, J NEUROSURG, V60, P219, DOI 10.3171/jns.1984.60.2.0219; HAIDER W, 1975, EUR J INTEN CARE MED, V1, P19, DOI 10.1007/BF00735865; HALTER JB, 1977, J CLIN ENDOCR METAB, V45, P936, DOI 10.1210/jcem-45-5-936; Harris J.A., 1919, PUBLICATIONS, V279, P223; KENNEDY SK, 1977, SURGERY, V82, P233; LEPAPE A, 1987, Annales Francaises d'Anesthesie et de Reanimation, V6, P129, DOI 10.1016/S0750-7658(87)80120-X; LONG CL, 1979, JPEN-PARENTER ENTER, V3, P69, DOI 10.1177/014860717900300269; MOORE R, 1989, J TRAUMA, V29, P1633, DOI 10.1097/00005373-198912000-00007; MOSS E, 1991, MONOGRAPHS ANAESTHES, V21, P247; OH TE, 1991, INTENS CARE MED, V17, P199, DOI 10.1007/BF01709877; PIEK J, 1989, CLIN NUTR, V8, P347, DOI 10.1016/0261-5614(89)90011-3; RALLEY FE, 1988, CAN J ANAESTH, V35, P332, DOI 10.1007/BF03010851; REGAN CJ, 1990, CRIT CARE MED, V18, P871, DOI 10.1097/00003246-199008000-00016; RODRIGUEZ JL, 1983, CIRCULATION, V68, P1238, DOI 10.1161/01.CIR.68.6.1238; SAVINO JA, 1985, J TRAUMA, V25, P1126, DOI 10.1097/00005373-198512000-00002; SHIKORA SA, 1990, CRIT CARE MED, V18, P157, DOI 10.1097/00003246-199002000-00006; STANLEY TH, 1980, ANESTHESIOLOGY, V53, P250, DOI 10.1097/00000542-198009000-00016; VIALE JP, 1988, ACTA ANAESTH SCAND, V32, P691, DOI 10.1111/j.1399-6576.1988.tb02810.x; WEISSMAN C, 1986, ANN SURG, V203, P408, DOI 10.1097/00000658-198604000-00012; WEISSMAN C, 1986, ANESTHESIOLOGY, V64, P673, DOI 10.1097/00000542-198606000-00001; WILLATTS SM, 1988, BRIT J ANAESTH, V61, pP502; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	39	57	58	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUL	1994	22	7					1114	1119		10.1097/00003246-199407000-00011			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA696	WOS:A1994PA69600011	8026200				2022-02-06	
J	TANIGUCHI, MH; MOYER, RS				TANIGUCHI, MH; MOYER, RS			ASSESSMENT OF RISK-FACTORS FOR PNEUMONIA IN DYSPHAGIC CHILDREN - SIGNIFICANCE OF VIDEOFLUOROSCOPIC SWALLOWING EVALUATION	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							ASPIRATION PNEUMONIA; ACID ASPIRATION; GASTROESOPHAGEAL REFLUX; PULMONARY ASPIRATION; NOSOCOMIAL PNEUMONIA; DISORDERS; TUBES; GASTROSTOMY; DISEASE; VOLUME	The purpose of this study was to investigate the relationship between aspiration, as identified by videofluoroscopic swallowing (VFS) study, and pneumonia in children with suspected dysphagia. Data were retrospectively collected and analysed from 142 children referred for VFS over a one-year period. The median age was 33 months. Aspiration was identified in 44 per cent of the children studied. A history of pneumonia within one year of the VFS was found in 35 per cent. Aspiration, gastro-oesophageal reflux, and age one year or less were significant risk factors for pneumonia. Children with traumatic brain-injury were at less risk for pneumonia than all other children with suspected dysphagia. These results lend objective support to the previously suspected relationship between aspiration and pneumonia in this patient population.	OHIO STATE UNIV,SCH MED,COLUMBUS,OH		TANIGUCHI, MH (corresponding author), UNIV MINNESOTA,SCH MED,DEPT PHYS MED & REHABIL,500 BOYNTON HLTH SERV SKYWAY,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.						ALESSI DM, 1986, OTOLARYNG HEAD NECK, V94, P486, DOI 10.1177/019459988609400414; BARISH CF, 1985, ARCH INTERN MED, V145, P1882, DOI 10.1001/archinte.145.10.1882; BOSCOE MJ, 1984, BRIT MED J, V289, P1421, DOI 10.1136/bmj.289.6456.1421; BROWNING DH, 1983, J PEDIATR-US, V102, P582, DOI 10.1016/S0022-3476(83)80191-7; BUI HD, 1989, AM J MENT RETARD, V94, P16; CHEN MYM, 1990, RADIOLOGY, V176, P641, DOI 10.1148/radiology.176.3.2389021; CHOKSHI SK, 1986, AM FAM PHYSICIAN, V33, P195; COGEN R, 1989, AM J GASTROENTEROL, V84, P1509; DEMEESTER TR, 1990, ANN SURG, V211, P337, DOI 10.1097/00000658-199003000-00005; GILBERT RW, 1987, ANN OTO RHINOL LARYN, V96, P561, DOI 10.1177/000348948709600516; GOITEIN KJ, 1984, CRIT CARE MED, V12, P19, DOI 10.1097/00003246-198401000-00005; GRIGGS CA, 1989, DEV MED CHILD NEUROL, V31, P303; HARKNESS GA, 1990, AM J MED, V89, P457, DOI 10.1016/0002-9343(90)90376-O; HORNER J, 1988, NEUROLOGY, V38, P1359; HORNER J, 1988, NEUROLOGY, V38, P317, DOI 10.1212/WNL.38.2.317; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; JAMES CF, 1984, ANESTH ANALG, V63, P665; KENNEDY TP, 1989, ANESTH ANALG, V69, P87; LAZARUS C, 1987, ARCH PHYS MED REHAB, V68, P79; LINDEN T, 1989, Biotechnology Techniques, V3, P189, DOI 10.1007/BF01875618; Logemann JA, 1983, EVALUATION TREATMENT; MACFADYEN UM, 1983, ARCH DIS CHILD, V58, P87, DOI 10.1136/adc.58.2.87; MANCHIKANTI L, 1985, ANESTH ANALG, V64, P11; METHENY NA, 1986, HEART LUNG, V15, P256; NASH M, 1988, OTOLARYNG CLIN N AM, V21, P701; RAIDOO DM, 1990, BRIT J ANAESTH, V65, P248, DOI 10.1093/bja/65.2.248; RUSSIN SJ, 1989, POSTGRAD MED, V85, P159; SHAPIRO MS, 1989, CLIN CHEST MED, V10, P617; SPLAINGARD ML, 1988, ARCH PHYS MED REHAB, V69, P637; Terry P B, 1989, Dysphagia, V3, P179, DOI 10.1007/BF02407220; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523; VEIS SL, 1985, ARCH PHYS MED REHAB, V66, P372	32	57	60	0	8	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	JUN	1994	36	6					495	502					8	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	NM358	WOS:A1994NM35800005	8005360				2022-02-06	
J	MCDONALD, CM; JAFFE, KM; FAY, GC; POLISSAR, NL; MARTIN, KM; LIAO, SQ; RIVARA, JB				MCDONALD, CM; JAFFE, KM; FAY, GC; POLISSAR, NL; MARTIN, KM; LIAO, SQ; RIVARA, JB			COMPARISON OF INDEXES OF TRAUMATIC BRAIN INJURY SEVERITY AS PREDICTORS OF NEUROBEHAVIORAL OUTCOME IN CHILDREN	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							CLOSED HEAD-INJURY; INTELLECTUAL ABILITY; COMPUTED-TOMOGRAPHY; PRACTICAL SCALE; AMNESIA TEST; RECOVERY; ADOLESCENTS; SEQUELAE; MEMORY; COMA		CHILDRENS HOSP & MED CTR,DEPT REHABIL MED,SEATTLE,WA; CHILDRENS HOSP & MED CTR,DEPT NEUROL,SEATTLE,WA; UNIV WASHINGTON,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT NEUROL SURG,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,CTR QUANTITAT SCI,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PUBL HLTH,SEATTLE,WA 98195		MCDONALD, CM (corresponding author), UNIV CALIF DAVIS,SACRAMENTO MED CTR,MED CTR,DEPT PHYS MED & REHABIL,4301 X ST,SACRAMENTO,CA 95817, USA.			McDonald, Craig/0000-0002-8779-3220	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR02299] Funding Source: Medline		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; BIJUR PE, 1990, PEDIATRICS, V86, P337; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BRUCE DA, 1979, CHILD BRAIN, V5, P174; BRUDE DA, 1986, CLIN PEDIATR, V19, P719; Bruininks R. H., 1984, SCALES INDEPENDENT B; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Conover W.J., 1998, PRACTICAL NONPARAMET; CORDOBES F, 1987, CHILD NERV SYST, V3, P235, DOI 10.1007/BF00274055; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; DELIS DC, 1989, CALIFORNIA VERBAL LE; DRAPER NR, 1981, APPLIED REGRESSION A; Edelbrock C., 1986, MANUAL TEACHERS REPO; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; FULD PA, 1977, DEV MED CHILD NEUROL, V19, P495; HEISKANEN O, 1974, DEV MED CHILD NEUROL, V16, P11; Humphreys RP, 1983, CONCEPTS PEDIATRIC N, V3, P191; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; POLISSAR NL, IN PRESS BRAIN INJUR; Reitan R.M., 1974, CLIN NEUROPSYCHOLOGY; RIVARA F, 1987, PEDIATRICS, V80, P579; RUIJS MBM, 1992, DEV MED CHILD NEUROL, V34, P885; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; STOVER SL, 1976, ARCH PHYS MED REHAB, V57, P201; TEASDALE G, 1974, LANCET, V2, P81; WAGSTYL J, 1987, J PEDIATR SURG, V22, P127, DOI 10.1016/S0022-3468(87)80427-X; Wechsler D., 1974, WECHSLER INTELLIGENC; Wilkinson, 1984, WIDE RANGE ACHIEVEME; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; ZIMMERMAN RA, 1981, J NEURORADIOLOGY, V8, P257; 1980, ABBREVIATED INJURY S; [No title captured]	50	57	58	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	1994	75	3					328	337		10.1016/0003-9993(94)90038-8			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	NA130	WOS:A1994NA13000018	8129588				2022-02-06	
J	BORGENS, RB; TOOMBS, JP; BLIGHT, AR; MCGINNIS, ME; BAUER, MS; WIDMER, WR; COOK, JR				BORGENS, RB; TOOMBS, JP; BLIGHT, AR; MCGINNIS, ME; BAUER, MS; WIDMER, WR; COOK, JR			EFFECTS OF APPLIED ELECTRIC-FIELDS ON CLINICAL CASES OF COMPLETE PARAPLEGIA IN DOGS	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						SPINAL CORD; REGENERATION; ELECTRIC FIELD; PARAPLEGIA; BEHAVIORAL RECOVERY; NEUROTRAUMA	SPINAL-CORD INJURY; IMPROVES NEUROLOGIC RECOVERY; DIRECT-CURRENT STIMULATION; MOTOR-EVOKED-POTENTIALS; GUINEA-PIG; CONTROLLED TRIAL; CHICK-EMBRYO; METHYLPREDNISOLONE; NALOXONE; TRAUMA	A clinical trial of applied, slowly oscillating, weak electric fields was performed in dogs with naturally occurring spinal cord injuries due to intervertebral disc herniation. Criteria for admission to the study were: complete paraplegia, defined by neurological examination and electrophysiological testing; intact segmental reflexes; radiologic and myelographic evidence of spinal cord compression due to disc herniation and a focal lesion, without appreciable rostrocaudal spread of necrosis; weight less than 16 kg; onset of paralysis less than 1 month before surgery. The injured cord was exposed by laminectomy, and decompressed by aspiration of disc material. Active (n = 13) or sham (n = 11) stimulators were implanted subcutaneously, with platinum/iridium electrodes sutured to muscle several millimeters above the cord surface, at either end of the laminectomy site. Active stimulators delivered 200 muA of direct current, switching polarity every 15 min, for 3, 6, or 15 weeks. Neurological and electrophysiological examinations were repeated approximately 6 weeks and 6 months after implantation. Few complications were noted. None were attributable to current application. The group of dogs with active stimulators showed greater improvement in function than the group with sham implants, with a trend towards greater recovery in all neurological measures, and evoked potentials. The combined neurological score derived from these separate tests was significantly different from controls at 6 weeks and 6 months (P < 0.05). Application of slowly oscillating electric fields thus appears to be beneficial in the treatment of paraplegia in dogs.	PURDUE UNIV,SCH VET MED,DEPT VET CLIN SCI,W LAFAYETTE,IN 47907		BORGENS, RB (corresponding author), PURDUE UNIV,SCH VET MED,DEPT ANAT,1244 CTR PARALYSIS RES,W LAFAYETTE,IN 47907, USA.						ANDERSON DK, 1988, J NEUROSURG, V69, P562, DOI 10.3171/jns.1988.69.4.0562; Anderson S.M., 1991, CALIF VET, V45, P24; BLACK P, 1971, Surgical Forum (Chicago), V22, P409; Blight AR, 1991, J NEUROTRAUM, V8, P103, DOI 10.1089/neu.1991.8.103; BLIGHT AR, 1990, J COMP NEUROL, V296, P614, DOI 10.1002/cne.902960408; Borgens R.B., 1989, ELECTRIC FIELDS VERT, P77; BORGENS RB, 1981, SCIENCE, V213, P611, DOI 10.1126/science.7256258; BORGENS RB, 1986, J COMP NEUROL, V250, P168, DOI 10.1002/cne.902500204; BORGENS RB, 1987, SCIENCE, V238, P366, DOI 10.1126/science.3659920; BORGENS RB, 1990, J COMP NEUROL, V296, P634, DOI 10.1002/cne.902960409; Borgens RB, 1989, ELECTRIC FIELDS VERT, P117; BORGENS RB, 1992, SPINAL CORD DYSFUNCT, V3, P110; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; BREZILE JE, 1968, J COMP NEUROL, V133, P373; BRIGHTON CT, 1984, ORTHOP CLIN N AM, V15, P1; BROWN NO, 1977, J AM ANIM HOSP ASSOC, V13, P665; COOK JR, 1990, AM J VET RES, V51, P1340; DWYER AF, 1974, MED J AUSTRALIA, V1, P73; FADEN AI, 1981, NEW ENGL J MED, V305, P1063, DOI 10.1056/NEJM198110293051806; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FEHLINGS MG, 1988, J NEUROSURG, V68, P781, DOI 10.3171/jns.1988.68.5.0781; FLAMM ES, 1982, NEUROSURGERY, V10, P227, DOI 10.1227/00006123-198202000-00009; FUNKQUIST B., 1962, ACTA VET SCAND, V3, P344; GAMBARDELLA PC, 1980, VET SURG, V9, P24, DOI 10.1111/j.1532-950X.1980.tb01647.x; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; HALL ED, 1984, J NEUROSURG, V61, P124, DOI 10.3171/jns.1984.61.1.0124; Hansebout R R, 1975, Surg Neurol, V4, P531; HANSEBOUT RR, 1982, EARLY MANAGEMENT ACU, P181; HANSEN H J, 1952, Acta Orthop Scand Suppl, V11, P1; Henry W. B. Jr., 1975, Journal of the American Animal Hospital Association, V11, P627; HINKLE L, 1981, J PHYSIOL-LONDON, V314, P121, DOI 10.1113/jphysiol.1981.sp013695; HOERLEIN BF, 1979, J AM ANIM HOSP ASSOC, V15, P535; HOERLEIN BF, 1978, J AM ANIM HOSP ASSOC, V14, P563; HOERLEIN BF, 1985, JAAHA, V21, P68; HOTARY KB, 1992, DEVELOPMENT, V114, P985; HOTARY KB, 1990, DEV BIOL, V140, P149, DOI 10.1016/0012-1606(90)90062-N; HURLBERT R J, 1990, Society for Neuroscience Abstracts, V16, P1115; JAFFE LF, 1977, ANNU REV BIOPHYS BIO, V6, P445, DOI 10.1146/annurev.bb.06.060177.002305; JAFFE LF, 1981, PHILOS T ROY SOC B, V295, P553, DOI 10.1098/rstb.1981.0160; KENNARD MA, 1954, J COMP NEUROL, V100, P511, DOI 10.1002/cne.901000304; LAVINE LS, 1987, J BONE JOINT SURG AM, V69A, P626, DOI 10.2106/00004623-198769040-00024; LEVY WJ, 1984, NEUROSURGERY, V15, P214, DOI 10.1227/00006123-198408000-00011; MCCAIG CD, 1986, J PHYSIOL-LONDON, V375, P55, DOI 10.1113/jphysiol.1986.sp016105; MCCAIG CD, 1987, DEVELOPMENT, V100, P31; MCCAIG CD, 1986, J EMBRYOL EXP MORPH, V94, P245; MEANS ED, 1981, J NEUROSURG, V55, P200, DOI 10.3171/jns.1981.55.2.0200; Nuccitelli R., 1988, ADV CELL BIOL, V2, P213, DOI [10.1016/S1569-2558(08)60435-X, DOI 10.1016/S1569-2558(08)60435-X]; PATEL N, 1982, J NEUROSCI, V2, P483; PRATA RG, 1981, J AM ANIM HOSP ASSOC, V17, P17; ROEDERER E, 1983, J NEUROSCI, V3, P153; SALZMAN SK, 1990, BRAIN RES, V521, P33, DOI 10.1016/0006-8993(90)91521-H; SHORES A, 1987, AM J VET RES, V48, P1525; STRAUTMAN AF, 1990, J NEUROSCI, V10, P3564; TARLOV IM, 1957, SPINAL CORD COMPRESS, P1; TATOR CH, 1973, J NEUROSURG, V39, P52, DOI 10.3171/jns.1973.39.1.0052; WALLACE MC, 1987, NEUROSURGERY, V20, P878; Young W, 1988, Clin Neurosurg, V34, P675; YOUNG W, 1985, CENTRAL NERVOUS SYST, P463	59	57	59	0	7	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.	SEP	1993	5	5-6					305	322					18	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MB152	WOS:A1993MB15200001	21551717				2022-02-06	
J	CHAPLIN, D; DEITZ, J; JAFFE, KM				CHAPLIN, D; DEITZ, J; JAFFE, KM			MOTOR-PERFORMANCE IN CHILDREN AFTER TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						BRAIN INJURIES; MOTOR PERFORMANCE; PEDIATRIC REHABILITATION	HEAD-INJURY		UNIV WASHINGTON,SCH MED,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT NEUROL SURG,SEATTLE,WA 98195		CHAPLIN, D (corresponding author), CHILDRENS HOSP & MED CTR,DIV OCCUPAT THERAPY,4800 SAND POINT WAY NE,POB C5371,SEATTLE,WA 98105, USA.				NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [2S07RR05655-17] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S07RR005655] Funding Source: NIH RePORTER		BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BROWN BW, 1977, STATISTICS BIOMEDICA, P232; BRUININKS RH, 1977, BRUININKS OSERETSKY; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Costeff H, 1985, Scand J Rehabil Med Suppl, V12, P10; CRATTY B, 1975, REMEDIAL MOTOR ACTIV, P12; ESPENSCHADE A, 1980, MOTOR DEV, P210; GODFREY K, 1985, NEW ENGL J MED, V313, P1450, DOI 10.1056/NEJM198512053132305; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; OAKLAND T, 1985, 9TH MENTAL MEASUREME, P1142; TEASDALE G, 1974, LANCET, V2, P81; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	14	57	57	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1993	74	2					161	164					4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	KL171	WOS:A1993KL17100009	8431100				2022-02-06	
J	WARREN, M				WARREN, M			A HIERARCHICAL MODEL FOR EVALUATION AND TREATMENT OF VISUAL PERCEPTUAL DYSFUNCTION IN ADULT ACQUIRED BRAIN INJURY .1.	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						CEREBROVASCULAR DISORDERS; REHABILITATION; VISUAL PERCEPTION	SPATIAL CONTRAST SENSITIVITY; GUIDED EYE-MOVEMENTS; RESIDUAL VISION; UNILATERAL NEGLECT; CEREBRAL BLINDNESS; ISCHEMIC LESIONS; CORTICALLY BLIND; STROKE PATIENTS; DISCRIMINATION; INATTENTION	A developmental framework for evaluation and treatment of visual perceptual deficits in adults with acquired brain injury is presented The framework is based on a review of research conducted on post-cerebrovascular accident subjects and subjects with traumatic brain injuries. Visual perceptual skill is conceptualized as a hierarchy of skill levels that interact and subserve each other. Higher level skills evolve from integration of lower level skills and are subsequently affected by disruption of lower level skills. Oculomotor control, visual field, and acuity form the foundation skills, followed by visual attention, scanning, pattern recognition, memory, and visual cognition. Brain injury can affect the integrity and interaction of each skill level and affect daily living function. Application of this framework dictates a bottom-up approach to evaluation and treatment, emphasizing identification and remediation of deficits in lower level skills to allow normal integration of higher level skill.			WARREN, M (corresponding author), UNIV MISSOURI, EYE FDN KANSAS CITY, DEPT OPHTHALMOL, 2300 HOLMES, KANSAS CITY, MO 64108 USA.						ALBERT ML, 1973, NEUROLOGY, V23, P658, DOI 10.1212/WNL.23.6.658; BELLEZA T, 1979, CORTEX, V15, P19, DOI 10.1016/S0010-9452(79)80003-9; BERGEN JR, 1983, NATURE, V303, P696, DOI 10.1038/303696a0; BISIACH E, 1979, BRAIN, V102, P609, DOI 10.1093/brain/102.3.609; BLYTHE IM, 1987, BRAIN, V110, P887, DOI 10.1093/brain/110.4.887; BODISWOL.I, 1972, SCIENCE, V178, P769, DOI 10.1126/science.178.4062.769; BODISWOLLNER I, 1976, BRAIN, V99, P695, DOI 10.1093/brain/99.4.695; BOSLEY TM, 1987, ANN NEUROL, V21, P444, DOI 10.1002/ana.410210505; BRUCE CJ, 1984, TRENDS NEUROSCI, V7, P436, DOI 10.1016/S0166-2236(84)80149-6; BULENS C, 1989, BRAIN, V112, P507, DOI 10.1093/brain/112.2.507; CAMPBELL FW, 1983, BEHAV BRAIN RES, V10, P87, DOI 10.1016/0166-4328(83)90154-7; CAMPION J, 1983, BEHAV BRAIN SCI, V6, P423, DOI 10.1017/S0140525X00016861; CAPLAN B, 1985, CORTEX, V21, P69, DOI 10.1016/S0010-9452(85)80016-2; CHEDRU F, 1973, Cortex, V9, P94; Cohen M, 1989, Brain Inj, V3, P187, DOI 10.3109/02699058909004551; CORBETTA M, 1990, BRAIN, V113, P603, DOI 10.1093/brain/113.3.603; COTMAN CW, 1980, BEHAVIORAL NEUROSCIE; De Renzi E., 1982, DISORDERS SPACE EXPL; Delis D C, 1983, Int Rehabil Med, V5, P132; DEREFELDT G, 1979, ACTA OPHTHALMOL, V57, P679; DERENZI E, 1989, CORTEX, V25, P231, DOI 10.1016/S0010-9452(89)80039-5; DERENZI E, 1982, ARCH NEUROL-CHICAGO, V39, P482, DOI 10.1001/archneur.1982.00510200024004; DILLER L, 1970, Archives of Physical Medicine and Rehabilitation, V51, P358; FESTINGER L, 1971, CONTROL EYE MOVEMENT; GIANUTSOS R, 1983, ARCH PHYS MED REHAB, V64, P456; GIANUTSOS R, 1988, ARCH PHYS MED REHAB, V69, P573; GIANUTSOS R, 1989, J HEAD TRAUMA REHAB, V4, P17; Gianutsos R., 1987, NEUROPSYCHOL REHABIL, P202; GIBSON EJ, 1976, AM SCI, V235, P98; GOURAS P, 1985, PRINCIPLES NEURAL SC, P571; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; HEILMAN KM, 1980, NEUROLOGY, V30, P327, DOI 10.1212/WNL.30.3.327; HEILMAN KM, 1979, ANN NEUROL, V5, P166, DOI 10.1002/ana.410050210; HESS RF, 1989, BRAIN, V112, P871, DOI 10.1093/brain/112.4.871; HIER DB, 1983, NEUROLOGY, V33, P334; HYVARINEN L, 1982, ACTA OPHTHALMOL    S, V157, P58; JOHNSON CA, 1983, ARCH OPHTHALMOL-CHIC, V101, P371; JULESZ B, 1981, NATURE, V290, P91, DOI 10.1038/290091a0; JULESZ B, 1985, PATTERN RECOGNITIO S, V111, P333; KANDEL E, 1985, PRINCIPLES NEURAL SC, P367; Kelly J. P., 1985, PRINCIPLES NEURAL SC, P356; LEIGH RJ, 1983, NEUROLOGY EYE MOVEME; LOCHER PJ, 1983, PERCEPT MOTOR SKILL, V57, P91, DOI 10.2466/pms.1983.57.1.91; MARSHALL JC, 1988, NATURE, V336, P766, DOI 10.1038/336766a0; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; MISHKIN M, 1983, TRENDS NEUROSCI, V6, P414, DOI 10.1016/0166-2236(83)90190-X; MISHKIN M, 1987, SCI AM, V256, P80, DOI 10.1038/scientificamerican0687-80; MOORE JC, 1991, SEP PED THER INT GRO; MORROW MJ, 1990, NEUROLOGY, V40, P284, DOI 10.1212/WNL.40.2.284; NAGELLEIBY S, 1990, BRAIN, V113, P237, DOI 10.1093/brain/113.1.237; NEGER RE, 1989, J HEAD TRAUMA REHAB, V4, P27; NOTON D, 1971, SCIENCE, V171, P308, DOI 10.1126/science.171.3968.308; OWSLEY C, 1983, VISION RES, V23, P689, DOI 10.1016/0042-6989(83)90210-9; PADULA WV, 1988, BEHAVIORAL VISION AP; PALMER T, 1990, BRAIN COGNITION, V13, P46, DOI 10.1016/0278-2626(90)90039-Q; PERENIN MT, 1975, NEUROPSYCHOLOGIA, V13, P1, DOI 10.1016/0028-3932(75)90041-X; PIERROTDESEILLIGNY C, 1986, BRAIN, V109, P81, DOI 10.1093/brain/109.1.81; Pommerenke K, 1989, Restor Neurol Neurosci, V1, P47, DOI 10.3233/RNN-1989-1106; POPPEL E, 1973, NATURE, V243, P295, DOI 10.1038/243295a0; Posner M.I., 1987, NEUROPSYCHOLOGICAL R, P182; PRING TR, 1981, CORTEX, V17, P227, DOI 10.1016/S0010-9452(81)80043-3; RAFAL RD, 1987, P NATL ACAD SCI USA, V84, P7349, DOI 10.1073/pnas.84.20.7349; RAPCSAK SZ, 1989, ARCH NEUROL-CHICAGO, V46, P178, DOI 10.1001/archneur.1989.00520380082018; RATCLIFF G, 1981, BRIT MED BULL, V37, P181, DOI 10.1093/oxfordjournals.bmb.a071698; RATCLIFF G, 1987, NEUROPSYCHOL REHABIL, P242; REGAN D, 1981, BRAIN, V104, P333, DOI 10.1093/brain/104.2.333; REUTERLORENZ PA, 1990, BRAIN COGNITION, V12, P240, DOI 10.1016/0278-2626(90)90018-J; ROSSI PW, 1990, NEUROLOGY, V40, P1597, DOI 10.1212/WNL.40.10.1597; SAGI D, 1985, SCIENCE, V228, P1217, DOI 10.1126/science.4001937; SCHEIBER F, 1988, TRANSPORTATION AGING, P325; SEKULER R, 1980, SCIENCE, V209, P1255, DOI 10.1126/science.7403884; SERGENT J, 1984, PSYCHOL BULL, V96, P99; SERGENT J, 1990, BRAIN COGNITION, V13, P98, DOI 10.1016/0278-2626(90)90043-N; SPIERS PA, 1990, NEUROLOGY, V40, P1600, DOI 10.1212/WNL.40.10.1600; STANWORTH A, 1974, BRIT J OPHTHALMOL, V58, P266, DOI 10.1136/bjo.58.3.266; TYLER HR, 1969, NEUROLOGY, V19, P105, DOI 10.1212/WNL.19.2.105; UZZELL BP, 1988, ARCH NEUROL-CHICAGO, V45, P420, DOI 10.1001/archneur.1988.00520280066017; WARREN M, 1990, AM J OCCUP THER, V44, P391, DOI 10.5014/ajot.44.5.391; WARREN M, 1981, AM J OCCUP THER, V35, P431, DOI 10.5014/ajot.35.7.431; WEINBERG J, 1982, Journal of Clinical Neuropsychology, V4, P59, DOI 10.1080/01688638208401117; WEINTRAUB S, 1988, J NEUROL NEUROSUR PS, V51, P1481, DOI 10.1136/jnnp.51.12.1481; WEISKRANTZ L, 1974, BRAIN, V97, P709, DOI 10.1093/brain/97.1.709; WEISKRANTZ L, 1987, BRAIN, V110, P77, DOI 10.1093/brain/110.1.77; Yarbus A.L., 1967, EYE MOVEMENTS VISION, P171, DOI [10.1007/978-1-4899-5379-7, DOI 10.1007/978-1-4899-5379-7_8]; ZIHL J, 1986, J NEUROL NEUROSUR PS, V49, P965, DOI 10.1136/jnnp.49.8.965; ZIHL J, 1981, EXP BRAIN RES, V44, P159; ZIHL J, 1985, BRAIN, V108, P335, DOI 10.1093/brain/108.2.335; ZIHL J, 1980, NEUROPSYCHOLOGIA, V18, P71, DOI 10.1016/0028-3932(80)90085-8; ZIHL J, 1979, BRAIN, V102, P835, DOI 10.1093/brain/102.4.835; Zihl J, 1982, Hum Neurobiol, V1, P5; ZIHL J, 1979, J NEUROL NEUROSUR PS, V42, P312, DOI 10.1136/jnnp.42.4.312	91	57	59	1	12	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	JAN	1993	47	1					42	54		10.5014/ajot.47.1.42			13	Rehabilitation	Social Science Citation Index (SSCI)	Rehabilitation	KC858	WOS:A1993KC85800007	8418676				2022-02-06	
J	SHAPIRA, Y; ARTRU, AA; LAM, AM				SHAPIRA, Y; ARTRU, AA; LAM, AM			KETAMINE DECREASES CEREBRAL INFARCT VOLUME AND IMPROVES NEUROLOGICAL OUTCOME FOLLOWING EXPERIMENTAL HEAD TRAUMA IN RATS	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						INTRAVENOUS ANESTHETICS; KETAMINE; BRAIN EDEMA; HEMORRHAGIC NECROSIS; NEUROLOGIC OUTCOME; EXCITATORY AMINO ACIDS; GLUTAMATE; N-METHYL-D-ASPARTATE RECEPTORS	METHYL-D-ASPARTATE; NMDA RECEPTOR ANTAGONIST; PROTECTS HIPPOCAMPAL-NEURONS; CULTURED CORTICAL-NEURONS; EXCITATORY AMINO-ACIDS; ISCHEMIC DAMAGE; GLUTAMATE ANTAGONIST; ARACHIDONIC-ACID; ARTERY OCCLUSION; BRAIN INJURY	In brain injury, concentrations of extracellular excitatory amino acids are increased and stimulate glutamate receptors in general and the N-methyl-D-aspartate (NMDA)-preferring subtype in particular. That stimulation causes substantial calcium influx, which appears to initiate a cascade of events leading to neuronal death. Blockage of NMDA receptors with specific antagonists or noncompetitive ion channel blockers provides protection against excitatory amino acid-induced neurotoxicity. We previously reported that the NMDA receptor antagonist dizocilpine maleate improved the neurological severity score (NSS) after head trauma in rats. The present study was designed to determine whether ketamine, a NMDA receptor antagonist like dizocilpine maleate, improves neurological outcome following head trauma in rats. Thirty-two male Sprague-Dawley rats (235-250 g) were divided into four groups. Groups A and B were surgically prepared only. Groups C and D were surgically prepared and then a nonpenetrating impact was delivered to the cranium over the left hemisphere. Groups A and C received no treatment. Groups B and D were treated with ketamine, 180 mg/kg i.p., 1 h after head trauma. The NSS was determined at 1, 2, 4, 10, 24, and 48 h following head trauma. After killing at 48 h, cortical slices were taken adjacent to the lesion on the traumatized hemisphere and from comparable sites on the nontraumatized hemisphere to measure the tissue specific gravity and water content. Brains were then placed in 4% formaldehyde and the volume of hemorrhagic necrosis measured 4 days later. Head trauma increased the NSS and, in the traumatized hemisphere, decreased the specific gravity, increased the water content, and caused cerebral infarction. With ketamine, the NSS at 24 and 48 h following head trauma was 7.4 +/- 2.6 and 6.7 +/- 2.6 (mean +/- SEM), respectively, significantly improved compared to the NSS in the untreated group of 12.6 +/- 2.6 and 11.3 +/- 2.6, respectively (p < 0.02, Mann-Whitney U test). With ketamine, the volume of hemorrhagic necrosis was 88.0 +/- 23.1 mm3, significantly less than that in the untreated group (147.4 +/- 22.4 mm3; p < 0.05, unpaired t test). The brain tissue specific gravity and water content at 48 h and the rectal temperature at 4 and 48 h after head trauma were not significantly different between treated and untreated groups. It is concluded that in this model of closed cranial impact, ketamine improves neurological outcome and decreases the volume of hemorrhagic necrosis without altering brain edema.	UNIV WASHINGTON,SCH MED,DEPT ANESTHESIOL,RN-10,SEATTLE,WA 98195								ALBERS GW, 1989, ANN NEUROL, V25, P398, DOI 10.1002/ana.410250412; Artru A A, 1989, J Neurosurg Anesthesiol, V1, P8, DOI 10.1097/00008506-198903000-00003; ARTRU AA, 1989, STATUS KETAMINE ANES, P119; BAKER AJ, 1991, STROKE, V22, P666, DOI 10.1161/01.STR.22.5.666; BARTH TM, 1990, STROKE, V21, P153; BAUGHMAN VL, 1990, J NEUROSURG ANESTH, V2, P290, DOI 10.1097/00008506-199012000-00007; BELOPAVLOVIC M, 1982, ACTA ANAESTH SCAND, V26, P458, DOI 10.1111/j.1399-6576.1982.tb01799.x; BENEVISTE H, 1984, J NEUROCHEM, V43, P1369; BUCHAN A, 1990, J NEUROSCI, V10, P311; BULLOCK R, 1990, J CEREBR BLOOD F MET, V10, P668, DOI 10.1038/jcbfm.1990.120; BULLOCK R, 1990, STROKE, V21, P32; CABARROCAS F, 1973, NEURORADIOLOGY, V5, P59; CAVAZZUTI M, 1987, J CEREBR BLOOD F MET, V7, P806, DOI 10.1038/jcbfm.1987.138; CHAN PH, 1989, BRAIN RES, V487, P380, DOI 10.1016/0006-8993(89)90845-7; CHEUNG JY, 1986, NEW ENGL J MED, V314, P1670; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHURCH J, 1988, SIGMA PHENCYCLIDINE, P747; COLE DJ, 1990, STROKE, V21, P1333, DOI 10.1161/01.STR.21.9.1333; COLE DJ, 1990, CAN J NEUROL SCI, V17, P372, DOI 10.1017/S0317167100030900; CORBETT D, 1990, BRAIN RES, V514, P300, DOI 10.1016/0006-8993(90)91424-F; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P263, DOI 10.1016/0166-2236(87)90170-6; CROSBY G, 1982, ANESTHESIOLOGY, V56, P437, DOI 10.1097/00000542-198206000-00005; DAVIS DW, 1988, ANESTHESIOLOGY, V69, P199, DOI 10.1097/00000542-198808000-00008; DAWSON B, 1971, ANESTH ANAL CURR RES, V50, P443; DESHPANDE JK, 1987, J CEREBR BLOOD F MET, V7, P89, DOI 10.1038/jcbfm.1987.13; DIEMER NH, 1990, STROKE, V21, P39; Domino EF, 1990, STATUS KETAMINE ANES; DRUMMOND JC, 1989, STROKE, V20, P1538, DOI 10.1161/01.STR.20.11.1538; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FENSKE A, 1978, J NEUROL, V219, P241, DOI 10.1007/BF00312977; FORD LM, 1989, ARCH NEUROL-CHICAGO, V46, P1090, DOI 10.1001/archneur.1989.00520460072016; FUKUDA S, 1983, ANESTH ANALG, V62, P553; GIBBS JM, 1972, BRIT J ANAESTH, V44, P1298, DOI 10.1093/bja/44.12.1298; GOLDBERG MP, 1990, STROKE, V21, P75; KIM JP, 1987, BRAIN RES, V437, P103, DOI 10.1016/0006-8993(87)91531-9; KOHMURA E, 1990, J CEREBR BLOOD F MET, V10, P877, DOI 10.1038/jcbfm.1990.144; LEES GJ, 1987, NEUROSCI LETT, V78, P180, DOI 10.1016/0304-3940(87)90630-6; LEES GJ, 1989, BRAIN RES, V502, P280, DOI 10.1016/0006-8993(89)90623-9; LEVY DI, 1990, NEUROLOGY, V40, P852, DOI 10.1212/WNL.40.5.852; LODGE D, 1986, J PHYSIOL-LONDON, V377, pP28; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MARCOUX FW, 1988, SIGMA PHENCYCLIDINE, P735; MARMAROU A, 1978, J NEUROSURG, V49, P503; MCINTOSH TK, 1988, 7TH INT S INTR PRESS, P199; MELDRUM BS, 1987, MED BIOL, V65, P153; MEYER FB, 1989, BRAIN RES REV, V14, P227, DOI 10.1016/0165-0173(89)90002-7; MEYER FB, 1990, J CEREBR BLOOD F MET, V10, P895, DOI 10.1038/jcbfm.1990.146; MICHENFELDER JD, 1989, BRAIN RES, V481, P228, DOI 10.1016/0006-8993(89)90798-1; NABESHIMA T, 1990, NEUROSCI LETT, V108, P321, DOI 10.1016/0304-3940(90)90661-R; NUSSMEIER NA, 1986, ANESTHESIOLOGY, V64, P165, DOI 10.1097/00000542-198602000-00006; OLNEY JW, 1986, NEUROSCI LETT, V68, P29, DOI 10.1016/0304-3940(86)90224-7; OZYURT E, 1988, J CEREBR BLOOD F MET, V8, P138, DOI 10.1038/jcbfm.1988.18; PATEL PM, 1991, ACTA NEUROPATHOL, V81, P339, DOI 10.1007/BF00305878; PFENNINGER E, 1989, STATUS KETAMINE ANES, P109; ROMAN R, 1989, NEUROSCI LETT, V104, P19, DOI 10.1016/0304-3940(89)90322-4; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; ROTHMAN SM, 1987, NEUROSCIENCE, V21, P673, DOI 10.1016/0306-4522(87)90028-5; SHAPIRA Y, 1992, ANESTHESIOLOGY, V77, P79, DOI 10.1097/00000542-199207000-00012; SHAPIRA Y, 1989, Neurological Research, V11, P169; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHAPIRA Y, 1990, J NEUROTRAUMA, V3, P131; SHAPIRO HM, 1972, BRIT J ANAESTH, V44, P1200, DOI 10.1093/bja/44.11.1200; SHINOJI K, 1987, BRAIN RES, V408, P385; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SHOHAMI E, 1988, NEUROSURGERY, V22, P859, DOI 10.1227/00006123-198805000-00007; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMON R, 1990, ANN NEUROL, V27, P606, DOI 10.1002/ana.410270604; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SKAPER SD, 1989, EXP NEUROL, V106, P297, DOI 10.1016/0014-4886(89)90163-5; STEINBERG GK, 1989, STROKE, V20, P1247, DOI 10.1161/01.STR.20.9.1247; STEVENS MK, 1990, J CEREBR BLOOD F MET, V10, P77, DOI 10.1038/jcbfm.1990.10; SWAN JH, 1990, J CEREBR BLOOD F MET, V10, P343, DOI 10.1038/jcbfm.1990.63; TAKESHITA H, 1972, ANESTHESIOLOGY, V36, P69, DOI 10.1097/00000542-197201000-00013; TROP D, 1978, 5TH EUR C AN AMST, P221; VANRIJEN PC, 1991, STROKE, V22, P343, DOI 10.1161/01.STR.22.3.343; WEISS J, 1986, BRAIN RES, V380, P186, DOI 10.1016/0006-8993(86)91447-2; WIELOCH T, 1982, J CEREBR BLOOD F MET, V2, pS5; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; WROBLEWSKI JT, 1987, P NATL ACAD SCI USA, V84, P5068, DOI 10.1073/pnas.84.14.5068; YU ACH, 1986, J NEUROCHEM, V47, P1181; YU ACH, 1987, J NEUROSCI RES, V17, P424, DOI 10.1002/jnr.490170414; ZAIDAN JR, 1991, ANESTHESIOLOGY, V74, P406, DOI 10.1097/00000542-199103000-00003	84	57	58	0	2	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	1992	4	4					231	240		10.1097/00008506-199210000-00001			10	Anesthesiology; Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology; Surgery	JQ572	WOS:A1992JQ57200001	15815471				2022-02-06	
J	DeBaun, MR; Jordan, LC; King, AA; Schatz, J; Vichinsky, E; Fox, CK; McKinstry, RC; Telfer, P; Kraut, MA; Daraz, L; Kirkham, FJ; Murad, MH				DeBaun, M. R.; Jordan, L. C.; King, A. A.; Schatz, J.; Vichinsky, E.; Fox, C. K.; McKinstry, R. C.; Telfer, P.; Kraut, M. A.; Daraz, L.; Kirkham, F. J.; Murad, M. H.			American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults	BLOOD ADVANCES			English	Article							SILENT CEREBRAL INFARCTS; DOPPLER FLOW VELOCITIES; HEALTH-CARE PROFESSIONALS; ACUTE ISCHEMIC-STROKE; BLOOD-TRANSFUSION THERAPY; FUNCTION PERFORMANCE-TEST; DECISION ETD FRAMEWORKS; TRAUMATIC BRAIN-INJURY; TRANSCRANIAL DOPPLER; EXECUTIVE FUNCTION	Background: Central nervous system (CNS) complications are among the most common, devastating sequelae of sickle cell disease (SCD) occurring throughout the lifespan. Objective: These evidence-based guidelines of the American Society of Hematology are intended to support the SCD community in decisions about prevention, diagnosis, and treatment of the most common neurological morbidities in SCD. Methods: The Mayo Evidence-Based Practice Research Program supported the guideline development process, including updating or performing systematic evidence reviews. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE evidence-to-decision frameworks, to assess evidence and make recommendations. Results: The panel placed a higher value on maintaining cognitive function than on being alive with significantly less than baseline cognitive function. The panel developed 19 recommendations with evidence-based strategies to prevent, diagnose, and treat CNS complications of SCD in low-middle- and high-income settings. Conclusions: Three of 19 recommendations immediately impact clinical care. These recommendations include: use of transcranial Doppler ultrasound screening and hydroxyurea for primary stroke prevention in children with hemoglobin SS (HbSS) and hemoglobin S beta(0) (HbS beta(0)) thalassemia living in low-middle-income settings; surveillance for developmental delay, cognitive impairments, and neurodevelopmental disorders in children; and use of magnetic resonance imaging of the brain without sedation to detect silent cerebral infarcts at least once in early-school-age children and once in adults with HbSS or HbS beta(0) thalassemia. Individuals with SCD, their family members, and clinicians should become aware of and implement these recommendations to reduce the burden of CNS complications in children and adults with SCD.	[DeBaun, M. R.] Vanderbilt Univ, Med Ctr, Vanderbilt Meharry Ctr Excellence Sickle Cell Dis, Dept Pediat, Nashville, TN 37203 USA; [Jordan, L. C.] Vanderbilt Univ, Med Ctr, Dept Pediat, Div Pediat Neurol, Nashville, TN 37203 USA; [King, A. A.] Washington Univ, Sch Med, Program Occupat Therapy, Dept Med,Dept Pediat,Div Hematol, St Louis, MO 63110 USA; [Schatz, J.] Univ South Carolina, Dept Psychol, Columbia, SC 29208 USA; [Vichinsky, E.] Childrens Hosp, Oakland Res Inst, 747 52nd St, Oakland, CA 94609 USA; [Fox, C. K.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Fox, C. K.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [McKinstry, R. C.] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA; [McKinstry, R. C.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Telfer, P.] Queen Mary Univ London, Blizard Inst, Ctr Genom & Child Hlth, London, England; [Kraut, M. A.] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; [Daraz, L.; Murad, M. H.] Mayo Clin, Evidence Based Practice Ctr, Rochester, MN USA; [Kirkham, F. J.] UCL Great Ormond St Inst Child Hlth, Dev Neurosci Sect, London, England; [Kirkham, F. J.] Univ Southampton, Clin & Expt Sci, Southampton, Hants, England; [Kirkham, F. J.] Univ Hosp Southampton, Dept Child Hlth, Southampton, Hants, England		DeBaun, MR (corresponding author), Vanderbilt Univ, Med Sch, Vanderbilt Meharry Ctr Excellence Sickle Cell Dis, 2525 West End Ave,Suite 750, Nashville, TN 37203 USA.	m.debaun@vumc.org	Murad, M. Hassan/AAW-4367-2020; Kirkham, Fenella/C-2442-2009	Kirkham, Fenella/0000-0002-2443-7958; Jordan, Lori/0000-0001-7240-0415; King, Allison/0000-0002-1951-6176; Murad, Mohammad Hassan/0000-0001-5502-5975; DeBaun, Michael/0000-0002-0574-1604			Abdullahi SU, 2019, PEDIATR NEUROL, V95, P73, DOI 10.1016/j.pediatrneurol.2019.01.008; Abraham M, 2013, CURRENT PROCEDURAL T; Adamkiewicz TV, 2009, BLOOD, V114, P4632, DOI 10.1182/blood-2009-02-203323; Adams RJ, 2005, NEW ENGL J MED, V353, P2769; Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102; Adams RJ, 2017, STROKE, V48, P686, DOI 10.1161/STROKEAHA.116.015412; Adegoke SA, 2018, J STROKE CEREBROVASC, V27, P425, DOI 10.1016/j.jstrokecerebrovasdis.2017.09.020; Ahn SN, 2017, NEUROREHABILITATION, V40, P285, DOI 10.3233/NRE-161416; AHO K, 1980, B WORLD HEALTH ORGAN, V58, P113; Akl EA, 2014, J CLIN EPIDEMIOL, V67, P1222, DOI 10.1016/j.jclinepi.2014.05.006; Alamri A, 2019, BRIT J NEUROSURG, V33, P161, DOI 10.1080/02688697.2017.1339227; Alexy T, 2006, TRANSFUSION, V46, P912, DOI 10.1111/j.1537-2995.2006.00823.x; Alonso-Coello P, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2089; Alonso-Coello P, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2016; American Psychological Association Practice Organization, DIST SCREEN ASS MENT; [Anonymous], 2015, FED REGISTER, V79, P67576; Atkins D, 2004, BMC HEALTH SERV RES, V4, DOI 10.1186/1472-6963-4-38; Aygun B, 2015, BRIT J HAEMATOL, V169, P262, DOI 10.1111/bjh.13280; Aygun B, 2012, AM J HEMATOL, V87, P428, DOI 10.1002/ajh.23105; Bardakdjian-Michau J, 2009, J CLIN PATHOL, V62, P31, DOI 10.1136/jcp.2008.058867; Barger B, 2018, DISABIL HEALTH J, V11, P420, DOI 10.1016/j.dhjo.2018.01.002; Baum CM, 2017, NEUROPSYCHOL REHABIL, V27, P603, DOI 10.1080/09602011.2016.1176934; Baum CM, 2008, AM J OCCUP THER, V62, P446, DOI 10.5014/ajot.62.4.446; Bernaudin F, 2020, HAEMATOLOGICA, V105, P91, DOI 10.3324/haematol.2018.213207; Bernaudin F, 2019, JAMA-J AM MED ASSOC, V321, P266, DOI 10.1001/jama.2018.20059; Bernaudin F, 2015, BLOOD, V125, P1653, DOI 10.1182/blood-2014-09-599852; Bond M, 2015, BRIT J HEALTH PSYCH, V20, P792, DOI 10.1111/bjhp.12142; Boustani M, 2003, SCREENING DEMENTIA; Brambilla DJ, 2007, PEDIATR BLOOD CANCER, V49, P318, DOI 10.1002/pbc.21142; Brito JP, 2013, J CLIN ENDOCR METAB, V98, P3246, DOI 10.1210/jc.2013-1814; Brush LN, 2013, NEUROLOGY, V80, P1225, DOI 10.1212/WNL.0b013e3182896ffb; Bush AM, 2016, AM J HEMATOL, V91, P912, DOI 10.1002/ajh.24441; Choudhury NA, 2018, NEUROLOGY, V90, pE239, DOI 10.1212/WNL.0000000000004832; Cicerone KD, 2019, ARCH PHYS MED REHAB, V100, P1515, DOI 10.1016/j.apmr.2019.02.011; COHEN AR, 1991, J PEDIATR-US, V118, P405, DOI 10.1016/S0022-3476(05)82155-9; Coupland AP, 2017, J ROY SOC MED, V110, P9, DOI 10.1177/0141076816680121; Day ME, 2019, BRIT J HAEMATOL, V185, P153, DOI 10.1111/bjh.15400; de la Fuente J, 2019, BIOL BLOOD MARROW TR, V25, P1197, DOI 10.1016/j.bbmt.2018.11.027; DeBaun MR, 2014, NEW ENGL J MED, V371, P699, DOI 10.1056/NEJMoa1401731; Debaun Michael R, 2016, Trans Am Clin Climatol Assoc, V127, P17; DeBaun MR, 2016, BLOOD, V127, P829, DOI 10.1182/blood-2015-09-618579; DeBaun MR, 2012, BLOOD, V119, P4587, DOI 10.1182/blood-2011-02-272682; Diamini N, 2017, NEUROLOGY, V89, P2406, DOI 10.1212/WNL.0000000000004728; Dichgans M, 2017, CIRC RES, V120, P573, DOI 10.1161/CIRCRESAHA.116.308426; Dobson SR, 2002, BLOOD, V99, P3144, DOI 10.1182/blood.V99.9.3144; Dormandy E, 2018, J PUBLIC HEALTH-UK, V40, pE291, DOI 10.1093/pubmed/fdx172; Drazen CH, 2016, PEDIATR BLOOD CANCER, V63, P504, DOI 10.1002/pbc.25838; Enninful-Eghan H, 2010, J PEDIATR-US, V157, P479, DOI 10.1016/j.jpeds.2010.03.007; Faye BF, 2017, ADV HEMATOL, V2017; Ferriero DM, 2019, STROKE, V50, pE51, DOI 10.1161/STR.0000000000000183; Files B, 2002, J PEDIAT HEMATOL ONC, V24, P284, DOI 10.1097/00043426-200205000-00013; Fitzhugh CD, 2017, BLOOD ADV, V1, P652, DOI 10.1182/bloodadvances.2016002972; Ford AL, 2018, BLOOD, V132, P1714, DOI 10.1182/blood-2018-04-841247; Fryer RH, 2003, PEDIATR NEUROL, V29, P124, DOI 10.1016/S0887-8994(03)00047-X; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; Galadanci NA, 2017, AM J HEMATOL, V92, P780, DOI 10.1002/ajh.24770; GLAUSER TA, 1995, J CHILD NEUROL, V10, P88, DOI 10.1177/088307389501000203; Guilliams KP, 2018, BLOOD, V131, P1012, DOI 10.1182/blood-2017-06-789842; Gulbis B, 2005, BLOOD, V105, P2685, DOI 10.1182/blood-2004-07-2704; Guyatt G, 2010, ANN INTERN MED, V152, P738, DOI 10.7326/0003-4819-152-11-201006010-00254; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Guyatt GH, 2016, J CLIN EPIDEMIOL, V80, P3, DOI 10.1016/j.jclinepi.2016.07.006; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012; Hall EM, 2016, PEDIATR BLOOD CANCER, V63, P1431, DOI 10.1002/pbc.26022; Hankins JS, 2015, AM J HEMATOL, V90, P1099, DOI 10.1002/ajh.24198; Hankinson TC, 2008, J NEUROSURG-PEDIATR, V1, P211, DOI 10.3171/PED/2008/1/3/211; Haskins E.C., 2012, COGNITIVE REHABILITA; Hassell KL, 2010, AM J PREV MED, V38, pS512, DOI 10.1016/j.amepre.2009.12.022; Hayes TL, 2009, J AGING HEALTH, V21, P567, DOI 10.1177/0898264309332836; Hogan AM, 2005, DEV MED CHILD NEUROL, V47, P824, DOI 10.1017/S001216220500174X; Hulbert ML, 2006, J PEDIATR-US, V149, P710, DOI 10.1016/j.jpeds.2006.06.037; Hulbert ML, 2011, BLOOD, V117, P772, DOI 10.1182/blood-2010-01-261123; HURLETJENSEN AM, 1994, STROKE, V25, P1688, DOI 10.1161/01.STR.25.8.1688; Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, 2011, CLIN PRACTICE GUIDEL; Jabbarli R, 2019, CURR NEUROVASC RES, V16, P63, DOI 10.2174/1567202616666190131160847; Johnston SC, 2000, JAMA-J AM MED ASSOC, V284, P2901, DOI 10.1001/jama.284.22.2901; Jordan LC, 2018, NEUROLOGY, V91, pE781, DOI 10.1212/WNL.0000000000006047; Jordan LC, 2019, AM J HEMATOL, V94, pE155, DOI 10.1002/ajh.25455; Jordan LC, 2018, AM J HEMATOL, V93, P760, DOI 10.1002/ajh.25085; Juttukonda MR, 2019, J MAGN RESON IMAGING, V49, P466, DOI 10.1002/jmri.26213; Kassim AA, 2016, BLOOD, V127, P2038, DOI 10.1182/blood-2016-01-694562; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kim HC, 2014, HEMATOL-AM SOC HEMAT, P450, DOI 10.1182/asheducation-2014.1.450; King AA, 2007, NEUROLOGY, V68, P2008, DOI 10.1212/01.wnl.0000264421.24415.16; King AA, 2019, BIOL BLOOD MARROW TR, V25, pE174, DOI 10.1016/j.bbmt.2019.01.008; King AA, 2014, AM J HEMATOL, V89, pE188, DOI 10.1002/ajh.23805; King AA, 2014, AM J HEMATOL, V89, P162, DOI 10.1002/ajh.23604; Krantz SB, 2015, THORAC SURG CLIN, V25, P155, DOI 10.1016/j.thorsurg.2014.11.003; Kratovil T, 2006, PEDIATR BLOOD CANCER, V47, P894, DOI 10.1002/pbc.20819; Kwiatkowski JL, 2011, PEDIATR BLOOD CANCER, V56, P777, DOI 10.1002/pbc.22951; Lagunju I A, 2013, Niger Postgrad Med J, V20, P181; Lagunju IA, 2013, PEDIATR BLOOD CANCER, V60, P1940, DOI 10.1002/pbc.24698; Lagunju I, 2019, PEDIATR BLOOD CANCER, V66, DOI 10.1002/pbc.27252; Lagunju I, 2015, PEDIATR BLOOD CANCER, V62, P1587, DOI 10.1002/pbc.25529; Lefevre N, 2008, BLOOD, V111, P963, DOI 10.1182/blood-2007-08-102244; Lo B., 2009, CONFLICT INTEREST ME; Lopes FCM, 2015, HAEMATOLOGICA, V100, P730, DOI 10.3324/haematol.2014.119727; Makin SDJ, 2015, STROKE, V46, P3142, DOI 10.1161/STROKEAHA.115.010665; Martin Leslie R, 2005, Ther Clin Risk Manag, V1, P189; Lopes FCM, 2014, MICROVASC RES, V94, P106, DOI 10.1016/j.mvr.2014.05.009; McCavit TL, 2013, PEDIATR BLOOD CANCER, V60, P823, DOI 10.1002/pbc.24392; McEwen SE, 2010, NEUROPSYCHOL REHABIL, V20, P541, DOI 10.1080/09602011003638194; Mentz RJ, 2018, AM HEART J, V200, P51, DOI 10.1016/j.ahj.2018.03.007; Murad MH, 2019, BLOOD ADV, V3, P3945, DOI 10.1182/bloodadvances.2019000931; Murad MH, 2017, MAYO CLIN PROC, V92, P423, DOI 10.1016/j.mayocp.2017.01.001; Ng J, 2012, CHILD NERV SYST, V28, P1041, DOI 10.1007/s00381-012-1743-7; Ohene-Frempong K, 1998, BLOOD, V91, P288; Panepinto JA, 2012, PEDIATR BLOOD CANCER, V59, P685, DOI 10.1002/pbc.24028; PEGELOW CH, 1995, J PEDIATR-US, V126, P896, DOI 10.1016/S0022-3476(95)70204-0; Pegelow CH, 2001, ARCH NEUROL-CHICAGO, V58, P2017, DOI 10.1001/archneur.58.12.2017; Pegelow CH, 1997, AM J MED, V102, P171; Petersen RC, 2018, NEUROLOGY, V90, P126, DOI 10.1212/WNL.0000000000004826; Piel FB, 2013, LANCET, V381, P142, DOI 10.1016/S0140-6736(12)61229-X; Polatajko HJ, 2012, AM J OCCUP THER, V66, P104, DOI 10.5014/ajot.2012.001784; Polatajko Helene J., 2001, Physical and Occupational Therapy in Pediatrics, V20, P107, DOI 10.1300/J006v20n02_07; POWARS D, 1978, AM J MED, V65, P461, DOI 10.1016/0002-9343(78)90772-6; Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158; Prohovnik I, 2009, J CEREBR BLOOD F MET, V29, P803, DOI 10.1038/jcbfm.2009.6; Prussien KV, 2019, J PEDIATR PSYCHOL, V44, P948, DOI 10.1093/jpepsy/jsz031; Qaseem A, 2012, ANN INTERN MED, V156, P525, DOI 10.7326/0003-4819-156-7-201204030-00009; Reeves SL, 2016, JAMA PEDIATR, V170, P550, DOI 10.1001/jamapediatrics.2015.4859; Rigano P, 2018, BLOOD CELL MOL DIS, V69, P82, DOI 10.1016/j.bcmd.2017.08.017; Rivkin MJ, 2016, PEDIATR NEUROL, V56, P8, DOI 10.1016/j.pediatrneurol.2016.01.016; Roebuck-Spencer TM, 2017, ARCH CLIN NEUROPSYCH, V32, P491, DOI 10.1093/arclin/acx021; Sacco RL, 2013, STROKE, V44, P2064, DOI 10.1161/STR.0b013e318296aeca; Sand N, 2005, PEDIATRICS, V116, P174, DOI 10.1542/peds.2004-1809; Saver JL, 2006, STROKE, V37, P263, DOI 10.1161/01.STR.0000196957.55928.ab; Schatz J, 2006, MENT RETARD DEV D R, V12, P200, DOI 10.1002/mrdd.20115; SCHMALZER EA, 1987, TRANSFUSION, V27, P228, DOI 10.1046/j.1537-2995.1987.27387235626.x; Schunemann HJ, 2014, CAN MED ASSOC J, V186, pE123, DOI 10.1503/cmaj.131237; Schunemann HJ, 2009, AM J RESP CRIT CARE, V180, P564, DOI 10.1164/rccm.200901-0126ST; Schunemann HJ, 2003, CAN MED ASSOC J, V169, P677; Schunemann HJ, 2017, J CLIN EPIDEMIOL, V81, P101, DOI 10.1016/j.jclinepi.2016.09.009; Schunemann HJ, 2016, J CLIN EPIDEMIOL, V76, P89, DOI 10.1016/j.jclinepi.2016.01.032; Schunemann HJ, 2015, ANN INTERN MED, V163, P548, DOI 10.7326/M14-1885; Scothorn DJ, 2002, J PEDIATR-US, V140, P348, DOI 10.1067/mpd.2002.122498; Seet RCS, 2012, CEREBROVASC DIS, V34, P106, DOI 10.1159/000339675; Silva GS, 2009, STROKE, V40, P2408, DOI 10.1161/STROKEAHA.108.537415; Smith ER, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.01.FOCUS08307; Stilley CS, 2010, HEALTH PSYCHOL, V29, P50, DOI 10.1037/a0016940; Swerdlow Paul S, 2006, Hematology Am Soc Hematol Educ Program, P48; Tarazi RA, 2007, CHILD NEUROPSYCHOL, V13, P155, DOI 10.1080/09297040600611312; Tate R, 2014, J HEAD TRAUMA REHAB, V29, P338, DOI 10.1097/HTR.0000000000000068; Therrell BL, 2015, SEMIN PERINATOL, V39, P238, DOI 10.1053/j.semperi.2015.03.008; Thornburg CD, 2009, PEDIATR BLOOD CANCER, V52, P609, DOI 10.1002/pbc.21738; Tshilolo L, 2019, NEW ENGL J MED, V380, P121, DOI [10.1056/NEJMoa1813598, 10.1056/nejmoa1813598]; VENKETASUBRAMANIAN N, 1994, STROKE, V25, P2153, DOI 10.1161/01.STR.25.11.2153; Vermeer SE, 2003, STROKE, V34, P1126, DOI 10.1161/01.STR.0000068408.82115.D2; Vichinsky EP, 2010, JAMA-J AM MED ASSOC, V303, P1823, DOI 10.1001/jama.2010.562; Vichinsky EP, 2001, TRANSFUSION, V41, P1086, DOI 10.1046/j.1537-2995.2001.41091086.x; Vieira C, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26342; Ware RE, 2016, LANCET, V387, P661, DOI 10.1016/S0140-6736(15)01041-7; Ware RE, 2012, BLOOD, V119, P3925, DOI 10.1182/blood-2011-11-392340; Winstead M, 2017, PEDIATR HEMAT ONCOL, V34, P100, DOI 10.1080/08880018.2017.1313917; Winstein CJ, 2016, STROKE, V47, pE98, DOI 10.1161/STR.0000000000000098; Wolf TJ, 2016, AM J OCCUP THER, V70, DOI 10.5014/ajot.2016.017293; Wood JC, 2016, BRIT J HAEMATOL, V172, P122, DOI 10.1111/bjh.13791; World Health Assembly, 2006, SICKL CELL AN REP SE; Yang WY, 2017, J NEUROSURG-PEDIATR, V20, P232, DOI 10.3171/2017.1.PEDS16576; Yawn BP, 2014, JAMA-J AM MED ASSOC, V312, P1033, DOI 10.1001/jama.2014.10517; Zimmerman SA, 2007, BLOOD, V110, P1043, DOI 10.1182/blood-2006-11-057893; ZINKHAM WH, 1994, J PEDIATR-US, V124, P215, DOI 10.1016/S0022-3476(94)70306-X	163	56	56	2	6	AMER SOC HEMATOLOGY	WASHINGTON	2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA	2473-9529	2473-9537		BLOOD ADV	Blood Adv.	APR 28	2020	4	8					1554	1588		10.1182/bloodadvances.2019001142			35	Hematology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Hematology	LJ4VF	WOS:000530164200001	32298430	Green Submitted, Green Published, gold			2022-02-06	
J	Mez, J; Daneshvar, DH; Abdolmohammadi, B; Chua, AS; Alosco, ML; Kiernan, PT; Evers, L; Marshall, L; Martin, BM; Palmisano, JN; Nowinski, CJ; Mahar, I; Cherry, JD; Alvarez, VE; Dwyer, B; Huber, BR; Stein, TD; Goldstein, LE; Katz, DI; Cantu, RC; Au, R; Kowall, NW; Stern, RA; McClean, MD; Weuve, J; Tripodis, Y; McKee, AC				Mez, Jesse; Daneshvar, Daniel H.; Abdolmohammadi, Bobak; Chua, Alicia S.; Alosco, Michael L.; Kiernan, Patrick T.; Evers, Laney; Marshall, Laura; Martin, Brett M.; Palmisano, Joseph N.; Nowinski, Christopher J.; Mahar, Ian; Cherry, Jonathan D.; Alvarez, Victor E.; Dwyer, Brigid; Huber, Bertrand R.; Stein, Thor D.; Goldstein, Lee E.; Katz, Douglas, I; Cantu, Robert C.; Au, Rhoda; Kowall, Neil W.; Stern, Robert A.; McClean, Michael D.; Weuve, Jennifer; Tripodis, Yorghos; McKee, Ann C.			Duration of American Football Play and Chronic Traumatic Encephalopathy	ANNALS OF NEUROLOGY			English	Article							ALZHEIMERS ASSOCIATION GUIDELINES; 21ST-CENTURY BRAIN BANKING; NEUROPATHOLOGIC ASSESSMENT; NATIONAL INSTITUTE; NERVOUS-SYSTEM; 1ST EXPOSURE; DEMENTIA; DISEASE; IMPACT; CONCUSSION	Objective Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with exposure to contact and collision sports, including American football. We hypothesized a dose-response relationship between duration of football played and CTE risk and severity. Methods In a convenience sample of 266 deceased American football players from the Veterans Affairs-Boston University-Concussion Legacy Foundation and Framingham Heart Study Brain Banks, we estimated the association of years of football played with CTE pathological status and severity. We evaluated the ability of years played to classify CTE status using receiver operating characteristic curve analysis. Simulation analyses quantified conditions that might lead to selection bias. Results In total, 223 of 266 participants met neuropathological diagnostic criteria for CTE. More years of football played were associated with having CTE (odds ratio [OR] = 1.30 per year played, 95% confidence interval [CI] = 1.19-1.41; p = 3.8 x 10(-9)) and with CTE severity (severe vs mild; OR = 1.14 per year played, 95% CI = 1.07-1.22; p = 3.1 x 10(-4)). Participants with CTE were 1/10th as likely to have played <4.5 years (negative likelihood ratio [LR] = 0.102, 95% CI = 0.100-0.105) and were 10 times as likely to have played >14.5 years (positive LR = 10.2, 95% CI = 9.8-10.7) compared with participants without CTE. Sensitivity and specificity were maximized at 11 years played. Simulation demonstrated that years played remained adversely associated with CTE status when years played and CTE status were both related to brain bank selection across widely ranging scenarios. Interpretation The odds of CTE double every 2.6 years of football played. After accounting for brain bank selection, the magnitude of the relationship between years played and CTE status remained consistent. ANN NEUROL 2019	[Mez, Jesse; Daneshvar, Daniel H.; Abdolmohammadi, Bobak; Chua, Alicia S.; Alosco, Michael L.; Kiernan, Patrick T.; Evers, Laney; Marshall, Laura; Martin, Brett M.; Palmisano, Joseph N.; Nowinski, Christopher J.; Mahar, Ian; Cherry, Jonathan D.; Alvarez, Victor E.; Huber, Bertrand R.; Stein, Thor D.; Goldstein, Lee E.; Cantu, Robert C.; Au, Rhoda; Kowall, Neil W.; Stern, Robert A.; Tripodis, Yorghos; McKee, Ann C.] Boston Univ, Sch Med, Alzheimers Dis & Chron Traumat Encephalopathy Ctr, Boston, MA 02118 USA; [Mez, Jesse; Abdolmohammadi, Bobak; Alosco, Michael L.; Kiernan, Patrick T.; Evers, Laney; Marshall, Laura; Mahar, Ian; Dwyer, Brigid; Huber, Bertrand R.; Goldstein, Lee E.; Katz, Douglas, I; Cantu, Robert C.; Kowall, Neil W.; Stern, Robert A.; McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Mez, Jesse; Stein, Thor D.; Au, Rhoda; McKee, Ann C.] Boston Univ, Framingham Heart Study, Sch Med, Boston, MA 02118 USA; [Daneshvar, Daniel H.] Stanford Univ, Sch Med, Dept Rehabil Med, Stanford, CA 94305 USA; [Chua, Alicia S.; Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA; [Kiernan, Patrick T.] Midwestern Univ, Arizona Coll Osteopath Med, Glendale, AZ USA; [Martin, Brett M.; Palmisano, Joseph N.] Boston Univ, Data Coordinating Ctr, Sch Publ Hlth, Boston, MA 02118 USA; [Nowinski, Christopher J.; Cantu, Robert C.] Concuss Legacy Fdn, Boston, MA USA; [Cherry, Jonathan D.; Alvarez, Victor E.; Huber, Bertrand R.; Stein, Thor D.; Kowall, Neil W.; McKee, Ann C.] US Dept Vet Affairs, VA Boston Healthcare Syst, Boston, MA USA; [Cherry, Jonathan D.; Alvarez, Victor E.; Huber, Bertrand R.; Stein, Thor D.; McKee, Ann C.] Dept Vet Affairs Med Ctr, Bedford, MA USA; [Dwyer, Brigid; Katz, Douglas, I] Braintree Rehabil Hosp, Braintree, MA USA; [Stein, Thor D.; Goldstein, Lee E.; Kowall, Neil W.; McKee, Ann C.] Boston Univ, Dept Pathol & Lab Med, Sch Med, Boston, MA 02118 USA; [Goldstein, Lee E.] Boston Univ, Dept Psychiat, Sch Med, Boston, MA 02118 USA; [Goldstein, Lee E.] Boston Univ, Dept Biomed Engn, Coll Engn, Boston, MA 02118 USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Dept Neurosurg, Sch Med, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Au, Rhoda; Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Au, Rhoda; Weuve, Jennifer] Boston Univ, Dept Epidemiol, Sch Publ Hlth, Boston, MA 02118 USA; [McClean, Michael D.] Boston Univ, Dept Environm Hlth, Sch Publ Hlth, Boston, MA 02118 USA		McKee, AC (corresponding author), Boston Univ, AD&CTE Ctr, 72 E Concord St,Robinson Suite 7800, Boston, MA 02118 USA.	amckee@bu.edu	Dwyer, Brigid/AAI-6199-2020; Lang, Steven/AAE-8102-2021; , Bob/ABA-8507-2020	Dwyer, Brigid/0000-0002-6446-8054; Lang, Steven/0000-0003-1669-9146; Mez, Jesse/0000-0003-1438-5442	NIH National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659, U01NS093334, R01NS078337, R56NS078337, K23NS10 2399]; NIH National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG13846, 0572063345, R01AG057902, R01AG061028, K23AG046377, R01AG1649, R21HD089088, F32NS09 6803]; Department of Veterans AffairsUS Department of Veterans Affairs [I01 CX001135, CSP 501, B6796-C]; Department of DefenseUnited States Department of Defense [W81XWH13-2-0095, W81XWH-13-2-0064, W81XWH1810580, PRARP-13267017]; Alzheimer's AssociationAlzheimer's Association [NIRG15-362697, NIRG-305779]; National Operating Committee on Standards for Athletic Equipment; Nick and Lynn Buoniconti Foundation; Concussion Legacy Foundation; Andlinger Foundation; World Wrestling Entertainment; NFL	This work was supported by the NIH National Institute of Neurological Disorders and Stroke (U01NS086659, U01NS093334, R01NS078337, R56NS078337, K23NS10 2399), NIH National Institute on Aging (P30AG13846; supplement 0572063345, R01AG057902, R01AG061028, K23AG046377, R01AG1649, R21HD089088, F32NS09 6803), Department of Veterans Affairs (I01 CX001135, CSP 501, B6796-C), Department of Defense (W81XWH13-2-0095, W81XWH-13-2-0064, W81XWH1810580, PRARP-13267017), Alzheimer's Association (NIRG15-362697, NIRG-305779), National Operating Committee on Standards for Athletic Equipment, Nick and Lynn Buoniconti Foundation, Concussion Legacy Foundation, Andlinger Foundation, World Wrestling Entertainment, and NFL.; We thank VA Boston Healthcare System (Boston, MA) and the Edith Nourse Rogers Memorial Veterans Hospital (Bedford, MA) for the use of resources and facilities; all members of the Boston University CTE Center, the VA-BU-CLF Brain Bank (including Kerry Cormier, Carol Kubilus, Rebecca Mathias, Ray Nicks and Madeline Uretsky), and the Concussion Legacy Foundation (including Lisa McHale); and the individuals and families whose participation and contributions made this work possible.	Adams JW, 2018, J NEUROPATH EXP NEUR, V77, P757, DOI 10.1093/jnen/nly065; Alosco ML, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.197; Alosco ML, 2018, ANN NEUROL, V83, P886, DOI 10.1002/ana.25245; Asken BM, 2017, JAMA NEUROL, V74, P1255, DOI 10.1001/jamaneurol.2017.2396; Au R, 2012, CURR ALZHEIMER RES, V9, P673; Baugh CM, 2015, J NEUROTRAUM, V32, P314, DOI 10.1089/neu.2014.3582; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Braak H, 2008, NEUROLOGY, V70, P1916, DOI 10.1212/01.wnl.0000312279.49272.9f; BROWNELL B, 1970, J NEUROL NEUROSUR PS, V33, P338, DOI 10.1136/jnnp.33.3.338; Cairns NJ, 2007, AM J PATHOL, V171, P227, DOI 10.2353/ajpath.2007.070182; Chene G, 2015, ALZHEIMERS DEMENT, V11, P310, DOI 10.1016/j.jalz.2013.10.005; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Dickson DW, 2010, INT J CLIN EXP PATHO, V3, P1; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Haneuse S, 2009, NEUROEPIDEMIOLOGY, V32, P229, DOI 10.1159/000197389; Hernan MA, 2004, EPIDEMIOLOGY, V15, P615, DOI 10.1097/01.ede.0000135174.63482.43; Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Ling HL, 2017, ACTA NEUROPATHOL, V133, P337, DOI 10.1007/s00401-017-1680-3; Ling HL, 2015, ACTA NEUROPATHOL, V130, P891, DOI 10.1007/s00401-015-1496-y; Litvan I, 1996, J NEUROPATH EXP NEUR, V55, P97, DOI 10.1097/00005072-199601000-00010; Liu XH, 2012, STAT MED, V31, P2676, DOI 10.1002/sim.4509; Mackenzie IRA, 2010, ACTA NEUROPATHOL, V119, P1, DOI 10.1007/s00401-009-0612-2; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKeith IG, 2006, ALZHEIMER'S DISEASE: A CENTURY OF SCIENTIFIC AND CLINICAL RESEARCH, P417; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Mez J, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0148-8; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Saczynski JS, 2010, NEUROLOGY, V75, P35, DOI 10.1212/WNL.0b013e3181e62138; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Vogel BL, 2019, STUDENT ATHLETES VS; Vonsattel JPG, 2008, CELL TISSUE BANK, V9, P247, DOI 10.1007/s10561-008-9079-y; Vonsattel JPG, 2008, ACTA NEUROPATHOL, V115, P509, DOI 10.1007/s00401-007-0311-9	45	56	56	9	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JAN	2020	87	1					116	131		10.1002/ana.25611		NOV 2019	16	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	LS0BE	WOS:000498077700001	31589352	Green Published, hybrid			2022-02-06	
J	Wang, JM; Jiang, C; Zhang, K; Lan, X; Chen, XM; Zang, WD; Wang, ZY; Guan, FX; Zhu, CL; Yang, XL; Lu, H; Wang, J				Wang, Junmin; Jiang, Chao; Zhang, Kun; Lan, Xi; Chen, Xuemei; Zang, Weidong; Wang, Zhongyu; Guan, Fangxia; Zhu, Changlian; Yang, Xiuli; Lu, Hong; Wang, Jian			Melatonin receptor activation provides cerebral protection after traumatic brain injury by mitigating oxidative stress and inflammation via the Nrf2 signaling pathway	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						Chronotherapy; Inflammation; NF-E2-related factor; Oxidative stress; Ramelteon; Traumatic brain injury	MONONUCLEAR-CELL TRANSPLANTATION; INTRACEREBRAL HEMORRHAGE; RAT MODEL; POSSIBLE INVOLVEMENT; RAMELTEON TAK-375; UP-REGULATION; NEUROINFLAMMATION; NEUROPROTECTION; AGONIST; SLEEP	Traumatic brain injury (TBI) is a principal cause of death and disability worldwide. Melatonin, a hormone made by the pineal gland, is known to have anti-inflammatory and antioxidant properties. In this study, using a weight-drop model of TBI, we investigated the protective effects of ramelteon, a melatonin MT1/MT2 receptor agonist, and its underlying mechanisms of action. Administration of ramelteon (10 mg/kg) daily at 10:00 a.m. alleviated TBI-induced early brain damage on day 3 and long-term neurobehavioral deficits on day 28 in C57BL/6 mice. Ramelteon also increased the protein levels of interleukin (IL)-10, IL-4, superoxide dismutase (SOD), glutathione, and glutathione peroxidase and reduced the protein levels of IL-1 beta, tumor necrosis factor, and malondialdehyde in brain tissue and serum on days 1, 3, and 7 post-TBI. Similarly, ramelteon attenuated microglial and astrocyte activation in the perilesional cortex on day 3. Furthermore, ramelteon decreased Keap 1 expression, promoted nuclear factor erythroid 2-related factor 2 (Nrf2) nuclear accumulation, and increased levels of downstream proteins, including SOD-1, heme oxygenase-1, and NQO1 on day 3 post-TBI. However, in Nrf2 knockout mice with TBI, ramelteon did not decrease the lesion volume, neuronal degeneration, or myelin loss on day 3; nor did it mitigate depression-like behavior or most motor behavior deficits on day 28. Thus, timed ramelteon treatment appears to prevent inflammation and oxidative stress via the Nrf2-antioxidant response element pathway and might represent a potential chronotherapeutic strategy for treating TBI.	[Wang, Junmin; Guan, Fangxia; Lu, Hong] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou 450000, Henan, Peoples R China; [Wang, Junmin; Chen, Xuemei; Zang, Weidong] Zhengzhou Univ, Coll Basic Med Sci, Dept Anat, Zhengzhou 450000, Henan, Peoples R China; [Wang, Junmin; Guan, Fangxia; Zhu, Changlian] Zhengzhou Univ, Affiliated Hosp 3, Zhengzhou 450052, Henan, Peoples R China; [Wang, Junmin; Lan, Xi; Wang, Jian] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; [Jiang, Chao] Zhengzhou Univ, Affiliated Hosp 5, Dept Neurol, Zhengzhou 450052, Henan, Peoples R China; [Zhang, Kun; Guan, Fangxia] Zhengzhou Univ, Sch Life Sci, Zhengzhou 450000, Henan, Peoples R China; [Wang, Zhongyu] Zhengzhou Univ, Affiliated Hosp 1, Dept Anesthesiol, Zhengzhou 450000, Henan, Peoples R China; [Zhu, Changlian] Zhengzhou Univ, Inst Neurosci, Henan Key Lab Child Brain Injury, Zhengzhou 450052, Henan, Peoples R China; [Zhu, Changlian] Univ Gothenburg, Inst Neurosci & Physiol, Ctr Brain Repair & Rehabil, S-40530 Gothenburg, Sweden; [Yang, Xiuli] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA		Wang, JM; Lu, H (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou 450000, Henan, Peoples R China.; Wang, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA.	wangjunmin@zzu.edu.cn; zzu_luhong@163.com; jwang79@jhmi.edu	Wang, Jian/I-4874-2019; Zhu, Changlian/AAN-6205-2020	Wang, Jian/0000-0003-2291-640X; Zhu, Changlian/0000-0002-5029-6730	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81671165]	The authors thank the Wang lab members for technical expertise and insightful input. This research was supported by a grant from the National Natural Science Foundation of China (Grant No. 81671165 to CJ).	Babaee A, 2015, IRAN J BASIC MED SCI, V18, P867; Otalora BB, 2012, CHRONOBIOL INT, V29, P822, DOI 10.3109/07420528.2012.699119; Bin Sayeed MS, 2017, J NEUROIMMUNOL, V313, P46, DOI 10.1016/j.jneuroim.2017.10.007; CAN A, 2012, JOVE J VIS EXP JAN, DOI DOI 10.3791/3769; Cardinali DP, 2012, J PINEAL RES, V52, P365, DOI 10.1111/j.1600-079X.2011.00962.x; Cheng T, 2016, FREE RADICAL BIO MED, V92, P15, DOI 10.1016/j.freeradbiomed.2015.12.027; Cheng T, 2015, CELL MOL NEUROBIOL, V35, P641, DOI 10.1007/s10571-015-0159-9; Dehghan F, 2013, ARCH MED RES, V44, P251, DOI 10.1016/j.arcmed.2013.04.002; Ding K, 2014, NEUROCHEM INT, V76, P23, DOI 10.1016/j.neuint.2014.06.015; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Dong W. W., 2017, P 12 BIENN C CHIN NE, P754; Emet M, 2016, EURASIAN J MED, V48, P135, DOI 10.5152/eurasianjmed.2015.0267; Esposito E, 2010, CURR NEUROPHARMACOL, V8, P228, DOI 10.2174/157015910792246155; Fernandez-Gajardo R, 2014, CNS DRUGS, V28, P229, DOI 10.1007/s40263-013-0138-y; Fisher SP, 2008, J PINEAL RES, V45, P125, DOI 10.1111/j.1600-079X.2008.00565.x; Galano A, 2011, J PINEAL RES, V51, P1, DOI 10.1111/j.1600-079X.2011.00916.x; Greenblatt DJ, 2007, J CLIN PHARMACOL, V47, P485, DOI 10.1177/0091270006298602; Han X., 2018, J CEREB BLOOD FLOW M; Han XN, 2016, J CEREBR BLOOD F MET, V36, P1059, DOI 10.1177/0271678X15606462; Hirai K, 2005, J BIOL RHYTHM, V20, P27, DOI 10.1177/0748730404269890; Jiang C, 2017, MOL NEUROBIOL, V54, P571, DOI 10.1007/s12035-015-9651-y; Jiang C, 2016, NEUROBIOL AGING, V42, P13, DOI 10.1016/j.neurobiolaging.2016.02.029; Jin W, 2008, ANN CLIN LAB SCI, V38, P221; Kasahara T, 2010, P NATL ACAD SCI USA, V107, P6412, DOI 10.1073/pnas.0914399107; Kast RE, 2015, WSPOLCZESNA ONKOL, V19, P157, DOI 10.5114/wo.2015.51421; Kragel PA, 2018, NAT NEUROSCI, V21, P283, DOI 10.1038/s41593-017-0051-7; Lan X, 2017, MOL NEUROBIOL, V54, P7898, DOI 10.1007/s12035-016-0271-y; Lan X, 2017, BRAIN BEHAV IMMUN, V61, P326, DOI 10.1016/j.bbi.2016.12.012; Laudon M, 2014, INT J MOL SCI, V15, P15924, DOI 10.3390/ijms150915924; Lauterbach EC, 2010, J NEUROPSYCH CLIN N, V22, P8, DOI 10.1176/appi.neuropsych.22.1.8; Lequerica A, 2015, ARCH PHYS MED REHAB, V96, P1802, DOI 10.1016/j.apmr.2015.05.011; Li B. X., 2017, P 12 BIENN C CHIN NE, P755; Li DP, 2016, CELL MOL NEUROBIOL, V36, P1045, DOI 10.1007/s10571-015-0295-2; Li Q, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90777; Li Q, 2017, NEUROBIOL DIS, V108, P173, DOI 10.1016/j.nbd.2017.08.011; Lin C, 2016, J PINEAL RES, V61, P177, DOI 10.1111/jpi.12337; Liu JB, 2016, ANNU REV PHARMACOL, V56, P361, DOI 10.1146/annurev-pharmtox-010814-124742; Miyamoto M, 2006, NEUROSCI LETT, V402, P201, DOI 10.1016/j.neulet.2006.02.049; Pan LN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099526; Pandi-Perumal S. R., 2010, SLEEP MENTAL ILLNESS, P119; Shimizu N, 2013, RES REP UROL, V5, P113, DOI 10.2147/RRU.S44502; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Slominski RM, 2012, MOL CELL ENDOCRINOL, V351, P152, DOI 10.1016/j.mce.2012.01.004; Tsai MC, 2011, J PINEAL RES, V51, P233, DOI 10.1111/j.1600-079X.2011.00885.x; Vivien-Roels B, 1998, J BIOL RHYTHM, V13, P403, DOI 10.1177/074873098129000228; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Wang JP, 2017, NEUROSCIENCE, V364, P202, DOI 10.1016/j.neuroscience.2017.09.025; Wang JP, 2016, MOL NEUROBIOL, V53, P6057, DOI 10.1007/s12035-015-9512-8; Wang JP, 2015, BRAIN BEHAV IMMUN, V45, P98, DOI 10.1016/j.bbi.2014.12.015; Wang JP, 2014, BEHAV BRAIN RES, V265, P171, DOI 10.1016/j.bbr.2014.02.033; Wang WZ, 2017, BRAIN BEHAV IMMUN, V64, P344, DOI 10.1016/j.bbi.2017.04.019; Wang WZ, 2016, MOL NEUROBIOL, V53, P4809, DOI 10.1007/s12035-015-9385-x; Wisor JP, 2009, BRAIN RES, V1296, P46, DOI 10.1016/j.brainres.2009.07.103; Wu G, 2016, MED SCI MONITOR, V22, P2161, DOI 10.12659/MSM.896568; Wu H, 2017, J CEREBR BLOOD F MET, V37, P39, DOI 10.1177/0271678X15625351; Wu H, 2015, NEUROBIOL AGING, V36, P1439, DOI 10.1016/j.neurobiolaging.2014.12.029; Wu H, 2012, NEUROBIOL DIS, V45, P388, DOI 10.1016/j.nbd.2011.08.028; Wu H, 2011, J CEREBR BLOOD F MET, V31, P1243, DOI 10.1038/jcbfm.2010.209; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yang YQ, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00580; Yuruker V, 2015, METAB BRAIN DIS, V30, P223, DOI 10.1007/s11011-014-9623-3; Zhang H, 2017, J CEREBR BLOOD F MET, V37, P3422, DOI 10.1177/0271678X17690165; Zhang L, 2018, MOL NEUROBIOL, V55, P1773, DOI 10.1007/s12035-017-0456-z; Zhu W, 2018, BRAIN BEHAV IMMUN, V69, P568, DOI 10.1016/j.bbi.2018.02.004; Zhu W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097423	68	56	58	3	36	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	FEB 1	2019	131						345	355		10.1016/j.freeradbiomed.2018.12.014			11	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	HG7TX	WOS:000455199300033	30553970				2022-02-06	
J	Ge, XT; Li, WZ; Huang, S; Yin, ZY; Xu, X; Chen, FL; Kong, XD; Wang, HC; Zhang, JN; Lei, P				Ge, Xintong; Li, Wenzhu; Huang, Shan; Yin, Zhenyu; Xu, Xin; Chen, Fanglian; Kong, Xiaodong; Wang, Haichen; Zhang, Jianning; Lei, Ping			The pathological role of NLRs and AIM2 inflammasome-mediated pyroptosis in damaged blood-brain barrier after traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; Blood-brain barrier; Pyroptosis; Inflammasome; NOD-like receptors; AIM2	THERAPEUTIC HYPOTHERMIA; CEREBROSPINAL-FLUID; CELL-DEATH; IN-VITRO; ACTIVATION; ASC; MICE; EXPRESSION; CHALLENGES; IMPROVES	Pyroptosis is a highly specific type of inflammatory programmed cell death that different from necrosis or apoptosis. It is initiated by cellular detection of acute damage via recognizing pathogen-associated molecular patterns (PAMPs) by NOD-like receptors (NLRs) or AIM2-like receptor (AIM2). NLRs and AIM2 could trigger the formation of a multi-protein complex, known as inflammasome. It also contains apoptotic speck-containing protein (ASC) and pro-Caspase-1, and could process the signals to induce a cascade of inflammatory response. Recently, growing evidence showed that inflammasome-mediated pyroptosis is involved in the pathogenesis of traumatic brain injury (TBI). However, less attention has been paid to their particular roles in regulating blood-brain barrier (BBB) damage, the central pathological change in secondary brain damage of TBI. Thus, we designed this research to explore the impact and mechanism of NLRs and AIM2 inflammasome-mediated pyroptosis in BBB after TBI. We employed the controlled cortical impact (CCI) mice model and manipulated the severity of pyroptosis in BBB using Caspase-1 inhibitor, Ac-YVAD-cmk. We found that TBI led to NLRs and AIM2 inflammasome-mediated pyroptosis in brain microvascular endothelial cells (BMVECs) from injured cerebral cortex. Ac-YVAD-cmk treatment inhibited pyroptosis in injured BMVECs by suppressing the expression of essential inflammasome subunit - Caspase-1 and pivotal downstream pro-inflammatory cytokines (IL-1 beta and IL-18), as well as hindering GSDMD cleavage and ASC oligomerization. In addition, inhibiting pyroptosis could alleviate TBI-induced BBB leakage, brain edema, loss of tight junction proteins, and the inflammatory response in injured BMVECs. These effects contributed to improving the neurological outcome of CCI mice. In conclusion, NLRs and AIM2 inflammasome-mediated pyroptosis could aggravate BBB damage after TBI. Targeting and controlling pyroptosis in injured BBB would be a promising therapeutic strategy for TBI in the future. (C) 2018 Elsevier B.V. All rights reserved.	[Ge, Xintong; Xu, Xin; Zhang, Jianning] Tianjin Med Univ, Dept Neurosurg, Gen Hosp, 154 Anshan Rd, Tianjin 300052, Peoples R China; [Ge, Xintong; Xu, Xin; Chen, Fanglian; Zhang, Jianning] Tianjin Med Univ, Key Lab Injuries Variat & Regenerat Nervous Syst, Tianjin Neurol Inst, Gen Hosp, Tianjin 300052, Peoples R China; [Ge, Xintong; Xu, Xin; Chen, Fanglian; Zhang, Jianning] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin 300052, Peoples R China; [Ge, Xintong; Li, Wenzhu; Huang, Shan; Yin, Zhenyu; Kong, Xiaodong; Lei, Ping] Tianjin Med Univ, Lab Neurotrauma & Neurodegenerat Disorders, Tianjin Geriatr Inst, Gen Hosp, Tianjin 300052, Peoples R China; [Li, Wenzhu; Huang, Shan; Yin, Zhenyu; Kong, Xiaodong; Lei, Ping] Tianjin Med Univ, Dept Geriatr, Gen Hosp, 154 Anshan Rd, Tianjin 300052, Peoples R China; [Wang, Haichen] Duke Univ, Dept Neurol, Med Ctr, Durham, NC 27710 USA		Zhang, JN (corresponding author), Tianjin Med Univ, Dept Neurosurg, Gen Hosp, 154 Anshan Rd, Tianjin 300052, Peoples R China.; Lei, P (corresponding author), Tianjin Med Univ, Dept Geriatr, Gen Hosp, 154 Anshan Rd, Tianjin 300052, Peoples R China.	jianningzhang@hotmail.com; leiping1974@163.com	Ge, Xintong/X-4889-2019	Xu, Xin/0000-0003-3395-9923; Ge, Xintong/0000-0001-7153-952X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81501055, 81772060, 81720108015, 81471252]; Tianjin Municipal Science and Technology Commission [16PTSYJC00180, 15JCYBJC50500]	This work was supported by the National Natural Science Foundation of China (grant numbers 81501055, 81772060, 81720108015 and 81471252); and the Tianjin Municipal Science and Technology Commission natural fund project (grant numbers 16PTSYJC00180, 15JCYBJC50500). The authors appreciate Chunsheng Kang, Shu Zhang, Li Liu, Weiyun Cui and Lei Zhou from Tianjin Neurological Institute for their technical support.	Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Antonopoulos C, 2013, J IMMUNOL, V191, P4789, DOI 10.4049/jimmunol.1300645; Awad F, 2018, PHARM THER; Baroja-Mazo A, 2014, NAT IMMUNOL, V15, P738, DOI 10.1038/ni.2919; Chavarria-Smith J, 2015, IMMUNOL REV, V265, P22, DOI 10.1111/imr.12283; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen X, 2014, J NEUROL SCI, V342, P93, DOI 10.1016/j.jns.2014.04.032; Chen X, 2013, CRIT CARE, V17, DOI 10.1186/cc13067; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Denes A, 2015, P NATL ACAD SCI USA, V112, P4050, DOI 10.1073/pnas.1419090112; Dick MS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11929; Dietrich WD, 2016, BRAIN RES, V1640, P94, DOI 10.1016/j.brainres.2015.12.034; Edwards P, 2005, LANCET, V365, P1957; Fan KH, 2017, CHEM-BIOL INTERACT, V271, P15, DOI 10.1016/j.cbi.2017.04.021; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Fernandes-Alnemri T, 2007, CELL DEATH DIFFER, V14, P1590, DOI 10.1038/sj.cdd.4402194; Franklin BS, 2014, NAT IMMUNOL, V15, P727, DOI 10.1038/ni.2913; Freeman LC, 2016, J NEUROCHEM, V136, P29, DOI 10.1111/jnc.13217; Ge X, 2018, J NEUROTRAUMA; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Ge XT, 2016, BRAIN RES, V1650, P31, DOI 10.1016/j.brainres.2016.07.015; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Geng FY, 2016, NEUROIMMUNOMODULAT, V23, P122, DOI 10.1159/000445689; Han ZL, 2015, DNA CELL BIOL, V34, P703, DOI 10.1089/dna.2015.2800; Huang S, 2018, FASEB J, V32, P512, DOI 10.1096/fj.201700673R; Huang XT, 2013, J NEUROTRAUM, V30, P2080, DOI 10.1089/neu.2013.2996; Irrera N, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00459; Ismael S., 2018, J NEUROTRAUM; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Lee SW, 2018, J NEUROTRAUM, V35, P1681, DOI 10.1089/neu.2017.5530; Leger M, 2013, NAT PROTOC, V8, P2531, DOI 10.1038/nprot.2013.155; Levin H, 2013, LANCET NEUROL, V12, P15, DOI 10.1016/S1474-4422(12)70300-9; Lin C, 2017, EXP NEUROL, V290, P115, DOI 10.1016/j.expneurol.2017.01.005; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu W, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1083-y; Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629; Lugrin J, 2017, BIO-PROTOCOL, V7, DOI 10.21769/BioProtoc.2292; Ma J, 2016, INFLAMMATION, V39, P2094, DOI 10.1007/s10753-016-0446-8; Ma MW, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6057609; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Mortezaee K, 2018, J CELL PHYSIOL, V233, P5160, DOI 10.1002/jcp.26287; Nagyoszi P, 2015, J NEUROCHEM, V135, P551, DOI 10.1111/jnc.13197; Nasser M, 2016, CNS NEUROL DISORD-DR, V15, P1030, DOI 10.2174/1871527315666160815093525; Qian HH, 2017, MOL MED REP, V16, P3922, DOI 10.3892/mmr.2017.7079; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035; Ruck T, 2014, JOVE-J VIS EXP, DOI 10.3791/52204; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Tomura S, 2012, J CEREBR BLOOD F MET, V32, P1939, DOI 10.1038/jcbfm.2012.99; Vaccari JPD, 2016, J NEUROCHEM, V136, P39, DOI 10.1111/jnc.13036; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Wallisch JS, 2017, NEUROCRIT CARE, V27, P44, DOI 10.1007/s12028-017-0378-7; Wang XL, 2015, TOXICOLOGY, V334, P104, DOI 10.1016/j.tox.2015.06.006; Wei X, 2016, J HUAZHONG U SCI-MED, V36, P576, DOI 10.1007/s11596-016-1628-1; Xu X, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0934-2; Zacharek A, 2006, NEUROSCI LETT, V404, P28, DOI 10.1016/j.neulet.2006.05.027; Zhang Y, 2014, CNS NEUROSCI THER, V20, P119, DOI 10.1111/cns.12170; Zhang YY, 2018, CELL RES, V28, P9, DOI 10.1038/cr.2017.133; Zhou KR, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/9238290; Zou P, 2018, MOL MED REP, V17, P3212, DOI 10.3892/mmr.2017.8241	68	56	59	2	42	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 15	2018	1697						10	20		10.1016/j.brainres.2018.06.008			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GR8LK	WOS:000442975200002	29886252				2022-02-06	
J	Chai, C; Song, LJ; Han, SY; Li, XQ; Li, M				Chai, Chang; Song, Lai-Jun; Han, Shuang-Yin; Li, Xi-Qing; Li, Ming			MicroRNA-21 promotes glioma cell proliferation and inhibits senescence and apoptosis by targeting SPRY1 via the PTEN/PI3K/AKT signaling pathway	CNS NEUROSCIENCE & THERAPEUTICS			English	Article						apoptosis; cell senescence; glioma; microRNA-21; PTEN; PI3K; AKT signaling pathway; Sprouty1	HEPATOCELLULAR-CARCINOMA; GLIOBLASTOMA CELLS; MALIGNANT GLIOMA; PI3K/AKT PATHWAY; TUMOR-SUPPRESSOR; EXPRESSION; GROWTH; CANCER; TUMORIGENESIS; ANGIOGENESIS	AimsOur study aims to investigate the effect of microRNA-21 (miR-21) on the proliferation, senescence, and apoptosis of glioma cells by targeting SPRY1 via the PTEN/PI3K/AKT signaling pathway. MethodsGlioma tissues and brain tissues were collected for this study after surgical decompression for traumatic brain injury. RT-qPCR was employed to measure mRNA levels of miR-21, SPRY1, PTEN, PI3K, and AKT, and Western blotting was conducted to determine protein levels of SPRY1, PTEN, PI3K, AKT, p-AKT, Caspase-3, Caspase-9, P53, GSK3, and p-GSK3. Human glioma U87 cells were assigned into the blank, negative control (NC), miR-21 mimics, miR-21 inhibitors, siRNA-SPRY1, and miR-21 inhibitors + siRNA-SPRY1 groups, with human HEB cells serving as the normal group. Cell proliferation, cell cycle, and apoptosis were determined by MTT and flow cytometry, respectively. ResultsCompared with control group, an increased expression of miR-21, PI3K, AKT, p-AKT, P53, and p-GSK3, and a decreased expression of SPRY1, PTEN, Caspase-3, and Caspase-9 were observed in the glioma group, and no significant differences were found in the expression of GSK3. SPRY1 was verified to be the target gene of miR-21. Compared with the blank and NC groups, levels of PI3K, AKT, p-AKT, P53, and p-GSK3 increased while levels of SPRY1, PTEN, Caspase-3, and Caspase-9 decreased in the miR-21 mimics and siRNA-SPRY1 groups; the miR-21 inhibitors group reversed the tendency; furthermore, the miR-21 inhibitors group showed decreased cell proliferation but promoted apoptosis, which were opposite to the results of the miR-21 mimics and siRNA-SPRY1 groups. ConclusionMicroRNA-21 might promote cell proliferation and inhibit cell senescence and apoptosis of human glioma cells by targeting SPRY1 via the PTEN/PI3K/AKT signaling pathway.	[Chai, Chang] Henan Prov Peoples Hosp, Henan Eye Inst, Zhengzhou, Henan, Peoples R China; [Song, Lai-Jun] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurosurg, Zhengzhou, Henan, Peoples R China; [Han, Shuang-Yin] Henan Prov Peoples Hosp, Dept Gastroenterol, Zhengzhou, Henan, Peoples R China; [Li, Xi-Qing] Henan Prov Peoples Hosp, Dept Oncol, Zhengzhou, Henan, Peoples R China; [Li, Ming] Henan Prov Peoples Hosp, Dept Neurosurg, Zhengzhou, Henan, Peoples R China		Li, M (corresponding author), Henan Prov Peoples Hosp, Dept Neurosurg, Zhengzhou, Henan, Peoples R China.	limingfromhn@163.com					Bao ZS, 2014, ONCOL REP, V32, P250, DOI 10.3892/or.2014.3176; Chen Y, 2008, CANCER LETT, V272, P197, DOI 10.1016/j.canlet.2008.06.034; Derlon JM, 2000, EUR J NUCL MED, V27, P778, DOI 10.1007/s002590000260; Falsini B, 2016, BRAIN, V139, P404, DOI 10.1093/brain/awv366; Fang J, 2007, CELL SIGNAL, V19, P2487, DOI 10.1016/j.cellsig.2007.07.025; Gallardo A, 2012, BRIT J CANCER, V106, P1367, DOI 10.1038/bjc.2012.85; Gao SF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03612-0; Haque R, 2017, MOL VIS, V23, P251; Kitagishi Yasuko, 2012, Depress Res Treat, V2012, P752563, DOI 10.1155/2012/752563; Kuracha MR, 2013, DEV BIOL, V383, P227, DOI 10.1016/j.ydbio.2013.09.014; Lin CJ, 2016, TOXICOL APPL PHARM, V304, P59, DOI 10.1016/j.taap.2016.05.018; Liu GL, 2017, J CELL BIOCHEM, V118, P3424, DOI 10.1002/jcb.25999; Liu XL, 2016, TOXICOL LETT, V252, P1, DOI 10.1016/j.toxlet.2016.04.015; Locatelli M, 2010, EUR CYTOKINE NETW, V21, P27, DOI 10.1684/ecn.2009.0184; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Qu Y, 2012, NEUROSCI LETT, V525, P168, DOI 10.1016/j.neulet.2012.07.025; Rychly B, 2008, Cesk Patol, V44, P35; Santosh V, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.02.18; Sathyanarayana P, 2012, BLOOD, V119, P5522, DOI 10.1182/blood-2011-11-392571; Shi L, 2010, BRAIN RES, V1352, P255, DOI 10.1016/j.brainres.2010.07.009; Sun C, 2014, NEUROREPORT, V25, P177, DOI 10.1097/WNR.0000000000000069; Tang C, 2009, ANTI-CANCER DRUG, V20, P249, DOI 10.1097/CAD.0b013e328327d476; Solomon MT, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-299; Tian Y, 2012, INT J ONCOL, V40, P1105, DOI 10.3892/ijo.2011.1306; Tu KS, 2016, INT J ONCOL, V48, P965, DOI 10.3892/ijo.2015.3309; Wang F, 2016, INT J MOL MED, V37, P1421, DOI 10.3892/ijmm.2016.2518; Wang HN, 2012, ONCOL REP, V28, P311, DOI 10.3892/or.2012.1788; Wang L, 2003, INT J MOL MED, V12, P783; Wang P, 2015, CELL SIGNAL, V27, P275, DOI 10.1016/j.cellsig.2014.11.011; Weng WH, 2013, ANTICANCER RES, V33, P5407; Yang CH, 2015, J BIOL CHEM, V290, P6037, DOI 10.1074/jbc.M114.632125; Yue X, 2012, ONCOL REP, V27, P1200, DOI 10.3892/or.2011.1588; Zhang BG, 2012, ONCOL REP, V27, P1019, DOI 10.3892/or.2012.1645; Zhang JG, 2010, CLIN CHIM ACTA, V411, P846, DOI 10.1016/j.cca.2010.02.074; Zhao P, 2015, ONCOTARGET, V6, P31901, DOI 10.18632/oncotarget.5043; Zhou X, 2010, INT J ONCOL, V36, P665, DOI 10.3892/ijo_00000542	36	56	57	3	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1755-5930	1755-5949		CNS NEUROSCI THER	CNS Neurosci. Ther.	MAY	2018	24	5					369	380		10.1111/cns.12785			12	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	GC8PW	WOS:000430058800001	29316313	Green Published, Bronze			2022-02-06	
J	Shen, M; Wang, S; Wen, X; Han, XR; Wang, YJ; Zhou, XM; Zhang, MH; Wu, DM; Lu, J; Zheng, YL				Shen, Min; Wang, Shan; Wen, Xin; Han, Xin-Rui; Wang, Yong-Jian; Zhou, Xiu-Min; Zhang, Man-He; Wu, Dong-Mei; Lu, Jun; Zheng, Yuan-Lin			Dexmedetomidine exerts neuroprotective effect via the activation of the PI3K/Akt/mTOR signaling pathway in rats with traumatic brain injury	BIOMEDICINE & PHARMACOTHERAPY			English	Article						Dexmedetomidine; PI3K/Akt/mTOR signaling pathway; Traumatic brain injury; Neuroprotective effect; Autophagy	INDUCED CELL-DEATH; ISCHEMIA-REPERFUSION; TIGHT JUNCTION; AUTOPHAGY; INHIBITION; CONTRIBUTES; DEFICITS; PROTEIN	Objective: : This study aims to explore the neuroprotective effects of dexmedetomidine (Dex) in rats suffering from traumatic brain injury (TBI) via the PI3K/Akt/mTOR signaling pathway. Methods: A weight drop model was performed for TBI model establishment. A total of 150 Sprague Dawley rats were selected and assigned into control, sham, TBI, TBI + Dex, TBI + LY294002 (LY) and TBI + Dex + LY groups. Modified Neurological Severity Score (mNSS) was conducted in order to evaluate the neurological injury. The water content in brain tissues was measured. The expressions of PI3K/Akt/mTOR signaling pathway-related proteins, tight junction proteins (ZO-1 and Claudin-5) and autophagy proteins (LC3 I/II and Beclin-1) were detected using Western blot assay. A TUNEL assay was applied for cell apoptosis, immunofluorescence was employed for the detection of the positive expression of LC3, and ELISA was applied for detection of levels of inflammatory factors [tumor necrosis factor-alph (TNF-a), interleukin-1 beta (IL-1 beta), interferon-gamma (INF-gamma) as well as IL-6], respectively. Results: Compared with the control group, the other four groups exhibited increased mNSS, brain water content, expression of LC3, TNF-a, IL-1 beta, INF-gamma and IL-6, and positive expression of LC3, expression of LC3 I/II and Beclin-1, but decreased expression of pp-PI3K/t-PI3K, p-Akt/t-Akt, p-mTOR/t-mTOR, ZO-1 and Claudin-5. Compared with the TBI group, the TBI + Dex group exhibited reduced mNSS, brain water content, expression of LC3, TNF-a, IL-1 beta, INF-gamma and IL-6, positive expression of LC3, as well as expression of LC3 I/II and Beclin-1 but demonstrated an elevated expression of pp-PI3K/t-PI3K, p-Akt/t-Akt, p-mTOR/t-mTOR, ZO-1 and Claudin-5, while opposite trends were observed in the TBI + LY group. The TBI + Dex group exhibited reduced mNSS, brain water content, expression of LC3, TNF-a, IL-1 beta, INF-gamma and IL-6, positive expression of LC3, as well as expression of LC3 I/II and Beclin-1 but demonstrated an elevated expression of pp-PI3K/t-PI3K, p-Akt/t-Akt, p-mTOR/t-mTOR, ZO-1 and Claudin-5, while opposite trends were observed in the TBI + LY group, as compared with the TBI + Dex + LY group. Conclusion: The data shows that Dex exerts a neuroprotective effect via the activation of the PI3K/Akt/mTOR signaling pathway in rats with TBI.	[Shen, Min; Wang, Shan; Wen, Xin; Han, Xin-Rui; Wang, Yong-Jian; Wu, Dong-Mei; Lu, Jun; Zheng, Yuan-Lin] Jiangsu Normal Univ, Sch Life Sci, Key Lab Biotechnol Med Plants Jiangsu Prov, Xuzhou 221116, Peoples R China; [Zhou, Xiu-Min; Zhang, Man-He] Tangshan Gongren Hosp, Dept Anesthesiol, Tangshan 063000, Peoples R China		Wu, DM; Lu, J; Zheng, YL (corresponding author), Jiangsu Normal Univ, Sch Life Sci, Key Lab Biotechnol Med Plants Jiangsu Prov, Xuzhou 221116, Peoples R China.	wdm8610@jsnu.edu.cn; lu-jun75@163.com; ylzheng@jsnu.edu.cn	Lu, Jun/N-6109-2019	Lu, Jun/0000-0002-2801-5330	Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); "333 Project" Award of Jiangsu Province; "Qinglan Project" of the Young and Middle-aged Academic Leader of Jiangsu College and University; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571055, 81400902, 81271225, 31201039, 81171012, 30950031]; Major Fundamental Research Program of the Natural Science Foundation of the Jiangsu Higher Education Institutions of China [13KJA180001]; Cultivate National Science Fund for Distinguished Young Scholars of Jiangsu Normal University; Graduate Student Innovation Program of Jiangsu Province [KYCX17_1625]	This work was supported by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); the 2016 "333 Project" Award of Jiangsu Province, the 2013 "Qinglan Project" of the Young and Middle-aged Academic Leader of Jiangsu College and University, the National Natural Science Foundation of China (81571055, 81400902, 81271225, 31201039, 81171012, and 30950031), the Major Fundamental Research Program of the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (13KJA180001), and grants from the Cultivate National Science Fund for Distinguished Young Scholars of Jiangsu Normal University and the Graduate Student Innovation Program of Jiangsu Province (KYCX17_1625). We would like to give our sincere appreciation to the reviewers for their helpful comments on this article.	Beziaud T, 2011, CRIT CARE MED, V39, P2300, DOI 10.1097/CCM.0b013e3182227e4a; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen A, 2013, MOL MED REP, V8, P1011, DOI 10.3892/mmr.2013.1628; Chen HW, 2011, J NAT PROD, V74, P2408, DOI 10.1021/np200631v; Chen SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045763; Farag E, 2012, CURR PHARM DESIGN, V18, P6257, DOI 10.2174/138161212803832272; Feng Y, 2016, INT J MOL MED, V37, P921, DOI 10.3892/ijmm.2016.2495; Gao YY, 2016, J SURG RES, V206, P67, DOI 10.1016/j.jss.2016.07.014; Hue CD, 2015, J CEREBR BLOOD F MET, V35, P1191, DOI 10.1038/jcbfm.2015.38; Kitagishi Y, 2013, ALZHEIMERS RES THER, V5, DOI [10.1186/alzrt208, 10.1186/1758-9193-5-42]; Li X, 2017, J OCCUP HEALTH, V59, P8, DOI 10.1539/joh.16-0089-OA; Li Y, 2016, POWER SYST, P1, DOI 10.1007/978-3-662-48627-6; Li YG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111707; Liu HQ, 2012, BRAIN RES BULL, V89, P65, DOI 10.1016/j.brainresbull.2012.06.010; Lou HY, 2011, BIOORGAN MED CHEM, V19, P4021, DOI 10.1016/j.bmc.2011.05.021; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; Orlans FB, 1997, ETHICS BEHAV, V7, P163, DOI 10.1207/s15327019eb0702_7; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sawauchi S, 2003, J NEUROTRAUM, V20, P613, DOI 10.1089/089771503322144536; Schoeler M, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-20; Skovira JW, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0769-2; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Sun LQ, 2014, MOL MED REP, V9, P77, DOI 10.3892/mmr.2013.1787; Wang JK, 2010, BRAIN RES, V1357, P142, DOI 10.1016/j.brainres.2010.08.009; Weigl W, 2016, J CEREBR BLOOD F MET, V36, P1825, DOI 10.1177/0271678X16667953; Wen JF, 2014, EXP THER MED, V8, P881, DOI 10.3892/etm.2014.1818; Wu YT, 2009, AUTOPHAGY, V5, P824, DOI 10.4161/auto.9099; Xie Chunyan, 2015, Zhonghua Jie He He Hu Xi Za Zhi, V38, P761; Xue JF, 2017, BIOMED PHARMACOTHER, V89, P1252, DOI 10.1016/j.biopha.2017.01.130; Yu CS, 2016, ASIAN AUSTRAL J ANIM, V29, P731, DOI 10.5713/ajas.15.0415; Zeng XZ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151620; Zhang XY, 2012, ANESTHESIOLOGY, V116, P1035, DOI 10.1097/ALN.0b013e3182503964; Zhang YL, 2017, J NEUROSURG, V126, P782, DOI 10.3171/2016.3.JNS152699; Zhao SF, 2012, NEUROL RES, V34, P400, DOI 10.1179/1743132812Y.0000000025; Zhua YM, 2013, BRAIN RES, V1494, P1, DOI 10.1016/j.brainres.2012.11.047	37	56	59	1	12	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	PARIS	23 RUE LINOIS, 75724 PARIS, FRANCE	0753-3322	1950-6007		BIOMED PHARMACOTHER	Biomed. Pharmacother.	NOV	2017	95						885	893		10.1016/j.biopha.2017.08.125			9	Medicine, Research & Experimental; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Pharmacology & Pharmacy	FP6OC	WOS:000417744400102	28903184				2022-02-06	
J	Donnelly, J; Czosnyka, M; Adams, H; Robba, C; Steiner, LA; Cardim, D; Cabella, B; Liu, XY; Ercole, A; Hutchinson, PJ; Menon, DK; Aries, MJH; Smielewski, P				Donnelly, Joseph; Czosnyka, Marek; Adams, Hadie; Robba, Chiara; Steiner, Luzius A.; Cardim, Danilo; Cabella, Brenno; Liu, Xiuyun; Ercole, Ari; Hutchinson, Peter John; Menon, David Krishna; Aries, Marcel J. H.; Smielewski, Peter			Individualizing Thresholds of Cerebral Perfusion Pressure Using Estimated Limits of Autoregulation	CRITICAL CARE MEDICINE			English	Article						autoregulation; cerebral hemodynamics; cerebral perfusion pressure; intracranial pressure; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CEREBROVASCULAR REACTIVITY; MANAGEMENT; BEDSIDE; TIME	Objectives: In severe traumatic brain injury, cerebral perfusion pressure management based on cerebrovascular pressure reactivity index has the potential to provide a personalized treatment target to improve patient outcomes. So far, the methods have focused on identifying "one" autoregulation-guided cerebral perfusion pressure target-called "cerebral perfusion pressure optimal". We investigated whether a cerebral perfusion pressure autoregulation range-which uses a continuous estimation of the "lower" and "upper" cerebral perfusion pressure limits of cerebrovascular pressure autoregulation (assessed with pressure reactivity index)-has prognostic value. Design: Single-center retrospective analysis of prospectively collected data. Setting: The neurocritical care unit at a tertiary academic medical center. Patients: Data from 729 severe traumatic brain injury patients admitted between 1996 and 2016 were used. Treatment was guided by controlling intracranial pressure and cerebral perfusion pressure according to a local protocol. Interventions: None. Methods and Main Results: Cerebral perfusion pressure-pressure reactivity index curves were fitted automatically using a previously published curve-fitting heuristic from the relationship between pressure reactivity index and cerebral perfusion pressure. The cerebral perfusion pressure values at which this "U-shaped curve" crossed the fixed threshold from intact to impaired pressure reactivity (pressure reactivity index = 0.3) were denoted automatically the "lower" and "upper" cerebral perfusion pressure limits of reactivity, respectively. The percentage of time with cerebral perfusion pressure below (% cerebral perfusion pressure < lower limit of reactivity), above (% cerebral perfusion pressure > upper limit of reactivity), or within these reactivity limits (% cerebral perfusion pressure within limits of reactivity) was calculated for each patient and compared across dichotomized Glasgow Outcome Scores. After adjusting for age, initial Glasgow Coma Scale, and mean intracranial pressure, percentage of time with cerebral perfusion pressure less than lower limit of reactivity was associated with unfavorable outcome (odds ratio % cerebral perfusion pressure < lower limit of reactivity, 1.04; 95% CI, 1.02- 1.06; p < 0.001) and mortality (odds ratio, 1.06; 95% CI, 1.04-1.08; p < 0.001). Conclusions: Individualized autoregulation-guided cerebral perfusion pressure management may be a plausible alternative to fixed cerebral perfusion pressure threshold management in severe traumatic brain injury patients. Prospective randomized research will help define which autoregulation-guided method is beneficial, safe, and most practical.	[Donnelly, Joseph; Czosnyka, Marek; Adams, Hadie; Cardim, Danilo; Cabella, Brenno; Liu, Xiuyun; Aries, Marcel J. H.; Smielewski, Peter] Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Brain Phys Lab, Cambridge Biomed Campus, Cambridge, England; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland; [Robba, Chiara; Ercole, Ari; Menon, David Krishna] Univ Cambridge, Addenbrookes Hosp, Dept Med, Div Anaesthesia, Cambridge, England; [Robba, Chiara] Univ Genoa, Dept Neurosci, Genoa, Italy; [Steiner, Luzius A.] Univ Basel, Univ Basel Hosp, Dept Anesthesia Surg Intens Care Prehosp Emergenc, Basel, Switzerland; [Hutchinson, Peter John] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge, England; [Aries, Marcel J. H.] Maastricht Univ, Med Ctr, Univ Maastricht, Dept Intens Care, Maastricht, Netherlands		Donnelly, J (corresponding author), Univ Cambridge, Dept Clin Neurosci, Div Neurosurg, Brain Phys Lab, Cambridge Biomed Campus, Cambridge, England.	jd634@cam.ac.uk	Donnelly, Joseph/E-9235-2018; Robba, Chiara/AAS-7421-2020; Cardim, Danilo Augusto/B-8447-2012; Steiner, Luzius/J-1987-2019; Cabella, Brenno C.T./G-6169-2012; Liu, Xiuyun/V-4427-2017; Donnelly, Joseph/N-6803-2019; Ercole, Ari/B-6288-2009	Donnelly, Joseph/0000-0002-6502-8069; Cardim, Danilo Augusto/0000-0002-9261-1321; Cabella, Brenno C.T./0000-0003-2214-645X; Liu, Xiuyun/0000-0001-9540-4865; Donnelly, Joseph/0000-0002-6502-8069; Ercole, Ari/0000-0001-8350-8093	Woolf Fisher scholarship; Cambridge Enterprise, Cambridge, United Kingdom; Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR; National Institute of Health Research (NIHR) Research Professorship; Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; Ornim Medical; Shire Medical; Neurovive; Calico; NIHRNational Institute for Health Research (NIHR); GlaxoSmithKlineGlaxoSmithKline; Brainscope; SolvaySolvay SA; NIHR Cambridge Biomedical Centre [RCZB/004]; NIHR Senior Investigator Award [RCZB/014]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0601025, G0600986] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G0601025] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013, NF-SI-0512-10090] Funding Source: researchfish	Dr. Donnelly received support from a Woolf Fisher scholarship. Dr. Czosnyka has financial interest in a fraction of the licensing fee, and his institution received funding from Cambridge Enterprise, Cambridge, United Kingdom. Dr. Cardim disclosed other support from use of software developed in-house for data analysis. Dr. Liu received support for article research from the Bill & Melinda Gates Foundation. Dr. Hutchinson disclosed that he is a Director of Technicam manufacturer of the Cranial Access Device and he received support from a National Institute of Health Research (NIHR) Research Professorship, Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship. Dr. Menon received other support from Ornim Medical, Shire Medical, Neurovive, and Calico; he received support for article research from the NIHR; his institution received funding from GlaxoSmithKline and Brainscope; and he received funding from Solvay and the NIHR Cambridge Biomedical Centre (RCZB/004) and an NIHR Senior Investigator Award (RCZB/014). Dr. Smielewski disclosed receiving a fraction of the licensing fees of the software, ICM+ (licensed by Cambridge Enterprise, United Kingdom), used for data collection and analysis in this study. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Al-Rawi PG, 2000, ZBL NEUROCHIR, V61, P74, DOI 10.1055/s-2000-8263; Aries MJH, 2016, CRIT CARE MED, V44, pE996, DOI 10.1097/CCM.0000000000001816; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Carney N, 2016, NEUROSURGERY, V24, ps1, DOI DOI 10.1227/NEU.0000000000001432; Depreitere B, 2014, J NEUROSURG, V120, P1451, DOI 10.3171/2014.3.JNS131500; Dias C, 2015, NEUROCRIT CARE, V23, P92, DOI 10.1007/s12028-014-0103-8; Dias C, 2015, NEUROCRIT CARE, V22, P192, DOI 10.1007/s12028-014-0045-1; Donnelly J, 2017, J CEREBR BLOOD F MET, V37, P694, DOI 10.1177/0271678X16639060; Donnelly J, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1293-6; Donnelly J, 2015, NEUROCRIT CARE, V22, P20, DOI 10.1007/s12028-014-0042-4; Donnelly J, 2015, EXPERT REV NEUROTHER, V15, P169, DOI 10.1586/14737175.2015.996552; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Griesdale DEG, 2015, J CRIT CARE, V30, P111, DOI 10.1016/j.jcrc.2014.07.026; Guiza F, 2015, INTENS CARE MED, V41, P1067, DOI 10.1007/s00134-015-3806-1; JENNETT B, 1975, LANCET, V1, P480; Lavinio A, 2007, BRIT J ANAESTH, V99, P237, DOI 10.1093/bja/aem118; Le Roux P, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-012-0331-2; Lewis PM, 2015, PEDIATR CRIT CARE ME, V16, P739, DOI 10.1097/PCC.0000000000000471; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Maas AIR, 2012, LANCET NEUROL, V11, P12, DOI 10.1016/S1474-4422(11)70267-8; McLeod A. I., 2017, BESTGLM BEST SUBSET; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Needham E, 2017, J NEUROTRAUM, V34, P963, DOI 10.1089/neu.2016.4450; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sekhon MS, 2015, NEUROCRIT CARE, V23, P210, DOI 10.1007/s12028-015-0141-x; Smirl JD, 2014, J APPL PHYSIOL, V116, P1614, DOI 10.1152/japplphysiol.01266.2013; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Wickham H, 2014, DPLYR GRAMMAR DATA M; Wickham H, 2009, ELEGANT GRAPHICS DAT; Young AMH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148817	40	56	58	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2017	45	9					1464	1471		10.1097/CCM.0000000000002575			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FD9LJ	WOS:000407843600025	28816837	Green Accepted			2022-02-06	
J	Majdan, M; Plancikova, D; Maas, A; Polinder, S; Feigin, V; Theadom, A; Rusnak, M; Brazinova, A; Haagsma, J				Majdan, Marek; Plancikova, Dominika; Maas, Andrew; Polinder, Suzanne; Feigin, Valery; Theadom, Alice; Rusnak, Martin; Brazinova, Alexandra; Haagsma, Juanita			Years of life lost due to traumatic brain injury in Europe: A cross-sectional analysis of 16 countries	PLOS MEDICINE			English	Article							GLOBAL BURDEN; EPIDEMIOLOGY; NEUROTRAUMA; DISEASE; IMPACT	Introduction Traumatic brain injuries (TBIs) are a major public health, medical, and societal challenge globally. They present a substantial burden to victims, their families, and the society as a whole. Although indicators such as incidence or death rates provide insight into the occurrence and outcome of TBIs in various populations, they fail to quantify the full extent of their public health and societal impact. Measures such as years of life lost (YLLs), which quantifies the number of years of life lost because the person dies prematurely due to a disease or injury, should be employed to better quantify the population impact. The aim of this study was to provide an in-depth analysis of the burden of deaths due to TBI by calculating TBI-specific YLLs in 16 European countries, analyzing their main causes and demographic patterns, using data extracted from death certificates under unified guidelines and collected in a standardized manner. Methods and findings A population-wide, cross-sectional epidemiological study was conducted in 16 European countries to estimate TBI YLLs for the year 2013. The data used for all analyses in this study were acquired from the statistical office of the European Union (Eurostat). A specifically tailored dataset of micro-level data was provided that listed the external cause of death (International Classification of Diseases-10th Revision [ICD-10] codes V01-Y98), the specific nature of injury (ICD-10 codes S00-T98), the age at death, and sex for each death. Overall number of TBI YLLs, crude and age-standardized TBI YLL rates, and TBI YLLs per case were calculated stratified for country, sex, and age. Pooled analyses were performed in order to estimate summary age-standardized rates of TBI YLLs. In order to evaluate the relative importance of TBI in the context of all injuries, proportions of TBI YLLs out of overall injury YLLs were calculated. The total number of TBI YLLs was estimated by extrapolating the pooled crude rate of TBI YLLs in the 16 analyzed countries to the total population of the 28 member states of the EU (EU-28). We found that a total of 17,049 TBI deaths occurred in 2013 in the 16 analyzed countries. These translated into a total of 374,636 YLLs. The pooled age-standardized rate of YLLs per 100,000 people per year was 259.1 (95% CI: 205.8 to 312.3) overall, 427.5 (95% CI: 290.0 to 564.9) in males, and 105.4 (95% CI: 89.1 to 121.6) in females. Males contributed substantially more to TBI YLLs than females (282,870 YLLs, 76% of all TBI YLLs), which translated into a rate ratio of 3.24 (95% CI: 3.22 to 3.27). Each TBI death was on average associated with 24.3 (95% CI: 22.0 to 26.6) YLLs overall, 25.6 (95% CI: 23.4 to 27.8) in males and 20.9 (17.9 to 24.0) in females. Falls and traffic crashes were the most common external causes of TBI YLLs. TBI contributed on average 41% (44% in males and 34% in females) to overall injury YLLs. Extrapolating our findings, about 1.3 million YLLs were attributable to TBI in the EU-28 in 2013 overall, 1.1 million in males and 271,000 in females. This study is based on administratively collected data from 16 countries, and despite the efforts to harmonize them to the greatest possible extent, there may be differences in coding practices or reporting between countries. If present, these would be inherited into our findings without our ability to control for them. The extrapolation of the pooled rates from the 16 countries to the EU-28 should be interpreted with caution. Conclusions Our study showed that TBI-related deaths and YLLs have a substantial impact at the individual and population level in Europe and present an important societal and economic burden that must not be overlooked. We provide information valuable for policy-makers, enabling them to evaluate and plan preventive activities and resource allocation, and to formulate and implement strategic decisions. In addition, our results can serve as a basis for analyzing the overall burden of TBI in the population.	[Majdan, Marek; Plancikova, Dominika; Rusnak, Martin; Brazinova, Alexandra] Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, Trnava, Slovakia; [Maas, Andrew] Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium; [Maas, Andrew] Univ Antwerp, Edegem, Belgium; [Polinder, Suzanne; Haagsma, Juanita] Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands; [Feigin, Valery; Theadom, Alice] Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand; [Haagsma, Juanita] Erasmus Univ, Med Ctr, Dept Emergency Med, Rotterdam, Netherlands		Majdan, M (corresponding author), Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, Trnava, Slovakia.	mmajdan@truni.sk	Brazinova, Alexandra/C-4265-2016; Majdan, Marek/K-5017-2012; Maas, Andrew IR/C-5584-2013; Feigin, Valery/AAF-2313-2019; Rusnak, Martin/K-9349-2016	Brazinova, Alexandra/0000-0003-0625-256X; Majdan, Marek/0000-0001-8037-742X; Maas, Andrew IR/0000-0003-1612-1264; Feigin, Valery L./0000-0002-6372-1740; Rusnak, Martin/0000-0003-3321-1042	European Union Seventh Framework Programme (FP7) [602150]	This study was conducted within the project Collaborative European Neurotrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) supported by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement number 602150. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ao BT, 2015, NEUROEPIDEMIOLOGY, V44, P255, DOI 10.1159/000431043; Borenstein M., 2009, INTRO META ANAL; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Brooks JC, 2015, ARCH PHYS MED REHAB, V96, P1000, DOI 10.1016/j.apmr.2015.02.002; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Eurostat, CAUS OF DEATH; Eurostat, POPULATION; Eurostat, CAUS DEATH HLTH CDEA; Eurostat, 2013, REV EUR STAND POP RE; Eurostat, LIF TABL; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Haagsma JA, 2016, INJURY PREV, V22, P3, DOI 10.1136/injuryprev-2015-041616; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Kassebaum NJ, 2016, LANCET, V388, P1603, DOI 10.1016/S0140-6736(16)31460-X; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2; Majdan M, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008672; Mauritz W, 2014, WIEN KLIN WOCHENSCHR, V126, P42, DOI 10.1007/s00508-013-0456-6; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Polinder S, 2007, B WORLD HEALTH ORGAN, V85, P27, DOI 10.2471/BLT.06.030973; Reilly P, 2007, PROG BRAIN RES, V161, P3, DOI 10.1016/S0079-6123(06)61001-7; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035; Scholten AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110905; Statistics New Zealand, HISTORICAL POPULATIO; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Theadom A, 2012, NEUROEPIDEMIOLOGY, V38, P18, DOI 10.1159/000334746	27	56	56	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1549-1277	1549-1676		PLOS MED	PLos Med.	JUL	2017	14	7							e1002331	10.1371/journal.pmed.1002331			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC1QA	WOS:000406611200006	28700588	Green Published, Green Submitted, gold			2022-02-06	
J	Hauer, J; Houtrow, AJ				Hauer, Julie; Houtrow, Amy J.		Sect Hosp Palliative Med; Council Children Disabilities	Pain Assessment and Treatment in Children With Significant Impairment of the Central Nervous System	PEDIATRICS			English	Article							SEVERE NEUROLOGICAL IMPAIRMENT; INTRATHECAL BACLOFEN THERAPY; TOXIN TYPE-A; SEVERE COGNITIVE IMPAIRMENTS; RANDOMIZED CONTROLLED-TRIAL; PEDIATRIC PALLIATIVE CARE; IRRITABLE-BOWEL-SYNDROME; CENTRAL POSTSTROKE PAIN; SPASTIC CEREBRAL-PALSY; TRAUMATIC BRAIN-INJURY	Pain is a frequent and significant problem for children with impairment of the central nervous system, with the highest frequency and severity occurring in children with the greatest impairment. Despite the significance of the problem, this population remains vulnerable to underrecognition and undertreatment of pain. Barriers to treatment may include uncertainty in identifying pain along with limited experience and fear with the use of medications for pain treatment. Behavioral pain-assessment tools are reviewed in this clinical report, along with other strategies for monitoring pain after an intervention. Sources of pain in this population include acute-onset pain attributable to tissue injury or inflammation resulting in nociceptive pain, with pain then expected to resolve after treatment directed at the source. Other sources can result in chronic intermittent pain that, for many, occurs on a weekly to daily basis, commonly attributed to gastroesophageal reflux, spasticity, and hip subluxation. Most challenging are pain sources attributable to the impaired central nervous system, requiring empirical medication trials directed at causes that cannot be identified by diagnostic tests, such as central neuropathic pain. Interventions reviewed include integrative therapies and medications, such as gabapentinoids, tricyclic antidepressants, alpha-agonists, and opioids. This clinical report aims to address, with evidence-based guidance, the inherent challenges with the goal to improve comfort throughout life in this vulnerable group of children.	[Hauer, Julie] Boston Childrens Hosp, Div Gen Pediat, Complex Care Serv, Boston, MA 02115 USA; [Hauer, Julie] Harvard Med Sch, Boston, MA 02115 USA; [Hauer, Julie] Seven Hills Pediat Ctr, Groton, MA 01450 USA; [Houtrow, Amy J.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Pediat Rehabil Med, Dept Phys Med & Rehabil,UPMC,Rehabil Inst, Pittsburgh, PA 15213 USA		Hauer, J (corresponding author), Boston Childrens Hosp, Div Gen Pediat, Complex Care Serv, Boston, MA 02115 USA.; Hauer, J (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Hauer, J (corresponding author), Seven Hills Pediat Ctr, Groton, MA 01450 USA.						Agrawal S., COMPLEX CILD E MAGAZ; Albright AL, 2003, J NEUROSURG, V98, P291, DOI 10.3171/jns.2003.98.2.0291; Ammerman S, 2015, PEDIATRICS, V135, pE769, DOI 10.1542/peds.2014-4147; Axelrod FB, 2009, PEDIATRICS, V124, P743, DOI 10.1542/peds.2008-3318; Baguley IJ, 2007, J NEUROL NEUROSUR PS, V78, P539, DOI 10.1136/jnnp.2006.096388; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Barwood S, 2000, DEV MED CHILD NEUROL, V42, P116, DOI 10.1017/S0012162200000220; Berde CB, PAIN INFANTS CHILDRE; BIERSDORFF KK, 1994, AM J MENT RETARD, V98, P619; Boldingh EJ, 2014, J PEDIATR ORTHOP B, V23, P86, DOI 10.1097/BPB.0b013e3283651a5d; Bonouvrie LA, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-175; Boyer EW, 2005, NEW ENGL J MED, V352, P1112, DOI 10.1056/NEJMra041867; Breau LM, 2004, DEV MED CHILD NEUROL, V46, P364, DOI 10.1017/S001216220400060X; Breau LM, 2003, ARCH PEDIAT ADOL MED, V157, P1219, DOI 10.1001/archpedi.157.12.1219; Breau LM, 2002, PAIN, V99, P349, DOI 10.1016/S0304-3959(02)00179-3; Breau LM, 2002, ANESTHESIOLOGY, V96, P528, DOI 10.1097/00000542-200203000-00004; BROWNE TR, 1978, NEW ENGL J MED, V299, P812; BROWNE TR, 1976, ARCH NEUROL-CHICAGO, V33, P326, DOI 10.1001/archneur.1976.00500050012003; Bruera Eduardo, 2002, J Palliat Med, V5, P127, DOI 10.1089/10966210252785097; Canavero S, CENTRAL PAIN SYNDROM; Cappuccio G, 2013, JIMD REP, V9, P113, DOI 10.1007/8904_2012_188; Carter B, 2002, J ADV NURS, V38, P449, DOI 10.1046/j.1365-2648.2002.02206.x; Center to Advance Palliative Care, ONC DAIL OR MORPH FO; Chaparro LE, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008943.pub2; Chelimsky G, 2001, CLIN AUTON RES, V11, P383, DOI 10.1007/BF02292771; Chelimsky G, 1999, CLIN PEDIATR, V38, P725, DOI 10.1177/000992289903801205; Chen-Lim ML, 2012, J PEDIATR NURS, V27, P750, DOI 10.1016/j.pedn.2012.03.023; Ciszkowski C, 2009, NEW ENGL J MED, V361, P827, DOI 10.1056/NEJMc0904266; Collin C, 2007, EUR J NEUROL, V14, P290, DOI 10.1111/j.1468-1331.2006.01639.x; Cramton REM, 2012, CURR OPIN PEDIATR, V24, P530, DOI 10.1097/MOP.0b013e328355b2c5; Crosta QR, 2014, J SPEC PEDIATR NURS, V19, P109, DOI 10.1111/jspn.12069; Croxford JL, 2003, CNS DRUGS, V17, P179, DOI 10.2165/00023210-200317030-00004; Cutter NC, 2000, ARCH PHYS MED REHAB, V81, P164, DOI 10.1016/S0003-9993(00)90135-7; Defrin R, 2006, PAIN, V124, P312, DOI 10.1016/j.pain.2006.04.031; Del Fabbro E, 2006, J PALLIAT MED, V9, P422; Delgado MR, 2010, NEUROLOGY, V74, P336, DOI 10.1212/WNL.0b013e3181cbcd2f; Delgado-Aros S, 2005, J CLIN GASTROENTEROL, V39, pS194, DOI 10.1097/01.mcg.0000156114.22598.1b; DeSantana Josimari M, 2008, Curr Rheumatol Rep, V10, P492; Devlin JW, 2009, CRIT CARE CLIN, V25, P431, DOI 10.1016/j.ccc.2009.03.003; Dickerson RN, 2003, NUTRITION, V19, P741, DOI 10.1016/S0899-9007(03)00123-0; Dickerson RN, 2002, JPEN-PARENTER ENTER, V26, P278, DOI 10.1177/0148607102026005278; Dunn HG, 2001, BRAIN DEV-JPN, V23, pS99, DOI 10.1016/S0387-7604(01)00354-0; Dworkin RH, 2007, PAIN, V132, P237, DOI 10.1016/j.pain.2007.08.033; Elawad MA, 2001, DEV MED CHILD NEUROL, V43, P829, DOI 10.1017/S0012162201001505; Feudtner C, 2013, PEDIATRICS, V132, P966, DOI 10.1542/peds.2013-2731; Finnerup NB, 2005, PAIN, V118, P289, DOI 10.1016/j.pain.2005.08.013; Foster-Barber A., 2011, NEUROPADIATRIE, V10, P20; Frese A, 2006, CLIN J PAIN, V22, P252, DOI 10.1097/01.ajp.0000173020.10483.13; Friedrichsdorf SJ, 2007, PEDIATR CLIN N AM, V54, P645, DOI 10.1016/j.pcl.2007.07.007; Gale R, 2017, JPEN-PARENTER ENTER, V41, P1366, DOI 10.1177/0148607116662970; Gardner JS, 2000, PHARMACOTHERAPY, V20, P1423, DOI 10.1592/phco.20.19.1423.34854; Gauger VT, 2009, J PEDIATR ORTHOPED, V29, P588, DOI 10.1097/BPO.0b013e3181b2ba08; Gilles EE., 2011, NEUROPADIATRIE KLIN, V10, P15; Gilron I, 2013, LANCET NEUROL, V12, P1084, DOI 10.1016/S1474-4422(13)70193-5; Gilron I, 2009, LANCET, V374, P1252, DOI 10.1016/S0140-6736(09)61081-3; Hadden KL, 2002, PAIN, V99, P281, DOI 10.1016/S0304-3959(02)00123-9; Haig GM, 2001, J CLIN PHARMACOL, V41, P507, DOI 10.1177/00912700122010384; Haney AL, 2009, PHARMACOTHERAPY, V29, P997, DOI 10.1592/phco.29.8.997; Hansel DE, 2003, PEDIATR NEUROL, V29, P203, DOI 10.1016/S0887-8994(03)00208-X; Hasler ML, 2003, GASTROENTEROL CLIN N, V32, pviii; Hasler WL, 2003, GASTROENTEROL CLIN N, V32, P707, DOI 10.1016/S0889-8553(03)00027-X; Hauer J., 2013, CARING CHILDREN WHO; Hauer JM., 2013, CARING CHILDREN WHO, P65; Hauer J, 2012, PROG PALLIAT CARE, V20, P349, DOI 10.1179/1743291X12Y.0000000032; Hauer JM, 2007, PEDIATRICS, V119, pE519, DOI 10.1542/peds.2006-1609; Hauer JM, 2015, J PALLIAT MED, V18, P453, DOI 10.1089/jpm.2014.0359; Hauer JM, 2015, PEDIATR PULM, V50, pE9, DOI 10.1002/ppul.23140; Hauer JM, 2014, CURR OPIN SUPPORT PA, V8, P296, DOI 10.1097/SPC.0000000000000063; Herr K, 2011, PAIN MANAG NURS, V12, P230, DOI 10.1016/j.pmn.2011.10.002; Hogan KA, 2006, J BONE JOINT SURG AM, V88A, P2624, DOI 10.2106/JBJS.E.00918; Houghton LA, 2007, GUT, V56, P1218, DOI 10.1136/gut.2006.110858; Houlihan CM, 2004, DEV MED CHILD NEUROL, V46, P305, DOI 10.1017/S0012162204000507; Hoving MA, 2009, EUR J PAEDIATR NEURO, V13, P247, DOI 10.1016/j.ejpn.2008.05.002; Huang BY, 2008, RADIOGRAPHICS, V28, P417, DOI 10.1148/rg.282075066; Hunt A, 2004, DEV MED CHILD NEUROL, V46, P9, DOI 10.1017/S0012162204000039; Hunt A, 2003, INT J NURS STUD, V40, P171, DOI 10.1016/S0020-7489(02)00058-5; Hunt A, 2007, J PAIN SYMPTOM MANAG, V33, P276, DOI 10.1016/j.jpainsymman.2006.08.011; International Association for the Study of Pain, IASP TAX; Intiso D, 2015, TOXINS, V7, P2454, DOI 10.3390/toxins7072454; Jackson N, 2008, POSTGRAD MED J, V84, P121, DOI 10.1136/pgmj.2007.062117; JAN JE, 1994, PEDIATR NEUROL, V10, P34, DOI 10.1016/0887-8994(94)90064-7; Kalachnik JE, 2003, J AUTISM DEV DISORD, V33, P349, DOI 10.1023/A:1024466819989; Kalachnik JE, 2002, AM J MENT RETARD, V107, P376, DOI 10.1352/0895-8017(2002)107<0376:BBSERA>2.0.CO;2; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Klit H, 2009, LANCET NEUROL, V8, P857, DOI 10.1016/S1474-4422(09)70176-0; Knaus A, 2009, ACTA ORTHOP, V80, P32, DOI 10.1080/17453670902804935; Koller D, 2012, J PEDIATR NURS, V27, P652, DOI 10.1016/j.pedn.2011.08.001; Kong CK, 2005, PEDIATRICS, V116, pE839, DOI 10.1542/peds.2005-1029; Korn-Merker E, 2000, EPILEPSY RES, V38, P27; Kuiken SD, 2005, ALIMENT PHARM THER, V21, P633, DOI 10.1111/j.1365-2036.2005.02392.x; Kuperminc MN, 2010, DEV MED CHILD NEUROL, V52, P824, DOI 10.1111/j.1469-8749.2010.03694.x; Lader M, 2009, CNS DRUGS, V23, P19, DOI 10.2165/0023210-200923010-00002; Lauder GR, 2005, PEDIATR ANESTH, V15, P412, DOI 10.1111/j.1460-9592.2005.01431.x; Lee GY, 2014, PEDIATRICS, V133, P500, DOI 10.1542/peds.2013-2744; Lee KJ, 2005, ALIMENT PHARM THERAP, V22, P981, DOI 10.1111/j.1365-2036.2005.02685.x; Liptak GS, 2005, MENT RETARD DEV D R, V11, P156, DOI 10.1002/mrdd.20066; Lubsch L, 2006, J CHILD NEUROL, V21, P1090, DOI 10.1177/7010.2006.00134; LUNDEBERG T, 1984, PAIN, V20, P13, DOI 10.1016/0304-3959(84)90807-8; LUNDEBERG T, 1987, SCAND J REHABIL MED, V19, P153; Lundy CT, 2009, DEV MED CHILD NEUROL, V51, P705, DOI 10.1111/j.1469-8749.2009.03315.x; Malviya S, 2006, PEDIATR ANESTH, V16, P258, DOI 10.1111/j.1460-9592.2005.01773.x; Mayell A, 2014, PEDIATR ANESTH, V24, P1239, DOI 10.1111/pan.12524; McCluggage HL, 2006, INT J PALLIAT NURS, V12, P254, DOI 10.12968/ijpn.2006.12.6.21450; Mccoy AA, 2006, ARCH PHYS MED REHAB, V87, P1503, DOI 10.1016/j.apmr.2006.07.270; Mink JW, 2013, MOVEMENT DISORD, V28, P921, DOI 10.1002/mds.25548; Moulin DE, 2014, PAIN RES MANAG, V19, P328; Mousa H, 2006, J PEDIATR GASTR NUTR, V43, P185, DOI 10.1097/01.mpg.0000228115.14111.24; Nader R, 2004, CLIN J PAIN, V20, P88, DOI 10.1097/00002508-200403000-00005; Nicholson BD, 2004, NEUROLOGY, V62, pS30, DOI 10.1212/WNL.62.5_suppl_2.S30; Nicholson B, 2008, EXPERT OPIN PHARMACO, V9, P1585, DOI [10.1517/14656566.9.9.1585, 10.1517/14656566.9.9.1585 ]; Nolan J, 2000, ANAESTHESIA, V55, P32, DOI 10.1046/j.1365-2044.2000.01065.x; Oberlander TF, 2001, DEV MED CHILD NEUROL, V43, P138, DOI 10.1017/S0012162201230254; Park ES, 2002, YONSEI MED J, V43, P65, DOI 10.3349/ymj.2002.43.1.65; Peebles KA, 2012, J INTELL DISABIL RES, V56, P441, DOI 10.1111/j.1365-2788.2011.01484.x; Penner M, 2013, PEDIATRICS, V132, pE407, DOI 10.1542/peds.2013-0224; Perquin CW, 2000, PAIN, V87, P51, DOI 10.1016/S0304-3959(00)00269-4; Raphael BS, 2010, CLIN ORTHOP RELAT R, V468, P1845, DOI 10.1007/s11999-009-1167-1; Rattaz C, 2013, PAIN, V154, P2007, DOI 10.1016/j.pain.2013.06.011; Renard D, 2014, BEHAV NEUROL, V2014, DOI 10.1155/2014/154631; Rieger D, 2013, DEV DISABIL RES REV, V17, P269, DOI 10.1002/ddrr.1120; Riss J, 2008, ACTA NEUROL SCAND, V118, P69, DOI 10.1111/j.1600-0404.2008.01004.x; Rivard PF, 2009, CLIN J PAIN, V25, P413, DOI 10.1097/AJP.0b013e31819a6d07; Rocker G, 2012, CAN MED ASSOC J, V184, pE497, DOI 10.1503/cmaj.111758; Roubertie A, 2012, EUR J NEUROL, V19, P1292, DOI 10.1111/j.1468-1331.2011.03649.x; Rusy LM, 2010, ANESTH ANALG, V110, P1393, DOI 10.1213/ANE.0b013e3181d41dc2; Sanger TD, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.1.e89; Seidel S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004844.pub3; Sgouros S, 2007, ACTA NEUROCHIR SUPPL, V97, P193; Siden H, 2008, PAIN CHILDREN PRACTI, P32; Siden HB, 2013, PAIN RES MANAG, V18, P243, DOI 10.1155/2013/193937; Smith H, 2001, Curr Opin Anaesthesiol, V14, P513, DOI 10.1097/00001503-200110000-00009; Smith HAB, 2011, CRIT CARE MED, V39, P150, DOI 10.1097/CCM.0b013e3181feb489; Solodiuk JC, 2014, J PAIN SYMPTOM MANAG, V48, P924, DOI 10.1016/j.jpainsymman.2014.01.006; Solodiuk JC, 2010, PAIN, V150, P231, DOI 10.1016/j.pain.2010.03.016; Stahle-oberg L., 2009, ADV PHYSIOTHERAPY, V11, P137, DOI [10.1080/14038190902906318, DOI 10.1080/14038190902906318]; Stallard P, 2002, J PEDIATR PSYCHOL, V27, P209, DOI 10.1093/jpepsy/27.2.209; Steele R, 2014, ARCH DIS CHILD, V99, P754, DOI 10.1136/archdischild-2013-305246; Strouse TB, 2009, J PALLIAT MED, V12, P1043, DOI 10.1089/jpm.2009.0127; Suedberg LE, 2008, EUR J PAEDIATR NEURO, V12, P89, DOI 10.1016/j.ejpn.2007.06.004; Suresh BSS, 2015, PEDIATR SURG INT, V31, P197, DOI 10.1007/s00383-014-3649-9; Symons FJ, 2011, NEUROSCI BIOBEHAV R, V35, P1266, DOI 10.1016/j.neubiorev.2011.01.002; Taenzer AH, 2010, PEDIATR ANESTH, V20, P135, DOI 10.1111/j.1460-9592.2009.03226.x; Tanaka E, 1999, J CLIN PHARM THER, V24, P347, DOI 10.1046/j.1365-2710.1999.00247.x; Taylor Charles P, 2004, CNS Drug Rev, V10, P183; Tomlinson D, 2010, PEDIATRICS, V126, pE1168, DOI 10.1542/peds.2010-1609; Traube C, 2014, CRIT CARE MED, V42, P656, DOI 10.1097/CCM.0b013e3182a66b76; U.S. Department of Health and Human Services N.I.o.H. National Cancer Institute Common Terminology, COMM TERM CRIT ADV E; U. S. Food and Drug Administration, 2017, FDA DRUG SAF COMM FD; Valencia FG, 2010, ORTHOP CLIN N AM, V41, P549, DOI 10.1016/j.ocl.2010.07.002; Vernon-Roberts A, 2010, DEV MED CHILD NEUROL, V52, P1099, DOI 10.1111/j.1469-8749.2010.03789.x; Voepel-Lewis T, 2008, ANESTH ANALG, V106, P72, DOI 10.1213/01.ane.0000287680.21212.d0; Williams DG, 2002, BRIT J ANAESTH, V89, P839, DOI 10.1093/bja/aef284; World Health Organization, WHO GUID PHARM TREAT; Wusthoff CJ, 2007, PEDIATR CLIN N AM, V54, pxi; Wusthoff CJ, 2007, PEDIATR CLIN N AM, V54, P709, DOI 10.1016/j.pcl.2007.06.004; Zangen T, 2003, J PEDIATR GASTR NUTR, V37, P287, DOI 10.1097/00005176-200309000-00016; Zernikow Boris, 2009, Paediatr Drugs, V11, P129, DOI 10.2165/00148581-200911020-00004; Zier JL, 2008, DEV MED CHILD NEUROL, V50, P854, DOI 10.1111/j.1469-8749.2008.03069.x	158	56	61	1	7	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUN	2017	139	6							e20171002	10.1542/peds.2017-1002			27	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	EW5HJ	WOS:000402536100061	28562301	Bronze			2022-02-06	
J	Amico, E; Marinazzo, D; Di Perri, C; Heine, L; Annen, J; Martial, C; Dzemidzic, M; Kirsch, M; Bonhomme, V; Laureys, S; Goni, J				Amico, Enrico; Marinazzo, Daniele; Di Perri, Carol; Heine, Lizette; Annen, Jitka; Martial, Charlotte; Dzemidzic, Mario; Kirsch, Murielle; Bonhomme, Vincent; Laureys, Steven; Goni, Joaquin			Mapping the functional connectome traits of levels of consciousness	NEUROIMAGE			English	Article						fMRI; Brain connectivity; Network science; Consciousness	TRAUMATIC BRAIN-INJURY; HUMAN CEREBRAL-CORTEX; COMA RECOVERY SCALE; RESTING-STATE; NETWORK CONNECTIVITY; DEFAULT NETWORK; DISORDERS; RECOMMENDATIONS; SYSTEM	Examining task-free functional connectivity (FC) in the human brain offers insights on how spontaneous integration and segregation of information relate to human cognition, and how this organization may be altered in different conditions, and neurological disorders. This is particularly relevant for patients in disorders of consciousness (DOC) following severe acquired brain damage and coma, one of the most devastating conditions in modern medical care. We present a novel data-driven methodology, connfCA, which implements Independent Component Analysis (ICA) for the extraction of robust independent FC patterns (FC-traits) from a set of individual functional connectomes, without imposing any a priori data stratification into groups. We here apply connlCA to investigate associations between network traits derived from task-free FC and cognitive/clinical features that define levels of consciousness. Three main independent FC-traits were identified and linked to consciousness-related clinical features. The first one represents the functional configuration of a "resting" human brain, and it is associated to a sedative (sevoflurane), the overall effect of the pathology and the level of arousal. The second FC-trait reflects the disconnection of the visual and sensory-motor connectivity patterns. It also relates to the time since the insult and to the ability of communicating with the external environment. The third FC-trait isolates the connectivity pattern encompassing the fronto-parietal and the default-mode network areas as well as the interaction between left and right hemispheres, which are also associated to the awareness of the self and its surroundings. Each FC-trait represents a distinct functional process with a role in the degradation of conscious states of functional brain networks, shedding further light on the functional sub-circuits that get disrupted in severe brain-damage.	[Amico, Enrico; Di Perri, Carol; Heine, Lizette; Annen, Jitka; Martial, Charlotte; Laureys, Steven] Univ Liege, GIGA Res Ctr, Coma Sci Grp, Liege, Belgium; [Amico, Enrico; Marinazzo, Daniele] Univ Ghent, Dept Data Anal, B-9000 Ghent, Belgium; [Di Perri, Carol; Heine, Lizette; Annen, Jitka; Martial, Charlotte; Kirsch, Murielle; Bonhomme, Vincent; Laureys, Steven] Univ Hosp Liege, Liege, Belgium; [Dzemidzic, Mario] Indiana Univ Sch Med, Dept Neurol & Radiol & Imaging Sci, Indianapolis, IN 46202 USA; [Goni, Joaquin] Purdue Univ, Sch Ind Engn, W Lafayette, IN 47907 USA; [Goni, Joaquin] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Goni, Joaquin] Purdue Univ, Purdue Inst Integrat Neurosci, W Lafayette, IN 47907 USA		Goni, J (corresponding author), Purdue Univ, Sch Ind Engn, W Lafayette, IN 47907 USA.	steven.laureys@ulg.ac.be; jgonicor@purdue.edu	Amico, Enrico/AAB-2581-2019; Bonhomme, Vincent/J-7144-2019; Annen, Jitka/ABH-5297-2020; Laureys, Steven/AAN-2097-2021; Martial, Charlotte/O-6703-2016; Laureys, Steven/A-3349-2011; Marinazzo, Daniele/H-4793-2019	Amico, Enrico/0000-0001-6705-9689; Bonhomme, Vincent/0000-0001-6356-547X; Annen, Jitka/0000-0002-7459-4345; Laureys, Steven/0000-0002-3096-3807; Martial, Charlotte/0000-0001-6291-3460; Marinazzo, Daniele/0000-0002-9803-0122; Heine, Lizette/0000-0003-1369-8199; Di Perri, Carol/0000-0003-0284-770X	Belgian Funds for Scientific Research (FRS)Fonds de la Recherche Scientifique - FNRS; European CommissionEuropean CommissionEuropean Commission Joint Research Centre; James McDonnell Foundation; European Space AgencyEuropean Space AgencyEuropean Commission; Belgian Science Policy (CEREBNET, BELSPO); Wallonia-Brussels Federation Concerted Research Action; Mind Science Foundation; Public Utility Foundation "Universite Europeenne du Travail"; "Fondazione Europea di Ricerca Biomedica", University; University Hospital of Liege; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01 MI-1108467-01]	We thank Marie-Aurelie Bruno, Athena Demertzi and Audrey Vanhaudenhuyse for help in acquiring the data. We thank Prof. Jaroslaw Harezlak and Prof. Thomas Talavage for useful comments. This research was supported by the This research was supported by the Belgian Funds for Scientific Research (FRS), European Commission, James McDonnell Foundation, European Space Agency, Belgian Science Policy (CEREBNET, BELSPO), Wallonia-Brussels Federation Concerted Research Action, Mind Science Foundation, Public Utility Foundation "Universite Europeenne du Travail" and "Fondazione Europea di Ricerca Biomedica", University and University Hospital of Liege. LH is a research fellow and SL a research director at FNRS. JG was supported by the National Institute of Health (1R01 MI-1108467-01).	Achard S, 2012, P NATL ACAD SCI USA, V109, P20608, DOI 10.1073/pnas.1208933109; Amico E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100012; Bernat JL, 2009, ANNU REV MED, V60, P381, DOI 10.1146/annurev.med.60.060107.091250; Blondel VD, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/10/P10008; Boly M, 2009, HUM BRAIN MAPP, V30, P2393, DOI 10.1002/hbm.20672; Boly M, 2012, BRAIN CONNECT, V2, P1, DOI 10.1089/brain.2011.0049; Boveroux P, 2010, ANESTHESIOLOGY, V113, P1038, DOI 10.1097/ALN.0b013e3181f697f5; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Calhoun VD, 2009, NEUROIMAGE, V45, pS163, DOI 10.1016/j.neuroimage.2008.10.057; Coupe P, 2012, IET IMAGE PROCESS, V6, P558, DOI 10.1049/iet-ipr.2011.0161; CRICK F, 1995, NATURE, V375, P121, DOI 10.1038/375121a0; Crone J. S., 2016, CEREB CORTEX; Crone JS, 2014, NEUROIMAGE-CLIN, V4, P240, DOI 10.1016/j.nicl.2013.12.005; Dehaene S, 2011, NEURON, V70, P200, DOI 10.1016/j.neuron.2011.03.018; Demertzi A, 2015, BRAIN, V138, P2619, DOI 10.1093/brain/awv169; Demertzi A, 2014, CORTEX, V52, P35, DOI 10.1016/j.cortex.2013.11.005; Deshpande G, 2010, BRAIN RES, V1318, P110, DOI 10.1016/j.brainres.2009.12.075; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Di Perri C, 2016, LANCET NEUROL, V15, P830, DOI 10.1016/S1474-4422(16)00111-3; Di Perri C, 2014, EPILEPSY BEHAV, V30, P28, DOI 10.1016/j.yebeh.2013.09.014; Erhardt EB, 2011, HUM BRAIN MAPP, V32, P2075, DOI 10.1002/hbm.21170; Fernandez-Espejo D, 2012, ANN NEUROL, V72, P335, DOI 10.1002/ana.23635; Fiset P, 2005, PROG BRAIN RES, V150, P245, DOI 10.1016/S0079-6123(05)50018-9; FORNITO A., 2016, FUNDAMENTALS BRAIN N; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4; Gazzaniga MS, 2014, P NATL ACAD SCI USA, V111, P18093, DOI 10.1073/pnas.1417892111; Gazzaniga MS, 2005, NAT REV NEUROSCI, V6, P653, DOI 10.1038/nrn1723; Giacino J, 2006, BRAIN INJURY; Giacino JT, 2014, NAT REV NEUROL, V10, P99, DOI 10.1038/nrneurol.2013.279; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Gomez S, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.016114; Gordon EM, 2016, CEREB CORTEX, V26, P288, DOI 10.1093/cercor/bhu239; Greicius M, 2008, CURR OPIN NEUROL, V21, P424, DOI 10.1097/WCO.0b013e328306f2c5; Greve DN, 2009, NEUROIMAGE, V48, P63, DOI 10.1016/j.neuroimage.2009.06.060; Guldenmund P, 2013, BRAIN CONNECT, V3, P273, DOI 10.1089/brain.2012.0117; Heine L, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00295; Hudetz AG, 2012, BRAIN CONNECT, V2, P291, DOI 10.1089/brain.2012.0107; Hyvarinen A, 1999, IEEE T NEURAL NETWOR, V10, P626, DOI 10.1109/72.761722; Iraji A, 2016, NEUROIMAGE, V134, P494, DOI 10.1016/j.neuroimage.2016.04.006; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Kalmar K, 2005, NEUROPSYCHOL REHABIL, V15, P454, DOI 10.1080/09602010443000425; Koch C, 2016, NAT REV NEUROSCI, V17, P307, DOI 10.1038/nrn.2016.22; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lancichinetti A, 2012, SCI REP-UK, V2, DOI 10.1038/srep00336; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2005, PROG BRAIN RES, V150, P495, DOI 10.1016/S0079-6123(05)50034-7; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Marinsek N, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00839; Misic B, 2016, CEREB CORTEX, V26, P3285, DOI 10.1093/cercor/bhw089; Monti MM, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003271; Mucha PJ, 2010, SCIENCE, V328, P876, DOI 10.1126/science.1184819; NEWMAN MEJ, 2004, PHYS REV E 2, V69, DOI DOI 10.1103/PHYSREVE.69.026113; Owen AM, 2009, PROG BRAIN RES, V177, P399, DOI 10.1016/S0079-6123(09)17728-2; Palanca BA, 2015, ANESTHESIOLOGY, V123, P346, DOI 10.1097/ALN.0000000000000731; Peltier SJ, 2005, NEUROREPORT, V16, P285, DOI 10.1097/00001756-200502280-00017; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Power JD, 2014, NEUROIMAGE, V84, P320, DOI 10.1016/j.neuroimage.2013.08.048; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Ranft A, 2016, ANESTHESIOLOGY, V125, P861, DOI 10.1097/ALN.0000000000001322; Samann PG, 2011, CEREB CORTEX, V21, P2082, DOI 10.1093/cercor/bhq295; Schnakers C, 2008, BRAIN INJURY, V22, P786, DOI 10.1080/02699050802403557; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Shen X, 2013, NEUROIMAGE, V82, P403, DOI 10.1016/j.neuroimage.2013.05.081; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smyser CD, 2011, NEUROIMAGE, V56, P1437, DOI 10.1016/j.neuroimage.2011.02.073; Soddu A, 2012, HUM BRAIN MAPP, V33, P778, DOI 10.1002/hbm.21249; Sporns O., 2011, NETWORKS BRAIN; Stamatakis EA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014224; Tagliazucchi E, 2012, NEUROIMAGE, V63, P63, DOI 10.1016/j.neuroimage.2012.06.036; Traag VA, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.036115; van den Heuvel MP, 2010, EUR NEUROPSYCHOPHARM, V20, P519, DOI 10.1016/j.euroneuro.2010.03.008; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Yeo BTT, 2011, J NEUROPHYSIOL, V106, P1125, DOI 10.1152/jn.00338.2011	76	56	57	1	27	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	MAR 1	2017	148						201	211		10.1016/j.neuroimage.2017.01.020			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EO6LD	WOS:000396803100020	28093358	Green Published, Green Submitted			2022-02-06	
J	Craig, A; Guest, R; Tran, Y; Middleton, J				Craig, Ashley; Guest, Rebecca; Tran, Yvonne; Middleton, James			Cognitive Impairment and Mood States after Spinal Cord Injury	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; neural injury; rehabilitation; SCI	TRAUMATIC BRAIN-INJURY; LONGITUDINAL ANALYSIS; CHRONIC PAIN; DEPRESSION; FATIGUE; MODEL; INFLAMMATION; RELIABILITY; PREVALENCE; VALIDITY	Spinal cord injury (SCI) is believed to be associated with high rates of cognitive impairment, which can result in complications in recovery. This study concerned two groups of adults with SCI. The first sample involved 150 participants with SCI who were assessed once for cognitive capacity with comparisons made with 45 able-bodied adults. Sample 2 were drawn from Sample 1, and included 88 participants with SCI who were prospectively assessed for mood states (anxiety, depressive mood, and fatigue) and pain intensity at three time periods: at admission to SCI rehabilitation, at discharge, and 6 months after transition into the community. Results showed that the SCI sample had significantly lower cognitive performance than the able-bodied control group. Further, almost 29% of the adults with SCI had lowered cognitive performance believed to be indicative of cognitive impairment. The risk of an adult with SCI having cognitive impairment was almost 13 times that of someone without an SCI. Results from Sample 2 revealed that the development of negative mood states was a significant problem in those with cognitive impairment after they transitioned into the community, a time when personal resources are severely challenged. Findings suggest all adults with SCI admitted to rehabilitation should receive a cognitive screen, and that rehabilitation strategies should then be guided by the cognitive performance of the person. Special attention should also be given to improving skills of those with cognitive impairment before they transition into the community, so as to reduce risk of comorbid mental health problems.	[Craig, Ashley; Guest, Rebecca; Tran, Yvonne; Middleton, James] Univ Sydney, Sydney Med School Northern, John Walsh Ctr Rehabil Res, Kolling Inst Med Res, Sydney, NSW 2006, Australia; [Tran, Yvonne] Univ Technol Sydney, Key Univ Ctr Hlth Technol, Broadway, Sydney, NSW 2007, Australia		Craig, A (corresponding author), Univ Sydney, Royal North Shore Hosp, John Walsh Ctr Rehabil Res, Sydney Med School Norhern,Kolling Inst Med Res, St Leonards, NSW 2065, Australia.	a.craig@sydney.edu.au		Tran, Yvonne/0000-0002-1741-4205	Lifetime Care Support Authority (NSW, Australia) [LTCSA 08/209]	We acknowledge financial support in the form of a competitive grant from the Lifetime Care Support Authority (NSW, Australia): LTCSA 08/209. We also thank Dr Dianah Rodrigues, Associate Professor Kathryn Nicholson Perry, and clinical psychologists Annalisa Dezarnaulds and Catherine Ephraums for assisting in collecting NUCOG assessments.	Ankeny DP, 2009, NEUROSCIENCE, V158, P1112, DOI 10.1016/j.neuroscience.2008.07.001; Cohen J., 1988, STAT POWER SOCIAL SC; Cotter I, 2008, PSYCHOL ASPECTS ASS, P175; Craig A, 1998, AUST NZ J PSYCHIAT, V32, P112, DOI 10.1046/j.1440-1614.1998.00376.x; Craig A, 2002, ARCH PHYS MED REHAB, V83, P1455, DOI 10.1053/apmr.2002.34624; Craig A, 2009, SPINAL CORD, V47, P108, DOI 10.1038/sc.2008.115; Craig A, 2016, SCREENING COGNITIVE; Craig A, 2015, BRIT J HEALTH PSYCH, V20, P807, DOI 10.1111/bjhp.12143; Craig A, 2015, ARCH PHYS MED REHAB, V96, P1426, DOI 10.1016/j.apmr.2015.02.027; Craig A, 2013, J PAIN, V14, P911, DOI 10.1016/j.jpain.2013.03.002; Craig A, 2012, J PSYCHOSOM RES, V73, P205, DOI 10.1016/j.jpsychores.2012.07.005; Davidoff G, 1990, Arch Clin Neuropsychol, V5, P77, DOI 10.1016/0887-6177(90)90009-E; Dowler RN, 1997, J INT NEUROPSYCH SOC, V3, P464, DOI 10.1017/S1355617797004645; Faul F., 2008, G POWER 3 0 10; Hess DW, 2003, REHABIL PSYCHOL, V48, P151, DOI 10.1037/0090-5550.48.3.151; Hill-Briggs F, 2007, ARCH CLIN NEUROPSYCH, V22, P389, DOI 10.1016/j.acn.2007.01.013; Jensen MP, 1999, PAIN, V83, P157, DOI 10.1016/S0304-3959(99)00101-3; Kennedy P, 2000, ARCH PHYS MED REHAB, V81, P932, DOI 10.1053/apmr.2000.5580; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Kurylo M, 2001, REHABIL PSYCHOL, V46, P247, DOI 10.1037/0090-5550.46.3.247; Luedtke K, 2014, J NEUROTRAUM, V31, P1107, DOI 10.1089/neu.2013.3204; Maldonado-Bouchard S, 2016, BRAIN BEHAV IMMUN, V51, P176, DOI 10.1016/j.bbi.2015.08.009; McDermott LM, 2009, J AFFECT DISORDERS, V119, P1, DOI 10.1016/j.jad.2009.04.022; Pollard C, 2007, BRIT J HEALTH PSYCH, V12, P347, DOI 10.1348/135910707X197046; RICHARDS JS, 1988, AM J PHYS MED REHAB, V67, P211, DOI 10.1097/00002060-198810000-00005; ROTH E, 1989, PARAPLEGIA, V27, P480, DOI 10.1038/sc.1989.75; Siddall PJ, 2003, PAIN, V103, P249, DOI 10.1016/S0304-3959(02)00452-9; Sommer MF., 2001, SPINAL CORD INJURY F; Tabachnick B. G., 1989, USING MULTIVARIATE S; Tolonen A, 2007, J REHABIL MED, V39, P622, DOI 10.2340/16501977-0101; Tun CG, 1997, REHABIL PSYCHOL, V42, P163, DOI 10.1037/0090-5550.42.3.163; Walterfang M, 2006, AUST NZ J PSYCHIAT, V40, P995, DOI 10.1111/j.1440-1614.2006.01923.x; Wijesuriya N, 2012, ARCH PHYS MED REHAB, V93, P319, DOI 10.1016/j.apmr.2011.09.008; Williams R, 2015, ARCH PHYS MED REHAB, V96, P133, DOI 10.1016/j.apmr.2014.08.016; Woolrich Rachel A, 2006, Psychol Health Med, V11, P80, DOI 10.1080/13548500500294211; Wu J., 2016, J NEUROTRAUMA; Wu JF, 2014, CELL CYCLE, V13, P2446, DOI 10.4161/cc.29420; Wu JF, 2014, J NEUROSCI, V34, P10989, DOI 10.1523/JNEUROSCI.5110-13.2014	38	56	56	1	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2017	34	6					1156	1163		10.1089/neu.2016.4632			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	EN7ZR	WOS:000396221200004	27717295				2022-02-06	
J	Finley, JW; Gao, S				Finley, John W.; Gao, Song			A Perspective on Crocus sativus L. (Saffron) Constituent Crocin: A Potent Water-Soluble Antioxidant and Potential Therapy for Alzheimer's Disease	JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY			English	Article						Alzheimer's disease; crocin; crocetin; saffron; Crocus sativus	LONG-TERM POTENTIATION; ISCHEMIA-REPERFUSION INJURY; ETHANOL-INDUCED IMPAIRMENT; MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; ACTIVE CONSTITUENTS; CEREBRAL-ISCHEMIA; SAFETY EVALUATION; EXTRACT PREVENTS	Alzheimer's disease (AD) is the most common form of dementia, in which the death of brain cells causes memory loss and cognitive decline. Several factors are thought to play roles in the development and course of AD. Existing medical therapies only modestly alleviate and delay cognitive symptoms. Current research has been focused on developing antibodies to remove the aggregates of amyloid-beta (A beta) and tau protein. This approach has achieved removal of A beta; however, no cognitive improvement in AD patients has been reported. The biological properties of saffron, the dry stigma of the plant Crocus sativus L., and particularly its main constituent crocin, have been studied extensively for many conditions including dementia and traumatic brain injury. Crocin is a unique antioxidant because it is a water-soluble carotenoid. Crocin has shown potential to improve learning and memory as well as protect brain cells. A search of the studies on saffron and crocin that have been published in recent years for their impact on AD as well as crocin's effects on A beta and tau protein has been conducted. This review demonstrates that crocin exhibits multifunctional protective activities in the brain and could be a promising agent applied as a supplement or drug for prevention or treatment of AD.	[Finley, John W.] Louisiana State Univ, Dept Nutr & Food Sci, 111 Food Sci Bldg, Baton Rouge, LA 70803 USA; [Finley, John W.] 14719 Secret Harbor Pl, Bradenton, FL 34202 USA; [Gao, Song] Qual Phytochem LLC, 13 Dexter Rd, East Brunswick, NJ 08816 USA		Finley, JW (corresponding author), Louisiana State Univ, Dept Nutr & Food Sci, 111 Food Sci Bldg, Baton Rouge, LA 70803 USA.; Finley, JW (corresponding author), 14719 Secret Harbor Pl, Bradenton, FL 34202 USA.	jfinle5@lsu.edu					ABDULLAEV FI, 1993, BIOFACTORS, V4, P83; Abdullaev FI, 2002, EXP BIOL MED, V227, P20, DOI 10.1177/153537020222700104; Abe K, 2000, PHYTOTHER RES, V14, P149, DOI 10.1002/(SICI)1099-1573(200005)14:3&lt;149::AID-PTR665&gt;3.0.CO;2-5; Abe K, 1998, BRAIN RES, V787, P132, DOI 10.1016/S0006-8993(97)01505-9; Abe K, 1999, BRAIN RES, V851, P287, DOI 10.1016/S0006-8993(99)02174-5; Ahn JH, 2011, BIOCHEM BIOPH RES CO, V414, P79, DOI 10.1016/j.bbrc.2011.09.025; Akhondzadeh S, 2010, J CLIN PHARM THER, V35, P581, DOI 10.1111/j.1365-2710.2009.01133.x; Akhondzadeh S, 2010, PSYCHOPHARMACOLOGY, V207, P637, DOI 10.1007/s00213-009-1706-1; Alavizadeh SH, 2014, FOOD CHEM TOXICOL, V64, P65, DOI 10.1016/j.fct.2013.11.016; Alonso G. L., 1999, P 1 INT C PFT PIGM F, V24-26, P341; Alonso GL, 2001, J FOOD QUALITY, V24, P219, DOI 10.1111/j.1745-4557.2001.tb00604.x; Asadi F, 2015, PHARMACOL BIOCHEM BE, V139, P47, DOI 10.1016/j.pbb.2015.10.011; Asai A, 2005, J AGR FOOD CHEM, V53, P7302, DOI 10.1021/jf0509355; Asdaq SMB, 2010, APPL BIOCHEM BIOTECH, V162, P358, DOI 10.1007/s12010-009-8740-7; Ayatollahi H, 2014, PHYTOTHER RES, V28, P539, DOI 10.1002/ptr.5021; Bandegi AR, 2014, ADV PHARM BULL, V4, P493, DOI 10.5681/apb.2014.073; BASKER D, 1983, ECON BOT, V37, P228, DOI 10.1007/BF02858789; Bathaie SZ, 2010, CRIT REV FOOD SCI, V50, P761, DOI 10.1080/10408390902773003; Bie XD, 2011, FITOTERAPIA, V82, P997, DOI 10.1016/j.fitote.2011.06.001; Bolhassani A, 2014, BBA-REV CANCER, V1845, P20, DOI 10.1016/j.bbcan.2013.11.001; Caballero-Ortega H., 2004, J FOOD QUALITY, V24, P219; Caballero-Ortega H, 2007, FOOD CHEM, V100, P1126, DOI 10.1016/j.foodchem.2005.11.020; Chryssanthi DG, 2011, J PHARMACEUT BIOMED, V55, P563, DOI 10.1016/j.jpba.2011.02.018; Dashti-R MH, 2012, EXCLI J, V11, P328; Deslauriers AM, 2011, J IMMUNOL, V187, P4788, DOI 10.4049/jimmunol.1004111; DHINGRA VK, 1975, INDIAN J CHEM, V13, P339; El-Beshbishy HA, 2012, ECOTOX ENVIRON SAFE, V83, P47, DOI 10.1016/j.ecoenv.2012.06.003; Fadai F, 2014, PHARMACOPSYCHIATRY, V47, P156, DOI 10.1055/s-0034-1382001; Farokhnia M, 2014, HUM PSYCHOPHARM CLIN, V29, P351, DOI 10.1002/hup.2412; Forchetti Concetta M, 2005, Prim Care Companion J Clin Psychiatry, V7, P155; Georgiadou G, 2014, PSYCHOPHARMACOLOGY, V231, P717, DOI 10.1007/s00213-013-3293-4; Geromichalos GD, 2012, J AGR FOOD CHEM, V60, P6131, DOI 10.1021/jf300589c; Ghadami MR, 2009, PHYSIOL PHARMACOL, V12, P287; Ghadrdoost B, 2011, EUR J PHARMACOL, V667, P222, DOI 10.1016/j.ejphar.2011.05.012; Ghaffari S, 2015, RES PHARM SCI, V10, P222; Ghahghaei A, 2013, CELL MOL BIOL LETT, V18, P328, DOI 10.2478/s11658-013-0092-1; Ghahghaei A, 2012, INT J PEPT RES THER, V18, P347, DOI 10.1007/s10989-012-9308-x; Hirota S, 2013, FOOD SCI TECHNOL RES, V19, P1121, DOI 10.3136/fstr.19.1121; Hosseinzadeh H., 2006, Journal of Medicinal Plants, V5, P40; Hosseinzadeh H, 2013, PHYTOTHER RES, V27, P475, DOI 10.1002/ptr.4784; Hosseinzadeh H, 2012, PHYTOTHER RES, V26, P381, DOI 10.1002/ptr.3566; Hosseinzadeh H, 2009, PHARMACOGN MAG, V5, P419; Hosseinzadeh H, 2010, PHYTOTHER RES, V24, P726, DOI 10.1002/ptr.3011; Howes MJR, 2011, DRUG AGING, V28, P439, DOI 10.2165/11591310-000000000-00000; Hsiung GYR, 2008, EXPERT OPIN PHARMACO, V9, P2575, DOI [10.1517/14656566.9.15.2575, 10.1517/14656566.9.15.2575 ]; Iqbal K, 2010, CURR ALZHEIMER RES, V7, P656, DOI 10.2174/156720510793611592; Jaliani HZ, 2013, IRAN J BASIC MED SCI, V16, P101; [金玉燕 Jin Yuyan], 2004, [中国药科大学学报, Journal of China Pharmaceutical University], V35, P283; Jnaneshwari S, 2013, J PHARM PHARMACOL, V65, P604, DOI 10.1111/jphp.12016; Johnson, 1999, Eur J Clin Nutr, V53, P830, DOI 10.1038/sj.ejcn.1600846; Karakani AM, 2015, IRAN J BASIC MED SCI, V18, P485; Kawabata K., 2012, ALTERN MED; Khajuria DK, 2010, LAT AM J PHARM, V29, P713; Khalili Mohsen, 2010, Iran Biomed J, V14, P59; Khan MB, 2012, NEUROL SCI, V33, P1011, DOI 10.1007/s10072-011-0880-1; Khazdair MR, 2015, AVICENNA J PHYTOMEDI, V5, P376; Konoshima T, 1998, PHYTOTHER RES, V12, P400, DOI 10.1002/(SICI)1099-1573(199809)12:6&lt;400::AID-PTR321&gt;3.0.CO;2-4; Lage M, 2009, SCI HORTIC-AMSTERDAM, V121, P366, DOI 10.1016/j.scienta.2009.02.017; Lautenschlager M, 2015, PHYTOMEDICINE, V22, P36, DOI 10.1016/j.phymed.2014.10.009; Lechtenberg M, 2008, PLANTA MED, V74, P764, DOI 10.1055/s-2008-1074535; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Li N, 1999, J CHROMATOGR A, V849, P349, DOI 10.1016/S0021-9673(99)00600-7; [李向阳 LI Xiang-yang], 2009, [中草药, Chinese Traditional and Herbal Drugs], V40, P1425; Liakopoulou-Kyriakides M., 2002, STUDIES NATURAL PROD, V26, P293, DOI DOI 10.1016/S1572-5995(02)80009-6]; Linardaki ZI, 2013, FOOD CHEM TOXICOL, V52, P163, DOI 10.1016/j.fct.2012.11.016; Lockhart IA, 2009, DEMENT GERIATR COGN, V28, P389, DOI 10.1159/000255578; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Massoud F, 2011, CAN J PSYCHIAT, V56, P579, DOI 10.1177/070674371105601003; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mehri S, 2012, CELL MOL NEUROBIOL, V32, P227, DOI 10.1007/s10571-011-9752-8; Melnyk J. P., 2010, Food Research International, V43, P1981, DOI 10.1016/j.foodres.2010.07.033; Milajerdi A., 2016, J NUTR INTERMEDIARY, V3, P23, DOI [10.1016/j.jnim.2015.12.332, DOI 10.1016/J.JNIM.2015.12.332]; Modaghegh MH, 2008, PHYTOMEDICINE, V15, P1032, DOI 10.1016/j.phymed.2008.06.003; Mohamadpour AH, 2013, IRAN J BASIC MED SCI, V16, P39; Mondragon-Rodriguez S., 2012, INT J ALZHEIMERS DIS; Moshiri M, 2015, DRUG RES, V65, P287, DOI 10.1055/s-0034-1375681; Mousavi B, 2015, AVICENNA J PHYTOMEDI, V5, P413; Mousavi SH, 2010, CELL MOL NEUROBIOL, V30, P185, DOI 10.1007/s10571-009-9441-z; Mousavi SZ, 2011, AVICENNA J PHYTOMEDI, V1, P57; Naghibi SM, 2012, ADV PHARMACOL SCI, V2012, DOI 10.1155/2012/494367; Naghizadeh B, 2013, PHYTOMEDICINE, V20, P537, DOI 10.1016/j.phymed.2012.12.019; Naghizadeh Bahareh, 2014, Acta Med Iran, V52, P101; Nam KN, 2010, EUR J PHARMACOL, V648, P110, DOI 10.1016/j.ejphar.2010.09.003; Nemati H, 2008, PHYTOMEDICINE, V15, P1038, DOI 10.1016/j.phymed.2008.07.008; Nikbakht-Jam I, 2016, EUR J INTEGR MED, V8, P307, DOI 10.1016/j.eujim.2015.12.008; Nisbet RM, 2015, ACTA NEUROPATHOL, V129, P207, DOI 10.1007/s00401-014-1371-2; Nygaard HB, 2013, CLIN THER, V35, P1480, DOI 10.1016/j.clinthera.2013.09.009; Ochiai T, 2004, NEUROSCI LETT, V362, P61, DOI 10.1016/j.neulet.2004.02.067; Ochiai T, 2004, NEUROCHEM INT, V44, P321, DOI 10.1016/S0197-0186(03)00174-8; Ochiai T, 2007, BBA-GEN SUBJECTS, V1770, P578, DOI 10.1016/j.bbagen.2006.11.012; Ordoudi SA, 2009, J AGR FOOD CHEM, V57, P3080, DOI 10.1021/jf804041g; Oruc S, 2016, LIFE SCI, V154, P79, DOI 10.1016/j.lfs.2016.04.028; Papandreou MA, 2006, J AGR FOOD CHEM, V54, P8762, DOI 10.1021/jf061932a; Papandreou MA, 2011, BEHAV BRAIN RES, V219, P197, DOI 10.1016/j.bbr.2011.01.007; Parsons CG, 2007, NEUROPHARMACOLOGY, V53, P699, DOI 10.1016/j.neuropharm.2007.07.013; Perry George, 2002, Journal of Biomedicine & Biotechnology, V2, P120, DOI 10.1155/S1110724302203010; PFANDER H, 1975, HELV CHIM ACTA, V58, P2233, DOI 10.1002/hlca.19750580736; Pitsikas N, 2007, BEHAV BRAIN RES, V183, P141, DOI 10.1016/j.bbr.2007.06.001; Pitsikas N, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/926284; Rao SV, 2016, NEUROTOXICOLOGY, V52, P230, DOI 10.1016/j.neuro.2015.12.010; Rashedinia M, 2015, ACTA NEUROBIOL EXP, V75, P208; Reitz C, 2011, NAT REV NEUROL, V7, P137, DOI [10.1038/nrneurol.2011.2, 10.1101/cshperspect.a006239]; Rios JL, 1996, PHYTOTHER RES, V10, P189, DOI 10.1002/(SICI)1099-1573(199605)10:3&lt;189::AID-PTR754&gt;3.0.CO;2-C; Rodda J, 2009, INT J GERIATR PSYCH, V24, P437, DOI 10.1002/gps.2165; Russo P, 2013, CURR MED CHEM, V20, P1686; Sarshoori JR, 2014, IRAN J BASIC MED SCI, V17, P895; Sekler A, 2008, DIS TREAT, V4, P715; Soeda S, 2001, LIFE SCI, V69, P2887, DOI 10.1016/S0024-3205(01)01357-1; Soeda S, 2007, J NAT MED, V61, P102, DOI 10.1007/s11418-006-0120-9; SPERANZA G, 1984, GAZZ CHIM ITAL, V114, P189; Sreenu G., 2015, INT J BIOASSAY, V4, P4223, DOI DOI 10.21746/IJBIO.2015.08.0012; Steiner GZ, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-0989-0; Sugiura M, 1995, P JPN ACAD B-PHYS, V71, P319, DOI 10.2183/pjab.71.319; SUGIURA M, 1995, JPN J PHARMACOL, V67, P395, DOI 10.1254/jjp.67.395; SUGIURA M, 1995, PHYTOTHER RES, V9, P100, DOI 10.1002/ptr.2650090204; SUGIURA M, 1994, J PHARMACOL EXP THER, V271, P703; Talaei A, 2015, J AFFECT DISORDERS, V174, P51, DOI 10.1016/j.jad.2014.11.035; Tamaddonfard E, 2013, IRAN J BASIC MED SCI, V16, P91; Tanaka T., 2015, GLOBAL J GASTOENTERO, V3, P31; TARANTILIS PA, 1995, J CHROMATOGR A, V699, P107, DOI 10.1016/0021-9673(95)00044-N; Tashakori-Sabzevar F, 2013, CURR NEUROVASC RES, V10, P325, DOI 10.2174/15672026113109990032; Terry AV, 2003, J PHARMACOL EXP THER, V306, P821, DOI 10.1124/jpet.102.041616; Torres LL, 2011, J ALZHEIMERS DIS, V26, P59, DOI 10.3233/JAD-2011-110284; Tsolaki M, 2016, J ALZHEIMERS DIS, V54, P129, DOI 10.3233/JAD-160304; Umigai N, 2011, PHYTOMEDICINE, V18, P575, DOI 10.1016/j.phymed.2010.10.019; Vakili A, 2014, J STROKE CEREBROVASC, V23, P106, DOI 10.1016/j.jstrokecerebrovasdis.2012.10.008; Vijaya Bhargava K, 2011, INT J PHARM PHARM SC, V3, P22; Wallin AK, 2011, NEUROPSYCH DIS TREAT, V7, P565, DOI 10.2147/NDT.S24196; Wang K, 2015, NEUROSCI LETT, V591, P53, DOI 10.1016/j.neulet.2015.02.016; WHO, 2007, MON SEL MED PLANTS, V3, P126; Willard P., 2002, SECRETS FAFFRON VAGA; Xi L, 2007, PHYTOMEDICINE, V14, P633, DOI 10.1016/j.phymed.2006.11.028; Yoshino F, 2011, J CLIN BIOCHEM NUTR, V49, P182, DOI 10.3164/jcbn.11-01; Yoshino Y., 2014, Pharmacology and Pharmacy, V5, P37, DOI 10.4236/pp.2014.51007; Zhang GF, 2015, NEUROCHEM INT, V89, P101, DOI 10.1016/j.neuint.2015.07.011; [张颖 Zhang Ying], 2012, [中国药学杂志, Chinese Pharmaceutical Journal], V47, P136; ZHANG YX, 1994, BIOL PHARM BULL, V17, P217, DOI 10.1248/bpb.17.217; Zheng YQ, 2007, BRAIN RES, V1138, P86, DOI 10.1016/j.brainres.2006.12.064	138	56	60	2	65	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0021-8561	1520-5118		J AGR FOOD CHEM	J. Agric. Food Chem.	FEB 8	2017	65	5					1005	1020		10.1021/acs.jafc.6b04398			16	Agriculture, Multidisciplinary; Chemistry, Applied; Food Science & Technology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Agriculture; Chemistry; Food Science & Technology	EK3SU	WOS:000393848600002	28098452				2022-02-06	
J	Ma, MW; Wang, J; Dhandapani, KM; Brann, DW				Ma, Merry W.; Wang, Jing; Dhandapani, Krishnan M.; Brann, Darrell W.			NADPH Oxidase 2 Regulates NLRP3 Inflammasome Activation in the Brain after Traumatic Brain Injury	OXIDATIVE MEDICINE AND CELLULAR LONGEVITY			English	Article							EXHALED BREATH CONDENSATE; CEREBROSPINAL-FLUID; OXIDATIVE STRESS; EXPRESSION; APOCYNIN; DAMAGE; NEUROINFLAMMATION; INHIBITION; REDUCTION; NOX2	Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. After the initial primary mechanical injury, a complex secondary injury cascade involving oxidative stress and neuroinflammation follows, which may exacerbate the injury and complicate the healing process. NADPH oxidase 2 (NOX2) is a major contributor to oxidative stress in TBI pathology, and inhibition of NOX2 is neuroprotective. The NLRP3 inflammasome can become activated in response to oxidative stress, but little is known about the role of NOX2 in regulating NLRP3 inflammasome activation following TBI. In this study, we utilized NOX2 knockout mice to study the role of NOX2 in mediating NLRP3 inflammasome expression and activation following a controlled cortical impact. Expression of NLRP3 inflammasome components NLRP3 and apoptosis-associated speck-like protein containing a CARD (ASC), as well as its downstream products cleaved caspase-1 and interleukin-1 beta (IL-1 beta), was robustly increased in the injured cerebral cortex following TBI. Deletion of NOX2 attenuated the expression, assembly, and activity of the NLRP3 inflammasome via a mechanism that was associated with TXNIP, a sensor of oxidative stress. The results support the notion that NOX2-dependent inflammasome activation contributes to TBI pathology.	[Ma, Merry W.; Wang, Jing; Dhandapani, Krishnan M.; Brann, Darrell W.] Charlie Norwood VA Med Ctr, One Freedom Way, Augusta, GA 30904 USA; [Ma, Merry W.; Wang, Jing; Brann, Darrell W.] Augusta Univ, Med Coll Georgia, Dept Neurosci & Regenerat Med, Augusta, GA 30912 USA; [Dhandapani, Krishnan M.] Augusta Univ, Med Coll Georgia, Dept Neurosurg, Augusta, GA USA		Brann, DW (corresponding author), Charlie Norwood VA Med Ctr, One Freedom Way, Augusta, GA 30904 USA.; Brann, DW (corresponding author), Augusta Univ, Med Coll Georgia, Dept Neurosci & Regenerat Med, Augusta, GA 30912 USA.	dbrann@augusta.edu		Brann, Darrell/0000-0002-4480-8859; Dhandapani, Krishnan/0000-0001-7044-1117	United States Department of Veteran's Affairs, Biomedical Laboratory Research, and Development Service [5l101BX001117]	This research presented in this article was conducted in partial fulfillment of the Ph.D. degree requirements set forth for Merry W. Ma and was supported by a VA Merit Review Award (5l101BX001117) from the United States Department of Veteran's Affairs, Biomedical Laboratory Research, and Development Service.	Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Altenhofer S, 2012, CELL MOL LIFE SCI, V69, P2327, DOI 10.1007/s00018-012-1010-9; Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312; Arend WP, 2008, IMMUNOL REV, V223, P20, DOI 10.1111/j.1600-065X.2008.00624.x; Barrett JP, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0843-4; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Ben Borgens R, 2012, Q REV BIOL, V87, P89, DOI 10.1086/665457; Chakraborty S, 2010, J NEUROSCI RES, V88, P1615, DOI 10.1002/jnr.22343; Chaubey S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054869; Chiu CC, 2016, J NEUROSCI METH, V272, P38, DOI 10.1016/j.jneumeth.2016.06.018; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Cifuentes-Pagano E, 2014, ANTIOXID REDOX SIGN, V20, P2741, DOI 10.1089/ars.2013.5620; Cooney SJ, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-155; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cristofori L, 2005, CLIN BIOCHEM, V38, P97, DOI 10.1016/j.clinbiochem.2004.09.013; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Freeman LC, 2016, J NEUROCHEM, V136, P29, DOI 10.1111/jnc.13217; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Gatto GJ, 2013, J ENZYM INHIB MED CH, V28, P95, DOI 10.3109/14756366.2011.636360; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; Heid ME, 2013, J IMMUNOL, V191, P5230, DOI 10.4049/jimmunol.1301490; Heumuller S, 2008, HYPERTENSION, V51, P211, DOI 10.1161/HYPERTENSIONAHA.107.100214; Hoover RC, 2004, J NEUROTRAUM, V21, P501, DOI 10.1089/089771504774129847; Jackman KA, 2009, BRIT J PHARMACOL, V156, P680, DOI 10.1111/j.1476-5381.2008.00073.x; Johnson DK, 2002, ENDOTHELIUM-J ENDOTH, V9, P191, DOI 10.1080/10623320213638; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Li Z, 2015, NEUROL SCI, V36, P61, DOI 10.1007/s10072-014-1909-z; Liao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068963; Lin C, 2017, EXP NEUROL, V290, P115, DOI 10.1016/j.expneurol.2017.01.005; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Lu XY, 2014, NEUROCHEM INT, V69, P14, DOI 10.1016/j.neuint.2014.02.006; Lucke-Wold B. P., 2015, TRANSL RES, V166, pe1, DOI DOI 10.1016/J.TRSL.2015.08.005.[; Lucke-Wold BP, 2015, TRANSL RES, V166, P509, DOI 10.1016/j.trsl.2015.08.005; Ma MW, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0150-7; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; McIntosh TK, 1996, LAB INVEST, V74, P315; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; Minutoli Letteria, 2016, Oxid Med Cell Longev, V2016, P2183026, DOI 10.1155/2016/2183026; Ransohoff RM, 2016, SCIENCE, V353, P777, DOI 10.1126/science.aag2590; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Sareddy GR, 2015, P NATL ACAD SCI USA, V112, pE6673, DOI 10.1073/pnas.1516729112; Singhal G, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00315; Stefanska J, 2012, PULM PHARMACOL THER, V25, P343, DOI 10.1016/j.pupt.2012.06.001; Stefanska J, 2012, EXP LUNG RES, V38, P90, DOI 10.3109/01902148.2011.649823; Stocchetti N, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1318-1; STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341; Thompson HJ, 2006, EUR J NEUROSCI, V24, P3063, DOI 10.1111/j.1460-9568.2006.05197.x; Vaccari JPD, 2016, J NEUROCHEM, V136, P39, DOI 10.1111/jnc.13036; Vaccari JPD, 2014, J CEREBR BLOOD F MET, V34, P369, DOI 10.1038/jcbfm.2013.227; Wakade C, 2010, J NEUROSURG, V113, P1195, DOI 10.3171/2010.3.JNS091212; Walsh JG, 2014, NAT REV NEUROSCI, V15, P84, DOI 10.1038/nrn3638; Yang F, 2014, J CEREBR BLOOD F MET, V34, P660, DOI 10.1038/jcbfm.2013.242; Zhang M, 2016, BIOMED PHARMACOTHER, V80, P73, DOI 10.1016/j.biopha.2016.02.036; Zhang QG, 2008, J NEUROSCI, V28, P8430, DOI 10.1523/JNEUROSCI.2752-08.2008; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831	64	56	59	0	5	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1942-0900	1942-0994		OXID MED CELL LONGEV	Oxidative Med. Cell. Longev.		2017	2017								6057609	10.1155/2017/6057609			18	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	FA4PC	WOS:000405424300001	28785377	Green Published, gold, Green Submitted			2022-02-06	
J	Lancaster, MA; Olson, DV; McCrea, MA; Nelson, LD; LaRoche, AA; Muftuler, LT				Lancaster, Melissa A.; Olson, Daniel V.; McCrea, Michael A.; Nelson, Lindsay D.; LaRoche, Ashley A.; Muftuler, L. Tugan			Acute white matter changes following sport-related concussion: A serial diffusion tensor and diffusion kurtosis tensor imaging study	HUMAN BRAIN MAPPING			English	Article						sport-related concussion; diffusion tensor imaging; diffusion kurtosis imaging; concussion management; concussion symptoms; mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; GAUSSIAN WATER DIFFUSION; MILD HEAD-INJURY; NCAA CONCUSSION; AXONAL DAMAGE; MRI; METAANALYSIS; ADOLESCENTS; ANISOTROPY	Recent neuroimaging studies have suggested that following sport-related concussion (SRC) physiological brain alterations may persist after an athlete has shown full symptom recovery. Diffusion MRI is a versatile technique to study white matter injury following SRC, yet serial follow-up studies in the very acute stages following SRC utilizing a comprehensive set of diffusion metrics are lacking. The aim of the current study was to characterize white matter changes within 24 hours of concussion in a group of high school and collegiate athletes, using Diffusion Tensor and Diffusion Kurtosis Tensor metrics. Participants were reassessed a week later. At 24 hours post-injury, the concussed group reported significantly more concussion symptoms than a well-matched control group and demonstrated poorer performance on a cognitive screening measure, yet these differences were nonsignificant at the 8-day follow-up. Similarly, within 24-hours after injury, the concussed group exhibited a widespread decrease in mean diffusivity, increased axial kurtosis and, to a lesser extent, decreased axial and radial diffusivities compared with control subjects. At 8 days post injury, the differences in these diffusion metrics were even more widespread in the injured athletes, despite improvement of symptoms and cognitive performance. These MRI findings suggest that the athletes might not have reached full physiological recovery a week after the injury. These findings have significant implications for the management of SRC because allowing an athlete to return to play before the brain has fully recovered from injury may have negative consequences. Hum Brain Mapp 37:3821-3834, 2016. (c) 2016 Wiley Periodicals, Inc.	[Lancaster, Melissa A.; McCrea, Michael A.; Nelson, Lindsay D.; Muftuler, L. Tugan] Med Coll Wisconsin, Dept Neurol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Lancaster, Melissa A.; McCrea, Michael A.; Nelson, Lindsay D.; LaRoche, Ashley A.; Muftuler, L. Tugan] Med Coll Wisconsin, Dept Neurosurg, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Olson, Daniel V.] Med Coll Wisconsin, Dept Biophys, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA		Muftuler, LT (corresponding author), Med Coll Wisconsin, Froedtert Hosp, Neurosurg, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	lmuftuler@mcw.edu	Muftuler, L. Tugan/AAG-7539-2021	Muftuler, L. Tugan/0000-0002-6635-5678; LaRoche, Ashley/0000-0003-0197-0853	GE-NFL Head Health Challenge I; U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-12-1-0004]; Clinical and Translational Science Institute [1UL1-RR031973 (-01)]; National Center for Advancing Translational Sciences, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [8UL1TR000055]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000055] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR031973] Funding Source: NIH RePORTER	Contract grant sponsor: GE-NFL Head Health Challenge I and the U.S. Army Medical Research and Materiel Command; Contract grant sponsor: W81XWH-12-1-0004; Contract grant sponsor: Clinical and Translational Science Institute; Contract grant sponsor: 1UL1-RR031973 (-01); Contract grant sponsor: National Center for Advancing Translational Sciences, National Institutes of Health; Contract grant sponsor: 8UL1TR000055	Andersson JLR, 2003, NEUROIMAGE, V20, P870, DOI 10.1016/S1053-8119(03)00336-7; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Borich M, 2013, J NEUROTRAUM, V30, P1243, DOI 10.1089/neu.2012.2818; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Coutu JP, 2014, NEUROBIOL AGING, V35, P1412, DOI 10.1016/j.neurobiolaging.2013.12.001; Croall ID, 2014, NEUROLOGY, V83, P494, DOI 10.1212/WNL.0000000000000666; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dimou S, 2014, J NEUROTRAUM, V31, P413, DOI 10.1089/neu.2013.3050; Echemendia RJ, 2015, BRAIN INJURY, V29, P185, DOI 10.3109/02699052.2014.965212; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Gardner A, 2014, J NEUROTRAUM, V31, P1, DOI 10.1089/neu.2013.3079; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Gosselin N, 2010, PHYSICIAN SPORTSMED, V38, P27, DOI 10.3810/psm.2010.10.1805; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132090, 10.3171/2013.12.JNS132093]; Helmick K., 2006, DEFENSE VETERANS BRA; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Kilinc D, 2009, EXP NEUROL, V219, P553, DOI 10.1016/j.expneurol.2009.07.014; LaRoche AA, 2016, CLIN J SPORT MED, V26, P33, DOI 10.1097/JSM.0000000000000192; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Narayana PA, 2015, NEUROIMAGE-CLIN, V7, P87, DOI 10.1016/j.nicl.2014.07.010; Nelson LD, 2015, AM J SPORT MED, V43, P2018, DOI 10.1177/0363546515587714; Paydar A, 2014, AM J NEURORADIOL, V35, P808, DOI 10.3174/ajnr.A3764; Pfefferbaum A, 2000, MAGNET RESON MED, V44, P259, DOI 10.1002/1522-2594(200008)44:2<259::AID-MRM13>3.0.CO;2-6; Pfefferbaum A, 2003, MAGNET RESON MED, V49, P953, DOI 10.1002/mrm.10452; Pulsipher DT, 2011, CURR SPORT MED REP, V10, P14, DOI 10.1249/JSR.0b013e31820711b8; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Steven AJ, 2014, AM J ROENTGENOL, V202, pW26, DOI 10.2214/AJR.13.11365; Stokum JA, 2015, BRAIN INJURY, V29, P47, DOI 10.3109/02699052.2014.947628; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Tremblay S, 2014, BRAIN, V137, P2997, DOI 10.1093/brain/awu236; Veeramuthu V, 2015, J NEUROTRAUM, V32, P1497, DOI 10.1089/neu.2014.3750; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhu Y., 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/548392; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	66	56	57	2	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	NOV	2016	37	11					3821	3834		10.1002/hbm.23278			14	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	DZ7VM	WOS:000386075900010	27237455	Green Published			2022-02-06	
J	Bosarge, PL; Raff, LA; McGwin, G; Carroll, SL; Bellot, SC; Diaz-Guzman, E; Kerby, JD				Bosarge, Patrick L.; Raff, Lauren Allen; McGwin, Gerald, Jr.; Carroll, Shannon L.; Bellot, Scott C.; Diaz-Guzman, Enrique; Kerby, Jeffrey D.			Early initiation of extracorporeal membrane oxygenation improves survival in adult trauma patients with severe adult respiratory distress syndrome	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						ECMO; ARDS; conventional ventilation; trauma	LIFE-SUPPORT; LUNG INJURY; FAILURE; EXPERIENCE; SHOCK; ECMO	BACKGROUND: The use of extracorporeal membrane oxygenation (ECMO) in the trauma population has been reported to have a mortality benefit in patients with severe refractory hypoxic respiratory failure. This study compares the early initiation of ECMO for the management of severe adult respiratory distress syndrome (ARDS) versus a historical control immediately preceding the use of ECMO for trauma patients. METHODS: A retrospective study was conducted at a single verified Level I trauma center. The study population was limited to trauma patients diagnosed with severe ARDS using the Berlin definition (PaO2/FIO2 ratio < 100). Patients managed with ECMO versus conventional ventilation (CONV) were compared. The primary outcome of interest was mortality; secondary outcomes included hospital length of stay, intensive care unit-free days, and ventilator-free days. RESULTS: Fifteen ECMO patients managed from March 2013 to November 2014 were identified, as were 14 CONV patients managed from March 2012 to February 2013 who met the Berlin definition of severe ARDS. Data related to age, Injury Severity Scores (ISSs), admission lactic acid levels, base deficit, the number of transfused red blood cell units within the first 24 hours, and presence of severe traumatic brain injury were collected and were not statistically different between the groups. Likewise, Murray Lung Injury (MLI), Sequential Organ Failure Assessment (SOFA), and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores determined at the onset of severe ARDS were not statistically different between the groups. Median hospital stay (CONV, 28.0 days [14.0-47.0]; ECMO, 43.5 days [30.0-93.0]; p = 0.15), intensive care unit-free days (CONV, 0.0 days [0.0-5.0]; ECMO, 5.0 days [0.0-7.0]; p = 0.26), and ventilator-free days (CONV, 0.0 days [0.0-10.0]; ECMO, 8.0 days [0.0-19.0]; p = 0.13) were not statistically different between the groups. Mortality in the ECMO group was significantly reduced compared with the CONV group (ECMO, 13.3%; CONV, 64%; p = 0.01). Timing from the onset of severe ARDS to ECMO intervention occurred at a mean 1.9 +/- 1.4 days. CONCLUSION: Patients who were treated with ECMO for severe ARDS had an improved mortality compared with historical controls. ECMO should be considered at the early onset of severe ARDS to improve survival. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.	[Bosarge, Patrick L.; Raff, Lauren Allen; McGwin, Gerald, Jr.; Carroll, Shannon L.; Bellot, Scott C.; Diaz-Guzman, Enrique; Kerby, Jeffrey D.] Univ Alabama Birmingham, Div Acute Care Surg, Birmingham, AL USA		Bosarge, PL (corresponding author), Univ Alabama Birmingham, Div Trauma Burns & Surg Crit Care, Med Ctr, 112 Lyons Harrison Res Bldg,701 19th St South, Birmingham, AL 35294 USA.	pbosarge@uabmc.edu	Cannon, Jeremy/T-3875-2019	Cannon, Jeremy/0000-0002-2969-9316			Arlt M, 2010, RESUSCITATION, V81, P804, DOI 10.1016/j.resuscitation.2010.02.020; Biderman P, 2013, J TRAUMA ACUTE CARE, V75, P907, DOI 10.1097/TA.0b013e3182a8334f; Burns KEA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014623; Chughtai T, 2001, J TRAUMA, V50, P1137, DOI 10.1097/00005373-200106000-00025; Cordell-Smith JA, 2006, INJURY, V37, P29, DOI 10.1016/j.injury.2005.03.027; Guirand DM, 2014, J TRAUMA ACUTE CARE, V76, P1275, DOI 10.1097/TA.0000000000000213; HILL JD, 1972, NEW ENGL J MED, V286, P629, DOI 10.1056/NEJM197203232861204; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; Michaels AJ, 1999, J TRAUMA, V46, P638, DOI 10.1097/00005373-199904000-00013; Muellenbach RM, 2012, J TRAUMA ACUTE CARE, V72, P1444, DOI 10.1097/TA.0b013e31824d68e3; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; Peek GJ, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14350; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Ried M, 2013, CRIT CARE, V17, DOI 10.1186/cc12782; Rubenfeld GD, 2007, CHEST, V131, P554, DOI 10.1378/chest.06-1976; Slutsky AS, 2013, NEW ENGL J MED, V369, P2126, DOI 10.1056/NEJMra1208707; Wu SC, 2015, AM J EMERG MED, V33, P658, DOI 10.1016/j.ajem.2015.02.007; Yuan KC, 2008, J TRAUMA, V65, P1151, DOI 10.1097/01.ta.0000235492.09223.83; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193	19	56	61	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	AUG	2016	81	2					236	243		10.1097/TA.0000000000001068			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	DS5CE	WOS:000380797300004	27032012				2022-02-06	
J	Melcangi, RC; Giatti, S; Garcia-Segura, LM				Melcangi, Roberto C.; Giatti, Silvia; Garcia-Segura, Luis M.			Levels and actions of neuroactive steroids in the nervous system under physiological and pathological conditions: Sex-specific features	NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS			English	Article; Proceedings Paper	8th International Meeting on Steroids and Nervous System	2015	Torino, ITALY			Aromatase; 5alpha-Reductase; Dihydroprogesterone; Dihydrotestosterone; Estradiol; Pregnenolone; Progesterone; Testosterone; Tetrahydroprogesterone	TRAUMATIC BRAIN-INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ESTROGEN-RECEPTOR MODULATORS; MYELIN BASIC-PROTEIN; SPINAL-CORD-INJURY; KAINIC ACID EXCITOTOXICITY; HUMAN NEUROBLASTOMA-CELLS; ACUTE REGULATORY PROTEIN; HORMONE PULSE FREQUENCY; ADULT-RAT HIPPOCAMPUS	Neuroactive steroids regulate the physiology of the central and peripheral nervous system, exert neuroprotective actions and represent interesting tools for therapeutic strategies against neurodegenerative and psychiatric disorders. Sex differences in their levels are detected not only under physiological conditions but are also modified in a sex-dependent way in different pathological alterations such as Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, traumatic brain injury, spinal cord injury, stroke, diabetic encephalopathy, psychiatric disorders and peripheral neuropathy. Interestingly, many of these disorders show sex differences in their incidence, symptomatology and/or neurodegenerative outcome. The neuroprotective actions of neuroactive steroids, together with the sex specific regulation of its levels might provide the basis to design sex-specific neuroprotective therapies. Indeed, some experiments here discussed suggest the viability of this approach. (C) 2015 Elsevier Ltd. All rights reserved.	[Melcangi, Roberto C.; Giatti, Silvia] Univ Milan, Dipartimento Sci Farmacol & Biomol, Milan, Italy; [Garcia-Segura, Luis M.] CSIC, Ist Cajal, Ave Doctor Arce 37, Madrid 28002, Spain		Melcangi, RC (corresponding author), Univ Milan, Dipartimento Sci Farmacol & Biomol, Milan, Italy.	roberto.melcangi@unimi.it	Giatti, Silvia/G-9334-2016; Garcia-Segura, Luis M/U-3711-2017; Melcangi, Roberto Cosimo/AAA-6534-2022	Giatti, Silvia/0000-0001-7741-826X; Garcia-Segura, Luis M/0000-0002-2450-2916; MELCANGI, COSIMO ROBERTO/0000-0003-0861-8967			Aaberg ML, 2008, J DIABETES COMPLICAT, V22, P83, DOI 10.1016/j.jdiacomp.2007.06.009; Acs P, 2009, GLIA, V57, P807, DOI 10.1002/glia.20806; Afifi M., 2007, SMJ Singapore Medical Journal, V48, P385; Albers JW, 1996, NEUROLOGY, V46, P85, DOI 10.1212/WNL.46.1.85; Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Ammendola A, 2000, ALCOHOL ALCOHOLISM, V35, P368, DOI 10.1093/alcalc/35.4.368; Andersen K, 1999, NEUROLOGY, V53, P1992, DOI 10.1212/WNL.53.9.1992; ANDREASEN NC, 1994, JAMA-J AM MED ASSOC, V272, P1763, DOI 10.1001/jama.272.22.1763; ANDREASEN NC, 1990, ARCH GEN PSYCHIAT, V47, P35; Arevalo MA, 2013, HORM BEHAV, V63, P216, DOI 10.1016/j.yhbeh.2012.02.021; Arevalo MA, 2012, J STEROID BIOCHEM, V131, P52, DOI 10.1016/j.jsbmb.2011.09.004; Arad M, 2010, NEUROPSYCHOPHARMACOL, V35, P2179, DOI 10.1038/npp.2010.89; Ardeshiri A, 2006, EUR J NEUROSCI, V24, P2567, DOI 10.1111/j.1460-9568.2006.05142.x; Arevalo MA, 2015, HORM BEHAV, V74, P19, DOI 10.1016/j.yhbeh.2015.04.016; Arevalo MA, 2015, NAT REV NEUROSCI, V16, P17, DOI 10.1038/nrn3856; Ayhan S, 2003, MICROSURG, V23, P49, DOI 10.1002/micr.10088; Ayoola C, 2014, PSYCHOPHARMACOLOGY, V231, P3503, DOI 10.1007/s00213-014-3588-0; Azcoitia I, 1999, J NEUROSCI RES, V58, P815, DOI 10.1002/(SICI)1097-4547(19991215)58:6<815::AID-JNR8>3.0.CO;2-R; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Azcoitia I, 2001, J NEUROBIOL, V47, P318, DOI 10.1002/neu.1038; Backstrom T, 2014, PROG NEUROBIOL, V113, P88, DOI 10.1016/j.pneurobio.2013.07.005; BARFIELD RJ, 1984, PSYCHONEUROENDOCRINO, V9, P217, DOI 10.1016/0306-4530(84)90002-7; BARRACLOUGH CA, 1986, NEUROENDOCRINOLOGY, V42, P6, DOI 10.1159/000124241; Barreto G, 2007, EUR J NEUROSCI, V25, P3039, DOI 10.1111/j.1460-9568.2007.05563.x; Barreto G, 2009, ENDOCRINOLOGY, V150, P5010, DOI 10.1210/en.2009-0352; Barreto GE, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00132; Basit Abdul, 2004, J Coll Physicians Surg Pak, V14, P79; Baudry M, 2013, NEUROSCIENCE, V239, P280, DOI 10.1016/j.neuroscience.2012.10.051; Bauman ML, 2005, INT J DEV NEUROSCI, V23, P183, DOI 10.1016/j.ijdevneu.2004.09.006; Bebo BF, 1999, J NEUROSCI RES, V55, P432, DOI 10.1002/(SICI)1097-4547(19990215)55:4<432::AID-JNR4>3.0.CO;2-2; Bebo BF, 1999, J IMMUNOL, V162, P35; Beinhoff U, 2008, J NEUROL, V255, P117, DOI 10.1007/s00415-008-0726-9; Lopez-Rodriguez AB, 2015, PSYCHONEUROENDOCRINO, V56, P1, DOI 10.1016/j.psyneuen.2015.02.018; Bender RA, 2010, CEREB CORTEX, V20, P2985, DOI 10.1093/cercor/bhq047; Benito-Leon J, 2003, MOVEMENT DISORD, V18, P267, DOI 10.1002/mds.10362; Biamonte F, 2009, NEUROBIOL DIS, V36, P103, DOI 10.1016/j.nbd.2009.07.001; Biessels GJ, 2008, LANCET NEUROL, V7, P184, DOI 10.1016/S1474-4422(08)70021-8; Biessels GJ, 2002, EUR J PHARMACOL, V441, P1, DOI 10.1016/S0014-2999(02)01486-3; Blanchard V, 2003, EXP NEUROL, V184, P247, DOI 10.1016/S0014-4886(03)00252-8; Bloch Y, 2005, J AFFECT DISORDERS, V84, P99, DOI 10.1016/j.jad.2004.10.002; Bode FJ, 2008, HUM MOL GENET, V17, P2595, DOI 10.1093/hmg/ddn159; Booya F, 2005, BMC NEUROL, V5, DOI 10.1186/1471-2377-5-24; Bourque M, 2009, FRONT NEUROENDOCRIN, V30, P142, DOI 10.1016/j.yfrne.2009.04.014; Bowers J Michael, 2010, Biol Sex Differ, V1, P8, DOI 10.1186/2042-6410-1-8; Bryant NL, 1999, AM J PSYCHIAT, V156, P603; Calabrese D, 2014, J ENDOCRINOL, V221, P1, DOI 10.1530/JOE-13-0541; Callahan MJ, 2001, AM J PATHOL, V158, P1173, DOI 10.1016/S0002-9440(10)64064-3; Callier S, 2001, SYNAPSE, V41, P131, DOI 10.1002/syn.1067; Calmarza-Font I, 2012, BEHAV BRAIN RES, V227, P287, DOI 10.1016/j.bbr.2011.10.036; Caruso D, 2010, J NEUROENDOCRINOL, V22, P1137, DOI 10.1111/j.1365-2826.2010.02064.x; Caruso D, 2008, J MOL NEUROSCI, V34, P249, DOI 10.1007/s12031-007-9029-3; Caruso D, 2014, J NEUROCHEM, V130, P591, DOI 10.1111/jnc.12745; Caruso D, 2013, PSYCHONEUROENDOCRINO, V38, P2278, DOI 10.1016/j.psyneuen.2013.04.016; Caruso D, 2013, NEUROBIOL AGING, V34, P1080, DOI 10.1016/j.neurobiolaging.2012.10.007; Caruso D, 2010, J NEUROCHEM, V114, P921, DOI 10.1111/j.1471-4159.2010.06825.x; Celec P, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00012; Cermenati G, 2013, J ENDOCRINOL INVEST, V36, P435, DOI 10.3275/8941; Cermenati G, 2012, J LIPID RES, V53, P300, DOI 10.1194/jlr.M021188; Chan JR, 2000, MOL BIOL CELL, V11, P2283, DOI 10.1091/mbc.11.7.2283; Chan JR, 1998, P NATL ACAD SCI USA, V95, P10459, DOI 10.1073/pnas.95.18.10459; Chavez-Delgado ME, 2005, J BIOMED MATER RES B, V74B, P589, DOI 10.1002/jbm.b.30243; Chisholm N. C., 2015, NEUROBIOL DIS; Chisholm NC, 2015, EPIGENETICS-US, V10, P142, DOI 10.1080/15592294.2014.1001219; Cho T, 2012, J NEUROENDOCRINOL, V24, P789, DOI 10.1111/j.1365-2826.2011.02272.x; CHOWEN JA, 1992, NEUROENDOCRINOLOGY, V56, P895, DOI 10.1159/000126321; Ciriza I, 2004, J NEUROBIOL, V61, P209, DOI 10.1002/neu.20043; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Ciriza I, 2006, J NEUROBIOL, V66, P916, DOI 10.1002/neu.20293; Clinton LK, 2007, NEUROBIOL DIS, V28, P76, DOI 10.1016/j.nbd.2007.06.013; Coers S, 2002, METAB BRAIN DIS, V17, P55, DOI 10.1023/A:1015415226799; Coirini H, 2002, NEUROSCIENCE, V113, P883, DOI 10.1016/S0306-4522(02)00224-5; Colciago A, 2015, J STEROID BIOCHEM, V150, P64, DOI 10.1016/j.jsbmb.2015.02.008; Confavreux C, 2003, BRAIN, V126, P770, DOI 10.1093/brain/awg081; Corbo RM, 2014, J NEUROL SCI, V344, P149, DOI 10.1016/j.jns.2014.06.045; CORPECHOT C, 1993, ENDOCRINOLOGY, V133, P1003, DOI 10.1210/en.133.3.1003; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Czlonkowska A, 2006, ENDOCRINE, V29, P243, DOI 10.1385/ENDO:29:2:243; Dalal M, 1997, J IMMUNOL, V159, P3; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; Day NL, 2013, J NEUROTRAUM, V30, P1531, DOI 10.1089/neu.2013.2854; de Lau LML, 2004, NEUROLOGY, V63, P1240, DOI 10.1212/01.WNL.0000140706.52798.BE; de Michele F, 2003, NEUROL SCI, V24, P172, DOI 10.1007/s10072-003-0115-1; Deniselle MCG, 2002, NEUROBIOL DIS, V11, P457, DOI 10.1006/nbdi.2002.0564; Devroey D, 2003, CEREBROVASC DIS, V16, P272, DOI 10.1159/000071127; Dina OA, 2007, NEUROSCIENCE, V145, P350, DOI 10.1016/j.neuroscience.2006.11.053; Diz-Chaves Y, 2012, EXP GERONTOL, V47, P93, DOI 10.1016/j.exger.2011.10.008; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dooley MA, 2003, CURR OPIN RHEUMATOL, V15, P99, DOI 10.1097/00002281-200303000-00002; Dorner JL, 2007, BEHAV BRAIN RES, V178, P90, DOI 10.1016/j.bbr.2006.12.004; Doulazmi M, 1999, J COMP NEUROL, V411, P267; El-Etr M, 2015, GLIA, V63, P104, DOI 10.1002/glia.22736; Elkabes S, 2014, EXP NEUROL, V259, P28, DOI 10.1016/j.expneurol.2014.01.008; Eriksson M, 2008, CEREBROVASC DIS, V25, P423, DOI 10.1159/000121343; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fernandez HH, 2000, MOVEMENT DISORD, V15, P490, DOI 10.1002/1531-8257(200005)15:3<490::AID-MDS1011>3.0.CO;2-E; Fombonne E, 1999, PSYCHOL MED, V29, P769, DOI 10.1017/S0033291799008508; Fombonne E, 2003, J AUTISM DEV DISORD, V33, P365, DOI 10.1023/A:1025054610557; Foot M, 2004, DEPRESS ANXIETY, V20, P123, DOI 10.1002/da.20031; Foroud T, 1999, J NEUROL NEUROSUR PS, V66, P52, DOI 10.1136/jnnp.66.1.52; Foy MR, 2008, LEARN MEMORY, V15, P820, DOI 10.1101/lm.1124708; Frankfurt M, 2015, HORM BEHAV, V74, P28, DOI 10.1016/j.yhbeh.2015.05.004; Fratiglioni L, 1997, NEUROLOGY, V48, P132, DOI 10.1212/WNL.48.1.132; Frye CA, 2000, PSYCHONEUROENDOCRINO, V25, P407, DOI 10.1016/S0306-4530(99)00068-2; Frye CA, 2008, HORM BEHAV, V54, P726, DOI 10.1016/j.yhbeh.2008.07.013; Frye CA, 2009, EPILEPSY BEHAV, V16, P418, DOI 10.1016/j.yebeh.2009.09.008; Galea LAM, 2008, BRAIN RES REV, V57, P332, DOI 10.1016/j.brainresrev.2007.05.008; Garay L, 2011, NEUROSCIENCE, V192, P588, DOI 10.1016/j.neuroscience.2011.06.065; Garay L, 2007, J STEROID BIOCHEM, V107, P228, DOI 10.1016/j.jsbmb.2007.03.040; Garay L, 2010, HORM MOL BIOL CLIN I, V1, P43, DOI 10.1515/HMBCI.2010.006; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; GARCIASEGURA LM, 1994, PROG NEUROBIOL, V44, P279, DOI 10.1016/0301-0082(94)90042-6; GARCIASEGURA LM, 1989, DEV BRAIN RES, V47, P298, DOI 10.1016/0165-3806(89)90186-7; Gemignani F, 2006, MOVEMENT DISORD, V21, P1254, DOI 10.1002/mds.20928; Ghorbanpoor S, 2014, ENDOCRINOLOGY, V155, P4341, DOI 10.1210/en.2014-1158; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Giatti S, 2012, J NEUROENDOCRINOL, V24, P851, DOI 10.1111/j.1365-2826.2012.02284.x; Giatti S, 2015, NEUROENDOCRINOLOGY, V101, P296, DOI 10.1159/000381064; Giatti S, 2012, J MOL ENDOCRINOL, V49, pR125, DOI 10.1530/JME-12-0127; Giatti S, 2010, NEUROCHEM INT, V56, P118, DOI 10.1016/j.neuint.2009.09.009; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Giraud SN, 2010, P NATL ACAD SCI USA, V107, P8416, DOI 10.1073/pnas.0910627107; Gispen WH, 2000, TRENDS NEUROSCI, V23, P542, DOI 10.1016/S0166-2236(00)01656-8; Gleicher N, 2007, J AUTOIMMUN, V28, P1, DOI 10.1016/j.jaut.2006.12.004; Goldstein JM, 2007, BIOL PSYCHIAT, V61, P935, DOI 10.1016/j.biopsych.2006.06.027; Goldstein JM, 2006, HORM BEHAV, V50, P612, DOI 10.1016/j.yhbeh.2006.06.029; Goldstein JM, 2002, ARCH GEN PSYCHIAT, V59, P154, DOI 10.1001/archpsyc.59.2.154; Goldstein JM, 1998, AM J PSYCHIAT, V155, P1358, DOI 10.1176/ajp.155.10.1358; GOLDSTEIN JM, 1988, J PSYCHIAT RES, V22, P141, DOI 10.1016/0022-3956(88)90078-7; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Gudemez E, 2002, MICROSURG, V22, P234, DOI 10.1002/micr.10039; Guennoun R, 2001, MOL BRAIN RES, V90, P75, DOI 10.1016/S0169-328X(01)00094-8; Guerra-Araiza C, 2007, DEV NEUROBIOL, V67, P510, DOI 10.1002/dneu.20383; Gur RE, 2004, BIOL PSYCHIAT, V55, P512, DOI 10.1016/j.biopsych.2003.10.009; Haaxma CA, 2007, J NEUROL NEUROSUR PS, V78, P819, DOI 10.1136/jnnp.2006.103788; HadjSahraoui N, 1996, J NEUROGENET, V11, P45, DOI 10.3109/01677069609107062; Hafner H, 2003, PSYCHONEUROENDOCRINO, V28, P17, DOI 10.1016/S0306-4530(02)00125-7; Halbreich U, 2003, PSYCHONEUROENDOCRINO, V28, P1, DOI 10.1016/S0306-4530(03)00098-2; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; Hammond J, 2001, J NEUROCHEM, V77, P1319, DOI 10.1046/j.1471-4159.2001.00345.x; Hankin BL, 1999, ANN MED, V31, P372, DOI 10.3109/07853899908998794; Hawkins SA, 1999, J NEUROL NEUROSUR PS, V67, P148, DOI 10.1136/jnnp.67.2.148; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Holroyd-Leduc JM, 2000, STROKE, V31, P1833, DOI 10.1161/01.STR.31.8.1833; Homann CN, 2003, J NEURAL TRANSM, V110, P885, DOI 10.1007/s00702-003-0009-7; Huppenbauer CB, 2005, J NEUROSCI, V25, P4004, DOI 10.1523/JNEUROSCI.5279-04.2005; Ibanez C, 2003, PROG NEUROBIOL, V71, P49, DOI 10.1016/j.pneurobio.2003.09.002; Ishihara Y, 2014, LIFE SCI, V99, P24, DOI 10.1016/j.lfs.2014.01.061; Ishrat T, 2010, EXP NEUROL, V226, P183, DOI 10.1016/j.expneurol.2010.08.023; Islamov RR, 2002, BRAIN RES, V943, P283, DOI 10.1016/S0006-8993(02)02827-5; JACKSON GL, 1991, BIOL REPROD, V45, P188, DOI 10.1095/biolreprod45.1.188; Jacobson AM, 2002, INT REV NEUROBIOL, V51, P455, DOI 10.1016/S0074-7742(02)51013-8; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; Jiang C, 2011, INT IMMUNOPHARMACOL, V11, P1925, DOI 10.1016/j.intimp.2011.08.001; JO D-H, 1989, Steroids, V54, P287, DOI 10.1016/0039-128X(89)90003-2; Jones KJ, 2001, BRAIN RES REV, V37, P372, DOI 10.1016/S0165-0173(01)00107-2; Perez-Alvarez MJ, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-157; Joseph EK, 2003, NEUROSCIENCE, V120, P907, DOI 10.1016/S0306-4522(03)00400-7; JungTestas I, 1996, CELL MOL NEUROBIOL, V16, P439, DOI 10.1007/BF02088110; Kapral MK, 2005, STROKE, V36, P809, DOI 10.1161/01.STR.0000157662.09551.e5; Kaye W, 2008, PHYSIOL BEHAV, V94, P121, DOI 10.1016/j.physbeh.2007.11.037; Kessing LV, 2005, SOC PSYCH PSYCH EPID, V40, P197, DOI 10.1007/s00127-005-0885-2; Khasnavis S, 2013, J BIOL CHEM, V288, P20843, DOI 10.1074/jbc.M112.443556; Kim HJ, 2003, MOL BRAIN RES, V115, P39, DOI 10.1016/S0169-328X(03)00177-3; Kimura K, 2005, CEREBROVASC DIS, V19, P171, DOI 10.1159/000083252; Kiziltan ME, 2007, J NEUROL SCI, V258, P75, DOI 10.1016/j.jns.2007.02.028; Kodl CT, 2008, ENDOCR REV, V29, P494, DOI 10.1210/er.2007-0034; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Kovacic U, 2004, EXP NEUROL, V189, P94, DOI 10.1016/j.expneurol.2004.05.015; Kovacic U, 2003, EXP NEUROL, V184, P479, DOI 10.1016/S0014-4886(03)00269-3; Kramar EA, 2013, NEUROSCIENCE, V239, P3, DOI 10.1016/j.neuroscience.2012.10.038; Kraszpulski M, 2001, ACTA NEUROL SCAND, V103, P88, DOI 10.1034/j.1600-0404.2001.103002088.x; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Kumar P, 2014, EUR J PHARMACOL, V723, P38, DOI 10.1016/j.ejphar.2013.11.036; Kumsar S, 2014, J SEX MED, V11, P529, DOI 10.1111/jsm.12394; Kurth F, 2014, NEUROIMAGE-CLIN, V4, P454, DOI 10.1016/j.nicl.2014.03.001; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Labombarda F, 2006, J NEUROTRAUM, V23, P181, DOI 10.1089/neu.2006.23.181; Labombarda F, 2009, GLIA, V57, P884, DOI 10.1002/glia.20814; Lagunas N, 2010, HORM BEHAV, V58, P786, DOI 10.1016/j.yhbeh.2010.07.014; Lavaque E, 2006, NEUROSCIENCE, V138, P741, DOI 10.1016/j.neuroscience.2005.05.060; Lavaque E, 2006, J NEUROBIOL, V66, P308, DOI 10.1002/neu.20221; Leonelli E, 2007, NEUROSCIENCE, V144, P1293, DOI 10.1016/j.neuroscience.2006.11.014; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Liu AL, 2012, ENDOCRINOLOGY, V153, P3747, DOI 10.1210/en.2012-1138; Liu HL, 2005, J NEUROSCI RES, V79, P861, DOI 10.1002/jnr.20424; Liu MY, 2007, J CEREBR BLOOD F MET, V27, P135, DOI 10.1038/sj.jcbfm.9600331; Liu SB, 2011, CLIN EXP PHARMACOL P, V38, P577, DOI 10.1111/j.1440-1681.2011.05549.x; Lloret A, 2008, FREE RADICAL BIO MED, V44, P2019, DOI 10.1016/j.freeradbiomed.2008.02.017; Rodriguez ABL, 2011, CEREB CORTEX, V21, P2046, DOI 10.1093/cercor/bhq277; Luchetti S, 2011, NEUROSCIENCE, V191, P6, DOI 10.1016/j.neuroscience.2011.04.010; Luchetti S, 2014, J NEUROPATH EXP NEUR, V73, P123, DOI 10.1097/NEN.0000000000000037; Luchetti S, 2011, NEUROBIOL AGING, V32, P1964, DOI 10.1016/j.neurobiolaging.2009.12.014; Luchetti S, 2010, BRAIN PATHOL, V20, P945, DOI 10.1111/j.1750-3639.2010.00396.x; LUQUIN S, 1993, J NEUROBIOL, V24, P913, DOI 10.1002/neu.480240705; Magnaghi V, 1999, MOL BRAIN RES, V70, P36, DOI 10.1016/S0169-328X(99)00124-2; Magnaghi V, 2004, MOL BRAIN RES, V126, P67, DOI 10.1016/j.molbrainres.2004.03.009; Magnaghi V, 2007, J MOL NEUROSCI, V31, P149, DOI 10.1385/JMN/31:02:149; Magnaghi V, 2006, J PERIPHER NERV SYST, V11, P111, DOI 10.1111/j.1085-9489.2006.00075.x; Mannix R, 2014, J NEUROSURG, V121, P1337, DOI 10.3171/2014.8.JNS14715; Manwani B, 2015, J CEREBR BLOOD F MET, V35, P221, DOI 10.1038/jcbfm.2014.186; Manwani B, 2013, EXP NEUROL, V249, P120, DOI 10.1016/j.expneurol.2013.08.011; Marcus SM, 2008, COMPR PSYCHIAT, V49, P238, DOI 10.1016/j.comppsych.2007.06.012; Markianos M, 2005, ANN NEUROL, V57, P520, DOI 10.1002/ana.20428; Martinelli P, 2003, NEUROL SCI, V24, P192, DOI 10.1007/s10072-003-0125-z; Martinez-Cerdeno V, 2006, EUR J NEUROSCI, V24, P3475, DOI 10.1111/j.1460-9568.2006.05239.x; Marx CE, 2011, NEUROSCIENCE, V191, P78, DOI 10.1016/j.neuroscience.2011.06.076; Marx CE, 2006, BIOL PSYCHIAT, V60, P1287, DOI 10.1016/j.biopsych.2006.06.017; Marx CE, 2009, NEUROPSYCHOPHARMACOL, V34, P1885, DOI 10.1038/npp.2009.26; Matarese G, 2001, EUR J IMMUNOL, V31, P1324, DOI 10.1002/1521-4141(200105)31:5<1324::AID-IMMU1324>3.0.CO;2-Y; McCall AL, 2002, INT REV NEUROBIOL, V51, P415, DOI 10.1016/S0074-7742(02)51012-6; McCarthy MM, 2008, J NEUROENDOCRINOL, V20, P777, DOI 10.1111/j.1365-2826.2008.01723.x; McCarthy MM, 2003, ANN NY ACAD SCI, V1007, P283, DOI 10.1196/annals.1286.027; MCEWEN BS, 1994, EXP GERONTOL, V29, P431, DOI 10.1016/0531-5565(94)90022-1; McHenry J, 2014, FRONT NEUROENDOCRIN, V35, P42, DOI 10.1016/j.yfrne.2013.09.001; McIntyre RS, 2006, PSYCHONEUROENDOCRINO, V31, P1029, DOI 10.1016/j.psyneuen.2006.06.005; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; Melcangi RC, 2008, CELL MOL LIFE SCI, V65, P777, DOI 10.1007/s00018-007-7403-5; Melcangi RC, 1999, J NEUROSCI RES, V56, P349, DOI 10.1002/(SICI)1097-4547(19990515)56:4<349::AID-JNR3>3.0.CO;2-H; Melcangi RC, 2005, BRAIN RES REV, V48, P328, DOI 10.1016/j.brainresrev.2004.12.021; Melcangi RC, 2003, PROG NEUROBIOL, V71, P57, DOI 10.1016/j.pneurobio.2003.09.003; Melcangi RC, 1998, NEUROSCIENCE, V85, P569, DOI 10.1016/S0306-4522(97)00628-3; Melcangi RC, 2000, J NEUROCYTOL, V29, P327, DOI 10.1023/A:1007105121765; Melcangi RC, 2000, PROG NEUROBIOL, V60, P291, DOI 10.1016/S0301-0082(99)00028-3; Melcangi RC, 2012, J MOL NEUROSCI, V46, P177, DOI 10.1007/s12031-011-9570-y; Mensah-Nyagan Ayikoe G, 2009, Psychoneuroendocrinology, V34 Suppl 1, pS169, DOI 10.1016/j.psyneuen.2009.06.004; Mercier G, 2001, MOL BRAIN RES, V97, P137, DOI 10.1016/S0169-328X(01)00311-4; Meyer L, 2011, PAIN, V152, P170, DOI 10.1016/j.pain.2010.10.015; Meyer L, 2010, CELL MOL LIFE SCI, V67, P3017, DOI 10.1007/s00018-010-0372-0; Micevych P, 2008, ENDOCRINOLOGY, V149, P2739, DOI 10.1210/en.2008-0011; Mitro N, 2014, J STEROID BIOCHEM, V143, P115, DOI 10.1016/j.jsbmb.2014.02.015; Moldovan IR, 2008, J NEUROIMMUNOL, V193, P161, DOI 10.1016/j.jneuroim.2007.10.010; Morales LBJ, 2006, J NEUROSCI, V26, P6823, DOI 10.1523/JNEUROSCI.0453-06.2006; Moriarty PJ, 2001, SCHIZOPHRENIA BULL, V27, P103, DOI 10.1093/oxfordjournals.schbul.a006850; Mosquera L, 2014, BRAIN RES, V1561, P11, DOI 10.1016/j.brainres.2014.03.002; Mottron L, 2015, MOL AUTISM, V6, DOI 10.1186/s13229-015-0024-1; Murphy DD, 2000, NEUROENDOCRINOLOGY, V72, P133, DOI 10.1159/000054580; Murray HE, 2003, NEUROSCIENCE, V116, P213, DOI 10.1016/S0306-4522(02)00578-X; Ng I, 2006, BRIT J NEUROSURG, V20, P73, DOI 10.1080/02688690600682259; Nguyen TV, 2010, J NEUROENDOCRINOL, V22, P1013, DOI 10.1111/j.1365-2826.2010.02044.x; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Niewada M, 2005, NEUROEPIDEMIOLOGY, V24, P123, DOI 10.1159/000082999; Nitkowska M, 2015, ACTA NEUROL SCAND, V131, P411, DOI 10.1111/ane.12334; Noonan CW, 2002, NEUROLOGY, V58, P136, DOI 10.1212/WNL.58.1.136; Noorbakhsh F, 2011, BRAIN, V134, P2703, DOI 10.1093/brain/awr200; Ooishi Y, 2012, J STEROID BIOCHEM, V131, P37, DOI 10.1016/j.jsbmb.2011.10.004; Orton SM, 2006, LANCET NEUROL, V5, P932, DOI 10.1016/S1474-4422(06)70581-6; Osborne DM, 2009, AGE, V31, P119, DOI 10.1007/s11357-009-9088-1; Ozacmak VH, 2009, PHYSIOL RES, V58, P909, DOI 10.33549/physiolres.931647; Padua L, 2006, NEUROL SCI, V27, P417, DOI 10.1007/s10072-006-0722-8; Palaszynski KM, 2004, J NEUROIMMUNOL, V146, P144, DOI 10.1016/j.jneuroim.2003.11.004; Palmen SJMC, 2004, BRAIN, V127, P2572, DOI 10.1093/brain/awh287; Pariante CM, 2004, BRIT J PSYCHIAT, V185, P5, DOI 10.1192/bjp.185.1.5; Parmenter BA, 2007, MULT SCLER J, V13, P25, DOI 10.1177/1352458506070682; Patte-Mensah C, 2014, PROG NEUROBIOL, V113, P70, DOI 10.1016/j.pneurobio.2013.07.004; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; Pekmezovic T, 2007, EUR J EPIDEMIOL, V22, P523, DOI 10.1007/s10654-007-9157-7; Pelfrey CM, 2002, J NEUROIMMUNOL, V130, P211, DOI 10.1016/S0165-5728(02)00224-2; Pesaresi M, 2011, NEUROSCIENCE, V199, P401, DOI 10.1016/j.neuroscience.2011.09.013; Pesaresi M, 2011, EXP NEUROL, V228, P215, DOI 10.1016/j.expneurol.2011.01.005; Pesaresi M, 2010, J MOL NEUROSCI, V42, P135, DOI 10.1007/s12031-010-9344-y; Pesaresi M, 2010, HORM BEHAV, V57, P46, DOI 10.1016/j.yhbeh.2009.04.008; Peterson BL, 2015, BEHAV BRAIN RES, V286, P152, DOI 10.1016/j.bbr.2015.03.005; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Pike CJ, 2009, FRONT NEUROENDOCRIN, V30, P239, DOI 10.1016/j.yfrne.2009.04.015; Platania P, 2005, NEUROBIOL DIS, V20, P461, DOI 10.1016/j.nbd.2005.03.025; Pozzilli C, 2003, EUR J NEUROL, V10, P95, DOI 10.1046/j.1468-1331.2003.00519.x; Quillinan N, 2014, EXP NEUROL, V259, P10, DOI 10.1016/j.expneurol.2014.02.004; Ramsden M, 2003, NEUROSCIENCE, V122, P573, DOI 10.1016/j.neuroscience.2003.08.048; Rao ML, 2003, PSYCHONEUROENDOCRINO, V28, P83, DOI 10.1016/S0306-4530(02)00126-9; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Reddy J, 2005, J IMMUNOL, V175, P5591, DOI 10.4049/jimmunol.175.9.5591; Reeves MJ, 2008, LANCET NEUROL, V7, P915, DOI 10.1016/S1474-4422(08)70193-5; Reite M, 1997, ARCH GEN PSYCHIAT, V54, P433; Reyna-Neyra A, 2002, BRAIN RES BULL, V58, P607, DOI 10.1016/S0361-9230(02)00829-8; Riecher-Rossler A, 2000, ACTA PSYCHIAT SCAND, V102, P58, DOI 10.1034/j.1600-0447.2000.00011.x; Rodriguez-Perez AI, 2013, NEUROBIOL DIS, V58, P209, DOI 10.1016/j.nbd.2013.06.004; Roglio I, 2008, NEUROSCIENCE, V155, P673, DOI 10.1016/j.neuroscience.2008.06.034; Roglio I, 2007, CELL MOL LIFE SCI, V64, P1158, DOI 10.1007/s00018-007-7002-5; Roglio I, 2009, J PERIPHER NERV SYST, V14, P36, DOI 10.1111/j.1529-8027.2009.00204.x; Romeo E, 1998, AM J PSYCHIAT, V155, P910, DOI 10.1176/ajp.155.7.910; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOS RAC, 1991, J MED GENET, V28, P515, DOI 10.1136/jmg.28.8.515; Roquer J, 2003, STROKE, V34, P1581, DOI 10.1161/01.STR.0000078562.82918.F6; Rosamond W, 2007, CIRCULATION, V115, pE69, DOI 10.1161/CIRCULATIONAHA.106.179918; Rosario ER, 2012, BRAIN RES, V1466, P137, DOI 10.1016/j.brainres.2012.05.011; Rosario ER, 2011, NEUROBIOL AGING, V32, P604, DOI 10.1016/j.neurobiolaging.2009.04.008; Rosario ER, 2010, BRAIN RES, V1359, P281, DOI 10.1016/j.brainres.2010.08.068; Rupprecht R, 1999, STEROIDS, V64, P83, DOI 10.1016/S0039-128X(98)00101-9; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Safarinejad MR, 2008, J NEUROENDOCRINOL, V20, P1368, DOI 10.1111/j.1365-2826.2008.01791.x; Saijo K, 2011, CELL, V145, P584, DOI 10.1016/j.cell.2011.03.050; Savettieri G, 2004, J NEUROL, V251, P1208, DOI 10.1007/s00415-004-0508-y; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schaeffer V, 2008, NEUROSCIENCE, V151, P758, DOI 10.1016/j.neuroscience.2007.11.032; Schaeffer V, 2008, NEUROCHEM INT, V52, P948, DOI 10.1016/j.neuint.2008.01.010; Schaeffer V, 2006, J NEUROBIOL, V66, P868, DOI 10.1002/neu.20267; Schneider T, 2008, PSYCHONEUROENDOCRINO, V33, P728, DOI 10.1016/j.psyneuen.2008.02.011; Schule C, 2014, PROG NEUROBIOL, V113, P79, DOI 10.1016/j.pneurobio.2013.09.003; Schwendimann RN, 2007, INT REV NEUROBIOL, V79, P377, DOI 10.1016/S0074-7742(07)79017-7; Seidman LJ, 1997, BIOL PSYCHIAT, V42, P104, DOI 10.1016/S0006-3223(96)00300-9; Selvamani A, 2014, CLIN SCI, V127, P77, DOI 10.1042/CS20130565; Shores MM, 2004, ARCH GEN PSYCHIAT, V61, P162, DOI 10.1001/archpsyc.61.2.162; Sicotte NL, 2007, ARCH NEUROL-CHICAGO, V64, P683, DOI 10.1001/archneur.64.5.683; Simonds VA, 2003, J AFFECT DISORDERS, V77, P197, DOI 10.1016/S0165-0327(02)00113-1; Singh M, 2005, ANN NY ACAD SCI, V1052, P145, DOI 10.1196/annals.1347.010; Siriphorn A, 2012, J COMP NEUROL, V520, P2630, DOI 10.1002/cne.23056; Skinner DC, 1998, P NATL ACAD SCI USA, V95, P10978, DOI 10.1073/pnas.95.18.10978; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Sohrabji F, 2015, FRONT NEUROENDOCRIN, V36, P1, DOI 10.1016/j.yfrne.2014.05.003; Spence RD, 2012, FRONT NEUROENDOCRIN, V33, P105, DOI 10.1016/j.yfrne.2011.12.001; Stack CM, 2008, EXP NEUROL, V211, P67, DOI 10.1016/j.expneurol.2008.01.003; STEINER RA, 1982, ENDOCRINOLOGY, V111, P2055, DOI 10.1210/endo-111-6-2055; Svenningsen AF, 1999, J NEUROSCI RES, V57, P124, DOI 10.1002/(SICI)1097-4547(19990701)57:1<124::AID-JNR13>3.0.CO;2-P; SZYMANSKI S, 1995, AM J PSYCHIAT, V152, P698; Takahashi T, 2003, BIOL PSYCHIAT, V53, P593, DOI 10.1016/S0006-3223(02)01483-X; Tanzer L, 2004, HORM BEHAV, V45, P339, DOI 10.1016/j.yhbeh.2004.01.002; Taylor LC, 2010, NEUROBIOL DIS, V39, P127, DOI 10.1016/j.nbd.2010.03.016; TORRESALEMAN I, 1992, GLIA, V6, P180, DOI 10.1002/glia.440060305; Tsutsui Kazuyoshi, 2011, Front Endocrinol (Lausanne), V2, P61, DOI 10.3389/fendo.2011.00061; Tsutsui K, 2012, CEREBELLUM, V11, P414, DOI 10.1007/s12311-011-0341-7; Tunez I, 2006, NEUROCHEM INT, V48, P367, DOI 10.1016/j.neuint.2005.11.011; Turtzo LC, 2008, CEREBROVASC DIS, V26, P462, DOI 10.1159/000155983; Uzunova V, 1998, P NATL ACAD SCI USA, V95, P3239, DOI 10.1073/pnas.95.6.3239; Van Den Eeden SK, 2003, AM J EPIDEMIOL, V157, P1015, DOI 10.1093/aje/kwg068; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; Veiga S, 2006, NEUROSCI LETT, V402, P150, DOI 10.1016/j.neulet.2006.03.058; Velazquez-Zamora DA, 2012, HORM BEHAV, V61, P512, DOI 10.1016/j.yhbeh.2012.01.010; Veliskova J, 2006, NEUROSCIENCE, V138, P837, DOI 10.1016/j.neuroscience.2005.07.005; VITA G, 1983, EXP NEUROL, V80, P279, DOI 10.1016/0014-4886(83)90282-0; VOLKMAR FR, 1993, J AUTISM DEV DISORD, V23, P579, DOI 10.1007/BF01046103; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Walf A. A., 2014, PHYSIOL BEHAV, V99, P169; Walf AA, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00040; Walf AA, 2010, PHYSIOL BEHAV, V99, P169, DOI 10.1016/j.physbeh.2009.09.017; Walf AA, 2009, PSYCHONEUROENDOCRINO, V34, P909, DOI [10.1016/j.psyneuen.2009.01.004, 10.1016/j.psyneuen.2009.07.005]; Wang JM, 2008, BRAIN RES REV, V57, P398, DOI 10.1016/j.brainresrev.2007.08.010; Wei T, 1997, BRAIN, V120, P1067, DOI 10.1093/brain/120.6.1067; Wirth Michelle M, 2011, Front Endocrinol (Lausanne), V2, P19, DOI 10.3389/fendo.2011.00019; Wooten GF, 2004, J NEUROL NEUROSUR PS, V75, P637, DOI 10.1136/jnnp.2003.020982; Yang SY, 2014, J STEROID BIOCHEM, V143, P460, DOI 10.1016/j.jsbmb.2014.07.001; Yorek MA, 2002, AM J PHYSIOL-ENDOC M, V283, pE1067, DOI 10.1152/ajpendo.00173.2002; YU WHA, 1989, BRAIN RES, V491, P379, DOI 10.1016/0006-8993(89)90075-9; YU WHA, 1982, EXP NEUROL, V77, P129; Yue X, 2005, P NATL ACAD SCI USA, V102, P19198, DOI 10.1073/pnas.0505203102; Zappia M, 2005, ARCH NEUROL-CHICAGO, V62, P601, DOI 10.1001/archneur.62.4.601; Zhang QG, 2014, MOL CELL ENDOCRINOL, V389, P84, DOI 10.1016/j.mce.2013.12.019; Zhang QG, 2009, J NEUROSCI, V29, P13823, DOI 10.1523/JNEUROSCI.3574-09.2009; Zhang Y, 2004, J NEUROSCI, V24, P5315, DOI 10.1523/JNEUROSCI.0913-04.2004; Zhu H, 2012, NEURAL REGEN RES, V7, P2424, DOI 10.3969/j.issn.1673-5374.2012.31.003; Zorumski CF, 2013, NEUROSCI BIOBEHAV R, V37, P109, DOI 10.1016/j.neubiorev.2012.10.005; Zuloaga KL, 2012, ENDOCRINOLOGY, V153, P5949, DOI 10.1210/en.2012-1316; Zup SL, 2014, NEUROSCIENCE, V281, P77, DOI 10.1016/j.neuroscience.2014.09.040	356	56	57	0	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-7634	1873-7528		NEUROSCI BIOBEHAV R	Neurosci. Biobehav. Rev.	AUG	2016	67						25	40		10.1016/j.neubiorev.2015.09.023			16	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Behavioral Sciences; Neurosciences & Neurology	DS2QD	WOS:000380627700004	26657814				2022-02-06	
J	Howell, D; Osternig, L; Chou, LS				Howell, David; Osternig, Louis; Chou, Li-Shan			Monitoring recovery of gait balance control following concussion using an accelerometer	JOURNAL OF BIOMECHANICS			English	Article						Acceleration; Center-of-mass; Balance; Locomotion; Mild traumatic brain injury	ERROR SCORING SYSTEM; STABILITY FOLLOWING CONCUSSION; OF-MASS ACCELERATION; TO-STAND MOVEMENT; DIVIDED ATTENTION; ADOLESCENTS; SPORTS; VALIDATION; PARAMETERS; STATEMENT	Despite medical best-practice recommendations, no consistent standard exists to systematically monitor recovery from concussion. Studies utilizing camera-based systems have reported center-of-mass (COM) motion control deficits persisting in individuals with concussion up to two months post-injury. The use of an accelerometer may provide an efficient and sensitive method to monitor COM alterations following concussion that can be employed in clinical settings. This study examined: (1) frontal/sagittal plane acceleration characteristics during dual-task walking for individuals with concussion and healthy controls; and (2) the effectiveness of utilizing acceleration characteristics to classify concussed and healthy individuals via receiver operating characteristic (ROC) curve analyses. Individuals with concussion completed testing within 72 h as well as I week, 2 weeks, 1 month, and 2 months post-injury. Control subjects completed the same protocol in similar time increments. Participants walked and simultaneously completed a cognitive task while wearing an accelerometer attached to L5. Participants with concussion walked with significantly less peak medial-lateral acceleration during 55-75% gait cycle (p= 0.04) throughout the testing period compared with controls. Moderate levels of sensitivity and specificity were found at the 72 h and I week testing times (sensitivity=0.70, specificity= 0.71). ROC analysis revealed significant AUC values at the 72 h (AUC= 0.889) and two week (AUC= 0.810) time points. Accelerometer-derived measurements may assist in detecting frontal plane control deficits during dual-task walking post-concussion, consistent with camera-based studies. These initial findings demonstrate potential for using accelerometry as a tool for clinicians to monitor gait balance control following concussion. (C) 2015 Elsevier Ltd. All rights reserved.	[Howell, David; Osternig, Louis; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA		Chou, LS (corresponding author), Univ Oregon, Dept Human Physiol, 122 Esslinger Hall,1240, Eugene, OR 97403 USA.	chou@uoregon.edu	Meijer, Anna/K-5118-2016	Chou, Li-Shan/0000-0002-2777-7034	Veterans AdministrationUS Department of Veterans Affairs [A4842C8, A4843C]; Translational Research Award from the University of Oregon; Peace Health Oregon Region; Department of Defense-TATRCUnited States Department of Defense [W81XWH-11-1-0717]; Eugene and Clarissa Evonuk Memorial Graduate Fellowship in Environmental, Cardiovascular, or Stress Physiology	This work was supported by Veterans Administration subcontract awards [A4842C8 & A4843C], Translational Research Award from the University of Oregon and Peace Health Oregon Region, the Department of Defense-TATRC Award (W81XWH-11-1-0717), and the Eugene and Clarissa Evonuk Memorial Graduate Fellowship in Environmental, Cardiovascular, or Stress Physiology. The authors would like to acknowledge Mr. Quinn Peterson and Ms. Madison Murray for their assistance with data collection.	Brown HJ, 2014, MED SCI SPORT EXER, V46, P1610, DOI 10.1249/MSS.0000000000000263; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Bugane F, 2012, COMPUT METH PROG BIO, V108, P129, DOI 10.1016/j.cmpb.2012.02.003; Doi S.A.R., 2013, SPRINGER SERIES EPID, P69; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Fan Jerome, 2006, CJEM, V8, P19; Fujimoto M, 2014, ANN BIOMED ENG, V42, P733, DOI 10.1007/s10439-013-0945-9; Fujimoto M, 2012, J BIOMECH, V45, P543, DOI 10.1016/j.jbiomech.2011.11.037; Furman GR, 2013, AM J SPORT MED, V41, P1404, DOI 10.1177/0363546513484446; Hahn ME, 2004, J BIOMECH, V37, P837, DOI 10.1016/j.jbiomech.2003.11.010; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Perry J, 1992, GAIT ANAL NORMAL PAT, P10; Register-Mihalik JK, 2013, NEUROPSYCHOL REV, V23, P300, DOI 10.1007/s11065-013-9238-1; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Zijlstra W, 2003, GAIT POSTURE, V18, P1, DOI 10.1016/S0966-6362(02)00190-X	25	56	56	2	24	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	SEP 18	2015	48	12					3364	3368		10.1016/j.jbiomech.2015.06.014			5	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	CT8ME	WOS:000363069900058	26152463				2022-02-06	
J	Dennis, EL; Ellis, MU; Marion, SD; Jin, Y; Moran, L; Olsen, A; Kernan, C; Babikian, T; Mink, R; Babbitt, C; Johnson, J; Giza, CC; Thompson, PM; Asarnow, RF				Dennis, Emily L.; Ellis, Monica U.; Marion, Sarah D.; Jin, Yan; Moran, Lisa; Olsen, Alexander; Kernan, Claudia; Babikian, Talin; Mink, Richard; Babbitt, Christopher; Johnson, Jeffrey; Giza, Christopher C.; Thompson, Paul M.; Asarnow, Robert F.			Callosal Function in Pediatric Traumatic Brain Injury Linked to Disrupted White Matter Integrity	JOURNAL OF NEUROSCIENCE			English	Article						corpus callosum; DTI; ERP; interhemispheric transfer time; traumatic brain injury	POTENTIAL INTERHEMISPHERIC TRANSMISSION; CLOSED-HEAD-INJURY; CORPUS-CALLOSUM; TRANSFER TIME; RADIAL DIFFUSIVITY; EVOKED-POTENTIALS; VISUAL PROCESSES; AXONAL INJURY; DISCONNECTION; INFORMATION	Traumatic brain injury (TBI) often results in traumatic axonal injury and white matter (WM) damage, particularly to the corpus callosum (CC). Damage to the CC can lead to impaired performance on neurocognitive tasks, but there is a high degree of heterogeneity in impairment following TBI. Here we examined the relation between CC microstructure and function in pediatric TBI. We used high angular resolution diffusion-weighted imaging (DWI) to evaluate the structural integrity of the CC in humans following brain injury in a sample of 32 children (23 males and 9 females) with moderate-to-severe TBI (msTBI) at 1-5 months postinjury, compared with well matched healthy control children. We assessed CC function through interhemispheric transfer time (IHTT) as measured using event-related potentials (ERPs), and related this to DWI measures of WM integrity. Finally, the relation between DWI and IHTT results was supported by additional results of neurocognitive performance assessed using a single composite performance scale. Half of the msTBI participants (16 participants) had significantly slower IHTTs than the control group. This slow IHTT group demonstrated lower CC integrity (lower fractional anisotropy and higher mean diffusivity) and poorer neurocognitive functioning than both the control group and the msTBI group with normal IHTTs. Lower fractional anisotropy-a common sign of impaired WM-and slower IHTTs also predicted poor neurocognitive function. This study reveals that there is a subset of pediatric msTBI patients during the post-acute phase of injury who have markedly impaired CC functioning and structural integrity that is associated with poor neurocognitive functioning.	[Dennis, Emily L.; Jin, Yan; Thompson, Paul M.] Univ So Calif, Keck Sch Med, Mary & Mark Stevens Inst Neuroimaging & Informat, Imaging Genet Ctr, Marina Del Rey, CA 90292 USA; [Ellis, Monica U.; Moran, Lisa; Olsen, Alexander; Kernan, Claudia; Babikian, Talin; Asarnow, Robert F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; [Ellis, Monica U.; Marion, Sarah D.] Fuller Theol Seminary, Sch Psychol, Pasadena, CA 91101 USA; [Olsen, Alexander] Norwegian Univ Sci & Technol, Dept Psychol, NO-7491 Trondheim, Norway; [Olsen, Alexander] Univ Trondheim Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, NO-7030 Trondheim, Norway; [Mink, Richard] Harbor UCLA Med Ctr, Torrance, CA 90502 USA; [Mink, Richard] Los Angeles BioMed Res Inst, Dept Pediat, Torrance, CA 90502 USA; [Babbitt, Christopher] Miller Childrens Hosp, Long Beach, CA 90806 USA; [Johnson, Jeffrey] LAC USC Med Ctr, Dept Pediat, Los Angeles, CA 90033 USA; [Giza, Christopher C.] Univ Calif Los Angeles, Brain Injury Res Ctr, Dept Neurosurg, Los Angeles, CA 90095 USA; [Giza, Christopher C.] Mattel Childrens Hosp, Div Pediat Neurol, Los Angeles, CA 90095 USA; [Thompson, Paul M.] Univ So Calif, Dept Neurol, Los Angeles, CA 90033 USA; [Thompson, Paul M.] Univ So Calif, Dept Pediat, Los Angeles, CA 90033 USA; [Thompson, Paul M.] Univ So Calif, Dept Psychiat, Los Angeles, CA 90033 USA; [Thompson, Paul M.] Univ So Calif, Dept Radiol, Los Angeles, CA 90033 USA; [Thompson, Paul M.] Univ So Calif, Dept Engn, Los Angeles, CA 90033 USA; [Thompson, Paul M.] Univ So Calif, Dept Ophthalmol, Los Angeles, CA 90033 USA; [Asarnow, Robert F.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA		Thompson, PM (corresponding author), Univ So Calif, Keck Sch Med, 2001 N Soto St, Los Angeles, CA 90033 USA.	pthomp@usc.edu	Jin, Yan/N-5037-2016; Olsen, Alexander/P-5235-2019; Thompson, Paul M/C-4194-2018; Dennis, Emily/AAD-5223-2021	Jin, Yan/0000-0001-9392-5552; Olsen, Alexander/0000-0001-8691-3860; Thompson, Paul M/0000-0002-4720-8867; Dennis, Emily/0000-0001-7112-4009	Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD061504]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U54 EB020403, R01 EB008432, R01 AG040060, R01 NS080655]; UCLA Brain Injury Research Center [NS027544, NS05489]; Child Neurology Foundation; Jonathan Drown Foundation; Staglin IMHRO Center for Cognitive Neuroscience; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061504] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB008432, P41EB015922, U54EB020403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS080655, K99NS096116, R01NS027544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG040060] Funding Source: NIH RePORTER	This study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Grant R01 HD061504). E.L.D., Y.J., and P.M.T. are also supported by the National Institutes of Health Grants U54 EB020403, R01 EB008432, R01 AG040060, and R01 NS080655 to P.M.T., C.C.G. is supported by the UCLA Brain Injury Research Center (Grants NS027544 and NS05489), the Child Neurology Foundation, and the Jonathan Drown Foundation. Scanning was supported by the Staglin IMHRO Center for Cognitive Neuroscience. We thank Alma Martinez and Alma Ramirez for assisting with participant recruitment and study coordination. Finally, we thank the participants and their families for contributing their time to this study.	ANDREASSI JL, 1975, PSYCHOPHYSIOLOGY, V12, P541, DOI 10.1111/j.1469-8986.1975.tb00043.x; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Babikian T, 2010, J NEUROTRAUM, V27, P473, DOI 10.1089/neu.2009.1058; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bartzokis G, 2010, NEUROBIOL AGING, V31, P1554, DOI 10.1016/j.neurobiolaging.2008.08.015; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brown WS, 1999, NEUROPSYCHOLOGIA, V37, P1165, DOI 10.1016/S0028-3932(99)00011-1; BROWN WS, 1993, NEUROPSYCHOLOGIA, V31, P1267, DOI 10.1016/0028-3932(93)90097-J; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Caeyenberghs K, 2011, J NEUROTRAUM, V28, P897, DOI 10.1089/neu.2010.1721; Catani M, 2007, P NATL ACAD SCI USA, V104, P17163, DOI 10.1073/pnas.0702116104; DAMASIO AR, 1980, J NEUROL NEUROSUR PS, V43, P351, DOI 10.1136/jnnp.43.4.351; Delis DC., 2001, DELIS KAPLAN EXECUTI; Delis DC., 1994, CALIFORNIA VERBAL LE; Dennis EL, 2015, NEUROIMAGE-CLIN, V7, P493, DOI 10.1016/j.nicl.2015.02.002; Ellis M. U., 2015, J NEUROTRAU IN PRESS; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; GAZZANIGA MS, 1973, NEUROLOGY, V23, P1126, DOI 10.1212/WNL.23.10.1126; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Jin Y, 2011, 2011 IEEE INT S BIOM; Jin Y, 2013, 2013 IEEE 10 INT S B; Jin Y, 2014, NEUROIMAGE, V100, P75, DOI 10.1016/j.neuroimage.2014.04.048; Jin Yan, 2012, Multimodal Brain Image Anal (2012), V7509, P147, DOI 10.1007/978-3-642-33530-3_12; Klawiter EC, 2011, NEUROIMAGE, V55, P1454, DOI 10.1016/j.neuroimage.2011.01.007; Kochunov P, 2012, NEUROBIOL AGING, V33, P9, DOI 10.1016/j.neurobiolaging.2010.01.014; Larson EB, 1997, NEUROPSYCHOLOGIA, V35, P573; LASSONDE M, 1988, BEHAV BRAIN RES, V30, P165, DOI 10.1016/0166-4328(88)90146-5; LEDLOW A, 1978, ANN NEUROL, V3, P525, DOI 10.1002/ana.410030613; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; LINDENBERG R, 1955, AM J PATHOL, V31, P297; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; Nagy Z, 2004, J COGNITIVE NEUROSCI, V16, P1227, DOI 10.1162/0898929041920441; Peru A, 2003, NEUROPSYCHOLOGIA, V41, P634, DOI 10.1016/S0028-3932(02)00203-8; RUGG MD, 1985, J NEUROL NEUROSUR PS, V48, P367, DOI 10.1136/jnnp.48.4.367; SARON CD, 1989, BEHAV NEUROSCI, V103, P1115, DOI 10.1037/0735-7044.103.5.1115; SAUERWEIN H, 1983, NEUROPSYCHOLOGIA, V21, P167, DOI 10.1016/0028-3932(83)90084-2; Schulte T, 2005, CEREB CORTEX, V15, P1384, DOI 10.1093/cercor/bhi020; Shiramizu H, 2008, NEUROL MED-CHIR, V48, P1, DOI 10.2176/nmc.48.1; Slawik H, 2009, J NEUROTRAUM, V26, P1891, DOI 10.1089/neu.2009.0942; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; SUGISHITA M, 1987, NEUROPSYCHOLOGIA, V25, P329, DOI 10.1016/0028-3932(87)90022-4; Thomason ME, 2011, ANNU REV CLIN PSYCHO, V7, P63, DOI 10.1146/annurev-clinpsy-032210-104507; VUILLEUMIER P, 1995, CLIN NEUROL NEUROSUR, V97, P39, DOI 10.1016/0303-8467(94)00056-C; WAXMAN SG, 1977, ARCH NEUROL-CHICAGO, V34, P585, DOI 10.1001/archneur.1977.00500220019003; Wechsler D, 2003, WECHSLER INTELLIGENC; Westerhausen R, 2006, NEUROSCI LETT, V409, P140, DOI 10.1016/j.neulet.2006.09.028; Whitford TJ, 2011, NEUROIMAGE, V54, P2318, DOI 10.1016/j.neuroimage.2010.10.048; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Zhang YJ, 2010, NEUROIMAGE, V52, P1289, DOI 10.1016/j.neuroimage.2010.05.049	55	56	57	0	6	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 15	2015	35	28					10202	10211		10.1523/JNEUROSCI.1595-15.2015			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CN3BO	WOS:000358298500010	26180196	Green Published, Bronze			2022-02-06	
J	Hinzman, JM; DiNapoli, VA; Mahoney, EJ; Gerhardt, GA; Hartings, JA				Hinzman, Jason M.; DiNapoli, Vince A.; Mahoney, Eric J.; Gerhardt, Greg A.; Hartings, Jed A.			Spreading depolarizations mediate excitotoxicity in the development of acute cortical lesions	EXPERIMENTAL NEUROLOGY			English	Article						Spreading depression; Stroke; Middle cerebral artery occlusion	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; EXTRACELLULAR GLUTAMATE; ANOXIC DEPOLARIZATION; RAT STRIATUM; IN-VIVO; ARTERY OCCLUSION; AMINO-ACIDS; INTRACEREBRAL MICRODIALYSIS	Spreading depolarizations (SD) are mass depolarizations of neurons and astrocytes that occur spontaneously in acute brain injury and mediate time-dependent lesion growth. Glutamate excitotoxicity has also been extensively studied as a mechanism of neuronal injury, although its relevance to in vivo pathology remains unclear. Here we hypothesized that excitotoxicity in acute lesion development occurs only as a consequence of SD. Using glutamate-sensitive microelectrodes, we found that SD induced by KCl in normal rat cortex elicits increases in extracellular glutamate (11.6 +/- 1.3 mu M) that are synchronous with the onset, sustainment, and resolution of the extracellular direct-current shift of SD. Inhibition of glutamate uptake with D,L-threo-beta-benzyloxyaspartate (TBOA, 0.5 and 1 mM) significantly prolonged the duration of the direct-current shift (148% and 426%, respectively) and the glutamate increase (167% and 374%, respectively) in a dose-dependent manner (P < 0.05). These prolonged events produced significant cortical lesions as indicated by Fluoro-Jade staining (P < 0.05), while no lesions were observed after SD in control conditions or after cortical injection of 1 mM glutamate (extracellular increase: 243 +/- 50.8 mu M) or 0.5 mM TBOA (glutamate increase: 8.5 +/- 1.6 mu M) without SD. We then used an embolic focal ischemia model to determine whether glutamate elevations occur independent of SD in the natural evolution of a cortical lesion. In both the ischemic core and penumbra, glutamate increased only in synchrony with anoxic terminal SD (6.1 +/- 1.1 mu M) and transient SDs (11.8 +/- 2.4 mu M), and not otherwise. Delayed terminal SDs were also observed in two animals at 98 and 150 min after ischemic onset and induced similar glutamate elevations. Durations of SDs and glutamate increases were significantly correlated in both normal and ischemic animals (P < 0.05). These data suggest that pathologically prolonged SDs are a required mechanism of acute cortical lesion development and that glutamate elevations and the mass electrochemical changes of SD and are merely different facets of the same pathophysiologic process. (C) 2015 Elsevier Inc. All rights reserved.	[Hinzman, Jason M.; DiNapoli, Vince A.; Mahoney, Eric J.; Hartings, Jed A.] Univ Cincinnati, Dept Neurosurg, Coll Med, Cincinnati, OH 45267 USA; [Hinzman, Jason M.; DiNapoli, Vince A.; Mahoney, Eric J.; Hartings, Jed A.] UC Neurosci Inst, Neurotrauma Ctr, Cincinnati, OH 45267 USA; [DiNapoli, Vince A.; Hartings, Jed A.] Mayfield Clin, Cincinnati, OH USA; [Gerhardt, Greg A.] Univ Kentucky, Morris K Udall Parkinsons Dis Res Ctr Excellence, Ctr Microelectrode Technol,Dept Anat & Neurobiol, Spinal Cord & Brain Injury Res Ctr,Chandler Med C, Lexington, KY USA		Hinzman, JM (corresponding author), Univ Cincinnati, Dept Neurosurg, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	jmhinz2@gmail.com		Hartings, Jed/0000-0001-8583-3471	Mayfield Education and Research Foundation	This work was funded by the Mayfield Education and Research Foundation.	Aiba I, 2012, J PHYSIOL-LONDON, V590, P5877, DOI 10.1113/jphysiol.2012.234476; Back T, 1996, J CEREBR BLOOD F MET, V16, P202, DOI 10.1097/00004647-199603000-00004; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bosche B, 2010, ANN NEUROL, V67, P607, DOI 10.1002/ana.21943; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Burmeister JJ, 2002, J NEUROSCI METH, V119, P163, DOI 10.1016/S0165-0270(02)00172-3; Burmeister JJ, 2001, ANAL CHEM, V73, P1037, DOI 10.1021/ac0010429; Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; Canals S, 2008, J CEREBR BLOOD F MET, V28, P1835, DOI 10.1038/jcbfm.2008.71; CHOI DW, 1987, J NEUROSCI, V7, P369; Dijkhuizen RM, 1999, BRAIN RES, V840, P194, DOI 10.1016/S0006-8993(99)01769-2; DiNapoli VA, 2006, J NEUROSCI METH, V154, P233, DOI 10.1016/j.jneumeth.2005.12.026; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Dreier JP, 2000, J NEUROSURG, V93, P658, DOI 10.3171/jns.2000.93.4.0658; Dunwiddie TV, 2001, ANNU REV NEUROSCI, V24, P31, DOI 10.1146/annurev.neuro.24.1.31; FABRICIUS M, 1993, BRAIN RES, V612, P61, DOI 10.1016/0006-8993(93)91644-8; GILL R, 1987, J NEUROSCI, V7, P3343; GILL R, 1988, NEUROSCIENCE, V25, P847, DOI 10.1016/0306-4522(88)90040-1; GILL R, 1992, J CEREBR BLOOD F MET, V12, P371, DOI 10.1038/jcbfm.1992.54; HABLITZ JJ, 1989, DEV BRAIN RES, V46, P243, DOI 10.1016/0165-3806(89)90288-5; HANSEN AJ, 1984, AN ACAD BRAS CIENC, V56, P457; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; Hartings JA, 2003, J NEUROSCI, V23, P11602; Hartings JA, 2014, ANN NEUROL, V76, P681, DOI 10.1002/ana.24256; Hartings JA, 2013, ACTA NEUROCHIR SUPPL, V115, P131, DOI 10.1007/978-3-7091-1192-5_27; Hartings JA, 2012, LANCET NEUROL, V11, P389, DOI 10.1016/S1474-4422(12)70085-6; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; Hayashi T., 1954, KEIJO J MED, V3, P192; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HEINEMANN U, 1977, BRAIN RES, V120, P231, DOI 10.1016/0006-8993(77)90903-9; Hemandez-Caceres J., 1987, BRAIN RES, V437, P360; Hertle DN, 2012, BRAIN, V135, P2390, DOI 10.1093/brain/aws152; HILLERED L, 1989, J CEREBR BLOOD F MET, V9, P607, DOI 10.1038/jcbfm.1989.87; Hinzman JM, 2014, BRAIN, V137, P2960, DOI 10.1093/brain/awu241; Hinzman JM, 2012, J NEUROTRAUM, V29, P1197, DOI 10.1089/neu.2011.2261; Hinzman JM, 2010, J NEUROTRAUM, V27, P889, DOI 10.1089/neu.2009.1238; Iijima T, 1998, NEUROSCI RES, V32, P201, DOI 10.1016/S0168-0102(98)00090-X; IIJIMA T, 1992, J CEREBR BLOOD F MET, V12, P727, DOI 10.1038/jcbfm.1992.103; Jarvis CR, 2001, CEREB CORTEX, V11, P249, DOI 10.1093/cercor/11.3.249; Jeffcote T, 2014, NEUROCRIT CARE, V20, P21, DOI 10.1007/s12028-013-9938-7; Koroleva VI, 1996, P NATL ACAD SCI USA, V93, P3710, DOI 10.1073/pnas.93.8.3710; KRAIG RP, 1978, NEUROSCIENCE, V3, P1045, DOI 10.1016/0306-4522(78)90122-7; Kunimatsu T, 1999, BRAIN RES, V831, P273, DOI 10.1016/S0006-8993(99)01481-X; Landolt H, 1998, J CLIN NEUROSCI, V5, P193, DOI 10.1016/S0967-5868(98)90037-6; LAURITZEN M, 1992, J CEREBR BLOOD F MET, V12, P223, DOI 10.1038/jcbfm.1992.32; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Lindquist BE, 2014, J CEREBR BLOOD F MET, V34, P1779, DOI 10.1038/jcbfm.2014.146; MASSIEU L, 1995, J NEUROCHEM, V64, P2262; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Muller M, 2000, J NEUROPHYSIOL, V83, P735, DOI 10.1152/jn.2000.83.2.735; Nakamura H, 2010, BRAIN, V133, P1994, DOI 10.1093/brain/awq117; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; Nallet H, 1999, BRAIN RES, V842, P148, DOI 10.1016/S0006-8993(99)01859-4; NEDERGAARD M, 1988, BRAIN RES, V449, P395, DOI 10.1016/0006-8993(88)91062-1; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Obeidat AS, 2000, J CEREBR BLOOD F MET, V20, P412, DOI 10.1097/00004647-200002000-00024; Obrenovitch TP, 1997, BRIT J PHARMACOL, V122, P372, DOI 10.1038/sj.bjp.0701372; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Oliveira-Ferreira AI, 2010, J CEREBR BLOOD F MET, V30, P1504, DOI 10.1038/jcbfm.2010.40; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; Raiteri L, 2007, J NEUROCHEM, V103, P952, DOI 10.1111/j.1471-4159.2007.04784.x; Risher WC, 2012, GLIA, V60, P1709, DOI 10.1002/glia.22390; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; Sanchez-Porras R, 2014, NEUROPHARMACOLOGY, V84, P52, DOI 10.1016/j.neuropharm.2014.04.018; SARANTIS M, 1990, BRAIN RES, V516, P322, DOI 10.1016/0006-8993(90)90935-5; Satoh M, 1999, BRAIN RES, V822, P142, DOI 10.1016/S0006-8993(99)01141-5; Shimamoto K, 1998, MOL PHARMACOL, V53, P195, DOI 10.1124/mol.53.2.195; Somjen GG, 2001, PHYSIOL REV, V81, P1065, DOI 10.1152/physrev.2001.81.3.1065; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Sword J, 2013, BRAIN, V136, P1446, DOI 10.1093/brain/awt026; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; UEDA Y, 1992, STROKE, V23, P253, DOI 10.1161/01.STR.23.2.253; VANHARREVELD A, 1959, J NEUROCHEM, V3, P300; WAHL F, 1994, J NEUROCHEM, V63, P1003; Zhang H, 2009, J NEUROSCI METH, V179, P191, DOI 10.1016/j.jneumeth.2009.01.023; Zhou N, 2013, J CEREBR BLOOD F MET, V33, P1582, DOI 10.1038/jcbfm.2013.113	85	56	58	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAY	2015	267						243	253		10.1016/j.expneurol.2015.03.014			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CH1AZ	WOS:000353754800023	25819105				2022-02-06	
J	Webster, SJ; Van Eldik, LJ; Watterson, DM; Bachstetter, AD				Webster, Scott J.; Van Eldik, Linda J.; Watterson, D. Martin; Bachstetter, Adam D.			Closed Head Injury in an Age-Related Alzheimer Mouse Model Leads to an Altered Neuroinflammatory Response and Persistent Cognitive Impairment	JOURNAL OF NEUROSCIENCE			English	Article						amyloid plaque; astrocytes; cytokines; microglia; neuroinflammation; traumatic brain injury	TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; A-BETA DEPOSITION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ATTENUATES SYNAPTIC DYSFUNCTION; CYTOKINE UP-REGULATION; GENE-TARGETED MICE; PROINFLAMMATORY CYTOKINE; REACTIVE ASTROCYTES; INDUCED INCREASES	Epidemiological studies have associated increased risk of Alzheimer's disease (AD)-related clinical symptoms with a medical history of head injury. Currently, little is known about pathophysiology mechanisms linked to this association. Persistent neuroinflammation is one outcome observed in patients after a single head injury. Neuroinflammation is also present early in relevant brain regions during AD pathology progression. In addition, previous mechanistic studies in animal models link neuroinflammation as a contributor to neuropathology and cognitive impairment in traumatic brain injury (TBI) or AD-related models. Therefore, we explored the potential interplay of neuroinflammatory responses in TBI and AD by analysis of the temporal neuroinflammatory changes after TBI in an AD model, the APP/PS1 knock-in (KI) mouse. Discrete temporal aspects of astrocyte, cytokine, and chemokine responses in the injured KI mice were delayed compared with the injured wild-type mice, with a peak neuroinflammatory response in the injured KI mice occurring at 7 d after injury. The neuroinflammatory responses were more persistent in the injured KI mice, leading to a chronic neuroinflammation. At late time points after injury, KI mice exhibited a significant impairment in radial arm water maze performance compared with sham KI mice or injured wild-type mice. Intervention with a small-molecule experimental therapeutic (MW151) that selectively attenuates proinflammatory cytokine production yielded improved cognitive behavior outcomes, consistent with a link between neuroinflammatory responses and altered risk for AD-associated pathology changes with head injury.	[Webster, Scott J.; Van Eldik, Linda J.; Bachstetter, Adam D.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Van Eldik, Linda J.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Van Eldik, Linda J.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Watterson, D. Martin] Northwestern Univ, Dept Pharmacol, Chicago, IL 60611 USA		Watterson, DM (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 800 S Limestone, Lexington, KY 40536 USA.	adam.bachstetter@uky.edu		Bachstetter, Adam/0000-0003-4646-6757; Watterson, Daniel/0000-0001-7605-5866	National Institutes of Health/National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K99AG044445]; National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32 NS084605]; Kentucky Spinal Cord and Head Injury Research Trust [12-20A]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS084605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K99AG044445] Funding Source: NIH RePORTER	This research was supported in part by National Institutes of Health/National Institute on Aging K99AG044445 to A.D.B., National Institutes of Health/National Institute of Neurological Disorders and Stroke F32 NS084605 to S.J.W., and the Kentucky Spinal Cord and Head Injury Research Trust 12-20A to L.J.V.E. We thank Danielle Goulding and Edgardo Dimayuga for assistance with various aspects of this work.	Abner EL, 2014, DEMENT GERIATR COGN, V37, P294, DOI 10.1159/000355478; Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Alamed J, 2006, NAT PROTOC, V1, P1671, DOI 10.1038/nprot.2006.275; Allaman I, 2011, TRENDS NEUROSCI, V34, P76, DOI 10.1016/j.tins.2010.12.001; Bachstetter AD, 2015, J NEUROINFL IN PRESS; Bachstetter AD, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-146; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Bachstetter AD, 2012, J NEUROSCI, V32, P10201, DOI 10.1523/JNEUROSCI.1496-12.2012; Berard JL, 2012, GLIA, V60, P1145, DOI 10.1002/glia.22342; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Chiu IM, 2013, CELL REP, V4, P385, DOI 10.1016/j.celrep.2013.06.018; Chrzaszcz M, 2010, J NEUROTRAUM, V27, P1283, DOI 10.1089/neu.2009.1227; Clarke LE, 2013, NAT REV NEUROSCI, V14, P311, DOI 10.1038/nrn3484; Craft JM, 2006, GLIA, V53, P484, DOI 10.1002/glia.20306; Craft JM, 2004, NEUROBIOL AGING, V25, P1283, DOI 10.1016/j.neurobiolaging.2004.01.006; Craft JM, 2004, J MOL NEUROSCI, V24, P115, DOI 10.1385/JMN:24:1:115; Cui W, 2001, GLIA, V34, P272, DOI 10.1002/glia.1061; Daigo K, 2014, IMMUNOL LETT, V161, P38, DOI 10.1016/j.imlet.2014.04.012; Deacon R, 2012, JOVE-J VIS EXP, DOI 10.3791/2607; Deacon RMJ, 2006, NAT PROTOC, V1, P1117, DOI 10.1038/nprot.2006.170; Egashira Y, 2014, STROKE, V45, P2141, DOI 10.1161/STROKEAHA.114.005307; Faul M, 2010, TRAUMATIC BRAIN INJU; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Flood DG, 2002, NEUROBIOL AGING, V23, P335, DOI 10.1016/S0197-4580(01)00330-X; Furman JL, 2012, J NEUROSCI, V32, P16129, DOI 10.1523/JNEUROSCI.2323-12.2012; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gouras GK, 2010, ACTA NEUROPATHOL, V119, P523, DOI 10.1007/s00401-010-0679-9; Halassa MM, 2010, ANNU REV PHYSIOL, V72, P335, DOI 10.1146/annurev-physiol-021909-135843; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Hu WH, 2007, BIOORG MED CHEM LETT, V17, P414, DOI 10.1016/j.bmcl.2006.10.028; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jenrow KA, 2013, RADIAT RES, V179, P549, DOI 10.1667/RR3026.1; Jin M, 2014, J CEREBR BLOOD F MET, V34, P1306, DOI 10.1038/jcbfm.2014.83; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Karpus WJ, 2008, J NEUROIMMUNOL, V203, P73, DOI 10.1016/j.jneuroim.2008.06.039; KIMELBERG HK, 1995, J CEREBR BLOOD F MET, V15, P409, DOI 10.1038/jcbfm.1995.51; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Laskowitz DT, 2010, J NEUROTRAUM, V27, P1983, DOI 10.1089/neu.2010.1396; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Macauley SL, 2014, J NEUROSCI, V34, P13077, DOI 10.1523/JNEUROSCI.2518-14.2014; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Mosher KI, 2014, BIOCHEM PHARMACOL, V88, P594, DOI 10.1016/j.bcp.2014.01.008; Murphy MP, 2007, NEUROBIOL DIS, V27, P301, DOI 10.1016/j.nbd.2007.06.002; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; Norden DM, 2015, NEUROPHARMACOLOGY, V96, P29, DOI 10.1016/j.neuropharm.2014.10.028; Obara M, 2008, NEUROCHEM INT, V52, P905, DOI 10.1016/j.neuint.2007.10.015; Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rathore KI, 2011, J NEUROSCI, V31, P13412, DOI 10.1523/JNEUROSCI.0116-11.2011; Reaume AG, 1996, J BIOL CHEM, V271, P23380, DOI 10.1074/jbc.271.38.23380; Reyes RC, 2012, ASN NEURO, V4, P33, DOI 10.1042/AN20110059; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rodriguez-Grande B, 2014, J CEREBR BLOOD F MET, V34, P480, DOI 10.1038/jcbfm.2013.224; Sama DM, 2013, AGEING RES REV, V12, P982, DOI 10.1016/j.arr.2013.05.008; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Schousboe A, 2004, NEUROCHEM INT, V45, P521, DOI 10.1016/j.neuint.2003.11.001; Schwetye KE, 2010, NEUROBIOL DIS, V40, P555, DOI 10.1016/j.nbd.2010.06.018; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Siman R, 2000, J NEUROSCI, V20, P8717; Simard M, 2004, NEUROSCIENCE, V129, P877, DOI 10.1016/j.neuroscience.2004.09.053; Sofroniew MV, 2014, NEUROSCIENTIST, V20, P160, DOI 10.1177/1073858413504466; Somera-Molina KC, 2007, EPILEPSIA, V48, P1785, DOI 10.1111/j.1528-1167.2007.01135.x; Somera-Molina KC, 2009, BRAIN RES, V1282, P162, DOI 10.1016/j.brainres.2009.05.073; Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078851; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Ubogu EE, 2006, TRENDS PHARMACOL SCI, V27, P48, DOI 10.1016/j.tips.2005.11.002; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Van Eldik LJ, 2007, INT REV NEUROBIOL, V82, P277, DOI 10.1016/S0074-7742(07)82015-0; Viola A, 2008, ANNU REV PHARMACOL, V48, P171, DOI 10.1146/annurev.pharmtox.48.121806.154841; Washington PM, 2014, J NEUROTRAUM, V31, P125, DOI 10.1089/neu.2013.3017; Webster SJ, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt182; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wyss-Coray T, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006346; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhang C, 2007, EXP NEUROL, V204, P77, DOI 10.1016/j.expneurol.2006.09.018	90	56	56	1	10	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	APR 22	2015	35	16					6554	6569		10.1523/JNEUROSCI.0291-15.2015			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CG6HL	WOS:000353399800027	25904805	Bronze, Green Published			2022-02-06	
J	Katz, PS; Sulzer, JK; Impastato, RA; Teng, SX; Rogers, EK; Molina, PE				Katz, Paige S.; Sulzer, Jesse K.; Impastato, Renata A.; Teng, Sophie X.; Rogers, Emily K.; Molina, Patricia E.			Endocannabinoid Degradation Inhibition Improves Neurobehavioral Function, Blood-Brain Barrier Integrity, and Neuroinflammation following Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						TBI; neuroinflammation; endocannabinoids; AEA; 2-AG	CLOSED-HEAD INJURY; FLUID-PERCUSSION MODEL; THERAPEUTIC IMPLICATIONS; CLINICAL-TRIAL; MOUSE MODEL; RAT MODEL; NEUROPROTECTION; CANNABINOIDS; CYCLOOXYGENASE-2; PATHOPHYSIOLOGY	Traumatic brain injury (TBI) is an increasingly frequent and poorly understood condition lacking effective therapeutic strategies. Inflammation and oxidative stress (OS) are critical components of injury, and targeted interventions to reduce their contribution to injury should improve neurobehavioral recovery and outcomes. Recent evidence reveals potential protective, yet short-lived, effects of the endocannabinoids (ECs), 2-arachidonoyl glycerol (2-AG) and N-arachidonoyl-ethanolamine (AEA), on neuroinflammatory and OS processes after TBI. The aim of this study was to determine whether EC degradation inhibition after TBI would improve neurobehavioral recovery by reducing inflammatory and oxidative damage. Adult male Sprague-Dawley rats underwent a 5-mm left lateral craniotomy, and TBI was induced by lateral fluid percussion. TBI produced apnea (17 +/- 5 sec) and a delayed righting reflex (479 +/- 21 sec). Thirty minutes post-TBI, rats were randomized to receive intraperitoneal injections of vehicle (alcohol, emulphor, and saline; 1:1:18) or a selective inhibitor of 2-AG (JZL184, 16 mg/kg) or AEA (URB597, 0.3 mg/kg) degradation. At 24 h post-TBI, animals showed significant neurological and -behavioral impairment as well as disruption of blood-brain barrier (BBB) integrity. Improved neurological and -behavioral function was observed in JZL184-treated animals. BBB integrity was protected in both JZL184- and URB597-treated animals. No significant differences in ipsilateral cortex messenger RNA expression of interleukin (IL)-1 beta, IL-6, chemokine (C-C motif) ligand 2, tumor necrosis factor alpha, cyclooxygenase 2 (COX2), or nicotinamide adenine dinucleotide phosphate oxidase (NOX2) and protein expression of COX2 or NOX2 were observed across experimental groups. Astrocyte and microglia activation was significantly increased post-TBI, and treatment with JZL184 or URB597 blocked activation of both cell types. These findings suggest that EC degradation inhibition post-TBI exerts neuroprotective effects. Whether repeated dosing would achieve greater protection remains to be examined.	[Katz, Paige S.; Sulzer, Jesse K.; Impastato, Renata A.; Teng, Sophie X.; Rogers, Emily K.; Molina, Patricia E.] Louisiana State Univ, Hlth Sci Ctr, Alcohol & Drug Abuse Ctr Excellence, Dept Physiol, New Orleans, LA 70112 USA		Molina, PE (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Alcohol & Drug Abuse Ctr Excellence, Dept Physiol, 1901 Perdido St,Room 7205, New Orleans, LA 70112 USA.	pmolin@lsuhsc.edu	Molina, Patricia E./AAK-9814-2021	Molina, Patricia E./0000-0002-3598-384X	Department of DefenseUnited States Department of Defense [DOD-W81XWH-11-2-0011]; National Institute on Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [NIAAA-007577, NIAAA-19587]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [F30AA019587, T32AA007577] Funding Source: NIH RePORTER	The authors thank Drs. Nicole LeCapitaine and Robert Siggins for their scientific guidance, Jane Schexnayder for her technical assistance, as well as Rebecca Gonzales for her editorial support. This work was supported by the Department of Defense (DOD-W81XWH-11-2-0011) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA-007577 and NIAAA-19587).	Biegon A, 2004, CURR PHARM DESIGN, V10, P2177, DOI 10.2174/1381612043384196; Boyko M, 2011, BEHAV BRAIN RES, V223, P17, DOI 10.1016/j.bbr.2011.03.019; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Correa F, 2005, MINI-REV MED CHEM, V5, P671, DOI 10.2174/1389557054368790; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; de Jonge HJM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000898; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Downer EJ, 2011, THESCIENTIFICWORLDJO, V11, P855, DOI 10.1100/tsw.2011.84; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Euser AG, 2008, EXP PHYSIOL, V93, P254, DOI 10.1113/expphysiol.2007.039966; Faul M, 2010, TRAUMATIC BRAIN INJU; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Hwang J, 2010, LIFE SCI, V86, P615, DOI 10.1016/j.lfs.2009.06.003; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Knoller N, 2002, CRIT CARE MED, V30, P548, DOI 10.1097/00003246-200203000-00009; Kozak KR, 2000, J BIOL CHEM, V275, P33744, DOI 10.1074/jbc.M007088200; Kozak KR, 2004, CURR PHARM DESIGN, V10, P659, DOI 10.2174/1381612043453081; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Ling G.S., 2004, CURR PROTOC NEUROSCI, V9, pUnit; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Mackie K, 2006, AAPS J, V8, pE298, DOI 10.1007/BF02854900; Mauler F, 2003, CNS DRUG REV, V9, P343; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mechoulam R, 2002, TRENDS MOL MED, V8, P58, DOI 10.1016/S1471-4914(02)02276-1; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; Nagayama T, 1999, J NEUROSCI, V19, P2987; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pitkanen A., 2005, DRUG DISCOV TODAY DI, V2, P409, DOI DOI 10.1016/J.DDMEC.2005.11.011; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Riggio S, 2011, NEUROL CLIN, V29, P35, DOI 10.1016/j.ncl.2010.10.008; Savinainen JR, 2001, BRIT J PHARMACOL, V134, P664, DOI 10.1038/sj.bjp.0704297; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shohami E, 2011, BRIT J PHARMACOL, V163, P1402, DOI 10.1111/j.1476-5381.2011.01343.x; Stella N, 2010, GLIA, V58, P1017, DOI 10.1002/glia.20983; Stella N, 2009, NEUROPHARMACOLOGY, V56, P244, DOI 10.1016/j.neuropharm.2008.07.037; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Tchantchou F, 2013, J NEUROTRAUM, V30, P565, DOI 10.1089/neu.2012.2647; Teng SX, 2014, J NEUROTRAUM, V31, P378, DOI 10.1089/neu.2013.3093; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Wang ZY, 2013, FREE RADICAL BIO MED, V65, P942, DOI 10.1016/j.freeradbiomed.2013.08.166; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weiss JM, 1998, J IMMUNOL, V161, P6896; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wilson RI, 2002, SCIENCE, V296, P678, DOI 10.1126/science.1063545; Xu QW, 2001, INVEST OPHTH VIS SCI, V42, P789; Yu M, 1997, J BIOL CHEM, V272, P21181, DOI 10.1074/jbc.272.34.21181	63	56	56	3	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2015	32	5					297	306		10.1089/neu.2014.3508			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CC0SD	WOS:000350045700002	25166905	Green Published			2022-02-06	
J	Robinson, ME; Lindemer, ER; Fonda, JR; Milberg, WP; McGlinchey, RE; Salat, DH				Robinson, Meghan E.; Lindemer, Emily R.; Fonda, Jennifer R.; Milberg, William P.; McGlinchey, Regina E.; Salat, David H.			Close-Range Blast Exposure is Associated With Altered Functional Connectivity in Veterans Independent of Concussion Symptoms at Time of Exposure	HUMAN BRAIN MAPPING			English	Article						fMRI; Veterans; blast injuries; traumatic brain injury; mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; INDUCED NEUROTRAUMA; MILITARY PERSONNEL; MOTOR CORTEX; IMPACT; AFGHANISTAN; NETWORKS; PAIN; IRAQ	Although there is emerging data on the effects of blast-related concussion (or mTBI) on cognition, the effects of blast exposure itself on the brain have only recently been explored. Toward this end, we examine functional connectivity to the posterior cingulate cortex, a primary region within the default mode network (DMN), in a cohort of 134 Iraq and Afghanistan Veterans characterized for a range of common military-associated comorbidities. Exposure to a blast at close range (<10 meters) was associated with decreased connectivity of bilateral primary somatosensory and motor cortices, and these changes were not different from those seen in participants with blast-related mTBI. These results remained significant when clinical factors such as sleep quality, chronic pain, or post traumatic stress disorder were included in the statistical model. In contrast, differences in functional connectivity based on concussion history and blast exposures at greater distances were not apparent. Despite the limitations of a study of this nature (e.g., assessments long removed from injury, self-reported blast history), these data demonstrate that blast exposure per se, which is prevalent among those who served in Iraq and Afghanistan, may be an important consideration in Veterans' health. It further offers a clinical guideline for determining which blasts (namely, those within 10 meters) are likely to lead to long-term health concerns and may be more accurate than using concussion symptoms alone. Hum Brain Mapp 36:911-922, 2015.Published 2014. This article is a U.S. Government work and is in the public domain in the USA.	[Robinson, Meghan E.; Lindemer, Emily R.; Salat, David H.] VA Boston Healthcare Syst, Neuroimaging Res Vet Ctr NeRVe, Boston, MA 02130 USA; [Robinson, Meghan E.; Lindemer, Emily R.; Fonda, Jennifer R.; Milberg, William P.; McGlinchey, Regina E.; Salat, David H.] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders TRACTS, Boston, MA 02130 USA; [Milberg, William P.; McGlinchey, Regina E.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Milberg, William P.; McGlinchey, Regina E.] VA Boston Healthcare Syst, GRECC, Boston, MA 02130 USA; [Salat, David H.] AA Martinos Ctr Biomed Imaging, Charlestown, MA USA		Robinson, ME (corresponding author), VA Boston Healthcare Syst, TRACTS 182, 150 S Huntington Ave, Boston, MA 02130 USA.	meghan.robinson@va.gov	McGlinchey, Regina E/R-1971-2016; Fonda, Jennifer R./ABG-2890-2021	Fonda, Jennifer R./0000-0001-9482-2918	Translational Research Center for TBI and Stress Disorders (TRACTS) VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B9254-C]	Contract grant sponsor: Translational Research Center for TBI and Stress Disorders (TRACTS) VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence; Contract grant number: B9254-C (R.E.M. and W.P.M).	Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Blake D, 2006, J TRAUMA STRESS, V8, P75; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chai XQJ, 2012, NEUROIMAGE, V59, P1420, DOI 10.1016/j.neuroimage.2011.08.048; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Department of Defense (DoD), 2012, DEM PROF MIL COMM; First M.B., 1996, STRUCTURED CLIN INTE; Fischer BL, 2014, J NEUROTRAUM, V31, P169, DOI 10.1089/neu.2013.2877; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fortier CB, 2014, J HEAD TRAUMA REHAB, V29, P89, DOI 10.1097/HTR.0b013e3182865859; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holdnack H.A., 2001, WECHSLER TEST ADULT; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Keller CJ, 2013, J NEUROSCI, V33, P6333, DOI 10.1523/JNEUROSCI.4837-12.2013; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Lee MH, 2013, AM J NEURORADIOL, V34, P1866, DOI 10.3174/ajnr.A3263; Lindemer ER, 2013, NEUROIMAGE-CLIN, V2, P601, DOI 10.1016/j.nicl.2013.04.009; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Otis JD, 2011, J CLIN PSYCHOL MED S, V18, P145, DOI 10.1007/s10880-011-9239-2; RAND, 2008, INVISIBLE WOUNDS WAR; Saljo A, 2002, J NEUROTRAUM, V19, P985, DOI 10.1089/089771502320317131; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shehzad Z, 2009, CEREB CORTEX, V19, P2209, DOI 10.1093/cercor/bhn256; Sripada RK, 2012, PSYCHOSOM MED, V74, P904, DOI 10.1097/PSY.0b013e318273bf33; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Tompkins P, 2013, J NEUROTRAUM, V30, P1888, DOI 10.1089/neu.2012.2674; Van Dijk KRA, 2010, J NEUROPHYSIOL, V103, P297, DOI 10.1152/jn.00783.2009; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4	53	56	56	0	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	MAR	2015	36	3					911	922		10.1002/hbm.22675			12	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CB4QI	WOS:000349612500008	25366378	Green Published			2022-02-06	
J	Wu, CH; Hung, TH; Chen, CC; Ke, CH; Lee, CY; Wang, PY; Chen, SF				Wu, Chun-Hu; Hung, Tai-Ho; Chen, Chien-Cheng; Ke, Chia-Hua; Lee, Chun-Yen; Wang, Pei-Yi; Chen, Szu-Fu			Post-Injury Treatment with 7,8-Dihydroxyflavone, a TrkB Receptor Agonist, Protects against Experimental Traumatic Brain Injury via PI3K/Akt Signaling	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; NEUROTROPHIC FACTOR; CEREBRAL-ISCHEMIA; NEURONAL INJURY; MOTOR FUNCTION; BLOOD-BRAIN; MOUSE MODEL; BDNF; PATHWAYS; KINASE	Tropomyosin-related kinase B (TrkB) signaling is critical for promoting neuronal survival following brain damage. The present study investigated the effects and underlying mechanisms of TrkB activation by the TrkB agonist 7,8-dihydroxyflavone (7,8-DHF) on traumatic brain injury (TBI). Mice subjected to controlled cortical impact received intraperitoneal 7,8-DHF or vehicle injection 10 min post-injury and subsequently daily for 3 days. Behavioral studies, histology analysis and brain water content assessment were performed. Levels of TrkB signaling-related molecules and apoptosis-related proteins were analyzed. The protective effect of 7,8-DHF was also investigated in primary neurons subjected to stretch injury. Treatment with 20 mg/kg 7,8-DHF attenuated functional deficits and brain damage up to post-injury day 28. 7,8-DHF also reduced brain edema, neuronal death, and apoptosis at day 4. These changes were accompanied by a significant decrease in cleaved caspase-3 and increase in Bcl-2/Bax ratio. 7,8-DHF enhanced phosphorylation of TrkB, Akt (Ser473/Thr308), and Bad at day 4, but had no effect on Erk 1/2 phosphorylation. Moreover, 7,8-DHF increased brain-derived neurotrophic factor levels and promoted cAMP response element-binding protein (CREB) activation. This beneficial effect was attenuated by inhibition of TrkB or PI3K/Akt. 7,8-DHF also promoted survival and reduced apoptosis in cortical neurons subjected to stretch injury. Remarkably, delayed administration of 7,8-DHF at 3 h post-injury reduced brain tissue damage. Our study demonstrates that activation of TrkB signaling by 7,8-DHF protects against TBI via the PI3K/Akt but not Erk pathway, and this protective effect may be amplified via the PI3K/Akt-CREB cascades.	[Wu, Chun-Hu; Ke, Chia-Hua; Chen, Szu-Fu] Natl Def Med Ctr, Dept Physiol, Taipei, Taiwan; [Wu, Chun-Hu; Ke, Chia-Hua; Chen, Szu-Fu] Natl Def Med Ctr, Dept Biophys, Taipei, Taiwan; [Wu, Chun-Hu] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; [Hung, Tai-Ho] Chang Gung Mem Hosp, Dept Obstet & Gynecol, Taipei 10591, Taiwan; [Hung, Tai-Ho] Chang Gung Univ, Coll Med, Taipei, Taiwan; [Chen, Chien-Cheng; Ke, Chia-Hua; Lee, Chun-Yen; Wang, Pei-Yi; Chen, Szu-Fu] Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan		Chen, SF (corresponding author), Natl Def Med Ctr, Dept Physiol, Taipei, Taiwan.	szufuchen@yahoo.com.tw	Hung, Tai-Ho/C-7584-2011; Hung, Tai-Ho/ABD-1800-2020; WU, CHUN-HU/P-3958-2018	WU, CHUN-HU/0000-0001-6851-7936; Hung, Tai-Ho/0000-0003-2354-7060	National Science Council of Taiwan, R.O.C.Ministry of Science and Technology, Taiwan [NSC 101-2314-B-350-001-MY3]; Cheng Hsin General Hospital	Funding provided by the National Science Council of Taiwan, R.O.C.(NSC 101-2314-B-350-001-MY3) and the Cheng Hsin General Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.0741951.x; Granado-Serrano AB, 2006, J NUTR, V136, P2715, DOI 10.1093/jn/136.11.2715; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Castello NA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091453; Chang CF, 2011, AM J PATHOL, V178, P1749, DOI 10.1016/j.ajpath.2010.12.023; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen J, 2011, NEUROSCI LETT, V499, P181, DOI 10.1016/j.neulet.2011.05.054; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045763; Chu CT, 2004, EUR J BIOCHEM, V271, P2060, DOI 10.1111/j.1432-1033.2004.04132.x; Devi L, 2012, NEUROPSYCHOPHARMACOL, V37, P434, DOI 10.1038/npp.2011.191; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; GOLDSTEIN LB, 1990, J NEUROSCI METH, V31, P101, DOI 10.1016/0165-0270(90)90154-8; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Han XH, 2014, NEUROCHEM INT, V64, P18, DOI 10.1016/j.neuint.2013.10.018; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; Hu BR, 2004, J CEREBR BLOOD F MET, V24, P934, DOI 10.1097/01.WCB.0000125888.56462.A1; Hung PL, 2013, STROKE, V44, P2275, DOI 10.1161/STROKEAHA.113.001552; Jang SW, 2010, P NATL ACAD SCI USA, V107, P2687, DOI 10.1073/pnas.0913572107; Jeon SJ, 2011, NEUROSCI RES, V69, P214, DOI 10.1016/j.neures.2010.11.008; Jiang ML, 2013, HUM MOL GENET, V22, P2462, DOI 10.1093/hmg/ddt098; Jiang SN, 2013, MOL THER, V21, P1985, DOI 10.1038/mt.2013.183; Kim DH, 2004, J NEUROSURG, V100, P79, DOI 10.3171/jns.2004.100.1.0079; Kong ANT, 2000, ARCH PHARM RES, V23, P1, DOI 10.1007/BF02976458; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Massa SM, 2010, J CLIN INVEST, V120, P1774, DOI 10.1172/JCI41356; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Numakawa T, 2010, HISTOL HISTOPATHOL, V25, P237, DOI 10.14670/HH-25.237; Park HY, 2012, INT J MOL MED, V29, P1146, DOI 10.3892/ijmm.2012.935; Park J, 2012, J CEREBR BLOOD F MET, V32, P330, DOI 10.1038/jcbfm.2011.131; Poduslo JF, 1996, MOL BRAIN RES, V36, P280, DOI 10.1016/0169-328X(95)00250-V; Rostami E, 2014, BRAIN RES, V1542, P195, DOI 10.1016/j.brainres.2013.10.047; Sommerfeld MT, 2000, J BIOL CHEM, V275, P8982, DOI 10.1074/jbc.275.12.8982; Swart C, 2014, EXP GERONTOL, V58, P279, DOI 10.1016/j.exger.2014.09.003; Thoenen H, 2002, NAT NEUROSCI, V5, P1046, DOI 10.1038/nn938; Tsai T, 2013, MOL CELL NEUROSCI; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Wagner AK, 2011, J CEREBR BLOOD F MET, V31, P1886, DOI 10.1038/jcbfm.2011.31; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Wang B, 2014, J MOL HISTOL, V45, P129, DOI 10.1007/s10735-013-9539-y; Wiese S, 1999, EUR J NEUROSCI, V11, P1668, DOI 10.1046/j.1460-9568.1999.00585.x; Xie LF, 2010, CARDIOVASC RES, V87, P628, DOI 10.1093/cvr/cvq138; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhang Y, 2006, BRAIN RES, V1111, P227, DOI 10.1016/j.brainres.2006.07.005	49	56	59	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2014	9	11							e113397	10.1371/journal.pone.0113397			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX4MM	WOS:000346906600045	25415296	Green Published, gold, Green Submitted			2022-02-06	
J	Donega, V; Nijboer, CH; Braccioli, L; Slaper-Cortenbach, I; Kavelaars, A; van Bel, F; Heijnen, CJ				Donega, Vanessa; Nijboer, Cora H.; Braccioli, Luca; Slaper-Cortenbach, Ineke; Kavelaars, Annemieke; van Bel, Frank; Heijnen, Cobi J.			Intranasal Administration of Human MSC for Ischemic Brain Injury in the Mouse: In Vitro and In Vivo Neuroregenerative Functions	PLOS ONE			English	Article							MESENCHYMAL STEM-CELLS; THERAPY POSITION STATEMENT; STROMAL CELLS; NEONATAL ENCEPHALOPATHY; INTERNATIONAL-SOCIETY; HYPOXIA-ISCHEMIA; TRANSPLANTATION; NEUROGENESIS; CYTOKINES; FATE	Intranasal treatment with C57BL/6 MSCs reduces lesion volume and improves motor and cognitive behavior in the neonatal hypoxic-ischemic (HI) mouse model. In this study, we investigated the potential of human MSCs (hMSCs) to treat HI brain injury in the neonatal mouse. Assessing the regenerative capacity of hMSCs is crucial for translation of our knowledge to the clinic. We determined the neuroregenerative potential of hMSCs in vitro and in vivo by intranasal administration 10 d post-HI in neonatal mice. HI was induced in P9 mouse pups. 1 x 10(6) or 2 x 10(6) hMSCs were administered intranasally 10 d post-HI. Motor behavior and lesion volume were measured 28 d post-HI. The in vitro capacity of hMSCs to induce differentiation of mouse neural stem cell (mNSC) was determined using a transwell co-culture differentiation assay. To determine which chemotactic factors may play a role in mediating migration of MSCs to the lesion, we performed a PCR array on 84 chemotactic factors 10 days following sham-operation, and at 10 and 17 days post-HI. Our results show that 2610 6 hMSCs decrease lesion volume, improve motor behavior, and reduce scar formation and microglia activity. Moreover, we demonstrate that the differentiation assay reflects the neuroregenerative potential of hMSCs in vivo, as hMSCs induce mNSCs to differentiate into neurons in vitro. We also provide evidence that the chemotactic factor CXCL10 may play an important role in hMSC migration to the lesion site. This is suggested by our finding that CXCL10 is significantly upregulated at 10 days following HI, but not at 17 days after HI, a time when MSCs no longer reach the lesion when given intranasally. The results described in this work also tempt us to contemplate hMSCs not only as a potential treatment option for neonatal encephalopathy, but also for a plethora of degenerative and traumatic injuries of the nervous system.	[Donega, Vanessa; Nijboer, Cora H.; Braccioli, Luca; Heijnen, Cobi J.] Univ Med Ctr Utrecht, Lab Neuroimmunol & Dev Origins Dis, Utrecht, Netherlands; [Slaper-Cortenbach, Ineke] Univ Med Ctr Utrecht, Cell Therapy Facil, Dept Clin Pharm, Utrecht, Netherlands; [Kavelaars, Annemieke; Heijnen, Cobi J.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA; [van Bel, Frank] Univ Med Ctr Utrecht, Dept Neonatol, Utrecht, Netherlands		Heijnen, CJ (corresponding author), Univ Med Ctr Utrecht, Lab Neuroimmunol & Dev Origins Dis, Utrecht, Netherlands.	CJHeijnen@mdanderson.org	Donega, Vanessa/M-8058-2014; Braccioli, Luca/P-8142-2019	Donega, Vanessa/0000-0002-3152-2675	Zon-MW Project [116002003]	This study was supported by Zon-MW Project (no 116002003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Borlongan CV, 2011, PEDIATR RES, V70, P3, DOI 10.1203/PDR.0b013e31821d0d00; Croft AP, 2009, EXP NEUROL, V216, P329, DOI 10.1016/j.expneurol.2008.12.010; Dammann O, 2011, PEDIATR RES, V70, P1, DOI 10.1203/01.pdr.0000403893.61640.b6; de Haan M, 2006, DEVELOPMENTAL SCI, V9, P350, DOI 10.1111/j.1467-7687.2006.00499.x; Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301-472X(00)00482-3; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Donega V, 2014, EXP NEUROL, V261, P53, DOI 10.1016/j.expneurol.2014.06.009; Donega V, 2013, J CEREBR BLOOD F MET, V33, P625, DOI 10.1038/jcbfm.2013.3; Donega V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051253; Ferriero DM, 2004, NEW ENGL J MED, V351, P1985, DOI 10.1056/NEJMra041996; Gonzalo-Daganzo R, 2009, CYTOTHERAPY, V11, P278, DOI 10.1080/14653240902807018; Graham EM, 2008, AM J OBSTET GYNECOL, V199, P587, DOI 10.1016/j.ajog.2008.06.094; Hack MA, 2005, NAT NEUROSCI, V8, P865, DOI 10.1038/nn1479; Hack MA, 2004, MOL CELL NEUROSCI, V25, P664, DOI 10.1016/j.mcn.2003.12.012; Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Lee JA, 2010, PEDIATR RES, V67, P42, DOI 10.1203/PDR.0b013e3181bf594b; Liu H, 2006, BRAIN, V129, P2734, DOI 10.1093/brain/awl207; Prins HJ, 2009, TISSUE ENG PT A, V15, P3741, DOI [10.1089/ten.tea.2008.0666, 10.1089/ten.TEA.2008.0666]; RANSOHOFF RM, 1993, FASEB J, V7, P592, DOI 10.1096/fasebj.7.6.8472896; Reglero-Real N, 2012, CELL MOL LIFE SCI, V69, P3079, DOI 10.1007/s00018-012-0987-4; Salem HK, 2010, STEM CELLS, V28, P585, DOI 10.1002/stem.269; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sofroniew MV, 2014, NEUROSCIENTIST, V20, P160, DOI 10.1177/1073858413504466; Titomanlio L, 2011, ANN NEUROL, V70, P698, DOI 10.1002/ana.22518; Toyama K, 2009, EXP NEUROL, V216, P47, DOI 10.1016/j.expneurol.2008.11.010; Tse WT, 2003, TRANSPLANTATION, V75, P389, DOI 10.1097/01.TP.0000045055.63901.A9; Ubogu EE, 2006, TRENDS PHARMACOL SCI, V27, P48, DOI 10.1016/j.tips.2005.11.002; van Handel M, 2007, EUR J PEDIATR, V166, P645, DOI 10.1007/s00431-007-0437-8; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; van Velthoven CTJ, 2014, MOL THER, V22, P645, DOI 10.1038/mt.2013.260; van Velthoven CTJ, 2012, ANN NEUROL, V71, P785, DOI 10.1002/ana.23543; van Velthoven CTJ, 2010, J NEUROSCI, V30, P9603, DOI 10.1523/JNEUROSCI.1835-10.2010; Velthoven C, 2011, BRAIN BEHAV IMMUN, V25, P1342; Wake H, 2013, TRENDS NEUROSCI, V36, P209, DOI 10.1016/j.tins.2012.11.007; Wang CC, 2008, CARDIOVASC RES, V77, P515, DOI 10.1093/cvr/cvm046; Yang B, 2012, STEM CELLS DEV, V21, P3332, DOI 10.1089/scd.2012.0037; Yasuhara T, 2008, J CEREBR BLOOD F MET, V28, P1804, DOI 10.1038/jcbfm.2008.68; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	40	56	58	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2014	9	11							e112339	10.1371/journal.pone.0112339			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AU4DF	WOS:000345558500047	25396420	Green Submitted, Green Published, gold			2022-02-06	
J	Gatson, JW; Barillas, J; Hynan, LS; Diaz-Arrastia, R; Wolf, SE; Minei, JP				Gatson, Joshua W.; Barillas, Jennifer; Hynan, Linda S.; Diaz-Arrastia, Ramon; Wolf, Steven E.; Minei, Joseph P.			Detection of neurofilament-H in serum as a diagnostic tool to predict injury severity in patients who have suffered mild traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						mild traumatic brain injury; neurofilament-H; serum	MINOR HEAD-INJURY; CEREBRAL CONCUSSION; CEREBROSPINAL-FLUID; AXONAL INJURY; PROTEIN; ACCUMULATION; APOPTOSIS; FOOTBALL; DAMAGE; S100B	Object. In previous studies of traumatic brain injury (TBI), neural biomarkers of injury correlate with injury severity and predict neurological outcome. The object of this paper was to characterize neurofilament-H (NFL-H) as a predictor of injury severity in patients who have suffered mild TBI (mTBI). Thus, the authors hypothesized that phosphorylated NFL-H (pNFL-H) levels are higher in mTBI patients than in healthy controls and identify which subjects experienced a more severe injury such as skull fractures, intracranial hemorrhaging, and/or contusions as detected by CT scans. Methods. In this prospective clinical study, blood (8 ml) was collected from subjects (n = 34) suffering from mTBI (as defined by the American Congress of Rehabilitation and Glasgow Coma Scale scores between 13 and 15) at Parkland Hospital, Dallas, Texas, on Days 1 and 3 after injury). Additional clinical findings from the CT scans were also used to categorize the TBI patients into those with and those without clinical findings on the scans (CT+ and CT groups, respectively). The serum levels of pNFL-H were measured using the enzyme-linked immunosorbent assay. Results. Compared with healthy controls, the mTBI patients exhibited a significant increase in the serum levels of pNFL-H on Days 1 (p = 0.00001) and 3 (p = 0.0001) after TBI. An inverse correlation was observed between pNFL-H serum levels and Glasgow Coma Scale scores, which was significant. Additionally, using receiver operating characteristic curve analysis to compare the mTBI cases with controls to determine sensitivity and specificity, an area under the curve of 100% was achieved for both (p = 0.0001 for both). pNFL-H serum levels were only significantly higher on Day 1 in mTBI patients in the CT+ group (p < 0.008) compared with the CT- group. The area under the curve (82.5%) for the CT+ group versus the CT- group was significant (p = 0.021) with a sensitivity of 87.5% and a specificity of 70%, using a cutoff of 1071 pg/ml of pNFL-H in serum. Conclusions. This study describes the serum profile of pNFL-H in patients suffering from mTBI with and without CT findings on Days 1 and 3 after injury. These results suggest that detection of pNFL-H may be useful in determining which individuals require CT imaging to assess the severity of their injury.	[Gatson, Joshua W.; Barillas, Jennifer; Wolf, Steven E.; Minei, Joseph P.] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA; [Hynan, Linda S.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Rockville, MD USA		Gatson, JW (corresponding author), 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	joshua.gatson@utsouthwesterm.edu	Hynan, Linda S/P-6473-2016	Wolf, Steven/0000-0003-2972-3440; Hynan, Linda/0000-0002-4642-7769; Diaz-Arrastia, Ramon/0000-0001-6051-3594	Division of Burn/Trauma/Critical Care; Department of Surgery; UT Southwestern Medical Center, Dallas, Texas	Funding was provided by the Division of Burn/Trauma/Critical Care; Department of Surgery; UT Southwestern Medical Center, Dallas, Texas. The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Denny-Brown D E, 1941, Proc R Soc Med, V34, P691; Faul M, 2010, TRAUMATIC BRAIN INJU; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; Giza CC, 2001, J ATHL TRAINING, V36, P228; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kavalci C, 2007, AM J EMERG MED, V25, P391, DOI 10.1016/j.ajem.2006.10.008; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; MAYEVSKY A, 1974, BRAIN RES, V65, P529, DOI 10.1016/0006-8993(74)90243-1; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Missler U, 1999, CLIN CHEM, V45, P138; Mondello S, 2014, MED RES REV, V34, P503, DOI 10.1002/med.21295; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Park E, 2007, EXP NEUROL, V204, P49, DOI 10.1016/j.expneurol.2006.09.012; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Rostami Elham, 2012, Front Neurol, V3, P115, DOI 10.3389/fneur.2012.00115; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Vajtr D, 2012, Soud Lek, V57, P7; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Withnall C, 2005, BRIT J SPORT MED, V39, pI40, DOI 10.1136/bjsm.2005.019174; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027; Zurek J, 2012, ACTA NEUROCHIR, V154, P93, DOI 10.1007/s00701-011-1175-2; Zurek J, 2011, BRAIN INJURY, V25, P221, DOI 10.3109/02699052.2010.541895	36	56	60	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2014	121	5					1232	1238		10.3171/2014.7.JNS132474			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AR4AM	WOS:000343530400031	25192482				2022-02-06	
J	Balakathiresan, NS; Chandran, R; Bhomia, M; Jia, M; Li, H; Maheshwari, RK				Balakathiresan, Nagaraja S.; Chandran, Raghavendar; Bhomia, Manish; Jia, Min; Li, He; Maheshwari, Radha K.			Serum and amygdala microRNA signatures of posttraumatic stress: Fear correlation and biomarker potential	JOURNAL OF PSYCHIATRIC RESEARCH			English	Article						Traumatic stress; Biomarker; microRNA; Serum; Amygdala; PTSD	TARGET GENES; BRAIN; EXPRESSION; MEMORY; PLASTICITY	Exposure to acute traumatic stress can cause permanent changes in neurological circuitry and may lead to the development of an anxiety disorder known as posttraumatic stress disorder (PTSD). Current diagnosis of PTSD is based on clinical or behavioral symptom assessment, however, these are not definitive due to overlapping symptoms with other psychiatric disorders or mild traumatic brain injury (mTBI). No FDA approved diagnostic tests or biomarkers are currently available for diagnosis of PTSD. Recently, circulating miRNAs have emerged as novel biomarkers of many diseases. In this study, we have examined the altered expression of serum and amygdala miRNAs in an animal model of PTSD. Differentially expressed and statistically significant miRNAs in serum were validated for their presence in amygdala of corresponding animals. A panel of nine stress-responsive miRNAs viz., miR-142-5p, miR-19b, miR-1928, miR-223-3p, miR-322*, miR-324, miR-421-3p and miR-463* and miR-674* were identified, and may have potential as biomarker(s) for PTSD. Further validations by bioinformatics and system biology approaches indicate that five miRNAs such as miR-142-5p, miR-19b, miR-1928, miR-223 and miR-421-3p may play a potential role in the regulation of genes associated with delayed and exaggerated fear. To the best of our knowledge, this is the first report demonstrating the plausibility of using circulating miRNAs as biomarkers of PTSD. Published by Elsevier Ltd.	[Balakathiresan, Nagaraja S.; Chandran, Raghavendar; Bhomia, Manish; Maheshwari, Radha K.] Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD 20814 USA; [Chandran, Raghavendar] Birla Inst Technol & Sci, Biol Sci Grp, Pilani 333031, Rajasthan, India; [Jia, Min; Li, He] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA		Maheshwari, RK (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	radha.maheshwari@usuhs.edu	Bhomia, Manish/C-7683-2015; Chandran, Raghavendar/AAB-9402-2019; Balakathiresan, Nagaraja Sethuraman/O-3213-2019	Bhomia, Manish/0000-0003-2808-9927; Chandran, Raghavendar/0000-0002-7915-2810; Balakathiresan, Nagaraja Sethuraman/0000-0001-5756-6070	Defense Medical Research and Development Program [D10_I_AR_J6_855]	This work was financially supported by a grant (# D10_I_AR_J6_855) from the Defense Medical Research and Development Program to Dr. Radha K Maheshwari.	Abu Fanne R, 2010, NEUROPHARMACOLOGY, V58, P972, DOI 10.1016/j.neuropharm.2009.12.017; Andero R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005656; Andrews JA, 2012, J NEUROCHEM, V120, P26, DOI 10.1111/j.1471-4159.2011.07545.x; Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Berna G, 2012, J ANXIETY DISORD, V26, P239, DOI 10.1016/j.janxdis.2011.11.011; Beveridge NJ, 2010, MOL PSYCHIATR, V15, P1176, DOI 10.1038/mp.2009.84; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Fanselow MS, 1999, NEURON, V23, P229, DOI 10.1016/S0896-6273(00)80775-8; Gao J, 2010, NATURE, V466, P1105, DOI 10.1038/nature09271; Griggs EM, 2013, J NEUROSCI, V33, P1734, DOI 10.1523/JNEUROSCI.2873-12.2013; Harraz MM, 2012, P NATL ACAD SCI USA, V109, P18962, DOI 10.1073/pnas.1121288109; Jia M, 2012, J VISUALIZED EXPT, P68; Jiang XL, 2011, J PSYCHOPHARMACOL, V25, P287, DOI 10.1177/0269881109106911; Jovicic A, 2013, J NEUROSCI, V33, P5127, DOI 10.1523/JNEUROSCI.0600-12.2013; Konopka W, 2010, J NEUROSCI, V30, P14835, DOI 10.1523/JNEUROSCI.3030-10.2010; Lai CY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021635; Lau P, 2013, EMBO MOL MED, V5, P1613, DOI 10.1002/emmm.201201974; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Li L, 2013, NEUROMOL MED, V15, P593, DOI 10.1007/s12017-013-8244-z; Lin Q, 2011, NAT NEUROSCI, V14, P1115, DOI 10.1038/nn.2891; Liu NK, 2009, EXP NEUROL, V219, P424, DOI 10.1016/j.expneurol.2009.06.015; Mahan AL, 2012, TRENDS NEUROSCI, V35, P24, DOI 10.1016/j.tins.2011.06.007; Malan-Muller S, 2013, MOL NEUROBIOL, V47, P726, DOI 10.1007/s12035-012-8374-6; Mannironi C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073385; Marchand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044532; Miska EA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r68; Morey RA, 2012, ARCH GEN PSYCHIAT, V69, P1169, DOI 10.1001/archgenpsychiatry.2012.50; Nader K, 2000, NATURE, V406, P722, DOI 10.1038/35021052; Oliveros J. C. Venny, INTERACTIVE TOOL COM; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Rong H, 2011, J PSYCHIATR RES, V45, P92, DOI 10.1016/j.jpsychires.2010.04.028; Sayed ASM, 2013, DIS MARKERS, V2013, P561, DOI 10.1155/2013/217948; Schmidt U, 2013, DIS MARKERS, V2013, P43, DOI 10.1155/2013/835876; Scholer N, 2010, EXP HEMATOL, V38, P1126, DOI 10.1016/j.exphem.2010.10.004; SERVATIUS RJ, 1995, BIOL PSYCHIAT, V38, P539, DOI 10.1016/0006-3223(94)00369-E; Sheinerman KS, 2012, AGING-US, V4, P590, DOI 10.18632/aging.100486; Shumyatsky GP, 2005, CELL, V123, P697, DOI 10.1016/j.cell.2005.08.038; Smalheiser NR, 2011, INT J NEUROPSYCHOPH, V14, P1315, DOI 10.1017/S1461145710001628; Sones HM, 2011, PSYCHIAT CLIN N AM, V34, P79, DOI 10.1016/j.psc.2010.11.001; Taguchi YH, 2013, BIODATA MIN, V6, DOI 10.1186/1756-0381-6-11; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wu D, 2011, NEUROSCIENCE, V190, P386, DOI 10.1016/j.neuroscience.2011.06.017; Zhang L, 2011, ANXIETY DISORDERS, P69	44	56	56	1	21	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3956	1879-1379		J PSYCHIATR RES	J. Psychiatr. Res.	OCT	2014	57						65	73		10.1016/j.jpsychires.2014.05.020			9	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	AO7RK	WOS:000341550100008	24998397				2022-02-06	
J	Zhao, JB; Chen, Z; Xi, GH; Keep, RF; Hua, Y				Zhao, Jinbing; Chen, Zhi; Xi, Guohua; Keep, Richard F.; Hua, Ya			Deferoxamine Attenuates Acute Hydrocephalus After Traumatic Brain Injury in Rats	TRANSLATIONAL STROKE RESEARCH			English	Article						Deferoxamine; Hydrocephalus; Lateral fluid percussion; Traumatic brain injury	INTRACEREBRAL HEMORRHAGE; POSTTRAUMATIC HYDROCEPHALUS; SUBARACHNOID HEMORRHAGE; COMPLEMENT ACTIVATION; IRON; MODEL; DIAGNOSIS; ATROPHY; EDEMA	Acute post-traumatic ventricular dilation and hydrocephalus are relatively frequent consequences of traumatic brain injury (TBI). Several recent studies have indicated that high iron levels in brain may relate to hydrocephalus development after intracranial hemorrhage. However, the role of iron in the development of post-traumatic hydrocephalus is still unclear. This study was to determine whether or not iron has a role in hydrocephalus development after TBI. TBI was induced by lateral fluid-percussion in male Sprague-Dawley rats. Some rats had intraventricular injection of iron. Acute hydrocephalus was measured by magnetic resonance T2-weighted imaging and brain hemorrhage was determined by T2* gradient-echo sequence imaging and brain hemoglobin levels. The effect of deferoxamine on TBI-induced hydrocephalus was examined. TBI resulted in acute hydrocephalus at 24 h (lateral ventricle volume: 24.1 +/- 3.0 vs. 9.9 +/- 0.2 mm(3) in sham group). Intraventricular injection of iron also caused hydrocephalus (25.7 +/- 3.4 vs. 9.0 +/- 0.6 mm(3) in saline group). Deferoxamine treatment attenuated TBI-induced hydrocephalus and heme oxygenase-1 upregulation. In conclusion, iron may contribute to acute hydrocephalus after TBI.	[Zhao, Jinbing; Chen, Zhi; Xi, Guohua; Keep, Richard F.; Hua, Ya] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA		Hua, Y (corresponding author), Univ Michigan, Dept Neurosurg, R5018 Biomed Sci Res Bldg,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	yahua@umich.edu		Chen, Zhi/0000-0002-8404-4937; Keep, Richard/0000-0001-6441-5334	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-073595, NS-079157, NS-084049]; NSFCNational Natural Science Foundation of China (NSFC) [81301049, 30872675]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS079157, R01NS073595, R21NS084049] Funding Source: NIH RePORTER	This study was supported by grants NS-073595, NS-079157 and NS-084049 from the National Institutes of Health (NIH) and grants 81301049 and 30872675 from NSFC. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and NSFC.	Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; CARDOSO ER, 1985, SURG NEUROL, V23, P261, DOI 10.1016/0090-3019(85)90092-8; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chen B, 2010, STROKE, V41, P2348, DOI 10.1161/STROKEAHA.110.584920; Chen Z, 2011, STROKE, V42, P465, DOI 10.1161/STROKEAHA.110.602755; de Backer ME, 2010, AM J NEURORADIOL, V31, P1577, DOI 10.3174/ajnr.A2264; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Faul M, 2010, TRAUMATIC BRAIN INJU; Guo FY, 2012, TRANSL STROKE RES, V3, P130, DOI 10.1007/s12975-011-0106-0; HAWKINS TD, 1976, CLIN RADIOL, V27, P279, DOI 10.1016/S0009-9260(76)80069-4; Hua Y, 2006, J NEUROSURG, V104, P305, DOI 10.3171/jns.2006.104.2.305; Hua Y, 2000, J NEUROSURG, V92, P1016, DOI 10.3171/jns.2000.92.6.1016; IWANOWSKI L, 1960, J NEUROPATH EXP NEUR, V19, P433, DOI 10.1097/00005072-196007000-00010; Jin H, 2013, TRANSL STROKE RES, V4, P130, DOI 10.1007/s12975-012-0232-3; Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112; KEBERLE H, 1964, ANN NY ACAD SCI, V119, P758; KISHORE PRS, 1978, NEURORADIOLOGY, V16, P261, DOI 10.1007/BF00395266; KJELLIN KG, 1967, ACTA NEUROL SCAND, V43, P299, DOI 10.1111/j.1600-0404.1967.tb05735.x; Kuker W, 2000, ACTA RADIOL, V41, P544, DOI 10.1034/j.1600-0455.2000.041006544.x; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Lee JY, 2010, J CEREBR BLOOD F MET, V30, P1793, DOI 10.1038/jcbfm.2010.137; Linfante I, 1999, STROKE, V30, P2263, DOI 10.1161/01.STR.30.11.2263; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; Losowska-Kaniewska D, 2007, Adv Med Sci, V52 Suppl 1, P176; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; Massicotte EM, 1999, J NEUROSURG, V91, P80, DOI 10.3171/jns.1999.91.1.0080; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moos T, 2000, CELL MOL NEUROBIOL, V20, P77, DOI 10.1023/A:1006948027674; Nahed BV, 2007, J NEUROSURG, V107, P236, DOI 10.3171/PED-07/09/236; Nakamura T, 2004, J NEUROSURG, V100, P672, DOI 10.3171/jns.2004.100.4.0672; Okauchi M, 2010, STROKE, V41, P375, DOI 10.1161/STROKEAHA.109.569830; Okauchi M, 2009, STROKE, V40, P1858, DOI 10.1161/STROKEAHA.108.535765; Onyszchuk G, 2009, NEUROSCI LETT, V452, P204, DOI 10.1016/j.neulet.2009.01.049; Qin ZY, 2007, STROKE, V38, P1362, DOI 10.1161/01.STR.0000259660.62865.eb; Raz E, 2011, AM J NEURORADIOL, V32, P1851, DOI 10.3174/ajnr.A2637; Rouault TA, 2009, METAB BRAIN DIS, V24, P673, DOI 10.1007/s11011-009-9169-y; Suzuki H, 2003, STROKE, V34, P2796, DOI 10.1161/01.STR.0000103743.62248.12; Suzuki H, 2006, J NEUROL, V253, P1170, DOI 10.1007/s00415-006-0184-1; TAKAGI H, 1981, SURG NEUROL, V16, P103, DOI 10.1016/0090-3019(81)90106-3; Turner CP, 1998, J CEREBR BLOOD F MET, V18, P257, DOI 10.1097/00004647-199803000-00004; Wan S, 2006, ACTA NEUROCHIR SUPPL, V96, P199; Wu G, 2010, TRANSL STROKE RES, V1, P31, DOI 10.1007/s12975-009-0008-6; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xi GH, 1999, STROKE, V30, P1247, DOI 10.1161/01.STR.30.6.1247; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Yoshimoto Y, 1996, AM J NEURORADIOL, V17, P1183; Zhang LJ, 2013, NEUROL SCI, V34, P639, DOI 10.1007/s10072-012-1090-1	50	56	57	2	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	OCT	2014	5	5					586	594		10.1007/s12975-014-0353-y			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AN1VV	WOS:000340373000008	24935175	Green Accepted			2022-02-06	
J	Wu, JF; Stoica, BA; Luo, T; Sabirzhanov, B; Zhao, ZR; Guanciale, K; Nayar, SK; Foss, CA; Pomper, MG; Faden, AI				Wu, Junfang; Stoica, Bogdan A.; Luo, Tao; Sabirzhanov, Boris; Zhao, Zaorui; Guanciale, Kelsey; Nayar, Suresh K.; Foss, Catherine A.; Pomper, Martin G.; Faden, Alan I.			Isolated spinal cord contusion in rats induces chronic brain neuroinflammation, neurodegeneration, and cognitive impairment Involvement of cell cycle activation	CELL CYCLE			English	Article						spinal cord injury; brain; inflammation; cognitive impairment; neurodegeneration; cell cycle activation	ASTROGLIAL SCAR FORMATION; CORTICOSPINAL NEURONS; MICROGLIAL ACTIVATION; NEUROPATHIC PAIN; INJURY; DEATH; CONTRIBUTES; AXOTOMY; INFLAMMATION; EXPRESSION	Cognitive dysfunction has been reported in patients with spinal cord injury (SCI), but it has been questioned whether such changes may reflect concurrent head injury, and the issue has not been addressed mechanistically or in a well-controlled experimental model. Our recent rodent studies examining SCI-induced hyperesthesia revealed neuroinflammatory changes not only in supratentorial pain-regulatory sites, but also in other brain regions, suggesting that additional brain functions may be impacted following SCI. Here we examined effects of isolated thoracic SCI in rats on cognition, brain inflammation, and neurodegeneration. We show for the first time that SCI causes widespread microglial activation in the brain, with increased expression of markers for activated microglia/macrophages, including translocator protein and chemokine ligand 21 (C-C motif). Stereological analysis demonstrated significant neuronal loss in the cortex, thalamus, and hippocampus. SCI caused chronic impairment in spatial, retention, contextual, and fear-related emotional memory-evidenced by poor performance in the Morris water maze, novel objective recognition, and passive avoidance tests. Based on our prior work implicating cell cycle activation (CCA) in chronic neuroinflammation after SCI or traumatic brain injury, we evaluated whether CCA contributed to the observed changes. Increased expression of cell cycle-related genes and proteins was found in hippocampus and cortex after SCI. Posttraumatic brain inflammation, neuronal loss, and cognitive changes were attenuated by systemic post-injury administration of a selective cyclin-dependent kinase inhibitor. These studies demonstrate that chronic brain neurodegeneration occurs after isolated SCI, likely related to sustained microglial activation mediated by cell cycle activation.	[Wu, Junfang; Stoica, Bogdan A.; Luo, Tao; Sabirzhanov, Boris; Zhao, Zaorui; Guanciale, Kelsey; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Wu, Junfang; Stoica, Bogdan A.; Luo, Tao; Sabirzhanov, Boris; Zhao, Zaorui; Guanciale, Kelsey; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA; [Nayar, Suresh K.; Foss, Catherine A.; Pomper, Martin G.] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD USA		Wu, JF (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA.	jwu@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Faden, Alan I./0000-0003-0128-2348	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS054221, R01 NR013601, R21 NR014053]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS054221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013601, R21NR014053] Funding Source: NIH RePORTER	We thank Katherine Cardiff and Angela Pan for expert technical support, Dr Soren M Bentzen and Ms Shari Kronsberg for expert statistical consultation and analysis. This study was supported by the National Institutes of Health Grants R01 NS054221 (AIF), R01 NR013601 (AIF), R21 NR014053 (JW).	Ankeny DP, 2009, NEUROSCIENCE, V158, P1112, DOI 10.1016/j.neuroscience.2008.07.001; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bonatz H, 2000, J NEUROSCI METH, V100, P105, DOI 10.1016/S0165-0270(00)00238-7; Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179; Byrnes KR, 2007, NEUROCHEM RES, V32, P1799, DOI 10.1007/s11064-007-9312-2; Chang CM, 2009, NEUROREPORT, V20, P968, DOI 10.1097/WNR.0b013e32832d0a28; Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Crawley AP, 2004, BRAIN RES, V1028, P19, DOI 10.1016/j.brainres.2004.08.060; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Dowler R N, 1995, Appl Neuropsychol, V2, P124, DOI 10.1207/s15324826an0203&4_4; Dowler RN, 1997, J INT NEUROPSYCH SOC, V3, P464, DOI 10.1017/S1355617797004645; Endo T, 2007, BRAIN, V130, P2951, DOI 10.1093/brain/awm237; Endres CJ, 2009, J NUCL MED, V50, P1276, DOI 10.2967/jnumed.109.062265; Felix MS, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00045; FERINGA ER, 1985, NEUROSCI LETT, V58, P283, DOI 10.1016/0304-3940(85)90067-9; Fumagalli F, 2009, NEUROSCIENCE, V159, P936, DOI 10.1016/j.neuroscience.2009.01.030; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; GANCHROW D, 1985, J NEUROSCI RES, V14, P71, DOI 10.1002/jnr.490140107; Giehl KM, 1996, EUR J NEUROSCI, V8, P1167, DOI 10.1111/j.1460-9568.1996.tb01284.x; Gomez-Pinilla F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032298; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Hains BC, 2003, J COMP NEUROL, V462, P328, DOI 10.1002/cne.10733; Hammond ENL, 1999, NEUROREPORT, V10, P2671, DOI 10.1097/00001756-199908200-00043; Hulsebosch CE, 2009, BRAIN RES REV, V60, P202, DOI 10.1016/j.brainresrev.2008.12.010; Jegede AB, 2010, CLIN AUTON RES, V20, P3, DOI 10.1007/s10286-009-0036-z; Jensen MP, 2007, ARCH PHYS MED REHAB, V88, P638, DOI 10.1016/j.apmr.2007.02.002; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kaas JH, 2008, EXP NEUROL, V209, P407, DOI 10.1016/j.expneurol.2007.06.014; Kabadi SV, 2014, J CEREBR BLOOD F MET, V34, P502, DOI 10.1038/jcbfm.2013.228; KALIL K, 1975, BRAIN RES, V89, P15, DOI 10.1016/0006-8993(75)90130-4; Klapka N, 2005, EUR J NEUROSCI, V22, P3047, DOI 10.1111/j.1460-9568.2005.04495.x; KOST SA, 1993, BRAIN RES BULL, V30, P469, DOI 10.1016/0361-9230(93)90280-O; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lau BYB, 2011, EXP NEUROL, V228, P283, DOI 10.1016/j.expneurol.2011.02.003; Lazzaro I, 2013, J CLIN NEUROPHYSIOL, V30, P59, DOI 10.1097/WNP.0b013e31827edb0c; Lee BH, 2004, BRAIN RES, V1020, P37, DOI 10.1016/j.brainres.2004.05.113; Maeda J, 2007, BRAIN RES, V1157, P100, DOI 10.1016/j.brainres.2007.04.054; Mason MRJ, 2003, EUR J NEUROSCI, V18, P789, DOI 10.1046/j.1460-9568.2003.02809.x; MERLINE M, 1990, J COMP NEUROL, V296, P506, DOI 10.1002/cne.902960313; MIKUCKI SA, 1991, J NEUROSCI RES, V30, P213, DOI 10.1002/jnr.490300122; Murray RF, 2007, SPINAL CORD, V45, P429, DOI 10.1038/sj.sc.3102022; Nardone R, 2013, BRAIN RES, V1504, P58, DOI 10.1016/j.brainres.2012.12.034; Nielson JL, 2011, J COMP NEUROL, V519, P2852, DOI 10.1002/cne.22661; Nielson JL, 2010, J NEUROSCI, V30, P11516, DOI 10.1523/JNEUROSCI.1433-10.2010; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Guerrero AR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-40; ROTH E, 1989, PARAPLEGIA, V27, P480, DOI 10.1038/sc.1989.75; Strubreither W, 1997, SPINAL CORD, V35, P487, DOI 10.1038/sj.sc.3100495; Tian DS, 2007, BRAIN RES, V1154, P206, DOI 10.1016/j.brainres.2007.04.005; Tian DS, 2007, BRAIN RES, V1135, P177, DOI 10.1016/j.brainres.2006.11.085; Tian DS, 2006, J NEUROSCI RES, V84, P1053, DOI 10.1002/jnr.20999; Wannier T, 2005, J NEUROTRAUM, V22, P703, DOI 10.1089/neu.2005.22.703; Wecht JM, 2013, J SPINAL CORD MED, V36, P74, DOI 10.1179/2045772312Y.0000000056; Wu J, 2012, PLOS ONE, V7; Wu JF, 2013, J NEUROSCI, V33, P12447, DOI 10.1523/JNEUROSCI.0846-13.2013; Wu JF, 2013, NEUROTHERAPEUTICS, V10, P520, DOI 10.1007/s13311-013-0198-1; Wu JF, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-169; Wu JF, 2012, CELL CYCLE, V11, P1782, DOI 10.4161/cc.20153; Wu JF, 2011, NEUROTHERAPEUTICS, V8, P221, DOI 10.1007/s13311-011-0028-2; Zhang B, 2011, J TRAUMA, V71, P1680, DOI 10.1097/TA.0b013e318231bce7; Zhao P, 2007, J NEUROSCI, V27, P8893, DOI 10.1523/JNEUROSCI.2209-07.2007; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511	64	56	60	1	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-4101	1551-4005		CELL CYCLE	Cell Cycle	AUG 1	2014	13	15					2446	2458		10.4161/cc.29420			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	AN6QL	WOS:000340720900019	25483194	Green Published, Bronze			2022-02-06	
J	Coulter, IC; Pesic-Smith, JD; Cato-Addison, WB; Khan, SA; Thompson, D; Jenkins, AJ; Strachan, RD; Mukerji, N				Coulter, Ian C.; Pesic-Smith, Jonathan D.; Cato-Addison, William B.; Khan, Shahid A.; Thompson, Daniel; Jenkins, Alistair J.; Strachan, Roger D.; Mukerji, Nitin			Routine but risky: A multi-centre analysis of the outcomes of cranioplasty in the Northeast of England	ACTA NEUROCHIRURGICA			English	Article						Decompressive craniectomy; Cranioplasty; Complications; Functional outcome	MIDDLE CEREBRAL-ARTERY; TRAUMATIC BRAIN-INJURY; EARLY DECOMPRESSIVE CRANIECTOMY; DEATH FOLLOWING CRANIOPLASTY; AFFECTING GRAFT INFECTION; CLINICAL ARTICLE; TITANIUM CRANIOPLASTY; MALIGNANT INFARCTION; RANDOMIZED-TRIAL; HEAD-INJURY	Cranioplasty is undertaken as a routine secondary operation following craniectomy. At a time when decompressive craniectomy is being evaluated by several large trials, we aimed to evaluate the morbidity associated with cranioplasty and investigate its potential effect on outcome. The outcomes of 166 patients undergoing cranioplasty at two centres in the United Kingdom between June 2006 and September 2011 were retrospectively analysed. Outcome measures included mortality, morbidity and functional outcome determined by the modified Rankin score (mRS) at last follow-up. A logistic regression analysis was performed to model and predict determinants related to neurological outcome following cranioplasty. Sixty-seven out of 166 patients (40.4 %) experienced at least one complication during a median follow-up time of 15 months (inter-quartile range 5-38 months). Thirty six patients (21.7 %) developed infection requiring antibiotics, with 27 (16.3 %) requiring removal of the cranioplasty. Nine of 25 patients (36 %) with bi-frontal defects developed an infection whereas 21 of the 153 patients (16.4 %) with a defect other than bi-frontal developed an infection (Chi square p = 0.009). Further surgery in the two groups was required in 16.4 % and 11.7, % respectively. Pseudomeningocoele (9 %), seizures (8.4 %) and poor cosmesis (7.2 %) were also commonly observed. Logistic regression analysis identified initial operation (p < 0.03), mRS at the time of cranioplasty (p < 0.0001) and complications (p < 0.04) as being predictive of neurological outcome at last follow-up. Age at the time of cranioplasty and the timing of cranioplasty were not predictive of last mRS score at follow-up. Cranioplasty harbours significant morbidity, a risk that appears to be higher with a bifrontal defect. The complications experienced influence subsequent functional outcome. The timing of cranioplasty, early or late, after the initial operation does not impact on the ultimate outcome. These findings should be considered when making decisions relating to craniectomy and cranioplasty.	[Coulter, Ian C.; Cato-Addison, William B.; Khan, Shahid A.; Strachan, Roger D.; Mukerji, Nitin] James Cook Univ Hosp, Dept Neurosurg, Middlesbrough TS4 3BW, Cleveland, England; [Pesic-Smith, Jonathan D.; Jenkins, Alistair J.] Royal Victoria Infirm, Dept Neurosurg, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Thompson, Daniel] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England		Coulter, IC (corresponding author), James Cook Univ Hosp, Dept Neurosurg, Middlesbrough TS4 3BW, Cleveland, England.	ian.coulter@doctors.org.uk	Strachan, Roger/AAT-8295-2020; Coulter, Ian/AAV-8522-2021; Mukerji, Nitin/AAF-8507-2020; Thompson, Daniel/R-5821-2018	Coulter, Ian/0000-0001-7500-5592; Thompson, Daniel/0000-0002-0698-4018			Agner C, 2002, ACTA NEUROCHIR, V144, P1033, DOI 10.1007/s00701-002-0996-4; Archavlis E, 2012, ACTA NEUROCHIR, V154, P1055, DOI 10.1007/s00701-012-1333-1; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Bender A, 2013, BRAIN INJURY, V27, P1073, DOI 10.3109/02699052.2013.794972; Bobinski L, 2013, CLIN NEUROL NEUROSUR, V115, P1788, DOI 10.1016/j.clineuro.2013.04.013; Broughton E, 2014, BRIT J NEUROSURG, V28, P34, DOI 10.3109/02688697.2013.815319; Cabraja M, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS091; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Goldstein JA, 2013, CURR OPIN OTOLARYNGO, V21, P400, DOI 10.1097/MOO.0b013e328363003e; Gooch MR, 2013, NEUROSURG FOCUS, V26, pE9; Hill CS, 2012, BRIT J NEUROSURG, V26, P832, DOI 10.3109/02688697.2012.692839; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Honeybul S, 2013, BRIT J NEUROSURG, V27, P636, DOI 10.3109/02688697.2013.817532; Honeybul S, 2011, BRIT J NEUROSURG, V25, P343, DOI 10.3109/02688697.2011.568643; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Kim H, 2013, ACTA NEUROCHIR, V155, P2171, DOI 10.1007/s00701-013-1877-8; Klinger DR, 2014, WORLD NEUROSURG, V82, pE525, DOI 10.1016/j.wneu.2013.08.005; Kolias AG, 2013, BRIT J NEUROSURG, DOI [10.3109/0288697, DOI 10.3109/0288697]; Kolias AG, 2013, NAT REV NEUROL, V9, P405, DOI 10.1038/nrneurol.2013.106; Kolias AG, 2013, ACTA NEUROCHIR, V155, P183, DOI 10.1007/s00701-012-1503-1; Lee CH, 2012, J TRAUMA ACUTE CARE, V73, P255, DOI 10.1097/TA.0b013e318256a150; Lee L, 2013, BRIT J NEUROSURG, V27, P629, DOI 10.3109/02688697.2013.815313; LUNDJOHANSEN M, 1994, NEUROSURGERY, V35, P839, DOI 10.1227/00006123-199411000-00006; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; Nagayama K, 2002, NEUROL SURG TOKYO, V30, P165; Piedra MP, 2013, J NEUROSURG, V118, P109, DOI 10.3171/2012.10.JNS121037; Piedra MP, 2012, J NEUROSURG-PEDIATR, V10, P268, DOI 10.3171/2012.6.PEDS1268; Rocque BG, 2013, J NEUROSURG-PEDIATR, V12, P120, DOI 10.3171/2013.4.PEDS12605; Roth J, 2011, NEUROSURGERY, V68, pE271, DOI 10.1227/NEU.0b013e3181fe6165; Stelling H, 2011, BRIT J NEUROSURG, V25, P407, DOI 10.3109/02688697.2011.566385; Stephens FL, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1026; Sundseth J, 2014, ACTA NEUROCHIR WIEN; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Thavarajah D, 2012, BRIT J NEUROSURG, V26, P78, DOI 10.3109/02688697.2011.603850; Tokoro K, 1989, Neurol Med Chir (Tokyo), V29, P196, DOI 10.2176/nmc.29.196; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Wachter D, 2013, CLIN NEUROL NEUROSUR, V115, P1293, DOI 10.1016/j.clineuro.2012.12.002; Walcott BP, 2013, J NEUROSURG, V118, P757, DOI 10.3171/2013.1.JNS121626; Wen L, 2007, J CRANIOFAC SURG, V18, P526, DOI 10.1097/scs.0b013e3180534348; Wiggins A, 2013, NEUROSURGERY, V72, P248, DOI 10.1227/NEU.0b013e31827b98f3; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470; Zebian B, 2011, BRIT J NEUROSURG, V25, P785, DOI 10.3109/02688697.2011.623801	50	56	59	1	13	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JUL	2014	156	7					1361	1368		10.1007/s00701-014-2081-1			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AK1SD	WOS:000338195300017	24752723				2022-02-06	
J	Mychasiuk, R; Farran, A; Esser, MJ				Mychasiuk, Richelle; Farran, Allyson; Esser, Michael J.			Assessment of an Experimental Rodent Model of Pediatric Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						sex differences; executive function; concussion; childhood; behavior	ELEVATED PLUS-MAZE; COGNITIVE DEFICITS; PROFESSIONAL FOOTBALL; EXECUTIVE FUNCTION; ANIMAL-MODEL; CONCUSSION; VULNERABILITY; CONSEQUENCES; BIOMECHANICS; AQUAPORIN-4	Childhood is one the highest risk periods for experiencing a mild traumatic brain injury (mTBI) from sports-related concussions, motor vehicle accidents, and falls. In addition, many children experience lingering symptomology (post-concussion syndrome) from these closed head injuries. Although the negative sequel of mTBI has been described, a clinically reliable animal model of mild pediatric brain injury has not. The purpose of this study was to examine the validity of a modified weight-drop technique as a model for the induction of mTBI/concussion in juvenile rats following a single impact. Male and female rats (P30) were exposed to a single mTBI or a sham injury followed by a behavioral test battery. Juvenile rats who experienced a single mTBI displayed significant motor/balance impairments when tested on the beam walking task and in the open field, as well as deficits of executive functioning as measured with the novel context mismatch task and the probe trial of the Morris water task. In addition, both male and female rats showed depression-like behavior in the forced swim task, with male rats also exhibiting decreased anxiety-related behaviors in the elevated plus maze. The results from this study suggest that the modified weight-drop technique induces a clinically relevant behavioral phenotype in juvenile rats, and may provide researchers with a reliable animal model of mTBI/concussion from which clinical therapeutic strategies could be developed.	[Mychasiuk, Richelle; Farran, Allyson; Esser, Michael J.] Univ Calgary, Fac Med, Alberta Childrens Hosp, Res Inst, Calgary, AB T2N 4N1, Canada		Mychasiuk, R (corresponding author), Univ Calgary, Fac Med, Alberta Childrens Hosp, Res Inst, Heritage Med Res Bldg Room 277 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	rmmychas@ucalgary.ca	Meijer, Anna/K-5118-2016		Department of Pediatrics at the University of Calgary; Alberta Children's Hospital Foundation (ACHF); Alberta Children's Hospital Research Institute (ACHRI); ACHF	The authors thank Irene Ma, Rose Tobias, and Dr. Jong Rho for their technical and organizational assistance. Funding for this study was provided to Dr. Esser by the Department of Pediatrics at the University of Calgary, the Alberta Children's Hospital Foundation (ACHF), and the Alberta Children's Hospital Research Institute (ACHRI). Dr. Mychasiuk's postdoctoral fellowship was funded by ACHF.	Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Andreollo NA, 2012, ABCD-ARQ BRAS CIR DI, V25, P49, DOI 10.1590/S0102-67202012000100011; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bolouri H, 2012, ACTA NEUROL SCAND, V125, P241, DOI 10.1111/j.1600-0404.2011.01614.x; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Carobrez AP, 2005, NEUROSCI BIOBEHAV R, V29, P1193, DOI 10.1016/j.neubiorev.2005.04.017; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Fukuda AM, 2012, NEUROSCIENCE, V222, P366, DOI 10.1016/j.neuroscience.2012.06.033; Fukuda AM, 2013, J CEREBR BLOOD F MET, V33, P1621, DOI 10.1038/jcbfm.2013.118; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kolb B., 2008, FUNDAMENTALS HUMAN N; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nagelhus EA, 2013, PHYSIOL REV, V93, P1543, DOI 10.1152/physrev.00011.2013; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schallert T., 2002, PHARM CEREB ISCHEMIA, V2002, P201; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Spanswick SC, 2010, LEARN MEMORY, V17, P241, DOI 10.1101/lm.1746710; SUTHERLAND RJ, 1988, J NEUROSCI, V8, P1863; Tait MJ, 2008, TRENDS NEUROSCI, V31, P37, DOI 10.1016/j.tins.2007.11.003; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Whishaw IQ, 2005, BEHAV LAB RAT HDB TE; Yadid G, 2001, BRAIN RES, V896, P43, DOI 10.1016/S0006-8993(00)03248-0; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	51	56	57	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2014	31	8					749	757		10.1089/neu.2013.3132			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AD7PX	WOS:000333457200006	24283269				2022-02-06	
J	O'Kane, JW; Spieker, A; Levy, MR; Neradilek, M; Polissar, NL; Schiff, MA				O'Kane, John W.; Spieker, Amy; Levy, Marni R.; Neradilek, Moni; Polissar, Nayak L.; Schiff, Melissa A.			Concussion Among Female Middle-School Soccer Players	JAMA PEDIATRICS			English	Article							STATES HIGH-SCHOOL; SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; FOOTBALL PLAYERS; POSTURAL CONTROL; EPIDEMIOLOGY; SYMPTOMS; RECOVERY	IMPORTANCE Despite recent increased awareness about sports concussions, little research has evaluated concussions among middle-school athletes. OBJECTIVES To evaluate the frequency and duration of concussions in female youth soccer players and to determine if concussions result in stopping play and seeking medical care. DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study from March 2008 through May 2012 among 4 soccer clubs from the Puget Sound region of Washington State, involving 351 elite female soccer players, aged 11 to 14 years, from 33 randomly selected youth soccer teams. Of the players contacted, 83.1% participated and 92.4% completed the study. MAIN OUTCOMES AND MEASURES Concussion cumulative incidence, incidence rate, and description of the number, type, and duration of symptoms. We inquired weekly about concussion symptoms and, if present, the symptom type and duration, the event resulting in symptom onset, and whether the player sought medical attention or played while symptomatic. RESULTS Among the 351 soccer players, there were 59 concussions with 43 742 athletic exposure hours. Cumulative concussion incidence was 13.0% per season, and the incidence rate was 1.2 per 1000 athletic exposure hours (95% CI, 0.9-1.6). Symptoms lasted a median of 4.0 days (mean, 9.4 days). Heading the ball accounted for 30.5% of concussions. Players with the following symptoms had a longer recover time than players without these symptoms: light sensitivity (16.0 vs 3.0 days, P = .001), emotional lability (15.0 vs 3.5 days, P = .002), noise sensitivity (12.0 vs 3.0 days, P = .004), memory loss (9.0 vs 4.0 days, P = .04), nausea (9.0 vs 3.0 days, P = .02), and concentration problems (7.0 vs 2.0 days, P = .02). Most players (58.6%) continued to play with symptoms, with almost half (44.1%) seeking medical attention. CONCLUSIONS AND RELEVANCE Concussion rates in young female soccer players are greater than those reported in older age groups, and most of those concussed report playing with symptoms. Heading the ball is a frequent precipitating event. Awareness of recommendations to not play and seek medical attention is lacking for this age group.	[O'Kane, John W.] Univ Washington, Sports Med Clin, Seattle, WA 98195 USA; [Spieker, Amy; Levy, Marni R.; Schiff, Melissa A.] Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Spieker, Amy; Levy, Marni R.; Schiff, Melissa A.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA; [Neradilek, Moni; Polissar, Nayak L.] Mt Whisper Light Stat, Seattle, WA USA		O'Kane, JW (corresponding author), Univ Washington, Sports Med Clin, 3950 Montlake Blvd,Bank Amer Arena Room 148, Seattle, WA 98195 USA.	jokane@u.washington.edu	Meijer, Anna/K-5118-2016		National Institute of ArthritisUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR051059]; Musculoskeletal and Skin Diseases of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR051059] Funding Source: NIH RePORTER	This study was supported by grant R01AR051059 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (Dr Schiff).	Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Bramley H, 2012, CLIN PEDIATR, V51, P332, DOI 10.1177/0009922811425233; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Haran FJ, 2013, INT J SPORTS MED, V34, P350, DOI 10.1055/s-0032-1304647; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kaminski TW, 2008, RES Q EXERCISE SPORT, V79, P235; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kontos AP, 2011, BRAIN INJURY, V25, P1234, DOI 10.3109/02699052.2011.608209; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Meehan WP, 2013, CLIN J SPORT MED, V23, P339, DOI 10.1097/JSM.0b013e318291d3b3; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Schiff MA, 2010, J ATHL TRAINING, V45, P238, DOI 10.4085/1062-6050-45.3.238; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; US Youth Soccer, 2013, GLANC; Yard EE, 2008, AM J SPORT MED, V36, P1930, DOI 10.1177/0363546508318047; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171	36	56	56	1	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	MAR	2014	168	3					258	264		10.1001/jamapediatrics.2013.4518			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	AC8GR	WOS:000332772000013	24446018	Bronze			2022-02-06	
J	Allison, MA; Kang, YS; Bolte, JH; Maltese, MR; Arbogast, KB				Allison, Mari A.; Kang, Yun Seok; Bolte, John H.; Maltese, Matthew R.; Arbogast, Kristy B.			Validation of a Helmet-Based System to Measure Head Impact Biomechanics in Ice Hockey	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						HEAD ACCELERATION; HEAD INJURY; CONCUSSION; mTBI; SENSORS; KINEMATICS	COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; ANGULAR ACCELERATION; MILD; SEVERITY; LOCATION; SOCCER	Purpose This study aimed to quantify differences between head acceleration measured by a helmet-based accelerometer system for ice hockey and an anthropometric test device (ATD) to validate the system's use in measuring on-ice head impacts. Methods A Hybrid III 50th percentile male ATD head and neck was fit with a helmet instrumented with the Head Impact Telemetry (HIT) System for hockey and impacted at various speeds and directions with different interfaces between the head and helmet. Error between the helmet-based and reference peak accelerations was quantified, and the influence of impact direction and helmet-head interface was evaluated. Regression equations were used to reduce error. System-reported impact direction was validated. Results Nineteen percent of impacts were removed from the data set by the HIT System processing algorithm and were not eligible for analysis. Errors in peak acceleration between the system and ATD varied from 18% to 31% and from 35% to 64% for linear and rotational acceleration, respectively, but were reduced via regression equations. The relationship between HIT System and reference acceleration varied by direction (P < 0.001) and head-helmet interface (P = 0.005). Errors in impact azimuth were approximately 4%, 10%, and 31% for side, back, and oblique back impacts, respectively. Conclusions This is the first comprehensive evaluation of peak head acceleration measured by the HIT System for hockey. The HIT System processing algorithm removed 19% of the impacts from the data set, the correlation between HIT System and reference peak resultant acceleration was strong and varied by head surface and impact direction, and the system error was larger than reported for the 6-degree-of-freedom HIT System for football but could be reduced via calibration factors. These findings must be considered when interpreting on-ice data.	[Allison, Mari A.; Arbogast, Kristy B.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA; [Allison, Mari A.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Kang, Yun Seok; Bolte, John H.] Ohio State Univ, Injury Biomech Res Lab, Columbus, OH 43210 USA; [Maltese, Matthew R.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Arbogast, Kristy B.] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA		Arbogast, KB (corresponding author), 3535 Market St,Suite 1150, Philadelphia, PA 19104 USA.	arbogast@email.chop.edu	Bolte, John/AAK-9695-2021	Bolte, John/0000-0001-9894-4998; Arbogast, Kristy/0000-0002-1694-4562			[Anonymous], 2003, C MILD TRAUM BRAIN I, P26; Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Chu, 2006, J BIOMECH, V39, DOI https://doi.org/10.1016/s0021-9290(06)83518-9; Chu JJ, 2006, J BIOMECH S1, V39, pS534; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Faul M., 2010, TRAUMATIC BRAIN INJU, P7; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Hanlon E, 2010, J APPL BIOMECH, V26, P424, DOI 10.1123/jab.26.4.424; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2012, ANN BIOMED ENG, V40, P141, DOI 10.1007/s10439-011-0405-3; Mihalik JP, 2011, CLIN J SPORT MED, V21, P416, DOI 10.1097/JSM.0B013E31822C8A5C; Mihalik JP, 2010, MED SCI SPORT EXER, V42, P1431, DOI 10.1249/MSS.0b013e3181d2521a; Ocwieja KE, 2012, ANN BIOMED ENG, V40, P90, DOI 10.1007/s10439-011-0401-7; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Reed N, 2010, INT J SPORTS MED, V31, P826, DOI 10.1055/s-0030-1263103; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Stojsih S, 2010, BRIT J SPORT MED, V44, P725, DOI 10.1136/bjsm.2008.052845; USA Hockey, EQ SIZ GUID; Versace J, 1971, SAE TECHNICAL PAPER, DOI [10.4271/710881, DOI 10.4271/710881]; Yoganandan N, 2008, J BIOMECH, V41, P2253, DOI 10.1016/j.jbiomech.2008.04.019	35	56	56	0	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JAN	2014	46	1					115	123		10.1249/MSS.0b013e3182a32d0d			9	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	AH0VT	WOS:000335839500017	23846161				2022-02-06	
J	Sosa, MAG; De Gasperi, R; Janssen, PL; Yuk, FJ; Anazodo, PC; Pricop, PE; Paulino, AJ; Wicinski, B; Shaughness, MC; Maudlin-Jeronimo, E; Hall, AA; Dickstein, DL; McCarron, RM; Chavko, M; Hof, PR; Ahlers, ST; Elder, GA				Sosa, Miguel A. Gama; De Gasperi, Rita; Janssen, Pierce L.; Yuk, Frank J.; Anazodo, Pamela C.; Pricop, Paul E.; Paulino, Alejandro J.; Wicinski, Bridget; Shaughness, Michael C.; Maudlin-Jeronimo, Eric; Hall, Aaron A.; Dickstein, Dara L.; McCarron, Richard M.; Chavko, Mikulas; Hof, Patrick R.; Ahlers, Stephen T.; Elder, Gregory A.			Selective vulnerability of the cerebral vasculature to blast injury in a rat model of mild traumatic brain injury	ACTA NEUROPATHOLOGICA COMMUNICATIONS			English	Article						Blast; Rat; Traumatic brain injury; Vascular pathology	POSTTRAUMATIC-STRESS-DISORDER; BLOOD-VESSELS; ANEURYSMS; EXPOSURE; PARAMETERS; PRESSURE; MATRIX	Background: Blast-related traumatic brain injury (TBI) is a common cause of injury in the military operations in Iraq and Afghanistan. How the primary blast wave affects the brain is not well understood. The aim of the present study was to examine whether blast exposure affects the cerebral vasculature in a rodent model. We analyzed the brains of rats exposed to single or multiple (three) 74.5 kPa blast exposures, conditions that mimic a mild TBI. Rats were sacrificed 24 hours or between 6 and 10 months after exposure. Blast-induced cerebral vascular pathology was examined by a combination of light microscopy, immunohistochemistry, and electron microscopy. Results: We describe a selective vascular pathology that is present acutely at 24 hours after injury. The vascular pathology is found at the margins of focal shear-related injuries that, as we previously showed, typically follow the patterns of penetrating cortical vessels. However, changes in the microvasculature extend beyond the margins of such lesions. Electron microscopy revealed that microvascular pathology is found in regions of the brain with an otherwise normal neuropil. This initial injury leads to chronic changes in the microvasculature that are still evident many months after the initial blast exposure. Conclusions: These studies suggest that vascular pathology may be a central mechanism in the induction of chronic blast-related injury.	[Sosa, Miguel A. Gama] Affairs Med Ctr, James J Peters Dept Vet, Gen Med Res Serv, 130 West Kingsbridge Rd, Bronx, NY 10451 USA; [De Gasperi, Rita; Anazodo, Pamela C.; Pricop, Paul E.; Paulino, Alejandro J.] Affairs Med Ctr, James J Peters Dept Vet, Res & Dev Serv, Bronx, NY USA; [Elder, Gregory A.] Affairs Med Ctr, James J Peters Dept Vet, Neurol Serv, Bronx, NY USA; [Sosa, Miguel A. Gama; De Gasperi, Rita; Anazodo, Pamela C.; Pricop, Paul E.; Paulino, Alejandro J.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Janssen, Pierce L.; Yuk, Frank J.; Wicinski, Bridget; Dickstein, Dara L.; Hof, Patrick R.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA; [Dickstein, Dara L.; Hof, Patrick R.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Care, New York, NY 10029 USA; [Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Sosa, Miguel A. Gama; De Gasperi, Rita; Dickstein, Dara L.; Hof, Patrick R.; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA; [Shaughness, Michael C.; Maudlin-Jeronimo, Eric; Hall, Aaron A.; McCarron, Richard M.; Chavko, Mikulas; Ahlers, Stephen T.] Naval Med Res Ctr, Operat & Undersea Med Directorate, Silver Spring, MD USA		Sosa, MAG (corresponding author), Affairs Med Ctr, James J Peters Dept Vet, Gen Med Res Serv, 130 West Kingsbridge Rd, Bronx, NY 10451 USA.	miguel.gama-sosa@mssm.edu	Dickstein, Dara/AAH-6603-2020	Wicinski, Bridget/0000-0002-2972-7081	Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Health AdministrationUS Department of Veterans Affairs; Rehabilitation Research and Development ServiceUS Department of Veterans Affairs [1I01RX000179-01, 1I01RX000996-01]; General Medical Research Service; VA Medical Center; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P50 AG005138]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005138] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000179, I01RX000996] Funding Source: NIH RePORTER	We thank Dr. Virginia Lee for the gift of the rat anti-GFAP monoclonal antibody. The research described here was supported by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Awards 1I01RX000179-01 and 1I01RX000996-01. MAGS is supported by the General Medical Research Service, James J. Peters VA Medical Center. PRH and DLD are supported in part by NIH grant P50 AG005138. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense nor the U.S. Government.	Abdul-Hussien H, 2007, AM J PATHOL, V170, P809, DOI 10.2353/ajpath.2007.060522; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Ahmed FA, 2013, ELECTROPHORESIS, V34, P2229, DOI 10.1002/elps.201300077; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Aoki T, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/535921; Bauman RA, 2009, INTRO CHAR COMB CAS; Bir C, 2012, MAGN RESON IMAGING, V30, P527, DOI [10.1016/j.mri.2011.12003, DOI 10.1016/J.MRI.2011.12003]; Bochicchio GV, 2008, AM SURGEON, V74, P267; CALEY DW, 1970, J COMP NEUROL, V138, P31, DOI 10.1002/cne.901380104; CAMPAGNE MV, 1991, J HISTOCHEM CYTOCHEM, V39, P1267, DOI 10.1177/39.9.1833448; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chalouhi N, 2012, J CEREBR BLOOD F MET, V32, P1659, DOI 10.1038/jcbfm.2012.84; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; COHEN H, 1946, ARCH PATHOL, V42, P12; Davis GE, 2005, CIRC RES, V97, P1093, DOI 10.1161/01.RES.0000191547.64391.e3; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Franciosi S, 2007, J NEUROSCI METH, V163, P76, DOI 10.1016/j.jneumeth.2007.02.020; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; HASHIMOTO N, 1978, SURG NEUROL, V10, P3; HASHIMOTO N, 1980, SURG NEUROL, V13, P41; HJELLE OP, 1994, EUR J NEUROSCI, V6, P793, DOI 10.1111/j.1460-9568.1994.tb00990.x; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Janssen WGM, 2005, EXP NEUROL, V191, pS28, DOI 10.1016/j.expneurol.2004.08.020; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; JUCKER M, 1992, BRAIN RES, V586, P166, DOI 10.1016/0006-8993(92)91390-Z; Kobeissy F, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00186; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Lucca JJD, 2012, J NEUROL SCI, V318, P146, DOI 10.1016/j.jns.2012.02.002; Matti ED, 1986, SCAN ELECT MICROSC, V4, P1501; MORI S, 1992, HISTOCHEMISTRY, V97, P237, DOI 10.1007/BF00267633; Mott FW, 1916, LANCET, V1, P441; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Prima V, 2013, J NEUROTRAUM, V30, P1881, DOI 10.1089/neu.2012.2758; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Redzic ZB, 2004, ADV DRUG DELIV REV, V56, P1695, DOI [10.10164.addr.2004.07.005, DOI 10.1016/J.ADDR.2004.07.005]; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Skotak M, 2013, NEUROTRAUMA, V30, P1147, DOI [10.1089/neu.2012.2652, DOI 10.1089/NEU.2012.2652]; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Sosa MAG, 2010, AM J PATHOL, V176, P353, DOI 10.2353/ajpath.2010.090482; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Szabo A, 2004, NEUROPATH APPL NEURO, V30, P169, DOI 10.1046/j.0305-1846.2003.00524.x; Turner RC, 2013, EXP NEUROL, V248, P520, DOI 10.1016/j.expneurol.2013.07.008; Valiyaveettil M, 2013, NEUROSCI LETT, V539, P1, DOI 10.1016/j.neulet.2013.01.028	57	56	56	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2051-5960			ACTA NEUROPATHOL COM	Acta Neuropathol. Commun.		2014	2								67	10.1186/2051-5960-2-67			18	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V9K3A	WOS:000422389300067	24938728	Green Published, gold			2022-02-06	
J	Sullivan, GM; Mierzwa, AJ; Kijpaisalratana, N; Tang, HY; Wang, Y; Song, SK; Selwyn, R; Armstrong, RC				Sullivan, Genevieve M.; Mierzwa, Amanda J.; Kijpaisalratana, Naruchorn; Tang, Haiying; Wang, Yong; Song, Sheng-Kwei; Selwyn, Reed; Armstrong, Regina C.			Oligodendrocyte Lineage and Subventricular Zone Response to Traumatic Axonal Injury in the Corpus Callosum	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Axonal damage; Corpus callosum; Diffusion tensor imaging; Oligodendrocyte progenitor; Redundant myelin; Regeneration	BRAIN-INJURY; EXPERIMENTAL DEMYELINATION; MULTIPLE-SCLEROSIS; HEAD-INJURY; MYELIN; WHITE; MATTER; REPAIR; REMYELINATION; DIAGNOSIS	Traumatic brain injury frequently causes traumatic axonal injury (TAI) in white matter tracts. Experimental TAI in the corpus callosum of adult mice was used to examine the effects on oligodendrocyte lineage cells and myelin in conjunction with neuroimaging. The injury targeted the corpus callosum over the subventricular zone, a source of neural stem/progenitor cells. Traumatic axonal injury was produced in the rostral body of the corpus callosum by impact onto the skull at the bregma. During the first week after injury, magnetic resonance diffusion tensor imaging showed that axial diffusivity decreased in the corpus callosum and that corresponding regions exhibited significant axon damage accompanied by hypertrophic microglia and reactive astrocytes. Oligodendrocyte progenitor proliferation increased in the subventricular zone and corpus callosum. Oligodendrocytes in the corpus callosum shifted toward upregulation of myelin gene transcription. Plp/CreER(T):R26IAP reporter mice showed normal reporter labeling of myelin sheaths 0 to 2 days after injury but labeling was increased between 2 and 7 days after injury. Electron microscopy revealed axon degeneration, demyelination, and redundant myelin figures. These findings expand the cell types and responses to white matter injuries that inform diffusion tensor imaging evaluation and identify pivotal white matter changes after TAI that may affect axon vulnerability vs. recovery after brain injury.	[Sullivan, Genevieve M.; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Program Mol & Cell Biol, Bethesda, MD 20814 USA; [Sullivan, Genevieve M.; Mierzwa, Amanda J.; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Dept Anat, Bethesda, MD 20814 USA; [Sullivan, Genevieve M.; Mierzwa, Amanda J.; Kijpaisalratana, Naruchorn; Tang, Haiying; Selwyn, Reed; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Tang, Haiying; Selwyn, Reed] Uniformed Serv Univ Hlth Sci, Dept Radiol, Bethesda, MD 20814 USA; [Wang, Yong; Song, Sheng-Kwei] Washington Univ, Dept Radiol, St Louis, MO USA; [Kijpaisalratana, Naruchorn] Chulalongkorn Univ, Fac Med, Dept Internal Med, Bangkok 10330, Thailand		Armstrong, RC (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	regina.armstrong@usuhs.edu	Sullivan, Genevieve/AAK-7415-2021; Kijpaisalratana, Naruchorn/AAX-6306-2021	Sullivan, Genevieve/0000-0002-3561-223X; 	Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS047592]; National Multiple Sclerosis SocietyNational Multiple Sclerosis Society [RG 4549A4/1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047592] Funding Source: NIH RePORTER	This work was funded by the Department of Defense in the Center for Neuroscience and Regenerative Medicine (RCA), National Institute of Health R01-NS047592 (S-KS), and National Multiple Sclerosis Society RG 4549A4/1 (SKS).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Aguirre A, 2007, NAT NEUROSCI, V10, P990, DOI 10.1038/nn1938; Armstrong RC, 2002, J NEUROSCI, V22, P8574; Armstrong RC, 2006, J NEUROPATH EXP NEUR, V65, P245, DOI 10.1097/01.jnen.0000205142.08716.7e; Badea TC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007859; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Clarner T, 2012, GLIA, V60, P1468, DOI 10.1002/glia.22367; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; DiLeonardi AM, 2012, J NEUROPATH EXP NEUR, V71, P959, DOI 10.1097/NEN.0b013e31826f5876; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; Doerflinger NH, 2003, GENESIS, V35, P63, DOI 10.1002/gene.10154; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Gallo V, 2008, CURR OPIN NEUROL, V21, P278, DOI 10.1097/WCO.0b013e3282fd1875; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kuo LW, 2008, NEUROIMAGE, V41, P7, DOI 10.1016/j.neuroimage.2008.02.016; Lindner M, 2008, NEUROPATH APPL NEURO, V34, P105, DOI 10.1111/j.1365-2990.2007.00879.x; Lotocki G, 2011, NEUROSCI LETT, V499, P143, DOI 10.1016/j.neulet.2011.05.056; Mason JL, 2007, NEUROPATHOL APPL NEU, V27, P50; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McMahon PJ, 2013, J NEUROTRAUM; Metting Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064461; Murtie JC, 2005, NEUROBIOL DIS, V19, P171, DOI 10.1016/j.nbd.2004.12.006; Nait-Oumesmar B, 2007, P NATL ACAD SCI USA, V104, P4694, DOI 10.1073/pnas.0606835104; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Peters A, 2002, J NEUROCYTOL, V31, P581, DOI 10.1023/A:1025731309829; Pierpaoli C., 2010, ISMRM 18 ANN M STOCK, P1597; Powers BE, 2013, P NATL ACAD SCI USA, V110, P4075, DOI 10.1073/pnas.1210293110; Rasmussen S, 2011, ANN NEUROL, V69, P878, DOI 10.1002/ana.22299; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; ROSENBLUTH J, 1966, J CELL BIOL, V28, P73, DOI 10.1083/jcb.28.1.73; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Simons M, 2012, BBA-MOL CELL BIOL L, V1821, P1146, DOI 10.1016/j.bbalip.2012.01.011; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; STURROCK RR, 1980, NEUROPATH APPL NEURO, V6, P415, DOI 10.1111/j.1365-2990.1980.tb00219.x; Sun SW, 2006, MAGN RESON MED, V55, P302, DOI 10.1002/mrm.20774; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tobin JE, 2011, J NEUROPATH EXP NEUR, V70, P157, DOI 10.1097/NEN.0b013e31820937e4; Wang Y, 2011, BRAIN, V134, P3587, DOI 10.1093/brain/awr307; Wedeen VJ, 2005, MAGN RESON MED, V54, P1377, DOI 10.1002/mrm.20642; White RE, 2011, J NEUROSCI, V31, P15173, DOI 10.1523/JNEUROSCI.3441-11.2011; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Wu C, 2012, J TRAUMA ACUTE CARE, V73, P1247, DOI 10.1097/TA.0b013e318265d24e; Xie MQ, 2010, J NEUROPATH EXP NEUR, V69, P704, DOI 10.1097/NEN.0b013e3181e3de90; Zakaria N, 2012, BRAIN RES, V1467, P81, DOI 10.1016/j.brainres.2012.05.046; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511; Zhou YX, 2012, NEUROBIOL DIS, V45, P196, DOI 10.1016/j.nbd.2011.08.004	60	56	61	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	DEC	2013	72	12					1106	1125		10.1097/NEN.0000000000000009			20	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	299ZC	WOS:000330433200001	24226267	Green Accepted, hybrid, Green Published			2022-02-06	
J	Sticozzi, C; Belmonte, G; Meini, A; Carbotti, P; Grasso, G; Palmi, M				Sticozzi, C.; Belmonte, G.; Meini, A.; Carbotti, P.; Grasso, G.; Palmi, M.			IL-1 beta INDUCES GFAP EXPRESSION IN VITRO AND IN VIVO AND PROTECTS NEURONS FROM TRAUMATIC INJURY-ASSOCIATED APOPTOSIS IN RAT BRAIN STRIATUM VIA NF kappa B/CA(2+)-CALMODULIN/ERK MITOGEN-ACTIVATED PROTEIN KINASE SIGNALING PATHWAY	NEUROSCIENCE			English	Article						interleukin-1beta; CNS; astrogliosis; apoptosis; signal transduction	ASTROCYTOMA CELL-LINE; NITRIC-OXIDE SYNTHASE; SPINAL-CORD-INJURY; U-373 MG CELLS; NF-KAPPA-B; INTRACELLULAR CA2+; REACTIVE ASTROCYTES; PANCREATIC-ISLETS; CALCIUM INFLUX; BETA-CELLS	Reactive astrogliosis, a feature of neuro-inflammation is induced by a number of endogenous mediators including cytokines. Despite interleukin-1 beta (IL-1 beta) stands out as the major inducer of this process, the underlying mechanism and its role on neuronal viability remain elusive. We investigated in human astrocytoma cells and the rat brain striatum, the role of the nuclear factor-kB (NF-kB) intracellular Ca2+ concentration ([Ca2+](i)) calmodulin (CaM) and extracellular regulated mitogen-activated protein kinases (ERK1/2) in IL-1 beta-induced expression of glial fibrillary acidic protein (GFAP) and neuronal apoptosis associated to a brain trauma. Cell data showed that IL-1 beta (1 ng/ml) increased NF-kB, pERK1/2 and GFAP expression. Nevertheless, further increase in IL-1 beta levels reversed progressively these responses. Preventing ERK1/2 activation with 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthiol]-butadiene antagonized 1L-1 beta-induced GFAP expression while inhibiting selectively nuclear translocation of NF-kB with caffeic-acid phenethyl-ester down-regulated both ERK1/2 and GFAP expression induced by IL-1 beta. The GFAP response was also prevented by antagonizing selectively increase in [Ca2+](i), CaM activity or inducible nitric oxide synthase expression with respectively ryanodine plus 2-aminoethoxydiphenyl-borate, N-(6-aminohexyl)-5-chloro-1-naphthalensulfonamide hydrochloride and N-[(3-(aminomethyl)-phenyl]methyl]-ethanimidamide dihydrochloride. Data in vivo supported these findings and showed that GFAP expression induced by IL-1 beta (50 ng/ml) correlated with attenuated glial scar formation and reduced neuronal apoptosis. Our data identified the NF-kB/Ca2+-CaM/ERK signaling pathway as a novel in vivo key regulator of IL-1 beta-induced astrogliosis which may represent a potential target in neurodegeneration. (C) 2013 Published by Elsevier Ltd. on behalf of IBRO.	[Sticozzi, C.] Univ Ferrara, Dept Life Sci & Biotechnol, I-44121 Ferrara, Italy; [Belmonte, G.; Meini, A.; Carbotti, P.; Grasso, G.; Palmi, M.] Univ Siena, Dept Med & Surg Sci & Neurosci, I-53100 Siena, Italy		Palmi, M (corresponding author), Univ Siena, Dept Med & Surg Sci & Neurosci, Via A Moro 2, I-53100 Siena, Italy.	palmi@unisi.it			Piano di Ateneo per la ricerca; Universite di Siena, Siena, Italy; Fondazione Monte dei Paschi di Siena	This study was supported by contribution from the Piano di Ateneo per la ricerca (PAR 2009-2010) Universite di Siena, Siena, Italy and grants (2011-2012) from Fondazione Monte dei Paschi di Siena.	Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; Aktan F, 2004, LIFE SCI, V75, P639, DOI 10.1016/j.lfs.2003.10.042; Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; BALASINGAM V, 1994, J NEUROSCI, V14, P846; Belanger Mireille, 2009, Dialogues Clin Neurosci, V11, P281; BERTOGLIO JH, 1987, LYMPHOKINE RES, V6, P83; Beskina O, 2007, AM J PHYSIOL-CELL PH, V293, pC1103, DOI 10.1152/ajpcell.00249.2007; Boran MS, 2007, J NEUROCHEM, V102, P216, DOI 10.1111/j.1471-4159.2007.04464.x; Brahmachari S, 2006, J NEUROSCI, V26, P4930, DOI 10.1523/JNEUROSCI.5480-05.2006; Clementi E, 1998, BIOCHEM PHARMACOL, V55, P713, DOI 10.1016/S0006-2952(97)00375-4; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dobryndeva Y, 2001, MOL PHARMACOL, V60, P541; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fields RD, 2002, SCIENCE, V298, P556, DOI 10.1126/science.298.5593.556; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; John GR, 2003, NEUROSCIENTIST, V9, P10, DOI 10.1177/1073858402239587; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KASAHARA T, 1990, BIOCHEM BIOPH RES CO, V167, P1242, DOI 10.1016/0006-291X(90)90657-9; Kim MJ, 2004, BIOCHEM PHARMACOL, V68, P1775, DOI 10.1016/j.bcp.2004.06.031; KWON G, 1995, ENDOCRINOLOGY, V136, P4790, DOI 10.1210/en.136.11.4790; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; Lieb K, 1996, J NEUROCHEM, V66, P1496; Maedler K, 2006, DIABETES, V55, P2713, DOI 10.2337/db05-1430; Matyash V, 2001, MOL CELL NEUROSCI, V18, P664, DOI 10.1006/mcne.2001.1047; Meini A, 2006, EUR J NEUROSCI, V23, P1690, DOI 10.1111/j.1460-9568.2006.04705.x; Meini A, 2003, EUR J NEUROSCI, V17, P692, DOI 10.1046/j.1460-9568.2003.02483.x; Meini A, 2000, J NEUROSCI, V20, P8980; Meini A, 2008, BRIT J PHARMACOL, V153, P1718; MOLLACE V, 1993, BIOCHEM BIOPH RES CO, V191, P327, DOI 10.1006/bbrc.1993.1221; Mosley RL, 2006, CLIN NEUROSCI RES, V6, P261, DOI 10.1016/j.cnr.2006.09.006; Nanetti L, 2005, BRAIN RES, V1054, P38, DOI 10.1016/j.brainres.2005.06.025; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Pahan K, 2000, FEBS LETT, V472, P203, DOI 10.1016/S0014-5793(00)01465-4; Palmi M, 2002, MOL NEUROBIOL, V25, P133, DOI 10.1385/MN:25:2:133; Palmi M, 1996, BRIT J PHARMACOL, V118, P1705, DOI 10.1111/j.1476-5381.1996.tb15595.x; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Sama MA, 2008, J BIOL CHEM, V283, P21953, DOI 10.1074/jbc.M800148200; Schofl C, 1999, ENDOCRINOLOGY, V140, P5516, DOI 10.1210/en.140.12.5516; Suryadevara R, 2003, GLIA, V44, P47, DOI 10.1002/glia.10266; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; Thornton P, 2006, J NEUROCHEM, V98, P258, DOI 10.1111/j.1471-4159.2006.03872.x; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Voutsinos-Porche B, 2003, NEURON, V37, P275, DOI 10.1016/S0896-6273(02)01170-4; Willmott NJ, 2000, FEBS LETT, V487, P239, DOI 10.1016/S0014-5793(00)02359-0; Woiciechowsky C, 2004, MED SCI MONITOR, V10, pBR325; Xia ZG, 1996, J NEUROSCI, V16, P5425; XIE QW, 1994, J BIOL CHEM, V269, P4705; YONG VW, 1992, J NEUROL SCI, V111, P92; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012	56	56	62	1	29	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	NOV 12	2013	252						367	383		10.1016/j.neuroscience.2013.07.061			17	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	236YS	WOS:000325836000033	23928073				2022-02-06	
J	Lei, BL; Dawson, HN; Roulhac-Wilson, B; Wang, HC; Laskowitz, DT; James, ML				Lei, Beilei; Dawson, Hana N.; Roulhac-Wilson, Briana; Wang, Haichen; Laskowitz, Daniel T.; James, Michael L.			Tumor necrosis factor alpha antagonism improves neurological recovery in murine intracerebral hemorrhage	JOURNAL OF NEUROINFLAMMATION			English	Article						Intracerebral hemorrhage; Microglia; Tumor necrosis factor alpha antagonism; Murine model; Cytokine; Remicade	TRAUMATIC BRAIN-INJURY; MICROGLIAL ACTIVATION; FUNCTIONAL RECOVERY; APOLIPOPROTEIN-E; RAT MODEL; EDEMA; INHIBITION; BARRIER; INFLAMMATION; ATTENUATION	Background: Intracerebral hemorrhage (ICH) is a devastating stroke subtype characterized by a prominent neuroinflammatory response. Antagonism of pro-inflammatory cytokines by specific antibodies represents a compelling therapeutic strategy to improve neurological outcome in patients after ICH. To test this hypothesis, the tumor necrosis factor alpha (TNF-alpha) antibody CNTO5048 was administered to mice after ICH induction, and histological and functional endpoints were assessed. Methods: Using 10 to 12-week-old C57BL/6J male mice, ICH was induced by collagenase injection into the left basal ganglia. Brain TNF-alpha concentration, microglia activation/macrophage recruitment, hematoma volume, cerebral edema, and rotorod latency were assessed in mice treated with the TNF-alpha antibody, CNTO5048, or vehicle. Results: After ICH induction, mice treated with CNTO5048 demonstrated reduction in microglial activation/ macrophage recruitment compared to vehicle-treated animals, as assessed by unbiased stereology (P = 0.049). This reduction in F4/80-positive cells was associated with a reduction in cleaved caspase-3 (P = 0.046) and cerebral edema (P = 0.026) despite similar hematoma volumes, when compared to mice treated with vehicle control. Treatment with CNTO5048 after ICH induction was associated with a reduction in functional deficit when compared to mice treated with vehicle control, as assessed by rotorod latencies (P = 0.024). Conclusions: Post-injury treatment with the TNF-alpha antibody CNTO5048 results in less neuroinflammation and improved functional outcomes in a murine model of ICH.	[Lei, Beilei; Roulhac-Wilson, Briana; Wang, Haichen; Laskowitz, Daniel T.; James, Michael L.] Multidisciplinary Neuroprotect Labs, Durham, NC 27710 USA; [Lei, Beilei; Laskowitz, Daniel T.; James, Michael L.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; [Dawson, Hana N.; Wang, Haichen; Laskowitz, Daniel T.; James, Michael L.] Dept Neurol, Durham, NC 27710 USA; [Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA		James, ML (corresponding author), Multidisciplinary Neuroprotect Labs, 132 Sands Bldg, Durham, NC 27710 USA.	michael.james@duke.edu	James, Michael L./AAJ-5592-2020	James, Michael L./0000-0002-8715-5210	American Heart Association Scientist Development GrantAmerican Heart Association	Funding for this study was provided by an American Heart Association Scientist Development Grant (MLJ). CNTO5048 was provided by Janssen. The authors would like to acknowledge Kathy Gage for her editorial assistance.	Albers GW, 2011, STROKE, V42, P2645, DOI 10.1161/STROKEAHA.111.618850; [Anonymous], 1998, REM INFL PACK INS; Arima H, 2012, STROKE, V43, P2236, DOI 10.1161/STROKEAHA.112.651422; Aslam M, 2012, CYTOKINE, V57, P269, DOI 10.1016/j.cyto.2011.10.016; Burguillos MA, 2011, NATURE, V472, P319, DOI 10.1038/nature09788; Campbell SJ, 2007, J NEUROCHEM, V103, P2245, DOI 10.1111/j.1471-4159.2007.04928.x; Candelario-Jalil E, 2007, J PHARMACOL EXP THER, V323, P488, DOI 10.1124/jpet.107.127035; Hernandez-Romero MC, 2012, NEUROTOXICOLOGY, V33, P347, DOI 10.1016/j.neuro.2012.01.018; Castellanos Mar, 2007, Cerebrovasc Dis, V24 Suppl 1, P7, DOI 10.1159/000107374; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Hua Y, 2006, NEUROSURGERY, V58, P542, DOI 10.1227/01.NEU.0000197333.55473.AD; Indraswari F, 2012, J NEUROTRAUM, V29, P1388, DOI 10.1089/neu.2011.2117; James ML, 2012, ANESTHESIOLOGY, V116, P1299, DOI 10.1097/ALN.0b013e318253a02a; James ML, 2010, J NEUROTRAUM, V27, P217, DOI 10.1089/neu.2009.1022; James ML, 2009, BIOMARKERS, V14, P388, DOI 10.1080/13547500903015784; James ML, 2009, J STROKE CEREBROVASC, V18, P144, DOI 10.1016/j.jstrokecerebrovasdis.2008.09.012; James ML, 2009, STROKE, V40, P632, DOI 10.1161/STROKEAHA.108.530402; Laskowitz DT, 2012, NEUROCRIT CARE, V16, P316, DOI 10.1007/s12028-011-9641-5; Lee ST, 2006, J NEUROCHEM, V96, P1728, DOI 10.1111/j.1471-4159.2006.03697.x; Lin J, 2008, CLIN IMMUNOL, V126, P13, DOI 10.1016/j.clim.2007.08.012; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; Mayne M, 2001, STROKE, V32, P240, DOI 10.1161/01.STR.32.1.240; Mendelow AD, 2005, LANCET, V365, P387; Morgan T, 2008, ACTA NEUROCHIR SUPPL, V105, P147; Morgenstern LB, 2005, STROKE, V36, pE23, DOI 10.1161/01.STR.0000155685.77775.4c; Nawashiro H, 1997, BRAIN RES, V778, P265, DOI 10.1016/S0006-8993(97)00981-5; Niemann JT, 2010, CRIT CARE MED, V38, P1162, DOI 10.1097/CCM.0b013e3181d44324; Onda A, 2004, SPINE, V29, P1857, DOI 10.1097/01.brs.0000137054.08788.b2; Perez la de Ossa N, 2010, STROKE, V41, P810; Qureshi AI, 2010, ARCH NEUROL-CHICAGO, V67, P570, DOI 10.1001/archneurol.2010.61; Reed SD, 2001, NEUROLOGY, V57, P305, DOI 10.1212/WNL.57.2.305; Rodriguez-Yanez M, 2008, CURR OPIN NEUROL, V21, P353, DOI 10.1097/WCO.0b013e3282ffafbf; Sharma HS, 2010, ANN NY ACAD SCI, V1199, P175, DOI 10.1111/j.1749-6632.2009.05327.x; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Sun W, 2012, J CLIN NEUROSCI, V19, P1096, DOI 10.1016/j.jocn.2011.11.020; Wagner KR, 1996, STROKE, V27, P490, DOI 10.1161/01.STR.27.3.490; Wang XK, 2004, MOL PHARMACOL, V65, P890, DOI 10.1124/mol.65.4.890; Wasserman JK, 2007, EXP NEUROL, V207, P227, DOI 10.1016/j.expneurol.2007.06.025; Watters O, 2011, J NEUROIMMUNOL, V234, P27, DOI 10.1016/j.jneuroim.2011.01.008; Wu J, 2008, ACTA NEUROCHIR SUPPL, V105, P59; Wu JM, 2009, NEUROL RES, V31, P183, DOI 10.1179/174313209X385680; YANG GY, 1994, J NEUROSURG, V81, P93, DOI 10.3171/jns.1994.81.1.0093; Zhao XR, 2007, ANN NEUROL, V61, P352, DOI 10.1002/ana.21097	47	56	58	0	13	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	AUG 20	2013	10								103	10.1186/1742-2094-10-103			9	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	207EQ	WOS:000323580600001	23962089	Green Published, gold			2022-02-06	
J	Abo-Zaid, G; Guo, BL; Deeks, JJ; Debray, TPA; Steyerberg, EW; Moons, KGM; Riley, RD				Abo-Zaid, Ghada; Guo, Boliang; Deeks, Jonathan J.; Debray, Thomas P. A.; Steyerberg, Ewout W.; Moons, Karel G. M.; Riley, Richard David			Individual participant data meta-analyses should not ignore clustering	JOURNAL OF CLINICAL EPIDEMIOLOGY			English	Article						Individual participant data meta-analysis; Individual patient data; Evidence synthesis; Cluster; Simulation; Binary outcome; Pooled analysis	DEEP-VEIN THROMBOSIS; RANDOMIZED CONTROLLED-TRIALS; LINEAR MIXED-MODEL; PATIENT DATA; COVARIATE ADJUSTMENT; CLINICAL-TRIALS; AGGREGATE DATA; D-DIMER; MANAGEMENT; FRAMEWORK	Objectives: Individual participant data (IPD) meta-analyses often analyze their IPD as if coming from a single study. We compare this approach with analyses that rather account for clustering of patients within studies. Study Design and Setting: Comparison of effect estimates from logistic regression models in real and simulated examples. Results: The estimated prognostic effect of age in patients with traumatic brain injury is similar, regardless of whether clustering is accounted for. However, a family history of thrombophilia is found to be a diagnostic marker of deep vein thrombosis [odds ratio, 1.30; 95% confidence interval (CI): 1.00, 1.70; P = 0.05] when clustering is accounted for but not when it is ignored (odds ratio, 1.06; 95% CI: 0.83, 1.37; P = 0.64). Similarly, the treatment effect of nicotine gum on smoking cessation is severely attenuated when clustering is ignored (odds ratio, 1.40; 95% CI: 1.02, 1.92) rather than accounted for (odds ratio, 1.80; 95% CI: 1.29, 2.52). Simulations show models accounting for clustering perform consistently well, but downwardly biased effect estimates and low coverage can occur when ignoring clustering. Conclusion: Researchers must routinely account for clustering in IPD meta-analyses; otherwise, misleading effect estimates and conclusions may arise. (C) 2013 Elsevier Inc. All rights reserved.	[Abo-Zaid, Ghada] Univ Exeter, Royal Cornwall Hosp, European Ctr Environm & Human Hlth, Peninsula Coll Med & Dent, Truro TR1 3HD, Cornwall, England; [Guo, Boliang] Univ Nottingham, Sch Community Hlth Sci, Fac Med & Hlth Sci, Nottingham NG8 1BB, England; [Deeks, Jonathan J.] Univ Birmingham, Sch Hlth & Populat Sci, Birmingham B15 2TT, W Midlands, England; [Debray, Thomas P. A.; Moons, Karel G. M.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands		Riley, RD (corresponding author), Univ Birmingham, Sch Hlth & Populat Sci, Public Hlth Bldg, Birmingham B15 2TT, W Midlands, England.	r.d.riley@bham.ac.uk	Abo-Zaid, Ghada/AAY-7516-2020; Deeks, Jon/AAV-5745-2020; Debray, Thomas/J-7413-2012; GUO, Boliang/ABG-6506-2020; Riley, Richard/G-2406-2011; Steyerberg, Ewout W/C-1509-2018; Riley, Richard David/ABE-5877-2020	Deeks, Jon/0000-0002-8850-1971; Debray, Thomas/0000-0002-1790-2719; GUO, Boliang/0000-0002-1844-705X; Steyerberg, Ewout W/0000-0002-7787-0122; Riley, Richard David/0000-0001-8699-0735	MRC Midlands Hub for Trials Methodology Research, at the University of Birmingham (Medical Research Council) [G0800808]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800808] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0800808] Funding Source: UKRI	Although undertaking this work, G.A.-Z., J.J.D., and R.D.R. were supported by funding from the MRC Midlands Hub for Trials Methodology Research, at the University of Birmingham (Medical Research Council grant ID G0800808).	Abo-Zaid G, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-56; Ahmed I, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.d7762; Altman Douglas G, 2002, BMC Med Res Methodol, V2, P3, DOI 10.1186/1471-2288-2-3; Anderson DR, 2003, J THROMB HAEMOST, V1, P645, DOI 10.1046/j.1538-7836.2003.00131.x; Bland J Martin, 2004, BMC Med Res Methodol, V4, P21, DOI 10.1186/1471-2288-4-21; Bradburn MJ, 2007, STAT MED, V26, P53, DOI 10.1002/sim.2528; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; Chu HT, 2006, J CLIN EPIDEMIOL, V59, P1331, DOI 10.1016/j.jclinepi.2006.06.011; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; GAIL MH, 1984, BIOMETRIKA, V71, P431; Greenland S, 1999, STAT SCI, V14, P29; Hamza TH, 2008, J CLIN EPIDEMIOL, V61, P41, DOI 10.1016/j.jclinepi.2007.03.016; Hernandez AV, 2004, J CLIN EPIDEMIOL, V57, P454, DOI 10.1016/j.jclinepi.2003.09.014; Higgins JPT, 2001, STAT MED, V20, P2219, DOI 10.1002/sim.918; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jackson D, 2009, STAT MED, V28, P338, DOI 10.1002/sim.3487; Jones AP, 2009, CLIN TRIALS, V6, P16, DOI 10.1177/1740774508100984; Kraaijenhagen RA, 2002, ARCH INTERN MED, V162, P907, DOI 10.1001/archinte.162.8.907; Lee KJ, 2005, CLIN TRIALS, V2, P163, DOI 10.1191/1740774505cn082oa; MANTEL N, 1959, J NATL CANCER I, V22, P719; Mathew T, 1999, BIOMETRICS, V55, P1221, DOI 10.1111/j.0006-341X.1999.01221.x; Mathew T, 2010, BIOMETRICAL J, V52, P271, DOI 10.1002/bimj.200900143; Olkin I, 1998, BIOMETRICS, V54, P317, DOI 10.2307/2534018; Peters TJ, 2003, INT J EPIDEMIOL, V32, P840, DOI 10.1093/ije/dyg228; Rice VH, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001188.pub3; Riley RD, 2008, STAT MED, V27, P1870, DOI 10.1002/sim.3165; Riley RD, 2007, J CLIN EPIDEMIOL, V60, P431, DOI 10.1016/j.jclinepi.2006.09.009; Riley RD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c221; Riley RD, 2008, STAT MED, V27, P6111, DOI 10.1002/sim.3441; ROBINSON LD, 1991, INT STAT REV, V59, P227, DOI 10.2307/1403444; Simmonds MC, 2005, CLIN TRIALS, V2, P209, DOI 10.1191/1740774505cn087oa; Smith CT, 2007, CLIN TRIALS, V4, P621, DOI 10.1177/1740774507085276; Smith CT, 2005, STAT MED, V24, P1307, DOI 10.1002/sim.2050; Sterne J.A.C., 2009, METAANALYSIS STATA U; Stevens SM, 2004, ANN INTERN MED, V140, P985, DOI 10.7326/0003-4819-140-12-200406150-00007; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; Stewart LA, 2002, EVAL HEALTH PROF, V25, P76, DOI 10.1177/0163278702025001006; Steyerberg EW, 2000, AM HEART J, V139, P745, DOI 10.1016/S0002-8703(00)90001-2; Stijnen T, 2010, STAT MED, V29, P3046, DOI 10.1002/sim.4040; Toll DB, 2008, FAM PRACT, V25, P3, DOI 10.1093/fampra/cmm075; Toll DB, 2006, J FAM PRACTICE, V55, P613; Turner EL, 2012, J CLIN EPIDEMIOL, V65, P474, DOI 10.1016/j.jclinepi.2011.08.012; Turner RM, 2000, STAT MED, V19, P3417, DOI 10.1002/1097-0258(20001230)19:24<3417::AID-SIM614>3.0.CO;2-L; Wells PS, 2003, NEW ENGL J MED, V349, P1227, DOI 10.1056/NEJMoa023153; Whitehead A, 2001, STAT MED, V20, P2243, DOI 10.1002/sim.919; Whitehead A., 2002, METAANALYSIS CONTROL; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	47	56	56	0	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0895-4356	1878-5921		J CLIN EPIDEMIOL	J. Clin. Epidemiol.	AUG	2013	66	8					865	873		10.1016/j.jclinepi.2012.12.017			9	Health Care Sciences & Services; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Health Care Sciences & Services; Public, Environmental & Occupational Health	188PZ	WOS:000322207300008	23651765	Green Published, hybrid			2022-02-06	
J	Togher, L; McDonald, S; Tate, R; Power, E; Rietdijk, R				Togher, Leanne; McDonald, Skye; Tate, Robyn; Power, Emma; Rietdijk, Rachael			TRAINING COMMUNICATION PARTNERS OF PEOPLE WITH SEVERE TRAUMATIC BRAIN INJURY IMPROVES EVERYDAY CONVERSATIONS: A MULTICENTER SINGLE BLIND CLINICAL TRIAL	JOURNAL OF REHABILITATION MEDICINE			English	Article						communication; communication partner; traumatic brain injury; clinical; rehabilitation	HEAD-INJURY; REHABILITATION; EXPERIENCE; APHASIA; INDIVIDUALS; POPULATION; ADULTS	Objective: To determine effectiveness of communication training for partners of people with severe traumatic brain injury. Design: Three arm non-randomized controlled trial comparing communication partner training (JOINT) with individual treatment (TBI SOLO) and a waitlist control group with 6 month follow-up. Participants: Forty-four outpatients with severe chronic traumatic brain injuries were recruited. Intervention: Ten-week conversational skills treatment program encompassing weekly group and individual sessions for both treatment groups. The JOINT condition focused on both the partner and the person with traumatic brain injury while the TBI SOLO condition focused on the individual with TBI only. Main outcome measures: Primary outcomes were blind ratings of the person with traumatic brain injury's level of participation during conversation on the Measure of Participation in Communication Adapted Kagan scales. Results: Communication partner training improved conversational performance relative to training the person with traumatic brain injury alone and a waitlist control group on the primary outcome measures. Results were maintained at six months post-training. Conclusion: Training communication partners of people with chronic severe traumatic brain injury was more efficacious than training the person with traumatic brain injury alone. The Adapted Kagan scales proved to be a robust and sensitive outcome measure for a conversational skills training program.	[Togher, Leanne; Power, Emma; Rietdijk, Rachael] Univ Sydney, Fac Hlth Sci, Lidcombe, NSW 1825, Australia; [McDonald, Skye] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Tate, Robyn] Univ Sydney, Fac Med, Northern Clin Sch, Rehabil Studies Unit, Lidcombe, NSW 1825, Australia; [Tate, Robyn] Royal Rehabil Ctr Sydney, Sydney, NSW, Australia		Togher, L (corresponding author), Univ Sydney, Fac Hlth Sci, POB 170, Lidcombe, NSW 1825, Australia.	leanne.togher@sydney.edu.au	Togher, Leanne/AAC-7083-2019; Power, Emma/A-9263-2015; Rietdijk, Rachael/J-6573-2012; McDonald, Skye/G-4118-2014	Power, Emma/0000-0002-2638-0406; Rietdijk, Rachael/0000-0003-4343-4039; McDonald, Skye/0000-0003-0723-6094; Togher, Leanne/0000-0002-4518-6748	NHMRCNational Health and Medical Research Council of Australia [402687]	We would like to acknowledge the contributions of the study participants, Dr Rob Heard for statistical advice, and Gaye Murrills, and the staff of the Brain Injury Rehabilitation Units at Liverpool Hospital, Royal Rehabilitation Centre Sydney and Westmead Hospital for their assistance with participant recruitment. The first author was supported by an NHMRC Senior Research Fellowship during the writing of this paper, and this project was funded by NHMRC Project Grant 402687.	Behn N, 2012, BRAIN INJURY, V26, P1702, DOI 10.3109/02699052.2012.722258; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Douglas Jacinta M., 2010, Seminars in Speech and Language, V31, P197, DOI 10.1055/s-0030-1257536; Eggins S., 1997, ANAL CASUAL CONVERSA; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; Kagan A, 2001, J SPEECH LANG HEAR R, V44, P624, DOI 10.1044/1092-4388(2001/051); Kagan Aura, 2004, Top Stroke Rehabil, V11, P67; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Larkins B, 1999, ASIA PACIFIC J SPEEC, V4, P183; Lefebvre H, 2012, BRAIN INJURY, V26, P1084, DOI 10.3109/02699052.2012.666364; Legg C, 2005, APHASIOLOGY, V19, P559, DOI 10.1080/02687030544000029; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; OFlaherty CA, 1997, APHASIOLOGY, V11, P889, DOI 10.1080/02687039708250463; Rebecca K, 2011, COGNITIVE REHABILITA; Saldert C, 2012, J INTERACT RES COM D, V3, P141, DOI 10.1558/jircd.v3i2.141; TATE RL, 1987, SCAND J REHABIL MED, V19, P19; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1997, APHASIOLOGY, V11, P491, DOI 10.1080/02687039708248486; Togher L, 2004, APHASIOLOGY, V18, P313, DOI 10.1080/02687030344000535; Togher L, 2012, DISABIL REHABIL, V34, P1562, DOI 10.3109/09638288.2012.656788; Togher L, 2010, APHASIOLOGY, V24, P914, DOI 10.1080/02687030903422478; Turner S, 2006, APHASIOLOGY, V20, P483, DOI 10.1080/02687030600589991; World Health Organization, 2007, INT CLASS FUNCT DIS; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002; Ylvisaker M, 2003, J HEAD TRAUMA REHAB, V18, P7, DOI 10.1097/00001199-200301000-00005; Ylvisaker M., 1993, STAFF DEV CLIN INTER, P57; Ylvisaker M, 1998, TRAUMATIC BRAIN INJU, P303; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104	32	56	57	0	30	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977			J REHABIL MED	J. Rehabil. Med.	JUL	2013	45	7					637	645		10.2340/16501977-1173			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	189TA	WOS:000322290000005	23803687	gold, Green Submitted			2022-02-06	
J	Moreau, OK; Cortet-Rudelli, C; Yollin, E; Merlen, E; Daveluy, W; Rousseaux, M				Moreau, Odile Kozlowski; Cortet-Rudelli, Christine; Yollin, Edwige; Merlen, Emilie; Daveluy, Walter; Rousseaux, Marc			Growth Hormone Replacement Therapy in Patients with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						activities of daily living; cognitive disorders; hormone replacement therapy; pituitary hormone deficiency; quality of life; traumatic brain injury	QUALITY-OF-LIFE; GH-DEFICIENT ADULTS; ANTERIOR-PITUITARY FUNCTION; HEALTHY OLDER-ADULTS; COGNITIVE FUNCTION; FACTOR-I; REPORTED OUTCOMES; SPATIAL MEMORY; KIMS DATABASE; HEAD-INJURY	In patients with severe traumatic brain injury (TBI), a growth hormone deficiency (GHD) is frequent and may contribute to the cognitive sequelae and reduction in quality of life (QoL). Recent studies have suggested that GH replacement therapy (GHRT) can improve processing speed and memory. The aim of the study was to analyze the efficacy of GHRT on cognition, activities of daily living (ADL), and QoL and the factors that predicted and contributed to these effects. We included patients at least 1 year after their TBI and assessed pituitary functions (with stimulation tests), cognition (attention, memory, and executive function), participation in ADL and QoL. GHD was treated for at least 1 year in 23 patients, who were compared with 27 non-treated patients. Other deficiencies were also treated. Measurements were performed at baseline and 1 year later. An analysis of variance of the factors group and session (p <= 0.05) showed that most cognitive parameters had improved at 1 year (evidencing a session effect). A stronger effect of GHRT (i. e. a group x session interaction) was found for Rey Osterrieth complex figure recall and 2/6 domains in the QoL questionnaire ("personal'' and "functional''). Trends (p <= 0.07) were also found for spatial orientation and immediate recall in the verbal memory test. Greatest improvements were associated with lower performance before treatment. The magnitude of the improvements in ADL and QoL was moderately correlated with the improvement in cognition. In conclusion, replacement therapy can improve cognition and QoL in patients with TBI who have GHD, especially in those with severe disabilities.	[Moreau, Odile Kozlowski; Daveluy, Walter; Rousseaux, Marc] Swynghedauw Hosp, Neurol Rehabil Unit, Lille, France; [Cortet-Rudelli, Christine; Yollin, Edwige; Merlen, Emilie] CHRU Lille, Huriez Hosp, Endocrinol Unit, F-59037 Lille, France; [Cortet-Rudelli, Christine; Yollin, Edwige; Merlen, Emilie] Univ Lille Nord France, Lille, France		Rousseaux, M (corresponding author), CHRU Lille, Hop Swynghedauw, Serv Reeduc Neurol, F-59037 Lille, France.	marc.rousseaux@chru-lille.fr					Aberg ND, 2006, THESCIENTIFICWORLDJO, V6, P53, DOI 10.1100/tsw.2006.22; Abrams P, 2008, EUR J ENDOCRINOL, V159, P825, DOI 10.1530/EJE-08-0448; Abs R, 2005, GROWTH HORM IGF RES, V15, P349, DOI 10.1016/j.ghir.2005.06.018; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Arwert LI, 2005, HORM BEHAV, V47, P343, DOI 10.1016/j.yhbeh.2004.11.015; Arwert LI, 2005, GROWTH HORM IGF RES, V15, P47, DOI 10.1016/j.ghir.2004.11.004; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Auernhammer CJ, 2007, PITUITARY, V10, P1, DOI 10.1007/s11102-007-0001-6; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Baker LD, 2012, ARCH NEUROL-CHICAGO, V69, P1420, DOI 10.1001/archneurol.2012.1970; Baum HBA, 1998, J CLIN ENDOCR METAB, V83, P3184, DOI 10.1210/jc.83.9.3184; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; Bhagia V, 2010, BRAIN INJURY, V24, P560, DOI 10.3109/02699051003601705; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Brooks N., 1994, EVALUATION TRAUMATIC, V1994, P1; Burman P, 1996, CLIN ENDOCRINOL, V44, P319, DOI 10.1046/j.1365-2265.1996.617439.x; Carlozzi NE, 2011, ARCH PHYS MED REHAB, V92, pS52, DOI 10.1016/j.apmr.2010.12.046; Chrisoulidou A, 1998, BAILLIERE CLIN ENDOC, V12, P261, DOI 10.1016/S0950-351X(98)80022-0; Colao A, 2009, J CLIN ENDOCR METAB, V94, P4414, DOI 10.1210/jc.2009-1134; DEBOER H, 1995, ENDOCR REV, V16, P63, DOI 10.1210/er.16.1.63; Deijen JB, 1998, PSYCHONEUROENDOCRINO, V23, P45, DOI 10.1016/S0306-4530(97)00092-9; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; FEHMWOLFSDORF G, 1991, PEPTIDES, V12, P1399, DOI 10.1016/0196-9781(91)90226-F; Ghigo E, 2008, GROWTH HORM IGF RES, V18, P1, DOI 10.1016/j.ghir.2007.07.004; High WM, 2010, J NEUROTRAUM, V27, P1565, DOI 10.1089/neu.2009.1253; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kreitschmann-Andermahr I, 2008, GROWTH HORM IGF RES, V18, P472, DOI 10.1016/j.ghir.2008.08.007; Lasaite Lina, 2004, Medicina (Kaunas), V40, P740; Leon-Carrion J, 2007, BRAIN INJURY, V21, P871, DOI 10.1080/02699050701484849; LOBIE PE, 1993, DEV BRAIN RES, V74, P225, DOI 10.1016/0165-3806(93)90008-X; Maric NP, 2010, J ENDOCRINOL INVEST, V33, P770, DOI [10.3275/7045, 10.1007/BF03350340]; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; Molitch ME, 2011, J CLIN ENDOCR METAB, V96, P1587, DOI 10.1210/jc.2011-0179; Moreau OK, 2012, J NEUROTRAUM, V29, P81, DOI 10.1089/neu.2011.2048; Nieves-Martinez E, 2010, J ENDOCRINOL, V204, P31, DOI 10.1677/JOE-09-0323; Oertel H, 2004, PSYCHONEUROENDOCRINO, V29, P839, DOI 10.1016/S0306-4530(03)00151-3; Radcliffe DJ, 2004, PHARMACOECONOMICS, V22, P499, DOI 10.2165/00019053-200422080-00003; Reimunde P, 2011, BRAIN INJURY, V25, P65, DOI 10.3109/02699052.2010.536196; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Rosilio M, 2004, J CLIN ENDOCR METAB, V89, P1684, DOI 10.1210/jc.2003-030134; Sathiavageeswaran M, 2007, EUR J ENDOCRINOL, V156, P439, DOI 10.1530/eje.1.02346; Schneider HJ, 2011, CLIN ENDOCRINOL, V75, P825, DOI 10.1111/j.1365-2265.2011.04137.x; Schneider HJ, 2003, EUR J ENDOCRINOL, V149, P377, DOI 10.1530/eje.0.1490377; STABLER B, 1992, CLIN ENDOCRINOL, V36, P467, DOI 10.1111/j.1365-2265.1992.tb02247.x; Steel J, 2010, J TRAUMA, V69, P523, DOI 10.1097/TA.0b013e3181e90c24; Stouthart PJHM, 2003, PSYCHONEUROENDOCRINO, V28, P612, DOI 10.1016/S0306-4530(02)00045-8; Svensson J, 2004, GROWTH HORM IGF RES, V14, P207, DOI 10.1016/j.ghir.2003.12.001; Svensson J, 2007, GROWTH HORM IGF RES, V17, P67, DOI 10.1016/j.ghir.2006.11.002; Tandon A, 2009, ACTA NEUROCHIR, V151, P1411, DOI 10.1007/s00701-009-0444-9; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Tazopoulou E, 2005, ACTA NEUROPSYCHOL, V1, P13; Thornton PL, 2000, J GERONTOL A-BIOL, V55, pB106; van Dam P Sylze, 2006, Treat Endocrinol, V5, P159; van Dam PS, 2004, EUR J PHARMACOL, V490, P87, DOI 10.1016/j.ejphar.2004.02.047; van Dam PS, 2000, GROWTH HORM IGF RES, V10, P69, DOI 10.1016/S1096-6374(00)80013-1; Van der Linden M.A., 2004, EVALUATION TROUBLES; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vitiello MV, 2006, NEUROBIOL AGING, V27, P318, DOI 10.1016/j.neurobiolaging.2005.01.010; Webb S M, 2008, J Endocrinol Invest, V31, P52; Woodhouse LJ, 2006, ENDOCR REV, V27, P287, DOI 10.1210/er.2004-0022; Zimmermann P., 1994, TEST ATTENTIONAL PER	63	56	57	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2013	30	11					998	1006		10.1089/neu.2012.2705			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	166WD	WOS:000320589300010	23323993				2022-02-06	
J	Pilla, AA				Pilla, Arthur A.			Nonthermal electromagnetic fields: From first messenger to therapeutic applications	ELECTROMAGNETIC BIOLOGY AND MEDICINE			English	Article						calmodulin; first messenger; nitric oxide; pulsed electromagnetic field; radio frequency; signaling; tissue repair	NITRIC-OXIDE SYNTHASE; POSTOPERATIVE PAIN; ALZHEIMERS-DISEASE; LORENTZ MODEL; THERMAL NOISE; DOUBLE-BLIND; IN-VITRO; CALMODULIN; NO; ANGIOGENESIS	Nonthermal pulsed electromagnetic fields, from low frequency to pulse-modulated radio frequency, have been successfully employed as adjunctive therapy for the treatment of delayed and non-union fractures, fresh fractures and chronic wounds. Recent increased understanding of the mechanism of action of electromagnetic fields (EMF) has permitted technologic advances allowing the development of EMF devices which are portable and disposable, can be incorporated into dressings, supports and casts, and can be used over clothing. This broadens the use of non-pharmacological, non-invasive EMF therapy to the treatment of postoperative pain and edema to enhance surgical recovery. EMF therapy is rapidly becoming a standard part of surgical care, and new, more significant, clinical applications for osteoarthritis, brain and cardiac ischemia and traumatic brain injury are in the pipeline. This study reviews recent evidence which suggests that calmodulin (CaM)-dependent nitric oxide signaling is involved in cell and tissue response to weak nonthermal EMF signals. There is abundant evidence that EMF signals can be configured a priori to increase the rate of CaM activation, which, in turn, can modulate the biochemical cascades living cells and tissues employ in response to external insult. Successful applications in pilot clinical trials, coupled with evidence at the cellular and animal levels, provide support that EMF is a first messenger that can modulate the response of challenged biological systems.	[Pilla, Arthur A.] Columbia Univ, Dept Biomed Engn, New York, NY USA; [Pilla, Arthur A.] Mt Sinai Sch Med, Dept Orthoped, New York, NY USA		Pilla, AA (corresponding author), 1 Winding Ridge, Oakland, NJ 07436 USA.	aap1@columbia.edu					Arendash GW, 2012, J ALZHEIMERS DIS, V32, P243, DOI 10.3233/JAD-2012-120943; Arendash GW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035751; Arendash GW, 2010, J ALZHEIMERS DIS, V19, P191, DOI 10.3233/JAD-2010-1228; Batchelor AM, 2010, P NATL ACAD SCI USA, V107, P22060, DOI 10.1073/pnas.1013147107; BLUMENTHAL DK, 1982, BIOCHEMISTRY-US, V21, P2386, DOI 10.1021/bi00539a017; Bootman MD, 2001, J CELL SCI, V114, P2213; Borhade N, 2012, CHEM PHARM BULL, V60, P465, DOI 10.1248/cpb.60.465; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brighton CT, 2008, J BONE JOINT SURG AM, V90A, P833, DOI 10.2106/JBJS.F.01437; BROUGHTON GH, 2006, PLAST RECONSTR SUR S, V117; Callaghan MJ, 2008, PLAST RECONSTR SURG, V121, P130, DOI 10.1097/01.prs.0000293761.27219.84; Chang K, 2004, EXP MOL MED, V36, P311, DOI 10.1038/emm.2004.42; Chen Y, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-13; Cheng DK, 1959, ANAL LINEAR SYSTEMS; CHIABRERA A, 1993, BIOELECTROCH BIOENER, V30, P35, DOI 10.1016/0302-4598(93)80060-8; Chiarini Anna, 2006, Italian Journal of Anatomy and Embryology, V111, P221; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Cooke JP, 2003, ATHEROSCLEROSIS SUPP, V4, P53, DOI 10.1016/S1567-5688(03)00034-5; Cury Y, 2011, NITRIC OXIDE-BIOL CH, V25, P243, DOI 10.1016/j.niox.2011.06.004; Daff S, 2003, BIOCHEM SOC T, V31, P502, DOI 10.1042/BST0310502; De Mattei M, 2009, OSTEOARTHR CARTILAGE, V17, P252, DOI 10.1016/j.joca.2008.06.002; DeFelice LJ, 1981, INTRO MEMBRANE NOISE, P243; Delle Monache S, 2008, BIOELECTROMAGNETICS, V29, P640, DOI 10.1002/bem.20430; Dragicevic N, 2011, NEUROSCIENCE, V185, P135, DOI 10.1016/j.neuroscience.2011.04.012; Duran WN, 2010, CARDIOVASC RES, V87, P254, DOI 10.1093/cvr/cvq139; EDMONDS DT, 1993, BIOELECTROCH BIOENER, V30, P3, DOI 10.1016/0302-4598(93)80057-2; Faas GC, 2011, NAT NEUROSCI, V14, P301, DOI 10.1038/nn.2746; Heden P, 2008, AESTHET PLAST SURG, V32, P660, DOI 10.1007/s00266-008-9169-z; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; KAVALIERS M, 1991, BIOL BULL, V180, P301, DOI 10.2307/1542401; Konieczny V, 2012, SEMIN CELL DEV BIOL, V23, P172, DOI 10.1016/j.semcdb.2011.09.006; Kowalczuk C, 2010, BIOELECTROMAGNETICS, V31, P556, DOI 10.1002/bem.20597; Kwon MS, 2012, BIOELECTROMAGNETICS, V33, P247, DOI 10.1002/bem.20702; Lauretti GR, 1999, ANESTHESIOLOGY, V90, P734, DOI 10.1097/00000542-199903000-00015; Lee RH, 2001, J SURG RES, V101, P104, DOI 10.1006/jsre.2001.6261; MARKOV MS, 1994, CHARGE FIELD EFFECTS, V4, P274; Mellstrom B, 2008, PHYSIOL REV, V88, P421, DOI 10.1152/physrev.00041.2005; Mo E, 2004, J BIOL CHEM, V279, P26149, DOI 10.1074/jbc.M400916200; Moffett J, 2010, J DIABET FOOT COMPLI, V2, P57; Moffett J., 2011, J DIABETES FOOT COMP, V2, P30; Moffett John, 2012, J Pain Res, V5, P347, DOI 10.2147/JPR.S35076; Muehsam DJ, 2009, BIOELECTROMAGNETICS, V30, P476, DOI 10.1002/bem.20493; Muehsam DJ, 2009, BIOELECTROMAGNETICS, V30, P462, DOI 10.1002/bem.20494; Nelson FR, 2012, RHEUMATOL INT; Palmi M, 2002, MOL NEUROBIOL, V25, P133, DOI 10.1385/MN:25:2:133; Parazzini M, 2007, RADIAT RES, V168, P608, DOI 10.1667/RR1020.1; Patel MK, 2006, J RECONSTR MICROSURG, V22, P611, DOI 10.1055/s-2006-956231; Pilla A., 2006, HDB BIOL EFFECTS ELE, P351; PILLA A A, 1974, Bioelectrochemistry and Bioenergetics, V1, P227, DOI 10.1016/0302-4598(74)85024-5; Pilla A. A., 1972, Proceedings of the 7th Intersociety Energy conversion Engineering conference, P761; PILLA AA, 1970, J ELECTROCHEM SOC, V117, P467, DOI 10.1149/1.2407544; PILLA AA, 1994, BIOELECTROCH BIOENER, V35, P63, DOI 10.1016/0302-4598(94)87013-6; Pilla AA, 1999, BIOELECTROCH BIOENER, V48, P27, DOI 10.1016/S0302-4598(98)00148-2; PILLA AA, 1974, ANN NY ACAD SCI, V238, P149, DOI 10.1111/j.1749-6632.1974.tb26785.x; Pilla AA, 2010, P 32 ANN M BIOEL SOC; Pilla A, 2011, BBA-GEN SUBJECTS, V1810, P1236, DOI 10.1016/j.bbagen.2011.10.001; Pilla AA, 2012, BIOCHEM BIOPH RES CO, V426, P330, DOI 10.1016/j.bbrc.2012.08.078; PRATO FS, 1995, FASEB J, V9, P807, DOI 10.1096/fasebj.9.9.7601344; Rawe IM, 2012, AESTHET PLAST SURG, V36, P458, DOI 10.1007/s00266-011-9828-3; Reale M, 2006, NITRIC OXIDE-BIOL CH, V15, P50, DOI 10.1016/j.niox.2005.11.010; Ren K, 2009, BRAIN RES REV, V60, P57, DOI 10.1016/j.brainresrev.2008.12.020; Rohde C, 2010, PLAST RECONSTR SURG, V125, P1620, DOI 10.1097/PRS.0b013e3181c9f6d3; Roland D, 2000, PLAST RECONSTR SURG, V105, P1371, DOI 10.1097/00006534-200004040-00016; Shen MYH, 2009, J AM COLL CARDIOL, V53, pA346; Sluka KA, 1999, J PHARMACOL EXP THER, V289, P840; Strauch B, 2006, P 28 ANN M BIOEL SOC; Strauch B, 2007, PLAST RECONSTR SURG, V120, P425, DOI 10.1097/01.prs.0000267700.15452.d0; Strauch B, 2006, J HAND SURG-AM, V31A, P1131, DOI 10.1016/j.jhsa.2006.03.024; Strauch B, 2009, AESTHET SURG J, V29, P135, DOI 10.1016/j.asj.2009.02.001; Tepper OM, 2004, FASEB J, V18, P1231, DOI 10.1096/fj.03-0847fje; Tsoukias N, 2008, MICROCIRCULATION, V15, P813, DOI 10.1080/10739680802010070; Varani K, 2011, BIOELECTROMAGNETICS, P276, DOI [10.1002/bem.20704.33, DOI 10.1002/BEM.20704.33:276-287]; Velazquez C, 2005, J MED CHEM, V48, P4061, DOI 10.1021/jm050211k; Vianale G, 2008, BRIT J DERMATOL, V158, P1189, DOI 10.1111/j.1365-2133.2008.08540.x; Wachten D., 2010, HDB CELL SIGNAL, V2, P937, DOI [10.1016/B978-0-12-374145-5.00117-0, DOI 10.1016/B978-0-12-374145-5.00117-0]; Wang ZY, 2006, J BONE JOINT SURG AM, V88A, P1053, DOI 10.2106/JBJS.E.00443; Weber RV, 2004, PLAST RECONSTR SURG, V114, P1185, DOI 10.1097/01.prs.0000135857.95310.13; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; YENPATTON GPA, 1988, J CELL PHYSIOL, V134, P37, DOI 10.1002/jcp.1041340105	79	56	60	3	17	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1536-8378	1536-8386		ELECTROMAGN BIOL MED	Electromagn. Biol. Med.	JUN	2013	32	2					123	136		10.3109/15368378.2013.776335			14	Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Life Sciences & Biomedicine - Other Topics; Biophysics	144LA	WOS:000318939500002	23675615				2022-02-06	
J	Loane, DJ; Stoica, BA; Byrnes, KR; Jeong, W; Faden, AI				Loane, David J.; Stoica, Bogdan A.; Byrnes, Kimberly R.; Jeong, William; Faden, Alan I.			Activation of mGluR5 and Inhibition of NADPH Oxidase Improves Functional Recovery after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						functional recovery; microglia; metabotropic glutamate receptor 5; NADPH oxidase; neuroprotection; traumatic brain injury	METABOTROPIC GLUTAMATE RECEPTORS; CELL-DEATH; NEURONAL APOPTOSIS; OXIDATIVE STRESS; MICROGLIA; LIPOPOLYSACCHARIDE; NEUROTOXICITY; EXPRESSION; NEUROINFLAMMATION; NEUROPROTECTION	Traumatic brain injury (TBI) induces microglial activation, which can contribute to secondary tissue loss. Activation of mGluR5 reduces microglial activation and inhibits microglial-mediated neurodegeneration in vitro, and is neuroprotective in experimental models of CNS injury. In vitro studies also suggest that the beneficial effects of mGluR5 activation involve nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibition in activated microglia. We hypothesized that activation of mGluR5 by the selective agonist CHPG after TBI in mice is neuroprotective and that its therapeutic actions are mediated by NADPH oxidase inhibition. Vehicle, CHPG, or CHPG plus the mGluR5 antagonist (MPEP), were administered centrally, 30 minutes post-TBI, and functional recovery and lesion volume was assessed. CHPG significantly attenuated post-traumatic sensorimotor and cognitive deficits, and reduced lesion volumes; these effects were blocked by MPEP, thereby indicating neuroprotection involved selective activation of mGluR5. CHPG treatment also reduced NF kappa B activity and nitrite production in lipopolysaccharide-stimulated microglia and the protective effects of CHPG treatment were abrogated in NADPH oxidase deficient microglial cultures (gp91(phox-/-)). To address whether the neuroprotective effects of CHPG are mediated via the inhibition of NADPH oxidase, we administered the NADPH oxidase inhibitor apocynin with or without CHPG treatment after TBI. Both apocynin or CHPG treatment alone improved sensorimotor deficits and reduced lesion volumes when compared with vehicle-treated mice; however, the combined CHPG + apocynin treatment was not superior to CHPG alone. These data suggest that the neuroprotective effects of activating mGluR5 receptors after TBI are mediated, in part, via the inhibition of NADPH oxidase.	[Loane, David J.; Stoica, Bogdan A.; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Loane, David J.; Stoica, Bogdan A.; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Natl Study Ctr Trauma & EMS, Baltimore, MD 21201 USA; [Loane, David J.; Stoica, Bogdan A.; Byrnes, Kimberly R.; Jeong, William; Faden, Alan I.] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; [Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA		Faden, AI (corresponding author), Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Hlth Sci Facil 2, S247,20 Penn St, Baltimore, MD 21201 USA.	afaden@anes.umm.edu	STOICA, BOGDAN/H-9782-2013; Loane, David/ABD-5177-2021	STOICA, BOGDAN/0000-0002-2501-6434; Loane, David/0000-0003-0393-3503; Faden, Alan I./0000-0003-0128-2348; Byrnes, Kimberly/0000-0002-7501-7734	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5R01NS037313]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313, R01NS052568] Funding Source: NIH RePORTER	We thank Dr. Mian Xie, Dr. Chun-shu Piao, and Ms. Titilola Akintola for expert technical support, and Dr. Shruti Kabadi for helpful discussion. This work was supported by a grant from the NIH/NINDS to A.I.F. (5R01NS037313).	Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Allen JW, 2000, CELL DEATH DIFFER, V7, P470, DOI 10.1038/sj.cdd.4400678; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bao WL, 2001, BRAIN RES, V922, P173, DOI 10.1016/S0006-8993(01)03062-1; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Byrnes KR, 2009, ANN NEUROL, V66, P63, DOI 10.1002/ana.21673; Byrnes KR, 2009, NEUROTHERAPEUTICS, V6, P94, DOI 10.1016/j.nurt.2008.10.038; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Chen H, 2011, NEUROBIOL DIS, V42, P341, DOI 10.1016/j.nbd.2011.01.027; Chen H, 2009, J CEREBR BLOOD F MET, V29, P1262, DOI 10.1038/jcbfm.2009.47; Chen T, 2012, NEUROCHEM RES, V37, P983, DOI 10.1007/s11064-011-0691-z; Chen T, 2012, INT J MOL MED, V29, P630, DOI 10.3892/ijmm.2011.870; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Drouin-Ouellet J, 2011, GLIA, V59, P188, DOI 10.1002/glia.21086; Farso MC, 2009, NEUROCHEM RES, V34, P1721, DOI 10.1007/s11064-009-9999-3; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; Lea PM, 2002, PHARMACOL BIOCHEM BE, V73, P287, DOI 10.1016/S0091-3057(02)00825-0; Loane David J, 2012, Wiley Interdiscip Rev Membr Transp Signal, V1, P136; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014; Movsesyan VA, 2004, J NEUROCHEM, V89, P1528, DOI 10.1111/j.1471-4159.2004.02451.x; Nicoletti E, 2011, NEUROPHARMACOLOGY, V60, P1017, DOI 10.1016/j.neuropharm.2010.10.022; Pawate S, 2004, J NEUROSCI RES, V77, P540, DOI 10.1002/jnr.20180; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Vincent AM, 1999, EXP NEUROL, V155, P79, DOI 10.1006/exnr.1998.6966; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wang JW, 2012, BRAIN RES, V1464, P73, DOI 10.1016/j.brainres.2012.05.014; Wang Q, 2006, BRAIN RES, V1090, P182, DOI 10.1016/j.brainres.2006.03.060; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhu PM, 2004, J NEUROSCI RES, V77, P525, DOI 10.1002/jnr.20175	36	56	56	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2013	30	5					403	412		10.1089/neu.2012.2589			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	103CI	WOS:000315891600010	23199080	Green Published			2022-02-06	
J	Fabbri, A; Servadei, F; Marchesini, G; Bronzoni, C; Montesi, D; Arietta, L				Fabbri, Andrea; Servadei, Franco; Marchesini, Giulio; Bronzoni, Carolina; Montesi, Danilo; Arietta, Luca		Soc Italiana Med Emergenza Urgenza	Antiplatelet therapy and the outcome of subjects with intracranial injury: the Italian SIMEU study	CRITICAL CARE			English	Article							TRAUMATIC BRAIN-INJURY; MODERATE HEAD-INJURY; ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE; INTRACEREBRAL HEMORRHAGE; SUBARACHNOID HEMORRHAGE; EUROPEAN-SOCIETY; RISK-FACTORS; TASK-FORCE; PROGRESSION; VALIDATION	Introduction: Pre-injury antithrombotic therapy might influence the outcome of subjects with head injuries and positive computed tomography (CT) scans. We aimed to determine the potential risk of pre-injury antiplatelet drug use on short-and long-term outcome of head injured subjects admitted to emergency departments (EDs) in Italy for extended observation. Methods: A total of 1,558 adult subjects with mild, moderate and severe head injury admitted to Italian EDs were studied. In multivariable logistic regression analyses, the short-term outcome was assessed by an evaluation of head CT scan at 6 to 24 hours after trauma and the long-term outcome by the Glasgow outcome scale (GOS) at six months. Results: Head CT scan comparisons showed that 201 subjects (12.9%) worsened. The risk of worsening was increased two fold by the use of antiplatelet drugs (106, 19.7% treated versus 95, 9.3% untreated; relative risk (RR) 2.09, 95% CI 1.63 to 2.71). The risk was particularly high in subjects on clopidogrel (RR 5.76, 95% CI 3.88 to 8.54), independent of the association with aspirin. By logistic regression, 5 of 14 items were independently associated with worsening (Glasgow coma scale (GCS), Marshall category, antiplatelet therapy, intraventricular hemorrhage, number of lesions). After six months, only 4 of 14 items were predictors of unfavorable outcome (GOS 1 to 3) (GCS score, Marshall category, age in decades, intracerebral hemorrhage/contusion). The risk increased by 50% in the group treated with antiplatelet therapy (RR 1.58, 95% CI 1.28 to 1.95; P < 0.001). Conclusions: Antithrombotic therapy (in particular clopidogrel) is a risk factor for both short-term and long-term unfavorable outcome in subjects with head injury, increasing the risk of progression and death, permanent vegetative state and severe disability.	[Fabbri, Andrea] Presidio Osped Morgagni Pierantoni, Dipartimento Emergenza, Azienda Unita Sanit Locale Forli, I-40121 Forli, Italy; [Servadei, Franco; Bronzoni, Carolina] Univ Parma, Azienda Osped, Dipartimento Emergenza Urgenza, I-43126 Parma, Italy; [Marchesini, Giulio] Univ Bologna, Dipartimento Sci Med & Chirurg, I-40138 Bologna, Italy; [Montesi, Danilo; Arietta, Luca] Univ Bologna, Dipartimento Informat Sci & Ingn, I-40127 Bologna, Italy		Fabbri, A (corresponding author), Presidio Osped Morgagni Pierantoni, Dipartimento Emergenza, Azienda Unita Sanit Locale Forli, Via Forlanini 34, I-40121 Forli, Italy.	dr.andrea.fabbri@gmail.com	Fabbri, Andrea/K-9994-2016; Vercelli, Alessandro/A-1926-2012	Fabbri, Andrea/0000-0002-9837-4638; Servadei, Franco/0000-0002-3595-3464; MONTESI, DANILO/0000-0002-4748-6867; Scaldaferri, Luca/0000-0001-8493-5628; Vercelli, Alessandro/0000-0002-5909-2128; Marchesini, Giulio/0000-0003-2407-9860			Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Bachelani AM, 2011, SURGERY, V150, P836, DOI 10.1016/j.surg.2011.07.059; Batchelor JS, 2012, BRIT J NEUROSURG, V26, P525, DOI 10.3109/02688697.2011.650736; Beynon C, 2012, CRIT CARE, V16, DOI 10.1186/cc11292; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; DEROSA M, 2007, COLLANA RAPPORTI ARN, V11, P1; Donze J, 2012, AM J MED, V125, P773, DOI 10.1016/j.amjmed.2012.01.033; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P1180, DOI 10.1136/jnnp.2007.135178; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P567, DOI 10.1136/jnnp.2007.120162; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; FABBRI A, J NEUROL NEUROSURG P, V81, P1275; Flint AC, 2008, J NEUROTRAUM, V25, P503, DOI 10.1089/neu.2007.0442; Giannoudis PV, 2009, INJURY, V40, P362, DOI 10.1016/j.injury.2008.10.016; Hamm CW, 2011, EUR HEART J, V32, P2999, DOI 10.1093/eurheartj/ehr236; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; *ISS AIFA, 2008, US FARM IT, P36; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martini SR, 2012, NEUROLOGY, V79, P2275, DOI 10.1212/WNL.0b013e318276896f; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Patrono C, 2004, EUR HEART J, V25, P166, DOI 10.1016/j.ehj.2003.10.013; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Servadei F, 2002, BRIT J NEUROSURG, V16, P36, DOI 10.1080/02688690120114255; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87; Smith SC, 2001, CIRCULATION, V104, P1577, DOI 10.1161/hc3801.097475; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TAN MSP, 2006, INTRO DATA MINING, P1; Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), 2010, Eur Heart J, V31, P2501, DOI 10.1093/eurheartj/ehq277; Visca A, 2006, BRIT J NEUROSURG, V20, P82, DOI 10.1080/02688690600682416; Yadav YR, 2006, NEUROL INDIA, V54, P377, DOI 10.4103/0028-3886.28109	40	56	56	1	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2013	17	2							R53	10.1186/cc12575			11	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	264OG	WOS:000327887300018	23514619	Green Published, gold			2022-02-06	
J	Mendez, MF; Owens, EM; Berenji, GR; Peppers, DC; Liang, LJ; Licht, EA				Mendez, Mario F.; Owens, Emily M.; Berenji, Gholam Reza; Peppers, Dominique C.; Liang, Li-Jung; Licht, Eliot A.			Mild traumatic brain injury from primary blast vs. blunt forces: Post-concussion consequences and functional neuroimaging	NEUROREHABILITATION			English	Article						Mild traumatic brain injury; blast forces; post-concussion; positron emission tomography imaging	PERSISTENT POSTCONCUSSIVE SYMPTOMS; POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL GLUCOSE-METABOLISM; OIF/OEF SERVICE MEMBERS; NEUROPSYCHOLOGICAL DEFICITS; WAR VETERANS; HEAD-INJURY; FDG-PET; MECHANISMS; STRESS	INTRODUCTION: Primary blast forces may cause dysfunction from mild traumatic brain injury (mTBI). OBJECTIVE: To investigate the effects of primary blast forces, independent of associated blunt trauma and post-traumatic stress disorder, on sensitive post-concussive measures. METHODS: This study investigated post-concussive symptoms, functional health and well-being, cognition, and positron emission tomography (PET) neuroimaging among 12 Iraq or Afghanistanwar veterans who sustained pure blast-force mTBI, compared to 12 who sustained pure blunt-force mTBI. RESULTS: Both groups had significantly lower scores than published norms on the Rivermead Post-Concussion Questionnaire (RPQ) and the SF36-V Health Survey. Compared to the Blunt Group, the Blast Group had poorer scores on the Paced Auditory Serial Addition Test (PASAT) and greater PET hypometabolism in the right superior parietal region. Only the Blast Group had significant correlations of their RPQ, SF36-V Mental Composite Score, and PASAT scores with specific regional metabolic changes. CONCLUSION: This pilot study suggests that pure blast force mTBI may have greater post-concussive sequelae including deficits in attentional control and regional brain metabolism, compared to blunt mTBI. A disturbance of a right parietal-frontal attentional network is one potential explanation for these findings.	[Mendez, Mario F.; Owens, Emily M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90024 USA; [Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA; [Mendez, Mario F.; Licht, Eliot A.] VA Greater Los Angeles Healthcare Ctr, Neurol Sect, Los Angeles, CA 90073 USA; [Berenji, Gholam Reza; Peppers, Dominique C.] VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA 90073 USA; [Liang, Li-Jung] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90024 USA		Mendez, MF (corresponding author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit 691 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	mmendez@UCLA.edu			Veterans Affairs AdministrationUS Department of Veterans Affairs	No conflicts of interest. This research was made possible by a grant from the Veterans Affairs Administration.	Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Drake AI, 2010, NEUROREHABILITATION, V26, P183, DOI 10.3233/NRE-2010-0554; Dubois B, 2000, NEUROLOGY, V55, P1621, DOI 10.1212/WNL.55.11.1621; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Ferrier-Auerbach AG, 2010, J PSYCHIATR RES, V44, P470, DOI 10.1016/j.jpsychires.2009.10.010; Fitzgerald KD, 2005, BIOL PSYCHIAT, V57, P287, DOI 10.1016/j.biopsych.2004.10.038; French LM, 2010, ANN NY ACAD SCI, V1208, P38, DOI 10.1111/j.1749-6632.2010.05696.x; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Hayes JP, 2012, NEUROCASE, V18, P258, DOI 10.1080/13554794.2011.588181; Heltemes KJ, 2012, INJURY, V43, P1990, DOI 10.1016/j.injury.2011.07.021; Hoffer Michael E, 2009, Int Tinnitus J, V15, P115; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kazis LE, 2004, HEALTH CARE FINANC R, V25, P43; Kazis Lewis E, 2004, J Ambul Care Manage, V27, P70; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; King NS, 2008, BRAIN INJURY, V22, P1, DOI 10.1080/02699050701829696; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kozminski M, 2010, J AM OSTEOPATH ASSOC, V110, P514; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Lull N, 2010, BRAIN INJURY, V24, P1098, DOI 10.3109/02699052.2010.494592; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MacGregor AJ, 2011, J HEAD TRAUMA REHAB, V26, P312, DOI 10.1097/HTR.0b013e3181e94404; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McDonald SD, 2010, CLIN PSYCHOL REV, V30, P976, DOI 10.1016/j.cpr.2010.06.012; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Silverman DHS, 2011, PSYCHONEUROENDOCRINO, V36, P502, DOI 10.1016/j.psyneuen.2010.08.002; Silverman DHS, 2004, J NUCL MED, V45, P594; Singh JA, 2005, J AM GERIATR SOC, V53, P108, DOI 10.1111/j.1532-5415.2005.53020.x; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tombaugh TN, 2006, ARCH CLIN NEUROPSYCH, V21, P53, DOI 10.1016/j.acn.2005.07.006; Vasquez BP, 2011, NEUROPSYCHOLOGIA, V49, P1741, DOI 10.1016/j.neuropsychologia.2011.02.052; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wilson JTL, 2005, ACTA NEUROCHIR SUPPL, V93, P75; Zakzanis KK, 2011, ARCH CLIN NEUROPSYCH, V26, P461, DOI 10.1093/arclin/acr021; Zhang J, 2010, J NEUROTRAUM, V27, P35, DOI 10.1089/neu.2009.1049	69	56	56	0	31	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2013	32	2					397	407		10.3233/NRE-130861			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	115ZT	WOS:000316851900025	23535805				2022-02-06	
J	Pineda, JA; Leonard, JR; Mazotas, IG; Noetzel, M; Limbrick, DD; Keller, MS; Gill, J; Doctor, A				Pineda, Jose A.; Leonard, Jeffrey R.; Mazotas, Ioanna G.; Noetzel, Michael; Limbrick, David D.; Keller, Martin S.; Gill, Jeff; Doctor, Allan			Effect of implementation of a paediatric neurocritical care programme on outcomes after severe traumatic brain injury: a retrospective cohort study	LANCET NEUROLOGY			English	Article							SEVERE HEAD-INJURY; INTENSIVE-CARE; CHILDREN; MORTALITY; EXPERIENCE; MANAGEMENT; RECOMMENDATIONS; VALIDITY; IMPACT; SCALE	Background Outcomes after traumatic brain injury are worsened by secondary insults; modern intensive-care units address such challenges through use of best-practice pathways. Organisation of intensive-care units has an important role in pathway effectiveness. We aimed to assess the effect of a paediatric neurocritical care programme (PNCP) on outcomes for children with severe traumatic brain injury. Methods We undertook a retrospective cohort study of 123 paediatric patients with severe traumatic brain injury (Glasgow coma scale scores <= 8, without gunshot or abusive head trauma, cardiac arrest, or Glasgow coma scale scores of 3 with fixed and dilated pupils) admitted to the paediatric intensive-care unit of the St Louis Children's Hospital (St Louis, MO, USA) between July 15, 1999, and Jan 15, 2012. The primary outcome was rate of categorised hospital discharge disposition before and after implementation of a PNCP on Sept 17, 2005. We developed an ordered probit statistical model to assess adjusted outcome as a function of initial injury severity. We assessed care-team behaviour by comparing timing of invasive neuromonitoring and scored intensity of therapies targeting intracranial hypertension. Findings Characteristics of treated patients (aged 3-219 months) were much the same between treatment periods. Before PNCP implementation, 33 (52%) of 63 patients had unfavourable disposition at hospital discharge (death or admission to an inpatient facility) and 30 (48%) had a favourable disposition (home with or without treatment); after PNCP implementation, 20 (33%) of 60 patients had unfavourable disposition and 40 (67%) had favourable disposition (p=0.01). Seven (11%) patients died before PNCP implementation compared with two (3%) deaths after implementation. The probit model indicated that outcome improved across the spectrum of Glasgow coma scale scores after resuscitation (p=0.02); this improvement progressed with increasing injury severity. Kaplan-Meier analysis suggested that neuromonitoring was started earlier and maintained longer after implementation of the PNCP (p=0.03). Therapeutic intensity scores were increased for the first 3 days of treatment after PNCP implementation (p=0.0298 for day 1, 1)=0.0292 for day 2, and p=0.0471 for day 3). The probit model suggested that increasing age (p=0.03), paediatric risk of mortality III scores (p=0.0003), and injury severity scores (p=0.02) were reliably associated with increased probability of unfavourable outcomes whereas white race (p=0.01), use of intracranial pressure monitoring (p=0.001), and increasing Glasgow coma scale scores after resuscitation (p=0.04) were associated with increased probability of favourable outcomes. Interpretation Outcomes for children with traumatic brain injury can be improved by altering the care system in a way that stably implements a cooperative programme of accepted best practice.	[Pineda, Jose A.; Doctor, Allan] Washington Univ, Sch Med, Dept Pediat, Div Crit Care Med, St Louis, MO 63110 USA; [Pineda, Jose A.; Noetzel, Michael] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Mazotas, Ioanna G.; Keller, Martin S.; Gill, Jeff] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; [Leonard, Jeffrey R.; Limbrick, David D.] Washington Univ, Sch Med, Dept Neurosurg, St Louis, MO 63110 USA; [Leonard, Jeffrey R.; Limbrick, David D.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Gill, Jeff] Washington Univ, Sch Med, Dept Polit Sci, St Louis, MO 63110 USA; [Gill, Jeff] Washington Univ, Sch Med, Dept Biostat, St Louis, MO 63110 USA; [Doctor, Allan] Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA		Pineda, JA (corresponding author), Washington Univ, Sch Med, Dept Pediat, Div Crit Care Med, Campus Box 8116,1 Childrens Pl, St Louis, MO 63110 USA.	pineda_j@kids.wustl.edu	Pineda, Jose/W-2806-2019	Doctor, Allan/0000-0002-6096-6400	St Louis Children's Hospital; Sean Glanvill Foundations	Funding St Louis Children's Hospital and the Sean Glanvill Foundations.	Beers SR, 2012, J NEUROTRAUM, V29, P1126, DOI 10.1089/neu.2011.2272; Bell MJ, 2009, NEUROCRIT CARE, V10, P4, DOI 10.1007/s12028-008-9061-3; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Crowe LM, 2012, J PEDIATR PSYCHOL, V37, P745, DOI 10.1093/jpepsy/jss070; Cuschieri J, 2012, ANN SURG, V255, P993, DOI 10.1097/SLA.0b013e31824f1ebc; Davis DA, 1997, CAN MED ASSOC J, V157, P408; Dean NP, 2007, J NEUROSURG, V107, P387, DOI 10.3171/PED-07/11/387; Dougherty D, 2008, JAMA-J AM MED ASSOC, V299, P2319, DOI 10.1001/jama.299.19.2319; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Figaji AA, 2009, CHILD NERV SYST, V25, P1325, DOI 10.1007/s00381-009-0822-x; Forsyth RJ, 2008, PEDIATR CRIT CARE ME, V9, P8, DOI 10.1097/01.PCC.0000298759.78616.3A; Glass HC, 2010, NEUROCRIT CARE, V12, P421, DOI 10.1007/s12028-009-9324-7; Guerguerian AM, 2009, CURR OPIN PEDIATR, V21, P737, DOI 10.1097/MOP.0b013e328332d11c; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Keller JM, 2012, J ORTHOP TRAUMA, V26, pE161, DOI 10.1097/BOT.0b013e3182324460; Knopf L, 2012, NEUROCRIT CARE, V16, P63, DOI 10.1007/s12028-011-9620-x; Logani S, 2011, CRIT CARE RES PRACT, V2011, DOI 10.1155/2011/170814; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Potoka DA, 2000, J TRAUMA, V49, P237, DOI 10.1097/00005373-200008000-00009; Randolph AG, 2002, J EVAL CLIN PRACT, V8, P1; Salorio CF, 2008, PEDIATR CRIT CARE ME, V9, P47, DOI 10.1097/01.PCC.0000298638.66240.0E; Scaife ER, 2010, CURR OPIN PEDIATR, V22, P339, DOI 10.1097/MOP.0b013e3283395f2b; Shi JX, 2009, BRAIN INJURY, V23, P602, DOI 10.1080/02699050903014907; Shore PM, 2006, CRIT CARE MED, V34, P1981, DOI 10.1097/01.CCM.0000220765.22184.ED; Society of Critical Care Medicine, 2003, Crit Care Med, V31, pS407; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Stocchetti N, 2010, MINERVA ANESTESIOL, V76, P1052; Sutton Gigi, 2011, J Healthc Qual, V33, P10, DOI 10.1111/j.1945-1474.2011.00138.x; Tasker RC, 2011, BRIT J NEUROSURG, V25, P68, DOI 10.3109/02688697.2010.538770; Wetzel RC, 2011, PEDIATR ANESTH, V21, P787, DOI 10.1111/j.1460-9592.2011.03595.x	35	56	57	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2013	12	1					45	52		10.1016/S1474-4422(12)70269-7			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	055PR	WOS:000312429400019	23200264				2022-02-06	
J	Rivara, FP; Koepsell, TD; Wang, J; Temkin, N; Dorsch, A; Vavilala, MS; Durbin, D; Jaffe, KM				Rivara, Frederick P.; Koepsell, Thomas D.; Wang, Jin; Temkin, Nancy; Dorsch, Andrea; Vavilala, Monica S.; Durbin, Dennis; Jaffe, Kenneth M.			Incidence of Disability Among Children 12 Months After Traumatic Brain Injury	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							QUALITY-OF-LIFE; HEAD; CONCUSSIONS; SPORT	Objectives. We examined the burden of disability resulting from traumatic brain injuries (TBIs) among children younger than 18 years. Methods. We derived our data from a cohort study of children residing in King County, Washington, who were treated in an emergency department for a TBI or for an arm injury during 2007-2008. Disabilities 12 months after injury were assessed according to need for specialized educational and community-based services and scores on standardized measures of adaptive functioning and social community participation. Results. The incidence of children receiving new services at 12 months was about 10-fold higher among those with a mild TBI than among those with a moderate or severe TBI. The population incidence of disability (defined according to scores below the norm means on the outcome measures included) was also consistently much larger (2.8-fold to 28-fold) for mild TBIs than for severe TBIs. Conclusions. The burden of disability caused by TBIs among children is primarily accounted for by mild injuries. Efforts to prevent these injuries as well as to decrease levels of disability following TBIs are warranted. (Am J Public Health. 2012;102:2074-2079. doi:10.2105/AJPH.2012.300696)	[Rivara, Frederick P.; Wang, Jin] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Rivara, Frederick P.; Koepsell, Thomas D.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Koepsell, Thomas D.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; [Temkin, Nancy; Jaffe, Kenneth M.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Dorsch, Andrea] Seattle Childrens Hosp, Dept Rehabil Med, Seattle, WA USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Dept Pain Med & Pediat, Seattle, WA 98195 USA; [Durbin, Dennis] Childrens Hosp Philadelphia, Dept Emergency Med, Philadelphia, PA USA; [Durbin, Dennis] Univ Penn, Philadelphia, PA 19104 USA; [Jaffe, Kenneth M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA		Rivara, FP (corresponding author), Harborview Injury Prevent & Res Ctr, Box 359960,325 9th Ave, Seattle, WA 98104 USA.	fpr@uw.edu	Durbin, Dennis/AAD-7829-2022		National Center for Injury Prevention and Control, Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CE 001021]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001021] Funding Source: NIH RePORTER	This project was supported by the National Center for Injury Prevention and Control, Centers for Disease Control and Prevention (grant R49 CE 001021).	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; [Anonymous], 2010, OFFICIAL POPULATION; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Bedell G., 2006, BRAIN INJ PROF, V3, P14; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Centers for Disease Control and Prevention, 2003, REPORT TO CONGRESS O; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guice KS, 2007, J TRAUMA, V63, pS68, DOI 10.1097/TA.0b013e31815acbb6; Harrison PL, 2003, ADAPTIVE BEHAVIOR AS; Koepsell TD, 2011, PEDIATRICS, V128, P946, DOI 10.1542/peds.2010-2259; Langlois J. A., 2000, TRAUMATIC BRAIN INJU; Marr A., 2004, CENTRAL NERVOUS SYST; McCarthy ML, 2007, J TRAUMA, V63, pS122, DOI 10.1097/TA.0b013e31815accdf; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Mitka M, 2010, JAMA-J AM MED ASSOC, V304, P1775, DOI 10.1001/jama.2010.1487; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Numminen HJ, 2011, EUR J NEUROL, V18, P460, DOI 10.1111/j.1468-1331.2010.03179.x; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Rivara FP, 2011, HEALTH SERV RES, V46, P964, DOI 10.1111/j.1475-6773.2010.01236.x; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Straume-Naesheim TM, 2009, NEUROSURGERY, V64, P719, DOI 10.1227/01.NEU.0000340681.12949.6D; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; US Equal Employment Opportunity Commission, SECTION 902 DEFINITI; Varni JW, 2009, PEDIATR CLIN N AM, V56, P843, DOI 10.1016/j.pcl.2009.05.016; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Washington State Legislature, CHILD WITH A DISABIL; World Health Organisation, 2001, INTERNATIONAL CLASSI; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	32	56	56	0	16	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	NOV	2012	102	11					2074	2079		10.2105/AJPH.2012.300696			6	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	028CB	WOS:000310399300014	22994196	Green Published			2022-02-06	
J	Tomura, S; Vaccari, JPD; Keane, RW; Bramlett, HM; Dietrich, WD				Tomura, Satoshi; Vaccari, Juan Pablo de Rivero; Keane, Robert W.; Bramlett, Helen M.; Dietrich, W. Dalton			Effects of therapeutic hypothermia on inflammasome signaling after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						caspase-1; hypothermia; IL-1; inflammasome; innate immunity; traumatic brain injury	INNATE IMMUNE-RESPONSE; POSTTRAUMATIC HYPOTHERMIA; CEREBROSPINAL-FLUID; PROTEIN-LEVELS; INTERLEUKIN-1-BETA; DAMAGE; MODEL; ACTIVATION; EXPRESSION; SUPPRESSION	Traumatic brain injury (TBI) activates the NALP1/NLRP1 inflammasome, which is an important component of the early innate inflammatory response to injury. We investigated the influence of therapeutic hypothermia on inflammasome activation after TBI. Adult male Sprague-Dawley rats were subjected to moderate fluid percussion brain injury. Temperature manipulation (33 degrees C or 37 degrees C) was initiated 30 minutes after TBI and maintained for 4 hours. At 4 or 24 hours after TBI, traumatized cortex and hippocampus were prepared for immunoblot or immunohistochemical analysis. In the normothermic groups, caspase-1, caspase-11 and expression of the purinergic receptor P2X7 increased at 24 hours after TBI. Posttraumatic hypothermia lead to decreased expression of these proteins at 24 hours compared with normothermic levels. Immunocytochemical studies showed that posttraumatic hypothermia also decreased caspase-1 staining in cerebral cortical neurons compared with normothermic TBI. Cultured cortical neurons subjected to stretch injury demonstrated significant secretion of caspase-1 into the culture medium and caspase-3 activation, both results reduced by hypothermic treatment. Posttraumatic hypothermia decreases inflammasome signaling in neurons and reduces the innate immune response to TBI at 24 hours after injury. Therapeutic hypothermia may protect the injured central nervous system by targeting the detrimental consequences of the innate immune response to injury. Journal of Cerebral Blood Flow & Metabolism (2012) 32, 1939-1947; doi:10.1038/jcbfm.2012.99; published online 11 July 2012	[Tomura, Satoshi; Vaccari, Juan Pablo de Rivero; Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; [Tomura, Satoshi; Vaccari, Juan Pablo de Rivero; Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; [Bramlett, Helen M.] Bruce W Carter Dept Vet Affairs Med Ctr, Miami, FL USA		Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, 1095 NW 14th Terrace, Miami, FL 33136 USA.	ddietrich@miami.edu	de Rivero Vaccari, Juan Pablo/ABE-3248-2020; de Rivero Vaccari, Juan Pablo/H-5718-2019	de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834; 	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS030291, NS 042133]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, P50NS030291] Funding Source: NIH RePORTER	This work was supported by NIH NS030291 and NS 042133.	Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; CLIFTON GL, 1992, J NEUROTRAUM, V9, pS487; Vaccari JPD, 2012, GLIA, V60, P414, DOI 10.1002/glia.22275; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dinarello CA, 2005, CRIT CARE MED, V33, pS460, DOI 10.1097/01.CCM.0000185500.11080.91; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Finsen B, 2011, FEBS LETT, V585, P3806, DOI 10.1016/j.febslet.2011.05.030; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Mawhinney LJ, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-123; Mirzoyev SA, 2010, RESUSCITATION, V81, P1632, DOI 10.1016/j.resuscitation.2010.08.007; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; Prieto R, 2011, BRAIN RES, V1404, P39, DOI 10.1016/j.brainres.2011.06.006; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Silverman WR, 2009, J BIOL CHEM, V284, P18143, DOI 10.1074/jbc.M109.004804; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Yenari MA, 2012, NAT REV NEUROSCI, V13, P267, DOI 10.1038/nrn3174; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	40	56	62	0	18	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2012	32	10					1939	1947		10.1038/jcbfm.2012.99			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	014KY	WOS:000309375800012	22781337	Green Published, Bronze			2022-02-06	
J	Li, LM; Kolias, AG; Guilfoyle, MR; Timofeev, I; Corteen, EA; Pickard, JD; Menon, DK; Kirkpatrick, PJ; Hutchinson, PJ				Li, Lucia M.; Kolias, Angelos G.; Guilfoyle, Mathew R.; Timofeev, Ivan; Corteen, Elizabeth A.; Pickard, John D.; Menon, David K.; Kirkpatrick, Peter J.; Hutchinson, Peter J.			Outcome following evacuation of acute subdural haematomas: a comparison of craniotomy with decompressive craniectomy	ACTA NEUROCHIRURGICA			English	Article						Traumatic brain injury; Craniotomy; Decompressive craniectomy; Acute subdural hematoma	TRAUMATIC BRAIN-INJURY; HEAD-INJURIES; MANAGEMENT; MORTALITY; COMPLICATIONS; EPIDEMIOLOGY	Acute subdural haematomas (ASDH) occur commonly following traumatic brain injury and may be evacuated by either craniotomy (CR) or decompressive craniectomy (DC). We reviewed a series of consecutive patients undergoing evacuation of a traumatic ASDH at a regional centre, comparing observed clinical outcomes (assessed by Glasgow Outcome Scale at six months) with those predicted by the CRASH-CT prognostic model. Retrospective review of prospectively collected data. Ninety-one patients were identified (51 DC and 40 CR ). Eighty-five had available admission data sets from which predicted outcome could be calculated. The DC group were younger than the CR group (p = 0.015). The DC group also had a greater proportion of patients whose pre-intubation GCS was a parts per thousand currency sign8 (p = 0.001), with significant extracranial injuries (p = 0.001) and obliterated basal cisterns (p = 0.001) on their pre-operative CT scan. Bone flaps in the DC group (n = 45) were longer (mean 11.6 cm; 95 % CI: 11.1-12.1) in comparison to bone flaps in the CR (n = 34) group [(mean 10.2 cm; 95 % CI: 9.35 - 10.9); p = 0.0024] The mean CRASH-CT predicted risk of 14-day mortality and of unfavourable outcome at six months was significantly higher in the DC group compared with the CR group. Eighty-eight patients had available 6-month Glasgow Outcome Scale scores. Favourable outcomes were observed in 42 % of DC versus 45 % of CR (p = 0.83). The overall mortality rate was 38 % in DC versus 32 % in CR (p = 0.65). The standardised morbidity ratio (observed/expected unfavourable outcomes) was 0.75 (95 % CI: 0.51-1.07) for DC and 0.90 (95 % CI: 0.57-1.35) for CR. CR and DC for traumatic ASDH are both commonly used for primary evacuation of ASDH. Primary DC may be more effective than CR for selected patients with ASDH. Class I evidence is required in order to refine the indications for DC following evacuation of ASDH.	[Li, Lucia M.; Kolias, Angelos G.; Guilfoyle, Mathew R.; Timofeev, Ivan; Corteen, Elizabeth A.; Pickard, John D.; Kirkpatrick, Peter J.; Hutchinson, Peter J.] Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 0QQ, England; [Li, Lucia M.; Kolias, Angelos G.; Guilfoyle, Mathew R.; Timofeev, Ivan; Corteen, Elizabeth A.; Pickard, John D.; Menon, David K.; Kirkpatrick, Peter J.; Hutchinson, Peter J.] Univ Cambridge, Cambridge CB2 0QQ, England; [Menon, David K.] Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 0QQ, England		Kolias, AG (corresponding author), Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Hills Rd, Cambridge CB2 0QQ, England.	angeloskolias@gmail.com	Timofeev, Ivan/AAE-7019-2019	Li, Lucia/0000-0001-7339-4854; Timofeev, Ivan/0000-0002-1168-0393; Corteen, Elizabeth/0000-0002-3069-9655; Kolias, Angelos/0000-0003-3992-0587	Academic Foundation Programme, East of England Deanery; Royal College of Surgeons of England Research Fellowship; Freemasons; Rosetrees TrustRosetrees Trust; National Institute for Health Research Academic Clinical Fellowship; Raymond and Beverly Sackler Studentship; Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0001237, G0600986, G0601025, G9439390] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0601025, G9439390, G0001237, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327, ACF-2011-14-003] Funding Source: researchfish	We thank Anne Manktelow for her assistance. LML is supported by an Academic Foundation Programme, East of England Deanery. AGK is supported by a Royal College of Surgeons of England Research Fellowship (funded by the Freemasons and the Rosetrees Trust), a National Institute for Health Research Academic Clinical Fellowship and a Raymond and Beverly Sackler Studentship. JDP and DKM are National Institute for Health Research Senior Investigators. PJH is supported by an Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship.	Bullock AR, 2006, NEUROSURGERY, V58, pVI; Chen SH, 2011, J TRAUMA; Compagnone C, 2005, NEUROSURGERY, V57, P1183; d'Avella D, 2003, ACTA NEUROCHIR, V145, P1037, DOI 10.1007/s00701-003-0150-y; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Hanif S, 2009, Ir Med J, V102, P255; Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13; Hlatky R, 2007, NEUROSURGERY, V61, P249, DOI [10.1227/01.NEU.0000143029.42638.2c, 10.1227/01.neu.0000279220.30633.45]; Kim KH, 2009, J KOREAN NEUROSURG S, V45, P143, DOI 10.3340/jkns.2009.45.3.143; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Kolias AG, 2012, ACTA NEUROCHIR WIEN; Leitgeb J, 2007, WIEN KLIN WOCHENSCHR, V119, P56, DOI 10.1007/s00508-006-0764-1; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Paci GM, 2009, J TRAUMA, V67, P531, DOI 10.1097/TA.0b013e3181b840e8; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Rothman K.J., 1979, EPIDEMIOLOGIC ANAL P; Sawauchi S, 2008, ACTA NEUROCHIR, V150, P531, DOI 10.1007/s00701-007-1497-2; Sawauchi S, 2007, NEUROL SURG TOKYO, V35, P665; Sawauchi S, 2007, NEUROL SURG TOKYO, V35, P43; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Senft C, 2009, NEUROL RES, V31, P1012, DOI 10.1179/174313209X409034; SHIGEMORI M, 1991, Neurologia Medico-Chirurgica, V31, P390, DOI 10.2176/nmc.31.390; SHIGEMORI M, 1980, ACTA NEUROCHIR, V54, P61, DOI 10.1007/BF01401944; Statistics OfN, 2008, REG TRENDS LOC AUTH; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Tagliaferri F, 2012, ACTA NEUROCHIR, V154, P919, DOI 10.1007/s00701-012-1318-0; Tallon JM, 2008, CAN J SURG, V51, P339; Taussky P, 2008, SWISS MED WKLY, V138, P281, DOI 2008/19/smw-12056; Timofeev I, 1800, Adv Tech Stand Neurosurg, V38, P115, DOI 10.1007/978-3-7091-0676-1_6; Tomita Y, 2000, ACTA NEUROCHIR SUPPL, V76, P213; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; van Leeuwen N, 2011, NEUROSURGERY; von Elm E, 2007, LANCET, V370, P1453, DOI [10.1371/journal.pmed.0040297, 10.1371/journal.pmed.0040296, 10.1157/13119325, 10.1016/S0140-6736(07)61602-X]; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Woertgen C, 2006, J CLIN NEUROSCI, V13, P718, DOI 10.1016/j.jocn.2005.08.019; Wong GKC, 2010, ACTA NEUROCHIR SUPPL, V106, P235, DOI 10.1007/978-3-211-98811-4_44; Yanaka Kiyoyuki, 1993, Neurologia Medico-Chirurgica, V33, P552, DOI 10.2176/nmc.33.552	40	56	57	0	5	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	SEP	2012	154	9					1555	1561		10.1007/s00701-012-1428-8			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	994UF	WOS:000307957500003	22752713				2022-02-06	
J	Moran, LM; Taylor, HG; Rusin, J; Bangert, B; Dietrich, A; Nuss, KE; Wright, M; Minich, N; Yeates, KO				Moran, Lisa M.; Taylor, H. Gerry; Rusin, Jerome; Bangert, Barbara; Dietrich, Ann; Nuss, Kathryn E.; Wright, Martha; Minich, Nori; Yeates, Keith O.			Quality of Life in Pediatric Mild Traumatic Brain Injury and its Relationship to Postconcussive Symptoms	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						brain injuries; child; postconcussive symptoms; quality of life	POST-CONCUSSIVE SYMPTOMS; CLOSED-HEAD INJURIES; CHILD HEALTH; NEUROBEHAVIORAL SYMPTOMS; FAMILY BURDEN; 1ST YEAR; INSTRUMENTS; ADOLESCENTS; AGREEMENT; OUTCOMES	Objectives Mild traumatic brain injury (TBI) and injury-related outcomes such as postconcussive symptoms (PCS) may influence health-related quality of life (HRQOL) in children. Methods We evaluated HRQOL in 186 8- to 15-year-old children with mild TBI and 99 children with orthopedic injuries (OI). Parents rated the frequency and severity of PCS at an initial assessment within 2-weeks postinjury and rated HRQOL at 3- and 12-months postinjury. Results The mild TBI and OI groups did not differ in psychosocial HRQOL, but the mild TBI group showed lower physical HRQOL at the 12-month follow-up. Somatic PCS were a significant predictor of physical HRQOL over time, and both cognitive and somatic PCS were significant predictors of psychosocial HRQOL over time. Children with higher PCS at the initial assessment had lower HRQOL scores at later time points. Conclusions Effective management of PCS may be associated with improvements in HRQOL following pediatric mild TBI.	[Yeates, Keith O.] Nationwide Childrens Hosp, Dept Psychol, Ctr Biobehav Hlth, Res Inst, Columbus, OH 43205 USA; [Moran, Lisa M.] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA; [Taylor, H. Gerry; Wright, Martha; Minich, Nori] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry; Wright, Martha] Univ Hosp, Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH 43205 USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Radiol, San Antonio, TX USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Neurosurg, San Antonio, TX USA; [Dietrich, Ann; Nuss, Kathryn E.] Ohio State Univ, Dept Pediat, Coll Med, Columbus, OH 43210 USA; [Dietrich, Ann; Nuss, Kathryn E.] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH 43205 USA		Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Ctr Biobehav Hlth, Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892; Nuss, Kathryn/0000-0003-2185-7364	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039834, K02HD044099] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD44099, HD39834] Funding Source: Medline		Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; *AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Anderson V, 2010, J NEUROTRAUM, V27, P863, DOI 10.1089/neu.2009.1169; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; Davis E, 2006, DEV MED CHILD NEUROL, V48, P311, DOI 10.1017/S0012162206000673; Drotar D, 2004, AMBUL PEDIATR, V4, P353, DOI 10.1367/1539-4409(2004)4<353:MCHSQC>2.0.CO;2; Eiser C, 2001, QUAL LIFE RES, V10, P347, DOI 10.1023/A:1012253723272; Eiser C, 2001, J DEV BEHAV PEDIATR, V22, P248, DOI 10.1097/00004703-200108000-00007; Eiser C, 2001, ARCH DIS CHILD, V84, P205, DOI 10.1136/adc.84.3.205; Eiser C, 2007, ARCH DIS CHILD, V92, P348, DOI 10.1136/adc.2005.086405; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Erickson SJ, 2010, DEV NEUROREHABIL, V13, P175, DOI 10.3109/17518420903479867; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Hajek CA, 2011, CHILD NEUROPSYCHOL, V17, P17, DOI 10.1080/09297049.2010.495058; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Landgraf JM, 1996, CHILD HLTH QUESTIONN; Leeuw J.D., 2008, HDB MULTILEVEL ANAL; Limond J, 2009, BRAIN INJURY, V23, P617, DOI 10.1080/02699050902997870; Matza LS, 2004, VALUE HEALTH, V7, P79, DOI 10.1111/j.1524-4733.2004.71273.x; McCarthy ML, 2007, J TRAUMA, V63, pS122, DOI 10.1097/TA.0b013e31815accdf; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Mittenberg W., 1997, CLIN NEUROPSYCHOL, V11, P305; Palermo TM, 2008, J PEDIATR PSYCHOL, V33, P983, DOI 10.1093/jpepsy/jsn038; Petersen C, 2008, BRAIN INJURY, V22, P215, DOI 10.1080/02699050801935245; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Raat H, 2006, CURR OPIN ALLERGY CL, V6, P180, DOI 10.1097/01.all.0000225157.67897.c2; Raudenbush SW., 2002, HIERARCHICAL LINEAR, V1; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Singer JD, 1998, J EDUC BEHAV STAT, V23, P323; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Taylor H. G., 2010, PEDIAT TRAUMATIC BRA, P145; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; TEASDALE G, 1974, LANCET, V2, P81; Theunissen NCM, 1998, QUAL LIFE RES, V7, P387, DOI 10.1023/A:1008801802877; Tilford JM, 2007, NEUROCRIT CARE, V7, P64, DOI 10.1007/s12028-007-0037-5; Upton P, 2008, QUAL LIFE RES, V17, P895, DOI 10.1007/s11136-008-9350-5; Winthrop AL, 2010, CURR OPIN PEDIATR, V22, P346, DOI 10.1097/MOP.0b013e3283394351; World Health Organization, 2020, CONST; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	50	56	56	0	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	AUG	2012	37	7					736	744		10.1093/jpepsy/jsr087			9	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	981KC	WOS:000306965500004	21994421	Green Published, Bronze			2022-02-06	
J	Ajao, DO; Pop, V; Kamper, JE; Adami, A; Rudobeck, E; Huang, L; Vlkolinsky, R; Hartman, RE; Ashwal, S; Obenaus, A; Badaut, J				Ajao, David O.; Pop, Viorela; Kamper, Joel E.; Adami, Arash; Rudobeck, Emil; Huang, Lei; Vlkolinsky, Roman; Hartman, Richard E.; Ashwal, Stephen; Obenaus, Andre; Badaut, Jerome			Traumatic Brain Injury in Young Rats Leads to Progressive Behavioral Deficits Coincident with Altered Tissue Properties in Adulthood	JOURNAL OF NEUROTRAUMA			English	Article						behavior; CNPase; juvenile traumatic brain injury; magnetic resonance imaging; myelin; neurofilament-200	CONTROLLED CORTICAL IMPACT; COGNITIVE DEFICITS; AXONAL INJURY; IMMATURE RAT; CHILDREN; TERM; PROTEIN; EXPRESSION; CONTUSION; RECOVERY	Traumatic brain injury (TBI) affects many infants and children, and results in enduring motor and cognitive impairments with accompanying changes in white matter tracts, yet few experimental studies in rodent juvenile models of TBI (jTBI) have examined the timeline and nature of these deficits, histologically and functionally. We used a single controlled cortical impact (CCI) injury to the parietal cortex of rats at post-natal day (P) 17 to evaluate behavioral alterations, injury volume, and morphological and molecular changes in gray and white matter, with accompanying measures of electrophysiological function. At 60 days post-injury (dpi), we found that jTBI animals displayed behavioral deficits in foot-fault and rotarod tests, along with a left turn bias throughout their early developmental stages and into adulthood. In addition, anxiety-like behaviors on the zero maze emerged in jTBI animals at 60 dpi. The final lesion constituted only similar to 3% of brain volume, and morphological tissue changes were evaluated using MRI, as well as immunohistochemistry for neuronal nuclei (NeuN), myelin basic protein (MBP), neurofilament-200 (NF200), and oligodendrocytes (CNPase). White matter morphological changes were associated with a global increase in MBP immunostaining and reduced compound action potential amplitudes at 60 dpi. These results suggest that brain injury early in life can induce long-term white matter dysfunction, occurring in parallel with the delayed development and persistence of behavioral deficits, thus modeling clinical and longitudinal TBI observations.	[Badaut, Jerome] Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92354 USA; [Ajao, David O.; Badaut, Jerome] Loma Linda Univ, Dept Physiol, Loma Linda, CA 92354 USA; [Kamper, Joel E.; Hartman, Richard E.] Loma Linda Univ, Dept Psychol, Loma Linda, CA 92354 USA; [Huang, Lei; Vlkolinsky, Roman; Obenaus, Andre] Loma Linda Univ, Dept Radiat Med, Loma Linda, CA 92354 USA; [Obenaus, Andre] Loma Linda Univ, Dept Biophys & Bioengn, Loma Linda, CA 92354 USA; [Obenaus, Andre] Loma Linda Univ, Dept Radiol, Loma Linda, CA 92354 USA; [Adami, Arash] Univ Calif Riverside, Dept Neurosci, Riverside, CA 92521 USA; [Rudobeck, Emil] Univ Calif Riverside, Dept Phys, Riverside, CA 92521 USA		Badaut, J (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, Room A1120,11175 Campus St, Loma Linda, CA 92354 USA.	jbadaut@llu.edu	Hartman, Richard/C-5767-2008; Kamper, Joel/V-2450-2019	Hartman, Richard/0000-0001-9235-3169; Kamper, Joel/0000-0001-5098-5176; Rudobeck, Emil/0000-0001-7949-4282	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD061946]; Pediatric Research Fund; Swiss Science FoundationSwiss National Science Foundation (SNSF) [FN 31003A-122166, IZK0Z3-128973]; Department of Pediatrics; NASANational Aeronautics & Space Administration (NASA) [NCC9-149]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061946] Funding Source: NIH RePORTER	The authors thank Mr. Dane W. Sorensen for his technical help in this work, and Monica Rubalcava at the Advanced Imaging and Microscopy facility at Loma Linda. This work was supported in part by the National Institutes of Health (R01HD061946), the Pediatric Research Fund, the Swiss Science Foundation (FN 31003A-122166 and IZK0Z3-128973), the Department of Pediatrics, and a NASA Cooperative Agreement (NCC9-149) to the Radiobiology Program, Department of Radiation Medicine, at Loma Linda University.	Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Akiyama K, 2002, J NEUROSCI RES, V68, P19, DOI 10.1002/jnr.10188; Badaut J, 2007, PEDIATR RES, V62, P248, DOI 10.1203/PDR.0b013e3180db291b; Badaut J, 2011, J CEREBR BLOOD F MET, V31, P819, DOI 10.1038/jcbfm.2010.163; Barreto G, 2010, J NEUROSURG ANESTH, V22, P214, DOI 10.1097/ANA.0b013e3181d56c98; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; BJELKE B, 1989, INT J DEV NEUROSCI, V7, P145, DOI 10.1016/0736-5748(89)90065-8; Bloch J, 2011, J COMP NEUROL, V519, P775, DOI 10.1002/cne.22547; BOLTON CF, 1980, J NEUROL NEUROSUR PS, V43, P925, DOI 10.1136/jnnp.43.10.925; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Brenner LA, 2007, J HEAD TRAUMA REHAB, V22, P56, DOI 10.1097/00001199-200701000-00007; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chan JR, 1998, P NATL ACAD SCI USA, V95, P10459, DOI 10.1073/pnas.95.18.10459; Choo AMT, 2009, J NEUROSCI METH, V181, P6, DOI 10.1016/j.jneumeth.2009.04.007; Fujii Daryl, 2002, Cogn Neuropsychiatry, V7, P41, DOI 10.1080/135468000143000131; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Glezer I, 2004, NEUROSCIENTIST, V10, P538, DOI 10.1177/1073858404263494; Goold D, 2009, J TRAUMA, V67, P71, DOI 10.1097/TA.0b013e3181b021ae; Hartman RE, 2005, J NEUROSCI, V25, P6213, DOI 10.1523/JNEUROSCI.0664-05.2005; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Huh JW, 2007, J NEUROTRAUM, V24, P1460, DOI 10.1089/neu.2006.3787; Iannotti CA, 2011, EXP NEUROL, V230, P3, DOI 10.1016/j.expneurol.2010.03.010; Ihara M, 2010, ACTA NEUROPATHOL, V119, P579, DOI 10.1007/s00401-009-0635-8; Jane JA, 1996, NEUROTRAUMA, P723; Kodama Y, 2008, DEV PSYCHOBIOL, V50, P332, DOI 10.1002/dev.20289; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lippert-Gruner M, 2006, BRAIN INJURY, V20, P569, DOI 10.1080/02699050600664467; Liu F, 2009, J NEUROSCI METH, V179, P1, DOI 10.1016/j.jneumeth.2008.12.028; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nishibe M, 2010, J NEUROTRAUM, V27, P2221, DOI 10.1089/neu.2010.1456; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Obenaus A, 2011, ANN NEUROL, V69, P282, DOI 10.1002/ana.22168; Ono M, 2008, NEUROSCIENCE, V156, P1103, DOI 10.1016/j.neuroscience.2008.07.078; Prigatano GP, 2008, J HEAD TRAUMA REHAB, V23, P414, DOI 10.1097/01.HTR.0000341438.97745.ee; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Recker R, 2009, J CEREBR BLOOD F MET, V29, P1305, DOI 10.1038/jcbfm.2009.56; RUSSELL PA, 1973, ANIM BEHAV, V21, P109, DOI 10.1016/S0003-3472(73)80047-8; Sandler SJI, 2010, CHILD NERV SYST, V26, P205, DOI 10.1007/s00381-009-1009-1; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Tanaka H, 2009, J NEUROSCI, V29, P8363, DOI 10.1523/JNEUROSCI.3216-08.2009; Velumian AA, 2011, J NEUROPHYSIOL, V105, P929, DOI 10.1152/jn.00435.2010; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Wilde EA, 2006, J CHILD NEUROL, V21, P769, DOI 10.1177/08830738060210090201; Wong SKF, 2004, ANAL BIOCHEM, V333, P265, DOI 10.1016/j.ab.2004.05.011; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	55	56	58	0	10	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	11					2060	2074		10.1089/neu.2011.1883			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	983CX	WOS:000307095800007	22697253	Green Published			2022-02-06	
J	Corrigan, F; Vink, R; Blumbergs, PC; Masters, CL; Cappai, R; van den Heuvel, C				Corrigan, Frances; Vink, Robert; Blumbergs, Peter C.; Masters, Colin L.; Cappai, Roberto; van den Heuvel, Corinna			sAPPa rescues deficits in amyloid precursor protein knockout mice following focal traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						amyloid precursor protein; sAPPa; traumatic brain injury	CONTROLLED CORTICAL IMPACT; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; HEAD-INJURY; HIPPOCAMPAL-NEURONS; NEURITE OUTGROWTH; SECRETED FORMS; BETA-PROTEIN; RISK-FACTOR; NEUTROPHIL INFILTRATION	J. Neurochem. (2012) 122, 208220. Abstract The amyloid precursor protein (APP) is thought to be neuroprotective following traumatic brain injury (TBI), although definitive evidence at moderate to severe levels of injury is lacking. In the current study, we investigated histological and functional outcomes in APP-/- mice compared with APP+/+ mice following a moderate focal injury, and whether administration of sAPPa restored the outcomes in knockout animals back to the wildtype state. Following moderate controlled cortical impact injury, APP-/- mice demonstrated greater impairment in motor and cognitive outcome as determined by the ledged beam and Barnes Maze tests respectively (p < 0.05). This corresponded with the degree of neuronal damage, with APP-/- mice having significantly greater lesion volume (25.0 +/- 1.6 vs. 20.3 +/- 1.6%, p < 0.01) and hippocampal damage, with less remaining CA neurons (839 +/- 245 vs. 1353 +/- 142 and 1401 +/- 263). This was also associated with an impaired neuroreparative response, with decreased GAP-43 immunoreactivity within the cortex around the lesion edge compared with APP+/+ mice. The deficits observed in the APP-/- mice related to a lack of sAPPa, as treatment with exogenously added sAPPa post-injury improved APP-/- mice histological and functional outcome to the point that they were no longer significantly different to APP+/+ mice (p < 0.05). This study shows that endogenous APP is potentially protective at moderate levels of TBI, and that this neuroprotective activity is related to the presence of sAPPa. Importantly, it indicates that the mechanism of action of exogenously added sAPPa is independent of the presence of endogenous APP.	[Corrigan, Frances; Vink, Robert; Blumbergs, Peter C.; van den Heuvel, Corinna] Univ Adelaide, Discipline Anat & Pathol, Sch Med Sci, Adelaide, SA 5005, Australia; [Corrigan, Frances; Vink, Robert; Blumbergs, Peter C.; van den Heuvel, Corinna] Hanson Inst, Ctr Neurol Dis, Adelaide, SA, Australia; [Masters, Colin L.] Univ Melbourne, Mental Hlth Res Inst, Melbourne, Vic 3010, Australia; [Cappai, Roberto] Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia; [Cappai, Roberto] Univ Melbourne, Mol Sci & BioTechnol Inst Bio21, Melbourne, Vic 3010, Australia		van den Heuvel, C (corresponding author), Univ Adelaide, Discipline Anat & Pathol, Sch Med Sci, Adelaide, SA 5005, Australia.	corinna.vandenheuvel@adelaide.edu.au	Vink, Robert/S-5616-2019; Vink, Robert/J-7351-2012; Cappai, Roberto/B-3347-2010	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Corrigan, Frances/0000-0001-6150-8893; , Corinna/0000-0003-0664-8935; Cappai, Roberto/0000-0002-9505-8496	Brain Foundation; Neurosurgical Research Foundation	We thank Prof. Hui Zheng for providing the APP knockout mice and Dr Mark Habgood (University of Melbourne), Dr Jenna Zeibell and Jim Manavis for expert technical assistance. We thank Dr. Chi Pham (The University of Melbourne) for purifying the sAPP alpha. We also thank the staff within the IMVS animal care facility. This work was funded, in part, by grants from the Brain Foundation and the Neurosurgical Research Foundation. RC is a National Health and Medical Research Council Senior Research Fellow. No authors have a conflict of interest to declare.	AdleBiassette H, 1996, NEUROBIOL AGING, V17, P415, DOI 10.1016/0197-4580(96)00029-2; ARAKI W, 1991, BIOCHEM BIOPH RES CO, V181, P265, DOI 10.1016/S0006-291X(05)81412-3; Bendotti C, 1997, EUR J NEUROSCI, V9, P93, DOI 10.1111/j.1460-9568.1997.tb01357.x; BHASIN R, 1991, P NATL ACAD SCI USA, V88, P10307, DOI 10.1073/pnas.88.22.10307; Braak H, 1997, NEUROBIOL AGING, V18, P351, DOI 10.1016/S0197-4580(97)00056-0; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chen UL, 2009, BIOCHEM BIOPH RES CO, V378, P57, DOI 10.1016/j.bbrc.2008.10.173; Cheng GJ, 2002, EXP NEUROL, V175, P407, DOI 10.1006/exnr.2002.7920; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Copanaki E, 2010, MOL CELL NEUROSCI, V44, P386, DOI 10.1016/j.mcn.2010.04.007; Corrigan F, 2012, BRAIN RES, V1451, P87, DOI 10.1016/j.brainres.2012.02.045; Corrigan F, 2012, NEUROSCI LETT, V515, P50, DOI 10.1016/j.neulet.2012.03.017; Corrigan F, 2011, BRAIN RES, V1378, P137, DOI 10.1016/j.brainres.2010.12.077; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Dawson GR, 1999, NEUROSCIENCE, V90, P1, DOI 10.1016/S0306-4522(98)00410-2; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; Emery DL, 2000, J COMP NEUROL, V424, P521; Emery DL, 2003, J NEUROTRAUM, V20, P1271, DOI 10.1089/089771503322686085; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; Furukawa K, 1998, NEUROSCIENCE, V83, P429, DOI 10.1016/S0306-4522(97)00398-9; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GOODMAN Y, 1994, EXP NEUROL, V128, P1, DOI 10.1006/exnr.1994.1107; Gralle M, 2009, J BIOL CHEM, V284, P15016, DOI 10.1074/jbc.M808755200; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Henry A, 1997, PROTEIN EXPRES PURIF, V10, P283, DOI 10.1006/prep.1997.0748; Herms J, 2004, EMBO J, V23, P4106, DOI 10.1038/sj.emboj.7600390; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Keyvani K, 2002, J NEUROPATH EXP NEUR, V61, P831, DOI 10.1093/jnen/61.10.831; Koopmans G, 2003, PHYSIOL BEHAV, V79, P683, DOI 10.1016/S0031-9384(03)00171-9; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Mao HJ, 2010, BIOMECH MODEL MECHAN, V9, P763, DOI 10.1007/s10237-010-0212-z; Markakis EA, 1999, J COMP NEUROL, V406, P449; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Ohsawa I, 1997, BIOCHEM BIOPH RES CO, V236, P59, DOI 10.1006/bbrc.1997.6903; Paxinos G., 2007, MOUSE BRAIN STEREOTA, P137; Phinney AL, 1999, NEUROSCIENCE, V90, P1207, DOI 10.1016/S0306-4522(98)00645-9; QIU WQ, 1995, J NEUROSCI, V15, P2157, DOI 10.1523/JNEUROSCI.15-03-02157.1995; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Ring S, 2007, J NEUROSCI, V27, P7817, DOI 10.1523/JNEUROSCI.1026-07.2007; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Senechal Y, 2008, BEHAV BRAIN RES, V186, P126, DOI 10.1016/j.bbr.2007.08.003; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; Stein TD, 2004, J NEUROSCI, V24, P7707, DOI 10.1523/JNEUROSCI.2211-04.2004; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; von Bohlen und Halbach O, 2007, CELL TISSUE RES, V329, P409, DOI 10.1007/s00441-007-0432-4; Walsh DM, 2002, BIOCHEM SOC T, V30, P552, DOI 10.1042/BST0300552; Young-Pearse TL, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-15; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X	79	56	59	0	12	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042			J NEUROCHEM	J. Neurochem.	JUL	2012	122	1					208	220		10.1111/j.1471-4159.2012.07761.x			13	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	956BG	WOS:000305064100020	22519988				2022-02-06	
J	Schatz, P; Moser, RS; Solomon, GS; Ott, SD; Karpf, R				Schatz, Philip; Moser, Rosemarie Scolaro; Solomon, Gary S.; Ott, Summer D.; Karpf, Robin			Prevalence of Invalid Computerized Baseline Neurocognitive Test Results in High School and Collegiate Athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						computerized testing; test validity; concussion testing; traumatic brain injuries	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; TEST-SCORES; PERFORMANCE; RECOVERY; PLAYERS; IMPACT	Context: Limited data are available regarding the prevalence and nature of invalid computerized baseline neurocognitive test data. Objective: To identify the prevalence of invalid baselines on the desktop and online versions of ImPACT and to document the utility of correcting for left-right (L-R) confusion on the desktop version of ImPACT. Design: Cross-sectional study of independent samples of high school (HS) and collegiate athletes who completed the desktop or online versions of ImPACT. Participants or Other Participants: A total of 3769 HS (desktop = 1617, online = 2152) and 2130 collegiate (desktop = 742, online = 1388) athletes completed preseason baseline assessments. Main Outcome Measure(s): Prevalence of 5 ImPACT validity indicators, with correction for L-R confusion (reversing left and right mouse-click responses) on the desktop version, by test version and group. Chi-square analyses were conducted for sex and attentional or learning disorders. Results: At least 1 invalid indicator was present on 11.9% (desktop) versus 6.3% (online) of the HS baselines and 10.2% (desktop) versus 4.1% (online) of collegiate baselines; correcting for L-R confusion (desktop) decreased this overall prevalence to 8.4% (HS) and 7.5% (collegiate). Online Impulse Control scores alone yielded 0.4% (HS) and 0.9% (collegiate) invalid baselines, compared with 9.0% (HS) and 5.4% (collegiate) on the desktop version; correcting for L-R confusion (desktop) decreased the prevalence of invalid Impulse Control scores to 5.4% (HS) and 2.6% (collegiate). Male athletes and HS athletes with attention deficit or learning disorders who took the online version were more likely to have at least 1 invalid indicator. Utility of additional invalidity indicators is reported. Conclusions: The online ImPACT version appeared to yield fewer invalid baseline results than did the desktop version. Identification of L-R confusion reduces the prevalence of invalid baselines (desktop only) and the potency of Impulse Control as a validity indicator. We advise test administrators to be vigilant in identifying invalid baseline results as part of routine concussion management and prevention programs.	[Schatz, Philip] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA; [Moser, Rosemarie Scolaro] Sports Concuss Ctr New Jersey, Lawrenceville, NJ USA; [Solomon, Gary S.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Ott, Summer D.] Methodist Neurol Inst Concuss Ctr, Houston, TX USA		Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, 222 Post Hall, Philadelphia, PA 19131 USA.	pschatz@sju.edu	Solomon, Gary/K-9011-2019	Schatz, Philip/0000-0002-6222-6545			[Anonymous], CONC ID MAN RET TO P; [Anonymous], CONC SPORTS STUD ATH; Bailey CM, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P171, DOI 10.1007/0-387-32565-4_8; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; IVERSON G, 2004, J INT NEUROPSYCH SOC, V10, P1; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Larini R, MONTCLAIR HIGH SCH F; Lovell M., IMPACT VERSION 2 0 C; Lovell M. R., 2002, Medicine & Science in Sports & Exercise, V34, pS298, DOI 10.1097/00005768-200205001-01680; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, IMPACT VERSION 6 0 C; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; Mihoces G, 2008, US TODAY        0618; Moss A, 2003, BRAIN INJURY, V17, P377, DOI 10.1080/0269905031000070125; Podell K, 2004, STUD NEUROPSYCHOL DE, P375; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Schatz P, 2010, ARCH CLIN NEUROPSYCH, V25, P285, DOI 10.1093/arclin/acq022; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schwarz A, 2010, NY TIMES        1130; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	34	56	56	0	14	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	MAY-JUN	2012	47	3					289	296		10.4085/1062-6050-47.3.14			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	953AJ	WOS:000304839000006	22892410	Green Published			2022-02-06	
J	Cheyuo, C; Jacob, A; Wu, RQ; Zhou, MA; Qi, L; Dong, WF; Ji, YX; Chaung, WW; Wang, HC; Nicastro, J; Coppa, GF; Wang, P				Cheyuo, Cletus; Jacob, Asha; Wu, Rongqian; Zhou, Mian; Qi, Lei; Dong, Weifeng; Ji, Youxin; Chaung, Wayne W.; Wang, Haichao; Nicastro, Jeffrey; Coppa, Gene F.; Wang, Ping			Recombinant human MFG-E8 attenuates cerebral ischemic injury: Its role in anti-inflammation and anti-apoptosis	NEUROPHARMACOLOGY			English	Article						MFG-E8; Cerebral ischemia; Inflammation; Apoptosis; Neuroprotection	FACTOR-VIII; PROTEIN; RATS; REPERFUSION; STROKE; INFARCTION; DOMAINS; DISEASE; MICE; INFILTRATION	Excessive inflammation and apoptosis contribute to the pathogenesis of ischemic stroke. MFG-E8 is a 66-kDa glycoprotein that has shown tissue protection in various models of organ injury. However, the potential role of MFG-E8 in cerebral ischemia has not been investigated. We found that levels of MFG-E8 protein in the brain were reduced at 24 h after cerebral ischemia. To assess the potential role of MFG-E8 in cerebral ischemia, adult male Sprague-Dawley rats were subjected to permanent middle cerebral artery occlusion (MCAO). At 1 h post-stroke onset, an intravenous administration of 1 ml saline as vehicle or 160 mu g/kg BW recombinant human MFG-E8 (rhMFG-E8) as treatment was given. The optimal dose of rhMFG-E8 was obtained from previous dose response organ protection in rat sepsis studies. Neurological scores were determined at 24 h and 48 h post-MCAO. Rats were sacrificed thereafter and brains rapidly removed and analyzed for infarct size, histopathology, and markers of inflammation and apoptosis. Compared with saline vehicle, rhMFG-E8 treatment led to significant decreases in sensorimotor and vestibulomotor deficits, and infarct size at 24 h and 48 h post-MCAO. Measures associated with improved outcome included reduced microglial inflammatory cytokine secretion, adhesion molecules and neutrophil influx, cleaved caspase-3, and upregulation of peroxisome proliferator activated receptor-gamma (PPAR-gamma), and Bcl-2/Bax ratio leading to decreased apoptosis. Thus, rhMFG-E8 treatment is neuroprotective against cerebral ischemia through suppression of inflammation and apoptosis. This article is part of a Special Issue entitled 'Post-Traumatic Stress Disorder'. (C) 2011 Elsevier Ltd. All rights reserved.	[Cheyuo, Cletus; Jacob, Asha; Wu, Rongqian; Zhou, Mian; Qi, Lei; Dong, Weifeng; Ji, Youxin; Chaung, Wayne W.; Wang, Haichao; Wang, Ping] Elmezzi Grad Sch Mol Med, Feinstein Inst Med Res, Ctr Immunol & Inflammat, Manhasset, NY 11030 USA; [Cheyuo, Cletus; Jacob, Asha; Wu, Rongqian; Zhou, Mian; Qi, Lei; Dong, Weifeng; Ji, Youxin; Chaung, Wayne W.; Nicastro, Jeffrey; Coppa, Gene F.; Wang, Ping] N Shore Univ Hosp, Dept Surg, Manhasset, NY USA; [Cheyuo, Cletus; Jacob, Asha; Wu, Rongqian; Zhou, Mian; Qi, Lei; Dong, Weifeng; Ji, Youxin; Chaung, Wayne W.; Nicastro, Jeffrey; Coppa, Gene F.; Wang, Ping] Long Isl Jewish Med Ctr, Manhasset, NY USA		Wang, P (corresponding author), Elmezzi Grad Sch Mol Med, Feinstein Inst Med Res, Ctr Immunol & Inflammat, 350 Community Dr, Manhasset, NY 11030 USA.	pwang@nshs.edu	Varghese, Asha/AAK-4922-2021; Wang, Haichao/AAU-2237-2021; ji, youxin/F-3802-2014; Wang, Haichao/K-6310-2012; Wu, Rongqian/I-3614-2012; Cheyuo, Cletus/AAM-5785-2021; Qi, Lei/A-2980-2009; ji, youxin/F-3802-2014	Wang, Haichao/0000-0002-0211-9000; ji, youxin/0000-0003-2895-4730; Wang, Haichao/0000-0002-0211-9000; Wu, Rongqian/0000-0003-0993-4531; Qi, Lei/0000-0002-9525-9132; ji, youxin/0000-0003-2303-8784; Wang, Ping/0000-0002-1557-0394	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL076179, R01 HL076179-05A1] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM057468-13, R01 GM053008-15, R01 GM053008, R01 GM057468] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL076179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM053008, R01GM057468] Funding Source: NIH RePORTER		Andersen MH, 1997, BIOCHEMISTRY-US, V36, P5441, DOI 10.1021/bi963119m; Antonsson B, 2004, MOL CELL BIOCHEM, V256, P141, DOI 10.1023/B:MCBI.0000009865.70898.36; Aziz MM, 2009, J IMMUNOL, V182, P7222, DOI 10.4049/jimmunol.0803711; Boddaert J, 2007, AM J PATHOL, V170, P921, DOI 10.2353/ajpath.2007.060664; Boscia F, 2009, STROKE, V40, P3608, DOI 10.1161/STROKEAHA.109.557439; Broughton BRS, 2009, STROKE, V40, pE331, DOI 10.1161/STROKEAHA.108.531632; Cheyuo C, 2011, SHOCK, V35, P258, DOI 10.1097/SHK.0b013e3181f48a37; Collins C, 1997, GENOMICS, V39, P117; Couto JR, 1996, DNA CELL BIOL, V15, P281, DOI 10.1089/dna.1996.15.281; Cui TP, 2010, AM J RESP CRIT CARE, V181, P238, DOI 10.1164/rccm.200804-625OC; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Fuller AD, 2008, J NEUROIMMUNE PHARM, V3, P246, DOI 10.1007/s11481-008-9118-2; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Hofmeijer J, 2004, BRAIN RES, V1013, P74, DOI 10.1016/j.brainres.2004.03.057; KAPLAN B, 1991, STROKE, V22, P1032, DOI 10.1161/01.STR.22.8.1032; Kawamata T, 1996, J CEREBR BLOOD F MET, V16, P542, DOI 10.1097/00004647-199607000-00003; Kleinschnitz C, 2011, STROKE, V42, P1081, DOI 10.1161/STROKEAHA.110.592238; Kozak W, 2008, J PHARMACOL EXP THER, V326, P773, DOI 10.1124/jpet.108.139618; Kranich J, 2010, J EXP MED, V207, P2271, DOI 10.1084/jem.20092401; LAROCCA D, 1991, CANCER RES, V51, P4994; Legos JJ, 2000, NEUROSCI LETT, V282, P189, DOI 10.1016/S0304-3940(00)00907-1; Leonardi-Essmann F, 2005, J NEUROIMMUNOL, V160, P92, DOI 10.1016/j.jneuroim.2004.11.012; Lu C, 2010, J CEREBR BLOOD F MET, V30, P1972, DOI 10.1038/jcbfm.2010.59; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; MEMEZAWA H, 1992, STROKE, V23, P552, DOI 10.1161/01.STR.23.4.552; Miksa M, 2006, SHOCK, V25, P586, DOI 10.1097/01.shk.0000209533.22941.d0; Noda M, 2011, J BIOL CHEM, V286, P2308, DOI 10.1074/jbc.M110.169839; Ozden H, 2011, BRAIN RES, V1370, P185, DOI 10.1016/j.brainres.2010.11.045; Qiang XL, 2011, INT J MOL MED, V28, P1071, DOI 10.3892/ijmm.2011.782; Raymond AS, 2010, MOL REPROD DEV, V77, P550, DOI 10.1002/mrd.21189; Ricote M, 2007, BBA-MOL CELL BIOL L, V1771, P926, DOI 10.1016/j.bbalip.2007.02.013; Schilling M, 2003, EXP NEUROL, V183, P25, DOI 10.1016/S0014-4886(03)00082-7; Shah KG, 2012, INTENS CARE MED, V38, P128, DOI 10.1007/s00134-011-2353-7; Shao C, 2008, J BIOL CHEM, V283, P7230, DOI 10.1074/jbc.M705195200; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; Wang CX, 2009, J CEREBR BLOOD F MET, V29, P1683, DOI 10.1038/jcbfm.2009.87; Wiessner R, 2009, TRANSPL P, V41, P3622, DOI 10.1016/j.transproceed.2009.05.039; Wu JS, 2009, CIRCULATION, V119, P1124, DOI 10.1161/CIRCULATIONAHA.108.812537; Wu RQ, 2009, ANN SURG, V250, P126, DOI 10.1097/SLA.0b013e3181ad85d6; Yu JH, 2008, INT J BIOCHEM CELL B, V40, P677, DOI 10.1016/j.biocel.2007.10.007; Zeng HK, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-153; Zhang HL, 2011, NEUROSCIENCE, V176, P381, DOI 10.1016/j.neuroscience.2010.12.029; Zimmerman SW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017256	45	56	60	2	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908			NEUROPHARMACOLOGY	Neuropharmacology	FEB	2012	62	2					890	900		10.1016/j.neuropharm.2011.09.018			11	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	909FZ	WOS:000301549300037	21964436	Green Accepted			2022-02-06	
J	DeVoe, ER; Ross, A				DeVoe, Ellen R.; Ross, Abigail			The Parenting Cycle of Deployment	MILITARY MEDICINE			English	Article							NATIONAL-GUARD SOLDIERS; OPERATION IRAQI FREEDOM; TRAUMATIC BRAIN-INJURY; MILITARY FAMILIES; PSYCHOLOGICAL SYMPTOMS; MARITAL SATISFACTION; MENTAL-HEALTH; CHILDREN; STRESS; RISK	Parents of dependent children comprise approximately 42% of Active Duty and National Guard/Reserve military members serving in Operation Iraqi Freedom/Operation Enduring Freedom. Recent estimates indicate that more than two million children have experienced parental deployment since the terrorist attacks on September 11, 2001. This article seeks to characterize the impact of the deployment life cycle on parenting roles among service members and at-home partners/caregivers of dependent children. Specifically, a new conceptual framework is presented for considering the ways in which parenting and co-parenting processes are affected by the demands and transitions inherent in contemporary deployment to a war zone. Although the phase-based emotional cycle of deployment continues to offer an instructive description of the broad challenges faced by military couples, a parenting cycle of deployment model shifts the perspective to the critical and largely ignored processes of parenting in the context of deployment and war, and to the realities faced by parents serving in the U.S. military. Implications for prevention, intervention, and future research related to military families are addressed.	[DeVoe, Ellen R.; Ross, Abigail] Boston Univ, Sch Social Work, Boston, MA 02215 USA		DeVoe, ER (corresponding author), Boston Univ, Sch Social Work, 264 Bay State Rd, Boston, MA 02215 USA.				Department of DefenseUnited States Department of Defense [W81XWH-08-1-0230]	The authors thank Ruth Paris, PhD, and Michelle Acker, PsyD, of Strong Families Strong Forces and Joseph Merighi, PhD, of Boston University School of Social Work for their contributions to this manuscript. This work was funded by Department of Defense, Award No. W81XWH-08-1-0230.	Adler L.B., 2001, J ARMY MED DEP, V2, P15; American Psychological Association Presidential Task Force on Military Deployment Services for Youth Families and Service Members, 2007, PSYCH NEED US MIL SE; Appleyard K, 2003, INFANT MENT HEALTH J, V24, P111, DOI 10.1002/imhj.10050; Barker LH, 2009, MIL MED, V174, P1033, DOI 10.7205/MILMED-D-04-1108; Barnes VA, 2007, MIL MED, V172, P40, DOI 10.7205/MILMED.172.1.40; BELSKY J, 1984, CHILD DEV, V55, P83, DOI 10.1111/j.1467-8624.1984.tb00275.x; Benedek T, 1946, INSIGHT PERSONALITY, P170; Boss P, 2007, FAM RELAT, V56, P105, DOI 10.1111/j.1741-3729.2007.00444.x; Bronfenbrenner U., 1979, ECOLOGY HUMAN DEV EX; Brott A, 2009, MILITARY FATHER HAND; Chandra A, 2010, J ADOLESCENT HEALTH, V46, P218, DOI 10.1016/j.jadohealth.2009.10.009; Chandra A, 2010, PEDIATRICS, V125, P16, DOI 10.1542/peds.2009-1180; Cowan C.P., 1992, PARTNERS BECOME PARE; Cozza SJ, 2005, PSYCHIAT QUART, V76, P371, DOI 10.1007/s11126-005-4973-y; COZZA SJ, 2007, ZERO 3, V27, P27; Cozza SJ, 2010, J TRAUMA STRESS, V23, P112, DOI 10.1002/jts.20488; DeVoe E, 2010, ZER 3 NAT TRAIN I DE; DeVoe ER, 2011, PSYCHOL TRAUMA-US, V3, P1, DOI 10.1037/a0020567; Faber AJ, 2008, J FAM PSYCHOL, V22, P222, DOI 10.1037/0893-3200.22.2.222; Fitzsimons VM, 2009, J SCH NURS, V25, P40, DOI 10.1177/1059840508326733; Flake EM, 2009, J DEV BEHAV PEDIATR, V30, P271, DOI 10.1097/DBP.0b013e3181aac6e4; Garbarino J, 1996, CHILD DEV, V67, P33, DOI 10.1111/j.1467-8624.1996.tb01717.x; GARMEZY N, 1983, STRESS COPING DEV CH, P47; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Gewirtz AH, 2011, PROF PSYCHOL-RES PR, V42, P56, DOI 10.1037/a0022345; Gewirtz AH, 2011, J FAM PSYCHOL, V25, P29, DOI 10.1037/a0022195; Gewirtz AH, 2010, J CONSULT CLIN PSYCH, V78, P599, DOI 10.1037/a0020571; Gibbs DA, 2007, JAMA-J AM MED ASSOC, V298, P528, DOI 10.1001/jama.298.5.528; Gorman LA, 2010, PSYCHIAT QUART, V81, P1, DOI 10.1007/s11126-009-9116-4; Haas DM, 2005, WOMEN HEALTH ISS, V15, P48, DOI 10.1016/j.whi.2004.12.002; Heltemes KJ, 2011, MIL MED, V176, P132, DOI 10.7205/MILMED-D-09-00238; Huebner AJ, 2007, FAM RELAT, V56, P112, DOI 10.1111/j.1741-3729.2007.00445.x; Kelley ML, 2001, J AM ACAD CHILD PSY, V40, P464, DOI 10.1097/00004583-200104000-00016; KOESKE GF, 1990, AM J ORTHOPSYCHIAT, V60, P440, DOI 10.1037/h0079164; Laor N, 1996, ARCH GEN PSYCHIAT, V53, P416, DOI 10.1001/archpsyc.1996.01830050052008; Laor N, 2001, AM J PSYCHIAT, V158, P1020, DOI 10.1176/appi.ajp.158.7.1020; Lapp CA, 2010, J FAM NURS, V16, P45, DOI 10.1177/1074840709357347; LECLERE FB, 1994, J MARRIAGE FAM, V56, P457, DOI 10.2307/353112; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Logan K.V., 1987, P MAGAZINE, V113, P43; Luthar S.S., 2006, DEV PSYCHO, VVol. 3, P739, DOI DOI 10.1002/9780470939406.CH20; MacDermid S., 2005, SITUATED FATHERING F; MacDermid SM, MULTIPLE TRANSITIONS; Maguen S, 2008, MIL MED, V173, P1; Mansfield AJ, 2010, NEW ENGL J MED, V362, P101, DOI 10.1056/NEJMoa0900177; National Military Family Association, 2005, REP CYCL DEPL SURV A; O'Boyle AL, 2005, SOUTH MED J, V98, P416, DOI 10.1097/01.SMJ.0000152759.37358.81; Office of the Deputy Under Secretary of Defense, 2010, 2008 DEM REP PROF MI; Otis JD, 2011, J CLIN PSYCHOL MED S, V18, P145, DOI 10.1007/s10880-011-9239-2; Padden DL, 2011, MIL MED, V176, P26; PESSAR LF, 1993, BRAIN INJURY, V7, P231, DOI 10.3109/02699059309029675; Polusny MA, 2009, MIL MED, V174, P353, DOI 10.7205/MILMED-D-01-1608; Renshaw KD, 2008, J FAM PSYCHOL, V22, P586, DOI 10.1037/0893-3200.22.3.586; Renshaw KD, 2009, ANXIETY STRESS COPIN, V22, P101, DOI 10.1080/10615800802354000; Rutter M., 1990, RISK PROTECTIVE FACT; SAMEROFF AJ, 1987, PEDIATRICS, V79, P343; Schumer CE, 2007, WAR ANY PRICE TOTAL; Sherman MD, 2009, MY STORY BLOGS 4 MIL; Speziale B, 2010, J SOC WORK DISABIL R, V9, P289, DOI 10.1080/1536710X.2010.523664; Stafford EM, 2003, PEDIATR ANN, V32, P110, DOI 10.3928/0090-4481-20030201-08; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Ternus MP, 2010, J ADOLESCENT HEALTH, V46, P203, DOI 10.1016/j.jadohealth.2009.12.019; Weins TW, 2006, MILITARY LIFE PSYCHO; Wieland D, 2011, PA NURSE, V65, P12; Wieland D, 2011, PA NURSE, V65, P4; Williams D, 2007, ZERO 3, V27, P13	66	56	56	0	31	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	FEB	2012	177	2					184	190		10.7205/MILMED-D-11-00292			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	886KC	WOS:000299852300013	22360065	Bronze			2022-02-06	
J	Park, J; Zhang, J; Qiu, JH; Zhu, XX; Degterev, A; Lo, EH; Whalen, MJ				Park, Juyeon; Zhang, Jimmy; Qiu, Jianhua; Zhu, Xiaoxia; Degterev, Alexei; Lo, Eng H.; Whalen, Michael J.			Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Akt; cognition; mammalian target of rapamycin; mice; protein kinase B; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CEREBRAL-ISCHEMIA; NEURONAL SURVIVAL; ACTIVATION; KINASE; PHOSPHORYLATION; HISTOPATHOLOGY; DAMAGE; DEATH; CELLS	Akt and mammalian target of rapamycin (mTOR) are both activated after traumatic brain injury (TBI), however complex interplay between the two hampers deciphering their functional implications in vivo. We examined the effects of single and combination inhibitors of Akt/mTOR in a mouse controlled cortical impact (CCI) model. Following CCI, phospho-Akt-473 (p-Akt) and -S6 ribosomal protein (p-S6RP), a downstream substrate of mTOR, were increased in cortical and hippocampal brain homogenates (P<0.05 versus sham). At 24 hours, p-S6RP was detected in neurons and was robustly induced in microglia and astrocytes in injured hippocampus. In vivo activity of Akt and mTOR inhibitors administered separately was confirmed by reduced expression of p-GSK3 beta (P<0.01) or p-S6RP (P<0.05), respectively, after CCI. Importantly, administration of Akt and mTOR inhibitors together (but not of either alone) improved postinjury motor (P=0.02) and cognitive deficits (hidden platform trials, P=0.001; probe trials, P<0.05), decreased propidium iodide-positive cells in CA1 and CA3 (P<0.005), and unexpectedly increased p-GSK3 beta in hippocampus. Although the roles of Akt and mTOR in the pathogenesis of TBI remain to be fully elucidated, dual inhibition of Akt and mTOR may have therapeutic potential for TBI. Journal of Cerebral Blood Flow & Metabolism (2012) 32, 330-340; doi:10.1038/jcbfm.2011.131; published online 21 September 2011	[Park, Juyeon; Zhang, Jimmy; Qiu, Jianhua; Zhu, Xiaoxia; Lo, Eng H.; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept PediatNeurosci Ctr, Charlestown, MA 02129 USA; [Zhu, Xiaoxia] Fudan Univ, Huashan Hosp, Dept Rheumatol, Shanghai 200433, Peoples R China; [Degterev, Alexei] Tufts Univ, Dept Biochem, Boston, MA 02111 USA; [Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA; [Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA		Whalen, MJ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept PediatNeurosci Ctr, Charlestown, MA 02129 USA.	mwhalen@partners.org			NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5RO1NS047447, 5RO1NS064545]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047447, R01NS064545] Funding Source: NIH RePORTER	This work was supported by grants from NINDS 5RO1NS047447 and 5RO1NS064545 (MJW).	Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Carloni S, 2010, AUTOPHAGY, V6, P366, DOI 10.4161/auto.6.3.11261; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chen SY, 2007, J CEREBR BLOOD F MET, V27, P939, DOI 10.1038/sj.jcbfm.9600393; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Endo H, 2006, J CEREBR BLOOD F MET, V26, P1479, DOI 10.1038/sj.jcbfm.9600303; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Guan KL, 2000, J BIOL CHEM, V275, P27354; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Hooper C, 2008, J NEUROCHEM, V104, P1433, DOI 10.1111/j.1471-4159.2007.05194.x; Hu LY, 2010, NEUROSCIENCE, V169, P1046, DOI 10.1016/j.neuroscience.2010.05.046; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jo J, 2011, NAT NEUROSCI, V14, P545, DOI 10.1038/nn.2785; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Komandirov MA, 2011, J MOL NEURO IN PRESS; Lewen A, 2001, NEUROBIOL DIS, V8, P380, DOI 10.1006/nbdi.2001.0396; Li J, 2008, J NEUROL SCI, V269, P105, DOI 10.1016/j.jns.2007.12.034; Maddika S, 2008, J CELL SCI, V121, P979, DOI 10.1242/jcs.009530; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Namikawa K, 2000, J NEUROSCI, V20, P2875; Neary JT, 2005, IUBMB LIFE, V57, P711, DOI 10.1080/15216540500319143; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Pignataro G, 2011, J CEREBR BLOOD F MET, V31, P362, DOI 10.1038/jcbfm.2010.100; Qi SH, 2010, NEUROSCI RES, V68, P88, DOI 10.1016/j.neures.2010.06.008; Ropelle ER, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003856; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Song YS, 2008, J CEREBR BLOOD F MET, V28, P1917, DOI 10.1038/jcbfm.2008.80; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Wu YT, 2009, AUTOPHAGY, V5, P824, DOI 10.4161/auto.9099; Wymann MP, 2003, BIOCHEM SOC T, V31, P275, DOI 10.1042/bst0310275; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005; Zhu ZF, 2010, BRAIN RES BULL, V83, P272, DOI 10.1016/j.brainresbull.2010.07.008	40	56	59	1	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2012	32	2					330	340		10.1038/jcbfm.2011.131			11	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	886LZ	WOS:000299857200013	21934697	Green Published			2022-02-06	
J	Mao, JC; Pace, E; Pierozynski, P; Kou, ZF; Shen, YM; VandeVord, P; Haacke, EM; Zhang, XG; Zhang, JS				Mao, Johnny C.; Pace, Edward; Pierozynski, Paige; Kou, Zhifeng; Shen, Yimin; VandeVord, Pamela; Haacke, E. Mark; Zhang, Xueguo; Zhang, Jinsheng			Blast-Induced Tinnitus and Hearing Loss in Rats: Behavioral and Imaging Assays	JOURNAL OF NEUROTRAUMA			English	Article						behavioral testing; blast; hearing loss; MRI; tinnitus; traumatic brain injury	TRAUMATIC BRAIN-INJURY; DORSAL COCHLEAR NUCLEUS; SALICYLATE-INDUCED TINNITUS; SPONTANEOUS NEURAL ACTIVITY; WHITE-MATTER INTEGRITY; DIFFUSION-TENSOR; INFERIOR COLLICULUS; PREPULSE INHIBITION; AUDITORY-CORTEX; INTENSE SOUND	The current study used a rat model to investigate the underlying mechanisms of blast-induced tinnitus, hearing loss, and associated traumatic brain injury (TBI). Seven rats were used to evaluate behavioral evidence of tinnitus and hearing loss, and TBI using magnetic resonance imaging following a single 10-msec blast at 14 psi or 194 dB sound pressure level (SPL). The results demonstrated that the blast exposure induced early onset of tinnitus and central hearing impairment at a broad frequency range. The induced tinnitus and central hearing impairment tended to shift towards high frequencies over time. Hearing threshold measured with auditory brainstem responses also showed an immediate elevation followed by recovery on day 14, coinciding with behaviorally-measured results. Diffusion tensor magnetic resonance imaging results demonstrated significant damage and compensatory plastic changes to certain auditory brain regions, with the majority of changes occurring in the inferior colliculus and medial geniculate body. No significant microstructural changes found in the corpus callosum indicates that the currently adopted blast exposure mainly exerts effects through the auditory pathways rather than through direct impact onto the brain parenchyma. The results showed that this animal model is appropriate for investigation of the mechanisms underlying blast-induced tinnitus, hearing loss, and related TBI. Continued investigation along these lines will help identify pathology with injury/recovery patterns, aiding development of effective treatment strategies.	[Mao, Johnny C.; Pace, Edward; Zhang, Xueguo; Zhang, Jinsheng] Wayne State Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Detroit, MI 48202 USA; [Kou, Zhifeng; Shen, Yimin; Haacke, E. Mark] Wayne State Univ, Sch Med, Dept Radiol, Detroit, MI 48202 USA; [Pierozynski, Paige; Zhang, Jinsheng] Wayne State Univ, Coll Liberal Arts & Sci, Dept Commun Sci & Disorders, Detroit, MI 48202 USA; [VandeVord, Pamela] Wayne State Univ, Coll Engn, Dept Biomed Engn, Detroit, MI 48202 USA; [VandeVord, Pamela] John D Dingell VA Med Ctr, Res & Dev Serv, Detroit, MI USA		Zhang, JS (corresponding author), Wayne State Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, 5E UHC,4201 St Antoine, Detroit, MI 48202 USA.	jinzhang@med.wayne.edu	VandeVord, Pamela/B-4606-2012		Wayne State University; Department of DefenseUnited States Department of Defense [W81XWH-11-2-0031]	This work was supported by the Wayne State University start-up funds and the Department of Defense (grant award #W81XWH-11-2-0031).	Adams P.F., 1995, VITAL HLTH STAT, P101; Andersson G, 2004, NORD J PSYCHIAT, V58, P287, DOI 10.1080/08039480410005792; Andersson G, 1998, AUDIOLOGY, V37, P174; Andersson G, 2002, CLIN PSYCHOL REV, V22, P977, DOI 10.1016/S0272-7358(01)00124-6; AXELSSON A, 1985, British Journal of Audiology, V19, P271, DOI 10.3109/03005368509078983; Basta D, 2005, NEUROSCI LETT, V381, P199, DOI 10.1016/j.neulet.2005.02.034; Bauer CA, 2008, J NEUROSCI RES, V86, P2564, DOI 10.1002/jnr.21699; Belli S, 2008, EUR ARCH OTO-RHINO-L, V265, P279, DOI 10.1007/s00405-007-0440-8; Bjornsson CS, 2006, J NEURAL ENG, V3, P196, DOI 10.1088/1741-2560/3/3/002; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Bowen GP, 2003, CEREB CORTEX, V13, P815, DOI 10.1093/cercor/13.8.815; Braff DL, 2001, PSYCHOPHARMACOLOGY, V156, P234, DOI 10.1007/s002130100810; Breeze J, 2011, J LARYNGOL OTOL, V125, P13, DOI 10.1017/S0022215110002215; Brozoski TJ, 2007, HEARING RES, V228, P168, DOI 10.1016/j.heares.2007.02.003; Brozoski TJ, 2002, J NEUROSCI, V22, P2383, DOI 10.1523/JNEUROSCI.22-06-02383.2002; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Campbell LE, 2007, EUR J NEUROSCI, V26, P2327, DOI 10.1111/j.1460-9568.2007.05858.x; Chang YS, 2004, FUNGAL DIVERS, V15, P15; CHEN GD, 1995, HEARING RES, V82, P158, DOI 10.1016/0378-5955(94)00174-O; Clarkson C, 2010, ACTA OTO-LARYNGOL, V130, P326, DOI [10.3109/00016480903150536, 10.1080/00016480903150536]; Concha L, 2006, NEUROIMAGE, V32, P1090, DOI 10.1016/j.neuroimage.2006.04.187; Crippa Alessandro, 2010, Open Neuroimag J, V4, P16, DOI 10.2174/1874440001004010016; Cronlein T, 2007, PROG BRAIN RES, V166, P227, DOI 10.1016/S0079-6123(07)66021-X; Dobie RA, 2003, OTOLARYNG CLIN N AM, V36, P383, DOI 10.1016/S0030-6665(02)00168-8; Dougherty AL, 2011, BRAIN INJURY, V25, P8, DOI 10.3109/02699052.2010.536195; Dror V, 2010, BRAIN RES, V1308, P176, DOI 10.1016/j.brainres.2009.10.032; Eggermont JJ, 2004, TRENDS NEUROSCI, V27, P676, DOI 10.1016/j.tins.2004.08.010; Eggermont JJ, 2000, HEARING RES, V142, P89, DOI 10.1016/S0378-5955(00)00024-1; Erlandsson SI, 2000, BRIT J AUDIOL, V34, P11, DOI 10.3109/03005364000000114; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Finlayson PG, 2009, HEARING RES, V256, P104, DOI 10.1016/j.heares.2009.07.006; Folmer RL, 2000, AM J OTOLARYNG, V21, P287, DOI 10.1053/ajot.2000.9871; Folmer RL, 1999, OTOLARYNG HEAD NECK, V121, P48, DOI 10.1016/S0194-5998(99)70123-3; Geckle L., 2004, FORC HLTH PROT C ALB; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Groschel M, 2010, J NEUROTRAUM, V27, P1499, DOI 10.1089/neu.2009.1246; Guitton Matthieu J., 2007, Neural Plasticity, V2007, P1, DOI 10.1155/2007/80904; HALFORD JBS, 1991, J PSYCHOSOM RES, V35, P383, DOI 10.1016/0022-3999(91)90033-K; Hebert S, 2007, EAR HEARING, V28, P649; Henry JA, 2009, J REHABIL RES DEV, V46, P619, DOI 10.1682/JRRD.2008.11.0157; HERBERT H, 1991, J COMP NEUROL, V304, P103, DOI 10.1002/cne.903040108; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Holt AG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014260; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Husain FT, 2011, BRAIN RES, V1369, P74, DOI 10.1016/j.brainres.2010.10.095; Johnston M, 1996, GEN HOSP PSYCHIAT, V18, P257, DOI 10.1016/0163-8343(96)00039-4; Kaltenbach JA, 1996, AUDIT NEUROSCI, V3, P57; Kaltenbach JA, 2004, NEUROSCI LETT, V355, P121, DOI 10.1016/j.neulet.2003.10.038; Kaltenbach JA, 1998, HEARING RES, V124, P78, DOI 10.1016/S0378-5955(98)00119-1; Kaltenbach JA, 2000, HEARING RES, V140, P165, DOI 10.1016/S0378-5955(99)00197-5; Kaltenbach JA, 2011, HEARING RES, V276, P52, DOI 10.1016/j.heares.2010.12.003; Kantarci K, 2010, NEUROLOGY, V74, P1814, DOI 10.1212/WNL.0b013e3181e0f7cf; Kim HJ, 2005, AM J NEURORADIOL, V26, P208; Kim JN, 1997, HEARING RES, V103, P169, DOI 10.1016/S0378-5955(96)00173-6; Kimura M, 1999, HEARING RES, V135, P146, DOI 10.1016/S0378-5955(99)00104-5; Komiya H, 2000, ACTA OTO-LARYNGOL, V120, P750; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kraus KS, 2010, NEUROSCIENCE, V167, P1216, DOI 10.1016/j.neuroscience.2010.02.071; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lanting CP, 2010, HEARING RES, V267, P78, DOI 10.1016/j.heares.2010.04.006; Lanting CP, 2009, HEARING RES, V255, P1, DOI 10.1016/j.heares.2009.06.009; Lee JW, 2006, J HEAD TRAUMA REHAB, V21, P272, DOI 10.1097/00001199-200605000-00007; Leske M C, 1981, ASHA, V23, P229; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; LEWIS JE, 1994, CLIN OTOLARYNGOL, V19, P50, DOI 10.1111/j.1365-2273.1994.tb01147.x; LIBERMAN MC, 1978, ACTA OTO-LARYNGOL, P5; Lin Y, 2008, J MAGN RESON IMAGING, V28, P598, DOI 10.1002/jmri.21464; Lockwood AH, 2001, NEUROLOGY, V56, P472, DOI 10.1212/WNL.56.4.472; LOEB M, 1967, J ACOUST SOC AM, V42, P453, DOI 10.1121/1.1910600; Lutz J, 2007, ACAD RADIOL, V14, P692, DOI 10.1016/j.acra.2007.02.014; Lutz J, 2008, ARTHRITIS RHEUM-US, V58, P3960, DOI 10.1002/art.24070; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Marciano E, 2003, INT J AUDIOL, V42, P4, DOI 10.3109/14992020309056079; McFeely WJ, 1999, OTOLARYNG HEAD NECK, V121, P367, DOI 10.1016/S0194-5998(99)70222-6; MCKENNA L, 1991, CLIN OTOLARYNGOL, V16, P452, DOI 10.1111/j.1365-2273.1991.tb01038.x; McKenna L., 2000, TINNITUS HDB, P59; Melcher JR, 2000, J NEUROPHYSIOL, V83, P1058, DOI 10.1152/jn.2000.83.2.1058; Miller EJ, 2010, NEUROSCIENCE, V165, P601, DOI 10.1016/j.neuroscience.2009.10.036; Mrena R, 2004, ACTA OTO-LARYNGOL, V124, P946, DOI 10.1080/00016480310017045; Mrena R, 2004, INT J AUDIOL, V43, P177, DOI 10.1080/14992020400050025; Mrena R, 2002, AUDIOL NEURO-OTOL, V7, P122, DOI 10.1159/000057660; Mulders WHAM, 2009, NEUROSCIENCE, V164, P733, DOI 10.1016/j.neuroscience.2009.08.036; Nageris Ben I., 2008, Journal of Basic and Clinical Physiology and Pharmacology, V19, P185; Newcombe VFJ, 2010, J NEUROL NEUROSUR PS, V81, P552, DOI 10.1136/jnnp.2009.196246; Norena AJ, 2005, J NEUROSCI, V25, P699, DOI 10.1523/JNEUROSCI.2226-04.2005; Norena AJ, 2003, HEARING RES, V183, P137, DOI 10.1016/S0378-5955(03)00225-9; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Penner, 1995, Int Tinnitus J, V1, P79; Ritenour AE, 2008, J TRAUMA, V64, pS174, DOI 10.1097/TA.0b013e318160773e; Roberts LE, 2010, J NEUROSCI, V30, P14972, DOI 10.1523/JNEUROSCI.4028-10.2010; Robinson Shannon K, 2003, Int Tinnitus J, V9, P97; Rossiter S, 2006, J SPEECH LANG HEAR R, V49, P150, DOI 10.1044/1092-4388(2006/012); Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Saunders GH, 2009, NOISE HEALTH, V11, P14, DOI 10.4103/1463-1741.45308; Seki S, 2003, HEARING RES, V180, P28, DOI 10.1016/S0378-5955(03)00074-1; Shargorodsky J, 2010, AM J MED, V123, P711, DOI 10.1016/j.amjmed.2010.02.015; Shen YM, 2007, MAGN RESON IMAGING, V25, P219, DOI 10.1016/j.mri.2006.09.018; Shulman Abraham, 2009, Int Tinnitus J, V15, P119; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Silva AC, 2004, NMR BIOMED, V17, P532, DOI 10.1002/nbm.945; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Smits M, 2007, NEURORADIOLOGY, V49, P669, DOI 10.1007/s00234-007-0231-3; Sobin C, 2005, AM J PSYCHIAT, V162, P1090, DOI 10.1176/appi.ajp.162.6.1090; Solano-Castiella E, 2010, NEUROIMAGE, V49, P2958, DOI 10.1016/j.neuroimage.2009.11.027; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Stevens C, 2007, INT J AUDIOL, V46, P208, DOI 10.1080/14992020601102329; Sun SW, 2006, MAGN RESON MED, V55, P302, DOI 10.1002/mrm.20774; Suneson A, 2000, MIL MED, V165, P119, DOI 10.1093/milmed/165.2.119; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Swerdlow NR, 2001, PSYCHOPHARMACOLOGY, V156, P194, DOI 10.1007/s002130100799; Takahashi K, 2007, BIOL PSYCHIAT, V62, P148, DOI 10.1016/j.biopsych.2006.06.035; Turner JG, 2008, AM J AUDIOL, V17, pS185, DOI 10.1044/1059-0889(2008/08-0006); Turner JG, 2006, BEHAV NEUROSCI, V120, P188, DOI 10.1037/0735-7044.120.1.188; Turner Oliver, 2007, Ann Gen Psychiatry, V6, P26, DOI 10.1186/1744-859X-6-26; Tyler RS, 2007, PROG BRAIN RES, V166, P425, DOI 10.1016/S0079-6123(07)66041-5; TYLER RS, 1983, J SPEECH HEAR RES, V26, P59, DOI 10.1044/jshr.2601.59; Walton JP, 1997, J COMP PHYSIOL A, V181, P161, DOI 10.1007/s003590050103; Wang H, 2009, NEUROSCIENCE, V164, P747, DOI 10.1016/j.neuroscience.2009.08.026; Wiley JL, 1996, BRAIN RES, V716, P47, DOI 10.1016/0006-8993(96)00045-5; Wu CM, 2009, AM J NEURORADIOL, V30, P1773, DOI 10.3174/ajnr.A1681; Wu CM, 2009, AUDIOL NEURO-OTOL, V14, P248, DOI 10.1159/000191282; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Yang G, 2007, HEARING RES, V226, P244, DOI 10.1016/j.heares.2006.06.013; Zhang JS, 2011, JARO-J ASSOC RES OTO, V12, P185, DOI 10.1007/s10162-010-0246-z; Zhang JS, 2010, BRAIN RES, V1311, P37, DOI 10.1016/j.brainres.2009.11.032; Zhang JS, 1998, NEUROSCI LETT, V250, P197, DOI 10.1016/S0304-3940(98)00482-0	132	56	57	0	27	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					430	444		10.1089/neu.2011.1934			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300022	21933015	Green Published			2022-02-06	
J	Miele, AS; Gunner, JH; Lynch, JK; McCaffrey, RJ				Miele, Andrea S.; Gunner, Jessica H.; Lynch, Julie K.; McCaffrey, Robert J.			Are Embedded Validity Indices Equivalent to Free-Standing Symptom Validity Tests?	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Symptom validity tests; Embedded validity indices; Embedded measures; Effort; Word Memory Test; Test of Memory Malingering; Victoria Symptom Validity Test; Rey 15-Item Test; Reliable Digit Span; Medico-legal	ADULT INTELLIGENCE SCALE; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; CROSS-VALIDATION; CATEGORY TEST; NEUROPSYCHOLOGICAL ASSESSMENT; AMERICAN-ACADEMY; SEASHORE RHYTHM; PERFORMANCE; IMPAIRMENT	Symptom validity assessment is an important part of neuropsychological evaluation. There are currently several free-standing symptom validity tests (SVTs), as well as a number of empirically derived embedded validity indices, that have been developed to assess that an examinee is putting forth an optimal level of effort during testing. The use of embedded validity indices is attractive since they do not increase overall testing time and may also be less vulnerable to coaching. In addition, there are some instances where embedded validity indices are the only tool available to the neuropsychological practitioner for assessing an examinee's level of effort. As with free-standing measures, the sensitivity and specificity of embedded validity indices to suboptimal effort varies. The present study evaluated the diagnostic validity of 17 embedded validity indices by comparing performance on these indices to performance on combinations of free-standing SVTs. Results from the current medico-legal sample revealed that of the embedded validity indices, Reliable Digit Span had the best classification accuracy; however, the findings do not support the use of this embedded validity index in the absence of free-standing SVTs.	[Miele, Andrea S.; Gunner, Jessica H.] SUNY Albany, Dept Psychol, Albany, NY 12222 USA; [Lynch, Julie K.] Albany Neuropsychol Associates, Guilderland, NY USA; [McCaffrey, Robert J.] SUNY Albany, Albany Neuropsychol Associates, Albany, NY 12222 USA		Miele, AS (corresponding author), SUNY Albany, Dept Psychol, 1400 Washington Ave, Albany, NY 12222 USA.	amiele@albany.edu					Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Bolter J. F., 1985, ANN M NAT AC NEUR PH; Boone K.B., 2007, ASSESSMENT FEIGNED C; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Committee on Mild Traumatic Brain Injury American Congress of Rehabilitation Medicine (ACRM), 1993, J HEAD TRAUMA REHAB, V8, P86; DiCarlo MA, 2000, ARCH CLIN NEUROPSYCH, V15, P399, DOI 10.1016/S0887-6177(99)00031-1; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; Forrest TJ, 2004, CLIN NEUROPSYCHOL, V18, P334, DOI 10.1080/13854040490501673; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gfeller JD, 1998, J CLIN PSYCHOL, V54, P431, DOI 10.1002/(SICI)1097-4679(199806)54:4<431::AID-JCLP5>3.0.CO;2-Q; GOEBEL RA, 1983, J CLIN PSYCHOL, V39, P731, DOI 10.1002/1097-4679(198309)39:5<731::AID-JCLP2270390515>3.0.CO;2-T; Green P., 2003, GREENS WORD MEMORY T; Green P., 2005, MANUAL WORD MEMORY T; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P1, DOI 10.1016/S0887-6177(01)00176-7; Jasinski LJ, 2011, J CLIN EXP NEUROPSYC, V33, P300, DOI 10.1080/13803395.2010.516743; Laatsch L., 1991, J CONSULT CLIN PSYCH, V3, P701; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; Lezak MD, 1976, NEUROPSYCHOLOGICAL A; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Loring DW, 2005, J CLIN EXP NEUROPSYC, V27, P610, DOI 10.1080/13803390490918471; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; PANKRATZ L, 1979, J CONSULT CLIN PSYCH, V47, P409, DOI 10.1037/0022-006X.47.2.409; Reitan R.M., 1993, HALSTEADREITAN NEURO; Rey A., 1964, EXAMEN CLIN PSYCHOL; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ross SR, 2006, CLIN NEUROPSYCHOL, V20, P798, DOI 10.1080/13854040500328477; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Slick D.J., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Sweet J. J., 2002, J FORENSIC NEUROPSYC, V3, P241; Tenhula W. N., 1994, ANN M NAT AC NEUR OR; Tenhula W. N., 1994, ANN M INT NEUR SOC C; Tenhula WN, 1996, CLIN NEUROPSYCHOL, V10, P104, DOI 10.1080/13854049608406669; Tombaugh T.N., 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Wechsler, 1997, WECHSLER ADULT INTEL; Wilson, 2003, J FORENSIC NEUROPSYC, V3, P55, DOI [10.1300/J151v03n03, DOI 10.1300/J151V03N03_04]	49	56	56	0	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2012	27	1					10	22		10.1093/arclin/acr084			13	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	885TE	WOS:000299802900002	22068442	Bronze			2022-02-06	
J	Panczykowski, DM; Puccio, AM; Scruggs, BJ; Bauer, JS; Hricik, AJ; Beers, SR; Okonkwo, DO				Panczykowski, David M.; Puccio, Ava M.; Scruggs, Bobby J.; Bauer, Joshua S.; Hricik, Allison J.; Beers, Sue R.; Okonkwo, David O.			Prospective Independent Validation of IMPACT Modeling as a Prognostic Tool in Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						assessment tools; outcome measures; traumatic brain injury	HEAD-INJURY; PREDICTORS; VARIABLES; TRIALS; DESIGN; TREE	Clinical trials in traumatic brain injury (TBI) have been fraught with failure due in part to heterogeneity in pathology and insensitive outcome measurements. The International Mission for Prognosis and Analysis of Clinical Trials in TBI (IMPACT) prognostic model has been purposed as a means of risk adjustment and outcome prediction for use in trial design and analysis. The purpose of this study was to evaluate the performance of the IMPACT model in predicting 6-month functional outcome and mortality using prospectively collected data at a large, Level 1 neurotrauma center. This population-based cohort study included all TBI patients >= 14 years of age admitted with a Glasgow Coma Scale (GCS) score of <= 8 (severe TBI) to the University of Pittsburgh Medical Center between July 1994 and May 2009. Clinical data were prospectively collected and linked to 6-month functional outcome (Glasgow Outcome Scale [GOS]) and mortality. The discriminatory power and calibration of the three iterations of the IMPACT model (core, extended, and lab) were assessed using multiple regression analyses and indicated by the area under the receiver operating characteristic curve (AUC). A sample of 587 patients was available for analysis; the mean age was 37.8 +/- 17 years. The median 6-month GOS was 3 (IQR 3); 6-month mortality was 41%. The prognostic models were composed of age, motor score, and pupillary reactivity (core model), Marshall grade on head CT and secondary insults (extended), and laboratory values (lab); all of these displayed good prediction ability for unfavorable outcome and mortality (unfavorable outcome AUC=0.76, 0.79, 0.76; mortality AUC=0.78, 0.83, 0.83, respectively). All model iterations displayed adequate calibration for predicting unfavorable outcome and mortality. Prospective, independent validation supports the IMPACT prognostic model's prediction of patient 6-month functional status and mortality after severe TBI. The IMPACT prognostic model is an effective instrument to assist TBI study design and analysis.	[Panczykowski, David M.; Puccio, Ava M.; Scruggs, Bobby J.; Bauer, Joshua S.; Hricik, Allison J.; Beers, Sue R.; Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15213 USA		Okonkwo, DO (corresponding author), Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Suite B-400,200 Lothrop St, Pittsburgh, PA 15213 USA.	okonkwodo@upmc.edu					Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRAIN TRAUM FD, 1996, J NEUROTRAUM, V13, P641; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Edwards P, 2005, LANCET, V365, P1957; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; JENNETT B, 1976, LANCET, V1, P1031; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Quigley MR, 1997, J TRAUMA, V42, P7, DOI 10.1097/00005373-199701000-00003; Schaan M, 2002, J TRAUMA, V52, P667, DOI 10.1097/00005373-200204000-00009; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568	23	56	56	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					47	52		10.1089/neu.2010.1482			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300004	21933014				2022-02-06	
J	Greco, T; Shafer, J; Fiskum, G				Greco, Tiffany; Shafer, Jonathan; Fiskum, Gary			Sulforaphane inhibits mitochondrial permeability transition and oxidative stress	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						Mitochondria; Calcium; Thiol; Nrf2; Sulforaphane; Antioxidant; Permeability transition pore; Redox state; Oxidative stress; Free radicals	TRAUMATIC BRAIN-INJURY; CYCLOPHILIN-D; RAT-LIVER; MOLECULAR-MECHANISM; REPERFUSION INJURY; REDUCTION STATE; CELL-DEATH; PORE; RELEASE; HEPATOCYTES	Exposure of mitochondria to oxidative stress and elevated Ca2+ promotes opening of the mitochondrial permeability transition pore (PTP), resulting in membrane depolarization, uncoupling of oxidative phosphorylation, and potentially cell death. This study tested the hypothesis that treatment of rats with sulforaphane (SFP), an activator of the Nrf2 pathway of antioxidant gene expression, increases the resistance of liver mitochondria to redox-regulated PTP opening and elevates mitochondrial levels of antioxidants. Rats were injected with SFP or drug vehicle and liver mitochondria were isolated 40 h later. Respiring mitochondria actively accumulated added Ca2+, which was then released through PIP opening induced by agents that either cause an oxidized shift in the mitochondrial redox state or directly oxidize protein thiol groups. SFP treatment of rats inhibited the rate of pro-oxidant-induced mitochondrial Ca2+ release and increased expression of the glutathione peroxidase/reductase system, thioredoxin, and malic enzyme. These results are the first to demonstrate that SFP treatment of animals increases liver mitochondrial antioxidant defenses and inhibits redox-sensitive PIP opening. This novel form of preconditioning could protect against a variety of pathologies that include oxidative stress and mitochondrial dysfunction in their etiologies. (C) 2011 Elsevier Inc. All rights reserved.	[Greco, Tiffany; Shafer, Jonathan; Fiskum, Gary] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Greco, Tiffany; Shafer, Jonathan; Fiskum, Gary] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res, Baltimore, MD 21201 USA; [Shafer, Jonathan] Univ Maryland Baltimore Cty, Baltimore, MD 21201 USA		Fiskum, G (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA.	gfiskum@anes.umm.edu	Greco, Tiffany/ABA-3519-2021		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1NS34152]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034152] Funding Source: NIH RePORTER	This study was supported by NIH RO1NS34152.	Aleksunes LM, 2007, TOXICOL PATHOL, V35, P459, DOI 10.1080/01926230701311344; Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Balogun E, 2003, BIOCHEM J, V371, P887, DOI 10.1042/BJ20021619; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Bianchi G, 1997, HEPATO-GASTROENTEROL, V44, P784; Burwell LS, 2009, J MOL CELL CARDIOL, V46, P804, DOI 10.1016/j.yjmcc.2009.02.026; DEVI BG, 1994, ALCOHOL CLIN EXP RES, V18, P1436, DOI 10.1111/j.1530-0277.1994.tb01447.x; Dinkova-Kostova AT, 2008, MOL NUTR FOOD RES, V52, pS128, DOI 10.1002/mnfr.200700195; Dinkova-Kostova AT, 2010, ARCH BIOCHEM BIOPHYS, V501, P116, DOI 10.1016/j.abb.2010.03.019; Esworthy RS, 1997, ARCH BIOCHEM BIOPHYS, V340, P59, DOI 10.1006/abbi.1997.9901; FISKUM G, 1986, CANCER RES, V46, P3459; Gogvadze V, 2010, INT J CANCER, V127, P1823, DOI 10.1002/ijc.25204; GONZALEZFLECHA B, 1993, J CLIN INVEST, V91, P456, DOI 10.1172/JCI116223; Greco T, 2010, J BIOENERG BIOMEMBR, V42, P491, DOI 10.1007/s10863-010-9312-9; Halestrap AP, 2010, BIOCHEM SOC T, V38, P841, DOI 10.1042/BST0380841; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Koehler CM, 2006, ANTIOXID REDOX SIGN, V8, P813, DOI 10.1089/ars.2006.8.813; Kowaltowski AJ, 2004, FREE RADICAL BIO MED, V37, P1845, DOI 10.1016/j.freeradbiomed.2004.09.005; KUKIELKA E, 1994, ARCH BIOCHEM BIOPHYS, V309, P377, DOI 10.1006/abbi.1994.1127; Lee JM, 2001, BIOCHEM BIOPH RES CO, V280, P286, DOI 10.1006/bbrc.2000.4106; LEHNINGER AL, 1978, P NATL ACAD SCI USA, V75, P1690, DOI 10.1073/pnas.75.4.1690; Lemasters JJ, 1997, MOL CELL BIOCHEM, V174, P159, DOI 10.1023/A:1006827601337; LIU SL, 1995, HEPATOLOGY, V22, P1474, DOI 10.1002/hep.1840220522; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; MOORE M, 1985, J BIOL CHEM, V260, P3035; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Norberg E, 2008, CELL DEATH DIFFER, V15, P1857, DOI 10.1038/cdd.2008.123; PACKER MA, 1994, FEBS LETT, V345, P237, DOI 10.1016/0014-5793(94)00461-7; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Piantadosi CA, 2008, CIRC RES, V103, P1232, DOI 10.1161/01.RES.0000338597.71702.ad; PONSODA X, 1995, TOXICOL IN VITRO, V9, P439, DOI 10.1016/0887-2333(95)00035-7; Ramachandran A, 2011, FREE RADICAL RES, V45, P156, DOI 10.3109/10715762.2010.520319; Rasola A, 2007, APOPTOSIS, V12, P815, DOI 10.1007/s10495-007-0723-y; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; SHIGESAWA T, 1992, J GASTROEN HEPATOL, V7, P7, DOI 10.1111/j.1440-1746.1992.tb00926.x; Stravitz RT, 2009, NAT REV GASTRO HEPAT, V6, P542, DOI 10.1038/nrgastro.2009.127; TAKEYAMA N, 1993, BIOCHEM J, V294, P719, DOI 10.1042/bj2940719; Thimmulappa RK, 2002, CANCER RES, V62, P5196; THORNILEY MS, 1995, HEPATOLOGY, V21, P1602, DOI 10.1016/0270-9139(95)90465-4; Toman J, 2011, J BIOENERG BIOMEMBR, V43, P3, DOI 10.1007/s10863-011-9337-8; Van Remmen H, 2001, AM J PHYSIOL-HEART C, V281, pH1422, DOI 10.1152/ajpheart.2001.281.3.H1422; VERCESI AE, 1984, BIOCHEM BIOPH RES CO, V119, P305, DOI 10.1016/0006-291X(84)91652-8; Yamamoto Y, 1998, BIOCHEM BIOPH RES CO, V247, P166, DOI 10.1006/bbrc.1998.8752; Zhu H, 2008, CARDIOVASC TOXICOL, V8, P115, DOI 10.1007/s12012-008-9020-4	49	56	61	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	DEC 15	2011	51	12					2164	2171		10.1016/j.freeradbiomed.2011.09.017			8	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	860PK	WOS:000297960000005	21986339	Green Accepted			2022-02-06	
J	Mckinlay, A; Bishop, A; Mclellan, T				Mckinlay, A.; Bishop, A.; Mclellan, T.			Public knowledge of 'concussion' and the different terminology used to communicate about mild traumatic brain injury (MTBI)	BRAIN INJURY			English	Article						Mild traumatic brain injury; head injury; concussion	HEAD-INJURY; ADOLESCENTS; CHILDREN	Primary objective: The primary objective was to investigate the public's general knowledge about concussion (mild traumatic brain injury) and to examine whether terminology influenced attributions made about individuals who experience concussion. Design: A random selection of the community was polled to identify public understanding of concussion. To encourage candid responses, a self-report survey method was used. Methods and procedures: One hundred and three members of the general public were asked to indicate if they associated specific attributes with brain injury or head injury, depending on the randomly assigned questionnaire they completed. Participants also completed a questionnaire about their knowledge of concussion and were asked to indicate whether they or someone they knew had experienced an injury to the head. Main outcomes and results: Participants incorrectly evaluated 20% (2/10) of statements regarding concussion knowledge and were relatively uncertain about another 20% (2/10) of statements. Negative attributes were associated more with brain than head injury, although those with prior experience made more positive attributions than those without. Fifty-nine per cent of participants who had experienced a concussion stated they had no brain/head injury. Conclusions: Overall, public knowledge about concussion and different terminology associated with this injury type is substantially inaccurate. More accurate information is required to increase understanding.	[Mckinlay, A.; Bishop, A.; Mclellan, T.] Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand; [Mckinlay, A.] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia		Mckinlay, A (corresponding author), Univ Canterbury, Dept Psychol, Private Bag 4800, Christchurch 1, New Zealand.	audrey.mckinlay@canterbury.ac.nz		McKinlay, Audrey/0000-0001-9846-8514	Health Research Council of New ZealandHealth Research Council of New Zealand; Accident Compensation Corporation	This research was conducted during the tenure of an ACC Post-Doctoral Research Career Development Award, Awarded to Dr McKinlay from the Health Research Council of New Zealand and the Accident Compensation Corporation.	ANDERSON NH, 1968, J PERS SOC PSYCHOL, V9, P272, DOI 10.1037/h0025907; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; DeMatteo CA, 2010, PEDIATRICS, V125, P327, DOI 10.1542/peds.2008-2720; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Hux D, 1998, BRAIN INJURY, V12, P667; LOVE H, 1997, PRACTICE ISSUES CLIN; Mackenzie JA, 2005, BRIT J CLIN PSYCHOL, V44, P417, DOI 10.1348/014466505X35696; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P3, DOI 10.1111/j.1365-2214.2009.01006.x; MCLELLAN T, 2010, J INT NEUROPSYCH SOC, V16, P1; Mulhern S, 2006, J PSYCHOSOM RES, V61, P439, DOI 10.1016/j.jpsychores.2006.03.004; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; PROVVIDENZA CF, 2009, BRIT SPORTS MED, V43, P186; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511	19	56	56	0	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2011	25	7-8					761	766		10.3109/02699052.2011.579935			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	769RJ	WOS:000291035600012	21619461				2022-02-06	
J	Timofeev, I; Czosnyka, M; Carpenter, KLH; Nortje, J; Kirkpatrick, PJ; Al-Rawi, PG; Menon, DK; Pickard, JD; Gupta, AK; Hutchinson, PJ				Timofeev, Ivan; Czosnyka, Marek; Carpenter, Keri L. H.; Nortje, Jurgens; Kirkpatrick, Peter J.; Al-Rawi, Pippa G.; Menon, David K.; Pickard, John D.; Gupta, Arun K.; Hutchinson, Peter J.			Interaction between Brain Chemistry and Physiology after Traumatic Brain Injury: Impact of Autoregulation and Microdialysis Catheter Location	JOURNAL OF NEUROTRAUMA			English	Article						autoregulation; brain injury; CPP; ICP; microdialysis	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; POSITRON-EMISSION-TOMOGRAPHY; INTRACRANIAL-PRESSURE; ENERGY-METABOLISM; INTRACEREBRAL MICRODIALYSIS; REGIONAL OXYGENATION; TISSUE OXYGEN; BLOOD-FLOW; ISCHEMIA	Bedside monitoring of cerebral metabolism in traumatic brain injury (TBI) with microdialysis is gaining wider clinical acceptance. The objective of this study was to examine the relationship between the fundamental physiological neuromonitoring modalities intracranial pressure (ICP), cerebral perfusion pressure (CPP), brain tissue oxygen (PbtO2), and cerebrovascular pressure reactivity index (PRx), and cerebral chemistry assessed with microdialysis, with particular focus on the lactate/pyruvate (LP) ratio as a marker of energy metabolism. Prospectively collected observational neuromonitoring data from 97 patients with TBI, requiring neurointensive care management and invasive cerebral monitoring, were analyzed. A linear mixed model analysis was used to account for individual patient differences. Perilesional tissue chemistry exhibited a significant independent relationship with ICP, PbtO2 and CPP thresholds, with increasing LP ratio in response to decrease in PbtO2 and CPP, and increase in ICP. The relationship between CPP and chemistry depended upon the state of PRx. Within the studied physiological range, tissue chemistry only changed in response to increasing ICP or drop in PbtO2 < 1.33 kPa (10 mmHg). In agreement with previous studies, significantly higher levels of cerebral lactate (p < 0.001), glycerol (p = 0.013), LP ratio (p < 0.001) and lactate/glucose (LG) ratio (p = 0.003) were found in perilesional tissue, compared to "normal" brain tissue (Mann-Whitney test). These differences remained significant following adjustment for the influences of other important physiological parameters (ICP, CPP, PbtO2, PbtCO2, PRx, and brain temperature; mixed linear model), suggesting that they may reflect inherent tissue properties related to the initial injury. Despite inherent biochemical differences between less-injured brain and "perilesional" cerebral tissue, both tissue types exhibited relationships between established physiological variables and biochemistry. Decreases in perfusion and oxygenation were associated with deteriorating neurochemistry and these effects were more pronounced in perilesional tissue and when cerebrovascular reactivity was impaired.	[Timofeev, Ivan; Czosnyka, Marek; Carpenter, Keri L. H.; Kirkpatrick, Peter J.; Al-Rawi, Pippa G.; Pickard, John D.; Hutchinson, Peter J.] Univ Cambridge, Div Neurosurg, Addenbrookes Hosp, Dept Clin Neurosci, Cambridge CB2 0QQ, England; [Carpenter, Keri L. H.; Nortje, Jurgens; Menon, David K.; Pickard, John D.; Hutchinson, Peter J.] Univ Cambridge, Wolfson Brain Imaging Ctr, Addenbrookes Hosp, Dept Clin Neurosci, Cambridge CB2 0QQ, England; [Nortje, Jurgens; Menon, David K.; Gupta, Arun K.] Univ Cambridge, Div Anaesthesia, Addenbrookes Hosp, Dept Med, Cambridge CB2 0QQ, England		Timofeev, I (corresponding author), Univ Cambridge, Div Neurosurg, Addenbrookes Hosp, Dept Clin Neurosci, Box 167,Hills Rd, Cambridge CB2 0QQ, England.	it227@cam.ac.uk	Timofeev, Ivan/AAE-7019-2019	Timofeev, Ivan/0000-0002-1168-0393; Carpenter, Keri/0000-0001-8236-7727	Codman Inc.; Evelyn Trust; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390 ID 65883, G0600986 ID79068]; BP-TNK Kapitza Scholarship; Academy of Medical Sciences/Health Foundation; National Institute for Health Research Biomedical Research Centre, CambridgeNational Institute for Health Research (NIHR); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G0001237, G0601025, G9439390] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001354, G0601025, G0001354B, G9439390, G0001237, G1000183B, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	We thank Dr. Peter Smielewski for help with digital data capture. Ivan Timofeev received a Codman Inc. grant, The Evelyn Trust grant, the Medical Research Council RESCUEicp trial grant, and a BP-TNK Kapitza Scholarship. Peter Hutchinson received an Academy of Medical Sciences/Health Foundation, Senior Surgical Scientist Fellowship. Dr. Keri Carpenter received support from the Medical Research Council Acute Brain Injury Programme Grant and the National Institute for Health Research Biomedical Research Centre, Cambridge. Study support (Medical Research Council Grant Nos. G9439390 ID 65883 and G0600986 ID79068).	Agren-Wilsson A, 2005, J NEUROL NEUROSUR PS, V76, P1088, DOI 10.1136/jnnp.2004.042838; [Anonymous], 2007, J NEUROTRAUMA S1, V24, pS1; Bauer R, 2004, INTENS CARE MED, V30, P159, DOI 10.1007/s00134-003-2015-5; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Berger C, 2005, STROKE, V36, pE4, DOI 10.1161/01.STR.0000151328.70519.e9; Boret H, 2006, ACTA ANAESTH SCAND, V50, P252, DOI 10.1111/j.1399-6576.2005.00862.x; Chan MTV, 2005, ACT NEUR S, V95, P113; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Cremer OL, 2008, EUR J ANAESTH, V25, P87, DOI 10.1017/S0265021507003237; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Czosnyka M, 2002, ACT NEUR S, V81, P117; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 1998, ACT NEUR S, V71, P74; Eide PK, 2007, ACTA ANAESTH SCAND, V51, P1273, DOI 10.1111/j.1399-6576.2007.01433.x; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hlatky R, 2004, NEUROSURGERY, V55, P1318, DOI 10.1227/01.NEU.0000143029.42638.2C; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Kett-White R, 2002, ACT NEUR S, V81, P363; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Poon WS, 2005, ACT NEUR S, V95, P9; Poon WS, 2002, ACT NEUR S, V81, P335; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Reinert M, 2007, NEUROL RES, V29, P455, DOI 10.1179/016164107X164175; Robertson CS, 1998, NEUROL RES, V20, pS91; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 2002, ACTA NEUROCHIR SUPPL, V81, P355; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Young Jeffrey S, 2003, Neurosurg Focus, V15, pE2	47	56	58	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2011	28	6					849	860		10.1089/neu.2010.1656			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	788PT	WOS:000292457600001	21488707	Green Published			2022-02-06	
J	Bernick, KB; Prevost, TP; Suresh, S; Socrate, S				Bernick, Kristin B.; Prevost, Thibault P.; Suresh, Subra; Socrate, Simona			Biomechanics of single cortical neurons	ACTA BIOMATERIALIA			English	Article						Atomic force microscopy; Neuron; Cell mechanics; Constitutive modeling; Finite elements	ATOMIC-FORCE MICROSCOPY; TRAUMATIC BRAIN-INJURY; VISCOELASTIC PROPERTIES; MECHANICAL-PROPERTIES; ARTICULAR CHONDROCYTES; CELL STIFFNESS; HEAD-INJURIES; CANCER-CELLS; MODEL; TISSUE	This study presents experimental results and computational analysis of the large strain dynamic behavior of single neurons in vitro with the objective of formulating a novel quantitative framework for the biomechanics of cortical neurons. Relying on the atomic force microscopy (AFM) technique, novel testing protocols are developed to enable the characterization of neural soma deformability over a range of indentation rates spanning three orders of magnitude, 10, 1, and 0.1 mu m s(-1). Modified spherical AFM probes were utilized to compress the cell bodies of neonatal rat cortical neurons in load, unload, reload and relaxation conditions. The cell response showed marked hysteretic features, strong non-linearities, and substantial time/rate dependencies. The rheological data were complemented with geometrical measurements of cell body morphology, i.e. cross-diameter and height estimates. A constitutive model, validated by the present experiments, is proposed to quantify the mechanical behavior of cortical neurons. The model aimed to correlate empirical findings with measurable degrees of (hyper)elastic resilience and viscosity at the cell level. The proposed formulation, predicated upon previous constitutive model developments undertaken at the cortical tissue level, was implemented in a three-dimensional finite element framework. The simulated cell response was calibrated to the experimental measurements under the selected test conditions, providing a novel single cell model that could form the basis for further refinements. (C) 2010 Acts Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Socrate, Simona] MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Bernick, Kristin B.; Suresh, Subra] MIT, Dept Biol Engn, Cambridge, MA 02139 USA; [Prevost, Thibault P.; Suresh, Subra] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA		Socrate, S (corresponding author), MIT, Div Hlth Sci & Technol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	ssocrate@mit.edu	Suresh, Subra/B-8289-2008	Suresh, Subra/0000-0002-6223-6831	US Army Research Office through the MIT Institute for Soldier Nanotechnologies [DAAD-19-02-D0002]; Joint Improvised Explosive Devices Defeat Organization [W911NF-07-1-0035]; National Science FoundationNational Science Foundation (NSF); National Institutes of Health Molecular, Cell, and Tissue BiomechanicsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Ecole Nationale des Ponts et Chaussees (Universite Paris-Est, France); Singapore-MIT AllianceSingapore-MIT Alliance for Research & Technology Centre (SMART); Interdisciplinary Research Group on Infectious Diseases at the Singapore-MIT Alliance for Research and Technology; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [T32EB006348] Funding Source: NIH RePORTER	This work was supported by the US Army Research Office through the MIT Institute for Soldier Nanotechnologies (DAAD-19-02-D0002) and the Joint Improvised Explosive Devices Defeat Organization (W911NF-07-1-0035), the National Science Foundation Graduate Research Fellowship Program, the National Institutes of Health Molecular, Cell, and Tissue Biomechanics Training Grant, the Ecole Nationale des Ponts et Chaussees (Universite Paris-Est, France), the Computational Systems Biology Programme of the Singapore-MIT Alliance, and the Interdisciplinary Research Group on Infectious Diseases at the Singapore-MIT Alliance for Research and Technology. The authors are grateful to Professor Sebastian Seung (Massachusetts Institute of Technology, Cambridge, MA) for providing cortical tissue, Professor Patricia Carvalho (Instituto Superior Tecnico, Lisbon, Portugal) for imaging SEM samples, and Dr Shelten Yuen and Daniel Rudoy (Harvard University, Cambridge, MA) for providing the MATLAB routine employed in the determination of the cell-cantilever contact point.	ARRUDA EM, 1993, J MECH PHYS SOLIDS, V41, P389, DOI 10.1016/0022-5096(93)90013-6; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bao G, 2003, NAT MATER, V2, P715, DOI 10.1038/nmat1001; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bergstrom JS, 2001, MECH MATER, V33, P523, DOI 10.1016/S0167-6636(01)00070-9; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Brewer GJ, 2007, NAT PROTOC, V2, P1490, DOI 10.1038/nprot.2007.207; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Costa KD, 2006, J BIOMECH ENG-T ASME, V128, P176, DOI 10.1115/1.2165690; Crowe LM, 2010, EMERG MED AUSTRALAS, V22, P56, DOI 10.1111/j.1742-6723.2009.01249.x; Darling EM, 2006, OSTEOARTHR CARTILAGE, V14, P571, DOI 10.1016/j.joca.2005.12.003; Desprat N, 2005, BIOPHYS J, V88, P2224, DOI 10.1529/biophysj.104.050278; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; EVANS E, 1984, BLOOD, V64, P1028; Fernandez P, 2006, BIOPHYS J, V90, P3796, DOI 10.1529/biophysj.105.072215; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Franz CM, 2008, CELL MOL BIOENG, V1, P289, DOI 10.1007/s12195-008-0037-3; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Gardel ML, 2006, P NATL ACAD SCI USA, V103, P1762, DOI 10.1073/pnas.0504777103; Guck J, 2001, BIOPHYS J, V81, P767, DOI 10.1016/S0006-3495(01)75740-2; Guilak F, 2000, BIOCHEM BIOPH RES CO, V269, P781, DOI 10.1006/bbrc.2000.2360; Guilak F, 2000, J BIOMECH, V33, P1663, DOI 10.1016/S0021-9290(00)00105-6; Gurtin M.E., 1981, INTRO CONTINUUM MECH; Henon S, 1999, BIOPHYS J, V76, P1145, DOI 10.1016/S0006-3495(99)77279-6; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Holzapfel GA., 2000, NONLINEAR SOLID MECH; Karcher H, 2003, BIOPHYS J, V85, P3336, DOI 10.1016/S0006-3495(03)74753-5; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lam WA, 2007, BLOOD, V109, P3505, DOI 10.1182/blood-2006-08-043570; LEE EH, 1969, J APPL MECH, V36, P1, DOI 10.1115/1.3564580; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Li QS, 2008, BIOCHEM BIOPH RES CO, V374, P609, DOI 10.1016/j.bbrc.2008.07.078; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Lulevich V, 2006, LANGMUIR, V22, P8151, DOI 10.1021/la060561p; Mahaffy RE, 2004, BIOPHYS J, V86, P1777, DOI 10.1016/S0006-3495(04)74245-9; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Massiera G, 2007, BIOPHYS J, V93, P3703, DOI 10.1529/biophysj.107.111641; Matei GA, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2336115; Mathur AB, 2001, J BIOMECH, V34, P1545, DOI 10.1016/S0021-9290(01)00149-X; McCrory P, 2005, BRIT J SPORT MED, V39, pI58, DOI 10.1136/bjsm.2005.020776; McGarry J G, 2004, Eur Cell Mater, V7, P27; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Merryman WD, 2006, AM J PHYSIOL-HEART C, V290, pH224, DOI 10.1152/ajpheart.00521.2005; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Mills JP, 2007, P NATL ACAD SCI USA, V104, P9213, DOI 10.1073/pnas.0703433104; Prevost TP, 2011, ACTA BIOMATER, V7, P83, DOI 10.1016/j.actbio.2010.06.035; Radmacher M, 1996, BIOPHYS J, V70, P556, DOI 10.1016/S0006-3495(96)79602-9; Radmacher M, 2007, METHOD CELL BIOL, V83, P347, DOI 10.1016/S0091-679X(07)83015-9; RAND RP, 1964, BIOPHYS J, V4, P115, DOI 10.1016/S0006-3495(64)86773-4; Rudoy D, 2010, J R STAT SOC C-APPL, V59, P573; SATO M, 1990, J BIOMECH ENG-T ASME, V112, P263, DOI 10.1115/1.2891183; SCHMIDSCHONBEIN GW, 1981, BIOPHYS J, V36, P243, DOI 10.1016/S0006-3495(81)84726-1; Shin D, 1999, J ORTHOP RES, V17, P880, DOI 10.1002/jor.1100170613; Spagnoli C, 2007, REV SCI INSTRUM, V78, DOI 10.1063/1.2534889; Storm C, 2005, NATURE, V435, P191, DOI 10.1038/nature03521; Suresh S, 2005, ACTA BIOMATER, V1, P15, DOI 10.1016/j.actbio.2004.09.001; Suresh S, 2007, ACTA BIOMATER, V3, P413, DOI 10.1016/j.actbio.2007.04.002; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tagawa H, 1997, CIRC RES, V80, P281, DOI 10.1161/01.RES.80.2.281; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Trepat X, 2004, AM J PHYSIOL-LUNG C, V287, pL1025, DOI 10.1152/ajplung.00077.2004; Trickey WR, 2004, J ORTHOPAED RES, V22, P131, DOI 10.1016/S0736-0266(03)00150-5; Unnikrishnan GU, 2007, J BIOMECH ENG-T ASME, V129, P315, DOI 10.1115/1.2720908; Van Vliet KJ, 2003, ACTA MATER, V51, P5881, DOI 10.1016/j.actamat.2003.09.001; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Xu JY, 2000, J BIOL CHEM, V275, P35886, DOI 10.1074/jbc.M002377200; Yilmaz S, 2007, AM J EMERG MED, V25, P97, DOI 10.1016/j.ajem.2006.04.014; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	70	56	57	3	53	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1742-7061	1878-7568		ACTA BIOMATER	Acta Biomater.	MAR	2011	7	3					1210	1219		10.1016/j.actbio.2010.10.018			10	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	725KP	WOS:000287643900032	20971217	Green Published, Green Accepted			2022-02-06	
J	Allen, BJ; Gfeller, JD				Allen, Brittany J.; Gfeller, Jeffrey D.			The Immediate Post-Concussion Assessment and Cognitive Testing battery and traditional neuropsychological measures: A construct and concurrent validity study	BRAIN INJURY			English	Article						ImPACT; sports related concussion; computer based assessment; construct validity; concurrent validity; neuropsychological assessment	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; REPEATABLE BATTERY; IMPACT; MANAGEMENT; MILD	Primary objective: This study examined the construct and concurrent validity of ImPACT, a computerized neuropsychological test battery used for evaluating sports-related concussion. Research design: Approximately 100 neurologically intact undergraduates completed ImPACT and a battery of traditional neuropsychological tests utilized by the National Football League (NFL). Methods and procedures: Participants completed the two batteries in a counterbalanced order. Factor analyses examined the component structure of ImPACT and the NFL battery's factor structure. Correlational analyses assessed relationships among variables within and across the two batteries. Main results: A four-factor solution explaining 70% of variance was found with the NFL battery, including general memory, mental processing speed, verbal memory and processing speed and auditory and verbal working memory. A five-factor solution explaining 69% of variance was found with the ImPACT battery, with components assessing forced choice efficiency, verbal and visual memory, inhibitory cognitive abilities, visual processing abilities with a memory component and a factor with a single loading from Colour Match Total Commissions. Correlations revealed a range of significant and nonsignificant correlations between the two batteries. Conclusions: While both batteries overlap regarding their assessed constructs (e.g. memory, inhibitory cognitive abilities) notable differences in their factor structures were present as well.	[Allen, Brittany J.] CoxHealth, Dept Psychol Serv, Springfield, MO 65807 USA; [Gfeller, Jeffrey D.] St Louis Univ, Dept Psychol, St Louis, MO 63103 USA		Allen, BJ (corresponding author), CoxHealth, Dept Psychol Serv, 3800 S Natl Ave,Suite 770, Springfield, MO 65807 USA.	brittany.allen1@coxhealth.com					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; *AM MED ASS, 2005, CPT 2006; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Benedict R., 1997, BRIEF VISUOSPATIAL M; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Brandt J, 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Delis DC, 2003, J INT NEUROPSYCH SOC, V9, P936, DOI 10.1017/S1355617703960139; Duff K, 2006, AM J GERIAT PSYCHIAT, V14, P976, DOI 10.1097/01.JGP.0000229690.70011.cd; Echemendia R., 2006, SPORTS NEUROPSYCHOLO; Garcia C, 2008, ARCH CLIN NEUROPSYCH, V23, P63, DOI 10.1016/j.acn.2007.08.008; Hamsher K., 1989, MULTILINGUAL APHASIA; Iverson G. L., 2003, 23 ANN M NAT AC NEUR; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lovell M.R., 2005, IMPACT IMMEDIATE POS; Lovell M.R.C.M., 2003, IMMEDIATE POSTCONCUS; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P287; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; LOVELL MR, 2004, ORTHOPEDIC TECHNOLOG, V6, P28; LOVELL MR, 2000, NEUROLOGIC ATHLETIC, P109; Lovell MR, 2006, SPORTS NEUROPSYCHOLO, P176; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Millis SR, 1999, J CLIN EXP NEUROPSYC, V21, P87, DOI 10.1076/jcen.21.1.87.937; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Randolph C, 2005, J ATHL TRAINING, V40, P139; Reitan RM, 1985, HALSTEADREITAN NEURO; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Schatz P, 2002, J HEAD TRAUMA REHAB, V17, P395, DOI 10.1097/00001199-200210000-00003; Sosin DM, 1996, BRAIN INJURY, V10, P47; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird	41	56	57	0	22	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2011	25	2					179	191		10.3109/02699052.2010.541897			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	731JJ	WOS:000288101800005	21219090				2022-02-06	
J	Paterniti, I; Mazzon, E; Gil, C; Impellizzeri, D; Palomo, V; Redondo, M; Perez, DI; Esposito, E; Martinez, A; Cuzzocrea, S				Paterniti, Irene; Mazzon, Emanuela; Gil, Carmen; Impellizzeri, Daniela; Palomo, Valle; Redondo, Myriam; Perez, Daniel I.; Esposito, Emanuela; Martinez, Ana; Cuzzocrea, Salvatore			PDE 7 Inhibitors: New Potential Drugs for the Therapy of Spinal Cord Injury	PLOS ONE			English	Article							NITRIC-OXIDE SYNTHASE; KAPPA-B ACTIVATION; CELL-DEATH; INFLAMMATORY RESPONSE; OXIDATIVE STRESS; MESSENGER-RNA; EXPRESSION; APOPTOSIS; PHOSPHODIESTERASES; NEURONS	Background: Primary traumatic mechanical injury to the spinal cord (SCI) causes the death of a number of neurons that to date can neither be recovered nor regenerated. During the last years our group has been involved in the design, synthesis and evaluation of PDE7 inhibitors as new innovative drugs for several neurological disorders. Our working hypothesis is based on two different facts. Firstly, neuroinflammation is modulated by cAMP levels, thus the key role for phosphodiesterases (PDEs), which hydrolyze cAMP, is undoubtedly demonstrated. On the other hand, PDE7 is expressed simultaneously on leukocytes and on the brain, highlighting the potential crucial role of PDE7 as drug target for neuroinflammation. Methodology/Principal Findings: Here we present two chemically diverse families of PDE7 inhibitors, designed using computational techniques such as virtual screening and neuronal networks. We report their biological profile and their efficacy in an experimental SCI model induced by the application of vascular clips (force of 24 g) to the dura via a four-level T5-T8 laminectomy. We have selected two candidates, namely S14 and VP1.15, as PDE7 inhibitors. These compounds increase cAMP production both in macrophage and neuronal cell lines. Regarding drug-like properties, compounds were able to cross the blood brain barrier using parallel artificial membranes (PAMPA) methodology. SCI in mice resulted in severe trauma characterized by edema, neutrophil infiltration, and production of a range of inflammatory mediators, tissue damage, and apoptosis. Treatment of the mice with S14 and VP1.15, two PDE7 inhibitors, significantly reduced the degree of spinal cord inflammation, tissue injury (histological score), and TNF-alpha, IL-6, COX-2 and iNOS expression. Conclusions/Significance: All these data together led us to propose PDE7 inhibitors, and specifically S14 and VP1.15, as potential drug candidates to be further studied for the treatment of SCI.	[Paterniti, Irene; Impellizzeri, Daniela; Esposito, Emanuela; Cuzzocrea, Salvatore] Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Messina, Italy; [Mazzon, Emanuela; Esposito, Emanuela; Cuzzocrea, Salvatore] IRCCS Ctr Neurolesi Bonino Pulejo, Messina, Italy; [Gil, Carmen; Palomo, Valle; Redondo, Myriam; Perez, Daniel I.; Martinez, Ana] CSIC, Inst Quim Med, E-28006 Madrid, Spain		Paterniti, I (corresponding author), Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Messina, Italy.	salvator@unime.it	Martinez, Ana/L-6414-2014; Perez Fernandez, Daniel Ignacio/L-6245-2014; del Valle Palomo Ruiz, Maria/N-2932-2016; Gil, Carmen/J-8932-2014; Mazzon, Emanuela/AAL-4334-2020	Martinez, Ana/0000-0002-2707-8110; Perez Fernandez, Daniel Ignacio/0000-0003-1774-4471; del Valle Palomo Ruiz, Maria/0000-0002-1473-4086; Gil, Carmen/0000-0002-3882-6081; Impellizzeri, Daniela/0000-0001-9492-3161; mazzon, emanuela/0000-0002-5073-717X	MICINNSpanish GovernmentEuropean Commission; ISCiiiInstituto de Salud Carlos III [SAF2009-13015-CO2-01, RD0060/0015]	The financial support of MICINN and ISCiii (projects no. SAF2009-13015-CO2-01 and RD0060/0015, programs SAF and RETICS respectively) are acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aizawa T, 2003, CIRC RES, V93, P406, DOI 10.1161/01.RES.0000091074.33584.F0; Allison AC, 2000, IMMUNOPHARMACOLOGY, V47, P63, DOI 10.1016/S0162-3109(00)00186-7; Bao F, 2003, J NEUROSCI RES, V71, P220, DOI 10.1002/jnr.10481; Bar-Peled O, 1999, J NEUROSCI RES, V55, P542, DOI 10.1002/(SICI)1097-4547(19990301)55:5<542::AID-JNR2>3.0.CO;2-7; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bhat NR, 1998, J NEUROSCI, V18, P1633; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Cardoso FL, 2010, BRAIN RES REV, V64, P328, DOI 10.1016/j.brainresrev.2010.05.003; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Castano T, 2009, CHEMMEDCHEM, V4, P866, DOI 10.1002/cmdc.200900043; Castro A, 2005, MED RES REV, V25, P229, DOI 10.1002/med.20020; Castro A, 2008, EUR J MED CHEM, V43, P1349, DOI 10.1016/j.ejmech.2007.10.027; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Choi SH, 2003, NEUROBIOL DIS, V14, P181, DOI 10.1016/S0969-9961(03)00085-8; Choi SH, 2003, J NEUROSCI, V23, P5877; Combs CK, 2001, J NEUROSCI, V21, P1179; Conti M, 2007, ANNU REV BIOCHEM, V76, P481, DOI 10.1146/annurev.biochem.76.060305.150444; Crivori P, 2000, J MED CHEM, V43, P2204, DOI 10.1021/jm990968+; Cuzzocrea S, 2006, J PHARMACOL EXP THER, V319, P127, DOI 10.1124/jpet.106.108076; de Castro R, 2004, EXP NEUROL, V190, P414, DOI 10.1016/j.expneurol.2004.05.046; Di L, 2003, EUR J MED CHEM, V38, P223, DOI 10.1016/S0223-5234(03)00012-6; Dyke HJ, 2002, EXPERT OPIN INV DRUG, V11, P1; Essayan DM, 1999, BIOCHEM PHARMACOL, V57, P965, DOI 10.1016/S0006-2952(98)00331-1; Genovese T, 2006, J PHARMACOL EXP THER, V316, P1006, DOI 10.1124/jpet.105.097188; Genovese T, 2006, J NEUROSURG-SPINE, V4, P145, DOI 10.3171/spi.2006.4.2.145; Giembycz MA, 1996, BRIT J PHARMACOL, V118, P1945, DOI 10.1111/j.1476-5381.1996.tb15629.x; Giembycz MA, 2005, CURR OPIN PHARMACOL, V5, P238, DOI 10.1016/j.coph.2005.04.001; Gil C, 2009, J NEUROCHEM, V110, P119; Gil C, 2008, EXPERT OPIN THER PAT, V18, P1127, DOI 10.1517/13543776.18.10.1127; Glaser J, 2006, J NEUROSCI RES, V84, P724, DOI 10.1002/jnr.20982; Haddad JJ, 2002, CELL SIGNAL, V14, P879, DOI 10.1016/S0898-6568(02)00053-0; Hong GY, 2010, J SURG RES, V159, P565, DOI 10.1016/j.jss.2008.12.018; Houslay MD, 2005, DRUG DISCOV TODAY, V10, P1503, DOI 10.1016/S1359-6446(05)03622-6; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; La Rosa G, 2004, J NEUROSURG-SPINE, V1, P311, DOI 10.3171/spi.2004.1.3.0311; Lee R, 2002, CELL SIGNAL, V14, P277, DOI 10.1016/S0898-6568(01)00250-9; Levy M L, 1999, Neurosurg Focus, V6, pe11; Li LS, 1999, SCIENCE, V283, P848, DOI 10.1126/science.283.5403.848; Lugnier C, 2006, PHARMACOL THERAPEUT, V109, P366, DOI 10.1016/j.pharmthera.2005.07.003; Maegele M, 2005, CRIT CARE MED, V33, P1136, DOI 10.1097/01.CCM.0000163269.42524.50; Manning CD, 1999, BRIT J PHARMACOL, V128, P1393, DOI 10.1038/sj.bjp.0702911; MARTINEZ AC, 2009, 5 IMINO SUBSTITUTED; Menniti FS, 2006, NAT REV DRUG DISCOV, V5, P660, DOI 10.1038/nrd2058; Mullane K, 1989, Prog Clin Biol Res, V301, P39; Nakata A, 2002, CLIN EXP IMMUNOL, V128, P460, DOI 10.1046/j.1365-2249.2002.01856.x; Nesic-Taylor O, 2005, J NEUROSCI RES, V79, P628, DOI 10.1002/jnr.20400; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; Rahman A, 2004, AM J PHYSIOL-LUNG C, V287, pL1017, DOI 10.1152/ajplung.00072.2004; Redondo M, 2009, DRUG FUTURE, V34, P142; Reyes-Irisarri E, 2005, NEUROSCIENCE, V132, P1173, DOI 10.1016/j.neuroscience.2005.01.050; RIVLIN AS, 1978, SURG NEUROL, V10, P39; Sirin BH, 2002, ACTA CARDIOL, V57, P279, DOI 10.2143/AC.57.4.2005427; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; Spina D, 2003, DRUGS, V63, P2575, DOI 10.2165/00003495-200363230-00002; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; vanAsperen J, 1997, J PHARM SCI, V86, P881, DOI 10.1021/js9701364; Verma IM, 2004, ANN RHEUM DIS, V63, P57, DOI 10.1136/ard.2004.028266; Yang GC, 2003, J IMMUNOL, V171, P6414, DOI 10.4049/jimmunol.171.12.6414	65	56	59	2	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2011	6	1							e15937	10.1371/journal.pone.0015937			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	714UK	WOS:000286834300030	21297958	gold, Green Published, Green Submitted			2022-02-06	
J	Rueda, MAF; Cui, L; Gilchrist, MD				Rueda, M. A. Forero; Cui, L.; Gilchrist, M. D.			Finite element modelling of equestrian helmet impacts exposes the need to address rotational kinematics in future helmet designs	COMPUTER METHODS IN BIOMECHANICS AND BIOMEDICAL ENGINEERING			English	Article						head impact; traumatic brain injury (TBI); concussion; sports helmets; horse racing	MULTIBODY DYNAMICS ANALYSIS; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; FALLS; RECONSTRUCTION; IRELAND	Jockey head injuries, especially concussions, are common in horse racing. Current helmets do help to reduce the severity and incidences of head injury, but the high concussion incidence rates suggest that there may be scope to improve the performance of equestrian helmets. Finite element simulations in ABAQUS/Explicit were used to model a realistic helmet model during standard helmeted rigid headform impacts and helmeted head model University College Dublin Brain Trauma Model (UCDBTM) impacts. Current helmet standards for impact determine helmet performance based solely on linear acceleration. Brain injury-related values (stress and strain) from the UCDBTM showed that a performance improvement based on linear acceleration does not imply the same improvement in head injury-related brain tissue loads. It is recommended that angular kinematics be considered in future equestrian helmet standards, as angular acceleration was seen to correlate with stress and strain in the brain.	[Rueda, M. A. Forero; Cui, L.; Gilchrist, M. D.] Univ Coll Dublin, Sch Elect Elect & Mech Engn, Dublin 2, Ireland; [Gilchrist, M. D.] Univ Ottawa, Sch Human Kinet, Ottawa, ON K1N 6N5, Canada		Gilchrist, MD (corresponding author), Univ Coll Dublin, Sch Elect Elect & Mech Engn, Dublin 2, Ireland.	michael.gilchrist@ucd.ie	Gilchrist, Michael D/B-6100-2017	Gilchrist, Michael D/0000-0003-1765-429X; Cui, Liang/0000-0002-5546-5097	Turf Club of Ireland; Enterprise Ireland; Science Foundation IrelandScience Foundation IrelandEuropean Commission	Financial support for this work has been provided by the Turf Club of Ireland, by Enterprise Ireland and by Science Foundation Ireland.	Aare M., 2003, INT RES COUNC BIOM I, P349; ABAQUS, 2009, ABAQUS AN US MAN V 6; Anderson RWG, 1999, P INT IRCOBI C BIOM, P107; Andersson T, 1993, 199342 SP SWED NAT T; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Cui L, 2009, MATER DESIGN, V30, P3414, DOI 10.1016/j.matdes.2009.03.044; Cui L, 2009, MAT SCI ENG A-STRUCT, V507, P215, DOI 10.1016/j.msea.2008.12.011; Deck C, 2006, INT J CRASHWORTHINES, V11, P561, DOI 10.1533/ijcr.2006.0149; Depreitere B, 2004, ACCIDENT ANAL PREV, V36, P561, DOI 10.1016/S0001-4575(03)00062-9; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; Doorly MC, 2009, INT J CRASHWORTHINES, V14, P503, DOI 10.1080/13588260902826554; Doorly M.C., 2007, THESIS U COLL DUBLIN; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Gilchrist MD, 2000, COMPUT MECH, V26, P229, DOI 10.1007/s004660000179; Gilchrist MD, 2001, INT J CRASHWORTHINES, V6, P253, DOI 10.1533/cras.2001.0176; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Halldin P, 2001, INT J CRASHWORTHINES, V6, P53, DOI 10.1533/cras.2001.0162; Harrison T.I., 1996, P INT IRCOBI C DUBL, P49; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; Mihora D, 2007, INT J CRASHWORTHINES, V12, P211, DOI 10.1080/13588260701440862; Miller R, 1998, SAE T, V107, P2798; Mills NJ, 2006, P I MECH ENG L-J MAT, V220, P167, DOI 10.1243/14644207JMDA100; Mills NJ, 2006, IRCOBI C, P425; Mills NJ, 2003, IRCOBI C; Mills NJ, 1990, BRIT J SPORT MED, V24, P56; NSAI, 2006, 9602006 NSAI IS EN; NSAI, 1997, 13841997 NSAI IS EN; NSAI, 2005, 145722005 NSAI IS EN; O'Riordain K, 2003, CLIN BIOMECH, V18, P590, DOI 10.1016/S0268-0033(03)00111-6; Rueda MAF, 2009, FORENSIC SCI INT, V191, P52, DOI 10.1016/j.forsciint.2009.06.007; Rueda MAF, 2009, MATER DESIGN, V30, P3405, DOI 10.1016/j.matdes.2009.03.037; Rueda MAF, 2010, INJURY, V41, P533, DOI 10.1016/j.injury.2009.05.009; Shreiber D.I., 1997, STAPP CAR CRASH J, V41, P277; Turner M, 2002, BRIT J SPORT MED, V36, P403, DOI 10.1136/bjsm.36.6.403; Van Lierde C, 2005, SOLID MECH APPL, V124, P247; Verschueren, 2009, THESIS KATHOLIEKE U; Willinger R, 2003, INT J CRASHWORTHINES, V8, P605, DOI 10.1533/ijcr.2003.0264; Willinger R, 2003, INT J VEHICLE DES, V32, P94, DOI 10.1504/IJVD.2003.003239; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	44	56	56	0	23	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1025-5842	1476-8259		COMPUT METHOD BIOMEC	Comput. Methods Biomech. Biomed. Eng.		2011	14	12					1021	1031		10.1080/10255842.2010.504922			11	Computer Science, Interdisciplinary Applications; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Computer Science; Engineering	880UX	WOS:000299434500001	20665294	Green Submitted			2022-02-06	
J	Covassin, T; Elbin, RJ; Nakayama, Y				Covassin, Tracey; Elbin, R. J.; Nakayama, Yusuke			Tracking Neurocognitive Performance Following Concussion in High School Athletes	PHYSICIAN AND SPORTSMEDICINE			English	Article						concussion; neurocognitive function; high school athletes; ImPACT	AGREEMENT STATEMENT; SPORTS CONCUSSION; RECOVERY; IMPACT; SENSITIVITY; VALIDITY; FOOTBALL; PLAY	Objective: To extend previous research designs and examine cognitive performance up to 30 days postconcussion. Method: A prospective cohort design was used to examine 2000 athletes from 8 mid-Michigan area high schools to compare baseline neurocognitive performance with postconcussion neurocognitive performance. All concussed athletes were readministered the Immediate Post Assessment and Cognitive Test (ImPACT) at 2, 7, 14, 21, and 30 days postconcussion. Results: A total of 72 high school athletes (aged 15.8 +/- 1.34 years) sustained a concussion. A significant within-subjects effect for reaction time (F = 10.01; P = 0.000), verbal memory (F = 3.05; P = 0.012), motor processing speed (F = 18.51; P = 0.000), and total symptoms following an injury (F = 16.45; P = 0.000) was found. Concussed athletes demonstrated a significant decrease in reaction time up to 14 days postconcussion (P = 0.001) compared with baseline reaction time. Reaction time returned to baseline levels at 21 days postinjury (P = 0.25). At 7 days postinjury, impairments in verbal memory (P = 0.003) and motor processing speed (P = 0.000) were documented and returned to baseline levels by 14 days postinjury. Concussed athletes self-reported significantly more symptoms at 2 days postconcussion (P = 0.000) and exhibited a resolution of symptoms by 7 days postinjury (P = 0.06). Conclusion: High school athletes could take up to 21 days to return to baseline levels for reaction time. These data support current recommendations for the conservative management of concussion in the high school athlete.	[Covassin, Tracey; Nakayama, Yusuke] Michigan State Univ, E Lansing, MI 48824 USA; [Elbin, R. J.] E Tennessee State Univ, Dept Kinesiol Leisure & Sport Sci, Johnson City, TN 37614 USA		Covassin, T (corresponding author), Michigan State Univ, 105 IM Sport Circle, E Lansing, MI 48824 USA.	covassin@msu.edu			Michigan State University	We would like to acknowledge Michigan State University for an IRPG grant.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, ARCH CLIN NEUROPSYCH, V19, P961; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2002, ARCH CLIN NEUROPSYCH, V17, P770; Kontos AP, 2004, J APPL SPORT PSYCHOL, V16, P220, DOI 10.1080/10413200490485568; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Sadovsky R, 2004, AM FAM PHYSICIAN, V69, P171; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	25	56	56	1	19	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0091-3847	2326-3660		PHYSICIAN SPORTSMED	Physician Sportsmed.	DEC	2010	38	4					87	93		10.3810/psm.2010.12.1830			7	Primary Health Care; Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Orthopedics; Sport Sciences	764LL	WOS:000290630900019	21150147				2022-02-06	
J	Kovacech, B; Novak, M				Kovacech, B.; Novak, M.			Tau Truncation is a Productive Posttranslational Modification of Neurofibrillary Degeneration in Alzheimer's Disease	CURRENT ALZHEIMER RESEARCH			English	Article						Tau truncation; Alzheimer's disease; neurofibrillary degeneration; tau transition	PAIRED HELICAL FILAMENTS; ACTIVATED NEUTRAL PROTEINASE; TRAUMATIC BRAIN-INJURY; CASPASE-CLEAVAGE; HYPERPHOSPHORYLATED-TAU; AMYLOID-BETA; IN-VITRO; ABNORMAL PHOSPHORYLATION; SENILE PLAQUES; FRONTOTEMPORAL DEMENTIA	Deposits of the misfolded neuronal protein tau are major hallmarks of neurodegeneration in Alzheimer's disease (AD) and other tauopathies. The etiology of the transformation process of the intrinsically disordered soluble protein tau into the insoluble misordered aggregate has attracted much attention. Tau undergoes multiple modifications in AD, most notably hyperphosphorylation and truncation. Hyperphosphorylation is widely regarded as the hottest candidate for the inducer of the neurofibrillary pathology. However, the true nature of the impetus that initiates the whole process in the human brains remains unknown. In AD, several site-specific tau cleavages were identified and became connected to the progression of the disease. In addition, western blot analyses of tau species in AD brains reveal multitudes of various truncated forms. In this review we summarize evidence showing that tau truncation alone is sufficient to induce the complete cascade of neurofibrillary pathology, including hyperphosphorylation and accumulation of misfolded insoluble forms of tau. Therefore, proteolytical abnormalities in the stressed neurons and production of aberrant tau cleavage products deserve closer attention and should be considered as early therapeutic targets for Alzheimer's disease.	[Kovacech, B.; Novak, M.] Slovak Acad Sci, Inst Neuroimmunol, AD Ctr, Bratislava 84510, Slovakia; [Kovacech, B.; Novak, M.] Axon Neurosci GmbH, Vienna, Austria		Novak, M (corresponding author), Slovak Acad Sci, Inst Neuroimmunol, AD Ctr, Dubravska Cesta 9, Bratislava 84510, Slovakia.	michal.novak@savba.sk	Kovacech, Brnislav/ABD-3254-2020		VEGAVedecka grantova agentura MSVVaS SR a SAV (VEGA)European Commission [2/6183/26, 2/0162/10, APVV 0631-07, APVV 0621-07, APVV 603-06, LPP-0326-06]	This work was supported by research grants VEGA 2/6183/26 and 2/0162/10, APVV 0631-07, APVV 0621-07, APVV 603-06 and LPP-0326-06.	Abraha A, 2000, J CELL SCI, V113, P3737; Adamec E, 2000, NEUROSCIENCE, V100, P663, DOI 10.1016/S0306-4522(00)00281-5; Alonso AD, 1997, P NATL ACAD SCI USA, V94, P298, DOI 10.1073/pnas.94.1.298; Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; Alonso AD, 2001, J BIOL CHEM, V276, P37967; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; Alonso AD, 2004, J BIOL CHEM, V279, P34873, DOI 10.1074/jbc.M405131200; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Alonso AD, 2006, P NATL ACAD SCI USA, V103, P8864, DOI 10.1073/pnas.0603214103; Arnold CS, 1996, J BIOL CHEM, V271, P28741, DOI 10.1074/jbc.271.46.28741; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Berry RW, 2003, BIOCHEMISTRY-US, V42, P8325, DOI 10.1021/bi027348m; Biernat J, 1999, MOL BIOL CELL, V10, P727, DOI 10.1091/mbc.10.3.727; Binder LI, 2005, BBA-MOL BASIS DIS, V1739, P216, DOI 10.1016/j.bbadis.2004.08.014; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Burack MA, 1996, NEUROSCIENCE, V72, P167, DOI 10.1016/0306-4522(95)00546-3; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; Canu N, 1998, J NEUROSCI, V18, P7061; Cataldo AM, 1996, J NEUROSCI, V16, P186; CENTE M, 2009, J ALZHEIMERS DIS; Cente M, 2006, EUR J NEUROSCI, V24, P1085, DOI 10.1111/j.1460-9568.2006.04986.x; Cho JH, 2004, J BIOL CHEM, V279, P54716, DOI 10.1074/jbc.M403364200; Chung CW, 2001, NEUROBIOL DIS, V8, P162, DOI 10.1006/nbdi.2000.0335; Csokova N, 2006, PROTEIN PEPTIDE LETT, V13, P941, DOI 10.2174/092986606778256180; Dawson HN, 2001, J CELL SCI, V114, P1179; Delobel P, 2008, AM J PATHOL, V172, P123, DOI 10.2353/ajpath.2008.070627; Deng YQ, 2009, AM J PATHOL, V175, P2089, DOI 10.2353/ajpath.2009.090157; Ding HP, 2006, J BIOL CHEM, V281, P19107, DOI 10.1074/jbc.M511697200; Dixit R, 2008, SCIENCE, V319, P1086, DOI 10.1126/science.1152993; ESMAELIAZAD B, 1994, J CELL SCI, V107, P869; Fasulo L, 1998, ALZHEIMERS REP, V1, P25; Fasulo L, 2005, J ALZHEIMERS DIS, V7, P3; Fasulo L, 2000, J NEUROCHEM, V75, P624, DOI 10.1046/j.1471-4159.2000.0750624.x; Filipcik P, 2009, CELL MOL NEUROBIOL, V29, P895, DOI 10.1007/s10571-009-9372-8; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Gamblin TC, 2003, BIOCHEMISTRY-US, V42, P2252, DOI 10.1021/bi0272510; Garcia-Sierra F, 2008, J ALZHEIMERS DIS, V14, P401; Garcia-Sierra F, 2003, J ALZHEIMERS DIS, V5, P65, DOI 10.3233/JAD-2003-5201; GARVER TD, 1994, J NEUROCHEM, V63, P2279; Gastard MC, 2003, ANN NEUROL, V54, P393, DOI 10.1002/ana.10680; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Goedert M, 1998, NEURON, V21, P955, DOI 10.1016/S0896-6273(00)80615-7; Gray J, 2001, J BIOL CHEM, V276, P32750, DOI 10.1074/jbc.M103150200; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Guo HS, 2004, AM J PATHOL, V165, P523, DOI 10.1016/S0002-9440(10)63317-2; Haase C, 2004, J NEUROCHEM, V88, P1509, DOI 10.1046/j.1471-4159.2003.02287.x; HANEMAAIJER R, 1991, J NEUROSCI RES, V30, P163, DOI 10.1002/jnr.490300117; Hanger DP, 2007, J BIOL CHEM, V282, P23645, DOI 10.1074/jbc.M703269200; Hanger DP, 2009, TRENDS MOL MED, V15, P112, DOI 10.1016/j.molmed.2009.01.003; Hanger DP, 1998, J NEUROCHEM, V71, P2465; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; Horiguchi T, 2003, AM J PATHOL, V163, P1021, DOI 10.1016/S0002-9440(10)63462-1; Hrnkova M, 2007, BRAIN RES, V1130, P206, DOI 10.1016/j.brainres.2006.10.085; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; IHARA Y, 1986, J BIOCHEM-TOKYO, V99, P1807, DOI 10.1093/oxfordjournals.jbchem.a135662; IQBAL K, 1994, FEBS LETT, V349, P104, DOI 10.1016/0014-5793(94)00650-4; Iqbal K, 2006, Bratisl Lek Listy, V107, P341; Iqbal Khalid, 2005, Current Alzheimer Research, V2, P335, DOI 10.2174/1567205054367810; Iqbal K, 2009, ACTA NEUROPATHOL, V118, P53, DOI 10.1007/s00401-009-0486-3; Ivins KJ, 1999, NEUROBIOL DIS, V6, P440, DOI 10.1006/nbdi.1999.0268; IWAMOTO N, 1991, BRAIN RES, V561, P177, DOI 10.1016/0006-8993(91)90766-O; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Ko LW, 1999, BRAIN RES, V830, P301, DOI 10.1016/S0006-8993(99)01415-8; KOPKE E, 1993, J BIOL CHEM, V268, P24374; Koson P, 2008, EUR J NEUROSCI, V28, P239, DOI 10.1111/j.1460-9568.2008.06329.x; Kovac A, 2009, J ALZHEIMERS DIS, V18, P897, DOI 10.3233/JAD-2009-1197; KSIEZAKREDING H, 1990, J NEUROSCI RES, V25, P420, DOI 10.1002/jnr.490250320; Ledesma MD, 1996, MOL CHEM NEUROPATHOL, V27, P249, DOI 10.1007/BF02815107; LEDESMA MD, 1994, J BIOL CHEM, V269, P21614; LEDESMA MD, 1995, J NEUROCHEM, V65, P1658; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; Liu F, 2004, P NATL ACAD SCI USA, V101, P10804, DOI 10.1073/pnas.0400348101; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mena R, 1996, ACTA NEUROPATHOL, V91, P633, DOI 10.1007/s004010050477; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; Neumar RW, 2001, EXP NEUROL, V170, P27, DOI 10.1006/exnr.2001.7708; Nixon RA, 2000, ANN NY ACAD SCI, V924, P117; NIXON RA, 1994, ANN NY ACAD SCI, V747, P77; NOVAK M, 1994, ACTA VIROL, V38, P173; Novak M, 1999, ALZHEIMER'S DISEASE AND RELATED DISORDERS, P281; NOVAK M, 1993, EMBO J, V12, P365, DOI 10.1002/j.1460-2075.1993.tb05665.x; Novak M, 1989, Prog Clin Biol Res, V317, P755; NOVAK M, 1991, P NATL ACAD SCI USA, V88, P5837, DOI 10.1073/pnas.88.13.5837; Paleologou KE, 2008, J BIOL CHEM, V283, P16895, DOI 10.1074/jbc.M800747200; PERRY G, 1987, P NATL ACAD SCI USA, V84, P3033, DOI 10.1073/pnas.84.9.3033; Pevalova M, 2006, Bratisl Lek Listy, V107, P346; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Quintanilla RA, 2009, J BIOL CHEM, V284, P18754, DOI 10.1074/jbc.M808908200; Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199; Reynolds MR, 2006, J NEUROSCI, V26, P10636, DOI 10.1523/JNEUROSCI.2143-06.2006; Rissman RA, 2004, J CLIN INVEST, V114, P121, DOI 10.1172/JCI200420640; Roberson ED, 2007, SCIENCE, V316, P750, DOI 10.1126/science.1141736; Rohn TT, 2002, NEUROBIOL DIS, V11, P341, DOI 10.1006/nbdi.2002.0549; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; Sevcik J, 2007, FEBS LETT, V581, P5872, DOI 10.1016/j.febslet.2007.11.067; SHIMOHAMA S, 1991, BRAIN RES, V558, P105, DOI 10.1016/0006-8993(91)90722-8; Skrabana R, 2006, ANAL BIOCHEM, V359, P230, DOI 10.1016/j.ab.2006.09.031; Smith MA, 1996, BRAIN RES, V717, P99, DOI 10.1016/0006-8993(95)01473-X; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; Sun Q, 2009, BIOCHEMISTRY-US, V48, P6002, DOI 10.1021/bi900602h; Tsuji T, 1998, NEUROSCI LETT, V248, P109, DOI 10.1016/S0304-3940(98)00348-6; Tucholski J, 1999, J NEUROCHEM, V73, P1871; Ugolini G, 1997, NEUROREPORT, V8, P3709, DOI 10.1097/00001756-199712010-00010; Vechterova L, 2003, NEUROREPORT, V14, P87, DOI 10.1097/00001756-200301200-00017; Wang JZ, 1996, NAT MED, V2, P871, DOI 10.1038/nm0896-871; Wang YP, 2009, HUM MOL GENET, V18, P4153, DOI 10.1093/hmg/ddp367; Watanabe A, 1999, J BIOL CHEM, V274, P7368, DOI 10.1074/jbc.274.11.7368; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4884, DOI 10.1073/pnas.85.13.4884; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; Yamashima T, 2004, CELL CALCIUM, V36, P285, DOI 10.1016/j.ceca.2004.03.001; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787; YAN SD, 1995, NAT MED, V1, P693, DOI 10.1038/nm0795-693; Yin HS, 2006, FEBS LETT, V580, P211, DOI 10.1016/j.febslet.2005.11.077; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x; Zilka N, 2006, FEBS LETT, V580, P3582, DOI 10.1016/j.febslet.2006.05.029; Zilka N, 2009, J NEUROIMMUNOL, V209, P16, DOI 10.1016/j.jneuroim.2009.01.013; Zilka N, 2009, ACTA NEUROPATHOL, V118, P71, DOI 10.1007/s00401-009-0499-y	122	56	57	0	10	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1567-2050	1875-5828		CURR ALZHEIMER RES	Curr. Alzheimer Res.	DEC	2010	7	8					708	716		10.2174/156720510793611556			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	692UZ	WOS:000285182300008	20678071				2022-02-06	
J	Zhu, ZF; Wang, QG; Han, BJ; William, CP				Zhu, Zu-Fu; Wang, Qing-Guang; Han, Bo-Jun; William, Callie P.			Neuroprotective effect and cognitive outcome of chronic lithium on traumatic brain injury in mice	BRAIN RESEARCH BULLETIN			English	Article						Lithium; Traumatic brain injury; Neuroprotection; Learning and memory	LONG-TERM POTENTIATION; CONTROLLED CORTICAL IMPACT; RAT DENTATE GYRUS; SYNAPTIC PLASTICITY; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; NMDA RECEPTOR; FLUORO-JADE; MEMORY; EXCITOTOXICITY	In vitro and in vivo studies have demonstrated that lithium treatment can protect neurons against excitotoxic and ischemic damage Yet the possible beneficial effect of chronic low dose lithium on a model of traumatic brain injury (TBI) has not been intensively investigated In this study lithium (1 mmol/kg) was given daily intraperitonealy for 14 days before the onset of moderate controlled TBI and was continued until the mice were sacrificed The results showed that in brain injured animals chronic lithium treatment attenuated the loss of hemispheric tissue cerebral edema and the expression of pro-inflammatory cytokine interleukin-1 beta The neuronal degeneration in hippocampal CA3 and dentate gyrus sub-regions was also attenuated in the chronic lithium-treated mice as shown by Fluoro-Jade B staining Moreover chronic lithium treatment enhanced spatial learning and memory performance of injured mice in the Morns water maze Our current study extended the protective role of lithium in the model of TBI and suggested that chronic lithium treatment might be a helpful therapeutic strategy for brain injury with multiple beneficial effects (C) 2010 Elsevier Inc All rights reserved	[Zhu, Zu-Fu; Wang, Qing-Guang; Han, Bo-Jun; William, Callie P.] Southeast Univ, Coll Med, Affiliated Jiangyin Hosp, Dept Neurol, Jiangyin 214400, Jiangsu Prov, Peoples R China		Zhu, ZF (corresponding author), Southeast Univ, Coll Med, Affiliated Jiangyin Hosp, Dept Neurol, 163 Shoushan Rd, Jiangyin 214400, Jiangsu Prov, Peoples R China.				Educational Commission of Jiangsu Province of China [05KJD320229]	This work was supported by a grant from the Educational Commission of Jiangsu Province of China (No 05KJD320229)	Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Ballanger F, 2008, ARCH DERMATOL RES, V300, P215, DOI 10.1007/s00403-007-0824-z; Basselin M, 2006, NEUROPSYCHOPHARMACOL, V31, P1659, DOI 10.1038/sj.npp.1300920; Bian QM, 2007, BRAIN RES, V1184, P270, DOI 10.1016/j.brainres.2007.09.054; Bielecka AM, 2008, PHARMACOL REP, V60, P771; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Cappuccio I, 2005, J NEUROSCI, V25, P2647, DOI 10.1523/JNEUROSCI.5230-04.2005; Chuang DM, 2002, BIPOLAR DISORD, V4, P129, DOI 10.1034/j.1399-5618.2002.01179.x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Dash PK, 2009, NEUROSCIENCE, V163, P1, DOI 10.1016/j.neuroscience.2009.06.028; De Ferrari GV, 2003, MOL PSYCHIATR, V8, P195, DOI 10.1038/sj.mp.4001208; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Goldstein BI, 2009, J CLIN PSYCHIAT, V70, P1078, DOI 10.4088/JCP.08r04505; Griebenow M, 2007, J NEUROTRAUM, V24, P1529, DOI 10.1089/neu.2007.0306; Hardingham GE, 2009, BIOCHEM SOC T, V37, P1147, DOI 10.1042/BST0371147; Hashimoto R, 2003, FEBS LETT, V538, P145, DOI 10.1016/S0014-5793(03)00167-4; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hogg S, 1998, J NEUROTRAUM, V15, P545, DOI 10.1089/neu.1998.15.545; Holscher C, 1999, J NEUROSCI RES, V58, P62; Hooper C, 2007, EUR J NEUROSCI, V25, P81, DOI 10.1111/j.1460-9568.2006.05245.x; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Liossi C, 2009, J NEUROPSYCH CLIN N, V21, P43, DOI 10.1176/appi.neuropsych.21.1.43; Mai L, 2002, J NEUROCHEM, V82, P75, DOI 10.1046/j.1471-4159.2002.00939.x; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nocjar C, 2007, NEUROSCIENCE, V150, P774, DOI 10.1016/j.neuroscience.2007.09.063; Nonaka S, 1998, P NATL ACAD SCI USA, V95, P2642, DOI 10.1073/pnas.95.5.2642; Nonaka S, 1998, NEUROREPORT, V9, P2081, DOI 10.1097/00001756-199806220-00031; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Ren M, 2003, P NATL ACAD SCI USA, V100, P6210, DOI 10.1073/pnas.0937423100; Rockenstein E, 2007, J NEUROSCI, V27, P1981, DOI 10.1523/JNEUROSCI.4321-06.2007; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Shao L, 2005, BIOL PSYCHIAT, V58, P879, DOI 10.1016/j.biopsych.2005.04.052; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Shim SS, 2007, PROG NEURO-PSYCHOPH, V31, P343, DOI 10.1016/j.pnpbp.2006.09.008; Sinha D, 2005, AM J PHYSIOL-RENAL, V288, pF703, DOI 10.1152/ajprenal.00189.2004; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Son H, 2003, J NEUROCHEM, V85, P872, DOI 10.1046/j.1471-4159.2003.01725.x; Tsaltas E, 2007, BEHAV BRAIN RES, V180, P241, DOI 10.1016/j.bbr.2007.03.017; Tsaltas E, 2007, BEHAV BRAIN RES, V177, P51, DOI 10.1016/j.bbr.2006.11.003; Tsaltas E, 2009, PSYCHOPHARMACOLOGY, V202, P457, DOI 10.1007/s00213-008-1311-8; Vasconcellos APS, 2003, PHYSIOL BEHAV, V79, P143, DOI 10.1016/S0031-9384(03)00113-6; Wada A, 2005, J PHARMACOL SCI, V99, P307, DOI 10.1254/jphs.CRJ05009X; Wada A, 2009, J PHARMACOL SCI, V110, P14, DOI 10.1254/jphs.09R02CR; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Xu JH, 2003, STROKE, V34, P1287, DOI 10.1161/01.STR.0000066308.25088.64; Yan XB, 2007, BEHAV BRAIN RES, V177, P282, DOI 10.1016/j.bbr.2006.11.021; Yu IT, 2003, BIOCHEM BIOPH RES CO, V303, P1193, DOI 10.1016/S0006-291X(03)00494-7; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhu LQ, 2007, J NEUROSCI, V27, P12211, DOI 10.1523/JNEUROSCI.3321-07.2007; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	57	56	58	1	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230			BRAIN RES BULL	Brain Res. Bull.	OCT 30	2010	83	5					272	277		10.1016/j.brainresbull.2010.07.008			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	683YN	WOS:000284514300015	20638460				2022-02-06	
J	Grubenhoff, JA; Kirkwood, M; Gao, DX; Deakyne, S; Wathen, J				Grubenhoff, Joseph A.; Kirkwood, Michael; Gao, Dexiang; Deakyne, Sara; Wathen, Joe			Evaluation of the Standardized Assessment of Concussion in a Pediatric Emergency Department	PEDIATRICS			English	Article						brain concussion; closed head injury; traumatic brain injury	TRAUMATIC BRAIN-INJURY; GLASGOW COMA SCALE; POSTCONCUSSION SYNDROME; COGNITIVE IMPAIRMENT; UNITED-STATES; SYMPTOMS	OBJECTIVE: The Standardized Assessment of Concussion (SAC) is a validated tool for identifying the effects of mild traumatic brain injury (mTBI). Previous research focused on sport-related sideline evaluation of adolescents and adults. Our goal was to evaluate performance of the SAC among subjects with and without head injury in a pediatric emergency department (ED). METHODS: This was an observational study of children 6 to 18 years of age who presented to an ED with blunt head injury (case-patients) or minor extremity injury (controls). SAC and graded-symptom-checklist scores were compared. American Academy of Neurology concussion grades, presence of loss of consciousness and posttraumatic amnesia were also compared with SAC and graded-symptom-checklist scores among case-patients. RESULTS: Three hundred forty-eight children were enrolled. SAC scores trended lower (greater cognitive deficits) for case-patients compared with controls but did not reach significance. Graded-symptom-checklist scores were significantly higher among case-patients. Presence of altered mental status magnified this effect. There was no correlation between SAC scores and other indicators of mTBI. There was a positive correlation between graded-symptom-checklist scores and posttraumatic amnesia and American Academy of Neurology concussion grade. CONCLUSIONS: The graded symptom checklist reliably identified mTBI symptoms for all children aged 6 years and older. SAC scores tended to be lower for case-patients compared with controls but did not reach significance. Patients with altered mental status at the time of injury manifest an increased number and severity of symptoms. Additional research into strategies to identify cognitive deficits related to mTBI and classify mTBI severity in children is needed. Pediatrics 2010;126:688-695	[Grubenhoff, Joseph A.; Deakyne, Sara; Wathen, Joe] Univ Colorado, Sch Med, Dept Pediat, Sect Emergency Med, Denver, CO USA; [Kirkwood, Michael] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Denver, CO USA; [Gao, Dexiang] Childrens Hosp, Clin Translat Res Ctr, Denver, CO 80218 USA		Grubenhoff, JA (corresponding author), Childrens Hosp, 13123 16th Ave,B-251, Aurora, CO 80045 USA.	grubenhoff.joe@tchden.org	Gao, Dexiang/ABC-8930-2020; Grubenhoff, Joseph A/H-9994-2019	Grubenhoff, Joseph A/0000-0001-5072-4064			Ahmed S, 2000, BRAIN INJURY, V14, P765; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Drake AI, 2006, BRAIN INJURY, V20, P469, DOI 10.1080/02699050600676370; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; JENNETT B, 1999, BRAIN INJURY, V13, P151; Kelly JP, 1997, NEUROLOGY, V48, P581; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Naunheim RS, 2008, J HEAD TRAUMA REHAB, V23, P116, DOI 10.1097/01.HTR.0000314530.30401.70; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Shores EA, 2008, J NEUROL NEUROSUR PS, V79, P1100, DOI 10.1136/jnnp.2007.132571; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	26	56	56	0	9	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	OCT	2010	126	4					688	695		10.1542/peds.2009-2804			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	658WW	WOS:000282526100039	20819901				2022-02-06	
J	Fang, BY; Wang, DJ; Huang, MF; Yu, GH; Li, H				Fang, Boyan; Wang, Dajiang; Huang, Meifeng; Yu, Guohua; Li, Hua			Hypothesis on the Relationship Between the Change in Intracellular pH and Incidence of Sporadic Alzheimer's Disease or Vascular Dementia	INTERNATIONAL JOURNAL OF NEUROSCIENCE			English	Article						Alzheimer's disease; intracellular pH; vascular dementia	AMYLOID PRECURSOR PROTEIN; INSULIN-DEGRADING ENZYME; SENSING ION-CHANNEL; NA+/H+ EXCHANGER; BETA-SECRETASE; NEURODEGENERATIVE DISEASES; CELLS; CANCER; ACTIVATION; LYMPHOBLASTS	In order to perform their normal physiological functions, it is important that cells maintain the intracellular pH within the physiological range. Intracellular enzyme activity, cytoskeleton component integration, and cellular growth and differentiation rates are all closely associated with the intracellular pH. It has been demonstrated that in nervous system diseases, such as ischemic stroke, traumatic brain injury, epilepsy, Parkinson's disease, and Alzheimer's disease (AD), the common characteristics are decreased pH or acidosis at both tissular and cellular levels. Particularly, some AD-associated enzymes will have altered activities under acidic conditions. We inferred that aging or ischemia may cause intracellular acidification. This acidification not only induces apoptosis but also substantially alters enzyme activities and promotes the development of AD or vascular dementia. The hypothesis of an intracellular pH role in sporadic AD or vascular dementia will be discussed in this paper. If confirmed, this hypothesis may lead to the formulation of new pathogenesis and new therapeutic approaches to AD or vascular dementia.	[Fang, Boyan; Huang, Meifeng; Yu, Guohua; Li, Hua] Liaoning Med Coll, Dept Neurol, First Affiliated Hosp, Jinzhou 121001, Peoples R China; [Wang, Dajiang] Chinese Peoples Liberat Army Gen Hosp, Dept Ophthalmol, Beijing, Peoples R China		Fang, BY (corresponding author), Liaoning Med Coll, Dept Neurol, First Affiliated Hosp, Renmin St 2, Jinzhou 121001, Peoples R China.	fangboyanv@yahoo.com.cn		Fang, Boyan/0000-0002-9935-433X	Liaoning Province, China [20060524]	This work was supported by the scientific technologic fund (no. 20060524) of Liaoning Province, China.	Bian L, 2004, NEUROLOGY, V63, P241, DOI 10.1212/01.WNL.0000129987.70037.DB; Cho JH, 2008, J NEUROPHYSIOL, V99, P426, DOI 10.1152/jn.00940.2007; DEITMER JW, 2007, ACID BASE TRANSPORT; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; GRIFFITHS JR, 1991, BRIT J CANCER, V64, P425, DOI 10.1038/bjc.1991.326; Guenette SY, 2003, NEUROMOL MED, V4, P147, DOI 10.1385/NMM:4:3:147; Harguindey S, 2005, BBA-REV CANCER, V1756, P1, DOI 10.1016/j.bbcan.2005.06.004; Harguindey S, 2007, CURR ALZHEIMER RES, V4, P53, DOI 10.2174/156720507779939841; Harguindey Salvador, 2008, Neuropsychiatr Dis Treat, V4, P1073; Hegde M, 2004, J PHARMACOL EXP THER, V310, P67, DOI 10.1124/jpet.103.065029; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herrera Y, 2008, J PHARMACOL EXP THER, V327, P491, DOI 10.1124/jpet.108.143974; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Ibarreta D, 1998, ANN NEUROL, V44, P216, DOI 10.1002/ana.410440212; Jovov B, 2003, HISTOCHEM CELL BIOL, V119, P437, DOI 10.1007/s00418-003-0525-4; Lagana A, 2000, J CELL SCI, V113, P3649; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Malo ME, 2006, CAN J PHYSIOL PHARM, V84, P1081, DOI 10.1139/Y06-065; Marinho CFM, 1997, EUR ARCH PSY CLIN N, V247, P275, DOI 10.1007/BF02900306; Mohajeri MH, 2002, J BIOL CHEM, V277, P35460, DOI 10.1074/jbc.M202899200; OSTOVSKAYA OI, 2003, NEUROPHYSIOLOGY, V35, P90; Prince M, 2004, INT J GERIATR PSYCH, V19, P178, DOI 10.1002/gps.1059; Reshkin SJ, 2000, J BIOL CHEM, V275, P5361, DOI 10.1074/jbc.275.8.5361; Rich IN, 2000, BLOOD, V95, P1427, DOI 10.1182/blood.V95.4.1427.004k48_1427_1434; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Song ES, 2003, J BIOL CHEM, V278, P49789, DOI 10.1074/jbc.M308983200; Urcelay E, 2001, NEUROBIOL DIS, V8, P289, DOI 10.1006/nbdi.2000.0381; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wang DS, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/58406; Xiong ZG, 2008, CURR OPIN PHARMACOL, V8, P25, DOI 10.1016/j.coph.2007.09.001; Xue SF, 2006, NEUROSCI LETT, V405, P231, DOI 10.1016/j.neulet.2006.07.013; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Zohar O, 2003, MOL BRAIN RES, V115, P63, DOI 10.1016/S0169-328X(03)00182-7	37	56	57	3	32	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0020-7454	1563-5279		INT J NEUROSCI	Int. J. Neurosci.	SEP	2010	120	9					591	595		10.3109/00207454.2010.505353			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	639XX	WOS:000281011500002	20707633				2022-02-06	
J	Weiner, GM; Lacey, MR; Mackenzie, L; Shah, DP; Frangos, SG; Grady, MS; Kofke, A; Levine, J; Schuster, J; Le Roux, PD				Weiner, Gregory M.; Lacey, Michelle R.; Mackenzie, Larami; Shah, Darshak P.; Frangos, Suzanne G.; Grady, M. Sean; Kofke, Andrew; Levine, Joshua; Schuster, James; Le Roux, Peter D.			Decompressive Craniectomy for Elevated Intracranial Pressure and Its Effect on the Cumulative Ischemic Burden and Therapeutic Intensity Levels After Severe Traumatic Brain Injury	NEUROSURGERY			English	Article						Craniectomy; Ischemia; Trauma	CEREBRAL PERFUSION-PRESSURE; TISSUE OXYGEN-PRESSURE; SEVERE HEAD-INJURIES; RANDOMIZED-TRIAL; HYPERTENSION; REACTIVITY; ICP; CLASSIFICATION; EXPERIENCE; MANAGEMENT	BACKGROUND: Increased intracranial pressure (ICP) can cause brain ischemia and compromised brain oxygen (PbtO(2) <= 20 mm Hg) after severe traumatic brain injury (TBI). OBJECTIVE: We examined whether decompressive craniectomy (DC) to treat elevated ICP reduces the cumulative ischemic burden (CIB) of the brain and therapeutic intensity level (TIL). METHODS: Ten severe TBI patients (mean age, 31.4 +/- 14.2 years) who had continuous PbtO(2) monitoring before and after delayed DC were retrospectively identified. Patients were managed according to the guidelines for the management of severe TBI. The CIB was measured as the total time spent between a PbtO2 of 15 to 20, 10 to 15, and 0 to 10 mm Hg. The TIL was calculated every 12 hours. Mixed-effects models were used to estimate changes associated with DC. RESULTS: DC was performed on average 2.8 days after admission. DC was found to immediately reduce ICP (mean [SEM] decrease was 7.86 mm Hg [2.4 mm Hg]; P = .005). TIL, which was positively correlated with ICP (r = 0.46, P <= .001), was reduced within 12 hours after surgery and continued to improve within the postsurgical monitoring period (P <= .001). The duration and severity of CIB were significantly reduced as an effect of DC in this group. The overall mortality rate in the group of 10 patients was lower than predicted at the time of admission (P = .015). CONCLUSION: These results suggest that a DC for increased ICP can reduce the CIB of the brain after severe TBI. We suggest that DC be considered early in a patient's clinical course, particularly when the TIL and ICP are increased.	[Le Roux, Peter D.] Univ Penn, Med Ctr, Div Clin Res, Dept Neurosurg,Sch Med, Philadelphia, PA 19104 USA; [Lacey, Michelle R.] Tulane Univ, Dept Math, New Orleans, LA 70118 USA; [Mackenzie, Larami; Levine, Joshua] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; [Kofke, Andrew; Levine, Joshua] Univ Penn, Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA		Le Roux, PD (corresponding author), Univ Penn, Med Ctr, Div Clin Res, Dept Neurosurg,Sch Med, Philadelphia, PA 19104 USA.	Peter.LeRoux@uphs.upenn.edu		Lacey, Michelle/0000-0002-0926-4593	Integra Neurosciences; Integra Foundation; Mary Elisabeth Groff Surgical and Medical Research Trust	This work was supported by research grants from Integra Neurosciences (the manufacturer of the Licox PbtO<INF>2</INF> monitor) (P. D. L. R.), the Integra Foundation (P. D. L. R.), and the Mary Elisabeth Groff Surgical and Medical Research Trust (P. D. L. R.). P. D. L. R. is a member of the Integra Speakers Bureau.	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; *AM ASS NEUR SURG, 2007, J NEUROTRAUMA S1, V24, pS65; Bullock AR, 2006, NEUROSURGERY, V58, pVI; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Chesnut RM, 1997, CRIT CARE MED, V25, P1275, DOI 10.1097/00003246-199708000-00011; Chibbaro S, 2007, SURG NEUROL, V68, P632, DOI 10.1016/j.surneu.2006.12.046; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; Czosnyka Marek, 1800, Neurosurg Focus, V22, pE10; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; HASE U, 1978, ACTA NEUROCHIR, V45, P1, DOI 10.1007/BF01774379; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Ho CL, 2008, J NEUROSURG, V108, P943, DOI 10.3171/JNS/2008/108/5/0943; Hollander M, 1999, NONPARAMETRIC STAT M; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Jaeger M, 2005, ACT NEUR S, V95, P117; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Pennings FA, 2008, J NEUROTRAUM, V25, P1173, DOI 10.1089/neu.2007.0402; Pinheiro JC, 2008, MIXED EFFECTS MODELS; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; R Development Core Team, 2008, R LANG ENV STAT COMP; Reithmeier T, 2005, ACTA NEUROCHIR, V147, P947, DOI 10.1007/s00701-005-0543-1; ROBERTSON C, 2004, YOUMANS NEUROLOGICAL; Rosenfeld JV, 2006, NEUROSURGERY, V59, P467, DOI 10.1227/00006123-200608000-00080; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Scheufler KM, 2004, J NEUROSURG ANESTH, V16, P210, DOI 10.1097/00008506-200407000-00005; Scheufler KM, 2002, ANESTH ANALG, V95, P1042, DOI 10.1097/00000539-200210000-00046; Schneider GH, 2002, ACT NEUR S, V81, P77; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; TEASDALE G, 1974, LANCET, V2, P81; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678	69	56	59	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUN	2010	66	6					1111	1118		10.1227/01.NEU.0000369607.71913.3E			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	600RY	WOS:000278006200031	20386136	Bronze			2022-02-06	
J	Topolovec-Vranic, J; Cullen, N; Michalak, A; Ouchterlony, D; Bhalerao, S; Masanic, C; Cusimano, MD				Topolovec-Vranic, Jane; Cullen, Nora; Michalak, Alicja; Ouchterlony, Donna; Bhalerao, Shree; Masanic, Cheryl; Cusimano, Michael D.			Evaluation of an online cognitive behavioural therapy program by patients with traumatic brain injury and depression	BRAIN INJURY			English	Article						Cognitive behaviour therapy; depression; Internet; outcomes; traumatic brain injury	RANDOMIZED CONTROLLED-TRIAL; REHABILITATION RESEARCH; MAJOR DEPRESSION; PRIMARY-CARE; CES-D; INTERNET; DISTRESS; INTERVENTIONS; PREVALENCE; DISORDERS	Primary objective: The most frequently reported psychiatric symptom after traumatic brain injury (TBI) is depression. This study examined whether internet-delivered cognitive behaviour therapy (CBT) could be appropriate and effective for patients with mild or moderate TBI and depression. Methods and procedures: Patients were recruited for an at-home, 6-week internet-based CBT program (MoodGYM). Participants were assessed during this period by weekly telephone calls and at 12 months post-enrolment. Intervention completion rates, predictors of adherence, user feedback and changes in scores on validated depression scales were assessed. Main outcomes and results: Twenty-one patients were recruited: 64% and 43% completed the 6-week intervention and the 12-month follow-up, respectively. Adherence rates were not predicted by demographic or injury characteristics in this small sample. Patients identified reading, memory and comprehension requirements as limitations of the program. Scores on the depression scales were significantly decreased upon completion of the intervention and at the 12-month follow-up. Conclusions: The MoodGYM program may be effective for treating symptoms of depression in patients with TBI. While adherence rates were not predicted by age, education level or injury severity, demands upon memory and concentration which may already be compromised in these patients need to be considered.	[Topolovec-Vranic, Jane] St Michaels Hosp, Trauma & Neurosurg Program, Toronto, ON M5B 1W8, Canada; [Cullen, Nora; Masanic, Cheryl] Toronto Rehabil Inst, Neurol Serv, Toronto, ON, Canada; [Michalak, Alicja; Ouchterlony, Donna; Masanic, Cheryl] St Michaels Hosp, Head Injury Clin, Toronto, ON M5B 1W8, Canada; [Bhalerao, Shree] St Michaels Hosp, Dept Psychiat, Toronto, ON M5B 1W8, Canada; [Cusimano, Michael D.] St Michaels Hosp, Div Neurosurg, Toronto, ON M5B 1W8, Canada		Topolovec-Vranic, J (corresponding author), St Michaels Hosp, Trauma & Neurosurg Program, 30 Bond St,Bond 4-016, Toronto, ON M5B 1W8, Canada.	topolovec-vranicj@smh.ca	Cusimano, Michael/X-4059-2019; Topolovec-Vranic, Jane/A-5293-2013	Topolovec-Vranic, Jane/0000-0001-7695-4212; Cullen, Nora/0000-0001-6359-9418; Cusimano, Michael/0000-0002-9989-0650	Ontario Neurotrauma Foundation	We thank Helen Christensen and Kathy Griffiths for allowing use of the MoodGYM website and supporting collaboration on this study. We also wish to acknowledge research assistants Sarah Johnston, Mary Ann Pollmann-Mudryj, Tatiana Santini, Amanda White McFarlan and Michelle Williams for their assistance with patient recruitment and data collection, Valerie Gilmore and Martine Andrews for input into the study design and data conduct, Wei Xiong for assistance with data analysis and The Ontario Neurotrauma Foundation for financially supporting this project.	Andrews G, 2001, AUST NZ J PUBL HEAL, V25, P494, DOI 10.1111/j.1467-842X.2001.tb00310.x; Andrews GA, 1999, UNMET NEED PSYCHIAT; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Batterham Philip J, 2008, Patient Prefer Adherence, V2, P97; Bebbington PE, 2000, PSYCHOL MED, V30, P1369, DOI 10.1017/S0033291799002974; Beck J.S., 1995, COGNITIVE THERAPY BA; Bell KR, 2008, AM J PHYS MED REHAB, V87, P330, DOI 10.1097/PHM.0b013e318168d092; Berger M, 2005, SOC SCI MED, V61, P1821, DOI 10.1016/j.socscimed.2005.03.025; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Carey JC, 2008, CYBERPSYCHOL BEHAV, V11, P188, DOI 10.1089/cpb.2007.0025; Christensen H, 2006, PSYCHOL MED, V36, P1737, DOI 10.1017/S0033291706008695; Christensen H, 2002, MED J AUSTRALIA, V177, pS122; Christensen H, 2004, BRIT MED J, V328, P265, DOI 10.1136/bmj.37945.566632.EE; Christensen H, 2002, J MED INTERNET RES, V4, DOI 10.2196/jmir.4.1.e3; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Giuffrida A, 1997, BRIT MED J, V315, P703, DOI 10.1136/bmj.315.7110.703; Groves C, 2003, WORKING OUT MOODGYM; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kaltenthaler E, 2002, Health Technol Assess, V6, P1; Kessler RC, 2001, HEALTH SERV RES, V36, P987; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LINTVEDT OK, 2006, EVALUATING EFFECTIVE, V50; Mackinnon A, 2008, BRIT J PSYCHIAT, V192, P130, DOI 10.1192/bjp.bp.106.032078; Mason S, 2006, BRIT J CLIN PSYCHOL, V45, P217, DOI 10.1348/014466505X50158; McCauley SR, 2006, BRAIN INJURY, V20, P519, DOI 10.1080/02699050600676651; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Nease DE, 2003, J FAM PRACTICE, V52, P118; Neil AL, 2009, J MED INTERNET RES, V11, DOI 10.2196/jmir.1050; O'Kearney Richard, 2006, Cognitive Behaviour Therapy, V35, P43, DOI 10.1080/16506070500303456; O'Kearney R, 2009, DEPRESS ANXIETY, V26, P65, DOI 10.1002/da.20507; Phillips VL, 2004, J HEAD TRAUMA REHAB, V19, P217, DOI 10.1097/00001199-200405000-00003; Proudfoot J, 2003, PSYCHOL MED, V33, P217, DOI 10.1017/S0033291702007225; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Rotondi AJ, 2005, J HEAD TRAUMA REHAB, V20, P173, DOI 10.1097/00001199-200503000-00005; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Wade SL, 2004, BEHAV RES METH INS C, V36, P261, DOI 10.3758/BF03195572; ZICH JM, 1990, INT J PSYCHIAT MED, V20, P259, DOI 10.2190/LYKR-7VHP-YJEM-MKM2	44	56	56	1	23	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAY	2010	24	5					762	772		10.3109/02699051003709599			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	592PJ	WOS:000277391300009	20370383				2022-02-06	
J	Norris, CM; Scheff, SW				Norris, Christopher M.; Scheff, Stephen W.			Recovery of Afferent Function and Synaptic Strength in Hippocampal CA1 following Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cortical contusion injury; deafferentation; excitatory postsynaptic potential; fiber volley; Schaffer collaterals	LONG-TERM POTENTIATION; FLUID PERCUSSION INJURY; NMDA RECEPTORS; AREA CA1; RAT; ACTIVATION; MECHANISMS; DEPRESSION; PLASTICITY; NITRATION	Cortical contusion injury can result in the partial loss of ipsilateral CA3 neurons within 48 h, leading to a proportional reduction in the number of afferent fibers to CA1 stratum radiatum. While the loss of afferent input to CA1 exhibits a remarkable, albeit incomplete, recovery over the next few weeks, little is known about the functional status of presynaptic afferents during the depletion and recovery phases following injury. Here, we prepared hippocampal slices from adult Sprague Dawley rats at 2, 7, and 14 days after lateral cortical contusion injury and measured fiber volley (FV) amplitudes extracellularly in CA1 stratum radiatum. Field excitatory postsynaptic potentials (EPSPs) were also measured and plotted as a function of FV amplitude to assess relative synaptic strength of residual and/or regenerated synaptic contacts. At 2 days post-injury, FV amplitude and synaptic strength were markedly reduced in the ipsilateral, relative to the contralateral, hippocampus. FV amplitude in ipsilateral CA1 showed a complete recovery by 7 days, indicative of a post-injury sprouting response. Synaptic strength in ipsilateral CA1 also showed a dramatic recovery over this time; however, EPSP-to-FV curves remained slightly suppressed at both the 7 and 14 day time points. Despite these deficits, ipsilateral slices retained the capacity to express long-term potentiation, indicating that at least some mechanisms for synaptic plasticity remain intact, or are compensated for. These results are in agreement with anatomical evidence showing a profound deafferentation, followed by a remarkable re-enervation, of ipsilateral CA1 in the first few weeks after traumatic brain injury. Although plasticity mechanisms appear to remain intact, synaptic strength deficits in CA1 could limit information throughput in the hippocampus, leading to persistent memory dysfunction.	[Norris, Christopher M.; Scheff, Stephen W.] Univ Kentucky, Coll Med, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Norris, Christopher M.] Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, Lexington, KY USA; [Scheff, Stephen W.] Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY USA		Norris, CM (corresponding author), 131 Sanders Brown Bldg,800 S Limestone St, Lexington, KY 40536 USA.	cnorr2@email.uky.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG21981]; Kentucky Spinal Cord; Head Injury Trust; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981, R01AG027297] Funding Source: NIH RePORTER	This work was supported by NIH grant AG21981 and an award from the Kentucky Spinal Cord and Head Injury Trust.	Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Boric K, 2008, J NEUROSCI, V28, P8034, DOI 10.1523/JNEUROSCI.2036-08.2008; Campbell LW, 1996, J NEUROSCI, V16, P6286; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; FOSTER TC, 1991, NEUROBIOL AGING, V12, P441, DOI 10.1016/0197-4580(91)90071-Q; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Nakazawa K, 2002, SCIENCE, V297, P211, DOI 10.1126/science.1071795; Nakazawa K, 2003, NEURON, V38, P305, DOI 10.1016/S0896-6273(03)00165-X; Norris CM, 1998, J NEUROSCI, V18, P3171; Norris CM, 1996, J NEUROSCI, V16, P5382; NORRIS CM, 2008, NEUROBIOLOGY, DOI DOI 10.1016/J.NEUROBIOLAGING.2008.03.026; Paxinos G., 2004, RAT NERVOUS SYSTEM; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Shankar S, 1998, J NEUROPHYSIOL, V79, P334, DOI 10.1152/jn.1998.79.1.334; Shetty AK, 2002, HIPPOCAMPUS, V12, P534, DOI 10.1002/hipo.10031; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Thibault O, 1996, SCIENCE, V272, P1017, DOI 10.1126/science.272.5264.1017; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052	35	56	59	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2009	26	12					2269	2278		10.1089/neu.2009.1029			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	536AI	WOS:000273013200014	19604098	Green Published, Green Accepted			2022-02-06	
J	Atif, F; Sayeed, I; Ishrat, T; Stein, DG				Atif, Fahim; Sayeed, Iqbal; Ishrat, Tauheed; Stein, Donald G.			Progesterone with Vitamin D Affords Better Neuroprotection against Excitotoxicity in Cultured Cortical Neurons than Progesterone Alone	MOLECULAR MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; 1,25-DIHYDROXYVITAMIN D-3; 1-ALPHA,25(OH)(2)-VITAMIN D-3; MEDROXYPROGESTERONE ACETATE; MULTIPLE-SCLEROSIS; GLUTAMATE RELEASE; INDUCED APOPTOSIS; NERVOUS-SYSTEM; D HORMONE; EXPRESSION	Because the complex heterogeneity of traumatic brain injury (TBI) is believed by many to be a major reason for the failed clinical trials of monotherapies, combining two (or more) drugs with some potentially different mechanisms of action may produce better effects than administering those agents individually. In this study, we investigated whether combinatorial treatment with progesterone (PROG) and 1,25-dihydroxyvitamin D-3 hormone (VDH) would produce better neuroprotection than PROG alone following excitotoxic neuronal injury in vitro. E18 rat primary cortical neurons were pretreated with various concentrations of PROG and VDH separately or in combination for 24 h and then exposed to glutamate (0.5 mu mol/L) for the next 24 h. Lactate dehydrogenase (LDH) release and 3-(4,5-dimethylthiazol-2-y1)-2,5-diphenyltetrazolium bromide (MTT) reduction assays were used to measure cell death. Both PROG and VDH significantly (P < 0.001) reduced neuronal loss when tested independently. Primary cortical cultures treated with VDH exhibited a U-shaped concentration-response curve. PROG at 20 mu mol/L and VDH at 100 nmol/L concentrations were the most neuroprotective. When the drugs were combined, the "best" doses of PROG (20 mu mol/L) and VDH (100 nmol/L), used individually, did not show substantial efficacy; rather, the lower dose of VDH (20 nmol/L) was most effective when used in combination with PROG (P < 0.01). We also examined the effect of combinatorial treatment on mitogen-activated protein kinase (MAPK) activation as a potential neuroprotective mechanism and observed that PROG and VDH activated MAPK alone and in combination. Interestingly, the best combination dose of PROG and VDH (20 mu mol/L and 20 nmol/L, respectively), as observed in cell death assays (LDH and MU), resulted in increased MAPK activation compared with either the most neuroprotective concentration of individual PROG (20 mu mol/L) and VDH (100 nmol/L) or the combination of these individual best doses. Such interactions must be considered in planning individualized combinatorial therapies. In conclusion, the findings of the present study can be taken to suggest that VDH warrants study as a potential partner for combination therapy with PROG. (C) 2009 The Feinstein Institute for Medical Research, www.feinsteininstitute.org Online address: http://www.molmed.org doi: 10.2119/molmed.2009.00016	[Atif, Fahim; Sayeed, Iqbal; Ishrat, Tauheed; Stein, Donald G.] Emory Univ, Dept Emergency Med, Brain Res Lab, Atlanta, GA 30322 USA		Stein, DG (corresponding author), Emory Univ, Dept Emergency Med, Brain Res Lab, 1365 B Clifton Rd NE,Suite 5100, Atlanta, GA 30322 USA.	dstei04@emory.edu	Stein, Donald/AAJ-5139-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01SO4851]	This research was supported by NIH grant R01SO4851. The authors would like to thank Leslie McCann for invaluable editorial assistance.	Alexianu ME, 1998, J NEUROSCI RES, V51, P58, DOI 10.1002/(SICI)1097-4547(19980101)51:1<58::AID-JNR6>3.0.CO;2-K; Asakura H, 2001, THROMB HAEMOSTASIS, V85, P287; Barrera D, 2007, J STEROID BIOCHEM, V103, P529, DOI 10.1016/j.jsbmb.2006.12.097; Behan LA, 2007, HORM RES, V68, P18, DOI 10.1159/000110466; Brewer LD, 2001, J NEUROSCI, V21, P98, DOI 10.1523/JNEUROSCI.21-01-00098.2001; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Buitrago CG, 2006, J CELL BIOCHEM, V97, P698, DOI 10.1002/jcb.20639; CEKIC M, 2009, NEUROBIOL AGING 0529; Cekic M, 2009, FRONT NEUROENDOCRIN, V30, P158, DOI 10.1016/j.yfrne.2009.04.002; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Eelen G, 2004, J BONE MINER RES, V19, P133, DOI 10.1359/JBMR.0301204; Garcion E, 1999, J NEUROCHEM, V73, P859, DOI 10.1046/j.1471-4159.1999.0730859.x; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Hayes CE, 1997, P SOC EXP BIOL MED, V216, P21, DOI 10.3181/00379727-216-44153A; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Kong J, 2003, AM J PHYSIOL-REG I, V285, pR255, DOI 10.1152/ajpregu.00517.2002; Kutuzova GD, 2004, ARCH BIOCHEM BIOPHYS, V432, P152, DOI 10.1016/j.abb.2004.09.004; Li YC, 2002, J CLIN INVEST, V110, P229, DOI [10.1172/JCI200215219, 10.1172/JCI0215219]; Lin AMY, 2003, FREE RADICAL BIO MED, V34, P1416, DOI 10.1016/S0891-5849(03)00105-9; Losem-Heinrichs E, 2005, ARCH BIOCHEM BIOPHYS, V439, P70, DOI 10.1016/j.abb.2005.04.021; Losem-Heinrichs E, 2004, J STEROID BIOCHEM, V89-90, P371, DOI 10.1016/j.jsbmb.2004.03.001; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; McCann JC, 2008, FASEB J, V22, P982, DOI 10.1096/fj.07-9326rev; Michaelis EK, 1998, PROG NEUROBIOL, V54, P369, DOI 10.1016/S0301-0082(97)00055-5; Mills CD, 2000, NEUROREPORT, V11, P3067, DOI 10.1097/00001756-200009280-00007; Munger KL, 2004, NEUROLOGY, V62, P60, DOI 10.1212/01.WNL.0000101723.79681.38; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P10506, DOI 10.1073/pnas.1334098100; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; Oermann E, 2004, J CHEM NEUROANAT, V28, P225, DOI 10.1016/j.jchemneu.2004.07.003; Pardo VG, 2006, INT J BIOCHEM CELL B, V38, P1181, DOI 10.1016/j.biocel.2005.12.018; Pardo VG, 2004, INT J BIOCHEM CELL B, V36, P489, DOI 10.1016/j.biocel.2003.08.005; Riaz SS, 2000, MOL BRAIN RES, V85, P179; Ronda AC, 2007, J STEROID BIOCHEM, V103, P462, DOI 10.1016/j.jsbmb.2006.11.005; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Sanchez B, 2002, MOL BRAIN RES, V108, P143, DOI 10.1016/S0169-328X(02)00545-4; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Shinpo K, 2000, J NEUROSCI RES, V62, P374, DOI 10.1002/1097-4547(20001101)62:3<374::AID-JNR7>3.0.CO;2-7; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Sribnick EA, 2004, J NEUROSCI RES, V76, P688, DOI 10.1002/jnr.20124; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Wang Y, 2000, NEUROPHARMACOLOGY, V39, P873, DOI 10.1016/S0028-3908(99)00255-5; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiang W, 2005, AM J PHYSIOL-ENDOC M, V288, pE125, DOI 10.1152/ajpendo.00224.2004; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xu Y, 2006, MOL PHARMACOL, V69, P56, DOI 10.1124/mol.105.017392	45	56	57	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1076-1551	1528-3658		MOL MED	Mol. Med.	SEP-OCT	2009	15	9-10					328	336		10.2119/molmed.2009.00016			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	575CW	WOS:000276043900006	19603099	gold, Green Published			2022-02-06	
J	Giorgi, RG; Woods, RL; Peli, E				Giorgi, Robert G.; Woods, Russell L.; Peli, Eli			Clinical and Laboratory Evaluation of Peripheral Prism Glasses for Hemianopia	OPTOMETRY AND VISION SCIENCE			English	Article						low vision; prism adaptation; rehabilitation; prism treatment; visual impairment; traumatic brain injury; stroke	UNILATERAL VISUAL NEGLECT; LOW-VISION REHABILITATION; HOMONYMOUS HEMIANOPIA; FIELD EXPANSION; SUCCESS; STROKE; SPECTACLES; ADAPTATION; BLINDNESS; SCOTOMAS	Purpose. Homonymous hemianopia (the loss of vision on the same side in each eye) impairs the ability to navigate and walk safely. We evaluated peripheral prism glasses as a low vision optical device for hemianopia in an extended wearing trial. Methods. Twenty-three patients with complete hemianopia (13 right) with neither visual neglect nor cognitive deficit enrolled in the 5-visit study. To expand the horizontal visual field, patients' spectacles were fitted with both upper and lower Press-On Fresnel prism segments (each 40 prism diopters) across the upper and lower portions of the lens on the hemianopic ("blind") side. Patients were asked to wear these spectacles as much as possible for the duration of the study, which averaged 9 (range: 5 to 13) weeks. Clinical success (continued wear, indicating perceived overall benefit), visual field expansion, perceived direction, and perceived quality of life were measured. Results. Clinical success: 14 of 21 (67%) patients chose to continue to wear the peripheral prism glasses at the end of the study (two patients did not complete the study for non-vision reasons). At long-term follow-up (8 to 51 months), 5 of 12 (42%) patients reported still wearing the device. Visual field expansion: expansion of about 220 in both the upper and lower quadrants was demonstrated for all patients (binocular perimetry, Goldmann V4e). Perceived direction: two patients demonstrated a transient adaptation to the change in visual direction produced by the peripheral prism glasses. Quality of life: at study end, reduced difficulty noticing obstacles on the hemianopic side was reported. Conclusions. The peripheral prism glasses provided reported benefits (usually in obstacle avoidance) to 2/3 of the patients completing the study, a very good success rate for a vision rehabilitation device. Possible reasons for long-term discontinuation and limited adaptation of perceived direction are discussed. (Optom Vis Sci 2009;86:492-502)	[Giorgi, Robert G.; Woods, Russell L.; Peli, Eli] Harvard Univ, Sch Med, Schepens Eye Res Inst, Dept Ophthalmol, Boston, MA 02114 USA		Peli, E (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, Dept Ophthalmol, 20 Staniford St, Boston, MA 02114 USA.	eli.peli@schepens.harvard.edu	Woods, Russell L/O-2600-2015	Woods, Russell L/0000-0002-7193-1211; Peli, Eli/0000-0002-1340-9257	NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY012890, R24EY012890] Funding Source: NIH RePORTER; NEI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01 EY012890, EY12890, R01 EY012890-08, R24 EY012890-05, R24 EY012890] Funding Source: Medline		BACK A, 1992, OPTOMETRY VISION SCI, V69, P474, DOI 10.1097/00006324-199206000-00011; BACK AP, 1989, OPTOMETRY VISION SCI, V66, P518, DOI 10.1097/00006324-198908000-00005; Bowers AR, 2008, ARCH OPHTHALMOL-CHIC, V126, P657, DOI 10.1001/archopht.126.5.657; DEMER JL, 1991, INVEST OPHTH VIS SCI, V32, P2826; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GAUTHIER CA, 1992, OPTOMETRY VISION SCI, V69, P858, DOI 10.1097/00006324-199211000-00004; Gottlieb DD, 1998, NEUROREHABILITATION, V11, P175, DOI 10.3233/NRE-1998-11303; Gottlieb DD., 1996, LIVING VISION LOSS; Greene HA, 2001, OPTOMETRY VISION SCI, V78, P297, DOI 10.1097/00006324-200105000-00013; HALLIGAN PW, 1993, UNILATERAL NEGLECT C, P3; Hamalainen H, 2000, SCAND J REHABIL MED, V32, P180, DOI 10.1080/003655000750060931; Haynes B, 1999, BRIT MED J, V319, P652, DOI 10.1136/bmj.319.7211.652; Jamara RJ, 2003, OPTOMETRY VISION SCI, V80, P495, DOI 10.1097/00006324-200307000-00011; Kasten E, 1998, NAT MED, V4, P1083, DOI 10.1038/2079; KERKHOFF G, 1992, RESTOR NEUROL NEUROS, V4, P245, DOI 10.3233/RNN-1992-4402; KERKHOFF G, 1994, ARCH NEUROL-CHICAGO, V51, P474, DOI 10.1001/archneur.1994.00540170050016; Kohler I, 1964, PSYCHOL ISSUES, V3, P1; Korner-Bitensky NA, 1998, AM J OCCUP THER, V52, P916, DOI 10.5014/ajot.52.10.916; LEAT SJ, 1994, OPTOMETRY VISION SCI, V71, P199, DOI 10.1097/00006324-199403000-00009; Lowe JB, 2000, OPTOMETRY VISION SCI, V77, P260, DOI 10.1097/00006324-200005000-00013; Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050; Massof RW, 2001, SURV OPHTHALMOL, V45, P531, DOI 10.1016/S0039-6257(01)00194-1; Massof RW, 1998, OPTOMETRY VISION SCI, V75, P349, DOI 10.1097/00006324-199805000-00025; Pambakian ALM, 1997, BRIT J OPHTHALMOL, V81, P324, DOI 10.1136/bjo.81.4.324; Peli E, 2000, OPTOMETRY VISION SCI, V77, P453, DOI 10.1097/00006324-200009000-00006; PICK HL, 1969, J EXP PSYCHOL, V80, P125, DOI 10.1037/h0027111; Rosenthal BP, 1996, REMEDIATION MANAGEME, P1; ROSSI PW, 1990, NEUROLOGY, V40, P1597, DOI 10.1212/WNL.40.10.1597; SCHENKENBERG T, 1980, NEUROLOGY, V30, P509, DOI 10.1212/WNL.30.5.509; Stelmack JA, 2002, INVEST OPHTH VIS SCI, V43, P2859; Szlyk JP, 2005, OPHTHAL PHYSL OPT, V25, P128, DOI 10.1111/j.1475-1313.2004.00265.x; Turano KA, 1999, INVEST OPHTH VIS SCI, V40, P865; VANDEUSEN J, 1984, PHYSICAL OCCUPATIONA, V3, P49; Vanier M, 1990, NEUROPSYCHOLOGY, V4, P87, DOI 10.1037/0894-4105.4.2.87; Verezen CA, 2006, OPTOMETRY VISION SCI, V83, P88, DOI 10.1097/01.opx.0000200679.81892.d4; WELCH RB, 1993, PERCEPT PSYCHOPHYS, V54, P195, DOI 10.3758/BF03211756; Williams GR, 1999, STROKE, V30, P2523, DOI 10.1161/01.STR.30.12.2523; Zhang X, 2006, NEUROLOGY, V66, P906, DOI 10.1212/01.wnl.0000203913.12088.93; Zhang X, 2006, NEUROLOGY, V66, P901, DOI 10.1212/01.wnl.0000203338.54323.22; Zhu SH, 2002, NEW ENGL J MED, V347, P1087, DOI 10.1056/NEJMsa020660; ZIHL J, 1995, BRAIN, V118, P891, DOI 10.1093/brain/118.4.891	41	56	58	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1040-5488	1538-9235		OPTOMETRY VISION SCI	Optom. Vis. Sci.	MAY	2009	86	5					492	502		10.1097/OPX.0b013e31819f9e4d			11	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	442AA	WOS:000265810800010	19357552	Green Accepted			2022-02-06	
J	Kanno, H; Ozawa, H; Sekiguchi, A; Itoi, E				Kanno, Haruo; Ozawa, Hiroshi; Sekiguchi, Akira; Itoi, Eiji			The role of autophagy in spinal cord injury	AUTOPHAGY			English	Article						autophagy; spinal cord injury; Beclin 1; apoptosis; autophagic cell death	PROGRAMMED CELL-DEATH; TRAUMATIC BRAIN-INJURY; CEREBRAL-ISCHEMIA; UP-REGULATION; APOPTOSIS; BECLIN-1; RAPAMYCIN; PROTEINS; MICE; NEURODEGENERATION	Previous studies have indicated that autophagy has an important function, not only in many neurodegenerative diseases, but also in traumatic and ischemic brain injury. However, no study has previously shown the contribution of autophagy to neural tissue damage after spinal cord injury. We recently investigated the alterations in Beclin 1 expression and the involvement of autophagy and autophagic cell death after spinal cord injury using a spinal cord hemisection model in mice. The results showed that the expression of Beclin 1 dramatically increased in the damaged neural tissue and induced autophagic cell death after a spinal cord injury. These observations suggested that the increased expression of Beclin 1 activates autophagy, while mediating a novel cell death mechanism at the lesion site in response to spinal cord injury. Here we discuss several unsolved issues and review the evidence in related articles regarding the role of autophagy and its contribution to the mechanism of cell death in spinal cord injury.	[Kanno, Haruo] Nishitaga Natl Hosp, Dept Orthopaed Surg, Sendai, Miyagi, Japan; [Kanno, Haruo; Ozawa, Hiroshi; Sekiguchi, Akira; Itoi, Eiji] Tohoku Univ, Sch Med, Dept Orthopaed Surg, Sendai, Miyagi 9808574, Japan		Kanno, H (corresponding author), Tohoku Univ, Sch Med, Dept Orthoped Surg, Aoba Ku, 1-1 Seiryomachi, Sendai, Miyagi 9808574, Japan.	kanno-h@isis.ocn.ne.jp	Kanno, Haruo/AAA-2187-2020	Kanno, Haruo/0000-0003-1985-2257	Health Labour Sciences Research [19591712]; Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; Japan Orthopaedics and Traumatology Foundation, Inc. [0138]; The General Insurance Association of Japan	This work was supported by a Health Labour Sciences Research Grant, by a Grant-in-Aid for Scientific Research (19591712) from the Japan Society for the Promotion of Science, by the Japan Orthopaedics and Traumatology Foundation, Inc., (No. 0138), and by a Grant in 2007 from The General Insurance Association of Japan.	Adhami F, 2007, AUTOPHAGY, V3, P42, DOI 10.4161/auto.3412; Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595; Carloni S, 2008, NEUROBIOL DIS, V32, P329, DOI 10.1016/j.nbd.2008.07.022; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Erlich S, 2007, AUTOPHAGY, V3, P561, DOI 10.4161/auto.4713; Espert L, 2006, J CLIN INVEST, V116, P2161, DOI 10.1172/JCI26185; Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447; Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liang XH, 2001, CANCER RES, V61, P3443; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Matsui Y, 2008, AUTOPHAGY, V4, P409, DOI 10.4161/auto.5638; Pan TH, 2008, NEUROBIOL DIS, V32, P16, DOI 10.1016/j.nbd.2008.06.003; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Rami A, 2008, NEUROBIOL DIS, V29, P132, DOI 10.1016/j.nbd.2007.08.005; Ravikumar B, 2006, HUM MOL GENET, V15, P1209, DOI 10.1093/hmg/ddl036; Sarkar S, 2009, CELL DEATH DIFFER, V16, P46, DOI 10.1038/cdd.2008.110; Scarlatti F, 2009, CELL DEATH DIFFER, V16, P12, DOI 10.1038/cdd.2008.101; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Suzuki C, 2008, BIOCHEM BIOPH RES CO, V368, P100, DOI 10.1016/j.bbrc.2008.01.059; Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645	39	56	60	3	8	LANDES BIOSCIENCE	AUSTIN	1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA	1554-8627			AUTOPHAGY	Autophagy	APR 1	2009	5	3					390	392		10.4161/auto.5.3.7724			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	439KP	WOS:000265626300017	19158496	Bronze			2022-02-06	
J	Robertson, JVG; Pradon, D; Bensmail, D; Fermanian, C; Bussel, B; Roche, N				Robertson, Johanna V. G.; Pradon, Didier; Bensmail, Djamel; Fermanian, Christophe; Bussel, Bernard; Roche, Nicolas			Relevance of botulinum toxin injection and nerve block of rectus femoris to kinematic and functional parameters of stiff knee gait in hemiplegic adults	GAIT & POSTURE			English	Article						Stiff knee gait; Rectus femoris; Nerve block; Botulinum toxin; Hemiplegic	MOTOR BRANCH-BLOCK; LEGGED GAIT; SWING-PHASE; FLEXION; MUSCLES; SPASTICITY; WALKING; STROKE; PERIOD	Stiff knee gait (SKG) is common in hemiplegic patients. The main focus of treatment is rectus femoris (RF) spasticity. The aims of this study were to evaluate the effect of botulinum toxin injection (BTI) in the RE muscle on peak knee flexion during swing phase and its quantitative and functional impact on gait. We also wished to evaluate the correlation between the effects of nerve block and BTI on peak knee flexion. 10 adult hemiplegic subjects (> 6 months post stroke or traumatic brain injury) with SKG and inappropriate RE EMG activity during mid-swing phase were included. 3D gait analysis, clinical and functional assessments (Timed Up and Go test, 10 m walk test, 6 min walk test and the time taken to ascend and descend a flight of stairs) were performed initially, 30 min after anaesthetic block of the RF nerve and one month post BTI. After BTI, there was a significant increase in knee flexion (8 degrees average) and a tendency towards improvement in gait and functional parameters. The effect of the nerve block on peak knee flexion was significantly correlated with the effect of BTI (11 degrees average increase in peak knee flexion after nerve block). We challenge the relevance of RF nerve blocks in this population when EMG and kinematic data are available. Our results indicate that BTI is an effective treatment for SKG in adult hemiplegic subjects, with a significant increase in peak knee flexion, no reduction in hip flexion and a tendency towards functional improvements. (C) 2008 Elsevier B.V. All rights reserved.	[Robertson, Johanna V. G.] Lab Neurophysiol & Physiol, CNRS UMR 8119, F-75006 Paris, France; [Pradon, Didier; Bensmail, Djamel; Bussel, Bernard] UVSQ, Hop Raymond Poincare, Serv Med Phys & Readaptat, AP HP, F-92380 Garches, France; [Roche, Nicolas] UVSQ, Hop Raymond Poincare, Serv Explorat Fonct, AP HP, F-92380 Garches, France; [Fermanian, Christophe] Hop Ambroise Pare, Unite Rech Clin Paris Ouest, F-92100 Boulogne, France; [Roche, Nicolas] Hop Raymond Poincare, Ctr Invest Clin & Innovat Technol, AP HP, F-92380 Garches, France		Robertson, JVG (corresponding author), Lab Neurophysiol & Physiol, CNRS UMR 8119, 45 Rue St Peres, F-75006 Paris, France.	johanna.robertson@univ-paris5.fr	Bensmail, Djamel/R-6035-2018; roche, nicolas/R-6080-2018	Bensmail, Djamel/0000-0001-9360-9330; 	Fondation Garches	This project was partially supported by a grant from the 'Fondation Garches'.	BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Chantraine F, 2005, ACTA NEUROL BELG, V105, P171; Filipetti P, 2003, NEUROCHIRURGIE, V49, P226; Goldberg SR, 2006, J BIOMECH, V39, P689, DOI 10.1016/j.jbiomech.2005.01.015; Goldberg SR, 2004, J BIOMECH, V37, P1189, DOI 10.1016/j.jbiomech.2003.12.005; Goldberg SR, 2003, J BIOMECH, V36, P1111, DOI 10.1016/S0021-9290(03)00106-4; HOLM S, 1979, SCAND J STAT, V6, P65; Kerrigan DC, 1998, GAIT POSTURE, V7, P117, DOI 10.1016/S0966-6362(97)00040-4; Kerrigan DC, 2001, AM J PHYS MED REHAB, V80, P244, DOI 10.1097/00002060-200104000-00002; Kerrigan DC, 2001, AM J PHYS MED REHAB, V80, P33, DOI 10.1097/00002060-200101000-00009; Kerrigan DCC, 1999, J HEAD TRAUMA REHAB, V14, P136, DOI 10.1097/00001199-199904000-00004; Kosak M, 2005, J REHABIL RES DEV, V42, P103, DOI 10.1682/JRRD.2003.11.0171; MATHIAS S, 1986, ARCH PHYS MED REHAB, V67, P387; Miller F, 1997, J PEDIATR ORTHOPED, V17, P603, DOI 10.1097/00004694-199709000-00006; Nene A, 1999, GAIT POSTURE, V9, P1, DOI 10.1016/S0966-6362(98)00042-3; PERRY J, 1992, NORMAL PATHOLOGICAL; Piazza SJ, 1996, J BIOMECH, V29, P723, DOI 10.1016/0021-9290(95)00144-1; Riley P O, 1999, IEEE Trans Rehabil Eng, V7, P420, DOI 10.1109/86.808945; Riley PO, 1998, J BIOMECH, V31, P835, DOI 10.1016/S0021-9290(98)00107-9; Sheean GL, 2001, CURR OPIN NEUROL, V14, P771, DOI 10.1097/00019052-200112000-00015; STOQUART GG, 2006, EUR SOC PHYS REH MED; Sung DH, 2003, ARCH PHYS MED REHAB, V84, P1028, DOI 10.1016/S0003-9993(03)00029-7; Sung DH, 2000, ARCH PHYS MED REHAB, V81, P910, DOI 10.1053/apmr.2000.5615; SUTHERLAND DH, 1990, J PEDIATR ORTHOPED, V10, P433; WADE DT, 1987, SCAND J REHABIL MED, V19, P25; WINTER DA, 1974, J BIOMECH, V7, P157, DOI 10.1016/0021-9290(74)90056-6	26	56	59	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362			GAIT POSTURE	Gait Posture	JAN	2009	29	1					108	112		10.1016/j.gaitpost.2008.07.005			5	Neurosciences; Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics; Sport Sciences	396LC	WOS:000262592200020	18771925				2022-02-06	
J	Lunemann, A; Lunemann, JD; Roberts, S; Messmer, B; da Silva, RB; Raine, CS; Muenz, C				Luenemann, Anna; Luenemann, Jan D.; Roberts, Susanne; Messmer, Brady; da Silva, Rosa Barreira; Raine, Cedric S.; Muenz, Christian			Human NK Cells Kill Resting but Not Activated Microglia via NKG2D-and NKp46-Mediated Recognition	JOURNAL OF IMMUNOLOGY			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; HUMAN DENDRITIC CELLS; ANTIGEN-PRESENTING CELLS; MULTIPLE-SCLEROSIS; T-CELLS; MEDIATED LYSIS; ADAPTIVE IMMUNITY; GLIAL-CELLS; OLIGODENDROCYTES	Microglia are resident macrophage-like APCs of the CNS. To avoid escalation of inflammatory processes and bystander damage within the CNS, microglia-driven inflammatory responses need to be tightly regulated and both spatially and temporally restricted. Following traumatic, infectious, and autoimmune-mediated brain injury, NK cells have been found in the CNS, but the functional significance of NK cell recruitment and their mechanisms of action during brain inflammation are not well understood. In this study, we investigated whether and by which mechanisms human NK cells might edit resting and activated human microglial cells via killing in vitro. IL-2-activated NK cells efficiently killed both resting allogeneic and autologous microglia in a cell-contact-dependent manner. Activated NK cells rapidly formed synapses with human microglial cells in which perforin had been polarized to the cellular interface. Ab-mediated NKG2D and NKp46 blockade completely prevented the killing of human microglia by activated NK cells. Up-regulation of MHC class I surface expression by TLR4 stimulation protected microglia from NK cell-mediated killing, whereas MHC class I blockade enhanced cytotoxic NK cell activity. These data suggest that brain-infiltrating NK cells might restrict innate and adaptive immune responses within the human CNS via elimination of resting microglia. The Journal of Immunology, 2008, 181: 6170-6177.	[Luenemann, Anna; Luenemann, Jan D.; Roberts, Susanne; Messmer, Brady; da Silva, Rosa Barreira; Muenz, Christian] Rockefeller Univ, Christopher H Browne Ctr Immunol & Immune Dis, Lab Viral Immunobiol, New York, NY 10065 USA; [Raine, Cedric S.] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA		Muenz, C (corresponding author), Univ Zurich, Univ Zurich Hosp, Inst Expt Immunol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	munzc@rockefeller.edu	Lunemann, Jan/G-8729-2011	Lunemann, Jan/0000-0002-3007-708X; Munz, Christian/0000-0001-6419-1940	NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA108609, R01CA101741] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA108609-04A2, R01CA108609, R01 CA108609, R01CA101741, R01 CA101741] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [BAA-06-19] Funding Source: Medline		Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Aloisi F, 2000, IMMUNOL TODAY, V21, P141, DOI 10.1016/S0167-5699(99)01512-1; Backstrom E, 2007, SCAND J IMMUNOL, V65, P353, DOI 10.1111/j.1365-3083.2007.01912.x; Backstrom E, 2003, EUR J IMMUNOL, V33, P92, DOI 10.1002/immu.200390012; Baker CA, 2003, P NATL ACAD SCI USA, V100, P675, DOI 10.1073/pnas.0237313100; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Busch DH, 1998, IMMUNITY, V8, P353, DOI 10.1016/S1074-7613(00)80540-3; Byram SC, 2003, BRAIN BEHAV IMMUN, V17, P417, DOI 10.1016/S0889-1591(03)00089-8; Carbone E, 1999, EUR J IMMUNOL, V29, P4022, DOI 10.1002/(SICI)1521-4141(199912)29:12<4022::AID-IMMU4022>3.0.CO;2-O; Cerboni C, 2007, BLOOD, V110, P606, DOI 10.1182/blood-2006-10-052720; Chambers BJ, 1996, IMMUNITY, V5, P311, DOI 10.1016/S1074-7613(00)80257-5; Chiesa MD, 2003, EUR J IMMUNOL, V33, P1657, DOI 10.1002/eji.200323986; Degli-Esposti MA, 2005, NAT REV IMMUNOL, V5, P112, DOI 10.1038/nri1549; Ferlazzo G, 2002, J EXP MED, V195, P343, DOI 10.1084/jem.20011149; Fischer K, 2002, J IMMUNOL METHODS, V259, P159, DOI 10.1016/S0022-1759(01)00507-5; Frohman EM, 2006, NEW ENGL J MED, V354, P942, DOI 10.1056/NEJMra052130; Hamerman JA, 2004, J IMMUNOL, V172, P2001, DOI 10.4049/jimmunol.172.4.2001; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Hansen DS, 2007, J IMMUNOL, V178, P5779, DOI 10.4049/jimmunol.178.9.5779; Huang D, 2006, FASEB J, V20, P896, DOI 10.1096/fj.05-5465com; Kettenmann H, 2006, NAT NEUROSCI, V9, P1463, DOI 10.1038/nn1206-1463; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; LEE SHC, 1992, LAB INVEST, V67, P465; Lee-MacAry AE, 2001, J IMMUNOL METHODS, V252, P83, DOI 10.1016/S0022-1759(01)00336-2; Lu LR, 2007, IMMUNITY, V26, P593, DOI 10.1016/j.immuni.2007.03.017; Lunemann A, 2006, GLIA, V53, P412, DOI 10.1002/glia.20301; Lunemann JD, 2008, BRAIN, V131, P1681, DOI 10.1093/brain/awn132; Matsumoto Y, 1998, EUR J IMMUNOL, V28, P1681, DOI 10.1002/(SICI)1521-4141(199805)28:05<1681::AID-IMMU1681>3.0.CO;2-T; Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Moretta A, 2008, CELL DEATH DIFFER, V15, P226, DOI 10.1038/sj.cdd.4402170; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; Morse RHA, 2001, J NEUROIMMUNOL, V116, P107, DOI 10.1016/S0165-5728(01)00289-2; Munz C, 2005, BLOOD, V105, P266, DOI 10.1182/blood-2004-06-2492; Nedvetzki S, 2007, BLOOD, V109, P3776, DOI 10.1182/blood-2006-10-052977; Parajuli P, 1999, J LEUKOCYTE BIOL, V65, P764, DOI 10.1002/jlb.65.6.764; Pende D, 2006, BLOOD, V107, P2030, DOI 10.1182/blood-2005-07-2696; Persson CM, 2008, SCAND J IMMUNOL, V67, P30, DOI 10.1111/j.1365-3083.2007.02034.x; Rabinovich BA, 2003, J IMMUNOL, V170, P3572, DOI 10.4049/jimmunol.170.7.3572; Raivich G, 2002, EXP NEUROL, V178, P186, DOI 10.1006/exnr.2002.8024; Roy S, 2008, J IMMUNOL, V180, P1729, DOI 10.4049/jimmunol.180.3.1729; Saikali P, 2007, J NEUROSCI, V27, P1220, DOI 10.1523/JNEUROSCI.4402-06.2007; SATOH J, 1990, J NEUROIMMUNOL, V26, P75, DOI 10.1016/0165-5728(90)90122-4; SATOH J, 1991, J NEUROIMMUNOL, V31, P199, DOI 10.1016/0165-5728(91)90041-5; SHRIKANT P, 1995, J IMMUNOL, V155, P1489; Shrikant P, 1996, J IMMUNOL, V157, P1819; Spaggiari GM, 2001, EUR J IMMUNOL, V31, P1656, DOI 10.1002/1521-4141(200106)31:6<1656::AID-IMMU1656>3.0.CO;2-V; Strowig T, 2008, J IMMUNOL, V180, P7785, DOI 10.4049/jimmunol.180.12.7785; TRAUGOTT U, 1984, ANN NY ACAD SCI, V436, P163, DOI 10.1111/j.1749-6632.1984.tb14788.x; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Vollmer TL, 2005, J IMMUNOL, V174, P2696, DOI 10.4049/jimmunol.174.5.2696; Walzer T, 2007, P NATL ACAD SCI USA, V104, P3384, DOI 10.1073/pnas.0609692104; Wilkinson RW, 2001, J IMMUNOL METHODS, V258, P183, DOI 10.1016/S0022-1759(01)00474-4; Wilson JL, 1999, J IMMUNOL, V163, P6365; Winkler-Pickett R, 2008, J IMMUNOL, V180, P4495, DOI 10.4049/jimmunol.180.7.4495; Xu W, 2005, J NEUROIMMUNOL, V163, P24, DOI 10.1016/j.jneuroim.2005.02.011; Zhang BN, 1997, J EXP MED, V186, P1677, DOI 10.1084/jem.186.10.1677	57	56	58	0	2	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	NOV 1	2008	181	9					6170	6177		10.4049/jimmunol.181.9.6170			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	368YI	WOS:000260659000042	18941207	Green Accepted, Bronze			2022-02-06	
J	Stravitz, RT				Stravitz, R. Todd			Critical Management Decisions in Patients With Acute Liver Failure	CHEST			English	Article						hepatitis; liver; liver failure	FULMINANT HEPATIC-FAILURE; TRAUMATIC BRAIN-INJURY; INTRACRANIAL-PRESSURE; CONTROLLED-TRIAL; MODERATE HYPOTHERMIA; CEREBRAL PERFUSION; N-ACETYLCYSTEINE; GASTROINTESTINAL HEMORRHAGE; THERAPEUTIC HYPOTHERMIA; ARTERIAL AMMONIA	Few admissions to the ICU present a greater clinical challenge than the patient with acute liver failure (ALF), the syndrome of abrupt loss of liver function in a previously unaffected individual. Although advances in the intensive care management of patients with ALF have improved survival, the prognosis of ALF remains poor, with a 33% mortality rate and a 25% liver transplant rate in the United States. ALF adversely affects nearly every organ system, with most deaths occurring from sepsis and subsequent multiorgan system failure, and cerebral edema, resulting in intracranial hypertension (ICH) and brainstem herniation. Unfortunately, the optimal management of ALF remains poorly defined, and practices are often based on local experience and case reports rather than on randomized, controlled clinical trials. The paramount question in any patient presenting with ALF remains defining an etiology, since specific antidotes can save lives and spare the liver. This article will consider recent advances in the assignment of an etiology, the administration of etiology-specific treatment to abate the liver injury, and the management of complications (eg, infection, cerebral edema, and the bleeding diathesis) in patients with ALF. New data on the administration of N-acetylcysteine to patients with non-acetaminophen ALF, the treatment of ICH, and assessment of the need for liver transplantation will also be presented. (CHEST 2008; 134:1092-1102)	[Stravitz, R. Todd] Virginia Commonwealth Univ, Hume Lee Transplant Ctr, Sect Hepatol, Richmond, VA 23298 USA		Stravitz, RT (corresponding author), Virginia Commonwealth Univ, Med Ctr, Sect Hepatol, POB 980341, Richmond, VA 23298 USA.	rstravit@hsc.vcu.edu					Bernal W, 2003, SEMIN LIVER DIS, V23, P227; Bernal W, 2002, LANCET, V359, P558, DOI 10.1016/S0140-6736(02)07743-7; Bernal W, 2007, HEPATOLOGY, V46, P1844, DOI 10.1002/hep.21838; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BERNUAU J, 1986, HEPATOLOGY, V6, P648, DOI 10.1002/hep.1840060417; BERNUAU J, 1991, HEPATOLOGY, V14, pA49; Bernuau J, 1999, OXFORD TXB CLIN HEPA, P1341; BLEI AT, 1993, LANCET, V341, P157, DOI 10.1016/0140-6736(93)90016-A; Blei AT, 2005, NEUROCHEM INT, V47, P71, DOI 10.1016/j.neuint.2005.04.009; CANALESE J, 1982, GUT, V23, P625, DOI 10.1136/gut.23.7.625; Clemmesen JO, 1997, HEPATOLOGY, V26, P1423; Clemmesen JO, 1999, HEPATOLOGY, V29, P648, DOI 10.1002/hep.510290309; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; Daas M, 1995, Liver Transpl Surg, V1, P210, DOI 10.1002/lt.500010403; Davern TJ, 2006, GASTROENTEROLOGY, V130, P687, DOI 10.1053/j.gastro.2006.01.033; DAVIES MH, 1994, LANCET, V343, P1329, DOI 10.1016/S0140-6736(94)92471-6; Demetriou AA, 2004, ANN SURG, V239, P660, DOI 10.1097/01.sla.0000124298.74199.e5; FORBES A, 1989, HEPATOLOGY, V10, P306, DOI 10.1002/hep.1840100309; GAZZARD BG, 1974, GUT, V15, P89, DOI 10.1136/gut.15.2.89; GAZZARD BG, 1975, GUT, V16, P617, DOI 10.1136/gut.16.8.617; GAZZARD BG, 1975, Q J MED, V44, P615; GIMSON AES, 1986, HEPATOLOGY, V6, P288, DOI 10.1002/hep.1840060222; HANID MA, 1980, GUT, V21, P866, DOI 10.1136/gut.21.10.866; HARRISON PM, 1991, NEW ENGL J MED, V324, P1852, DOI 10.1056/NEJM199106273242604; HARRISON PM, 1990, BMJ-BRIT MED J, V301, P964, DOI 10.1136/bmj.301.6758.964; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Ichai P, 2007, LIVER TRANSPLANT, V13, P996, DOI 10.1002/lt.21036; Ilan Y, 2007, ALIMENT PHARM THER, V26, P1293, DOI 10.1111/j.1365-2036.2007.03519.x; Jalan R, 2004, GASTROENTEROLOGY, V127, P1338, DOI 10.1053/j.gastro.2004.08.005; Jalan R, 2003, TRANSPLANTATION, V75, P2034, DOI 10.1097/01.TP.0000066240.42113.FF; Jalan R, 1999, LANCET, V354, P1164, DOI 10.1016/S0140-6736(98)12440-6; Jalan R, 2001, HEPATOLOGY, V34, P50, DOI 10.1053/jhep.2001.25386; James LP, 2006, PEDIATRICS, V118, pE676, DOI 10.1542/peds.2006-0069; KEAYS R, 1991, Q J MED, V79, P425; Kortsalioudaki C, 2008, LIVER TRANSPLANT, V14, P25, DOI 10.1002/lt.21246; Kumar M, 2007, HEPATOLOGY, V45, P97, DOI 10.1002/hep.21486; LANGLEY PG, 1990, EUR J CLIN INVEST, V20, P627, DOI 10.1111/j.1365-2362.1990.tb01911.x; Larson AM, 2005, HEPATOLOGY, V42, P1364, DOI 10.1002/hep.20948; Lee WM, 2007, HEPATOLOGY, V46, p268A; Lee WM, 2003, SEMIN LIVER DIS, V23, P217; LIDOFSKY SD, 1992, HEPATOLOGY, V16, P1, DOI 10.1002/hep.1840160102; Lisman T, 2002, HEPATOLOGY, V35, P616, DOI 10.1053/jhep.2002.31771; Lisman T, 2007, DIGEST SURG, V24, P250, DOI 10.1159/000103655; MACDOUGALL BRD, 1978, GASTROENTEROLOGY, V74, P464; MACDOUGALL BRD, 1977, LANCET, V1, P617; MacQuillan GC, 2005, LIVER TRANSPLANT, V11, P1073, DOI 10.1002/lt.20427; MAKIN AJ, 1997, ACUTE LIVER FAILURE, P32; McKenzie TJ, 2008, SEMIN LIVER DIS, V28, P210, DOI 10.1055/s-2008-1073120; Mitchell I, 1998, CRIT CARE MED, V26, P279, DOI 10.1097/00003246-199802000-00026; MUNOZ S, 2009, CLIN LIVER IN PRESS; MUNOZ SJ, 1989, TRANSPLANT P, V21, P3535; Murphy N, 2004, HEPATOLOGY, V39, P464, DOI 10.1002/hep.20056; OGRADY JG, 1993, LANCET, V342, P273; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; Pavese P, 2005, CAN J ANAESTH, V52, P26, DOI 10.1007/BF03018576; PEREIRA LMMB, 1992, GUT, V33, P98, DOI 10.1136/gut.33.1.98; Pereira SP, 2005, J HEPATOL, V42, P365, DOI 10.1016/j.jhep.2004.11.030; PERNAMBUCO JRB, 1993, HEPATOLOGY, V18, P1350, DOI 10.1016/0270-9139(93)90223-A; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Polson J, 2008, CLIN CHIM ACTA, V391, P24, DOI 10.1016/j.cca.2008.01.018; Polson J, 2008, SEMIN LIVER DIS, V28, P218, DOI 10.1055/s-2008-1073121; Rana R, 2006, TRANSFUSION, V46, P1478, DOI 10.1111/j.1537-2995.2006.00930.x; Riordan SM, 2008, SEMIN LIVER DIS, V28, P137, DOI 10.1055/s-2008-1073113; Roberts MS, 2004, LIVER TRANSPLANT, V10, P886, DOI 10.1002/lt.20137; Rolando N, 1996, Liver Transpl Surg, V2, P8, DOI 10.1002/lt.500020103; ROLANDO N, 1991, J HEPATOL, V12, P1, DOI 10.1016/0168-8278(91)90900-V; Rolando N, 2000, HEPATOLOGY, V32, P734, DOI 10.1053/jhep.2000.17687; Rolando N, 1996, SEMIN LIVER DIS, V16, P389, DOI 10.1055/s-2007-1007252; ROLANDO N, 1990, HEPATOLOGY, V11, P49, DOI 10.1002/hep.1840110110; ROLANDO N, 1993, HEPATOLOGY, V17, P196, DOI 10.1002/hep.1840170206; Schmidt LE, 2007, HEPATOLOGY, V45, P789, DOI 10.1002/hep.21503; Schmidt LE, 2004, CLIN GASTROENTEROL H, V2, P418, DOI 10.1016/S1542-3565(04)00128-4; Schmidt LE, 2005, HEPATOLOGY, V41, P26, DOI 10.1002/hep.20511; Schmidt LE, 2002, HEPATOLOGY, V36, P659, DOI 10.1053/jhep.2002.35069; Shami VM, 2003, LIVER TRANSPLANT, V9, P138, DOI 10.1053/jlts.2003.50017; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; Stadbauer V, 2007, CURR OPIN CRIT CARE, V13, P215, DOI 10.1097/MCC.0b013e328052c4cc; Stravitz RT, 2008, NEUROCRIT CARE, V9, P90, DOI 10.1007/s12028-008-9090-y; Stravitz RT, 2007, CRIT CARE MED, V35, P2498, DOI 10.1097/01.CCM.0000287592.94554.5F; Tillmann HL, 2006, J VIRAL HEPATITIS, V13, P256, DOI 10.1111/j.1365-2893.2005.00695.x; Tofteng F, 2004, J CEREBR BLOOD F MET, V24, P798, DOI 10.1097/01.WCB.0000125648.03213.1D; TREY C, 1970, Progress in Liver Diseases, P282; Vaquero J, 2005, LIVER TRANSPLANT, V11, P1581, DOI 10.1002/lt.20625; Vaquero J, 2005, J CLIN GASTROENTEROL, V39, pS147, DOI 10.1097/01.mcg.0000155515.94843.55; Vaquero J, 2003, GASTROENTEROLOGY, V125, P755, DOI 10.1016/S0016-5085(03)01051-5; Vaquero J, 2007, GASTROENTEROLOGY, V132, P372, DOI 10.1053/j.gastro.2006.11.025; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Wijdicks EFM, 2002, TRANSPLANT P, V34, P1220, DOI 10.1016/S0041-1345(02)02804-X; Zimmerman H.J., 1999, HEPATOTOXICITY ADVER	91	56	62	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0012-3692	1931-3543		CHEST	Chest	NOV	2008	134	5					1092	1102		10.1378/chest.08-1071			11	Critical Care Medicine; Respiratory System	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Respiratory System	372RF	WOS:000260918500034	18988787				2022-02-06	
J	Parker, TM; Osternig, LR; van Donkelaar, P; Chou, LS				Parker, Tonya M.; Osternig, Louis R.; van Donkelaar, Paul; Chou, Li-Shan			Balance control during gait in athletes and non-athletes following concussion	MEDICAL ENGINEERING & PHYSICS			English	Article; Proceedings Paper	International Symposium on Biomedical Engineering	DEC 14-16, 2006	Natl Taiwan Univ, Taipei, TAIWAN		Natl Taiwan Univ	Concussion; Gait; Sub-concussion; Uninjured controls; Dual-task; Balance control	TRAUMATIC BRAIN-INJURY; STABILITY FOLLOWING CONCUSSION; PROFESSIONAL FOOTBALL; NEUROPSYCHOLOGICAL IMPAIRMENT; COGNITIVE IMPAIRMENT; POSTURAL STABILITY; HUMAN WALKING; HEAD-INJURY; SPORTS; MANAGEMENT	Current literature provides only limited information regarding performance on dynamic motor tasks following concussion. However, recent investigations have suggested that participation in contact sports may have a negative effect on cognitive function without the existence of a medically diagnosed concussion. The purpose of this study was to examine balance control during gait in concussed and uninjured athletes and non-athletes. Twenty-eight Grade 2 concussed individuals (14 athletes and 14 non-athletes) and 28 uninjured matched controls (14 athletes and 14 non-athletes) were assessed for their gait performance within 48 h, 5, 14, and 28 days post-injury under conditions of divided and undivided attention. Athletes, whether concussed or not, walked slower and swayed more and faster than non-athletes. Athletes consistently demonstrated gait imbalance even in the absence of concussion. The findings of this study support the supposition that participation in high-impact sports has a measurable and possibly detrimental effect on balance control in the absence of a medically diagnosed concussion. (C) 2007 Elsevier Ltd. All rights reserved. Published by Elsevier Ltd. All rights reserved.	[Parker, Tonya M.; Osternig, Louis R.; van Donkelaar, Paul; Chou, Li-Shan] 1240 Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA		Chou, LS (corresponding author), 1240 Univ Oregon, Dept Human Physiol, 122 Esslinger Hall, Eugene, OR 97403 USA.	chou@uoregon.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR021735, CCR023203] Funding Source: Medline		Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Bauby CE, 2000, J BIOMECH, V33, P1433, DOI 10.1016/S0021-9290(00)00101-9; BELL R, 1977, AM FAM PHYSICIAN, V16, P145; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Donelan JM, 2004, J BIOMECH, V37, P827, DOI 10.1016/j.jbiomech.2003.06.002; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hahn ME, 2004, J BIOMECH, V37, P837, DOI 10.1016/j.jbiomech.2003.11.010; Johnson PD, 2002, CLIN J SPORT MED, V12, P12, DOI 10.1097/00042752-200201000-00006; Kelly JP, 1997, NEUROLOGY, V48, P581; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rutherford A, 2005, J CLIN EXP NEUROPSYC, V27, P299, DOI 10.1080/13803390490515504; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; WINTER DA, 1990, BIOMECHANICS MOTOR C, P56; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	30	56	56	3	21	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1350-4533			MED ENG PHYS	Med. Eng. Phys.	OCT	2008	30	8			SI		959	967		10.1016/j.medengphy.2007.12.006			9	Engineering, Biomedical	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Engineering	367IR	WOS:000260546200004	18243036				2022-02-06	
J	Leon-Carrion, J; Martin-Rodriguez, JF; Damas-Lopez, J; Martin, JMBY; Dominguez-Morales, MR				Leon-Carrion, J.; Martin-Rodriguez, J. F.; Damas-Lopez, J.; Barroso y Martin, J. M.; Dominguez-Morales, M. R.			Brain function in the minimally conscious state: A quantitative neurophysiological study	CLINICAL NEUROPHYSIOLOGY			English	Article						vegetative state; severe neurocognitive disorder; consciousness; minimally conscious state; LORETA	INDEPENDENT COMPONENT ANALYSIS; REGIONAL CEREBRAL METABOLISM; PERSISTENT VEGETATIVE STATE; HEAD-INJURY; EEG; DISORDERS; COMA; INFORMATION; DEFINITION; RECOVERY	Objective: To explore possible EEG power spectrum and coherence differences between patients in minimally conscious state (MCS) and patients with severe neurocognitive disorders (SND), who show signs of awareness. We also try to find EEG cortical sources that differentiate between both conditions using LORETA source analysis. Methods: We studied 16 patients with traumatic brain injury (7 MCS, 9 SND; aged 18-49) and compared EEG power spectra, coherence, and LORETA sources at rest for both groups. Results: EEG power spectra revealed significant differences in the delta range of both conditions. Patients in MCS showed a notably increased power in this band, compared to SND patients. LORETA analysis showed that posterior sources of delta and theta frequencies had higher amplitude in MCS patients than in SND patients. Regarding fast frequencies, lower source magnitudes in temporal and frontal lobes were found for MCS patients. Conclusions: Our results stress the importance of fronto-temporal-parietal associative cortices within the "awareness-regions" model. Our results also suggest a relation between excess of slow wave activity and diminished level of awareness in brain injury population. Significance: Neurophysiological correlates in brain damaged patients who are severely impaired could be used to assess the integrity of brain areas responsible for awareness. (C) 2008 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Leon-Carrion, J.; Martin-Rodriguez, J. F.; Barroso y Martin, J. M.] Univ Seville, Sch Psychol, Dept Expt Psychol, Human Neuropsychol Lab, Seville 41018, Spain; [Leon-Carrion, J.; Martin-Rodriguez, J. F.; Damas-Lopez, J.; Dominguez-Morales, M. R.] Ctr Brain Injury Rehabil CRECER, Seville, Spain		Leon-Carrion, J (corresponding author), Univ Seville, Sch Psychol, Dept Expt Psychol, Human Neuropsychol Lab, C Camilo Jose Cela S-N, Seville 41018, Spain.	leoncarrion@us.es	Barroso y Martin, Juan Manuel/AAB-9758-2020	Martin Rodriguez, Juan Francisco/0000-0003-1392-8775			Babiloni C, 2004, NEUROIMAGE, V22, P57, DOI 10.1016/j.neuroimage.2003.09.028; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Borthwick CJ, 2004, NEUROREHABILITATION, V19, P381; Broicolo A, 1973, J NEUROSURG SCI, V17, P278; Davey MP, 2000, CLIN NEUROPHYSIOL, V111, P1949, DOI 10.1016/S1388-2457(00)00435-1; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Greicius MD, 2004, J COGNITIVE NEUROSCI, V16, P1484, DOI 10.1162/0898929042568532; Groenewegen HJ, 2000, PROG BRAIN RES, V126, P3; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Hagen C., 1972, LEVELS COGNITIVE FUN; Hal KM, 1997, J REHABILITATION OUT, V1, P63; Iriarte J, 2003, J CLIN NEUROPHYSIOL, V20, P249, DOI 10.1097/00004691-200307000-00004; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; John ER, 2006, CLIN EEG NEUROSCI, V37, P135, DOI 10.1177/155005940603700210; KAISER DA, 2001, J NEUROTHER, V15, P1; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kobylarz EJ, 2005, NEUROPSYCHOL REHABIL, V15, P323, DOI 10.1080/09602010443000605; KOBYLARZ EJ, 2003, ASS SCI STUD CONSC A; Kotchoubey B, 2005, CLIN NEUROPHYSIOL, V116, P2441, DOI 10.1016/j.clinph.2005.03.028; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S., 2003, European Journal of Neurology, V10, P224; Laureys S, 2006, J CLIN INVEST, V116, P1823, DOI 10.1172/JCI29172; Leon-Carrion J, 2002, NEUROREHABILITATION, V17, P115; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Pascual-Marqui RD, 1994, ISBET NEWSLETTER, V5, P4; Phillips C, 2002, NEUROIMAGE, V17, P287, DOI 10.1006/nimg.2002.1175; Rappaport M, 2005, NEUROPSYCHOL REHABIL, V15, P442, DOI 10.1080/09602010443000335; Schiff ND, 1999, TRENDS COGN SCI, V3, P43, DOI 10.1016/S1364-6613(98)01268-6; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Talairach J., 1988, COPLANAR STEREOTAXIC; Thatcher RW, 1999, INTRO QUANTITATIVE E, P29; TOMMASINO C, 1995, J NEUROSURG ANESTH, V7, P109, DOI 10.1097/00008506-199504000-00006; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021	39	56	66	1	13	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457			CLIN NEUROPHYSIOL	Clin. Neurophysiol.	JUL	2008	119	7					1506	1514		10.1016/j.clinph.2008.03.030			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	326KK	WOS:000257657300006	18486547				2022-02-06	
J	Choi, I; Park, HK; Chang, JC; Cho, SJ; Choi, SK; Byun, BJ				Choi, Il; Park, Hyung-Ki; Chang, Jae-Chil; Cho, Sung-Jin; Choi, Soon-Kwan; Byun, Bark-Jang			Clinical factors for the development of posttraumatic hydrocephalus after decompressive craniectomy	JOURNAL OF KOREAN NEUROSURGICAL SOCIETY			English	Article						hydrocephalus; craniotomy; craniocerebral trauma	HEMICRANIECTOMY	Objective : Earlier reports have revealed that the incidence of posttraumatic hydrocephalus (PTH) is higher among patients who underwent decompressive craniectomy (DC). The aim of this study was to determine the influencing factors for the development of PTH after DC. Methods : A total of 693 head trauma patients admitted in our hospital between March 2004 and May 2007 were reviewed. Among thee, we analyzed 55 patients with severe traumatic brain injury who underwent DC. We excluded patients who had confounding variables. The 33 patients were finally enrolled in the study and data were collected retrospectively for these patients. The patients were divided into two groups: non-hydrocephalus group (Group I) and hydrocephalus group (Group II). Related factors assessed were individual Glasgow Coma Score (GCS), age, sex, radiological findings, type of operation, re-operation and outcome. Results : Of the 693 patients with head trauma, 28 (4.0%) developed PTH. Fifty-five patients underwent DC and 13 (23.6%) developed PTH. Eleven of the 33 study patients (30.3%) who had no confounding factors were diagnosed with PTH. Significant differences in the type of craniectomy and re-operation were found between Group I and II. Conclusion : It is suggested that the size of DC and repeated operation may promote posttraumatic hydrocephalus in severe head trauma patients who underwent DC.	[Choi, Il; Park, Hyung-Ki; Chang, Jae-Chil; Cho, Sung-Jin; Choi, Soon-Kwan; Byun, Bark-Jang] Soonchunhyang Univ, Coll Med, Dept Neurosurg, Hannam Dong 657, Seoul 140743, South Korea		Park, HK (corresponding author), Soonchunhyang Univ, Coll Med, Dept Neurosurg, Hannam Dong 657, Seoul 140743, South Korea.	phk007@hosp.sch.ac.kr	Choi, IL/ABI-4106-2020	Choi, IL/0000-0003-0120-6564			BEYERL B, 1984, NEUROSURGERY, V15, P257, DOI 10.1227/00006123-198408000-00020; BRET P, 1985, NEUROSURGERY, V16, P44, DOI 10.1227/00006123-198501000-00009; CARDOSO ER, 1985, SURG NEUROL, V23, P261, DOI 10.1016/0090-3019(85)90092-8; Dandy WE, 1914, AM J DIS CHILD, V8, P406; Erban P, 2006, CLIN NEUROL NEUROSUR, V108, P384, DOI 10.1016/j.clineuro.2005.06.008; FOLTZ EL, 1956, J NEUROSURG, V13, P546, DOI 10.3171/jns.1956.13.6.0546; FOROGLOU G, 1972, Acta Radiologica Diagnosis, V13, P524; GUDEMAN SK, 1981, RADIOLOGY, V141, P397, DOI 10.1148/radiology.141.2.6974874; HAWKINS TD, 1976, CLIN RADIOL, V27, P279, DOI 10.1016/S0009-9260(76)80069-4; Jiao Qing-fang, 2007, Chin J Traumatol, V10, P159; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; Loshakov V A, 1993, Zh Vopr Neirokhir Im N N Burdenko, P18; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; PEDERSEN KK, 1973, ACTA NEUROL SCAND, V49, P10; PHILIPPON J, 1976, NEUROCHIRURGIE, V22, P111; Phuenpathom Nakornchai, 1999, Journal of the Medical Association of Thailand, V82, P46; Shin HS, 2000, J KOREAN NEUROSURG S, V29, P1179; TABADDOR K, 1976, J NEUROSURG, V44, P506, DOI 10.3171/jns.1976.44.4.0506; UPTON ML, 1985, J NEUROSURG, V63, P867, DOI 10.3171/jns.1985.63.6.0867; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Woertgen C, 2006, J CLIN NEUROSCI, V13, P718, DOI 10.1016/j.jocn.2005.08.019; Yoo DS, 2001, J KOREAN NEUROSURG S, V30, P295; 이진훈, 2003, [Journal of Korean Neurosurgical Society, 대한신경외과학회지], V34, P531; 박진열, 2002, [Journal of Korean Neurosurgical Society, 대한신경외과학회지], V31, P33	25	56	61	0	0	KOREAN NEUROSURGICAL SOC	SEOUL	BLDG B, #402, 27, CHILPAE-RO, JUNG-GU, SEOUL, 04511, SOUTH KOREA	2005-3711	1598-7876		J KOREAN NEUROSURG S	J. Korean. Neurosurg. Soc.	MAY	2008	43	5					227	231		10.3340/jkns.2008.43.5.227			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	320CQ	WOS:000257211700002	19096601	Green Published			2022-02-06	
J	Esquenazi, A; Mayer, N; Garreta, R				Esquenazi, Alberto; Mayer, Nathaniel; Garreta, Roser			Influence of botulinum toxin type A treatment of elbow flexor spasticity on hemiparetic gait	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						spasticity; botulinum toxin type A; gait	UPPER-LIMB SPASTICITY; HEMIPLEGIC GAIT; WALKING SPEED; DOUBLE-BLIND; COORDINATION; INJECTION; ARM; INHIBITION; EXTREMITY; DYSTONIA	Objective: To assess whether walking velocity could be improved in patients with disorders related to upper-motor neuron syndrome (UMNS) by treating elbow flexor spasticity with botulinum toxin type A (BoNTA). Design: This was a prospective, open-label, multicenter, interventional evaluation. The study group of 15 patients (mean age, 51.3 yrs; ten men, five women) were independent ambulators with residual hemiparesis attributable to stroke or traumatic brain injury of at least 18-mo duration. Patients were injected with 120-200 units of BoNTA (BOTOX, Allergan, Inc., Irvine, CA) to the affected biceps, brachialis, and/or brachiora-dialis. Modified Ashworth scores and gait velocity were assessed before and after BoNTA treatment. An untreated control group was employed to assess the potential impact of time on test-retest reliability of the selected temporal spatial gait parameters. Results: The BoNTA group demonstrated a statistically significant increase in walking velocity from 0.56 m/sec before treatment to 0.63 m/sec after treatment (P = 0.037). The mean modified Ashworth score was significantly reduced from 2.6 before BoNTA treatment to 1.4 after treatment (P = 0.00003). Conclusions: Treatment of upper-limb spasticity may be an important adjuvant treatment for patients with gait disturbance related to the UMNS.	Moss Rehab, Philadelphia, PA 19141 USA; [Esquenazi, Alberto; Mayer, Nathaniel] Albert Einstein Med Ctr, Philadelphia, PA 19141 USA; [Garreta, Roser] Hosp Mutua Terrassa, Dept Phys Med & Rehabil, Terrassa, Spain								Abe M, 2001, EXP BRAIN RES, V139, P120, DOI 10.1007/s002210100761; *ALL INC, 2002, BOTOX PACK INS; BOHANNON RW, 1991, PERCEPT MOTOR SKILL, V73, P146, DOI 10.2466/PMS.73.4.146-146; Boroojerdi B, 2003, NEUROLOGY, V61, P1546, DOI 10.1212/01.WNL.0000095965.36574.0F; Brashear A, 2002, NEW ENGL J MED, V347, P395, DOI 10.1056/NEJMoa011892; Childers MK, 2004, ARCH PHYS MED REHAB, V85, P1063, DOI 10.1016/j.apmr.2003.10.015; Curra A, 2004, MOVEMENT DISORD, V19, pS60, DOI 10.1002/mds.20011; Donker SF, 2001, J MOTOR BEHAV, V33, P86, DOI 10.1080/00222890109601905; Eke-Okoro ST, 1997, CLIN BIOMECH, V12, P516, DOI 10.1016/S0268-0033(97)00050-8; ESQUENAZI A, 2000, PHYS MED REHABILITAT, P242; Gilio F, 2000, ANN NEUROL, V48, P20, DOI 10.1002/1531-8249(200007)48:1<20::AID-ANA5>3.3.CO;2-L; Gordon MF, 2004, NEUROLOGY, V63, P1971, DOI 10.1212/01.WNL.0000144349.95487.91; Graham HK, 2001, EUR J NEUROL, V8, P30, DOI 10.1046/j.1468-1331.2001.00036.x; Hirsch MA, 2005, MOVEMENT DISORD, V20, P1014, DOI 10.1002/mds.20499; Kanovsky P, 1998, MOVEMENT DISORD, V13, P108, DOI 10.1002/mds.870130122; Kavanagh J, 2006, EXP BRAIN RES, V172, P454, DOI 10.1007/s00221-006-0353-6; Koman LA, 2000, J PEDIATR ORTHOPED, V20, P108, DOI 10.1097/00004694-200001000-00022; Kwakkel G, 2002, PHYS THER, V82, P432, DOI 10.1093/ptj/82.5.432; Mancini F, 2005, NEUROL SCI, V26, P26, DOI 10.1007/s10072-005-0378-9; Mayer Nathaniel H, 2003, Phys Med Rehabil Clin N Am, V14, P855, DOI 10.1016/S1047-9651(03)00093-7; Murray M P, 1967, Phys Ther, V47, P272; PARK CI, 2000, 5 ANN GAIT CLIN MOV; PRIORI A, 1995, BRAIN, V118, P801, DOI 10.1093/brain/118.3.801; vanEmmerik REA, 1996, J BIOMECH, V29, P1175, DOI 10.1016/0021-9290(95)00128-X; VONSCHROEDER HP, 1995, J REHABIL RES DEV, V32, P25; Wagenaar RC, 2000, J BIOMECH, V33, P853, DOI 10.1016/S0021-9290(00)00020-8; WAGENAAR RC, 1992, J BIOMECH, V25, P1007, DOI 10.1016/0021-9290(92)90036-Z; WEBB D, 1994, AM J PHYS ANTHROPOL, V93, P477, DOI 10.1002/ajpa.1330930407; Wilson DJ, 1997, BRAIN INJURY, V11, P157, DOI 10.1080/026990597123610; Yelnik A, 1999, STROKE, V30, P580, DOI 10.1161/01.STR.30.3.580	30	56	59	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	APR	2008	87	4					305	310		10.1097/PHM.0b013e318168d36c			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	279TU	WOS:000254378400008	18437721				2022-02-06	
J	Martin, EM; Lu, WC; Helmick, K; French, L; Warden, DL				Martin, Elisabeth Moy; Lu, Wei C.; Helmick, Katherine; French, Louis; Warden, Deborah L.			Traumatic brain injuries sustained in the Afghanistan and Iraq wars	AMERICAN JOURNAL OF NURSING			English	Article							REHABILITATION; CLIENTS	Overview: When traumatic brain injury (TBI) occurs simultaneously with more obviously life-threatening wounds, it may go unrecognized. Civilians and military personnel working in or near combat zones are at risk for this injury. Blast-related and closed-head injuries, rather than penetrating injuries, constitute the majority of TBIs in this population. The authors describe the experiences of the Defense and Veterans Brain Injury Center team at Walter Reed Army Medical Center in Washington, DC, and present a composite case to illustrate the nurse's role in the assessment and care of the TBI patient.	[Martin, Elisabeth Moy; Lu, Wei C.; Helmick, Katherine; French, Louis; Warden, Deborah L.] Walter Reed Army Med Ctr, DVBIC, Washington, DC 20307 USA		Martin, EM (corresponding author), Walter Reed Army Med Ctr, DVBIC, Washington, DC 20307 USA.	lisamoymartin@yaboo.com	french, louis/AAB-2083-2020				CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; GOLDBERG MS, 2007, DEPUTY ASSISTANT DIR; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Martin EM, 2006, REHABIL NURS, V31, P54, DOI 10.1002/j.2048-7940.2006.tb00125.x; Martin EM, 2003, AM J NURS, V103, P75, DOI 10.1097/00000446-200310000-00036; MCCREA M, 2000, STANDARDIED ASSESSME; *NAT CTR INJ PREV, 2007, TRAUMATIC BRAIN INJU; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; SNYDER V, 2007, STATEMENT SUBCOMMITT; SUNSHINE RA, 2007, ASSISTANT DIRECTOR B; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Walker R, 2007, J HEAD TRAUMA REHAB, V22, P360, DOI 10.1097/01.HTR.0000300231.90619.50; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2005, J NEUROTRAUM, V22, P1178; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Weathers F. W., 1994, PTSD CHECKLIST CIVIL; 2007, INT HERALD TRIB 1203	23	56	59	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0002-936X			AM J NURS	Am. J. Nurs.	APR	2008	108	4					40	47		10.1097/01.NAJ.0000315260.92070.3f			8	Nursing	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Nursing	283SV	WOS:000254657700016	18367927				2022-02-06	
J	Singh, S; Smith, GA; Fields, SK; McKenzie, LB				Singh, Shubha; Smith, Gary A.; Fields, Sarah K.; McKenzie, Lara B.			Gymnastics-related injuries to children treated in emergency departments in the United States, 1990-2005	PEDIATRICS			English	Article						gymnastics; sports; injury prevention; emergency department; NEISS; children; adolescents	WOMENS GYMNASTICS; FEMALE GYMNASTS; EPIDEMIOLOGY; SPORTS; SCHOOL; ELITE	OBJECTIVE. The objective of this study was to describe the epidemiology of gymnastics-related injuries among children in the United States. METHODS. A retrospective analysis was conducted of data for children 6 through 17 years of age from the National Electronic Injury Surveillance System of the US Consumer Product Safety Commission for 1990 through 2005. Sample weights provided by the National Electronic Injury Surveillance System were used to calculate national estimates of gymnastics-related injuries. Injury rates were calculated for the most frequently occurring types of injury using gymnastics participation data. RESULTS. An estimated 425 900 children 6 through 17 years of age were treated in US hospital emergency departments for gymnastics-related injuries during the 16-year period of 1990-2005. The number of injuries averaged 26 600 annually. The number of injuries sustained per 1000 gymnastics participants per year for the pediatric population was 4.8. The number of injuries sustained per 1000 participants per year was greater for the ages 12 to 17 years ( 7.4) than for the ages 6 to 11 years ( 3.6). The place where an injury occurred include school ( 40.0%), a place of recreation or sports ( 39.7%), home ( 14.5%), or on other public property ( 5.8%). The body parts injured were upper extremity ( 42.3%), lower extremity ( 33.8%), head/ neck ( 12.9%), trunk ( 10.4%), and other ( 0.6%). Injury diagnoses were strain/ sprain ( 44.5%), fracture/ dislocation ( 30.4%), abrasion/ contusion ( 15.6%), laceration/ avulsion ( 3.7%), concussion/ closed head injury ( 1.7%), and other ( 4.2%). The majority ( 97.1%) of patients with gymnastics-related injuries were treated and released from the emergency department. CONCLUSIONS. Gymnastics has one of the highest injury rates of all girls' sports. Establishment of a national database for gymnastics-related injuries, including exposure data for direct calculation of injury rates, would permit better identification and monitoring of risk factors for gymnastics-related injuries and aid in the development, implementation, and evaluation of injury prevention strategies based on epidemiologic evidence.	[Smith, Gary A.; McKenzie, Lara B.] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; [Fields, Sarah K.] Ohio State Univ, Sch Phys Act & Educat Serv, Columbus, OH 43210 USA; [Singh, Shubha; Smith, Gary A.; McKenzie, Lara B.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA		McKenzie, LB (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	lara.mckenzie@nationwidechildrens.org	McKenzie, Lara/C-5122-2012	McKenzie, Lara/0000-0003-2889-0001			*AM SPORTS DAT INC, 2006, 2006 SUP SPORTS PART, P97; BACKX FJG, 1991, AM J SPORT MED, V19, P124, DOI 10.1177/036354659101900206; CAINE D, 1989, AM J SPORT MED, V17, P811, DOI 10.1177/036354658901700616; Caine D, 2005, MED SPORT SCI, V48, P18, DOI 10.1159/000084282; Caine D, 2006, CLIN J SPORT MED, V16, P500, DOI 10.1097/01.jsm.0000251181.36582.a0; DIXON M, 1993, MED SCI SPORT EXER, V25, P1322; GARRICK JG, 1980, AM J SPORT MED, V8, P261, DOI 10.1177/036354658000800409; *GYM SPORTS RES CT, GYMN INJ; KERR G, 1990, CAN J SPORT SCI, V15, P227; Kessler E., 1999, NEISS SAMPLE DESIGN; KOLT G, 1996, AUSTR PHYSIOTHERAPY, V42, P121; Kolt GS, 1999, BRIT J SPORT MED, V33, P312, DOI 10.1136/bjsm.33.5.312; LINDNER KJ, 1990, CAN J SPORT SCI, V15, P254; LOWRY CB, 1982, AM J SPORT MED, V10, P237, DOI 10.1177/036354658201000409; McDonald A K, 1996, Inj Prev, V2, P77, DOI 10.1136/ip.2.1.77; McGeehan J, 2004, PEDIATRICS, V114, P124, DOI 10.1542/peds.114.1.124; MCLAIN LG, 1989, PEDIATRICS, V84, P446; *NCCSI, 23 NCCSI; Ortega HW, 2004, CLIN PEDIATR, V43, P251, DOI 10.1177/000992280404300306; Ryan J, 1995, PRETTY GIRLS LITTLE; SANDS WA, 1993, AM J SPORT MED, V21, P271, DOI 10.1177/036354659302100218; Sands WA, 2000, SPORTS MED, V30, P359, DOI 10.2165/00007256-200030050-00004; Schroeder T., 2001, NEISS SAMPLE DESIGN; Shields BJ, 2006, PEDIATRICS, V117, P122, DOI 10.1542/peds.2005-1139; Smith GA, 1998, PEDIATRICS, V101, P406, DOI 10.1542/peds.101.3.406; Smith GA, 1998, ARCH PEDIAT ADOL MED, V152, P694; *SPSS INC, 2006, SPSS WIND COMP PROGR; Steele V A, 1986, Br J Sports Med, V20, P31; *USA GYMN, 2001, NEW VAULT TABL APP A; WEIKER GG, 1985, CLIN SPORT MED, V4, P39; Weiss H B, 1996, Inj Prev, V2, P166, DOI 10.1136/ip.2.2.166; Weiss H B, 1996, Inj Prev, V2, P61, DOI 10.1136/ip.2.1.61; SPORTS GEAR 101	33	56	58	0	15	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	APR	2008	121	4					E954	E960		10.1542/peds.2007-0767			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	282OJ	WOS:000254576800076	18381523				2022-02-06	
J	Forsberg, JA; Elster, EA; Andersen, RC; Nylen, E; Brown, TS; Rose, MW; Stojadinovic, A; Becker, KL; McGuigan, FX				Forsberg, Jonathan Agner; Elster, Eric A.; Andersen, Romney C.; Nylen, Eric; Brown, Trevor S.; Rose, Matthew W.; Stojadinovic, Alexander; Becker, Kenneth L.; McGuigan, Francis Xavier			Correlation of procalcitonin and cytokine expression with dehiscence of wartime extremity wounds	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							OPERATION-IRAQI-FREEDOM; VACUUM-ASSISTED CLOSURE; ORTHOPEDIC INJURIES; DIAGNOSTIC-VALUE; PRESSURE ULCERS; TOTAL HIP; SEPSIS; INFECTION; SERUM; TRAUMA	Background: Despite technological advances in the treatment of severe extremity trauma, the timing of wound closure remains the subjective clinical decision of the treating surgeon. Traditional serum markers are poor predictors of wound-healing. The objective of this study was to evaluate the cytokine and chemokine profiles of severe extremity wounds prior to closure to determine if wound effluent markers can be used to predict healing. Methods: Serum and effluent (exudate) samples were collected prospectively from adult volunteers with multiple high-energy penetrating extremity wounds sustained during military combat. Samples were collected prior to definitive wound closure or flap coverage. Wounds were followed clinically for six weeks. The primary clinical outcome measures were wound-healing and dehiscence. Control serum samples were collected from normal age and sex-matched adult volunteers. All samples were analyzed for the following cytokines and chemokines: procalcitonin; eotaxin; granulocyte macrophage colony stimulating factor; interferon (IFN)-gamma; interieukin (IL)-1 through 8, 10, 12, 13, and 15; IFN-gamma inducible protein-10; monocyte chemotactic protein-1; macrophage inflammatory protein-la; the protein regulated on activation, normal T expressed and secreted (RANTES); and tumor necrosis factor (TNF)-alpha. Results: Fifty wounds were analyzed in twenty patients. Four of the fifty wounds dehisced. An increased rate of wound dehiscence was observed in patients with a concomitant closed head injury as well as in those with an associated arterial injury of the affected limb (p < 0.05). Among the serum chemokines and cytokines, only serum procalcitonin levels correlated with wound dehiscence (p < 0.05). Effluent analysis showed that, compared with wounds that healed, wounds that dehisced were associated with elevated procalcitonin, decreased RANTES protein, and decreased IL-13 concentrations (p < 0.05). No wound with an effluent procalcitonin concentration of < 220 pg/mL, an IL-13 concentration of > 12 pg/mL, or a RANTES protein concentration of > 1000 pg/mL failed to heal. Conclusions: Effluent procalcitonin, IL-13, and RANTES protein levels as well as serum procalcitonin levels correlate with wound dehiscence following closure of severe open extremity wounds. These preliminary results indicate that effluent biomarker analysis may be an objective means of determining the timing of traumatic wound closure.	[Forsberg, Jonathan Agner; Elster, Eric A.; Andersen, Romney C.; Nylen, Eric; Brown, Trevor S.; Rose, Matthew W.; Stojadinovic, Alexander; Becker, Kenneth L.; McGuigan, Francis Xavier] Natl Naval Med Ctr, Dept Orthopaed Surg, Bethesda, MD 20889 USA		Forsberg, JA (corresponding author), Natl Naval Med Ctr, Dept Orthopaed Surg, 8901 Wisconsin Ave, Bethesda, MD 20889 USA.	onathan.forsberg@med.navy.mil	Elster, Eric A/G-2332-2010; Elster, Eric/ABG-6091-2021; Forsberg, Jonathan/K-2116-2012; Brown, Trevor/F-7392-2015	Elster, Eric/0000-0002-0981-2748; Stojadinovic, Alexander/0000-0002-2829-8967; Brown, Trevor/0000-0001-7042-785X			Arkader R, 2004, J CARDIOTHOR VASC AN, V18, P160, DOI 10.1053/j.jvca.2004.01.021; ASSICOT M, 1993, LANCET, V341, P515, DOI 10.1016/0140-6736(93)90277-N; BASSIM CW, 2007, ANN M INT ASS DENT R; BATINICA J, 1995, MIL MED, V160, P124, DOI 10.1093/milmed/160.3.124; Batty CG, 1999, MIL MED, V164, P336, DOI 10.1093/milmed/164.5.336; Becker KL, 2004, J CLIN ENDOCR METAB, V89, P1512, DOI 10.1210/jc.2002-021444; BETTIN D, 1989, Z ORTHOP GRENZGEB, V127, P518, DOI 10.1055/s-2008-1044718; Bouza E, 2006, DIAGN MICR INFEC DIS, V56, P345, DOI 10.1016/j.diagmicrobio.2006.06.012; BREIDENBACH WC, 1995, PLAST RECONSTR SURG, V95, P860, DOI 10.1097/00006534-199595050-00015; Bucalo Brian, 1993, Wound Repair and Regeneration, V1, P181, DOI 10.1046/j.1524-475X.1993.10308.x; Centers for Disease Control and Prevention, 2004, MMWR MORB MORTAL WKL, V53, P1063; Chambers LW, 2005, ARCH SURG-CHICAGO, V140, P26, DOI 10.1001/archsurg.140.1.26; Champion HR, 2003, J TRAUMA, V54, pS13, DOI 10.1097/01.TA.0000057151.02906.27; CHESNEY RW, 1983, J LAB CLIN MED, V101, P576; Covey CDC, 2002, J BONE JOINT SURG AM, V84A, P1221, DOI 10.2106/00004623-200207000-00022; DAMAS P, 1992, ANN SURG, V215, P356, DOI 10.1097/00000658-199204000-00009; Davis KA, 2005, EMERG INFECT DIS, V11, P1218, DOI 10.3201/1108.050103; Di Cesare PE, 2005, J BONE JOINT SURG AM, V87A, P1921, DOI 10.2106/JBJS.D.01803; Drugea I, 2003, METH MOLEC MED, V78, P359; Frank S, 2000, BIOCHEM J, V347, P265, DOI 10.1042/0264-6021:3470265; Gofrit ON, 1997, MIL MED, V162, P24, DOI 10.1093/milmed/162.1.24; GUNBY P, 1991, JAMA-J AM MED ASSOC, V266, P619, DOI 10.1001/jama.266.5.619; GUSTILO RB, 1984, J TRAUMA, V24, P742, DOI 10.1097/00005373-198408000-00009; Haaker R, 2004, ORTHOPADE, V33, P431, DOI 10.1007/s00132-003-0624-x; HACK CE, 1989, BLOOD, V74, P1704; Harris I R, 1995, Exp Dermatol, V4, P342, DOI 10.1111/j.1600-0625.1995.tb00058.x; Islinger RB, 2000, MIL MED, V165, P463, DOI 10.1093/milmed/165.6.463; Joseph E, 2000, WOUNDS, V12, P60; KATZ MH, 1991, J AM ACAD DERMATOL, V25, P1054, DOI 10.1016/0190-9622(91)70306-M; Kingsley Andrew, 2003, Ostomy Wound Manage, V49, P1; KRIZEK TJ, 1967, SURG FORUM, V18, P518; Ladwig GP, 2002, WOUND REPAIR REGEN, V10, P26, DOI 10.1046/j.1524-475X.2002.10903.x; LIAPPIS AP, 2007, ANN M END SOC JUN TO; Lin DL, 2004, J ORTHOP TRAUMA, V18, P300; LONDON PS, 1983, J BONE JOINT SURG BR, V65, P507, DOI 10.1302/0301-620X.65B4.6874724; Mabry RL, 2000, J TRAUMA, V49, P515, DOI 10.1097/00005373-200009000-00021; Mast Bruce A., 1996, Wound Repair and Regeneration, V4, P411, DOI 10.1046/j.1524-475X.1996.40404.x; Morgenthaler NG, 2003, HORM METAB RES, V35, P290; Muller B, 2001, J CLIN ENDOCR METAB, V86, P396, DOI 10.1210/jc.86.1.396; Nudelman R, 1983, Adv Pediatr, V30, P517; Nwomeh BC, 1998, CLIN PLAST SURG, V25, P341; Nylen E, 2003, CLIN INFECT DIS, V36, P823, DOI 10.1086/368088; Nylen ES, 1998, CRIT CARE MED, V26, P1001, DOI 10.1097/00003246-199806000-00015; Nylen ES, 2001, BEST PRACT RES CL EN, V15, P553, DOI 10.1053/beem.2001.0169; Pallister I, 2005, J AM ACAD ORTHOP SUR, V13, P93, DOI 10.5435/00124635-200503000-00002; Patel TH, 2004, J TRAUMA, V57, P201, DOI 10.1097/01.TA.0000133638.30269.38; Pinzur MS, 2003, J BONE JOINT SURG AM, V85A, P1667, DOI 10.2106/00004623-200309000-00003; Robbins Graham M, 2002, J Am Acad Orthop Surg, V10, P86; Robson M C, 1968, Surg Forum, V19, P501; Robson M C, 1970, J Surg Oncol, V2, P379, DOI 10.1002/jso.2930020410; ROBSON MC, 1969, MIL MED, V134, P19, DOI 10.1093/milmed/134.1.19; Song K M, 2001, J Am Acad Orthop Surg, V9, P166; Southwood LL, 2003, AM J VET RES, V64, P727, DOI 10.2460/ajvr.2003.64.727; SPALDING TJW, 1991, BRIT J SURG, V78, P1102, DOI 10.1002/bjs.1800780921; Spangehl MJ, 1999, J BONE JOINT SURG AM, V81A, P672, DOI 10.2106/00004623-199905000-00008; Stechmiller JK, 2006, WOUND REPAIR REGEN, V14, P371, DOI 10.1111/j.1743-6109.2006.00134.x; Szalay L, 2003, SHOCK, V20, P245, DOI 10.1097/00024382-200309000-00008; Uzzan B, 2006, CRIT CARE MED, V34, P1996, DOI 10.1097/01.CCM.0000226413.54364.36; VANDEUREN M, 1992, J PATHOL, V168, P349, DOI 10.1002/path.1711680403; Viallon A, 2000, INTENS CARE MED, V26, P1082, DOI 10.1007/s001340051321; Yager DR, 1999, WOUND REPAIR REGEN, V7, P433, DOI 10.1046/j.1524-475X.1999.00433.x; Yamaguchi M, 2003, J CELL BIOCHEM, V89, P356, DOI 10.1002/jcb.10510; Zedler S, 2006, CURR OPIN CRIT CARE, V12, P595, DOI 10.1097/MCC.0b013e3280106806; Zorrilla P, 2004, CLIN ORTHOP RELAT R, P304, DOI 10.1097/01.blo.0000126231.32385.dd	64	56	56	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0021-9355	1535-1386		J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	MAR	2008	90A	3					580	588		10.2106/JBJS.G.00265			9	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	273QJ	WOS:000253946500015	18310708				2022-02-06	
J	Maiya, B; Newcombe, V; Nortje, J; Bradley, P; Bernard, F; Chatfield, D; Outtrim, J; Hutchinson, P; Matta, B; Antoun, N; Menon, D				Maiya, Balachandra; Newcombe, Virginia; Nortje, Jurgens; Bradley, Peter; Bernard, Francis; Chatfield, Dot; Outtrim, Joanne; Hutchinson, Peter; Matta, Basil; Antoun, Nagui; Menon, David			Magnetic resonance imaging changes in the pituitary gland following acute traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						traumatic brain injury; hypopituitarism; magnetic resonance imaging	HEAD-INJURY; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; HYPOPITUITARISM; HYPOGONADISM	Objective: The objective was to study the anatomical changes in the pituitary gland following acute moderate or severe traumatic brain injury (TBI). Design: Retrospective, observational, case-control study. Setting: Neurosciences Critical Care Unit of a university hospital. Patients: Forty-one patients with moderate or severe TBI who underwent magnetic resonance imaging (MRI) during the acute phase (less than seven days) of TBI. MRI scans of 43 normal healthy volunteers were used as controls. Interventions: None. Measurements and main results: Patient demographics, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, Injury Severity Score (ISS), post-resuscitation Glasgow Coma Score (GCS), Glasgow Outcome Score (GOS), mean intracranial pressure (ICP), mean cerebral perfusion pressure (CPP), computed tomography (CT) data, pituitary gland volumes and structural lesions in the pituitary on MRI scans. The pituitary glands were significantly enlarged in the TBI group (the median and interquartile range were as follows: cases 672mm(3) (range 601-783mm3) and controls 552mm(3) (range 445-620mm(3)); p value<0.0001). APACHE II, GCS, GOS and ICP were not significantly correlated with the pituitary volume. Twelve of the 41 cases (30%) demonstrated focal changes in the pituitary gland (haemorrhage/haemorrhagic infarction (n=5), swollen gland with bulging superior margin (n=5), heterogeneous signal intensities in the anterior lobe (n=2) and partial transection of the infundibular stalk (n=1). Conclusions: Acute TBI is associated with pituitary gland enlargement with specific lesions, which are seen in approximately 30% of patients. MRI of the pituitary may provide useful information about the mechanisms involved in post-traumatic hypopituitarism.	[Maiya, Balachandra; Newcombe, Virginia; Nortje, Jurgens; Bradley, Peter; Chatfield, Dot; Outtrim, Joanne; Hutchinson, Peter; Matta, Basil; Menon, David] Univ Cambridge, Fdn Hosp NHS Trust, Div Anaesthesia, Cambridge CB2 2QQ, England; [Bernard, Francis] Univ Montreal, Sacred Heart Hosp, Montreal, PQ, Canada; [Antoun, Nagui] Univ Cambridge, Fdn Hosp NHS Trust, Dept Radiol, Cambridge CB2 2QQ, England		Maiya, B (corresponding author), Univ Cambridge, Fdn Hosp NHS Trust, Div Anaesthesia, Hills Rd,Box 93, Cambridge CB2 2QQ, England.	bm331@cam.ac.uk		Outtrim, Joanne/0000-0001-8118-6430; Newcombe, Virginia/0000-0001-6044-9035	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0601025, G0001237, G0600986, G9439390] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0601025, G0001237, G0600986] Funding Source: Medline		ADAMS JH, 1966, J NEUROL NEUROSUR PS, V29, P545, DOI 10.1136/jnnp.29.6.545; ADAMS JH, 1966, LANCET, V1, P263; Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Alexander GM, 1998, HORM BEHAV, V33, P85, DOI 10.1006/hbeh.1998.1439; BASAVARAJU N, 1989, J AM GERIATR SOC, V37, P49, DOI 10.1111/j.1532-5415.1989.tb01568.x; Benvenga Salvatore, 2005, Pituitary, V8, P193, DOI 10.1007/s11102-006-6040-6; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Ceballos R, 1966, Ala J Med Sci, V3, P185; Chang YC, 2006, J FORMOS MED ASSOC, V105, P172, DOI 10.1016/S0929-6646(09)60341-7; CLARK JDA, 1988, CLIN ENDOCRINOL, V29, P153, DOI 10.1111/j.1365-2265.1988.tb00257.x; Cryan E, 1918, DEUT MED WOCHENSCHR, V44, P1261; DANIEL P. M., 1956, QUART JOUR EXPTL PHYSIOL, V41, P215; DANIEL PM, 1959, LANCET, V2, P927; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; LAVALLEE G, 1995, AM J NEURORADIOL, V16, P1939; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Lorenzo Monica, 2005, Pituitary, V8, P233, DOI 10.1007/s11102-006-6046-0; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Rollero A, 1998, NEUROPSYCHOBIOLOGY, V38, P73, DOI 10.1159/000026520; Sassi RB, 2001, BIOL PSYCHIAT, V50, P271, DOI 10.1016/S0006-3223(01)01086-1; SHEEHAN HL, 1949, Q J MED, V18, P319; Sosin DM, 1996, BRAIN INJURY, V10, P47; WOLMAN L, 1956, J PATHOL BACTERIOL, V72, P575, DOI 10.1002/path.1700720225; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x	31	56	59	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAR	2008	34	3					468	475		10.1007/s00134-007-0902-x			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263EQ	WOS:000253200800012	18046535				2022-02-06	
J	Fernandez-Espejo, D; Junque, C; Vendrell, P; Bernabeu, M; Roig, T; Bargallo, N; Mercader, JM				Fernandez-Espejo, Davinia; Junque, Carme; Vendrell, Pere; Bernabeu, Montserrat; Roig, Teresa; Bargallo, Nuria; Mercader, Jose Maria			Cerebral response to speech in vegetative and minimally conscious states after traumatic brain injury	BRAIN INJURY			English	Article						Functional magnetic resonance imaging; minimally conscious state; traumatic brain injury; vegetative state	OWN NAME; PERSISTENT; ACTIVATION; AWARENESS; SCALE; COMA; PET	Primary objective: To study cerebral response in a functional magnetic resonance imaging (fMRI) task of speech perception in a sample of patients in vegetative state (VS) and minimally conscious state (MCS) after traumatic brain injury. Methods: Three patients in VS, four patients in MCS and 19 healthy volunteers were enrolled for the study. All subjects underwent an fMRI task of passive listening of narratives played forward and backward, alternated with periods of silence. This study analysed cerebral response to language and to complex sound processing in the healthy subjects' group and in each patient, using SPM5. Results: One patient in VS and one in MCS showed cerebral responses to language and to complex sound very similar to those shown by the healthy volunteers. Two more patients, one in VS and one in MCS, showed significant responses to complex sound only. Finally, one patient in VS and one patient in MCS failed to show significant activation in response to either stimulus. Conclusions: Some patients in VS and MCS can preserve cerebral responses to language and auditory stimuli. fMRI may be useful to identify these responses, which may pass unnoticed in a bedside examination.	[Fernandez-Espejo, Davinia; Junque, Carme; Vendrell, Pere] Univ Barcelona, IDIBAPS, Dept Psychiat & Clin Psychobiol, E-08036 Barcelona, Spain; [Fernandez-Espejo, Davinia; Junque, Carme; Vendrell, Pere; Bargallo, Nuria; Mercader, Jose Maria] IDIBAPS, Inst Biomed Res August Pi & Sunyer, Barcelona, Spain; [Bernabeu, Montserrat; Roig, Teresa] Inst Univ Neurorehabil Guttmann, Dept Neuropsychol, Badalona, Spain; [Bernabeu, Montserrat] Inst Univ Neurorehabil Guttmann, Head Injury Unit, Badalona, Spain; [Bargallo, Nuria; Mercader, Jose Maria] Hosp Clin Barcelona, CDI, Dept Radiol, Neuroradiol Sect, Barcelona, Spain		Junque, C (corresponding author), Univ Barcelona, IDIBAPS, Dept Psychiat & Clin Psychobiol, Casanova 143, E-08036 Barcelona, Spain.	cjunque@ub.edu	Junque, Carme/B-4400-2011; Fernandez-Espejo, Davinia/AAT-5481-2021; Bargallo, Nuria/G-6854-2016; Vendrell, Pere/B-4392-2011	Junque, Carme/0000-0002-6381-3063; Fernandez-Espejo, Davinia/0000-0001-5941-7546; Bargallo, Nuria/0000-0001-6284-5402; Vendrell, Pere/0000-0001-8918-5440	Spanish Ministry of Education and ScienceSpanish Government [SAF2007-66077, AP2006-00862]	This study was supported by grant SAF2007-66077 and fellowship AP2006-00862, from the Spanish Ministry of Education and Science. Part of this research work was presented at the Seventh World Congress on Brain Injury (Lisbon, 2008).	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Bernat JL, 2007, NEUROLOGY, V68, P885, DOI 10.1212/01.wnl.0000258973.95355.68; Binder JR, 2000, CEREB CORTEX, V10, P512, DOI 10.1093/cercor/10.5.512; Black D, 1996, J ROY COLL PHYS LOND, V30, P119; Boly M, 2007, NEUROIMAGE, V36, P979, DOI 10.1016/j.neuroimage.2007.02.047; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Brett M., 2002, 8 INT C FUNCT MAPP H, V16; Coleman MR, 2007, BRAIN, V130, P2494, DOI 10.1093/brain/awm170; Davis MH, 2007, P NATL ACAD SCI USA, V104, P16032, DOI 10.1073/pnas.0701309104; Dehaene-Lambertz G, 2002, SCIENCE, V298, P2013, DOI 10.1126/science.1077066; Di HB, 2007, NEUROLOGY, V68, P895, DOI 10.1212/01.wnl.0000258544.79024.d0; Eilander HJ, 2005, BRAIN INJURY, V19, P425, DOI 10.1080/02699050400025299; Friston KJ, 1996, NEUROIMAGE, V4, P223, DOI 10.1006/nimg.1996.0074; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Hagen C, 1979, REHABILITATION HEAD, P87; HAGEN C, 1984, LANGUAGE DISORDERS A, P247; JENNETT B, 1972, LANCET, V1, P734; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; Laureys S, 2006, J CLIN INVEST, V116, P1823, DOI 10.1172/JCI29172; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rousseau MC, 2008, BRAIN INJURY, V22, P123, DOI 10.1080/02699050801895415; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Shiel A, 2004, BRIT J NEUROSURG, V18, P5, DOI 10.1080/02688690410001660625; Staffen W, 2006, J NEUROL NEUROSUR PS, V77, P1383, DOI 10.1136/jnnp.2006.095166	32	56	56	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	11					882	890		10.1080/02699050802403573			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	371RT	WOS:000260849700007	18850346				2022-02-06	
J	Chibbaro, S; Tacconi, L				Chibbaro, Salvatore; Tacconi, Leonello			Role of decompressive craniectomy in the management of severe head injury with refractory cerebral edema and intractable intracranial pressure. Our experience with 48 cases	SURGICAL NEUROLOGY			English	Article						decompressive craniectomy; malignant brain edema; diffuse brain injury; refractory ICP; cranioplasty	TRAUMATIC BRAIN-INJURY; HYPERTENSION	Background: The effects of decompressive craniectomy in the treatment of severe head injury remain unclear. Only very few randomized studies relating to this topic exist in the literature, including a very small number of patients with no class I evidence. Methods: We rretrospectively reviewed a series of 221 patients operated on for a head injury during a 25-month period. Of these, 48 patients underwent a decompressive craniectomy. All data available on patients' Glasgow Coma Scale score, pupil size and reaction, and intracranial pressure were collected and analyzed. The patients' outcome was evaluated by the Glasgow Outcome Scale (GOS) and the results compared with the data available in the Traumatic Coma Data Bank. Furthermore, the results were analyzed in respect of the time of surgical intervention (early or late), age, and the preoperative Glasgow Coma Score. Results: Decompressive craniectomy reduced the midline shift in all patients with monolateral diffuse brain edema and contusions having a median value of 7 mm; in the remaining, it ameliorated the basal cisterns effacement. At a mean follow-up of 14 months, 6 (12.5%) patients died, 7 (15%) were discharged home with a GOS of 5, 18 (40%) showed a favorable outcome after rehabilitation with a GOS of 4 and 5, 6 (12.5%) had a severe disability (GOS 3), 9 (20%) were in a vegetative state (GOS 2), and 2 were lost to follow-up. The younger age, earlier surgery, and higher preoperative Glasgow Coma Scale score were related to better outcome (P < .001, P < .05, and P < .034, respectively). Conclusion: Our results seem to support the idea that decompressive craniectomy coupled with neurointensive care may be an effective way to reduce intractable raised intracranial pressure, and probably to improve patient outcome. However, it should be obvious that our results and those available in the literature can not be considered conclusive. (c) 2007 Published by Elsevier Inc.	[Chibbaro, Salvatore; Tacconi, Leonello] Univ Hosp, Dept Neurosurg, I-34100 Trieste, Italy		Chibbaro, S (corresponding author), Univ Hosp, Dept Neurosurg, I-34100 Trieste, Italy.	leonello.tacconi@aots.sanita.fvg.it	Chibbaro, Salvatore/AAI-6368-2020	tacconi, leonello/0000-0003-3915-5635; chibbaro, salvatore/0000-0003-1318-1245			Bostrom S, 2005, ACTA NEUROCHIR, V147, P279, DOI 10.1007/s00701-004-0480-4; Brain Trauma Foundation The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P527; DeWitt D S, 1995, New Horiz, V3, P376; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GAAB MR, ACTA NEUROCHIR S51, P326; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Hutchinson PJ, 2005, ACTA NEUROCHIR, V147, P1, DOI 10.1007/s00701-004-0400-7; Jennett B., 1991, NIMODIPINE PHARM CLI, P225; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kawaguchi T, 2003, NEUROL MED-CHIR, V43, P320, DOI 10.2176/nmc.43.320; KLEISTWELCH GW, 1999, J NEUROSURG, V90, P157; Koh MS, 2000, SURG NEUROL, V53, P225, DOI 10.1016/S0090-3019(00)00163-4; KUNZE E, ACTA NEUROCHIR S71, P16; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LANGFITT TW, 1976, INTRACRANIAL PRESSUR, V3, P67; LUERSSEN TG, 1989, INTRACRANIAL PRESSUR, V7, P598; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Narayan RK, 2001, NEW ENGL J MED, V344, P602, DOI 10.1056/NEJM200102223440810; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Safar P, 2001, NEW ENGL J MED, V345, P66; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; Stefini R, 1999, NEUROSURGERY, V45, P626, DOI 10.1097/00006123-199909000-00038; WHITFIELD PC, 2000, BRIT J NEUROSURG, V14, P292	32	56	61	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	DEC	2007	68	6					632	638		10.1016/j.surneu.2006.12.046			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	245NU	WOS:000251943000010	17765952				2022-02-06	
J	McCaffrey, MA; Mihalik, JP; Crowell, DH; Shields, EW; Guskiewicz, KM				McCaffrey, Meghan A.; Mihalik, Jason P.; Crowell, Dean H.; Shields, Edgar W.; Guskiewicz, Kevin M.			Measurement of head impacts in collegiate football players: Clinical measures of concussion after high- and low-magnitude impacts	NEUROSURGERY			English	Article						biomechanics; helmet; injury threshold; mild traumatic brain injury; subconcussive injury	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; POSTURAL STABILITY; SPORTS; PERFORMANCE; RECOVERY; ACCELERATION	OBJECTIVE: It has been speculated that a theoretical injury threshold of 70 to 75 g may exist for concussions in football players. We aimed to investigate acute balance and neurocognitive performance after head impacts exceeding a theoretical injury threshold in the absence of both self-reported symptoms and a concussion diagnosis 24 hours before testing. METHODS: Forty-three Division I collegiate football players participated in this double-blind, repeated-measures study. Subjects participated in three test sessions (baseline, low impact, and high impact) separated by at least 2 weeks. The Head Impact Telemetry System (Simbex, Lebanon, NH) recorded real-time head impacts sustained during practices and games. The Automated Neuropsychological Assessment Metrics assessed neurocognitive performance. The NeuroCom Sensory Organization Test (NeuroCom International Inc., Clackamas, OR) assessed postural stability. The Graded Symptom Checklist evaluated symptom presence and severity in our participants. RESULTS: After the low-impact test session (< 60 g), we observed improvements in the Math Processing (F-1,F- (26) = 9.797; P = 0.004), Matching to Sample (F-1,F- 26 = 6.504; P 0.017), and Sternberg Procedure (F-1,F- (26) = 5.323; P = 0.030) Automated Neuropsychological Assessment Metrics test modules. Statistically significant differences were also observed after the high-impact test session (> 90g) with improvements in Math Processing (F-1,F- 22 = 16.629; P < 0.001), Procedural Reaction Time (F-1,F- 22 = 14.668; P < 0.001), and the total number of symptoms reported (F-1,F- 22 = 10.267; P = 0.004). Neurocognitive improvements were likely attributed to a learning effect. CONCLUSION: Our findings suggest that sustaining an impact greater than 90 g does not result in acute observable balance and neurocognitive deficits within 24 hours of sustaining the impact. Although previous studies have suggested a theoretical injury threshold, none have been founded on empirical data collected on the playing field in real-time. Future studies should consider the cumulative effects of impacts of varying magnitudes.	[McCaffrey, Meghan A.; Mihalik, Jason P.; Shields, Edgar W.; Guskiewicz, Kevin M.] Univ N Carolina, Curriculum Human Movement, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; [Shields, Edgar W.] Univ N Carolina, Campus Hlth Serv, Div Sports Med, Chapel Hill, NC 27599 USA		Guskiewicz, KM (corresponding author), Univ N Carolina, Curriculum Human Movement, Dept Exercise & Sport Sci, 209 Fetzer Gymnasium CB 8700,S Rd, Chapel Hill, NC 27599 USA.	gus@email.unc.edu	Mihalik, Jason P/E-7059-2010	Guskiewicz, Kevin/0000-0002-8682-2130; Mihalik, Jason/0000-0001-6085-8322	NCIPC CDC HHS [5-R49-CE000196] Funding Source: Medline; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000196] Funding Source: NIH RePORTER		Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Collins Michael W, 2002, Curr Sports Med Rep, V1, P12; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; DiMasi FP, 1995, TRANSFORMATION 9 ACC; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gagnon I, 2001, J HEAD TRAUMA REHAB, V16, P595, DOI 10.1097/00001199-200112000-00007; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Levinson DM, 1997, ARCH CLIN NEUROPSYCH, V12, P155, DOI 10.1016/S0887-6177(96)00026-1; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Mueller F O, 2001, N C Med J, V62, P368; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Patel AV, 2007, J ATHL TRAINING, V42, P66; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Woodard J., 2002, J INT NEUROPSYCHOLOG, V8, P175; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	28	56	56	0	17	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2007	61	6					1236	1243		10.1227/01.neu.0000306102.91506.8b			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	246YN	WOS:000252044400034	18162903				2022-02-06	
J	Dressler, J; Hanisch, U; Kuhlisch, E; Geiger, KD				Dressler, J.; Hanisch, U.; Kuhlisch, E.; Geiger, K. D.			Neuronal and glial apoptosis in human traumatic brain injury	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						apoptosis; traumatic brain injury aging; biostatistics; immunohistochemistry	CELL-DEATH; DNA FRAGMENTATION; WHITE-MATTER; CASPASE; PATHWAYS; MECHANISMS; EXPRESSION; OCCURS	To establish reliable methods to aid the timing of brain damage after traumatic brain injury (TBI), brain tissue from 56 autopsy cases with TBI and known survival times, ranging from a few minutes to 126 days, were tested for apoptotic changes to the neuronal and glial cells. Apoptosis was established using the TdT-inediated dUTP nick end labelling (TUNEL) method of in-situ labelling and immunohistochemical reaction of caspase 3. In addition, cellular reaction and astroglial cell differentiation were investigated using histological and immunohistochemical markers. From a survival time of 120 min up to 12 days, TUNEL-positive apoptotic neuronal cells were frequently detected in the contusion zone. The earliest positive caspase 3 reaction in cortical neurons was evident after a posttraurnatic interval of 80 min. Detection of apoptotic glial cells using the TUNEL technique showed that as in the case of neuronal cells, the earliest positive TUNEL reaction was obtained after 110 min. In cases of survival times of 120 min up to 4 days, apoptotic glial cells could frequently be detected. However, the first caspase 3-positive glial cells appeared 5 h after injury. Cerebral apoptosis was significantly associated with TBI cases as compared to control cases (P < 0.001). The reference histological findings of neutrophilic granulocytes, CD3-positive T-lymphocytes, CD68-positive activated microglial cells/macrophages and TUNEL-positive neuronal cells increases the degree of certainty in determining the probable age of traumatic brain injury to 87.5%.	Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Med Legale, D-01307 Dresden, Germany; Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Med Informat & Biometry, D-01307 Dresden, Germany; Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Pathol, Dept Neuropathol, D-01307 Dresden, Germany		Dressler, J (corresponding author), Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Med Legale, D-01307 Dresden, Germany.	Jan.Dressler@tu-dresden.de					Ang BT, 2003, J NEUROSURG, V99, P125, DOI 10.3171/jns.2003.99.1.0125; Bonini P, 2004, J NEUROSCI RES, V75, P83, DOI 10.1002/jnr.10822; CROOKS DA, 1991, NEUROPATH APPL NEURO, V17, P407, DOI 10.1111/j.1365-2990.1991.tb00740.x; Davison FD, 1995, HISTOCHEM J, V27, P983; Dressler J, 2005, INT J LEGAL MED, V119, P177, DOI 10.1007/s00414-004-0480-1; DRESSLER J, 1998, RECHTSMEDIZIN S1, V8, pA25; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Fisher LD., 1993, BIOSTATISTICS METHOD; Fowler J, 2002, CLIN NEUROPATHOL, V21, P156; GEIGER KD, 1997, NEUROMETH, V29, P217; Giffard R, 2004, J BIOENERG BIOMEMBR, V36, P313, DOI 10.1023/B:JOBB.0000041760.23917.e1; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Hausmann R, 2000, INT J LEGAL MED, V113, P70, DOI 10.1007/PL00007711; Hausmann R, 2000, INT J LEGAL MED, V113, P288, DOI 10.1007/s004149900126; Hausmann R, 2006, INT J LEGAL MED, V120, P219, DOI 10.1007/s00414-005-0021-6; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; Hausmann R, 2004, INT J LEGAL MED, V118, P32, DOI 10.1007/s00414-003-0413-4; Hausmann R, 2001, INT J LEGAL MED, V114, P338, DOI 10.1007/s004140000199; Hostettler ME, 2002, GLIA, V38, P228, DOI 10.1002/glia.10065; HUMMEL K, 1972, BIOSTATISTISCHE ABST; Kam PCA, 2000, ANAESTHESIA, V55, P1081, DOI 10.1046/j.1365-2044.2000.01554.x; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; OEHMICHEN M, 2001, BRAIN HYPOXIA ISCHEM; Onaya M, 2002, NEUROPATHOLOGY, V22, P243, DOI 10.1046/j.1440-1789.2002.00456.x; Padosch SA, 2001, ANAESTHESIST, V50, P905, DOI 10.1007/s00101-001-0247-8; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Riedout HJ, 2001, HISTOL HISTOPATHOL, V16, P895, DOI 10.14670/HH-16.895; Rohn TT, 2001, AM J PATHOL, V158, P189, DOI 10.1016/S0002-9440(10)63957-0; Schallock K, 1997, CLIN NEUROPATHOL, V16, P133; Springer JE, 2001, CLIN CHEM LAB MED, V39, P299, DOI 10.1515/CCLM.2001.046; Suzuki A, 2001, HISTOL HISTOPATHOL, V16, P583, DOI 10.14670/HH-16.583; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; WITESIDE G, 1998, BRAIN RES BRAIN RES, V2, P160; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131	37	56	60	0	4	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0937-9827	1437-1596		INT J LEGAL MED	Int. J. Legal Med.	SEP	2007	121	5					365	375		10.1007/s00414-006-0126-6			11	Medicine, Legal	Science Citation Index Expanded (SCI-EXPANDED)	Legal Medicine	207IM	WOS:000249244800005	17106737				2022-02-06	
J	Beckwith, JG; Chu, JJ; Greenwald, RM				Beckwith, Jonathan G.; Chu, Jeffrey J.; Greenwald, Richard M.			Validation of a noninvasive system for measuring head acceleration for use during boxing competition	JOURNAL OF APPLIED BIOMECHANICS			English	Article						mild traumatic brain injury (MTBI); concussion; biomechanics; amateur boxing	COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; CONCUSSION; IMPACTS; TIME; ACCELEROMETERS; AMATEUR; BOXER	Although the epidemiology and mechanics of concussion in sports have been investigated for many years, the biomechanical factors that contribute to mild traumatic brain injury remain unclear because of the difficulties in measuring impact events in the field. The purpose of this study was to validate an instrumented boxing headgear (IBH) that can be used to measure impact severity and location during play. The instrumented boxing headgear data were processed to determine linear and rotational acceleration at the head center of gravity, impact location, and impact severity metrics, such as the Head Injury Criterion (HIC) and Gadd Severity Index (GSI). The instrumented boxing headgear was fitted to a Hybrid III (HIII) head form and impacted with a weighted pendulum to characterize accuracy and repeatability. Fifty-six impacts over 3 speeds and 5 locations were used to simulate blows most commonly observed in boxing. A high correlation between the HIII and instrumented boxing headgear was established for peak linear and rotational acceleration (r(2) = 0.91), HIC (r(2) = 0.88), and GSI (r(2)= 0.89). Mean location error was 9.7 5.2 degrees. Based on this study, the IBH is a valid system for measuring head acceleration and impact location that can be integrated into training and competition.	Simbex, Lebanon, NH USA; Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA		Beckwith, JG (corresponding author), Simbex, Lebanon, NH USA.						CHU JJ, 2006, PUBL C P 5 WORLD C B; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; DUMA S, 2004, AM SOC BIOM POTL OR; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; GADD CW, 1966, SOC AUTOMOTIVE ENG, P164; GERBEDING JL, 2003, STEPS PREVENT SERIOU, P1; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P287; MASTER EJT, 2000, PHYS SPORTSMEDICINE, V28; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Miele VJ, 2004, MED SCI SPORT EXER, V36, P1852, DOI 10.1249/01.MSS.0000145470.16938.7A; MITAL NK, 1979, J APPL MECH-T ASME, V46, P925, DOI 10.1115/1.3424679; Moriarity J, 2004, NEUROLOGY, V62, P1497, DOI 10.1212/WNL.62.9.1497; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Ravdin LD, 2003, CLIN J SPORT MED, V13, P21, DOI 10.1097/00042752-200301000-00005; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Withnall C, 2005, BRIT J SPORT MED, V39, pI49, DOI 10.1136/bjsm.2005.019182; Zazryn T, 2006, BRIT J SPORT MED, V40, P670, DOI 10.1136/bjsm.2006.025924; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	23	56	56	0	18	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1065-8483			J APPL BIOMECH	J. Appl. Biomech.	AUG	2007	23	3					238	244		10.1123/jab.23.3.238			7	Engineering, Biomedical; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Sport Sciences	199NR	WOS:000248703000009	18089922				2022-02-06	
J	Obenaus, A; Robbins, M; Blanco, G; Galloway, NR; Snissarenko, E; Gillard, E; Lee, S; Curras-Collazo, M				Obenaus, Andre; Robbins, Michael; Blanco, Glen; Galloway, Nicholas R.; Snissarenko, Eugene; Gillard, Elizabeth; Lee, Stefan; Curras-Collazo, Margarita			Multi-modal magnetic resonance imaging alterations in two rat models of mild neurotrauma	JOURNAL OF NEUROTRAUMA			English	Article						immunohistochemistry; apparent diffusion coefficient; T2 weighted imaging; fluid percussion; controlled cortical impact; traumatic brain injury; microglia; astrocytes	TRAUMATIC BRAIN-INJURY; LATERAL FLUID PERCUSSION; CORTICAL IMPACT INJURY; CLOSED-HEAD INJURY; TIME-COURSE; DIFFUSION; EDEMA; HISTOLOGY; HIPPOCAMPUS; PERFUSION	Magnetic resonance imaging (MRI) is increasingly used in the assessment of the severity and progression of neurotrauma. We evaluated temporal and regional changes after mild fluid percussion (FPI) and controlled cortical impact (CCI) injury using T2-weighted-imaging (T2WI) and diffusion-weighted imaging (DWI) MRI over 7 days. Region of interest analysis of brain areas distant to the injury site (such as the hippocampus, retrosplenial and piriform cortices, and the thalamus) was undertaken. In the hippocampus of CCI animals, we found a slow increase (51%) in apparent diffusion coefficients (ADC) over 72 h, which returned to control values. The hippocampal T2 values in the CCI animals were elevated by 18% over the 7-day time course compared to control, indicative of edema formation. Histological analysis supported the lack of overt cellular loss in most brain regions after mild CCI injury. FPI animals showed a generalized decrease in hippocampal ADC values over the first 72 h, which then returned to sham levels, with decreased T2 values over the same period, which remained depressed at 7 days. Histological assessment of FPI animals revealed numerous shrunken cells in the hippocampus and thalamus, but other regions showed little damage. Increased immunohistochemical staining for microglia and astroglia at 7 days post-injury was greater in FPI animals within the affected brain regions. In summary, traumatic brain injury is less severe in mild CCI than FPI, based on the temporal events assessed with MRI.	Loma Linda Univ, Dept Radiat Med, Radiobiol Program, Loma Linda, CA 92354 USA; Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA USA; Univ Calif Los Angeles, Div Neurosurg, Brain Injury Res Ctr, Los Angeles, CA USA		Obenaus, A (corresponding author), Loma Linda Univ, Dept Radiat Med, Radiobiol Program, 11175 Campus St,CSP A1010, Loma Linda, CA 92354 USA.	aobenaus@dominion.llumc.edu					Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Faden AI, 2005, NEUROPHARMACOLOGY, V49, P410, DOI 10.1016/j.neuropharm.2005.04.001; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Kadri Munaf, 2003, J Perinatol, V23, P181, DOI 10.1038/sj.jp.7210913; Kato H, 1986, No To Shinkei, V38, P295; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Maeda T, 2005, J NEUROTRAUM, V22, P763, DOI 10.1089/neu.2005.22.763; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Pirko Istvan, 2005, NeuroRx, V2, P250, DOI 10.1602/neurorx.2.2.250; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; Stroop R, 1998, ACT NEUR S, V71, P303; Thomas DL, 2000, PHYS MED BIOL, V45, pR97, DOI 10.1088/0031-9155/45/8/201; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Unterberg AW, 1997, ACT NEUR S, V70, P106; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; van Pul C, 2005, AM J NEURORADIOL, V26, P469; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Vorisek I, 2002, MAGNET RESON MED, V48, P994, DOI 10.1002/mrm.10305; Wall CJ, 2000, AM J NEURORADIOL, V21, P1841; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	36	56	56	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2007	24	7					1147	1160		10.1089/neu.2006.0211			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	186DV	WOS:000247760200006	17610354				2022-02-06	
J	Ettelt, S; Ruhrmann, S; Barnow, S; Buthz, F; Hochrein, A; Meyer, K; Kraft, S; Reck, C; Pukrop, R; Klosterkotter, J; Falkai, P; Maier, W; Wagner, M; Freyberger, HJ; Grabe, HJ				Ettelt, S.; Ruhrmann, S.; Barnow, S.; Buthz, F.; Hochrein, A.; Meyer, K.; Kraft, S.; Reck, C.; Pukrop, R.; Klosterkoetter, J.; Falkai, P.; Maier, W.; Wagner, M.; Freyberger, H. J.; Grabe, H. J.			Impulsiveness in obsessive-compulsive disorder: results from a family study	ACTA PSYCHIATRICA SCANDINAVICA			English	Article						obsessive-compulsive disorder; impulsiveness; cognitive impulsiveness; neuropsychological disinhibition	TRAUMATIC BRAIN-INJURY; EPIDEMIOLOGY; PERSONALITY; INVENTORY; SYMPTOMS	Objective: Although obsessive-compulsive disorder (OCD) is usually conceptualized as an anxiety disorder some studies suggested it to be a deficit of impulse control. The purpose of this study was to assess impulsiveness in OCD families and compare it to control families. Method: Seventy cases and their 139 relatives were compared with 70 controls and their 134 relatives from a German family study on OCD (German Epidemiologic Network for OCD Studies). All subjects were interviewed and diagnosed according DSM-IV criteria and were administered the Barratt Impulsiveness Scale (BIS) and PADUA-Inventory to assess obsessive-compulsive symptoms. Results: OCD subjects had significantly higher scores of cognitive impulsiveness. However, first-degree relatives of OCD cases and of controls had comparable BIS-11 scores. Significant associations of aggressive obsessions and checking with cognitive impulsiveness were found. Conclusion: OCD is a severe mental disorder that is characterized by a lack of cognitive inhibition. However, impulsiveness does not represent a familial trait in families of OCD subjects.	Ernst Moritz Arndt Univ Greifswald, Dept Psychiat & Psychotherapy, D-18437 Stralsund, Germany; Univ Cologne, Dept Psychiat & Psychotherapy, Cologne, Germany; Univ Bonn, Dept Psychiat & Psychotherapy, D-5300 Bonn, Germany; Univ Homburg, Dept Psychiat & Psychotherapy, D-6650 Homburg, Germany		Ettelt, S (corresponding author), Ernst Moritz Arndt Univ Greifswald, Klinikum Hansestadt Stralsund, Rostocker Chaussee 70, D-18437 Stralsund, Germany.	ettelt@uni-greifswald.de	Wagner, Michael/E-2325-2011; Falkai, Peter/E-3273-2017; Ruhrmann, Stephan/AAG-9470-2020	Wagner, Michael/0000-0003-2589-6440; Falkai, Peter/0000-0003-2873-8667; Ruhrmann, Stephan/0000-0002-6022-2364			Barratt E. S, 1985, MOTIVATION EMOTION P, V5, P137; Berthier ML, 2001, NEUROPSY NEUROPSY BE, V14, P23; Buss A.H., 1975, TEMPERAMENT THEORY P; Caci H, 2003, ACTA PSYCHIAT SCAND, V107, P34, DOI 10.1034/j.1600-0447.2003.01464.x; Chamberlain SR, 2005, NEUROSCI BIOBEHAV R, V29, P399, DOI 10.1016/j.neubiorev.2004.11.006; Denys D, 2004, J CLIN PSYCHIAT, V65, P11; DONOVAN NJ, 1994, AM J PSYCHIAT, V151, P618; Eysenck S.B, 1975, MANUAL EYSENCK PERSO; Fontenelle LE, 2005, PSYCHIAT CLIN NEUROS, V59, P30, DOI 10.1111/j.1440-1819.2005.01328.x; GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006; Grabe HJ, 2000, EUR ARCH PSY CLIN N, V250, P262, DOI 10.1007/s004060070017; GRABE HJ, 2006, IN PRESS J PSYCHIAT; Grados MA, 2003, INT REV PSYCHIATR, V15, P350, DOI 10.1080/09540260310001606737; Hand I., 1991, VERHALTENSTHER, V1, P223, DOI DOI 10.1159/000257972; HEATH AC, 1994, J PERS SOC PSYCHOL, V66, P762, DOI 10.1037/0022-3514.66.4.762; Herpertz S, 1997, NERVENARZT, V68, P171, DOI 10.1007/s001150050112; HOLLANDER E, HDB PSYCHIAQT MEASUR, P691; John U, 2001, SOZ PRAVENTIV MED, V46, P186, DOI 10.1007/BF01324255; KARNO M, 1988, ARCH GEN PSYCHIAT, V45, P1094, DOI 10.1001/archpsyc.1988.01800360042006; Ketzenberger KE, 1998, PSYCHOL REP, V83, P303, DOI 10.2466/PR0.83.5.303-306; Kochman F, 2001, PRESSE MED, V30, P1747; KOLADA JL, 1994, ACTA PSYCHIAT SCAND, V89, P24, DOI 10.1111/j.1600-0447.1994.tb05788.x; Lyoo IK, 2003, ACTA PSYCHIAT SCAND, V107, P298, DOI 10.1034/j.1600-0447.2003.00054.x; MANNUZZA S, 1986, J PSYCHIAT RES, V20, P317, DOI 10.1016/0022-3956(86)90034-8; Mannuzza S., 1985, FAMILY INFORMANT SCH; Mataix-Cols D, 2004, ARCH GEN PSYCHIAT, V61, P564, DOI 10.1001/archpsyc.61.6.564; MAX JE, 1995, J AM ACAD CHILD PSY, V34, P45, DOI 10.1097/00004583-199501000-00012; Mohammadi MR, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-2; PFOHL B, 1990, BIOL PSYCHIAT, V28, P41, DOI 10.1016/0006-3223(90)90430-A; SANAVIO E, 1988, BEHAV RES THER, V26, P169, DOI 10.1016/0005-7967(88)90116-7; Schruers K, 2005, ACTA PSYCHIAT SCAND, V111, P261, DOI 10.1111/j.1600-0447.2004.00502.x; Sieg J, 2003, VERHALTENSTHERAPIE, V13, P96, DOI 10.1159/000072182; Snider LA, 2004, MOL PSYCHIATR, V9, P900, DOI 10.1038/sj.mp.4001542; STEIN DJ, 1994, J NERV MENT DIS, V182, P240, DOI 10.1097/00005053-199404000-00009; WEISSMAN MM, 1994, J CLIN PSYCHIAT, V55, P5; ZIMMERMANN P, 2002, TESTBATTERIE AUFME 1	36	56	57	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-690X	1600-0447		ACTA PSYCHIAT SCAND	Acta Psychiatr. Scand.	JAN	2007	115	1					41	47		10.1111/j.1600-0447.2006.00835.x			7	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	117GO	WOS:000242861300007	17201865				2022-02-06	
J	Powell, T; Ekin-Wood, A; Collin, C				Powell, Trevor; Ekin-Wood, Abigail; Collin, Christine			Post-traumatic growth after head injury: A long-term follow-up	BRAIN INJURY			English	Article						post-traumatic growth; head injury; TBI; follow up; adjustment	TRAUMATIC BRAIN INJURY; SCALE	Primary objective: To investigate the time course of any positive psychological changes after traumatic brain injury (TBI) by comparing questionnaire responses in two groups of TBI survivors, early, 1-3 years post-injury and late, 10-12 years post-injury. Research design: A cross-sectional, between-group design. Method and Procedure: TBI survivors were selected from the Reading Head Injury out-patient records by date of registration, early survivors from 2002-2004 and late survivors from 1993-1996 and sent a battery of postal questionnaires. These included The Post-traumatic Growth Inventory, The Life Satisfaction Checklist and The Hospital Anxiety and Depression Scale. Individuals were also given the opportunity to answer questions about their perception of their condition and to provide free text responses to reflect best and worst advice received, to describe positive and negative changes in themselves and to identify their most useful coping strategies. Results: 61 'early' and 65 'late' people were contacted with study details and 52 consented to the study, receiving questionnaires which provided 23 'early' and 25 'late' responses. There was a significantly greater degree of post-traumatic growth, as measured on 'The Post-traumatic Growth Inventory', reported by the later group (*p = 0.000), but no other significant differences between the groups in terms of all the other variables. Both groups reported greater life satisfaction pre-injury. Conclusion: Measures of Post-traumatic Growth (Relating to Others, Personal Strength, New Possibilities, Appreciation of Life and Spirituality) appear to increase over time after head injury. This is a positive message that clinicians should note and reinforce and could help to shape future adjustment.	Berkshire Healthcare NHS Trust, Erleigh Rd Clin, Reading RG1 5LE, Berks, England; Royal Berkshire Hosp, RBBH NHS Trust, Reading, Berks, England		Powell, T (corresponding author), Berkshire Healthcare NHS Trust, Erleigh Rd Clin, 25 Erleigh Rd, Reading RG1 5LE, Berks, England.	trevor.powell@berkshire.nhs.uk					Affleck G., 1991, INFANTS CRISIS PAREN; ANDERSONPARENTE JK, 1990, COGNITIVE REHABI JAN, P22; Anke AGW, 2003, CLIN REHABIL, V17, P431, DOI 10.1191/0269215503cr629oa; [Anonymous], 2003, SPSS PC VERS 14 0 IB; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Burt M.R., 1987, J INTERPERS VIOLENCE, V2, P57, DOI [10.1177/088626087002001004, DOI 10.1177/088626087002001004]; Caplan G., 1964, PRINCIPLES PREVENTIV; COLLINS RL, 1990, SOC COGNITION, V8, P263, DOI 10.1521/soco.1990.8.3.263; Cordova MJ, 2001, HEALTH PSYCHOL, V20, P176, DOI 10.1037//0278-6133.20.3.176; Evers AWM, 2001, J CONSULT CLIN PSYCH, V69, P1026, DOI 10.1037//0022-006X.69.6.1026; Frankl V.E., 1963, MANS SEARCH MEANING; Fromm K, 1996, J BEHAV MED, V19, P221, DOI 10.1007/BF01857767; JENNETT B, 1975, LANCET, V1, P480; JOSEPH S, 1993, J TRAUMA STRESS, V6, P271, DOI 10.1002/jts.2490060209; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Linley P. A., 2000, J TRAUMA STRESS, V17, P11; MCGRATH J, 2004, 2 EUR POS PSYCH C VE; MCMILLAN JC, 1999, SOC WORK, V44, P468; MOORE A, 1993, BRAIN INJURY, V7, P247, DOI 10.3109/02699059309029677; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Park CL, 1996, J PERS, V64, P71, DOI 10.1111/j.1467-6494.1996.tb00815.x; Polatinsky S, 2000, J TRAUMA STRESS, V13, P709, DOI 10.1023/A:1007870419116; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; SBORDONE RJ, 1990, COMMUNITY INTEGRATIO; SNAPE MC, 1997, PSYCHOL HEALTH MED, V2, P237, DOI DOI 10.1080/13548509708400581; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Tedeschi R. G., 2006, HDB POSTTRAUMATIC GR; Tedeschi RG, 1996, J TRAUMA STRESS, V9, P455, DOI 10.1007/BF02103658; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	30	56	62	0	12	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2007	21	1					31	38		10.1080/02699050601106245			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	141FQ	WOS:000244564600004	17364517				2022-02-06	
J	Salehi, F; Kovacs, K; Scheithauer, BW; Pfeifer, EA; Cusimano, M				Salehi, Fateme; Kovacs, Kalman; Scheithauer, Bernd W.; Pfeifer, Eric A.; Cusimano, Michael			Histologic study of the human pituitary gland in acute traumatic brain injury	BRAIN INJURY			English	Article						histology; hypopituitarism; necrosis; pituitary; traumatic brain injury	ANTERIOR-PITUITARY; HEAD-INJURY; HYPOPITUITARISM; ABNORMALITIES; NECROSIS; LESIONS	Purpose: Approximately 25% of patients with traumatic brain injury (TBI) may develop partial or complete hypopituitarism. The causative mechanisms involved in its development are not clear. To the authors' knowledge, there have been no recent morphologic studies of the pituitary following TBI. Methods: To characterize the resultant histologic changes, this study investigated the pituitaries of 42 patients who died following a motor vehicle accident, all from the Mayo Tissue Registry. Twelve patients died instantly at the scene of the accident (Group I) whereas 30 survived between 3 hours and 7 days (Group II). All pituitary specimens were obtained at autopsy, formalin- fixed and paraffin-embedded. Hematoxylin-eosin sections cut in horizontal or sagittal plane were examined light- microscopically. Results: No infarction was noted in the pituitary specimens from group I. In group II, 13 of 30 43%) showed acute infarcts of varying size. The extent of infarction in group II ranged from focal to sub-total necrosis involving 90% of the adenohypophysis. Conclusions: Underlying adenohypophysial pathology in patients dying after TBI is acute infarction. Loss of large numbers of adenohypophysial cells causes reduced secretion of adenohypophysial hormones and may contribute to post- traumatic hypopituitarism.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Univ Toronto, St Michaels Hosp, Dept Lab Med, Toronto, ON M5B 1W8, Canada; Univ Toronto, St Michaels Hosp, Dept Neurosurg, Toronto, ON M5B 1W8, Canada		Scheithauer, BW (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, 200 1st St SW, Rochester, MN 55905 USA.	scheithauer.bernd@mayo.edu	Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650			Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J ENDOCRINOL INVEST, V28, P984, DOI 10.1007/BF03345336; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2005, THESCIENTIFICWORLDJO, V5, P777, DOI 10.1100/tsw.2005.100; Baldelli Roberto, 2005, Pituitary, V8, P255, DOI 10.1007/s11102-006-6050-4; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Benvenga Salvatore, 2005, Pituitary, V8, P193, DOI 10.1007/s11102-006-6040-6; BEVILACQUA G, 1975, ACTA NEUROPATHOL, V31, P171, DOI 10.1007/BF00688151; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Casanueva FF, 2005, J ENDOCRINOL INVEST, V28, P299; Ceballos R, 1966, Ala J Med Sci, V3, P185; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; DANIEL PM, 1959, LANCET, V2, P927; DANIEL PM, 1958, LANCET, V1, P1101; Estes Susie M, 2005, Pituitary, V8, P267, DOI 10.1007/s11102-006-6053-1; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Giordano Giulio, 2005, Pituitary, V8, P227, DOI 10.1007/s11102-006-6045-1; HARPER CG, 1986, J CLIN PATHOL, V39, P769, DOI 10.1136/jcp.39.7.769; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Lorenzo Monica, 2005, Pituitary, V8, P233, DOI 10.1007/s11102-006-6046-0; Masel Brent E, 2005, Pituitary, V8, P263, DOI 10.1007/s11102-006-6052-2; Popovic Vera, 2005, Pituitary, V8, P239, DOI 10.1007/s11102-006-6047-z; Schneider M, 2005, J NEUROTRAUM, V22, P937, DOI 10.1089/neu.2005.22.937; Sheehan HL, 1937, J PATHOL BACTERIOL, V45, P189, DOI 10.1002/path.1700450118; TREIP CS, 1970, J NEUROL NEUROSUR PS, V33, P715, DOI 10.1136/jnnp.33.5.715-a; Urban RJ, 2005, BRAIN INJURY, V19, P349, DOI 10.1080/02699050400004807; WOLMAN L, 1956, J PATHOL BACTERIOL, V72, P575, DOI 10.1002/path.1700720225; [No title captured]	31	56	61	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	6					651	656		10.1080/02699050701426956			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	192LU	WOS:000248204100012	17577716				2022-02-06	
J	Huynh, T; Jacobs, DG; Dix, S; Sing, RF; Miles, WS; Thomason, MH				Huynh, Toan; Jacobs, David G.; Dix, Stephanie; Sing, Ronald F.; Miles, William S.; Thomason, Michael H.			Utility of neurosurgical consultation for mild traumatic brain injury	AMERICAN SURGEON			English	Article; Proceedings Paper	74th Annual Scientific Meeting of the Southeastern-Surgical-Congress	FEB 18-21, 2006	Lake Buena Vista, FL	SE Surg Congress			COMPUTED-TOMOGRAPHY; HEAD TRAUMA; MANAGEMENT	Trauma patients presenting with a Glasgow Coma Scale (GCS) score of 14-15 are considered to have mild traumatic brain injury (TBI) with overall good neurologic outcomes. Current practice consists of initial stabilization, followed by a head CT, and neurosurgical consultation. Aside from serial neurologic examinations, patients with a GCS of 15 rarely require neurosurgical intervention. In this study, we examined the added value of neurosurgical consultation in the care of patients after TBI with a GCS of 15. We retrospectively reviewed the medical records of patients presenting after blunt trauma with an abnormal head CT and GCS of 15 between January 2004 and January 2005. Patients with a normal head CT and < 48 hours hospital stay were excluded. Data included demographics, mechanisms of injury, Injury Severity Score, the radiologists' dictated interpretations of the head CT, and neurosurgical interventions. Fifty-six patients met the inclusion criteria. The mean age was 41 +/- 2.3 years, and the mean Injury Severity Scores was 10.2 +/- 0.6. Mechanisms of injury included 64 per cent motor vehicle crash, 16 per cent motorcycle crash, 13 per cent fall, and 7 per cent all-terrain vehicle crash. The initial CT scans showed 43 per cent parenchymal contusions, 38 per cent subarachnoid hemorrhage, 14 per cent subdural hematomas, and 5 per cent epidural hematomas. All patients received a routine follow-up head CT, and 16 per cent showed changes (five improved and four were worse compared with initial CT scans). None of these patients received a neurosurgical intervention, and two were transferred to a rehabilitation service. In this era of limited resources, trauma patients who present with a GCS score of 15 after mild TBI can be safely managed without neurosurgical consultation, even in the presence of an abnormal head CT scan.	Carolinas Med Ctr, Sammy Ross Jr Trauma Ctr, Charlotte, NC 28232 USA		Huynh, T (corresponding author), Carolinas Med Ctr, Sammy Ross Jr Trauma Ctr, 1000 Blythe Blvd,POB 32861, Charlotte, NC 28232 USA.						Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Blostein P, 2003, J TRAUMA, V55, P450, DOI 10.1097/01.TA.0000038545.24879.4D; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X	17	56	57	0	1	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	DEC	2006	72	12					1162	1165					4	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	114OQ	WOS:000242675900005	17216813				2022-02-06	
J	Brown, CVR; Rhee, P; Neville, AL; Sangthong, B; Salim, A; Demetriades, D				Brown, Carlos V. R.; Rhee, Peter; Neville, Angela L.; Sangthong, Burapat; Salim, Ali; Demetriades, Demetrios			Obesity and traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						obesity; traumatic brain injury; head injury; blunt trauma	NECROSIS-FACTOR-ALPHA; BLUNT TRAUMA; HEAD-INJURY; INSULIN-RESISTANCE; ADIPOSE-TISSUE; MORTALITY; OUTCOMES; IMPACT; RISK	Background: As obesity continues to run rampant in our society, an understanding of its adverse effect after traumatic injury is starting to unfold. We hypothesize that obesity negatively impacts head-injured patients, and the current study intends to compare obese and lean patients with traumatic brain injury (TBI). Methods: This is a retrospective study evaluating all blunt trauma patients with TBI admitted to the intensive care unit (ICU) in our urban, Level I trauma center from 1998 until 2003. Body mass index (BMI) was used to categorize patients as either lean (BMI < 30 kg/m(2)) or obese (BMI >= 30 kg/m(2)). Admission demographics, type and severity of head injury, and associated injuries were recorded for each patient. Primary outcome was mortality, while secondary outcomes were cause of death, complications, and for survivors, days of mechanical ventilation, ICU length of stay, and hospital length of stay. Obese and lean patients were compared using univariate analysis and multivariate stepwise logistic regression. In addition, a subgroup analysis of patients with isolated head injury was performed. Results:There were 690 patients with TBI admitted to the ICU during the study period, with 129 (19%) obese patients (BMI = 34 +/- 5 kg/m(2)) and 561 (81%) lean patients (BMI = 24 +/- 4 kg/m(2)). The two groups were similar with the exceptions that obese patients were older (46 +/- 20 years versus 39 years, p < 0.01), had lower admission systolic blood pressure (125 +/- 38 mm Hg versus 134 +/- 30 mm Hg,p = 0.01), and more often sustained an associated chest injury (46% versus 35%, p = 0.03). Obese patients with TBI had a trend toward more complications (34% versus 28%, p = 0.17) and a higher mortality (36% versus 25%, p = 0.02). However, stepwise logistic regression failed to identify obesity as an independent risk factor for either morbidity or mortality. In addition, obese patients with isolated head injury had no increase in complications or death. Conclusions: Although obese patients suffer more complications and higher mortality than lean patients after TBI, this adverse effect seems to be due to age, lower admission blood pressure, and more associated chest injury, rather than a direct result of the obese state.	Univ So Calif, Los Angeles Cty Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90033 USA		Brown, CVR (corresponding author), Univ So Calif, Los Angeles Cty Med Ctr, Dept Surg, Div Trauma & Crit Care, 1200 N State St 6341, Los Angeles, CA 90033 USA.	carlosbr@usc.edu					BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BOULANGER BR, 1994, CRIT CARE CLIN, V10, P613, DOI 10.1016/S0749-0704(18)30121-0; BOULANGER BR, 1992, J TRAUMA, V33, P228, DOI 10.1097/00005373-199208000-00011; BOWERS SA, 1980, NEUROSURGERY, V6, P237; Brown CVR, 2005, J TRAUMA, V59, P1048, DOI 10.1097/01.ta.0000189047.65630.c5; BULLOCK MR, 2000, GUIDELINES MANAGEMEN; Das UN, 2001, NUTRITION, V17, P953, DOI 10.1016/S0899-9007(01)00672-4; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Engstrom G, 2003, DIABETES, V52, P2097, DOI 10.2337/diabetes.52.8.2097; Festa A, 2001, INT J OBESITY, V25, P1407, DOI 10.1038/sj.ijo.0801792; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; HORAN TC, 2004, HOSP EPIDEMIOLOGY IN, P1659; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; Mokdad AH, 2000, JAMA-J AM MED ASSOC, V284, P1650, DOI 10.1001/jama.284.13.1650; Neville AL, 2004, ARCH SURG-CHICAGO, V139, P983, DOI 10.1001/archsurg.139.9.983; SMITHCHOBAN P, 1991, J TRAUMA, V31, P1253; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972, DOI 10.1161/01.ATV.19.4.972	20	56	57	2	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2006	61	3					572	576		10.1097/01.ta.0000200842.19740.38			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	084YL	WOS:000240570200014	16966989				2022-02-06	
J	Watts, AJ; Douglas, JM				Watts, Amy J.; Douglas, Jacinta M.			Interpreting facial expression and communication competence following severe traumatic brain injury	APHASIOLOGY			English	Article							DISCOURSE; RECOGNITION; PERCEPTION; ABILITY; SKILLS	Background: Facial expression is generally understood as playing a crucial role in communication, conveying both information and emotion. This study explored the nexus between the ability to interpret facial expression and communication competence for individuals with traumatic brain injury (TBI). Aims: Three research questions were addressed. The first two questions involved a comparison of TBI and control participants on perceived communication competence, and ability to interpret facial expression. The third research question addressed whether a relationship exists between ability to interpret facial expression and perceived communication competence, in individuals with TBI. Methods & Procedures: Participants included 12 individuals with severe TBI ( PTA. 7 days), and a group of matched controls. A measure of perceived communication competence ( the La Trobe Communication Questionnaire, LCQ) and a measure related to the interpretation of facial expression ( the Emotion Evaluation Test) were administered to TBI and control participants All participants nominated a ''close-other'' who completed the close-other form of the LCQ. Outcomes & Results: Results revealed that TBI participants were perceived to have significantly more difficulties with communication than control participants ( p = .002). Similarly, results also revealed that TBI participants had significantly more difficulty interpreting facial expression than control participants (p < .001). Pearson's Correlation Coefficient ( r) calculations demonstrated a significant relationship between ability to interpret facial expression and close-other perception of communication competence ( r = 5.532). Conclusions: Results are consistent with previous research, and suggest that ability to interpret facial expression is closely related to perceived communication competence, in individuals with TBI. This understanding has implications for rehabilitation and may inform the development of treatment strategies specifically targeting impairment in the ability to read facial expression.	La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3083, Australia		Douglas, JM (corresponding author), La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3083, Australia.	J.Douglas@latrobe.edu.au	Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624; Watts, Amy/0000-0001-8790-5678			Bracy C., 2005, BRAIN IMPAIR, V6, P1, DOI DOI 10.1375/brim.6.1.1.65476; Braun C M, 1989, Brain Inj, V3, P5, DOI 10.3109/02699058909008068; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Damico J. S., 1985, COMMUNICATION SKILLS, P165; DOUGLAS J, 2004, EVIDENCE BASED PRACT; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Frattali C. M., 1995, ASHA FUNCTIONAL ASSE; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Grice H. P., 1975, SYNTAX SEMANTICS, P41; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Karow Colleen M., 2003, Seminars in Speech and Language, V24, P69, DOI 10.1055/s-2003-38900; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2000, APHASIOLOGY, V14, P339, DOI 10.1080/026870300401397; McDonald S., 2005, BRAIN IMPAIR, V6, P58, DOI [DOI 10.1375/BRIM.6.1.56.65481, 10.1375/brim.6.1.56.65481]; McDonald S., 1999, BRAIN DAM B; MCDONALD S, 2002, TVTC AWARENESS SOCIA; MCNEILLBROWN D, 1997, INT PERSPECTIVES TRA, P247; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Murdoch BE, 2001, TRAUMATIC BRAIN INJU; NOWICKI S, 1993, J SOC PSYCHOL, V133, P749, DOI 10.1080/00224545.1993.9713934; PRIGATANO GP, 1982, PERCEPT MOTOR SKILL, V54, P859, DOI 10.2466/pms.1982.54.3.859; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow P, 1997, BRAIN INJURY, V11, P409; SNOW P, 1999, BRAIN DAM B, P271; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Ylvisaker M., 2001, LANGUAGE INTERVENTIO, P745	34	56	57	0	6	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology	AUG	2006	20	8					707	722		10.1080/02687030500489953			16	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	077MM	WOS:000240033500001					2022-02-06	
J	Chamberlain, DJ				Chamberlain, DJ			The experience of surviving traumatic brain injury	JOURNAL OF ADVANCED NURSING			English	Article						disability; head injury; narrative methodologies; rehabilitation nursing; self-recovery	SCALE	Aim: This paper reports a study describing the experience of surviving traumatic brain injury as narrated by individuals 1 year after injury. Background: The experience of surviving traumatic brain injury is an individual and invisible experience. Healing and resolution of grief is still problematic for many years after injury. This experience includes those with severe injury. There is limited literature focusing on the survivor. Methodology: Sixty people with hospital admission diagnoses of traumatic brain injury were interviewed 1 year after injury using the Extended Glasgow Outcome Score questionnaire. Survivors then described their experiences of recovery. Data were collected through unstructured in-depth interviews, transcribed from audio-tapes and analysed into references. Qualitative content analysis was used to compile their frequencies from recurring themes. Findings: Sixty survivors with a median age of 35 years were enrolled in the study, with 100% follow-up. Twelve per cent returned to full preinjury functioning, 35% had residual psychosocial and physical sequelae, 38% had significant restrictions in lifestyle and work capacity, and 15% were unable to care for themselves throughout the 24-hour period. The common narratives were classified into five categories: 'regret and grief within self'; 'insensitivity of health professionals'; 'invisibility of self'; 'stranded self'; and 'recovery in self'. These self-narratives reflected renewed ways to view the self, which were conceptualized to be intact 'in spite of' or to be worthwhile 'because of' the traumatic brain injury. Conclusion: Self-narratives could be a worthwhile focus of psychological intervention by substituting positive narratives for negative ones, demonstrating hope and a positive outlook on life in order to enhance self-reflection and improve mental health. They can assist people to minimize, avoid or overcome devaluation and, as such, provide a basis for considerable nursing rehabilitation practice, even in those with severe injury.	Flinders Univ S Australia, Sch Nursing & Midwifery, Adelaide, SA 5001, Australia		Chamberlain, DJ (corresponding author), Flinders Univ S Australia, Sch Nursing & Midwifery, GPO Box 2100, Adelaide, SA 5001, Australia.	di.chamberlain@flinders.edu.au		Chamberlain, Diane/0000-0002-4157-9966			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bay E, 2002, J NURS SCHOLARSHIP, V34, P221, DOI 10.1111/j.1547-5069.2002.00221.x; Berg B.L., 1989, QUALITATIVE RES METH; Bowlby J, 1980, ATTACHMENT LOSS LOSS, V3; BUGEN LA, 1979, DEATH DYING THEORY R; Burnard P, 1991, Nurse Educ Today, V11, P461, DOI 10.1016/0260-6917(91)90009-Y; Charmaz K., 1987, RES SOCIOLOGY HLTH C, V6, P283, DOI DOI 10.1111/1467-9566.EP10491512; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); CONNOR P, 2002, HOSPITALISATION DUE; Deegan P, 1996, PSYCHIATR REHABIL J, V19, P91, DOI 10.1037/h0101301; Eadie TL, 2003, AM J SPEECH-LANG PAT, V12, P189, DOI 10.1044/1058-0360(2003/065); FOUCAULT M, 1982, CRIT INQUIRY, V8, P777, DOI 10.1086/448181; Foucault M., 1997, ETHICS SUBJECTIVITY, V1, P223, DOI DOI 10.1111/J.1083-6101.1995.TB00328.X; Foucault Michel, 1973, BIRTH CLIN ARCHAEOLO; FRAK AW, 1991, WILL BODY REFLECTION; FRANK AW, 1993, SOCIOL QUART, V34, P39, DOI 10.1111/j.1533-8525.1993.tb00129.x; FRANK AW, 1994, LIT MED, V13, P1, DOI 10.1353/lm.2011.0180; GOLDSTEIN G, 1998, REHABILITATION; JENNETT B, 1975, LANCET, V1, P480; Kothari S, 2003, J HEAD TRAUMA REHAB, V18, P379, DOI 10.1097/00001199-200307000-00008; LEVIN HS, 2000, CEREBRAL REOARGANIZA; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; NOCHI M, 2001, EVIDENCE BASED MENTA, V4, P127; RAMSAY RW, 1979, TRENDS BEHAVIOUR THE, P217; Rapp C.A., 1998, STRENGTHS MODEL CASE; RUBIN SS, 1996, CONTINUING BONDS NEW, P217; Sanders CM, 1989, GRIEF MOURNING DEALI; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Strachey James, 1957, STANDARD EDITION COM, P243; STUSS DT, 1999, COGNITIVE NEUROREHAB; Tishelman C, 1998, QUAL HEALTH RES, V8, P48, DOI 10.1177/104973239800800104; WHO, 2002, INT CLASS FUNCT DIS; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WORDEN JW, 1991, GRIEF COUNSELLING GR	36	56	56	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0309-2402	1365-2648		J ADV NURS	J. Adv. Nurs.	MAY	2006	54	4					407	417		10.1111/j.1365-2648.2006.03840.x			11	Nursing	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Nursing	038VN	WOS:000237257700001	16671970				2022-02-06	
J	Fakhry, SM; Scanlon, JM; Robinson, L; Askari, R; Watenpaugh, RL; Fata, P; Hauda, WE; Trask, A				Fakhry, SM; Scanlon, JM; Robinson, L; Askari, R; Watenpaugh, RL; Fata, P; Hauda, WE; Trask, A			Prehospital rapid sequence intubation for head trauma: Conditions for a successful program	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	18th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 11-15, 2005	Ft Lauderdale, FL	Eastern Assoc Surg Trauma		prehospital intubation; head trauma; complications; quality control	BRAIN-INJURY; ENDOTRACHEAL INTUBATION; LIFE-SUPPORT; FIELD; VENTILATION; HYPOTENSION	Background: Recent reports have questioned the safety and efficacy of prehospital rapid sequence intubation (RSI) for patients with head trauma. The purpose of this study is to determine the rate of successful prehospital RSI, associated complications, and delays in transport of critically injured trauma patients treated by a select, well-trained group of paramedics with frequent exposure to this procedure and a rigorous quality control system. Methods: A helicopter paramedic group's database of patient flight records (1999 to 2003) was merged with registry data of a suburban Level I trauma center. Both databases included comprehensive performance improvement data. After Institutional Review Board approval, data were analyzed to determine RSI success rate, impact. on oxygenation, delays in transport and complications associated with attempted RSI. Attempted RSI was defined as any insertion of the laryngoscope into the oropharynx. Results: In all, 1,117 trauma patients were transported. One hundred and seventy-five had attempted RSI (74% male, mean age 31.1 +/- 19.2 years, 91% blunt trauma, 88% with Head/Neck AIS >= 2, mean Injury Severity Score 25.6, mean scene Glasgow Coma Scale score 4.8 +/- 2.4). One hundred and sixty-nine patients (96.6%) had successful scene RSI. Seventy percent were intubated on the first attempt, 89% by the second attempt, and 96% by the third attempt. Of the six patients (3.4% overall) who failed RSI, (2.3% overall) had scene cricothyroidotomy and two (1.1% overall) were managed by bag-valve mask. Complications included five (2.9%) right mainstem intubations and 2 (1.2%) endotracheal tube dislodgments en route. There were no esophageal intubations. Four patients in extremis (2.3%) had arterial desaturations associated with RSL Arterial blood gas analyzed upon arrival revealed (mean pCO(2) 36.6 +/- 8, median 37). Attempted RSI was associated with a mean of 6 minutes of added scene time. Conclusion: Prehospital RSI for trauma patients can be safely and effectively performed with low rates of complication and without significant delay in transport. This study suggests that resources for prehospital airway management should be focused on training, regular experience, and close monitoring of a limited group of providers, thereby maximizing their exposure and experience with this procedure. This is particularly important given the high rates of traumatic brain injury encountered.	Inova Fairfax Hosp, Trauma Serv, Inova Reg Trauma Ctr, Falls Church, VA USA; George Washington Univ, Dept Surg, Med Ctr, Washington, DC 20052 USA; Fairfax Cty Police Helicopter Div, Fairfax, VA USA		Fakhry, SM (corresponding author), Inova Fairfax Hosp, Trauma Serv, Inova Reg Trauma Ctr, 3300 Gallos Rd, Falls Church, VA USA.	samir.fakhry@inova.com		Hauda II, William/0000-0003-1425-7715			Atkinson JLD, 2000, MAYO CLIN PROC, V75, P37, DOI 10.4065/75.1.37; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Davis DP, 2003, J TRAUMA, V55, P713, DOI 10.1097/01.TA.0000037428.65987.12; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Dunham CM, 2003, J TRAUMA, V55, P162, DOI 10.1097/01.ta.0000083335.93868.2c; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Helm M, 2003, BRIT J ANAESTH, V90, P327, DOI 10.1093/bja/aeg069; Helm M, 2002, BRIT J ANAESTH, V88, P345, DOI 10.1093/bja/88.3.345; Liberman M, 2000, J TRAUMA, V49, P584, DOI 10.1097/00005373-200010000-00003; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Ummenhofer Wolfgang, 2002, Curr Opin Crit Care, V8, P559, DOI 10.1097/00075198-200212000-00013; Wang HE, 2002, ANN EMERG MED, V40, P168, DOI 10.1067/mem.2002.126370; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	18	56	59	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2006	60	5					997	1001		10.1097/01.ta.0000217285.94057.5e			5	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	044NB	WOS:000237678100019	16688061				2022-02-06	
J	Schofield, PW; Butler, TG; Hollis, SJ; Smith, NE; Lee, SJ; Kelso, WM				Schofield, Peter W.; Butler, Tony G.; Hollis, Stephanie J.; Smith, Nadine E.; Lee, Stephen J.; Kelso, Wendy M.			Traumatic brain injury among Australian prisoners: Rates, recurrence and sequelae	BRAIN INJURY			English	Article						prisoners; traumatic brain injury; head injury; forensic; criminal justice system	HEAD-INJURY; PSYCHIATRIC-DISORDERS; POPULATION; PREVALENCE; BEHAVIOR; VIOLENCE; COUNTY	Primary objective: To establish the prevalence, severity, recurrence and sequelae of past traumatic brain injury (TBI) among individuals recently received into custody. Research design: Cross-sectional random sample of men recently received into the New South Wales' ( NSW) criminal justice system. Procedures: Participants were screened for a history of TBI including the injury setting, severity, treatment and sequelae of up to five separate TBI episodes. Outcomes and results: Of 200 study participants, 82% endorsed a history of at least one TBI of any severity and 65% a history of TBI with a loss of consciousness (LOC). Multiple past TBIs were common, as were ongoing sequelae. Treatment for the TBI was more common among those TBIs with a LOC compared with no LOC (66% vs .39%). Conclusions: Among individuals entering the criminal justice system, past TBI is common and often associated with ongoing neuropsychiatric and social sequelae. Screening for TBI at the point of reception may be warranted to better understand and treat those with ongoing neuropsychiatric sequelae arising from the TBI.	Ctr Hlth Res Criminal Justice, Eastgardens, NSW 2036, Australia; Univ Newcastle, Ctr Mental Hlth Studies, Newcastle, NSW 2308, Australia; Univ New S Wales, Sch Publ Hlth & Community Med, Kensington, NSW 2033, Australia		Butler, TG (corresponding author), Ctr Hlth Res Criminal Justice, Suite 302,Westfield Off Tower,152 Bunnerong Rd, Eastgardens, NSW 2036, Australia.	tbutler2@optusnet.com.au	Hollis, Stephanie J/B-5977-2011; Schofield, Peter/J-7133-2013; Butler, Tony/F-4614-2012	Butler, Tony/0000-0002-2679-2769; Schofield, Peter/0000-0001-8298-8590			ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BACHYRITA G, 1974, AM J PSYCHIAT, V131, P1015; Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; BRAGG WD, 1992, SOUTHERN MED J, V85, P365, DOI 10.1097/00007611-199204000-00007; BUTLER T, 2003, 2001 INMATE HLTH SUR; Butler T., 2004, AUSTR J HLTH PROMOTI, V15, P146; Butterworth P, 2004, J CLIN EPIDEMIOL, V57, P742, DOI 10.1016/j.jclinepi.2003.10.015; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; CORBEN S, 2004, STAT PUBLICATION, V25; Freedman D, 2000, SOC SCI MED, V50, P1757, DOI 10.1016/S0277-9536(99)00417-7; GRONWALL D, 1975, LANCET, V995, P997; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; Miller E, 1999, J FORENSIC PSYCHIATR, V10, P157, DOI 10.1080/09585189908402146; MILLER L, 1998, J COGNITIVE REHABILI, V22, P12; *NSW DEP JUV JUST, 2003, YOUNG PEOPL CUST HLT; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; *SAS I, 1999, SAS STAT SOFTW VERS; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; *SPSS INC, 2004, SPSS VERS 12 COMP PR; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; TEMPLER DI, 1992, PERCEPT MOTOR SKILL, V75, P195, DOI 10.2466/PMS.75.4.195-202; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; UALTIERI O, 1991, BRAIN INJURY, V5, P219; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x	27	56	56	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2006	20	5					499	506		10.1080/02699050600664749			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	045GO	WOS:000237730800006	16716996				2022-02-06	
J	Schonberger, M; Humle, F; Teasdale, TW				Schonberger, M; Humle, F; Teasdale, TW			The development of the therapeutic working alliance, patients' awareness and their compliance during the process of brain injury rehabilitation	BRAIN INJURY			English	Article						therapeutic working alliance; awareness; compliance; acquired brain injury; rehabilitation; process research	HEAD-INJURY; SELF-AWARENESS; DEFICITS	Purpose: To examine the development and interaction of the therapeutic alliance, patients' compliance and awareness during the process of brain injury rehabilitation and the role of demographic and injury related variables in this process. Subjects were 86 patients who underwent a holistic neuropsychological outpatient rehabilitation programme. Patients had suffered a traumatic brain injury (n = 27), a cerebrovascular accident (n = 49) or another neurological insult (n = 10). Measures: The therapeutic alliance between clients and their primary therapists, clients' awareness and their compliance were rated four times during the 14-week rehabilitation programme. The therapeutic alliance was rated by both clients and therapist using the Working Alliance Inventory (WAI), awareness and compliance were rated by the therapists. Results: The development of the process measures over time is described in the article. Clients' and therapists' perspectives on their alliance tended to converge over time. Clients' experience of their emotional bond with their therapist added as much to the prediction of clients' awareness as the localization of their brain injury. Clients' awareness was related to their compliance and mediated the impact of the therapeutic alliance on their compliance. Discussion: A good working alliance is the basis of successful rehabilitative work. The article discusses therapeutic implications of the results.	Univ Copenhagen, Ctr Rehabil Brain Injury, DK-2300 Copenhagen S, Denmark; Univ Copenhagen, Dept Psychol, DK-2300 Copenhagen, Denmark		Schonberger, M (corresponding author), Univ Copenhagen, Ctr Rehabil Brain Injury, Njalsgade 88, DK-2300 Copenhagen S, Denmark.	michael.schoenberger@psy.ku.dk					BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P33; Bieman-Copland S, 2000, BRAIN COGNITION, V44, P1; CAETANO C, 2000, INT HDB NEUROPSYCHOL, P259; CHRISTENSEN AL, 1992, ACTA NEUROL SCAND, V85, P32; CONSTANTINO MJ, 2002, WORKING ALLIANCE FLA, P81; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Fleming JM, 1996, BRAIN INJURY, V10, P1; Hatcher RL, 1999, PSYCHOTHER RES, V9, P405, DOI 10.1093/ptr/9.4.405; HORVATH AO, 1991, J COUNS PSYCHOL, V38, P139, DOI 10.1037/0022-0167.38.2.139; HORVATH AO, 1989, J COUNS PSYCHOL, V36, P223, DOI 10.1037/0022-0167.36.2.223; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; Lewis L., 1991, AWARENESS DEFICIT BR, P223; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Norcross, 2002, PSYCHOTHERAPY RELATI, P17; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; SCHONBERGER M, 2005, IN PRESS NEUROPSYCHO; Stuss D. T., 1999, COGNITIVE NEUROREHAB, P188; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; Tracey T.J., 1989, J CONSULT CLIN PSYCH, V1, P207, DOI [10.1037/1040-3590.1.3.207, DOI 10.1037/1040-3590.1.3.207, 10.1037/1040-3590.1.3.207.]; VOLMER T, 1998, COMPLIANCE SELBSTMAN, P45	28	56	57	0	13	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	2006	20	4					445	454		10.1080/02699050600664772			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	045GN	WOS:000237730700009	16716990				2022-02-06	
J	Houlden, H; Edwards, M; McNeil, J; Greenwood, R				Houlden, H; Edwards, M; McNeil, J; Greenwood, R			Use of the Barthel Index and the Functional Independence Measure during early inpatient rehabilitation after single incident brain injury	CLINICAL REHABILITATION			English	Article							STROKE; DISABILITY; RESPONSIVENESS; SCALES	Objective: To compare the appropriateness and responsiveness of the Barthel Index and the Functional Independence Measure (FIM) during early inpatient rehabilitation after single incident brain injury. Design: Cohort study. Setting: A regional neurological rehabilitation unit. Patients: Two hundred and fifty-nine consecutive patients undergoing inpatient comprehensive neurological rehabilitation following a vascular brain injury due to single cerebral infarction (n = 75), spontaneous intracerebral haemorrhage (n = 34) and subarachnoid haemorrhage (n = 43), and 107 patients who had sustained traumatic brain injury. Measurements: Admission and discharge FIM total, physical and cognitive scores and the Barthel Index were recorded. Appropriateness and responsiveness in the study samples were determined by examining score distributions and floor and ceiling effects, and by an effect size calculation respectively. Non-parametric statistical analysis was used to calculate the significance of the change in scores. Results: In all patient groups there was a significant improvement (Wilcoxon's rank sum, P < 0.0001) in the Barthel Index (mean change score: vascular 3.9, traumatic 3.95) and FIM (mean change score: vascular 17.3, traumatic 17.4) scores during rehabilitation, and similar effect sizes were found for the Barthel Index (effect size: vascular 0.65, traumatic 0.55) and FIM total (effect size: vascular 0.59, traumatic 0.48) and physical scores in all patient groups. In each patient group the cognitive component of the FIM had the smallest effect size (0.35-0.43). Conclusions: All measures were appropriate for younger (less than 65 years of age) patients undergoing early inpatient rehabilitation after single incident vascular or traumatic brain injury. The Barthel Index and the total and physical FIM scores showed similar responsiveness, whilst the cognitive FIM score was least responsive. These findings suggest that none of the FIM scores have any advantage over the Barthel Index in evaluating change in these circumstances.	Homerton Hosp, Reg Neurol Rehabil Unit, London E9 6SR, England		Greenwood, R (corresponding author), Homerton Hosp, Reg Neurol Rehabil Unit, Homerton Row, London E9 6SR, England.	Richard.Greenwood@homerton.nhs.uk	Houlden, Henry/C-1532-2008	Houlden, Henry/0000-0002-2866-7777			Bates BE, 2000, ARCH PHYS MED REHAB, V81, P1468, DOI 10.1053/apmr.2000.17808; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Desrosiers J, 2003, ARCH GERONTOL GERIAT, V37, P157, DOI 10.1016/S0167-4943(03)00044-X; Dromerick AW, 2003, J REHABIL RES DEV, V40, P1, DOI 10.1682/JRRD.2003.01.0001; Edwards MJ, 2003, DISABIL REHABIL, V25, P405, DOI 10.1080/0963828031000062642; Eng JJ, 2002, ARCH PHYS MED REHAB, V83, P483, DOI 10.1053/apmr.2002.31203; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; Hobart JC, 1996, J NEUROL S2, V243, pS25; Hoffman C, 1996, JAMA-J AM MED ASSOC, V276, P1473, DOI 10.1001/jama.276.18.1473; Holmes WC, 1997, QUAL LIFE RES, V6, P561, DOI 10.1023/A:1018464200708; Hsueh IP, 2002, J NEUROL NEUROSUR PS, V73, P188, DOI 10.1136/jnnp.73.2.188; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; Kwon S, 2004, STROKE, V35, P918, DOI 10.1161/01.STR.0000119385.56094.32; MAHONEY F I, 1965, Md State Med J, V14, P61; McMillan T. M., 1993, CLIN REHABIL, V7, P346; McPherson KM, 1997, INT J REHABIL RES, V20, P1, DOI 10.1097/00004356-199703000-00001; Novak S., 1996, CLIN REHABILITATION, V10, P128; O'Connor RJ, 2004, NEUROLOGY, V62, P1842, DOI 10.1212/01.WNL.0000116136.22922.D6; Turner-Stokes L, 1999, CLIN REHABIL, V13, P273, DOI 10.1191/026921599670005973; TURNERSTOKES L, 2003, REHABILITATION FOLLO; van der Putten JJMF, 1999, J NEUROL NEUROSUR PS, V66, P480, DOI 10.1136/jnnp.66.4.480; Wade D, 1992, MEASUREMENT NEUROLOG; Wallace D, 2002, J CLIN EPIDEMIOL, V55, P922, DOI 10.1016/S0895-4356(02)00410-9	25	56	61	0	10	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	FEB	2006	20	2					153	159		10.1191/0269215506cr917oa			7	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	015DB	WOS:000235531000008	16541936				2022-02-06	
J	[Anonymous]				[Anonymous]			Concussion (mild traumatic brain injury) and the team physician: A consensus statement	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article							NEUROPSYCHOLOGICAL TEST-PERFORMANCE; PROFESSIONAL FOOTBALL; HEAD-INJURY; SPORT	This document provides an overview of select medical issues that are important to team physicians who are responsible for athletes with concussion. It is not intended as a standard of care. and should not be interpreted as such. This document is only a guide, and as such, is of a general nature, consistent with the reasonable, objective practice of the healthcare professional. Individual treatment will turn on the specific facts and circumstances presented to the physician. Adequate insurance should be in place to help protect the physician. the athlete. and the sponsoring organization. This statement was developed by a collaboration of six major professional associations concerned about clinical sports medicine issues: they have committed to forming an ongoing project-based alliance to bring together sports medicine organizations to best serve active people and athletes. The organizations are: American Academy of Family Physicians, American Academy of Orthopaedic Surgeons, American College of Sports Medicine. American Medical Society for Sports Medicine, American Orthopaedic Society for Sports Medicine, and the American Osteopathic Academy of Sports Medicine.									*AM COLL SPORTS ME, 2001, MED SCI SPORTS EXERC, V33, P846; Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Barth JT, 1989, MILD HEAD INJURY, P257; Cantu R, 2004, LANCET NEUROL, V3, P437; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Herring SA, 2002, MED SCI SPORT EXER, V34, P1212; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; JOHNSTON K, 2002, PHYSICIAN SPORTSMED, V30, P57; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; PUTUKIAN M, 2004, ORTHO KNOWLEDGE UPDA, P29	26	56	57	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	FEB	2006	38	2					395	399		10.1249/01.mss.0000202025.48774.31			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	016SY	WOS:000235641900029	16531912				2022-02-06	
J	Laskowitz, DT; Fillit, H; Yeung, N; Toku, K; Vitek, MP				Laskowitz, D. T.; Fillit, H.; Yeung, N.; Toku, K.; Vitek, M. P.			Apolipoprotein E-derived peptides reduce CNS inflammation: implications for therapy of neurological disease	ACTA NEUROLOGICA SCANDINAVICA			English	Article; Proceedings Paper	Conference on Cholesterol, Alzheimers Disease and Statins (CAS)	APR 14-15, 2005	Stockholm, SWEDEN	Swedish Fdn Old Servants, Int Task Force Prevent Coronary Heart Dis		apolipoprotein E; inflammation; peptides; neuroprotection	GLOBAL CEREBRAL-ISCHEMIA; E-MIMETIC PEPTIDES; E-DEFICIENT MICE; APOE GENOTYPE; MICROGLIAL ACTIVATION; NEURONAL DAMAGE; TYPE-4 ALLELE; PROTEIN; BINDING; RISK	The apolipoprotein E4 isoform (apoE4) was initially identified as a susceptibility gene for the development of Alzheimer's disease, and has also recently been associated with poor outcome after acute traumatic and ischemic brain injury. One mechanism by which apoE may influence outcome in acute and chronic neurological disease is by downregulating glial activation and the neuroinflammatory response. Because it does not readily cross the blood-brain barrier (BBB), the apoE holoprotein has limited therapeutic potential. However, smaller peptides derived from the receptor binding region of apoE have been developed that mimic the functional anti-inflammatory and neuroprotective effects of the intact apoE protein. These apoE-derived therapeutic peptides cross the BBB and have been demonstrated to improve functional and histological outcomes in murine models of brain injury. Thus, the development of apoE-derived peptides represent a novel therapeutic strategy for the treatment of acute and chronic neurological disease.	Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; Inst Study Aging, New York, NY USA; Cognosci Inc, Res Triangle Pk, NC USA		Laskowitz, DT (corresponding author), Duke Univ, Med Ctr, Dept Med Neurol, Box 2900, Durham, NC 27710 USA.	danl@neuro.duke.edu		Vitek, Michael/0000-0001-8140-8048	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS4487, 5R44 NS 043954] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44NS043954] Funding Source: NIH RePORTER		ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Andersen OM, 2003, CHEMBIOCHEM, V4, P1137, DOI 10.1002/cbic.200300580; Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; AVILA EM, 1982, J BIOL CHEM, V257, P5900; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Bart RD, 1998, NEUROREPORT, V9, P2615, DOI 10.1097/00001756-199808030-00035; Colton CA, 2004, J NEUROIMMUNOL, V147, P62, DOI 10.1016/j.jneuroim.2003.10.015; Colton CA, 2002, NEUROBIOL AGING, V23, P777, DOI 10.1016/S0197-4580(02)00016-7; Colton CA, 2002, ANN NY ACAD SCI, V962, P212, DOI 10.1111/j.1749-6632.2002.tb04070.x; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Croy JE, 2004, BIOCHEMISTRY-US, V43, P7328, DOI 10.1021/bi036208p; CURTISS LK, 1981, J IMMUNOL, V126, P1382; de Bont N, 1999, J LIPID RES, V40, P680; Fleming LM, 1996, EXP NEUROL, V138, P252, DOI 10.1006/exnr.1996.0064; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GALLO G, 1994, AM J PATHOL, V145, P526; GURUNATH R, 1994, BIOCHEM BIOPH RES CO, V202, P241, DOI 10.1006/bbrc.1994.1918; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Horsburgh K, 1999, NEUROREPORT, V10, P837, DOI 10.1097/00001756-199903170-00031; Hu JR, 1998, J NEUROCHEM, V71, P1626; Laskowitz DT, 2000, J LIPID RES, V41, P613; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Laskowitz DT, 1998, NEUROREPORT, V9, P615, DOI 10.1097/00001756-199803090-00010; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; MARSHALL GR, 1990, P NATL ACAD SCI USA, V87, P487, DOI 10.1073/pnas.87.1.487; McAdoo JD, 2005, NEUROSCI LETT, V381, P305, DOI 10.1016/j.neulet.2005.02.036; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; STOLL G, 1989, GLIA, V2, P170, DOI 10.1002/glia.440020306; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WELLONS JC, 2000, NEUROSURGERY, V47, P2000	43	56	61	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.		2006	114			185			15	20		10.1111/j.1600-0404.2006.00680.x			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	069HX	WOS:000239438100004	16866906				2022-02-06	
J	Mullis, BH; Dahners, LE				Mullis, BH; Dahners, LE			Hip arthroscopy to remove loose bodies after traumatic dislocation	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						hip dislocation; hip arthroscopy; loose bodies; acetabulum; femoral head	POSTERIOR DISLOCATION; FRACTURE; BODY; JOINT	Objectives: This study was designed to review the incidence of arthroscopically detected intra-articular loose bodies found in patients after traumatic hip dislocation or small acetabular wall fracture which would not otherwise be treated without surgery. Design: Retrospective review Setting: Level 1 academic trauma center. Patients: Thirty-six patients who sustained traumatic hip injuries and subsequently had 39 hip arthroscopies between November 1997 and January 2004 were reviewed. Intervention: All patients had standard AP pelvis x-rays and CT scans performed. At our institution, patients with hip dislocations or acetabular wall fractures not otherwise requiring Surgery are routinely offered hip arthroscopy to remove loose bodies. The radiographs were reviewed to determine incidence of loose bodies or nonconcentric reduction before hip arthroscopy. Chart review provided incidence of loose bodies found during arthroscopy. Main Outcome Measurements: Comparison was made between radiographic data obtained preoperatively and operative findings. Results: Loose bodies were found in the hips of 33 of 36 patient (92%) who were arthroscoped. Loose bodies were found in 7 of 9 cases (78%) in which standard radiographic Studies (AP pelvis x-rays and CT scan) found no loose bodies and a concentric reduction. Conclusions: Loose bodies are routinely present after closed treatment of hip dislocations or wall fractures not otherwise requiring surgery, even when radiographs are negative. Hip arthroscopy may be indicated for loose body removal when open treatment is not otherwise necessary.	Univ N Carolina, Dept Orthopaed, Chapel Hill, NC 27599 USA; Florida Orthopaed Inst, Dept Orthopaed, Tampa, FL USA		Dahners, LE (corresponding author), Univ N Carolina, Dept Orthopaed, CB 7055,Room 3153, Chapel Hill, NC 27599 USA.	led@med.unc.edu	MULLIS, BRIAN/Q-3123-2019				BAIRD RA, 1982, RADIOLOGY, V145, P661, DOI 10.1148/radiology.145.3.7146393; Bartlett CS, 1998, J ORTHOP TRAUMA, V12, P294, DOI 10.1097/00005131-199805000-00014; Dahners LE, 1997, J ORTHOP TRAUMA, V11, P374, DOI 10.1097/00005131-199707000-00014; EPSTEIN HC, 1973, CLIN ORTHOP RELAT R, P116; EPSTEIN HC, 1974, J BONE JOINT SURG AM, VA 56, P1103, DOI 10.2106/00004623-197456060-00001; ERIKSSON E, 1986, ORTHOPEDICS, V9, P169; EVANS CH, 1984, ARTHRITIS RHEUM, V27, P200, DOI 10.1002/art.1780270212; FRICK SL, 1995, J ORTHOP TRAUMA, V9, P388, DOI 10.1097/00005131-199505000-00005; Glick J M, 1987, Arthroscopy, V3, P4, DOI 10.1016/S0749-8063(87)80003-8; Kashiwagi N, 2001, ARTHROSCOPY, V17, P67, DOI 10.1053/jars.2001.8024; KEENE GS, 1994, INJURY, V25, P507, DOI 10.1016/0020-1383(94)90090-6; LEVIN PE, 1998, SKELETAL TRAUMA FRAC, P1713; Routt ML, 2005, J ORTHOP TRAUMA, V19, P223; Sampson TG, 2001, CLIN SPORT MED, V20, P831, DOI 10.1016/S0278-5919(05)70288-X; Svoboda SJ, 2003, ARTHROSCOPY, V19, P777, DOI 10.1016/S0749-8063(03)00696-0; UPADHYAY SS, 1983, J BONE JOINT SURG BR, V65, P150, DOI 10.1302/0301-620X.65B2.6826619; UPADHYAY SS, 1981, J BONE JOINT SURG BR, V63, P548, DOI 10.1302/0301-620X.63B4.7298682; Yamamoto Y, 2003, ARTHROSCOPY, V19, P269, DOI 10.1053/jars.2003.50033	18	56	61	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0890-5339	1531-2291		J ORTHOP TRAUMA	J. Orthop. Trauma	JAN	2006	20	1					22	26		10.1097/01.bot.0000188038.66582.ed			5	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	014QP	WOS:000235495200005	16424806				2022-02-06	
J	von Gertten, C; Morales, AF; Holmin, S; Mathiesen, T; Nordqvist, ACS				von Gertten, C; Morales, AF; Holmin, S; Mathiesen, T; Nordqvist, ACS			Genomic responses in rat cerebral cortex after traumatic brain injury	BMC NEUROSCIENCE			English	Article							BINDING-PROTEIN-DELTA; GENE-EXPRESSION; PROTHYMOSIN-ALPHA; MICROARRAY ANALYSIS; ALTERED EXPRESSION; GROWTH-FACTOR; GLIAL-CELLS; OSTEOPONTIN; HIPPOCAMPUS; CD44	Background: Traumatic brain injury (TBI) initiates a complex sequence of destructive and neuroprotective cellular responses. The initial mechanical injury is followed by an extended time period of secondary brain damage. Due to the complicated pathological picture a better understanding of the molecular events occurring during this secondary phase of injury is needed. This study was aimed at analysing gene expression patterns following cerebral cortical contusion in rat using high throughput microarray technology with the goal of identifying genes involved in an early and in a more delayed phase of trauma, as genomic responses behind secondary mechanisms likely are time-dependent. Results: Among the upregulated genes 1 day post injury, were transcription factors and genes involved in metabolism, e. g. STAT-3, C/EBP-delta and cytochrome p450. At 4 days post injury we observed increased gene expression of inflammatory factors, proteases and their inhibitors, like cathepsins, alpha-2-macroglobulin and C1q. Notably, genes with biological function clustered to immune response were significantly upregulated 4 days after injury, which was not found following 1 day. Osteopontin and one of its receptors, CD-44, were both upregulated showing a local mRNA- and immunoreactivity pattern in and around the injury site. Fewer genes had decreased expression both 1 and 4 days post injury and included genes implicated in transport, metabolism, signalling, and extra cellular matrix formation, e. g. vitronectin, neuroserpin and angiotensinogen. Conclusion: The different patterns of gene expression, with little overlap in genes, 1 and 4 days post injury showed time dependence in genomic responses to trauma. An early induction of factors involved in transcription could lead to the later inflammatory response with strongly upregulated CD-44 and osteopontin expression. An increased knowledge of genes regulating the pathological mechanisms in trauma will help to find future treatment targets. Since trauma is a risk factor for development of neurodegenerative disease, this knowledge may also reduce late negative effects.	Karolinska Inst, Karolinska Hosp, Dept Clin Neurosci, Sect Clin CNS Res, SE-17176 Stockholm, Sweden; Karolinska Inst, Dept Mol Med, Stockholm, Sweden		von Gertten, C (corresponding author), Karolinska Inst, Karolinska Hosp, Dept Clin Neurosci, Sect Clin CNS Res, SE-17176 Stockholm, Sweden.	Christina.von.Gertten@cns.ki.se; Amilcar.Flores@molmed.ki.se; Staffan.Holmin@karolinska.se; Tiit.Mathiesen@karolinska.se; Anki.Nordqvist@cns.ki.se	mathiesen, tiit/ABC-3627-2021	Mathiesen, Tiit/0000-0001-9463-1919; Holmin, Staffan/0000-0002-1628-1615			Boan F, 2001, CYTOGENET CELL GENET, V93, P171, DOI 10.1159/000056980; Cortes-Canteli M, 2004, J BIOL CHEM, V279, P14409, DOI 10.1074/jbc.M313253200; Dang CV, 1999, MOL CELL BIOL, V19, P1; Ellison JA, 1999, ANN NY ACAD SCI, V890, P204, DOI 10.1111/j.1749-6632.1999.tb07996.x; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Flores-Morales A, 2001, ENDOCRINOLOGY, V142, P3163, DOI 10.1210/en.142.7.3163; Gao CJ, 2003, BIOCHEM BIOPH RES CO, V309, P120, DOI 10.1016/S0006-291X(03)01534-1; Huang AM, 2004, ONCOGENE, V23, P1549, DOI 10.1038/sj.onc.1207285; Ji CH, 2003, MOL ENDOCRINOL, V17, P1834, DOI 10.1210/me.2002-0235; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; Jones LL, 2000, J COMP NEUROL, V426, P468, DOI 10.1002/1096-9861(20001023)426:3<468::AID-CNE9>3.0.CO;2-I; Kakinuma Y, 1998, NAT MED, V4, P1078, DOI 10.1038/2070; Karetsou Z, 2002, EMBO REP, V3, P361, DOI 10.1093/embo-reports/kvf071; Kim MD, 2004, J NEUROIMMUNOL, V151, P78, DOI 10.1016/j.jneuroim.2004.02.014; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; KURY P, 2004, FASEB J, V29, P29; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Marshall J, 2003, NEURON, V39, P625, DOI 10.1016/S0896-6273(03)00496-3; Mathiesen T, 1995, ACTA NEUROCHIR, V137, P155, DOI 10.1007/BF02187188; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Meller R, 2005, J CEREBR BLOOD F MET, V25, P217, DOI 10.1038/sj.jcbfm.9600022; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Niquet J, 1996, GLIA, V16, P359, DOI 10.1002/(SICI)1098-1136(199604)16:4<359::AID-GLIA8>3.0.CO;2-V; NORDQVIST ACS, 1996, BRAIN RES MOL BRAIN, V38, P285; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rollo EE, 1996, J LEUKOCYTE BIOL, V60, P397, DOI 10.1002/jlb.60.3.397; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; Shin T, 2005, BRAIN RES, V1041, P95, DOI 10.1016/j.brainres.2005.02.019; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Tang Y, 2002, EUR J NEUROSCI, V15, P1937, DOI 10.1046/j.1460-9568.2002.02030.x; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang XK, 2002, J NEUROCHEM, V83, P1172, DOI 10.1046/j.1471-4159.2002.01225.x; Weber GF, 2002, J LEUKOCYTE BIOL, V72, P752; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Won JS, 2003, J NEUROSCI, V23, P7470; Yang CH, 2004, EXP CELL RES, V298, P197, DOI 10.1016/j.yexcr.2004.04.008; Zalewska T, 2003, BRAIN RES, V977, P62, DOI 10.1016/S0006-8993(03)02742-2	49	56	57	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	NOV 30	2005	6								69	10.1186/1471-2202-6-69			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	992PV	WOS:000233897100001	16318630	Green Published, gold			2022-02-06	
J	Chung, RS; Staal, JA; McCormack, GH; Dickson, TC; Cozens, MA; Chuckowree, JA; Quilty, MC; Vickers, JC				Chung, RS; Staal, JA; McCormack, GH; Dickson, TC; Cozens, MA; Chuckowree, JA; Quilty, MC; Vickers, JC			Mild axonal stretch injury in vitro induces a progressive series of neurofilament alterations ultimately leading to delayed axotomy	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; axotomy; cytoskeleton; diffuse axonal injury; neurofilament; traumatic brain injury	TRAUMATIC BRAIN-INJURY; PHYSICAL INJURY; RAT; CYTOSKELETAL; DAMAGE	We report a new model of transient axonal stretch injury involving pressurized fluid deflection of bundles of axons, resulting in a transient 1-6% increase in original axon length to investigate the slow progression of axonal alterations that are characteristic of diffuse axonal injury (DAI). We found no discernable difference in axon bundle morphology or cytoskeletal neurofilament protein arrangement between unstretched and stretched axonal bundles at 24 h post-injury. However, by 48 h post-injury, there was a stereotypical response of stretched axons involving characteristic neurorilament alterations that bear similarities to in vivo neuronal responses associated with DAI that have been reported previously. For instance, neurofilament protein immunoreactivity (SMI-312) was increased in axons contained within 51% of all injured axon bundles at 48 h compared to surrounding unstretched axon bundles, suggestive of neurofilament compaction. Furthermore, axonal bundle derangement occurred in 25% of injured axon bundles, with individual fibres segregating from each other and becoming undulating and wavy. By 72 h post-stretch, 70% of injured axon bundles underwent secondary axotomy, becoming completely severed at the site of initial stretch injury. While these results suggest a temporal series of stereotypical responses of axons to injury, we were able to distinguish very clear differences between mildly (100-103% increase in original axonal length) injured and strongly injured (106%+) axons. For instance, mildly injured axons developed increased neurofilament immunoreactivtity (SMI-312) within 48 h, and the-marked development of ring-like neurofilament immunoreactive structures within axonal bundles, which were rarely axotomized. Conversely, at more severe strain levels increased neurofilament immunoreactivity was less apparent, while axons often became distorted and disorganised within axonal bundles and eventually became completely disconnected. Almost no ring-like neurorilament structures were observed in these severely injured axonal bundles. This suggests that axons do not respond in a stereotypical manner to a transient stretch insult, and indeed that variable degrees of stretch injury activate different responses within axons, with dramatically different outcomes. Hence, it is possible that the cytoskeletal characteristics that we have used in this study may be useful parameters for discriminating between mildly and severely injured axons following TBI.	Univ Tasmania, Sch Med, NeuroRepair Grp, Hobart, Tas 7001, Australia		Chung, RS (corresponding author), Univ Tasmania, Sch Med, NeuroRepair Grp, Private Bag 58, Hobart, Tas 7001, Australia.	rschung@utas.edu.au	Vickers, James C/J-7464-2014; Chung, Roger/ABF-8395-2020	Vickers, James C/0000-0001-5671-4879; Dickson, Tracey/0000-0002-9196-1661; Chuckowree, Jyoti/0000-0002-1245-1402; Chung, Roger/0000-0002-9286-947X			Adlard PA, 2000, ACTA NEUROPATHOL, V100, P183, DOI 10.1007/s004019900160; Chuckowree JA, 2003, J NEUROSCI, V23, P3715; Chung RS, 2003, J NEUROSCI, V23, P3336; Dickson TC, 1999, EXP NEUROL, V156, P100, DOI 10.1006/exnr.1998.7010; Dickson TC, 2000, J NEUROTRAUM, V17, P1095, DOI 10.1089/neu.2000.17.1095; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; GRAY JAB, 1954, J PHYSIOL-LONDON, V124, P84, DOI 10.1113/jphysiol.1954.sp005087; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; King CE, 1997, NEUROREPORT, V8, P1663; King CE, 2001, NEUROPATH APPL NEURO, V27, P115, DOI 10.1046/j.1365-2990.2001.00317.x; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Nakayama Y, 2001, J NEUROTRAUM, V18, P545, DOI 10.1089/089771501300227341; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611	23	56	61	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2005	22	10					1081	1091		10.1089/neu.2005.22.1081			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	977ZS	WOS:000232842600005	16238485				2022-02-06	
J	Kazemi, M; Shearer, H; Choung, YS				Kazemi, M; Shearer, H; Choung, YS			Pre-competition habits and injuries in Taekwondo athletes	BMC MUSCULOSKELETAL DISORDERS			English	Article							RAPID WEIGHT-LOSS; PERFORMANCE; WRESTLERS; ANXIETY	Background: Over the past decade, there has been heightened interest in injury rates sustained by martial arts athletes, and more specifically, Taekwondo athletes. Despite this interest, there is a paucity of research on pre-competition habits and training of these athletes. The purpose of this pilot study was to assess training characteristics, competition preparation habits, and injury profiles of Taekwondo athletes. Methods: A retrospective survey of Canadian male and female Taekwondo athletes competing in a national tournament was conducted. Competitors at a Canadian national level tournament were given a comprehensive survey prior to competition. Items on training characteristics, diet, and injuries sustained during training and competition were included. Questionnaires were distributed to 60 athletes. Results: A response rate of 46.7% was achieved. Of those that responded, 54% dieted prior to competition, and 36% dieted and exercised pre-competition. Sixty-four percent of the athletes practised between 4 - 6 times per week, with 54% practicing 2 hours per session. Lower limb injuries were the most common (46.5%), followed by upper extremity (18%), back (10%), and head (3.6%). The majority of injuries consisted of sprains/strains (45%), followed by contusions, fractures, and concussions. More injuries occurred during training, including 59% of first injuries. Conclusion: More research needs to be conducted to further illustrate the need for appropriate regulations on weight cycling and injury prevention.	Canadian Mem Chiropract Coll, Toronto, ON, Canada		Kazemi, M (corresponding author), Canadian Mem Chiropract Coll, Toronto, ON, Canada.	mkazemi@cmcc.ca; hshearer@cmcc.ca; masterchoung@rogers.com					Alderman BL, 2004, MED SCI SPORT EXER, V36, P249, DOI 10.1249/01.MSS.0000113668.03443.66; [Anonymous], 2005, STEDMANS MED DICT HL; Birrer RB, 1996, AM J SPORT MED, V24, pS72, DOI 10.1177/036354659602406S21; Buschbacher R M, 1999, Phys Med Rehabil Clin N Am, V10, P35; Chapman C, 1997, PERCEPT MOTOR SKILL, V85, P1275, DOI 10.2466/pms.1997.85.3f.1275; Feehan M, 1995, BRIT J SPORT MED, V29, P258, DOI 10.1136/bjsm.29.4.258; Filaire E, 2001, INT J SPORTS MED, V22, P454, DOI 10.1055/s-2001-16244; FINKENBERG ME, 1992, PERCEPT MOTOR SKILL, V75, P239, DOI 10.2466/PMS.75.4.239-243; FOGELHOLM GM, 1993, MED SCI SPORT EXER, V25, P371, DOI 10.1249/00005768-199303000-00012; Hall CJ, 2001, BRIT J SPORT MED, V35, P390, DOI 10.1136/bjsm.35.6.390; Kazemi M, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471-2474-5-22; KOH JO, 2002, BOUNDARIES, V1, P79; Pieter W, 1999, J SPORT MED PHYS FIT, V39, P147; Smith M, 2001, INT J SPORT NUTR EXE, V11, P238, DOI 10.1123/ijsnem.11.2.238; WASLEN PE, 1993, CLIN J SPORT MED, V3, P235; Wenos DL, 1998, PERCEPT MOTOR SKILL, V87, P975, DOI 10.2466/pms.1998.87.3.975; WORRELL TW, 1994, SPORTS MED, V17, P338, DOI 10.2165/00007256-199417050-00006; Zemper E D, 1989, Br J Sports Med, V23, P161	18	56	60	0	17	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2474			BMC MUSCULOSKEL DIS	BMC Musculoskelet. Disord.	MAY 27	2005	6								26	10.1186/1471-2474-6-26			9	Orthopedics; Rheumatology	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Rheumatology	942VZ	WOS:000230312300001	15921510	Green Published, gold			2022-02-06	
J	Chen, X; Li, Y; Kline, AE; Dixon, CE; Zafonte, RD; Wagner, AK				Chen, X; Li, Y; Kline, AE; Dixon, CE; Zafonte, RD; Wagner, AK			Gender and environmental brain-derived neurotrophic effects on regional factor expression after experimental traumatic brain injury	NEUROSCIENCE			English	Article						traumatic brain injury; brain-derived neurotrophic factor; environmental enrichment; frontal cortex; hippocampus; gender	BDNF MESSENGER-RNA; RAT-BRAIN; COGNITIVE FUNCTION; PREFRONTAL CORTEX; RESPONSE ELEMENT; GENE-EXPRESSION; SPATIAL MEMORY; FEMALE RATS; ENRICHMENT; HIPPOCAMPUS	Alterations in brain-derived neurotrophic factor expression have been reported in multiple brain regions acutely after traumatic brain injury, however neither injury nor post-injury environmental enrichment has been shown to affect hippocampal brain-derived neurotrophic factor gene expression in male rats chronically post-injury. Studies have demonstrated hormone-related neuroprotection for female rats after traumatic brain injury, and estrogen and exercise both influence brain-derived neurotrophic factor levels. Despite recent studies suggesting that exposure post-traumatic brain injury to environmental enrichment improves cognitive recovery in male rats, we have shown that environmental enrichment mediated improvements with spatial learning are gender specific and only positively affect males. Therefore the purpose of this study was to evaluate the effect of gender and environmental enrichment on chronic post-injury cortical and hippocampal brain-derived neurotrophic factor protein expression. Sprague-Dawley male and cycling female rats were placed into environmental enrichment or standard housing after controlled cortical impact or sham surgery. Four weeks post-surgery, hippocampal and frontal cortex brain-derived neurotrophic factor expression were examined using Western blot. Results revealed significant increases in brain-derived neurotrophic factor expression in the frontal cortex ipsilateral to injury for males (P=0.03). Environmental enrichment did not augment this effect. Neither environmental enrichment nor injury significantly affected cortical brain-derived neurotrophic factor expression for females. In the hippocampus ipsilateral to injury brain-derived neurotrophic factor expression for both males and females was half (49% and 51% respectively) of that observed in shams housed in the standard environment. For injured males, there was a trend in this region for environmental enrichment to restore brain-derived neurotrophic factor levels to sham values. However, there were robust increases in hippocampal brain-derived neurotrophic factor expression ipsilateral to the injury for injured females in environmental enrichment compared with both sham and injured females placed in standard housing (P <= 0.005). In the hippocampus contralateral to injury, there were also significant injury related increases in brain-derived neurotrophic factor expression for females (P <= 0.05) that were not further augmented by environmental enrichment. These results show significant, region-specific gender differences in brain-derived neurotrophic factor expression with both injury and environmental enrichment that may be important for recovery. However, these data do not support a critical role for brain-derived neurotrophic factor in environmental enrichment mediated improvements with spatial learning. (c) 2005 IBRO. Published by Elsevier Ltd. All rights reserved.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD40833, R03HD41399] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD041399, K08HD040833] Funding Source: NIH RePORTER		Altar CA, 1998, TRENDS NEUROSCI, V21, P433, DOI 10.1016/S0166-2236(98)01273-9; Belz EE, 2003, PHARMACOL BIOCHEM BE, V76, P481, DOI 10.1016/j.pbb.2003.09.005; Berchtold NC, 2001, EUR J NEUROSCI, V14, P1992, DOI 10.1046/j.0953-816x.2001.01825.x; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Bontke CF, 1996, PHYS MED REHABILITAT, P1027; Conner JM, 1997, J NEUROSCI, V17, P2295; Dahlqvist P, 2004, EUR J NEUROSCI, V19, P2288, DOI 10.1111/j.0953-816X.2004.03248.x; de Oliveira RWD, 2003, PSYCHOPHARMACOLOGY, V170, P51, DOI 10.1007/s00213-003-1511-1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Gibbs RB, 1998, BRAIN RES, V787, P259, DOI 10.1016/S0006-8993(97)01511-4; Gillespie LN, 2003, CLIN EXP PHARMACOL P, V30, P724, DOI 10.1046/j.1440-1681.2003.03909.x; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; Johansson BB, 2004, RESTOR NEUROL NEUROS, V22, P163; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Lee I, 2003, J NEUROSCI, V23, P1517, DOI 10.1523/JNEUROSCI.23-04-01517.2003; Lu B, 1997, REV NEUROSCIENCE, V8, P1; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Rampon C, 2000, P NATL ACAD SCI USA, V97, P12880, DOI 10.1073/pnas.97.23.12880; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Schaaf MJM, 1998, BRAIN RES, V813, P112, DOI 10.1016/S0006-8993(98)01010-5; Singh M, 1999, J NEUROSCI, V19, P1179; Sobreviela T, 1996, J COMP NEUROL, V375, P417; SOHRABJI F, 1995, P NATL ACAD SCI USA, V92, P11110, DOI 10.1073/pnas.92.24.11110; Torasdotter M, 1996, NEUROSCI LETT, V218, P107, DOI 10.1016/S0304-3940(96)13127-X; Turner CA, 2003, PHYSIOL BEHAV, V80, P259, DOI 10.1016/j.physbeh.2003.07.008; Vafaei AA, 2004, BEHAV BRAIN RES, V149, P61, DOI 10.1016/S0166-4328(03)00209-2; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Widenfalk J, 1999, NEUROSCI RES, V34, P125, DOI 10.1016/S0168-0102(99)00051-6; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Zhao LR, 2000, NEUROSCIENCE, V97, P177, DOI 10.1016/S0306-4522(00)00023-3; Zhou Y, 1996, ENDOCRINOLOGY, V137, P2163, DOI 10.1210/en.137.5.2163	38	56	59	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2005	135	1					11	17		10.1016/j.neuroscience.2005.05.041			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	965GP	WOS:000231938900002	16084663				2022-02-06	
B	DeLuca, J		DeLuca, J		DeLuca, John			Fatigue, Cognition, and Mental Effort	FATIGUE AS A WINDOW TO THE BRAIN	Issues in Clinical and Cognitive Neuropsychology		English	Article; Book Chapter							MULTIPLE-SCLEROSIS PATIENTS; TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; CORTICAL ACTIVATION; BASAL GANGLIA; PERFORMANCE; IMPAIRMENT; MRI; ATTENTION; TASK		[DeLuca, John] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; [DeLuca, John] Kessler Med Rehabil Res & Educ Corp, Neurosci Res, W Orange, NJ USA		DeLuca, J (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, 185 S Orange Ave, Newark, NJ 07103 USA.						Abe K, 2000, BEHAV NEUROL, V12, P103, DOI 10.1155/2000/580683; Bakshi R, 1999, NEUROLOGY, V53, P1151, DOI 10.1212/WNL.53.5.1151; Beaumont M, 2001, J SLEEP RES, V10, P265, DOI 10.1046/j.1365-2869.2001.00266.x; BELZA BL, 1993, NURS RES, V42, P93; Blackwood SK, 1998, J NEUROL NEUROSUR PS, V65, P541, DOI 10.1136/jnnp.65.4.541; Brassington JC, 1998, NEUROPSYCHOL REV, V8, P43, DOI 10.1023/A:1025621700003; BRITTAIN JL, 1991, CLIN NEUROPSYCHOL, V5, P163, DOI DOI 10.1080/13854049108403300; Broadbent D. E., 1971, DECISION STRESS; BRUNO RL, 1993, ARCH PHYS MED REHAB, V74, P1061, DOI 10.1016/0003-9993(93)90062-F; Bryant D, 2004, REHABIL PSYCHOL, V49, P114, DOI 10.1037/0090-5550.49.2.114; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; Chiaravalloti ND, 2003, CLIN REHABIL, V17, P58, DOI 10.1191/0269215503cr586oa; CHIARAVALLOTI ND, J CLIN EXPT IN PRESS; Chollet Francois, 1994, Current Opinion in Neurobiology, V4, P226, DOI 10.1016/0959-4388(94)90077-9; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Claypoole K, 2001, Appl Neuropsychol, V8, P31, DOI 10.1207/S15324826AN0801_5; Colombo B, 2000, J NEUROL, V247, P506, DOI 10.1007/s004150070148; Elkins L E, 2000, Semin Clin Neuropsychiatry, V5, P58; Filippi M, 2002, NEUROIMAGE, V15, P559, DOI 10.1006/nimg.2001.1011; Fisk JD, 2001, J INT NEUROPSYCH SOC, V7, P363, DOI 10.1017/S1355617701733103; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Gandevia S, 1995, FATIGUE NEURAL MUSCU; Heesen C, 2002, PSYCHONEUROENDOCRINO, V27, P505, DOI 10.1016/S0306-4530(01)00071-3; Herndon R. M., 2003, MULTIPLE SCLEROSIS I; Hillary FG, 2003, J CLIN EXP NEUROPSYC, V25, P965, DOI 10.1076/jcen.25.7.965.16490; Iriarte J, 2000, MULT SCLER, V6, P124, DOI 10.1191/135245800678827572; JENNEKENSSCHINKEL A, 1988, J NEUROL SCI, V85, P173, DOI 10.1016/0022-510X(88)90154-2; Johnson S K, 1997, Appl Neuropsychol, V4, P145, DOI 10.1207/s15324826an0403_1; Johnson SK, 1998, COGNITIVE NEUROPSYCH, V3, P269, DOI DOI 10.1080/135468098396099; KINKEL RP, 2000, INT J MS CARE S  OCT; KOMAROFF AL, 1991, REV INFECT DIS, V13, pS8; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Krupp LB, 2000, NEUROLOGY, V55, P934, DOI 10.1212/WNL.55.7.934; KUJALA P, 1995, J NEUROL NEUROSUR PS, V59, P77, DOI 10.1136/jnnp.59.1.77; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lamanca John J., 1998, American Journal of Medicine, V105, p59S, DOI 10.1016/S0002-9343(98)00171-5; LANGE G, CHRONIC FATIGU UNPUB; Leocani L, 2001, NEUROIMAGE, V13, P1186, DOI 10.1006/nimg.2001.0759; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Lorist MM, 2000, PSYCHOPHYSIOLOGY, V37, P614, DOI 10.1111/1469-8986.3750614; Lorist MM, 2002, J PHYSIOL-LONDON, V545, P313, DOI 10.1113/jphysiol.2002.027938; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Michiels V, 2001, ACTA PSYCHIAT SCAND, V103, P84, DOI 10.1034/j.1600-0447.2001.00017.x; Millikin CP, 2003, J CLIN EXP NEUROPSYC, V25, P201, DOI 10.1076/jcen.25.2.201.13644; Morris TL, 1996, BIOL PSYCHOL, V42, P343, DOI 10.1016/0301-0511(95)05166-X; Mosso Angelo, 1904, FATIGUE; Neri DF, 2002, AVIAT SPACE ENVIR MD, V73, P654; NEWSHOLME EA, 1995, FATIGUE NEURAL MUSCU, V5, P315; Parmenter BA, 2003, MULT SCLER, V9, P111, DOI 10.1191/1352458503ms859oa; Paul MA, 2001, AVIAT SPACE ENVIR MD, V72, P965; Paul RH, 1998, APPL NEUROPSYCHOL, V5, P143, DOI 10.1207/s15324826an0503_5; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; Riese H, 1999, NEUROPSYCHOL REHABIL, V9, P189, DOI 10.1080/713755600; Roelcke U, 1997, NEUROLOGY, V48, P1566, DOI 10.1212/WNL.48.6.1566; SANDRONI P, 1992, ARCH NEUROL-CHICAGO, V49, P517, DOI 10.1001/archneur.1992.00530290105019; Schmaling KB, 2003, PSYCHOSOM MED, V65, P129, DOI 10.1097/01.PSY.0000038942.33335.9B; Schultheis MT, 2001, NEUROLOGY, V56, P1089, DOI 10.1212/WNL.56.8.1089; Schwartz CE, 1996, ARCH PHYS MED REHAB, V77, P165, DOI 10.1016/S0003-9993(96)90162-8; Schwid SR, 2003, MULT SCLER, V9, P503, DOI 10.1191/1352458503ms946oa; Sheean GL, 1997, BRAIN, V120, P299, DOI 10.1093/brain/120.2.299; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; SNYDER PJ, 1993, J CLIN EXP NEUROPSYC, V15, P18; Staffen W, 2002, BRAIN, V125, P1275, DOI 10.1093/brain/awf125; STOKES MJ, 1988, BRIT MED J, V297, P1014, DOI 10.1136/bmj.297.6655.1014; Tietzel AJ, 2002, J SLEEP RES, V11, P213, DOI 10.1046/j.1365-2869.2002.00299.x; van der Linden D, 2003, ACTA PSYCHOL, V113, P45, DOI 10.1016/S0001-6918(02)00150-6; Wessely S, 1998, CHRONIC FATIGUE ITS	69	56	56	0	2	M I T PRESS	CAMBRIDGE	FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA			978-0-262-25135-8	ISS CLIN COGN NEUROP			2005							37	57					21	Neurosciences; Psychiatry; Psychology	Book Citation Index – Science (BKCI-S)	Neurosciences & Neurology; Psychiatry; Psychology	BPS59	WOS:000279778900005					2022-02-06	
J	Lu, DY; Mahmood, A; Goussev, A; Qu, CS; Zhang, ZG; Chopp, M				Lu, DY; Mahmood, A; Goussev, A; Qu, CS; Zhang, ZG; Chopp, M			Delayed thrombosis after traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						atorvastatin; delayed thrombosis; rat; traumatic brain injury	COA REDUCTASE INHIBITORS; CENTRAL-NERVOUS-SYSTEM; VON-WILLEBRAND-FACTOR; ACUTE HEAD-INJURY; TISSUE FACTOR; INTRAVASCULAR COAGULATION; PLATELET ACTIVATION; CEREBRAL-ISCHEMIA; ATORVASTATIN; EXPRESSION	Secondary thrombosis may contribute to cerebral ischemia caused by traumatic brain injury (TBI). In this study, we sought to investigate the temporal and spatial profiles of intravascular thrombosis and to evaluate the effect of atorvastatin, a beta-hydroxy-beta-methylglutaryl coenzyme-A (HMG-CoA) reductase inhibitor, on thrombosis after TBI. Young male Wistar rats weighing 350-400 g were subjected to controlled cortical impact injury, and were sacrificed at 1 and 4 h, and 1, 3, 8, and 15 days after TBI (5 rats/time point), respectively. For the evaluation of the effects of atorvastatin on intravascular thrombosis, rats were subjected to TBI, and subsequently atorvastatin (1 mg/kg) was orally administered starting 1 day after TBI and then daily until sacrifice at 3, 8, and 15 days after TBI (5 rats/time point). Before sacrifice of animals, blood was withdrawn and employed for the measurement of von Willibrand factor and platelet activity using enzyme-linked immunoabsorbant assay (ELISA). Brain tissues were prepared for histological analysis. The data show that (1) delayed thrombosis is present in the lesion boundary zone and in the hippocampal CA3 region, starting at 1-4 h, peaking at 1-3 days, and then declining at 8 and 15 days after TBI; (2) intravascular thrombosis also occurs in the other areas of cortex, striatum, and corpus callosum, but with a scattered distribution; (3) delayed thrombi are composed of platelets, fibrin, and vWF; and (4) reduction of the plasma vWF level and platelet activity by atorvastatin decreases delayed thrombosis after TBI. These data suggest that atorvastatin reduces intravascular thrombosis attributed to hemostatic disturbances caused by TBI.	Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Oakland Univ, Dept Phys, Rochester, MI 48063 USA		Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, 2799 W Brand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS40225] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [P01 42345] Funding Source: Medline		Atalar E, 2002, INT J CARDIOL, V84, P227, DOI 10.1016/S0167-5273(02)00148-1; AUER L, 1978, ACTA NEUROCHIR, V43, P51, DOI 10.1007/BF01809225; Barron E., 1992, Society for Neuroscience Abstracts, V18, P1492; Bellosta S, 2000, ANN MED, V32, P164, DOI 10.3109/07853890008998823; Bocan Thomas M A, 2002, Curr Opin Investig Drugs, V3, P1312; Bostrom K, 1986, Acta Neurochir Suppl (Wien), V36, P51; Bourcier T, 2000, ARTERIOSCL THROM VAS, V20, P556, DOI 10.1161/01.ATV.20.2.556; Bruni F, 2003, CLIN EXP MED, V3, P45, DOI 10.1007/s102380300015; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Cortellaro M, 2002, THROMB HAEMOSTASIS, V88, P41; Cortiana M, 1986, J Neurosurg Sci, V30, P133; CUNNINGHAM DD, 1993, THROMB HAEMOSTASIS, V70, P168; de Groot PG, 2002, SEMIN THROMB HEMOST, V28, P133, DOI 10.1055/s-2002-27815; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dujovne CA, 2000, AM J CARDIOL, V85, P350, DOI 10.1016/S0002-9149(99)00745-6; EDDLESTON M, 1993, J CLIN INVEST, V92, P349, DOI 10.1172/JCI116573; Eto M, 2003, ENDOTHELIUM-J ENDOTH, V10, P35, DOI 10.1080/10623320303359; FURIE B, 1992, NEW ENGL J MED, V326, P800; GADDAM V, J CARDIOVASC PHARM T, V7, P247; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GonzalezDunia D, 1996, J VIROL, V70, P5812, DOI 10.1128/JVI.70.9.5812-5820.1996; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOOTS WK, 1996, NEUROTRAUMA, P673; Jackson SP, 2003, J THROMB HAEMOST, V1, P1602, DOI 10.1046/j.1538-7836.2003.00267.x; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Joukhadar C, 2001, THROMB HAEMOSTASIS, V85, P47, DOI 10.1055/s-0037-1612902; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; Kaufmann CR, 1997, J TRAUMA, V42, P716, DOI 10.1097/00005373-199704000-00023; Krysiak R, 2003, DRUGS, V63, P1821, DOI 10.2165/00003495-200363170-00005; Lafuente JV, 1999, J NEUROTRAUM, V16, P425, DOI 10.1089/neu.1999.16.425; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; Laufs U, 2003, EUR J CLIN PHARMACOL, V58, P719, DOI 10.1007/s00228-002-0556-0; Laufs U, 2003, ARTERIOSCL THROM VAS, V23, P156, DOI 10.1161/01.ATV.0000051360.79309.4E; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Meisel SR, 2003, CLIN LAB HAEMATOL, V25, P321, DOI 10.1046/j.1365-2257.2003.00544.x; Morikawa Shigeru, 2002, J Atheroscler Thromb, V9, P178; Muellner A, 2003, J NEUROTRAUM, V20, P745, DOI 10.1089/089771503767869971; Murshid WR, 2002, BRIT J NEUROSURG, V16, P362, DOI 10.1080/0268869021000007597; Ninomia T, 2000, J CEREBR BLOOD F MET, V20, P998, DOI 10.1097/00004647-200006000-00012; Nordoy A, 2003, J THROMB HAEMOST, V1, P690, DOI 10.1046/j.1538-7836.2003.00140.x; Pearl GS, 1998, CLIN LAB MED, V18, P39; Pokrovskaya EV, 2003, KARDIOLOGIYA, V43, P4; Puccetti L, 2002, EUR J CLIN INVEST, V32, P901, DOI 10.1046/j.1365-2362.2002.01086.x; Ruggeri ZM, 2003, J THROMB HAEMOST, V1, P1335, DOI 10.1046/j.1538-7836.2003.00260.x; Seljeflot I, 2002, ATHEROSCLEROSIS, V162, P179, DOI 10.1016/S0021-9150(01)00696-7; Seljeflot I, 2002, THROMB RES, V105, P285, DOI 10.1016/S0049-3848(02)00034-8; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; Shi JM, 2003, BLOOD COAGUL FIBRIN, V14, P575, DOI 10.1097/00001721-200309000-00010; Sinzinger H, 1999, ATHEROSCLEROSIS, V145, P415; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; STOLTENBURGDIDI.G, 2000, BRAIN PATHOL, V10, pC13; Stutzmann JM, 2002, CNS DRUG REV, V8, P1; Takahashi H, 1997, J NEUROSURG, V86, P768, DOI 10.3171/jns.1997.86.5.0768; Tikk A, 1979, Acta Neurochir Suppl (Wien), V28, P96; VANDERSANDE JJ, 1981, J NEUROSURG, V54, P21, DOI 10.3171/jns.1981.54.1.0021; Vanhoorelbeke K., 2003, Current Drug Targets - Cardiovascular & Haematological Disorders, V3, P125, DOI 10.2174/1568006033481500; Wahl F, 2000, J NEUROTRAUM, V17, P1055, DOI 10.1089/neu.2000.17.1055; White CM, 1999, J CLIN PHARMACOL, V39, P111, DOI 10.1177/00912709922007642; Xi GH, 2002, NEUROSURG CLIN N AM, V13, P371, DOI 10.1016/S1042-3680(02)00007-4; Yamamoto J, 1997, JPN J PHYSIOL, V47, P431, DOI 10.2170/jjphysiol.47.431; ZLOKOVIC BV, 1997, NEUROSURG FOCUS 0602; 1989, LANCET, V2, P957	67	56	60	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2004	21	12					1756	1766		10.1089/neu.2004.21.1756			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	877FY	WOS:000225554400007	15684767				2022-02-06	
J	Panerai, RB; Kerins, V; Fan, L; Yeoman, PM; Hope, T; Evans, DH				Panerai, RB; Kerins, V; Fan, L; Yeoman, PM; Hope, T; Evans, DH			Association between dynamic cerebral autoregulation and mortality in severe head injury	BRITISH JOURNAL OF NEUROSURGERY			English	Article						cerebral autoregulation; cerebral blood flow; Doppler ultrasound; intracranial pressure; severe head injury	TRAUMATIC BRAIN-INJURY; BLOOD-FLOW; SPONTANEOUS FLUCTUATIONS; PRESSURE AUTOREGULATION; REACTIVITY; RESPONSES; HUMANS	The objective of the study was to test the hypothesis that dynamic cerebral pressure-autoregulation is associated with the outcome of patients with severe head injury and to derive optimal criteria for future studies on the predictive value of autoregulation indices. Repeated measurements were performed on 32 patients with severe head injury. Arterial blood pressure (ABP) was measured continuously with an intravascular catheter, intracranial pressure (ICP) was recorded with a subdural semiconductor transducer and cerebral blood flow velocity (CBFV) was measured with Doppler ultrasound in the middle cerebral artery. Transfer function analysis was performed on mean beat-to-beat values, using ABP or CBFV as input variables and CBFV or ICP as the output variables. A dynamic index of autoregulation (ARI) ranging between 0 and 9 was extracted from the CBFV step response for a change in ABP. No significant differences between survivors and non-survivors were found due to mean values of ICP, ABP, CPP, CBFV, pCO(2), GCS, age or heart rate. The transfer functions between ABP-ICP and CBFV-ICP did not show any significant differences either. The median [ lower, upper quartiles] ARI was significantly lower for non-survivors compared with survivors [4.8 (0.0, 5.9) v. 6.9 (5.9, 7.4), p = 0.004]. The correlation between ARI and GOS was also significant (r = 0.464, p = 0.011). Cohen's coefficient was optimal for a threshold of ARI = 5.86 (kappa = 0.51, p = 0.0036), leading to a sensitivity for death of 75%, specificity = 76.5%, odds ratio = 9.75 and overall precision = 75.8%. The difference in ARI values between survivors and non-survivors persisted when results were adjusted for GCS (p = 0.028). A similar analysis for the Marshall CT scale did not reach significance (p = 0.072). A logistic regression analysis confirmed that apart from the ARI, no other variables had a significant contribution to predict outcome. In this group of patients, death following severe head injury could not be explained by traditional indices of risk, but was strongly correlated to indices of dynamic cerebral pressure-autoregulation extracted by means of transfer function analysis. Future studies using a prospective design are needed to validate the predictive value of the ARI index, as estimated by transfer function analysis, in relation to death and other unfavourable outcomes.	Univ Leicester, Leicester Royal Infirm, Fac Med, Dept Cardiovasc Sci, Leicester LE1 5WW, Leics, England; Queens Med Ctr, Adult Intens Care Unit, Nottingham NG7 2UH, England; Queens Med Ctr, Dept Neurosurg, Nottingham NG7 2UH, England		Panerai, RB (corresponding author), Univ Leicester, Leicester Royal Infirm, Fac Med, Dept Cardiovasc Sci, Sandringham Bldg Room 126, Leicester LE1 5WW, Leics, England.	rp9@le.ac.uk					AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bendat J., 2010, RANDOM DATA ANAL MEA; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Hlatky R, 2002, J NEUROSURG, V97, P1054, DOI 10.3171/jns.2002.97.5.1054; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Minassian A.T., 2002, CRIT CARE MED, V0, P1616; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; Muller M, 2003, STROKE, V34, P1197, DOI 10.1161/01.STR.0000068409.81859.C5; Newell DW, 1997, ACTA NEUROCHIR, V139, P804, DOI 10.1007/BF01411398; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; Panerai RB, 2003, PHYSIOL MEAS, V24, P367, DOI 10.1088/0967-3334/24/2/312; Panerai RB, 1998, MED BIOL ENG COMPUT, V36, P315, DOI 10.1007/BF02522477; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; Panerai RB, 2002, PHYSIOL MEAS, V23, P59, DOI 10.1088/0967-3334/23/1/306; Panerai RB, 1998, STROKE, V29, P2341, DOI 10.1161/01.STR.29.11.2341; Panerai RB, 1999, AM J PHYSIOL-HEART C, V277, pH1089, DOI 10.1152/ajpheart.1999.277.3.H1089; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; ROSENTHAL R, 1978, PSYCHOL BULL, V85, P185, DOI 10.1037/0033-2909.85.1.185; Serrador JM, 2000, STROKE, V31, P1672, DOI 10.1161/01.STR.31.7.1672; *STATSOFT INC, 1997, STATISTICA WIND COMP, V3, P3053; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Wagner BP, 2002, CRIT CARE MED, V30, P2014, DOI 10.1097/00003246-200209000-00010; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233	35	56	58	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	OCT	2004	18	5					471	479		10.1080/02688690400012343			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	881JL	WOS:000225863000004	15799148				2022-02-06	
J	Bahloul, M; Chelly, H; Ben Hmida, M; Ben Hamida, C; Ksibi, H; Kallel, H; Chaari, A; Kassis, M; Rekik, N; Bouaziz, M				Bahloul, M; Chelly, H; Ben Hmida, M; Ben Hamida, C; Ksibi, H; Kallel, H; Chaari, A; Kassis, M; Rekik, N; Bouaziz, M			Prognosis of traumatic head injury in South Tunisia: A multivariate analysis of 437 cases	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						trauma; acute head injury; adult patients; intensive care unit; multivariate analysis; prognosis; motor vehicle crash	COMA DATA-BANK; BRAIN-INJURY; DIABETES-INSIPIDUS; INAPPROPRIATE SECRETION; SECONDARY INSULTS; PRACTICAL SCALE; SEVERITY SCORE; BLOOD-GLUCOSE; HYPERGLYCEMIA; DIAGNOSIS	Background: This study aimed to determine predictive factors of mortality after posttraumatic brain injury. Methods: A retrospective study conducted over a 3-year period (1997-1999) involved 437 adult patients with head injury admitted to the intensive care unit of a university hospital in Sfax, Tunisia. Basic demographic, clinical, biologic, and radiologic data were recorded at admission and during the intensive care unit stay. Results: This study included 393 men (90%) and 44 women with a mean age of 36 +/- 17 years. Traffic accidents were the main cause of trauma (85.6%). In 58% of the cases, the injury was serious (Glasgow Coma Score, <8). The mean simplified acute physiology score was 39 +/- 15, and the mean Injury Severity Score was 34.5 +/- 17. Of the 437 patients, 127 (29.1%) died. According to multivariate analysis, the factors that correlated with a poor prognosis were age older than 40 years (p < 0.01), simplified acute physiology score exceeding 40 (p < 0.001), Glasgow Coma Score lower than 7 (p = 0.03), intracranial mass lesion (p = 0.02), a cerebral herniation (p < 0.001), diabetes insipidus (p < 0.001), and blood sugar level higher than 10 mmol/L (p < 0. 001). Conclusions: In Tunisia, head injury is a frequent cause of hospitalization, comprising 14.4% of all adult admissions. It is observed most often among young patients involved in traffic accidents. The short-term prognosis is poor, with a high (29%) mortality rate, and determined by demographic, clinical, radiologic, and biologic factors. Prevention is highly advised.	Habib Bourguiba Univ Hosp, Dept Intens Care, Sfax 3029, Tunisia; Hedi Chaker Univ Hosp, Dept Nephrol, Sfax, Tunisia; Hedi Chaker Univ Hosp, Dept Epidemiol, Sfax, Tunisia		Bahloul, M (corresponding author), Habib Bourguiba Univ Hosp, Dept Intens Care, Sfax 3029, Tunisia.	bahloulmab@yahoo.fr		Bahloul, Mabrouk/0000-0002-6488-8294			BORN JD, 1985, SURG NEUROL, V23, P383, DOI 10.1016/0090-3019(85)90212-5; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; BULL JP, 1978, INJURY, V9, P184, DOI 10.1016/0020-1383(78)90004-9; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Deloof T, 1979, Acta Neurochir Suppl (Wien), V28, P113; Diamond PT, 1996, BRAIN INJURY, V10, P413, DOI 10.1080/026990596124278; DUROCHER A, 1988, INTENS CARE MED, V14, P39, DOI 10.1007/BF00254120; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Fandino J, 2000, J CLIN NEUROSCI, V7, P226, DOI 10.1054/jocn.1999.0202; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Fukuda T, 1996, NEUROL SURG TOKYO, V24, P723; GABOW PA, 1982, MEDICINE, V61, P141, DOI 10.1097/00005792-198205000-00002; GAILLARD M, 1989, ANN PEDIATR-PARIS, V36, P194; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENTLEMAN D, 1993, BRIT MED J, V307, P547, DOI 10.1136/bmj.307.6903.547; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; GREGER NG, 1986, AM J DIS CHILD, V140, P551, DOI 10.1001/archpedi.1986.02140200061028; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HICKS IR, 1994, INJURY, V25, P545, DOI 10.1016/0020-1383(94)90098-1; Hill DA, 1997, J TRAUMA, V42, P62, DOI 10.1097/00005373-199701000-00011; JENNETT B, 1975, LANCET, V1, P480; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; KARUS JF, 1996, NEUROL CLIN, V14, P435; KERN KB, 1984, J TRAUMA, V24, P69, DOI 10.1097/00005373-198401000-00012; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; Meldon SW, 2002, J TRAUMA, V52, P79, DOI 10.1097/00005373-200201000-00014; MERGUERIAN PA, 1981, CRIT CARE MED, V9, P838, DOI 10.1097/00003246-198112000-00007; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; NOTMAN DD, 1980, J TRAUMA, V20, P599, DOI 10.1097/00005373-198007000-00009; PENTELENYI T, 1979, INJURY, V10, P201, DOI 10.1016/0020-1383(79)90009-3; PENTELENYI T, 1977, INJURY, V8, P264, DOI 10.1016/0020-1383(77)90099-7; PFENNINGER EG, 1991, ACTA ANAESTH SCAND, V35, P148, DOI 10.1111/j.1399-6576.1991.tb03263.x; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; Raggueneau J L, 1988, Agressologie, V29, P433; Ritter AM, 1999, NEUROSURGERY, V44, P941, DOI 10.1097/00006123-199905000-00005; ROCCA B, 1989, J TRAUMA, V29, P299, DOI 10.1097/00005373-198903000-00004; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; TABADDOR K, 1982, SURG NEUROL, V18, P212, DOI 10.1016/0090-3019(82)90395-0; TEASDALE G, 1974, LANCET, V2, P81; TIRET L, 1986, INT J EPIDEMIOL, V19, P133; *TUN NAT GUARD, TUN NAT GUARD STAT D; TWIJNSTRA A, 1980, CLIN NEUROL NEUROSUR, V82, P263, DOI 10.1016/0303-8467(80)90018-9; *US DEP HHS, 1994, AHCPR PUBL, P12; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	53	56	56	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2004	57	2					255	261		10.1097/01.TA.0000083004.35231.1E			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	859YG	WOS:000224303700010	15345970				2022-02-06	
J	Kazemi, M; Pieter, W				Kazemi, M; Pieter, W			Injuries at a Canadian National Taekwondo championships: a prospective study	BMC MUSCULOSKELETAL DISORDERS			English	Article							SACROILIAC JOINT; INHIBITION; PAIN	Background: The purpose of this prospective study was to assess the injury rates in male and female adult Canadian Taekwondo athletes relative to total number of injuries, type and body part injured. Methods: Subjects ( 219 males, 99 females) participated in the 1997 Canadian National Taekwondo Championships in Toronto, Canada. Injuries were recorded on an injury form to documents any injury seen and treatment provided by the health care team. These data were later used for this study. The injury form describes the athlete and nature, site, severity and mechanism of the injury. Results: The overall rate of injuries was 62.9/1,000 athlete-exposures (A-E). The males (79.9/1,000 A-E) sustained significantly more injuries than the females (25.3/1,000 A-E). The lower extremities were the most commonly injured body region in the men (32.0/1,000 A-E), followed by the head and neck (18.3/1,000 A-E). Injuries to the spine ( neck, upper back, low back and coccyx) were the third most often injured body region in males (13.8/1,000 A-E). All injuries to the women were sustained to the lower extremities. The most common type of injury in women was the contusion (15.2/1,000 A-E). However, men's most common type of injury was the sprain (22.8/1,000 A-E) followed by joint dysfunction (13.7/1,000 A-E). Concussions were only reported in males (6.9/1,000 A-E). Compared to international counterparts, the Canadian men and women recorded lower total injury rates. However, the males incurred more cerebral concussions than their American colleagues (4.7/1,000 A-E). Conclusions: Similar to what was found in previous studies, the current investigation seems to suggest that areas of particular concern for preventive measures involve the head and neck as well as the lower extremities. This is the first paper to identify spinal joint dysfunction.	Canadian Mem Chiropract Coll, Dept Clin Studies, Toronto, ON, Canada; Univ Sci Malaysia, Sch Hlth Sci, Kelantan, Malaysia		Kazemi, M (corresponding author), Canadian Mem Chiropract Coll, Dept Clin Studies, Toronto, ON, Canada.	mkazemi@cmcc.ca; yshin516@yahoo.com					BARRAULT D, 1983, SYMB, V15, P144; Beis K, 2001, EUR J SPORT TRAUMA R, V23, P130; *CO MED SOC, 1991, REP SPORTS MED COMM; Dah C, 1989, CINESIOLOGIE, V28, P153; Greenwald P, 1996, IARC SCI PUBL, P13; HALDEMAN S, 1992, PRINCIPLES PRACTICE, P623; Harrison DE, 1997, J MANIP PHYSIOL THER, V20, P607; Hillman S., 1993, AUS J SCI MED SPORT, V25, P73; James G, 2003, BIOL SPORT, V20, P25; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; KNUSTSON GA, 1999, J MANIP PHYSIOL THER, V22, P491; Kokmeyer DJ, 2002, J MANIP PHYSIOL THER, V25, P42, DOI 10.1067/mmt.2002.120418; LINDENFELD TN, 1994, AM J SPORT MED, V22, P364, DOI 10.1177/036354659402200312; Maigne J Y, 2001, Spine (Phila Pa 1976), V26, pE479, DOI 10.1097/00007632-200110150-00024; Maigne JY, 2001, SPINE, V26, pE484; McKeag DB, 1993, PRIMARY CARE SPORTS, P63; MCLATCHIE GR, 1976, BR J ACC SURG, V8, P132; Phillips JS, 2001, SA J PHYS, V57, P32; Pieter W., 1994, Journal of Sports Traumatology and Related Research, V16, P49; PIETER W, 1995, P 38 WORLD C P GAIN, P165; Pieter W, 1997, P 2 ANN C EUR COLL S; Pieter W., 2001, ACTA KINESIOLOGIAE U, V6, P102; PIETER W, 1998, KINESIOLOGY, V30, P22, DOI DOI 10.1589/JPTS.28.231; Pieter W, 1995, J HUM MOVEMENT STUD, V28, P1; PIETER W, 1999, P 5 IOC WORLD C SPOR; PIETER W, 2000, P 1 WORLD C COMB SPO; PIETER W, 1996, EPIDEMIOLOGY SPORTS, P268; Suter E, 2000, J MANIP PHYSIOL THER, V23, P76, DOI 10.1016/S0161-4754(00)90071-X; Suter E, 1999, J MANIP PHYSIOL THER, V22, P149, DOI 10.1016/S0161-4754(99)70128-4; Taylor P, 1990, J CAN CHIROPRACT ASS, V34, P82; Toussaint R, 1999, J MANIP PHYSIOL THER, V22, P134, DOI 10.1016/S0161-4754(99)70125-9; Tuominen Risto, 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P44; Zemper E D, 1989, Br J Sports Med, V23, P161	33	56	59	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2474			BMC MUSCULOSKEL DIS	BMC Musculoskelet. Disord.	JUL 27	2004	5								22	10.1186/1471-2474-5-22			8	Orthopedics; Rheumatology	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Rheumatology	844AK	WOS:000223129000001	15279679	Green Published, gold			2022-02-06	
J	Young, KD; Okada, PJ; Sokolove, PE; Palchak, MJ; Panacek, EA; Baren, JM; Huff, KR; McBride, DQ; Inkelis, SH; Lewis, RJ				Young, KD; Okada, PJ; Sokolove, PE; Palchak, MJ; Panacek, EA; Baren, JM; Huff, KR; McBride, DQ; Inkelis, SH; Lewis, RJ			A randomized, double-blinded, placebo-controlled trial of phenytoin for the prevention of early posttraumatic seizures in children with moderate to severe blunt head injury	ANNALS OF EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; EMERGENCY RESEARCH; INFORMED-CONSENT; CLINICAL-TRIALS; EPILEPSY; COMA; PROPHYLAXIS; PREDICTORS; INFANTS	Study objective: We determine the efficacy of prophylactic phenytoin in preventing early posttraumatic seizures in children with moderate to severe blunt head injury. Methods: Children younger than 16 years and experiencing moderate to severe blunt head injury were randomized to receive phenytoin or placebo within 60 minutes of presentation at 3 pediatric trauma centers. The primary endpoint was posttraumatic seizures within 48 hours; secondary endpoints were survival and neurologic outcome 30 days after injury. A Bayesian decision-theoretic clinical trial design was used to determine the probability of remaining posttraumatic seizure free for each treatment group. Results: One hundred two patients were enrolled, with a median age of 6.1 years. Sixty-eight percent were boys. The 2 treatment groups were well matched. During the 48-hour observation period, 3 (7%) of 46 patients given phenytoin and 3 (5%) of 56 patients given placebo experienced a posttraumatic seizure. There were no significant differences between the treatment groups in survival or neurologic outcome after 30 days. According to these results, the probability that phenytoin has the originally hypothesized effect of reducing the rate of early posttraurnatic seizures by 12.5% is 0.0053. The probability that phenytoin has any prophylactic efficacy is 0.383. The median effect size in this trial was -0.015 (seizure rate increased by 1.5% in the phenytoin group), 95% probability interval -0.127 to 0.091 (12.7% higher rate of posttraumatic seizures to a 9.1% lower rate of posttraumatic seizures with phenytoin). Conclusion: The rate of early posttraumatic seizures in children may be much lower than previously reported. Phenytoin did not substantially reduce that rate.	Harbor UCLA Med Ctr, Dept Emergency Med, Torrance, CA 90509 USA; Harbor UCLA Med Ctr, Dept Pediat, Torrance, CA 90509 USA; Harbor UCLA Med Ctr, Dept Neurosurg, Torrance, CA 90509 USA; Univ Texas, SW Childrens Med Ctr, Dept Pediat, Dallas, TX 75230 USA; Univ Calif Davis, Ctr Med, Dept Emergency Med, Sacramento, CA 95817 USA; Univ Penn, Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA		Lewis, RJ (corresponding author), Harbor UCLA Med Ctr, Dept Emergency Med, 1000 W Carson St,Box 21, Torrance, CA 90509 USA.	roger@emedharbor.edu					Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Appleton RE, 2002, J NEUROL NEUROSUR PS, V72, P669, DOI 10.1136/jnnp.72.5.669; BERRY DA, 1987, AM STAT, V41, P117, DOI 10.2307/2684222; BIROS MH, 1995, JAMA-J AM MED ASSOC, V273, P1283, DOI 10.1001/jama.273.16.1283; Biros MH, 1998, ACAD EMERG MED, V5, P359, DOI 10.1111/j.1553-2712.1998.tb02722.x; BRAILOWSKY S, 1986, BRAIN RES, V376, P71, DOI 10.1016/0006-8993(86)90900-5; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P549, DOI DOI 10.1089/NEU.2000.17.549; Bruce D A, 1990, Curr Probl Pediatr, V20, P61; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; ELLIS G, 2004, 933 OPRR; Fost Norman, 1980, IRB, V2, P5, DOI 10.2307/3564363; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; Haltiner AM, 1999, J NEUROSURG, V91, P588, DOI 10.3171/jns.1999.91.4.0588; HAUSER WA, 1990, NEW ENGL J MED, V323, P540, DOI 10.1056/NEJM199008233230809; HENDRICK EB, 1968, J TRAUM, V8, P547; Hunt EA, 2002, ARCH DIS CHILD, V86, P62, DOI 10.1136/adc.86.1.62; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVINE RJ, 1991, CONTROL CLIN TRIALS, V12, P546, DOI 10.1016/0197-2456(91)90012-B; LEWIS RJ, 1994, J AM STAT ASSOC, V89, P1528, DOI 10.2307/2291016; Lewis RJ, 2001, ACAD EMERG MED, V8, P1179, DOI 10.1111/j.1553-2712.2001.tb01137.x; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; Lewis RJ, 1996, BAYESIAN BIOSTATISTI, P279; Mansfield RT, 1997, CRIT CARE CLIN, V13, P611, DOI 10.1016/S0749-0704(05)70331-6; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; MORI A, 1990, PAVLOVIAN J BIOL SCI, V25, P54; Okada PJ, 2003, ACAD EMERG MED, V10, P1034, DOI 10.1197/S1069-6563(03)00364-6; OKADA PJ, 1995, ARCH PEDIAT ADOLESC, V149, pP65; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; Ratan SK, 1999, PEDIATR NEUROSURG, V30, P127, DOI 10.1159/000028779; Schierhout G, 1998, J NEUROL NEUROSUR PS, V64, P108, DOI 10.1136/jnnp.64.1.108; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; *US FDA, 1995, EX SUMM PUBL FOR INF; US Food and Drug Administration, 1995, FED REGISTER, V60, P49085; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; Yablon SA, 1998, ARCH PHYS MED REHAB, V79, P594; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231	44	56	59	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	APR	2004	43	4					435	446		10.1016/j.annemergmed.2003.09.016			12	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	807KV	WOS:000220501300001	15039684				2022-02-06	
J	Fabbri, A; Servadei, F; Marchesini, G; Morselli-Labate, AM; Dente, M; Iervese, T; Spada, M; Vandelli, A				Fabbri, A; Servadei, F; Marchesini, G; Morselli-Labate, AM; Dente, M; Iervese, T; Spada, M; Vandelli, A			Prospective validation of a proposal for diagnosis and management of patients attending the emergency department for mild head injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; PROGNOSIS; ADULTS; RULES; SCALE	Background: In mild head injury, predictors to select patients for computed tomography (CT) and/or to plan proper management are needed. The strength of evidence of published recommendations is insufficient for current use. We assessed the diagnostic accuracy and the clinical validity of the proposal of the Neurotraumatology Committee of the World Federation of Neurosurgical Societies on mild head injury from an emergency department perspective. Methods: In a three year period, 5578 adolescent and adult subjects were prospectively recruited and managed according to the proposed protocol. Outcome measures were: ( a) any post-traumatic lesion; (b) need for neurosurgical intervention; ( c) unfavourable outcome ( death, permanent vegetative state or severe disability) after six months. The predictive value of a model based on five variables ( Glasgow coma score, clinical findings, risk factors, neurological deficits, and skull fracture) was tested by logistic regression analysis. Findings: At first CT evaluation 327 patients (5.9%) had intracranial post-traumatic lesions. In 16 cases (0.3%) previously undiagnosed lesions were detected after re-evaluation within seven days. Neurosurgical intervention was needed in 71 patients (1.3%) and an unfavourable outcome occurred in 39 cases (0.7%). The area under the ROC curve of the variables in predicting post-traumatic lesions was 0.906 (0.009) ( sensitivity 70.0%, specificity 94.1% at best cut off), neurosurgical intervention was 0.926 (0.016) ( sensitivity 81.7%, specificity 94.1%), and unfavourable outcome was 0.953 (0.014) ( sensitivity 88.1%, specificity 95.1%). Interpretation: The variables prove highly accurate in the prediction of clinically meaningful outcomes, when applied to a consecutive set of patients with mild head injury in the clinical setting of a 1st level emergency department.	Osped GB Morgagni, Azienda USL Forli, Dipartimento Emergenza Urgenza Accettaz, I-47100 Forli, Italy; Osped Gen Provinciale M Bufalini, Azienda Unita Sanitaria Locale Cesena, Div Neurochirurg Traumatol, Cesena, Italy; Univ Bologna, Dipartimento Med Interna & Gastroenterol, I-40126 Bologna, Italy		Fabbri, A (corresponding author), Osped GB Morgagni, Azienda USL Forli, Dipartimento Emergenza Urgenza Accettaz, 1 Ple Solieri 1, I-47100 Forli, Italy.	andfabbri@libero.it	Fabbri, Andrea/K-9994-2016	Fabbri, Andrea/0000-0002-9837-4638; Marchesini, Giulio/0000-0003-2407-9860; Servadei, Franco/0000-0002-3595-3464; Morselli/Labate, Antonio Maria/0000-0001-9318-8564			BELL RS, 1987, NEW ENGL J MED, V316, P84; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; GALBRAITH S, 1976, BMJ-BRIT MED J, V1, P1438, DOI 10.1136/bmj.1.6023.1438; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Graham ID, 1998, ACAD EMERG MED, V5, P134, DOI 10.1111/j.1553-2712.1998.tb02598.x; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; National Institute for Clinical Excellence, HEAD INJ INF CHILDR; NORUSIS MJ, 1992, SPSS PC BASE SYSTEM; Pezzilli R, 1999, CLIN CHEM, V45, P1762; Servadei F, 2002, NEUROEPIDEMIOLOGY, V21, P297, DOI 10.1159/000065523; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; VOSS M, 1995, BRIT MED J, V311, P1395, DOI 10.1136/bmj.311.7017.1395; ZWEIG MH, 1993, CLIN CHEM, V39, P561	23	56	56	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAR 1	2004	75	3					410	416		10.1136/jnnp.2003.016113			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	774FW	WOS:000188970000015	14966157	Bronze, Green Published			2022-02-06	
J	Fischer, S; Trexler, LE; Gauggel, S				Fischer, S; Trexler, LE; Gauggel, S			Awareness of activity limitations and prediction of performance in patients with brain injuries and orthopedic disorders	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						awareness; activity limitations; predicted performance; brain injury	IMPAIRED AWARENESS; BEHAVIORAL LIMITATIONS; UNAWARENESS; DEFICITS; ADULTS	The aim of this study was to compare the accuracy of performance predictions in experimental tasks with patients' awareness of activity limitations. Participants were 24 patients with brain injuries (i.e., traumatic brain injury and cerebrovascular disorders) and 22 patients with orthopedic disorders. Prediction of performance was examined in a memory task (word list learning) and a motor task (finger tapping). Awareness of activity limitations was measured by comparing patients' self-ratings and staff ratings in the Patient Competency Rating Scale (PCRS). Results for the PCRS showed that patients with orthopedic disorders underestimated and patients with brain injuries (i.e., patients with TBI) overestimated their level of functioning in the total scale and the social/emotional subscale in comparison to staff ratings. Both patient groups agreed with staff ratings in physical/basic self-care items. In the predicted performance tasks a similar pattern could be observed: None of the groups showed an overestimation of performance in the motor task, whereas patients with brain injuries overestimated their competency in the memory task. However, the agreement between both awareness measures (PCRS, predicted performance) was only low, which indicates that they might measure different aspects or levels of self-awareness.	Univ Technol Chemnitz, Dept Psychol, D-09120 Chemnitz, Germany; Praxis Neuropsychol Rehabil Prof Fries, Munich, Germany; Community Hosp Indianapolis, Hook Rehabil Ctr, Indianapolis, IN USA; Indiana Univ, Sch Med, Bloomington, IN 47405 USA		Fischer, S (corresponding author), Univ Technol Chemnitz, Dept Psychol, D-09120 Chemnitz, Germany.	sonja.fischer@s2001.tu-chemnitz.de		Gauggel, Siegfried/0000-0002-2742-4917			Alfano MS, 2000, J CLIN PSYCHOL, V56, P975, DOI 10.1002/1097-4679(200007)56:7<975::AID-JCLP13>3.0.CO;2-Z; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; BECK AT, 1996, BDI II MANUAL; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Cohen J., 2013, STAT POWER ANAL BEHA; Dunlap WP, 1996, PSYCHOL METHODS, V1, P170, DOI 10.1037/1082-989X.1.2.170; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FISCHER S, 1999, Z NEUROPSYCHOLOGIE, V10, P103; Fleming JM, 1996, BRAIN INJURY, V10, P1; Gasquoine P., 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187, https://doi.org/10.1037/0894-4105.6.3.187]; Gauggel S, 2002, J CLIN EXP NEUROPSYC, V24, P1070, DOI 10.1076/jcen.24.8.1070.8377; Gauggel S, 2000, J HEAD TRAUMA REHAB, V15, P710, DOI 10.1097/00001199-200002000-00009; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Halstead WC, 1947, BRAIN INTELLIGENCE Q; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Heilbronner R L, 1989, Brain Inj, V3, P387, DOI 10.3109/02699058909004562; Mazzoni G, 1998, METACOGNITION AND COGNITIVE NEUROPSYCHOLOGY, pIX; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; Robins R.W., 1997, HDB PERSONALITY PSYC, P649, DOI [10.1016/B978-012134645-4/50026-3, DOI 10.1016/B978-012134645-4/50026-3]; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55; Trexler L, 2000, INT HDB NEUROPSYCHOL, P215; WAGNER MT, 1994, ARCH CLIN NEUROPSYCH, V9, P57, DOI 10.1016/0887-6177(94)90014-0; WALKER DE, 1987, J CLIN PSYCHOL, V43, P699, DOI 10.1002/1097-4679(198711)43:6<699::AID-JCLP2270430610>3.0.CO;2-9; WALLSTON KA, 1978, HEALTH EDUC QUART, V6, P160, DOI 10.1177/109019817800600107; Wechsler, 1997, WECHSLER ADULT INTEL; Wilkinson G.S., 1993, WIDE RANGE ACHIEVEME; Wyller TB, 1996, DISABIL REHABIL, V18, P454, DOI 10.3109/09638289609165909	37	56	56	0	3	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2004	10	2					190	199		10.1017/S1355617704102051			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	780KA	WOS:000189378800005	15012839				2022-02-06	
J	Sifri, ZC; Livingston, DH; Lavery, RF; Homnick, AT; Mosenthal, AC; Mohr, AM; Hauser, CJ				Sifri, ZC; Livingston, DH; Lavery, RF; Homnick, AT; Mosenthal, AC; Mohr, AM; Hauser, CJ			Value of repeat cranial computed axial tomography scanning in patients with minimal head injury	AMERICAN JOURNAL OF SURGERY			English	Article						cranial computed axial tomography scan; neurological status; neurosurgical intervention; traumatic brain injury	CT SCANS; UTILITY; MANAGEMENT; ADMISSION; MODERATE	Background: Patients with minimal head injury (MHI) and a cranial computed axial tomography (CAT) scan positive for the presence of intracranial injury routinely undergo a repeat CAT scan within 24 hours after injury. The value of this repeat cranial CAT scan is unclear in those patients who are neurologically normal or improving. Methods: A retrospective analysis of all adult patients admitted to a level-1 trauma center with MHI and a positive cranial CAT scan during a 32-month period was performed. The need for neurosurgical intervention after repeat CAT scan in patients with a persistently normal or improved neurological examination was recorded. Results: One hundred fifty-one patients had a persistently normal or improved neurological examination, but none of these patients required neurosurgical intervention after the repeat cranial CAT scan. Conclusions: A persistently normal or improving neurological examination in a patient with MHI appears to exclude the need for neurosurgical intervention and thus a repeat cranial CAT scan. (C) 2004 Excerpta Medica, Inc. All rights reserved.	Univ Med & Dent New Jersey, Dept Surg, Div Trauma, Newark, NJ 07103 USA		Livingston, DH (corresponding author), Univ Med & Dent New Jersey, Dept Surg, Div Trauma, M-243,150 Bergen St, Newark, NJ 07103 USA.	livingst@umdnj.edu	Hauser, Carl J./Y-1189-2019; Mohr, Alicia M/E-3016-2015	Mohr, Alicia/0000-0003-1732-1313; Hauser, Carl/0000-0003-3167-1846			Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; MORAN SG, 1994, AM SURGEON, V60, P533; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; Valadka A, 2000, TRAUMA, P377	14	56	57	0	1	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	MAR	2004	187	3					338	342		10.1016/j.amjsurg.2003.12.015			5	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	801PL	WOS:000220107700005	15006561				2022-02-06	
J	Nakase-Thompson, R; Sherer, M; Yablon, SA; Nick, TG; Trzepacz, PT				Nakase-Thompson, R; Sherer, M; Yablon, SA; Nick, TG; Trzepacz, PT			Acute confusion following traumatic brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; POSTTRAUMATIC AMNESIA; GALVESTON ORIENTATION; DIAGNOSTIC-CRITERIA; DELIRIUM; SCALE; RECOVERY; VALIDATION; SURVIVORS; BEHAVIOR	Primary objective: To determine the incidence, duration and symptoms associated with acute confusion/ delirium among traumatic brain injury (TBI) neuro-rehabilitation admissions. Research design: Prospective evaluation of neurobehavioural impairments following TBI among inpatient neurorehabilitation admissions. Methods and procedures: Eighty-five consecutive TBI model system patients were evaluated using measures of orientation, cognition, motor restlessness and delirium. Main outcomes and results: Fifty-nine individuals met Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition Delirium Diagnostic Criteria ( DDC) on initial evaluation and 42 of these resolved delirium during inpatient rehabilitation. Multivariable logistic regression analyses revealed significant unique associations of the Galveston Orientation and Amnesia Test ( GOAT), Delirium Rating Scale, Cognitive Test for Delirium and time elapsed since injury with DDC status. Conclusions: Findings indicate that delirium is common among neuro-rehabilitation admissions with TBI. Use of a single measure ( e. g. GOAT) will result in poor characterization of the multi-faceted symptom complex shown by patients with post-traumatic confusion.	Methodist Rehabil Ctr, Dept Neuropsychol, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; Lilly Res Labs, Indianapolis, IN USA		Nakase-Thompson, R (corresponding author), Methodist Rehabil Ctr, Dept Neuropsychol, 1350 E Woodrow Wilson Dr, Jackson, MS 39216 USA.		Trzepacz, Paula/AAQ-3330-2021				American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P124; ARTIOLA I, 1980, J NEUROL NEUROSUR PS, V43, P377; Bogner JA, 1999, J HEAD TRAUMA REHAB, V14, P91, DOI 10.1097/00001199-199902000-00012; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Fladby T, 1999, J GERIATR PSYCH NEUR, V12, P16, DOI 10.1177/089198879901200105; FRANCIS J, 1992, J AM GERIATR SOC, V40, P601, DOI 10.1111/j.1532-5415.1992.tb02111.x; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Hart RP, 1996, PSYCHOSOMATICS, V37, P533, DOI 10.1016/S0033-3182(96)71517-7; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1993, HEAD INJURY, P525; LEVIN HS, 1992, J NEUROTRAUM, V9, P359; MCEVOY JP, 1981, ANN INTERN MED, V95, P212, DOI 10.7326/0003-4819-95-2-212; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; OCONNOR M, 1987, MED J AUSTRALIA, V147, P481, DOI 10.5694/j.1326-5377.1987.tb133639.x; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; RABINS PV, 1982, BRIT J PSYCHIAT, V140, P149, DOI 10.1192/bjp.140.2.149; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Sessler CN, 1992, CHEST, V102, p191S; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith A., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Symonds C. P, 1937, P ROY SOC MED, V30, P33; SYMONDS CP, 1943, LANCET, P7; Tate RL, 2000, J NEUROL NEUROSUR PS, V68, P178, DOI 10.1136/jnnp.68.2.178; Trzepacz Paula T., 1994, P189; TRZEPACZ PT, 1988, PSYCHIAT RES, V23, P89, DOI 10.1016/0165-1781(88)90037-6; TRZEPACZ PT, 1994, PSYCHOSOMATICS, V35, P374, DOI 10.1016/S0033-3182(94)71759-X; TRZEPACZ PT, 2002, AM PSYCHIAT PUBLISHI, P525; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091	42	56	58	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2004	18	2					131	142		10.1080/0269905031000149542			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	751DR	WOS:000187038000003	14660226				2022-02-06	
J	Walker, N; Mellick, D; Brooks, CA; Whiteneck, GG				Walker, N; Mellick, D; Brooks, CA; Whiteneck, GG			Measuring participation across impairment groups using the Craig handicap assessment reporting technique	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						disability; outcomes research; handicap; surveys; reliability; validity	AGREEMENT	Objective: To assess the efficacy, across a range of disability groups, of the Craig Handicap Assessment and Reporting Technique (CHART), a measure of societal participation. Design: Cross-sectional analysis survey methodology. A total of 1110 community-based, nonhospitalized Coloradans with spinal cord injury, traumatic brain injury, multiple sclerosis, stroke, burn, or amputation were interviewed twice, 2 wks apart, using the CHART and a single administration of the FIM(TM). Results: Across all impairment groups, the intraclass correlation for the total score and the subscales of CHART-R were high. In addition, the CHART-R discriminated among the impairment categories in a direction that parallels increasing disability. Conclusions: CHART may be an appropriate measure of handicap for a range of physical or cognitive impairments.	Craig Hosp, Dept Res, Englewood, CO 80110 USA		Mellick, D (corresponding author), Craig Hosp, Dept Res, 3425 S Clarkson St, Englewood, CO 80110 USA.						BLAND JM, 1990, COMPUT BIOL MED, V20, P337, DOI 10.1016/0010-4825(90)90013-F; Dijkers M., 1991, J AM PARAPLEGIA SOC, V14, P85; GRANGER CV, 1997, ASSESSING MED REHABI, P103; Hall K., 1998, TOP SPINAL CORD INJ, V4, P16, DOI DOI 10.1310/V5RU-FRFE-50E6-E2NA; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; *STAT U NEW YORK B, 1996, GUID UN DAT SET MED; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; World Health Organization, 1993, INT CLASS IMP DIS HA; World Health Organization (WHO), 1997, INT CLASS IMP ACT PA	11	56	56	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	DEC	2003	82	12					936	941		10.1097/01.PHM.0000098041.42394.9A			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	744ZM	WOS:000186662800005	14627930				2022-02-06	
J	Hellal, F; Pruneau, D; Palmier, B; Faye, P; Croci, N; Plotkine, M; Marchand-Verrecchia, C				Hellal, F; Pruneau, D; Palmier, B; Faye, P; Croci, N; Plotkine, M; Marchand-Verrecchia, C			Detrimental role of bradykinin B-2 receptor in a murine model of diffuse brain injury	JOURNAL OF NEUROTRAUMA			English	Article						B-2 receptor null mice; bradykinin B-2 receptor antagonist; brain edema; closed head injury; inflammation; neuroprotection	NITRIC-OXIDE SYNTHASE; CLOSED-HEAD TRAUMA; KININ RECEPTORS; NEUTROPHIL ACCUMULATION; CEREBRAL-ISCHEMIA; SMOOTH-MUSCLE; AXONAL INJURY; LF 16-0687MS; RAT MODEL; ANTAGONIST	Inhibition of the bradykinin B-2 receptor type (B2R) has been shown to improve neurological outcome in models of focal traumatic brain injury. However, the involvement of B2R in trauma-induced diffuse injury has not yet been explored. This is an important point, since in humans a pattern of diffuse injury is commonly found in severely injured patients and has been associated with a poor neurological outcome and prognosis. Using the non-peptide BY antagonist LF 16-0687 Ms and B2R null (B2R-/-) mice, we investigated the role of B2R in a model of closed head trauma (CHT). LF 16-0687 Ms given 30 min after injury reduced the neurological deficit by 26% and the cerebral edema by 22% when evaluated 4 h after CHT. Neurological function after CHT was improved in B2R-/- mice compared to B2R+/+ mice, although there was no difference in the development of brain edema. Treatment with LF 16-0687 Ms and B2R gene deletion decreased the accumulation of neutrophils at 24 h after CHT (50% and 36%, respectively). In addition, the inducible NO synthase (iNOS) mRNA level increased markedly, and this was reduced by LF 16-0687 Ms. Taken together, these data support a detrimental role of B2R in the development of the neurological deficit and of the inflammatory secondary damage resulting from diffuse traumatic brain injury. Therefore, blockade of bradykinin B-2 receptors might represent an attractive therapeutic approach in the pharmacological treatment of traumatic brain injury.	Univ Paris 05, Pharmacol Lab, UPRESEA 2510, F-75270 Paris 06, France; Ctr Rech Labs Fournier, Daix, France		Marchand-Verrecchia, C (corresponding author), Univ Paris 05, Pharmacol Lab, UPRESEA 2510, F-75270 Paris 06, France.	Verrecchia@pharmacie.univ-paris5.fr	Hellal, Farida/E-8533-2013; Hellal, Farida/D-1834-2015; MARCHAND-LEROUX, Catherine/L-7453-2017	Hellal, Farida/0000-0002-9344-1846; MARCHAND-LEROUX, Catherine/0000-0003-0113-5348			Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Bockmann S, 2000, J LEUKOCYTE BIOL, V68, P587; BORKOWSKI JA, 1995, J BIOL CHEM, V270, P13706, DOI 10.1074/jbc.270.23.13706; Campos MM, 1998, PEPTIDES, V19, P1269, DOI 10.1016/S0196-9781(98)00087-4; Chabrier PE, 1999, P NATL ACAD SCI USA, V96, P10824, DOI 10.1073/pnas.96.19.10824; Charriaut-Marlangue C, 1999, DEV BRAIN RES, V116, P133, DOI 10.1016/S0165-3806(99)00084-X; Choudhri TF, 1997, STROKE, V28, P2296, DOI 10.1161/01.STR.28.11.2296; CHRISTOPHER TA, 1994, AM J PHYSIOL, V266, pH867, DOI 10.1152/ajpheart.1994.266.3.H867; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Costa SKP, 2002, NEUROSCI LETT, V318, P158, DOI 10.1016/S0304-3940(01)02498-3; Couture R, 2000, HAND CHEM N, V16, P241; DRAY A, 1993, TRENDS NEUROSCI, V16, P99, DOI 10.1016/0166-2236(93)90133-7; DRAY A, 1997, KININ SYSTEM, P157; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; FIGUEROA CD, 1989, BRIT J HAEMATOL, V72, P321, DOI 10.1111/j.1365-2141.1989.tb07711.x; FRANCEL PC, 1992, J NEUROTRAUM, V9, pS27; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; Gorlach C, 2001, J NEUROTRAUM, V18, P833, DOI 10.1089/089771501316919193; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; Kaplanski J, 2002, J NEUROTRAUM, V19, P953, DOI 10.1089/089771502320317104; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Levy D, 2000, PAIN, V86, P265, DOI 10.1016/S0304-3959(00)00256-6; Lo EJ, 1999, NEUROREPORT, V10, P3821, DOI 10.1097/00001756-199912160-00018; Marceau F, 1998, CLIN REV ALLERG IMMU, V16, P385, DOI 10.1007/BF02737658; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Milia AF, 2001, HYPERTENSION, V37, P1473, DOI 10.1161/01.HYP.37.6.1473; Niess C, 2002, ACTA NEUROPATHOL, V104, P79, DOI 10.1007/s00401-002-0525-9; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PERKINS MN, 1993, PAIN, V53, P191, DOI 10.1016/0304-3959(93)90080-9; Plesnila N, 2001, J NEUROTRAUM, V18, P1049, DOI 10.1089/08977150152693746; Pruneau D, 1999, J NEUROTRAUM, V16, P1057, DOI 10.1089/neu.1999.16.1057; Relton JK, 1997, STROKE, V28, P1430, DOI 10.1161/01.STR.28.7.1430; Rodell TC, 1996, IMMUNOPHARMACOLOGY, V33, P279, DOI 10.1016/0162-3109(96)00071-9; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Schilling L, 1997, KIDNEY INT, pS69; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; Tomita M, 1996, ACT NEUR S, V66, P32; UNTERBERG A, 1984, J CEREBR BLOOD F MET, V4, P574, DOI 10.1038/jcbfm.1984.82; Wahl M, 1996, IMMUNOPHARMACOLOGY, V33, P257, DOI 10.1016/0162-3109(96)00068-9; Wahl M, 1993, Acta Neurochir Suppl (Wien), V57, P64; WALKER K, 1995, NEUROCHEM INT, V26, P1, DOI 10.1016/0197-0186(94)00114-A; WHITTLE IR, 1992, ACTA NEUROCHIR, V115, P53, DOI 10.1007/BF01400591; Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067	53	56	56	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2003	20	9					841	851		10.1089/089771503322385773			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	725BB	WOS:000185521800003	14577862				2022-02-06	
J	Amirjamshidi, A; Abbassioun, K; Rahmat, H; Hunt, CD				Amirjamshidi, A; Abbassioun, K; Rahmat, H; Hunt, CD			Minimal debridement or simple wound closure as the only surgical treatment in war victims with low-velocity penetrating head injuries - Indications and management protocol based upon more than 8 years follow-up of 99 cases from Iran-Iraq conflict	SURGICAL NEUROLOGY			English	Article						bone fragment; epilepsy; head injury; missile wound; surgical infection; war wound	MISSILE WOUNDS; BRAIN-ABSCESS; CRANIOCEREBRAL INJURIES; BONE FRAGMENTS; INFECTIONS; FISTULAS	BACKGROUND During military conflicts, surviving victims traditionally underwent large enough craniectomy or craniotomy to achieve extensive debridement of the in-driven bone, shell fragments, and debris. Meanwhile, the completely as well as the partially devitalized adjacent brain tissue would also be debrided. This might have led to additional neurologic deficit or lesser degree of recovery of functions. METHOD We studied the efficacy and safety of much more limited or even absence of surgical intervention in a selected group of wartime head-wounded patients. Among 1,150 war victims with penetrating head wounds referred to two major centers affiliated with Tehran University of Medical Sciences during the 8-year period spanning the Iran-Iraq conflict, there were 191 head-wounded patients who underwent either no surgical intervention or a very limited debridement. We have attempted to follow up as closely as possible for more than 8 years. Ninety-nine of them fulfilled the criteria to be included in this series. Close follow-up for development of cerebral infections, functional recovery, or development of new neurologic deficits and epilepsy were performed. At least 3 contrast-enhanced CT scans were taken for each patient. All patients were victims of the battle-field areas with low- to moderate-velocity missile or shell fragment injury. The Glasgow Coma Scale (GCS) scores of the patients were between 8-14 when visited by the first attending neurosurgery staff. The factors considered to be effective in the outcome analysis were the entry point, the number of the in-driven bone fragments, the retained shell fragments, the brain compartments affected, and the paranasal sinus or skull base involvement with or without cerebrospinal fluid (CSF) fistula. RESULTS There were 13 unilobar, 44 bilobar, 4 trilobar, 38 transventricular, and 3 skull base lesions. The number of retained metal fragments varied between 1 to 6. The number of retained bone fragments varied between 1 to 5 in 73 victims and more than five chips in other cases. The outcome was good (back to work) in 90 patients and poor (severely disabled) in 4. Five patients died because of severity of brain damage and meningitis. The effect of the different enumerated variables upon the outcome was measured using chi(2) and Fisher exact test, which was nonsignificant for all of the variables except for the orbitofacial entry point of injury (p = 0.00006). CONCLUSION This study seems to indicate that not only is reoperation for retained bone or shell fragments unnecessary, but surgeons having modern neuroradiological instruments available to detect the proper explanation for changes in GCS of the patients may decide not to proceed with any surgical intervention in a good number of patients. As a result of the "no surgical treatment protocol," one can preserve cerebral tissue without exposing the patient to undue risk of seizures, infection, or death by leaving behind some or all the in-driven bone and shell fragments. (C) 2003 Elsevier Inc. All rights reserved.	Sina Hosp, Dept Neurosurg, Tehran, Iran; Univ Tehran Med Sci, Tehran, Iran; Dr Shariati Hosp, Dept Neurosurg, Tehran, Iran; UMDNY, Sch Med, Dept Neurosurg, Newark, NJ USA		Amirjamshidi, A (corresponding author), POB 19585-678, Tehran 678, Iran.						Aarabi B, 1998, NEUROSURGERY, V42, P500, DOI 10.1097/00006123-199803000-00014; ABBOTT K H, 1946, Mil Surg, V98, P469; Abou Nader M, 2000, SURG NEUROL, V54, P397, DOI 10.1016/S0090-3019(00)00279-2; ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; Amirjamshidi A, 1996, J NEUROSURG, V84, P769, DOI 10.3171/jns.1996.84.5.0769; Ascroft PB, 1943, LANCET, V2, P211; BARATHAM G, 1972, J NEUROL NEUROSUR PS, V35, P698, DOI 10.1136/jnnp.35.5.698; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; CAIRNS H, 1947, BR J SURG WAR SURG S, V1, P198; CAREY ME, 1972, SURG GYNECOL OBSTETR, V135, P386; CAREY ME, 1974, J NEUROSURG, V41, P542, DOI 10.3171/jns.1974.41.5.0542; Cushing H, 1918, BRIT J SURG, V5, P558; DREW JH, 1954, J NEUROSURG, V11, P386, DOI 10.3171/jns.1954.11.4.0386; DZENITIS AJ, 1965, J NEUROSURG, V22, P169, DOI 10.3171/jns.1965.22.2.0169; ECKLUND JM, 2000, CLIN NEUROSURG, V48, pCH47; GEORGE ED, 1999, MISSILE WOUNDS HEAD, V1, pCH10; HAGAN RE, 1971, J NEUROSURG, V34, P132, DOI 10.3171/jns.1971.34.2part1.0132; HAMMON WM, 1971, J NEUROSURG, V34, P142, DOI 10.3171/jns.1971.34.2part1.0142; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; HAYNES WG, 1945, J NEUROSURG, V2, P463, DOI 10.3171/jns.1945.2.6.0463; HAYNES WG, 1945, J NEUROSURG, V2, P365, DOI 10.3171/jns.1945.2.5.0365; KAUFMAN HH, 1991, SURG NEUROL, V36, P370, DOI 10.1016/0090-3019(91)90026-6; Lee JH, 2000, J NEUROSURG, V93, P477, DOI 10.3171/jns.2000.93.3.0477; MALTBY GL, 1946, J NEUROSURG, V3, P239, DOI 10.3171/jns.1946.3.3.0239; Marquardt G, 2000, BRIT J NEUROSURG, V14, P246; MATSON DD, 1958, SURGERY WORLD WAR 2, V1, P123; MEIROWSKY AM, 1982, J NEUROSURG, V57, P617, DOI 10.3171/jns.1982.57.5.0617; MEIROWSKY AM, 1981, J NEUROSURG, V54, P44, DOI 10.3171/jns.1981.54.1.0044; MYERS PW, 1989, J NEUROSURG, V70, pA319; PENECK TL, 1986, J NEUROSURG, V64, P813; PITLYK PJ, 1970, J NEUROSURG, V33, P19, DOI 10.3171/jns.1970.33.1.0019; RISH BL, 1981, NEUROSURGERY, V9, P535, DOI 10.1227/00006123-198111000-00008; RISH BL, 1980, J NEUROSURG, V53, P772, DOI 10.3171/jns.1980.53.6.0772; SOLOMON RA, 1988, SURG NEUROL, V30, P321, DOI 10.1016/0090-3019(88)90307-2; Splavski B, 1998, SURG NEUROL, V50, P194, DOI 10.1016/S0090-3019(98)00047-0; TAHA JM, 1991, NEUROSURGERY, V29, P380, DOI 10.1227/00006123-199109000-00007; TAHA JM, 1991, NEUROSURGERY, V29, P864, DOI 10.1227/00006123-199112000-00010; WANNAMAKER GT, 1958, J NEUROSURG, V15, P512, DOI 10.3171/jns.1958.15.5.0512	38	56	62	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0090-3019			SURG NEUROL	Surg. Neurol.	AUG	2003	60	2					105	111		10.1016/S0090-3019(03)00358-6			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	707WB	WOS:000184531900003	12900110				2022-02-06	
J	Malessy, MJA; Bakker, D; Dekker, J; Van Dijk, JG; Thomeer, RTWM				Malessy, MJA; Bakker, D; Dekker, J; Van Dijk, JG; Thomeer, RTWM			Functional magnetic resonance imaging and control over the biceps muscle after intercostal-musculocutaneous nerve transfer	JOURNAL OF NEUROSURGERY			English	Article						brachial plexus; functional magnetic resonance imaging; intercostal nerve; motor cortex; nerve transfer; plasticity	BRACHIAL-PLEXUS INJURY; PRIMARY MOTOR CORTEX; HUMAN BRAIN; MRI; FMRI; REORGANIZATION; STIMULATION; ACTIVATION; RECOVERY; REPAIR	Object. Recent progress in the understanding of cerebral plastic changes that occur after an intercostal nerve (ICN)musculocutaneous nerve (MCN) transfer motivated a study with functional magnetic resonance (fMR) imaging to map reorganization in the primary motor cortex. Methods. Eleven patients with traumatic root avulsions of the brachial plexus were studied. Nine patients underwent ICN-MCN transfer to restore biceps function and two patients were studied prior to surgery. The biceps muscle recovered well in seven patients who had undergone surgery and remained paralytic in the other two patients. Maps of neural activity within the motor cortex were generated for both arms in each patient by using fMR imaging, and the active pixels were counted. The motor task consisted of biceps muscle contraction. Patients with a paralytic biceps were asked to contract this muscle virtually. The location and intensity of motor activation of the seven surgically treated arms that required good biceps muscle function were compared with those of the four arms with a paralytic biceps and with activity obtained in the contralateral hemisphere regulating the control arms. Activity could be induced in the seven surgically treated patients whose biceps muscles had regained function and was localized within the primary motor area. In contrast, activity could not be induced in the four patients whose biceps muscles were paralytic. Neither the number of active pixels nor the mean value of their activations differed between the seven arms with good biceps function and control arms. The weighted center of gravity of the distribution of activity also did not appear to differ. Conclusions. Reactivation of the neural input activity for volitional biceps control after ICN-MCN transfer, as reflected on fMR images, is induced by successful biceps muscle reinnervation. In addition, the restored input activity does not differ from the normal activity regulating biceps contraction and, therefore, has MCN acceptor qualities. After ICN-MCN transfer, cerebral activity cannot reach the biceps muscle following the normal nervous system pathway. The presence of a common input response between corticospinal neurons of the ICN donor and the MCN acceptor seems crucial to obtain a functional result after transfer. It may even be the case that a common input response between donor and acceptor needs to be present in all types of nerve transfer to become functionally effective.	Leiden Univ, Med Ctr, Dept Neurosurg, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Radiol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Neurol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Neurophysiol, NL-2300 RC Leiden, Netherlands		Malessy, MJA (corresponding author), Leiden Univ, Med Ctr, Dept Neurosurg, POB 9600, NL-2300 RC Leiden, Netherlands.	M.J.A.Malessy@lumc.nl	Malessy, Martijn/AAZ-9996-2021	Malessy, Martijn/0000-0003-1936-3664			Bakay RAE, 2001, NEUROSURGERY, V49, P367; BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; Cheng H, 1997, J COMP NEUROL, V380, P155, DOI 10.1002/(SICI)1096-9861(19970407)380:2<155::AID-CNE1>3.0.CO;2-2; Dai TH, 2001, EXP BRAIN RES, V140, P290, DOI 10.1007/s002210100815; Dale AM, 1997, HUM BRAIN MAPP, V5, P329, DOI 10.1002/(SICI)1097-0193(1997)5:5<329::AID-HBM1>3.0.CO;2-5; Dettmers C, 1999, NEUROSCI LETT, V263, P41, DOI 10.1016/S0304-3940(99)00105-6; Evans KC, 1999, J PHYSIOL-LONDON, V520, P383, DOI 10.1111/j.1469-7793.1999.00383.x; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; Giraux P, 2001, NAT NEUROSCI, V4, P691, DOI 10.1038/89472; Hallett M, 2000, NATURE, V406, P147, DOI 10.1038/35018000; KAWAI H, 1994, J BONE JOINT SURG BR, V76B, P666; Kawai H, 2000, BRACHIAL PLEXUS PALS, P161; KAWASHIMA R, 1995, NEUROREPORT, V6, P238, DOI 10.1097/00001756-199501000-00003; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Krings T, 1997, NEUROLOGY, V48, P1406, DOI 10.1212/WNL.48.5.1406; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Malessy MJA, 1998, J NEUROSURG, V88, P266, DOI 10.3171/jns.1998.88.2.0266; Malessy MJA, 1999, J NEUROSURG, V91, P601, DOI 10.3171/jns.1999.91.4.0601; MALESSY MJA, 1993, CLIN NEUROL NEUROSUR, V95, pS95; Malessy MJA, 1998, NEUROSURGERY, V42, P787, DOI 10.1097/00006123-199804000-00062; Malessy MJA, 1999, J NEUROSURG, V91, P636, DOI 10.3171/jns.1999.91.4.0636; Malessy MJA, 1998, J NEUROSURG, V89, P568, DOI 10.3171/jns.1998.89.4.0568; MANO Y, 1995, ANN NEUROL, V38, P15, DOI 10.1002/ana.410380106; Nudo RJ, 2001, MUSCLE NERVE, V24, P1000, DOI 10.1002/mus.1104; PENFIELD W, 1954, EPILEPSY FUNCTIONAL, P52; RAO SM, 1995, NEUROLOGY, V45, P919, DOI 10.1212/WNL.45.5.919; Rees G, 2000, NAT NEUROSCI, V3, P716, DOI 10.1038/76673; Rosen BR, 1998, P NATL ACAD SCI USA, V95, P773, DOI 10.1073/pnas.95.3.773; Roth R, 1996, NEUROREPORT, V7, P1280, DOI 10.1097/00001756-199605170-00012; Seddon HJ, 1954, PERIPHERAL NERVE INJ; THOMEER RTWM, 1993, CLIN NEUROL NEUROSUR, V95, pS65; WASSERMANN EM, 1992, ELECTROEN CLIN NEURO, V85, P1, DOI 10.1016/0168-5597(92)90094-R; XUE M, 1996, P SOC MAGN RES, P447	34	56	60	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	FEB	2003	98	2					261	268		10.3171/jns.2003.98.2.0261			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	643RB	WOS:000180873300001	12593609				2022-02-06	
J	Pavone, A; Cardile, T				Pavone, A; Cardile, T			An in vitro study of new antiepileptic drugs and astrocytes	EPILEPSIA			English	Article						AEDs; epilepsy; glial cells; rat	GLUTAMINE-SYNTHETASE ACTIVITY; RAT ASTROCYTES; NITRIC-OXIDE; DNA-DAMAGE; RELEASE; QUANTITATION; TIAGABINE; PROTEINS; CULTURES; STRESS	Purpose: The aim of our research was to study some biochemical modifications elicited in primary rat astrocyte cultures by treatment with gabapentin (GBP), carbamazepine (CBZ), lamotrigine (LTG), topiramate (TPM), oxcarbazepine (OXC), tiagabine (TGB), and levetiracetam (LEV), commonly used in the treatment of epilepsy. We investigated the biologic effects of these anticonvulsants (AEDs) at concentrations of 1, 10, 50, and 100 mug/ml. Methods: The study was performed by examining cell viability (MTT assay), cell toxicity [lactate dehydrogenase (LDH) release in the medium], glutamine synthetase (GS) activity, reactive oxygen species (ROS) production, lipoperoxidation level (malondialdehyde; MDA), and DNA fragmentation (COMET assay). The level of the expression of 70-kDa heat-shock protein (HSP70) and inducible nitric oxide synthase (iNOS) as oxidative stress-modulated genes also was determined. Results: Our experiments indicate that CBZ, TPM, and OXC induce stress on astrocytes at all concentrations. GBP, LTG, TGB, and LEV, at low concentrations, do not significantly change the metabolic activities examined and do not demonstrate toxic actions on astrocytes. They do so at higher concentrations. Conclusions: Most AEDs have effects on glial cells and, when used at an appropriate cell-specific (concentrations, may be well tolerated by cortical astrocytes. However, at higher concentrations, GBP, LTG, TGB, and LEV seem to be better tolerated than are CBZ, TPM, and OXC. These findings may reveal novel ways of producing large numbers of new AEDs capable of reducing the extent of inflammation, neuronal damage, and death under pathological conditions such as epilepsy and/or traumatic brain injury.	Univ Catania, Dept Physiol Sci, I-95125 Catania, Italy; Garibaldi Hosp, Dept Neurol, Catania, Italy		Cardile, T (corresponding author), Univ Catania, Dept Physiol Sci, Vle A Doria 6, I-95125 Catania, Italy.	cardile@mbox.unict.it		CARDILE, Venera/0000-0001-9902-3736			Aghdasi B, 1997, J BIOL CHEM, V272, P25462, DOI 10.1074/jbc.272.41.25462; AIRD RB, 1989, EPILEPSY RES, V3, P77, DOI 10.1016/0920-1211(89)90071-5; ALTAR AC, 1996, NEURODEGENERATION NE, P116; Araque A, 2001, ANNU REV PHYSIOL, V63, P795, DOI 10.1146/annurev.physiol.63.1.795; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cardile V, 1996, BRAIN RES, V715, P98, DOI 10.1016/0006-8993(95)01564-7; Cardile V, 2001, NEUROSCI LETT, V306, P17, DOI 10.1016/S0304-3940(01)01836-5; Cardile V, 2000, NEUROSCI LETT, V288, P49, DOI 10.1016/S0304-3940(00)01206-4; Chanvitayapongs S, 1997, NEUROREPORT, V8, P1499, DOI 10.1097/00001756-199704140-00035; DING AH, 1988, J IMMUNOL, V141, P2407; Fraser CM, 1999, BRIT J PHARMACOL, V126, P1634, DOI 10.1038/sj.bjp.0702472; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loscher W, 2002, J PHARMACOL EXP THER, V301, P7, DOI 10.1124/jpet.301.1.7; McGeer EG, 1997, MOVEMENT DISORD, V12, P855, DOI 10.1002/mds.870120604; McNaught KSP, 2000, NEUROSCI LETT, V285, P61, DOI 10.1016/S0304-3940(00)00982-4; Miyamae Y, 1998, Mutat Res, V415, P229, DOI 10.1016/S1383-5718(97)00192-7; Moller P, 2000, CANCER EPIDEM BIOMAR, V9, P1005; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nicolson A, 2001, CNS DRUGS, V15, P955, DOI 10.2165/00023210-200115120-00005; Renis M, 1998, BRAIN RES, V783, P143, DOI 10.1016/S0006-8993(97)01321-8; Shen HM, 1996, FREE RADICAL BIO MED, V21, P139, DOI 10.1016/0891-5849(96)00019-6; Sills Graeme J., 1998, Epilepsia, V39, P40; SINGH NP, 1991, MUTAT RES, V252, P289, DOI 10.1016/0165-1161(91)90008-V; Sisodiya SM, 2002, BRAIN, V125, P22, DOI 10.1093/brain/awf002; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063	26	56	59	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia		2003	44			10			34	39		10.1046/j.1528-1157.44.s10.5.x			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	733YK	WOS:000186028100007	14511393	Bronze			2022-02-06	
J	Kochanek, PM; Hendrich, KS; Dixon, CE; Schiding, JK; Williams, DS; Ho, C				Kochanek, PM; Hendrich, KS; Dixon, CE; Schiding, JK; Williams, DS; Ho, C			Cerebral blood flow at one year after controlled cortical impact in rats: Assessment by magnetic resonance imaging	JOURNAL OF NEUROTRAUMA			English	Article						atrophy; dementia; perfusion; spin-lattice relaxation; traumatic brain injury	SPIN-LABELED MRI; BRAIN INJURY; ARTERIAL WATER; PERFUSION; AGE; TRAUMA; REACTIVITY; LESION	Progressive tissue loss and delayed cognitive deficits are seen in rats during the initial year after experimental traumatic brain injury (TBI). As much as 10% of parenchymal volume is lost even in the contralateral hemisphere by 1 year after controlled cortical impact (CCI) in rats. Progressive declines in cerebral blood flow (CBF) are also associated with advanced age and neurodegenerative diseases. Surprisingly, the long-term effects of TBI on CBF remain undefined. CBF was quantified by continuous arterial spin-labeled magnetic resonance imaging (MRI) and measurements of spin-lattice relaxation time in a slice through the plane of injury at 1 year after experimental TBI produced by CCI (n = 4) or sham surgery (n = 4) in rats. CBF was quantified in six regions of interest (ROIs) that were anatomically identified on the control images in each hemisphere and included a medial cortical segment (contusion-enriched, beneath the impact site, on the ipsilateral side) cortex, hippocampus, thalamus, amygdala/pyriform cortex, and hemisphere. At 1 year after injury, CBF was dramatically (96%) reduced in structures within the large cystic lesion that was seen in three of four rats and variably included cortex and hippocampus. Overall, there was an 80% reduction in CBF in the ipsilateral medial cortical segment comparing CCI and sham groups. Similarly, 52% and 67% reductions were seen in CBF in the cortical and hippocampal ROIs ipsilateral to impact (CCI vs. sham), respectively. These are regions both with marked CBF disturbances early after injury and that ultimately suffer considerable tissue loss over the 1-year interval. However, at 1 year after CCI, CBF was not different from sham in other ROIs, including ipsilateral thalamus, or either contralateral hippocampus or hemisphere. We conclude that, at 1 year after CCI, CBF is reduced in anatomic structures at or near the impact site, including injured cortex and hippocampus, and this translates into a reduction in hemispheric CBF. However, despite both significant occult tissue loss ipsilateral and contralateral to the injury and delayed cognitive deficits, widespread reductions in CBF are not observed. This suggests the possibility of remodeling or repackaging of the brain that preserves CBF outside of the cystic lesion.	Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Dept Crit Care Med, Pittsburgh, PA USA; Dept Anesthesiol, Pittsburgh, PA USA; Dept Pediat, Pittsburgh, PA USA; Dept Neurosurg, Pittsburgh, PA USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA USA; Carnegie Mellon Univ, Pittsburgh NMR Ctr Biomed Res, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA		Kochanek, PM (corresponding author), Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	Kochanekpm@ccm.upmc.edu	Ho, Chien/O-6112-2016; Kochanek, Patrick M/D-2371-2015	Ho, Chien/0000-0002-4094-9232; Kochanek, Patrick M/0000-0002-2627-913X	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR003631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, P50NS030318, P20NS030318, R01NS038087] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41-RR03631] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30318, NS 38087] Funding Source: Medline		BERMAN RF, 1988, NEUROBIOL AGING, V9, P691, DOI 10.1016/S0197-4580(88)80134-9; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; CAO WH, 1989, NEUROSCI LETT, V107, P135, DOI 10.1016/0304-3940(89)90805-7; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Donaldson HH, 1931, J COMP NEUROL, V53, P263, DOI 10.1002/cne.900530202; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; Friel KM, 2000, NEUROREHAB NEURAL RE, V14, P187, DOI 10.1177/154596830001400304; Hendrich KS, 2001, MAGNET RESON MED, V46, P202, DOI 10.1002/mrm.1178; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HOVDA DA, 1993, J CEREB BLOOD FLOW M, V13, pS574; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KOCHANEK PM, 1997, J NEUROTRAUM, V14, P783; LARTAUD I, 1993, AM J PHYSIOL, V264, pH851, DOI 10.1152/ajpheart.1993.264.3.H851; Liepert J, 1999, CURR OPIN NEUROL, V12, P709, DOI 10.1097/00019052-199912000-00009; NAMBA H, 1991, NEUROSCI RES, V12, P463, DOI 10.1016/0168-0102(91)90079-E; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; Nobili F, 2001, DEMENT GERIATR COGN, V12, P89, DOI 10.1159/000051241; Otsuka H, 2000, J NEUROSURG, V93, P298, DOI 10.3171/jns.2000.93.2.0298; PIERCE JES, 1995, J NEUROTRAUM, V12, P964; Rapoport S I, 1982, Exp Brain Res, VSuppl 5, P86; Rodriguez G, 1998, ITAL J NEUROL SCI, V19, P367, DOI 10.1007/BF02341784; Scremin OU, 1996, LIFE SCI, V58, P2011, DOI 10.1016/0024-3205(96)00192-0; Scremin OU, 1997, J NEUROTRAUM, V14, P573, DOI 10.1089/neu.1997.14.573; Shiozaki T, 2001, J NEUROTRAUM, V18, P665, DOI 10.1089/089771501750357618; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Sonntag WE, 1997, ENDOCRINOLOGY, V138, P3515, DOI 10.1210/en.138.8.3515; Sorger D, 1999, NUCL MED BIOL, V26, P9, DOI 10.1016/S0969-8051(98)00059-6; Strupp JP, 1996, NEUROIMAGE, V3, pS607; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Uchida S, 2000, NEUROSCI LETT, V294, P109, DOI 10.1016/S0304-3940(00)01556-1; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; ZHANG WG, 1995, MAGNET RESON MED, V33, P370, DOI 10.1002/mrm.1910330310; ZHANG WG, 1993, MAGNET RESON MED, V29, P416, DOI 10.1002/mrm.1910290323	41	56	57	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2002	19	9					1029	1037		10.1089/089771502760341947			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	598KW	WOS:000178275900004	12482116				2022-02-06	
J	Aradi, I; Soltesz, I				Aradi, I; Soltesz, I			Modulation of network behaviour by changes in variance in interneuronal properties	JOURNAL OF PHYSIOLOGY-LONDON			English	Article							HIPPOCAMPUS IN-VITRO; TRAUMATIC BRAIN INJURY; DENTATE BASKET CELLS; RAT HIPPOCAMPUS; PYRAMIDAL NEURONS; FEBRILE SEIZURES; CA1 INTERNEURONS; GRANULE CELLS; LONG-TERM; INHIBITORY INTERNEURONS	Interneurones are important regulators of neuronal networks. The conventional approach to interneurones is to focus on the mean values of various parameters. Here we tested the hypothesis that changes in the variance of interneuronal properties (e.g. in the degree of scattering of parameter values of individual cells around the population mean) may modify the behaviour of networks. Biophysically based multicompartmental models of principal cells and interneurones showed that changes in the variance in the electrophysiological and anatomical properties of interneurones significantly alter the input-output functions, rhythmicity and synchrony of principal cells, even if the mean values were unchanged. In most cases, increased heterogeneity in interneurones resulted in stronger inhibition of principal cell firing; however, there were parameter ranges where increased interneuronal variance decreased the inhibition of principal cells. Electrophysiological recordings showed that the variance in the resting membrane potential of CA1 stratum oriens interneurones persistently increased following experimental complex febrile seizures in developing rats, without a change in the mean resting membrane potential, indicating that lasting alterations in interneuronal heterogeneity can take place in real neuronal systems. These computational and experimental data demonstrate that modifications in interneuronal population variance influence the behaviour of neuronal networks, and suggest a physiological role for interneuronal diversity. Furthermore, the results indicate that interneuronal heterogeneity can change in neurological diseases, and raise the possibility that neuromodulators may act by regulating the variance of key parameters in interneuronal populations.	Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA		Soltesz, I (corresponding author), Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA.	isoltesz@uci.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35951] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035951] Funding Source: NIH RePORTER		Ali AB, 1999, EUR J NEUROSCI, V11, P1741, DOI 10.1046/j.1460-9568.1999.00592.x; Aradi I, 1999, NEUROCOMPUTING, V26-7, P45, DOI 10.1016/S0925-2312(99)00087-9; Aradi I, 1999, J COMPUT NEUROSCI, V6, P215, DOI 10.1023/A:1008801821784; Banks MI, 2000, NEURON, V25, P449, DOI 10.1016/S0896-6273(00)80907-1; Baram TZ, 1997, DEV BRAIN RES, V98, P265, DOI 10.1016/S0165-3806(96)00190-3; Bergles DE, 1996, J NEUROSCI, V16, P572; Buckmaster PS, 1996, HIPPOCAMPUS, V6, P330, DOI 10.1002/(SICI)1098-1063(1996)6:3<330::AID-HIPO9>3.0.CO;2-Q; BUHL EH, 1994, J NEUROPHYSIOL, V71, P1289, DOI 10.1152/jn.1994.71.4.1289; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; BUHL EH, 1995, EUR J NEUROSCI, V7, P1989, DOI 10.1111/j.1460-9568.1995.tb00721.x; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; Caillard O, 1999, J NEUROSCI, V19, P7568, DOI 10.1523/JNEUROSCI.19-17-07568.1999; CAJAL SRY, 1911, HIST SYSTEME NERVEAU, V2; Chen K, 1999, NAT MED, V5, P888, DOI 10.1038/11330; Chen K, 2001, NAT MED, V7, P331, DOI 10.1038/85480; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dube C, 2000, ANN NEUROL, V47, P336, DOI 10.1002/1531-8249(200003)47:3<336::AID-ANA9>3.3.CO;2-N; Fisahn A, 1998, NATURE, V394, P186, DOI 10.1038/28179; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; FREUND TF, 1988, NATURE, V336, P170, DOI 10.1038/336170a0; Geiger JRP, 1997, NEURON, V18, P1009, DOI 10.1016/S0896-6273(00)80339-6; GOLOMB D, 1993, PHYS REV E, V48, P4810, DOI 10.1103/PhysRevE.48.4810; GULYAS AI, 1993, EUR J NEUROSCI, V5, P1729, DOI 10.1111/j.1460-9568.1993.tb00240.x; Gupta A, 2000, SCIENCE, V287, P273, DOI 10.1126/science.287.5451.273; Hajos N, 1997, J NEUROSCI, V17, P8427; HALASY K, 1993, EUR J NEUROSCI, V5, P411, DOI 10.1111/j.1460-9568.1993.tb00508.x; Halasy K, 1996, HIPPOCAMPUS, V6, P306, DOI 10.1002/(SICI)1098-1063(1996)6:3<306::AID-HIPO8>3.0.CO;2-K; HAN ZS, 1993, EUR J NEUROSCI, V5, P395, DOI 10.1111/j.1460-9568.1993.tb00507.x; Hines M, 1995, HDB BRAIN THEORY NEU, P226; Hines ML, 1997, NEURAL COMPUT, V9, P1179, DOI 10.1162/neco.1997.9.6.1179; Hollrigel GS, 1998, NEUROSCIENCE, V84, P71, DOI 10.1016/S0306-4522(97)00499-5; JAFFE DB, 1994, J NEUROPHYSIOL, V71, P1065, DOI 10.1152/jn.1994.71.3.1065; Jones MV, 1997, J NEUROSCI, V17, P7626; KNEISLER TB, 1995, J PHYSIOL-LONDON, V487, P125, DOI 10.1113/jphysiol.1995.sp020866; KNEISLER TB, 1995, HIPPOCAMPUS, V5, P151, DOI 10.1002/hipo.450050302; LACAILLE JC, 1988, J NEUROSCI, V8, P1400; LI XG, 1992, EXP BRAIN RES, V90, P519; LISMAN JE, 1995, SCIENCE, V267, P1512, DOI 10.1126/science.7878473; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; Maccaferri G, 2000, J PHYSIOL-LONDON, V524, P91, DOI 10.1111/j.1469-7793.2000.t01-3-00091.x; MacNeil MA, 1998, NEURON, V20, P971, DOI 10.1016/S0896-6273(00)80478-X; Mainen ZF, 1996, NATURE, V382, P363, DOI 10.1038/382363a0; Markram H, 1997, J PHYSIOL-LONDON, V500, P409, DOI 10.1113/jphysiol.1997.sp022031; MCBAIN CJ, 1993, J PHYSIOL-LONDON, V462, P373, DOI 10.1113/jphysiol.1993.sp019560; MCBAIN CJ, 1994, J NEUROSCI, V14, P4433; MCCORMICK DA, 1993, CEREB CORTEX, V3, P387, DOI 10.1093/cercor/3.5.387; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McMahon LL, 1997, J NEUROPHYSIOL, V78, P2493, DOI 10.1152/jn.1997.78.5.2493; McQuiston AR, 1999, J NEUROSCI, V19, P5693, DOI 10.1523/JNEUROSCI.19-14-05693.1999; Miles R, 2000, SCIENCE, V287, P244, DOI 10.1126/science.287.5451.244; Miles R, 1996, NEURON, V16, P815, DOI 10.1016/S0896-6273(00)80101-4; MILES R, 1986, J PHYSIOL-LONDON, V373, P397, DOI 10.1113/jphysiol.1986.sp016055; Miller KK, 1997, J NEUROSCI, V17, P4994; Morales M, 1997, J NEUROSCI, V17, P3157; MOTT DD, 1997, J NEUROSCI, V17, P3390; Nusser Z, 1997, NEURON, V19, P697, DOI 10.1016/S0896-6273(00)80382-7; Parra P, 1998, NEURON, V20, P983, DOI 10.1016/S0896-6273(00)80479-1; Ross ST, 2001, P NATL ACAD SCI USA, V98, P8874, DOI 10.1073/pnas.141042398; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916, DOI 10.1152/jn.2000.83.5.2916; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; SCHARFMAN HE, 1995, HIPPOCAMPUS, V5, P287, DOI 10.1002/hipo.450050403; SIK A, 1995, J NEUROSCI, V15, P6651; SOLTESZ I, 1993, J NEUROPHYSIOL, V70, P97, DOI 10.1152/jn.1993.70.1.97; Sprent P., 2001, APPL NONPARAMETRIC S; SPRUSTON N, 1992, J NEUROPHYSIOL, V67, P508, DOI 10.1152/jn.1992.67.3.508; Spruston N, 1997, J COMP NEUROL, V385, P427; STALEY KJ, 1992, J NEUROPHYSIOL, V67, P1346, DOI 10.1152/jn.1992.67.5.1346; Svoboda KR, 1999, J NEUROSCI, V19, P85, DOI 10.1523/JNEUROSCI.19-01-00085.1999; Thomson AM, 2000, EUR J NEUROSCI, V12, P425, DOI 10.1046/j.1460-9568.2000.00915.x; Tiesinga PHE, 2000, NETWORK-COMP NEURAL, V11, P1, DOI 10.1088/0954-898X/11/1/301; Toth Z, 1997, J NEUROSCI, V17, P8106; TRAUB RD, 1991, J NEUROPHYSIOL, V66, P635, DOI 10.1152/jn.1991.66.2.635; Traub RD, 1996, J PHYSIOL-LONDON, V493, P471, DOI 10.1113/jphysiol.1996.sp021397; Traub RD, 1999, FAST OSCILLATIONS CO; Van Vreeswijk C, 1994, J Comput Neurosci, V1, P313; WANG XJ, 1993, NEUROSCIENCE, V53, P899, DOI 10.1016/0306-4522(93)90474-T; Wang XJ, 1996, J NEUROSCI, V16, P6402; White JA, 2000, P NATL ACAD SCI USA, V97, P8128, DOI 10.1073/pnas.100124097; White JA, 1998, J COMPUT NEUROSCI, V5, P5, DOI 10.1023/A:1008841325921; YLINEN A, 1995, HIPPOCAMPUS, V5, P78, DOI 10.1002/hipo.450050110; YUEN GLF, 1991, NEUROSCIENCE, V41, P411, DOI 10.1016/0306-4522(91)90337-N; Zar J.H., 1999, BIOSTAT ANAL, V4	84	56	56	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3751	1469-7793		J PHYSIOL-LONDON	J. Physiol.-London	JAN 1	2002	538	1					227	251		10.1113/jphysiol.2001.013054			25	Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Physiology	517XT	WOS:000173636300022	11773331	Green Published			2022-02-06	
J	Vink, R; Mullins, PGM; Temple, MD; Bao, WL; Faden, AI				Vink, R; Mullins, PGM; Temple, MD; Bao, WL; Faden, AI			Small shifts in craniotomy position in the lateral fluid percussion injury model are associated with differential lesion development	JOURNAL OF NEUROTRAUMA			English	Article						behavioral outcome; lesions; magnetic resonance imaging; neurotrauma	TRAUMATIC BRAIN INJURY; COGNITIVE DEFICITS; MAGNETIC-RESONANCE; HEAD-INJURY; RAT; SPECTROSCOPY; DYSFUNCTION; METABOLISM; DISRUPTION; DECLINE	Previous studies have shown that location and direction of injury may affect outcome in experimental models of traumatic brain injury. Significant variability in outcome data has also been noted in studies using the lateral fluid percussion brain injury model (FPI) in rats. In recent studies from our laboratory, we observed considerable variability in localization and severity of tissue damage as a function of small changes in craniotomy position. To further address this issue, we examined the relationship between craniotomy position and brain lesion size/location in rats subjected to moderate FPI (2.28 +/- 0.18 atmospheres). With placement of a 5-mm craniotomy adjacent to the sagittal suture, there was both ipsilateral and contralateral damage as detected at 3 weeks posttrauma using T-2-weighted magnetic resonance imaging (MRI). The MRI lesions were generally restricted to the hippocampus and subcortical layers. Shifting of the craniotomy site laterally was associated with increased ipsilateral tissue damage and a greater cortical component that correlated with distance from the sagittal suture. In contrast, the contralateral MRI lesion did not change significantly in size or location unless the center of the craniotomy was placed more than 3.5 mm from the sagittal suture, under which condition contralateral damage could no longer be detected. Ipsilateral tissue damage as determined from the MRI scans was linearly correlated to motor outcome but not with cognitive outcome as assessed by the Morris Water Maze. We conclude that craniotomy position is critical in determining extent and location of tissue injury produced during the lateral FPI model in rats. Addressing such potential variability is essential for studies that address either injury mechanisms or therapeutic treatments.	Georgetown Univ, Sch Med, Dept Neurosci, Seattle, WA USA		Vink, R (corresponding author), Univ Adelaide, Dept Pathol, GPO Box 498, Adelaide, SA 5005, Australia.		Vink, Robert/J-7351-2012; Vink, Robert/S-5616-2019	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Mullins, Paul/0000-0002-1339-6361	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR 306634] Funding Source: Medline		Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1988, J NEUROTRAUM, V5, P99; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196, DOI 10.1152/ajpregu.1999.277.4.R1196; FLOYD CL, 1997, J NEUROTRAUM, V14, P766; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Glass TF, 1999, J NEUROTRAUM, V16, P771, DOI 10.1089/neu.1999.16.771; Golding EM, 1996, MAGNET RESON MED, V35, P174, DOI 10.1002/mrm.1910350208; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; Pierce JES, 1996, J NEUROSCI, V16, P1083; PRASAD MR, 1994, J NEUROCHEM, V63, P773; Qian Liang, 1996, Bulletin of Tokyo Medical and Dental University, V43, P53; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1988, J BIOL CHEM, V263, P757	35	56	60	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2001	18	8					839	847		10.1089/089771501316919201			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	464AG	WOS:000170509600010	11526990				2022-02-06	
J	Verger, K; Junque, C; Levin, HS; Jurado, MA; Perez-Gomez, M; Bartres-Faz, D; Barrios, M; Alvarez, A; Bartumeus, F; Mercader, JM				Verger, K; Junque, C; Levin, HS; Jurado, MA; Perez-Gomez, M; Bartres-Faz, D; Barrios, M; Alvarez, A; Bartumeus, F; Mercader, JM			Correlation of atrophy measures on MRI with neuropsychological sequelae in children and adolescents with traumatic brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; DIFFUSE AXONAL INJURY; CORPUS-CALLOSUM; DEGENERATIVE CHANGES; CLINICAL-FEATURES; CT; COMA; MORPHOLOGY; DAMAGE; INDEX	To examine the relationship between neuropsychological sequelae and atrophy parameters from magnetic resonance imaging (MRI) following paediatric moderate- to- severe traumatic brain injury (TBI), 19 head- injured children and adolescents were studied at least 6 years after injury. Three-dimensional MRI scans were obtained. A semi- automatic computerized method was used to estimate ventricular volumes and the corpus callosum area. Tests of intellectual, memory, visuospatial, frontal lobe, and motor speed functioning were administered to all patients and to 19 matched normal control subjects. Patients' performance significantly differed from controls in general intellectual function, visual memory, visuospatial and frontal lobe tests. The corpus callosum area correlated strongly with several measures involving processing speed and visuospatial function. Ventricular enlargement was less related to neuropsychological outcome. In conclusion, quantitative measurement of the corpus callosum on MRI reflects neuropsychological outcome better than ventricular dilation in paediatric patients.	Univ Barcelona, Dept Psychiat & Clin Psychobiol, Barcelona 08035, Spain; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Univ Barcelona, Dept Methodol Behav Sci, Barcelona, Spain; Hosp Santa Creu & Sant Pau, Dept Neurosurg, E-08025 Barcelona, Spain; Hosp Clin Barcelona, Dept Radiol, Barcelona, Spain		Junque, C (corresponding author), Univ Barcelona, Dept Psychiat & Clin Psychobiol, Passeig Vall Hebron 171, Barcelona 08035, Spain.	cjun-que@psi.ub.es	JURADO, MARIA ANGELES/E-1745-2011; Junque, Carme/B-4400-2011; Bartres-Faz, David/C-8997-2011; Barrios, Maite/J-5738-2013	JURADO, MARIA ANGELES/0000-0002-9403-1670; Junque, Carme/0000-0002-6381-3063; Bartres-Faz, David/0000-0001-6020-4118; Barrios, Maite/0000-0003-1979-0818			ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; BENTON A L, 1978, Archives of Neurology, V35, P364; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; BIGLER ED, 1992, ARCH CLIN NEUROPSYCH, V7, P449, DOI 10.1016/0887-6177(92)90158-J; BIGLER ED, 1994, BRAIN INJURY, V8, P231, DOI 10.3109/02699059409150975; Bigler ED, 1996, J LEARN DISABIL-US, V29, P515, DOI 10.1177/002221949602900507; BIGLER ED, 1996, NEUROIMAGING, V2; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; Bowen JM, 1997, DEV MED CHILD NEUROL, V39, P17; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; EDWINGCOBBS L, 1987, J CLIN EXPT NEUROPSY, V9, P575; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; Giedd JN, 1996, DEV BRAIN RES, V91, P274; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; Heaton R.K., 1981, WISCONSIN CARD SORTI; ICHISE M, 1994, J NUCL MED, V35, P217; JACK CR, 1989, RADIOLOGY, V172, P549, DOI 10.1148/radiology.172.2.2748838; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEVIN HS, 1992, NEUROSURGERY, V31, P1117, DOI 10.1227/00006123-199212000-00021; LEVIN HS, 1985, ARCH NEUROL-CHICAGO, V42, P963, DOI 10.1001/archneur.1985.04060090045012; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; PUJOL J, 1993, ANN NEUROL, V34, P71, DOI 10.1002/ana.410340113; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; REY A, 1987, TEST COPIA UNA FIGUR; Rey A., 1964, EXAMEN CLIN PSYCHOL; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Verger K, 2000, BRAIN INJURY, V14, P495; WECHSLER D, 1976, ESCALA INTELIGENCIA	41	56	57	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2001	15	3					211	221					11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	407ZM	WOS:000167302100002	11260770				2022-02-06	
J	Webster, JB; Bell, KR; Hussey, JD; Natale, TK; Lakshminarayan, S				Webster, JB; Bell, KR; Hussey, JD; Natale, TK; Lakshminarayan, S			Sleep apnea in adults with traumatic brain injury: A preliminary investigation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	59th Annual Assembly of the American-Academy-of-Physical-Medicine-and-Rehabilitation	NOV 13-16, 1997	ATLANTA, GEORGIA	Amer Acad Phys Med & Rehabil		brain injuries; sleep apnea syndromes; rehabilitation	EXCESSIVE DAYTIME SLEEPINESS; PREVALENCE; EPIDEMIOLOGY; DISTURBANCES; COMPLAINTS; STROKE; MEN	Objective: To determine the occurrence and nature of sleep-related breathing disorders in adults with traumatic brain injury (TBI). Design: Prospective, observational, consecutive sample en rollment of subjects admitted for rehabilitation after TBT. Setting: Inpatient rehabilitation and subacute rehabilitation units of a tertiary care university medical system. Participants: Subjects (n = 28) included adults with TBI and a Rancho Los Amigos Scale level of 3 or greater who were less than 3 months postinjury and admitted for comprehensive inpatient rehabilitation. Interventions: Overnight sleep study using portable 6-channel monitoring system. Main Outcome Measure: Respiratory disturbance index (RDI), which is the number of apneic and hypopneic episodes per hour of sleep. Results: Evidence of sleep apnea was found in 10 of 28 (36%) subjects as measured by a RDI level of 5 or greater and in 3 of 28 (11%) subjects as measured by a RDI level of 10 or greater. This rate of sleep apnea is significantly (p = .002) higher than would be predicted based on population norms. No correlation was found between the occurrence of significant sleep apnea and measures of TBI severity or other demographic variables. Sleep-related breathing disorders were primarily central though obstructive apneas were also noted. Conclusion: In this preliminary investigation, sleep-related breathing disorders as defined by a respiratory disturbance index of 5 or greater appears to be common in adult subjects with TBI.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; VA Puget Sound Hlth Care Syst, Dept Resp Therapy, Seattle, WA USA; VA Puget Sound Hlth Care Syst, Dept Pulm Med, Seattle, WA USA		Webster, JB (corresponding author), E Carolina Univ, Dept PM&R, Moye Blvd, Greenville, NC 27858 USA.		Lang, Steven/AAE-8102-2021; Sanguansri, Luz/B-6630-2011	Lang, Steven/0000-0003-1669-9146; Sanguansri, Luz/0000-0003-1908-7604; Bell, Kathleen/0000-0002-0928-2046			*AM SLEEP DIS ASS, 1990, INT CLASS SLEEP DIS; ASKENASY JM, 1988, STROKE, V9, P637; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BERGAMASCO B, 1968, ELECTROEN CLIN NEURO, V24, P374, DOI 10.1016/0013-4694(68)90198-3; Bixler EO, 1998, AM J RESP CRIT CARE, V157, P144, DOI 10.1164/ajrccm.157.1.9706079; BONNET MH, 1993, SLEEP, V16, P65; BRESNITZ EA, 1994, EPIDEMIOL REV, V16, P210, DOI 10.1093/oxfordjournals.epirev.a036151; CIRIGNOTTA F, 1989, ACTA NEUROL SCAND, V79, P366, DOI 10.1111/j.1600-0404.1989.tb03802.x; CLINCHOT DM, 1996, ARCH PHYS MED REHAB, V77, P947; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; EMESELLEM HA, 1990, S MED J, V83, P748; FINDLEY LJ, 1986, CHEST, V90, P686, DOI 10.1378/chest.90.5.686; Good DC, 1996, STROKE, V27, P252, DOI 10.1161/01.STR.27.2.252; GREENBERG GD, 1987, SLEEP, V10, P259; GUILLEMINAULT C, 1992, NEUROLOGY, V42, P53; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; HEYMAN A, 1958, NEUROLOGY, V8, P694, DOI 10.1212/WNL.8.9.694; Hudgel DW, 1996, CHEST, V109, P1346, DOI 10.1378/chest.109.5.1346; JENNUM P, 1993, INT J EPIDEMIOL, V22, P439, DOI 10.1093/ije/22.3.439; KANESMART SL, 1996, ARCH PHYS MED REHAB, V77, P943; KAPEN S, 1991, Neurology, V41, P125; Kraus JF, 1993, HEAD INJURY, P1; LANGEVIN B, 1992, SLEEP S6, V15, P525; MANN NR, 1997, ARCH PHYS MED REHAB, V78, P1055; MARTIN JM, 1997, INT J EPIDEMIOL, V26, P381; MOHSENIN V, 1995, ARCH PHYS MED REHAB, V76, P71, DOI 10.1016/S0003-9993(95)80046-8; Neven AK, 1998, THORAX, V53, P638, DOI 10.1136/thx.53.8.638; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; REDLINE S, 1991, CHEST, V100, P1281, DOI 10.1378/chest.100.5.1281; ROEHRS T, 1983, SLEEP, V6, P319, DOI 10.1093/sleep/6.4.319; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; STRADLING JR, 1995, THORAX, V50, P683, DOI 10.1136/thx.50.6.683; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	33	56	56	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2001	82	3					316	321		10.1053/apmr.2001.20840			6	Rehabilitation; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	407RG	WOS:000167284100005	11245752				2022-02-06	
J	Goldstein, FC; Levin, HS				Goldstein, FC; Levin, HS			Cognitive outcome after mild and moderate traumatic brain injury in older adults	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; BEHAVIORAL SEQUELAE; AGE; CLASSIFICATION; CONSEQUENCES; PREDICTION; RECOVERY; FALLS; SCALE; RISK	This paper presents findings on the cognitive outcome of older adults sustaining mild traumatic brain injury (TBI). Results indicate that mild TBI patients who are 50 years or older, unlike those with moderate TBI, exhibit cognitive functioning that is comparable to noninjured controls by 1-2-months postinjury. However, these patients continue to report significant anxiety, depression, and somatic preoccupation despite their improvement on objective neuropsychological measures. The lowest postresuscitation Glasgow Coma Scale (GCS) score and the presence of intracranial pathology are more strongly associated with outcome than the durations of posttraumatic amnesia and impaired consciousness, possibly reflecting measurement issues in older persons who are likely to be injured in low velocity falls and to suffer delayed complications. A classification system that considers not only the GCS score but also the presence of intracranial pathology is sensitive to differences in the outcome of older adults, similar to the findings in young patients. The implications of these findings for older TBI patients and directions for research are discussed.	Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30329 USA; Emory Univ, Wesley Woods Ctr, Atlanta, GA 30329 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA		Goldstein, FC (corresponding author), Emory Univ, Sch Med, Dept Neurol, 1841 Clifton Rd NE, Atlanta, GA 30329 USA.						ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; AMACHER AL, 1987, NEUROSURGERY, V20, P954; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Benton A., 1976, MULTILINGUAL APHASIA; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DAVIS CS, 1988, J AM GERIATR SOC, V36, P225, DOI 10.1111/j.1532-5415.1988.tb01805.x; DIKMEN S, 1995, J HEAD TRAUMA REHAB, V10, P74, DOI 10.1097/00001199-199502000-00008; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; FIELDS RB, 1997, HDB NEUROPSYCHOLOGY, P280; FRANKOWSKI RF, 1985, CENTRAL NERVOUS SYST; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Goldstein FC, 1999, J NEUROPSYCH CLIN N, V11, P38, DOI 10.1176/jnp.11.1.38; Goldstein FC, 1996, NEUROPSYCHOLOGY, V10, P147; GOODMAN H, 1992, PHYSICAL MED REHABIL, P441; Grant PT, 2000, INJURY, V31, P519, DOI 10.1016/S0020-1383(00)00038-3; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; HANNAY HJ, 1988, CONTINUOUS RECOGNITI; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; Kannus P, 1999, AM J EPIDEMIOL, V149, P143; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KOTWICA Z, 1992, ACTA NEUROCHIR, V118, P98, DOI 10.1007/BF01401293; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1987, HEAD INJURY; Leipzig RM, 1999, J AM GERIATR SOC, V47, P30, DOI 10.1111/j.1532-5415.1999.tb01898.x; Levin, 1997, Semin Clin Neuropsychiatry, V2, P207; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Libon DJ, 1996, CLIN NEUROPSYCHOL, V10, P237, DOI 10.1080/13854049608406686; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MACKENZIE EJ, 1990, AM J PUBLIC HEALTH, V80, P217, DOI 10.2105/AJPH.80.2.217; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; MAZZUCCHI A, 1992, J NEUROL, V239, P256; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; *OFF POP CENS SURV, 1992, 1991 CENS; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ross A M, 1992, J Neurosci Nurs, V24, P88; ROSS BL, 1994, AM J PHYS MED REHAB, V73, P341, DOI 10.1097/00002060-199409000-00007; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); TEASDALE G, 1974, LANCET, V2, P281; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; *US DEP COMM BUR C, 1997, STAT ABSTR US 1997; Verhaeghen P, 1997, PSYCHOL BULL, V122, P231, DOI 10.1037/0033-2909.122.3.231; Vollmer DG, 1991, J NEUROSURG S, V75, P37; War Department Adjutant General's Office, 1944, ARM IND TEST BATT MA; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Winocur G., 1992, HDB AGING COGNITION, P315; YSEVAGE JA, 1983, J PSYCHIAT RES, V17, P37	69	56	58	0	6	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2001	23	6					739	753		10.1076/jcen.23.6.739.1028			15	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	535QL	WOS:000174655200004	11910541				2022-02-06	
J	Smith, FM; Raghupathi, R; MacKinnon, MA; McIntosh, TK; Saatman, KE; Meaney, DF; Graham, DI				Smith, FM; Raghupathi, R; MacKinnon, MA; McIntosh, TK; Saatman, KE; Meaney, DF; Graham, DI			TUNEL-positive staining of surface contusions after fatal head injury in man	ACTA NEUROPATHOLOGICA			English	Article						human traumatic brain injury; TUNEL staining	TRAUMATIC BRAIN INJURY; SPINAL-CORD INJURY; GLUTATHIONE-S-TRANSFERASE; SELECTIVE NEURONAL DEATH; PROGRAMMED CELL-DEATH; ALZHEIMERS-DISEASE; DNA FRAGMENTATION; CORTICAL IMPACT; APOPTOSIS; RATS	In frontal lobe contusions obtained post mortem from 18 patients who survived between 6 h and 10 days after head injury, DNA fragmentation associated with either apoptotic and/or necrotic cell death was identified by the terminal deoxynucleotidyl transferase-mediated biotinylated deoxyuridine triphosphate nick end labelling (TUNEL) histochemical technique. Additional histological techniques were also used to identify regional and temporal patterns of tissue damage. TUNEL-positive cells were present in both the grey and white matter of the contusion, where they peaked in number between 25 and 48 h, and were still identifiable at 10 days post injury. Fewer TUNEL-positive cells were observed in grey than in white matter; and most TUNEL-positive neurons in the grey matter demonstrated the morphological features of necrosis. However, the morphology of some TUNEL stained neurons, and of TUNEL-stained oligodendroglia and macrophages in white matter was suggestive of apoptosis. Apoptosis was not seen in age- and sex-matched controls, none of whom had died from intracranial pathology or had pre-existing neurological disease. These findings suggest that multiple cell types in frontal lobe contusions exhibit DNA fragmentation and that both necrosis and apoptosis are likely to contribute to post-traumatic pathology. These findings provide further evidence that the observations made in animal models of traumatic brain injury have fidelity with clinical head injury.	Univ Glasgow, So Gen Hosp NHS Trust, Inst Neurol Sci, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Bioengn, Philadelphia, PA 19104 USA		Graham, DI (corresponding author), Univ Glasgow, So Gen Hosp NHS Trust, Inst Neurol Sci, Dept Neuropathol, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.			Meaney, David/0000-0002-0954-4122	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803, R0I-NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P50NS008803] Funding Source: NIH RePORTER		ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Beattie MS, 1998, NEUROSCIENTIST, V4, P163, DOI 10.1177/107385849800400312; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bien A, 1999, J NEUROTRAUM, V16, P153, DOI 10.1089/neu.1999.16.153; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BURKE MJ, 1996, BRAIN PATHOL, V6, P427; CAMMER W, 1992, J COMP NEUROL, V321, P40, DOI 10.1002/cne.903210105; CharriautMarlangue C, 1996, TRENDS NEUROSCI, V19, P109, DOI 10.1016/S0166-2236(96)80039-7; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; FUNG KM, 1995, AM J PATHOL, V146, P1376; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GEHRMANN J, 1991, ACTA NEUROPATHOL, V82, P442, DOI 10.1007/BF00293378; GEHRMANN J, 1992, LAB INVEST, V67, P100; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENNARELLI TA, 1979, P 23 STAPP CAR CRASH, P561; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Graham DI, 1997, GREENFIELDS NEUROPAT, P197; Johnson EM, 1996, BRAIN PATHOL, V6, P397, DOI 10.1111/j.1750-3639.1996.tb00872.x; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LI Y, 1994, STROKE, V25, P849, DOI 10.1161/01.STR.25.4.849; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Lipton SA, 1996, BRAIN PATHOL, V6, P507, DOI 10.1111/j.1750-3639.1996.tb00879.x; MACMANUS JP, 1995, J CEREBR BLOOD F MET, V15, P728, DOI 10.1038/jcbfm.1995.93; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; NAMASHIMA K, 1999, J NEUROTRAUM, V16, P143; PETITO CK, 1995, J NEUROPATH EXP NEUR, V54, P761, DOI 10.1097/00005072-199511000-00002; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Probst-Cousin S, 1998, J NEUROPATH EXP NEUR, V57, P814, DOI 10.1097/00005072-199809000-00002; Raine CS, 1997, J NEUROIMMUNOL, V77, P135, DOI 10.1016/S0165-5728(97)00073-8; RINK A, 1995, AM J PATHOL, V147, P1575; Sheng JG, 1998, J NEUROPATH EXP NEUR, V57, P714, DOI 10.1097/00005072-199807000-00008; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH FM, 1997, J NEUROTRAUM, V15, P54; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; Taniike M, 1999, J NEUROPATH EXP NEUR, V58, P644, DOI 10.1097/00005072-199906000-00009; TANSEY FA, 1991, J NEUROCHEM, V57, P95, DOI 10.1111/j.1471-4159.1991.tb02104.x; THOMAS LB, 1995, EXP NEUROL, V133, P265, DOI 10.1006/exnr.1995.1029; Troncoso JC, 1996, J NEUROPATH EXP NEUR, V55, P1134, DOI 10.1097/00005072-199611000-00004; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; YOSHIKAWA N, 1994, DERMATOLOGY, V188, P207, DOI 10.1159/000247141	53	56	58	1	4	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	NOV	2000	100	5					537	545		10.1007/s004010000222			9	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	352GK	WOS:000089206800012	11045676				2022-02-06	
J	Wagner, AK; Hammond, FM; Sasser, HC; Wiercisiewski, D; Norton, HJ				Wagner, AK; Hammond, FM; Sasser, HC; Wiercisiewski, D; Norton, HJ			Use of injury severity variables in determining disability and community integration after traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						traumatic brain injury; outcome; disability; community integration; trauma scores; injury severity	GLASGOW COMA SCALE; SEVERE HEAD-INJURY; SCORE SYSTEMS; RATING-SCALE; CHILDREN; REHABILITATION; VALIDATION; PREDICTION; VIOLENCE; SURVIVAL	Background: Long-term outcome is important in managing traumatic brain injury (TBI), an epidemic in the United States. Many injury severity variables have been shown to predict major morbidity and mortality. Less is known about their relationship with specific long-term outcomes. Methods: Glasgow Coma Scale, Revised Trauma Score, Injury Severity Score, and Trauma and Injury Severity Score, along with other demographic and premorbid values, were obtained for 378 consecutive patients hospitalized after TBI at a Level I trauma center between September 1997 and May 1998, Of this cohort, 120 patients were contacted for 1-year follow-up assessment with the Disability Rating Scale, Community Integration Questionnaire, and employment data. Results: Univariate analyses showed these to be significant single predictors of 1-year outcome. Multivariate analyses revealed that the Revised Trauma Score and Glasgow Coma Scale had significant additive value in predicting injury variables Disability Rating Scale scores when combined with other demographic and premorbid variables studied. Predictive models of 1-year outcome were developed. Conclusion: Injury severity variables are significant single outcome predictors and, in combination with premorbid and demographic variables, help predict long-term disability and community integration for individuals hospitalized with TBI.	Charlotte Inst Rehabil, Charlotte, NC USA; Carolinas Hlth Care Syst, Charlotte, NC USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Kaufmann Bldg,Suite 901, Pittsburgh, PA 15213 USA.						Ashley MJ, 1997, BRAIN INJURY, V11, P677; Bontke CF, 1996, PHYS MED REHABILITAT, P1027; Bouillon B, 1997, J TRAUMA, V42, P652, DOI 10.1097/00005373-199704000-00012; BOUILLON B, 1993, UNFALLCHIRURG, V96, P55; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; CHEADLE WG, 1989, ANN SURG, V209, P541, DOI 10.1097/00000658-198905000-00005; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 1998, NEUROREHABILITATION, V10, P3, DOI 10.3233/NRE-1998-10102; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Katz D, 1992, J HEAD TRAUMA REHAB, V72, P1, DOI [10.1097/00001199-200501000-00008, DOI 10.1097/00001199-200501000-00008]; MACIVER IN, 1958, LANCET, V1, P390; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; MCGONIGAL MD, 1993, J TRAUMA, V34, P863, DOI 10.1097/00005373-199306000-00018; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wagner AK, 2000, AM J PHYS MED REHAB, V79, P235, DOI 10.1097/00002060-200005000-00004; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; Zafonte RD, 1997, BRAIN INJURY, V11, P403; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P456, DOI 10.1097/00002060-199611000-00011	37	56	58	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2000	49	3					411	419		10.1097/00005373-200009000-00005			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	355DA	WOS:000089369300004	11003316				2022-02-06	
J	Weinstock, M; Goren, T; Youdim, MBH				Weinstock, M; Goren, T; Youdim, MBH			Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities	DRUG DEVELOPMENT RESEARCH			English	Article						propargylamine; selective brain MAO inhibition; antidepressant; neuroprotection	CLOSED-HEAD INJURY; B INHIBITOR; LONG-TERM; MEMORY; RATS; RASAGILINE; R(-)-DEPRENYL; RIVASTIGMINE; DEPRESSION; DEMENTIA	TV3326 [(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate] is a novel aminoindan derivative possessing both cholinesterase (ChE) and monoamine oxidase (MAO)-inhibitory activity. In doses of 35-100 mu mol/kg administered orally to rats, it inhibits ChE by 25%-40% and antagonises scopolamine-induced impairments in spatial memory. After daily oral administration of 75 mu mol/kg for 2 weeks, TV3326 inhibits MAO-A and -B in the brain by similar to 80% but has little or no effect on the enzymes in the intestine or liver. This reduces the likelihood of it producing the "cheese effect" if administered with tyramine-containing foods or beverages. TV3326 has activity in the forced-swim test, consistent with that of known antidepressants. Both TV3326 and its S- isomer, TV3279, which inhibits ChE but lacks MAO-inhibitory activity, have neuroprotective effects against a variety of insults in PC12 cells and in vivo. TV3326 significantly reduces hippocampal cell damage caused by global ischaemia in gerbils and the cerebral oedema induced by closed head injury in mice and speeds recovery of their motor and memory deficits. These pharmacological actions of TV3326 could clearly be of clinical importance for the treatment of Alzheimer's disease, and the drug is currently in development for this purpose. Drug Dev. Res. 50:216-222, 2000. (C) 2000 Wiley-Liss, Inc.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pharmacol, IL-91120 Jerusalem, Israel; Teva Pharmaceut Ind Ltd, Netanya, Israel; Technion Israel Inst Technol, Fac Med, Eve Topf Neurodegenerat Dis Ctr Res & Teaching, Haifa, Israel		Weinstock, M (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pharmacol, IL-91120 Jerusalem, Israel.	martar@cc.huji.ac.il					Abu-Raya S, 1999, J NEUROSCI RES, V58, P456, DOI 10.1002/(SICI)1097-4547(19991101)58:3<456::AID-JNR12>3.0.CO;2-S; ANISMAN H, 1982, BEHAV BRAIN SCI, V5, P89, DOI 10.1017/S0140525X00010633; ANSARI KS, 1993, J NEUROSCI, V13, P4042; BEATTY WW, 1986, BEHAV NEURAL BIOL, V45, P196, DOI 10.1016/S0163-1047(86)90772-7; Bejar C, 1999, EUR J PHARMACOL, V383, P231, DOI 10.1016/S0014-2999(99)00643-3; Braida D, 1996, EUR J PHARMACOL, V302, P13, DOI 10.1016/0014-2999(96)00072-6; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; Cummings JL, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.1_Suppl_1.S2; DAWSON GR, 1991, PHARMACOL BIOCHEM BE, V39, P865, DOI 10.1016/0091-3057(91)90045-4; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; EDWARDS JG, 1995, CNS DRUGS, V4, P141, DOI 10.2165/00023210-199504020-00006; Filip V, 1999, J PSYCHIATR NEUROSCI, V24, P234; Finberg JPM, 1996, J NEURAL TRANSM-SUPP, P95; Finberg JPM, 1998, NEUROREPORT, V9, P703; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; Giacobini E, 1997, JPN J PHARMACOL, V74, P225, DOI 10.1254/jjp.74.225; Good PF, 1996, AM J PATHOL, V149, P21; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; KOPELMAN MD, 1988, BRAIN, V111, P1079, DOI 10.1093/brain/111.5.1079; Kragten E, 1998, J BIOL CHEM, V273, P5821, DOI 10.1074/jbc.273.10.5821; Lahtinen H, 1997, BRAIN RES, V757, P260, DOI 10.1016/S0006-8993(97)00227-8; Magyar K, 1998, J NEURAL TRANSM-SUPP, P109; MARIN RS, 1995, J NEUROPSYCH CLIN N, V7, P23; MCGEER PL, 1994, ALZ DIS ASSOC DIS, V8, P149, DOI 10.1097/00002093-199408030-00001; PALMER AM, 1988, ANN NEUROL, V23, P616, DOI 10.1002/ana.410230616; PORSOLT RD, 1978, EUR J PHARMACOL, V47, P379, DOI 10.1016/0014-2999(78)90118-8; SANO M, 1909, NEW ENGL J MED, V336, P1216; SAURA J, 1994, NEUROSCIENCE, V62, P15, DOI 10.1016/0306-4522(94)90311-5; SPEIZER Z, 1998, PHARM BIOCH BEHAV, V60, P1; STROLINBENEDETT.M, 1983, BIOCHEM PHARMACOL, V32, P47; Tatton WG, 1996, NEUROLOGY, V47, pS171, DOI 10.1212/WNL.47.6_Suppl_3.171S; Weinstock M, 1999, CNS DRUGS, V12, P307, DOI 10.2165/00023210-199912040-00005; WEINSTOCK M, 1999, NEUROSCI LETT S, V54, pS44; YOUDIM MBH, 1999, NEUROSCI LETT, V54, pS45; Zhang X, 1996, J NEUROSCI RES, V43, P482, DOI 10.1002/(SICI)1097-4547(19960215)43:4<482::AID-JNR9>3.0.CO;2-B	37	56	58	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0272-4391	1098-2299		DRUG DEVELOP RES	Drug Dev. Res.	JUL-AUG	2000	50	3-4					216	222		10.1002/1098-2299(200007/08)50:3/4<216::AID-DDR4>3.3.CO;2-Q			7	Chemistry, Medicinal; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	359TK	WOS:000089628000004					2022-02-06	
J	Morris, MW; Smith, S; Cressman, J; Ancheta, J				Morris, MW; Smith, S; Cressman, J; Ancheta, J			Evaluation of infants with subdural hematoma who lack external evidence of abuse	PEDIATRICS			English	Article						subdural hematoma; intracranial hemorrhage; traumatic brain injury; child abuse; child protection	PERMANENT BRAIN-DAMAGE; SHAKEN BABY SYNDROME; MENTAL-RETARDATION; YOUNG-CHILDREN; HEAD-INJURY; SHAKING; TRAUMA	Objective. Advances in radiologic technique have increased the recognition of subdural hematoma. No study to date has addressed the role of child protective investigation into the cause and management of subdural hematoma in children who lack other indicators of abuse. Methods. Medical records, radiology studies, and social service notes for all infants and children referred for child abuse investigation who had any form of intracranial hemorrhage were reviewed. The study covered the 12 months of 1997. All referrals were to the Suncoast Child Protection Team (St Petersburg, FL). Results. There were 19 investigations because of subdural hematoma. Eight children had retinal hemorrhage as well as other major findings of trauma, such as bruises and/or fractures; all 8 were victims of child abuse. Two infants had tiny subdurals adjacent to accidental linear skull fractures. Nine infants were investigated for the possibility of abuse that had no findings of trauma apart from the subdural hematoma. These 9 cases form the basis for this study. The age range was 11 days to 15 months. Inflicted cerebral trauma was the medical diagnosis in 8 of the 9 cases; 1 case had a final diagnosis of possible inflicted injury in a high-risk setting. Conclusions. Infants with subdural hematoma but no other findings of abuse present a difficult challenge to child protection workers. Investigation by a medically oriented team can uncover the circumstances of the trauma in most instances and can usefully direct protective efforts. The high incidence of severe sequelae in infants with inflicted cerebral trauma warrants a vigorous approach.	Suncoast Child Protect Team Inc, Pinellas Pk, FL 33782 USA; Univ S Florida, All Childrens Hosp, Dept Pediat Med, St Petersburg, FL 33701 USA; Univ S Florida, All Childrens Hosp, Dept Pediat Radiol, St Petersburg, FL 33701 USA; Univ S Florida, Sch Med, Dept Pediat, Tampa, FL 33620 USA		Morris, MW (corresponding author), Suncoast Child Protect Team Inc, 8800 49th St N,Suite 410, Pinellas Pk, FL 33782 USA.	markmorris@prodigy.net					ALEXANDER R, 1990, AM J DIS CHILD, V144, P724, DOI 10.1001/archpedi.1990.02150300124032; AOKI N, 1990, J NEUROSURG, V73, P201, DOI 10.3171/jns.1990.73.2.0201; BARKOVICH AJ, 1992, PEDIATR NEUROSURG, V18, P65; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; EWINGCOBBS L, 1995, J HEAD TRAUMA REHAB, V10, P13, DOI 10.1097/00001199-199510000-00004; FELDMAN KW, 1977, BATTERED CHILD, P194; HANIGAN WC, 1987, PEDIATRICS, V80, P618; HANSEN KK, 1994, ARCH PEDIAT ADOL MED, V148, P1345, DOI 10.1001/archpedi.1994.02170120107021; HARWOODNASH DC, 1992, AM J NEURORADIOL, V13, P569; HELFER RE, 1977, PEDIATRICS, V60, P533; HOBBS CJ, 1984, ARCH DIS CHILD, V59, P246, DOI 10.1136/adc.59.3.246; KLEIN M, 1971, AM J DIS CHILD, V122, P15, DOI 10.1001/archpedi.1971.02110010051005; Kleinman PK, 1998, DIAGNOSTIC IMAGING C, P312; KRUGMAN RD, 1993, PEDIATRICS, V92, P872; PARENT AD, 1992, PEDIATR NEUROSURG, V18, P266, DOI 10.1159/000120674; REECE RM, 1994, CHILD ABUSE MED DIAG, P8	22	56	58	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	MAR	2000	105	3					549	553		10.1542/peds.105.3.549			5	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	290MZ	WOS:000085681100027	10699108				2022-02-06	
J	Chen, E; Hornig, S; Shepherd, SM; Hollander, JE				Chen, E; Hornig, S; Shepherd, SM; Hollander, JE			Primary closure of mammalian bites	ACADEMIC EMERGENCY MEDICINE			English	Article						lacerations; wounds, mammalian bites; dog; cat; human; infection	RISK-FACTORS; WOUNDS; INFECTION; ANTIBIOTICS; EMERGENCY; LACERATIONS; APPEARANCE; MANAGEMENT; INJURIES; CHILDREN	Objective: Suturing of bite wounds remains controversial. The authors evaluated the incidence of wound infection in 145 mammalian bite wounds treated with primary closure. Methods: Consecutive patients with bite wounds receiving primary closure at a university hospital ED had structured closed-question data sheets completed at the time of wound management and suture removal. Infection was determined at the time of suture removal using a previously validated definition. Data included demographics medical history time from injury to evaluation wound characteristics and location details of wound cleansing methods, debridement, foreign body removal, and wound closure methods use of antibiotics and follow-up wound evaluation. Proportions and 95% confidence intervals were calculated. Results: One hundred forty-five mammalian bite patients were enrolled: 88 dog, 45 cat, and 12 human bites. Patients had a mean (+/-SD) age of 21 +/- 20 years; 58% were male; 86% were white; and they presented a mean (+/-SD) of 1.8 +/- 1.2 hours after injury. Bites occurred on the head and neck (57%), upper extremity (36%), and lower extremity (6%). Wounds had a mean length and width of 2.5 cm and 4.8 mm, respectively. Twelve percent involved structures deep to subcutaneous tissue. After primary wound closure, wound infections occurred in eight patients (5.5%; 95% confidence interval = 1.8% to 9.2%). Conclusions: The data suggest that carefully selected mammalian bite wounds can be sutured with approximately a 6% rate of infection. This infection rate may be acceptable in lacerations where cosmesis is a primary concern.	Hosp Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA		Hollander, JE (corresponding author), Hosp Univ Penn, Dept Emergency Med, Ground Floor,3400 Spruce St,Ravdin Bldg, Philadelphia, PA 19104 USA.		Shepherd, Suzanne M./G-9137-2014	Hollander, Judd/0000-0002-1318-2785			AGHABABIAN RV, 1980, ANN EMERG MED, V9, P79, DOI 10.1016/S0196-0644(80)80335-0; CALLAHAM M, 1980, ANN EMERG MED, V9, P410, DOI 10.1016/S0196-0644(80)80153-3; CALLAHAM M, 1988, ANN EMERG MED, V17, P1321, DOI 10.1016/S0196-0644(88)80359-7; CALLAHAM ML, 1978, JACEP-J AM COLL EMER, V7, P83, DOI 10.1016/S0361-1124(78)80063-X; CUMMINGS P, 1994, ANN EMERG MED, V23, P535, DOI 10.1016/S0196-0644(94)70073-7; Dire D J, 1994, Acad Emerg Med, V1, P258; Dire Daniel J., 1992, Emergency Medicine Clinics of North America, V10, P719; DIRE DJ, 1990, ANN EMERG MED, V19, P704, DOI 10.1016/S0196-0644(05)82484-9; DIRE DJ, 1995, ACAD EMERG MED, V2, P4, DOI 10.1111/j.1553-2712.1995.tb03070.x; DIRE DJ, 1991, ANN EMERG MED, V20, P973, DOI 10.1016/S0196-0644(05)82975-0; EARLEY MJ, 1984, BRIT J PLAST SURG, V37, P458, DOI 10.1016/0007-1226(84)90130-9; Galvin J R, 1976, JACEP, V5, P332, DOI 10.1016/S0361-1124(76)80056-1; GOLDSTEIN EJC, 1992, CLIN INFECT DIS, V14, P633, DOI 10.1093/clinids/14.3.633; GOSNOLD JK, 1977, PRACTITIONER, V218, P584; GUY RJ, 1986, ANN PLAS SURG, V17, P45, DOI 10.1097/00000637-198607000-00009; Hollander JE, 1997, ACAD EMERG MED, V4, P225, DOI 10.1111/j.1553-2712.1997.tb03747.x; HOLLANDER JE, 1995, ACAD EMERG MED, V2, P983, DOI 10.1111/j.1553-2712.1995.tb03126.x; HOLLANDER JE, 1995, ANN EMERG MED, V25, P675, DOI 10.1016/S0196-0644(95)70183-4; LACKMANN GM, 1992, J CRANIO MAXILL SURG, V20, P81, DOI 10.1016/S1010-5182(05)80472-X; LEUNG AKC, 1992, PEDIATR EMERG CARE, V8, P255, DOI 10.1097/00006565-199210000-00001; LINDSEY D, 1987, J TRAUMA, V27, P45, DOI 10.1097/00005373-198701000-00008; MAIMARIS C, 1988, ARCH EMERG MED, V5, P156; Rest J G, 1985, Emerg Med Clin North Am, V3, P117; RUTHERFORD WH, 1980, ANN EMERG MED, V9, P350, DOI 10.1016/S0196-0644(80)80110-7; SINGER AJ, 1995, AM J EMERG MED, V13, P265, DOI 10.1016/0735-6757(95)90197-3; Singer AJ, 1997, ACAD EMERG MED, V4, P133, DOI 10.1111/j.1553-2712.1997.tb03720.x; THOMSON HG, 1973, J TRAUMA, V13, P20, DOI 10.1097/00005373-197301000-00004; Weiss HB, 1998, JAMA-J AM MED ASSOC, V279, P51, DOI 10.1001/jama.279.1.51; WILEY JF, 1990, CLIN PEDIATR, V29, P283, DOI 10.1177/000992289002900506; ZUBOWICZ VN, 1991, PLAST RECONSTR SURG, V88, P111, DOI 10.1097/00006534-199107000-00019	30	56	60	0	2	HANLEY & BELFUS INC	PHILADELPHIA	210 S 13TH ST, PHILADELPHIA, PA 19107 USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	FEB	2000	7	2					157	161		10.1111/j.1553-2712.2000.tb00519.x			5	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	293XN	WOS:000085880700008	10691074	Bronze			2022-02-06	
J	Simpson, G; Mohr, R; Redman, A				Simpson, G; Mohr, R; Redman, A			Cultural variations in the understanding of traumatic brain injury and brain injury rehabilitation	BRAIN INJURY			English	Article							BLUNT HEAD-INJURY; BEHAVIORAL LIMITATIONS; RELATIVES VIEW; AWARENESS; FAMILIES; SERVICES; PATTERNS; PACIFIC; MODEL	Little is known about how people from different cultures experience and understand traumatic brain injury (TBI) and the process of brain injury rehabilitation. The Brain Injury Rehabilitation Unit (BIRU) undertook a qualitative project to research cultural variations in the understanding of TBI and the rehabilitation process, interviewing 39 people with TBI and family members from Italian, Lebanese and Vietnamese backgrounds. The focus was on the reporting of sequelae of the TBI; valued qualities of service providers; barriers to effective communication; the role of the families in the rehabilitation process; and the experience of social stigma. Findings suggest there is a universal experience of TBI that transcends individual cultures. Study participants valued attentiveness, friendliness and guidance from rehabilitation staff. Family support was not always available to the person with TBI due to family conflict. Generally, people with TBI and family members valued the assistance of health interpreters facilitating their communication with rehabilitation staff People with TBI from all three cultures experienced problems of stigma and social isolation. The findings have a number of implications for how brain injury rehabilitation staff can approach service provision to people from diverse cultural backgrounds.	Liverpool Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia; Univ Wollongong, Fac Law, Wollongong, NSW, Australia		Simpson, G (corresponding author), Liverpool Hosp, Brain Injury Rehabil Unit, Locked Bag 7103, Liverpool, NSW 1871, Australia.		Simpson, Grahame K/W-1074-2019	Simpson, Grahame K/0000-0001-8156-9060; Mohr, Richard/0000-0003-2127-0440			BRANNON E, 1986, MULTI CULTURAL COUNS; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CAVALLO MM, 1995, J HEAD TRAUMA REHAB, V10, P66, DOI 10.1097/00001199-199504000-00008; DIKENGIL A, 1993, J COGNITIVE REHABILI, V11, P10; DYCK I, 1992, AM J OCCUP THER, V46, P696, DOI 10.5014/ajot.46.8.696; Fitzgerald M.H., 1997, AUST OCCUP THER J, V44, P1, DOI [https://doi.org/10.1111/j.1440-1630.1997.tb00749.x, DOI 10.1111/J.1440-1630.1997.TB00749.X]; FITZGERALD MH, 1992, J REHABIL, V58, P38; FITZGERALD MH, 1993, WESTERN J MED, V159, P50; Gregory RJ, 1996, DISABIL REHABIL, V18, P47, DOI 10.3109/09638289609167089; KAKAKIOS M, 1995, HLTH SERVICE CULTURA; KLEINMAN A, 1978, SOC SCI MED-MED ANTH, V12, P85, DOI 10.1016/0160-7987(78)90014-5; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Man DWK, 1998, BRAIN INJURY, V12, P245, DOI 10.1080/026990598122728; Miles M. B., 1994, QUALITATIVE DATA ANA, V2nd; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; MOSELEY A, 1995, BRAIN INJURY, V9, P355, DOI 10.3109/02699059509005775; NOCKLEBY DM, 1987, INT J CLIN NEUROPSYC, V9, P145; Patton M.Q., 1990, QUALITATIVE EVALUATI; Pauwels A., 1995, CROSS CULTURAL COMMU; PONSFORD JL, 1995, 2 INT NEUR SOC ASSBI; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; *S W SYDN AR HLTH, 1995, HLTH PLAN NONENGL SP; SMART JF, 1992, J REHABIL, V58, P29; Sue DW, 1990, COUNSELLING CULTURAL; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; VASQUEZ C, 1991, HOSP COMMUNITY PSYCH, V42, P163; Williams DE, 1991, REV COMPUTATIONAL CH, P219, DOI DOI 10.1039/C3CC48479C; YAMAMOTO J, 1986, ETHNIC PSYCHIAT, P89	34	56	56	0	14	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2000	14	2					125	140		10.1080/026990500120790			16	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	281GW	WOS:000085151000003	10695569				2022-02-06	
J	Achiron, A; Miron, S; Lavie, V; Margalit, R; Biegon, A				Achiron, A; Miron, S; Lavie, V; Margalit, R; Biegon, A			Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis	JOURNAL OF NEUROIMMUNOLOGY			English	Article						EAE; multiple sclerosis; TNF-alpha inhibition; relapse; animal model	CLOSED-HEAD INJURY; NONCOMPETITIVE NMDA ANTAGONIST; NECROSIS-FACTOR-ALPHA; RAT; METHYLPREDNISOLONE; NEUROPROTECTANT; CANNABINOIDS; SUPPRESSION; ISCHEMIA; TERM	Dexanabinol (HU-211) is a synthetic non-psychotropic cannabinoid which suppresses TNF-a production in the brain and peripheral blood. The effects of dexanabinol in rat experimental autoimmune encephalomyelitis (EAE) were studied using different doses, modes of administration and time regimes. Dexanabinol, 5 mg/kg i.v. given once after disease onset (day 10), significantly reduced maximal EAE score. Increasing the dose or treatment duration resulted in further suppression of EAE. Drug administration at earlier phases during disease induction was not effective. Histological studies supported the clinical findings demonstrating reduction in the inflammatory response in the brain and spinal cord in animals treated with dexanabinol. The results suggest that dexanabinol may provide an alternative mode of treatment for acute exacerbations of multiple sclerosis (MS). (C) 2000 Elsevier Science B.V. All rights reserved.	Chaim Sheba Med Ctr, Multiple Sclerosis Ctr, IL-52621 Tel Hashomer, Ramat Gan, Israel; Kiryat Weizmann, Pharmos, Rehovot, Israel; Weizmann Inst Sci, Dept Cell Biol, IL-76100 Rehovot, Israel		Achiron, A (corresponding author), Chaim Sheba Med Ctr, Multiple Sclerosis Ctr, IL-52621 Tel Hashomer, Ramat Gan, Israel.						BARJOSEPH A, 1994, MOL CHEM NEUROPATHOL, V23, P125, DOI 10.1007/BF02815406; Bass R, 1996, J INFECT DIS, V173, P735, DOI 10.1093/infdis/173.3.735; BELAYEV L, 1995, BRAIN RES, V702, P266, DOI 10.1016/0006-8993(95)01127-9; BELAYEV L, 1995, STROKE, V26, P2313, DOI 10.1161/01.STR.26.12.2313; BIEGON A, 1993, AM SOC NEUR ABSTR, V19, P1485; Brewster ME, 1997, INT J CLIN PHARM TH, V35, P361; BURNETTECURLEY D, 1995, P SOC EXP BIOL MED, V210, P64, DOI 10.3181/00379727-210-43926; ESHHAR N, 1995, EUR J PHARMACOL, V283, P19, DOI 10.1016/0014-2999(95)00271-L; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; FREQUIN STFM, 1994, ACTA NEUROL SCAND, V90, P105; Gallily R, 1997, J PHARMACOL EXP THER, V283, P918; Hautecoeur P, 1997, ACTA NEUROL BELG, V97, P240; LYMAN WD, 1989, J NEUROIMMUNOL, V23, P73, DOI 10.1016/0165-5728(89)90075-1; MARTIN R, 1995, CRIT REV CLIN LAB SC, V32, P82; MECHOULAM R, 1990, TETRAHEDRON-ASYMMETR, V1, P315, DOI 10.1016/S0957-4166(00)86322-3; MECHOULAM R, 1988, EXPERIENTIA, V44, P762, DOI 10.1007/BF01959156; MILLIGAN NM, 1987, J NEUROL NEUROSUR PS, V50, P511, DOI 10.1136/jnnp.50.5.511; NADLER V, 1993, NEUROSCI LETT, V159, P1; OLSSON T, 1995, NEUROLOGY, V45, pS11, DOI 10.1212/WNL.45.6_Suppl_6.S11; Philippe J, 1996, CLIN NEUROL NEUROSUR, V98, P286, DOI 10.1016/0303-8467(96)00041-8; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; van Oosten BW, 1998, ARCH NEUROL-CHICAGO, V55, P793, DOI 10.1001/archneur.55.6.793; WIRGUIN I, 1994, IMMUNOPHARMACOLOGY, V28, P209, DOI 10.1016/0162-3109(94)90056-6; Yoles E, 1996, J NEUROTRAUM, V13, P49, DOI 10.1089/neu.1996.13.49; [No title captured]	27	56	56	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	JAN 3	2000	102	1					26	31		10.1016/S0165-5728(99)00149-6			6	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	270PV	WOS:000084545400004	10626663				2022-02-06	
J	Barone, FC; Ohlstein, EH; Hunter, AJ; Campbell, CA; Hadingham, SH; Parsons, AA; Yang, Y; Shohami, E				Barone, FC; Ohlstein, EH; Hunter, AJ; Campbell, CA; Hadingham, SH; Parsons, AA; Yang, Y; Shohami, E			Selective antagonism of endothelin-A-receptors improves outcome in both head trauma and focal stroke in rat	JOURNAL OF CARDIOVASCULAR PHARMACOLOGY			English	Article; Proceedings Paper	6th International Symposium on Endothelin	OCT 10-14, 1999	MONTREAL, CANADA			closed head injury (CHI); focal stroke; neuroprotection; neurological deficits; brain edema; brain injury; endothelin antagonists; SE 234551; SE 209670	CEREBRAL-ARTERY OCCLUSION; BRAIN-BARRIER PERMEABILITY; PHARMACOLOGICAL CHARACTERIZATION; ISCHEMIA; INJURY; MODEL; IMMUNOREACTIVITY; SB-209670; DAMAGE; MOTOR	Increased levels of endothelin (ET) have been demonstrated in the ischemic brain, and ET receptor antagonism has been shown to improve outcome in cerebral ischemia. However, no previous work has been carried out evaluating the role of ET and its antagonism in brain trauma as compared to experimental stroke. In this study, we evaluated changes in brain ET levels following closed head injury (CHI) and the effects of SB 234551, an endothelin-A- (ETA) selective antagonist, and SE 209670, a mixed endothelin-A and -B- (ETA/ETB) antagonist, on outcome in CHI and focal stroke. Male Sabra rats were subjected to CHI (weight drop model). Male Sprague Dawley rats were subjected to focal stroke (intraluminal suture model). Motor function(s) were assessed and immunoreactive ET (irET) and the degree of cerebral edema were measured for 24 h after CHI. Brain swelling (edema), neurological deficits and forebrain infarct volumes were measured 24 h after focal stroke. Antagonists (total doses of 7.5, 15, 30 or 60 mg/kg) were administered intravenously fur 6-24 h (beginning 15 min after injury). Control rats were infused with vehicle. CHI resulted in increased ET levels in the directly contused hemisphere at 12 and 24 h. In addition, SB 234551 significantly reduced neurological deficits (decreased 30%) and brain edema (decreased 40%) following CHI (p < 0.05 at 60 mg/kg dose). SE 209670 had no effects on CHI outcome. Focal stroke studies yielded similar results. SE 234551 reduced focal stroke-induced neurological deficits by 50%, brain swelling by 54% and the degree of infarction by 36% (p < 0.05 at 30 mg/kg). SE 209670 did not provide any neuroprotection in focal stroke. These data indicate that ET plays a significant role in the pathophysiology of CHI, and that selectively targeting ETA-receptors similarly in both CHI and stroke might be a therapeutic opportunity.	SmithKline Beecham Pharmaceut, Dept Cardiovasc Pharmacol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Neurosci Res, Harlow CM19 5AD, Essex, England; Hebrew Univ Jerusalem, Sch Pharm, IL-91120 Jerusalem, Israel		Barone, FC (corresponding author), SmithKline Beecham Pharmaceut, Dept Cardiovasc Pharmacol, 709 Swedeland Rd,POB 1539, King Of Prussia, PA 19406 USA.						BALAYEV L, 1995, STROKE, V26, P2313; BARONE FC, 1995, J CARDIOVASC PHARM, V26, pS404; BARONE FC, 1994, J CEREBR BLOOD F MET, V14, P337, DOI 10.1038/jcbfm.1994.41; BARONE FC, 1992, NEUROSCI BIOBEHAV R, V16, P219, DOI 10.1016/S0149-7634(05)80182-4; BARONE FC, 1995, NEUROL RES, V17, P259, DOI 10.1080/01616412.1995.11740323; BIAN LG, 1994, NEUROSCI LETT, V174, P47, DOI 10.1016/0304-3940(94)90115-5; CINTRA A, 1989, ACTA PHYSIOL SCAND, V137, P557, DOI 10.1111/j.1748-1716.1989.tb08799.x; Gartshore G, 1997, EXP NEUROL, V147, P353, DOI 10.1006/exnr.1997.6635; Hama H, 1997, J NEUROSCI RES, V47, P590, DOI 10.1002/(SICI)1097-4547(19970315)47:6<590::AID-JNR4>3.0.CO;2-8; JIANG MH, 1993, NEUROREPORT, V4, P935, DOI 10.1097/00001756-199307000-00024; LONGA ZZ, 1980, STROKE, V20, P84; Mackay KB, 1996, NEURODEGENERATION, V5, P319, DOI 10.1006/neur.1996.0043; McAuley MA, 1996, EUR J PHARMACOL, V307, P171, DOI 10.1016/0014-2999(96)00251-8; OHLSTEIN EH, 1994, J PHARMACOL EXP THER, V271, P762; Ohlstein EH, 1998, J PHARMACOL EXP THER, V286, P650; OHLSTEIN EH, 1994, P NATL ACAD SCI USA, V91, P8052, DOI 10.1073/pnas.91.17.8052; OSBORNE KA, 1987, J NEUROL NEUROSUR PS, V50, P402, DOI 10.1136/jnnp.50.4.402; PATEL TR, 1995, J CARDIOVASC PHARM, V26, pS412; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; SALOM JB, 1995, CEREBROVAS BRAIN MET, V7, P131; Sato M, 1998, BRAIN RES, V809, P39, DOI 10.1016/S0006-8993(98)00817-8; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; VIOSSAT I, 1993, J CARDIOVASC PHARM, V22, pS306, DOI 10.1097/00005344-199322008-00080; Willette RN, 1998, J CARDIOVASC PHARM, V31, pS149, DOI 10.1097/00005344-199800001-00044; Wu W, 1996, Chin Med Sci J, V11, P228; YAMASHITA K, 1994, J NEUROCHEM, V63, P1042; YAMASHITA K, 1995, CLIN EXP PHARM PHYSL, V1, pS277	29	56	58	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0160-2446			J CARDIOVASC PHARM	J. Cardiovasc. Pharmacol.		2000	36			1			S357	S361		10.1097/00005344-200036001-00104			5	Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology; Pharmacology & Pharmacy	368RF	WOS:000090130800103	11078420				2022-02-06	
J	Marion, DW; Spiegel, TP				Marion, DW; Spiegel, TP			Changes in the management of severe traumatic brain injury: 1991-1997	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; acute care; intracranial hypertension; guidelines; survey	SEVERE HEAD-INJURY	Objective: To survey the management of head-injured patients in 1997 and to identify differences compared with a survey conducted in 1991, Design: A two-page questionnaire was mailed to all neurosurgeons in North America certified by the American Board of Neurologic Surgeons, asking their views regarding the most appropriate acute care of patients with severe traumatic brain injury (TBI), Setting: North American neurosurgical practices. Patients: Not applicable, Interventions: None. Measurements and Main Results: Compared with a 1991 survey, there was a significant increase in the proportion of neuro-surgeons who felt these patients should have intracranial pressure monitoring (28% vs, 83%) and a decrease in the proportion who used prophylactic hyperventilation therapy (83% vs, 36%) and steroids (64% vs, 19%). Ninety-seven percent of respondents felt that the cerebral perfusion pressure should be maintained at >70 mm Hg, and 44% indicated that patients with severe TBI should be treated at Level I trauma centers, Conclusions: There have been significant changes in the acute management of patients with severe TBI since 1991, Current practices more closely reflect the recommendations of evidence based guidelines.	Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Brain Trauma Res Ctr, Pittsburgh, PA 15213 USA		Marion, DW (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Brain Trauma Res Ctr, 200 Lothrop St,Suite B400, Pittsburgh, PA 15213 USA.		Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-30318-5] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P01NS030318, P50NS030318] Funding Source: NIH RePORTER		BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Kraus JF, 1987, HEAD INJURY, V2, P1; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; REGEL G, 1995, J TRAUMA, V38, P70, DOI 10.1097/00005373-199501000-00020	8	56	63	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	JAN	2000	28	1					16	18		10.1097/00003246-200001000-00003			3	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279QV	WOS:000085057400003	10667493				2022-02-06	
J	Sagara, Y; Hendler, S; Khoh-Reiter, S; Gillenwater, G; Carlo, D; Schubert, D; Chang, J				Sagara, Y; Hendler, S; Khoh-Reiter, S; Gillenwater, G; Carlo, D; Schubert, D; Chang, J			Propofol hemisuccinate protects neuronal cells from oxidative injury	JOURNAL OF NEUROCHEMISTRY			English	Article						oxidative injury; glutamate; propofol; neurotrauma; neuronal cells; antioxidant	SPINAL-CORD INJURY; NERVOUS-SYSTEM TRAUMA; LIPID-PEROXIDATION; GLUTAMATE TOXICITY; TIRILAZAD MESYLATE; ALPHA-TOCOPHEROL; VITAMIN-E; BRAIN SYNAPTOSOMES; COMPRESSION INJURY; CONTROLLED TRIAL	Oxidative stress contributes to the neuronal death observed in neurodegenerative disorders and neurotrauma. Some antioxidants for CNS injuries, however, have yet to show mitigating effects in clinical trials, possibly due to the impermeability of antioxidants across the blood-brain barrier (BBB). Propofol (2,6-diisopropylphenol), the active ingredient of a commonly used anesthetic, acts as an antioxidant, but it is insoluble in water. Therefore, we synthesized its water-soluble prodrug, propofol hemisuccinate sodium salt (PHS), and tested for its protective efficacy in neuronal death caused by non-receptor-mediated, oxidative glutamate toxicity. Glutamate induces apoptotic death in rat cortical neurons and the mouse hippocampal cell line HT-22 by blocking cystine uptake and causing the depletion of intracellular glutathione, resulting in the accumulation of reactive oxygen species (ROS). PHS has minimal toxicity and protects both cortical neurons and MT-22 cells from glutamate. The mechanism of protection is attributable to the antioxidative property of PHS because PHS decreases the ROS accumulation caused by glutamate. Furthermore, PHS protects MT-22 cells from oxidative injury induced by homocysteic acid, buthionine sulfoximine, and hydrogen peroxide. For comparison, we also tested alpha-tocopherol succinate (TS) and methylprednisolone succinate (MPS) in the glutamate assay. Although TS is protective against glutamate at lower concentrations than PHS, TS is toxic to HT-22 cells. In contrast, MPS is nontoxic but also nonprotective against glutamate. Taken together, PHS, a water-soluble prodrug of propofol, is a candidate drug to treat CNS injuries owing to its antioxidative properties, low toxicity, and permeability across the BBB.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; Vyrex Corp, La Jolla, CA USA; Immune Response Corp, Carlsbad, CA USA		Sagara, Y (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS010032, P01NS028121, R01NS009658] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS10032, 5PO1NS28121, R01NS09658] Funding Source: Medline		Abe K, 1996, J NEUROCHEM, V67, P2074; Bagenholm R, 1997, BRAIN RES, V773, P132, DOI 10.1016/S0006-8993(97)00776-2; Baldwin SA, 1998, J NEUROSURG, V88, P874, DOI 10.3171/jns.1998.88.5.0874; Bao YP, 1998, BRIT J ANAESTH, V81, P584, DOI 10.1093/bja/81.4.584; BASS DA, 1983, J IMMUNOL, V130, P1910; BECK T, 1990, BRAIN RES, V532, P336, DOI 10.1016/0006-8993(90)91779-G; Bhat NR, 1999, J NEUROCHEM, V72, P112, DOI 10.1046/j.1471-4159.1999.0720112.x; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; BRAUGHLER JM, 1985, J NEUROCHEM, V44, P1282, DOI 10.1111/j.1471-4159.1985.tb08755.x; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BRAUGHLER JM, 1982, J NEUROSURG, V56, P838, DOI 10.3171/jns.1982.56.6.0838; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DAVIS JB, 1994, BRAIN RES, V652, P169, DOI 10.1016/0006-8993(94)90334-4; De la Cruz JP, 1998, ANESTH ANALG, V87, P1141, DOI 10.1097/00000539-199811000-00031; ERIKSSON O, 1992, BIOCHEM PHARMACOL, V44, P391, DOI 10.1016/0006-2952(92)90026-F; Froissard P, 1997, EUR J PHARMACOL, V326, P93, DOI 10.1016/S0014-2999(97)00155-6; GRIFFITH OW, 1983, J BIOL CHEM, V258, P1591; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HALL ED, 1992, J NEUROTRAUM, V9, pS165; HALL ED, 1995, J NEUROTRAUM, V12, P245, DOI 10.1089/neu.1995.12.245; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; KATO S, 1992, NEUROSCIENCE, V48, P903, DOI 10.1016/0306-4522(92)90278-A; Katoh D, 1996, SPINAL CORD, V34, P234, DOI 10.1038/sc.1996.43; Kokita N, 1996, ANESTHESIOLOGY, V84, P117, DOI 10.1097/00000542-199601000-00014; KVAM C, 1993, BIOCHEM BIOPH RES CO, V193, P927, DOI 10.1006/bbrc.1993.1714; LEMKE M, 1990, NEUROSCI LETT, V108, P201, DOI 10.1016/0304-3940(90)90731-N; Li GL, 1997, FREE RADICAL RES, V27, P187, DOI 10.3109/10715769709097851; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; MACHLIN LJ, 1982, ANN NY ACAD SCI, V393, P48, DOI 10.1111/j.1749-6632.1982.tb31231.x; Maher P, 1996, J NEUROSCI, V16, P6394; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MAY PC, 1985, J NEUROL SCI, V70, P101, DOI 10.1016/0022-510X(85)90192-3; MIYAMOTO M, 1989, J PHARMACOL EXP THER, V250, P1132; MORIMOTO BH, 1990, NEURON, V5, P875, DOI 10.1016/0896-6273(90)90347-I; MURPHY PG, 1992, BRIT J ANAESTH, V68, P613, DOI 10.1093/bja/68.6.613; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; MUSACCHIO E, 1991, PHARMACOL TOXICOL, V69, P75, DOI 10.1111/j.1600-0773.1991.tb00414.x; OKA A, 1993, J NEUROSCI, V13, P1441; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; PIETRONIGRO DD, 1983, J NEUROCHEM, V41, P1072, DOI 10.1111/j.1471-4159.1983.tb09053.x; RATAN RR, 1994, J NEUROSCI, V14, P4385; Sagara Y, 1998, J NEUROCHEM, V71, P1002, DOI 10.1046/j.1471-4159.1998.71031002.x; Sagara Y, 1998, J NEUROSCI, V18, P6662; Sagara Y, 1998, FREE RADICAL BIO MED, V24, P1375, DOI 10.1016/S0891-5849(97)00457-7; SALAH N, 1995, ARCH BIOCHEM BIOPHYS, V322, P339, DOI 10.1006/abbi.1995.1473; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; SCHUBERT D, 1992, P NATL ACAD SCI USA, V89, P8264, DOI 10.1073/pnas.89.17.8264; Springer JE, 1997, J NEUROCHEM, V68, P2469; Tan SL, 1998, J NEUROCHEM, V71, P95; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; VOGT M, 1963, P NATL ACAD SCI USA, V49, P171, DOI 10.1073/pnas.49.2.171; Young Y, 1997, EUR J ANAESTH, V14, P320, DOI 10.1046/j.1365-2346.1997.00130.x	58	56	79	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3042			J NEUROCHEM	J. Neurochem.	DEC	1999	73	6					2524	2530		10.1046/j.1471-4159.1999.0732524.x			7	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	256JX	WOS:000083723100035	10582614				2022-02-06	
J	Oehmichen, M; Meissner, C; Schmidt, V; Pedal, I; Konig, HG; Saternus, KS				Oehmichen, M; Meissner, C; Schmidt, V; Pedal, I; Konig, HG; Saternus, KS			Axonal injury - a diagnostic tool in forensic neuropathology? A review	FORENSIC SCIENCE INTERNATIONAL			English	Article; Proceedings Paper	76th Congress of the German-Society-of-Legal-Medicine	SEP, 1997	JENA, GERMANY	German Soc Legal Med		axonal injury; traumatic brain injury; vitality; survival time; biomechanics; diffuse; axonal injury	AMYLOID PRECURSOR PROTEIN; NONMISSILE HEAD-INJURY; TRAUMATIC BRAIN INJURY; BETA-APP; HUMANS; MARKER	We used beta-amyloid precursor protein (beta-APP) to investigate our own forensic neuropathological case material (n=252) in light of the current literature on the phenomenon "axonal injury" (AI) to determine the incidence, specificity and biomechanical significance of AI and its significance for determining vitality and survival time. The case material consisted of cases of fatal nonmissile closed-head injury (n=119), gunshot injury (n=30), fatal cerebral ischemia/hypoxia (n=51), brain death caused by mechanical trauma (n=14) or nonmechanical injury (n=18), and acute hemorrhagic shock (n=20). AI was observed in 65% to 100% of cases of closed-head injury, fatal cerebral ischemia/hypoxia, and brain death with a survival time of more than 3 h; AI could not be detected in the cases of acute hemorrhagic shock. A statistically significant difference between traumatically and nontraumatically induced (nondisruptive) AI was not found. There was no statistical evidence of a correlation between AI and the different types of external force, since AI could be demonstrated after both acceleration/deceleration injuries and traumatic impact. Therefore, biomechanical inferences for reconstruction purposes are not possible. On the other hand, beta-APP was found to be a definite marker of vitality. In our material, cases with a posttraumatic interval of under 180 min did not express beta-APP. Moreover, the literature shows that the posttraumatic interval can be determined by other methods for demonstration of AI such as by ubiquitin immunostaining (360 min), silver staining (15-18 h), hematoxylin and eosin staining (about 24 h), or by demonstration of a microglial reaction (about 4 to 10 days) or of a few remaining isolated bulbs, without accompanying fibers, which can be detected after a survival time of up to 17 months. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.	Univ Lubeck, Dept Legal Med, D-23562 Lubeck, Germany; Univ Halle, Dept Legal Med, Halle, Germany; Univ Heidelberg, Dept Legal Med, D-6900 Heidelberg, Germany; Univ Tubingen, Dept Legal Med, D-72074 Tubingen, Germany; Univ Gottingen, Dept Legal Med, D-3400 Gottingen, Germany		Oehmichen, M (corresponding author), Univ Lubeck, Dept Legal Med, Kahlhorststr 31-35, D-23562 Lubeck, Germany.						ADAMS JH, 1986, ARCH PATHOL LAB MED, V110, P485; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; GEAN AD, 1995, IMAGING HEAD TRAUMA; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; Gennarelli TA, 1996, NEUROPATHOL APPL S1, V22, P44; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; Graham DI, 1996, NEUROPATH APPL NEURO, V22, P505, DOI 10.1111/j.1365-2990.1996.tb01125.x; Graham DI, 1997, GREENFIELDS NEUROPAT, P197; JAFARI SS, 1997, NEUROCYTOL, V26, P207; KATZ DI, 1994, HDB NEUROREHABILITAT, P493; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MILLER JD, 1978, NEURAL TRAUMA, P173; OEHMICHEN M, 1980, Z RECHTSMED, V84, P79, DOI 10.1007/BF02114577; Oehmichen M, 1997, RES LEG MED, V17, P203; Oehmichen M, 1981, Beitr Gerichtl Med, V39, P57; OEHMICHEN M, 1997, NEUROTRAUMATOLOGY BI; OEHMICHEN M, 1992, KOPFSCHUSS SPANNUNGS, P37; OEHMICHEN M, 1998, IN PRESS INT J LEGAL; OEHMICHEN M, 1998, IN PRESS INT J FOREN; OEHMICHEN M, 1995, NEUROPATHOLOGIE, P197; Olsson Y, 1996, NEUROPATH APPL NEURO, V22, P518, DOI 10.1111/j.1365-2990.1996.tb01129.x; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 1997, RES LEG MED, V17, P175; SCHWEITZER JB, 1993, ACTA NEUROPATHOL, V85, P503; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHIGEMATSU K, 1992, AM J PATHOL, V140, P787; SIKAL RR, 1969, BIOMETRY, P607; STRICH SJ, 1968, J NEUROL NEUROSUR PS, V31, P110, DOI 10.1136/jnnp.31.2.110; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; VANEZIS P, 1997, FORENS SCI INT, V35, P1; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; [No title captured]; [No title captured]	44	56	63	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	JUL 6	1998	95	1					67	83		10.1016/S0379-0738(98)00075-9			17	Medicine, Legal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Legal Medicine	106TN	WOS:000075166700008	9718672				2022-02-06	
J	Soblosky, JS; Colgin, LL; Chorney-Lane, D; Davidson, JF; Carey, ME				Soblosky, JS; Colgin, LL; Chorney-Lane, D; Davidson, JF; Carey, ME			Ladder beam and camera video recording system for evaluating forelimb and hindlimb deficits after sensorimotor cortex injury in rats	JOURNAL OF NEUROSCIENCE METHODS			English	Article						sensorimotor cortex; brain lesion; hindlimb; forelimb; motor recovery; beam-walking; wire-grid test; rat	TRAUMATIC BRAIN INJURY; CORTICAL DAMAGE; MOTOR CORTEX; RECOVERY; ORGANIZATION; AMPHETAMINE; LESIONS; MEMORY; MODEL	Hindlimb and forelimb deficits in rats caused by sensorimotor cortex lesions are frequently tested by using the narrow flat beam (hindlimb), the narrow pegged beam (hindlimb and forelimb) or the grid-walking (forelimb) tests. Although these are excellent tests, the narrow flat beam generates non-parametric data so that using more powerful parametric statistical analyses are prohibited. All these tests can be difficult to score if the rat is moving rapidly. Foot misplacements, especially on the grid-walking test, are indicative of an ongoing deficit, but have not been reliably and accurately described and quantified previously. In this paper we present an easy to construct and use horizontal ladder-beam with a camera system on rails which can be used to evaluate both hindlimb and forelimb deficits in a single test. By slow motion videotape playback we were able to quantify and demonstrate foot misplacements which go beyond the recovery period usually seen using more conventional measures (i.e. footslips and footfaults). This convenient system provides a rapid and reliable method for recording and evaluating rat performance on any type of beam and may be useful for measuring sensorimotor recovery following brain injury. (C) 1997 Elsevier Science B.V.	Louisiana State Univ, Med Ctr, Dept Neurosurg, Neurotrauma Res Lab, New Orleans, LA 70112 USA		Soblosky, JS (corresponding author), Louisiana State Univ, Med Ctr, Dept Neurosurg, Neurotrauma Res Lab, 1542 Tulane Ave, New Orleans, LA 70112 USA.			Lane, Diane/0000-0001-7313-557X; Colgin, Laura/0000-0002-4853-8913			BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BOYESON MG, 1993, PHARMACOL BIOCHEM BE, V44, P297, DOI 10.1016/0091-3057(93)90465-6; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GENTILE AM, 1978, BEHAV BIOL, V22, P417, DOI 10.1016/S0091-6773(78)92547-6; GOLDSTEIN LB, 1990, J NEUROSCI METH, V31, P101, DOI 10.1016/0165-0270(90)90154-8; GOLDSTEIN LB, 1993, NEUROSCI PROTOCOLS, P1; HALL RD, 1974, BRAIN RES, V66, P23, DOI 10.1016/0006-8993(74)90076-6; JONES TA, 1992, BEHAV BRAIN RES, V51, P1, DOI 10.1016/S0166-4328(05)80306-7; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; NEAFSEY EJ, 1986, BRAIN RES REV, V11, P77, DOI 10.1016/0165-0173(86)90011-1; PELLEGRINO I, 1979, STEREOTAXIC ATLAS RA; SCHALLERT T, 1982, PHARMACOL BIOCHEM BE, V16, P455, DOI 10.1016/0091-3057(82)90452-X; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Soblosky J. S., 1994, Society for Neuroscience Abstracts, V20, P194; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Soblosky JS, 1996, BEHAV BRAIN RES, V80, P185, DOI 10.1016/0166-4328(96)00034-4; SOBLOSKY JS, IN PRESS BEHAV BRAIN	22	56	56	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270			J NEUROSCI METH	J. Neurosci. Methods	DEC 30	1997	78	1-2					75	83		10.1016/S0165-0270(97)00131-3			9	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	YV689	WOS:000071852900008	9497003				2022-02-06	
J	Armstead, WM				Armstead, WM			Brain injury impairs ATP-sensitive K+ channel function in piglet cerebral arteries	STROKE			English	Article						newborn; cerebral circulation; pigs; nucleotides, nitric oxide	GENE-RELATED PEPTIDE; SMOOTH-MUSCLE CELLS; POTASSIUM CHANNELS; NITRIC-OXIDE; MESENTERIC-ARTERIES; BASILAR ARTERY; BLOOD-VESSELS; ACTIVATION; RESPONSES; DILATION	Background and Purpose Traumatic injury is the leading cause of death for infants and children, and mortality is increased with head injury. Previous studies have shown that pial arteries constricted and that responses to several nitric oxide (NO)-dependent dilator stimuli were blunted after fluid percussion injury (FPI) in newborn pigs. Membrane potential of vascular muscle is a major determinant of vascular tone, and activity of K+ channels is a major regulator of membrane potential. Recent data show that the NO releasers sodium nitroprusside (SNP) and S-nitroso-N-acetylpenicillamine (SNAP) and 8-bromo-cGMP elicit dilation via ATP-sensitive K+ channel (K-ATP) activation. The present study was designed to investigate the effect of FPI on K-ATP channel function. Methods Chloralose-anesthetized newborn pigs equipped with a closed cranial window were connected to a percussion device that consisted of a saline-filled cylindrical reservoir and a metal pendulum. Brain injury of moderate severity (1.9 to 2.1 atm) was produced by allowing the pendulum to strike a piston on the cylinder. Pial artery diameter was measured with a video microscaler. Data were analyzed by repeated measures ANOVA. An alpha level of P<.05 was considered significant. Results FPI blunted dilation to cromakalim (10(-8), 10(-6) mol/L), a K-ATP agonist (10+/-1% and 27+/-2% versus 3+/-1% and 7+/-2% before and after FPI, respectively, n=8). Similarly, FPI blunted dilation to calcitonin gene-related peptide, an endogenous K-ATP activator. FPI also blunted dilator responses to SNP, S-nitroso-N-acetylpenicillamine, and 8-bromo-cGMP (10(-6) to 10(-8) mol/L) (10+/-1% and 20+/-1% versus 2+/-1% and 8+/-2% for SNP before and after FPI; 9+/-1% and 16+/-1% versus 2+/-1% and 4+/-1% for 8-bromo-cGMP before and after FPI, respectively, n=8). In contrast, responses to papaverine and brain natriuretic peptide were unchanged after FPI. Conclusions These data show that K-ATP channel function is impaired after FPI. Furthermore, these data suggest that impaired function of mechanisms distal to NO synthase contribute to altered cerebral hemodynamics after FPI.	UNIV PENN, DEPT PHARMACOL, CHILDRENS HOSP PHILADELPHIA, PHILADELPHIA, PA 19104 USA		Armstead, WM (corresponding author), UNIV PENN, DEPT ANESTHESIA, CHILDRENS HOSP PHILADELPHIA, 34TH & CIV CTR BLVD, PHILADELPHIA, PA 19104 USA.						Armstead WM, 1996, AM J PHYSIOL-HEART C, V270, pH1272; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1997, AM J PHYSIOL-HEART C, V272, pH1785, DOI 10.1152/ajpheart.1997.272.4.H1785; Armstead WM, 1996, AM J PHYSIOL-HEART C, V270, pH423, DOI 10.1152/ajpheart.1996.270.2.H423; ASANO M, 1993, J PHARMACOL EXP THER, V267, P1277; Bari F, 1996, STROKE, V27, P1874, DOI 10.1161/01.STR.27.10.1874; Bari F, 1996, J CEREBR BLOOD F MET, V16, P1158, DOI 10.1097/00004647-199611000-00010; BONNET P, 1991, PFLUG ARCH EUR J PHY, V418, P292, DOI 10.1007/BF00370529; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; COLOMBANI PM, 1985, J PEDIATR SURG, V20, P8, DOI 10.1016/S0022-3468(85)80382-1; DEVINE JO, 1995, BRAIN RES, V675, P257, DOI 10.1016/0006-8993(95)00081-Z; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; EDVINSSON L, 1987, J CEREBR BLOOD F MET, V7, P720, DOI 10.1038/jcbfm.1987.126; FARACI FM, 1994, STROKE, V25, P1679, DOI 10.1161/01.STR.25.8.1679; FREDRICKS KT, 1994, AM J PHYSIOL, V267, pH580, DOI 10.1152/ajpheart.1994.267.2.H580; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Kasemsri T, 1997, STROKE, V28, P190, DOI 10.1161/01.STR.28.1.190; KITAZONO T, 1993, HYPERTENSION, V22, P677, DOI 10.1161/01.HYP.22.5.677; KITAZONO T, 1995, STROKE, V26, P1713, DOI 10.1161/01.STR.26.9.1713; KITAZONO T, 1993, AM J PHYSIOL, V265, pH581, DOI 10.1152/ajpheart.1993.265.2.H581; Kontos HA, 1996, AM J PHYSIOL-HEART C, V271, pH1498, DOI 10.1152/ajpheart.1996.271.4.H1498; KUBO M, 1994, CIRC RES, V74, P471, DOI 10.1161/01.RES.74.3.471; LEE WS, 1993, LIFE SCI, V52, P1527; Louis TM, 1996, STROKE, V27, P134, DOI 10.1161/01.STR.27.1.134; MAYHAN WG, 1993, AM J PHYSIOL, V265, pH152, DOI 10.1152/ajpheart.1993.265.1.H152; MCCARRON JG, 1991, AM J PHYSIOL, V261, pH287, DOI 10.1152/ajpheart.1991.261.2.H287; MIYOSHI Y, 1992, CIRC RES, V70, P612, DOI 10.1161/01.RES.70.3.612; NAGAO T, 1991, STROKE, V22, P221, DOI 10.1161/01.STR.22.2.221; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799, DOI 10.1152/ajpcell.1995.268.4.C799; NELSON MT, 1990, AM J PHYSIOL, V259, pC3; SAITO A, 1989, J PHARMACOL EXP THER, V248, P455; SHANKAR V, 1995, AM J PHYSIOL-HEART C, V269, pH997, DOI 10.1152/ajpheart.1995.269.3.H997; Sobey CG, 1996, AM J PHYSIOL-HEART C, V271, pH126, DOI 10.1152/ajpheart.1996.271.1.H126; TAGUCHI H, 1995, CIRC RES, V76, P1057, DOI 10.1161/01.RES.76.6.1057; Thorogood MC, 1996, ANESTHESIOLOGY, V84, P614, DOI 10.1097/00000542-199603000-00017; THOROGOOD MC, 1995, AM J PHYSIOL-HEART C, V269, pH1776; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Wilderman MJ, 1996, AM J PHYSIOL-HEART C, V270, pH869, DOI 10.1152/ajpheart.1996.270.3.H869	38	56	56	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	NOV	1997	28	11					2273	2279		10.1161/01.STR.28.11.2273			7	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	YE841	WOS:A1997YE84100033	9368576				2022-02-06	
J	Dixon, CE; Ma, XC; Marion, DW				Dixon, CE; Ma, XC; Marion, DW			Reduced evoked release of acetylcholine in the rodent neocortex following traumatic brain injury	BRAIN RESEARCH			English	Article						brain injury; neocortex; acetylcholine; microdialysis; rat	NERVE GROWTH-FACTOR; NUCLEUS BASALIS MAGNOCELLULARIS; CONTROLLED CORTICAL IMPACT; FOREBRAIN CHOLINERGIC NEURONS; FIMBRIA-FORNIX TRANSECTION; FLUID-PERCUSSION INJURY; HEAD-INJURY; RAT; MEMORY; ACETYLTRANSFERASE	Neocortical acetylcholine (ACh) release was examined in awake, freely-moving rats at 14 days following lateral controlled cortical impact. Extracellular ACh was measured prior to and after an intraperitoneal administration of scopolamine, which evokes ACh release by blocking autoreceptors. At 14 days post-injury there was a significant reduction in scopolamine-evoked ACh release. The data suggest that neocortical cholinergic neurotransmission is chronically compromised, and may contribute to post-traumatic memory deficits.			Dixon, CE (corresponding author), UNIV PITTSBURGH,DEPT NEUROSURG,3434 5TH AVE,SUITE 201,PITTSBURGH,PA 15260, USA.		Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033150, P01NS031998] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS31998, NS33150] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49-CCR303547] Funding Source: Medline		ARMSTRONG DM, 1987, J COMP NEUROL, V264, P421, DOI 10.1002/cne.902640309; BERGERSWEENEY J, 1994, J NEUROSCI, V14, P4507; BLAKER SN, 1988, J COMP NEUROL, V272, P127, DOI 10.1002/cne.902720109; CARROLL PT, 1980, SCIENCE, V210, P641, DOI 10.1126/science.7433989; COLLERTON D, 1986, NEUROSCIENCE, V19, P1, DOI 10.1016/0306-4522(86)90002-3; DEKKER AJ, 1992, NEUROSCIENCE, V48, P111, DOI 10.1016/0306-4522(92)90342-Y; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Dixon C. E., 1995, Journal of Neurotrauma, V12, P491; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1995, NEUROSCI LETT, V198, P111, DOI 10.1016/0304-3940(95)11979-7; DIXON CE, 1991, J NEUROSCI METH, V39, P253; GAGE FH, 1988, J COMP NEUROL, V269, P147, DOI 10.1002/cne.902690112; GAGE FH, 1986, NEUROSCIENCE, V19, P241, DOI 10.1016/0306-4522(86)90018-7; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAROUTUNIAN V, 1989, BRAIN RES, V487, P200, DOI 10.1016/0006-8993(89)90960-8; HASSELMO ME, 1993, TRENDS NEUROSCI, V16, P218, DOI 10.1016/0166-2236(93)90159-J; JIANG JY, 1994, BRAIN RES, V640, P240; JOHNSTON MV, 1981, EXP BRAIN RES, V43, P159; JOHNSTON MV, 1987, NEUROCHEM RES, V12, P985, DOI 10.1007/BF00970927; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MANDEL RJ, 1989, EXP NEUROL, V104, P208, DOI 10.1016/0014-4886(89)90031-9; MARKOWSKA AL, 1990, BEHAV NEURAL BIOL, V54, P13, DOI 10.1016/0163-1047(90)91211-S; MESULAM MM, 1983, NEUROSCIENCE, V10, P1185, DOI 10.1016/0306-4522(83)90108-2; POSMANTUR R, 1996, J NEUROPATHOL EXP NE, V55, P65; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SONFRONIEW M, 1987, BRAIN RES, V411, P310; SONFRONIEW MV, 1983, BRAIN RES, V289, P370; SPENCER DG, 1983, DRUG DEVELOP RES, V3, P489, DOI 10.1002/ddr.430030602; WINKLER J, 1995, NATURE, V375, P484, DOI 10.1038/375484a0	34	56	60	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 21	1997	749	1					127	130		10.1016/S0006-8993(96)01310-8			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WL911	WOS:A1997WL91100016	9070636				2022-02-06	
J	Heinemann, AW; Kirk, P; Hastie, BA; Semik, P; Hamilton, BB; Linacre, JM; Wright, BD; Granger, C				Heinemann, AW; Kirk, P; Hastie, BA; Semik, P; Hamilton, BB; Linacre, JM; Wright, BD; Granger, C			Relationships between disability measures and nursing effort during medical rehabilitation for patients with traumatic brain and spinal cord injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							FUNCTIONAL INDEPENDENCE MEASURE; CLASSIFICATION-SYSTEM; LIFE SATISFACTION; ASSESSMENT SCALES; FOLLOW-UP; IMPAIRMENT; HANDICAP; HEAD; STROKE	Objective: The increasing use of disability measures requires that the validity of these instruments be adequately demonstrated. This study sought to evaluate the concurrent validity of one disability measure, the Functional Independence Measure (FIM(SM)) using minutes of care reported by nursing staff. Study Design: Correlational, cohort design. Setting: Eight inpatient medical rehabilitation hospitals that subscribe to the Uniform Data System for Medical Rehabilitation. Patients or Other Participants: 129 patients with traumatic brain injury (TBI) and 53 patients with traumatic spinal cord injury (SCI). Interventions: Routine rehabilitation care. Main Outcome Measures: Patient-nurse contact times were recorded with a stop watch for a 24-hour period during the first and last weeks of inpatient rehabilitation. The FIM was also completed during the first and last weeks of rehabilitation. Results: Contact times declined from the first to last weeks of rehabilitation, concurrent with improving scores on motor and cognitive measures derived from the FIM. Statistically significant correlations between contact times and FIM measures were observed for medication dispensing, treatment provision, and teaching/activities of daily living at admission and discharge. Smaller and usually nonsignificant correlations were observed in activities that did not involve direct patient contact. Contact times increased exponentially as disability increased. Conclusions: These results support the construct validity of the FIM by demonstrating strong relationships (r values in the range of .40 to .60) between burden of care and a measure of disability. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	NORTHWESTERN UNIV,SCH MED,DEPT PHYS MED & REHABIL,EVANSTON,IL 60208; UNIV CHICAGO,DEPT EDUC,MESA PSYCHOMETR LAB,CHICAGO,IL 60637; VET AFFAIRS MED CTR,DURHAM,NC 27705; SUNY BUFFALO,CTR FUNCT ASSESSMENT RES,BUFFALO,NY 14260		Heinemann, AW (corresponding author), REHABIL INST CHICAGO,ROOM 1374,345 E SUPERIOR ST,CHICAGO,IL 60611, USA.		Heinemann, Allen W/K-6283-2012; Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR503609] Funding Source: Medline		Brown S. C., 1993, J DISABIL POLICY STU, V4, P57; DEGROOT HA, 1989, J NURS ADMIN, V19, P24; DeVivo M, 1995, SPINAL CORD INJURY C, P234; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DISLER PB, 1993, ARCH PHYS MED REHAB, V74, P139; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; GIOVANETTI P, 1978, HRA7827 DHEW; GIOVANETTI P, 1984, NURS MANAGE, V15, P35; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; HAMILITON BB, 1994, PHYS THER, V74, P494, DOI 10.1093/ptj/74.5.494; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Hamilton BB, 1987, REHABILITATION OUTCO; Heinemann Allen W, 1994, Top Stroke Rehabil, V1, P1; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HEINEMANN AW, 1995, 103 ANN CONV AM PSYC; JOHNSTON MV, 1992, ARCH PHYS MED REHAB, V73, pS3; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Kelleher C, 1992, Nurs Econ, V10, P31; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; LEWIS NL, 1984, NURSING STAFFING PAT; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; MENTER RR, 1991, PARAPLEGIA, V29, P613, DOI 10.1038/sc.1991.90; OBRIENPALLAS L, 1992, J NURS ADMIN, V22, P17; PARDUE S, 1986, J PSYCHOSOC NURS, V2, P23; PHILLIPS CY, 1992, J NURS ADMIN, V22, P46, DOI 10.1097/00005110-199204000-00012; RINTALA DH, 1993, AM SPIN INJ ASS M SA; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; *SUNY, 1993, GUID UN DAT SET MED; *U AL, 1994, SPIN CORD INJ FACTS; UNGER J, 1985, J NURS ADMIN, V15, P18; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; Wrona-Sexton S, 1992, Nurs Manage, V23, P38, DOI 10.1097/00006247-199212000-00010	36	56	58	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1997	78	2					143	149		10.1016/S0003-9993(97)90255-0			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	WH072	WOS:A1997WH07200006	9041894				2022-02-06	
J	Day, LB; Schallert, T				Day, LB; Schallert, T			Anticholinergic effects on acquisition of place learning in the Morris water task: Spatial mapping deficit or inability to inhibit nonplace strategies?	BEHAVIORAL NEUROSCIENCE			English	Article							CHOLINERGIC RECEPTOR BLOCKADE; TRAUMATIC BRAIN INJURY; HIPPOCAMPAL-LESIONS; SWIMMING POOL; AGED RATS; NAVIGATION; LOCALIZATION; HYPOTHERMIA; IMPAIRMENT; CUES	The role of central cholinergic blockage in spatial learning was examined by testing atropine sulfate-treated (50 mg/kg) rats and saline-injected controls in the Morris water task using training procedures designed to promote the use of a spatial search strategy. First, constraints used in early trials deterred thigmotaxis. Second, an originally oversized hidden platform that nearly occupied the entire pool was effectively ''shrunk'' into the southwest quadrant of the pool by substituting smaller platforms over trials, a procedure intended to focus attention on the hidden platform in relation to extramaze cues. Task acquisition did not differ between groups, and on the probe trial both groups increased distance and latency and swam preferentially in the previously correct quadrant. Impairments caused by atropine sulfate may be the result of deficits in ability to inhibit nonefficient escape strategies.	UNIV TEXAS,DEPT PSYCHOL,AUSTIN,TX 78712; UNIV TEXAS,INST NEUROSCI,AUSTIN,TX 78712					Day, Lainy/0000-0002-9122-3044			AMSEL A, 1993, HIPPOCAMPUS, V3, P251, DOI 10.1002/hipo.450030302; BAXTER MG, 1995, BEHAV NEUROSCI, V109, P714, DOI 10.1037/0735-7044.109.4.714; BERGERSWEENEY J, 1994, J NEUROSCI, V14, P4507; BLODGETT HC, 1949, J EXP PSYCHOL, V39, P800, DOI 10.1037/h0058978; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; DEVIETTI TL, 1985, BEHAV NEUROSCI, V99, P1128, DOI 10.1037/0735-7044.99.6.1128; DIMATTIA BD, 1988, BEHAV NEUROSCI, V102, P471, DOI 10.1037/0735-7044.102.4.471; DOUGLAS RJ, 1967, PSYCHOL BULL, V67, P416, DOI 10.1037/h0024599; GABRIEL M, 1987, EXP BRAIN RES, V67, P131, DOI 10.1007/BF00269462; GAGE FH, 1984, NEUROBIOL AGING, V5, P43, DOI 10.1016/0197-4580(84)90084-8; GALLAGHER M, 1993, BEHAV NEUROSCI, V107, P618, DOI 10.1037/0735-7044.107.4.618; GRAY JA, 1983, NEUROSCI BIOBEHAV R, V7, P119, DOI 10.1016/0149-7634(83)90014-3; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; KIMBLE DP, 1968, PSYCHOL BULL, V70, P285, DOI 10.1037/h0026470; KOLB B, 1983, BEHAV NEUROSCI, V97, P12; LINDNER MD, 1988, BEHAV NEUROSCI, V102, P621, DOI 10.1037/0735-7044.102.5.621; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; NILSSON OG, 1992, NEUROREPORT, V3, P1005, DOI 10.1097/00001756-199211000-00015; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OKeefe J., 1978, HIPPOCAMPUS COGNITIV; RAPP PR, 1987, BEHAV NEUROSCI, V101, P3, DOI 10.1037/0735-7044.101.1.3; Saucier D, 1996, BEHAV NEUROSCI, V110, P103, DOI 10.1037/0735-7044.110.1.103; SCHALLERT T, 1980, J COMP PHYSIOL PSYCH, V94, P1, DOI 10.1037/h0077656; SUTHERLAND RJ, 1982, J COMP PHYSIOL PSYCH, V96, P563, DOI 10.1037/h0077914; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; WHISHAW IQ, 1985, BEHAV NEUROSCI, V99, P979, DOI 10.1037/0735-7044.99.5.979; WHISHAW IQ, 1995, J NEUROSCI, V15, P5779; YAMAMURA HI, 1974, BRAIN RES, V80, P170, DOI 10.1016/0006-8993(74)90738-0	31	56	56	0	3	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242	0735-7044			BEHAV NEUROSCI	Behav. Neurosci.	OCT	1996	110	5					998	1005					8	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	VQ506	WOS:A1996VQ50600013	8919002				2022-02-06	
J	Kreutzer, JS; Witol, AD; Sander, AM; Cifu, DX; Marwitz, JH; Delmonico, R				Kreutzer, JS; Witol, AD; Sander, AM; Cifu, DX; Marwitz, JH; Delmonico, R			A prospective longitudinal multicenter analysis of alcohol use patterns among persons with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						alcohol use; substance abuse	HEAD-INJURY; SUBSTANCE-ABUSE; FOLLOW-UP; REHABILITATION	Objective: To characterize long-term post injury drinking patterns of persons with traumatic brain injury and to identify injury-related and sociodemographic factors related to post injury consumption, Design: A cross-sectional design (n=322) was first used to characterize drinking patterns at three time intervals. A longitudinal design (n=73) nas then used to examine changes in consumption patterns. chi(2) analyses and Wilcoxon matched-pairs signed-ranks test (t-tests) were conducted to investigate the relationship between patients' reported alcohol use and time post injury. Spearman rank-order correlations, chi(2) analyses. and Fisher's exact probability tests were used to examine relationships among drinking classifications and injury-related and sociodemographic characteristics. Setting: Rehabilitation center outpatient clinics affiliated with the four brain injury model Systems programs. Patients: Patients with moderate and severe brain injury who received acute medical care and inpatient rehabilitation. Inclusion criteria were: patient >16 years old, participation in follow-up medical and psychologic evaluations, and willingness to provide information regarding alcohol consumption Main Outcome. Measures: Quantity Frequency Variability index, Disability Rating Scale, and Functional Independence Measure scores. Results: At each follow up interval, the proportion of persons classified as moderate or heavy drinkers was generally comparable to that in the general population, Abstention rates, however, were markedly higher than those within the general population. For the cross-sectional sample, chi(2) analyses revealed no significant differences in the distribution of drinking classifications across follow-up intervals. For the longitudinal group however, Wilcoxon matched-pairs signed-ranks tests revealed substantial differences in drinking ratings for individuals over time. A pattern of increasing consumption was indicated. Correlational analyses revealed higher consumption levels for younger persons and those with higher admission blood alcohol levels. Furthermore. relationships were observed between injury severity and consumption levels, Higher levels of disability were associated with loner consumption rates. Conclusions: These data suggest that alcohol use patterns are dynamic during the first 4 years after injury. Also, long-term monitoring of alcohol use patterns may be cost-effective. particularly for younger persons and those with a preinjury history of problem drinking.	SANTA CLARA VALLEY MED CTR,PSYCHOL SERV,SAN JOSE,CA		Kreutzer, JS (corresponding author), VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,DEPT PHYS MED & REHABIL,MCV BOX 980542,RICHMOND,VA 23298, USA.			Cifu, David/0000-0003-1600-9387			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P642; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FORER S, 1982, J ORGAN REHABIL EVAL, V2, P29; Glow B., 1989, ALCOHOLISM SUBSTANCE; GOLD MA, 1993, J ADOLESCENT HEALTH, V14, P80, DOI 10.1016/1054-139X(93)90089-8; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HILTON ME, 1987, ALCOHOL CLIN EXP RES, V11, P167, DOI 10.1111/j.1530-0277.1987.tb01283.x; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MAISTO SA, 1979, J CONSULT CLIN PSYCH, V47, P106, DOI 10.1037/0022-006X.47.1.106; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; MOORE D, 1991, INT J ADDICT, V26, P65, DOI 10.3109/10826089109056240; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PORKORNY AD, 1972, AM J PSYCHIAT, V129, P342; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; SANDER A, 1996, 20 ANN POSTGR COURS; SIEGEL D, 1956, NONPARAMETRIC STAT B; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; *WI DEP HLTH SOC S, 1985, ALC US PERS DIS PREL	33	56	56	0	6	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1996	11	5					58	69		10.1097/00001199-199610000-00006			12	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	VP053	WOS:A1996VP05300006					2022-02-06	
J	Cherian, L; Robertson, CS; Goodman, JC				Cherian, L; Robertson, CS; Goodman, JC			Secondary insults increase injury after controlled cortical impact in rats	JOURNAL OF NEUROTRAUMA			English	Article						cortical impact injury; secondary ischemia; secondary insults; traumatic brain injury	TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; ENERGY PHOSPHATE-METABOLISM; FLUID-PERCUSSION INJURY; SEVERE HEAD-INJURY; OXYGEN DELIVERY; CATS; RESPONSES; HYPOXIA; HYPOTENSION	Secondary ischemic insults are common after severe head injury and contribute to poor neurological outcome. To study the increased vulnerability of the traumatized brain to secondary insults, bilateral carotid occlusion was produced after a controlled cortical impact injury in rats. The injury produced by either the impact injury or the bilateral carotid occlusion was mild to moderate when studied individually. The 1 and 3 m/sec impact injuries alone caused no detectable contusion at the impact side and minimal neuronal loss in the hippocampus. The 5 m/sec impact injury alone resulted in a small contusion with a median volume of 5.4 mm(3). The 40-min period of bilateral carotid occlusion alone caused no cortical injury and no neuronal loss in the CA1 region of the hippocampus. When the 40 min of bilateral carotid occlusion was produced 1 h after the impact injury, there was an increase in the damage produced. The contusion volume was significantly larger after the 3 and 5 m/sec impact injuries and the hippocampal neuronal loss was significantly greater after the 1 and 3 m/sec impact injuries. When varying durations of bilateral carotid occlusion were produced 1 h after a 3 m/sec impact injury, contusion volume was significantly larger after bilateral carotid occlusion duration of 40 min, and CA1 neuronal loss was significantly greater after bilateral carotid occlusion durations of 30 and 40 min. When 40 min of bilateral carotid occlusion was produced at different time intervals after a 3 m/sec injury, the increased contusion volume was maximal when bilateral carotid occlusion occurred at 4 h after the impact injury, and the increased neuronal loss in the CA3 region of the hippocampus was maximal when bilateral carotid occlusion occurred at 1 h after the impact injury. By 24 h after the impact injury, 40 min of bilateral carotid occlusion had minimal consequences, similar to the effect in sham-injured animals. These results mimic the clinical situation where secondary insults of a severity that would not cause permanent neurological damage in a normal person are associated with a marked worsening of neurological outcome after head injury and where the injured brain is most susceptible to secondary insults in the first few hours after injury.	BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030		Cherian, L (corresponding author), BAYLOR COLL MED,DEPT NEUROSURG,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER		BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR SUPP, V59, P121; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276, DOI 10.1152/ajpheart.1992.263.4.H1276; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; TSUJI O, 1994, INTRACRANIAL PRESSUR, V9, P268; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137	30	56	57	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	1996	13	7					371	383		10.1089/neu.1996.13.371			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	VB732	WOS:A1996VB73200003	8863193				2022-02-06	
J	Turkstra, LS; McDonald, S; Kaufmann, PM				Turkstra, LS; McDonald, S; Kaufmann, PM			Assessment of pragmatic communication skills in adolescents after traumatic brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; LANGUAGE-SKILLS; CHILDREN; ABILITY; DISCOURSE; REQUESTS	Deficits in pragmatic communication ability have a significant impact on functional outcome from traumatic brain injury (TBI), particularly during adolescence, when sophisticated social communication skills are developing. There are few published tests designed to assess pragmatic skills in this age group. In the present study, four tasks designed to tap various aspects of pragmatic communication ability were administered to three brain-injured adolescents and 36 of their uninjured peers aged 15-18 years. The tasks evaluated the ability to negotiate, hint, describe a simple procedure, and understand sarcasm. The four tasks were found to tap distinct aspects of pragmatic ability in control subjects. Further, within the control group, task performance was related more to non-verbal reasoning ability than vocabulary skills. Scores for two of the three TBI subjects were poorer than chose of their peers, while a third mildly injured subject performed within normal limits. Pragmatic task scores were consistent with the results of neuropsychological testing in the three TBI subjects. Implications for clinical management and recommendations for future research are discussed.	NATL CTR NEUROGEN COMMUN DISORDERS,TUCSON,AZ; UNIV NEW S WALES,DEPT PSYCHOL,KENSINGTON,NSW 2033,AUSTRALIA; UNIV ARIZONA,DEPT PEDIAT,TUCSON,AZ 85721				Turkstra, Lyn/ABC-5831-2021; McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094; Turkstra, Lyn/0000-0002-6948-6921	NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC-01409] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [P60DC001409] Funding Source: NIH RePORTER		ABBEDUTO L, 1989, SCHOOL PSYCHOL REV, V18, P502; BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; BURKE W H, 1990, Brain Injury, V4, P371, DOI 10.3109/02699059009026190; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; DEATON AV, 1987, J LEARN DISABIL, V20, P581, DOI 10.1177/002221948702001003; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; DONDERS J, 1993, BRAIN INJURY, V7, P431, DOI 10.3109/02699059309029686; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1985, SPEECH LANGUAGE EVAL, P71; FLAVELL JH, 1968, DEV ROLE TAKING COMM; FRANCIK EP, 1985, J MEM LANG, V24, P560, DOI 10.1016/0749-596X(85)90046-4; GOLDMAN PS, 1977, NATURE, V267, P613, DOI 10.1038/267613a0; Goldman PS, 1974, PLASTICITY RECOVERY; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; HADI AS, 1994, J ROY STAT SOC B MET, V56, P393; Hartley L. L, 1995, COGNITIVE COMMUNICAT; ISAACSON RL, 1975, ABERRANT DEV INFANCY, P1; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; KENNARD M, 1942, ARCH NEUROL PSYCHIAT, V47, P227; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Levin HS., 1982, NEUROBEHAVIORAL CONS; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; MCDONALD S, 1995, IN PRESS BRAIN INJUR; MILTON SB, 1987, CLIN APHASIOLOGY, V14, P114; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/PMS.73.8.1139-1150; Phelps-Terasaki D., 1992, TEST PRAGMATIC LANGU; Prutting C., 1983, PRAGMATIC ASSESSMENT, P29; REITER S, 1990, CAN J PSYCHIAT, V35, P669, DOI 10.1177/070674379003500804; Slater E.J., 1989, J ADOLESCENT RES, V4, P371; SMITH A, 1984, EARLY BRAIN DAMAGE, V1, P229; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; TAYLOR HG, 1984, EARLY BRAIN DAMAGE, V1, P325; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TIMMERMAN S, 1991, COGNITIVE REHABILITA, P26; Towne R.L., 1993, LANG SPEECH HEAR SER, V24, P100; WIIG EH, 1988, TEST LANGUAGE COMPET; Ylvisaker M., 1989, MILD MODERATE HEAD I, P203; [No title captured]; [No title captured]	44	56	56	1	12	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAY	1996	10	5					329	345		10.1080/026990596124359			17	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	UL742	WOS:A1996UL74200002	8735664				2022-02-06	
J	Wallis, RA; Panizzon, KL; Girard, JM				Wallis, RA; Panizzon, KL; Girard, JM			Traumatic neuroprotection with inhibitors of nitric oxide and ADP-ribosylation	BRAIN RESEARCH			English	Article						ADP-ribosylation; mono-ADP-ribosylation; poly-ADP-ribosylation; nitric oxide; N-methyl-D-aspartate; traumatic brain injury; CA1; hippocampus	HEAD-INJURY; POLY(ADP-RIBOSE) SYNTHETASE; RAT-LIVER; ARGININE; RIBOSYLTRANSFERASE; IDENTIFICATION	N-Methyl-D-aspartate (NMDA) receptor activation is known to contribute to neuronal damage from head trauma. Additionally, NMDA neurotoxicity occurs in part through the generation of nitric oxide (NO), and injury from NO has been shown to be mediated by ADP-ribosylation. Therefore, we investigated whether inhibitors of NO and ADP-ribosylation would protect against acute CA1 traumatic neuronal injury in hippocampal slices subjected to fluid percussion. Treatment with the nitric oxide synthase (NOS) inhibitor, methyl-L-arginine 170 mu M for 35 min after trauma injury, improved CA1 antidromic population spike (PS) recovery to 91 +/- 2%, compared to unmediated slices which recovered to only a mean of 20 +/- 4%, 90 min after trauma. Similarly, hemoglobin 50 mu M, which directly binds NO, protected against traumatic neuronal injury and yielded a mean CA1 PS recovery of 92 +/- 1%. Treatment with inhibitors of poly-ADP-ribosylation was also strongly protective, with the vitamin nicotinamide 10 mM and 3-aminobenzamide 1 mM yielding PS recoveries of 98 +/- 2% and 90 +/- 3%, respectively. Protection was also seen with inhibitors of mono-ADP-ribosylation, including novobiocin 500 mu M and meta-iodobenzylguanidine 20 mu M which yielded recoveries of 89 +/- 6% and 96 +/- 26%. Novobiocin also protected against direct application of NO and NMDA. These findings suggest that NO and ADP-ribosylation are mediators of acute traumatic neuronal injury.	VET AFFAIRS MED CTR 111N1,SEPULVEDA,CA 91343		Wallis, RA (corresponding author), UNIV CALIF LOS ANGELES,DEPT NEUROL,16111 PLUMMER,SEPULVEDA,CA 91343, USA.						Adams RD, 1989, PRINCIPLES NEUROLOGY; BANASIK M, 1992, J BIOL CHEM, V267, P1569; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DIMMELER S, 1991, BIOCHEM BIOPH RES CO, V178, P848, DOI 10.1016/0006-291X(91)90968-D; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GENNARELLI TA, 1993, J EMERG MED S1, V11, pS5; GIRARD JM, 1993, SOC NEUR ABSTR, V23, P1876; Ikonomidou C., 1994, Society for Neuroscience Abstracts, V20, P1677; KALLMANN B, 1992, LIFE SCI, V51, P671, DOI 10.1016/0024-3205(92)90240-P; KAWAICHI M, 1981, J BIOL CHEM, V256, P9483; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MOSS J, 1981, J BIOL CHEM, V256, P7830; OBRIEN P, 1994, COMMUNICATION   1007; Olney J, 1978, KAINIC ACID TOOL NEU, P95; SAKUMA I, 1988, P NATL ACAD SCI USA, V85, P8664, DOI 10.1073/pnas.85.22.8664; SCAIFE RM, 1992, BIOCHEMISTRY-US, V31, P310, DOI 10.1021/bi00116a042; SCHURR A, 1984, BRAIN RES, V297, P357, DOI 10.1016/0006-8993(84)90576-6; SMETS LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P49, DOI 10.1016/0167-4889(90)90204-Q; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SUGIYAMA K, 1989, NEUROSCIENCE, V32, P770; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; VOLPE BT, 1992, BEHAV NEUROSCI, V106, P457, DOI 10.1037/0735-7044.106.3.457; WALLIS RA, 1992, NEUROREPORT, V3, P645, DOI 10.1097/00001756-199207000-00026; WALLIS RA, 1993, NEUROREPORT, V5, P245; WALLIS RA, 1994, BRAIN RES, V664, P115, DOI 10.1016/0006-8993(94)91961-5; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	30	56	57	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 26	1996	710	1-2					169	177		10.1016/0006-8993(95)01278-8			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UA126	WOS:A1996UA12600020	8963656				2022-02-06	
J	BOHNEN, NI; JOLLES, J; TWIJNSTRA, A; MELLINK, R; WIJNEN, G				BOHNEN, NI; JOLLES, J; TWIJNSTRA, A; MELLINK, R; WIJNEN, G			LATE NEUROBEHAVIORAL SYMPTOMS AFTER MILD HEAD-INJURY	BRAIN INJURY			English	Article							CONCUSSION	The present study examined whether patients (n = 11) with post-concussional symptoms (PCS) 12-34 months after mild head injury (MHI) performed less well on selected neuropsychological tests than patients with MHI without PCS (n = 11) and healthy controls (n = 11). Patients with PCS were individually matched with controls for the time elapsed after the injury, age, sex, education and IQ. There were no overall gross differences between the groups in cognitive functioning, except for an isolated deficit on a sustained attention task. Post-hoc analysis of results obtained with two behavioural rating scales showed that patients with higher ratings on a post-concussive/cognitive complaints scale performed less well on a sustained attention task than subjects with lower ratings.	UNIV LIMBURG,DEPT NEUROPSYCHOL & PSYCHOBIOL,MAASTRICHT,NETHERLANDS; UNIV LIMBURG HOSP,DEPT NEUROL,MAASTRICHT,NETHERLANDS								BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BRAND N, 1985, J GEN PSYCHOL, V112, P201, DOI 10.1080/00221309.1985.9711004; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1989, MILD HEAD INJURY, P229; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GENTILINI M, 1989, MILD HEAD INJURY, P163; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1974, LANCET, V2, P605; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Luteijn F., 1983, HANDLEIDING GRONINGE; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; NOVICK MR, 1966, J MATH PSYCHOL, V3, P1, DOI 10.1016/0022-2496(66)90002-2; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; van Zomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; Verhage R, 1964, THESIS ASSEN; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008; 1985, SAS USERS GUIDE STAT	23	56	56	0	0	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1995	9	1					27	33		10.3109/02699059509004568			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	QB052	WOS:A1995QB05200004	7874093				2022-02-06	
J	LEVIN, LA; JOSEPH, MP; RIZZO, JF; LESSELL, S				LEVIN, LA; JOSEPH, MP; RIZZO, JF; LESSELL, S			OPTIC CANAL DECOMPRESSION IN INDIRECT OPTIC-NERVE TRAUMA	OPHTHALMOLOGY			English	Article								Background: The proper management of neurogenic visual loss after blunt head trauma is controversial. Non-treatment, corticosteroids, and surgical decompression of the optic canal are all currently considered to be reasonable alternatives. The goal of this study was to identify factors affecting improvement in patients treated with canal decompression. Methods: A retrospective analysis of 31 cases in which transethmoidal decompression of the optic canal had been performed for neurogenic visual loss after closed head trauma was conducted. Each patient was alert and free of injury to the globe when evaluated before surgery. Surgery was performed within 6 days of injury, and all were given perioperative steroids. Results: Visual acuity improved in 22 (71%) patients, with 6 (19%) regaining visual acuity of 20/40 or better. The mean improvement from preoperative visual deficit was 42.0% +/- 6.6%, with a median improvement of 45.2%. Both univariate and multivariate analysis suggested that vision improved more in patients who were younger than 40 years of age than in patients who were 40 years of age or older. Interval between injury and surgery, preoperative visual acuity, and the presence of optic canal fracture did not affect outcome. Conclusion: Any future randomized trials of therapy should stratify patients based on age. Enrollment of patients with no light perception or who experienced delay between injury and treatment may be reasonably considered.	MASSACHUSETTS EYE & EAR INFIRM, DEPT OPHTHALMOL, NEUROOPHTHALMOL UNIT, BOSTON, MA 02114 USA								ANDERSON RL, 1982, OPHTHALMOLOGY, V89, P445; COSTA VP, 1993, OPHTHALMOLOGY, V100, P599; Gottlob I, 1990, J Pediatr Ophthalmol Strabismus, V27, P40; HUGHES B, 1962, B JOHNS HOPKINS HOSP, V111, P98; JOSEPH MP, 1990, ARCH OPHTHALMOL-CHIC, V108, P1091, DOI 10.1001/archopht.1990.01070100047032; Kertesz A, 1984, Adv Neurol, V42, P23; KLINE LB, 1984, NEUROSURGERY, V14, P756, DOI 10.1227/00006123-198406000-00021; LESSELL S, 1989, ARCH OPHTHALMOL-CHIC, V107, P382, DOI 10.1001/archopht.1989.01070010392031; LUDWIN SK, 1980, LAB INVEST, V43, P382; Reinvang I, 1984, Adv Neurol, V42, P13; SPOOR TC, 1990, AM J OPHTHALMOL, V110, P665, DOI 10.1016/S0002-9394(14)77065-5; Walsh F, 1969, CLIN NEUROOPHTHALMOL; Winer BJ., 1971, STAT PRINCIPLES EXPT	13	56	62	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0161-6420	1549-4713		OPHTHALMOLOGY	Ophthalmology	MAR	1994	101	3					566	569					4	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	NB220	WOS:A1994NB22000032	8127578				2022-02-06	
J	MARTIN, RC; BOLTER, JF; TODD, ME; GOUVIER, WD; NICCOLLS, R				MARTIN, RC; BOLTER, JF; TODD, ME; GOUVIER, WD; NICCOLLS, R			EFFECTS OF SOPHISTICATION AND MOTIVATION ON THE DETECTION OF MALINGERED MEMORY PERFORMANCE USING A COMPUTERIZED FORCED-CHOICE TASK	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							FAKING; PROSPECTS; DEFICITS; AMNESIA	The present study employed a computerized forced-choice recognition memory task, the Multi-Digit Memory Test (MDMT), to examine the effects of instructional set (i.e., dissimulation information provided subjects) and motivation (i.e., monetary incentive) on simulated malingering behavior in a group of 119 university undergraduate students and 33 patients sustaining varying severity of closed-head injury. For the nonpatient groups, a significant effect of instructional set was revealed. Motivational incentive, however did not affect forced-choice performance. Overall, significant performance differences emerged between all groups with nonmalingering students performing nearly perfectly, the brain-injured patients performing well above chance levels, sophisticated student malingers performing at chance, and naive student malingers performing well below chance levels. These results suggest the MDMT may offer a clinically useful and convenient addition to a neuropsychological assessment when there is suspicion of feigned memory problems. These data also support the use of naive and sophisticated malingering subjects in further analog studies addressing this topic.			MARTIN, RC (corresponding author), LOUISIANA STATE UNIV,DEPT PSYCHOL,BATON ROUGE,LA 70803, USA.			Martin, Roy/0000-0001-9328-0846			American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; BRANDT J, 1985, ANN NY ACAD SCI, V444, P502, DOI 10.1111/j.1749-6632.1985.tb37625.x; BRANDT J, 1988, CLIN ASSESSMENT MALI; DULANEY EF, 1982, HUM COMMUN RES, V9, P75, DOI 10.1111/j.1468-2958.1982.tb00684.x; GOEBEL RA, 1983, J CLIN PSYCHOL, V39, P731, DOI 10.1002/1097-4679(198309)39:5<731::AID-JCLP2270390515>3.0.CO;2-T; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HEILVEIL I, 1981, PSYCHOTHER-THEOR RES, V18, P329, DOI 10.1037/h0088382; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Jennett B, 1981, MANAGEMENT HEAD INJU; KERR KL, 1990, J CLIN EXPT NEUROPSY, V11, P57; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Niccolls R., 1991, MULTIDIGIT MEMORY TE; PANKRATZ L, 1983, PERCEPT MOTOR SKILL, V57, P367, DOI 10.2466/pms.1983.57.2.367; PANKRATZ L, 1988, CLIN ASSESSMENT MALI; ROGERS R, 1988, CLIN ASSESSMENT MALI; Sax D. S., 1984, ADV CLIN NEUROPSYCHO, P127; SCHACTER DL, 1986, BEHAVIORAL SCI LAW, V4, P47, DOI DOI 10.1002/BSL.2370040104; SMITH A, 1961, DIS NERV SYST, V22, P69; WIGGINS EC, 1988, LAW HUMAN BEHAV, V12, P57, DOI 10.1007/BF01064274	23	56	56	0	5	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	NOV	1993	15	6					867	880		10.1080/01688639308402604			14	Psychology, Clinical; Clinical Neurology; Psychology	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Neurosciences & Neurology	MM923	WOS:A1993MM92300003	8120124				2022-02-06	
J	CLIFTON, GL; KREUTZER, JS; CHOI, SC; DEVANY, CW; EISENBERG, HM; FOULKES, MA; JANE, JA; MARMAROU, A; MARSHALL, LF				CLIFTON, GL; KREUTZER, JS; CHOI, SC; DEVANY, CW; EISENBERG, HM; FOULKES, MA; JANE, JA; MARMAROU, A; MARSHALL, LF			RELATIONSHIP BETWEEN GLASGOW OUTCOME SCALE AND NEUROPSYCHOLOGICAL MEASURES AFTER BRAIN INJURY	NEUROSURGERY			English	Article						BRAIN INJURY; GLASGOW OUTCOME SCALE; NEUROPSYCHOLOGICAL EXAMINATION	SEVERE HEAD-INJURY; REHABILITATION; RECOVERY; PREDICTION	THE PRESENT STUDY was conducted to further our understanding of the relationship between performance on neuropsychological tests and functional status after head injury and to provide information on the relative usefulness of neuropsychological tests as outcome measures in clinical trials of brain injury. We sought to select the fewest number of 19 neuropsychological tests administered to 110 patients that, in combination, were most closely related to outcome (as measured by the Glasgow Outcome Scale (GOS) and to the remaining neuropsychological measures. The relationship of memory and intellectual deficits to functional status was also considered. To address these questions, we analyzed 19 neuropsychological measures and GOS scores of 110 severely brain injured patients from the Traumatic Coma Data Bank. Of 19 neuropsychological measures compared with GOS at 3 and 6 months, four tests (Controlled Oral Word Association, Grooved Pegboard, Trailmaking Part B, and Rey-Osterrieth Complex Figure Delayed Recall) provided the closest relationship to GOS and to the remaining 15 tests. Similar analyses were performed on 30 moderately injured patients to test the generality of our findings across different levels of patient severity. The same four tests were found to be highly predictive of GOS. Grooved Pegboard, a test of fine motor coordination, accounted for 80% of the variation in GOS. Fifteen percent of 116 patients with severe brain injury could not complete a neuropsychological battery and 39% were excluded because of previous brain injury or known substance abuse.	UNIV CALIF SAN DIEGO,SAN DIEGO HEAD INJURY CTR,SAN DIEGO,CA 92103; UNIV VIRGINIA,DEPT NEUROSURG,CHARLOTTESVILLE,VA 22903; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT REHABIL MED,DIV NEUROL SURG,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT BIOSTAT,RICHMOND,VA 23298; UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550; NINCDS,BETHESDA,MD 20892		CLIFTON, GL (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,6431 FANNIN ST,SUITE 7-148,HOUSTON,TX 77030, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01-NS-3-2340, N01-NS-3-2341, N01-NS-3-2339] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS032341, N01NS032340, N01NS032339] Funding Source: NIH RePORTER		ANDERSON TP, 1974, ARCH PHYS MED REHAB, V55, P544; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BENYISHA.Y, 1970, J CONSULT CLIN PSYCH, V34, P436, DOI 10.1037/h0029366; BOND MR, 1976, SCAND J REHABIL MED, V8, P127; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; GILBERSTADT H, 1968, J GERONTOL, V23, P483, DOI 10.1093/geronj/23.4.483; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LEHMANN JF, 1975, ARCH PHYS MED REHAB, V56, P383; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1982, NEUROBEHAVIORAL CONS, P63; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LORENZE EJ, 1963, ARCH PHYS MED REHAB, V43, P514; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MCSWEENY AJ, 1985, J CLIN EXP NEUROPSYC, V7, P281, DOI 10.1080/01688638508401260; REITAN RM, 1985, HALSTEAD REITAN NEUR, P10; SUNDET K, 1988, J CLIN EXP NEUROPSYC, V10, P363, DOI 10.1080/01688638808408245; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; [No title captured]	20	56	57	0	4	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	JUL	1993	33	1					34	39					6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	LK123	WOS:A1993LK12300005	8355845				2022-02-06	
J	RUGG, MD; PICKLES, CD; POTTER, DD; DOYLE, MC; PENTLAND, B; ROBERTS, RC				RUGG, MD; PICKLES, CD; POTTER, DD; DOYLE, MC; PENTLAND, B; ROBERTS, RC			COGNITIVE BRAIN POTENTIALS IN A 3-STIMULUS AUDITORY ODDBALL TASK AFTER CLOSED HEAD-INJURY	NEUROPSYCHOLOGIA			English	Article							EVENT-RELATED POTENTIALS; PERFORMANCE; DYSFUNCTION; STIMULI; P300	Event-related potentials (ERPs) were recorded in a three stimulus oddball task from 16 patients who had sustained a severe closed head injury at least 6 months before testing, and from 16 control subjects. The stimuli comprised a random sequence of frequent non-target tones (P = 0.70), rare target tones (P = 0.15), and rare novel sounds (P = 0.15). The task requirement was to respond promptly to each target tone. From a latency of 200 msec onwards, the ERPs evoked by frequent nontargets were substantially more negative-going in the head-injured than in the control group. When this difference in the ERPs to the frequent tones was taken into account, there was no evidence to suggest that either the latency or the amplitude of the target-evoked N2 and P3b components differed between the groups. The novel stimuli evoked a prominent P3a component. The amplitude and scalp distribution of this component differed little between the groups, but its peak latency was reliably longer in the head-injured subjects. The findings in respect of the N2 and P3b components suggest that impairments in early processing of task-relevant stimuli are not an invariant feature of closed head injury. The findings regarding P3a suggest that, in the majority of patients, head injury has only a limited effect on the neural systems underlying involuntary shifts of attention.	ASTLEY AINSLIE HOSP,DEPT REHABIL MED,EDINBURGH,SCOTLAND; UNIV DUNDEE,DEPT MED,DUNDEE DD1 4HN,SCOTLAND; DUNDEE ROYAL INFIRM,DEPT NEUROL,DUNDEE,SCOTLAND		RUGG, MD (corresponding author), UNIV ST ANDREWS,DEPT PSYCHOL,WELLCOME BRAIN RES GRP,ST ANDREWS KY16 9JU,FIFE,SCOTLAND.				Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		CAMPBELL KB, 1986, CEREBRAL PSYCHOPHYSI, P486; COURCHESNE E, 1975, ELECTROEN CLIN NEURO, V39, P131, DOI 10.1016/0013-4694(75)90003-6; CURRY SH, 1980, MOTIVATION MOTOR SEN, P507; DEACON D, 1991, ELECTROEN CLIN NEURO, V78, P133, DOI 10.1016/0013-4694(91)90113-I; DEACON D, 1991, J CLIN EXP NEUROPSYC, V13, P639, DOI 10.1080/01688639108401079; FITZGERALD PG, 1983, BIOL PSYCHOL, V17, P241, DOI 10.1016/0301-0511(83)90003-0; GARCIALARREA L, 1992, NEUROPSYCHOLOGIA, V30, P723, DOI 10.1016/0028-3932(92)90042-K; GRAHAM FK, 1991, HDB COGNITIVE PSYCHO, P253; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; HOLDSTOCK JH, IN PRESS NEW DEV EVE; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; KNIGHT RT, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P139; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; Levin HS., 1982, NEUROBEHAVIORAL CONS; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MCCARTHY G, 1985, ELECTROEN CLIN NEURO, V62, P203, DOI 10.1016/0168-5597(85)90015-2; Miller E, 1970, Cortex, V6, P121; *MIN STAT SOFTW, 1988, REF MAN REL 6 1; NAATANEN R, 1990, BEHAV BRAIN SCI, V13, P201, DOI 10.1017/S0140525X00078407; NAATANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375, DOI 10.1111/j.1469-8986.1987.tb00311.x; NAATANEN R, 1986, CEREBRAL PSYCHOPHYSI, P169; Naatanen R., 1983, TUTORIALS ERP RES, VVolume 10, P119, DOI DOI 10.1016/S0166-4115(08)62036-1; OTOOLE DM, 1987, PSYCHOPHYSIOLOGY, V24, P487, DOI 10.1111/j.1469-8986.1987.tb00325.x; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; RUGG MD, 1992, HDB NEUROPSYCHOLOGIC, P393; SCABINI D, 1989, Society for Neuroscience Abstracts, V15, P477; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; STEPHENSON WA, 1951, ELECTROEN CLIN NEURO, V3, P237, DOI 10.1016/0013-4694(51)90017-X; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Van Zomeren A. H., 1981, REACTION TIME ATTENT; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VERLEGER R, 1988, BEHAV BRAIN SCI, V11, P343, DOI 10.1017/S0140525X00058015; Woods DL., 1990, EVENT RELATED BRAIN, P178; [No title captured]	38	56	58	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	APR	1993	31	4					373	393		10.1016/0028-3932(93)90161-R			21	Behavioral Sciences; Neurosciences; Psychology, Experimental	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychology	LB263	WOS:A1993LB26300007	8502373				2022-02-06	
J	LEE, ST; LUI, TN				LEE, ST; LUI, TN			EARLY SEIZURES AFTER MILD CLOSED HEAD-INJURY	JOURNAL OF NEUROSURGERY			English	Article						POSTTRAUMATIC SEIZURE; EARLY SEIZURE; CLOSED HEAD INJURY	COMPUTED TOMOGRAPHIC SCANS; TRAUMA; EPILEPSY; CHILDREN; POPULATION; ADMISSION; COUNTY; RISK	The authors review the seizure incidence in 4232 adult patients with mild closed head injury who did not receive prophylactic anticonvulsant agents. One hundred patients (2.36%) experienced seizures within 1 week after head injury; 43 of these (1.02% of the series) had seizures within 24 hours after trauma. Most of the seizures (84%) that developed during the 1st week after injury were of the generalized tonic-clonic type. The incidence of generalized tonic-clonic seizures was higher than that of partial seizures with motor symptoms both within 24 hours (91% vs. 9%) and during the Day 2 to 7 period (79% vs. 21%). No definite intracranial pathological findings were detected by computerized tomography (CT) in 53% of patients with early posttraumatic seizures; six patients had intracranial hemorrhage without intracranial parenchymal damage (three with epidural hematoma and three with subarachnoid hemorrhage). The most common positive CT findings in the early posttraumatic-seizure group were intracerebral hemorrhage (24%), followed by acute subdural hematoma with intracerebral hemorrhage (17%). Intracerebral parenchymal damage could be identified on CT scans in 41 (48.8%) of 84 patients with generalized tonic-clonic seizures and five (31%) of 16 patients with partial seizures with motor symptoms. The intracerebral parenchymal damage was most commonly detected in the frontal lobe (21%) and the temporal lobe (19%). Seven patients with early posttraumatic seizures received emergency craniotomy to remove an intracranial hematoma (epidural in three, subdural and intracerebral in four) because the mass effect resulted in significant midline shift as seen on CT scans. This review suggests that early posttraumatic seizures after mild closed head injury have a high incidence (53%) in patients with normal CT scan findings. Although the possibility of surgically correctable intracranial hemorrhage is low (7%), the condition may be devastating if not treated properly.	CHANG GUNG MEM HOSP,DEPT SURG,DIV NEUROSURG,TAIPEI,TAIWAN		LEE, ST (corresponding author), TAIPEI MUNICIPAL CHUNG HSIAO HOSP,DEPT NEUROSURG,87 TUNGTEH RD,TAIPEI,TAIWAN.						ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; CAVENESS WF, 1961, EPILEPSIA, V2, P123; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DALESSANDRO R, 1988, ARCH NEUROL-CHICAGO, V45, P42, DOI 10.1001/archneur.1988.00520250048019; DESAI BT, 1983, EPILEPSIA, V24, P289, DOI 10.1111/j.1528-1157.1983.tb04892.x; ELVIDGE AR, 1960, INJURIES BRAIN SPINA, P285; FEUERMAN T, 1988, NEUROSURGERY, V22, P449, DOI 10.1227/00006123-198803000-00001; FISCHER RP, 1981, J TRAUMA, V21, P920, DOI 10.1097/00005373-198111000-00002; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; JAMISON DL, 1974, ARCH DIS CHILD, V49, P376, DOI 10.1136/adc.49.5.376; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1975, J NEUROL NEUROSUR PS, V38, P378, DOI 10.1136/jnnp.38.4.378; JENNETT B, 1974, ARCH NEUROL-CHICAGO, V30, P394, DOI 10.1001/archneur.1974.00490350052008; JENNETT B, 1981, MANAGEMENT HEAD INJU, P301; JENNETT B, 1975, EPILEPSY NONMISSILE; JONES JJ, 1981, LANCET, V2, P850; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KARPMAN RR, 1980, ARIZ MED, V37, P772; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KLONOFF H, 1969, CAN MED ASSOC J, V100, P235; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEE ST, 1990, J TRAUMA, V30, P194, DOI 10.1097/00005373-199002000-00010; MENDELOW AD, 1990, BRIT MED J, V285, P1530; MISES J, 1976, EPILEPSIA, V11, P37; RISH BL, 1973, J NEUROSURG, V38, P155, DOI 10.3171/jns.1973.38.2.0155; RIVARA F, 1987, PEDIATRICS, V80, P579; ROS S P, 1989, Pediatric Emergency Care, V5, P216, DOI 10.1097/00006565-198912000-00003; SAINSBURY CPQ, 1984, ARCH DIS CHILD, V59, P856, DOI 10.1136/adc.59.9.856; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; TEASDALE G, 1974, LANCET, V2, P81; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006	34	56	58	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	MAR	1992	76	3					435	439		10.3171/jns.1992.76.3.0435			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	HF274	WOS:A1992HF27400007	1738023				2022-02-06	
J	CICERONE, KD; WOOD, JC				CICERONE, KD; WOOD, JC			PLANNING DISORDER AFTER CLOSED HEAD-INJURY - A CASE-STUDY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article											CICERONE, KD (corresponding author), ROBERT WOOD JOHNSON JR LIFESTYLE INST,DEPT COGNIT REHABIL,EDISON,NJ 08820, USA.						Ayres A. J., 1980, SO CALIFORNIA SENSOR; GLASGOW RE, 1977, J CLIN PSYCHOL, V33, P1049, DOI 10.1002/1097-4679(197710)33:4<1049::AID-JCLP2270330429>3.0.CO;2-V; HEPPNER PP, 1983, INNOVATIONS CLIN PRA, V2, P73; HUMPHREY LL, 1982, J CONSULT CLIN PSYCH, V50, P624, DOI 10.1037/0022-006X.50.5.624; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kazdin A., 1982, SINGLE CASE RES DESI; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; Luria A.R., 1981, LANGUAGE COGNITION; MALEC J, 1983, ARCH PHYS MED REHAB, V64, P436; Meichenbaum D., 1979, COGNITIVE BEHAVIORAL, P11; MEICHENBAUM D, 1980, HELPING PEOPLE CHANG, P390; MEICHENBAUM DH, 1971, J ABNORM PSYCHOL, V77, P115, DOI 10.1037/h0030773; Miller G.A., 1960, PLANS STRUCTURE BEHA; ODDY M, 1984, CLOSED HEAD INJURY P, P108; RUSSELL EW, 1975, J CONSULT CLIN PSYCH, V43, P800, DOI 10.1037/0022-006X.43.6.800; SCHACTER DL, 1985, J CLIN EXP NEUROPSYC, V7, P79, DOI 10.1080/01688638508401243; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; WEINBERG J, 1979, ARCH PHYS MED REHAB, V60, P491; ZIHL J, 1979, J NEUROL NEUROSUR PS, V42, P312, DOI 10.1136/jnnp.42.4.312	19	56	56	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1987	68	2					111	115					5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	G0247	WOS:A1987G024700009	3813856				2022-02-06	
J	Rowell, SE; Meier, EN; McKnight, B; Kannas, D; May, S; Sheehan, K; Bulger, EM; Idris, AH; Christenson, J; Morrison, LJ; Frascone, RJ; Bosarge, PL; Colella, MR; Johannigman, J; Cotton, BA; Callum, J; McMullan, J; Dries, DJ; Tibbs, B; Richmond, NJ; Weisfeldt, ML; Tallon, JM; Garrett, JS; Zielinski, MD; Aufderheide, TP; Gandhi, RR; Schlamp, R; Robinson, BRH; Jui, J; Klein, L; Rizoli, S; Gamber, M; Fleming, M; Hwang, J; Vincent, LE; Williams, C; Hendrickson, A; Simonson, R; Klotz, P; Sopko, G; Witham, W; Ferrara, M; Schreiber, MA				Rowell, Susan E.; Meier, Eric N.; McKnight, Barbara; Kannas, Delores; May, Susanne; Sheehan, Kellie; Bulger, Eileen M.; Idris, Ahamed H.; Christenson, Jim; Morrison, Laurie J.; Frascone, Ralph J.; Bosarge, Patrick L.; Colella, M. Riccardo; Johannigman, Jay; Cotton, Bryan A.; Callum, Jeannie; McMullan, Jason; Dries, David J.; Tibbs, Brian; Richmond, Neal J.; Weisfeldt, Myron L.; Tallon, John M.; Garrett, John S.; Zielinski, Martin D.; Aufderheide, Tom P.; Gandhi, Rajesh R.; Schlamp, Rob; Robinson, Bryce R. H.; Jui, Jonathan; Klein, Lauren; Rizoli, Sandro; Gamber, Mark; Fleming, Michael; Hwang, Jun; Vincent, Laura E.; Williams, Carolyn; Hendrickson, Audrey; Simonson, Robert; Klotz, Patricia; Sopko, George; Witham, William; Ferrara, Michael; Schreiber, Martin A.			Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	TXA in Trauma Symposium	JUL 05, 2019	Melbourne, AUSTRALIA				SEIZURES	Importance Traumatic brain injury (TBI) is the leading cause of death and disability due to trauma. Early administration of tranexamic acid may benefit patients with TBI. Objective To determine whether tranexamic acid treatment initiated in the out-of-hospital setting within 2 hours of injury improves neurologic outcome in patients with moderate or severe TBI. Design, Setting, and Participants Multicenter, double-blinded, randomized clinical trial at 20 trauma centers and 39 emergency medical services agencies in the US and Canada from May 2015 to November 2017. Eligible participants (N = 1280) included out-of-hospital patients with TBI aged 15 years or older with Glasgow Coma Scale score of 12 or less and systolic blood pressure of 90 mm Hg or higher. Interventions Three interventions were evaluated, with treatment initiated within 2 hours of TBI: out-of-hospital tranexamic acid (1 g) bolus and in-hospital tranexamic acid (1 g) 8-hour infusion (bolus maintenance group; n = 312), out-of-hospital tranexamic acid (2 g) bolus and in-hospital placebo 8-hour infusion (bolus only group; n = 345), and out-of-hospital placebo bolus and in-hospital placebo 8-hour infusion (placebo group; n = 309). Main Outcomes and Measures The primary outcome was favorable neurologic function at 6 months (Glasgow Outcome Scale-Extended score >4 [moderate disability or good recovery]) in the combined tranexamic acid group vs the placebo group. Asymmetric significance thresholds were set at 0.1 for benefit and 0.025 for harm. There were 18 secondary end points, of which 5 are reported in this article: 28-day mortality, 6-month Disability Rating Scale score (range, 0 [no disability] to 30 [death]), progression of intracranial hemorrhage, incidence of seizures, and incidence of thromboembolic events. Results Among 1063 participants, a study drug was not administered to 96 randomized participants and 1 participant was excluded, resulting in 966 participants in the analysis population (mean age, 42 years; 255 [74%] male participants; mean Glasgow Coma Scale score, 8). Of these participants, 819 (84.8%) were available for primary outcome analysis at 6-month follow-up. The primary outcome occurred in 65% of patients in the tranexamic acid groups vs 62% in the placebo group (difference, 3.5%; [90% 1-sided confidence limit for benefit, -0.9%]; P = .16; [97.5% 1-sided confidence limit for harm, 10.2%]; P = .84). There was no statistically significant difference in 28-day mortality between the tranexamic acid groups vs the placebo group (14% vs 17%; difference, -2.9% [95% CI, -7.9% to 2.1%]; P = .26), 6-month Disability Rating Scale score (6.8 vs 7.6; difference, -0.9 [95% CI, -2.5 to 0.7]; P = .29), or progression of intracranial hemorrhage (16% vs 20%; difference, -5.4% [95% CI, -12.8% to 2.1%]; P = .16). Conclusions and Relevance Among patients with moderate to severe TBI, out-of-hospital tranexamic acid administration within 2 hours of injury compared with placebo did not significantly improve 6-month neurologic outcome as measured by the Glasgow Outcome Scale-Extended. This randomized clinical trial compares the effects of an out-of-hospital tranexamic acid bolus vs placebo within 2 hours of traumatic brain injury (TBI) on 6-month functional neurologic outcome (Glasgow Coma Scale-Extended score >4) in patients with moderate or severe TBI. Question Does early administration of tranexamic acid to patients with moderate or severe traumatic brain injury improve neurologic outcome at 6 months? Findings In this randomized multicenter clinical trial that included 966 participants enrolled in the out-of-hospital setting by paramedics, treatment with tranexamic acid as an out-of-hospital bolus with or without in-hospital infusion, compared with placebo as an out-of-hospital bolus and in-hospital infusion, resulted in a favorable neurologic outcome (defined as Glasgow Outcome Scale-Extended score >4) in 65% vs 62% of patients at 6 months, a difference that was not statistically significant. Meaning Among participants suspected of having moderate or severe traumatic brain injury, out-of-hospital administration of tranexamic acid compared with placebo did not significantly improve 6-month neurologic recovery.	[Rowell, Susan E.; Fleming, Michael; Schreiber, Martin A.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA; [Rowell, Susan E.] Duke Univ, Sch Med, Dept Surg, Durham, NC USA; [Meier, Eric N.; McKnight, Barbara; Kannas, Delores; May, Susanne; Sheehan, Kellie; Hwang, Jun] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Bulger, Eileen M.; Robinson, Bryce R. H.; Klotz, Patricia] Univ Washington, Dept Surg, Seattle, WA 98195 USA; [Idris, Ahamed H.] Univ Texas Southwestern Med Ctr Dallas, Dept Emergency Med, Dallas, TX 75390 USA; [Idris, Ahamed H.] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Christenson, Jim; Tallon, John M.] Univ British Columbia, Dept Emergency Med, Vancouver, BC, Canada; [Christenson, Jim] Providence Hlth Care Res Inst, Vancouver, BC, Canada; [Morrison, Laurie J.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Rescu, Toronto, ON, Canada; [Morrison, Laurie J.] Univ Toronto, Div Emergency Med, Dept Med, Toronto, ON, Canada; [Frascone, Ralph J.] Reg Hosp, Dept Emergency Med, St Paul, MN USA; [Bosarge, Patrick L.; Williams, Carolyn] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA; [Bosarge, Patrick L.] Univ Arizona, Dept Surg, Phoenix, AZ USA; [Colella, M. Riccardo; Aufderheide, Tom P.] Med Coll Wisconsin, Dept Emergency Med, Milwaukee, WI 53226 USA; [Johannigman, Jay] Univ Cincinnati, Dept Surg, 231 Bethesda Ave, Cincinnati, OH 45267 USA; [Cotton, Bryan A.; Vincent, Laura E.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, McGovern Med Sch, Houston, TX 77030 USA; [Callum, Jeannie] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [McMullan, Jason] Univ Cincinnati, Dept Emergency Med, Cincinnati, OH USA; [Dries, David J.] Reg Hosp, Dept Surg, St Paul, MN USA; [Tibbs, Brian] Texas Hlth Presbyterian Hosp, Trauma Surg, Dallas, TX USA; [Richmond, Neal J.] John Peter Smith Hlth Network, Dept Emergency Med, Ft Worth, TX USA; [Weisfeldt, Myron L.] Johns Hopkins Sch Med, Baltimore, MD USA; [Tallon, John M.; Schlamp, Rob] British Columbia Emergency Hlth Serv, Vancouver, BC, Canada; [Garrett, John S.; Ferrara, Michael] Baylor Univ, Med Ctr, Dept Emergency Med, Dallas, TX USA; [Zielinski, Martin D.] Mayo Clin, Dept Surg, Rochester, MN USA; [Gandhi, Rajesh R.] John Peter Smith Hlth Network, Dept Surg, Ft Worth, TX USA; [Jui, Jonathan] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA; [Klein, Lauren; Hendrickson, Audrey] Hennepin Cty Med Ctr, Dept Emergency Med, Minneapolis, MN 55415 USA; [Rizoli, Sandro] St Michaels Hosp, Dept Surg, Toronto, ON, Canada; [Gamber, Mark] Med City Plano, Dept Emergency Med, Plano, TX USA; [Simonson, Robert] Methodist Dallas Med Ctr, Emergency Med, Dallas, TX USA; [Sopko, George] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA; [Witham, William] Texas Hlth Harris Methodist Hosp, Trauma Surg, Ft Worth, TX USA		Rowell, SE (corresponding author), Duke Univ, Sch Med, Dept Surg, Div Trauma & Crit Care Surg, 2301 Erwin Rd, Durham, NC 27707 USA.	susan.rowell@duke.edu	McMullan, Jason/ABB-9691-2020; morrison, laurie J/A-6325-2012	McMullan, Jason/0000-0002-7656-7447; morrison, laurie J/0000-0001-8369-9774	National Heart, Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [W81XWH-13-2-0090, U01 HL077863, U01 HL077866, U01 HL077871, U01 HL077873, U01 HL077881, U01 HL077887]	The Resuscitation Outcomes Consortium institutions participating in the trial were supported by a series of cooperative agreements from the National Heart, Lung and Blood Institute administered by the US Army Medical Research & Material Command (W81XWH-13-2-0090), including U01 HL077863 (University of Washington Data Coordinating Center), U01 HL077866 (Medical College of Wisconsin), U01 HL077871 (University of Pittsburgh), U01 HL077873 (Oregon Health and Science University), U01 HL077881 (University of Alabama at Birmingham), and U01 HL077887 (University of Texas Southwestern Medical Center/Dallas).	Alderson P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000196.pub2; Boudreau RM, 2019, J SURG RES, V233, P132, DOI 10.1016/j.jss.2018.07.074; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; Feigin VL, 2019, LANCET NEUROL, V18, P459, DOI 10.1016/S1474-4422(18)30499-X; Gausden EB, 2017, J ORTHOP TRAUMA, V31, P513, DOI 10.1097/BOT.0000000000000913; Keyl C, 2011, EUR J CARDIO-THORAC, V39, pE114, DOI 10.1016/j.ejcts.2010.12.030; Kobayashi T, 1966, J Jpn Obstet Gynecol Soc, V13, P158; Lewis SR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001048.pub5; Lin Z, 2016, SEIZURE-EUR J EPILEP, V36, P70, DOI 10.1016/j.seizure.2016.02.011; Ma JP, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008409.pub4; Murkin JM, 2010, ANESTH ANALG, V110, P350, DOI 10.1213/ANE.0b013e3181c92b23; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Pacheco LD, 2017, OBSTET GYNECOL, V130, P765, DOI 10.1097/AOG.0000000000002253; Peterson AB, 2019, SURVEILLANCE REPORT; Roberts I, 2019, LANCET, V394, P1713, DOI 10.1016/S0140-6736(19)32233-0; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Shukla D, 2011, CLIN NEUROL NEUROSUR, V113, P435, DOI 10.1016/j.clineuro.2011.02.013; van Buuren S, 2007, STAT METHODS MED RES, V16, P219, DOI 10.1177/0962280206074463; Weng ST, 2019, WORLD NEUROSURG, V123, P128, DOI 10.1016/j.wneu.2018.11.214; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; 2011, BMJ-BRIT MED J, V343, DOI DOI 10.1136/BMJ.D3795	21	55	55	2	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2020	324	10					961	974		10.1001/jama.2020.8958			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	NR9EX	WOS:000571867000019	32897344	Bronze, Green Published			2022-02-06	
J	Ekstrand, J; Krutsch, W; Spreco, A; van Zoest, W; Roberts, C; Meyer, T; Bengtsson, H				Ekstrand, Jan; Krutsch, Werner; Spreco, Armin; van Zoest, Wart; Roberts, Craig; Meyer, Tim; Bengtsson, Hakan			Time before return to play for the most common injuries in professional football: a 16-year follow-up of the UEFA Elite Club Injury Study	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						soccer; injuries; return to play; epidemiology	HAMSTRING INJURIES; MUSCLE INJURIES; CONSENSUS STATEMENT; SPORT; RISK; CONCUSSION	Objectives The objective was to describe the typical duration of absence following the most common injury diagnoses in professional football. Methods Injuries were registered by medical staff members of football clubs participating in the Union of European Football Association Elite Club Injury Study. Duration of absence due to an injury was defined by the number of days that passed between the date of the injury occurrence and the date when the medical team allowed the player to return to full participation. In total, 22942 injuries registered during 494 team-seasons were included in the study. Results The 31 most common injury diagnoses constituted a total of 78 % of all reported injuries. Most of these injuries were either mild (leading to a median absence of 7 days or less, 6440 cases = 42%) or moderate (median absence: 7-28 days, 56% = 8518 cases) while only few (2% = 311 cases) were severe (median absence of >28 days). The mean duration of absence from training and competition was significantly different (p < 0.05) between index injuries and re-injuries for six diagnoses (Achilles tendon pain, calf muscle injury, groin adductor pain, hamstring muscle injuries and quadriceps muscle injury) with longer absence following re-injuries for all six diagnoses Conclusions The majority of all time loss due to injuries in professional football stems from injuries with an individual absence of up to 4 weeks. This article can provide guidelines for expected time away from training and competition for the most common injury types as well as for its realistic range.	[Ekstrand, Jan; Bengtsson, Hakan] Linkoping Univ, Dept Med & Hlth Sci, S-58221 Linkoping, Sweden; [Ekstrand, Jan] Aspetar Orthopaed & Sports Med Hosp, Doha, Qatar; [Krutsch, Werner] Univ Klinikum Regensburg, Dept Trauma Surg, Regensburg, Germany; [Spreco, Armin] Linkoping Univ, Athlet Res Ctr, Dept Med & Hlth Sci, Linkoping, Sweden; [van Zoest, Wart] St Anna Hosp, Dept Orthopaed Surg, Eindhoven, Netherlands; [Roberts, Craig] AFC Bournemouth, Bournemouth, Dorset, England; [Meyer, Tim] Univ Saarland, Inst Sports & Prevent Med, Saarbrucken, Germany		Ekstrand, J (corresponding author), Linkoping Univ, Dept Med & Hlth Sci, S-58221 Linkoping, Sweden.	jan.ekstrand@telia.com			UEFA; Swedish Football Association; Swedish Research Council for Sport Science	The Football Research Group was established in Linkoping, Sweden, in cooperation with Linkoping University. It was supported by grants from UEFA, the Swedish Football Association, and the Swedish Research Council for Sport Science.	Ardern CL, 2016, BRIT J SPORT MED, V50, P853, DOI 10.1136/bjsports-2016-096278; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bahr R, 2018, BRIT J SPORT MED, V52, P1018, DOI 10.1136/bjsports-2017-098160; Cohen SB, 2011, SPORTS HEALTH, V3, P423, DOI 10.1177/1941738111403107; Comin J, 2013, AM J SPORT MED, V41, P111, DOI 10.1177/0363546512463679; Dijkstra HP, 2017, BRIT J SPORT MED, V51, P419, DOI 10.1136/bjsports-2016-096209; Ekstrand J, 2016, BRIT J SPORT MED, V50, P709, DOI 10.1136/bjsports-2016-096333; Ekstrand J, 2016, BRIT J SPORT MED, V50, P731, DOI 10.1136/bjsports-2015-095359; Ekstrand J, 2013, BRIT J SPORT MED, V47, P732, DOI 10.1136/bjsports-2013-092394; Ekstrand J, 2012, BRIT J SPORT MED, V46, P112, DOI 10.1136/bjsports-2011-090155; Ekstrand J, 2011, AM J SPORT MED, V39, P1226, DOI 10.1177/0363546510395879; Fuller CW, 2006, BRIT J SPORT MED, V40, P193, DOI 10.1136/bjsm.2005.025270; Gajhede-Knudsen M, 2013, BRIT J SPORT MED, V47, P763, DOI 10.1136/bjsports-2013-092271; Grindem H, 2016, BRIT J SPORT MED, V50, P804, DOI 10.1136/bjsports-2016-096031; Hagglund M, 2005, BRIT J SPORT MED, V39, P340, DOI 10.1136/bjsm.2005.018267; Hagglund M, 2005, SCAND J MED SCI SPOR, V15, P21, DOI 10.1111/j.1600-0838.2004.00395.x; Hallen A, 2014, J SPORT SCI, V32, P1229, DOI 10.1080/02640414.2014.905695; Koulouris G, 2007, AM J SPORT MED, V35, P1500, DOI 10.1177/0363546507301258; Kristenson K, 2013, BRIT J SPORT MED, V47, P775, DOI 10.1136/bjsports-2013-092266; Krutsch W, 2018, UNFALLCHIRURG, V121, P433, DOI 10.1007/s00113-018-0487-6; McCall A, 2017, BRIT J SPORT MED, V51, P702, DOI 10.1136/bjsports-2016-096752; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McLendon LA, 2016, PEDIATR NEUROL, V62, P9, DOI 10.1016/j.pediatrneurol.2016.03.009; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Orchard J, 2005, CLIN J SPORT MED, V15, P436, DOI 10.1097/01.jsm.0000188206.54984.65; van Melick N, 2016, BRIT J SPORT MED, V50, P1506, DOI 10.1136/bjsports-2015-095898; Wangensteen A, 2016, AM J SPORT MED, V44, P2112, DOI 10.1177/0363546516646086	27	55	54	1	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR	2020	54	7					421	426		10.1136/bjsports-2019-100666			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	LB2ZI	WOS:000524506500010	31182429	Green Published, hybrid			2022-02-06	
J	Mu, XY; He, H; Wang, JY; Long, W; Li, QF; Liu, HL; Gao, YL; Ouyang, LF; Ren, QJ; Sun, S; Wang, JY; Yang, J; Liu, Q; Sun, YM; Liu, CL; Zhang, XD; Hu, WP				Mu, Xiaoyu; He, Hua; Wang, Junying; Long, Wei; Li, Qifeng; Liu, Haile; Gao, Yalong; Ouyang, Lufei; Ren, Qinjuan; Sun, Si; Wang, Jingya; Yang, Jiang; Liu, Qiang; Sun, Yuanming; Liu, Changlong; Zhang, Xiao-Dong; Hu, Wenping			Carbogenic Nanozyme with Ultrahigh Reactive Nitrogen Species Selectivity for Traumatic Brain Injury	NANO LETTERS			English	Article						Traumatic brain injury; reactive oxygen and nitrogen species; nanozyme; catalytic selectivity	SIRNA DELIVERY; RENAL CLEARANCE; NANOPARTICLES; NEUROINFLAMMATION; NEUROPROTECTION; SUPEROXIDE; GENERATION; EFFICIENT	Reactive oxygen and nitrogen species (RONS), especially reactive nitrogen species (RNS) are intermediate products during incidence of nervous system diseases, showing continuous damage for traumatic brain injury (TBI). Here, we developed a carbogenic nanozyme, which shows an antioxidant activity 12 times higher than ascorbic acid (AA) and behaves as multienzyme mimetics. Importantly, the nanozyme exhibits an ultrahigh scavenging efficiency (similar to 16 times higher than AA) toward highly active RNS, such as (NO)-N-center dot and ONOO- as well as traditional reactive oxygen species (ROS) including O-2(center dot-), H2O2, and (OH)-O-center dot. In vitro experiments show that neuron cells injured by H2O2 or lipopolysaccharide can be significantly recovered after carbogenic nanozyme treatment via scavenging all kinds of RONS. Moreover, the carbogenic nanozyme can serve as various enzyme mimetics and eliminate the harmful peroxide and glutathione disulfide from injured mice, demonstrating its potential as a therapeutic for acute TBI.	[Mu, Xiaoyu; Wang, Junying; Liu, Haile; Ouyang, Lufei; Ren, Qinjuan; Sun, Si; Liu, Changlong; Zhang, Xiao-Dong; Hu, Wenping] Tianjin Univ, Sch Sci, Tianjin Key Lab Low Dimens Mat Phys & Preparing T, Tianjin 300350, Peoples R China; [He, Hua] China Univ Petr East China, State Key Lab Heavy Oil Proc, Qingdao 266580, Shandong, Peoples R China; [He, Hua] China Univ Petr East China, Ctr Bioengn & Biotechnol, Qingdao 266580, Shandong, Peoples R China; [Long, Wei; Wang, Jingya; Liu, Qiang; Sun, Yuanming] Chinese Acad Med Sci, Inst Radiat Med, Tianjin Key Lab Mol Nucl Med, 238 Baidi Rd, Tianjin 300192, Peoples R China; [Long, Wei; Wang, Jingya; Liu, Qiang; Sun, Yuanming] Peking Union Med Coll, 238 Baidi Rd, Tianjin 300192, Peoples R China; [Li, Qifeng; Gao, Yalong] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Li, Qifeng; Gao, Yalong] Tianjin Med Univ, Gen Hosp, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin 300052, Peoples R China; [Yang, Jiang] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Zhang, Xiao-Dong; Hu, Wenping] Tianjin Collaborat Innovat Ctr Chem Sci & Engn, Tianjin 300072, Peoples R China		Zhang, XD (corresponding author), Tianjin Univ, Sch Sci, Tianjin Key Lab Low Dimens Mat Phys & Preparing T, Tianjin 300350, Peoples R China.; Zhang, XD (corresponding author), Tianjin Collaborat Innovat Ctr Chem Sci & Engn, Tianjin 300072, Peoples R China.	xiaodongzhang@tju.edu.cn	Nanozymes, Nanozymes/D-8197-2019; Zhang, Xiaodong/F-4665-2015	Zhang, Xiaodong/0000-0002-7212-0138; He, Hua/0000-0002-6084-1034	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [21874154, 81471786, 91859101]; Independent Innovation Foundation of Tianjin University	We gratefully acknowledge the financial support from the National Natural Science Foundation of China (No. 21874154, No. 81471786 and No. 91859101), and the Independent Innovation Foundation of Tianjin University.	Bao QQ, 2018, ACS NANO, V12, P6794, DOI 10.1021/acsnano.8b01994; Bitner BR, 2012, ACS NANO, V6, P8007, DOI 10.1021/nn302615f; Choi HS, 2007, NAT BIOTECHNOL, V25, P1165, DOI 10.1038/nbt1340; Choi YK, 2016, NAT MED, V22, P1335, DOI 10.1038/nm.4188; Fan KL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03903-8; Fan KL, 2017, CHEM COMMUN, V53, P424, DOI 10.1039/c6cc08542c; Gao L, 2015, ACS NANO, V9, P10979, DOI 10.1021/acsnano.5b04261; Gaudin A, 2014, NAT NANOTECHNOL, V9, P1054, DOI [10.1038/NNANO.2014.274, 10.1038/nnano.2014.274]; Heckman KL, 2013, ACS NANO, V7, P10582, DOI 10.1021/nn403743b; Holthoff JH, 2010, BIOCHEM PHARMACOL, V80, P1260, DOI 10.1016/j.bcp.2010.06.027; Hou CX, 2012, ACS NANO, V6, P8692, DOI 10.1021/nn302270b; Huang YY, 2019, CHEM REV, V119, P4357, DOI 10.1021/acs.chemrev.8b00672; Huang YY, 2016, ANGEW CHEM INT EDIT, V55, P6646, DOI 10.1002/anie.201600868; Jalilov AS, 2017, ACS NANO, V11, P2024, DOI 10.1021/acsnano.6b08211; Kang JY, 2016, ADV MATER, V28, P7962, DOI 10.1002/adma.201600634; Kim CK, 2012, ANGEW CHEM INT EDIT, V51, P11039, DOI 10.1002/anie.201203780; Kozielski KL, 2014, ACS NANO, V8, P3232, DOI 10.1021/nn500704t; Kwon EJ, 2016, ACS NANO, V10, P7926, DOI 10.1021/acsnano.6b03858; Kwon HJ, 2018, ANGEW CHEM INT EDIT, V57, P9408, DOI 10.1002/anie.201805052; Kwon HJ, 2016, ACS NANO, V10, P2860, DOI 10.1021/acsnano.5b08045; Li F, 2017, ANGEW CHEM INT EDIT, V56, P9910, DOI 10.1002/anie.201705989; Li JC, 2018, ANGEW CHEM INT EDIT, V57, P3995, DOI 10.1002/anie.201800511; Liu Y., 2017, J AM CHEM SOC, V139, P856; Liu Y, 2018, ACS NANO, V12, P4886, DOI 10.1021/acsnano.8b01893; Lv W, 2018, ACS NANO, V12, P5417, DOI 10.1021/acsnano.8b00477; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Samuel ELG, 2015, P NATL ACAD SCI USA, V112, P2343, DOI 10.1073/pnas.1417047112; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Soh M, 2017, ANGEW CHEM INT EDIT, V56, P11399, DOI 10.1002/anie.201704904; Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443; Turjanski AG, 2000, J AM CHEM SOC, V122, P10468, DOI 10.1021/ja002006u; vanAcker SABE, 1996, FREE RADICAL BIO MED, V20, P331, DOI 10.1016/0891-5849(95)02047-0; Vernekar AA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6301; Wei H, 2013, CHEM SOC REV, V42, P6060, DOI 10.1039/c3cs35486e; Wu JJX, 2019, CHEM SOC REV, V48, P1004, DOI 10.1039/c8cs00457a; Xu BL, 2019, ANGEW CHEM INT EDIT, V58, P4911, DOI 10.1002/anie.201813994; Xu JL, 2016, ADV FUNCT MATER, V26, P4124, DOI 10.1002/adfm.201504416; Xu ZB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06164-7; Yao J, 2018, CHEM SCI, V9, P2927, DOI 10.1039/c7sc05476a; Yin WY, 2016, ACS NANO, V10, P11000, DOI 10.1021/acsnano.6b05810; Yoo D, 2017, ACS NANO, V11, P8600, DOI 10.1021/acsnano.7b03426; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; Zhang H, 2018, NANO LETT, V18, P4985, DOI 10.1021/acs.nanolett.8b01818; Zhang P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08731-y; Zhang W, 2016, J AM CHEM SOC, V138, P5860, DOI 10.1021/jacs.5b12070; Zhang XD, 2016, ADV MATER, V28, P6872, DOI 10.1002/adma.201600706; Zhang XD, 2016, ACS NANO, V10, P4511, DOI 10.1021/acsnano.6b00321; Zhang XD, 2014, ADV MATER, V26, P4565, DOI 10.1002/adma.201400866; Zhu P, 2018, ACS NANO, V12, P3780, DOI 10.1021/acsnano.8b00999	49	55	56	33	173	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1530-6984	1530-6992		NANO LETT	Nano Lett.	JUL	2019	19	7					4527	4534		10.1021/acs.nanolett.9b01333			8	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Science & Technology - Other Topics; Materials Science; Physics	II9QA	WOS:000475533900040	31244237				2022-02-06	
J	Bisicchia, E; Sasso, V; Catanzaro, G; Leuti, A; Besharat, ZM; Chiacchiarini, M; Molinari, M; Ferretti, E; Viscomi, MT; Chiurchiu, V				Bisicchia, Elisa; Sasso, Valeria; Catanzaro, Giuseppina; Leuti, Alessandro; Besharat, Zein Mersini; Chiacchiarini, Martina; Molinari, Marco; Ferretti, Elisabetta; Viscomi, Maria Teresa; Chiurchiu, Valerio			Resolvin D1 Halts Remote Neuroinflammation and Improves Functional Recovery after Focal Brain Damage Via ALX/FPR2 Receptor-Regulated MicroRNAs	MOLECULAR NEUROBIOLOGY			English	Article						Specialized pro-resolving mediators; Inflammation resolution; Neuroinflammation; Remote brain damage; Epigenetics	SPINAL-CORD-INJURY; MICROGLIAL ACTIVATION; LIPID MEDIATORS; INFLAMMATION; RESOLUTION; OMEGA-3-FATTY-ACIDS; DEGENERATION; INFECTION; PROMOTE; CELLS	Remote damage is a secondary phenomenon that usually occurs after a primary brain damage in regions that are distant, yet functionally connected, and that is critical for determining the outcomes of several CNS pathologies, including traumatic brain and spinal cord injuries. The understanding of remote damage-associated mechanisms has been mostly achieved in several models of focal brain injury such as the hemicerebellectomy (HCb) experimental paradigm, which helped to identify the involvement of many key players, such as inflammation, oxidative stress, apoptosis and autophagy. Currently, few interventions have been shown to successfully limit the progression of secondary damage events and there is still an unmet need for new therapeutic options. Given the emergence of the novel concept of resolution of inflammation, mediated by the newly identified omega 3-derived specialized pro-resolving lipid mediators, such as resolvins, we reported a reduced ability of HCb-injured animals to produce resolvin D1 (RvD1) and an increased expression of its target receptor ALX/FPR2 in remote brain regions. The in vivo administration of RvD1 promoted functional recovery and neuroprotection by reducing the activation of Iba-1+ microglia and GFAP+ astrocytes as well as by impairing inflammatory-induced neuronal cell death in remote regions. These effects were counteracted by intracerebroventricular neutralization of ALX/FPR2, whose activation by RvD1 also down-regulated miR-146b- and miR-219a-1-dependent inflammatory markers. In conclusion, we propose that innovative therapies based on RvD1-ALX/FPR2 axis could be exploited to curtail remote damage and enable neuroprotective effects after acute focal brain damage.	[Bisicchia, Elisa; Sasso, Valeria; Leuti, Alessandro; Molinari, Marco; Viscomi, Maria Teresa; Chiurchiu, Valerio] IRCCS Santa Lucia Fdn, Via Fosso di Fiorano 64, I-00143 Rome, Italy; [Catanzaro, Giuseppina; Besharat, Zein Mersini; Ferretti, Elisabetta] Sapienza Univ Rome, Dept Expt Med, Rome, Italy; [Chiacchiarini, Martina] Sapienza Univ Rome, Dept Mol Med, Rome, Italy; [Ferretti, Elisabetta] IRCCS Neuromed, Pozzilli, Italy; [Chiurchiu, Valerio] Campus Biomed Univ Rome, Dept Med, Rome, Italy		Viscomi, MT; Chiurchiu, V (corresponding author), IRCCS Santa Lucia Fdn, Via Fosso di Fiorano 64, I-00143 Rome, Italy.; Chiurchiu, V (corresponding author), Campus Biomed Univ Rome, Dept Med, Rome, Italy.	mt.viscomi@hsantalucia.it; v.chiurchiu@hsantalucia.it	Viscomi, Maria Teresa/AAL-6625-2021; Besharat, Zein Mersini/P-4486-2019; Bisicchia, Elisa/AAC-3703-2022; Viscomi, Maria Teresa/AAB-9412-2022; Chiacchiarini, Martina/AAC-7264-2022; Molinari, Marco/A-9624-2010; Leuti, Alessandro/AAB-6479-2019; catanzaro, giuseppina/J-8158-2018; Ferretti, Elisabetta/G-5413-2013; Chiurchiu, Valerio/G-6227-2011	Besharat, Zein Mersini/0000-0003-0317-9854; Viscomi, Maria Teresa/0000-0002-9096-4967; Molinari, Marco/0000-0001-9808-9688; Leuti, Alessandro/0000-0002-5982-0682; catanzaro, giuseppina/0000-0001-8427-9691; Chiacchiarini, Martina/0000-0001-9229-0372; Ferretti, Elisabetta/0000-0001-7265-6429; Chiurchiu, Valerio/0000-0002-0316-7311	Fondazione Italiana Sclerosi Multipla (FISM)Fondazione Italiana Sclerosi Multipla (FISM) [2015/R/8]; Italian Ministry of Health (Progetto Giovani Ricercatori Project) [GR-2010.2310524]	This work was funded by Fondazione Italiana Sclerosi Multipla (FISM) (grant 2015/R/8 to V.C.) and by the Italian Ministry of Health (Progetto Giovani Ricercatori Project Code GR-2010.2310524 to M.T.V.).	Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Basil MC, 2016, NAT REV IMMUNOL, V16, P51, DOI 10.1038/nri.2015.4; Bays HE, 2007, AM J CARDIOL, V99, p35C, DOI 10.1016/j.amjcard.2006.11.020; Bazan NG, 2007, CURR OPIN CLIN NUTR, V10, P136, DOI 10.1097/MCO.0b013e32802b7030; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90; Beynon SB, 2012, NEUROSCIENCE, V225, P162, DOI 10.1016/j.neuroscience.2012.07.029; Bisicchia E, 2013, CELL MOL LIFE SCI, V70, P2191, DOI 10.1007/s00018-012-1253-5; Biswas SK, 2012, IMMUNOL RES, V53, P11, DOI 10.1007/s12026-012-8291-9; Block F, 2005, PROG NEUROBIOL, V75, P342, DOI 10.1016/j.pneurobio.2005.03.004; Caiello I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107886; Catanzaro G, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2683042; Cavallucci V, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.511; Chiurchiu V, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf7483; Chiurchiu V, 2011, ANTIOXID REDOX SIGN, V15, P2605, DOI 10.1089/ars.2010.3547; Codagnone M, 2017, MUCOSAL IMMUNOL; Hall JCE, 2012, J NEUROCHEM, V121, P738, DOI 10.1111/j.1471-4159.2012.07726.x; Jensen CJ, 2013, J NEUROIMMUNE PHARM, V8, P824, DOI 10.1007/s11481-013-9480-6; Kong Y, 2010, J NEUROSCI, V30, P11848, DOI 10.1523/JNEUROSCI.2985-10.2010; Kongsui R, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0182-7; Kotas ME, 2015, CELL, V160, P816, DOI 10.1016/j.cell.2015.02.010; Li LY, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-72; Michael-Titus AT, 2014, TRENDS NEUROSCI, V37, P30, DOI 10.1016/j.tins.2013.10.005; Molteni M, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6978936; Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029; Nayak D, 2014, ANNU REV IMMUNOL, V32, P367, DOI 10.1146/annurev-immunol-032713-120240; O'Neill LA, 2011, NAT REV IMMUNOL, V11, P163, DOI 10.1038/nri2957; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Recchiuti A, 2011, FASEB J, V25, P544, DOI 10.1096/fj.10-169599; Rey C, 2016, BRAIN BEHAV IMMUN, V55, P249, DOI 10.1016/j.bbi.2015.12.013; Rius B, 2014, FASEB J, V28, P836, DOI 10.1096/fj.13-235614; Samaddar S, 2016, ADV NEUROBIOL, V12, P27, DOI 10.1007/978-3-319-28383-8_2; Serhan CN, 2017, FASEB J, V31, P1273, DOI [10.1096/fj.201601222R, 10.1096/fj.201601222r]; Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479; Sheedy FJ, 2008, ANN RHEUM DIS, V67, P50, DOI 10.1136/ard.2008.100289; Sheets KG, 2013, MOL VIS, V19, P1747; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Viscomi MT, 2008, CEREBELLUM, V7, P401, DOI 10.1007/s12311-008-0042-z; Viscomi MT, 2008, NEUROSCIENCE, V154, P1267, DOI 10.1016/j.neuroscience.2008.04.024; Viscomi MT, 2015, CEREBELLUM, V14, P15, DOI 10.1007/s12311-014-0603-2; Viscomi MT, 2014, MOL NEUROBIOL, V50, P368, DOI 10.1007/s12035-013-8629-x; Wang G, 2016, SCI REP-UK, V6, DOI 10.1038/srep25946; Wang XZ, 2015, ALZHEIMERS DEMENT, V11, P40, DOI 10.1016/j.jalz.2013.12.024; Xu ZZ, 2013, J NEUROIMMUNE PHARM, V8, P37, DOI 10.1007/s11481-012-9394-8; Zhang L., 2017, SCI REP, V7; Zhu MQ, 2016, MOL NEUROBIOL, V53, P2733, DOI 10.1007/s12035-015-9544-0	47	55	58	0	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	AUG	2018	55	8					6894	6905		10.1007/s12035-018-0889-z			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GO1YO	WOS:000439758300045	29357041	Green Published			2022-02-06	
J	Lilja, G; Nielsen, N; Bro-Jeppesen, J; Dunford, H; Friberg, H; Hofgren, C; Horn, J; Insorsi, A; Kjaergaard, J; Nilsson, F; Pelosi, P; Winters, T; Wise, MP; Cronberg, T				Lilja, Gisela; Nielsen, Niklas; Bro-Jeppesen, John; Dunford, Hannah; Friberg, Hans; Hofgren, Caisa; Horn, Janneke; Insorsi, Angelo; Kjaergaard, Jesper; Nilsson, Fredrik; Pelosi, Paolo; Winters, Tineke; Wise, Matt P.; Cronberg, Tobias			Return to Work and Participation in Society After Out-of-Hospital Cardiac Arrest	CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES			English	Article						cognitive dysfunction; depression; fatigue; sick leave; temperature; heart arrest	PORTLAND ADAPTABILITY INVENTORY; TARGET TEMPERATURE MANAGEMENT; TRAUMATIC BRAIN-INJURY; FOCUSED FOLLOW-UP; COGNITIVE FUNCTION; INTERNATIONAL-CLASSIFICATION; LIFE; SURVIVORS; FATIGUE; HEALTH	BACKGROUND: The aim of this study was to describe out-of-hospital cardiac arrest (OHCA) survivors' ability to participate in activities of everyday life and society, including return to work. The specific aim was to evaluate potential effects of cognitive impairment. METHODS AND RESULTS: Two hundred eighty-seven OHCA survivors included in the TTM trial (Target Temperature Management) and 119 matched control patients with ST-segment-elevation myocardial infarction participated in a follow-up 180 days post-event that included assessments of participation, return to work, emotional problems, and cognitive impairment. On the Mayo-Portland Adaptability Inventory-4 Participation Index, OHCA survivors (n=270) reported more restricted participation In everyday life and in society (47% versus 30%; P<0.001) compared with ST-segment-elevation myocardial infarction controls (n=118). Furthermore, 27% (n=36) of pre-event working OHCA survivors (n=135) compared with 7% (n=3) of pre-event working ST-segment-elevation myocardial infarction controls (n=45) were on sick leave (odds ratio, 4.9; 95% confidence interval, 1.4-16.8; P=0.01). Among the OHCA survivors assumed to return to work (n=135), those with cognitive impairment (n=55) were 3x more likely (odds ratio, 3.3; 95% confidence interval, 1.2-9.3; P=0.02) to be on sick leave compared with those without cognitive impairment (n=40; 36%, n=20, versus 15%, n=6). For OHCA survivors, the variables that were found most predictive for a lower participation were depression, restricted mobility, memory impairment, novel problem-solving difficulties, fatigue, and slower processing speed. CONCLUSIONS: OHCA survivors reported a more restricted societal participation 6 months post-arrest, and their return to work was lower compared with ST-segment-elevation myocardial infarction controls. Cognitive impairment was significantly associated with lower participation, together with the closely related symptoms of fatigue, depression, and restricted mobility. These predictive variables may be used during follow-up to identify OHCA survivors at risk of a less successful recovery that may benefit from further support and rehabilitation.	[Lilja, Gisela; Cronberg, Tobias] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Lund, Sweden; [Nielsen, Niklas; Friberg, Hans] Lund Univ, Dept Clin Sci Anesthesiol & Intens Care Med, Skane Univ Hosp, Lund, Sweden; [Bro-Jeppesen, John; Kjaergaard, Jesper] Copenhagen Univ Hosp, Rigshosp, Dept Cardiol, Heart Ctr, Copenhagen, Denmark; [Dunford, Hannah; Wise, Matt P.] Univ Hosp Wales, Adult Crit Care, Cardiff, S Glam, Wales; [Hofgren, Caisa] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Sect Hlth & Rehabil, Gothenburg, Sweden; [Horn, Janneke; Winters, Tineke] Acad Med Ctr, Intens Care, Amsterdam, Netherlands; [Insorsi, Angelo] IRCCS AOU San Martino IST, Anesthesia & Intens Care, Genoa, Italy; [Nilsson, Fredrik] Res & Dev Ctr Skane, Med Stat & Epidemiol, Lund, Sweden; [Pelosi, Paolo] Univ Genoa, Dept Surg Sci & Integrated Diagnost, Osped Policlin San Martino, IRCCS Oncol, Genoa, Italy		Lilja, G (corresponding author), Lund Univ, Skane Univ Hosp, Ctr Cardiac Arrest, Barngatan 2B 4th Floor, S-22185 Lund, Sweden.	gisela.lilja@med.lu.se	Nilsson, Fredrik/N-2771-2017; Rocco, Patricia/I-7460-2012	Nilsson, Fredrik/0000-0002-7526-6327; Rocco, Patricia/0000-0003-1412-7136; Pelosi, Paolo/0000-0001-5055-3023; Kjaergaard, Jesper/0000-0001-5244-0399	European Union Interreg IVA programme; Swedish Heart and Lung AssociationSwedish Heart-Lung Foundation; Skane University Hospital Foundations; Gyllenstierna-Krapperup Foundation; Academy of Caring Sciences at Skane University Hospital; Swedish National Health System (ALF); County Council of Skane; Swedish Society of Medicine; Koch Foundation; Swedish Heart-Lung FoundationSwedish Heart-Lung Foundation; AFA Insurance Foundation; Hans-Gabriel and Alice Trolle-Wachtmeister Foundation for medical research; Segerfalk Foundation; Tryg Foundation	This work was supported by The European Union Interreg IVA programme, The Swedish Heart and Lung Association, the Skane University Hospital Foundations, the Gyllenstierna-Krapperup Foundation, Academy of Caring Sciences at Skane University Hospital, the Swedish National Health System (ALF), the County Council of Skane, the Swedish Society of Medicine, the Koch Foundation, the Swedish Heart-Lung Foundation, AFA Insurance Foundation, the Hans-Gabriel and Alice Trolle-Wachtmeister Foundation for medical research, the Segerfalk Foundation and the Tryg Foundation. The study sponsors have no involvement in the study design; in the collection, analysis, and interpretation of the data; in the writing of the manuscript, or in the decision to submit the manuscript for publication.	Alexander MP, 2011, J INT NEUROPSYCH SOC, V17, P364, DOI 10.1017/S1355617710001633; Becker LB, 2011, CIRCULATION, V124, P2158, DOI 10.1161/CIR.0b013e3182340239; Beesems SG, 2014, RESUSCITATION, V85, P1269, DOI 10.1016/j.resuscitation.2014.05.027; Boyce-van der Wal LW, 2015, RESUSCITATION, V93, P63, DOI 10.1016/j.resuscitation.2015.05.029; Dubois B, 2000, NEUROLOGY, V55, P1621, DOI 10.1212/WNL.55.11.1621; Elliott VJ, 2011, RESUSCITATION, V82, P247, DOI 10.1016/j.resuscitation.2010.10.030; Hemmingsson H, 2005, AM J OCCUP THER, V59, P569, DOI 10.5014/ajot.59.5.569; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Kamphuis HCM, 2002, EUROPACE, V4, P417, DOI 10.1053/eupc.2002.0258; KELSEY SF, 1986, AM J EMERG MED, V4, P72; Kragholm K, 2015, CIRCULATION, V131, P1682, DOI 10.1161/CIRCULATIONAHA.114.011366; Ladwig KH, 1999, AM J PSYCHIAT, V156, P912, DOI 10.1176/ajp.156.6.912; Langa KM, 2014, JAMA-J AM MED ASSOC, V312, P2551, DOI 10.1001/jama.2014.13806; Larsson IM, 2014, RESUSCITATION, V85, P215, DOI 10.1016/j.resuscitation.2013.09.017; Lilja G, 2015, RESUSCITATION, V97, P68, DOI 10.1016/j.resuscitation.2015.09.389; Lilja G, 2015, CIRCULATION, V131, P1340, DOI 10.1161/CIRCULATIONAHA.114.014414; Lilja G, 2013, BMC CARDIOVASC DISOR, V13, DOI 10.1186/1471-2261-13-85; Malec JF, 2004, ARCH PHYS MED REHAB, V85, P1989, DOI 10.1016/j.apmr.2004.01.032; Malec JF, 2004, BRAIN INJURY, V18, P563, DOI 10.1080/02699050310001646134; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; Middelkamp W, 2007, CLIN REHABIL, V21, P425, DOI 10.1177/0269215507075307; Mollayeva T, 2014, NEUROSCI BIOBEHAV R, V47, P684, DOI 10.1016/j.neubiorev.2014.10.024; Moulaert VRM, 2016, RESUSCITATION, V106, P30, DOI 10.1016/j.resuscitation.2016.06.015; Moulaert VRM, 2015, INT J CARDIOL, V193, P8, DOI 10.1016/j.ijcard.2015.04.229; Moulaert VRMP, 2010, J REHABIL MED, V42, P553, DOI 10.2340/16501977-0547; Moulaert VRMP, 2009, RESUSCITATION, V80, P297, DOI 10.1016/j.resuscitation.2008.10.034; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Nolan JP, 2015, INTENS CARE MED, V41, P2039, DOI 10.1007/s00134-015-4051-3; Norrie J, 2010, BRAIN INJURY, V24, P1528, DOI 10.3109/02699052.2010.531687; O'Neil A, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-95; Resnik L, 2009, ARCH PHYS MED REHAB, V90, P856, DOI 10.1016/j.apmr.2008.11.010; SAUVE MJ, 1995, HEART LUNG, V24, P133, DOI 10.1016/S0147-9563(05)80008-1; Sinha SS, 2016, CIRC-CARDIOVASC QUAL, V9, P749, DOI 10.1161/CIRCOUTCOMES.116.002916; Smith A., 1982, SYMBOL DIGIT MODALIT; Smith K, 2015, CIRCULATION, V131, P174, DOI 10.1161/CIRCULATIONAHA.114.011200; Snaith R., 1994, HOSP ANXIETY DEPRESS; Wachelder EM, 2009, RESUSCITATION, V80, P517, DOI 10.1016/j.resuscitation.2009.01.020; Wilson BA, 1991, RIVERMEAD BEHAV MEMO; World Health Organization, 2002, COMM LANG FUNCT DIS	39	55	55	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1941-7705	1941-7713		CIRC-CARDIOVASC QUAL	Circ.-Cardiovasc. Qual. Outcomes	JAN	2018	11	1							e003566	10.1161/CIRCOUTCOMES.117.003566			11	Cardiac & Cardiovascular Systems	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	FS9WB	WOS:000422768600003	29326145	Bronze			2022-02-06	
J	Hislop, MD; Stokes, KA; Williams, S; Mckay, CD; England, ME; Kemp, SPT; Trewartha, G				Hislop, Michael D.; Stokes, Keith A.; Williams, Sean; Mckay, Carly D.; England, Mike E.; Kemp, Simon P. T.; Trewartha, Grant			Reducing musculoskeletal injury and concussion risk in schoolboy rugby players with a pre-activity movement control exercise programme: a cluster randomised controlled trial	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							LOWER-LIMB INJURIES; CERVICAL RANGE; WARM-UP; TRAINING-PROGRAM; PREVENTION; STATEMENT; FOOTBALL; SOCCER; UNION; PERFORMANCE	Background Injury risk in youth rugby has received much attention, highlighting the importance of establishing evidence-based injury reduction strategies. Aim To determine the efficacy of a movement control exercise programme in reducing injuries in youth rugby players and to investigate the effect of programme dose on injury measures. Methods In a cluster-randomised controlled trial, 40 independent schools (118 teams, 3188 players aged 14-18 years) were allocated to receive either the intervention or a reference programme, both of which were to be delivered by school coaches. The intervention comprised balance training, whole-body resistance training, plyometric training, and controlled rehearsal of landing and cutting manoeuvres. Time-loss (> 24 hours) injuries arising from school rugby matches were recorded by coaches and medical staff. Results 441 time-loss match injuries (intervention, 233; control, 208) were reported across 15 938 match exposure-hours (intervention, 9083; control, 6855). Intention-to-treat results indicated unclear effects of trial arm on overall match injury incidence (rate ratio (RR)=0.85, 90% confidence limits 0.61 to 1.17), although clear reductions were evident in the intervention arm for concussion incidence (RR=0.71, 0.48 to 1.05). When trial arm comparisons were limited to teams who had completed three or more weekly programme sessions on average, clear reductions in overall match injury incidence (RR=0.28, 0.14 to 0.51) and concussion incidence (RR=0.41, 0.17 to 0.99) were noted in the intervention group. Conclusion A preventive movement control exercise programme can reduce match injury outcomes, including concussion, in schoolboy rugby players when compared with a standardised control exercise programme, although to realise the greatest effects players should complete the programme at least three times per week.	[Hislop, Michael D.; Stokes, Keith A.; Williams, Sean; Mckay, Carly D.; Trewartha, Grant] Univ Bath, Dept Hlth, Bath BA2 7AY, Avon, England; [England, Mike E.; Kemp, Simon P. T.] Rugby Football Union, Twickenham, England		Stokes, KA (corresponding author), Univ Bath, Dept Hlth, Bath BA2 7AY, Avon, England.	k.stokes@bath.ac.uk	Hislop, Michael David/I-2339-2019; Williams, Sean/AAB-2790-2022; Williams, Sean/AAA-9361-2022; Stokes, Keith/C-2605-2009	Williams, Sean/0000-0003-1460-0085; Williams, Sean/0000-0003-1460-0085; Kemp, Simon/0000-0002-3250-2713; McKay, Carly/0000-0001-7664-3211; Stokes, Keith/0000-0002-5049-2838			Andersson SH, 2016, BRIT J SPORT MED; Archbold HAP, 2017, BRIT J SPORT MED, V51, P600, DOI 10.1136/bjsports-2015-095491; Batten J, 2016, BRIT J SPORT MED, V50, P1293, DOI 10.1136/bjsports-2015-095949; Batterham AM, 2006, INTJ SPORT PHYSIOL, V1, P50, DOI 10.1123/ijspp.1.1.50; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Bleakley C, 2011, J ATHL TRAINING, V46, P555; Brooks JHM, 2008, CLIN SPORT MED, V27, P51, DOI 10.1016/j.csm.2007.09.001; Carter M, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h26; Collins CL, 2014, J PRIM PREV, V35, P309, DOI 10.1007/s10935-014-0355-2; Finch C, 2006, J SCI MED SPORT, V9, P3, DOI 10.1016/j.jsams.2006.02.009; Fortington LV, 2015, J SCI MED SPORT, V18, P272, DOI 10.1016/j.jsams.2014.05.001; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Grooms DR, 2013, J ATHL TRAINING, V48, P782, DOI 10.4085/1062-6050-48.4.08; Hagglund M, 2013, BRIT J SPORT MED, V47, P974, DOI 10.1136/bjsports-2013-092644; Hamilton DF, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004975; Hanson D, 2014, BRIT J SPORT MED, V48, P682, DOI 10.1136/bjsports-2012-091434; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; Herman K, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-75; Hopkins W.G., 2010, SPORTSCIENCE, V14, P49; Hopkins WG, 2016, SPORTSCI, V20; Hopkins WG, 2007, SPORTSCI, V11; Impellizzeri FM, 2013, J SPORT SCI, V31, P1491, DOI 10.1080/02640414.2013.802926; Junge A, 2004, BRIT J SPORT MED, V38, P168, DOI 10.1136/bjsm.2002.003020; Lark SD, 2007, J SPORT SCI, V25, P887, DOI 10.1080/02640410600944543; Lark SD, 2010, J SPORT SCI, V28, P649, DOI 10.1080/02640411003631968; Lark SD, 2009, J SPORT SCI, V27, P491, DOI 10.1080/02640410802632136; Longo UG, 2012, AM J SPORT MED, V40, P996, DOI 10.1177/0363546512438761; Maconi F, 2016, SPORT SCI HLTH, V12, P443, DOI DOI 10.1007/s11332-016-0314-9; Maffulli N, 2010, BRIT J SPORT MED, V44, P21, DOI 10.1136/bjsm.2009.069526; Maffulli N, 2010, PHYSICIAN SPORTSMED, V38, P29, DOI 10.3810/psm.2010.06.1780; Niederbracht Y, 2008, J STRENGTH COND RES, V22, P140, DOI 10.1519/JSC.0b013e31815f5634; Ogaki R, 2014, INT J SPORT HLTH SCI, V12, P31; Owoeye OBA, 2014, J SPORT SCI MED, V13, P321; Palmer-Green DS, 2013, AM J SPORT MED, V41, P749, DOI 10.1177/0363546512473818; Patel DR, 2005, SPORTS MED, V35, P671, DOI 10.2165/00007256-200535080-00002; Pollock AM, 2016, BRIT J SPORT MED, V50, P963, DOI 10.1136/bjsports-2016-096220; Rae K, 2007, CLIN J SPORT MED, V17, P201, DOI 10.1097/JSM.0b013e318059b536; Schneider KJ, 2013, CLIN J SPORT MED, V23, P267, DOI 10.1097/JSM.0b013e318281f09f; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Schulz KF, 2011, INT J SURG, V9, P672, DOI [10.7326/0003-4819-152-11-201006010-00232, 10.1016/j.ijsu.2011.09.004]; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Silvers-Granelli H, 2015, AM J SPORT MED, V43, P2628, DOI 10.1177/0363546515602009; Soligard T, 2010, BRIT J SPORT MED, V44, P787, DOI 10.1136/bjsm.2009.070672; Steffen K, 2010, EUR J SPORT SCI, V10, P223, DOI 10.1080/17461390903585173; Sugimoto D, 2016, BRIT J SPORT MED, V50, P1259, DOI 10.1136/bjsports-2015-095596; Sugimoto Dai, 2015, Curr Phys Med Rehabil Rep, V3, P43; Sugimoto D, 2014, SPORTS MED, V44, P551, DOI 10.1007/s40279-013-0135-9; Tucker R, 2016, BRIT J SPORT MED, V50, P921, DOI 10.1136/bjsports-2016-096322; Twomey D, 2009, J SCI MED SPORT, V12, P452, DOI 10.1016/j.jsams.2008.04.002; Williams S., 2016, BMJ OPEN SPORT EXERC, V2	50	55	55	2	34	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2017	51	15					1140	+		10.1136/bjsports-2016-097434			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	FA9US	WOS:000405792300010	28515056	Green Published, hybrid, Green Submitted			2022-02-06	
J	Johnson, MA; Williams, TK; Ferencz, SAE; Davidson, AJ; Russo, RM; O'Brien, WT; Galante, JM; Grayson, JK; Neff, LP				Johnson, M. Austin; Williams, Timothy K.; Ferencz, Sarah-Ashley E.; Davidson, Anders J.; Russo, Rachel M.; O'Brien, William T., Sr.; Galante, Joseph M.; Grayson, J. Kevin; Neff, Lucas P.			The effect of resuscitative endovascular balloon occlusion of the aorta, partial aortic occlusion and aggressive blood transfusion on traumatic brain injury in a swine multiple injuries model	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	30th Annual Scientific Assembly of the Eastern-Association-for-the-Surgery-of-Trauma (EAST)	JAN 09-14, 2017	Hollywood, FL	Eastern Assoc Surg Trauma		Traumatic brain injury; shock; endovascular; resuscitation; intra-aortic balloon	CEREBRAL PERFUSION; HEMORRHAGIC-SHOCK; PORCINE MODEL; HEAD-INJURY; INTRACRANIAL-PRESSURE; TORSO HEMORRHAGE; SPINAL-CORD; REBOA; MORTALITY; IMPACT	BACKGROUND: Despite clinical reports of poor outcomes, the degree to which resuscitative endovascular balloon occlusion of the aorta (REBOA) exacerbates traumatic brain injury (TBI) is not known. We hypothesized that combined effects of increased proximal mean arterial pressure (pMAP), carotid blood flow (Qcarotid), and intracranial pressure (ICP) from REBOA would lead to TBI progression compared with partial aortic occlusion (PAO) or no intervention. METHODS: Twenty-one swine underwent a standardized TBI via computer Controlled cortical impact followed by 25% total blood volume rapid hemorrhage. After 30 minutes of hypotension, animals were randomized to 60 minutes of continued hypotension (Control), REBOA, or PAO. REBOA and PAO animals were then weaned from occlusion. All animals were resuscitated with shed blood via a rapid blood infuser. Physiologic parameters were recorded continuously and brain computed tomography obtained at specified intervals. RESULTS: There were no differences in baseline physiology or during the initial 30 minutes of hypotension. During the 60-minute intervention period, REBOA resulted in higher maximal pMAP (REBOA, 105.3 +/- 8.8; PAO, 92.7 +/- 9.2; Control, 48.9 +/- 7.7; p = 0.02) and higher Qcarotid (REBOA, 673.1 +/- 57.9; PAO, 464.2 +/- 53.0; Control, 170.3 +/- 29.4; p < 0.01). Increases in ICP were greatest during blood resuscitation, with Control animals demonstrating the largest peak ICP (Control, 12.8 +/- 1.2; REBOA, 5.1 +/- 0.6; PAO, 9.4 +/- 1.1; p < 0.01). There were no differences in the percentage of animals with hemorrhage progression on CT (Control, 14.3%; 95% confidence interval [CI], 3.6-57.9; REBOA, 28.6%; 95% CI, 3.7-71.0; and PAO, 28.6%; 95% CI, 3.7-71.0). CONCLUSION: In an animal model of TBI and shock, REBOA increased Qcarotid and pMAP, but did not exacerbate TBI progression. PAO resulted in physiology closer to baseline with smaller increases in ICP and pMAP. Rapid blood resuscitation, not REBOA, resulted in the largest increase in ICP after intervention, which occurred in Control animals. Continued studies of the cerebral hemodynamics of aortic occlusion and blood transfusion are required to determine optimal resuscitation strategies for multi-injured patients.Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.	[Johnson, M. Austin] UC Davis Med Ctr, Dept Emergency Med, 2315 Stockton Blvd,4150 V St Suite 2100, Sacramento, CA 95817 USA; [Johnson, M. Austin; Williams, Timothy K.; Ferencz, Sarah-Ashley E.; Davidson, Anders J.; Russo, Rachel M.; Grayson, J. Kevin; Neff, Lucas P.] David Grant Med Ctr, Clin Invest Facil, Travis Afb, CA USA; [Williams, Timothy K.] David Grant Med Ctr, Heart Lung & Vasc Ctr, Travis Afb, CA USA; [Ferencz, Sarah-Ashley E.; Davidson, Anders J.; Russo, Rachel M.; Galante, Joseph M.] UC Davis Med Ctr, Dept Surg, Sacramento, CA USA; [Ferencz, Sarah-Ashley E.] Wright State Univ, Dept Surg, Boonshoft Sch Med, Miami Valley Hosp, Dayton, OH 45435 USA; [O'Brien, William T., Sr.] David Grant Med Ctr, Dept Radiol, Travis Afb, CA USA; [Neff, Lucas P.] Emory Univ, Sch Med, Dept Surg, Div Pediat Surg, Atlanta, GA 30322 USA		Johnson, MA (corresponding author), UC Davis Med Ctr, Dept Emergency Med, 2315 Stockton Blvd,4150 V St Suite 2100, Sacramento, CA 95817 USA.	ausjohnson@ucdavis.edu		Rasmussen, Todd/0000-0003-1120-4116	National Heart, Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K12HL108964]; National Center for Advancing Translational Sciences, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000002, TL1 TR000133]; Clinical Investigation Facility, David Grant Medical Center; Travis Air Force Base, California; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001860] Funding Source: NIH RePORTER	There are no personal conflicts of interest. Dr. Johnson is the recipient of a training grant from the National Heart, Lung and Blood Institute: K12HL108964. This project was partly supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant number UL1 TR000002 and TL1 TR000133. The Clinical Investigation Facility, David Grant Medical Center, Travis Air Force Base, California provided funding for this study.	Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Barmparas G, 2014, J TRAUMA ACUTE CARE, V77, P592, DOI 10.1097/TA.0000000000000382; Batchinsky A, 2015, 45 ANN M W TRAUM ASS; Biffl WL, 2015, J TRAUMA ACUTE CARE, V78, P1054, DOI 10.1097/TA.0000000000000609; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Czosnyka M, 2006, ACTA NEUROCHIR SUPPL, V96, P114; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Fortuna G, 2016, J TRAUMA ACUTE CARE, V81, P63, DOI 10.1097/TA.0000000000000996; Fuller G, 2014, INJURY, V45, P612, DOI 10.1016/j.injury.2013.09.008; Hambly PR, 1996, RESUSCITATION, V31, P127, DOI 10.1016/0300-9572(95)00910-8; Hammer M, 2009, CEREBROVASC DIS, V28, P406, DOI 10.1159/000235628; Holcomb JB, 2014, J TRAUMA ACUTE CARE, V76, P888, DOI 10.1097/TA.0000000000000133; Johnson MA, 2016, J TRAUMA ACUTE CARE, V81, pS133, DOI 10.1097/TA.0000000000001146; Juratli TA, 2014, J NEUROTRAUM, V31, P1521, DOI 10.1089/neu.2013.3241; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Lylyk P, 2005, NEUROL RES, V27, pS129, DOI 10.1179/016164105X35512; Malone DL, 2003, J TRAUMA, V54, P898, DOI 10.1097/01.TA.0000060261.10597.5C; Markov NP, 2013, SURGERY, V153, P848, DOI 10.1016/j.surg.2012.12.001; Miller J D, 1972, Prog Brain Res, V35, P411; Norii T, 2015, J TRAUMA ACUTE CARE, V78, P721, DOI 10.1097/TA.0000000000000578; Ogura T, 2015, J TRAUMA ACUTE CARE, V78, P132, DOI 10.1097/TA.0000000000000473; Park TS, 2015, J TRAUMA ACUTE CARE, V79, P930, DOI 10.1097/TA.0000000000000877; Prathep S, 2014, CRIT CARE MED, V42, P142, DOI 10.1097/CCM.0b013e318298a890; Riskin DJ, 2009, J AM COLL SURGEONS, V209, P198, DOI 10.1016/j.jamcollsurg.2009.04.016; Russo RM, 2016, SHOCK, V46, P12, DOI 10.1097/SHK.0000000000000641; Russo RM, 2016, J AM COLL SURGEONS, V223, P359, DOI 10.1016/j.jamcollsurg.2016.04.037; Russo RM, 2016, J TRAUMA ACUTE CARE, V80, P372, DOI 10.1097/TA.0000000000000940; Sellmann T, 2012, DTSCH ARZTEBL INT, V109, P849, DOI 10.3238/arztebl.2012.0849; Shuaib A, 2011, STROKE, V42, P1680, DOI 10.1161/STROKEAHA.110.609933; Slim J., 2014, J EMERGENCY MED, V46, P602; Sondeen JL, 2007, SHOCK, V28, P426, DOI 10.1097/shk.0b013e31804a5791; Strauch JT, 2003, EUR J CARDIO-THORAC, V24, P817, DOI 10.1016/S1010-7940(03)00460-3; Symon L, 1977, Adv Exp Med Biol, V94, P775; Tsurukiri J, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0205-8; Uchino H, 2016, AM J CASE REP, V17, P810, DOI 10.12659/AJCR.900267; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; White JM, 2011, SURGERY, V150, P400, DOI 10.1016/j.surg.2011.06.010; Williams TK, 2016, J TRAUMA ACUTE CARE, V81, P294, DOI 10.1097/TA.0000000000001075; Yuan L, 2005, SPINE, V30, P483, DOI 10.1097/01.brs.0000154622.49240.ff; Zafar SN, 2011, J TRAUMA, V71, P1179, DOI 10.1097/TA.0b013e3182140d38	44	55	55	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2017	83	1					61	70		10.1097/TA.0000000000001518			10	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	EY3VP	WOS:000403903100011	28166165	Green Accepted			2022-02-06	
J	Wallace, J; Covassin, T; Beidler, E				Wallace, Jessica; Covassin, Tracey; Beidler, Erica			Sex Differences in High School Athletes' Knowledge of Sport-Related Concussion Symptoms and Reporting Behaviors	JOURNAL OF ATHLETIC TRAINING			English	Article						mild traumatic brain injuries; secondary school; sport culture	FOOTBALL PLAYERS; ICE HOCKEY; STATEMENT; PERFORMANCE; ATTITUDES; EDUCATION; RECOVERY; IDENTITY; INJURY	Context: Recent researchers have reported that athletes' knowledge of sport-related concussion (SRC) has increased but that athletes still lack knowledge of all the signs and symptoms of SRC. Understanding the signs and symptoms of SRC and the dangers of playing while symptomatic are critical to reporting behaviors in high school athletes. Objective: To examine sex differences in knowledge of SRC symptoms and reasons for not reporting a suspected SRC to an authoritative figure in high school athletes. Design: Cross-sectional study. Setting: Survey. Patients or Other Participants: A total of 288 athletes across 7 sports (198 males [68.8%] and 90 females [31.2%]). Main Outcome Measure(s): A validated knowledge-of-SRC survey consisted of demographic questions, a list of 21 signs and symptoms of SRC, and reasons why athletes would not report their SRC. The independent variable was sex. Athlete knowledge of SRC symptoms was assessed by having participants identify the signs and symptoms of SRC from a list of 21 symptoms. Knowledge scores were calculated by summing the number of correct answers; scores ranged from 0 to 21, with a score closer to 21 representing greater knowledge. Reporting-behavior questions asked athletes to choose reasons why they decided not to report any possible SRC signs and symptoms to an authoritative figure. Results: A sex difference in total SRC symptom knowledge was found (F-286 = 4.97, P = .03, d = 0.26). Female high school athletes had more total SRC symptom knowledge (mean 6 standard deviation = 15.06 +/- 2.63; 95% confidence interval = 14.54, 15.57) than males (14.36 +/- 2.76; 95% confidence interval = 13.97, 14.74). Chi-square tests identified significant relationships between sex and 8 different reasons for not reporting an SRC. Conclusions: High school males and females had similar SRC symptom knowledge; however, female athletes were more likely to report their concussive symptoms to an authoritative figure.	[Wallace, Jessica] Youngstown State Univ, Youngstown, OH 44555 USA; [Wallace, Jessica; Covassin, Tracey] Michigan State Univ, E Lansing, MI 48824 USA; [Beidler, Erica] Duquesne Univ, Pittsburgh, PA 15219 USA		Wallace, J (corresponding author), Youngstown State Univ, Beeghly Ctr 307L, 1 Univ Plaza, Youngstown, OH 44555 USA.	jwallace02@ysu.edu					Anderson B, 2013, PED AC SOC ANN M WAS; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; BREWER BW, 1993, INT J SPORT PSYCHOL, V24, P237; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Centers for Disease Control and Prevention, CONC MILD TBI; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Cohen J., 1988, STAT POWER BEHAV SCI; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Cournoyer J, 2014, J ATHL TRAINING, V49, P654, DOI 10.4085/1062-6050-49.3.34; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Korngold C, 2013, J AM ACAD PSYCHIATRY, V41, P430; Kroshus E, 2015, ANN BEHAV MED, V49, P95, DOI 10.1007/s12160-014-9636-5; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Kurowski B, 2014, J TRAUMA ACUTE CARE, V77, pS12, DOI 10.1097/TA.0000000000000316; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Martin SB, 2005, J APPL SPORT PSYCHOL, V17, P127, DOI 10.1080/10413200590932434; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckinlay A, 2011, BRAIN INJURY, V25, P761, DOI 10.3109/02699052.2011.579935; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; Messner Michael A., 1992, POWER PLAY SPORTS PR; Pietrosimone B, 2015, MED SCI SPORT EXER, V47, P2366, DOI 10.1249/MSS.0000000000000684; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Steinfeldt JA, 2009, PSYCHOL MEN MASCULIN, V10, P261, DOI 10.1037/a0017223; Swanik CB, 2007, AM J SPORT MED, V35, P943, DOI 10.1177/0363546507299532; Wilkerson GB, 2012, INT J ATHL THER TRAI, V17, P4, DOI 10.1123/ijatt.17.6.4; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	36	55	54	0	11	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL	2017	52	7					682	688		10.4085/1062-6050-52.3.06			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	FB4RH	WOS:000406128700008	28561626	Green Published, Bronze			2022-02-06	
J	Cox, CS; Hetz, RA; Liao, GP; Aertker, BM; Ewing-Cobbs, L; Juranek, J; Savitz, SI; Jackson, ML; Romanowska-Pawliczek, AM; Triolo, F; Dash, PK; Pedroza, C; Lee, DA; Worth, L; Aisiku, IP; Choi, HA; Holcomb, JB; Kitagawa, RS				Cox, Charles S., Jr.; Hetz, Robert A.; Liao, George P.; Aertker, Benjamin M.; Ewing-Cobbs, Linda; Juranek, Jenifer; Savitz, Sean I.; Jackson, Margaret L.; Romanowska-Pawliczek, Anna M.; Triolo, Fabio; Dash, Pramod K.; Pedroza, Claudia; Lee, Dean A.; Worth, Laura; Aisiku, Imoigele P.; Choi, Huimahn A.; Holcomb, John B.; Kitagawa, Ryan S.			Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells	STEM CELLS			English	Article						traumatic brain injury; bone marrow stromal cells; cellular therapy; clinical trials; diffusion tensor imaging; adult stem cells; adult human bone marrow	MESENCHYMAL STEM-CELLS; STROMAL CELLS; TRANSPLANTATION; RATS; MICE; DEFINITION; ISCHEMIA; DELIVERY; MODERATE; THERAPY	Preclinical studies using bone marrow derived cells to treat traumatic brain injury have demonstrated efficacy in terms of blood-brain barrier preservation, neurogenesis, and functional outcomes. Phase 1 clinical trials using bone marrow mononuclear cells infused intravenously in children with severe traumatic brain injury demonstrated safety and potentially a central nervous system structural preservation treatment effect. This study sought to confirm the safety, logistic feasibility, and potential treatment effect size of structural preservation/inflammatory biomarker mitigation in adults to guide Phase 2 clinical trial design. Adults with severe traumatic brain injury (Glasgow Coma Scale 5-8) and without signs of irreversible brain injury were evaluated for entry into the trial. A dose escalation format was performed in 25 patients: 5 controls, followed 5 patients in each dosing cohort ( 6, 9, 12 310 6 cells/kgbody weight), then 5 more controls. Bone marrow harvest, cell processing to isolate the mononuclear fraction, and re-infusion occurred within 48 hours after injury. Patients were monitored for harvest-related hemodynamic changes, infusional toxicity, and adverse events. Outcome measures included magnetic resonance imaging-based measurements of supratentorial and corpus callosal volumes as well as diffusion tensor imaging-based measurements of fractional anisotropy and mean diffusivity of the corpus callosum and the corticospinal tract at the level of the brainstem at 1 month and 6 months postinjury. Functional and neurocognitive outcomes were measured and correlated with imaging data. Inflammatory cytokine arrays were measured in the plasma pretreatment, posttreatment, and at 1 and 6 month follow-up. There were no serious adverse events. There was a mild pulmonary toxicity of the highest dose that was not clinically significant. Despite the treatment group having greater injury severity, there was structural preservation of critical regions of interest that correlated with functional outcomes. Key inflammatory cytokines were downregulated. Treatment of severe, adult traumatic brain injury using an intravenously delivered autologous bone marrow mononuclear cell infusion is safe and logistically feasible. There appears to be a treatment signal as evidenced by central nervous system structural preservation, consistent with previous pediatric trial data. Inflammatory biomarkers are downregulated after cell infusion.	[Cox, Charles S., Jr.; Jackson, Margaret L.; Triolo, Fabio] Univ Texas Houston, McGovern Med Sch, Dept Pediat Surg, Houston, TX USA; [Hetz, Robert A.; Liao, George P.; Holcomb, John B.] Univ Texas Houston, McGovern Med Sch, Dept Surg, Houston, TX USA; [Aertker, Benjamin M.; Choi, Huimahn A.] Univ Texas Houston, McGovern Med Sch, Dept Neurol, Houston, TX USA; [Ewing-Cobbs, Linda; Juranek, Jenifer; Romanowska-Pawliczek, Anna M.] Univ Texas Houston, McGovern Med Sch, Dept Pediat, Houston, TX USA; [Ewing-Cobbs, Linda] Univ Texas Houston, McGovern Med Sch, Dept Psychiat & Behav Sci, Houston, TX USA; [Dash, Pramod K.] Univ Texas Houston, McGovern Med Sch, Dept Neurobiol & Anat, Houston, TX USA; [Pedroza, Claudia] Univ Texas Houston, McGovern Med Sch, Ctr Clin Res & Evidence Based Med, Houston, TX USA; [Choi, Huimahn A.; Kitagawa, Ryan S.] Univ Texas Houston, McGovern Med Sch, Dept Neurosurg, Houston, TX USA; [Lee, Dean A.] Nationwide Childrens, Dept Hematol & Oncol, Columbus, OH USA; [Worth, Laura] MD Anderson Canc Ctr, Dept Pediat, Houston, TX USA; [Aisiku, Imoigele P.] Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA		Cox, CS (corresponding author), Univ Texas Houston, Sch Med, Dept Pediat Surg, 6431 Fannin St,MSB 5-234, Houston, TX 77030 USA.	Charles.S.Cox@uth.tmc.edu		Pedroza, Claudia/0000-0003-4235-1282; holcomb, john/0000-0001-8312-9157	DODUnited States Department of Defense [W81XWH-11-10460]; NIH 2T32United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM 0879201-11]; Glassell fundation Stem Cell Research Program; Brown Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER	Research Coordinators: Steven Kosmach, RN, MSN., MaryClare Day, RN, BSN; Fernando Jimenez, RN, MS. Cell Processing Team: Andrew Havens, Sufira Kiran, James Roye, Philippa Smith, Suchit Sahai, Ph. D., Marysuna Wilkerson. Technical Support: Anthony Moore10. All Cellular Processing was performed at UTHealth-Medical School, The Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory, FDA Establishment Identifier 3009561521. Funding Sources: DOD Grant: W81XWH-11-10460 (Cox, PI); NIH 2T32 GM 0879201-11 (Holcomb,PI); Glassell fundation Stem Cell Research Program (Cox, PI). Brown Foundation (Cox, PI).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Anbari F, 2014, NEURAL REGEN RES, V9, P919, DOI 10.4103/1673-5374.133133; Antonelli M, 1999, INTENS CARE MED, V25, P389, DOI 10.1007/s001340050863; Arien-Zakay H, 2014, J NEUROTRAUM, V31, P1405, DOI 10.1089/neu.2013.3270; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Bedi SS, 2013, J TRAUMA ACUTE CARE, V75, P410, DOI 10.1097/TA.0b013e31829617c6; Brenneman M, 2010, J CEREBR BLOOD F MET, V30, P140, DOI 10.1038/jcbfm.2009.198; Brezova V, 2014, NEUROIMAGE-CLIN, V5, P128, DOI 10.1016/j.nicl.2014.03.012; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Centers for Disease Control and Prevention, 2015, C TRAUM BRAIN INJ US; Cotton BA, 2012, J TRAUMA ACUTE CARE, V72, P1470, DOI 10.1097/TA.0b013e31824d56ad; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Francois M, 2012, CYTOTHERAPY, V14, P147, DOI 10.3109/14653249.2011.623691; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Jiang JD, 2012, NEURAL REGEN RES, V7, P46, DOI 10.3969/j.issn.1673-5374.2012.01.008; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Li LA, 2011, J NEUROTRAUM, V28, P535, DOI 10.1089/neu.2010.1619; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2003, NEUROSURGERY, V53, P3; Moll G, 2012, STEM CELLS, V30, P1565, DOI 10.1002/stem.1111; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; Ohtaki H, 2008, P NATL ACAD SCI USA, V105, P14638, DOI 10.1073/pnas.0803670105; Osanai T, 2012, NEUROSURGERY, V70, P435, DOI 10.1227/NEU.0b013e318230a795; Pischiutta F, 2014, NEUROPHARMACOLOGY, V79, P119, DOI 10.1016/j.neuropharm.2013.11.001; Salamon N, 2005, NEURORADIOLOGY, V47, P895, DOI 10.1007/s00234-005-1439-8; Sanberg PR, 2010, J CELL MOL MED, V14, P553, DOI 10.1111/j.1582-4934.2009.00903.x; Savitz SI, 2016, STEM CELLS, V34, P537, DOI 10.1002/stem.2253; Savitz SI, 2011, ANN NEUROL, V70, P59, DOI 10.1002/ana.22458; Sharma S, 2010, J NEUROSCI RES, V88, P2869, DOI 10.1002/jnr.22452; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Suda S, 2015, STEM CELLS DEV, V24, P2756, DOI 10.1089/scd.2015.0107; TEASDALE G, 1974, LANCET, V2, P81; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Turtzo LC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126551; Vahidy FS, 2016, STROKE, V47, P1632, DOI 10.1161/STROKEAHA.116.012701; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Watanabe J, 2013, NEUROBIOL DIS, V59, P86, DOI 10.1016/j.nbd.2013.06.017; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Yang B, 2011, J NEUROSCI RES, V89, P833, DOI 10.1002/jnr.22614; Zanier ER, 2011, CRIT CARE MED, V39, P2501, DOI 10.1097/CCM.0b013e31822629ba; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106	49	55	56	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	APR	2017	35	4					1065	1079		10.1002/stem.2538			15	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	EQ5DM	WOS:000398102000020	27800660	Green Accepted, Bronze			2022-02-06	
J	Liu, XC; Chen, H; Bo, QG; Fan, F; Jia, CX				Liu, Xianchen; Chen, Hua; Bo, Qi-Gui; Fan, Fang; Jia, Cun-Xian			Poor sleep quality and nightmares are associated with non-suicidal self-injury in adolescents	EUROPEAN CHILD & ADOLESCENT PSYCHIATRY			English	Article						Sleep; Nightmares; Self-injury; Adolescents	TRAUMATIC BRAIN-INJURY; SUICIDAL-BEHAVIOR; CHINESE ADOLESCENTS; COMMUNITY SAMPLE; YOUNG-PEOPLE; HARM; PREVALENCE; DEPRESSION; INSOMNIA; HEALTH	Non-suicidal self-injury (NSSI) is prevalent and is associated with increased risk of suicidal behavior in adolescents. This study examined which sleep variables are associated with NSSI, independently from demographics and mental health problems in Chinese adolescents. Participants consisted of 2090 students sampled from three high schools in Shandong, China and had a mean age of 15.49 years. Participants completed a sleep and health questionnaire to report their demographic and family information, sleep duration and sleep problems, impulsiveness, hopelessness, internalizing and externalizing problems, and NSSI. A series of regression analyses were conducted to examine the associations between sleep variables and NSSI. Of the sample, 12.6 % reported having ever engaged in NSSI and 8.8 % engaged during the last year. Univariate logistic analyses demonstrated that multiple sleep variables including short sleep duration, insomnia symptoms, poor sleep quality, sleep insufficiency, unrefreshed sleep, sleep dissatisfaction, daytime sleepiness, fatigue, snoring, and nightmares were associated with increased risk of NSSI. After adjusting for demographic and mental health variables, NSSI was significantly associated with sleeping < 6 h per night, poor sleep quality, sleep dissatisfaction, daytime sleepiness, and frequent nightmares. Stepwise logistic regression model demonstrated that poor sleep quality (OR = 2.18, 95 % CI = 1.37-3.47) and frequent nightmares (OR = 2.88, 95 % CI = 1.45-5.70) were significantly independently associated with NSSI. In conclusion, while multiple sleep variables are associated with NSSI, poor sleep quality and frequent nightmares are independent risk factors of NSSI. These findings may have important implications for further research of sleep self-harm mechanisms and early detection and prevention of NSSI in adolescents.	[Liu, Xianchen; Chen, Hua; Jia, Cun-Xian] Shandong Univ, Sch Publ Hlth, Dept Epidemiol, 44 Wenhuaxi Rd, Jinan 250012, Peoples R China; [Liu, Xianchen; Chen, Hua; Jia, Cun-Xian] Shandong Univ, Ctr Suicide Prevent Res, 44 Wenhuaxi Rd, Jinan 250012, Peoples R China; [Liu, Xianchen] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; [Bo, Qi-Gui] Ctr Dis Control & Prevent Lijin Cty, Lijin 257400, Peoples R China; [Fan, Fang] South China Normal Univ, Sch Psychol, Guangzhou 510631, Guangdong, Peoples R China		Liu, XC; Jia, CX (corresponding author), Shandong Univ, Sch Publ Hlth, Dept Epidemiol, 44 Wenhuaxi Rd, Jinan 250012, Peoples R China.; Liu, XC; Jia, CX (corresponding author), Shandong Univ, Ctr Suicide Prevent Res, 44 Wenhuaxi Rd, Jinan 250012, Peoples R China.	xliu69@uthsc.edu; jiacunxian@sdu.edu.cn			Shandong Scientific Technique Development Plan [2014GSF118163]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81573233]	This work was funded by Shandong Scientific Technique Development Plan (Grant No. 2014GSF118163) and National Natural Science Foundation of China (Grant No. 81573233).	Achenbach T.M., 1991, MANUAL YOUTH SELF RE; Agargun MY, 1998, COMPR PSYCHIAT, V39, P198; Argyropoulos SV, 2003, PSYCHIAT RES, V120, P179, DOI 10.1016/S0165-1781(03)00187-2; BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; Brent DA, 1999, J AM ACAD CHILD PSY, V38, P1497, DOI 10.1097/00004583-199912000-00010; Brent DA, 2013, J AM ACAD CHILD PSY, V52, P1260, DOI 10.1016/j.jaac.2013.09.009; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carroll R, 2016, J AFFECT DISORDERS, V192, P8, DOI 10.1016/j.jad.2015.12.007; CHOQUET M, 1990, ACTA PSYCHIAT SCAND, V81, P170, DOI 10.1111/j.1600-0447.1990.tb06474.x; Cooper J, 2005, AM J PSYCHIAT, V162, P297, DOI 10.1176/appi.ajp.162.2.297; Duval M, 2013, J NERV MENT DIS, V201, P767, DOI 10.1097/NMD.0b013e3182a214a1; EYSENCK SBG, 1985, PERS INDIV DIFFER, V6, P613, DOI 10.1016/0191-8869(85)90011-X; Giletta M, 2012, PSYCHIAT RES, V197, P66, DOI 10.1016/j.psychres.2012.02.009; Guan K, 2012, J CONSULT CLIN PSYCH, V80, P842, DOI 10.1037/a0029429; Harvey AG, 2008, SLEEP, V31, P383, DOI 10.1093/sleep/31.3.383; Hawton K, 2002, BMJ-BRIT MED J, V325, P1207, DOI 10.1136/bmj.325.7374.1207; Hawton K, 2005, BRIT MED J, V330, P891, DOI 10.1136/bmj.330.7496.891; Hawton K, 2015, COCHRANE DB SYST REV, V12; Hawton K, 2012, J CHILD PSYCHOL PSYC, V53, P1212, DOI 10.1111/j.1469-7610.2012.02559.x; Hawton K, 2012, LANCET, V379, P2373, DOI 10.1016/S0140-6736(12)60322-5; Hysing M, 2015, BRIT J PSYCHIAT, V207, P306, DOI 10.1192/bjp.bp.114.146514; Levin R, 2002, SLEEP, V25, P205; Liu X., 1997, CHIN MENT HLTH J, V11, P200; Liu XC, 2006, CURR OPIN PSYCHIATR, V19, P288, DOI 10.1097/01.yco.0000218600.40593.18; Liu XC, 2005, J AFFECT DISORDERS, V86, P195, DOI 10.1016/j.jad.2005.01.016; Liu XC, 2004, SLEEP, V27, P1351, DOI 10.1093/sleep/27.7.1351; Liu XC, 2008, PEDIATRICS, V121, P1165, DOI 10.1542/peds.2007-1464; Liu XC, 2015, PSYCHIAT RES, V228, P797, DOI 10.1016/j.psychres.2015.05.023; Lundh LG, 2013, J PSYCHOPATHOL BEHAV, V35, P85, DOI 10.1007/s10862-012-9307-4; Maciejewski DF, 2014, JAMA PSYCHIAT, V71, P699, DOI 10.1001/jamapsychiatry.2014.89; Martin G, 2004, CHILD ABUSE NEGLECT, V28, P491, DOI 10.1016/j.chiabu.2003.08.006; Matamura M, 2014, J SLEEP RES, V23, P290, DOI 10.1111/jsr.12127; McLoughlin AB, 2015, QJM-INT J MED, V108, P765, DOI 10.1093/qjmed/hcv026; Owens C, 2016, BRIT J PSYCHIAT, V208, P286, DOI 10.1192/bjp.bp.113.141242; Owens J, 2014, PEDIATRICS, V134, pE921, DOI 10.1542/peds.2014-1696; Perlis ML, 2016, SLEEP MED REV, V29, P101, DOI 10.1016/j.smrv.2015.10.003; Pigeon Wilfred R, 2012, J Clin Psychiatry, V73, pe1160, DOI 10.4088/JCP.11r07586; Roberts RE, 2001, J YOUTH ADOLESCENCE, V30, P1, DOI 10.1023/A:1005230820074; Roberts RE, 2008, J ADOLESCENT HEALTH, V42, P294, DOI 10.1016/j.jadohealth.2007.09.016; Roberts RE, 2014, SLEEP, V37, P239, DOI 10.5665/sleep.3388; SHEK DTL, 2012, THESCIENTIFICWORLDJO, DOI DOI 10.1100/2012/932540; Sullivan KA, 2015, J NEUROTRAUM, V32, P474, DOI 10.1089/neu.2013.3284; Swannell SV, 2014, SUICIDE LIFE-THREAT, V44, P273, DOI 10.1111/sltb.12070; Tanskanen A, 2001, SLEEP, V24, P844; Tham SW, 2015, J NEUROTRAUM, V32, P847, DOI 10.1089/neu.2014.3559; Wan YH, 2011, EUR CHILD ADOLES PSY, V20, P517, DOI 10.1007/s00787-011-0213-1; Wan YH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131239; Wilkinson P, 2011, AM J PSYCHIAT, V168, P495, DOI 10.1176/appi.ajp.2010.10050718; Wong MM, 2012, J PSYCHIATR RES, V46, P953, DOI 10.1016/j.jpsychires.2012.04.008; Zetterqvist M, 2015, CHILD ADOL PSYCH MEN, V9, DOI 10.1186/s13034-015-0062-7; Zhang J, 2012, J CLIN PSYCHOL, V68, P1313, DOI 10.1002/jclp.21907	51	55	58	3	41	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1018-8827	1435-165X		EUR CHILD ADOLES PSY	Eur. Child Adolesc. Psych.	MAR	2017	26	3					271	279		10.1007/s00787-016-0885-7			9	Psychology, Developmental; Pediatrics; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Pediatrics; Psychiatry	EM0HY	WOS:000395000600002	27383464				2022-02-06	
J	Khalin, I; Alyautdin, R; Wong, TW; Gnanou, J; Kocherga, G; Kreuter, J				Khalin, Igor; Alyautdin, Renad; Wong, Tin Wui; Gnanou, Justin; Kocherga, Ganna; Kreuter, Joerg			Brain-derived neurotrophic factor delivered to the brain using poly (lactide-co-glycolide) nanoparticles improves neurological and cognitive outcome in mice with traumatic brain injury	DRUG DELIVERY			English	Article						Blood-brain barrier; brain-derived neurotrophic factor; drug-delivery; nanoparticles; traumatic brain injury	POLY(BUTYL CYANOACRYLATE) NANOPARTICLES; CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN; FUNCTIONAL RECOVERY; BODY DISTRIBUTION; DRUG-DELIVERY; ANIMAL-MODELS; FACTOR BDNF; RAT; CELLS	Currently, traumatic brain injury (TBI) is the leading cause of death or disabilities in young individuals worldwide. The multi-complexity of its pathogenesis as well as impermeability of the blood-brain barrier (BBB) makes the drug choice and delivery very challenging. The brain-derived neurotrophic factor (BDNF) regulates neuronal plasticity, neuronal cell growth, proliferation, cell survival and long-term memory. However, its short half-life and low BBB permeability are the main hurdles to be an effective therapeutic for TBI. Poly (lactic-co-glycolic acid) (PLGA) nanoparticles coated by surfactant can enable the delivery of a variety of molecules across the BBB by receptor-mediated transcytosis. This study examines the ability of PLGA nanoparticles coated with poloxamer 188 (PX) to deliver BDNF into the brain and neuroprotective effects of BNDF in mice with TBI. C57bl/6 mice were subjected to weight-drop closed head injuries under anesthesia. Using enzyme-linked immunosorbent assay, we demonstrated that the intravenous (IV) injection of nanoparticle-bound BDNF coated by PX (NP-BDNF-PX) significantly increased BDNF levels in the brain of sham-operated mice (p<0.001) and in both ipsi-(p<0.001) and contralateral (p<0.001) parts of brain in TBI mice compared to controls. This study also showed using the passive avoidance (PA) test, that IV injection of NP-BDNF-PX 3h post-injury prolonged the latent time in mice with TBI thereby reversing cognitive deficits caused by brain trauma. Finally, neurological severity score test demonstrated that our compound efficiently reduced the scores at day 7 after the injury indicating the improvement of neurological deficit in animals with TBI. This study shows that PLGA nanoparticles coated with PX effectively delivered BDNF into the brain, and improved neurological and cognitive deficits in TBI mice, thereby providing a neuroprotective effect.	[Khalin, Igor; Gnanou, Justin] Natl Def Univ Malaysia, Fac Med & Def Hlth, Kuala Lumpur, Malaysia; [Alyautdin, Renad] Sci Ctr Expertise Med Applicat Prod, Moscow, Russia; [Wong, Tin Wui] Univ Teknol MARA, Nondestruct Biomed & Pharmaceut Res Ctr, iPROMISE, Selangor, Malaysia; [Kocherga, Ganna] Int Med Ctr Oftalm, Ophthalm Microsurg Dept, Kharkov, Ukraine; [Kreuter, Joerg] Goethe Univ, Inst Pharmaceut Technol, Frankfurt, Germany		Khalin, I (corresponding author), Natl Def Univ Malaysia, Fac Med & Def Hlth, Kuala Lumpur, Malaysia.	igor@upnm.edu.my	Alyautdin, Renad N/L-9261-2014	Alyautdin, Renad N/0000-0002-4647-977X; Khalin, Igor/0000-0003-1041-5747	Ministry of Higher Education of MalaysiaMinistry of Education, Malaysia [RAGS/2013/UPNM/SKK/01/2]	The authors report no conflicts of interest in this work. The study was supported by a grant from the Ministry of Higher Education of Malaysia (RAGS/2013/UPNM/SKK/01/2).	Allen SJ, 2013, PHARMACOL THERAPEUT, V138, P155, DOI 10.1016/j.pharmthera.2013.01.004; Alyautdin RN, 1997, PHARMACEUT RES, V14, P325, DOI 10.1023/A:1012098005098; Alyautdin RN, 1998, J MICROENCAPSUL, V15, P67, DOI 10.3109/02652049809006836; ANDERSON KD, 1995, J COMP NEUROL, V357, P296, DOI 10.1002/cne.903570209; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Blurton-Jones M, 2009, P NATL ACAD SCI USA, V106, P13594, DOI 10.1073/pnas.0901402106; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Casalbore P, 2010, J CELL PHYSIOL, V224, P710, DOI 10.1002/jcp.22170; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Cowansage Kiriana K, 2010, Curr Mol Pharmacol, V3, P12; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gelperina S, 2010, EUR J PHARM BIOPHARM, V74, P157, DOI 10.1016/j.ejpb.2009.09.003; Geral Claire, 2013, Pharmaceutics, V5, P127, DOI 10.3390/pharmaceutics5010127; Grafman J, 2015, TRAUMATIC BRAIN IN 1; Graham D.I., 2002, GREENFIELDS NEUROPAT; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Kasarskis EJ, 1999, NEUROLOGY, V52, P1427; Khalin I, 2016, NEURAL REGEN RES, V11, P630, DOI 10.4103/1673-5374.180749; Khalin I, 2015, INT J NANOMED, V10, P3245, DOI 10.2147/IJN.S77480; Kiprianova I, 1999, EXP NEUROL, V159, P511, DOI 10.1006/exnr.1999.7109; Klein AB, 2011, INT J NEUROPSYCHOPH, V14, P347, DOI 10.1017/S1461145710000738; Kober M, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/15/155501; Kreuter J, 2000, BLOOD-BRAIN BARRIER AND DRUG DELIVERY TO THE CNS, P205; KREUTER J, 1995, BRAIN RES, V674, P171, DOI 10.1016/0006-8993(95)00023-J; Kreuter J, 2014, ADV DRUG DELIVER REV, V71, P2, DOI 10.1016/j.addr.2013.08.008; Kume T, 1997, BRAIN RES, V756, P200, DOI 10.1016/S0006-8993(97)00195-9; Kurakhmaeva KB, 2009, J DRUG TARGET, V17, P564, DOI 10.1080/10611860903112842; LI JT, 1994, LANGMUIR, V10, P4475, DOI 10.1021/la00024a016; Liu ZH, 2007, J HUAZHONG U SCI-MED, V27, P233, DOI 10.1007/s11596-007-0304-x; Lu JM, 2009, EXPERT REV MOL DIAGN, V9, P325, DOI 10.1586/ERM.09.15; Ma HY, 2012, NEUROCHEM RES, V37, P69, DOI 10.1007/s11064-011-0584-1; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; MEY J, 1993, BRAIN RES, V602, P304, DOI 10.1016/0006-8993(93)90695-J; Michaelis K, 2006, J PHARMACOL EXP THER, V317, P1246, DOI 10.1124/jpet.105.097139; Moghimi SM, 1997, BBA-GEN SUBJECTS, V1336, P1, DOI 10.1016/S0304-4165(97)00060-3; Moghimi SM, 2000, TRENDS BIOTECHNOL, V18, P412, DOI 10.1016/S0167-7799(00)01485-2; Numakawa T, 2010, HISTOL HISTOPATHOL, V25, P237, DOI 10.14670/HH-25.237; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Pan WH, 1998, NEUROPHARMACOLOGY, V37, P1553, DOI 10.1016/S0028-3908(98)00141-5; Pardridge WM, 2016, EXPERT OPIN DRUG DEL, V13, P963, DOI 10.1517/17425247.2016.1171315; PARDRIDGE WM, 1994, PHARMACEUT RES, V11, P738, DOI 10.1023/A:1018940732550; Petri B, 2007, J CONTROL RELEASE, V117, P51, DOI 10.1016/j.jconrel.2006.10.015; Poduslo JF, 1996, MOL BRAIN RES, V36, P280, DOI 10.1016/0169-328X(95)00250-V; Quertemont E, 2004, PSYCHOPHARMACOLOGY, V177, P84, DOI 10.1007/s00213-004-1911-x; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; Sakane T, 1997, PHARMACEUT RES, V14, P1085, DOI 10.1023/A:1012117815460; Schroeder U, 2000, LIFE SCI, V66, P495, DOI 10.1016/S0024-3205(99)00619-0; Sharma A, 2012, EXPERT OPIN DRUG MET, V8, P47, DOI 10.1517/17425255.2012.637916; Singh M, 2008, FRONT BIOSCI-LANDMRK, V13, P1083, DOI 10.2741/2746; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Steiniger SCJ, 2004, INT J CANCER, V109, P759, DOI 10.1002/ijc.20048; Tosi G, 2010, J CONTROL RELEASE, V145, P49, DOI 10.1016/j.jconrel.2010.03.008; Wagner S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032568; Wallace SJ, 2012, DRUG DELIV TRANSL RE, V2, P284, DOI 10.1007/s13346-012-0064-4; Wang ZT, 2013, J MOL NEUROSCI, V49, P409, DOI 10.1007/s12031-012-9908-0; Wohlfart S, 2012, J CONTROL RELEASE, V161, P264, DOI 10.1016/j.jconrel.2011.08.017; Wu CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113397; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; YAN Q, 1994, EXP NEUROL, V127, P23, DOI 10.1006/exnr.1994.1076; Zensi A, 2009, J CONTROL RELEASE, V137, P78, DOI 10.1016/j.jconrel.2009.03.002; Zhang JM, 2003, EXP NEUROL, V183, P469, DOI 10.1016/S0014-4886(03)00222-X; Zheng WH, 2004, J NEUROCHEM, V89, P844, DOI 10.1111/j.1471-4159.2004.02350.x; Zhu JM, 2011, J INT MED RES, V39, P488, DOI 10.1177/147323001103900216	67	55	55	5	31	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1071-7544	1521-0464		DRUG DELIV	Drug Deliv.	NOV	2016	23	9					3520	3528		10.1080/10717544.2016.1199609			9	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	EF1TU	WOS:000390108500034	27278330	Bronze			2022-02-06	
J	Ko, J; Hemphill, MA; Gabrieli, D; Wu, L; Yelleswarapu, V; Lawrence, G; Pennycooke, W; Singh, A; Meaney, DF; Issadore, D				Ko, Jina; Hemphill, Matthew A.; Gabrieli, David; Wu, Leon; Yelleswarapu, Venkata; Lawrence, Gladys; Pennycooke, Wesley; Singh, Anup; Meaney, Dave F.; Issadore, David			Smartphone-enabled optofluidic exosome diagnostic for concussion recovery	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; MECHANICAL INJURY; AMPA RECEPTORS; IN-VITRO; PROTEIN; QUANTIFICATION; CONSEQUENCES; BIOMARKERS; FLUID	A major impediment to improving the treatment of concussion is our current inability to identify patients that will experience persistent problems after the injury. Recently, brain-derived exosomes, which cross the blood-brain barrier and circulate following injury, have shown great potential as a noninvasive biomarker of brain recovery. However, clinical use of exosomes has been constrained by their small size (30-100 nm) and the extensive sample preparation (>24 hr) needed for traditional exosome measurements. To address these challenges, we developed a smartphone-enabled optofluidic platform to measure brain-derived exosomes. Sample-to-answer on our chip is 1 hour, 10x faster than conventional techniques. The key innovation is an optofluidic device that can detect enzyme amplified exosome biomarkers, and is read out using a smartphone camera. Using this approach, we detected and profiled GluR2+ exosomes in the post-injury state using both in vitro and murine models of concussion.	[Ko, Jina; Hemphill, Matthew A.; Gabrieli, David; Wu, Leon; Yelleswarapu, Venkata; Lawrence, Gladys; Pennycooke, Wesley; Singh, Anup; Meaney, Dave F.; Issadore, David] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA; [Issadore, David] Univ Penn, Sch Engn & Appl Sci, Dept Elect & Syst Engn, Philadelphia, PA 19104 USA; [Meaney, Dave F.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA		Issadore, D (corresponding author), Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA.; Issadore, D (corresponding author), Univ Penn, Sch Engn & Appl Sci, Dept Elect & Syst Engn, Philadelphia, PA 19104 USA.	issadore@seas.upenn.edu	Yelleswarapu, Venkata/J-9222-2015	Yelleswarapu, Venkata/0000-0003-3529-2819; Meaney, David/0000-0002-0954-4122	Pennsylvania Department of Health Commonwealth Universal Research Enhancement Program; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R21CA182336-01A1, RO1 NS 088176]; Army Research Office [W911NF-10-1-0526]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R21CA182336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS088176] Funding Source: NIH RePORTER	This work was funded by the Pennsylvania Department of Health Commonwealth Universal Research Enhancement Program, the National Institute of Health: 1R21CA182336-01A1, RO1 NS 088176, and the Army Research Office: W911NF-10-1-0526.	Agoston D. V., 2012, FRONTIERS NEUROLOGY, V3; Alvarez ML, 2012, KIDNEY INT, V82, P1024, DOI 10.1038/ki.2012.256; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67; Chen Y., 2014, FRONTIERS NEUROLOGY, V5; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; Chueh BH, 2007, ANAL CHEM, V79, P3504, DOI 10.1021/ac062118p; Chumo B, 2013, BIOMICROFLUIDICS, V7, DOI 10.1063/1.4840575; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; Davis JE, 2004, NEUROCHEM RES, V29, P1113, DOI 10.1023/B:NERE.0000023598.04937.83; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Dudani JS, 2015, BIOMICROFLUIDICS, V9, DOI 10.1063/1.4907807; Faure J, 2006, MOL CELL NEUROSCI, V31, P642, DOI 10.1016/j.mcn.2005.12.003; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Guerriero RM, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0545-1; Gullotti DM, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027873; Huang JH, 2013, NEUROL RES, V35, P221, DOI 10.1179/1743132813Y.0000000178; Im H, 2014, NAT BIOTECHNOL, V32, P490, DOI 10.1038/nbt.2886; Isaac JTR, 2007, NEURON, V54, P859, DOI 10.1016/j.neuron.2007.06.001; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jeter C. B., 2012, INJURY RES THEORIES, P337; Kanwar SS, 2014, LAB CHIP, V14, P1891, DOI 10.1039/c4lc00136b; Kiesel P., 2007, United States patent, Patent No. [US 7, 248-361, 7248361]; Ko J, 2016, ANALYST, V141, P450, DOI 10.1039/c5an01610j; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Linder V, 2005, ANAL CHEM, V77, P64, DOI 10.1021/ac049071x; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Muluneh M, 2014, LAB CHIP, V14, P4638, DOI 10.1039/c4lc00819g; Muluneh M, 2014, ADV HEALTHC MATER, V3, P1078, DOI 10.1002/adhm.201300502; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Patel TP, 2015, J NEUROSCI METH, V243, P26, DOI 10.1016/j.jneumeth.2015.01.020; Patel TP, 2012, ANN BIOMED ENG, V40, P23, DOI 10.1007/s10439-011-0390-6; PellegriniGiampietro DE, 1997, TRENDS NEUROSCI, V20, P464, DOI 10.1016/S0166-2236(97)01100-4; Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103; Shao HL, 2012, NAT MED, V18, P1835, DOI 10.1038/nm.2994; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Son KJ, 2016, ANALYST, V141, P679, DOI 10.1039/c5an01648g; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; Sparvero LJ, 2010, J NEUROCHEM, V115, P1322, DOI 10.1111/j.1471-4159.2010.07055.x; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Taylor DD, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0503; Wang J, 2010, LAB CHIP, V10, P3157, DOI [10.1039/c0lc00132e, 10.1039/c01c00132e]; Wang ZX, 2013, LAB CHIP, V13, P2879, DOI 10.1039/c3lc41343h; Xu ZR, 2008, LAB CHIP, V8, P1658, DOI 10.1039/b805774e; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang P, 2016, LAB CHIP, V16, P3033, DOI 10.1039/c6lc00279j	47	55	55	1	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	AUG 8	2016	6								31215	10.1038/srep31215			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DS8BT	WOS:000381008400001	27498963	gold, Green Published			2022-02-06	
J	Baker, JG; Leddy, JJ; Darling, SR; Shucard, J; Makdissi, M; Willer, BS				Baker, John G.; Leddy, John J.; Darling, Scott R.; Shucard, Jennifer; Makdissi, Michael; Willer, Barry S.			Gender Differences in Recovery From Sports-Related Concussion in Adolescents	CLINICAL PEDIATRICS			English	Article							SEX-DIFFERENCES; SYMPTOMS; INJURY; RELIABILITY		[Baker, John G.; Leddy, John J.; Darling, Scott R.; Shucard, Jennifer; Makdissi, Michael; Willer, Barry S.] Univ Buffalo, Buffalo, NY USA; [Makdissi, Michael] Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia		Baker, JG (corresponding author), Univ Buffalo, Orthoped & Sports Med, 160 Farber Hall, Buffalo, NY 14214 USA.	jgbaker@buffalo.edu		makdissi, michael/0000-0003-0334-7133	Robert Rich Family Foundation; Program for Understanding Childhood Concussion and Stroke; Buffalo Bills (Ralph Wilson) Team Physician Fund; Buffalo Sabres Foundation	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was financially supported by The Robert Rich Family Foundation, Program for Understanding Childhood Concussion and Stroke, Buffalo Bills (Ralph Wilson) Team Physician Fund, and the Buffalo Sabres Foundation.	Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2003, J ATHL TRAINING, V38, P238; Darling SR, 2014, CLIN J SPORT MED, V24, P128, DOI 10.1097/JSM.0000000000000026; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Esposito G, 1996, J NUCL MED, V37, P559; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; King N, 2014, NEUROREHABILITATION, V34, P741, DOI 10.3233/NRE-141072; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; McCrory P, 2009, BRIT J SPORT MED S1, V43, pi85; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Zuckerman SL, 2012, J NEUROSURG-PEDIATR, V10, P504, DOI 10.3171/2012.8.PEDS12139	18	55	55	0	24	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228	1938-2707		CLIN PEDIATR	Clin. Pediatr.	JUL	2016	55	8					771	775		10.1177/0009922815606417			5	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	DP3NV	WOS:000378402500013	26378093				2022-02-06	
J	Kawata, K; Rubin, LH; Lee, JH; Sim, T; Takahagi, M; Szwanki, V; Bellamy, A; Darvish, K; Assari, S; Henderer, JD; Tierney, R; Langford, D				Kawata, Keisuke; Rubin, Leah H.; Lee, Jong Hyun; Sim, Thomas; Takahagi, Masahiro; Szwanki, Victor; Bellamy, Al; Darvish, Kurosh; Assari, Soroush; Henderer, Jeffrey D.; Tierney, Ryan; Langford, Dianne			Association of Football Subconcussive Head Impacts With Ocular Near Point of Convergence	JAMA OPHTHALMOLOGY			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; SPORT-RELATED CONCUSSION; HIGH-SCHOOL; INSTRUMENTED MOUTHGUARD; IN-VIVO; PLAYERS; SYMPTOMS; VERGENCE; EXPOSURE; SYSTEM	IMPORTANCE An increased understanding of the relationship between subconcussive head impacts and near point of convergence (NPC) ocular-motor function may be useful in delineating traumatic brain injury. OBJECTIVE To investigate whether repetitive subconcussive head impacts during preseason football practice cause changes in NPC. DESIGN, SETTING, AND PARTICIPANTS This prospective, observational study of 29 National Collegiate Athletic Association Division I football players included baseline and preseason practices (1 noncontact and 4 contact), and postseason follow-up and outcome measures were obtained for each time. An accelerometer-embedded mouthguard measured head impact kinematics. Based on the sum of head impacts from all 5 practices, players were categorized into lower (n = 7) or higher (n = 22) impact groups. EXPOSURES Players participated in regular practices, and all head impacts greater than 10g from the 5 practices were recorded using the i1Biometerics Vector mouthguard (i1 Biometrics Inc). MAIN OUTCOMES AND MEASURES Near point of convergence measures and symptom scores. RESULTS A total of 1193 head impacts were recorded from 5 training camp practices in the 29 collegiate football players; 22 were categorized into the higher-impact group and 7 into the lower-impact group. There were significant differences in head impact kinematics between lower-and higher-impact groups (number of impacts, 6 vs 41 [lower impact minus higher impact = 35; 95% CI, 21-51; P < .001]; linear acceleration, 99g vs 1112g [lower impact minus higher impact = 1013; 95% CI, 621-1578; P < .001]; angular acceleration, 7589 radian/s(2) vs 65016 radian/s(2) [lower impact minus higher impact = 57 427; 95% CI, 31 123-80 498; P < .001], respectively). The trajectory and cumulative burden of subconcussive impacts on NPC differed by group (F for group x linear trend(1, 238) = 12.14, P < .001 and F for group x quadratic trend(1,) (238) = 12.97, P < .001). In the higher-impact group, there was a linear increase in NPC over time (B for linear trend, unstandardized coefficient [SE]: 0.76[0.12], P < .001) that plateaued and resolved by postseason follow-up (B for quadratic trend [SE]: -0.06[0.008], P < .001). In the lower-impact group, there was no change in NPC over time. Group differences were first observed after the first contact practice and remained until the final full-gear practice. No group differences were observed postseason follow-up. There were no differences in symptom scores between groups over time. CONCLUSIONS AND RELEVANCE Although asymptomatic, these data suggest that repetitive subconcussive head impacts were associated with changes in NPC. The increase in NPC highlights the vulnerability and slow recovery of the ocular-motor system following subconcussive head impacts. Changes in NPC may become a useful clinical tool in deciphering brain injury severity.	[Kawata, Keisuke; Lee, Jong Hyun; Langford, Dianne] Temple Univ, Lewis Katz Sch Med, Dept Neurosci, 3500 N Broad St,Med Educ & Res Bldg, Philadelphia, PA 19140 USA; [Kawata, Keisuke; Sim, Thomas; Tierney, Ryan] Temple Univ, Dept Kinesiol, Philadelphia, PA 19122 USA; [Rubin, Leah H.] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA; [Takahagi, Masahiro; Szwanki, Victor; Bellamy, Al] Temple Univ, Dept Athlet, Philadelphia, PA 19122 USA; [Darvish, Kurosh; Assari, Soroush] Temple Univ, Dept Mech Engn, Philadelphia, PA 19122 USA; [Henderer, Jeffrey D.] Temple Univ, Dept Ophthalmol, Lewis Katz Sch Med, Philadelphia, PA 19122 USA		Langford, D (corresponding author), Temple Univ, Lewis Katz Sch Med, Dept Neurosci, 3500 N Broad St,Med Educ & Res Bldg, Philadelphia, PA 19140 USA.	tdl@temple.edu		Darvish, Kurosh/0000-0002-6674-266X	Pennsylvania Athletic Trainers' Society; seed grant from Temple University Office of the Vice Provost for Research	Dr Kawata received support from a research grant from the Pennsylvania Athletic Trainers' Society. Dr Langford received support from Athole G. Jacobi, MD, the Marianne Garman Burton Foundation for Caregivers, and a seed grant from Temple University Office of the Vice Provost for Research.	Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bartsch Adam, 2014, Stapp Car Crash J, V58, P1; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Hamed MM, 2013, INDIAN J OPHTHALMOL, V61, P325, DOI 10.4103/0301-4738.97553; Hedeker D., 2006, LONGITUDINAL DATA AN; Higgins M, 2007, J ATHL TRAINING, V42, P5; HUNG GK, 1980, IEEE T BIO-MED ENG, V27, P439, DOI 10.1109/TBME.1980.326752; HUNG GK, 1986, DOC OPHTHALMOL, V62, P165, DOI 10.1007/BF00229128; HUNG GK, 1994, INVEST OPHTH VIS SCI, V35, P3486; Hung GK, 1997, VISION RES, V37, P1197, DOI 10.1016/S0042-6989(97)00271-X; Hwang S, 2016, J NEUROTRAUMA; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johnson B, 2015, NEUROLOGY, V85, P1163, DOI 10.1212/WNL.0000000000001968; Johnson B, 2015, BRAIN IMAGING BEHAV, V9, P564, DOI 10.1007/s11682-014-9316-x; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Kawata K, 2016, INT J SPORTS MED; King D, 2015, AM J SPORT MED, V43, P614, DOI 10.1177/0363546514560876; McCrory P, 2013, J SCI MED SPORT, V16, P178, DOI 10.1016/j.jsams.2013.02.009; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Phillips J, 2015, J EYE MOVEMENT RES, V8; Reynolds BB, 2016, J NEUROSURG, V124, P501, DOI 10.3171/2015.5.JNS15573; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Von Noorden GK, 2002, BINOCULAR VISION OCU, V6th; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3	41	55	55	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6165	2168-6173		JAMA OPHTHALMOL	JAMA Ophthalmol.	JUL	2016	134	7					763	769		10.1001/jamaophthalmol.2016.1085			7	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	DR0KA	WOS:000379595200012	27257799	Bronze			2022-02-06	
J	Li, HX; Sun, J; Wang, FY; Ding, GQ; Chen, WQ; Fang, RC; Yao, Y; Pang, MQ; Lu, ZQ; Liu, JM				Li, Haixiao; Sun, Jing; Wang, Fangyan; Ding, Guoqiang; Chen, Wenqian; Fang, Renchi; Yao, Ye; Pang, Mengqi; Lu, Zhong-Qiu; Liu, Jiaming			Sodium butyrate exerts neuroprotective effects by restoring the blood-brain barrier in traumatic brain injury mice	BRAIN RESEARCH			English	Article						Traumatic brain injury; Blood-brain barrier; Sodium butyrate; Neuronal degeneration; Brain oedema	CLOSED-HEAD INJURY; PARKINSONS-DISEASE; RAT MODEL; EDEMA; PERMEABILITY; DISRUPTION; INHIBITION; INTEGRITY; DYSFUNCTION; LEUKOCYTE	Sodium butyrate (SB) has been widely used to treat cerebral diseases. The aim of the present study is to examine the neuroprotective effects of SB on early TBI in mice and to explore the underlying mechanisms of these effects. TBI was induced using a modified weight-drop method. Neurological deficits were evaluated according to the neurological severity score (NSS), brain oedema was measured by brain water content, and blood-brain barrier (BBB) permeability was evaluated by Evans blue (EB) dye extravasation. Neuronal injury was assessed by hematoxylin and eosin (H&E) staining and Fluoro-jade C staining. The expression of tight junction-associated proteins, such as occludin and zonula occludens-1 (ZO-1), was analysed by western blotting and immunofluorescence. Our results showed that mice subjected to TBI exhibited worsened NSS, brain oedema, neuronal damage and BBB permeability. However, these were all attenuated by SB. Moreover, SB reversed the decrease in occludin and ZO-1 expression induced by TBI. These findings suggest that SB might attenuate neurological deficits, brain oedema, neuronal change and BBB damage, as well as increase occludin and ZO-1 expression in the brain to protect against TBI. The protective effect of SB may be correlated with restoring the BBB following its impairment. (C) 2016 Elsevier B.V. All rights reserved.	[Li, Haixiao; Lu, Zhong-Qiu] Wenzhou Med Univ, Dept Emergency Med, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China; [Sun, Jing] Wenzhou Med Univ, Dept Neurol, Affiliated Hosp 2, 109 Coll West Rd, Wenzhou 325027, Zhejiang, Peoples R China; [Wang, Fangyan] Wenzhou Med Univ, Dept Pathophysiol, 1210 Univ Town, Wenzhou 325035, Zhejiang, Peoples R China; [Ding, Guoqiang] Wenzhou Med Univ, Dept Stomatol, Affiliated Yiwu Hosp, Yiwu 322000, Zhejiang, Peoples R China; [Chen, Wenqian; Fang, Renchi; Yao, Ye; Pang, Mengqi; Lu, Zhong-Qiu; Liu, Jiaming] Wenzhou Med Univ, Sch Environm Sci & Publ Hlth, 1210 Univ Town, Wenzhou 325035, Zhejiang, Peoples R China		Lu, ZQ (corresponding author), Wenzhou Med Univ, Dept Emergency Med, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China.; Liu, JM (corresponding author), Wenzhou Med Univ, Sch Environm Sci & Publ Hlth, 1210 Univ Town, Wenzhou 325035, Zhejiang, Peoples R China.			LU, Zhongqiu/0000-0002-0569-4182	Zhejiang Science and Technology Development Funds [2015C37010]; Zhejiang Province Medical and Health Science and Technology Funds [2016136369]	The research was supported by Zhejiang Science and Technology Development Funds (2015C37010), Zhejiang Province Medical and Health Science and Technology Funds (2016136369).	Al-Asmakh M, 2015, TISSUE BARRIERS, V3, DOI 10.1080/21688370.2015.1039691; Alvarez JI, 2011, SCIENCE, V334, P1727, DOI 10.1126/science.1206936; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Bartels AL, 2008, J NEURAL TRANSM, V115, P1001, DOI 10.1007/s00702-008-0030-y; Blixt J, 2015, BRAIN RES, V1611, P18, DOI 10.1016/j.brainres.2015.03.004; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Dash PK, 2009, NEUROSCIENCE, V163, P1, DOI 10.1016/j.neuroscience.2009.06.028; Ding K, 2015, J SURG RES, V194, P239, DOI 10.1016/j.jss.2014.09.026; Fabene PF, 2013, MOL IMMUNOL, V55, P100, DOI 10.1016/j.molimm.2012.12.009; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Friedman A, 2015, SEMIN CELL DEV BIOL, V38, P1, DOI 10.1016/j.semcdb.2015.03.006; Griseri P, 2003, GUT, V52, P1154, DOI 10.1136/gut.52.8.1154; Harrison JL, 2014, EXP BRAIN RES, V232, P2709, DOI 10.1007/s00221-014-3948-3; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hurst RD, 1999, NEUROCHEM INT, V35, P261, DOI 10.1016/S0197-0186(99)00069-8; Istvan Pregun, 2007, Orvosi Hetilap, V148, P923, DOI 10.1556/OH.2007.27995; Janigro D, 2012, EPILEPSIA, V53, P26, DOI 10.1111/j.1528-1167.2012.03472.x; Katz PS, 2015, J NEUROTRAUM, V32, P297, DOI 10.1089/neu.2014.3508; Kotunia A., 2004, J PHYSIOL PHARMACOL, V55, P559; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; Li SS, 2015, NEUROPSYCH DIS TREAT, V11, P1573, DOI 10.2147/NDT.S65816; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; Lu M, 2012, CLIN EXP PHARMACOL P, V39, P577, DOI 10.1111/j.1440-1681.2011.05650.x; Lucke-Wold BP, 2015, MOL NEUROBIOL, V52, P1119, DOI 10.1007/s12035-014-8902-7; Luh C, 2010, J NEUROCHEM, V112, P1015, DOI 10.1111/j.1471-4159.2009.06514.x; Lundblad C, 2004, J NEUROTRAUM, V21, P741, DOI 10.1089/0897715041269614; Ma X, 2012, J ANIM SCI, V90, P266, DOI 10.2527/jas.50965; Mark KS, 2002, AM J PHYSIOL-HEART C, V282, pH1485, DOI 10.1152/ajpheart.00645.2001; Moretti R, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00040; Mustafa AG, 2013, NEUROSCIENCES, V18, P222; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; QUARLESS SA, 1987, MOL BRAIN RES, V2, P235, DOI 10.1016/0169-328X(87)90030-1; Ragaisis Vytautas, 2002, Medicina (Kaunas), V38, P243; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schwarzmaier SM, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00358; Shelef, 2011, CARDIOVASC PSYCHIAT, V2011, DOI [DOI 10.1155/2011/765923, 10.1155/2011/765923]; Shi H, 2015, CNS NEUROSCI THER, V21, P374, DOI 10.1111/cns.12366; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Si DW, 2014, EXP THER MED, V8, P1010, DOI 10.3892/etm.2014.1840; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Sun J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/395895; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Varela RB, 2015, J PSYCHIATR RES, V61, P114, DOI 10.1016/j.jpsychires.2014.11.003; Wang HB, 2012, DIGEST DIS SCI, V57, P3126, DOI 10.1007/s10620-012-2259-4; Wang ZF, 2011, J CEREBR BLOOD F MET, V31, P52, DOI 10.1038/jcbfm.2010.195; Wen JF, 2014, EXP THER MED, V8, P881, DOI 10.3892/etm.2014.1818; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Yu Qiong, 2011, Front Biosci (Elite Ed), V3, P978; Zhao YZ, 2015, NEURAL REGEN RES, V10, P1076, DOI 10.4103/1673-5374.160097	54	55	56	2	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 1	2016	1642						70	78		10.1016/j.brainres.2016.03.031			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DP7EI	WOS:000378661600008	27017959				2022-02-06	
J	Debski, KJ; Pitkanen, A; Puhakka, N; Bot, AM; Khurana, I; Harikrishnan, KN; Ziemann, M; Kaspi, A; El-Osta, A; Lukasiuk, K; Kobow, K				Debski, Konrad J.; Pitkanen, Asla; Puhakka, Noora; Bot, Anna M.; Khurana, Ishant; Harikrishnan, K. N.; Ziemann, Mark; Kaspi, Antony; El-Osta, Assam; Lukasiuk, Katarzyna; Kobow, Katja			Etiology matters - Genomic DNA Methylation Patterns in Three Rat Models of Acquired Epilepsy	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; DIFFERENTIAL EXPRESSION ANALYSIS; EPIGENETIC MECHANISMS; PROMOTER METHYLATION; STATUS EPILEPTICUS; MESSENGER-RNA; GENE LISTS; EPILEPTOGENESIS; ISSUES; MEMORY	This study tested the hypothesis that acquired epileptogenesis is accompanied by DNA methylation changes independent of etiology. We investigated DNA methylation and gene expression in the hippocampal CA3/dentate gyrus fields at 3 months following epileptogenic injury in three experimental models of epilepsy: focal amygdala stimulation, systemic pilocarpine injection, or lateral fluid-percussion induced traumatic brain injury (TBI) in rats. In the models studies, DNA methylation and gene expression profiles distinguished controls from injured animals. We observed consistent increased methylation in gene bodies and hypomethylation at non-genic regions. We did not find a common methylation signature in all three different models and few regions common to any two models. Our data provide evidence that genome-wide alteration of DNA methylation signatures is a general pathomechanism associated with epileptogenesis and epilepsy in experimental animal models, but the broad pathophysiological differences between models (i.e. pilocarpine, amygdala stimulation, and post-TBI) are reflected in distinct etiology-dependent DNA methylation patterns.	[Debski, Konrad J.; Bot, Anna M.; Lukasiuk, Katarzyna] Polish Acad Sci, M Nencki Inst Expt Biol, Dept Mol & Cellular Neurobiol, Lab Epileptogenesis, Warsaw, Poland; [Pitkanen, Asla; Puhakka, Noora] Univ Eastern Finland, Epilepsy Res Lab, AI Virtanen Inst Mol Sci, POB 1627, FIN-70211 Kuopio, Finland; [Khurana, Ishant; Harikrishnan, K. N.; Ziemann, Mark; Kaspi, Antony; El-Osta, Assam] Alfred Med Res & Educ Precinct, Baker IDI Heart & Diabet Inst, Epigenet Human Hlth & Dis, Melbourne, Vic, Australia; [Kobow, Katja] Univ Hosp Erlangen, Dept Neuropathol, Schwabachanlage 6, D-91054 Erlangen, Germany		Kobow, K (corresponding author), Univ Hosp Erlangen, Dept Neuropathol, Schwabachanlage 6, D-91054 Erlangen, Germany.	katja.kobow@uk-erlangen.de	Lukasiuk, Katarzyna/F-4636-2010; Ziemann, Mark Daniel/AAE-8466-2019	Kaspi, Antony/0000-0001-6576-5862; El-Osta, Assam/0000-0001-7968-7375; Lukasiuk, Katarzyna/0000-0002-1582-0920; Debski, Konrad/0000-0001-5949-9211; Khurana, Ishant/0000-0001-9050-2749; Ziemann, Mark/0000-0002-7688-6974; El-Osta, Assam/0000-0003-2969-9137; Bot, Anna/0000-0003-1811-3647	Polish Ministry of Science and Higher EducationMinistry of Science and Higher Education, Poland [888/N-ESF-EuroEPINOMICS/10/2011/0]; National Science Centre, PolandNational Science Centre, Poland [2014/13/N/NZ2/00587]; Academy of Finland ESF-EuroEPINOMICS/grantAcademy of Finland; University of Eastern Finland Spearhead Funding; German Research Foundation (DFG) within the EUROCORES Programme EuroEPINOMICS/EpiGENet of the European Science Foundation [BL 421/3-1]	This work was supported by Polish Ministry of Science and Higher Education grant 888/N-ESF-EuroEPINOMICS/10/2011/0 (AB, KD, KL); the National Science Centre, Poland grant 2014/13/N/NZ2/00587 (KD); the Academy of Finland ESF-EuroEPINOMICS/2012 grant (AP), the University of Eastern Finland Spearhead Funding (AP); and the German Research Foundation (DFG, grant BL 421/3-1) within the EUROCORES Programme EuroEPINOMICS/EpiGENet of the European Science Foundation (KK).	Belhedi N, 2014, EPILEPSY RES, V108, P144, DOI 10.1016/j.eplepsyres.2013.10.007; Curia G, 2008, J NEUROSCI METH, V172, P143, DOI 10.1016/j.jneumeth.2008.04.019; Galanopoulou AS, 2012, EPILEPSIA, V53, P571, DOI 10.1111/j.1528-1167.2011.03391.x; Golzenleuchter M, 2015, EPIGENETICS-US, V10, P200, DOI 10.1080/15592294.2015.1006493; Guzik-Kornacka A, 2011, ACTA NEUROBIOL EXP, V71, P193; Hayward NMEA, 2010, J NEUROTRAUM, V27, P2203, DOI 10.1089/neu.2010.1448; Karolchik D, 2004, NUCLEIC ACIDS RES, V32, pD493, DOI 10.1093/nar/gkh103; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kobow K, 2014, PROG BRAIN RES, V213, P279, DOI 10.1016/B978-0-444-63326-2.00014-4; Kobow K, 2013, ACTA NEUROPATHOL, V126, P741, DOI 10.1007/s00401-013-1168-8; Kobow K, 2013, EPILEPSIA, V54, P41, DOI 10.1111/epi.12183; Kobow K, 2009, J NEUROPATH EXP NEUR, V68, P356, DOI 10.1097/NEN.0b013e31819ba737; Kolde Raivo, 2015, F1000Res, V4, P574, DOI 10.12688/f1000research.6925.1; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Laxer KD, 2014, EPILEPSY BEHAV, V37, P59, DOI 10.1016/j.yebeh.2014.05.031; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp324, 10.1093/bioinformatics/btp100]; Lim ASP, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004792; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Loscher W, 2013, NAT REV DRUG DISCOV, V12, P757, DOI 10.1038/nrd4126; Lukasiuk K, 2006, PROG BRAIN RES, V158, P223, DOI 10.1016/S0079-6123(06)58011-2; Machnes ZM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076299; Malousi A, 2012, MOL GENET GENOMICS, V287, P631, DOI 10.1007/s00438-012-0703-y; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Miller-Delaney SFC, 2015, BRAIN, V138, P616, DOI 10.1093/brain/awu373; Miller-Delaney SFC, 2012, J NEUROSCI, V32, P1577, DOI 10.1523/JNEUROSCI.5180-11.2012; Murphy GG, 2013, EPILEPSY CURR, V13, P26, DOI 10.5698/1535-7511-13.1.26; Ngugi AK, 2010, EPILEPSIA, V51, P883, DOI 10.1111/j.1528-1167.2009.02481.x; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Oberdoerffer S, 2012, TRANSCR-AUSTIN, V3, P106, DOI 10.4161/trns.19816; Parrish RR, 2015, ANN CLIN TRANSL NEUR, V2, P401, DOI 10.1002/acn3.183; Parrish RR, 2013, NEUROSCIENCE, V248, P602, DOI 10.1016/j.neuroscience.2013.06.029; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pirola L, 2011, GENOME RES, V21, P1601, DOI 10.1101/gr.116095.110; Pitkanen A, 2013, EPILEPSIA, V54, P35, DOI 10.1111/epi.12297; Pitkanen A, 2011, NEUROSCI LETT, V497, P163, DOI 10.1016/j.neulet.2011.02.033; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; R Core Team, 2013, GPLOTS VAR R PROGR T; R Development Core Team, 2012, R LANG ENV STAT COMP; Reimand J, 2007, NUCLEIC ACIDS RES, V35, pW193, DOI 10.1093/nar/gkm226; Reimand J, 2011, NUCLEIC ACIDS RES, V39, pW307, DOI 10.1093/nar/gkr378; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rodrigues GM, 2015, BEHAV BRAIN RES, V279, P123, DOI 10.1016/j.bbr.2014.11.023; Roopra A, 2012, EPILEPSIA, V53, P2, DOI 10.1111/epi.12030; Sati S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031621; Schor IE, 2013, EMBO J, V32, P2264, DOI 10.1038/emboj.2013.167; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Simonato M, 2014, LANCET NEUROL, V13, P949, DOI 10.1016/S1474-4422(14)70076-6; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Urdinguio RG, 2009, LANCET NEUROL, V8, P1056, DOI 10.1016/S1474-4422(09)70262-5; Williams-Karnesky RL, 2013, J CLIN INVEST, V123, P3552, DOI 10.1172/JCI65636; Xiao YH, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0086344, 10.1371/journal.pone.0095875]; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhu Q, 2012, J MOL NEUROSCI, V46, P420, DOI 10.1007/s12031-011-9602-7	55	55	56	0	13	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	2045-2322			SCI REP-UK	Sci Rep	MAY 9	2016	6								25668	10.1038/srep25668			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DL1WD	WOS:000375422600001	27157830	Green Published, Green Submitted, gold			2022-02-06	
J	Fralick, M; Thiruchelvam, D; Tien, HC; Redelmeier, DA				Fralick, Michael; Thiruchelvam, Deva; Tien, Homer C.; Redelmeier, Donald A.			Risk of suicide after a concussion	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Article							TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; EMERGENCY-DEPARTMENT; WEEKEND WARRIOR; POPULATION; MORTALITY; HEALTH; PREVENTION; ONTARIO; SYMPTOMS	Background: Head injuries have been associated with subsequent suicide among military personnel, but outcomes after a concussion in the community are uncertain. We assessed the long-term risk of suicide after concussions occurring on weekends or weekdays in the community. Methods: We performed a longitudinal cohort analysis of adults with diagnosis of a concussion in Ontario, Canada, from Apr. 1, 1992, to Mar. 31, 2012 (a 20-yr period), excluding severe cases that resulted in hospital admission. The primary outcome was the long-term risk of suicide after a weekend or weekday concussion. Results: We identified 235 110 patients with a concussion. Their mean age was 41 years, 52% were men, and most (86%) lived in an urban location. A total of 667 subsequent suicides occurred over a median follow-up of 9.3 years, equivalent to 31 deaths per 100 000 patients annually or 3 times the population norm. Weekend concussions were associated with a one-third further increased risk of suicide compared with weekday concussions (relative risk 1.36, 95% confidence interval 1.14-1.64). The increased risk applied regardless of patients' demographic characteristics, was independent of past psychiatric conditions, became accentuated with time and exceeded the risk among military personnel. Half of these patients had visited a physician in the last week of life. Interpretation: Adults with a diagnosis of concussion had an increased long-term risk of suicide, particularly after concussions on weekends. Greater attention to the long-term care of patients after a concussion in the community might save lives because deaths from suicide can be prevented.	[Fralick, Michael; Redelmeier, Donald A.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Fralick, Michael; Thiruchelvam, Deva; Tien, Homer C.; Redelmeier, Donald A.] Sunnybrook Res Inst, Evaluat Clin Sci, Toronto, ON, Canada; [Thiruchelvam, Deva] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Tien, Homer C.] Canadian Forces Hlth Serv, Toronto, ON, Canada		Redelmeier, DA (corresponding author), Univ Toronto, Dept Med, Toronto, ON, Canada.; Redelmeier, DA (corresponding author), Sunnybrook Res Inst, Evaluat Clin Sci, Toronto, ON, Canada.	dar@ices.on.ca			Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) Funding Source: Medline		Aldridge D, 2012, COMPREHENSIVE GUIDE; Alter DA, 2011, HEALTH AFFAIR, V30, P274, DOI 10.1377/hlthaff.2009.0669; [Anonymous], 2014, HLTH TRENDS ONT; [Anonymous], 2012, GLOB HLTH OBS GHO DA; Ardal S, 2012, HLTH ANAL TOOLKIT; Armstrong J. S., 2001, PRINCIPLES FORECASTI; Bahraini NH, 2013, BRAIN IMPAIR, V14, P92, DOI 10.1017/BrImp.2013.11; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Beghi M, 2013, NEUROPSYCH DIS TREAT, V9, P1725, DOI 10.2147/NDT.S40213; Bell CM, 2001, NEW ENGL J MED, V345, P663, DOI 10.1056/NEJMsa003376; Bogaert L, 2013, SUICIDE CANADIAN FOR; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Burke MJ, 2015, BRAIN INJURY, V29, P300, DOI 10.3109/02699052.2014.974673; Carroll CP, 2012, NEUROSURGERY, V71, P1064, DOI 10.1227/NEU.0b013e31826f7c16; [Centers for Disease Control and Prevention National Center for Injury Prevention and Control], 2010, WEB BAS INJ STAT QUE; Chambers A, 2015, AM J PUBLIC HEALTH, V105, P338, DOI 10.2105/AJPH.2014.302223; Colantonio A, 2012, WORK, V43, P195, DOI 10.3233/WOR-2012-1377; Colantonio A, 2009, BRAIN INJURY, V23, P873, DOI 10.1080/02699050903036033; Croxford R., 2006, CANADIAN I HLTH INFO; Cunningham J, 2011, J EMERG MED, V40, P262, DOI 10.1016/j.jemermed.2008.08.017; DeMatteo CA, 2010, PEDIATRICS, V125, P327, DOI 10.1542/peds.2008-2720; Dwiggins George A, 2002, Appl Occup Environ Hyg, V17, P237, DOI 10.1080/10473220252826510; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Fallucco EM, 2010, PEDIATRICS, V125, P953, DOI 10.1542/peds.2009-2135; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Festinger L., 1957, THEORY COGNITIVE DIS; Finkelstein Y, 2015, JAMA PSYCHIAT, V72, P570, DOI 10.1001/jamapsychiatry.2014.3188; Fotuhi O, 2013, TOB CONTROL, V22, P52, DOI 10.1136/tobaccocontrol-2011-050139; Fralick M, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6196; Freijy T, 2013, BRIT J HEALTH PSYCH, V18, P310, DOI 10.1111/bjhp.12035; Gjertsen F, 2011, J CLIN EPIDEMIOL, V64, P1102, DOI 10.1016/j.jclinepi.2010.12.015; Glazier RH, 2003, CAN J PUBLIC HEALTH, V94, P140, DOI 10.1007/BF03404588; Gonda Xenia, 2007, Ann Gen Psychiatry, V6, P23, DOI 10.1186/1744-859X-6-23; Gosling P, 2006, J PERS SOC PSYCHOL, V90, P722, DOI 10.1037/0022-3514.90.5.722; GRIMBLE S, 1993, ARCH EMERG MED, V10, P203; Haegerich TM, 2014, LANCET, V384, P64, DOI 10.1016/S0140-6736(14)60074-X; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harris EC, 1997, BRIT J PSYCHIAT, V170, P205, DOI 10.1192/bjp.170.3.205; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Hawton K, 2009, LANCET, V373, P1372, DOI 10.1016/S0140-6736(09)60372-X; Henry DA., 2012, PAYMENTS ONTARIO PHY; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Ilie G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094936; Improving health care data in Ontario, 2005, IMPR HLTH CAR DAT ON; Iron K., 2008, LIVING DYING ONTARIO; Ivens UI, 1998, AM J IND MED, V33, P182; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Keshavarz Homa, 2013, CMAJ Open, V1, pE159, DOI 10.9778/cmajo.20130030; King D, 2014, SPORTS MED, V44, P449, DOI 10.1007/s40279-013-0134-x; Kisely S, 2013, CAN MED ASSOC J, V185, pE50, DOI 10.1503/cmaj.121077; Korngold C, 2013, J AM ACAD PSYCHIATRY, V41, P430; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; LeardMann CA, 2013, JAMA-J AM MED ASSOC, V310, P1076, DOI 10.1001/jama.2013.276547; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Li ZY, 2011, SOC SCI MED, V72, P608, DOI 10.1016/j.socscimed.2010.11.008; Links PS, 2011, CAN MED ASSOC J, V183, P1987, DOI 10.1503/cmaj.111008; Lombardi DA, 2003, J OCCUP ENVIRON MED, V45, P832, DOI 10.1097/01.jom.0000083030.56116.1a; Macpherson AK., 2005, INJURIES ONTARIO ICE; Mann JJ, 2005, JAMA-J AM MED ASSOC, V294, P2064, DOI 10.1001/jama.294.16.2064; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Morrish J, 2013, CANADA INJURY COMPAS; Mustard CA, 2010, CAN J PSYCHIAT, V55, P369, DOI 10.1177/070674371005500606; Nishri ED, 2015, INT J CANCER, V136, P639, DOI 10.1002/ijc.29024; Nock MK, 2008, EPIDEMIOL REV, V30, P133, DOI 10.1093/epirev/mxn002; Oquendo MA, 2014, AM J PSYCHIAT, V171, P1259, DOI 10.1176/appi.ajp.2014.14020194; Parai JL, 2006, ANN EPIDEMIOL, V16, P805, DOI 10.1016/j.annepidem.2006.01.006; Pernin C.G., 2011, WAR PREVENTING SUICI; Peskind ER, 2013, J CLIN PSYCHIAT, V74, P180, DOI 10.4088/JCP.12011co1c; Pompili M, 2014, WORLD J PSYCHIATR, V4, P141, DOI 10.5498/wjp.v4.i4.141; Posner K, 2011, AM J PSYCHIAT, V168, P1266, DOI 10.1176/appi.ajp.2011.10111704; Psoinos CM, 2012, J TRAUMA ACUTE CARE, V73, P469, DOI 10.1097/TA.0b013e318258437c; Ratnasingham S, 2013, CAN J PSYCHIAT, V58, P529; REDELMEIER DA, 1990, NEW ENGL J MED, V322, P1162, DOI 10.1056/NEJM199004193221620; Redelmeier DA, 2007, NEW ENGL J MED, V356, P1164, DOI 10.1056/NEJMe068310; Roberts DJ, 2014, CAN J SURG, V57, pE62, DOI 10.1503/cjs.030812; Ronquillo L, 2012, J EMERG MED, V43, P836, DOI 10.1016/j.jemermed.2012.08.015; Ross L., 2011, PERSON SITUATION PER; Rychetnik L, 2002, J EPIDEMIOL COMMUN H, V56, P119, DOI 10.1136/jech.56.2.119; Sedgwick P., 2010, BMJ-BRIT MED J, V341, pc4804, DOI [10.1136/bmj.c4804, DOI 10.1136/BMJ.C4804]; Shore AD, 2005, BRAIN INJURY, V19, P613, DOI 10.1080/02699050400013568; Shuchman M, 2014, CAN MED ASSOC J, V186, pE532, DOI 10.1503/cmaj.109-4897; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Skinner R, 2012, CAN MED ASSOC J, V184, P1029, DOI 10.1503/cmaj.111867; Statistics Canada, 2014, SUIC SUIC RAT SEX AG; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Suokas J, 2001, ACTA PSYCHIAT SCAND, V104, P117, DOI 10.1034/j.1600-0447.2001.00243.x; Tator CH, 2013, CAN MED ASSOC J, V185, P975, DOI 10.1503/cmaj.120039; TAYLOR SE, 1990, AM PSYCHOL, V45, P40, DOI 10.1037/0003-066X.45.1.40; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thomas KH, 2013, BRIT J CLIN PHARMACO, V76, P145, DOI 10.1111/bcp.12059; Van Orden KA, 2010, PSYCHOL REV, V117, P575, DOI 10.1037/a0018697; Wenzel A, 2011, J AFFECT DISORDERS, V132, P375, DOI 10.1016/j.jad.2011.03.006; West TA, 2014, J NEUROTRAUM, V31, P159, DOI 10.1089/neu.2013.3031; WHO, 2011, INT STAT CLASS DIS R; Wilkins R, 1993, Health Rep, V5, P157; Wilkins R, 2004, AUTOMATED GEOGRAPHIC; Williams JI, 1996, PATTERNS HLTH CARE O; Wilson A, 2010, DEATH STUD, V34, P625, DOI 10.1080/07481181003761567; World Health Organization, 1997, INT CLASS DIS	106	55	55	0	14	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0820-3946	1488-2329		CAN MED ASSOC J	Can. Med. Assoc. J.	APR 19	2016	188	7					497	504		10.1503/cmaj.150790			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	DK3BQ	WOS:000374790500014	26858348	Green Published, gold			2022-02-06	
J	Howell, DR; Mannix, RC; Quinn, B; Taylor, JA; Tan, CO; Meehan, WP				Howell, David R.; Mannix, Rebekah C.; Quinn, Bridget; Taylor, J. Andrew; Tan, Can Ozan; Meehan, William P., III			Physical Activity Level and Symptom Duration Are Not Associated After Concussion	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						brain concussion; mild traumatic brain injury; physical activity; rehabilitation	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; HEAD-DOWN-TILT; HIGH-SCHOOL; POSTCONCUSSION SYNDROME; PROLONGED RECOVERY; PREDICTORS; EXERCISE; ADOLESCENTS; RETURN	Background: Physical rest after a concussion has been described as a key component in the management of the injury. Evidence supporting this recommendation, however, is limited. Purpose: To examine the association between physical activity and symptom duration in a cohort of patients after a concussion. Study Design: Cohort study; Level of evidence, 2. Methods: This study included 364 patients who were diagnosed with a concussion, were seen by a physician within 3 weeks of injury, and completed a questionnaire at the initial clinic visit. The questionnaire assessed the postconcussion symptom scale (PCSS) score, previous number of concussions, presence of the loss of consciousness or amnesia at the time of injury, and prior treatment for headaches. During each follow-up clinic visit, physical activity level was self-reported. A Cox proportional hazard model was constructed to determine the association between symptom duration, initial clinic visit responses, and self-reported physical activity level after the injury. Results: Study participants ranged in age from 8 to 27 years (mean age, 15.0 years) and had sustained a mean of 0.8 prior concussions; 222 patients (61%) were male. On initial examination, the mean PCSS score was 34.7. The mean symptom duration was 48.9 days after the injury. Among the variables included in the model, initial PCSS score and female sex were independently associated with symptom duration, while physical activity level after the injury was not. For participants aged between 13 and 18 years, however, higher levels of physical activity after the injury were associated with a shorter symptom duration. Conclusion: Results from this study indicate that physical activity after the injury may not be universally detrimental to the recovery of concussion symptoms.	[Howell, David R.; Mannix, Rebekah C.; Quinn, Bridget; Taylor, J. Andrew; Tan, Can Ozan; Meehan, William P., III] Boston Childrens Hosp, Dept Orthopaed, Div Sports Med, Sports Concuss Clin, Boston, MA USA; [Howell, David R.; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, 9 Hope Ave,Suite 100, Waltham, MA 02453 USA; [Howell, David R.; Mannix, Rebekah C.] Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA; [Mannix, Rebekah C.; Meehan, William P., III] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Mannix, Rebekah C.; Meehan, William P., III] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Taylor, J. Andrew; Tan, Can Ozan] Spaulding Hosp Cambridge, Cardiovasc Res Lab, Cambridge, MA USA; [Taylor, J. Andrew; Tan, Can Ozan] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Meehan, William P., III] Harvard Univ, Sch Med, Dept Orthopaed, Boston, MA USA		Howell, DR (corresponding author), Micheli Ctr Sports Injury Prevent, 9 Hope Ave,Suite 100, Waltham, MA 02453 USA.	David.Howell2@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020; Tan, Can Ozan/E-2598-2016	Tan, Can Ozan/0000-0001-9673-9907; Howell, David/0000-0002-2955-0191; Taylor, J Andrew/0000-0003-2802-4330	National Football League Players Association; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER	One or more of the authors has declared the following potential conflict of interest or source of funding: W.P.M. receives publishing royalties from ABC-Clio and Wolters Kluwer. He is under contract with ABC-Clio for a future book entitled Concussions and with Springer International for a future book entitled Head and Neck Injuries in Young Athletes. His research is funded in part by a grant from the National Football League Players Association and by philanthropic support from the National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament.	Bailey DM, 2013, CLIN SCI, V124, P177, DOI 10.1042/CS20120259; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Broglio SP, 2015, CLIN SPORT MED, V34, P213, DOI 10.1016/j.csm.2014.12.005; Brown DA, 2015, SPORTS MED, V45, P1027, DOI 10.1007/s40279-015-0335-6; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Carson JD, 2014, CAN FAM PHYSICIAN, V60, pE310; Chan ST, 2009, BRAIN RES, V1291, P53, DOI 10.1016/j.brainres.2009.07.057; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Dougan BK, 2014, J INT NEUROPSYCH SOC, V20, P64, DOI 10.1017/S1355617712001464; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gibson TB, 2015, JAMA PEDIATR, V169, P163, DOI 10.1001/jamapediatrics.2014.2320; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Hilz MJ, 2011, J NEUROTRAUM, V28, P1727, DOI 10.1089/neu.2010.1497; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; KAWAI Y, 1993, J APPL PHYSIOL, V74, P3046, DOI 10.1152/jappl.1993.74.6.3046; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; LEDDY MH, 1994, RES Q EXERCISE SPORT, V65, P347, DOI 10.1080/02701367.1994.10607639; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Moser RS, 2015, BRAIN INJURY, V29, P58, DOI 10.3109/02699052.2014.964771; Ocon AJ, 2009, AM J PHYSIOL-HEART C, V297, pH2084, DOI 10.1152/ajpheart.00705.2009; Powers KC, 2014, GAIT POSTURE, V39, P611, DOI 10.1016/j.gaitpost.2013.05.026; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Simon L, 2015, DETECTING MULTICOLLI; Tan CO, 2014, NEUROLOGY, V83, P1665, DOI 10.1212/WNL.0000000000000944; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Tsushima WT, 2009, BRAIN INJURY, V23, P809, DOI 10.1080/02699050903200530; Zhang R, 1997, J APPL PHYSIOL, V83, P2139, DOI 10.1152/jappl.1997.83.6.2139	40	55	56	0	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	APR	2016	44	4					1040	1046		10.1177/0363546515625045			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	DI7FX	WOS:000373665800034	26838933	Green Accepted			2022-02-06	
J	Jourdan, C; Bayen, E; Pradat-Diehl, P; Ghout, I; Darnoux, E; Azerad, S; Vallat-Azouvi, C; Charanton, J; Aegerter, P; Ruet, A; Azouvi, P				Jourdan, C.; Bayen, E.; Pradat-Diehl, P.; Ghout, I.; Darnoux, E.; Azerad, S.; Vallat-Azouvi, C.; Charanton, J.; Aegerter, P.; Ruet, A.; Azouvi, P.			A comprehensive picture of 4-year outcome of severe brain injuries. Results from the PariS-TBI study	ANNALS OF PHYSICAL AND REHABILITATION MEDICINE			English	Article						Brain injuries; Craniocerebral trauma; Quality of life; International classification of functioning, disability and health	QUALITY-OF-LIFE; SEVERE HEAD-INJURY; FOLLOW-UP; PROGNOSTIC-FACTORS; DEPRESSION SCALE; HOSPITAL ANXIETY; PRACTICAL SCALE; COHORT; VALIDITY; MODERATE	Objectives: Survivors of severe traumatic brain injury have a great variety of impairments and participation restrictions. Detailed descriptions of their long-term outcome are critical. We aimed to assess brain injury outcome for subjects with traumatic brain injury in terms of the International classification of functioning, disability and health. Materials and methods: Four-year follow-up of an inception cohort of adults with severe traumatic brain injury by using face-to-face interviews with patients and proxies. Results: Among 245 survivors at 4 years, 147 were evaluated (80% male, mean age: 32.5 +/- 14.2 years at injury); 46 (32%) presented severe disability, 58 (40%) moderate disability, and 40 (28%) good recovery. Most frequent somatic problems were fatigue, headaches, other pain, and balance. One quarter of subjects had motor impairments. Rates of cognitive complaints ranged from 25 to 68%, the most frequent being memory, irritability, slowness and concentration. With the Hospital Anxiety and Depression Scale, 43% had anxiety and 25% depression. Overall, 79% were independent in daily living activities and 40 to 50% needed help for outdoor or organizational activities on the BICRO-39. Most had regular contacts with relatives or close friends but few contacts with colleagues or new acquaintances. Subjects spent little time in productive activities such as working, studying, looking after children or voluntary work. Quality of life on the QOLIBRI scale was associated with disability level (P < 0.0001). Conclusion: Management of late brain injury needs to focus on cognitive difficulties, particularly social skills, to enhance patient participation in life. (C) 2015 Elsevier Masson SAS. All rights reserved.	[Jourdan, C.; Vallat-Azouvi, C.; Ruet, A.; Azouvi, P.] Hop Raymond Poincare, AP HP, Dept Med Phys & Readaptat, 104 Blvd Raymond Poincare, F-92380 Garches, France; [Jourdan, C.; Azouvi, P.] Univ Versailles St Quentin, UFR Sci Sante Simone Veil, HANDIReSP EA 4047, 2 Ave Source de la Bievre, F-78180 Montigny Le Bretonneux, France; [Bayen, E.] Univ Paris 09, Lab Econ & Gest Org Sante LEDa LEGOS, F-75016 Paris, France; [Bayen, E.; Pradat-Diehl, P.; Vallat-Azouvi, C.] Univ Paris 06, F-75005 Paris, France; [Bayen, E.; Pradat-Diehl, P.] Hop Univ Pitie Salpetriere Charles Foix, AP HP, Serv Med Phys & Readaptat, F-75013 Paris, France; [Ghout, I.; Darnoux, E.; Azerad, S.; Aegerter, P.] Hop Ambroise Pare, AP HP, URC, F-92012 Boulogne, France; [Vallat-Azouvi, C.] Hop Raymond Poincare, Antenne UEROS UGECAM IDF SAMSAH92, F-92380 Garches, France; [Charanton, J.] CRFTC, F-75014 Paris, France; [Aegerter, P.] Univ Versailles St Quentin, UMR S 1168, UFR Sci Sante Simone Veil, 2 Ave Source de la Bievre, F-78180 Montigny Le Bretonneux, France		Jourdan, C (corresponding author), Hop Raymond Poincare, AP HP, Dept Med Phys & Readaptat, 104 Blvd Raymond Poincare, F-92380 Garches, France.	claire.jourdan@rpc.aphp.fr	RUET, Alexis/L-8726-2015; AEGERTER, Philippe/AAY-6003-2021	RUET, Alexis/0000-0002-5080-5734; AEGERTER, Philippe/0000-0002-9156-5028	French Ministry of Health (Programme hospitalier de recherche clinique) [AOM04084]; AP-HP (Departement de la recherche clinique et du developpement); Institut de recherche en sante publique (IRESP)	The authors thank all members of the CRFTC Steering Committee (Centre ressource francilien des traumatises craniens) for their valuable help. The first part of this study was funded by a grant from the French Ministry of Health (Programme hospitalier de recherche clinique 2004, AOM04084) and sponsored by AP-HP (Departement de la recherche clinique et du developpement). The second part of this study was funded by a grant from the Institut de recherche en sante publique (IRESP).	Andelic N, 2014, PM&R, V6, P1013, DOI 10.1016/j.pmrj.2014.05.005; Azerad S., 2014, NEUROPSYCHOL REHABIL, V18, P1; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Bayen E, 2014, J HEAD TRAUMA REHABI; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Fayol P., 2004, Annales de Readaptation et de Medecine Physique, V47, P142, DOI 10.1016/j.annrmp.2004.01.004; Hours M, 2010, ACCIDENT ANAL PREV, V42, P412, DOI 10.1016/j.aap.2009.09.002; Jacobsson LJ, 2009, ACTA NEUROL SCAND, V120, P389, DOI 10.1111/j.1600-0404.2009.01238.x; Jaeger M., 2014, Annals of Physical and Rehabilitation Medicine, V57, P436, DOI 10.1016/j.rehab.2014.06.001; JENNETT B, 1975, LANCET, V1, P480; Jourdan C, 2013, BRAIN INJURY, V27, P1000, DOI 10.3109/02699052.2013.794971; Jourdan C, 2015, J HEAD TRAUMA REHABI; Jourdan C, 2015, BRAIN INJURY, V29, P701, DOI 10.3109/02699052.2015.1004646; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; MAHONEY F I, 1965, Md State Med J, V14, P61; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mazaux JM, 2002, ACT NEUR S, V79, P49; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; Nash S., 2014, Annals of Physical and Rehabilitation Medicine, V57, P600, DOI 10.1016/j.rehab.2014.08.010; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Peeters W, 2015, ACTA NEUROCHIR WIEN; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; Pradat-Diehl P., 2012, Annals of Physical and Rehabilitation Medicine, V55, P546, DOI 10.1016/j.rehab.2012.07.002; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; TEASDALE G, 1974, LANCET, V2, P81; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; Ubukata S, 2014, NEUROPSYCH DIS TREAT, V10, P2061, DOI 10.2147/NDT.S68156; Vallat-Azouvi C, PRM SOFMER 2015 MONT; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1016/S0003-9993(00)90114-X; von Steinbuechel N, 2012, J NEUROL NEUROSUR PS, V83, P1041, DOI 10.1136/jnnp-2012-302361; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	42	55	56	0	5	ELSEVIER MASSON	MILANO	VIA PALEOCAPA 7, 20121 MILANO, ITALY	1877-0657	1877-0665		ANN PHYS REHABIL MED	Ann. Phys. Rehabil. Med.	APR	2016	59	2					100	106		10.1016/j.rehab.2015.10.009			7	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	FO5OL	WOS:000416909600005	26704071	hybrid			2022-02-06	
J	Wright, AD; Jarrett, M; Vavasour, I; Shahinfard, E; Kolind, S; van Donkelaar, P; Taunton, J; Li, D; Rauscher, A				Wright, Alexander D.; Jarrett, Michael; Vavasour, Irene; Shahinfard, Elham; Kolind, Shannon; van Donkelaar, Paul; Taunton, Jack; Li, David; Rauscher, Alexander			Myelin Water Fraction Is Transiently Reduced after a Single Mild Traumatic Brain Injury - A Prospective Cohort Study in Collegiate Hockey Players	PLOS ONE			English	Article							SPORTS-RELATED CONCUSSION; TENSOR IMAGING FINDINGS; WHITE-MATTER INTEGRITY; DIFFUSE AXONAL INJURY; MULTIPLE-SCLEROSIS; CORPUS-CALLOSUM; UNMYELINATED AXONS; N-ACETYLASPARTATE; NERVOUS-SYSTEM; DAMAGE	Impact-related mild traumatic brain injuries (mTBI) are a major public health concern, and remain as one of the most poorly understood injuries in the field of neuroscience. Currently, the diagnosis and management of such injuries are based largely on patient-reported symptoms. An improved understanding of the underlying pathophysiology of mTBI is urgently needed in order to develop better diagnostic and management protocols. Specifically, dynamic post-injury changes to the myelin sheath in the human brain have not been examined, despite 'compromised white matter integrity' often being described as a consequence of mTBI. In this preliminary cohort study, myelin water imaging was used to prospectively evaluate changes in myelin water fraction, derived from the T2 decay signal, in two varsity hockey teams (45 players) over one season of athletic competition. 11 players sustained a concussion during competition, and were scanned at 72 hours, 2 weeks, and 2 months post-injury. Results demonstrated a reduction in myelin water fraction at 2 weeks post-injury in several brain areas relative to preseason scans, including the splenium of the corpus callosum, right posterior thalamic radiation, left superior corona radiata, left superior longitudinal fasciculus, and left posterior limb of the internal capsule. Myelin water fraction recovered to pre-season values by 2 months post-injury. These results may indicate transient myelin disruption following a single mTBI, with subsequent remyelination of affected neurons. Myelin disruption was not apparent in the athletes who did not experience a concussion, despite exposure to repetitive subconcussive trauma over a season of collegiate hockey. These findings may help to explain many of the metabolic and neurological deficits observed clinically following mTBI.	[Wright, Alexander D.] Univ British Columbia, MD PhD Program, Vancouver, BC V5Z 1M9, Canada; [Wright, Alexander D.] Univ British Columbia Okanagan, Southern Med Program, Kelowna, BC, Canada; [Wright, Alexander D.] Univ British Columbia, Dept Expt Med, Vancouver, BC V5Z 1M9, Canada; [Jarrett, Michael; Vavasour, Irene; Shahinfard, Elham; Rauscher, Alexander] Univ British Columbia, UBC MRI Res Ctr, Vancouver, BC V5Z 1M9, Canada; [Kolind, Shannon] Univ British Columbia, Div Neurol, Fac Med, Vancouver, BC V5Z 1M9, Canada; [van Donkelaar, Paul] Univ British Columbia Okanagan, Sch Hlth & Exercise Sci, Kelowna, BC, Canada; [Taunton, Jack] Univ British Columbia, Fac Med, Div Sports Med, Vancouver, BC, Canada; [Li, David] Univ British Columbia, Fac Med, Dept Radiol, Vancouver, BC, Canada; [Rauscher, Alexander] Univ British Columbia, Dept Pediat, Div Neurol, Vancouver, BC V6T 1W5, Canada		Rauscher, A (corresponding author), Univ British Columbia, UBC MRI Res Ctr, Vancouver, BC V5Z 1M9, Canada.	rauscher@physics.ubc.ca		Rauscher, Alexander/0000-0002-1961-8252; Jarrett, Michael/0000-0002-3702-2014; Shahinfard, Elham/0000-0002-3526-0086	London Drugs Award for Research Excellence in Radiology; Canadian Institutes for Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [201109MSH-261306-183304]; Vanier Canada Graduate Scholarships program	This research was funded by a London Drugs Award for Research Excellence in Radiology (no grant number) and by a New Investigator Award to Alexander Rauscher from the Canadian Institutes for Health Research (CIHR, grant #201109MSH-261306-183304). Alexander Rauscher is also a Canada Research Chair in Developmental Neuroimaging. Alexander D. Wright was supported by the Vanier Canada Graduate Scholarships program. No persons other than the listed authors had substantial scientific input into this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armstrong R.C., 2015, EXP NEUROL; Bailes JE, 2014, PROG NEUROL SURG, V28, P50, DOI 10.1159/000358765; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Benarroch EE, 2009, NEUROLOGY, V72, P1779, DOI 10.1212/WNL.0b013e3181a6b123; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Blennow K, 2011, ACTA NEUROL SCAND, V123, P245, DOI 10.1111/j.1600-0404.2010.01408.x; Chong CD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0485-0; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Dennis EL, 2015, J NEUROSCI, V35, P10202, DOI 10.1523/JNEUROSCI.1595-15.2015; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; Donovan V, 2014, J CEREBR BLOOD F MET, V34, P715, DOI 10.1038/jcbfm.2014.6; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Faisal A.A., 2011, BMC NEUROSCI, V12, pP100, DOI [10.1186/1471-2202-12-S1-P100, DOI 10.1186/1471-2202-12-S1-P100]; Faul M, 2010, TRAUMATIC BRAIN INJU; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Gareau PJ, 2000, J MAGN RESON IMAGING, V11, P586, DOI 10.1002/1522-2586(200006)11:6<586::AID-JMRI3>3.0.CO;2-V; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hsieh S-T, 1993, BRAIN PATHOL, V3, P307; Jarrett M, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00011; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kozlowski P, 2008, MAGN RESON MED, V59, P796, DOI 10.1002/mrm.21527; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Laule C, 2006, MULT SCLER, V12, P747, DOI 10.1177/1352458506070928; Laule C, 2007, NEUROTHERAPEUTICS, V4, P460, DOI 10.1016/j.nurt.2007.05.004; Li SX, 2013, INT J LEGAL MED, V127, P159, DOI 10.1007/s00414-012-0712-8; Liang ALW, 2012, J NEUROL, V259, P1151, DOI 10.1007/s00415-011-6318-0; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; MacKay A, 2006, MAGN RESON IMAGING, V24, P515, DOI 10.1016/j.mri.2005.12.037; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Maxwell WL, 2015, J NEUROTRAUMA; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MEHTA V, 1995, MOL BRAIN RES, V31, P151, DOI 10.1016/0169-328X(95)00044-S; Meier TB, 2015, JAMA NEUROL; Meyers SM, 2013, J MAGN RESON IMAGING, V38, P1445, DOI 10.1002/jmri.24106; Meyers SM, 2009, MAGN RESON IMAGING, V27, P1096, DOI 10.1016/j.mri.2009.02.001; Mierzwa AJ, 2015, J NEUROPATH EXP NEUR, V74, P218, DOI 10.1097/NEN.0000000000000165; Miyamoto N, 2013, STROKE, V44, P3516, DOI 10.1161/STROKEAHA.113.002813; Narayanan S, 1997, ANN NEUROL, V41, P385, DOI 10.1002/ana.410410314; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Nordengen K, 2015, BRAIN STRUCT FUNCT, V220, P899, DOI 10.1007/s00429-013-0691-7; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Oh J, 2007, J NEUROIMAGING, V17, P156, DOI 10.1111/j.1552-6569.2007.00098.x; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prasloski T, 2012, NEUROIMAGE, V63, P533, DOI 10.1016/j.neuroimage.2012.06.064; Reeves TM, 2012, J NEUROPATH EXP NEUR, V71, P198, DOI 10.1097/NEN.0b013e3182482590; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Sanchez I, 1996, J NEUROSCI, V16, P5095; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shi H., 2015, EXP NEUROL; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Stanisz GJ, 2004, MAGNET RESON MED, V51, P473, DOI 10.1002/mrm.20008; STEWART WA, 1993, MAGNET RESON MED, V29, P767, DOI 10.1002/mrm.1910290608; Sullivan GM, 2013, J NEUROPATH EXP NEUR, V72, P1106, DOI 10.1097/NEN.0000000000000009; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Tsunoda I, 2002, SPRINGER SEMIN IMMUN, V24, P105, DOI 10.1007/s00281-002-0105-z; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vavasour IM, 2009, J NEUROL SCI, V276, P49, DOI 10.1016/j.jns.2008.08.022; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; WAXMAN SG, 1977, ARCH NEUROL-CHICAGO, V34, P585, DOI 10.1001/archneur.1977.00500220019003; Webb S, 2003, MAGNET RESON MED, V49, P638, DOI 10.1002/mrm.10411; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	81	55	55	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2016	11	2							e0150215	10.1371/journal.pone.0150215			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	DF2LW	WOS:000371175700062	26913900	Green Submitted, Green Published, gold			2022-02-06	
J	Koerte, IK; Hufschmidt, J; Muehlmann, M; Tripodis, Y; Stamm, JM; Pasternak, O; Giwerc, MY; Coleman, MJ; Baugh, CM; Fritts, NG; Heinen, F; Lin, A; Stern, RA; Shenton, ME				Koerte, Inga K.; Hufschmidt, Jakob; Muehlmann, Marc; Tripodis, Yorghos; Stamm, Julie M.; Pasternak, Ofer; Giwerc, Michelle Y.; Coleman, Michael J.; Baugh, Christine M.; Fritts, Nathan G.; Heinen, Florian; Lin, Alexander; Stern, Robert A.; Shenton, Martha E.			Cavum Septi Pellucidi in Symptomatic Former Professional Football Players	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; head trauma; MRI; neurodegenerative disorders; traumatic brain injury	CHRONIC TRAUMATIC ENCEPHALOPATHY; REPETITIVE BRAIN TRAUMA; MRI FINDINGS; SCHIZOPHRENIA; INJURY; DEMENTIA; DISORDER; DISEASE; BOXERS; IMPACT	Post-mortem studies reveal a high rate of cavum septi pellucidi (CSP) in chronic traumatic encephalopathy (CTE). It remains, however, to be determined whether or not the presence of CSP may be a potential in vivo imaging marker in populations at high risk to develop CTE. The aim of this study was to evaluate CSP in former professional American football players presenting with cognitive and behavioral symptoms compared with noncontact sports athletes. Seventy-two symptomatic former professional football players (mean age 54.53 years, standard deviation [SD] 7.97) as well as 14 former professional noncontact sports athletes (mean age 57.14 years, SD 7.35) underwent high-resolution structural 3T magnetic resonance imaging. Two raters independently evaluated the CSP, and interrater reliability was calculated. Within National Football League players, an association of CSP measures with cognitive and behavioral functioning was evaluated using a multivariate mixed effects model. The measurements of the two raters were highly correlated (CSP length: rho=0.98; Intraclass Correlation Coefficient [ICC] 0.99; p<0.0001; septum length: rho=0.93; ICC 0.96; p<0.0001). For presence versus absence of CSP, there was high agreement (Cohen kappa=0.83, p<0.0001). A higher rate of CSP, a greater length of CSP, as well as a greater ratio of CSP length to septum length was found in symptomatic former professional football players compared with athlete controls. In addition, a greater length of CSP was associated with decreased performance on a list learning task (Neuropsychological Assessment Battery List A Immediate Recall, p=0.04) and decreased test scores on a measure of estimate verbal intelligence (Wide Range Achievement Test Fourth Edition Reading Test, p=0.02). Given the high prevalence of CSP in neuropathologically confirmed CTE in addition to the results of this study, CSP may serve as a potential early in vivo imaging marker to identify those at high risk for CTE. Future research is needed to investigate the pathomechanism underlying the development of CSP after repetitive head impacts, and its potential association with neuropathologically confirmed CTE.	[Koerte, Inga K.; Hufschmidt, Jakob; Muehlmann, Marc; Stamm, Julie M.; Pasternak, Ofer; Giwerc, Michelle Y.; Coleman, Michael J.; Lin, Alexander; Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Psychiat Neuroimaging Lab,Dept Psychiat, Boston, MA 02115 USA; [Koerte, Inga K.; Muehlmann, Marc] Univ Munich, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany; [Hufschmidt, Jakob; Heinen, Florian] Univ Munich, Dr von Hauner Childrens Hosp, Dept Pediat Neurol, Munich, Germany; [Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Tripodis, Yorghos; Stamm, Julie M.; Baugh, Christine M.; Fritts, Nathan G.; Stern, Robert A.] Boston Univ, Sch Med, CTE Ctr, Boston, MA 02118 USA; [Tripodis, Yorghos; Stern, Robert A.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Stamm, Julie M.; Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Baugh, Christine M.] Harvard Univ, Interfac Initiat Hlth Policy, Cambridge, MA 02138 USA; [Lin, Alexander; Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Lin, Alexander] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Clin Spect,Dept Radiol, Boston, MA 02115 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Brockton Div, Brockton, MA USA		Koerte, IK (corresponding author), Brigham & Womens Hosp, Psychiat Neuroimaging Lab, 1249 Boylston St, Boston, MA 02215 USA.	ikoerte@bwh.harvard.edu	Baugh, Christine/AAG-2324-2020; Koerte, Inga Katharina/AAW-3031-2021; Shenton, Martha/V-8780-2019; Heinen, Florian/B-6594-2015; , Bob/ABA-8507-2020	Baugh, Christine/0000-0002-9340-6338; Heinen, Florian/0000-0002-3872-6136; Tripodis, Yorghos/0000-0003-2190-7608	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS081957, R01NS078337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1-TR000157] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG13846, P30 AG013846] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32 MH019733] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31 NS 081957, R01 NS078337] Funding Source: Medline		Areza-Fegyveres R, 2007, ARQ NEURO-PSIQUIAT, V65, P830, DOI 10.1590/S0004-282X2007000500019; Aviv RI, 2010, CAN ASSOC RADIOL J, V61, P29, DOI 10.1016/j.carj.2009.09.002; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Beaton EA, 2010, PSYCHIAT RES-NEUROIM, V181, P108, DOI 10.1016/j.pscychresns.2009.10.009; BOGDANOFF B, 1989, NEUROLOGY, V39, P991, DOI 10.1212/WNL.39.7.991; Born CM, 2004, EUR ARCH PSY CLIN N, V254, P295, DOI 10.1007/s00406-004-0496-z; Brent BK, 2013, CHILD ADOL PSYCH CL, V22, P689, DOI 10.1016/j.chc.2013.06.003; Clay MB, 2013, J CHIROPR MED, V12, P230, DOI 10.1016/j.jcm.2012.11.005; Costanza A, 2011, NEUROPATH APPL NEURO, V37, P570, DOI 10.1111/j.1365-2990.2011.01186.x; Filipovic B, 2004, EUR ARCH PSY CLIN N, V254, P228, DOI 10.1007/s00406-004-0483-4; Flashman LA, 2007, PSYCHIAT RES-NEUROIM, V154, P147, DOI 10.1016/j.pscychresns.2006.09.001; Gardner R. C., 2015, J NEUROTRAUMA; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gur RE, 2013, AM J NEURORADIOL, V34, P2021, DOI 10.3174/ajnr.A3525; Hagino H, 2001, AM J PSYCHIAT, V158, P1717, DOI 10.1176/appi.ajp.158.10.1717; Handratta V, 2010, NEUROCASE, V16, P125, DOI 10.1080/13554790903329166; Hasiloglu ZI, 2011, AM J NEURORADIOL, V32, P99, DOI 10.3174/ajnr.A2250; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; Kwon JS, 1998, AM J PSYCHIAT, V155, P509, DOI 10.1176/ajp.155.4.509; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; McCarley RW, 1999, BIOL PSYCHIAT, V45, P1099, DOI 10.1016/S0006-3223(99)00018-9; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Montenigro PH, 2015, ANNU REV CLIN PSYCHO, V11, P309, DOI 10.1146/annurev-clinpsy-032814-112814; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Ng TSC, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt239; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; Pittella JEH, 2005, SURG NEUROL, V63, P30, DOI 10.1016/j.surneu.2004.09.012; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Shenton ME, 2001, SCHIZOPHR RES, V49, P1, DOI 10.1016/S0920-9964(01)00163-3; Silk T, 2013, PSYCHIAT RES-NEUROIM, V213, P186, DOI 10.1016/j.pscychresns.2013.03.001; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stamm J. M., 2015, J NEUROTRAUMA; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Winter TC, 2010, J ULTRAS MED, V29, P427, DOI 10.7863/jum.2010.29.3.427	39	55	55	0	20	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2016	33	4					346	353		10.1089/neu.2015.3880			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DD2NH	WOS:000369758800004	26414478	Green Published			2022-02-06	
J	Hakkarainen, TW; Arbabi, S; Willis, MM; Davidson, GH; Flum, DR				Hakkarainen, Timo W.; Arbabi, Saman; Willis, Margaret M.; Davidson, Giana H.; Flum, David R.			Outcomes of Patients Discharged to Skilled Nursing Facilities After Acute Care Hospitalizations	ANNALS OF SURGERY			English	Article						post-acute care outcomes; skilled nursing facility; trauma	TRAUMATIC BRAIN-INJURY; MORTALITY; SURVIVAL	Objectives:To evaluate previously independent older patients discharged to skilled nursing facilities (SNFs) and identify risk factors for failure to return home and death and development of a predictive tool to determine likelihood of adverse outcome.Background:Little is known about the likelihood of return to home, and higher than expected mortality rates in SNFs have recently been described, which may represent an opportunity for quality improvement.Methods:Retrospective cohort of older hospitalized patients discharged to SNFs during 2007 to 2009 in 5 states using Centers for Medicare & Medicaid Services linked minimum data set data from SNFs. We assessed mortality, hospital readmission, discharge to home, and logistic regression models for predicting risk of each outcome.Results:Of 416,997 patients, 3.8% died during the initial SNF stay, 28.6% required readmission, and 60.5% were ultimately discharged home. Readmission to a hospital was the strongest predictor of death in the years after SNF admission (unadjusted hazard ratio, 28.2; 95% confidence interval, 27.2-29.3; P<0.001). Among all patients discharged to SNFs, 7.8% eventually died in an SNF and overall 1-year mortality was 26.1%. Risk factors associated with mortality and failure to return home were increasing age, male sex, increasing comorbidities, decreased cognitive function, decreased functional status, parenteral nutrition, and pressure ulcers.Conclusions:A large proportion of older patients discharging to SNFs never return home. A better understanding of the natural history of patients sent to SNFs after hospitalization and risk factors for failure to return to home, readmission, and death should help identify opportunities for interventions to improved outcome.	Univ Washington, Comparat Effectiveness Res Translat Network, Surg Outcomes Res Ctr, Dept Surg, Seattle, WA 98195 USA; Univ Washington, Harborview Injury Prevent Res Ctr, Seattle, WA 98195 USA		Davidson, GH (corresponding author), Univ Washington, Dept Surg, 1959 NE Pacific St,Box 356410, Seattle, WA 98195 USA.	ghd@uw.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1T32DK070555-01A1]; Washington State's Life Science Discovery Fund and Agency for Healthcare Research and Quality through Surgical Care and Outcomes Assessment Program (SCOAP) [1 R01 HS 20025-01]; Comparative Effectiveness Research Translation Network (CERTAIN); Harborview Injury Prevention Research Center; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS020025] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [T32DK070555] Funding Source: NIH RePORTER	Supported by NIH training grant 1T32DK070555-01A1 and by the Washington State's Life Science Discovery Fund and Agency for Healthcare Research and Quality Grant Number 1 R01 HS 20025-01 through the Surgical Care and Outcomes Assessment Program (SCOAP), the Comparative Effectiveness Research Translation Network (CERTAIN), and the Harborview Injury Prevention Research Center. None of the authors have any financial or personal conflicts of interests pertaining to this work.	Aitken LM, 2010, J AM GERIATR SOC, V58, P442, DOI 10.1111/j.1532-5415.2010.02728.x; [Anonymous], 2013, C MED PAYM POL; Claridge JA, 2010, J AM COLL SURGEONS, V210, P788, DOI 10.1016/j.jamcollsurg.2009.12.035; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; Cook CH, 1999, J AM COLL SURGEONS, V189, P437, DOI 10.1016/S1072-7515(99)00191-X; Davidson GH, 2011, JAMA-J AM MED ASSOC, V305, P1001, DOI 10.1001/jama.2011.259; Fleischman RJ, 2010, J AM GERIATR SOC, V58, P1843, DOI 10.1111/j.1532-5415.2010.03065.x; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Legner VJ, 2009, ANN SURG, V249, P250, DOI 10.1097/SLA.0b013e318195e12f; Mor V, 2011, HLTH AFF MILLWOOD, V29, P57; Morris JN, 1999, J GERONTOL A-BIOL, V54, pM546, DOI 10.1093/gerona/54.11.M546; Osler T, 1996, J TRAUMA, V41, P380, DOI 10.1097/00005373-199609000-00002; Ouslander JG, 2009, J AM MED DIR ASSOC, V10, P644, DOI 10.1016/j.jamda.2009.07.001; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Wunsch H, 2010, JAMA-J AM MED ASSOC, V303, P849, DOI 10.1001/jama.2010.216; Yu P, 2011, J SURG RES, V170, pE217, DOI 10.1016/j.jss.2011.05.040	16	55	55	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	FEB	2016	263	2					280	285		10.1097/SLA.0000000000001367			6	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Surgery	DD8TP	WOS:000370200100014	26445466	Green Accepted			2022-02-06	
J	Meier, TB; Bergamino, M; Bellgowan, PSF; Teague, TK; Ling, JM; Jeromin, A; Mayer, AR				Meier, Timothy B.; Bergamino, Maurizio; Bellgowan, Patrick S. F.; Teague, T. K.; Ling, Josef M.; Jeromin, Andreas; Mayer, Andrew R.			Longitudinal Assessment of White Matter Abnormalities Following Sports-Related Concussion	HUMAN BRAIN MAPPING			English	Article						diffusion tensor imaging; mTBI; fractional anisotropy; tau	TRAUMATIC BRAIN-INJURY; TENSOR IMAGING FINDINGS; COLLEGIATE FOOTBALL PLAYERS; CEREBROSPINAL-FLUID; NCAA CONCUSSION; NERVOUS-SYSTEM; DIFFUSION; BIOMARKERS; RECOVERY; ADOLESCENTS	There is great interest in developing physiological-based biomarkers such as diffusion tensor imaging to aid in the management of concussion, which is currently entirely dependent on clinical judgment. However, the time course for recovery of white matter abnormalities following sportsrelated concussion (SRC) is unknown. We collected diffusion tensor imaging and behavioral data in forty concussed collegiate athletes on average 1.64 days (T1; n = 33), 8.33 days (T2; n = 30), and 32.15 days post-concussion (T3; n = 26), with healthy collegiate contact-sport athletes (HA) serving as controls (n = 46). We hypothesized that fractional anisotropy (FA) would be increased acutely and partially recovered by one month post-concussion. Mood symptoms were assessed using structured interviews. FA differences were assessed using both traditional and subject-specific analyses. An exploratory analysis of tau plasma levels was conducted in a subset of participants. Results indicated that mood symptoms improved over time post-concussion, but remained elevated at T3 relative to HA. Across both group and subject-specific analyses, concussed athletes exhibited increased FA in several white matter tracts at each visit post-concussion with no longitudinal evidence of recovery. Increased FA at T1 and T3 was significantly associated with an independent, real-world outcome measure for return-to-play. Finally, we observed a nonsignificant trend for reduced tau in plasma of concussed athletes at T1 relative to HA, with tau significantly increasing by T2. These results suggest white matter abnormalities following SRC may persist beyond one month and have potential as an objective biomarker for concussion outcome. (C) 2015 Wiley Periodicals, Inc.	[Meier, Timothy B.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Meier, Timothy B.; Ling, Josef M.; Mayer, Andrew R.] Lovelace Biomed & Environm Res Inst, Mind Res Network, Albuquerque, NM USA; [Meier, Timothy B.; Bergamino, Maurizio] Laureate Inst Brain Res, Tulsa, OK USA; [Bellgowan, Patrick S. F.] NINDS, NIH, North Bethesda, MD USA; [Teague, T. K.] Univ Oklahoma, Coll Med, Dept Surg, Tulsa, OK USA; [Teague, T. K.] Univ Oklahoma, Coll Med, Dept Psychiat, Tulsa, OK USA; [Teague, T. K.] Univ Oklahoma, Coll Pharm, Dept Pharmaceut Sci, Tulsa, OK USA; [Teague, T. K.] Oklahoma State Univ, Ctr Hlth Sci, Dept Biochem & Microbiol, Tulsa, OK USA; [Jeromin, Andreas] Quanterix Corp, Lexington, MA USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; [Meier, Timothy B.; Mayer, Andrew R.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA		Meier, TB (corresponding author), Neurosci Res Ctr, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	tmeier@mcw.edu	Teague, T. Kent/A-2527-2008	Teague, T. Kent/0000-0002-4680-5440	Laureate Institute for Brain Research	Contract grant sponsor: Laureate Institute for Brain Research	Arun P, 2013, NEUROSCI LETT, V552, P87, DOI 10.1016/j.neulet.2013.07.047; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Borich M, 2013, J NEUROTRAUM, V30, P1243, DOI 10.1089/neu.2012.2818; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Chen G, 2013, NEUROIMAGE, V73, P176, DOI 10.1016/j.neuroimage.2013.01.047; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Dodd AB, 2014, J NEUROTRAUM, V31, P1235, DOI 10.1089/neu.2014.3337; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132090, 10.3171/2013.12.JNS132093]; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jones TB, 2010, NEUROIMAGE, V49, P401, DOI 10.1016/j.neuroimage.2009.07.051; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Ling J, 2012, HUM BRAIN MAPP, V33, P50, DOI 10.1002/hbm.21192; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2014, HUM BRAIN MAPP, V35, P5457, DOI 10.1002/hbm.22563; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Mori S, 2007, AM J PSYCHIAT, V164, P1005, DOI 10.1176/appi.ajp.164.7.1005; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Rissin DM, 2010, NAT BIOTECHNOL, V28, P595, DOI 10.1038/nbt.1641; Roebuck-Spencer TM, 2013, ARCH CLIN NEUROPSYCH, V28, P700, DOI 10.1093/arclin/act055; Rosenblum WI, 2007, J NEUROPATH EXP NEUR, V66, P771, DOI 10.1097/nen.0b013e3181461965; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Singh R, 2015, J NEUROL NE IN PRESS; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Talairach J., 1988, COPLANAR STEREOTAXIC; Thorne DR, 2006, BEHAV RES METHODS, V38, P569; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; Turken And U, 2009, BMC Med Imaging, V9, P20, DOI 10.1186/1471-2342-9-20; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	54	55	55	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	FEB	2016	37	2					833	845		10.1002/hbm.23072			13	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	DD9KB	WOS:000370243000030	26663463	Green Published			2022-02-06	
J	Black, AM; Macpherson, AK; Hagel, BE; Romiti, MA; Palacios-Derflingher, L; Kang, J; Meeuwisse, WH; Emery, CA				Black, Amanda M.; Macpherson, Alison K.; Hagel, Brent E.; Romiti, Maria A.; Palacios-Derflingher, Luz; Kang, Jian; Meeuwisse, Willem H.; Emery, Carolyn A.			Policy change eliminating body checking in non-elite ice hockey leads to a threefold reduction in injury and concussion risk in 11-and 12-year-old players	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Hockey; Risk factor	INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; SPORT HELD; ZURICH	Background In ice hockey, body checking is associated with an increased risk of injury. In 2011, provincial policy change disallowed body checking in non-elite Pee Wee (ages 11-12 years) leagues. Objective To compare the risk of injury and concussion between non-elite Pee Wee ice hockey players in leagues where body checking is permitted (2011-12 Alberta, Canada) and leagues where policy change disallowed body checking (2011-12 Ontario, Canada). Method Non-elite Pee Wee players (lower 70%) from Alberta (n=590) and Ontario (n=281) and elite Pee Wee players (upper 30%) from Alberta (n=294) and Ontario (n=166) were recruited to participate in a cohort study. Baseline information, injury and exposure data was collected using validated injury surveillance. Results Based on multiple Poisson regression analyses (adjusted for clustering by team, exposure hours, year of play, history of injury/concussion, level of play, position and body checking attitude), the incidence rate ratio (IRR) associated with policy allowing body checking was 2.97 (95% CI 1.33 to 6.61) for all game injury and 2.83 (95% CI 1.09 to 7.31) for concussion. There were no differences between provinces in concussion [IRR=1.50 (95% CI 0.84 to 2.68)] or injury risk [IRR=1.22 (95% CI 0.69 to 2.16)] in elite levels of play where both provinces allowed body checking. Conclusions The rate of injury and concussion were threefold greater in non-elite Pee Wee ice hockey players in leagues where body checking was permitted. The rate of injury and concussion did not differ between provinces in elite levels, where body checking was allowed.	[Black, Amanda M.; Hagel, Brent E.; Romiti, Maria A.; Palacios-Derflingher, Luz; Kang, Jian; Meeuwisse, Willem H.; Emery, Carolyn A.] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB T2N 1N4, Canada; [Macpherson, Alison K.] York Univ, Sch Kinesiol & Hlth Sci, Fac Hlth, Toronto, ON M3J 2R7, Canada; [Emery, Carolyn A.] Univ Calgary, Alberta Childrens Hosp, Res Inst Child & Maternal Hlth, Dept Pediat,Cumming Sch Med, Calgary, AB T2N 1N4, Canada; [Hagel, Brent E.; Palacios-Derflingher, Luz; Emery, Carolyn A.] Univ Calgary, Commun Hlth Sci, Cumming Sch Med, Calgary, AB T2N 1N4, Canada		Black, AM (corresponding author), Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB T2N 1N4, Canada.	ablack@ucalgary.ca	Black, Amanda/O-7675-2017; Hagel, Brent/AAK-3319-2020; Emery, Carolyn/AAI-2761-2020	Black, Amanda/0000-0001-5668-9706; 	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Alberta Children's Hospital Institute for Child and Maternal Health; Max Bell Foundation; Hotchkiss Brain Institute; Alberta Children's Hospital Foundation Chair in Pediatric Rehabilitation; CIHR Chair in Child and Youth Health Services and Policy Research; Alberta Innovates [201201160] Funding Source: researchfish	This study was funded by the Canadian Institutes of Health Research (CIHR), Alberta Children's Hospital Institute for Child and Maternal Health and the Max Bell Foundation. AMB is supported by the Hotchkiss Brain Institute Dr T Chen Fong Doctoral Scholarship in Neuroscience. CAE is supported by an Alberta Children's Hospital Foundation Chair in Pediatric Rehabilitation. AKM is supported by a CIHR Chair in Child and Youth Health Services and Policy Research. The role of the sponsors and funding bodies was to provide financial support for this research and the translation of the findings to all community partners.	Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Emery CA, 2010, INJURY PREV, V16, P113, DOI 10.1136/ip.2009.022764; Fraser-Thomas J, 2014, INT J SPORT EXERC PS, V12, P121, DOI 10.1080/1612197X.2013.837091; Hecimovich, 2004, J AM CHIROPR ASS, V41, P32; Hockey Canada, 2012, HOCK CAN 2012 ANN RE; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meeuwisse WH, 1998, CLIN J SPORT MED, V8, P164, DOI 10.1097/00042752-199807000-00003; Slutzky CB, 2009, PSYCHOL SPORT EXERC, V10, P381, DOI 10.1016/j.psychsport.2008.09.006; Williamson US, 2009, J ASTM INT, V6; Zullig KJ, 2011, APPL RES QUAL LIFE, V6, P277, DOI 10.1007/s11482-010-9129-z	13	55	55	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2016	50	1					55	61		10.1136/bjsports-2015-095103			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	DA0BW	WOS:000367462700011	26702018				2022-02-06	
S	Cullen, DK; Harris, JP; Browne, KD; Wolf, JA; Duda, JE; Meaney, DF; Margulies, SS; Smith, DH		Kobeissy, F; Dixon, CE; Hayes, RL; Mondello, S		Cullen, D. Kacy; Harris, James P.; Browne, Kevin D.; Wolf, John A.; Duda, John E.; Meaney, David F.; Margulies, Susan S.; Smith, Douglas H.			A Porcine Model of Traumatic Brain Injury via Head Rotational Acceleration	INJURY MODELS OF THE CENTRAL NERVOUS SYSTEM: METHODS AND PROTOCOLS	Methods in Molecular Biology		English	Article; Book Chapter						Traumatic brain injury (TBI); Biomechanics; Neuropathology; Diffuse brain injury (DBI); Axonal injury; Modeling; Degeneration; Concussion	DIFFUSE AXONAL INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; SWINE MODEL; CEREBRAL CONCUSSION; ANIMAL-MODELS; AMYLOID-BETA; INTRACRANIAL HEMORRHAGE; WHITE-MATTER; NEONATAL PIG; CORTICAL-NEURONS	Unique from other brain disorders, traumatic brain injury (TBI) generally results from a discrete biomechanical event that induces rapid head movement. The large size and high organization of the human brain makes it particularly vulnerable to traumatic injury from rotational accelerations that can cause dynamic deformation of the brain tissue. Therefore, replicating the injury biomechanics of human TBI in animal models presents a substantial challenge, particularly with regard to addressing brain size and injury parameters. Here we present the historical development and use of a porcine model of head rotational acceleration. By scaling up the rotational forces to account for difference in brain mass between swine and humans, this model has been shown to produce the same tissue deformations and identical neuropathologies found in human TBI. The parameters of scaled rapid angular accelerations applied for the model reproduce inertial forces generated when the human head suddenly accelerates or decelerates in falls, collisions, or blunt impacts. The model uses custom-built linkage assemblies and a powerful linear actuator designed to produce purely impulsive nonimpact head rotation in different angular planes at controlled rotational acceleration levels. Through a range of head rotational kinematics, this model can produce functional and neuropathological changes across the spectrum from concussion to severe TBI. Notably, however, the model is very difficult to employ, requiring a highly skilled team for medical management, biomechanics, neurological recovery, and specialized outcome measures including neuromonitoring, neurophysiology, neuroimaging, and neuropathology. Nonetheless, while challenging, this clinically relevant model has proven valuable for identifying mechanisms of acute and progressive neuropathologies as well as for the evaluation of noninvasive diagnostic techniques and potential neuroprotective treatments following TBI.	[Cullen, D. Kacy; Harris, James P.; Browne, Kevin D.; Wolf, John A.; Meaney, David F.; Margulies, Susan S.; Smith, Douglas H.] Univ Penn, Perelman Sch Med, Ctr Brain Injury & Repair, Dept Neurosurg, Philadelphia, PA 19104 USA; [Harris, James P.; Browne, Kevin D.; Wolf, John A.; Duda, John E.] Philadelphia Vet Affairs Med Ctr, Perelman Sch Med, Dept Neurol, Philadelphia, PA USA; [Margulies, Susan S.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA		Cullen, DK (corresponding author), Univ Penn, Perelman Sch Med, Ctr Brain Injury & Repair, Dept Neurosurg, Philadelphia, PA 19104 USA.		Wolf, John A/A-1034-2007	Wolf, John A/0000-0002-6950-2303; Harris, James/0000-0002-8458-5434; Meaney, David/0000-0002-0954-4122	NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01 EB021293] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS050598, T32 NS043126, R01 NS038104, R01 NS092398, R01 NS101108, R01 NS088176] Funding Source: Medline; RRD VA [IK2 RX001479, I01 RX001097] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS043126, R01NS088176, R01NS038104, R01NS050598] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [IK2RX001479, I01RX001097] Funding Source: NIH RePORTER		Aare M, 2004, INT J CRASHWORTHINES, V9, P15, DOI 10.1533/ijcr.2004.0268; Adams J H, 1981, Acta Neuropathol Suppl, V7, P26; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Bailey EL, 2009, STROKE, V40, pE451, DOI 10.1161/STROKEAHA.108.528430; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; CHOI DW, 1994, ANN NY ACAD SCI, V747, P162; Clevenger AC, 2015, J NEUROTRAUM, V32, P120, DOI 10.1089/neu.2014.3570; Coats B, 2012, INT J DEV NEUROSCI, V30, P191, DOI 10.1016/j.ijdevneu.2011.12.009; Coats B, 2010, INVEST OPHTH VIS SCI, V51, P4792, DOI 10.1167/iovs.10-5211; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Cullen DK, 2007, BRAIN RES, V1158, P103, DOI 10.1016/j.brainres.2007.04.070; Cullen DK, 2006, J NEUROTRAUM, V23, P1304, DOI 10.1089/neu.2006.23.1304; Cullen DK, 2011, J NEUROTRAUM, V28, P2219, DOI 10.1089/neu.2011.1841; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; De Monte VE, 2006, BRAIN INJURY, V20, P1345, DOI 10.1080/02699050601082073; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Denny-Brown D E, 1941, Proc R Soc Med, V34, P691; Duhaime AC, 2006, DEV NEUROSCI-BASEL, V28, P380, DOI 10.1159/000094164; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Faul M, 2010, TRAUMATIC BRAIN INJU; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; Friess SH, 2012, LAB ANIM-UK, V46, P164, DOI 10.1258/la.2011.011084; Friess SH, 2007, EXP NEUROL, V204, P234, DOI 10.1016/j.expneurol.2006.10.010; Friess SH, 2015, J NEUROTRAUM, V32, P237, DOI 10.1089/neu.2014.3468; Friess SH, 2012, CRIT CARE MED, V40, P2400, DOI 10.1097/CCM.0b013e31825333e6; Friess SH, 2011, NEUROSURGERY, V69, P1139, DOI 10.1227/NEU.0b013e3182284aa1; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Gennarelli T., 2003, ANN P ASS ADV AUTOMO, V47, P624; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; Gennarelli TA, 1972, STAPP CAR CRASH J, V16, P296; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Graham D I, 1988, Prog Clin Biol Res, V264, P159; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Howells DW, 2010, J CEREBR BLOOD F MET, V30, P1412, DOI 10.1038/jcbfm.2010.66; Humphreys I, 2013, CLINICOECONOMIC OUTC, V5, P281, DOI 10.2147/CEOR.S44625; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ibrahim NG, 2010, J NEUROTRAUM, V27, P1021, DOI 10.1089/neu.2009.1212; Ibrahim NG, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000956; Jaber SM, 2015, DEV NEUROPSYCHOL, V40, P34, DOI 10.1080/87565641.2014.969733; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Kilbaugh TJ, 2011, J NEUROTRAUM, V28, P763, DOI 10.1089/neu.2010.1635; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; Kleiven Svein, 2013, Front Bioeng Biotechnol, V1, P15; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LETCHER FS, 1973, J NEUROSURG, V39, P167, DOI 10.3171/jns.1973.39.2.0167; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Margulies SS, 2015, BRAIN PATHOL, V25, P289, DOI 10.1111/bpa.12247; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.0.CO;2-6; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mcintosh TK, 1999, TRAUMATIC BRAIN INJU, P39; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meng X, 2012, ELECTRON LETT, V48, P363, DOI 10.1049/el.2012.0281; Meng X, 2013, NAT NEUR SOC ANN M; MILLER RT, 1998, 42 STAPP CAR CRASH C; Monti JM, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00041; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Naim MY, 2010, DEV NEUROSCI-BASEL, V32, P466, DOI 10.1159/000322448; Newman J A, 2000, Stapp Car Crash J, V44, P215; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; OMMAYA AK, 1973, J NEUROSURG, V39, P152, DOI 10.3171/jns.1973.39.2.0152; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OMMAYA AK, 1967, P 11 STAPP CAR CRASH, P73; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prado GR, 2005, J NEURAL ENG, V2, P148, DOI 10.1088/1741-2560/2/4/011; Prevention C. f. D. C. a. and Control N. C. f. I. P. a., 2003, REP C MILD TRAUM BRA; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; SAHAY KB, 1992, J BIOMECH, V25, P319, DOI 10.1016/0021-9290(92)90029-Z; Santiago LA, 2012, BRAIN INJURY, V26, P107, DOI 10.3109/02699052.2011.635363; Sattler R, 2000, J MOL MED, V78, P3, DOI 10.1007/s001090000077; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 2015, J NEUROTRAUM, V32, P1725, DOI 10.1089/neu.2014.3861; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Spicer M.A.C.M., 2014, SPORTS RELATED CONCU; Stein DG, 2015, BRAIN INJURY, V29, P1259, DOI 10.3109/02699052.2015.1065344; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Sullivan S, 2015, BIOMECH MODEL MECHAN, V14, P877, DOI 10.1007/s10237-014-0643-z; Sullivan S, 2013, J NEUROTRAUM, V30, P1770, DOI 10.1089/neu.2013.2913; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tekriwal A, 2015, NAT NEUR SOC ANN M; Thibault L., 1971, P 15 STAPP CAR CRASH; Thibault LE, 1989, P 10 INT TECHN C EXP; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Weeks D, 2014, J NEUROTRAUM, V31, P206, DOI 10.1089/neu.2013.3113; Wolf JA, 2014, WINT C BRAIN RES; Wolf JA, CONCUSSION IN PRESS; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; YARNELL P, 1969, B NEW YORK ACAD MED, V45, P39; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhang K, 2000, P NATL ACAD SCI USA, V97, P5621, DOI 10.1073/pnas.090504197; Zhou C, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3146814; Zhu Q, 2006, DEV NEUROSCI-BASEL, V28, P388, DOI 10.1159/000094165	157	55	56	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA	1064-3745	1940-6029	978-1-4939-3816-2; 978-1-4939-3814-8	METHODS MOL BIOL	Methods Mol. Biol.		2016	1462						289	324		10.1007/978-1-4939-3816-2_17	10.1007/978-1-4939-3816-2		36	Biochemical Research Methods; Biochemistry & Molecular Biology; Neurosciences	Book Citation Index – Science (BKCI-S)	Biochemistry & Molecular Biology; Neurosciences & Neurology	BH1UG	WOS:000398551500019	27604725	Green Accepted			2022-02-06	
J	Failla, MD; Conley, YP; Wagner, AK				Failla, Michelle D.; Conley, Yvette P.; Wagner, Amy K.			Brain-Derived Neurotrophic Factor (BDNF) in Traumatic Brain Injury-Related Mortality: Interrelationships Between Genetics and Acute Systemic and Central Nervous System BDNF Profiles	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; aging; BDNF; genetics; mortality; Rehabilomics	ACTIVITY-DEPENDENT SECRETION; TRKB MESSENGER-RNA; VAL66MET POLYMORPHISM; REHABILITATION RESEARCH; OUTCOME PREDICTION; HUMAN PLATELETS; TRUNCATED TRKB; RESEARCH MODEL; SEVERE TBI; LIFE-SPAN	Background. Older adults have higher mortality rates after severe traumatic brain injury (TBI) compared to younger adults. Brain-derived neurotrophic factor (BDNF) signaling is altered in aging and is important to TBI given its role in neuronal survival/plasticity and autonomic function. Following experimental TBI, acute BDNF administration has not been efficacious. Clinically, genetic variation in BDNF (reduced signaling alleles: rs6265, Met-carriers; rs7124442, C-carriers) can be protective against acute mortality. Postacutely, these genotypes carry lower mortality risk in older adults and greater mortality risk among younger adults. Objective. Investigate BDNF levels in mortality/outcome following severe TBI in the context of age and genetic risk. Methods. Cerebrospinal fluid (CSF) and serum BDNF were assessed prospectively during the first week following severe TBI (n = 203) and in controls (n = 10). Age, BDNF genotype, and BDNF levels were assessed as mortality/outcome predictors. Results. CSF BDNF levels tended to be higher post-TBI (P = .061) versus controls and were associated with time until death (P = .042). In contrast, serum BDNF levels were reduced post-TBI versus controls (P < .0001). Both gene * BDNF serum and gene * age interactions were mortality predictors post-TBI in the same multivariate model. CSF and serum BDNF tended to be negatively correlated post-TBI (P = .07). Conclusions. BDNF levels predicted mortality, in addition to gene * age interactions, suggesting levels capture additional mortality risk. Higher CSF BDNF post-TBI may be detrimental due to injury and age-related increases in pro-apoptotic BDNF target receptors. Negative CSF and serum BDNF correlations post-TBI suggest blood-brain barrier transit alterations. Understanding BDNF signaling in neuronal survival, plasticity, and autonomic function may inform treatment.	[Failla, Michelle D.; Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Conley, Yvette P.] Univ Pittsburgh, Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15213 USA; [Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Hlth Promot & Dev, Pittsburgh, PA 15213 USA; [Conley, Yvette P.; Wagner, Amy K.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Phys Med & Rehabil, 3471 Fifth Ave Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Failla, Michelle/AAI-3788-2021	Failla, Michelle/0000-0001-9734-3373; Conley, Yvette/0000-0002-1784-6067	National Institute on Disability and Rehabilitation Research [NIDRR H133A120087]; National Institute of Nursing ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR008424, R01NR013342]; US Department of DefenseUnited States Department of Defense [W81XWH-07-1-0701]; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048162]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048162] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013342, R01NR008424] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: National Institute on Disability and Rehabilitation Research (Grant Number: NIDRR H133A120087, Wagner); National Institute of Nursing Research (Grant Number: R01NR008424, Conley; R01NR013342, Conley); US Department of Defense (Grant Number: W81XWH-07-1-0701, Wagner); National Institute of Child Health and Human Development (Grant Number: R01HD048162, Wagner).	Alexander N, 2010, PSYCHONEUROENDOCRINO, V35, P949, DOI 10.1016/j.psyneuen.2009.12.008; Almeida RD, 2005, CELL DEATH DIFFER, V12, P1329, DOI 10.1038/sj.cdd.4401662; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barker PA, 2009, NAT NEUROSCI, V12, P105, DOI 10.1038/nn0209-105; Barrett GL, 2000, PROG NEUROBIOL, V61, P205, DOI 10.1016/S0301-0082(99)00056-8; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Brady R, 1999, J NEUROSCI, V19, P2131; Brooks JC, 2013, ARCH PHYS MED REHAB, V94, P2203, DOI 10.1016/j.apmr.2013.07.005; Brunoni AR, 2008, INT J NEUROPSYCHOPH, V11, P1169, DOI 10.1017/S1461145708009309; Bus BAA, 2012, WORLD J BIOL PSYCHIA, V13, P39, DOI 10.3109/15622975.2010.545187; Caporali A, 2009, PHYSIOL REV, V89, P279, DOI 10.1152/physrev.00007.2008; Cernak I, 2010, DEV NEUROSCI-BASEL, V32, P442, DOI 10.1159/000320085; Chen ZY, 2004, J NEUROSCI, V24, P4401, DOI 10.1523/JNEUROSCI.0348-04.2004; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; COX DR, 1972, J R STAT SOC B, V34, P187; Dawood T, 2007, MOL PSYCHIATR, V12, P981, DOI 10.1038/sj.mp.4002059; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Erickson KI, 2010, J NEUROSCI, V30, P5368, DOI 10.1523/JNEUROSCI.6251-09.2010; Failla MD, 2015, NEUROREHAB NEURAL RE, V29, P234, DOI 10.1177/1545968314542617; Freedman ML, 2004, NAT GENET, V36, P388, DOI 10.1038/ng1333; Fujimura H, 2002, THROMB HAEMOSTASIS, V87, P728; Gomes JR, 2012, J NEUROSCI, V32, P4610, DOI 10.1523/JNEUROSCI.0374-12.2012; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Hallden S, 2013, HEART, V99, P949, DOI 10.1136/heartjnl-2013-303634; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JENNETT B, 1975, LANCET, V1, P480; Kalish H, 2010, J CHROMATOGR B, V878, P194, DOI 10.1016/j.jchromb.2009.10.022; Kernie SG, 2000, EMBO J, V19, P1290, DOI 10.1093/emboj/19.6.1290; Krabbe KS, 2009, J AM GERIATR SOC, V57, P1447, DOI 10.1111/j.1532-5415.2009.02345.x; Kudielka BM, 2004, PSYCHONEUROENDOCRINO, V29, P83, DOI 10.1016/S0306-4530(02)00146-4; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; Lommatzsch M, 2005, NEUROBIOL AGING, V26, P115, DOI 10.1016/j.neurobiolaging.2004.03.002; Martinowich K, 2008, NEUROPSYCHOPHARMACOL, V33, P73, DOI 10.1038/sj.npp.1301571; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Nakahashi T, 2000, FEBS LETT, V470, P113, DOI 10.1016/S0014-5793(00)01302-8; Nettiksimmons J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091339; Oakley R, 2014, AGING DIS, V5, P114, DOI 10.14336/AD.2014.0500114; Orefice LL, 2013, J NEUROSCI, V33, P11618, DOI 10.1523/JNEUROSCI.0012-13.2013; Pan WH, 1998, NEUROPHARMACOLOGY, V37, P1553, DOI 10.1016/S0028-3908(98)00141-5; PELLEYMOUNTER MA, 1995, EXP NEUROL, V131, P229, DOI 10.1016/0014-4886(95)90045-4; Piccinni A, 2008, CHRONOBIOL INT, V25, P819, DOI 10.1080/07420520802387773; Pillai A, 2010, INT J NEUROPSYCHOPH, V13, P535, DOI 10.1017/S1461145709991015; Rasmussen P, 2009, EXP PHYSIOL, V94, P1062, DOI 10.1113/expphysiol.2009.048512; Ritter C, 2012, CRIT CARE, V16, DOI 10.1186/cc11902; Romanczyk TB, 2002, EUR J NEUROSCI, V15, P269, DOI 10.1046/j.0953-816x.2001.01858.x; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Rostami E, 2014, BRAIN RES, V1542, P195, DOI 10.1016/j.brainres.2013.10.047; Rothman SM, 2012, ANN NY ACAD SCI, V1264, P49, DOI 10.1111/j.1749-6632.2012.06525.x; Santarsieri M, 2015, BRAIN BEHAV IMMUN, V45, P15, DOI 10.1016/j.bbi.2014.09.003; Santarsieri M, 2014, J NEUROTRAUM, V31, P699, DOI 10.1089/neu.2013.3177; Shalev I, 2009, PSYCHONEUROENDOCRINO, V34, P382, DOI 10.1016/j.psyneuen.2008.09.017; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tapia-Arancibia L, 2008, BRAIN RES REV, V59, P201, DOI 10.1016/j.brainresrev.2008.07.007; Terracciano A, 2013, WORLD J BIOL PSYCHIA, V14, P583, DOI 10.3109/15622975.2011.616533; Trajkovska V, 2007, BRAIN RES BULL, V73, P143, DOI 10.1016/j.brainresbull.2007.03.009; Tsuchimine S, 2014, NEUROPSYCHOBIOLOGY, V69, P83, DOI 10.1159/000358061; Vidaurre OG, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.143; Wagner AK, 2010, EUR J PHYS REHAB MED, V46, P549; Wagner Amy K, 2013, Pathophysiology, V20, P39, DOI 10.1016/j.pathophys.2012.02.007; Wagner AK, 2011, J CEREBR BLOOD F MET, V31, P1886, DOI 10.1038/jcbfm.2011.31; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Wan RQ, 2014, J NEUROCHEM, V129, P573, DOI 10.1111/jnc.12656; Wang H, 2002, NEUROSCIENCE, V112, P967, DOI 10.1016/S0306-4522(02)00085-4; Webster MJ, 2006, GENE EXPR PATTERNS, V6, P941, DOI 10.1016/j.modgep.2006.03.009; Wise EK, 2012, ARCH PHYS MED REHAB, V93, P1319, DOI 10.1016/j.apmr.2012.05.009; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; Yang AC, 2010, AM J MED GENET B, V153B, P1024, DOI 10.1002/ajmg.b.31069; Zuccato C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022966	72	55	57	2	15	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JAN	2016	30	1					83	93		10.1177/1545968315586465			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	CZ5VH	WOS:000367169900008	25979196	Green Accepted			2022-02-06	
J	Chesnut, RM; Bleck, TP; Citerio, G; Classen, J; Cooper, DJ; Coplin, WM; Diringer, MN; Grande, PO; Hemphill, JC; Hutchinson, PJ; Le Roux, P; Mayer, SA; Menon, DK; Myburgh, JA; Okonkwo, DO; Robertson, CS; Sahuquillo, J; Stocchetti, N; Sung, G; Temkin, N; Vespa, PM; Videtta, W; Yonas, H				Chesnut, Randall M.; Bleck, Thomas P.; Citerio, Giuseppe; Classen, Jan; Cooper, D. James; Coplin, William M.; Diringer, Michael N.; Graende, Per-Olof; Hemphill, J. Claude, III; Hutchinson, Peter J.; Le Roux, Peter; Mayer, Stephan A.; Menon, David K.; Myburgh, John A.; Okonkwo, David O.; Robertson, Claudia S.; Sahuquillo, Juan; Stocchetti, Nino; Sung, Gene; Temkin, Nancy; Vespa, Paul M.; Videtta, Walter; Yonas, Howard			A Consensus-Based Interpretation of the Benchmark Evidence from South American Trials: Treatment of Intracranial Pressure Trial	JOURNAL OF NEUROTRAUMA			English	Article						BEST TRIP trial; Consensus Development Conference; intracranial pressure; neurocritical care; traumatic brain injury	TRAUMATIC BRAIN-INJURY	Widely-varying published and presented analyses of the Benchmark Evidence From South American Trials: Treatment of Intracranial Pressure (BEST TRIP) randomized controlled trial of intracranial pressure (ICP) monitoring have suggested denying trial generalizability, questioning the need for ICP monitoring in severe traumatic brain injury (sTBI), re-assessing current clinical approaches to monitored ICP, and initiating a general ICP-monitoring moratorium. In response to this dissonance, 23 clinically-active, international opinion leaders in acute-care sTBI management met to draft a consensus statement to interpret this study. A Delphi method-based approach employed iterative pre-meeting polling to codify the group's general opinions, followed by an in-person meeting wherein individual statements were refined. Statements required an agreement threshold of more than 70% by blinded voting for approval. Seven precisely-worded statements resulted, with agreement levels of 83% to 100%. These statements, which should be read in toto to properly reflect the group's consensus positions, conclude that the BEST TRIP trial: 1) studied protocols, not ICP-monitoring per se; 2) applies only to those protocols and specific study groups and should not be generalized to other treatment approaches or patient groups; 3) strongly calls for further research on ICP interpretation and use; 4) should be applied cautiously to regions with much different treatment milieu; 5) did not investigate the utility of treating monitored ICP in the specific patient group with established intracranial hypertension; 6) should not change the practice of those currently monitoring ICP; and 7) provided a protocol, used in non-monitored study patients, that should be considered when treating without ICP monitoring. Consideration of these statements can clarify study interpretation.	[Chesnut, Randall M.; Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Bleck, Thomas P.] Rush Univ, Med Ctr, Dept Neurol, Chicago, IL 60612 USA; [Citerio, Giuseppe] Univ Milano Bicocca, Dept Hlth Sci, Milan, Italy; [Classen, Jan] Columbia Univ, Div Crit Care Neurol, New York, NY USA; [Classen, Jan] Columbia Univ, Comprehens Epilepsy Ctr, New York, NY USA; [Cooper, D. James] Alfred Hosp, Dept Intens Care, Melbourne, Vic, Australia; [Coplin, William M.] St Anthony Hosp, Neurosurg Intens Care, Lakewood, CO USA; [Diringer, Michael N.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Graende, Per-Olof] Univ Lund Hosp, Anesthesiol & Intens Care, S-22185 Lund, Sweden; [Hemphill, J. Claude, III] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Hemphill, J. Claude, III] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Hutchinson, Peter J.] Addenbrookes Hosp, Div Neurosurg, Cambridge, England; [Hutchinson, Peter J.] Univ Cambridge, Cambridge, England; [Le Roux, Peter] Lankenau Med Ctr, Neurosurg, Wynnewood, PA USA; [Mayer, Stephan A.] Icahn Sch Med Mt Sinai, Inst Crit Care Med, New York, NY 10029 USA; [Menon, David K.] Univ Cambridge, Div Anaesthesia, Cambridge, England; [Myburgh, John A.] Univ New S Wales, Dept Intens Care Med, Sydney, NSW, Australia; [Myburgh, John A.] George Inst Global Hlth, Sydney, NSW, Australia; [Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurol Surg, Houston, TX 77030 USA; [Sahuquillo, Juan] Vall dHebron Univ Hosp, Dept Neurol Surg, Barcelona, Spain; [Stocchetti, Nino] Univ Milan, Dept Physiopathol & Transplant, Milan, Italy; [Stocchetti, Nino] Neuro ICU Fdn IRCCS Ca Granda Osped Maggiore Poli, Milan, Italy; [Sung, Gene] Univ So Calif, Dept Neurol, Los Angeles, CA USA; [Vespa, Paul M.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Videtta, Walter] Hosp Nacl Prof Alejandro Posadas, Intens Care Med, Buenos Aires, DF, Argentina; [Yonas, Howard] Univ New Mexico, Dept Neurol Surg, Albuquerque, NM 87131 USA		Chesnut, RM (corresponding author), Univ Washington, Harborview Med Ctr, Dept Neurol Surg, Mailstop 359766,325 Ninth Ave, Seattle, WA 98104 USA.	chesnutr@uw.edu	Citerio, Giuseppe/B-1839-2015; Stocchetti, Nino/O-7444-2017; Bleck, Thomas/R-2286-2019; Sahuquillo, Juan/B-3577-2008; Diringer, Michael N/C-1165-2008; Hemphill, Claude/AAY-5630-2021; Cooper, D. James/G-7961-2013; Demchuk, Andrew M/E-1103-2012; Bleck, Thomas/D-3772-2009	Citerio, Giuseppe/0000-0002-5374-3161; Stocchetti, Nino/0000-0003-3250-6834; Bleck, Thomas/0000-0002-8267-9787; Sahuquillo, Juan/0000-0003-0713-5875; Diringer, Michael N/0000-0003-2337-5537; Hemphill, Claude/0000-0003-4019-7525; Cooper, D. James/0000-0002-5872-9051; Demchuk, Andrew M/0000-0002-4930-7789; Hutchinson, Peter/0000-0002-2796-1835; Chesnut, Randall/0000-0001-6377-3666	University of Washington Department of Neurological Surgery; Brain Trauma Foundation; Integra Lifesciences Corp.; Codman & Shurtleff, Inc.; Neuroptics Inc.; Sophysa USA Inc.; Raumedic Inc.; Orsan Medical Technologies; Moberg Research Inc; Integra LifeSciences; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090, NIHR-RP-R3-12-013] Funding Source: researchfish	This meeting was supported by internal funding from the University of Washington Department of Neurological Surgery, a grant from the Brain Trauma Foundation, and unrestricted grants solicited from the following industrial partners: Integra Lifesciences Corp., Codman & Shurtleff, Inc., Neuroptics Inc., Sophysa USA Inc., Raumedic Inc., Orsan Medical Technologies, and Moberg Research Inc. Industrial support was solicited and accepted under the conditions of allowing silent observation of the meeting without any input, interaction, or involvement in the conference proceedings, analysis of statements, or the writing or editing of any manuscripts resulting from this meeting.; Prof. Chesnut has an Endowed Neurotrauma Professorship from Integra LifeSciences and is a consultant for Orsan Medical and InnerSpace. Prof. Citerio is a consultant for Codman. Dr. Claassen is on the advisory board of Actelion and SAGE for research planning. Dr. Coplin is a consultant for Integra LifeSciences. Prof. Hutchinson is director of Technicam as manufacturer of a cranial access device and has received honoraria from Codman. Dr. LeRoux is a consultant for Integra LifeSciences and Codman and receives research funding from Integra LifeSciences. Prof. Mayer is a consultant for Orsan Medical. Prof. Stocchetti is a consultant for Orsan Medical.	Albuquerque FC, 2013, WORLD NEUROSURG, V79, P598, DOI 10.1016/j.wneu.2013.03.045; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chesnut RM, 2013, INTENS CARE MED, V39, P771, DOI 10.1007/s00134-013-2852-9; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; De Bonis P, 2013, NEW ENGL J MED, V368, P1749, DOI 10.1056/NEJMc1301076; Hartl R, 2013, WORLD NEUROSURG, V79, P599, DOI 10.1016/j.wneu.2013.03.046; Hutchinson PJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1000; Levitt MR, 2013, WORLD NEUROSURG, V79, P600, DOI 10.1016/j.wneu.2013.03.047; Mattei TA, 2013, WORLD NEUROSURG, V79, P602, DOI 10.1016/j.wneu.2013.03.048; Pilge S, 2013, ANAESTHESIST, V62, P562, DOI 10.1007/s00101-013-2194-6; Romner B, 2013, NAT REV NEUROL, V9, P185, DOI 10.1038/nrneurol.2013.37; Ropper AE, 2013, NEUROSURGERY, V72, pN19, DOI 10.1227/01.neu.0000428424.83867.87; Ropper AH, 2012, NEW ENGL J MED, V367, P2539, DOI 10.1056/NEJMe1212289	13	55	57	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2015	32	22					1722	1724		10.1089/neu.2015.3976			3	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CV6ST	WOS:000364401500002	26061135				2022-02-06	
J	Lafrenaye, AD; Todani, M; Walker, SA; Povlishock, JT				Lafrenaye, Audrey D.; Todani, Masaki; Walker, Susan A.; Povlishock, John T.			Microglia processes associate with diffusely injured axons following mild traumatic brain injury in the micro pig	JOURNAL OF NEUROINFLAMMATION			English	Article						Mild traumatic brain injury; Diffuse axonal injury; Neuroinflammation; Microglia; Micro pig	SYNAPSE INTERACTIONS; OPTIC-NERVE; ACTIVATION; INFLAMMATION; MATTER; WHITE; NEUROINFLAMMATION; MACROPHAGES; ATROPHY; PATHOPHYSIOLOGY	Background: Mild traumatic brain injury (mTBI) is an all too common occurrence that exacts significant personal and societal costs. The pathophysiology of mTBI is complex, with reports routinely correlating diffuse axonal injury (DAI) with prolonged morbidity. Progressive chronic neuroinflammation has also recently been correlated to morbidity, however, the potential association between neuroinflammatory microglia and DAI is not well understood. The majority of studies exploring neuroinflammatory responses to TBI have focused on more chronic phases of injury involving phagocytosis associated with Wallerian change. Little, however, is known regarding the neuroinflammatory response seen acutely following diffuse mTBI and its potential relationship to early DAI. Additionally, while inflammation is drastically different in rodents compared to humans, pigs and humans share very similar inflammatory profiles and responses. Methods: In the current study, we employed a modified central fluid percussion model in micro pigs. Using this model of diffuse mTBI, paired with various immunohistological endpoints, we assessed the potential association between acute thalamic DAI and neuroinflammation 6 h following injury. Results: Injured micro pigs displayed substantial axonal damage reflected in the presence of APP+ proximal axonal swellings, which were particularly prominent in the thalamus. In companion, the same thalamic sites displayed extensive neuroinflammation, which was observed using Iba-1 immunohistochemistry. The physical relationship between microglia and DAI, assessed via confocal 3D analysis, revealed a dramatic increase in the number of Iba-1+ microglial processes that contacted APP+ proximal axonal swellings compared to uninjured myelinated thalamic axons in sham animals. Conclusions: In aggregate, these studies reveal acute microglial process convergence on proximal axonal swellings undergoing DAI, an interaction not previously recognized in the literature. These findings transform our understanding of acute neuroinflammation following mTBI and may suggest its potential as a diagnostic and/or a therapeutic target.	[Lafrenaye, Audrey D.; Todani, Masaki; Walker, Susan A.; Povlishock, John T.] Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, Richmond, VA 23298 USA; [Todani, Masaki] Yamaguchi Univ, Adv Med Emergency & Crit Care Ctr, Yamaguchi, Japan		Lafrenaye, AD (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	forrestad@vcu.edu			U.S. ArmyUnited States Department of Defense [W81XWH-10-1-0623, WH81XWH-14-2-0018]; NIH-NINDS CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P30NS047463]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463] Funding Source: NIH RePORTER	The authors would like to thank Dr. Scott Henderson for his expertise in microscopy and image analysis, Dr. Robert Hamm for his biostatistical assistance and knowledge as well as Drs. David Loane, Kevin Wang, Patrick Kochanek, and Michelle Block for invigorating scientific discussions and suggestions. We would also like to recognize Lynn Davis, Jesse Sims, Karen Gorse, Judy Williamson, Frances White, and Dr. Thomas Taetzsch for invaluable technical assistance. This work was performed as a component of the Operation Brain Trauma Therapy consortium, which is supported by U.S. Army grants W81XWH-10-1-0623 and WH81XWH-14-2-0018. Microscopy was performed at the VCU Department of Anatomy and Neurobiology Microscopy Facility, supported, in part, with funding from NIH-NINDS Center core grant 5P30NS047463.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Baalman K, 2015, J NEUROSCI, V35, P2283, DOI 10.1523/JNEUROSCI.3751-14.2015; Banati RB, 2002, GLIA, V40, P206, DOI 10.1002/glia.10144; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Batchelor PE, 2002, MOL CELL NEUROSCI, V21, P436, DOI 10.1006/mcne.2002.1185; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bove AA, 2014, AM J RESP CRIT CARE, V189, P1479, DOI 10.1164/rccm.201309-1662CI; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Chen ZH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5486; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Eyo UB, 2015, J NEUROSCI, V35, P2417, DOI 10.1523/JNEUROSCI.3279-14.2015; Eyo UB, 2014, J NEUROSCI, V34, P10528, DOI 10.1523/JNEUROSCI.0416-14.2014; Fairbairn L, 2011, J LEUKOCYTE BIOL, V89, P855, DOI 10.1189/jlb.1110607; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Girard S, 2013, GLIA, V61, P813, DOI 10.1002/glia.22478; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Gyoneva S, 2015, TRENDS PHARMACOL SCI, P1; Hanell A, 2015, ACTA NEUROPATHOL, V129, P317, DOI 10.1007/s00401-014-1376-x; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Heinz S, 2003, J BIOL CHEM, V278, P21502, DOI 10.1074/jbc.M301476200; Hemphill MA, 2015, NEURON, V85, P1177, DOI 10.1016/j.neuron.2015.02.041; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Howell OW, 2010, J NEUROPATH EXP NEUR, V69, P1017, DOI 10.1097/NEN.0b013e3181f3a5b1; Jebelli J, 2015, ANN NY ACAD SCI, V1351, P1, DOI 10.1111/nyas.12711; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Karve I.P., 2015, BR J PHARM; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kondo Y, 2011, J NEUROSCI, V31, P3610, DOI 10.1523/JNEUROSCI.6344-10.2011; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; Krabbe G, 2012, BRAIN BEHAV IMMUN, V26, P419, DOI 10.1016/j.bbi.2011.12.002; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kyritsis N, 2012, SCIENCE, V338, P1353, DOI 10.1126/science.1228773; Lafrenaye AD, 2014, J CEREBR BLOOD F MET, V34, P1628, DOI 10.1038/jcbfm.2014.122; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; LoPachin RM, 1997, TOXICOL APPL PHARM, V143, P233, DOI 10.1006/taap.1997.8106; Martinez FO, 2013, BLOOD, V121, pE57, DOI 10.1182/blood-2012-06-436212; McGinn Melissa J, 2015, Handb Clin Neurol, V127, P67, DOI 10.1016/B978-0-444-52892-6.00005-2; Mckay SM, 2007, J NEUROPATH EXP NEUR, V66, P698, DOI 10.1097/nen.0b013e3181256b32; Miyamoto A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00070; MURPHY PM, 1993, CELL, V72, P823, DOI 10.1016/0092-8674(93)90571-7; Nemeth CL, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0174-7; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Oehmichen M, 1999, ACTA NEUROPATHOL, V97, P491, DOI 10.1007/s004010051018; OGURA K, 1994, NEUROREPORT, V5, P1224, DOI 10.1097/00001756-199406020-00016; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Roshick C, 2006, INFECT IMMUN, V74, P225, DOI 10.1128/IAI.74.1.225-238.2006; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; Ryu J, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0153-3; Schafer DP, 2013, GLIA, V61, P24, DOI 10.1002/glia.22389; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Taetzsch T, 2015, GLIA, V63, P423, DOI 10.1002/glia.22762; Tam WY, 2014, SCI REP-UK, V4, DOI 10.1038/srep07279; Tang Y, 2015, MOL NEUROBIOL, DOI 10.1007/s12035-014-9070-5; Thomson L, 2014, PAEDIATR RESPIR REV, V15, P120, DOI 10.1016/j.prrv.2014.03.003; Tonges L, 2014, GLIA, V62, P217, DOI 10.1002/glia.22601; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Wake H, 2013, TRENDS NEUROSCI, V36, P209, DOI 10.1016/j.tins.2012.11.007; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wang JQ, 2013, J NEUROPATH EXP NEUR, V72, P768, DOI 10.1097/NEN.0b013e31829d8d9d; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Wernersson R, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-70; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yamasaki R, 2014, J EXP MED, V211, P1533, DOI 10.1084/jem.20132477	94	55	57	0	14	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	OCT 6	2015	12								186	10.1186/s12974-015-0405-6			15	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	CS6AH	WOS:000362158900001	26438203	gold, Green Published			2022-02-06	
J	Hoffmire, CA; Kemp, JE; Bossarte, RM				Hoffmire, Claire A.; Kemp, Janet E.; Bossarte, Robert M.			Changes in Suicide Mortality for Veterans and Nonveterans by Gender and History of VHA Service Use, 2000-2010	PSYCHIATRIC SERVICES			English	Article							ADVERSE CHILDHOOD EXPERIENCES; DEATH REPORTING SYSTEM; TRAUMATIC BRAIN-INJURY; 16 STATES; RISK; AFGHANISTAN; INDIVIDUALS; INCREASE; RATES	Objective: Veterans are believed to be at high risk of suicide. However, research comparing suicide rates between veterans and nonveterans is limited, and even less is known regarding differences by history of Veterans Health Administration (VHA) service use. This study directly compared veteran and nonveteran suicide risk while for the first time differentiating veterans by VHA service use. Methods: The cross-sectional study analyzed data from 173,969 adult suicide decedents from 23 states (2000-2010) included in the U.S. Department of Veterans Affairs suicide data archive. Annual standardized mortality ratios (SMRs) were computed for veterans compared with nonveterans and for veterans who used VHA services compared with veterans who did not, overall and separately for males and females. Results: After the analysis controlled for age and gender differences, the number of observed veteran suicides was approximately 20% higher than expected in 2000 (SMR=1.19, 95% confidence interval [CI]=1.10-1.28), and this increased to 60% higher by 2010 (SMR=1.63, CI=1.58-1.68). The elevated risk for female veterans (2010 SMR=5.89) was higher than that observed for male veterans (2010 SMR=1.54). Trends for non-VHA-utilizing veterans mirrored those of the veteran population as a whole, and the SMR for VHA-utilizing veterans declined. Since 2003, the number of suicides among VHA-utilizing veterans was less than expected when compared directly with the suicide rate among non-VHA-utilizing veterans. Conclusions: Veterans are members of the community and, as such, are an important part of observed increases in U.S. suicide rates. Not all veterans are at equal or increasing risk of suicide, however. VHA-utilizing veterans appear to have declining absolute and relative suicide rates.	[Hoffmire, Claire A.; Kemp, Janet E.] US Dept Vet Affairs, Ctr Excellence Suicide Prevent VISN2, Canandaigua, NY USA; [Bossarte, Robert M.] US Dept Vet Affairs, Off Publ Hlth, Washington, DC USA; [Hoffmire, Claire A.; Bossarte, Robert M.] Univ Rochester, Dept Psychiat, Rochester, NY USA		Hoffmire, CA (corresponding author), US Dept Vet Affairs, Ctr Excellence Suicide Prevent VISN2, Canandaigua, NY USA.	claire.hoffmire@va.gov	Bossarte, Robert/AAF-8571-2019				[Anonymous], 2013, DAT STAT; [Anonymous], 2008, 116001 VAH; Armed Forces Health Surveillance Center (AFHSC), 2012, MSMR, V19, P7; Baker SP, 2013, AM J PREV MED, V44, P146, DOI 10.1016/j.amepre.2012.10.010; Black SA, 2011, MIL PSYCHOL, V23, P433, DOI 10.1080/08995605.2011.590409; Blosnich JR, 2014, JAMA PSYCHIAT, V71, P1041, DOI 10.1001/jamapsychiatry.2014.724; Blow FC, 2012, AM J PUBLIC HEALTH, V102, pS98, DOI 10.2105/AJPH.2011.300441; Bossarte RM, 2013, PSYCHIAT SERV, V64, P713, DOI 10.1176/appi.ps.201300128; Bossarte RM, 2010, MIL MED, V175, P703, DOI 10.7205/MILMED-D-10-00247; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Centers for Disease Control and Prevention (CDC), 1800, MMWR Morb Mortal Wkly Rep, V62, P321; Erlangsen A, 2014, LANCET PSYCHIAT; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Goldman DA, 2000, STAT MED, V19, P1081, DOI 10.1002/(SICI)1097-0258(20000430)19:8<1081::AID-SIM406>3.3.CO;2-1; Hoffmire CA, 2013, ANN EPIDEMIOL, V23, P298, DOI 10.1016/j.annepidem.2013.03.007; Hoyert Donna L, 2012, Natl Vital Stat Rep, V61, P1; Kang HK, 2008, JAMA-J AM MED ASSOC, V300, P652, DOI 10.1001/jama.300.6.652; Kaplan MS, 2012, AM J PUBLIC HEALTH, V102, pS21, DOI 10.2105/AJPH.2011.300611; Karch Debra L., 2012, Morbidity and Mortality Weekly Report, V61, P1; Katz IR, 2012, AM J PUBLIC HEALTH, V102, pS105, DOI 10.2105/AJPH.2011.300503; Kimerling R, 2010, AM J PUBLIC HEALTH, V100, P1409, DOI 10.2105/AJPH.2009.171793; Klein RJSC., 2001, HLTH PEOPLE STAT NOT, V20; McCarthy JF, 2009, AM J EPIDEMIOL, V169, P1033, DOI 10.1093/aje/kwp010; McIntosh JL, 2012, US SUIC 2010 OFF FIN; Miller M, 2012, AM J PUBLIC HEALTH, V102, pS20, DOI 10.2105/AJPH.2011.300572; National Strategy for Suicide Prevention, 2012, GOALS OBJ ACT REP US; Reeves A, 2012, LANCET, V380, P1813, DOI 10.1016/S0140-6736(12)61910-2; Rockett Ian R H, 2012, Am J Public Health, V102, pe84, DOI 10.2105/AJPH.2012.300960; Rockett IRH, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-705; US Department of Defense, 2013, DEP DEF ANN REP SEX, V1; VENZON DJ, 1988, J R STAT SOC C-APPL, V37, P87, DOI 10.2307/2347496; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006; Yip PSF, 2011, J EPIDEMIOL COMMUN H, V65, P733, DOI 10.1136/jech.2010.110726	33	55	55	0	4	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	1075-2730	1557-9700		PSYCHIAT SERV	Psychiatr. Serv.	SEP	2015	66	9					959	965		10.1176/appi.ps.201400031			7	Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry	DE6EB	WOS:000370725400016	25930036	Green Submitted, Bronze			2022-02-06	
J	Kehoe, A; Rennie, S; Smith, JE				Kehoe, A.; Rennie, S.; Smith, J. E.			Glasgow Coma Scale is unreliable for the prediction of severe head injury in elderly trauma patients	EMERGENCY MEDICINE JOURNAL			English	Article							BRAIN-INJURY; MORTALITY; WORSE; AGE	Objectives and background Elderly patients comprise an ever-increasing proportion of major trauma patients. The presenting GCS in elderly patients with traumatic brain injury (TBI) may not reflect the severity of injury as accurately as it does in the younger patient population. However, GCS is often used as part of the decision tool to define the population transferred directly to a major trauma centre. The aim of this study was to explore the relationship between age and presenting GCS in patients with isolated TBI. Methods A retrospective database review was undertaken using the Trauma Audit and Research Network database. All patients presenting to Derriford Hospital, Plymouth, between 1 January 2009 and 31 May 2014 with isolated TBI were included. Demographic, mechanistic, physiological, resource use and outcome data were collected. Abbreviated injury scale (AIS) was recorded for all patients. Patients were categorised into those older and younger than 65 years on presentation. Distribution of GCS, categorised into severe (GCS 3-8), moderate (GCS 9-12) and mild TBI (13-15), was compared between the age groups. Median GCS at each AIS level was also compared. Results The distribution of GCS differed between young and old patients with TBI (22.1% vs 9.8% had a GCS 3-8, respectively) despite a higher burden of anatomical injury in the elderly group. Presenting GCS was higher in the elderly at each level of AIS. The difference was more apparent in the presence of more severe injury (AIS 5). Conclusions Elderly patients who have sustained isolated severe TBI may present with a higher GCS than younger patients. Triage tools using GCS may need to be modified and validated for use in elderly patients with TBI.	[Kehoe, A.; Rennie, S.; Smith, J. E.] Derriford Hosp, Emergency Dept, Plymouth PL6 8DH, Devon, England; [Smith, J. E.] Royal Ctr Def Med Res & Acad, Acad Dept Mil Emergency Med, Med Directorate, Joint Med Command, Birmingham, W Midlands, England		Smith, JE (corresponding author), Derriford Hosp, Emergency Dept, Derriford Rd, Plymouth PL6 8DH, Devon, England.	jasonesmith@doctors.org.uk	Smith, Jason Edward/H-9380-2013	Smith, Jason Edward/0000-0002-6143-0421			*ASS ADV AUT MED, 1994, INJ IMP SCAL 1994; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Field V., 2012, EMERG MED J, V19, P737; Harrison DA, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17230; Lecky FE, 2002, EMERG MED J, V19, P520, DOI 10.1136/emj.19.6.520; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Potter D, 2013, J R Nav Med Serv, V99, P16; Santos AP, 2014, EMERG MED J, V31, P148, DOI 10.1136/emermed-2012-201782; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEASDALE G, 1974, LANCET, V2, P81; Yates D, 2007, BMJ-BRIT MED J, V335, P719, DOI 10.1136/bmj.39331.702951.47	17	55	55	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205	1472-0213		EMERG MED J	Emerg. Med. J.	AUG	2015	32	8					613	615		10.1136/emermed-2013-203488			3	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	CN7BK	WOS:000358588300007	25280479				2022-02-06	
J	Harish, G; Mahadevan, A; Pruthi, N; Sreenivasamurthy, SK; Puttamallesh, VN; Prasad, TSK; Shankar, SK; Bharath, MMS				Harish, Gangadharappa; Mahadevan, Anita; Pruthi, Nupur; Sreenivasamurthy, Sreelakshmi K.; Puttamallesh, Vinuth N.; Prasad, Thottethodi Subrahmanya Keshava; Shankar, Susarla Krishna; Bharath, Muchukunte Mukunda Srinivas			Characterization of traumatic brain injury in human brains reveals distinct cellular and molecular changes in contusion and pericontusion	JOURNAL OF NEUROCHEMISTRY			English	Article						human brain; mitochondria; neurotrauma; oxidative stress; proteomics; synaptic terminal	SUPEROXIDE-DISMUTASE EXPRESSION; FIBRILLARY ACIDIC PROTEIN; HUMAN CEREBROSPINAL-FLUID; HUMAN HEAD-INJURY; OXIDATIVE STRESS; IMMUNOHISTOCHEMICAL EVALUATION; PROTEOMIC IDENTIFICATION; TREATMENT STRATEGIES; YKL-40 EXPRESSION; PERCUSSION INJURY	Traumatic brain injury (TBI) contributes to fatalities and neurological disabilities worldwide. While primary injury causes immediate damage, secondary events contribute to long-term neurological defects. Contusions (Ct) are primary injuries correlated with poor clinical prognosis, and can expand leading to delayed neurological deterioration. Pericontusion (PC) (penumbra), the region surrounding Ct, can also expand with edema, increased intracranial pressure, ischemia, and poor clinical outcome. Analysis of Ct and PC can therefore assist in understanding the pathobiology of TBI and its management. This study on human TBI brains noted extensive neuronal, astroglial and inflammatory changes, alterations in mitochondrial, synaptic and oxidative markers, and associated proteomic profile, with distinct differences in Ct and PC. While Ct displayed petechial hemorrhages, thrombosis, inflammation, neuronal pyknosis, and astrogliosis, PC revealed edema, vacuolation of neuropil, axonal loss, and dystrophic changes. Proteomic analysis demonstrated altered immune response, synaptic, and mitochondrial dysfunction, among others, in Ct, while PC displayed altered regulation of neurogenesis and cytoskeletal architecture, among others. TBI brains displayed oxidative damage, glutathione depletion, mitochondrial dysfunction, and loss of synaptic proteins, with these changes being more profound in Ct. We suggest that analysis of markers specific to Ct and PC may be valuable in the evaluation of TBI pathobiology and therapeutics. We have characterized the primary injury in human traumatic brain injury (TBI). Contusions (Ct) - the injury core displayed hemorrhages, inflammation, and astrogliosis, while the surrounding pericontusion (PC) revealed edema, vacuolation, microglial activation, axonal loss, and dystrophy. Proteomic analysis demonstrated altered immune response, synaptic and mitochondrial dysfunction in Ct, and altered regulation of neurogenesis and cytoskeletal architecture in PC. Ct displayed more oxidative damage, mitochondrial, and synaptic dysfunction compared to PC.	[Harish, Gangadharappa; Bharath, Muchukunte Mukunda Srinivas] Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neurochem, Bangalore 560029, Karnataka, India; [Mahadevan, Anita; Shankar, Susarla Krishna] Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neuropathol, Bangalore, Karnataka, India; [Pruthi, Nupur] Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neurosurg, Bangalore, Karnataka, India; [Sreenivasamurthy, Sreelakshmi K.; Puttamallesh, Vinuth N.; Prasad, Thottethodi Subrahmanya Keshava] Whitefield, Inst Bioinformat, Bangalore, Karnataka, India; [Sreenivasamurthy, Sreelakshmi K.] Manipal Univ, Manipal, Karnataka, India		Bharath, MMS (corresponding author), Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neurochem, 2900 Hosur Rd, Bangalore 560029, Karnataka, India.	bharath@nimhans.kar.nic.in	Prasad, Keshava/F-7631-2010; Sreenivasamurthy, Sreelakshmi/ABD-4253-2021; Sreenivasamurthy, Sreelakshmi Kenkere/W-1942-2019	Prasad, Keshava/0000-0002-6206-2384; Sreenivasamurthy, Sreelakshmi/0000-0002-8891-3714; 	Indian Council of Medical Research (ICMR) (IRIS) [2009-09910]; DBT, IndiaDepartment of Biotechnology (DBT) India [BT/01/COE/08/05]; University Grants Commission, IndiaUniversity Grants Commission, India	The authors thank all donors and their relatives for tissue samples. These tissues are archived at the Human Brain Bank, NIMHANS, Bangalore, India. This study was supported by the Indian Council of Medical Research (ICMR) (IRIS No. 2009-09910 to MMSB). GH is the senior research fellow of ICMR. TSK and S.K. Shankar are supported by 'DBT Programme Support on Neuroproteomics of Neurological Disorders' by DBT, India (BT/01/COE/08/05). Sreelakshmi K. Sreenivasamurthy is a recipient of Junior Research Fellowship from the University Grants Commission, India. We thank Agilent Technologies for instrumentation support. The authors have no conflicts of interest to declare.	Awasthi D, 2003, NEUROSCI LETT, V345, P29, DOI 10.1016/S0304-3940(03)00497-X; Bagnyukova TV, 2003, J THERM BIOL, V28, P21, DOI 10.1016/S0306-4565(02)00031-1; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Bemeur C, 2004, NEUROCHEM INT, V45, P1167, DOI 10.1016/j.neuint.2004.06.010; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Bonneh-Barkay D, 2012, BRAIN PATHOL, V22, P530, DOI 10.1111/j.1750-3639.2011.00550.x; Bonneh-Barkay D, 2010, J NEUROTRAUM, V27, P1215, DOI 10.1089/neu.2010.1310; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Boutte AM, 2012, ELECTROPHORESIS, V33, P3693, DOI 10.1002/elps.201200196; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chandana R, 2009, INDIAN J MED RES, V129, P189; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Choi Angela O., 2007, Journal of Nanobiotechnology, V5, P1, DOI 10.1186/1477-3155-5-1; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Conti A, 2004, J NEUROTRAUM, V21, P854, DOI 10.1089/0897715041526212; Daly C, 2000, P NATL ACAD SCI USA, V97, P6120, DOI 10.1073/pnas.97.11.6120; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Fabian RH, 1998, J NEUROTRAUM, V15, P433, DOI 10.1089/neu.1998.15.433; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Galluzzi L, 2008, METHOD ENZYMOL, V442, P355, DOI 10.1016/S0076-6879(08)01418-3; Gao WM, 2007, J NEUROTRAUM, V24, P43, DOI 10.1089/neu.2006.0061; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Goel R, 2012, MOL BIOSYST, V8, P453, DOI 10.1039/c1mb05340j; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Harish G, 2013, NEUROPATH APPL NEURO, V39, P298, DOI 10.1111/j.1365-2990.2012.01285.x; Harish G, 2013, NEUROCHEM RES, V38, P186, DOI 10.1007/s11064-012-0907-x; Harish G, 2012, BIOPRESERV BIOBANK, V10, P253, DOI 10.1089/bio.2012.0001; Harish G, 2011, BIOPRESERV BIOBANK, V9, P379, DOI 10.1089/bio.2011.0033; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415; Jiang XF, 2013, J SURG RES, V184, pE27, DOI 10.1016/j.jss.2013.03.067; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kandasamy K, 2009, NUCLEIC ACIDS RES, V37, pD773, DOI 10.1093/nar/gkn701; KITTO GB, 1967, BIOCHIM BIOPHYS ACTA, V139, P1, DOI 10.1016/0005-2744(67)90107-6; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Lee CG, 2011, ANNU REV PHYSIOL, V73, P479, DOI 10.1146/annurev-physiol-012110-142250; Liu L, 2012, CHINESE MED J-PEKING, V125, P3831, DOI 10.3760/cma.j.issn.0366-6999.2012.21.016; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Minambres E, 2008, J NEUROTRAUM, V25, P581, DOI 10.1089/neu.2007.0398; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Muthusamy Babylakshmi, 2013, Curr Protoc Bioinformatics, VChapter 1, DOI 10.1002/0471250953.bi0121s41; Narotam PK, 1998, ACTA NEUROCHIR, V140, P793, DOI 10.1007/s007010050181; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Oli MW, 2009, METHODS MOL BIOL, V566, P293, DOI 10.1007/978-1-59745-562-6_19; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Papa Linda, 2008, Expert Opin Med Diagn, V2, P937, DOI 10.1517/17530059.2.8.937; Pawar H, 2011, CANCER BIOL THER, V12, P510, DOI 10.4161/cbt.12.6.16833; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Peluffo H, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-12; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Prasad TSK, 2009, METHODS MOL BIOL, V577, P67, DOI 10.1007/978-1-60761-232-2_6; Ragaisis Vytautas, 2002, Medicina (Kaunas), V38, P243; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ramadasan-Nair R, 2014, J BIOL CHEM, V289, P485, DOI 10.1074/jbc.M113.493270; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reed TT, 2009, J NEUROSCI RES, V87, P408, DOI 10.1002/jnr.21872; Renjini R, 2012, NEUROCHEM RES, V37, P885, DOI 10.1007/s11064-011-0683-z; Rojo AI, 2004, J NEUROSCI, V24, P7324, DOI 10.1523/JNEUROSCI.2111-04.2004; SCHALEN W, 1991, ACTA ANAESTH SCAND, V35, P113, DOI 10.1111/j.1399-6576.1991.tb03258.x; Shojo H, 2006, BRAIN RES, V1078, P198, DOI 10.1016/j.brainres.2006.01.063; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sjodin MOD, 2010, J CHROMATOGR B, V878, P2003, DOI 10.1016/j.jchromb.2010.05.036; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Sotgiu S, 2005, EUR NEUROL, V54, P149, DOI 10.1159/000089935; Srere P. A., 1969, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(69)13005-0; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vizcaino JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Yang XY, 2009, BRAIN INJURY, V23, P830, DOI 10.1080/02699050903196670; Yasha TC, 1997, INDIAN J MED RES, V105, P141; Zheng WM, 2013, J NEUROTRAUM, V30, P1872, DOI 10.1089/neu.2010.1579; Zupanc GKH, 2007, PROTEOM CLIN APPL, V1, P1362, DOI 10.1002/prca.200700420	88	55	56	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUL	2015	134	1					156	172		10.1111/jnc.13082			17	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	CK6WH	WOS:000356368800016	25712633				2022-02-06	
J	Newgard, CD; Meier, EN; Bulger, EM; Buick, J; Sheehan, K; Lin, S; Minei, JR; Barnes-Mackey, RA; Brasel, K				Newgard, Craig D.; Meier, Eric N.; Bulger, Eileen M.; Buick, Jason; Sheehan, Kellie; Lin, Steve; Minei, Joseph R.; Barnes-Mackey, Roxy A.; Brasel, Karen		ROC Investigators	Revisiting the "Golden Hour": An Evaluation of Out-of-Hospital Time in Shock and Traumatic Brain Injury	ANNALS OF EMERGENCY MEDICINE			English	Article							PREHOSPITAL TIME; RESPONSE-TIME; TRIAGE RULE; HYPERTONIC RESUSCITATION; PARAMEDIC JUDGMENT; AMERICAN-COLLEGE; MAJOR TRAUMA; SURVIVAL; IMPACT; CARE	Study objective: We evaluate patients with shock and traumatic brain injury who were previously enrolled in an out-ofhospital clinical trial to test the association between out-of-hospital time and outcome. Methods: This was a secondary analysis of patients with shock and traumatic brain injury who were aged 15 years or older and enrolled in a Resuscitation Outcomes Consortium out-of-hospital clinical trial by 81 emergency medical services agencies transporting to 46 Level I and II trauma centers in 11 sites (May 2006 through May 2009). Inclusion criteria were systolic blood pressure less than or equal to 70 mm Hg or systolic blood pressure 71 to 90 mm Hg with pulse rate greater than or equal to 108 beats/min (shock cohort) and Glasgow Coma Scale score less than or equal to 8 (traumatic brain injury cohort); patients meeting both criteria were placed in the shock cohort. Primary outcomes were 28-day mortality (shock cohort) and 6-month Glasgow Outcome Scale-Extended score less than or equal to 4 (traumatic brain injury cohort). Results: There were 778 patients in the shock cohort (26% 28-day mortality) and 1,239 patients in the traumatic brain injury cohort (53% 6-month Glasgow Outcome Scale-Extended score <4). Out-of-hospital time greater than 60 minutes was not associated with worse outcomes after accounting for important confounders in the shock cohort (adjusted odds ratio [a0R] 1.42; 95% confidence interval [Cl] 0.77 to 2.62) or traumatic brain injury cohort (aOR 0.77; 95% Cl 0.51 to 1.15). However, shock patients requiring early critical hospital resources and arriving after 60 minutes had higher 28day mortality (aOR 2.37; 95% Cl 1.05 to 5.37); this finding was not observed among a similar traumatic brain injury subgroup. Conclusion: Among out-of-hospital trauma patients meeting physiologic criteria for shock and traumatic brain injury, there was no association between time and outcome. However, the subgroup of shock patients requiring early critical resources and arriving after 60 minutes had higher mortality.	[Newgard, Craig D.] Oregon Hlth & Sci Univ, Ctr Policy & Res Emergency Med, Dept Emergency Med, Portland, OR 97201 USA; [Meier, Eric N.; Sheehan, Kellie] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Bulger, Eileen M.] Univ Washington, Dept Surg, Seattle, WA 98195 USA; [Buick, Jason; Lin, Steve] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Rescu, Toronto, ON, Canada; [Minei, Joseph R.] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA; [Barnes-Mackey, Roxy A.] Vancouver Fire Dept, Vancouver, WA USA; [Barnes-Mackey, Roxy A.] Providence Med Grp, Happy Valley, OR USA; [Brasel, Karen] Med Coll Wisconsin, Dept Surg, Milwaukee, WI 53226 USA		Newgard, CD (corresponding author), Oregon Hlth & Sci Univ, Ctr Policy & Res Emergency Med, Dept Emergency Med, Portland, OR 97201 USA.	newgardc@ohsu.edu	Buick, Jason E/K-4816-2013; Lin, Steve/H-3723-2013	Buick, Jason E/0000-0002-1859-1713; Lin, Steve/0000-0002-8644-9719	(University of Washington Data Coordinating Center) from the National Heart, Lung, and Blood Institute [5U01 HL077863]; (Medical College of Wisconsin) from the National Heart, Lung, and Blood Institute [HL077866]; (University of Washington) from the National Heart, Lung, and Blood Institute [HL077867]; (University of Pittsburgh) from the National Heart, Lung, and Blood Institute [HL077871]; (St. Michael's Hospital) from the National Heart, Lung, and Blood Institute [HL077872]; (Oregon Health & Science University) from the National Heart, Lung, and Blood Institute [HL077873]; (University of Alabama at Birmingham) from the National Heart, Lung, and Blood Institute [HL077881]; (Ottawa Health Research Institute) from the National Heart, Lung, and Blood Institute [HL077885]; (University of Texas Southwest Medical Center/Dallas) from the National Heart, Lung, and Blood Institute [HL077887]; (University of California San Diego) from the National Heart, Lung, and Blood Institute [HL077908]; US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); Canadian Institutes of Health Research-Institute of Circulatory and Respiratory HealthCanadian Institutes of Health Research (CIHR); Defence Research and Development Canada; Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; American Heart AssociationAmerican Heart Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL077885, U01HL077866, U01HL077863, U01HL077881, U01HL077908, U01HL077871, U01HL077873, U01HL077872, U01HL077887, U01HL077867] Funding Source: NIH RePORTER	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist and provided the following details: The Resuscitation Outcomes Consortium is supported by a series of cooperative agreements to multiple regional clinical centers and 1 data coordinating center (5U01 HL077863, University of Washington Data Coordinating Center; HL077866, Medical College of Wisconsin; HL077867, University of Washington; HL077871, University of Pittsburgh; HL077872, St. Michael's Hospital; HL077873, Oregon Health & Science University; HL077881, University of Alabama at Birmingham; HL077885, Ottawa Health Research Institute; HL077887, University of Texas Southwest Medical Center/Dallas; and HL077908, University of California San Diego) from the National Heart, Lung, and Blood Institute, in partnership with the US Army Medical Research and Material Command, the Canadian Institutes of Health Research-Institute of Circulatory and Respiratory Health, Defence Research and Development Canada, the Heart and Stroke Foundation of Canada, and the American Heart Association.	BAXT WG, 1990, ANN EMERG MED, V19, P1401, DOI 10.1016/S0196-0644(05)82608-3; Becker LR, 2003, ACCIDENT ANAL PREV, V35, P941, DOI 10.1016/S0001-4575(02)00102-1; Blackwell TH, 2002, ACAD EMERG MED, V9, P288, DOI 10.1111/j.1553-2712.2002.tb01321.x; Brasel KJ, 2008, J AM COLL SURGEONS, V206, P220, DOI 10.1016/j.jamcollsurg.2007.07.020; Bulger EM, 2011, ANN SURG, V253, P431, DOI 10.1097/SLA.0b013e3181fcdb22; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P154; Committee on Trauma, 2006, RESOURCES OPTIMAL CA; De Maio VJ, 2003, ANN EMERG MED, V42, P242, DOI 10.1067/mem.2003.266; Di Bartolomeo S, 2007, INJURY, V38, P305, DOI 10.1016/j.injury.2006.10.005; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; Engum SA, 2000, J PEDIATR SURG, V35, P82, DOI 10.1016/S0022-3468(00)80082-2; FRIES GR, 1994, ANN EMERG MED, V24, P885, DOI 10.1016/S0196-0644(94)70207-1; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Hannan EL, 2005, J AM COLL SURGEONS, V200, P584, DOI 10.1016/j.jamcollsurg.2004.12.016; Henry MC, 1996, ACAD EMERG MED, V3, P992, DOI 10.1111/j.1553-2712.1996.tb03340.x; Kahn C A, 2001, Prehosp Emerg Care, V5, P261, DOI 10.1080/10903120190939751; Lerner EB, 2014, J TRAUMA ACUTE CARE, V76, P1157, DOI 10.1097/TA.0000000000000189; Lerner EB, 2003, ACAD EMERG MED, V10, P949, DOI 10.1197/S1069-6563(03)00313-0; Lerner EB, 2001, ACAD EMERG MED, V8, P758, DOI 10.1111/j.1553-2712.2001.tb00201.x; Mackersie RC, 2006, PREHOSP EMERG CARE, V10, P287, DOI 10.1080/10903120600721636; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; McConnell KJ, 2005, HEALTH SERV RES, V40, P435, DOI 10.1111/j.1475-6773.2005.0u367.x; McCoy CE, 2013, ANN EMERG MED, V61, P167, DOI 10.1016/j.annemergmed.2012.08.026; Newgard CD, 2006, ACAD EMERG MED, V13, P314, DOI 10.1197/j.aem.2005.09.011; Newgard CD, 2005, ACAD EMERG MED, V12, P679, DOI 10.1197/j.aem.2005.03.526; Newgard CD, 2007, ACAD EMERG MED, V14, P669, DOI 10.1197/j.aem.2006.11.038; Newgard CD, 2015, J TRAUMA ACUTE CARE, V78, P342, DOI 10.1097/TA.0000000000000478; Newgard CD, 2010, ANN EMERG MED, V55, P235, DOI 10.1016/j.annemergmed.2009.07.024; Newgard CD, 2010, J TRAUMA, V68, P452, DOI 10.1097/TA.0b013e3181ae20c9; Osterwalder Joseph J, 2002, Prehosp Disaster Med, V17, P75; PEPE PE, 1987, ANN EMERG MED, V16, P293, DOI 10.1016/S0196-0644(87)80174-9; Petri R W, 1995, Prehosp Disaster Med, V10, P24; PHILLIPS JA, 1993, J TRAUMA, V34, P127, DOI 10.1097/00005373-199301000-00024; Pons PT, 2005, ACAD EMERG MED, V12, P594, DOI 10.1197/j.aem.2005.02.013; Pons PT, 2002, J EMERG MED, V23, P43, DOI 10.1016/S0736-4679(02)00460-2; Pracht EE, 2007, MED CARE RES REV, V64, P83, DOI 10.1177/1077558706296241; Qazi K, 1998, ACAD EMERG MED, V5, P1002, DOI 10.1111/j.1553-2712.1998.tb02780.x; Rubin DB, 1987, MULTIPLE IMPUTATIN; Sampalis JS, 1999, J TRAUMA, V46, P565, DOI 10.1097/00005373-199904000-00004; SAMPALIS JS, 1993, J TRAUMA, V34, P252, DOI 10.1097/00005373-199302000-00014; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; Stiell IG, 2008, CAN MED ASSOC J, V178, P1141, DOI 10.1503/cmaj.071154; Terkelsen CJ, 2010, JAMA-J AM MED ASSOC, V304, P763, DOI 10.1001/jama.2010.1139; Wang HE, 2008, ANN EMERG MED, V52, P256, DOI 10.1016/j.annemergmed.2008.02.011; Wears RL, 2005, ANN EMERG MED, V46, P253, DOI 10.1016/j.annemergmed.2005.05.007; Wilde ET, 2013, HEALTH ECON, V22, P790, DOI 10.1002/hec.2851; ZECHNICH AD, 1995, ACAD EMERG MED, V2, P1043	48	55	56	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	JUL	2015	66	1					30	41		10.1016/j.annemergmed.2014.12.004			12	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	CM3AU	WOS:000357554400009	25596960	Green Accepted			2022-02-06	
J	Finfer, S				Finfer, Simon		Australian New Zealand Intensive C; Canadian Critical Care Trials Grp	Intensive versus conventional glucose control in critically ill patients with traumatic brain injury: long-term follow-up of a subgroup of patients from the NICE-SUGAR study	INTENSIVE CARE MEDICINE			English	Article						Brain injury; Blood glucose; Hypoglycemia; Treatment outcome; Randomized trial	TIGHT GLYCEMIC CONTROL; INSULIN THERAPY; HEAD-INJURY; HOSPITALIZED-PATIENTS; HYPERGLYCEMIA; MULTICENTER; METABOLISM; MORTALITY; IMPACT; SCORE	To compare the effect of intensive versus conventional blood glucose control in patients with traumatic brain injury. In a large international randomized trial patients were randomly assigned to a target blood glucose (BG) range of either 4.5-6.0 mmol/L (intensive control) or < 10 mmol/L (conventional control). Patients with traumatic brain injury (TBI) were identified at randomization and data were collected to examine the extended Glasgow outcome score (includes mortality) at 24 months. Of the 6104 randomized patients, 391 satisfied diagnostic criteria for TBI; 203 (51.9 %) were assigned to intensive and 188 (48.1 %) to conventional control; the primary outcome was available for 166 (81.8 %) and 149 (79.3 %) patients, respectively. The two groups had similar baseline characteristics. At 2 years 98 (58.7 %) patients in the intensive group and 79 (53.0 %) in the conventional group had a favorable neurological outcome (odds ratio [OR] 1.26, 95 % CI 0.81-1.97; P = 0.3); 35 patients (20.9 %) in the intensive group and 34 (22.8 %) in the conventional group had died (OR 0.90, 95 % CI 0.53-1.53; P = 0.7); moderate hypoglycemia (BG 2.3-3.9 mmol/L; 41-70 mg/dL) occurred in 160/202 (79.2 %) and 17/188 (9.0 %), respectively (OR 38.3, 95 % CI 21.0-70.1; P < 0.0001); severe hypoglycemia (BG a parts per thousand currency sign 2.2 mmol/L; a parts per thousand currency sign40 mg/dL) in 10 (4.9 %) and 0 (0.0 %), respectively (OR 20.5 95 % CI 1.2-351.6, P = 0.003). Although patients with traumatic brain injury randomly assigned to intensive compared to conventional glucose control experienced moderate and severe hypoglycemia more frequently, we found no significant difference in clinically important outcomes.	George Inst Global Hlth, Sydney, NSW 2001, Australia		Finfer, S (corresponding author), George Inst Global Hlth, GPO Box 5389, Sydney, NSW 2001, Australia.	sfinfer@georgeinstitute.org	Higgins, Alisa/AAM-8088-2020; Billot, Laurent/Y-1241-2019; Mehta, Sangeeta/C-4623-2015; Ranse, Jamie/AAU-1649-2020; Ferguson, Niall/D-7619-2019; Young, John D/M-9756-2016	Higgins, Alisa/0000-0001-8295-7559; Billot, Laurent/0000-0002-4975-9793; Ranse, Jamie/0000-0002-5265-6365; Ferguson, Niall/0000-0002-6213-5264; SHEHABI, Yahya/0000-0003-4707-7462; Whereat, Sarah/0000-0002-1933-5914; Parr, Michael/0000-0003-3507-474X; French, Craig/0000-0003-1363-9711; /0000-0002-4157-5148; Bellomo, Rinaldo/0000-0002-1650-8939; Young, John Duncan/0000-0002-6838-4835; MacMahon, Stephen/0000-0003-2064-7699; Lipman, Jeffrey/0000-0002-5965-9876; Micallef, Sharon/0000-0002-8496-2324; Finfer, Simon/0000-0002-2785-5864; McEvoy, Suzanne/0000-0002-9804-4276; Hammond, Naomi/0000-0002-6559-7747; Bass, Frances/0000-0003-3826-8558; Mitchell, Imogen/0000-0001-6013-4922			Annane D, 2010, JAMA-J AM MED ASSOC, V303, P341, DOI 10.1001/jama.2010.2; [Anonymous], 2012, DIABETES CARE, V35, pS11, DOI [10.2337/dc35-S011, 10.2337/dc12-s004, 10.2337/dc12-s011]; Arabi YM, 2008, CRIT CARE MED, V36, P3190, DOI 10.1097/CCM.0b013e31818f21aa; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Cinotti R, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0498-9; Coester A, 2010, J TRAUMA, V68, P904, DOI 10.1097/TA.0b013e3181c9afc2; De la Rosa GD, 2008, CRIT CARE, V12, DOI 10.1186/cc7017; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Egi M, 2010, MAYO CLIN PROC, V85, P217, DOI 10.4065/mcp.2009.0394; FINFER S, 2009, NEW ENGL J MED, V360, P1346; Finfer S, 2012, NEW ENGL J MED, V367, P1108, DOI 10.1056/NEJMoa1204942; Gale SC, 2007, AM SURGEON, V73, P454; Griesdale DE, 2009, CMAJ, V180, P831; Griesdale DEG, 2009, NEUROCRIT CARE, V11, P311, DOI 10.1007/s12028-009-9249-1; Hermanides J, 2010, CRIT CARE MED, V38, P1430, DOI 10.1097/CCM.0b013e3181de562c; Kalfon P, 2014, INTENS CARE MED, V40, P171, DOI 10.1007/s00134-013-3189-0; Kansagara D, 2011, ANN INTERN MED, V154, P268, DOI 10.7326/0003-4819-154-4-201102150-00008; Kaukonen KM, 2009, ACTA ANAESTH SCAND, V53, P61, DOI 10.1111/j.1399-6576.2008.01795.x; Kramer AH, 2012, CRIT CARE, V16, DOI 10.1186/cc11812; Krinsley JS, 2003, MAYO CLIN PROC, V78, P1471, DOI 10.4065/78.12.1471; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Liu-DeRyke X, 2009, NEUROCRIT CARE, V11, P151, DOI 10.1007/s12028-009-9228-6; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Meierhans R, 2010, CRIT CARE, V14, DOI 10.1186/cc8869; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Preiser JC, 2009, INTENS CARE MED, V35, P1738, DOI 10.1007/s00134-009-1585-2; Qaseem A, 2011, ANN INTERN MED, V154, P260, DOI 10.7326/0003-4819-154-4-201102150-00007; Salim A, 2009, AM SURGEON, V75, P25; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2012, CRIT CARE MED, V40, P1923, DOI 10.1097/CCM.0b013e31824e0fcc; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Yang M, 2009, INT J NURS STUD, V46, P753, DOI 10.1016/j.ijnurstu.2009.01.004; Yang SY, 1995, SURG NEUROL, V44, P373, DOI 10.1016/0090-3019(96)80243-6	40	55	58	0	14	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	JUN	2015	41	6					1037	1047		10.1007/s00134-015-3757-6			11	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CL2UO	WOS:000356801200008	26088909				2022-02-06	
J	Di Battista, AP; Buonora, JE; Rhind, SG; Hutchison, MG; Baker, AJ; Rizoli, SB; Diaz-Arrastia, R; Mueller, GP				Di Battista, Alex P.; Buonora, John E.; Rhind, Shawn G.; Hutchison, Michael G.; Baker, Andrew J.; Rizoli, Sandro B.; Diaz-Arrastia, Ramon; Mueller, Gregory P.			Blood biomarkers in moderate-to-severe traumatic brain injury: potential utility of a multi-marker approach in characterizing outcome	FRONTIERS IN NEUROLOGY			English	Article						s100B; GFAP; NSE; BDNF; MCP-1; ICAM-5; PRDX-6	NEURON-SPECIFIC ENOLASE; NEUROTROPHIC FACTOR; PROGNOSTIC VALUE; S100B LEVELS; SERUM; HEAD; PROTEIN; MCP-1; NEUROINFLAMMATION; INFLAMMATION	Background: Blood biomarkers are valuable tools for elucidating complex cellular and molecular mechanisms underlying traumatic brain injury (TBI). Profiling distinct classes of biomarkers could aid in the identification and characterization of initial injury and secondary pathological processes. This study characterized the prognostic performance of a recently developed multi-marker panel of circulating biomarkers that reflect specific pathogenic mechanisms including neuroinflammation, oxidative damage, and neuroregeneration, in moderate-to-severe TBI patients. Materials and methods: Peripheral blood was drawn from 85 isolated TBI patients (n = 60 severe, n = 25 moderate) at hospital admission, 6-, 12-, and 24-h post-injury. Mortality and neurological outcome were assessed using the extended Glasgow Outcome Scale. A multiplex platform was designed on MULTI-SPOT plates to simultaneously analyze human plasma levels of s100 calcium binding protein beta (s100B), glial fibrillary acidic protein (GFAP), neuron specific enolase (NSF), brain-derived neurotrophic factor (BDNF), monocyte chemoattractant protein (MCP)-1, intercellular adhesion molecule (ICAM)-5, and peroxiredoxin (PRDX)-6. Multivariable logistic regression and area under the receiver-operating characteristic curve (AUC) were used to evaluate both individual and combined predictive abilities of these markers for 6-month neurological outcome and mortality after TBI. Results: Unfavorable neurological outcome was associated with elevations in s100B, GFAP, and MCP-1. Mortality was related to differences in six of the seven markers analyzed. Combined admission concentrations of s100B, GFAP, and MCP-1 were able to discriminate favorable versus unfavorable outcome (AUC = 0.83), and survival versus death (AUG = 0.87), although not significantly better than s100B alone (AUG = 0.82 and 0.86, respectively). Conclusion: The multi-marker panel of TBI-related biomarkers performed well in discriminating unfavorable and favorable outcomes in the acute period after moderateto-severe TBI. However, the combination of these biomarkers did not outperform s100B alone.	[Di Battista, Alex P.; Baker, Andrew J.; Rizoli, Sandro B.] Univ Toronto, Inst Med Sci, Fac Med, Toronto, ON M3K 2C9, Canada; [Di Battista, Alex P.; Rhind, Shawn G.] Toronto Res Ctr, Def Res & Dev Canada, Toronto, ON, Canada; [Di Battista, Alex P.; Baker, Andrew J.; Rizoli, Sandro B.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada; [Buonora, John E.; Mueller, Gregory P.] Univ Hlth Sci, Uniformed Serv, Dept Anat Physiol & Genet, Bethesda, MD USA; [Buonora, John E.] US Army, Grad Program Anesthesia Nursing, Ft Sam Houston, TX USA; [Rhind, Shawn G.; Hutchison, Michael G.] Univ Toronto, Fac Kinesiol & Phys Educ, David L Maclntosh Sport Med Clin, Toronto, ON, Canada; [Baker, Andrew J.; Rizoli, Sandro B.] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada; [Baker, Andrew J.; Rizoli, Sandro B.] Univ Toronto, Dept Surg & Crit Care Med, Toronto, ON, Canada; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA		Di Battista, AP (corresponding author), Univ Toronto, Inst Med Sci, Fac Med, 1133 Sheppard Ave West, Toronto, ON M3K 2C9, Canada.	alex.dibattista@mail.utoronto.ca		Rhind, Shawn/0000-0003-2300-0620; Di Battista, Alex/0000-0002-3325-6833; Diaz-Arrastia, Ramon/0000-0001-6051-3594	Defence Research and Development Canada Technology Investment Fund Programme; Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; Tr-Service Nursing Research Program [HT9404-12-1-T513]	The authors gratefully acknowledge the technical assistance of Ms. Maria Shiu and Mr. Shahid Hassan. This research was funded by the Defence Research and Development Canada Technology Investment Fund Programme, the Center for Neuroscience and Regenerative Medicine, and the Tr-Service Nursing Research Program, Grant #HT9404-12-1-T513.	Balu R, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-014-0484-2; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Bigler ED, 2013, BRAIN, V136, P9, DOI 10.1093/brain/aws342; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Buonora JE, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00068; Chabok SY, 2012, J TRAUMA ACUTE CARE, V72, P1654, DOI 10.1097/TA.0b013e318246887e; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; DeFazio MV, 2014, WORLD NEUROSURG, V81, P151, DOI 10.1016/j.wneu.2013.01.015; Denes A, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00382; Di Battista AP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00044; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Egea-Guerrero JJ, 2012, BRAIN INJURY, V26, P76, DOI 10.3109/02699052.2011.635360; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Finnie JW, 2014, VET RES COMMUN, V38, P297, DOI 10.1007/s11259-014-9616-z; Gaddam Samson Sujit Kumar, 2015, Handb Clin Neurol, V127, P205, DOI 10.1016/B978-0-444-52892-6.00014-3; Gradisek P, 2012, BRAIN INJURY, V26, P1472, DOI 10.3109/02699052.2012.694567; Guo H, 2000, ANN NEUROL, V48, P590, DOI 10.1002/1531-8249(200010)48:4<590::AID-ANA5>3.3.CO;2-Z; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Jaerve A, 2012, CELL TISSUE RES, V349, P229, DOI 10.1007/s00441-012-1427-3; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; Leclerc E, 2009, BBA-MOL CELL RES, V1793, P993, DOI 10.1016/j.bbamcr.2008.11.016; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; Lesko MM, 2014, BRAIN INJURY, V28, P987, DOI 10.3109/02699052.2014.890743; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Mahmood A, 2009, NEUROSURGERY, V65, P187, DOI 10.1227/01.NEU.0000343540.24780.D6; Manevich Y, 2014, FREE RADICAL BIO MED, V72, P210, DOI 10.1016/j.freeradbiomed.2014.04.002; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; Mondello Stefania, 2015, Handb Clin Neurol, V127, P245, DOI 10.1016/B978-0-444-52892-6.00016-7; Olivecrona Z, 2015, BRAIN INJURY, V29, P446, DOI 10.3109/02699052.2014.989403; Papa L, 2015, NEUROCRIT CARE, V22, P52, DOI 10.1007/s12028-014-0028-2; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Rhodes J, 2009, J TRAUMA, V66, P1591, DOI 10.1097/TA.0b013e31819a0344; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shanmugam N, 2003, J BIOL CHEM, V278, P34834, DOI 10.1074/jbc.M302828200; Siironen J, 2007, STROKE, V38, P2858, DOI 10.1161/STROKEAHA.107.485441; Tulsawani R, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-125; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wang KKW, 2013, PROC SPIE, V8723, DOI 10.1117/12.2020030; Wolf H, 2015, J NEUROTRAUM, V32, P23, DOI 10.1089/neu.2013.3202; Yang HP, 2012, COMP FUNCT GENOM, DOI 10.1155/2012/368938; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zurek J, 2012, ACTA NEUROCHIR, V154, P93, DOI 10.1007/s00701-011-1175-2	49	55	55	1	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	MAY 26	2015	6								110	10.3389/fneur.2015.00110			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CU9DC	WOS:000363842300002	26074866	Green Published, gold			2022-02-06	
J	Kroshus, E; Baugh, CM; Daneshvar, DH; Nowinski, CJ; Cantu, RC				Kroshus, Emily; Baugh, Christine M.; Daneshvar, Daniel H.; Nowinski, Christopher J.; Cantu, Robert C.			Concussion Reporting Intention: A Valuable Metric for Predicting Reporting Behavior and Evaluating Concussion Education	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; intention; knowledge; hockey; education	SOCIAL-SCIENCES THEORIES; ICE HOCKEY; INJURY; KNOWLEDGE; BRAIN; INTERVENTION; MODELS	Objective: This study aimed to evaluate whether preseason concussion knowledge and reporting intention predicted in-season concussion reporting behavior. Design: Prospective cohort study. Setting: Collegiate athletic facility of each participating team. Participants: National Collegiate Athletic Association Division I men's ice hockey players in 1 conference of competition (n = 116). Independent Variables: Intention to report symptoms of a "minor" concussion and concussion knowledge were assessed at preseason. Main Outcome Measures: Postseason recall of non-report of postimpact symptoms. Results: Preseason concussion knowledge was not significantly associated with in-season reporting behavior. Intention to report concussion symptoms was significantly related to in-season reporting behavior. There was a significant interaction between the number of different symptoms experienced and both preseason reporting intention and in-season reporting behavior. Conclusions: Evaluations of concussion education programs tend to measure concussion knowledge. The present findings suggest that reporting intention may be more strongly predictive of reporting behavior than concussion knowledge and should be included in evaluations of concussion effectiveness. New concussion education initiatives should consider targeting psychosocial constructs that increase reporting intention.	[Kroshus, Emily] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA; [Baugh, Christine M.; Daneshvar, Daniel H.; Nowinski, Christopher J.; Cantu, Robert C.] Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA; [Baugh, Christine M.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Daneshvar, Daniel H.; Nowinski, Christopher J.; Cantu, Robert C.] Boston Univ, Sch Med, Sports Legacy Inst, Boston, MA 02118 USA; [Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA		Kroshus, E (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, 677 Huntington Ave,Kresge Bldg, Boston, MA 02115 USA.	emk329@mail.harvard.edu	Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338; Daneshvar, Daniel/0000-0003-3691-9513	National Collegiate Athletic Association Graduate Student Research Grant	Supported in part by the National Collegiate Athletic Association Graduate Student Research Grant (E.K.).	Abraham C, 1998, PSYCHOL HEALTH, V13, P569, DOI 10.1080/08870449808407420; AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Ajzen I, 2011, BASIC APPL SOC PSYCH, V33, P101, DOI 10.1080/01973533.2011.568834; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; BANDURA A, 1980, SOCIAL FDN THOUGHT A; Borden BP, 2007, AM J SPORTS MED, V35, P1075; Chan DKC, 2012, SPORTS MED, V42, P725, DOI 10.2165/11633040-000000000-00000; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Cohen J., 2013, STAT POWER ANAL BEHA; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Echlin P. S., 2010, NEUROSURG FOCUS, V29, P1, DOI DOI 10.3171/2010.9FOCUS10187; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Elder JP, 1999, AM J PREV MED, V17, P275, DOI 10.1016/S0749-3797(99)00094-X; Fishbein M, 2003, COMMUN THEOR, V13, P164, DOI 10.1111/j.1468-2885.2003.tb00287.x; Fishbein M, 2001, HANDBOOK OF HEALTH PSYCHOLOGY, P3; Fishbein M., 1975, BELIEF ATTITUDE INTE; Gielen AC, 2003, EPIDEMIOL REV, V25, P65, DOI 10.1093/epirev/mxg004; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Keats MR, 2012, SPORTS MED, V42, P175, DOI 10.2165/11597050-000000000-00000; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McEachan RRC, 2011, HEALTH PSYCHOL REV, V5, P97, DOI 10.1080/17437199.2010.521684; McGlashan AJ, 2010, SPORTS MED, V40, P841, DOI 10.2165/11534960-000000000-00000; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; Montano DE., 2008, HLTH BEHAV HLTH ED T, V1, P67; NCAA, 2013 14 NCAA SPORTS; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; ROGERS RW, 1975, J PSYCHOL, V91, P93, DOI 10.1080/00223980.1975.9915803; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Sarris CE, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.7.FOCUS12224; Sheeran P., 2002, EUR REV SOC PSYCHOL, V12, P1, DOI [10.1080/14792772143000003, DOI 10.1002/0470013478.CH1, DOI 10.1080/14792772143000003]; Tator CH, 2012, J CLIN SPORT PSYCHOL, V6, P293, DOI 10.1123/jcsp.6.3.293; Trifiletti LB, 2005, HEALTH EDUC RES, V20, P298, DOI 10.1093/her/cyg126; Verhagen EALM, 2010, SPORTS MED, V40, P899, DOI 10.2165/11536890-000000000-00000; Webb TL, 2006, PSYCHOL BULL, V132, P249, DOI 10.1037/0033-2909.132.2.249	39	55	56	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2015	25	3					243	247		10.1097/JSM.0000000000000137			5	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	CH3EX	WOS:000353911700008	25051193				2022-02-06	
J	Hutchison, MG; Comper, P; Meeuwisse, WH; Echemendia, RJ				Hutchison, Michael G.; Comper, Paul; Meeuwisse, Willem H.; Echemendia, Ruben J.			A systematic video analysis of National Hockey League (NHL) concussions, part I: who, when, where and what?	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Contact sports; Ice hockey; Injury Prevention	INJURY SURVEILLANCE SYSTEM; MILD HEAD-INJURY; MENS ICE HOCKEY; DESCRIPTIVE EPIDEMIOLOGY; INCIDENT ANALYSIS; FOOTBALL PLAYERS; HIGH-SCHOOL; RECOVERY; SPORT; MECHANISMS	Background Although there is a growing understanding of the consequences of concussions in hockey, very little is known about the precipitating factors associated with this type of injury. Aim To describe player characteristics and situational factors associated with concussions in the National Hockey League (NHL). Methods Case series of medically diagnosed concussions for regular season games over a 3.5-year period during the 2006-2010 seasons using an inclusive cohort of professional hockey players. Digital video records were coded and analysed using the Heads Up Checklist. Results Of 197 medically diagnosed concussions, 88% involved contact with an opponent. Forwards accounted for more concussions than expected compared with on-ice proportional representation (95% CI 60 to 73; p=0.04). Significantly more concussions occurred in the first period (47%) compared with the second and third periods (p=0.047), with the majority of concussions occurring in the defensive zone (45%). Approximately 47% of the concussions occurred in open ice, 53% occurred in the perimeter. Finally, 37% of the concussions involved injured players' heads contacting the boards or glass. Conclusions This study describes several specific factors associated with concussions in the NHL, including period of the game, player position, body size, and specific locations on the ice and particular situations based on a player's position.	[Hutchison, Michael G.; Comper, Paul] Univ Toronto, Fac Kinesiol & Phys Educ, David L MacIntosh Sport Med Clin, Toronto, ON M5S 2W6, Canada; [Hutchison, Michael G.] St Michaels Hosp, Keenan Res Ctr, Injury Prevent Res Off, Toronto, ON M5B 1W8, Canada; [Comper, Paul] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON M5S 2W6, Canada; [Comper, Paul] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON M5S 2W6, Canada; [Meeuwisse, Willem H.] Univ Calgary, Fac Kinesiol, Calgary, AB, Canada; [Meeuwisse, Willem H.] Univ Calgary, Hotchkiss Brain Inst, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Echemendia, Ruben J.] Psychol & Neurobehav Associates Inc, State Coll, PA USA; [Echemendia, Ruben J.] Univ Missouri, Kansas City, MO 64110 USA		Hutchison, MG (corresponding author), Univ Toronto, Fac Kinesiol & Phys Educ, David L MacIntosh Sport Med Clin, 55 Harbord St, Toronto, ON M5S 2W6, Canada.	michael.hutchison@utoronto.ca	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462	Ontario Neurotrauma Foundation (ONF); Pashby Sports Safety Fund	This study received funding by Ontario Neurotrauma Foundation (ONF) and The Pashby Sports Safety Fund. The organisations that contributed funds to the research had no role in the design of the study, the collection, analysis and interpretation of the data.	Agel J, 2007, J ATHL TRAINING, V42, P241; Agel J, 2007, J ATHL TRAINING, V42, P249; Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; [Anonymous], MAC OS X VERS 10 5 8; Arnason A, 2004, AM J SPORT MED, V32, P1459, DOI 10.1177/0363546504262973; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Hutchison MG, 2014, BRIT J SPORT MED, V48, P125, DOI 10.1136/bjsports-2012-092059; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Krosshaug T, 2007, AM J SPORT MED, V35, P359, DOI 10.1177/0363546506293899; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Olsen OE, 2004, AM J SPORT MED, V32, P1002, DOI 10.1177/0363546503261724; PASHBY TJ, 1979, CAN MED ASSOC J, V121, P643; Schick DM, 2003, AM J SPORT MED, V31, P47, DOI 10.1177/03635465030310011901; Stevens ST, 2006, J SCI MED SPORT, V9, P238, DOI 10.1016/j.jsams.2006.03.025; Stevens Sean T, 2008, Res Sports Med, V16, P68, DOI 10.1080/15438620701879020; Tommasone BA, 2006, J ATHL TRAINING, V41, P470	30	55	55	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR	2015	49	8					547	551		10.1136/bjsports-2013-092234			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	CF4OI	WOS:000352529000012	23766438				2022-02-06	
J	Carr, W; Polejaeva, E; Grome, A; Crandall, B; LaValle, C; Eonta, SE; Young, LA				Carr, Walter; Polejaeva, Elena; Grome, Anna; Crandall, Beth; LaValle, Christina; Eonta, Stephanie E.; Young, Lee Ann			Relation of Repeated Low-Level Blast Exposure With Symptomology Similar to Concussion	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						blast; concussion; military; survey; symptoms	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; OPERATION-IRAQI-FREEDOM; POSTCONCUSSIVE SYMPTOMS; HEAD-INJURY; HEALTH; ASSOCIATION; MECHANISMS; PERSONNEL; SEQUELAE	Objective: To investigate anecdotal reports suggesting that repeated exposure to low-level explosive blast has myriad health impacts, including an array of neurological effects. Participants: A total of 184 anonymous survey respondents from military and nonmilitary law enforcement populations (135 exposed to occupational blast and 49 controls). Design: Survey of self-reported history of occupational exposure to repeated low-level blast (breaching blast) and symptomology similar to concussion. Results: Findings suggest that number and severity of symptoms increase with history of chronic blast exposure (F = 18.26, P < .001) and that symptoms can interfere with daily activity (t = 2.60, P = .010). Conclusion: Given the prevalence of repeated exposure to blast among some military and civilian law enforcement occupations, the results of this survey study support a role for blast surveillance programs as well as continued research on health impacts of low-level repeated blast exposure.	[Carr, Walter; LaValle, Christina; Eonta, Stephanie E.] Walter Reed Army Inst Res, Dept Behav Biol, Silver Spring, MD 20910 USA; [Polejaeva, Elena] Naval Med Res Ctr, Dept Neurotrauma, Silver Spring, MD USA; [Grome, Anna; Crandall, Beth; Young, Lee Ann] Appl Res Associates, Albuquerque, NM USA		Carr, W (corresponding author), Walter Reed Army Inst Res, Dept Behav Biol, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	walter.s.carr.mil@mail.mil		LaValle, Christina/0000-0003-1529-4761	Army MOMRP.accelleration.A0908	This work was supported by Army MOMRP.accelleration.A0908.	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; [Anonymous], 2011, JOINT MENT HLTH ADV; [Anonymous], 2012, VETERANS HLTH ADM TR; Bagchi A, 2013, EVALUATION HEADBORNE; Baker AJ, 2011, J TRAUMA, V71, pS472, DOI 10.1097/TA.0b013e318232e7da; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; BOWEN IG, 1968, ANN NY ACAD SCI, V152, P122, DOI 10.1111/j.1749-6632.1968.tb11971.x; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Casscells S.W., 2007, TRAUMATIC BRAIN INJU; Casscells SW, 2007, CONSOLIDATION TRAUMA; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Embrey EP, 2008, SYMPTOM MANAGEMENT M; Fear NT, 2012, J EPIDEMIOL COMMUN H, V66, pA35, DOI 10.1136/jech-2012-201753.091; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hayward P, 2008, LANCET NEUROL, V7, P200, DOI 10.1016/S1474-4422(08)70032-2; Heltemes KJ, 2012, INJURY, V43, P1990, DOI 10.1016/j.injury.2011.07.021; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Miller KJ, 2013, J HEAD TRAUMA REHAB, V28, P31, DOI 10.1097/HTR.0b013e318255ceae; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ryan LM, 1999, ARCH CLIN NEUROPSYCH, V14, P42, DOI 10.1093/arclin/14.1.42a; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; St Onge Paul, 2011, US Army Med Dep J, P97; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Tate CM, 2013, J NEUROTRAUM, V30, P1620, DOI 10.1089/neu.2012.2683; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f	37	55	55	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2015	30	1					47	55		10.1097/HTR.0000000000000064			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AY8BW	WOS:000347780400014	24901327				2022-02-06	
J	Defrin, R; Riabinin, M; Feingold, Y; Schreiber, S; Pick, CG				Defrin, Ruth; Riabinin, Miri; Feingold, Yelena; Schreiber, Shaul; Pick, Chaim G.			Deficient Pain Modulatory Systems in Patients with Mild Traumatic Brain and Chronic Post-Traumatic Headache: Implications for its Mechanism	JOURNAL OF NEUROTRAUMA			English	Article						post-traumatic headache; brain injury; pain modulation; pain adaptation	NOXIOUS INHIBITORY CONTROLS; STRESS-DISORDER SYMPTOMS; TENSION-TYPE HEADACHE; PRESSURE PAIN; REDUCED HABITUATION; TEMPORAL SUMMATION; SPATIAL SUMMATION; MIGRAINE PATIENTS; US SOLDIERS; INJURY	Although the prevalence rate of chronic post-traumatic headache (CPTHA) after mild traumatic brain injury (TBI) reaches up to 95%, its mechanism is unknown, and little is known about the characteristics of the pain system in this condition. Our aim was to investigate the capabilities of two pain modulatory systems among individuals with CPTHA and study their association with CPTHA, here for the first time. Forty-six subjects participated; 16 with TBI and CPTHA, 12 with TBI without CPTHA, and 18 healthy controls. Testing included the measurement of heat-pain (HPT) and pressure-pain (PPT) thresholds in the forehead and forearm, pain adaptation to tonic noxious heat, and conditioned pain modulation (CPM).The participants completed a post-traumatic stress disorder (PTSD) questionnaire. The two TBI groups did not differ in the TBI and background characteristics. However, TBI patients with CPTHA had significantly higher HPT and lower PPT in the cranium and higher PTSD symptomatology than TBI patients without CPTHA and healthy controls. Adaptation to pain and CPM were diminished in the CPTHA group compared with the two control groups. The intensity of CPTHA correlated negatively with cranial PPT, magnitude of pain adaptation, and CPM. CPTHA intensity correlated positively with PTSD symptomatology. CPTHA appears to be characterized by cranial hyperalgesia and dysfunctional pain modulation capabilities, which are associated with CPTHA magnitude. It is concluded that damage to pain modulatory systems along with chronic cranial sensitization underlies the development of CPTHA. PTSD may reinforce CPTHA and vice versa. Clinical implications are discussed.	[Defrin, Ruth] Tel Aviv Univ, Sackler Fac Med, Dept Phys Therapy, IL-69978 Tel Aviv, Israel; [Riabinin, Miri; Pick, Chaim G.] Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Riabinin, Miri; Pick, Chaim G.] Tel Aviv Univ, Sackler Fac Med, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel; [Feingold, Yelena] Chaim Sheba Med Ctr, Dept Neurol, IL-52621 Tel Hashomer, Israel; [Schreiber, Shaul] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Psychiat, IL-69978 Tel Aviv, Israel; [Schreiber, Shaul] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel		Defrin, R (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Phys Therapy, IL-69978 Tel Aviv, Israel.	rutidef@post.tau.ac.il	Schreiber, Shaul/E-5821-2010	Schreiber, Shaul/0000-0002-2189-0693	National Association of Insurance Companies [1644063]	The authors thank Yuval Levitan, from the Department of Head Injury at Sheba Medical Center for his help in recruitment, and Hila Gruener for her help in data collection. This work was supported by a grant from the National Association of Insurance Companies (grant number 1644063).	Ashina M, 2000, CEPHALALGIA, V20, P919, DOI 10.1046/j.1468-2982.2000.00150.x; Asmundson GJG, 2009, DEPRESS ANXIETY, V26, P888, DOI 10.1002/da.20600; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Bartsch T, 2002, BRAIN, V125, P1496, DOI 10.1093/brain/awf166; BASBAUM AI, 1976, P NATL ACAD SCI USA, V73, P4685, DOI 10.1073/pnas.73.12.4685; Basbaum AI, 2000, PRINCIPLES NEURAL SC; Bendtsen L, 2000, CEPHALALGIA, V20, P486, DOI 10.1046/j.1468-2982.2000.00070.x; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bezov D, 2011, HEADACHE, V51, P262, DOI 10.1111/j.1526-4610.2010.01768.x; BOUHASSIRA D, 1992, BRAIN RES, V595, P353, DOI 10.1016/0006-8993(92)91071-L; Bowsher D, 1999, Am J Hosp Palliat Care, V16, P593, DOI 10.1177/104990919901600408; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Buchgreitz L, 2006, PAIN, V123, P19, DOI 10.1016/j.pain.2006.01.040; Budai D, 1998, J NEUROPHYSIOL, V79, P677, DOI 10.1152/jn.1998.79.2.677; Burstein R, 2000, ANN NEUROL, V47, P614, DOI 10.1002/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N; Campbell CM, 2008, J PAIN, V9, P759, DOI 10.1016/j.jpain.2008.03.010; Cathcart S, 2010, HEADACHE, V50, P403, DOI 10.1111/j.1526-4610.2009.01545.x; de Tommaso M, 2003, PAIN, V104, P111, DOI 10.1016/S0304-3959(02)00485-2; de Tommaso Marina, 2005, J Headache Pain, V6, P195; de Tommaso M, 2012, CNS NEUROL DISORD-DR, V11, P110, DOI 10.2174/187152712800269759; Defrin R, 2003, PAIN, V106, P471, DOI 10.1016/j.pain.2003.09.010; Defrin R, 2001, PAIN, V89, P253, DOI 10.1016/S0304-3959(00)00369-9; Defrin R, 2008, PAIN, V138, P450, DOI 10.1016/j.pain.2008.05.006; Defrin R, 2010, PAIN, V151, P489, DOI 10.1016/j.pain.2010.08.009; Defrin R, 2010, EUR J PAIN, V14, P924, DOI 10.1016/j.ejpain.2010.03.004; Drummond PD, 2011, HEADACHE, V51, P375, DOI 10.1111/j.1526-4610.2010.01779.x; Edwards RR, 2003, PAIN, V101, P155, DOI 10.1016/S0304-3959(02)00324-X; Elliott MB, 2012, HEADACHE, V52, P966, DOI 10.1111/j.1526-4610.2012.02160.x; Fernandez-De-Las-Penas C, 2007, CEPHALALGIA, V27, P383, DOI 10.1111/j.1468-2982.2007.01295.x; Fernandez-de-las-Penas C, 2009, CEPHALALGIA, V29, P670, DOI 10.1111/j.1468-2982.2008.01831.x; Finnerup NB, 2012, CURR PAIN HEADACHE R, V16, P207, DOI 10.1007/s11916-012-0259-x; Finnerup NB, 2003, BRAIN, V126, P57, DOI 10.1093/brain/awg007; Headache classification Subcommettee of the international headache society, 2004, INT CLASS HEAD DIS; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jamora CW, 2012, BRAIN INJURY, V26, P36, DOI 10.3109/02699052.2011.635352; Jenewein J, 2009, J TRAUMA STRESS, V22, P540, DOI 10.1002/jts.20453; JENSEN R, 1993, PAIN, V52, P193, DOI 10.1016/0304-3959(93)90131-8; Kasch H, 2001, CEPHALALGIA, V21, P189, DOI 10.1046/j.1468-2982.2001.00179.x; Kirov II, 2013, J NEUROTRAUM, V30, P1200, DOI 10.1089/neu.2012.2696; Kjeldgaard D, 2014, CEPHALALGIA, V34, P191, DOI 10.1177/0333102413505236; Kumar B, 2009, ANESTH ANALG, V108, P1645, DOI 10.1213/ane.0b013e31819d644c; Le Bars D, 2002, BRAIN RES REV, V40, P29, DOI 10.1016/S0165-0173(02)00186-8; Leonard G, 2009, PAIN, V147, P217, DOI 10.1016/j.pain.2009.09.009; Lev R, 2010, CEPHALALGIA, V30, P910, DOI 10.1177/0333102409357249; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; Mainero C, 2011, ANN NEUROL, V70, P838, DOI 10.1002/ana.22537; Mayer CL, 2013, HEADACHE, V53, P1523, DOI 10.1111/head.12173; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Nahman-Averbuch H, 2013, HEADACHE, V53, P1104, DOI 10.1111/head.12117; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Normand E, 2011, J CLIN PSYCHIAT, V72, P219, DOI 10.4088/JCP.08m04969blu; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; PACKARD RC, 1993, HEADACHE, V33, P133, DOI 10.1111/j.1526-4610.1993.hed3303133.x; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Perrotta A, 2008, CEPHALALGIA, V28, P950, DOI 10.1111/j.1468-2982.2008.01631.x; Perrotta A, 2010, CEPHALALGIA, V30, P272, DOI 10.1111/j.1468-2982.2009.01914.x; Pielsticker A, 2005, PAIN, V118, P215, DOI 10.1016/j.pain.2005.08.019; Restuccia D, 2014, CEPHALALGIA, V34, P201, DOI 10.1177/0333102413508241; Romesser J, 2012, J REHABIL RES DEV, V49, P1127, DOI 10.1682/JRRD.2010.12.0238; Rosenthal JF, 2013, HEADACHE, V53, P1564, DOI 10.1111/head.12200; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Sandrini G, 2006, CEPHALALGIA, V26, P782, DOI 10.1111/j.1468-2982.2006.01130.x; Sandrini G, 2002, NEUROSCI LETT, V317, P135, DOI 10.1016/S0304-3940(01)02447-8; Sarmento E, 2009, HEADACHE, V49, P1345, DOI 10.1111/j.1526-4610.2009.01494.x; Scott D, 2005, CLIN J PAIN, V21, P175, DOI 10.1097/00002508-200503000-00009; Siddall PJ, 2001, SPINAL CORD, V39, P63, DOI 10.1038/sj.sc.3101116; SOLOMON Z, 1993, ISRAEL J PSYCHIAT, V30, P110; Staud R, 2003, PAIN, V101, P167, DOI 10.1016/S0304-3959(02)00325-1; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Theeler BJ, 2012, CURR TREAT OPTION NE, V14, P36, DOI 10.1007/s11940-011-0157-2; Ullrich PM, 2013, ARCH PHYS MED REHAB, V94, P80, DOI 10.1016/j.apmr.2012.07.018; Valeriani M, 2003, PAIN, V105, P57, DOI 10.1016/S0304-3959(03)00137-4; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Wasner G, 2008, BRAIN, V131, P2387, DOI 10.1093/brain/awn169; Weissman-Fogel I, 2003, PAIN, V104, P693, DOI 10.1016/S0304-3959(03)00159-3; Weissman-Fogel I, 2008, EXP BRAIN RES, V186, P79, DOI 10.1007/s00221-007-1206-7; Yarnitsky D, 2008, PAIN, V138, P22, DOI 10.1016/j.pain.2007.10.033; Zeilig G, 2012, BRAIN, V135, P418, DOI 10.1093/brain/awr270	84	55	55	1	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2015	32	1					28	37		10.1089/neu.2014.3359			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AX4JX	WOS:000346900100005	25068510	Green Published			2022-02-06	
S	Montenigro, PH; Corp, DT; Stein, TD; Cantu, RC; Stern, RA		Cannon, TD; Widiger, T		Montenigro, Philip H.; Corp, Daniel T.; Stein, Thor D.; Cantu, Robert C.; Stern, Robert A.			Chronic Traumatic Encephalopathy: Historical Origins and Current Perspective	ANNUAL REVIEW OF CLINICAL PSYCHOLOGY, VOL 11	Annual Review of Clinical Psychology		English	Article; Book Chapter						chronic traumatic encephalopathy; concussion; traumatic brain injury; neurodegenerative disorders; football; history	APOLIPOPROTEIN-E-GENOTYPE; REPETITIVE BRAIN TRAUMA; LONG-TERM CONSEQUENCES; WHITE-MATTER INTEGRITY; MILD HEAD-INJURY; HIGH-SCHOOL; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; RECURRENT CONCUSSION; FOOTBALL PLAYERS	Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease that is most often identified in postmortem autopsies of individuals exposed to repetitive head impacts, such as boxers and football players. The neuropathology of CTE is characterized by the accumulation of hyperphosphorylated tau protein in a pattern that is unique from that of other neurodegenerative diseases, including Alzheimer's disease. The clinical features of CTE are often progressive, leading to dramatic changes in mood, behavior, and cognition, frequently resulting in debilitating dementia. In some cases, motor features, including parkinsonism, can also be present. In this review, the historical origins of CTE are revealed and an overview of the current state of knowledge of CTE is provided, including the neuropathology, clinical features, proposed clinical and pathological diagnostic criteria, potential in vivo biomarkers, known risk factors, and treatment options.	[Montenigro, Philip H.; Corp, Daniel T.; Stein, Thor D.; Stern, Robert A.] Boston Univ, Sch Med, Chron Traumat Encephalopathy Ctr, Boston, MA 02118 USA; [Montenigro, Philip H.; Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Corp, Daniel T.] Deakin Univ, Sch Psychol, Cognit Neurosci Unit, Burwood, Vic 3125, Australia; [Stein, Thor D.] Dept Vet Affairs Med Ctr, Bedford, MA 02130 USA; [Stein, Thor D.] Dept Vet Affairs Med Ctr, Boston, MA 01730 USA; [Stein, Thor D.; Stern, Robert A.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Stein, Thor D.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Cantu, Robert C.] Sports Legacy Inst, Waltham, MA 02451 USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA 01742 USA		Stern, RA (corresponding author), Boston Univ, Sch Med, Chron Traumat Encephalopathy Ctr, Boston, MA 02118 USA.	valmont@bu.edu; dcorp@deakin.edu.au; tdstein@bu.edu; rcantu@emersonhosp.org; bobstern@bu.edu	, Bob/ABA-8507-2020	Corp, Daniel/0000-0003-2435-077X; Stern, Robert/0000-0002-5008-077X; Montenigro, Philip/0000-0003-4442-9207; Stein, Thor/0000-0001-6954-4477	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001038] Funding Source: NIH RePORTER; VAUS Department of Veterans Affairs [5I01CX001038-04] Funding Source: Federal RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG13846] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS078337] Funding Source: Medline; CSRD VA [I01 CX001038] Funding Source: Medline		Abbas K, 2014, BRAIN CONNE IN PRESS; [Anonymous], 1936, N Y STATE J MED, V36, P1654; [Anonymous], 1933, HAHNEMANNIAN MON, V68, P305; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Beach TG, 2012, J NEUROPATH EXP NEUR, V71, P266, DOI 10.1097/NEN.0b013e31824b211b; Bernick C, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt177; Bowman KM, 1940, INJURIES SKULL BRAIN, P309; Braak H, 2011, J NEUROPATH EXP NEUR, V70, P960, DOI 10.1097/NEN.0b013e318232a379; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Brock S, 1940, INJURIES SKULL BRAIN; Carroll EJ, 1936, AM J MED SCI, V191, P706, DOI 10.1097/00000441-193619150-00014; Chien DT, 2013, J ALZHEIMERS DIS, V34, P457, DOI 10.3233/JAD-122059; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Crawford F, 2009, NEUROSCIENCE, V159, P1349, DOI 10.1016/j.neuroscience.2009.01.033; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Fainaru-Wada Mark, 2013, LEAGUE DENIAL NFL CO; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Finnoff JT, 2011, PM&R, V3, pS452, DOI 10.1016/j.pmrj.2011.07.014; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Ford JH, 2013, J NEUROTRAUM, V30, P1683, DOI 10.1089/neu.2012.2535; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gandy S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004274; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1046/j.1365-2990.1996.2598025.x; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; JOHNSON J, 1969, BRIT J PSYCHIAT, V115, P45, DOI 10.1192/bjp.115.518.45; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 1998, NEUROBIOLOGY OF PRIMARY DEMENTIA, P191; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Jordan BD, 1992, MED ASPECTS BOXING, P150; Kapogiannis D, 2015, FASEB J, V29, P589, DOI 10.1096/fj.14-262048; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Koerte IK, 2015, IMAGING NEU IN PRESS; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Landau SM, 2013, J NUCL MED, V54, P70, DOI 10.2967/jnumed.112.109009; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Levin B, 2014, NEUROCRIT CARE, V20, P334, DOI 10.1007/s12028-013-9931-1; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Martland H, 1928, N Y PATHOL SOC T ARC, V6, P542; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Martland HS, 1943, THER INT DIS, V3, P291; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Mueller FO, 2001, J ATHL TRAINING, V36, P312; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Ng TSC, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt239; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Osnato M, 1930, AM J PSYCHIAT, V9, P643; Osnato M, 1927, ARCH NEURO PSYCHIATR, V18, P181, DOI 10.1001/archneurpsyc.1927.02210020025002; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Provenzano FA, 2010, NUCL MED COMMUN, V31, P952, DOI 10.1097/MNM.0b013e32833e37c4; Roberts AH, 1969, BRAIN DAMAGE BOXERS; Sayed N, 2013, J NEUROTRAUM, V30, P1117, DOI 10.1089/neu.2012.2638; Scully F, 1937, MILWAUKEE J     0929, P3; Scully F, 1937, LIBERTY, V14, P35; Shah SA, 2006, EXP GERONTOL, V41, P1201, DOI 10.1016/j.exger.2006.07.006; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shin W, 2014, AM J NEURORADIOL, V35, P285, DOI 10.3174/ajnr.A3676; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Stamm JM, 2015, NEUROLOGY IN PRESS; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Sundstrom A, 2007, INT PSYCHOGERIATR, V19, P159, DOI 10.1017/S1041610206003498; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; THORNDIKE A, 1952, NEW ENGL J MED, V247, P554, DOI 10.1056/NEJM195210092471504; Turner RC, 2013, FRONT NEUROL, V3, DOI 10.3389/fneur.2012.00186; Victoroff J, 2013, NEUROREHABILITATION, V32, P211, DOI 10.3233/NRE-130839; Zazryn T, 2007, SPORTS MED, V37, P467, DOI 10.2165/00007256-200737060-00001; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	98	55	55	2	44	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA	1548-5943		978-0-8243-3911-1	ANNU REV CLIN PSYCHO	Annu. Rev. Clin. Psychol.		2015	11						309	330		10.1146/annurev-clinpsy-032814-112814			22	Psychology, Clinical; Psychology	Book Citation Index – Social Sciences & Humanities (BKCI-SSH); Book Citation Index – Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	BC3WH	WOS:000352014000013	25581233				2022-02-06	
J	Solanki, N; Alkadhi, I; Atrooz, F; Patki, G; Salim, S				Solanki, Naimesh; Alkadhi, Isam; Atrooz, Fatin; Patki, Gaurav; Salim, Samina			Grape powder prevents cognitive, behavioral, and biochemical impairments in a rat model of posttraumatic stress disorder	NUTRITION RESEARCH			English	Article						single-prolonged stress; PTSD; depression; anxiety; cognition; grape powder	ANXIETY-LIKE BEHAVIOR; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; OXIDATIVE STRESS; NEUROTROPHIC FACTOR; MEMORY IMPAIRMENT; SEED EXTRACT; BDNF GENE; EPIGENETIC REGULATION; SOCIAL DEFEAT	Previously, using the single-prolonged stress (SPS) rat model of posttraumatic stress disorder, we reported that moderate treadmill exercise, via modulation of oxidative stress-related mechanisms, rescued anxiety- and depression-like behaviors and reversed SPS-induced memory impairment. In this study using the SPS model (2-hour restrain, 20-minute forced swimming, 15-minute rest, and 1-2 minute diethyl ether exposure), we hypothesized that antioxidant rich grape powder (GP) prevents SPS-induced behavioral and memory impairment in rats. Male Sprague Dawley rats were randomly assigned into control (CON) (provided tap water), SPS (provided tap water), GP-SPS (provided 15 g/L GP in tap water for 3 weeks followed by SPS), or GP-CON (3 weeks of GP followed by CON exposure). Anxiety- and depression-like behaviors were significantly greater in SPS rats, when compared with CON- or GP-treated rats, and GP reversed these behavioral deficits. Single-prolonged stress rats made significantly more errors in both short- and long-term memory tests compared with CON- or GP-treated rats, which were prevented in GP-SPS rats. Grape powder prevented SPS-induced increase in plasma corticosterone level. Furthermore, brain-derived neurotrophic factor levels were significantly decreased in amygdala of SPS rats but not in GP-SPS rats compared with CON or GP-CON rats. In addition, GP significantly increased acetylated histone 3 and histone deacetylase 5 in hippocampus and amygdala of SPS rats as compared with CON or GP-CON rats. In conclusion, we suggest protective role of GP in SPS-induced behavioral, cognitive, and biochemical impairments in rats. Perhaps, epigenetic regulation of brain-derived neurotrophic factor enables GP-mediated prevention of SPS-induced deficits in rats. Published by Elsevier Inc.	[Solanki, Naimesh; Alkadhi, Isam; Atrooz, Fatin; Patki, Gaurav; Salim, Samina] Univ Houston, Dept Pharmacol & Pharmaceut Sci, Houston, TX 77251 USA		Salim, S (corresponding author), Univ Houston, Dept Pharmacol & Pharmaceut Sci, Houston, TX 77251 USA.	ssalim@uh.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R15 G103327]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R15MH093918] Funding Source: NIH RePORTER	Funding for this research was provided by National Institutes of Health R15 G103327 grant awarded to Samina Salim.	Allam F, 2013, J NUTR, V143, P835, DOI 10.3945/jn.113.174649; Almeida RD, 2005, CELL DEATH DIFFER, V12, P1329, DOI 10.1038/sj.cdd.4401662; Balu M, 2006, BRAIN RES BULL, V68, P469, DOI 10.1016/j.brainresbull.2005.10.007; Beck CT, 2011, ARCH PSYCHIAT NURS, V25, P1, DOI 10.1016/j.apnu.2010.05.005; Berger W, 2009, PROG NEURO-PSYCHOPH, V33, P169, DOI 10.1016/j.pnpbp.2008.12.004; Bert B, 2002, NEUROBIOL LEARN MEM, V78, P11, DOI 10.1006/nlme.2001.4040; BORSINI F, 1988, PSYCHOPHARMACOLOGY, V94, P147; Bouayed J, 2007, EUR J PHARMACOL, V564, P146, DOI 10.1016/j.ejphar.2007.02.055; Boulle F, 2012, MOL PSYCHIATR, V17, P584, DOI 10.1038/mp.2011.107; Calvo N, 2011, NEUROSCIENCE, V183, P81, DOI 10.1016/j.neuroscience.2011.03.046; Carpagnano GE, 2003, CHEST, V124, P1386, DOI 10.1378/chest.124.4.1386; Cougle JR, 2009, BEHAV RES THER, V47, P1012, DOI 10.1016/j.brat.2009.07.014; CRUZ APM, 1994, PHARMACOL BIOCHEM BE, V49, P171, DOI 10.1016/0091-3057(94)90472-3; de Assis MA, 2008, CLINICS, V63, P473, DOI 10.1590/S1807-59322008000400010; de Oliveira MR, 2007, NEUROTOXICOLOGY, V28, P1191, DOI 10.1016/j.neuro.2007.07.008; Dell'Osso L, 2009, PROG NEURO-PSYCHOPH, V33, P899, DOI 10.1016/j.pnpbp.2009.04.018; Devi SA, 2006, MED SCI MONITOR, V12, pBR124; El-Alfy AT, 2005, PHARMACOL RES, V52, P264, DOI 10.1016/j.phrs.2005.04.003; Fuchikami M, 2010, PSYCHIAT INVEST, V7, P251, DOI 10.4306/pi.2010.7.4.251; Fuchikami M, 2009, INT J NEUROPSYCHOPH, V12, P73, DOI 10.1017/S1461145708008997; Fuhrman B, 2005, J NUTR, V135, P722, DOI 10.1093/jn/135.4.722; Gingrich JA, 2005, NAT MED, V11, P1281, DOI 10.1038/nm1205-1281; Halliwell B, 2005, AM J CLIN NUTR, V81, p268S, DOI 10.1093/ajcn/81.1.268S; Hovatta I, 2010, NEUROSCI RES, V68, P261, DOI 10.1016/j.neures.2010.08.007; Hwang IK, 2004, LIFE SCI, V75, P1989, DOI 10.1016/j.lfs.2004.05.013; Jang JH, 2003, FREE RADICAL BIO MED, V34, P1100, DOI 10.1016/S0891-5849(03)00062-5; Janle EM, 2010, J MED FOOD, V13, P926, DOI 10.1089/jmf.2009.0157; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kohda K, 2007, NEUROSCIENCE, V148, P22, DOI 10.1016/j.neuroscience.2007.05.041; Lee BH, 2010, PSYCHIAT INVEST, V7, P231, DOI 10.4306/pi.2010.7.4.231; Liberzon I, 1997, PSYCHONEUROENDOCRINO, V22, P443, DOI 10.1016/S0306-4530(97)00044-9; Lisa M, 2013, NUTR TODAY, V48, P47, DOI DOI 10.1097/NT.0B013E31823DB374; Masood A, 2008, J PHARMACOL EXP THER, V326, P369, DOI 10.1124/jpet.108.137208; Nagahara AH, 2009, NAT MED, V15, P331, DOI 10.1038/nm.1912; Narita K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014575; Patki G, 2013, BRAIN RES, V1539, P73, DOI 10.1016/j.brainres.2013.09.033; Patki G, 2014, PHYSIOL BEHAV, V130, P135, DOI 10.1016/j.physbeh.2014.04.011; Patki G, 2014, PHYSIOL BEHAV, V130, P47, DOI 10.1016/j.physbeh.2014.03.016; Patki G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074522; Pezzuto JM, 2008, J AGR FOOD CHEM, V56, P6777, DOI 10.1021/jf800898p; Pezzuto JM, 2009, J NUTR, V139, p1783S, DOI 10.3945/jn.109.107458; Pinent M, 2004, ENDOCRINOLOGY, V145, P4985, DOI 10.1210/en.2004-0764; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Salim S, 2010, BRAIN RES, V1359, P178, DOI 10.1016/j.brainres.2010.08.093; Salim S, 2010, BEHAV BRAIN RES, V208, P545, DOI 10.1016/j.bbr.2009.12.039; Shukitt-Hale B, 2006, NUTRITION, V22, P295, DOI 10.1016/j.nut.2005.07.016; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Souza CG, 2007, LIFE SCI, V81, P198, DOI 10.1016/j.lfs.2007.05.001; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thomas P, 2009, MUTAT RES-FUND MOL M, V661, P25, DOI 10.1016/j.mrfmmm.2008.10.016; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Virgili M, 2000, NEUROSCI LETT, V281, P123, DOI 10.1016/S0304-3940(00)00820-X; Vollert C, 2011, BEHAV BRAIN RES, V224, P233, DOI 10.1016/j.bbr.2011.05.010; Wang YJ, 2009, NEUROTOX RES, V15, P3, DOI 10.1007/s12640-009-9000-x; Wilson CB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076146; Yamamoto S, 2009, DEPRESS ANXIETY, V26, P1110, DOI 10.1002/da.20629; YEHUDA R, 1993, BIOL PSYCHIAT, V33, P479, DOI 10.1016/0006-3223(93)90001-T; Yoshii T, 2008, NEUROSCIENCE, V156, P466, DOI 10.1016/j.neuroscience.2008.07.049; Zen AL, 2012, HEALTH PSYCHOL, V31, P194, DOI 10.1037/a0025989; Zhuang H, 2003, ANN NY ACAD SCI, V993, P276, DOI 10.1111/j.1749-6632.2003.tb07534.x	62	55	55	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0271-5317	1879-0739		NUTR RES	Nutr. Res.	JAN	2015	35	1					65	75		10.1016/j.nutres.2014.11.008			11	Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Nutrition & Dietetics	AY7MX	WOS:000347745200009	25533441	Green Accepted			2022-02-06	
J	Mannix, R; Berglass, J; Berkner, J; Moleus, P; Qiu, JH; Andrews, N; Gunner, G; Berglass, L; Jantzie, LL; Robinson, S; Meehan, WP				Mannix, Rebekah; Berglass, Jacqueline; Berkner, Justin; Moleus, Philippe; Qiu, Jianhua; Andrews, Nick; Gunner, Georgia; Berglass, Laura; Jantzie, Lauren L.; Robinson, Shenandoah; Meehan, William P., III			Chronic gliosis and behavioral deficits in mice following repetitive mild traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						closed head injury; concussion; traumatic brain injury; behavior; gliosis	COLLEGIATE FOOTBALL PLAYERS; HEAD-INJURY; MOUSE MODEL; COGNITIVE IMPAIRMENT; POSTURAL STABILITY; NCAA CONCUSSION; RECOVERY-TIME; ENCEPHALOPATHY; HYPERACTIVITY; PERFORMANCE	Object. With the recent increasing interest in outcomes after repetitive mild traumatic brain injury (rmTBI; e.g., sports concussions), several models of rmTBI have been established. Characterizing these models in terms of behavioral and histopathological outcomes is vital to assess their clinical translatability. The purpose of this study is to provide an in-depth behavioral and histopathological phenotype of a clinically relevant model of rmTBI. Methods. The authors used a previously published weight-drop model of rmTBI (7 injuries in 9 days) in 2- to 3-month-old mice that produces cognitive deficits without persistent loss of consciousness, seizures, gross structural imaging findings, or microscopic evidence of structural brain damage. Injured and sham-injured (anesthesia only) mice were subjected to a battery of behavioral testing, including tests of balance (rotarod), spatial memory (Morris water maze), anxiety (open field plus maze), and exploratory behavior (hole-board test). After behavioral testing, brains were assessed for histopathological outcomes, including brain volume and microglial and astrocyte immunolabeling. Results. Compared with sham-injured mice, mice subjected to rmTBI showed increased exploratory behavior and had impaired balance and worse spatial memory that persisted up to 3 months after injury. Long-term behavioral deficits were associated with chronic increased astrocytosis and microgliosis but no volume changes. Conclusions. The authors demonstrate that their rmTBI model results in a characteristic behavioral phenotype that correlates with the clinical syndrome of concussion and repetitive concussion. This model offers a platform from which to study therapeutic interventions for rmTBI.	[Mannix, Rebekah; Berglass, Jacqueline; Berkner, Justin; Moleus, Philippe; Qiu, Jianhua; Berglass, Laura; Meehan, William P., III] Boston Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; [Andrews, Nick; Gunner, Georgia] Boston Childrens Hosp, Neurodev Behav Core, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA; [Jantzie, Lauren L.; Robinson, Shenandoah] Boston Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA; [Meehan, William P., III] Boston Childrens Hosp, Div Sports Med, Sports Concuss Clin, Boston, MA 02115 USA; [Mannix, Rebekah; Qiu, Jianhua; Jantzie, Lauren L.; Robinson, Shenandoah; Meehan, William P., III] Harvard Univ, Sch Med, Boston, MA USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA		Mannix, R (corresponding author), Boston Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.	rebekah.mannix@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020		Children's Hospital Boston Intellectual and Developmental Disabilities Research Center (CHB IDDRC) [P30 RD18655]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM103400] Funding Source: NIH RePORTER	Dr. Andrews receives salary support from the Children's Hospital Boston Intellectual and Developmental Disabilities Research Center (CHB IDDRC, P30 RD18655). The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	Barreto GE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027881; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Carobrez AP, 2005, NEUROSCI BIOBEHAV R, V29, P1193, DOI 10.1016/j.neubiorev.2005.04.017; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Engel S, 1996, Acta Neurochir Suppl, V66, P89; GRAHMANN H, 1957, Psychiatr Neurol (Basel), V134, P261; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Hylin MJ, 2013, J NEUROTRAUM, V30, P716, DOI 10.1089/neu.2012.2717; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Konrad KN, 2000, BRAIN INJURY, V14, P859; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mouton PR, 2002, BRAIN RES, V956, P30, DOI 10.1016/S0006-8993(02)03475-3; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Randolph C, 2013, J INT NEUROPSYCH SOC, V19, P873, DOI 10.1017/S1355617713000805; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; WALSH RN, 1976, PSYCHOL BULL, V83, P482, DOI 10.1037/0033-2909.83.3.482; Yen YC, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00103	43	55	57	0	20	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2014	121	6					1342	1350		10.3171/2014.7.JNS14272			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AU3CP	WOS:000345490700007	25267088	Bronze, Green Accepted			2022-02-06	
J	Takematsu, M; Hoffman, RS; Nelson, LS; Schechter, JM; Moran, JH; Wiener, SW				Takematsu, M.; Hoffman, R. S.; Nelson, L. S.; Schechter, J. M.; Moran, J. H.; Wiener, S. W.			A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid	CLINICAL TOXICOLOGY			English	Article						Synthetic cannabinoid; Ischemic stroke; XLR-11; JWH-018; Marijuana; Acute kidney injury	QUANTITATIVE MEASUREMENT; METABOLITES; JWH-018	Objective. Synthetic cannabinoids are increasingly used in the United States as marijuana substitutes. However, reports of severe toxicity, resulting from their use, are limited. We present the case of acute cerebral infarction following synthetic cannabinoid inhalation. Case report. A 33-year-old man with no significant medical history presented at the emergency department with right-sided weakness and aphasia. He had smoked a synthetic cannabinoid (SC) product called "WTF" prior to the onset of symptoms. Physical examination showed right hemiparesis, dysarthria, and aphasia. Laboratory evaluation, electrocardiography, and computed tomography (CT) of the head were unremarkable. Following administration of intravenous tissue plasminogen activator, his symptoms improved. A repeat head CT showed acute infarction in the left insular cortex. His hypercoagulability panel was unremarkable, and the patient was discharged neurologically intact. Urine toxicology results were unremarkable. Analysis of the product by gas chromatography-mass spectrometry (GC-MS) procedure confirmed the presence of a synthetic cannabinoid known as XLR-11. Conclusion. XLR-11 has previously been associated with acute kidney injury in humans. However, there are no reports of it causing acute cerebral ischemic events. The close temporal association between XLR-11 inhalation and his stroke is concerning. Acute cerebral infarction may occur after XLR-11 use in healthy patients.	[Takematsu, M.] Albert Einstein Coll Med, Montefiore Med Ctr, Dept Emergency Med, Div Med Toxicol, New York, NY 10467 USA; [Hoffman, R. S.; Nelson, L. S.] NYU, Sch Med, Dept Emergency Med, Div Med Toxicol, New York, NY USA; [Nelson, L. S.] New York City Poison Control Ctr, New York, NY USA; [Schechter, J. M.; Wiener, S. W.] Suny Downstate Med Ctr, Dept Emergency Med, Brooklyn, NY 11203 USA; [Schechter, J. M.; Wiener, S. W.] Kings Cty Hosp, Dept Emergency Med, New York, NY USA; [Moran, J. H.] Arkansas Dept Hlth, Arkansas Publ Hlth Lab, Little Rock, AR 72205 USA		Takematsu, M (corresponding author), Albert Einstein Coll Med, Montefiore Med Ctr, Dept Emergency Med, Div Med Toxicol, 111 E210 St, New York, NY 10467 USA.	mtakemat@montefiore.org		Hoffman, Robert/0000-0002-0091-9573; Nelson, Lewis/0000-0001-9551-3922			BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Brust JCM, 2013, NEUROLOGY, V81, P2064, DOI 10.1212/01.wnl.0000437310.96160.fa; Chimalakonda KC, 2011, ANAL CHEM, V83, P6381, DOI 10.1021/ac201377m; Freeman MJ, 2013, NEUROLOGY, V81, P2090, DOI 10.1212/01.wnl.0000437297.05570.a2; Hillebrand J, 2010, SUBST USE MISUSE, V45, P330, DOI 10.3109/10826080903443628; Lapoint J, 2011, CLIN TOXICOL, V49, P760, DOI 10.3109/15563650.2011.609822; Mir A, 2011, PEDIATRICS, V128, pE1622, DOI 10.1542/peds.2010-3823; Moran CL, 2011, ANAL CHEM, V83, P4228, DOI 10.1021/ac2005636; Murphy TD, 2013, MMWR-MORBID MORTAL W, V62, P93; Patton AL, 2013, ANAL CHEM, V85, P9390, DOI 10.1021/ac4024704; Schneir AB, 2011, J EMERG MED, V40, P296, DOI 10.1016/j.jemermed.2010.10.014; Seely KA, 2011, MOL INTERV, V11, P36, DOI 10.1124/mi.11.1.6; Simmons JR, 2011, ANN EMERG MED, V57, P187, DOI 10.1016/j.annemergmed.2010.08.039	13	55	55	0	18	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1556-3650	1556-9519		CLIN TOXICOL	Clin. Toxicol.	NOV	2014	52	9					973	975		10.3109/15563650.2014.958614			3	Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Toxicology	AS6FH	WOS:000344359400010	25241766				2022-02-06	
J	Bolton, AN; Saatman, KE				Bolton, Amanda N.; Saatman, Kathryn E.			Regional Neurodegeneration and Gliosis Are Amplified by Mild Traumatic Brain Injury Repeated at 24-Hour Intervals	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Astrocytosis; Axonal injury; Cerebellum; Concussion; Entorhinal cortex; Loss of consciousness; Microgliosis; Traumatic brain injury	FLUID PERCUSSION MODEL; CLOSED-HEAD-INJURY; AXONAL INJURY; MOUSE MODEL; COGNITIVE DEFICITS; MICE; RATS; PATHOPHYSIOLOGY; VULNERABILITY; CONCUSSION	Most traumatic brain injuries (TBIs) that occur every year are classified as "mild.'' Individuals involved in high-risk activities may sustain multiple mild TBIs. We evaluated the acute physiologic and histopathologic consequences of mild TBI in a mouse model, comparing sham injury, single impact, or 5 impacts at a 24- or 48-hour interinjury interval. A single closed skull impact resulted in bilateral gliosis in the hippocampus and entorhinal cortex that was proportional to impact depth. Midline impact, at a depth just above the threshold to induce transient unconsciousness, produced occasional axonal injury and degenerating neurons accompanied by astrogliosis in the entorhinal cortex and cerebellum. Mild TBI repeated every 24 hours resulted in bilateral hemorrhagic lesions in the entorhinal cortex along with significantly increased neurodegeneration and microglial activation despite diminished durations of apnea and unconsciousness with subsequent impacts. Astrogliosis and diffusely distributed axonal injury were also observed bilaterally in the cerebellum and the brainstem. When the interval between mild TBIs was increased to 48 hours, the pathologic consequences were comparable to those of a single TBI. Together, these data suggest that, in mice, the brain remains at an increased risk for damage for 24 hours after mild TBI despite reduced acute physiologic responses to subsequent mild impacts.	[Bolton, Amanda N.; Saatman, Kathryn E.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA; [Bolton, Amanda N.; Saatman, Kathryn E.] Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY USA; [Saatman, Kathryn E.] Univ Kentucky, Coll Med, Dept Neurosurg, Lexington, KY USA		Saatman, KE (corresponding author), Spinal Cord & Brain Injury Res Ctr, B473 Biomed & Biol Res Bldg,741 S Limestone St, Lexington, KY 40536 USA.	k.saatman@uky.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 NS077889, P01 NS058484, P30 NS051220]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, P01NS058484, T32NS077889] Funding Source: NIH RePORTER	This study was supported by grants from the National Institutes of Health (T32 NS077889 to Amanda N. Bolton and P01 NS058484 and P30 NS051220 to Kathryn E. Saatman).	Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Centers for Disease Control and Prevention (CDC), 2003, REP C MILD TRAUM BRA, P1; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; de Hoz R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083733; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Diniz LP, 2012, J BIOL CHEM, V287, P41432, DOI 10.1074/jbc.M112.380824; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Faul M, 2010, TRAUMATIC BRAIN INJU; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FRANK GB, 1963, BRIT J PHARM CHEMOTH, V21, P1; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Fujita M, 2012, J NEUROTRAUM, V29, P2172, DOI 10.1089/neu.2012.2357; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Hardman R, 1997, BRAIN RES, V758, P187, DOI 10.1016/S0006-8993(97)00223-0; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kubo K, 2009, J PHARMACOL EXP THER, V329, P592, DOI 10.1124/jpet.109.151456; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Redell JB, 2013, J NEUROTRAUM, V30, P752, DOI 10.1089/neu.2012.2437; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; Veasey Sigrid C, 2012, Front Neurol, V3, P139, DOI 10.3389/fneur.2012.00139; Wilkinson AE, 1999, ACTA NEUROPATHOL, V98, P197, DOI 10.1007/s004010051069; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	50	55	56	1	15	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	OCT	2014	73	10					933	947		10.1097/NEN.0000000000000115			15	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	AQ3JN	WOS:000342688800003	25232942	Green Accepted			2022-02-06	
J	Young, TJ; Daniel, RW; Rowson, S; Duma, SM				Young, Tyler J.; Daniel, Ray W.; Rowson, Steven; Duma, Stefan M.			Head Impact Exposure in Youth Football: Elementary School Ages 7-8 Years and the Effect of Returning Players	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; brain injury; biomechanics; pediatric; acceleration; helmet	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; COLLEGIATE; ACCELERATION; CONCUSSIONS; PERFORMANCE; KINEMATICS; MAGNITUDE	Objective: To provide data describing the head impact exposure of 7- to 8-year-old football players. Design: Head impact data were collected from 19 players over the course of 2 seasons using helmet-mounted accelerometer arrays. Setting: Data were collected from 2 youth football teams in Blacksburg, VA, spanning 2 seasons. Participants: A total of 19 youth football players aged 7-8 years. Independent Variables: Type of session (practice or game) and the player's experience. Main Outcome Measures: Head impact frequency, acceleration magnitude, and impact location for games, practices, and the season as a whole were measured. Results: The average instrumented player sustained 9 +/- 6 impacts per practice, 11 +/- 11 impacts per game, and 161 +/- 111 impacts per season. The average instrumented player had a median impact of 16 +/- 2 g and 686 +/- 169 rad/s(2) and a 95th percentile impact of 38 +/- 13 g and 2052 +/- 664 rad/s(2) throughout a season. Impacts of 40 g or greater tended to occur more frequently in practices than in games, and practices had a significantly higher 95th percentile impact magnitude than games (P = 0.023). Returning players had significantly more impacts than first time players (P = 0.007). Conclusions: These data are a further step toward developing effective strategies to reduce the incidence of concussion in youth football and have applications toward youth-specific football helmet designs.	[Young, Tyler J.; Daniel, Ray W.; Rowson, Steven; Duma, Stefan M.] Wake Forest Univ, Virginia Tech, Sch Biomed Engn & Sci, Blacksburg, VA USA		Rowson, S (corresponding author), 440 Kelly Hall,325 Stanger St,MC 0194, Blacksburg, VA 24061 USA.	srowson@vt.edu	Duma, Stefan/A-8368-2012; Rowson, Steven/B-1270-2012	Rowson, Steven/0000-0002-3227-0596	National Highway Traffic Safety Administration	The authors gratefully acknowledge the National Highway Traffic Safety Administration for supporting this work.	Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Chu JJ, 2006, J BIOMECH S1, V39, pS534; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2010, J ATHL TRAINING, V45, p54q9; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Duma SM, 2011, EXERC SPORT SCI REV, V39, P2, DOI 10.1097/JES.0b013e318203dfdb; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hamilton NA, 2010, SEMIN PEDIATR SURG, V19, P271, DOI 10.1053/j.sempedsurg.2010.06.005; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rowson S, 2008, CLIN J SPORT MED, V18, P316, DOI 10.1097/JSM.0b013e31817f016a; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2010, CLIN J SPORT MED, V20, P344, DOI 10.1097/JSM.0b013e3181ed7e50; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Shain KS, 2010, CLIN J SPORT MED, V20, P422, DOI 10.1097/JSM.0b013e3181f7db25; Viano DC, 2012, ANN BIOMED ENG, V40, P97, DOI 10.1007/s10439-011-0377-3; Viano DC, 2012, ANN BIOMED ENG, V40, P160, DOI 10.1007/s10439-011-0384-4; Viano DC, 2012, ANN BIOMED ENG, V40, P47, DOI 10.1007/s10439-011-0399-x; Viano DC, 2012, ANN BIOMED ENG, V40, P175, DOI 10.1007/s10439-011-0395-1	37	55	55	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2014	24	5					416	421					6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	AP3OO	WOS:000341986300014	24326933				2022-02-06	
J	Niesman, IR; Schilling, JM; Shapiro, LA; Kellerhals, SE; Bonds, JA; Kleschevnikov, AM; Cui, WH; Voong, A; Krajewski, S; Ali, SS; Roth, DM; Patel, HH; Patel, PM; Head, BP				Niesman, Ingrid R.; Schilling, Jan M.; Shapiro, Lee A.; Kellerhals, Sarah E.; Bonds, Jacqueline A.; Kleschevnikov, Alexander M.; Cui, Weihua; Voong, April; Krajewski, Stan; Ali, Sameh S.; Roth, David M.; Patel, Hemal H.; Patel, Piyush M.; Head, Brian P.			Traumatic brain injury enhances neuroinflammation and lesion volume in caveolin deficient mice	JOURNAL OF NEUROINFLAMMATION			English	Article							STATUS EPILEPTICUS; A(2A) RECEPTOR; POSTTRAUMATIC SEIZURES; ADENOSINE RECEPTORS; SPATIAL MEMORY; MESSENGER-RNA; EXPRESSION; EPILEPTOGENESIS; ACTIVATION; MECHANISMS	Background: Traumatic brain injury (TBI) enhances pro-inflammatory responses, neuronal loss and long-term behavioral deficits. Caveolins (Cavs) are regulators of neuronal and glial survival signaling. Previously we showed that astrocyte and microglial activation is increased in Cav-1 knock-out (KO) mice and that Cav-1 and Cav-3 modulate microglial morphology. We hypothesized that Cavs may regulate cytokine production after TBI. Methods: Controlled cortical impact (CCI) model of TBI (3 m/second; 1.0 mm depth; parietal cortex) was performed on wild-type (WT; C57Bl/6), Cav-1 KO, and Cav-3 KO mice. Histology and immunofluorescence microscopy (lesion volume, glia activation), behavioral tests (open field, balance beam, wire grip, T-maze), electrophysiology, electron paramagnetic resonance, membrane fractionation, and multiplex assays were performed. Data were analyzed by unpaired t tests or analysis of variance (ANOVA) with post-hoc Bonferroni's multiple comparison. Results: CCI increased cortical and hippocampal injury and decreased expression of MLR-localized synaptic proteins (24 hours), enhanced NADPH oxidase (Nox) activity (24 hours and 1 week), enhanced polysynaptic responses (1 week), and caused hippocampal-dependent learning deficits (3 months). CCI increased brain lesion volume in both Cav-3 and Cav-1 KO mice after 24 hours (P < 0.0001, n = 4; one-way ANOVA). Multiplex array revealed a significant increase in expression of IL-1 beta, IL-9, IL-10, KC (keratinocyte chemoattractant), and monocyte chemoattractant protein 1 (MCP-1) in ipsilateral hemisphere and IL-9, IL-10, IL-17, and macrophage inflammatory protein 1 alpha (MIP-1 alpha) in contralateral hemisphere of WT mice after 4 hours. CCI increased IL-2, IL-6, KC and MCP-1 in ipsilateral and IL-6, IL-9, IL-17 and KC in contralateral hemispheres in Cav-1 KO and increased all 10 cytokines/chemokines in both hemispheres except for IL-17 (ipsilateral) and MIP-1 alpha (contralateral) in Cav-3 KO (versus WT CCI). Cav-3 KO CCI showed increased IL-1 beta, IL-9, KC, MCP-1, MIP-1 alpha, and granulocyte-macrophage colony-stimulating factor in ipsilateral and IL-1 beta, IL-2, IL-9, IL-10, and IL-17 in contralateral hemispheres (P = 0.0005, n = 6; two-way ANOVA) compared to Cav-1 KO CCI. Conclusion: CCI caused astrocyte and microglial activation and hippocampal neuronal injury. Cav-1 and Cav-3 KO exhibited enhanced lesion volume and cytokine/chemokine production after CCI. These findings suggest that Cav isoforms may regulate neuroinflammatory responses and neuroprotection following TBI.	[Niesman, Ingrid R.; Schilling, Jan M.; Kellerhals, Sarah E.; Bonds, Jacqueline A.; Cui, Weihua; Voong, April; Ali, Sameh S.; Roth, David M.; Patel, Hemal H.; Patel, Piyush M.; Head, Brian P.] Vet Affairs San Diego Healthcare Syst, La Jolla, CA 92161 USA; [Niesman, Ingrid R.; Schilling, Jan M.; Kellerhals, Sarah E.; Bonds, Jacqueline A.; Cui, Weihua; Voong, April; Ali, Sameh S.; Roth, David M.; Patel, Hemal H.; Patel, Piyush M.; Head, Brian P.] Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA; [Shapiro, Lee A.] Cent Texas Vet Hlth Syst, Scott & White Hosp, Neurosci Res Inst, Temple, TX USA; [Shapiro, Lee A.] Texas A&M Hlth Sci Ctr, Coll Med, Dept Neurosci & Expt Therapeut, Dept Surg,Dept Neurosurg, Temple, TX USA; [Kleschevnikov, Alexander M.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Krajewski, Stan] Sanford Burnham Med Res Inst, La Jolla, CA USA; [Cui, Weihua] Capital Med Univ, Beijing Tiantan Hosp, Dept Anesthesiol, Beijing, Peoples R China; [Ali, Sameh S.] Zewail City Sci & Technol, Ctr Aging & Associated Dis, Helmy Inst Med Sci, Giza, Egypt		Head, BP (corresponding author), Vet Affairs San Diego Healthcare Syst, 3350 La Jolla Village Dr, La Jolla, CA 92161 USA.	bhead@ucsd.edu	Patel, Hemal/C-7325-2019; Kleschevnikov, Alexander/R-6926-2016	Patel, Hemal/0000-0001-6722-9625; Ali, Sameh Saad/0000-0002-0339-6106; Kleschevnikov, Alexander/0000-0002-1562-6706	VAUS Department of Veterans Affairs [5I01BX001963-04] Funding Source: Federal RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL107200, R01HL091071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS073653] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX000783, I01BX001963] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL107200, HL091071, R01 HL107200] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS073653, R01 NS073653] Funding Source: Medline; BLRD VA [I01 BX001963, I01 BX000783] Funding Source: Medline		Adewuya AO, 2005, EPILEPSY BEHAV, V7, P497, DOI 10.1016/j.yebeh.2005.07.011; Adibhatla Rao Muralikrishna, 2008, V49, P241, DOI 10.1007/978-1-4020-8831-5_9; Ali SS, 2011, BRAIN RES, V1368, P65, DOI 10.1016/j.brainres.2010.11.009; Andjelkovic AV, 2002, J NEUROSCI RES, V70, P219, DOI 10.1002/jnr.10372; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Atkins CM, 2009, NEUROSCI LETT, V459, P52, DOI 10.1016/j.neulet.2009.04.064; Babb TL, 2000, EPILEPSIA, V41, pS76, DOI 10.1111/j.1528-1157.2000.tb01561.x; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Beghi E, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s10.1.x; Biagini G, 2012, JASPERS BASIC MECH E; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Boison D, 2010, CELL DEATH DIFFER, V17, P1071, DOI 10.1038/cdd.2009.131; Brambilla R, 2003, GLIA, V43, P190, DOI 10.1002/glia.10243; Carter R J, 2001, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0812s15; Cheret C, 2008, J NEUROSCI, V28, P12039, DOI 10.1523/JNEUROSCI.3568-08.2008; Chidlow JH, 2010, CARDIOVASC RES, V86, P219, DOI 10.1093/cvr/cvq075; Conte V, 2008, RESTOR NEUROL NEUROS, V26, P45; Deacon RMJ, 2006, NAT PROTOC, V1, P7, DOI 10.1038/nprot.2006.2; Di Virgilio F, 2009, TRENDS NEUROSCI, V32, P79, DOI 10.1016/j.tins.2008.11.003; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Dixon AK, 1997, J NEUROCHEM, V69, P315; Duchowny M, 2000, NEUROLOGY, V55, P423, DOI 10.1212/WNL.55.3.423; Fedele DE, 2006, EXP NEUROL, V200, P184, DOI 10.1016/j.expneurol.2006.02.133; Fields RD, 2006, NAT REV NEUROSCI, V7, P423, DOI 10.1038/nrn1928; Foresti ML, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-40; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Ge SJ, 2004, J BIOL CHEM, V279, P6688, DOI 10.1074/jbc.M311769200; Gioiosa L, 2008, BEHAV BRAIN RES, V188, P255, DOI 10.1016/j.bbr.2007.11.002; Gomes C, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-16; Goodrich GS, 2013, J NEUROTRAUM, V30, P1434, DOI 10.1089/neu.2012.2712; Gu Y, 2012, J NEUROCHEM, V120, P147, DOI 10.1111/j.1471-4159.2011.07542.x; Guzik-Kornacka A, 2011, ACTA NEUROBIOL EXP, V71, P193; Hagiwara Y, 2000, HUM MOL GENET, V9, P3047, DOI 10.1093/hmg/9.20.3047; Hasko G, 2005, TRENDS PHARMACOL SCI, V26, P511, DOI 10.1016/j.tips.2005.08.004; Head BP, 2008, FASEB J, V22, P828, DOI 10.1096/fj.07-9299com; Head BP, 2011, J BIOL CHEM, V286, P33310, DOI 10.1074/jbc.M111.255976; Head BP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015697; Heverin M, 2012, BRAIN RES, V1480, P81, DOI 10.1016/j.brainres.2012.08.018; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Jasmin JF, 2011, AM J PHYSIOL-HEART C, V300, pH1274, DOI 10.1152/ajpheart.01173.2010; Kim JH, 2013, BRAIN RES, V1499, P163, DOI 10.1016/j.brainres.2013.01.007; Kleschevnikov AM, 2012, J NEUROSCI, V32, P9217, DOI 10.1523/JNEUROSCI.1673-12.2012; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Krajewska M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024341; Krajewska M, 2009, J HISTOCHEM CYTOCHEM, V57, P649, DOI 10.1369/jhc.2009.952812; Mirza MK, 2010, AM J PATHOL, V176, P2344, DOI 10.2353/ajpath.2010.091088; Mukherjee S, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00021; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Neary JT, 2005, J NEUROTRAUM, V22, P491, DOI 10.1089/neu.2005.22.491; Niesman IR, 2013, MOL CELL NEUROSCI, V56, P283, DOI 10.1016/j.mcn.2013.07.002; Orr AG, 2009, NAT NEUROSCI, V12, P872, DOI 10.1038/nn.2341; Patel H. H., 2008, V186, P167, DOI 10.1007/978-3-540-72843-6_7; Paylor R, 1998, LEARN MEMORY, V5, P302; Pitkanen A, 2009, EPILEPSY BEHAV, V14, P16, DOI 10.1016/j.yebeh.2008.09.023; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Ribeiro JA, 2002, PROG NEUROBIOL, V68, P377, DOI 10.1016/S0301-0082(02)00155-7; Schierhout G, 2001, COCHRANE DB SYST REV, V4; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Sharma S, 2010, LIFE SCI, V87, P521, DOI 10.1016/j.lfs.2010.09.004; Shen HY, 2009, CURR NEUROPHARMACOL, V7, P195, DOI 10.2174/157015909789152191; Shin T, 2005, J NEUROIMMUNOL, V165, P11, DOI 10.1016/j.jneuroim.2005.03.019; Silva WI, 2007, J NEUROCHEM, V103, P101, DOI 10.1111/j.1471-4159.2007.04712.x; Spuch C, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00269; Stern CM, 2010, CELL MOL LIFE SCI, V67, P3785, DOI 10.1007/s00018-010-0447-y; Truong TQ, 2006, BBA-MOL CELL BIOL L, V1761, P24, DOI 10.1016/j.bbalip.2005.12.004; Watts LT, 2013, J NEUROTRAUM, V30, P55, DOI 10.1089/neu.2012.2488; Wu LH, 2005, J CELL BIOCHEM, V96, P1021, DOI 10.1002/jcb.20596	68	55	58	0	19	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAR 3	2014	11								39	10.1186/1742-2094-11-39			14	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	AD4SN	WOS:000333240900001	24593993	Green Published, gold			2022-02-06	
J	Hammoud, S; Bedi, A; Voos, JE; Mauro, CS; Kelly, BT				Hammoud, Sommer; Bedi, Asheesh; Voos, James E.; Mauro, Craig S.; Kelly, Bryan T.			The Recognition and Evaluation of Patterns of Compensatory Injury in Patients With Mechanical Hip Pain	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						femoroacetabular impingement; compensatory injury; hip; athletic pubalgia; iliopsoas impingement		Context: In active individuals with femoroacetabular impingement (FAI), the resultant reduction in functional range of motion leads to high impaction loads at terminal ranges. These increased forces result in compensatory effects on bony and soft tissue structures within the hip joint and hemipelvis. An algorithm is useful in evaluating athletes with pre-arthritic, mechanical hip pain and associated compensatory disorders. Evidence Acquisition: A literature search was performed by a review of PubMed articles published from 1976 to 2013. Results: Increased stresses across the bony hemipelvis result when athletes with FAI attempt to achieve supraphysiologic, terminal ranges of motion (ROM) through the hip joint required for athletic competition. This can manifest as pain within the pubic joint (osteitis pubis), sacroiliac joint, and lumbosacral spine. Subclinical posterior hip instability may result when attempts to increase hip flexion and internal rotation are not compensated for by increased motion through the hemipelvis. Prominence of the anterior inferior iliac spine (AIIS) at the level of the acetabular rim can result in impingement of the anterior hip joint capsule or iliocapsularis muscle origin against the femoral head-neck junction, resulting in a distinct form of mechanical hip impingement (AIIS subspine impingement). Iliopsoas impingement (IPI) has also been described as an etiology for anterior hip pain. IPI results in a typical 3-o'clock labral tear as well as an inflamed capsule in close proximity to the overlying iliopsoas tendon. Injury in athletic pubalgia occurs during high-energy twisting activities in which abnormal hip ROM and resultant pelvic motion lead to shearing across the pubic symphysis. Conclusion: Failure to recognize and address concomitant compensatory injury patterns associated with intra-articular hip pathology can result in significant disability and persistent symptoms in athletes with pre-arthritic, mechanical hip pain. Strength-of-Recommendation Taxonomy (SORT): B	[Hammoud, Sommer; Kelly, Bryan T.] Thomas Jefferson Univ, Rothman Inst, Philadelphia, PA 19107 USA; [Bedi, Asheesh] Univ Michigan, Div Sports Med & Shoulder Surg, MedSport, Ann Arbor, MI 48109 USA; [Voos, James E.] Orthopaed & Sports Med Clin, Kansas City, MO USA; [Mauro, Craig S.] Select Specialty Hosp Pittsburgh, Pittsburgh, PA USA		Bedi, A (corresponding author), Univ Michigan, MedSport, 24 Frank Lloyd Wright Dr, Ann Arbor, MI 48106 USA.	abedi@umich.edu					Ahumada LA, 2005, ANN PLAS SURG, V55, P393, DOI 10.1097/01.sap.0000181344.22386.fa; Anderson K, 2001, AM J SPORT MED, V29, P521, DOI 10.1177/03635465010290042501; Anderson SA, 2008, AM J SPORT MED, V36, P2363, DOI 10.1177/0363546508322130; Antolak SJ, 2002, MED HYPOTHESES, V59, P349, DOI 10.1016/S0306-9877(02)00218-9; Armfield DR, 2006, CLIN SPORT MED, V25, P803, DOI 10.1016/j.csm.2006.06.011; Bankart ASB, 1938, BRIT J SURG, V26, P23, DOI 10.1002/bjs.18002610104; Bedi A, 2011, ARTHROSCOPY, V27, P1720, DOI 10.1016/j.arthro.2011.08.288; Benson ER, 1999, J BONE JOINT SURG AM, V81A, P941, DOI 10.2106/00004623-199907000-00006; Brophy RH, 2010, AM J SPORT MED, V38, P1166, DOI 10.1177/0363546509357836; Byrd J W Thomas, 2006, Instr Course Lect, V55, P347; Caudill P, 2008, BRIT J SPORT MED, V42, P954, DOI 10.1136/bjsm.2008.047373; Cibulka MT, 1998, SPINE, V23, P1009, DOI 10.1097/00007632-199805010-00009; Clemente C, 1985, GRAYS ANATOMY ANATOM; COOPER DE, 1991, AM J SPORT MED, V19, P322, DOI 10.1177/036354659101900319; Cross Michael B, 2010, HSS J, V6, P223, DOI 10.1007/s11420-010-9156-1; de Almeida DB, 2009, ARQ NEURO-PSIQUIAT, V67, P268, DOI 10.1590/S0004-282X2009000200018; Delp SL, 1999, J BIOMECH, V32, P493, DOI 10.1016/S0021-9290(99)00032-9; Domb BG, 2011, HSS J, V7, P1; Dreyfuss P, 2004, J AM ACAD ORTHOP SUR, V12, P255, DOI 10.5435/00124635-200407000-00006; Farber AJ, 2007, J AM ACAD ORTHOP SUR, V15, P507, DOI 10.5435/00124635-200708000-00007; Feeley BT, 2008, AM J SPORT MED, V36, P2187, DOI 10.1177/0363546508319898; Frank JB, 2007, J AM ACAD ORTHOP SUR, V15, P356, DOI 10.5435/00124635-200706000-00005; Fredericson M, 2005, PHYSICIAN SPORTSMED, V33, P32, DOI 10.3810/psm.2005.05.89; Freiberg AH, 1937, ARCH SURG-CHICAGO, V34, P337, DOI 10.1001/archsurg.1937.01190080138007; Gamradt SC, 2009, AM J SPORT MED, V37, P1370, DOI 10.1177/0363546509333477; Greene HS, 2001, AM J SPORT MED, V29, P795, DOI 10.1177/03635465010290062001; HASSELMAN CT, 1995, AM J SPORT MED, V23, P493, DOI 10.1177/036354659502300421; Hetsroni I, 2013, CLIN ORTHOP RELAT R, V471, P2497, DOI 10.1007/s11999-013-2847-4; Heyworth BE, 2010, HIP PELVIS INJURIES, P192; Heyworth BE, 2007, PEDIATR ANN, V36, P713, DOI 10.3928/0090-4481-20071101-07; Hsu JC, 2005, AM J SPORT MED, V33, P1085, DOI 10.1177/0363546504273045; Ilizaliturri VM, 2011, AM J SPORT MED, V39, p50S, DOI 10.1177/0363546511411642; Ilizaliturri VM, 2010, SPORTS MED ARTHROSC, V18, P120, DOI 10.1097/JSA.0b013e3181dc57a5; Irshad K, 2001, SURGERY, V130, P759, DOI 10.1067/msy.2001.118093; Kachingwe AF, 2008, J ORTHOP SPORT PHYS, V38, P768, DOI 10.2519/jospt.2008.2846; Kennedy MJ, 2009, GAIT POSTURE, V30, P41, DOI 10.1016/j.gaitpost.2009.02.008; KNOCKAERT DC, 1989, POSTGRAD MED J, V65, P632, DOI 10.1136/pgmj.65.767.632; Lachiewicz PF, 2009, J AM ACAD ORTHOP SUR, V17, P337, DOI 10.5435/00124635-200906000-00002; Lacroix VJ, 1998, CLIN J SPORT MED, V8, P5, DOI 10.1097/00042752-199801000-00002; Lamontagne M, 2009, CLIN ORTHOP RELAT R, V467, P645, DOI 10.1007/s11999-008-0620-x; Larson CM, 2011, ARTHROSCOPY, V27, P768, DOI 10.1016/j.arthro.2011.01.018; Lawrence JP, 2006, J AM ACAD ORTHOP SUR, V14, P726, DOI 10.5435/00124635-200612000-00004; Leunig M, 2009, CLIN ORTHOP RELAT R, V467, P616, DOI 10.1007/s11999-008-0646-0; Martin HD, 2011, ARTHROSCOPY, V27, P172, DOI 10.1016/j.arthro.2010.07.008; METZMAKER JN, 1985, AM J SPORT MED, V13, P349, DOI 10.1177/036354658501300510; Meyers WC, 2000, AM J SPORT MED, V28, P2, DOI 10.1177/03635465000280011501; Meyers WC, 2008, ANN SURG, V248, P656, DOI 10.1097/SLA.0b013e318187a770; Miller SF, 2004, AM J SPORT MED, V32, P928, DOI 10.1177/0363546503262194; Moorman CT, 2003, J BONE JOINT SURG AM, V85A, P1190, DOI 10.2106/00004623-200307000-00002; Murata Yasuaki, 2009, Spine J, V9, pe16, DOI 10.1016/j.spinee.2009.01.004; Nelson Erik N, 2005, Magn Reson Imaging Clin N Am, V13, P727, DOI 10.1016/j.mric.2005.08.009; Ouellette H, 2006, SKELETAL RADIOL, V35, P665, DOI 10.1007/s00256-006-0162-9; Paajanen H, 2008, AM J SPORT MED, V36, P117, DOI 10.1177/0363546507305454; PACE JB, 1976, WESTERN J MED, V124, P435; Pallia Chris S, 2002, Curr Sports Med Rep, V1, P338; Pan HL, 2008, J BONE JOINT SURG BR, V90B, P677, DOI 10.1302/0301-620X.90B5.20005; Pfirrmann CWA, 2006, RADIOLOGY, V240, P778, DOI 10.1148/radiol.2403050767; Philippon MJ, 2009, ARTHROSCOPY, V25, P169, DOI 10.1016/j.arthro.2008.09.013; Radic R, 2008, AM J SPORT MED, V36, P122, DOI 10.1177/0363546507306160; Rajasekhar C, 2001, INT ORTHOP, V24, P364, DOI 10.1007/s002640000184; Sairyo K, 2005, AM J SPORT MED, V33, P583, DOI 10.1177/0363546504269035; Shindle MK, 2007, J BONE JOINT SURG AM, V89A, P29, DOI 10.2106/JBJS.G.00603; Tibor LM, 2008, ARTHROSCOPY, V24, P1407, DOI 10.1016/j.arthro.2008.06.019; Tortolani P Justin, 2002, Spine J, V2, P251, DOI 10.1016/S1529-9430(02)00198-5; van der Wurff P, 2000, MANUAL THER, V5, P30, DOI 10.1016/S1356-689X(99)90228-X; Verrall GM, 2007, J SCI MED SPORT, V10, P463, DOI 10.1016/j.jsams.2006.11.006; Verrall GM, 2005, J SCI MED SPORT, V8, P77, DOI 10.1016/S1440-2440(05)80027-1; WATERS PM, 1988, CLIN SPORT MED, V7, P513; Weber M, 1997, J ORTHOP TRAUMA, V11, P382, DOI 10.1097/00005131-199707000-00018; Williams J G, 1978, Br J Sports Med, V12, P129; Yoshio Masaharu, 2002, J Orthop Sci, V7, P199, DOI 10.1007/s007760200034; Zebala Lukas P, 2007, Iowa Orthop J, V27, P71; Ziprin P, 1999, BRIT J SURG, V86, P566, DOI 10.1046/j.1365-2168.1999.01081.x	73	55	57	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	MAR-APR	2014	6	2					108	118		10.1177/1941738114522201			11	Sport Sciences	Emerging Sources Citation Index (ESCI)	Sport Sciences	V20EK	WOS:000214869700003	24587859	Green Published			2022-02-06	
J	Grabenstatter, HL; Del Angel, YC; Carlsen, J; Wempe, MF; White, AM; Cogswell, M; Russek, SJ; Brooks-Kayal, AR				Grabenstatter, H. L.; Del Angel, Y. Cruz; Carlsen, J.; Wempe, M. F.; White, A. M.; Cogswell, M.; Russek, S. J.; Brooks-Kayal, A. R.			The effect of STAT3 inhibition on status epilepticus and subsequent spontaneous seizures in the pilocarpine model of acquired epilepsy	NEUROBIOLOGY OF DISEASE			English	Article							TRAUMATIC BRAIN-INJURY; SPONTANEOUS RECURRENT SEIZURES; FOCAL CEREBRAL-ISCHEMIA; TEMPORAL-LOBE EPILEPSY; PROGRAMMED CELL-DEATH; CYCLIN D1; SIGNAL TRANSDUCERS; DENTATE GYRUS; KAINIC ACID; JAK-STAT	Pilocarpine-induced status epilepticus (SE), which results in temporal lobe epilepsy (TLE) in rodents, activates the JAK/STAT pathway. In the current study, we evaluate whether brief exposure to a selective inhibitor of the JAK/STAT pathway (WP1066) early after the onset of SE affects the severity of SE or reduces later spontaneous seizure frequency via inhibition of STAT3-regulated gene transcription. Rats that received systemic WP1066 or vehicle at the onset of SE were continuously video-EEG monitored during SE and for one month to assess seizure frequency overtime. Protein and/or mRNA levels for pSTAT3, and STAT3-regulated genes including: ICER, Gabral, c-myc, md-1, cyclin D1, and bcl-xl were evaluated in WP1066 and vehicle-treated rats during stages of epileptogenesis to determine the acute effects of WP1066 administration on SE and chronic epilepsy. WP1066 (two 50 mg/kg doses) administered within the first hour after onset of SE results in transient inhibition of pSTAT3 and long-term reduction in spontaneous seizure frequency. WP1066 alters the severity of chronic epilepsy without affecting SE or cell death. Early WP1066 administration reduces known downstream targets of STAT3 transcription 24 h after SE including cyclin D1 and mcl-1 levels, known for their roles in cell-cycle progression and cell survival, respectively. These findings uncover a potential effect of the JAK/STAT pathway after brain injury that is physiologically important and may provide a new therapeutic target that can be harnessed for the prevention of epilepsy development and/or progression. (C) 2013 Elsevier Inc. All rights reserved.	[Grabenstatter, H. L.; Del Angel, Y. Cruz; Carlsen, J.; White, A. M.; Brooks-Kayal, A. R.] Univ Colorado, Sch Med, Dept Pediat, Div Neurol, Boulder, CO 80309 USA; [Grabenstatter, H. L.; Del Angel, Y. Cruz; Carlsen, J.; White, A. M.; Brooks-Kayal, A. R.] Univ Colorado, Sch Med, Translat Epilepsy Res Program, Boulder, CO 80309 USA; [Wempe, M. F.; Brooks-Kayal, A. R.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Aurora, CO USA; [Cogswell, M.; Russek, S. J.] Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA; [Brooks-Kayal, A. R.] Univ Colorado, Sch Med, Dept Neurol, Boulder, CO 80309 USA; [Brooks-Kayal, A. R.] Childrens Hosp Colorado, Aurora, CO USA		Brooks-Kayal, AR (corresponding author), Univ Colorado, Sch Med, Dept Pediat, Div Neurol, Boulder, CO 80309 USA.	amy.brooks-kayal@childrenscolorado.org			NIH, National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051710]; Citizens United for Research in Epilepsy (CURE); Epilepsy Foundation; NIH/NCATS Colorado Clinical Translational Science Award [UL1 RR025780]; Colorado Center for Drug Discovery; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051710] Funding Source: NIH RePORTER	The authors would like to thank Dr. Yogendra Raol and the University of Colorado Neurophysiology Core for assistance related to EEG monitoring and Dana Hund for technical assistance with histology. These studies were funded by NIH, National Institute of Neurological Disorders and Stroke R01NS051710 (to ABK and SJR), Citizens United for Research in Epilepsy (CURE) (to ABK and SJR), Epilepsy Foundation (to HG), NIH/NCATS Colorado Clinical Translational Science Award UL1 RR025780 (to the University of Colorado Medicinal Chemistry Core), and the Colorado Center for Drug Discovery (to ABK and MFW).	Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Arbour N, 2008, J NEUROSCI, V28, P6068, DOI 10.1523/JNEUROSCI.4940-07.2008; Azuma Y, 1996, NEUROCHEM INT, V29, P289, DOI 10.1016/0197-0186(95)00157-3; BALISH M, 1991, EPILEPSIA, V32, P642, DOI 10.1111/j.1528-1157.1991.tb04703.x; Bauer J, 2001, SEIZURE-EUR J EPILEP, V10, P239, DOI 10.1053/seiz.2000.0499; Berg AT, 2003, NEUROLOGY, V60, P186, DOI 10.1212/01.WNL.0000031792.89992.EC; Bernard Sandra, 2006, V42, P329, DOI 10.1007/004; Blume WT, 2006, EPILEPSIA, V47, P71, DOI 10.1111/j.1528-1167.2006.00665.x; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cha BH, 2004, BRAIN DEV-JPN, V26, P394, DOI 10.1016/j.braindev.2003.12.006; Choi JS, 2003, MOL BRAIN RES, V119, P10, DOI 10.1016/j.molbrainres.2003.08.010; Crino PB, 2005, J CHILD NEUROL, V20, P330, DOI 10.1177/08830738050200041101; Croll SD, 2004, ADV EXP MED BIOL, V548, P57; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; England MJ, 2012, EPILEPSY BEHAV, V25, P266, DOI 10.1016/j.yebeh.2012.06.016; Ferrajoli A, 2007, CANCER RES, V67, P11291, DOI 10.1158/0008-5472.CAN-07-0593; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; GILLARDON F, 1995, NEUROSCI LETT, V192, P85, DOI 10.1016/0304-3940(95)11619-8; Goffin K, 2007, EXP NEUROL, V205, P501, DOI 10.1016/j.expneurol.2007.03.008; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; Haut SR, 2006, LANCET NEUROL, V5, P148, DOI 10.1016/S1474-4422(06)70348-9; Haut SR, 2002, EPILEPSIA, V43, P711, DOI 10.1046/j.1528-1157.2002.26401.x; Henshall DC, 2000, NEUROLOGY, V55, P250, DOI 10.1212/WNL.55.2.250; Hu YH, 2008, J BIOL CHEM, V283, P9328, DOI 10.1074/jbc.M705110200; Hussain SF, 2007, CANCER RES, V67, P9630, DOI 10.1158/0008-5472.CAN-07-1243; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Iwamaru A, 2007, ONCOGENE, V26, P2435, DOI 10.1038/sj.onc.1210031; Jeon WJ, 2008, EXP MOL MED, V40, P435, DOI 10.3858/emm.2008.40.4.435; Kabadi SV, 2012, J NEUROTRAUM, V29, P813, DOI 10.1089/neu.2011.1980; Kim R, 2005, BIOCHEM BIOPH RES CO, V333, P336, DOI 10.1016/j.bbrc.2005.04.161; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Koeller HB, 2008, NEUROBIOL DIS, V31, P230, DOI 10.1016/j.nbd.2008.04.010; Kupferman Michael E, 2009, J Exp Ther Oncol, V8, P117; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lindsten T, 2005, NEUROSCIENTIST, V11, P10, DOI 10.1177/1073858404269267; Liu HT, 2003, BLOOD, V102, P344, DOI 10.1182/blood-2002-11-3396; Lopez E, 1999, NEUROSCIENCE, V91, P1461, DOI 10.1016/S0306-4522(98)00704-0; Lund IV, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1162396; Malone CD, 2012, MOL CELL NEUROSCI, V49, P439, DOI 10.1016/j.mcn.2012.02.003; Mankan AK, 2011, EXPERT OPIN INV DRUG, V20, P1263, DOI 10.1517/13543784.2011.601739; Masuda M, 2002, CANCER RES, V62, P3351; Mohapel P, 2004, NEUROBIOL DIS, V15, P196, DOI 10.1016/j.nbd.2003.11.010; Mori M, 2004, CELL DEATH DIFFER, V11, P1223, DOI 10.1038/sj.cdd.4401483; Murashima YL, 2007, EPILEPSIA, V48, P119, DOI 10.1111/j.1528-1167.2007.01299.x; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Orlova KA, 2010, J NEUROPATH EXP NEUR, V69, P850, DOI 10.1097/NEN.0b013e3181eac1f5; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Planas AM, 1996, EUR J NEUROSCI, V8, P2612, DOI 10.1111/j.1460-9568.1996.tb01556.x; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Raible DJ, 2012, J NEUROTRAUM, V29, P2548, DOI 10.1089/neu.2012.2483; Reich NC, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.290pe61; Ribak CE, 2002, PROG BRAIN RES, V136, P319; Scharfman HE, 2004, ADV EXP MED BIOL, V548, P192; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Shukla Garima, 2012, Epilepsy Res Treat, V2012, P195073, DOI 10.1155/2012/195073; SIMONATO M, 1991, MOL BRAIN RES, V11, P115, DOI 10.1016/0169-328X(91)90113-C; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; Suzuki S, 2001, EXP NEUROL, V170, P63, DOI 10.1006/exnr.2001.7701; Timsit S, 1999, EUR J NEUROSCI, V11, P263, DOI 10.1046/j.1460-9568.1999.00434.x; Wang YZ, 2011, ONCOL REP, V26, P1173, DOI 10.3892/or.2011.1396; Williams PA, 2009, J NEUROSCI, V29, P2103, DOI 10.1523/JNEUROSCI.0980-08.2009; Xu ZC, 2011, NEUROCHEM RES, V36, P2208, DOI 10.1007/s11064-011-0576-1; Yang-Yen HF, 2006, J BIOMED SCI, V13, P201, DOI 10.1007/s11373-005-9064-4; Zhao JB, 2011, NEUROSCI LETT, V498, P147, DOI 10.1016/j.neulet.2011.05.001; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; Zushi SI, 1998, INT J CANCER, V78, P326, DOI 10.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4	75	55	56	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	FEB	2014	62						73	85		10.1016/j.nbd.2013.09.003			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	301SY	WOS:000330553600008	24051278	Green Accepted			2022-02-06	
J	Huang, MX; Nichols, S; Baker, DG; Robb, A; Angeles, A; Yurgil, KA; Drake, A; Levy, M; Song, T; Mclay, R; Theilmann, RJ; Diwakar, M; Risbrough, VB; Ji, ZW; Huang, C; Chang, DG; Harrington, DL; Muzzatti, L; Canive, JM; Edgar, JC; Chen, YH; Lee, RR				Huang, Ming-Xiong; Nichols, Sharon; Baker, Dewleen G.; Robb, Ashley; Angeles, Annemarie; Yurgil, Kate A.; Drake, Angela; Levy, Michael; Song, Tao; McLay, Robert; Theilmann, Rebecca J.; Diwakar, Mithun; Risbrough, Victoria B.; Ji, Zhengwei; Huang, CharlesW.; Chang, Douglas G.; Harrington, Deborah L.; Muzzatti, Laura; Canive, Jose M.; Edgar, J. Christopher; Chen, Yu-Han; Lee, Roland R.			Single-subject-based whole-brain MEG slow-wave imaging approach for detecting abnormality in patients with mild traumatic brain injury	NEUROIMAGE-CLINICAL			English	Article						Magnetoencephalography; Traumatic brain injury; Slow-wave; Blast; Axonal injury	DIFFUSE AXONAL INJURY; SIGNAL SPACE SEPARATION; WHITE-MATTER INJURY; HEAD-INJURY; DELTA WAVES; POSTCONCUSSIVE SYNDROME; CLINICAL MANAGEMENT; STATE; MAGNETOENCEPHALOGRAPHY; LOCALIZATION	Traumatic brain injury (TBI) is a leading cause of sustained impairment in military and civilian populations. However, mild TBI (mTBI) can be difficult to detect using conventional MRI or CT. Injured brain tissues in mTBI patients generate abnormal slow-waves (1-4 Hz) that can be measured and localized by resting-state magnetoencephalography (MEG). In this study, we develop a voxel-based whole-brain MEG slow-wave imaging approach for detecting abnormality in patients with mTBI on a single-subject basis. A normative database of resting-state MEG source magnitude images (1-4 Hz) from 79 healthy control subjects was established for all brain voxels. The high resolution MEG source magnitude images were obtained by our recent Fast-VESTAL method. In 84 mTBI patients with persistent post-concussive symptoms (36 from blasts, and 48 from non-blast causes), our method detected abnormalities at the positive detection rates of 84.5%, 86.1%, and 83.3% for the combined (blast-induced plus with non-blast causes), blast, and non-blastmTBI groups, respectively. We found that prefrontal, posterior parietal, inferior temporal, hippocampus, and cerebella areas were particularly vulnerable to head trauma. The result also showed that MEG slow-wave generation in prefrontal areas positively correlated with personality change, trouble concentrating, affective lability, and depression symptoms. Discussion is provided regarding the neuronal mechanisms of MEG slow-wave generation due to deafferentation caused by axonal injury and/or blockages/limitations of cholinergic transmission in TBI. This study provides an effective way for using MEG slow-wave source imaging to localize affected areas and supports MEG as a tool for assisting the diagnosis of mTBI. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license	[Huang, Ming-Xiong; Baker, Dewleen G.; Robb, Ashley; Angeles, Annemarie; Yurgil, Kate A.; Risbrough, Victoria B.; Harrington, Deborah L.; Lee, Roland R.] VA San Diego Healthcare Syst, Serv Radiol, San Diego, CA USA; [Huang, Ming-Xiong; Baker, Dewleen G.; Robb, Ashley; Angeles, Annemarie; Yurgil, Kate A.; Risbrough, Victoria B.; Harrington, Deborah L.; Lee, Roland R.] VA San Diego Healthcare Syst, Res Serv, San Diego, CA USA; [Huang, Ming-Xiong; Baker, Dewleen G.; Robb, Ashley; Angeles, Annemarie; Yurgil, Kate A.; Risbrough, Victoria B.; Harrington, Deborah L.; Lee, Roland R.] VA San Diego Healthcare Syst, Psychiat Serv, San Diego, CA USA; [Huang, Ming-Xiong; Song, Tao; Theilmann, Rebecca J.; Diwakar, Mithun; Ji, Zhengwei; Harrington, Deborah L.; Muzzatti, Laura; Lee, Roland R.] Univ Calif San Diego, Dept Radiol, San Diego, CA 92121 USA; [Nichols, Sharon] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92121 USA; [Baker, Dewleen G.; Risbrough, Victoria B.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92121 USA; [Baker, Dewleen G.; Risbrough, Victoria B.] VA Ctr Excellence Stress & Mental Hlth, San Diego, CA USA; [Drake, Angela] Natl Univ, San Diego, CA USA; [Levy, Michael] Univ Calif San Diego, Rady Childrens Hosp San Diego, San Diego, CA 92121 USA; [McLay, Robert] Naval Med Ctr San Diego, San Diego, CA USA; [Huang, CharlesW.] Westview High Sch, San Diego, CA USA; [Chang, Douglas G.] Univ Calif San Diego, Dept Orthopaed, San Diego, CA 92121 USA; [Canive, Jose M.] New Mexico VA Healthcare Syst, Albuquerque, NM USA; [Canive, Jose M.] Univ New Mexico, Dept Psychiat, Albuquerque, NM 87131 USA; [Canive, Jose M.] Univ New Mexico, Dept Neurosci, Albuquerque, NM 87131 USA; [Edgar, J. Christopher; Chen, Yu-Han] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Edgar, J. Christopher; Chen, Yu-Han] Univ Penn, Philadelphia, PA 19104 USA		Huang, MX (corresponding author), Univ Calif San Diego, Radiol Imaging Lab, 3510 Dunhill St, San Diego, CA 92121 USA.	mxhuang@ucsd.edu	Risbrough, Victoria/X-3344-2019; Baker, Dewleen/O-4957-2019; Levy, Michael/AAL-4647-2020	Baker, Dewleen/0000-0002-1736-9838; Chang, Douglas/0000-0001-7006-6206	Department of Veterans AffairsUS Department of Veterans Affairs [I01-CX000499, NURC-022-10F, NEUC-044-06S]; National Football League Charity Grant [20105076]; McDonnell Foundation via Brain Trauma Foundation [220020185]; MRS-II from Headquarters Marine Corps [N62645-11-C-4037]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007198] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX000499, I01CX000146] Funding Source: NIH RePORTER	This work was supported in part by Merit Review Grants from the Department of Veterans Affairs to M.X. Huang (I01-CX000499, NURC-022-10F, NEUC-044-06S), D.L. Harrington (I01-CX000146), National Football League Charity Grant (20105076, M. X. Huang and R. R. Lee), McDonnell Foundation via Brain Trauma Foundation (220020185, PI: J. Ghajar, site PIs: R.R. Lee and M.X. Huang), and MRS-II (Navy BUMED contract #N62645-11-C-4037) from Headquarters Marine Corps (D.G. Baker, M.A. Geyer, M.X. Huang, V.B. Risbrough). We acknowledge the MRS-II administrative core, Anjana Patel, Andrew De La Rosa, and members of the MRS-II Team, including logistic coordinators, clinician-interviewers, and data collection staff. We thank the staff at the Veterans Medical Research Foundation (VRMF). We also thank the Marine and veteran volunteers for military service and participation in this study.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; BALL GJ, 1977, ELECTROEN CLIN NEURO, V43, P346, DOI 10.1016/0013-4694(77)90258-9; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bigler ED, 2004, STUD NEUROPSYCHOL DE, P71; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Carlson N.R., 2013, PHYSL BEHAV; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cohen D, 2002, P 13 INT C BIOM, P919; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Downing PE, 2001, SCIENCE, V293, P2470, DOI 10.1126/science.1063414; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; FISCH BJ, 1999, FISCH SPEHLMANNS EEG; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; Huang M, 1998, EVOKED POTENTIAL, V108, P32, DOI 10.1016/S0168-5597(97)00091-9; Huang MX, 2007, NEUROIMAGE, V37, P731, DOI 10.1016/j.neuroimage.2007.06.002; Huang MX, 2014, NEUROIMAGE, V84, P585, DOI 10.1016/j.neuroimage.2013.09.022; Huang MX, 2012, NEUROIMAGE, V61, P1067, DOI 10.1016/j.neuroimage.2012.04.029; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huang MX, 2006, NEUROIMAGE, V31, P1025, DOI 10.1016/j.neuroimage.2006.01.029; Huang MX, 2005, NEUROIMAGE, V28, P99, DOI 10.1016/j.neuroimage.2005.05.036; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Kandel E.R., 2000, PRINCIPLES NEURAL SC; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Leahy RM, 1998, ELECTROEN CLIN NEURO, V107, P159, DOI 10.1016/S0013-4694(98)00057-1; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Luo Q, 2013, J NEUROTRAUM, V30, P1702, DOI 10.1089/neu.2012.2679; MacGregor AJ, 2011, J HEAD TRAUMA REHAB, V26, P312, DOI 10.1097/HTR.0b013e3181e94404; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Mosher JC, 1999, IEEE T BIO-MED ENG, V46, P245, DOI 10.1109/10.748978; Niedermeyer E., 2005, ELECTROENCEPHALOGRAP; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Rapoport MJ, 2012, CNS DRUGS, V26, P111, DOI 10.2165/11599560-000000000-00000; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Robinson S., 1999, RECENT ADV BIOMAGNET, P302, DOI DOI 10.1016/J.NEUROIMAGE.2018.05.016; Rockstroh BS, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-44; Rowan A. J., 2003, PRIMER EEG MINI ATLA; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Schaul N, 1998, ELECTROEN CLIN NEURO, V106, P101, DOI 10.1016/S0013-4694(97)00111-9; SCHAUL N, 1978, BRAIN RES, V143, P475, DOI 10.1016/0006-8993(78)90358-X; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Sekihara K, 2001, IEEE T BIO-MED ENG, V48, P760, DOI 10.1109/10.930901; Selden NR, 1998, BRAIN, V121, P2249, DOI 10.1093/brain/121.12.2249; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; Song T, 2008, MED BIOL ENG COMPUT, V46, P923, DOI 10.1007/s11517-007-0290-y; Tarapore PE, 2013, J NEUROSURG, V118, P1306, DOI 10.3171/2013.3.JNS12398; Taulu S, 2004, BRAIN TOPOGR, V16, P269, DOI 10.1023/b:brat.0000032864.93890.f9; Taulu S, 2004, Neurol Clin Neurophysiol, V2004, P35; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; VanVeen BD, 1997, IEEE T BIO-MED ENG, V44, P867, DOI 10.1109/10.623056; Weiner KS, 2010, NEUROIMAGE, V52, P1559, DOI 10.1016/j.neuroimage.2010.04.262; Wienbruch C, 2007, J NEUROSCI METH, V163, P119, DOI 10.1016/j.jneumeth.2007.02.018; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	75	55	55	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2014	5						109	119		10.1016/j.nicl.2014.06.004			11	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CB5LF	WOS:000349667800014	25009772	Green Published, gold			2022-02-06	
S	Omalu, B		Niranjan, A; Lunsford, LD		Omalu, Bennet			Chronic Traumatic Encephalopathy	CONCUSSION	Progress in Neurological Surgery		English	Article; Book Chapter							ALZHEIMERS ASSOCIATION GUIDELINES; POSTTRAUMATIC EPILEPSY; BRAIN-INJURY; NEUROPATHOLOGIC ASSESSMENT; MOLECULAR-MECHANISMS; NATIONAL INSTITUTE; DISEASE; PATHOLOGY; SPECTRUM; PLAYERS	Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative syndrome, which is caused by single, episodic, or repetitive blunt force impacts to the head and transfer of acceleration-deceleration forces to the brain. CTE presents clinically as a composite syndrome of mood disorders and behavioral and cognitive impairment, with or without sensorimotor impairment. Symptoms of CTE may begin with persistent symptoms of acute traumatic brain injury (TBI) following a documented episode of brain trauma or after a latent period that may range from days to weeks to months and years, up to 40 years following a documented episode of brain trauma or cessation of repetitive TBI. Posttraumatic encephalopathy is distinct from CTE, can be comorbid with CTE, and is a clinicopathologic syndrome induced by focal and/or diffuse, gross and/or microscopic destruction of brain tissue following brain trauma. The brain of a CTE sufferer may appear grossly unremarkable, but shows microscopic evidence of primary and secondary proteinopathies. The primary proteinopathy of CTE is tauopathy, while secondary proteinopathies may include, but are not limited to, amyloidopathy and TDP proteinopathy. Reported prevalence rates of CTE in cohorts exposed to TBI ranges from 3 to 80% across age groups. (C) 2014 S. Karger AG, Basel	[Omalu, Bennet] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA; [Omalu, Bennet] San Joaquin Gen Hosp, French Camp, CA USA; [Omalu, Bennet] San Joaquin Cty Coroners Div, French Camp, CA 95231 USA		Omalu, B (corresponding author), San Joaquin Cty Coroners Div, 7000 Michael Canlis Blvd, French Camp, CA 95231 USA.	bomalu@sjgov.org					Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; [Anonymous], 2014, HDB NEUROLO IN PRESS; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; BIGLER ED, 1987, J LEARN DISABIL, V20, P458, DOI 10.1177/002221948702000804; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Casson Ira R, 2006, Neurosurgery, V59, pE1152; Casson Ira R, 2006, Neurosurgery, V58, pE1003, DOI 10.1227/01.NEY.0000217313.15590.C5; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; Chen-Plotkin AS, 2010, NAT REV NEUROL, V6, P211, DOI 10.1038/nrneurol.2010.18; Clavaguera F, 2013, BRAIN PATHOL, V23, P342, DOI 10.1111/bpa.12044; Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, VIn: Vol 12, P386; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Critchley M., 1949, HOMMAGE CLOVIS VINCE, P131; Diaz-Arrastia R, 2009, EPILEPSIA, V50, P14, DOI 10.1111/j.1528-1167.2008.02006.x; Dichter MA, 2009, EPILEPSIA, V50, P41, DOI 10.1111/j.1528-1167.2008.02009.x; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1046/j.1365-2990.1996.2598025.x; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Jucker M, 2013, NATURE, V501, P45, DOI 10.1038/nature12481; KAPLAN HA, 1954, JAMA-J AM MED ASSOC, V156, P1138, DOI 10.1001/jama.1954.02950120012004; Le Meghan N, 2012, Am J Neurodegener Dis, V1, P316; Mackenzie IRA, 2009, ACTA NEUROPATHOL, V117, P15, DOI 10.1007/s00401-008-0460-5; MCCOWN IA, 1959, AM J SURG, V98, P509, DOI 10.1016/0002-9610(59)90545-8; MCCOWN IA, 1959, JAMA-J AM MED ASSOC, V169, P1409, DOI 10.1001/jama.1959.03000300005002; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; Patt S, 1999, EXP TOXICOL PATHOL, V51, P119, DOI 10.1016/S0940-2993(99)80084-0; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; Randolph C, 2013, J INT NEUROPSYCH SOC, V19, P873, DOI 10.1017/S1355617713000805; Roberts AH, 1969, STUD PREV TRAUM ENC; Royal College of Physicians of London. Committee on Boxing, 1969, COMM BOX, P11; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Statler KD, 2006, DEV NEUROSCI-BASEL, V28, P354, DOI 10.1159/000094162; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Thom M, 2011, BRAIN, V134, P2969, DOI 10.1093/brain/awr209; Valsamis M P, 1994, Neurosurg Clin N Am, V5, P175; Walker KR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00029	54	55	55	0	17	KARGER	BASEL	POSTFACH, CH-4009 BASEL, SWITZERLAND	0079-6492		978-3-318-02649-8; 978-3-318-02648-1	PROG NEUROL SURG			2014	28						38	49		10.1159/000358761	10.1159/isbn.978-3-318-02649-8		12	Clinical Neurology; Surgery	Book Citation Index – Science (BKCI-S)	Neurosciences & Neurology; Surgery	BC8EJ	WOS:000355566000005	24923391				2022-02-06	
J	Ryu, J; Horkayne-Szakaly, I; Xu, L; Pletnikova, O; Leri, F; Eberhart, C; Troncoso, JC; Koliatsos, VE				Ryu, Jiwon; Horkayne-Szakaly, Iren; Xu, Leyan; Pletnikova, Olga; Leri, Francesco; Eberhart, Charles; Troncoso, Juan C.; Koliatsos, Vassilis E.			The problem of axonal injury in the brains of veterans with histories of blast exposure	ACTA NEUROPATHOLOGICA COMMUNICATIONS			English	Article						Traumatic brain injury; Diffuse axonal injury; APP; Axon bulbs; Opiate; Microglia	AMYLOID PRECURSOR PROTEIN; POSTTRAUMATIC-STRESS-DISORDER; WHITE-MATTER; POSTCONCUSSIVE SYMPTOMS; EXPERIMENTAL-MODELS; HEAD-INJURY; BETA-APP; MILD; ACCUMULATION; DEGENERATION	Introduction: Blast injury to brain, a hundred-year old problem with poorly characterized neuropathology, has resurfaced as health concern in recent deployments in Iraq and Afghanistan. To characterize the neuropathology of blast injury, we examined the brains of veterans for the presence of amyloid precursor protein (APP)-positive axonal swellings typical of diffuse axonal injury (DAI) and compared them to healthy controls as well as controls with opiate overdose, anoxic-ischemic encephalopathy, and non-blast TBI (falls and motor vehicle crashes). Results: In cases with blast history, we found APP (+) axonal abnormalities in several brain sites, especially the medial dorsal frontal white matter. In white matter, these abnormalities were featured primarily by clusters of axonal spheroids or varicosities in a honeycomb pattern with perivascular distribution. Axonal abnormalities colocalized with IBA1 (+) reactive microglia and had an appearance that was distinct from classical DAI encountered in TBI due to motor vehicle crashes. Opiate overdose cases also showed APP (+) axonal abnormalities, but the intensity of these lesions was lower compared to cases with blast histories and there was no clear association of such lesions with microglial activation. Conclusions: Our findings demonstrate that many cases with history of blast exposure are featured by APP (+) axonopathy that may be related to blast exposure, but an important role for opiate overdose, antemortem anoxia, and concurrent blunt TBI events in war theater or elsewhere cannot be discounted.	[Ryu, Jiwon; Xu, Leyan; Pletnikova, Olga; Eberhart, Charles; Troncoso, Juan C.; Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA; [Horkayne-Szakaly, Iren] Def Hlth Agcy, Joint Pathol Ctr, Dept Neuropathol & Ophthalm Pathol, Silver Spring, MD 20910 USA; [Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; [Leri, Francesco] Univ Guelph, Dept Psychol, Guelph, ON N1G 2W1, Canada		Koliatsos, VE (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA.	koliat@jhmi.edu		Ryu, Jiwon/0000-0003-0251-7858	Johns Hopkins Alzheimer's Disease Research Center [RFA AG-09-001]; Kate Sidran Family Foundation; Sam and Sheila Giller family	This work was supported from the Johns Hopkins Alzheimer's Disease Research Center grant RFA AG-09-001 and generous gifts from the Kate Sidran Family Foundation and Sam and Sheila Giller family. The antibodies against phosphorylated tau; PHF1, CP13 and MC1, were generous gift from Dr. Peter Davies (Albert Einstein College of Medicine, Bronx, NY).	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Buttner A, 2011, NEUROPATH APPL NEURO, V37, P118, DOI 10.1111/j.1365-2990.2010.01131.x; Buttner A, 2006, ADDICTION, V101, P1339, DOI 10.1111/j.1360-0443.2006.01505.x; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; Department of Defense, 2012, DOD WORLDW NUMB TRAU; Dolinak D, 2000, ACTA NEUROPATHOL, V100, P553, DOI 10.1007/s004010000218; Engel M., 2007, PARENTS BLAME VA FAT; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; GLASS JD, 1993, J NEUROCYTOL, V22, P311, DOI 10.1007/BF01195555; Goldstein LE, SCI TRANSL MED; Griffin John W., 1995, P375; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; HEDREEN JC, 1994, J NEUROPATH EXP NEUR, V53, P663, DOI 10.1097/00005072-199411000-00013; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; Mac DC, 2013, PLOS ONE, V8, DOI 10.1371/journalpone.0055823; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Miller KJ, 2013, J HEAD TRAUMA REHAB, V28, P31, DOI 10.1097/HTR.0b013e318255ceae; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Mott FW, 1916, LANCET, V1, P331; Niess C, 2002, ACTA NEUROPATHOL, V104, P79, DOI 10.1007/s00401-002-0525-9; Oehmichen M, 1998, FORENSIC SCI INT, V95, P67, DOI 10.1016/S0379-0738(98)00075-9; Omalu B, 2011, NEUROSURG FOCUS, V31, pF3, DOI [10.3171/2011.91CKUS11178, DOI 10.3171/2011.91CKUS11178]; Pakaski M, 2005, IMIPRAMINE CITALOPRA; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Shively SB, 2012, J HEAD TRAUMA REHAB, V27, P234, DOI 10.1097/HTR.0b013e318250e9dd; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Wang HC, 2010, J CLIN NEUROSCI, V17, P157, DOI 10.1016/j.jocn.2009.07.099; WAXMAN SG, 1992, BRAIN RES, V574, P105, DOI 10.1016/0006-8993(92)90806-K; Zoroya G, 2008, US TODAY	56	55	55	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2051-5960			ACTA NEUROPATHOL COM	Acta Neuropathol. Commun.		2014	2								153	10.1186/s40478-014-0153-3			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V9K3A	WOS:000422389300119	25422066	Green Published, gold			2022-02-06	
J	Susarla, BTS; Villapol, S; Yi, JH; Geller, HM; Symes, AJ				Susarla, Bala T. S.; Villapol, Sonia; Yi, Jae-Hyuk; Geller, Herbert M.; Symes, Aviva J.			Temporal patterns of cortical proliferation of glial cell populations after traumatic brain injury in mice	ASN NEURO			English	Article						astrocytes; BrdU; microglia; neurogenesis; NG2; proliferation; traumatic brain injury (TBI)	CENTRAL-NERVOUS-SYSTEM; ADULT-RAT; ENHANCED NEUROGENESIS; SUBVENTRICULAR ZONE; EXPRESSING CELLS; IMPACT INJURY; SPINAL-CORD; SCAR; ASTROCYTES; MICROGLIA	TBI (traumatic brain injury) triggers an inflammatory cascade, gliosis and cell proliferation following cell death in the pericontusional area and surrounding the site of injury. In order to better understand the proliferative response following CCI (controlled cortical impact) injury, we systematically analyzed the phenotype of dividing cells at several time points post-lesion. C57BL/6 mice were subjected to mild to moderate CCI over the left sensory motor cortex. At different time points following injury, mice were injected with BrdU (bromodeoxyuridine) four times at 3-h intervals and then killed. The greatest number of proliferating cells in the pericontusional region was detected at 3 dpi (days post-injury). At 1 dpi, NG2(+) cells were the most proliferative population, and at 3 and 7 dpi the Iba-1(+) microglial cells were proliferating more. A smaller, but significant number of GFAP(+) (glial fibrillary acidic protein) astrocytes proliferated at all three time points. Interestingly, at 3 dpi we found a small number of proliferating neuroblasts [DCX+ (doublecortin)] in the injured cortex. To determine the cell fate of proliferative cells, mice were injected four times with BrdU at 3 dpi and killed at 28 dpi. Approximately 70% of proliferative cells observed at 28 dpi were GFAP+ astrocytes. In conclusion, our data suggest that the specific glial cell types respond differentially to injury, suggesting that each cell type responds to a specific pattern of growth factor stimulation at each time point after injury.	[Susarla, Bala T. S.; Villapol, Sonia; Yi, Jae-Hyuk; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Susarla, Bala T. S.; Villapol, Sonia; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; [Yi, Jae-Hyuk; Geller, Herbert M.] NHLBI, Dev Neurobiol Sect, Div Intramural Res, NIH, Bethesda, MD 20892 USA		Symes, AJ (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA.	aviva.symes@usuhs.edu	; Symes, Aviva/S-7471-2016	Villapol, Sonia/0000-0002-6174-4113; Geller, Herbert/0000-0002-7048-6144; Symes, Aviva/0000-0003-2557-9939	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [300604-11.0-60855]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [ZIAHL006021] Funding Source: NIH RePORTER	This work was funded by a grant from the Center for Neuroscience and Regenerative Medicine [grant number 300604-11.0-60855].	ADRIAN EK, 1962, J NEUROPATH EXP NEUR, V21, P597, DOI 10.1097/00005072-196210000-00007; Aguirre A, 2007, NAT NEUROSCI, V10, P990, DOI 10.1038/nn1938; Alonso G, 2005, GLIA, V49, P318, DOI 10.1002/glia.20121; Beach JR, 1999, OCCUP MED-OXFORD, V49, P377, DOI 10.1093/occmed/49.6.377; Benarroch EE, 2013, NEUROLOGY, V81, P1079, DOI 10.1212/WNL.0b013e3182a4a577; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Butt AM, 2005, J ANAT, V207, P695, DOI 10.1111/j.1469-7580.2005.00458.x; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; Cao Y, 1999, TALANTA, V49, P377, DOI 10.1016/S0039-9140(98)00386-5; CAVANAGH JB, 1970, J ANAT, V106, P471; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dawson MRL, 2003, MOL CELL NEUROSCI, V24, P476, DOI 10.1016/S1044-7431(03)00210-0; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Gensert JM, 2001, J NEUROBIOL, V48, P75, DOI 10.1002/neu.1043.abs; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; Gotz M, 2005, NAT REV MOL CELL BIO, V6, P777, DOI 10.1038/nrm1739; Haselkorn ML, 2010, J NEUROTRAUM, V27, P901, DOI 10.1089/neu.2009.1075; Hayes NL, 2002, DEV BRAIN RES, V134, P77, DOI 10.1016/S0165-3806(01)00324-8; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Itoh T, 2011, J NEURAL TRANSM, V118, P193, DOI 10.1007/s00702-010-0495-3; Kawano H, 2012, CELL TISSUE RES, V349, P169, DOI 10.1007/s00441-012-1336-5; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Laabs T, 2005, CURR OPIN NEUROBIOL, V15, P116, DOI 10.1016/j.conb.2005.01.014; Lagraoui Mouna, 2012, Front Neurol, V3, P155, DOI 10.3389/fneur.2012.00155; Liu L, 2000, EXP BRAIN RES, V131, P64, DOI 10.1007/s002219900273; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Marin-Teva JL, 2011, NEURON GLIA BIOL, V7, P25, DOI 10.1017/S1740925X12000014; Nakagomi T, 2012, STEM CELLS DEV, V21, P2350, DOI 10.1089/scd.2011.0657; Nishiyama A, 1999, J NEUROPATH EXP NEUR, V58, P1113, DOI 10.1097/00005072-199911000-00001; Nishiyama A, 2002, J NEUROCYTOL, V31, P437, DOI 10.1023/A:1025783412651; Nishiyama A, 2009, NAT REV NEUROSCI, V10, P9, DOI 10.1038/nrn2495; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Qiu Lin, 2007, Neurosci Bull, V23, P46, DOI 10.1007/s12264-007-0007-0; Qu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067094; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rhodes KE, 2006, NEUROSCIENCE, V140, P87, DOI 10.1016/j.neuroscience.2006.01.055; Rhodes KE, 2003, NEUROSCIENCE, V120, P41, DOI 10.1016/S0306-4522(03)00285-9; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Robel S, 2011, J NEUROSCI, V31, P12471, DOI 10.1523/JNEUROSCI.2696-11.2011; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Tan AM, 2005, J ANAT, V207, P717, DOI 10.1111/j.1469-7580.2005.00452.x; Tatsumi K, 2005, NEUROCHEM INT, V46, P381, DOI 10.1016/j.neuint.2004.12.007; Taupin P, 2007, BRAIN RES REV, V53, P198, DOI 10.1016/j.brainresrev.2006.08.002; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Villapol S, 2012, NEUROPSYCHOPHARMACOL, V37, P2817, DOI 10.1038/npp.2012.152; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Yi JH, 2012, J COMP NEUROL, V520, P3295, DOI 10.1002/cne.23156; Zhang RL, 2007, J NEUROSCI, V27, P3157, DOI 10.1523/JNEUROSCI.4969-06.2007; Zhao JW, 2009, EUR J NEUROSCI, V29, P1853, DOI 10.1111/j.1460-9568.2009.06736.x; Zhu XQ, 2008, NEURON GLIA BIOL, V4, P19, DOI 10.1017/S1740925X09000015	59	55	55	0	7	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1759-0914			ASN NEURO	ASN Neuro		2014	6	3							e00143	10.1042/AN20130034			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AJ2BT	WOS:000337460700003	24670035	Green Published, Green Submitted, gold			2022-02-06	
J	Takano, T; He, W; Han, XN; Wang, FS; Xu, QW; Wang, XH; Bush, NAO; Cruz, N; Dienel, GA; Nedergaard, M				Takano, Takahiro; He, Wei; Han, Xiaoning; Wang, Fushun; Xu, Qiwu; Wang, Xiaohai; Bush, Nancy Ann Oberheim; Cruz, Nancy; Dienel, Gerald A.; Nedergaard, Maiken			Rapid Manifestation of Reactive Astrogliosis in Acute Hippocampal Brain Slices	GLIA			English	Article						astrohcytes; interstitial space; NADH; two-photon microscopy; mitochondria; electron microscopy; purinergic receptors	GREEN FLUORESCENT PROTEIN; DIFFERENTIAL EXPRESSION; OXIDATIVE-METABOLISM; ENERGY-METABOLISM; GUINEA-PIG; ASTROCYTES; CALCIUM; GLYCOGEN; CONNEXIN-43; INHIBITION	A flurry of studies over the past decade has shown that astrocytes play a more active role in neural function than previously recognized. Hippocampal slices prepared from young rodent pups have served as a popular model for studying the pathways by which astrocytes participate in synaptic transmission. It is, however, not known how well astrocytes tolerate traumatic injury and hypoxia, which are unavoidable when preparing acute slices. We here showed that astrocytes exhibit striking changes in expression of several receptors and structural proteins, including re-expression of the developmental marker nestin within 90 min following preparation of live vibratome slices. Moreover, immunoelectron microscopy showed a 2.7-fold loss of astrocytic processes in acute hippocampal slices prepared from glial fibrillary acidic protein-green fluorescent protein reporter mice. A sharp decrease in the number of mitochondria was also noted in acute slices, concurrently with an increase in mitochondrial size. Glycogen content decreased 3-fold upon slice preparation and did not recover despite stable recordings of field excitatory postsynaptic current. Analysis of Ca2+ signaling showed that astrocytic responses to purine receptor and mGluR5 agonists differed in slice versus in vivo. These observations suggest that the functional properties and the fine structure of astrocytes in slices may be reflective of early stages of reactive gliosis and should be confirmed in vivo when possible. GLIA 2013;62:78-95	[Takano, Takahiro; He, Wei; Han, Xiaoning; Wang, Fushun; Xu, Qiwu; Wang, Xiaohai; Bush, Nancy Ann Oberheim; Nedergaard, Maiken] Univ Rochester, Med Ctr, Div Glial Dis & Therapeut, Ctr Translat Neuromed, Rochester, NY 14642 USA; [Cruz, Nancy; Dienel, Gerald A.] Univ Arkansas Med Sci, Dept Neurol, Little Rock, AR 72205 USA		Nedergaard, M (corresponding author), Univ Rochester, Med Ctr, Div Glial Dis & Therapeut, Ctr Translat Neuromed, Rochester, NY 14642 USA.	Nedergaard@urmc.rochester.edu		Wang, Xiaohai/0000-0001-5814-4072; Takano, Takahiro/0000-0002-6235-6673	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS075177, NS078304, DK081936]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01DE022743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK081936] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078304, R01NS078167, R01NS075177] Funding Source: NIH RePORTER; Novo Nordisk FondenNovo Nordisk Foundation [NNF13OC0004258] Funding Source: researchfish	Grant sponsor: NIH, NS075177, NS078304 (to MN); DK081936 (to GAD).	Abbracchio MP, 2009, TRENDS NEUROSCI, V32, P19, DOI 10.1016/j.tins.2008.10.001; Agulhon C, 2008, NEURON, V59, P932, DOI 10.1016/j.neuron.2008.09.004; AITKEN PG, 1995, J NEUROSCI METH, V59, P139, DOI 10.1016/0165-0270(94)00204-T; Allen NJ, 2009, NATURE, V457, P675, DOI 10.1038/457675a; Ball KK, 2007, J NEUROSCI RES, V85, P3267, DOI 10.1002/jnr.21376; Bekar L, 2008, NAT MED, V14, P75, DOI 10.1038/nm1693; BOOTH RFG, 1980, J NEUROCHEM, V34, P17, DOI 10.1111/j.1471-4159.1980.tb04616.x; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; CLARKE SR, 1994, NEUROREPORT, V5, P1885, DOI 10.1097/00001756-199410000-00011; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Cruz NF, 2002, J CEREBR BLOOD F MET, V22, P1476, DOI 10.1097/01.WCB.0000034362.37277.C0; DERMIETZEL R, 1989, P NATL ACAD SCI USA, V86, P10148, DOI 10.1073/pnas.86.24.10148; Dienel GA, 2002, J CEREBR BLOOD F MET, V22, P1490, DOI 10.1097/01.WCB.0000034363.37277.89; Dienel GA, 2012, ASN NEURO, V4, P267, DOI 10.1042/AN20120021; DODT HU, 1990, BRAIN RES, V537, P333, DOI 10.1016/0006-8993(90)90380-T; Duchen MR, 2010, ESSAYS BIOCHEM, V47, P115, DOI [10.1042/BSE0470115, 10.1042/bse0470115]; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Fiala JC, 2003, J COMP NEUROL, V465, P90, DOI 10.1002/cne.10825; Franke H, 2012, PURINERG SIGNAL, V8, P629, DOI 10.1007/s11302-012-9300-0; Galic MA, 2012, FRONT NEUROENDOCRIN, V33, P116, DOI 10.1016/j.yfrne.2011.12.002; Gibbs ME, 2006, GLIA, V54, P214, DOI 10.1002/glia.20377; Guthrie PB, 1999, J NEUROSCI, V19, P520, DOI 10.1523/jneurosci.19-02-00520.1999; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Hertz L, 2007, J CEREBR BLOOD F MET, V27, P219, DOI 10.1038/sj.jcbfm.9600343; Hom JR, 2007, J CELL PHYSIOL, V212, P498, DOI 10.1002/jcp.21051; Huang CL, 2012, J NEUROSCI, V32, P3333, DOI 10.1523/JNEUROSCI.1216-11.2012; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Kaneko Y, 2012, CELL MED, V4, P55, DOI 10.3727/215517912X639306; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Kasischke KA, 2004, SCIENCE, V305, P99, DOI 10.1126/science.1096485; Kasischke KA, 2011, J CEREBR BLOOD F MET, V31, P68, DOI 10.1038/jcbfm.2010.158; Kerkut GA, 1981, ELECTROPHYSIOLOGY IS, P107; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kimelberg HK, 2007, NEURON GLIA BIOL, V3, P181, DOI 10.1017/S1740925X08000094; KNULL HR, 1982, NEUROCHEM RES, V7, P1307, DOI 10.1007/BF00965901; Koizumi S, 2013, GLIA, V61, P47, DOI 10.1002/glia.22358; Langmoen I, 1981, ELECTROPHYSIOLOGY IS, P51; Li Y, 1999, BRAIN RES, V838, P1, DOI 10.1016/S0006-8993(99)01502-4; Liem RKH, 2009, J CLIN INVEST, V119, P1814, DOI 10.1172/JCI38003; Lin JHC, 2008, J NEUROSCI, V28, P681, DOI 10.1523/JNEUROSCI.3827-07.2008; LIPTON P, 1989, J NEUROSCI METH, V28, P147, DOI 10.1016/0165-0270(89)90019-8; LIPTON P, 1995, J NEUROSCI METH, V59, P151, DOI 10.1016/0165-0270(94)00205-U; LLANO I, 1988, P NATL ACAD SCI USA, V85, P3221, DOI 10.1073/pnas.85.9.3221; Lovatt D, 2007, J NEUROSCI, V27, P12255, DOI 10.1523/JNEUROSCI.3404-07.2007; Mathiisen TM, 2010, GLIA, V58, P1094, DOI 10.1002/glia.20990; Nakase T, 2006, GLIA, V54, P369, DOI 10.1002/glia.20399; Nedergaard M, 2012, GLIA, V60, P1013, DOI 10.1002/glia.22288; NEHER E, 1976, NATURE, V260, P799, DOI 10.1038/260799a0; NICHOLSON C, 1992, CAN J PHYSIOL PHARM, V70, pS314, DOI 10.1139/y92-278; Nicholson C, 2011, COMPUT VIS SCI, V14, P309, DOI 10.1007/s00791-012-0185-9; Nielsen S, 1997, J NEUROSCI, V17, P171; Oberheim NA, 2008, J NEUROSCI, V28, P3264, DOI 10.1523/JNEUROSCI.4980-07.2008; Oberheim NA, 2009, J NEUROSCI, V29, P3276, DOI 10.1523/JNEUROSCI.4707-08.2009; Peters A., 1991, FINE STRUCTURE NERVO, V3rd ed.; PFEIFFER B, 1993, HISTOCHEMISTRY, V100, P265, DOI 10.1007/BF00270045; Ransohoff RM, 2012, NAT REV IMMUNOL, V12, P623, DOI 10.1038/nri3265; Regan MR, 2007, J NEUROSCI, V27, P6607, DOI 10.1523/JNEUROSCI.0790-07.2007; SARVEY JM, 1989, J NEUROSCI METH, V28, P109, DOI 10.1016/0165-0270(89)90016-2; SCHWARTZKROIN PA, 1975, BRAIN RES, V89, P107, DOI 10.1016/0006-8993(75)90138-9; SIGWORTH FJ, 1980, NATURE, V287, P447, DOI 10.1038/287447a0; Skrede K, 1971, BRAIN RES B, V5, P391; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sun W, 2013, SCIENCE, V339, P197, DOI 10.1126/science.1226740; Suzuki A, 2011, CELL, V144, P810, DOI 10.1016/j.cell.2011.02.018; Sykova E, 2008, PHYSIOL REV, V88, P1277, DOI 10.1152/physrev.00027.2007; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Torres A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002160; Tulapurkar ME, 2006, J NEUROCHEM, V96, P624, DOI 10.1111/j.1471-4159.2005.03594.x; VanSlyke JK, 2005, MOL BIOL CELL, V16, P5247, DOI 10.1091/mbc.E05-05-0415; Verkhratsky A, 2012, ASN NEURO, V4, DOI 10.1042/AN20120010; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; WHITTINGHAM TS, 1984, J NEUROCHEM, V43, P689, DOI 10.1111/j.1471-4159.1984.tb12788.x; YAMAMOTO C, 1966, J NEUROCHEM, V13, P1333, DOI 10.1111/j.1471-4159.1966.tb04296.x; Zhuo L, 1997, DEV BIOL, V187, P36, DOI 10.1006/dbio.1997.8601; Zonta M, 2003, NAT NEUROSCI, V6, P43, DOI 10.1038/nn980	75	55	55	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JAN	2014	62	1					78	95		10.1002/glia.22588			18	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	255JM	WOS:000327235200007	24272704	Green Accepted			2022-02-06	
J	Sala, N; Suys, T; Zerlauth, JB; Bouzat, P; Messerer, M; Bloch, J; Levivier, M; Magistretti, PJ; Meuli, R; Oddo, M				Sala, Nathalie; Suys, Tamarah; Zerlauth, Jean-Baptiste; Bouzat, Pierre; Messerer, Mahmoud; Bloch, Jocelyne; Levivier, Marc; Magistretti, Pierre J.; Meuli, Reto; Oddo, Mauro			Cerebral extracellular lactate increase is predominantly nonischemic in patients with severe traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cerebral blood flow; cerebral metabolism; cerebral microdialysis; lactate; traumatic brain injury	SEVERE HEAD TRAUMA; POSITRON-EMISSION-TOMOGRAPHY; NUCLEAR-MAGNETIC-RESONANCE; ENERGY-METABOLISM; PERFUSION-CT; SUBARACHNOID HEMORRHAGE; COMBINED MICRODIALYSIS; SYNAPTIC FUNCTION; BLOOD LACTATE; GLUCOSE	Growing evidence suggests that endogenous lactate is an important substrate for neurons. This study aimed to examine cerebral lactate metabolism and its relationship with brain perfusion in patients with severe traumatic brain injury (TBI). A prospective cohort of 24 patients with severe TBI monitored with cerebral microdialysis (CMD) and brain tissue oxygen tension (PbtO(2)) was studied. Brain lactate metabolism was assessed by quantification of elevated CMD lactate samples (>4 mmol/L); these were matched to CMD pyruvate and PbtO(2) values and dichotomized as glycolytic (CMD pyruvate >119 mu mol/L vs. low pyruvate) and hypoxic (PbtO(2) <20 mm Hg vs. nonhypoxic). Using perfusion computed tomography (CT), brain perfusion was categorized as oligemic, normal, or hyperemic, and was compared with CMD and PbtO(2) data. Samples with elevated CMD lactate were frequently observed (41 +/- 8%), and we found that brain lactate elevations were predominantly associated with glycolysis and normal PbtO(2) (73 8%) rather than brain hypoxia (14 +/- 6%). Furthermore, glycolytic lactate was always associated with normal or hyperemic brain perfusion, whereas all episodes with hypoxic lactate were associated with diffuse oligemia. Our findings suggest predominant nonischemic cerebral extracellular lactate release after TBI and support the concept that lactate may be used as an energy substrate by the injured human brain.	[Sala, Nathalie; Suys, Tamarah; Bouzat, Pierre; Oddo, Mauro] CHUV Lausanne Univ Hosp, Neurosci Crit Care Res Unit, Dept Intens Care Med, CH-1011 Lausanne, Switzerland; [Zerlauth, Jean-Baptiste; Meuli, Reto] CHUV Lausanne Univ Hosp, Dept Radiol, CH-1011 Lausanne, Switzerland; [Bouzat, Pierre] Univ Grenoble 1, Grenoble, France; [Messerer, Mahmoud; Bloch, Jocelyne; Levivier, Marc] CHUV Lausanne Univ Hosp, Serv Neurosurg, Dept Clin Neurosci, CH-1011 Lausanne, Switzerland; [Magistretti, Pierre J.] Ecole Polytech Fed Lausanne, Brain Mind Inst, Lab Neuroenerget & Cellular Dynam, CH-1015 Lausanne, Switzerland; [Magistretti, Pierre J.] Univ Lausanne, Lausanne, Switzerland		Oddo, M (corresponding author), CHUV Lausanne Univ Hosp, Neurosci Crit Care Res Unit, Dept Intens Care Med, Rue Bugnon 46,BH 08-623, CH-1011 Lausanne, Switzerland.	mauro.oddo@chuv.ch	Bouzat, Pierre/AAC-4105-2019; Messerer, Mahmoud/AAZ-3527-2020; Bloch, Jocelyne/A-9668-2017; Oddo, Mauro/R-3370-2016; Bouzat, Pierre/L-6881-2014	Bouzat, Pierre/0000-0003-4667-6738; Bloch, Jocelyne/0000-0002-6405-1590; Oddo, Mauro/0000-0002-6155-2525; Messerer, Mahmoud/0000-0002-0493-6151; Levivier, Marc/0000-0002-6273-2595; Magistretti, Pierre Julius/0000-0002-6678-320X	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [320030_138191]; European Critical Care Research Network, European Society of Intensive Care Medicine	This work was supported by grants from the Swiss National Science Foundation (Grant No. 320030_138191) and the European Critical Care Research Network, European Society of Intensive Care Medicine.	Belanger M, 2011, CELL METAB, V14, P724, DOI 10.1016/j.cmet.2011.08.016; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Berthet C, 2012, CEREBROVASC DIS, V34, P329, DOI 10.1159/000343657; Berthet C, 2009, J CEREBR BLOOD F MET, V29, P1780, DOI 10.1038/jcbfm.2009.97; Bhatia A, 2007, INTENS CARE MED, V33, P1322, DOI 10.1007/s00134-007-0660-9; Boumezbeur F, 2010, J NEUROSCI, V30, P13983, DOI 10.1523/JNEUROSCI.2040-10.2010; Bouzier-Sore AK, 2003, J CEREBR BLOOD F MET, V23, P1298, DOI 10.1097/01.WCB.0000091761.61714.25; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Lee YJ, 2012, NATURE, V487, P443, DOI 10.1038/nature11314; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Ros J, 2001, J NEUROSCI RES, V66, P790, DOI 10.1002/jnr.10043; Samuelsson C, 2007, J CEREBR BLOOD F MET, V27, P1309, DOI 10.1038/sj.jcbfm.9600433; Schurr A, 1999, J NEUROSCI, V19, P34, DOI 10.1523/JNEUROSCI.19-01-00034.1999; Schurr A, 1997, BRAIN RES, V744, P105, DOI 10.1016/S0006-8993(96)01106-7; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; Smith D, 2003, J CEREBR BLOOD F MET, V23, P658, DOI 10.1097/01.WCB.0000063991.19746.11; Suzuki A, 2011, CELL, V144, P810, DOI 10.1016/j.cell.2011.02.018; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; van Hall G, 2009, J CEREBR BLOOD F MET, V29, P1121, DOI 10.1038/jcbfm.2009.35; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Wintermark M, 2006, J NEURORADIOLOGY, V33, P27, DOI 10.1016/S0150-9861(06)77225-X; Wintermark M, 2004, CRIT CARE MED, V32, P1579, DOI 10.1097/01.CCM.0000130171.08842.72; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; Wintermark M, 2001, AM J NEURORADIOL, V22, P905	37	55	58	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2013	33	11					1815	1822		10.1038/jcbfm.2013.142			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	246SL	WOS:000326559300019	23963367	Green Published, Bronze			2022-02-06	
J	Sun, CR; Sun, H; Wu, S; Lee, CC; Akamatsu, Y; Wang, RKK; Kernie, SG; Liu, JL				Sun, Chongran; Sun, Hui; Wu, Steven; Lee, Chih Cheng; Akamatsu, Yosuke; Wang, Ruikang K.; Kernie, Steven G.; Liu, Jialing			Conditional Ablation of Neuroprogenitor Cells in Adult Mice Impedes Recovery of Poststroke Cognitive Function and Reduces Synaptic Connectivity in the Perforant Pathway	JOURNAL OF NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; HIPPOCAMPAL NEUROGENESIS; GENERATED NEURONS; PROGENITOR CELLS; GAIT IMPAIRMENT; DENTATE GYRUS; STROKE; CIRCUITRY; MEMORIES; ISCHEMIA	The causal relationship between neurogenesis and the recovery of poststroke cognitive function has not been properly explored. The current study aimed to determine whether depleting neuroprogenitor cells (NPCs) affects poststroke functional outcome in nestin-delta-HSV-TK-EGFP transgenic mice, in which the expression of a truncated viral thymidine kinase gene and EGFP was restricted to nestin-expressing NPCs. Ganciclovir (GCV; 200 mg/kg/d) or saline was continuously administered via osmotic pumps in mice for 4 weeks before the induction of experimental stroke. Both baseline and stroke-induced type 1 and type 2 NPCs were conditionally ablated. GCV eliminated NPCs in a duration-dependent fashion, but it did not attenuate the genesis of astroglia or oligodendrocytes in the peri-infarct cortex, nor did it affect infarct size or cerebral blood reperfusion after stroke. Transgenic stroke mice given GCV displayed impaired spatial learning and memory in the Barnes maze test compared with saline control or wild-type stroke mice given GCV, suggesting a contributing role of stroke-induced neurogenesis in the recovery of cognitive function. However, there was no significant difference in poststroke motor function between transgenic mice treated with GCV and those treated with vehicle, despite a significant ablation of NPCs in the subventricular zone of the former. Furthermore, nestin-delta-HSV-TK-EGFP mice treated with GCV had fewer retrogradely labeled neurons in the entorhinal cortex (EC) when injected with the polysynaptic viral marker PRV614 in the dentate gyrus (DG), suggesting that there might be reduced synaptic connectivity between the DG and EC following ablation of NPCs, which may contribute to impaired poststroke memory function.	[Sun, Chongran; Sun, Hui; Wu, Steven; Lee, Chih Cheng; Akamatsu, Yosuke; Liu, Jialing] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94121 USA; [Sun, Chongran; Sun, Hui; Wu, Steven; Lee, Chih Cheng; Akamatsu, Yosuke; Liu, Jialing] San Francisco VA Med Ctr, San Francisco, CA 94121 USA; [Sun, Chongran] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Neurol Surg, Hangzhou 310009, Zhejiang, Peoples R China; [Sun, Hui] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Neurol Surg, Shanghai 201101, Peoples R China; [Akamatsu, Yosuke] Tohoku Univ, Grad Sch Med, Dept Neurol Surg, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Wang, Ruikang K.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; [Wang, Ruikang K.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; [Kernie, Steven G.] Columbia Univ, Dept Pediat, New York, NY 10032 USA; [Kernie, Steven G.] Columbia Univ, Dept Pathol, New York, NY 10032 USA; [Kernie, Steven G.] Columbia Univ, Dept Cell Biol, New York, NY 10032 USA		Liu, JL (corresponding author), Univ Calif San Francisco, Dept Neurol Surg 112C, 4150 Clement St, San Francisco, CA 94121 USA.	jialing.liu@ucsf.edu	Kernie, Steven/AAT-9912-2020; Wang, Ruikang K./L-3889-2019; Liu, Jialing/A-8627-2012	Wang, Ruikang K./0000-0001-5169-8822; Liu, Jialing/0000-0003-4420-4382; Kernie, Steven/0000-0003-1371-0549	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS071050]; AHA EIAAmerican Heart Association [0940065N]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048192, R01NS071050] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grants R01 NS071050 (J.L.) and AHA EIA 0940065N (J.L.). We thank Dr. Lin An for his technical assistance in the analysis of blood perfusion by optical coherence tomography.	Aimone JB, 2011, NEURON, V70, P589, DOI 10.1016/j.neuron.2011.05.010; An L, 2010, OPT EXPRESS, V18, P8220, DOI 10.1364/OE.18.008220; Arruda-Carvalho M, 2011, J NEUROSCI, V31, P15113, DOI 10.1523/JNEUROSCI.3432-11.2011; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; BRAGIN A, 1995, J NEUROSCI, V15, P47; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Deisseroth K, 2004, NEURON, V42, P535, DOI 10.1016/S0896-6273(04)00266-1; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Dupret D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001959; Hou SW, 2008, STROKE, V39, P2837, DOI 10.1161/STROKEAHA.107.510982; Imayoshi I, 2008, NAT NEUROSCI, V11, P1153, DOI 10.1038/nn.2185; Jia YL, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3432654; Jin KL, 2010, P NATL ACAD SCI USA, V107, P7993, DOI 10.1073/pnas.1000154107; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kim ES, 2002, J NEUROTRAUM, V19, P787, DOI 10.1089/08977150260139156; Lee JW, 2000, J COMP NEUROL, V418, P484; Leutgeb JK, 2007, SCIENCE, V315, P961, DOI 10.1126/science.1135801; Lichtenwalner RJ, 2006, J CEREBR BLOOD F MET, V26, P1, DOI 10.1038/sj.jcbfm.9600170; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Matsumori Y, 2006, NEUROBIOL DIS, V22, P187, DOI 10.1016/j.nbd.2005.10.015; Neumann M, 2009, J NEUROSCI METH, V176, P34, DOI 10.1016/j.jneumeth.2008.08.026; Pendlebury Sarah T, 2009, Cerebrovasc Dis, V27 Suppl 3, P1, DOI 10.1159/000209260; Pendlebury ST, 2009, LANCET NEUROL, V8, P1006, DOI 10.1016/S1474-4422(09)70236-4; Raber J, 2004, ANN NEUROL, V55, P381, DOI 10.1002/ana.10853; Rafuse VF, 2005, NEUROSCIENCE, V131, P899, DOI 10.1016/j.neuroscience.2004.11.048; Rinaman L, 2000, J NEUROSCI, V20, P2731; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Santra M, 2006, NEUROSCIENCE, V142, P739, DOI 10.1016/j.neuroscience.2006.06.065; Song J, 2012, DEV NEUROBIOL, V72, P1032, DOI 10.1002/dneu.22014; Sun H, 2011, NEUROBIOL DIS, V44, P73, DOI 10.1016/j.nbd.2011.06.006; Toni N, 2011, EUR J NEUROSCI, V33, P1062, DOI 10.1111/j.1460-9568.2011.07604.x; Wang XM, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0038932, 10.1371/journal.pone.0052707, 10.1371/journal.pone.0045036, 10.1371/journal.pone.0047429, 10.1371/journal.pone.0036663, 10.1371/journal.pone.0052082, 10.1371/journal.pone.0040857, 10.1371/journal.pone.0040711, 10.1371/journal.pone.0045939, 10.1371/journal.pone.0045380, 10.1371/journal.pone.0040084]; Wang Y., 2011, AM J NEUROPROT NEURO, V3, P66, DOI [10.1166/ajnn.2011.1027, DOI 10.1166/AJNN.2011.1027]; Wang YG, 2011, J NEUROTRAUM, V28, P259, DOI 10.1089/neu.2010.1648; Wang YG, 2008, J CEREBR BLOOD F MET, V28, P1936, DOI 10.1038/jcbfm.2008.82; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009	37	55	55	0	13	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	OCT 30	2013	33	44					17314	17325		10.1523/JNEUROSCI.2129-13.2013			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	246BB	WOS:000326509800009	24174664	Bronze, Green Published			2022-02-06	
J	Brooks, BL; McKay, CD; Mrazik, M; Barlow, KM; Meeuwisse, WH; Emery, CA				Brooks, Brian L.; McKay, Carly D.; Mrazik, Martin; Barlow, Karen M.; Meeuwisse, Willem H.; Emery, Carolyn A.			Subjective, but not Objective, Lingering Effects of Multiple Past Concussions in Adolescents	JOURNAL OF NEUROTRAUMA			English	Article						baseline; concussion; cumulative; lingering; mild traumatic brain injury; pediatric	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; WORKING-MEMORY; BODY CHECKING; NOVEMBER 2008; PLAYERS; IMPACT	The existing literature on lingering effects from concussions in children and adolescents is limited and mixed, and there are no clear answers for patients, clinicians, researchers, or policy makers. The purpose of this study was to examine whether there are lingering effects of past concussions in adolescent athletes. Participants in this study included 643 competitive Bantam and Midget hockey players (most elite 20% by division of play) between 13 and 17 years of age (mean age = 15.5, SD = 1.2). Concussion history at baseline assessment was retrospectively documented using a pre-season questionnaire (PSQ), which was completed at home by parents and players in advance of baseline testing. Players with English as a second language, self-reported attention or learning disorders, a concussion within 6 months of baseline, or suspected invalid test profiles were excluded from these analyses. Demographically adjusted standard scores for the five composites/domains and raw symptom ratings from the brief Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) computerized battery were analyzed. Adolescent athletes with one or two or more prior concussions did not have significantly worse neurocognitive functioning on ImPACT than did those with no previous concussions. There were significantly more symptoms reported in those with two or more prior concussions than in those with no or one prior concussion. Adolescents with multiple previous concussions had higher levels of baseline symptoms, but there were not group differences in neurocognitive functioning using this brief computerized battery.	[Brooks, Brian L.; Barlow, Karen M.] Alberta Childrens Prov Gen Hosp, Neurosci Brain Injury & Rehabil Programs, Calgary, AB T3B 6A8, Canada; [Brooks, Brian L.; Barlow, Karen M.] Univ Calgary, Fac Med, Dept Paediat, Calgary, AB, Canada; [Brooks, Brian L.; Barlow, Karen M.] Univ Calgary, Fac Med, Dept Clin Neurosci, Calgary, AB, Canada; [Brooks, Brian L.; Barlow, Karen M.] Alberta Childrens Prov Gen Hosp, Res Inst Child & Mat Hlth, Calgary, AB T3B 6A8, Canada; [McKay, Carly D.; Meeuwisse, Willem H.; Emery, Carolyn A.] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Mrazik, Martin] Univ Alberta, Dept Educ Psychol, Edmonton, AB T6G 2E1, Canada		Brooks, BL (corresponding author), Alberta Childrens Prov Gen Hosp, Neurosci Program, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	brian.brooks@albertahealthservices.ca	Meijer, Anna/K-5118-2016; Emery, Carolyn/AAI-2761-2020; Barlow, Karen/C-1323-2014; Barlow, Karen/I-6492-2019	Barlow, Karen/0000-0003-2612-8507; Barlow, Karen/0000-0003-2612-8507; McKay, Carly/0000-0001-7664-3211	Calgary; ImPACTEuropean Commission; International Olympic Committee; Alberta Innovates Health Solutions (AIHS); Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Alberta Children's Hospital Research Institute for Child & Maternal Health (ACHRI)	The authors thank the following people for their help with data collection (in alphabetical order): Tracy Blake, Andrea Jubinville, Nicole Lemke, Maria Romiti, and Kathryn Schneider. The authors thank Emily Tam for assistance with data management, and Dr. Helen Carlson for her help with data management, entering the demographically adjusted normative scores for this entire sample, and formatting the manuscript. The authors also thank Hockey Calgary, Girls Hockey Calgary, Hockey Edmonton, Edmonton Girls Hockey, the Edge School (Calgary), the team designates, research assistants, coaches, families, and the players who participated in this study. Computerized cognitive testing in this study was funded in Calgary by the McCarthy Tetrault award (administered by the Alberta Children's Hospital Research Institute for Child & Maternal Health) to Dr. Brooks (computers, test credits) and in Edmonton by funding provided to and in-kind support by ImPACT to Dr. Mrazik. The Sport Injury Prevention Research Centre is one of the International Research Centres for Prevention of Injury and Protection of Athlete Health supported by the International Olympic Committee. Drs. Meeuwisse and Emery acknowledge funding from Alberta Innovates Health Solutions (AIHS), Canadian Institutes of Health Research (CIHR), and the Alberta Children's Hospital Research Institute for Child & Maternal Health (ACHRI; Professorship in pediatric rehabilitation for Dr. Emery).	[Anonymous], 1999, JAMA, V282, P974; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; BELLIVEAU JW, 1991, SCIENCE, V254, P716, DOI 10.1126/science.1948051; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Blake T.A., 2012, CLIN J SPORT MED, V22, P307; Brooks B.L., 2013, ARCH CLIN NEUROPSYCH; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Elbin RJ, 2012, BRAIN INJURY, V26, P1217, DOI 10.3109/02699052.2012.672788; Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Emery CA, 2009, CLIN J SPORT MED, V19, P207, DOI 10.1097/JSM.0b013e31819d658e; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2001, J ATHL TRAINING, V36, P228; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/316575; Iverson GL, 2010, BRAIN INJURY, V24, P1246, DOI 10.3109/02699052.2010.490513; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McKay C, 2012, CLIN J SPORT MED, V22, P307; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Pardini JE, 2010, NEUROSURGERY, V67, P1020, DOI 10.1227/NEU.0b013e3181ee33e2; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schneider K., 2010, CLIN J SPORT MED, V20, P232; Schneider K.J., 2012, CLIN J SPORT MED, V22, P307; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Talavage TM, 2013, J NEUROTRAUMA; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Thomas DG, 2011, ACAD EMERG MED, V18, P246, DOI 10.1111/j.1553-2712.2011.01015.x; Thornton AE, 2008, J CLIN EXP NEUROPSYC, V30, P398, DOI 10.1080/13803390701443662; Tsushima WT, 2013, APPL NEUROPSYCH-CHIL, V2, P13, DOI 10.1080/09084282.2011.643967	46	55	55	0	68	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2013	30	17					1469	1475		10.1089/neu.2012.2720			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	202HX	WOS:000323205800001	23560947	Green Submitted, Green Published			2022-02-06	
J	Tosetti, P; Hicks, RR; Theriault, E; Phillips, A; Koroshetz, W; Draghia-Akli, R				Tosetti, Patrizia; Hicks, Ramona R.; Theriault, Elizabeth; Phillips, Anthony; Koroshetz, Walter; Draghia-Akli, Ruxandra		Workshop Participants	Toward an International Initiative for Traumatic Brain Injury Research	JOURNAL OF NEUROTRAUMA			English	Article						geriatric brain injury; head trauma; human studies; pediatric brain injury	COMMON DATA ELEMENTS; SEVERE HEAD-INJURY; OUTCOME MEASURES; CLINICAL-TRIALS; RECOMMENDATIONS; MANAGEMENT; CARE	The European Commission (EC) and the National Institutes of Health (NIH) jointly sponsored a workshop on October 18-20, 2011 in Brussels to discuss the feasibility and benefits of an international collaboration in the field of traumatic brain injury (TBI) research. The workshop brought together scientists, clinicians, patients, and industry representatives from around the globe as well as funding agencies from the EU, Spain, the United States, and Canada. Sessions tackled both the possible goals and governance of a future initiative and the scientific questions that would most benefit from an integrated international effort: how to optimize data collection and sharing; injury classification; outcome measures; clinical study design; and statistical analysis. There was a clear consensus that increased dialogue and coordination of research at an international level would be beneficial for advancing TBI research, treatment, and care. To this end, the EC, the NIH, and the Canadian Institutes of Health Research expressed interest in developing a framework for an international initiative for TBI Research (InTBIR). The workshop participants recommended that InTBIR initially focus on collecting, standardizing, and sharing clinical TBI data for comparative effectiveness research, which will ultimately result in better management and treatments for TBI.	[Tosetti, Patrizia; Draghia-Akli, Ruxandra] DG RTD, European Commiss, Brussels, Belgium; [Hicks, Ramona R.] NINDS, Bethesda, MD 20892 USA; [Theriault, Elizabeth; Phillips, Anthony; Koroshetz, Walter] Canadian Inst Hlth Res, Inst Neurosci Mental Hlth & Addict, Vancouver, BC, Canada		Hicks, RR (corresponding author), NINDS, Ctr Neurosci, 6001 Executive Blvd,Room 2208, Bethesda, MD 20892 USA.	hicksra@ninds.nih.gov	Sahuquillo, Juan/B-3577-2008	Sahuquillo, Juan/0000-0003-0713-5875; Draghia-Akli, Ruxandra/0000-0001-6372-4039	National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish		Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Bauer R, 2009, INJURIES EUROPEAN UN; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Clayton TJ, 2004, BRIT J ANAESTH, V93, P761, DOI 10.1093/bja/aeh249; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Duhaime AC, 2012, J NEUROTRAUM, V29, P629, DOI 10.1089/neu.2011.1927; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; GELPKE GJ, 1983, J NEUROSURG, V59, P745, DOI 10.3171/jns.1983.59.5.0745; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Honeybul S, 2011, J NEUROSURG SCI, V55, P343; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Institute of Medicine, 2009, IN NAT PRIOR COMP EF; Jacobsson LJ, 2009, ACTA NEUROL SCAND, V120, P389, DOI 10.1111/j.1600-0404.2009.01238.x; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Leibson CL, 2011, EPIDEMIOLOGY, V22, P836, DOI 10.1097/EDE.0b013e318231d535; Lingsma HF, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-201; Maas AI, 2008, J TRAUMA, V65, P966, DOI 10.1097/TA.0b013e318184ee7b; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Olesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.x; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Stocchetti N, 2001, Eur J Emerg Med, V8, P215, DOI 10.1097/00063110-200109000-00009; TEASDALE G, 1974, LANCET, V2, P81; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Weiner Michael W, 2013, Alzheimers Dement, V9, pe111, DOI [10.1016/j.jalz.2011.09.172, 10.1016/j.jalz.2013.05.1769]; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033	35	55	56	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2013	30	14					1211	1222		10.1089/neu.2013.2896			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	183MV	WOS:000321821100001	23731282	Green Published			2022-02-06	
J	Berz, K; Divine, J; Foss, KB; Heyl, R; Ford, KR; Myer, GD				Berz, Kate; Divine, Jon; Foss, Kim Barber; Heyl, Rachel; Ford, Kevin R.; Myer, Gregory D.			Sex-Specific Differences in the Severity of Symptoms and Recovery Rate Following Sports-Related Concussion in Young Athletes	PHYSICIAN AND SPORTSMEDICINE			English	Article						concussion; sports-related concussion; athletes; sex differences; symptom scores	TRAUMATIC BRAIN-INJURY; SEGMENT DYNAMIC STABILIZATION; STATES HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; GENDER-DIFFERENCES; HEAD-INJURIES; CHILDREN; ZURICH	Introduction: While research on adult recovery from concussion indicates sex-specific symptoms and recovery rates, there is little existing data on younger patient populations. Objective: To determine sex-specific differences in the severity of presenting symptoms and recovery rate between groups of young athletes who presented <= 7 or. 7 days after sports-related concussion. Methods: This study was a retrospective review of athletes aged 9 to 17 years who were referred for evaluation of a sports-related concussion over a 24-month period. The study groups were divided by sex and post-injury presentation to the clinic at <= 7 days and. 7 days from the date of injury. Athletes with learning disabilities were excluded from the study and data analysis. Age, height, and weight were recorded for each subject. Each subject also reported their initial degree of confusion, amnesia, or loss of consciousness, and whether a helmet was worn when the injury was sustained. A 22-item post-concussion symptom score (SS) scale was completed by both groups on initial assessment (SS1) and follow-up visit (SS2). The recovery rate (SSR) was calculated as (SS2-SS1)/days between SS2 and SS1. Sex and group comparisons for SS1 and SSR were performed using 2 x 2 analysis of variance. A similar analysis was also performed for effects of sex on SS1 and SSR in patients who were not wearing a helmet. Results: Thirty-seven athletes aged 15.0 +/- 1.9 years were evaluated. Males, regardless of day of presentation, had a lower SS1 evaluation than females (15.8 vs 30.9; P, < 0.05). Males without helmets did not differ from females without helmets, but this was not significantly different (14.1 vs 29.6; P = 0.1). There was not a significant difference in SS1 evaluation between the groups who presented at <= 7 or. 7 days. The overall mean SSR was -1.2/day, with no significant difference seen between groups or sex. There were no significant differences in degree of loss of consciousness, amnesia, confusion, or age between the sexes or groups. Conclusion: Whether presenting at <= 7 or. 7 days following a sports-related concussion, female athletes reported a higher SS1 evaluation. With SSR being similar between sexes, the current data suggest that young, female athletes may take longer to become symptom free following sports-related concussion. This information may be an important factor in returning a young athlete to sport after sports-related concussion.	[Berz, Kate; Foss, Kim Barber; Ford, Kevin R.; Myer, Gregory D.] Cincinnati Childrens Hosp Med Ctr, Div Sports Med, Cincinnati, OH 45229 USA; [Berz, Kate; Ford, Kevin R.; Myer, Gregory D.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Divine, Jon; Myer, Gregory D.] Univ Cincinnati, Coll Med, Dept Orthopaed & Sports Med, Cincinnati, OH USA; [Foss, Kim Barber] Coll Mt St Joseph, Dept Athlet Training, Div Hlth Sci, Cincinnati, OH USA; [Heyl, Rachel] Wellington Orthopaed & Sports Med, Cincinnati, OH USA; [Ford, Kevin R.] High Point Univ, Dept Phys Therapy, Sch Hlth Sci, High Point, NC USA; [Myer, Gregory D.] Ohio State Univ, Sch Allied Med Profess, Athlet Training Div, Columbus, OH 43210 USA		Berz, K (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Sports Med, Cincinnati, OH 45229 USA.		Myer, Gregory/H-6572-2016; Ford, Kevin/L-3986-2013	Myer, Gregory/0000-0002-9983-8422; Ford, Kevin/0000-0001-5402-6845			Adirim TA, 2003, SPORTS MED, V33, P75, DOI 10.2165/00007256-200333010-00006; [Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Covassin T, 2003, J ATHL TRAINING, V38, P238; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dvorak J, 2007, BRIT J SPORT MED, V41, pI44, DOI 10.1136/bjsm.2007.037960; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; Granito V.J., 2002, J SPORT BEHAV, V25, P243; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Knowles SB, 2006, AM J EPIDEMIOL, V164, P1209, DOI 10.1093/aje/kwj337; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Mansell J, 2005, J ATHL TRAINING, V40, P310; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Myer GD, 2010, CLIN BIOMECH, V25, P700, DOI 10.1016/j.clinbiomech.2010.04.001; Orchard J, 1998, J Sci Med Sport, V1, P83, DOI 10.1016/S1440-2440(98)80016-9; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Spinos P, 2010, J TRAUMA, V69, P789, DOI 10.1097/TA.0b013e3181edea67; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	41	55	55	0	19	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0091-3847	2326-3660		PHYSICIAN SPORTSMED	Physician Sportsmed.	MAY	2013	41	2					58	63		10.3810/psm.2013.05.2015			6	Primary Health Care; Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Orthopedics; Sport Sciences	AR2EZ	WOS:000343397700007	23703518				2022-02-06	
J	Rogers, ML; Feuerstein, D; Leong, CL; Takagaki, M; Niu, XZ; Graf, R; Boutelle, MG				Rogers, Michelle L.; Feuerstein, Delphine; Leong, Chi Leng; Takagaki, Masatoshi; Niu, Xize; Graf, Rudolf; Boutelle, Martyn G.			Continuous Online Microdialysis Using Microfluidic Sensors: Dynamic Neurometabolic Changes during Spreading Depolarization	ACS CHEMICAL NEUROSCIENCE			English	Article						Microfluidic; biosensor; microdialysis; real-time; spreading depolarization	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; LACTATE LEVELS; PERIINFARCT DEPOLARIZATIONS; BLOOD-FLOW; DEPRESSION; GLUCOSE; ANESTHETICS; DAMAGE	Microfluidic glucose biosensors and potassium ion selective electrodes were used in an in vivo study to measure the neurochemical effects of spreading depolarizations (SD), which have been shown to be detrimental to the injured human brain. A microdialysis probe implanted in the cortex of rats was connected to a microfluidic PDMS chip containing the sensors. The dialysate was also analyzed using our gold standard, rapid sampling microdialysis (rsMD). The glucose biosensor performance was validated against rsMD with excellent results. The glucose biosensors successfully monitored concentration changes, in response to SD wave induction, in the range of 10-400 mu M with a second time-resolution. The data show that during a SD wave, there is a time delay of 62 +/- 24.8 s (n = 4) between the onset of the increase in potassium and the decrease in glucose. This delay can be for the first time demonstrated, thanks to the high-temporal resolution of the microfluidic sensors sampling from a single tissue site (the microdialysis probe), and it indicates that the decrease in glucose is due to the high demand of energy required for repolarization.	[Rogers, Michelle L.; Leong, Chi Leng; Boutelle, Martyn G.] Univ London Imperial Coll Sci Technol & Med, Dept Bioengn, London, England; [Feuerstein, Delphine; Takagaki, Masatoshi; Graf, Rudolf] Max Planck Inst Neurol Res, D-50931 Cologne, Germany; [Niu, Xize] Univ Southampton, Southampton, Hants, England		Boutelle, MG (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Bioengn, London, England.	m.boutelle@imperial.ac.uk	Niu, Xize/D-4627-2013	Leong, Chi Leng/0000-0002-2654-1345; Rogers, Michelle/0000-0002-1434-2322	Wellcome Trust/DOH HICF fund; Alexander von Humboldt FoundationAlexander von Humboldt Foundation; BBSRCUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)	The authors thank the Wellcome Trust/DOH HICF fund, Alexander von Humboldt Foundation, and the BBSRC.	[Anonymous], 2010, LANCET NEUROL, V9, P331, DOI 10.1016/S1474-4422(10)70069-7; Back T, 1996, J CEREBR BLOOD F MET, V16, P202, DOI 10.1097/00004647-199603000-00004; Caesar K, 2008, J PHYSIOL-LONDON, V586, P1337, DOI 10.1113/jphysiol.2007.144154; CLARKE WL, 1987, DIABETES CARE, V10, P622, DOI 10.2337/diacare.10.5.622; Clough GF, 2002, J PHARMACOL EXP THER, V302, P681, DOI 10.1124/jpet.102.035634; Dijkhuizen RM, 1999, BRAIN RES, V840, P194, DOI 10.1016/S0006-8993(99)01769-2; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Dunn AK, 2001, J CEREBR BLOOD F MET, V21, P195, DOI 10.1097/00004647-200103000-00002; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Feuerstein D., 2013, CAPACITY RAISE UNPUB; Feuerstein D, 2010, J CEREBR BLOOD F MET, V30, P1343, DOI 10.1038/jcbfm.2010.17; Feuerstein D, 2009, ANAL CHEM, V81, P4987, DOI 10.1021/ac900161x; Finkelstein E., 2006, INCIDENCE EC BURDEN; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hashemi P, 2009, J CEREBR BLOOD F MET, V29, P166, DOI 10.1038/jcbfm.2008.108; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Horn T, 2010, NEUROCHEM INT, V57, P940, DOI 10.1016/j.neuint.2010.09.014; Hu YB, 1997, J NEUROCHEM, V69, P1484; Hutchens MP, 2006, NEUROCRIT CARE, V4, P54, DOI 10.1385/NCC:4:1:054; Kudo C, 2008, EXP NEUROL, V212, P201, DOI 10.1016/j.expneurol.2008.03.026; Kumagai T, 2011, J CEREBR BLOOD F MET, V31, P580, DOI 10.1038/jcbfm.2010.128; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; Leong C., 2013, ON LINE POTASS UNPUB; Luckl J, 2009, J NEUROSCI RES, V87, P1219, DOI 10.1002/jnr.21933; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; MIES G, 1993, J NEUROCHEM, V60, P360, DOI 10.1111/j.1471-4159.1993.tb05860.x; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nakamura H, 2010, BRAIN, V133, P1994, DOI 10.1093/brain/awq117; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Oliver NS, 2009, DIABETIC MED, V26, P197, DOI 10.1111/j.1464-5491.2008.02642.x; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; Patel BA, 2011, BIOSENS BIOELECTRON, V26, P2890, DOI 10.1016/j.bios.2010.11.033; Richter F, 2003, J NEUROPHYSIOL, V90, P2163, DOI 10.1152/jn.00388.2003; Richter F, 2002, NEUROSCI LETT, V334, P123, DOI 10.1016/S0304-3940(02)01120-5; Rogers M, 2011, PHYS CHEM CHEM PHYS, V13, P5298, DOI 10.1039/c0cp02810j; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; STRONG AJ, 2003, J CEREB BLOOD FLO S1, V23, P300; Strong AJ, 2007, BRAIN, V130, P995, DOI 10.1093/brain/awl392; Takagaki M., 2013, ISOFLURANE SUP UNPUB; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; VYSKOCIL F, 1972, BRAIN RES, V39, P255, DOI 10.1016/0006-8993(72)90802-5; Whitfield P., 2009, HEAD INJURY A MULTID, P309; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263	46	55	57	0	51	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	MAY	2013	4	5					799	807		10.1021/cn400047x			9	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	148ND	WOS:000319250400017	23574576	Green Published, hybrid			2022-02-06	
J	Atif, F; Yousuf, S; Sayeed, I; Ishrat, T; Hua, F; Stein, DG				Atif, Fahim; Yousuf, Seema; Sayeed, Iqbal; Ishrat, Tauheed; Hua, Fang; Stein, Donald G.			Combination treatment with progesterone and vitamin D hormone is more effective than monotherapy in ischemic stroke: The role of BDNF/TrkB/Erk1/2 signaling in neuroprotection	NEUROPHARMACOLOGY			English	Article						Cerebral ischemia; Combination treatment; Progesterone; Vitamin D; BDNF/TrkB/Erk1/2 signaling	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; MEDROXYPROGESTERONE ACETATE; NEUROTROPHIC FACTOR; INFLAMMATORY RESPONSE; INFARCT VOLUME; D DEFICIENCY; RATS; EXPRESSION; BDNF	We investigated whether combinatorial post-injury treatment with progesterone (P4) and vitamin D hormone (VDH) would reduce ischemic injury more effectively than P4 alone in an oxygen glucose deprivation (OGD) model in primary cortical neurons and in a transient middle cerebral artery occlusion (tMCAO) model in rats. In the OGD model, P4 and VDH each showed neuroprotection individually, but combination of the "best" doses did not show substantial efficacy; instead, the lower dose of VDH in combination with P4 was the most effective. In the tMCAO model, P4 and VDH were given alone or in combination at different times post-occlusion for 7 days. In vivo data confirmed the in vitro findings and showed better infarct reduction at day 7 and functional outcomes (at 3, 5 and 7 days post-occlusion) after combinatorial treatment than when either agent was given alone. VDH, but not P4, upregulated heme oxygenase-1, suggesting a pathway for the neuroprotective effects of VDH differing from that of P4. The combination of P4 and VDH activated brain-derived neurotrophic factor and its specific receptor, tyrosine kinase receptor-B. Under specific conditions VDH potentiates P4's neuroprotective efficacy and should be considered as a potential partner of P4 in a low-cost, safe and effective combinatorial treatment for stroke. (c) 2012 Elsevier Ltd. All rights reserved.	[Atif, Fahim; Yousuf, Seema; Sayeed, Iqbal; Ishrat, Tauheed; Hua, Fang; Stein, Donald G.] Emory Univ, Dept Emergency Med, Brain Res Lab, Atlanta, GA 30322 USA		Stein, DG (corresponding author), Emory Univ, Dept Emergency Med, Brain Res Lab, 1365B Clifton Rd NE,Suite 5100, Atlanta, GA 30322 USA.	donald.stein@emory.edu	Stein, Donald/AAJ-5139-2020		BHR Pharmaceuticals; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 HD061971]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061971] Funding Source: NIH RePORTER	DG Stein is entitled to royalties from products of BHR Pharmaceuticals Ltd related to the use of P4 in TBI and stroke, and may receive research funding from BHR Pharmaceuticals, which is developing products related to this research. In addition, he serves as a consultant to BHR Pharmaceuticals and receives compensation for these services. The terms of this arrangement have been reviewed and approved by Emory University, which receives the largest share of fees in accordance with its conflict of interest policies.; This research was supported by NIH grant RO1 HD061971. The authors would like to thank Leslie McCann for invaluable editorial assistance.	Abe K, 1997, BRAIN RES, V776, P230, DOI 10.1016/S0006-8993(97)01041-X; Atif F, 2009, MOL MED, V15, P328, DOI 10.2119/molmed.2009.00016; Balden R, 2012, ENDOCRINOLOGY, V153, P2420, DOI 10.1210/en.2011-1783; Cekic M, 2011, NEUROBIOL AGING, V32, P864, DOI 10.1016/j.neurobiolaging.2009.04.017; Cekic M, 2009, FRONT NEUROENDOCRIN, V30, P158, DOI 10.1016/j.yfrne.2009.04.002; Coughlan T, 2009, INT J NEUROSCI, V119, P1718, DOI 10.1080/00207450903116430; Dang J, 2011, BRAIN BEHAV IMMUN, V25, P715, DOI 10.1016/j.bbi.2011.01.013; Dore S, 1999, MOL MED, V5, P656, DOI 10.1007/BF03401984; Endres M, 2004, J CLIN INVEST, V113, P1711, DOI 10.1172/JCI200420926; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; Greenberg ME, 2009, J NEUROSCI, V29, P12764, DOI 10.1523/JNEUROSCI.3566-09.2009; Hua F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-42; Ishrat T, 2009, BRAIN RES, V1257, P94, DOI 10.1016/j.brainres.2008.12.048; Jodhka PK, 2009, ENDOCRINOLOGY, V150, P3162, DOI 10.1210/en.2008-1247; Kojima G, 2012, STROKE, V43, P2163, DOI 10.1161/STROKEAHA.112.651752; Liu AL, 2012, ENDOCRINOLOGY, V153, P3747, DOI 10.1210/en.2012-1138; Liu LF, 2010, ENDOCRINOLOGY, V151, P5782, DOI 10.1210/en.2010-0005; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Losem-Heinrichs E, 2005, ARCH BIOCHEM BIOPHYS, V439, P70, DOI 10.1016/j.abb.2005.04.021; Lu B, 2003, LEARN MEMORY, V10, P86, DOI 10.1101/lm.54603; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Makariou S.E., 2012, CURR VASC PHARM; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Mattson MP, 2004, TRENDS NEUROSCI, V27, P589, DOI 10.1016/j.tins.2004.08.001; Mizuno M, 2000, J NEUROSCI, V20, P7116, DOI 10.1523/JNEUROSCI.20-18-07116.2000; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P10506, DOI 10.1073/pnas.1334098100; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; Oermann E, 2004, J CHEM NEUROANAT, V28, P225, DOI 10.1016/j.jchemneu.2004.07.003; Pilz S, 2008, J CLIN ENDOCR METAB, V93, P3927, DOI 10.1210/jc.2008-0784; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Shi QD, 2009, NEUROSCI LETT, V465, P220, DOI 10.1016/j.neulet.2009.08.049; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein Donald G, 2011, Dialogues Clin Neurosci, V13, P352; Sun Q, 2012, STROKE, V43, P1470, DOI 10.1161/STROKEAHA.111.636910; Wang JP, 2011, MOL MED REP, V4, P319, DOI 10.3892/mmr.2011.418; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Zeng Y, 2011, J NEUROSCI, V31, P17800, DOI 10.1523/JNEUROSCI.3878-11.2011	43	55	56	0	29	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	APR	2013	67						78	87		10.1016/j.neuropharm.2012.10.004			10	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	097ME	WOS:000315477400010	23154302	Green Accepted			2022-02-06	
J	Becker, EH; Watson, JD; Dreese, JC				Becker, Edward H.; Watson, Jeffrey D.; Dreese, James C.			Investigation of Multiligamentous Knee Injury Patterns With Associated Injuries Presenting at a Level I Trauma Center	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						multiligamentous knee injury; peroneal nerve injury; anterior cruciate ligament; posterior cruciate ligament; posterolateral corner	COMMON PERONEAL NERVE; VASCULAR INJURIES; COMPLETE DISLOCATION; SURGICAL FINDINGS; RECONSTRUCTION; ARTERIOGRAPHY; MANAGEMENT; REPAIR	Objectives: To characterize multiligamentous knee injury patterns and describe associated morbidities. Design: Retrospective. Setting: Level I trauma center. Patients: One hundred two patients (106 knees) with multiligamentous knee injuries and/or dislocations from 2000 through 2008. Subgroup of 82 knees with appropriate magnetic resonance images available assessed for ligamentous injury patterns. Intervention: Data obtained from medical records for 106 knees. Main Outcome Measurements: Presence of arterial injuries, nerve injuries, associated fracture patterns, and whole-body morbidities. Results: The most common (43%) injury pattern was a combined disruption of the anterior cruciate ligament, posterior cruciate ligament, and posterolateral corner. Twenty-five percent of knees had associated ipsilateral tibial plateau fractures, and 19% had associated ipsilateral femoral fractures. Peroneal nerve injury occurred in 25% of knees, arterial injury in 21%, and compartment syndrome in 16%. An intra-abdominal injury was present in 13% of patients, a severe closed head injury in 10%, and a symptomatic pulmonary embolism in 5%. Conclusions: Nearly half the multiligamentous knee injuries involved the anterior cruciate ligament, posterior cruciate ligament, and posterolateral corner; one-fourth had associated ipsilateral tibial plateau fractures. The incidence of peroneal nerve injury (25%) was higher than previously reported (20%), whereas the incidence of arterial injury (21%) was comparable to previous reports (19%). Posterolateral corner injuries were more prevalent than previously reported and were highly associated with peroneal nerve injury. We found a substantial incidence of associated morbidities of the whole body. Multiligamentous knee injuries are a marker of concomitant trauma and should be closely evaluated at presentation and during the hospital course to allow for early intervention for life-or limb-threatening comorbidities.	[Becker, Edward H.; Watson, Jeffrey D.; Dreese, James C.] Univ Maryland, Dept Orthopaed, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA		Dreese, JC (corresponding author), 2200 Kernan Dr,Suite 1154, Baltimore, MD 21207 USA.	jdreese@umoa.umm.edu					ALMEKINDERS LC, 1992, CLIN ORTHOP RELAT R, P203; BOISRENOULT P, 2009, REV CHIR ORTHOP TRAU, V95, P621, DOI DOI 10.1016/J.OTSR.2009.10.002; Bottomley N, 2005, J BONE JOINT SURG BR, V87B, P1225, DOI 10.1302/0301-620X.87B9.16122; Bui KL, 2008, SKELETAL RADIOL, V37, P653, DOI 10.1007/s00256-008-0490-z; FRASSICA FJ, 1991, CLIN ORTHOP RELAT R, P200; Good, 1995, J Am Acad Orthop Surg, V3, P284; GREEN NE, 1977, J BONE JOINT SURG AM, V59, P236, DOI 10.2106/00004623-197759020-00017; Harner CD, 2004, J BONE JOINT SURG AM, V86A, P262, DOI 10.2106/00004623-200402000-00008; Hegyes MS, 2000, CLIN SPORT MED, V19, P519, DOI 10.1016/S0278-5919(05)70222-2; Johnson ME, 2008, AM J SPORT MED, V36, P2448, DOI 10.1177/0363546508325669; KAUFMAN SL, 1992, RADIOLOGY, V184, P153, DOI 10.1148/radiology.184.1.1609074; KENDALL RW, 1993, J TRAUMA, V35, P875, DOI 10.1097/00005373-199312000-00013; Liow RYL, 2003, J BONE JOINT SURG BR, V85B, P845, DOI 10.1302/0301-620X.85B6.13972; Lustig S, 2009, ORTHOP TRAUMATOL-SUR, V95, P614, DOI 10.1016/j.otsr.2009.10.005; MCCOY GF, 1987, J BONE JOINT SURG BR, V69, P285, DOI 10.1302/0301-620X.69B2.3818761; McDonough EB, 2009, AM J SPORT MED, V37, P156, DOI 10.1177/0363546508324313; Niall DM, 2005, J BONE JOINT SURG BR, V87B, P664, DOI 10.1302/0301-620X.87B5.15607; OMALLEY KF, 1990, J TRAUMA, V30, P748, DOI 10.1097/00005373-199006000-00018; Peltola EK, 2009, AM J ROENTGENOL, V192, P101, DOI 10.2214/AJR.07.3593; Potter HG, 2000, CLIN SPORT MED, V19, P425, DOI 10.1016/S0278-5919(05)70216-7; Richter M, 2002, AM J SPORT MED, V30, P718, DOI 10.1177/03635465020300051601; Rios A, 2003, J TRAUMA, V55, P489, DOI 10.1097/01.TA.0000043921.09208.76; Robertson A, 2006, J BONE JOINT SURG BR, V88B, P706, DOI 10.1302/0301-620X.88B6; SISTO DJ, 1985, CLIN ORTHOP RELAT R, P94; Stannard JP, 2004, J BONE JOINT SURG AM, V86A, P910, DOI 10.2106/00004623-200405000-00004; TREIMAN GS, 1992, ARCH SURG-CHICAGO, V127, P1056; Twaddle BC, 2003, J ORTHOP TRAUMA, V17, P198, DOI 10.1097/00005131-200303000-00008; Twaddle BC, 1996, J BONE JOINT SURG BR, V78B, P573, DOI 10.1302/0301-620X.78B4.0780573; VARNELL RM, 1989, AM SURGEON, V55, P699; Wascher DC, 1997, J ORTHOP TRAUMA, V11, P525, DOI 10.1097/00005131-199710000-00011; Wascher DC, 2000, CLIN SPORT MED, V19, P457, DOI 10.1016/S0278-5919(05)70218-0; Werier J, 1998, KNEE, V5, P255, DOI 10.1016/S0968-0160(98)00015-5; WRIGHT DG, 1995, J ORTHOP TRAUMA, V9, P135, DOI 10.1097/00005131-199504000-00008	33	55	57	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0890-5339			J ORTHOP TRAUMA	J. Orthop. Trauma	APR	2013	27	4					226	231		10.1097/BOT.0b013e318270def4			6	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	112SY	WOS:000316614900015	22955332				2022-02-06	
J	Hellyer, PJ; Leech, R; Ham, TE; Bonnelle, V; Sharp, DJ				Hellyer, Peter J.; Leech, Robert; Ham, Timothy E.; Bonnelle, Valerie; Sharp, David J.			Individual prediction of white matter injury following traumatic brain injury	ANNALS OF NEUROLOGY			English	Article							AXONAL INJURY; DIFFUSION; ADULTS; CONNECTIVITY; DETECTS; LESIONS; DAMAGE; NERVE; MODEL; TIME	Objective Traumatic brain injury (TBI) often results in traumatic axonal injury (TAI). This can be difficult to identify using conventional imaging. Diffusion tensor imaging (DTI) offers a method of assessing axonal damage in vivo, but has previously mainly been used to investigate groups of patients. Machine learning techniques are increasingly used to improve diagnosis based on complex imaging measures. We investigated whether machine learning applied to DTI data can be used to diagnose white matter damage after TBI and to predict neuropsychological outcome in individual patients. Methods We trained pattern classifiers to predict the presence of white matter damage in 25 TBI patients with microbleed evidence of TAI compared to neurologically healthy age-matched controls. We then applied these classifiers to 35 additional patients with no conventional imaging evidence of TAI. Finally, we used regression analyses to predict indices of neuropsychological outcome for information processing speed, executive function, and associative memory in a group of 70 heterogeneous patients. Results The classifiers discriminated between patients with microbleeds and age-matched controls with a high degree of accuracy, and outperformed other methods. When the trained classifiers were applied to patients without microbleeds, patients having likely TAI showed evidence of greater cognitive impairment in information processing speed and executive function. The classifiers were also able to predict the extent of impairments in information processing speed and executive function. Interpretation The work provides a proof of principle that multivariate techniques can be used with DTI to provide diagnostic information about clinically significant TAI. ANN NEUROL 2013;73:489-499	[Hellyer, Peter J.; Leech, Robert; Ham, Timothy E.; Bonnelle, Valerie; Sharp, David J.] Univ London Imperial Coll Sci Technol & Med, Div Expt Med, Computat Cognit & Clin Neuroimaging Lab, London, England; [Bonnelle, Valerie] Univ London Imperial Coll Sci Technol & Med, Fac Med, MRC Clin Sci Ctr, Expt & Clin Neurosci Sect,Cognit Neuroimaging Res, London, England		Leech, R (corresponding author), Hammersmith Hosp, Computat Cognit & Clin Neuroimaging Lab, 3rd Floor,Burlington Danes Bldg,Cane Rd, London W12 0NN, England.	r.leech@imperial.ac.uk	Hellyer, Peter J/F-7112-2013; Sharp, David J/A-2119-2013; Leech, Robert/AAE-8254-2019	Hellyer, Peter J/0000-0002-5139-3401; Leech, Robert/0000-0002-5801-6318	Medical Research Council (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); Imperial College Healthcare Charity; Research Councils United Kingdom; PfizerPfizer; Homerton Hospital (UK); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0701951] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0701951, 1110783] Funding Source: researchfish	This work was supported by grants from the Medical Research Council (UK) to D.J.S. and P.J.H., Imperial College Healthcare Charity to D.J.S., Research Councils United Kingdom to R.L, and Pfizer to D.J.S. We thank the subjects who took part in this study.; D.J.S.: speaking fees, Homerton Hospital (UK).	ADAMS JH, 1982, INJURY, V13, P444, DOI 10.1016/0020-1383(82)90105-X; Baddeley A, 1994, DOORS PEOPLE TEST TE; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Efron B., 1993, INTRO BOOTSTRAP, P237; Good P, 2005, PERMUTATION PARAMETR; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Klawiter EC, 2011, NEUROIMAGE, V55, P1454, DOI 10.1016/j.neuroimage.2011.01.007; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levine B, 2005, COGN BEHAV NEUROL, V18, P45, DOI 10.1097/01.wnn.0000152227.13001.c3; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Platt JC, 2000, ADV NEUR IN, P61; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Sajda P, 2006, ANNU REV BIOMED ENG, V8, P537, DOI 10.1146/annurev.bioeng.8.061505.095802; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Squarcina L, 2012, NEUROIMAGE, V63, P779, DOI 10.1016/j.neuroimage.2012.07.016; WAXMAN SG, 1980, MUSCLE NERVE, V3, P141, DOI 10.1002/mus.880030207; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246	36	55	57	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	APR	2013	73	4					489	499		10.1002/ana.23824			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	152HY	WOS:000319523800010	23426980				2022-02-06	
J	Shi, HY; Hwang, SL; Lee, KT; Lin, CL				Shi, Hon-Yi; Hwang, Shiuh-Lin; Lee, King-Teh; Lin, Chih-Lung			In-hospital mortality after traumatic brain injury surgery: a nationwide population-based comparison of mortality predictors used in artificial neural network and logistic regression models Clinical article	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; in-hospital mortality; artificial neural network; logistic regression	UNITED-STATES; HEAD-INJURY; VALIDATION; SURVIVAL; ACCURACY	Object. Most reports compare artificial neural network (ANN) models and logistic regression models in only a single data set, and the essential issue of internal validity (reproducibility) of the models has not been adequately addressed. This study proposes to validate the use of the ANN model for predicting in-hospital mortality after traumatic brain injury (TBI) surgery and to compare the predictive accuracy of ANN with that of the logistic regression model. Methods. The authors of this study retrospectively analyzed 16,956 patients with TBI nationwide who were surgically treated in Taiwan between 1998 and 2009. For every 1000 pairs of ANN and logistic regression models, the area under the receiver operating characteristic curve (AUC), Hosmer-Lemeshow statistics, and accuracy rate were calculated and compared using paired t-tests. A global sensitivity analysis was also performed to assess the relative importance of input parameters in the ANN model and to rank the variables in order of importance. Results. The ANN model outperformed the logistic regression model in terms of accuracy in 95.15% of cases, in terms of Hosmer-Lemeshow statistics in 43.68% of cases, and in terms of the AUC in 89.14% of cases. The global sensitivity analysis of in-hospital mortality also showed that the most influential (sensitive) parameters in the ANN model were surgeon volume followed by hospital volume, Charlson comorbidity index score, length of stay, sex, and age. Conclusions. This work supports the continued use of ANNs for predictive modeling of neurosurgery outcomes. However, further studies are needed to confirm the clinical efficacy of the proposed model. (http://thejns.org/doi/abs/10.3171/2013.1.JNS121130)	[Shi, Hon-Yi; Lee, King-Teh] Kaohsiung Med Univ, Dept Healthcare Adm & Med Informat, Kaohsiung, Taiwan; [Hwang, Shiuh-Lin; Lin, Chih-Lung] Kaohsiung Med Univ Hosp, Dept Neurosurg, Kaohsiung 80708, Taiwan; [Hwang, Shiuh-Lin; Lin, Chih-Lung] Kaohsiung Med Univ, Coll Med, Fac Med, Kaohsiung, Taiwan; [Lee, King-Teh] Kaohsiung Med Univ, Dept Surg, Div Hepatobiliary Surg, Kaohsiung, Taiwan		Lin, CL (corresponding author), Kaohsiung Med Univ Hosp, Dept Neurosurg, 100 Shih Chun 1st Rd, Kaohsiung 80708, Taiwan.	hshi@kmu.edu.tw			National Science Council, TaiwanMinistry of Science and Technology, Taiwan [NSC99-2314-B-037-069-MY3]	This study was supported by funding from the National Science Council, Taiwan (NSC99-2314-B-037-069-MY3). The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bullock MR, 2007, J NEUROTRAUMA S1, V24; Cadotte DW, 2011, J NEUROSURG, V114, P1502, DOI 10.3171/2010.12.JNS10808; Curry WT, 2005, J NEUROSURG, V102, P977, DOI 10.3171/jns.2005.102.6.0977; Das A, 2003, LANCET, V362, P1261, DOI 10.1016/S0140-6736(03)14568-0; de Jongh MAC, 2010, BRIT J SURG, V97, P1805, DOI 10.1002/bjs.7216; Defillo A, 2010, J NEUROSURG, V113, P399, DOI 10.3171/2009.10.JNS091500; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; DiRusso SM, 2000, J TRAUMA, V49, P212, DOI 10.1097/00005373-200008000-00006; Eftekhar Behzad, 2005, BMC Med Inform Decis Mak, V5, P3; Farahvar A, 2011, J NEUROSURG, V115, P191, DOI 10.3171/2011.4.JNS101116a; FORSSTROM JJ, 1995, ANN MED, V27, P509, DOI 10.3109/07853899509002462; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Grossman R, 2011, ANN SURG ONCOL, V18, P521, DOI 10.1245/s10434-010-1299-2; Hampton T, 2011, JAMA-J AM MED ASSOC, V306, P477, DOI 10.1001/jama.2011.1092; Hotchkiss JR, 2006, CRIT CARE MED, V34, P1267, DOI 10.1097/01.CCM.0000208148.13721.AE; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Lang EW, 1997, NEUROL RES, V19, P274, DOI 10.1080/01616412.1997.11740813; Livingston EH, 2010, JAMA-J AM MED ASSOC, V304, P95, DOI 10.1001/jama.2010.905; Nakagawa TA, 2011, CRIT CARE MED, V39, P2139, DOI 10.1097/CCM.0b013e31821f0d4f; Pastorius Benziger Catherine, 2011, Crit Pathw Cardiol, V10, P99, DOI 10.1097/HPC.0b013e318223e375; Rughani AI, 2010, J NEUROSURG, V113, P585, DOI 10.3171/2009.11.JNS09857; Sandberg IW, 2001, NONLINEAR DYNAMICAL; Sarani B, 2009, J TRAUMA, V67, P954, DOI 10.1097/TA.0b013e3181ae6d39; Segal ME, 2006, J HEAD TRAUMA REHAB, V21, P298, DOI 10.1097/00001199-200607000-00003; Servadei F, 2007, CURR OPIN CRIT CARE, V13, P163, DOI 10.1097/MCC.0b013e32807f2a94; Shamim MS, 2011, J NEUROSURG, V115, P1007, DOI 10.3171/2011.7.JNS101829; Shi HY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035781; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Terrin N, 2003, J CLIN EPIDEMIOL, V56, P721, DOI 10.1016/S0895-4356(03)00120-3; Tu JV, 1996, J CLIN EPIDEMIOL, V49, P1225, DOI 10.1016/S0895-4356(96)00002-9; WHISNANT JP, 1993, J NEUROSURG, V78, P726, DOI 10.3171/jns.1993.78.5.0726; Zou Jinming, 2008, V458, P15	33	55	57	0	12	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2013	118	4					746	752		10.3171/2013.1.JNS121130			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	114BT	WOS:000316715700010	23373802				2022-02-06	
J	Shultz, SR; Bao, F; Weaver, LC; Cain, DP; Brown, A				Shultz, Sandy R.; Bao, Feng; Weaver, Lynne C.; Cain, Donald P.; Brown, Arthur			Treatment with an anti-CD11d integrin antibody reduces neuroinflammation and improves outcome in a rat model of repeated concussion	JOURNAL OF NEUROINFLAMMATION			English	Article							TRAUMATIC BRAIN-INJURY; LONG-EVANS RAT; PROFESSIONAL FOOTBALL PLAYERS; FLUID-PERCUSSION INJURY; ELEVATED PLUS-MAZE; HEAD-INJURY; RECURRENT CONCUSSION; ANIMAL-MODEL; BEHAVIORAL IMPAIRMENTS; REACTIVE ASTROCYTES	Background: Concussions account for the majority of traumatic brain injuries (TBI) and can result in cumulative damage, neurodegeneration, and chronic neurological abnormalities. The underlying mechanisms of these detrimental effects remain poorly understood and there are presently no specific treatments for concussions. Neuroinflammation is a major contributor to secondary damage following more severe TBI, and recent findings from our laboratory suggest it may be involved in the cumulative properties of repeated concussion. We previously found that an anti-CD11d monoclonal antibody that blocks the CD11d/CD18 integrin and adhesion molecule interaction following severe experimental TBI reduces neuroinflammation, oxidative activity, and tissue damage, and improves functional recovery. As similar processes may be involved in repeated concussion, here we studied the effects of the anti-CD11d treatment in a rat model of repeated concussion. Methods: Rats were treated 2 h and 24 h after each of three repeated mild lateral fluid percussion injuries with either the CD11d antibody or an isotype-matched control antibody, 1B7. Injuries were separated by a five-day inter-injury interval. After the final treatment and either an acute (24 to 72 h post-injury) or chronic (8 weeks post-injury) recovery period had elapsed, behavioral and pathological outcomes were examined. Results: The anti-CD11d treatment reduced neutrophil and macrophage levels in the injured brain with concomitant reductions in lipid peroxidation, astrocyte activation, amyloid precursor protein accumulation, and neuronal loss. The anti-CD11d treatment also improved outcome on tasks of cognition, sensorimotor ability, and anxiety. Conclusions: These findings demonstrate that reducing inflammation after repeated mild brain injury in rats leads to improved behavioral outcomes and that the anti-CD11d treatment may be a viable therapy to improve post-concussion outcomes.	[Shultz, Sandy R.; Cain, Donald P.] Univ Western Ontario, Dept Psychol, London, ON N6A 5C2, Canada; [Shultz, Sandy R.; Cain, Donald P.] Univ Western Ontario, Grad Program Neurosci, London, ON N6A 5C2, Canada; [Bao, Feng; Weaver, Lynne C.; Brown, Arthur] Univ Western Ontario, Schulich Sch Med, Robarts Res Inst, London, ON N6A 5K8, Canada		Brown, A (corresponding author), Univ Western Ontario, Schulich Sch Med, Robarts Res Inst, 100 Perth Dr St, London, ON N6A 5K8, Canada.	abrown@robarts.ca	Brown, Arthur/K-8328-2013; Weaver, Lynne C/K-8491-2013; Brown, Arthur/K-6837-2013; Baker, James/C-1674-2008	Brown, Arthur/0000-0002-8725-3195; Baker, James/0000-0002-7223-2279; Shultz, Sandy/0000-0002-2525-8775	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR	This work was supported the Canadian Institutes of Health Research (LCW and AB) and the Natural Sciences and Engineering Research Council of Canada (DPC).	Anthony D, 1998, CURR BIOL, V8, P923, DOI 10.1016/S0960-9822(07)00373-9; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.immunol.11.1.767; Bigler ED, 2012, NEUROSCI LETT, V509, P1, DOI 10.1016/j.neulet.2011.12.009; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Cantu RC, 2009, CURR SPORT MED REP, V8, P6, DOI 10.1249/JSR.0b013e31819677db; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Geremia NM, 2012, J NEUROTRAUM, V29, P539, DOI 10.1089/neu.2011.1976; Grady MS, 1999, J NEUROTRAUM, V16, P13, DOI 10.1089/neu.1999.16.13; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Gris P, 2009, J NEUROIMMUNOL, V209, P104, DOI 10.1016/j.jneuroim.2009.02.002; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hogg N, 2001, J LEUKOCYTE BIOL, V69, P893; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Leski ML, 2001, FREE RADICAL BIO MED, V30, P613, DOI 10.1016/S0891-5849(00)00500-1; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; McCrory P, 2011, CLIN SPORT MED, V30, P201, DOI 10.1016/j.csm.2010.08.002; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Saucier DM, 2008, ANIM COGN, V11, P129, DOI 10.1007/s10071-007-0096-1; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shultz SR, 2012, BEHAV BRAIN RES, V229, P145, DOI 10.1016/j.bbr.2011.12.015; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Shultz SR, 2009, BEHAV BRAIN RES, V200, P33, DOI 10.1016/j.bbr.2008.12.023; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Utagawa A, 2008, BRAIN RES, V1207, P155, DOI 10.1016/j.brainres.2008.02.057; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44	45	55	55	0	14	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	FEB 15	2013	10								26	10.1186/1742-2094-10-26			15	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	100RM	WOS:000315719200001	23414334	Green Published, gold			2022-02-06	
J	Olthof, DC; Joosse, P; van der Vlies, CH; de Haan, RJ; Goslings, JC				Olthof, Dominique C.; Joosse, Pieter; van der Vlies, Cornelis H.; de Haan, Rob J.; Goslings, J. Carel			Prognostic factors for failure of nonoperative management in adults with blunt splenic injury: A systematic review	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Nonoperative management; failure; prognostic factors; blunt splenic injury	SOLID-ORGAN INJURIES; PREDICTIVE FACTORS; BURN PATIENTS; TRAUMA; SPLEEN; METAANALYSIS; SPLENECTOMY; MULTICENTER; MORTALITY; CRITERIA	BACKGROUND: Contradictory findings are reported in the literature concerning prognostic factors for failure of nonoperative management (NOM) in the treatment of adults with blunt splenic injury. The objective of this systematic review was to identify prognostic factors for failure of NOM, with or without angiography and embolization. METHODS: MEDLINE, Embase, and the Cochrane Library databases were searched. Prospective or retrospective cohort studies addressing failure of nonoperative treatment, with and/or without angiography and embolization, of blunt abdominal injuries were included. Methodological quality of the studies was assessed. RESULTS: A total of 335 titles and abstracts were screened, of which 31 fulfilled the inclusion criteria. No randomized controlled trials were found. Ten articles were qualified as high-quality articles and used for data extraction (best-evidence synthesis). A total of 25 prognostic factors were investigated, of which 14 were statistically significant in one or more studies. Strong evidence exists that age of 40 years or above, Injury Severity Score (ISS) of 25 or greater, and splenic injury grade of 3 or greater are prognostic factors for failure of NOM. Moderate evidence was found for a splenic Abbreviated Injury Scale score of 3 or greater, trauma and ISS of less than 0.80, the presence of an intraparenchymal contrast blush, as well as transfusion of 1 unit of packed red blood cells or more. Limited evidence was found for large hemoperitoneum, lower Revised Trauma Score, lower Glasgow Coma Scale score, lower systolic blood pressure, male sex, the presence of traumatic brain injury, and splenic embolization as protective factor for failure of NOM. CONCLUSION: Awareness for failure ofNOMis required in patients aged 40 years or older, in patients with an ISS of 25 or higher or those with splenic injury grade 3 or higher. The prognostic factors for failure that we identified should be confirmed in future prospective cohort studies or meta-analyses using individual patient data. (J Trauma Acute Care Surg. 2013;74: 546-557. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Olthof, Dominique C.; Joosse, Pieter; Goslings, J. Carel] Univ Amsterdam, Acad Med Ctr, Dept Surg, Trauma Unit, NL-1105 AZ Amsterdam, Netherlands; [de Haan, Rob J.] Univ Amsterdam, Acad Med Ctr, Clin Res Unit, NL-1105 AZ Amsterdam, Netherlands; [van der Vlies, Cornelis H.] Maasstad Ziekenhuis Rotterdam, Rotterdam, Netherlands		Goslings, JC (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Surg, Trauma Unit, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	j.c.goslings@amc.nl					Altman DG, 2001, BMJ-BRIT MED J, V323, P224, DOI 10.1136/bmj.323.7306.224; Barone JE, 1999, J TRAUMA, V46, P87, DOI 10.1097/00005373-199901000-00014; Bee TK, 2001, J TRAUMA, V50, P230, DOI 10.1097/00005373-200102000-00007; Bhangu A, 2012, INJURY, V43, P1337, DOI 10.1016/j.injury.2011.09.010; Borghouts JAJ, 1998, PAIN, V77, P1, DOI 10.1016/S0304-3959(98)00058-X; Cocanour CS, 2000, J TRAUMA, V48, P606, DOI 10.1097/00005373-200004000-00005; Cohn SM, 2009, AM SURGEON, V75, P133; Demetriades D, 2012, J TRAUMA ACUTE CARE, V72, P229, DOI 10.1097/TA.0b013e31823fe0b6; Duchesne JC, 2008, J TRAUMA, V65, P1346, DOI 10.1097/TA.0b013e31818c29ea; Fu CY, 2010, WORLD J SURG, V34, P2745, DOI 10.1007/s00268-010-0723-x; Galvan DA, 2006, CURR OPIN CRIT CARE, V12, P590, DOI 10.1097/MCC.0b013e328010d4ad; Gaunt WT, 1999, AM SURGEON, V65, P689; Germann G, 1997, BURNS, V23, P195, DOI 10.1016/S0305-4179(96)00112-X; Gonzalez M, 2008, J CHIR-PARIS, V145, P561, DOI 10.1016/S0021-7697(08)74687-8; Haan JM, 2005, J TRAUMA, V58, P492, DOI 10.1097/01.TA.0000154575.49388.74; Hashemzadeh SH, 2010, MINERVA CHIR, V65, P267; Jeremitsky E, 2011, AM SURGEON, V77, P215; Lehman R, 2012, BRIT MED J, V344, DOI 10.1136/bmj.d8158; Lievense AM, 2002, ARTHRIT RHEUM-ARTHR, V47, P556, DOI 10.1002/art.10660; McIntyre LK, 2005, ARCH SURG-CHICAGO, V140, P563, DOI 10.1001/archsurg.140.6.563; Meguid AA, 2003, AM SURGEON, V69, P238; MRC Clinical Trials Unit, 2012, IND PAT DAT MET; Nix JA, 2001, J TRAUMA, V50, P835, DOI 10.1097/00005373-200105000-00010; OCONNOR D, 2008, COCHRANE HDB SYSTEMA; Peitzman AB, 2000, J TRAUMA, V49, P177, DOI 10.1097/00005373-200008000-00002; Post B, 2007, MOVEMENT DISORD, V22, P1839, DOI 10.1002/mds.21537; Renzulli P, 2010, BRIT J SURG, V97, P1696, DOI 10.1002/bjs.7203; Schroeppel TJ, 2007, CURR OPIN CRIT CARE, V13, P399, DOI 10.1097/MCC.0b013e32825a6a32; SCHURR MJ, 1995, J TRAUMA, V39, P507; SLAVIN RE, 1995, J CLIN EPIDEMIOL, V48, P9, DOI 10.1016/0895-4356(94)00097-A; SMITH DL, 1994, J TRAUMA, V37, P655, DOI 10.1097/00005373-199410000-00021; Smith J, 2008, J TRAUMA, V64, P656, DOI 10.1097/TA.0b013e3181650fb4; Velmahos GC, 2000, ARCH SURG-CHICAGO, V135, P674, DOI 10.1001/archsurg.135.6.674; Velmahos GC, 2008, AM SURGEON, V74, P297; Velmahos GC, 2010, ARCH SURG-CHICAGO, V145, P456, DOI 10.1001/archsurg.2010.58; Watson GA, 2006, J TRAUMA, V61, P1113, DOI 10.1097/01.ta.0000241363.97619.d6	36	55	57	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2013	74	2					546	557		10.1097/TA.0b013e31827d5e3a			12	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	108UH	WOS:000316321200044	23354249				2022-02-06	
J	Choo, AM; Miller, WJ; Chen, YC; Nibley, P; Patel, TP; Goletiani, C; Morrison, B; Kutzing, MK; Firestein, BL; Sul, JY; Haydon, PG; Meaney, DF				Choo, Anthony M.; Miller, William J.; Chen, Yung-Chia; Nibley, Philip; Patel, Tapan P.; Goletiani, Cezar; Morrison, Barclay, III; Kutzing, Melinda K.; Firestein, Bonnie L.; Sul, Jai-Yoon; Haydon, Philip G.; Meaney, David F.			Antagonism of purinergic signalling improves recovery from traumatic brain injury	BRAIN			English	Article						neuroprotection; calcium waves; in vivo imaging; MRS 2179; astrocytes	INTERCELLULAR CALCIUM WAVES; SYNAPTIC-TRANSMISSION; GLUTAMATE EXOCYTOSIS; REACTIVE ASTROCYTES; EXTRACELLULAR ATP; PYRAMIDAL NEURONS; CLINICAL-TRIALS; CREB SHUTOFF; RECEPTORS; P2Y(1)	The recent public awareness of the incidence and possible long-term consequences of traumatic brain injury only heightens the need to develop effective approaches for treating this neurological disease. In this report, we identify a new therapeutic target for traumatic brain injury by studying the role of astrocytes, rather than neurons, after neurotrauma. We use in vivo multiphoton imaging and show that mechanical forces during trauma trigger intercellular calcium waves throughout the astrocytes, and these waves are mediated by purinergic signalling. Subsequent in vitro screening shows that astrocyte signalling through the 'mechanical penumbra' affects the activity of neural circuits distant from the injury epicentre, and a reduction in the intercellular calcium waves within astrocytes restores neural activity after injury. In turn, the targeting of different purinergic receptor populations leads to a reduction in hippocampal cell death in mechanically injured organotypic slice cultures. Finally, the most promising therapeutic candidate from our in vitro screen (MRS 2179, a P2Y1 receptor antagonist) also improves histological and cognitive outcomes in a preclinical model of traumatic brain injury. This work shows the potential of studying astrocyte signalling after trauma to yield new and effective therapeutic targets for treating traumatic brain injury.	[Choo, Anthony M.; Miller, William J.; Chen, Yung-Chia; Nibley, Philip; Patel, Tapan P.; Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Goletiani, Cezar; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY USA; [Kutzing, Melinda K.; Firestein, Bonnie L.] Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ USA; [Sul, Jai-Yoon] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; [Haydon, Philip G.] Tufts Univ, Dept Neurosci, Boston, MA 02111 USA		Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, Suite 240,Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Patel, Tapan/0000-0001-8959-6645; Meaney, David/0000-0002-0954-4122; Firestein, Bonnie/0000-0002-1679-3565	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 35712, HS 41699]; Department of DefenseUnited States Department of Defense [W911NF-10-1-0526]; State of New Jersey [10-3209-BIR-E-3]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035712] Funding Source: NIH RePORTER	National Institutes of Health (NS 35712, HS 41699); Department of Defense (W911NF-10-1-0526); the State of New Jersey (10-3209-BIR-E-3).	Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bezzi P, 2004, NAT NEUROSCI, V7, P613, DOI 10.1038/nn1246; Bowser DN, 2004, J NEUROSCI, V24, P8606, DOI 10.1523/JNEUROSCI.2660-04.2004; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Charles A, 1998, GLIA, V24, P39, DOI 10.1002/(SICI)1098-1136(199809)24:1<39::AID-GLIA5>3.0.CO;2-W; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CHRISTIE BR, 1995, J NEUROPHYSIOL, V73, P2553, DOI 10.1152/jn.1995.73.6.2553; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; de Mendonca A, 2000, BRAIN RES REV, V33, P258, DOI 10.1016/S0165-0173(00)00033-3; Deng P, 2011, J NEUROTRAUM, V28, P1173, DOI 10.1089/neu.2010.1683; Ding S, 2007, J NEUROSCI, V27, P10674, DOI 10.1523/JNEUROSCI.2001-07.2007; Domercq M, 2006, J BIOL CHEM, V281, P30684, DOI 10.1074/jbc.M606429200; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fellin T, 2004, NEURON, V43, P729, DOI 10.1016/j.neuron.2004.08.011; Franke H, 2001, BRIT J PHARMACOL, V134, P1180, DOI 10.1038/sj.bjp.0704353; Franklin K.P.G., 1996, MOUSE BRAIN STEREOTA; Gordon GRJ, 2009, NEURON, V64, P391, DOI 10.1016/j.neuron.2009.10.021; Guthrie PB, 1999, J NEUROSCI, V19, P520, DOI 10.1523/jneurosci.19-02-00520.1999; Hardingham GE, 2002, BBA-PROTEINS PROTEOM, V1600, P148, DOI 10.1016/S1570-9639(02)00455-7; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 2010, NAT REV NEUROSCI, V11, P682, DOI 10.1038/nrn2911; Haydon PG, 2006, PHYSIOL REV, V86, P1009, DOI 10.1152/physrev.00049.2005; Howard C.V., 1998, UNBIASED STEREOLOGY, V1; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Jayaraman V, 2007, FRONT NEURAL CIRCUIT, V1, DOI [10.3389/neuro.04.003.2007, 10.3389/neuro.04/003.2007]; Jourdain P, 2007, NAT NEUROSCI, V10, P331, DOI 10.1038/nn1849; Kawamura M, 2004, J NEUROSCI, V24, P10835, DOI 10.1523/JNEUROSCI.3028-04.2004; Kuboyama K, 2011, J CEREBR BLOOD F MET, V31, P1930, DOI 10.1038/jcbfm.2011.49; Kunapuli SP, 2003, CURR PHARM DESIGN, V9, P2303, DOI 10.2174/1381612033453947; Liu QS, 2004, P NATL ACAD SCI USA, V101, P3172, DOI 10.1073/pnas.0306731101; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Mendoza-Fernandez V, 2000, J PHARMACOL EXP THER, V293, P172; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; Newman EA, 2001, J NEUROSCI, V21, P2215, DOI 10.1523/JNEUROSCI.21-07-02215.2001; Oliveira-da-Silva A, 2010, NEUROSCIENCE, V167, P163, DOI 10.1016/j.neuroscience.2010.01.060; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916; Peden M., 2004, WORLD REPORT ROAD TR; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Rodrigues RJ, 2005, J NEUROSCI, V25, P6286, DOI 10.1523/JNEUROSCI.0628-05.2005; Rodriguez-Zayas AE, 2012, J MOL NEUROSCI, V46, P167, DOI 10.1007/s12031-011-9567-6; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Shreiber DI, 1999, NEUROSCI LETT, V259, P5, DOI 10.1016/S0304-3940(98)00853-2; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Starkov AA, 2004, CELL CALCIUM, V36, P257, DOI 10.1016/j.ceca.2004.02.012; Tian GF, 2006, ADV DRUG DELIVER REV, V58, P773, DOI 10.1016/j.addr.2006.07.001; Tonazzini I, 2007, EUR J NEUROSCI, V26, P890, DOI 10.1111/j.1460-9568.2007.05697.x; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Van Hedel HJA, 2006, J NEUROTRAUM, V23, P1621, DOI 10.1089/neu.2006.23.1621; Venance L, 1997, J NEUROSCI, V17, P1981; Ventura R, 1999, J NEUROSCI, V19, P6897, DOI 10.1523/JNEUROSCI.19-16-06897.1999; WU LG, 1994, NEURON, V12, P1139, DOI 10.1016/0896-6273(94)90321-2; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; YUSTE R, 1992, SCIENCE, V257, P666, DOI 10.1126/science.1496379	58	55	56	1	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JAN	2013	136		1				65	80		10.1093/brain/aws286			16	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	089KR	WOS:000314909900007	23293266	Green Published, Bronze			2022-02-06	
J	Jin, G; Duggan, M; Imam, A; deMoya, MA; Sillesen, M; Hwabejire, J; Jepsen, CH; Liu, BL; Mejaddam, AY; Lu, J; Smith, WM; Velmahos, GC; Socrate, S; Alam, HB				Jin, Guang; Duggan, Michael; Imam, Ayesha; deMoya, Marc A.; Sillesen, Martin; Hwabejire, John; Jepsen, Cecilie H.; Liu, Baoling; Mejaddam, Ali Y.; Lu, Jennifer; Smith, William Michael; Velmahos, George C.; Socrate, Simona; Alam, Hasan B.			Pharmacologic resuscitation for hemorrhagic shock combined with traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	42nd Annual Meeting of the Western-Trauma-Association	FEB 26-MAR 03, 2012	Vail, CO	Western Trauma Assoc		Brain; trauma; resuscitation; valproic acid; swine	FOCAL CEREBRAL-ISCHEMIA; VALPROIC ACID; FLUID RESUSCITATION; ADHESION MOLECULES; HEAD-INJURY; ACTIVATION; SYSTEM; MODEL; HEMODILUTION; COAGULATION	BACKGROUND: We have previously demonstrated that valproic acid (VPA), a histone deacetylase inhibitor, can improve survival after hemorrhagic shock (HS), protect neurons from hypoxia-induced apoptosis, and attenuate the inflammatory response. We have also shown that administration of 6% hetastarch (Hextend [Hex]) after traumatic brain injury (TBI) decreases brain swelling, without affecting size of the lesion. This study was performed to determine whether addition of VPA to flex would decrease the lesion size in a clinically relevant large animal model of TBI + HS. METHODS: Yorkshire swine (42-50 kg) were instrumented to measure hemodynamic parameters, intracranial pressure, and brain tissue oxygenation. A custom-designed, computer-controlled cortical impact device was used to create a TBI through a 20-mm craniotomy: 15-mm cylindrical tip impactor at 4-m/s velocity, 100-millisecond dwell time, and 12-mm penetration depth. Volume-controlled hemorrhage was started (40% blood volume) concurrent with the TBI. After 2 hours of shock, animals were randomized to one of three resuscitation groups (n = 7 per group) as follows: (1) isotonic sodium chloride solution; (2) 6% hetastarch, Hex; and (3) Hex and VPA 300 mg/kg (Hex + VPA). Volumes of Hex matched the shed blood, whereas that of the isotonic sodium chloride solution was three times the volume. VPA treatment was started after an hour of shock. After 6 hours of postresuscitation monitoring, brains were sectioned into 5-mm slices and stained with 2, 3, 5-Triphenyltetrazolium chloride to quantify the lesion size (mm(3)) and brain swelling (percent change compared with uninjured side). Levels of acetylated histone H3 were determined to quantify acetylation, and myeloperoxidase and interleuldne-1 beta (IL-1 beta) levels were measured as markers of brain inflammation. RESULTS:. Combination of 40% blood loss with cortical impact and a period of shock (2 hours) and resuscitation resulted in a highly reproducible brain injury. Lesion size and brain swelling in the Hex + VPA group (1,989 [156.8] mm(3), and 19% [1.6%], respectively) were significantly smaller than the isotonic sodium chloride solution group (3,335 [287.9] mm(3) and 36% [2.2%], respectively). Hex alone treatment significantly decreased the swelling (27% [1.6%]) without reducing the lesion size. The number of CD11b-positive cells as well as myeloperoxidase and IL-1 levels in the brains were significantly reduced by the VPA treatment. CONCLUSION: In a combined HS and TBI model, treatment with artificial colloid (Hex) improves hemodynamic parameters and reduces swelling, without affecting the actual size of the brain lesion. Addition of VPA effectively reduces both the size of brain lesion and associated swelling by attenuating the inflammatory response. (J Trauma Acute Care Surg. 2012;73: 1461-1470. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Alam, Hasan B.] Univ Michigan Hosp, Taubman Ctr 2920, Dept Surg, Ann Arbor, MI 48109 USA; [Jin, Guang; Duggan, Michael; Imam, Ayesha; deMoya, Marc A.; Hwabejire, John; Jepsen, Cecilie H.; Liu, Baoling; Mejaddam, Ali Y.; Lu, Jennifer; Smith, William Michael; Velmahos, George C.; Alam, Hasan B.] Harvard Univ, Sch Med, Dept Surg,Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02115 USA; [Socrate, Simona] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA		Alam, HB (corresponding author), Univ Michigan Hosp, Taubman Ctr 2920, Dept Surg, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu		Sillesen, Martin/0000-0001-9494-5475			Alam HB, 2011, J TRAUMA, V70, P636, DOI 10.1097/TA.0b013e31820d0dcc; Alam HB, 2009, SURGERY, V146, P325, DOI 10.1016/j.surg.2009.04.007; Atmaca A, 2007, BRIT J CANCER, V97, P177, DOI 10.1038/sj.bjc.6603851; Bartfai T, 2007, ANN NY ACAD SCI, V1113, P173, DOI 10.1196/annals.1391.022; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Bourguignon PR, 1998, ARCH SURG-CHICAGO, V133, P390, DOI 10.1001/archsurg.133.4.390; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; Carson MJ, 2006, CLIN NEUROSCI RES, V6, P237, DOI 10.1016/j.cnr.2006.09.004; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Crookes BA, 2004, J TRAUMA, V57, P547, DOI 10.1097/01.TA.0000135162.85859.4C; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Engelhardt B, 2008, J NEUROL SCI, V274, P23, DOI 10.1016/j.jns.2008.05.019; Exo JL, 2009, J NEUROTRAUM, V26, P2403, DOI 10.1089/neu.2009.0980; Fukudome EY, 2010, J SURG RES, V163, P118, DOI 10.1016/j.jss.2010.04.013; Gonzales ER, 2008, J TRAUMA, V65, P554, DOI 10.1097/TA.0b013e31818233ef; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; Ichiyama T, 2000, BRAIN RES, V857, P246, DOI 10.1016/S0006-8993(99)02439-7; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Jin G, 2011, ACTA BIOMATER; Jin G, 2010, TRANSL STROKE RES, V1, P65, DOI 10.1007/s12975-009-0009-5; Jin G, 2011, SURGERY, V150, P429, DOI 10.1016/j.surg.2011.07.001; Jin G, 2009, EXP NEUROL, V217, P165, DOI 10.1016/j.expneurol.2009.02.004; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Kasotakis G, TRAUMATIC BRAIN INJU; Kim K, 2012, RESUSCITATION, V83, P243, DOI 10.1016/j.resuscitation.2011.07.029; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Lheureux PER, 2005, CRIT CARE, V9, P431, DOI 10.1186/cc3742; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Li YQ, 2008, J TRAUMA, V64, P863, DOI 10.1097/TA.0b013e318166b822; Li YQ, 2012, ADV EXP MED BIOL, V710, P107, DOI 10.1007/978-1-4419-5638-5_11; Maekawa K, 1998, J TRAUMA, V44, P460, DOI 10.1097/00005373-199803000-00007; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; McKeating EG, 1998, BRIT J ANAESTH, V80, P77, DOI 10.1093/bja/80.1.77; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Navarro JC, 2012, J NEUROTRAUM, V29, P322, DOI 10.1089/neu.2011.1979; OHTAKI M, 1993, SURG NEUROL, V40, P196, DOI 10.1016/0090-3019(93)90068-C; Peiniger S, 2011, CRIT CARE, V15, DOI 10.1186/cc10048; Rhind SG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-5; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; Shults C, 2008, J TRAUMA, V64, P629, DOI 10.1097/TA.0b013e3181650ff3; Soriano SG, 2008, EUR J ANAESTH, V25, P154, DOI 10.1017/S0265021507003390; Takano K, 1997, STROKE, V28, P1255, DOI 10.1161/01.STR.28.6.1255; TU YK, 1988, J NEUROSURG, V69, P72, DOI 10.3171/jns.1988.69.1.0072; Wang ZF, 2011, J CEREBR BLOOD F MET, V31, P52, DOI 10.1038/jcbfm.2010.195; West MA, 2008, J TRAUMA, V64, P870; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Yu CH, 2011, J VET SCI, V12, P299, DOI 10.4142/jvs.2011.12.3.299; Zhang Z, 2008, CELL MOL LIFE SCI, V65, P4055, DOI 10.1007/s00018-008-8521-4	51	55	55	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	DEC	2012	73	6					1461	1470		10.1097/TA.0b013e3182782641			10	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	058FV	WOS:000312620400017	23188239				2022-02-06	
J	Hollis, SJ; Stevenson, MR; McIntosh, AS; Shores, EA; Finch, CF				Hollis, Stephanie J.; Stevenson, Mark R.; McIntosh, Andrew S.; Shores, E. Arthur; Finch, Caroline F.			Compliance with return-to-play regulations following concussion in Australian schoolboy and community rugby union players	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; INJURY; HEAD; GUIDELINES; MANAGEMENT; SPORT; RISK	Background There is a risk of concussion when playing rugby union. Appropriate management of concussion includes compliance with the return-to-play regulations of the sports body for reducing the likelihood of premature return-to-play by injured players. Purpose To describe the proportion of rugby union players who comply with the sports body's regulations on returning to play postconcussion. Study design Prospective cohort study. Methods 1958 community rugby union players (aged 15-48 years) in Sydney (Australia) were recruited from schoolboy, grade and suburban competitions and followed over >= 1 playing seasons. Club doctors/physiotherapists/coaches or trained injury recorders who attended the game reported players who sustained a concussion. Concussed players were followed up over a 3-month period and the dates when they returned to play (including either a game or training session) were recorded, as well as any return-to-play advice they received. Results 187 players sustained >= 1 concussion throughout the follow-up. The median number of days before players returned to play (competition game play or training) following concussion was 3 (range 1-84). Most players (78%) did not receive return-to-play advice postconcussion, and of those who received correct advice, all failed to comply with the 3-week stand-down regulation. Conclusions The paucity of return-to-play advice received by community rugby union players postconcussion and the high level of non-compliance with return-to-play regulations highlight the need for better dissemination and implementation of the return-to-play regulations and improved understanding of the underlying causes of why players do not adhere to return-toplay practices.	[Hollis, Stephanie J.; Stevenson, Mark R.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia; [Hollis, Stephanie J.] George Inst Global Hlth, Sydney, NSW, Australia; [Stevenson, Mark R.] Monash Univ, Accident Res Ctr, Monash Injury Res Inst, Melbourne, Vic 3004, Australia; [Stevenson, Mark R.] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia; [McIntosh, Andrew S.] Univ New S Wales, Sch Risk & Safety Sci, Sydney, NSW, Australia; [Shores, E. Arthur] Macquarie Univ, Dept Psychol, Sydney, NSW 2109, Australia; [Finch, Caroline F.] Monash Univ, Australian Ctr Res Injury Sport & Its Prevent, Monash Injury Res Inst, Melbourne, Vic 3004, Australia		Hollis, SJ (corresponding author), Univ Sydney, Sydney Med Sch, 25 Nichols Parade, Mt Riverview, NSW 2774, Australia.	shollis@georgeinstitute.org.au	Hollis, Stephanie J/B-5977-2011; stevenson, mark/AAE-9706-2019	stevenson, mark/0000-0003-3166-5876; Shores, Edwin A/0000-0003-1553-5131	International Olympic Committee (IOC); NIH Centres for Disease Prevention and Control; University of Pittsburgh, Pennsylvania, USA; National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia; scholarship from the New South Wales Sporting Injuries Committee; George Institute for Global Health; School of Public Health, The University of Sydney, Australia	The authors thank the New South Wales Sporting Injuries Committee (NSW SIC) for their continued support of new researchers in sports medicine research in Australia and the Australian Centre for Research into Injury in Sport and its Prevention (ACRISP) as one of the International Research Centres for Prevention of Injury and Protection of Athlete Health supported by the International Olympic Committee (IOC).; The main funding for the study was provided by the NIH Centres for Disease Prevention and Control, The University of Pittsburgh, Pennsylvania, USA. The primary author received a National Health and Medical Research Council (NHMRC) postgraduate research scholarship during 2 years of PhD candidature, a scholarship from the New South Wales Sporting Injuries Committee and additional financial support from The George Institute for Global Health and the School of Public Health, The University of Sydney, Australia.	Ackery A, 2009, CAN J NEUROL SCI, V36, P207, DOI 10.1017/S0317167100120281; [Anonymous], 2009, SPSS STAT SOFTW PROG; Australian Rugby Union, ARU MED SAF REC; Beardmore AL, 2005, PHYS THER SPORT, V6, P24, DOI 10.1016/j.ptsp.2004.04.002; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Finch CF, 2010, BRIT J SPORT MED, V44, P973, DOI 10.1136/bjsm.2008.056069; Finch C, 2006, J SCI MED SPORT, V9, P3, DOI 10.1016/j.jsams.2006.02.009; Gardner A, 2010, EVOLUTION, V64, P25, DOI 10.1111/j.1558-5646.2009.00842.x; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hollis SJ, 2009, AM J SPORT MED, V37, P2328, DOI 10.1177/0363546509341032; International Rugby Board (IRB), REG REL GAM; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kelly JP, 1997, NEUROLOGY, V48, P581; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; McIntosh AS, 2010, BRIT J SPORT MED, V44, P188, DOI 10.1136/bjsm.2007.041400; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Twomey D, 2009, J SCI MED SPORT, V12, P452, DOI 10.1016/j.jsams.2008.04.002; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171	24	55	57	0	15	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	AUG	2012	46	10					735	740		10.1136/bjsm.2011.085332			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	985XG	WOS:000307303200013	21705397				2022-02-06	
J	Olson, SD; Pollock, K; Kambal, A; Cary, W; Mitchell, GM; Tempkin, J; Stewart, H; McGee, J; Bauer, G; Kim, HS; Tempkin, T; Wheelock, V; Annett, G; Dunbar, G; Nolta, JA				Olson, Scott D.; Pollock, Kari; Kambal, Amal; Cary, Whitney; Mitchell, Gaela-Marie; Tempkin, Jeremy; Stewart, Heather; McGee, Jeannine; Bauer, Gerhard; Kim, Hyun Sook; Tempkin, Teresa; Wheelock, Vicki; Annett, Geralyn; Dunbar, Gary; Nolta, Jan A.			Genetically Engineered Mesenchymal Stem Cells as a Proposed Therapeutic for Huntington's Disease	MOLECULAR NEUROBIOLOGY			English	Article						Human mesenchymal stem cells; Neurite outgrowth; Neurodegenerative diseases; Hypoxia; Tissue repair; Huntington's disease; Clinical trials; BDNF	AMYOTROPHIC-LATERAL-SCLEROSIS; SPONTANEOUS MALIGNANT-TRANSFORMATION; IMMUNE-DEFICIENT MICE; SPINAL-CORD-INJURY; BONE-MARROW; STROMAL CELLS; NEUROTROPHIC FACTOR; MULTIPLE-SCLEROSIS; MOUSE MODEL; PROGENITOR CELLS	There is much interest in the use of mesenchymal stem cells/marrow stromal cells (MSC) to treat neurodegenerative disorders, in particular those that are fatal and difficult to treat, such as Huntington's disease. MSC present a promising tool for cell therapy and are currently being tested in FDA-approved phase I-III clinical trials for many disorders. In preclinical studies of neurodegenerative disorders, MSC have demonstrated efficacy, when used as delivery vehicles for neural growth factors. A number of investigators have examined the potential benefits of innate MSC-secreted trophic support and augmented growth factors to support injured neurons. These include overexpression of brain-derived neurotrophic factor and glial-derived neurotrophic factor, using genetically engineered MSC as a vehicle to deliver the cytokines directly into the microenvironment. Proposed regenerative approaches to neurological diseases using MSC include cell therapies in which cells are delivered via intracerebral or intrathecal injection. Upon transplantation, MSC in the brain promote endogenous neuronal growth, encourage synaptic connection from damaged neurons, decrease apoptosis, reduce levels of free radicals, and regulate inflammation. These abilities are primarily modulated through paracrine actions. Clinical trials for MSC injection into the central nervous system to treat amyotrophic lateral sclerosis, traumatic brain injury, and stroke are currently ongoing. The current data in support of applying MSC-based cellular therapies to the treatment of Huntington's disease is discussed.	[Olson, Scott D.; Pollock, Kari; Kambal, Amal; Cary, Whitney; Mitchell, Gaela-Marie; Tempkin, Jeremy; Stewart, Heather; McGee, Jeannine; Bauer, Gerhard; Kim, Hyun Sook; Annett, Geralyn; Nolta, Jan A.] Univ Calif Davis Hlth Syst, Stem Cell Program, Sacramento, CA 95817 USA; [Olson, Scott D.; Pollock, Kari; Kambal, Amal; Cary, Whitney; Mitchell, Gaela-Marie; Tempkin, Jeremy; Stewart, Heather; McGee, Jeannine; Bauer, Gerhard; Kim, Hyun Sook; Annett, Geralyn; Nolta, Jan A.] Univ Calif Davis Hlth Syst, Inst Regenerat Cures, Sacramento, CA 95817 USA; [Tempkin, Teresa; Wheelock, Vicki] Univ Calif Davis Hlth Syst, Dept Neurol, Sacramento, CA 95817 USA; [Kim, Hyun Sook] CHA Univ Sch Med, Dept Neurol, Bundang, South Korea; [Dunbar, Gary] Cent Michigan Univ, Dept Psychol, Mt Pleasant, MI 48859 USA		Nolta, JA (corresponding author), Univ Calif Davis Hlth Syst, Stem Cell Program, 2921 Stockton Blvd,Room 1300, Sacramento, CA 95817 USA.	Jan.nolta@ucdmc.ucdavis.edu		Olson, Scott/0000-0001-8032-3755; Nolta, Jan/0000-0003-4576-8542; Tempkin, Jeremy/0000-0002-1602-6649	California Institute for Regenerative Medicine (CIRM)California Institute for Regenerative Medicine [TR1-01257, DR2-05415]; UC Davis CTSC [2P51RR000169-49]; NIH NHLBIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [1RO1 HL073256-01]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01GM099688, 5P30AG010129-19]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P51RR000169] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL073256] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM099688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010129] Funding Source: NIH RePORTER	Our work on MSC therapy for Huntington's disease and other neurodegenerative disorders is funded by the California Institute for Regenerative Medicine (CIRM) grants no. TR1-01257 (Nolta) and DR2-05415 (Wheelock), UC Davis CTSC pilot project 2P51RR000169-49, CIRM Training Grant to UC Davis, CIRM Bridges to Stem Cell Training Grant to California State University, Sacramento, NIH NHLBI 1RO1 HL073256-01 (Nolta), NIH Director's transformative award 1R01GM099688 (Nolta), 5P30AG010129-19 (DeCarli PI: Olson-Pilot project PI), and philanthropic donors from the HD community including the Roberson family and TeamKJ. We thank the HD patients and their families who provide daily inspiration to our group.	Aizman I, 2009, J NEUROSCI RES, V87, P3198, DOI 10.1002/jnr.22146; Alberch J, 2004, PROG BRAIN RES, V146, P195, DOI 10.1016/S0079-6123(03)46014-7; Altar CA, 1997, NATURE, V389, P856, DOI 10.1038/39885; Amin EM, 2008, NEUROL RES, V30, P1086, DOI 10.1179/174313208X327955; Arregui L, 2011, CELL MOL NEUROBIOL, V31, P1229, DOI 10.1007/s10571-011-9725-y; Bachoud-Levi AC, 2006, LANCET NEUROL, V5, P303, DOI 10.1016/S1474-4422(06)70381-7; Bantubungi K, 2008, MOL CELL NEUROSCI, V37, P454, DOI 10.1016/j.mcn.2007.11.001; Baquet ZC, 2004, J NEUROSCI, V24, P4250, DOI 10.1523/JNEUROSCI.3920-03.2004; Bauer G, 2008, MOL THER, V16, P1308, DOI 10.1038/mt.2008.93; Biglan KM, 2009, MOVEMENT DISORD, V24, P1763, DOI 10.1002/mds.22601; Bonab MM, 2010, IRAN J IMMUNOL, V4, P50; Boudreau RL, 2009, MOL THER, V17, P1053, DOI 10.1038/mt.2009.17; Bruno S, 2009, J AM SOC NEPHROL, V20, P1053, DOI 10.1681/ASN.2008070798; Busch SA, 2011, J NEUROSCI, V31, P944, DOI 10.1523/JNEUROSCI.3566-10.2011; Capoccia BJ, 2009, BLOOD, V113, P5340, DOI 10.1182/blood-2008-04-154567; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Choi YH, 2011, HUM GENE THER, V22, P3, DOI 10.1089/hum.2010.211; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Croft AP, 2009, EXP NEUROL, V216, P329, DOI 10.1016/j.expneurol.2008.12.010; Croll SD, 1999, NEUROSCIENCE, V93, P1491, DOI 10.1016/S0306-4522(99)00296-1; Danielyan L, 2009, EUR J CELL BIOL, V88, P315, DOI 10.1016/j.ejcb.2009.02.001; Dao MA, 1997, STEM CELLS, V15, P443, DOI 10.1002/stem.150443; Delcroix GJR, 2010, BIOMATERIALS, V31, P2105, DOI 10.1016/j.biomaterials.2009.11.084; Delcroix GJR, 2009, BRAIN RES, V1255, P18, DOI 10.1016/j.brainres.2008.12.013; Dey ND, 2010, BEHAV BRAIN RES, V214, P193, DOI 10.1016/j.bbr.2010.05.023; DiFiglia M, 2007, P NATL ACAD SCI USA, V104, P17204, DOI 10.1073/pnas.0708285104; Dryden GW, 2009, EXPERT OPIN BIOL TH, V9, P841, DOI 10.1517/14712590902956615; Edalatmanesh MA, 2010, NEUROL RES, V32, P166, DOI 10.1179/174313209X409025; Gahan PB, 2010, CELL BIOCHEM FUNCT, V28, P529, DOI 10.1002/cbf.1690; Gaura V, 2004, BRAIN, V127, P65, DOI 10.1093/brain/awh003; Gerdes HH, 2008, CURR OPIN CELL BIOL, V20, P470, DOI 10.1016/j.ceb.2008.03.005; Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com; Hardy SA, 2008, CURR STEM CELL RES T, V3, P43; Hare JM, 2009, J AM COLL CARDIOL, V54, P2277, DOI 10.1016/j.jacc.2009.06.055; Harper SQ, 2005, P NATL ACAD SCI USA, V102, P5820, DOI 10.1073/pnas.0501507102; Im W., 2010, PLOS CURR, V2; Jiang YF, 2011, NEUROL RES, V33, P331, DOI 10.1179/016164110X12816242542571; Josse C, 2010, STEM CELLS DEV, V19, P1167, DOI 10.1089/scd.2009.0264; Joyce N, 2010, REGEN MED, V5, P933, DOI 10.2217/RME.10.72; KARUSSIS D, 2010, MULTIPLE SCLEROSIS A; Karussis D, 2008, J NEUROL SCI, V265, P131, DOI 10.1016/j.jns.2007.05.005; Karussis D, 2010, ARCH NEUROL-CHICAGO, V67, P1187, DOI 10.1001/archneurol.2010.248; Kassis I, 2008, ARCH NEUROL-CHICAGO, V65, P753, DOI 10.1001/archneur.65.6.753; Kebriaei P, 2011, CYTOTHERAPY, V13, P262, DOI 10.3109/14653249.2010.549688; Kidd S, 2008, CYTOTHERAPY, V10, P657, DOI 10.1080/14653240802486517; Kidd S, 2009, STEM CELLS, V27, P2614, DOI 10.1002/stem.187; Kim HJ, 2009, STEM CELLS, V27, P390, DOI 10.1634/stemcells.2007-1047; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Laflamme MA, 2005, NAT BIOTECHNOL, V23, P845, DOI 10.1038/nbt1117; Le Blanc K, 2006, CYTOTHERAPY, V8, P559, DOI 10.1080/14653240601045399; Lee ST, 2009, ANN NEUROL, V66, P671, DOI 10.1002/ana.21788; Lescaudron L, 2003, INT J NEUROSCI, V113, P945, DOI 10.1080/00207450390207759; Liang J, 2009, MULT SCLER J, V15, P644, DOI 10.1177/1352458509104590; Lin YT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022924; Lombardi MS, 2009, EXP NEUROL, V217, P312, DOI 10.1016/j.expneurol.2009.03.004; Matthay MA, 2010, CHEST, V138, P965, DOI 10.1378/chest.10-0518; Mays RW, 2007, EXPERT OPIN BIOL TH, V7, P173, DOI 10.1517/14712598.7.2.173; Mazzini L, 2003, AMYOTROPH LATERAL SC, V4, P158, DOI 10.1080/14660820310014653; Mazzini L, 2010, EXP NEUROL, V223, P229, DOI 10.1016/j.expneurol.2009.08.007; Meyerrose T, 2006, ESTABLISHMENT TRANSD; Meyerrose T, 2010, ADV DRUG DELIVER REV, V62, P1167, DOI 10.1016/j.addr.2010.09.013; Meyerrose TE, 2008, STEM CELLS, V26, P1713, DOI 10.1634/stemcells.2008-0008; Meyerrose TE, 2007, STEM CELLS, V25, P220, DOI 10.1634/stemcells.2006-0243; Montzka K, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-16; Morita E, 2008, EXP NEUROL, V213, P431, DOI 10.1016/j.expneurol.2008.07.011; Munoz JR, 2005, P NATL ACAD SCI USA, V102, P18171, DOI 10.1073/pnas.0508945102; Murphy JM, 2003, ARTHRITIS RHEUM-US, V48, P3464, DOI 10.1002/art.11365; Newman Robert E., 2009, Inflammation & Allergy Drug Targets, V8, P110; NOLTA JA, 1994, BLOOD, V83, P3041, DOI 10.1182/blood.V83.10.3041.3041; NOLTA JA, 1990, HUM GENE THER, V1, P257, DOI 10.1089/hum.1990.1.3-257; Nolta JA, 1996, P NATL ACAD SCI USA, V93, P2414, DOI 10.1073/pnas.93.6.2414; Nolta JA., 2006, GENETIC ENG MESENCHY; Olson SD, 2011, MOL NEUROLO IN PRESS; Paulsen JS, 2006, BIOL PSYCHIAT, V59, P57, DOI 10.1016/j.biopsych.2005.06.003; Pfister EL, 2009, CURR BIOL, V19, P774, DOI 10.1016/j.cub.2009.03.030; Quesenberry PJ, 2008, STEM CELL REV, V4, P137, DOI 10.1007/s12015-008-9036-y; Ratajczak J, 2006, LEUKEMIA, V20, P847, DOI 10.1038/sj.leu.2404132; Rosland GV, 2009, CANCER RES, V69, P5331, DOI 10.1158/0008-5472.CAN-08-4630; Rosova I, 2008, STEM CELLS, V26, P2173, DOI 10.1634/stemcells.2007-1104; Rossignol J, 2011, BEHAV BRAIN RES, V217, P369, DOI 10.1016/j.bbr.2010.11.006; Rossignol J, 2009, J CELL MOL MED, V13, P2547, DOI 10.1111/j.1582-4934.2009.00657.x; Saccardi R, 2006, MULT SCLER, V12, P814, DOI 10.1177/1352458506071301; Sadan O, 2008, STEM CELLS, V26, P2542, DOI 10.1634/stemcells.2008-0240; Sadan O, 2009, ISR MED ASSOC J, V11, P201; Satija NK, 2009, J CELL MOL MED, V13, P4385, DOI 10.1111/j.1582-4934.2009.00857.x; Sharp J, 2009, NEUROSCI LETT, V456, P107, DOI 10.1016/j.neulet.2008.04.106; Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007; Skinner AM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006219; Spees JL, 2006, P NATL ACAD SCI USA, V103, P1283, DOI 10.1073/pnas.0510511103; Spitkovsky D, 2008, MINIM INVASIV THER, V17, P79, DOI 10.1080/13645700801969758; Taylor DD, 2011, SEMIN IMMUNOPATHOL, V33, P441, DOI 10.1007/s00281-010-0234-8; Ting AE, 2008, CRIT REV ONCOL HEMAT, V65, P81, DOI 10.1016/j.critrevonc.2007.09.007; Torsvik A, 2010, CANCER RES, V70, P6393, DOI 10.1158/0008-5472.CAN-10-1305; Tsark EC, 2001, J IMMUNOL, V166, P170, DOI 10.4049/jimmunol.166.1.170; Venkataramana NK, 2010, TRANSL RES, V155, P62, DOI 10.1016/j.trsl.2009.07.006; Vercelli A, 2008, NEUROBIOL DIS, V31, P395, DOI 10.1016/j.nbd.2008.05.016; Wang XL, 2003, BLOOD, V101, P4201, DOI 10.1182/blood-2002-05-1338; Wang YL, 2005, NEUROSCI RES, V53, P241, DOI 10.1016/j.neures.2005.06.021; Watts C, 2000, CELL TRANSPLANT, V9, P65, DOI 10.1177/096368970000900109; Wilkins A, 2011, STEM CELL RES; Wright KT, 2011, STEM CELLS, V29, P169, DOI 10.1002/stem.570; Wu GD, 2003, TRANSPLANTATION, V75, P679, DOI 10.1097/01.TP.0000048488.35010.95; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126; Zhang Y, 2009, J NEUROCHEM, V108, P82, DOI 10.1111/j.1471-4159.2008.05734.x; Zhang ZX, 2008, CYTOTHERAPY, V10, P134, DOI 10.1080/14653240701883061; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581; Zuccato C, 2007, PROG NEUROBIOL, V81, P294, DOI 10.1016/j.pneurobio.2007.01.003; Zuccato C, 2010, PHYSIOL REV, V90, P905, DOI 10.1152/physrev.00041.2009; Zuccato C, 2009, NAT REV NEUROL, V5, P311, DOI 10.1038/nrneurol.2009.54	109	55	58	0	29	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	FEB	2012	45	1					87	98		10.1007/s12035-011-8219-8			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	879YN	WOS:000299370800007	22161544	hybrid, Green Submitted, Green Published			2022-02-06	
J	Egea-Guerrero, JJ; Revuelto-Rey, J; Murillo-Cabezas, F; Munoz-Sanchez, MA; Vilches-Arenas, A; Sanchez-Linares, P; Dominguez-Roldan, JM; Leon-Carrion, J				Egea-Guerrero, J. J.; Revuelto-Rey, J.; Murillo-Cabezas, F.; Munoz-Sanchez, M. A.; Vilches-Arenas, A.; Sanchez-Linares, P.; Dominguez-Roldan, J. M.; Leon-Carrion, J.			Accuracy of the S100 beta protein as a marker of brain damage in traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; S100 beta protein; CT scan; biomarkers; brain damage	MINOR HEAD-INJURY; NEURON-SPECIFIC ENOLASE; COMPUTED-TOMOGRAPHY; S100B LEVELS; SERUM S100B; S-100B; BIOMARKER; ELIMINATION; MANAGEMENT; TAU	Introduction: This study tested the hypothesis that S100 beta is a useful screening tool for detecting intracranial lesion (IL) in patients with a normal level of consciousness after traumatic brain injury (TBI). Methods: One hundred and forty-three post-TBI patients without a decrease in consciousness (GCS = 15) and with at least one neurological symptom (e.g. transitory loss of consciousness, amnesia, headache, dizziness or vomiting) were prospectively included. A blood sample was drawn at 6-hours post-TBI. A routine CT scan was obtained within 24 hours post-injury. Diagnostic properties of S100 beta for IL prediction in CT scan findings were tested using ROC-analysis. Results: A total of 15 patients (10.5%) had IL. Serum levels were significantly higher in these patients. Significant differences were found between S100 beta levels and CT scan findings (p = 0.007). ROC-analysis showed that S100 beta is a useful tool for detecting the presence of IL in CT scans (p = 0.007). In this series, the best cut-off for S100 beta is 0.130 mu g L(-1), with 100% sensitivity and 32.81% specificity. Conclusion: Within the first 6 hours post-TBI, serum S100 beta seems to be an effective biochemical indicator of IL in patients without a decrease in consciousness. These results indicate that higher S100 beta cut-off values substantially improve the clinical relevance of this protein.	[Egea-Guerrero, J. J.; Revuelto-Rey, J.; Murillo-Cabezas, F.; Dominguez-Roldan, J. M.] Virgen Rocio Univ Hosp, NeuroCrit Care Unit, Seville 41013, Spain; [Munoz-Sanchez, M. A.] Virgen Rocio Univ Hosp, Emergency Dept, Seville 41013, Spain; [Vilches-Arenas, A.] Univ Seville, Dept Stat, Seville, Spain; [Sanchez-Linares, P.] Virgen Rocio Univ Hosp, Dept Med Biochem, Seville 41013, Spain; [Leon-Carrion, J.] Univ Seville, Human Neuropsychol Lab, Seville, Spain; [Leon-Carrion, J.] Ctr Brain Injury Rehabil CRECER, Seville, Spain		Egea-Guerrero, JJ (corresponding author), Virgen Rocio Univ Hosp, NeuroCrit Care Unit, Avda Manuel Siurot S-N, Seville 41013, Spain.	juanj.egea.sspa@juntadeandalucia.es	Murillo-Cabezas, Francisco/AAO-3348-2021; Dominguez-Roldan, Jose-Maria/M-1728-2016; Vilches-Arenas, Angel/C-1167-2015; Egea-Guerrero, Juan Jose JJ/P-5080-2014; IBIS, NEUROCRITICOS/C-1805-2016	Dominguez-Roldan, Jose-Maria/0000-0003-1933-1478; Vilches-Arenas, Angel/0000-0003-2197-3760; Egea-Guerrero, Juan Jose JJ/0000-0002-4166-313X; Revuelto-Rey, Jaume/0000-0001-8350-9555			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Beaudeux JL, 1999, ANN BIOL CLIN-PARIS, V57, P261; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2004, UNFALLCHIRURG, V107, P197, DOI 10.1007/s00113-004-0730-1; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Murillo-Cabezas F, 2010, BRAIN INJURY, V24, P609, DOI 10.3109/02699051003652823; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7	23	55	58	0	19	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2012	26	1					76	82		10.3109/02699052.2011.635360			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	858HY	WOS:000297787900008	22149446				2022-02-06	
J	Mayers, LB; Redick, TS				Mayers, Lester B.; Redick, Thomas S.			Clinical utility of ImPACT assessment for postconcussion return-to-play counseling: Psychometric issues	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Athlete; Concussion; Neuropsychological testing; Reliability; Validity	TEST-RETEST RELIABILITY; LONG-TERM; NEUROCOGNITIVE PERFORMANCE; CONCUSSION ASSESSMENT; SPORTS CONCUSSION; PROCESSING SPEED; HIGH-SCHOOL; RECOVERY; MANAGEMENT; STATEMENT	Computerized neuropsychological testing is commonly utilized in the management of sport-related concussion. In particular, the Immediate Postconcussion Assessment and Cognitive Testing 2.0 program (ImPACT) is widely used to assess the cognitive functioning of athletes before and after a concussion. We review the evidence for the clinical utility of this program in terms of validity, reliability, and use in return-to-play decisions. We conclude that the empirical evidence does not support the use of ImPACT testing for determining the time of postconcussion return to play.	[Mayers, Lester B.] Pace Univ, Div Sports Med, Athlet Dept, Pleasantville, NY 10570 USA; [Redick, Thomas S.] Indiana Univ Purdue Univ, Div Sci, Columbus, IN USA		Mayers, LB (corresponding author), Pace Univ, Div Sports Med, Athlet Dept, 861 Bedford Rd, Pleasantville, NY 10570 USA.	lmayers@pace.edu	Redick, Thomas S/P-2027-2015				Ashare AB, 2009, ACTA PAEDIATR, V98, P774, DOI 10.1111/j.1651-2227.2009.01300.x; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Brown CN, 2007, J ATHL TRAINING, V42, P515; Campbell DT., 1963, EXPT QUASI EXPT DESI; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Iverson G, 2002, ARCH CLIN NEUROPSYCH, V17, P769; Iverson G. L., 2003, 23 ANN C NAT AC NEUR; Iverson G.L., 2011, IMMEDIATE POSTCONCUS; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Kirkwood MW, 2009, ACTA PAEDIATR, V98, P1409, DOI 10.1111/j.1651-2227.2009.01448.x; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Mayers L, 2008, ARCH NEUROL-CHICAGO, V65, P1158, DOI 10.1001/archneur.65.9.1158; Mayers LB, 2011, J CLIN EXP NEUROPSYC, V33, P532, DOI 10.1080/13803395.2010.535506; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; MURPHY KR, 1998, PSYCHOL TESTING PRIN; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2006, APPL NEUROPSYCHOL, V13, P151, DOI 10.1207/s15324826an1303_2; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schwarz A, 2009, NY TIMES, pB10; Shuttleworth-Rdwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P511, DOI 10.1016/j.acn.2008.05.002; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Urbina S, 1997, PSYCHOL TESTING; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	45	55	55	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2012	34	3					235	242		10.1080/13803395.2011.630655			8	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	916EE	WOS:000302080100002	22149547				2022-02-06	
J	Cooper, DB; Nelson, L; Armistead-Jehle, P; Bowles, AO				Cooper, Douglas B.; Nelson, Lonnie; Armistead-Jehle, Patrick; Bowles, Amy O.			Utility of the Mild Brain Injury Atypical Symptoms Scale as a Screening Measure for Symptom Over-Reporting in Operation Enduring Freedom/Operation Iraqi Freedom Service Members with Post-Concussive Complaints	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Mild traumatic brain injury; Post-concussion syndrome; Posttraumatic stress disorder; Symptom over-reporting	POSTTRAUMATIC-STRESS-DISORDER; MMPI-2 VALIDITY SCALES; COMBAT VETERANS; COMPENSATION-SEEKING; POSTCONCUSSIVE SYMPTOMS; PSYCHOMETRIC PROPERTIES; PTSD CHECKLIST; EXAGGERATION; PERFORMANCE; RBS	Evaluation of post-deployment conditions such as post-concussive syndrome (PCS) and posttraumatic stress disorder (PTSD) frequently relies upon brief, self-report checklists which are face valid and highly susceptible to potential symptom validity issues such as symptom exaggeration. We investigated the psychometric prope1rties of a 5-item measure of symptom exaggeration (mild brain injury atypical symptoms [mBIAS] scale) embedded in commonly used PCS and PTSD screening instruments in a sample of 403 patients seen in a brain injury clinic at a large military medical center. Exploratory factor analysis, examining measures of posttraumatic stress, post-concussive symptoms, and symptom over-reporting revealed a 6-factor model with the mBIAS scale items representing a unique factor. Analysis of psychometric properties demonstrated that a score of 8 on the mBIAS was optimal for the detection of symptom over-reporting (sensitivity = 0.94, specificity = 0.92) and appears to be the most favorable cut score for interpretive use. The findings provide a strong initial support for the use of the mBIAS in post-deployment populations.	[Cooper, Douglas B.] Brooke Army Med Ctr, Traumat Brain Injury Serv, Dept Orthoped & Rehabil, MCHE DOR TBI, Ft Sam Houston, TX 78234 USA; [Nelson, Lonnie] Def & Vet Brain Injury Ctr, Washington, DC USA		Cooper, DB (corresponding author), Brooke Army Med Ctr, Traumat Brain Injury Serv, Dept Orthoped & Rehabil, MCHE DOR TBI, 3851 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.	douglas.b.cooper@us.army.mil	Armistead-Jehle, Patrick/AAU-5741-2020	Armistead-Jehle, Patrick/0000-0002-6784-1432			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; BENPORATH YS, 2008, MMPI 2 RF MINN MULT; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; BUTCHER JN, 2001, MMPI 2 MAN ADM SCOR; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Casscells SW, 2007, CONSOLIDATION TRAUMA; CICCERONE K, 1995, J HEAD TRAUMA REHAB, V10, P1; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; *DEF VET BRAIN INJ, 2008, OP IR FREED OIF OP E; DELIS DC, 2007, ARCH CLIN NEUROPSYCH, V24, P145; DeViva JC, 2003, J TRAUMA STRESS, V16, P503, DOI 10.1023/A:1025766713188; Engel CC, 2006, CNS SPECTRUMS, V11, P187, DOI 10.1017/S1092852900014358; Freeman T, 2008, PSYCHIAT RES, V158, P374, DOI 10.1016/j.psychres.2007.04.002; Frueh BC, 2000, CLIN PSYCHOL REV, V20, P853, DOI 10.1016/S0272-7358(99)00015-X; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Gervais RO, 2010, ARCH CLIN NEUROPSYCH, V25, P274, DOI 10.1093/arclin/acq018; Gold PB, 1999, J NERV MENT DIS, V187, P680, DOI 10.1097/00005053-199911000-00005; Green P., 2003, GREENS WORD MEMORY T; Green P, 2004, GREENS MED SYMPTOM V; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Interian A, 2004, PSYCHOSOM MED, V66, P141, DOI 10.1097/01.PSY.0000107883.14385.EC; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; Labbate LA, 1998, PSYCHOTHER PSYCHOSOM, V67, P275, DOI 10.1159/000012292; McCrea M., 2008, MILD TRAUMATIC BRAIN; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; *PASW, 2010, COMP SOFTW; ROGERS R, 1992, STRUCTED INTERVIEW R; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Smith DW, 1996, PSYCHOL ASSESSMENT, V8, P3, DOI 10.1037/1040-3590.8.1.3; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; Whitney KA, 2008, ARCH CLIN NEUROPSYCH, V23, P777, DOI 10.1016/j.acn.2008.09.001	38	55	55	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	DEC	2011	26	8					718	727		10.1093/arclin/acr070			10	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	849UX	WOS:000297151900003	21873326	Bronze			2022-02-06	
J	Xiong, Y; Zhang, YL; Mahmood, A; Meng, YL; Qu, CS; Chopp, M				Xiong, Ye; Zhang, Yanlu; Mahmood, Asim; Meng, Yuling; Qu, Changsheng; Chopp, Michael			Erythropoietin Mediates Neurobehavioral Recovery and Neurovascular Remodeling Following Traumatic Brain Injury in Rats by Increasing Expression of Vascular Endothelial Growth Factor	TRANSLATIONAL STROKE RESEARCH			English	Article						Angiogenesis; Erythropoietin; Neurogenesis; Traumatic brain injury; Vascular endothelial growth factor	FUNCTIONAL RECOVERY; ENHANCES NEUROGENESIS; PROGENITOR CELLS; SPATIAL MEMORY; ANGIOGENESIS; RECEPTOR; STROKE; VEGF; PROTECTION; NEUROPROTECTION	Erythropoietin (EPO) improves functional recovery after traumatic brain injury (TBI). Here, we investigated the role of vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2) on EPO-induced therapeutic efficacy in rats after TBI. Young male Wistar rats were subjected to unilateral controlled cortical impact injury and then infused intracerebroventricularly with either a potent selective VEGFR2 inhibitor SU5416 or vehicle dimethyl sulfoxide. Animals from both groups received delayed EPO treatment (5,000 U/kg in saline) administered intraperitoneally daily at 1, 2, and 3 days post-injury. TBI rats treated with saline administered intraperitoneally daily at 1, 2, and 3 days post-injury served as EPO treatment controls. 5-Bromo-2'-deoxyuridine was administered to label dividing cells. Spatial learning and sensorimotor function were assessed using a modified Morris water maze test and modified neurological severity score, respectively. Animals were sacrificed at 4 days post-injury for measurement of VEGF and VEGFR2 or 35 days post-injury for evaluation of cell proliferation, angiogenesis, and neurogenesis. EPO treatment promoted sensorimotor and cognitive functional recovery after TBI. EPO treatment increased brain VEGF expression and phosphorylation of VEGFR2. EPO significantly increased cell proliferation, angiogenesis, and neurogenesis in the dentate gyrus after TBI. Compared to the vehicle, SU5416 infusion significantly inhibited phosphorylation of VEGFR2, cell proliferation, angiogenesis, and neurogenesis as well as abolished functional recovery in EPO-treated TBI rats. These findings indicate the VEGF/VEGFR2 activation plays an important role in EPO-mediated neurobehavioral recovery and neurovascular remodeling after TBI.	[Xiong, Ye; Zhang, Yanlu; Mahmood, Asim; Meng, Yuling; Qu, Changsheng] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI 48309 USA		Xiong, Y (corresponding author), Henry Ford Hosp, Dept Neurosurg, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	yxiong1@hfhs.org		Xiong, Ye/0000-0001-9770-6031	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS62002, PO1 NS023393]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1 NS62002, PO1 NS023393]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS062002, P01NS023393] Funding Source: NIH RePORTER	This work was supported by NIH grants RO1 NS62002 to Y. Xiong and PO1 NS023393 to M. Chopp. Special thanks to Ms. Susan MacPhee-Gray for editorial assistance.; This study was financially supported by NINDS grants RO1 NS62002 (Ye Xiong) and PO1 NS023393 (Michael Chopp).	Arai K, 2009, FEBS J, V276, P4644, DOI 10.1111/j.1742-4658.2009.07176.x; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Beck H, 2009, ACTA NEUROPATHOL, V117, P481, DOI 10.1007/s00401-009-0483-6; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Byts Nadiya, 2009, Exp Transl Stroke Med, V1, P4, DOI 10.1186/2040-7378-1-4; Cerami A, 2001, SEMIN HEMATOL, V38, P33, DOI 10.1053/shem.2001.27484; Chen Jieli, 2006, NeuroRx, V3, P466, DOI 10.1016/j.nurx.2006.07.007; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2004, BRAIN RES, V1005, P21, DOI 10.1016/j.brainres.2003.11.080; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Chopp M, 2007, STROKE, V38, P827, DOI 10.1161/01.STR.0000250235.80253.e9; Clausen F, 2005, NEUROSURGERY, V57, P154, DOI 10.1227/01.NEU.0000163412.07546.57; Cotena S, 2008, PANMINERVA MED, V50, P185; Davis A E, 2000, Crit Care Nurs Q, V23, P1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dore-Duffy P, 2007, NEUROL RES, V29, P395, DOI 10.1179/016164107X204729; Fong TAT, 1999, CANCER RES, V59, P99; Gonzalez FF, 2007, DEV NEUROSCI-BASEL, V29, P321, DOI 10.1159/000105473; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Grasso G, 2009, NEUROSURGERY, V65, P763, DOI 10.1227/01.NEU.0000347475.73347.5F; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; Hansen TM, 2008, CURR NEUROVASC RES, V5, P236, DOI 10.2174/156720208786413433; Itokawa T, 2002, MOL CANCER THER, V1, P295; Iwai M, 2007, STROKE, V38, P2795, DOI 10.1161/STROKEAHA.107.483008; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Lee C, 2009, EXP NEUROL, V220, P400, DOI 10.1016/j.expneurol.2009.08.019; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Li L, 2007, BRAIN RES, V1132, P185, DOI 10.1016/j.brainres.2006.10.098; Lin B, 2001, J NEUROTRAUM, V18, P389, DOI 10.1089/089771501750170958; Liu ZW, 2011, STROKE, V42, P740, DOI 10.1161/STROKEAHA.110.607226; Liu ZW, 2009, STROKE, V40, P2546, DOI 10.1161/STROKEAHA.109.547265; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu KT, 2011, J NEUROTRAUM, V28, P441, DOI 10.1089/neu.2010.1473; Madri JA, 2009, J PHYSIOL PHARMACOL, V60, P95; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Mendel DB, 2000, CLIN CANCER RES, V6, P4848; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Morris DC, 2010, NEUROSCIENCE, V169, P674, DOI 10.1016/j.neuroscience.2010.05.017; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ning RZ, 2011, BRAIN RES, V1384, P140, DOI 10.1016/j.brainres.2011.01.099; Noguchi Constance Tom, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000860; Qu CS, 2011, BRAIN RES, V1371, P129, DOI 10.1016/j.brainres.2010.10.088; Rabie T, 2008, PHYSIOLOGY, V23, P263, DOI 10.1152/physiol.00016.2008; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Skold MK, 2006, EUR J NEUROSCI, V23, P21, DOI 10.1111/j.1460-9568.2005.04527.x; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006; Velly L, 2010, PHARMACOL THERAPEUT, V128, P445, DOI 10.1016/j.pharmthera.2010.08.002; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang L, 2008, J CEREBR BLOOD F MET, V28, P1361, DOI 10.1038/jcbfm.2008.32; Wang L, 2007, J BIOL CHEM, V282, P32462, DOI 10.1074/jbc.M706880200; Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Xiong Y, 2011, J NEUROSURG, V114, P102, DOI 10.3171/2010.4.JNS10118; Xiong Y, 2011, J NEUROSURG, V114, P549, DOI 10.3171/2010.10.JNS10925; Xiong Y, 2010, DISCOV MED, V10, P434; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Xiong Y, 2010, J NEUROTRAUM, V27, P205, DOI 10.1089/neu.2009.1001; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhang YL, 2009, BRAIN RES, V1294, P153, DOI 10.1016/j.brainres.2009.07.077	74	55	58	2	15	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	DEC	2011	2	4			SI		619	632		10.1007/s12975-011-0120-2			14	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	943YJ	WOS:000304163700019	22707988	Green Accepted			2022-02-06	
J	Schonberger, M; Ponsford, J; Olver, J; Ponsford, M; Wirtz, M				Schoenberger, Michael; Ponsford, Jennie; Olver, John; Ponsford, Michael; Wirtz, Markus			Prediction of functional and employment outcome 1 year after traumatic brain injury: a structural equation modelling approach	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							REHABILITATION; ASSOCIATION; MULTICENTER; DEPRESSION; VALIDATION; DURATION; RETURN; STATE	Background Traumatic brain injury (TBI) can cause lasting functional changes and lead to unemployment. The purpose of this study was to create and test a structural equation model (SEM) of the prediction of functional and employment outcome after TBI. Methods Participants were 949 individuals with predominantly moderate to severe TBI (74% males, median age 25.7 years) who attended a follow-up interview 1 year post-injury. Outcome (employment and mood, cognitive and behavioural changes) was measured using the Structured Outcome Questionnaire. An SEM, based on existing research, was developed, tested and modified. Results A comparative fit index of 0.99 and a root mean square error of approximation of 0.03 supported the fit of the final model. Age, education, pre-injury employment, injury severity and limb injuries were direct predictors of employment outcome. Gender, pre-injury psychiatric disorders and limb injuries were related to employment outcome by their association with mood, cognitive and behavioural changes. Conclusions The results demonstrate the complex interplay between various factors predicting outcome after TBI and provide evidence for the importance of tailoring rehabilitation to the individual's needs. Further research, including other conditions, can build on this model and include additional predictor and outcome measures.	[Schoenberger, Michael] Univ Freiburg, Inst Psychol, Dept Rehabil Psychol, D-79106 Freiburg, Germany; [Schoenberger, Michael; Ponsford, Jennie] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Schoenberger, Michael; Ponsford, Jennie; Olver, John; Ponsford, Michael] Epworth Med Fdn, Monashe Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia; [Wirtz, Markus] Univ Educ, Freiburg, Germany		Schonberger, M (corresponding author), Univ Freiburg, Inst Psychol, Dept Rehabil Psychol, Engelberger Str 41, D-79106 Freiburg, Germany.	michael.schoenberger@psychologie.uni-freiburg.de	Wirtz, Markus Antonius/AAA-5565-2021	Wirtz, Markus Antonius/0000-0002-9392-0484; Olver, John/0000-0001-7069-1191	Victorian Transport Accident Commission; Victorian Neurotrauma Initiative	The study was funded by the Victorian Transport Accident Commission and the Victorian Neurotrauma Initiative.	ABS, 2001, AUSTR SOC TRENDS; *ABS, 2007, AUSTR SOC TRENDS; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Boomsma A, 2000, STRUCT EQU MODELING, V7, P461, DOI 10.1207/S15328007SEM0703_6; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; *ED EMPL OECD COUN, 2008, UNESCO INT I ED PLAN; Ferguson SD, 2009, J PERS DISORD, V23, P230, DOI 10.1521/pedi.2009.23.3.230; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; Kelly G, 2008, BRAIN INJURY, V22, P457, DOI 10.1080/02699050802060647; Kline R.B., 2005, PRINCIPLES PRACTICE, V2nd; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; *OECD, 2006, IMPR INC WORK OECD; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Soo CA, 2007, BRAIN IMPAIR, V8, P101, DOI DOI 10.1375/BRIM.8.2.101; Ullman J. B., 2007, USING MULTIVARIATE S; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Walker WC, 2010, J NEUROL NEUROSUR PS, V81, P87, DOI 10.1136/jnnp.2008.161570; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; World Health Organisation, 2001, WORLD HLTH REP MENT; Zasler ND, 1997, ARCH PHYS MED REHAB, V78, pS12, DOI 10.1016/S0003-9993(97)90150-7	36	55	55	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2011	82	8					936	941		10.1136/jnnp.2010.210021			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	789TE	WOS:000292538400070	21217165				2022-02-06	
J	Simpson, GK; Tate, RL; Whiting, DL; Cotter, RE				Simpson, Grahame K.; Tate, Robyn L.; Whiting, Diane L.; Cotter, Rachel E.			Suicide Prevention After Traumatic Brain Injury: A Randomized Controlled Trial of a Program for the Psychological Treatment of Hopelessness	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						hopelessness; randomized controlled trial; suicide ideation; suicide prevention; traumatic brain injury	EVENTUAL SUICIDE; POSTTRAUMATIC GROWTH; PROTECTIVE FACTORS; HOSPITAL ANXIETY; SELF-ESTEEM; DEPRESSION; ASSOCIATION; THERAPY; PHARMACOTHERAPY; INDIVIDUALS	Objective: To evaluate the efficacy of a psychological treatment to reduce moderate to severe hopelessness after severe traumatic brain injury (TBI). Method: Randomized controlled trial. Participants were aged between 18 and 65 years, experienced posttraumatic amnesia more than 1day and moderate to severe hopelessness (Beck Hopelessness Scale [BHS]) and/or suicide ideation. Intervention comprised a 20-hour manualized group cognitive behavior therapy program. Participants were randomly allocated using concealed allocation (treatment n = 8; wait-list n = 9); all remained in their allocated group. Outcome variables were collected by assessors blind to group allocation. Results: No between-groups differences were observed on demographic, injury, cognitive, and psychosocial variables at baseline (time 1). A significant group-by-time interaction was found for BHS in the treatment group (F-1,F-15 = 13.20, P = .002), reflecting a reduction in mean BHS scores between time 1 and time 2 (posttreatment) with no main effects for group or time. At 3-month follow-up (time 3), the treatment gains were maintained or improved for 75% (6/8) of participants. Secondary outcome variables (suicide ideation, depression, social problem solving, self-esteem, hopefulness) displayed no significant group-by-time interactions or main effects. Conclusions: This trial provides initial evidence for the efficacy of a psychological intervention in reducing hopelessness among long-term survivors with severe TBI.	[Simpson, Grahame K.; Whiting, Diane L.; Cotter, Rachel E.] Liverpool Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia; [Simpson, Grahame K.; Tate, Robyn L.] Univ Sydney, Fac ofMedicine, Rehabil Studies Unit, Sydney, NSW 2006, Australia		Simpson, GK (corresponding author), Brain Injury Rehabil Unit, Locked Bag 7103, Liverpool Bc, NSW 1871, Australia.	grahame.simpson@sswahs.nsw.gov.au	Simpson, Grahame K/W-1074-2019; Whiting, Diane/AAN-2522-2021	Simpson, Grahame K/0000-0001-8156-9060; Whiting, Diane/0000-0003-1912-6626	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [ID 358769]	This project was funded by a National Health and Medical Research Council Health Professional Fellowship grant (ID 358769).	ACHTE KA, 1971, ACTA PSYCHIAT SCAND, P1; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Beck A.T., 1988, MANUAL BECK HOPELESS; BECK AT, 1989, J AFFECT DISORDERS, V17, P203, DOI 10.1016/0165-0327(89)90001-3; BECK AT, 1989, J CONSULT CLIN PSYCH, V57, P309, DOI 10.1037/0022-006X.57.2.309; BECK AT, 1985, AM J PSYCHIAT, V142, P559; Beck AT., 1991, MANUAL BECK SCALE SU; Benton A., 1976, MULTILINGUAL APHASIA; BLACKBURN IM, 1983, BRIT J PSYCHIAT, V143, P609, DOI 10.1192/bjp.143.6.609; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Brenner LA, 2009, REHABIL PSYCHOL, V54, P390, DOI 10.1037/a0017802; Burgess P, 1996, BEHAV ASSESSMENT DYS; Calhoun, 1995, TRAUMA TRANSFORMATIO; D'Zurilla T.J., 2002, SOCIAL PROBLEM SOLVI; Dahlsgaard KK, 1998, SUICIDE LIFE-THREAT, V28, P197; DIXON RA, 1999, COGNITIVE NEUROREHAB; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fergusson D, 2005, BMJ-BRIT MED J, V330, P396, DOI 10.1136/bmj.330.7488.396; GrayLittle B, 1997, PERS SOC PSYCHOL B, V23, P443, DOI 10.1177/0146167297235001; Hawton K, 2000, COCHRANE DB SYST REV, V2; HERTH K, 1992, J ADV NURS, V17, P1251, DOI 10.1111/j.1365-2648.1992.tb01843.x; Hopewell S, 2008, LANCET, V371, P281, DOI 10.1016/S0140-6736(07)61835-2; Jacobs D.G., 2003, PRACTICE GUIDELINE A; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Khan-Bourne N, 2003, NEUROPSYCHOL REHABIL, V13, P89, DOI 10.1080/09602010244000318; Kuipers P, 2000, J HEAD TRAUMA REHAB, V15, P1275, DOI 10.1097/00001199-200012000-00007; LINEHAN MM, 1991, ARCH GEN PSYCHIAT, V48, P1060; Malone KM, 2000, AM J PSYCHIAT, V157, P1084, DOI 10.1176/appi.ajp.157.7.1084; Manchester D, 2001, BRAIN DAM B, P157; McGrath JC, 2006, BRAIN INJURY, V20, P767, DOI 10.1080/02699050600664566; Moher D, 2010, BMJ-BRIT MED J, V340, DOI [10.1136/bmj.c869, 10.1016/j.ijsu.2011.10.001, 10.1016/j.jclinepi.2010.03.004]; MOOREY S, 1991, BRIT J PSYCHIAT, V158, P255, DOI 10.1192/bjp.158.2.255; Nordentoft M, 2002, BRIT J PSYCHIAT, V181, pS98, DOI 10.1192/bjp.181.43.s98; Rosenberg M., 1965, SOC ADOLESCENT SELF; Rosenberg M., 1986, CONCEIVING SELF; RUSH AJ, 1982, AM J PSYCHIAT, V139, P862; SILBER E, 1965, PSYCHOL REP, V16, P1017, DOI 10.2466/pr0.1965.16.3c.1017; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2005, J NERV MENT DIS, V193, P680, DOI 10.1097/01.nmd.0000180743.65943.c8; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; SIMPSON GK, 2001, SUICIDE PREVENTION T; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Soo C, 2007, COCHRANE DB SYST REV, V3; Spreen O, 1991, COMPENDIUM NEUROPSYC; Tabachnik B.G., 1996, USING MULTIVARIATE S, V3rd ed.; Tate RL, 2004, BRAIN IMPAIR, V5, P81, DOI [DOI 10.1375/BRIM.5.1.81.35408, 10.1375/brim.5.1.81.35408, DOI 10.1375/brim.5.1.81.35408]; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Tedeschi RG, 2004, PSYCHOL INQ, V15, P1, DOI 10.1207/s15327965pli1501_01; Tsaousides T, 2011, J HEAD TRAUMA REHAB, V26, P265, DOI 10.1097/HTR.0b013e3182225271; vanderSande R, 1997, ACTA PSYCHIAT SCAND, V96, P43; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Wasserman L, 2008, BRAIN INJURY, V22, P811, DOI 10.1080/02699050802372166; WESCHLER D, 1981, WAIS R MANUAL; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	56	55	55	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2011	26	4					290	300		10.1097/HTR.0b013e3182225250			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	789FZ	WOS:000292501700006	21734512				2022-02-06	
J	Hunt, RF; Scheff, SW; Smith, BN				Hunt, Robert F.; Scheff, Stephen W.; Smith, Bret N.			Synaptic Reorganization of Inhibitory Hilar Interneuron Circuitry after Traumatic Brain Injury in Mice	JOURNAL OF NEUROSCIENCE			English	Article							TEMPORAL-LOBE EPILEPSY; CONTROLLED CORTICAL IMPACT; DENTATE GRANULE CELLS; CA3 PYRAMIDAL CELLS; RAT HIPPOCAMPUS; POSTTRAUMATIC EPILEPSY; STATUS EPILEPTICUS; SOMATOSTATIN INTERNEURONS; IMMUNOREACTIVE NEURONS; GABAERGIC INTERNEURONS	Functional plasticity of synaptic networks in the dentate gyrus has been implicated in the development of posttraumatic epilepsy and in cognitive dysfunction after traumatic brain injury, but little is known about potentially pathogenic changes in inhibitory circuits. We examined synaptic inhibition of dentate granule cells and excitability of surviving GABAergic hilar interneurons 8-13 weeks after cortical contusion brain injury in transgenic mice that express enhanced green fluorescent protein in a subpopulation of inhibitory neurons. Whole-cell voltage-clamp recordings in granule cells revealed a reduction in spontaneous and miniature IPSC frequency after head injury; no concurrent change in paired-pulse ratio was found in granule cells after paired electrical stimulation of the hilus. Despite reduced inhibitory input to granule cells, action potential and EPSC frequencies were increased in hilar GABA neurons from slices ipsilateral to the injury versus those from control or contralateral slices. Furthermore, increased excitatory synaptic activity was detected in hilar GABA neurons ipsilateral to the injury after glutamate photostimulation of either the granule cell or CA3 pyramidal cell layers. Together, these findings suggest that excitatory drive to surviving hilar GABA neurons is enhanced by convergent input from both pyramidal and granule cells, but synaptic inhibition of granule cells is not fully restored after injury. This rewiring of circuitry regulating hilar inhibitory neurons may reflect an important compensatory mechanism, but it may also contribute to network destabilization by increasing the relative impact of surviving individual interneurons in controlling granule cell excitability in the posttraumatic dentate gyrus.	[Smith, Bret N.] Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Scheff, Stephen W.; Smith, Bret N.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA		Smith, BN (corresponding author), Univ Kentucky, Coll Med, Dept Physiol, MS508 Chandler Med Ctr,800 Rose St, Lexington, KY 40536 USA.	bret.smith@uky.edu	Ritter, Stefanie L/D-9312-2012	Hunt, Robert/0000-0003-4490-8718	Epilepsy Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG21981, NS052302]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS052302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER	This work was supported by an Epilepsy Foundation predoctoral fellowship (R. F. H.) and funding from National Institutes of Health Grants AG21981 (S. W. S.) and NS052302 (B.N.S.). Thanks to Dr. Peter Gyarmati for helpful discussion during the preparation of this manuscript.	Acsady L, 1998, J NEUROSCI, V18, P3386; BABB TL, 1989, J NEUROSCI, V9, P2562; BAKST I, 1986, J NEUROSCI, V6, P1452; Bhaskaran MD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010683; Bonifazi P, 2009, SCIENCE, V326, P1419, DOI 10.1126/science.1175509; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Buckmaster PS, 2002, J COMP NEUROL, V445, P360, DOI 10.1002/cne.10183; CALLAWAY EM, 1993, P NATL ACAD SCI USA, V90, P7661, DOI 10.1073/pnas.90.16.7661; Chang BS, 2003, NEW ENGL J MED, V349, P1257, DOI 10.1056/NEJMra022308; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; Cossart R, 2001, NAT NEUROSCI, V4, P52, DOI 10.1038/82900; Dantzker JL, 2000, NAT NEUROSCI, V3, P701, DOI 10.1038/76656; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Doherty J, 2001, J NEUROSCI, V21, P2048, DOI 10.1523/JNEUROSCI.21-06-02048.2001; Dudek FE, 1997, J CLIN NEUROPHYSIOL, V14, P90, DOI 10.1097/00004691-199703000-00002; ESCLAPEZ M, 1995, NEUROSCIENCE, V64, P339, DOI 10.1016/0306-4522(94)00406-U; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Halabisky B, 2006, J NEUROPHYSIOL, V96, P834, DOI 10.1152/jn.01079.2005; Halabisky B, 2010, J NEUROPHYSIOL, V104, P2214, DOI 10.1152/jn.00147.2010; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hirsch JC, 1999, NAT NEUROSCI, V2, P499, DOI 10.1038/9142; Hunt RF, 2010, J NEUROPHYSIOL, V103, P1490, DOI 10.1152/jn.00957.2009; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; JOHANSEN FF, 1987, ACTA NEUROPATHOL, V73, P110, DOI 10.1007/BF00693775; Jones DL, 2007, J NEUROPHYSIOL, V98, P2737, DOI 10.1152/jn.00938.2007; Katona I, 1999, NEUROSCIENCE, V88, P37, DOI 10.1016/S0306-4522(98)00302-9; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; KNEISLER TB, 1995, J PHYSIOL-LONDON, V487, P125, DOI 10.1113/jphysiol.1995.sp020866; Kobayashi M, 2003, J NEUROSCI, V23, P2440; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; LERANTH C, 1990, J COMP NEUROL, V295, P111, DOI 10.1002/cne.902950110; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; Mangin JM, 2008, J NEUROSCI, V28, P7610, DOI 10.1523/JNEUROSCI.1355-08.2008; MATHERN GW, 1995, J NEUROSCI, V15, P3990; Mathew SS, 2008, J NEUROSCI, V28, P725, DOI 10.1523/JNEUROSCI.3625-07.2008; Miles R, 1996, NEURON, V16, P815, DOI 10.1016/S0896-6273(00)80101-4; Morgan RJ, 2008, P NATL ACAD SCI USA, V105, P6179, DOI 10.1073/pnas.0801372105; Mtchedlishvili Z, 2010, NEUROBIOL DIS, V38, P464, DOI 10.1016/j.nbd.2010.03.012; Oliva AA, 2000, J NEUROSCI, V20, P3354, DOI 10.1523/JNEUROSCI.20-09-03354.2000; Patrylo PR, 1998, J NEUROPHYSIOL, V79, P418, DOI 10.1152/jn.1998.79.1.418; PEARCE RA, 1993, NEURON, V10, P189, DOI 10.1016/0896-6273(93)90310-N; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; SCHARFMAN HE, 1990, NEUROSCIENCE, V37, P693, DOI 10.1016/0306-4522(90)90100-I; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shao LR, 2005, J NEUROPHYSIOL, V94, P952, DOI 10.1152/jn.01342.2004; Shibley H, 2002, EPILEPSY RES, V49, P109, DOI 10.1016/S0920-1211(02)00012-8; Sloviter RS, 2003, J COMP NEUROL, V459, P44, DOI 10.1002/cne.10630; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; SOLTESZ I, 1995, NEURON, V14, P1273, DOI 10.1016/0896-6273(95)90274-0; SPENCER WA, 1961, J NEUROPHYSIOL, V24, P272, DOI 10.1152/jn.1961.24.3.272; Sun CS, 2007, J COMP NEUROL, V500, P876, DOI 10.1002/cne.21207; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; Szabadics J, 2001, J NEUROSCI, V21, P5824, DOI 10.1523/JNEUROSCI.21-15-05824.2001; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Toth Z, 1997, J NEUROSCI, V17, P8106; TRAUB RD, 1982, SCIENCE, V216, P745, DOI 10.1126/science.7079735; vandenPol AN, 1996, J NEUROSCI, V16, P4283; Waldbaum S, 2009, EPILEPSIA, V50, P904, DOI 10.1111/j.1528-1167.2008.01939.x; Wendling F, 2002, EUR J NEUROSCI, V15, P1499, DOI 10.1046/j.1460-9568.2002.01985.x; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Wittner L, 2006, EUR J NEUROSCI, V24, P1286, DOI 10.1111/j.1460-9568.2006.04992.x; WONG RKS, 1979, P NATL ACAD SCI USA, V76, P986, DOI 10.1073/pnas.76.2.986; WONG RKS, 1981, J NEUROPHYSIOL, V45, P86, DOI 10.1152/jn.1981.45.1.86; Wuarin JP, 2001, J NEUROPHYSIOL, V85, P1067, DOI 10.1152/jn.2001.85.3.1067; Zhang W, 2009, J NEUROSCI, V29, P14247, DOI 10.1523/JNEUROSCI.3842-09.2009; Zhang W, 2009, J NEUROSCI, V29, P7846, DOI 10.1523/JNEUROSCI.6199-08.2009	72	55	57	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAY 4	2011	31	18					6880	6890		10.1523/JNEUROSCI.0032-11.2011			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	759AO	WOS:000290212100030	21543618	Green Accepted, Bronze, Green Published			2022-02-06	
J	Shi, XQ; Lim, TKY; Lee, S; Zhao, YQ; Zhang, J				Shi, Xiang Qun; Lim, Tony K. Y.; Lee, Seunghwan; Zhao, Yuan Qing; Zhang, Ji			Statins alleviate experimental nerve injury-induced neuropathic pain	PAIN			English	Article						HMG-CoA reductase; Peripheral inflammation; Central inflammation; Cytokines; Glia; Pain behavior	COA REDUCTASE INHIBITORS; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; RAT MODEL; IN-VIVO; ATORVASTATIN; SIMVASTATIN; ROSUVASTATIN; ACTIVATION; THERAPY	The statins are a well-established class of drugs that lower plasma cholesterol levels by inhibiting HMG-CoA (3-hydroxy-3-methyl-glutaryl-coenzyme A) reductase. They are widely used for the treatment of hypercholesterolemia and for the prevention of coronary heart disease. Recent studies suggest that statins have anti-inflammatory effects beyond their lipid-lowering properties. We sought to investigate whether statins could affect neuropathic pain by mediating nerve injury-associated inflammatory responses. The effects of hydrophilic rosuvastatin and lipophilic simvastatin were examined in the mouse partial sciatic nerve ligation model. Systemic daily administration of either statin from days 0 to 14 completely prevented the development of mechanical allodynia and thermal hyperalgesia. When administered from days 8 to 14 after injury, both statins dose-dependently reduced established hypersensitivity. After treatment, the effects of the statins were washed out within 2 to 7 days, depending on dose. Effects of both statins in alleviating mechanical allodynia were further confirmed in a different injury-associated neuropathic pain model, mental nerve chronic constriction, in rats. Both statins were able to abolish interleukin-1 beta expression in sciatic nerve triggered by nerve ligation. Additionally, quantitative analysis with Iba-1 and glial fibrillary acid protein immunoreactivity demonstrated that rosuvastatin and simvastatin significantly reduced the spinal microglial and astrocyte activation produced by sciatic nerve injury. The increase of interleukin-1 beta mRNA in the ipsilateral side of spinal cords was also reduced by the treatment of either statin. We identified a potential new application of statins in the treatment of neuropathic pain. The pain-alleviating effects of statins are likely attributable to their immunomodulatory effects. (C) 2011 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	[Shi, Xiang Qun; Lim, Tony K. Y.; Lee, Seunghwan; Zhao, Yuan Qing; Zhang, Ji] McGill Univ, Alan Edwards Ctr Res Pain, Montreal, PQ, Canada		Zhang, J (corresponding author), McGill Univ, Alan Edwards Ctr Res Pain, 740 Dr Penfield Ave, Montreal, PQ, Canada.	Ji.Zhang@mcgill.ca	Zhang, Ji/L-5922-2019	Lim, Tony/0000-0003-1843-0060	Canadian Institutes for Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [MOP-77624]	The study was supported by Canadian Institutes for Health Research (CIHR) Grant MOP-77624 to J.Z., and the CIHR neuroinflammation training program. T.L. holds a CIHR Frederick Banting and Charles Best Canada Graduate (doctoral) scholarship. J.Z. holds a CIHR new investigator award.	Azkue JJ, 1998, EUR J NEUROSCI, V10, P2204, DOI 10.1046/j.1460-9568.1998.00260.x; Barsante MM, 2005, EUR J PHARMACOL, V516, P282, DOI 10.1016/j.ejphar.2005.05.005; BOWSHER D, 1991, BRIT MED BULL, V47, P644, DOI 10.1093/oxfordjournals.bmb.a072498; Brass LM, 2006, AM J CARDIOL, V97, p86C, DOI 10.1016/j.amjcard.2005.12.017; Brown WV, 2008, CURR OPIN LIPIDOL, V19, P558, DOI 10.1097/MOL.0b013e328319baba; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chello M, 2006, CRIT CARE MED, V34, P660, DOI 10.1097/01.CCM.0000201407.89977.EA; Chong PH, 2004, PHARMACOTHERAPY, V24, P1194, DOI 10.1592/phco.24.13.1194.38084; Clarke RM, 2007, NEUROPHARMACOLOGY, V52, P136, DOI 10.1016/j.neuropharm.2006.07.031; Cordle A, 2005, J NEUROSCI, V25, P299, DOI 10.1523/JNEUROSCI.2544-04.2005; Daglioglu E, 2010, FOLIA NEUROPATHOL, V48, P49; Davidson MH, 2002, EXPERT OPIN INV DRUG, V11, P125, DOI 10.1517/13543784.11.1.125; Davis TME, 2008, DIABETOLOGIA, V51, P562, DOI 10.1007/s00125-007-0919-2; DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301; Echeverry S., 2010, P 13 WORLD C PAIN AU; ENDO A, 1979, BIOCHIM BIOPHYS ACTA, V575, P266; Ferroni P, 2003, CIRCULATION, V108, P1673, DOI 10.1161/01.CIR.0000094732.02060.27; GABAY E, 2010, EUR J PAIN; Gordh T, 2006, PAIN, V124, P211, DOI 10.1016/j.pain.2006.05.020; Graham KL, 2008, ARTHRITIS RHEUM, V58, P2098, DOI 10.1002/art.23605; Grelik C, 2005, EUR J NEUROSCI, V21, P2475, DOI 10.1111/j.1460-9568.2005.04089.x; GRUNDY SM, 1988, NEW ENGL J MED, V319, P24; Han HC, 2000, PAIN, V84, P253; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hemandez-Romero MD, 2008, J NEUROCHEM, V105, P445, DOI 10.1111/j.1471-4159.2007.05148.x; Hu Y, 2009, DIABETES VASC DIS RE, V6, P262, DOI 10.1177/1479164109339966; Inoue K, 2009, GLIA, V57, P1469, DOI 10.1002/glia.20871; Jensen MP, 2007, NEUROLOGY, V68, P1178, DOI 10.1212/01.wnl.0000259085.61898.9e; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Lin CS, 2007, REGION ANESTH PAIN M, V32, P209, DOI 10.1016/j.rapm.2007.01.005; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Malmberg AB, 1998, PAIN, V76, P215, DOI 10.1016/S0304-3959(98)00045-1; Matthews EA, 2001, PAIN, V92, P235, DOI 10.1016/S0304-3959(01)00255-X; Mayanagi K, 2008, J CEREBR BLOOD F MET, V28, P1927, DOI 10.1038/jcbfm.2008.81; McDermott AM, 2006, EUR J PAIN, V10, P127, DOI 10.1016/j.ejpain.2005.01.014; McTaggart F, 2001, AM J CARDIOL, V87, p28B; MERSKEY H, 1994, CLASSIFICATION CHRON, pR11; Mika J, 2010, NEUROSCIENCE, V165, P1420, DOI 10.1016/j.neuroscience.2009.11.064; Mika J, 2007, EUR J PHARMACOL, V560, P142, DOI 10.1016/j.ejphar.2007.01.013; Mix E, 2006, J AUTOIMMUN, V27, P251, DOI 10.1016/j.jaut.2006.09.006; NEZASA K, 2000, ATHEROSCLEROSIS, V151, P39; O'Connor AB, 2009, PHARMACOECONOMICS, V27, P95, DOI 10.2165/00019053-200927020-00002; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pan HC, 2010, NEUROSURGERY, V67, P376, DOI 10.1227/01.NEU.0000371729.47895.A0; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; Reichert F, 1996, EUR J NEUROSCI, V8, P530, DOI 10.1111/j.1460-9568.1996.tb01237.x; SAHEKI A, 1994, PHARMACEUT RES, V11, P305, DOI 10.1023/A:1018975928974; Santodomingo-Garzon T, 2006, BRIT J PHARMACOL, V149, P14, DOI 10.1038/sj.bjp.0706836; Schachter M, 2005, FUND CLIN PHARMACOL, V19, P117, DOI 10.1111/j.1472-8206.2004.00299.x; SELTZER Z, 1990, PAIN, V43, P205, DOI 10.1016/0304-3959(90)91074-S; Smith BH, 2007, CLIN J PAIN, V23, P143, DOI 10.1097/01.ajp.0000210956.31997.89; Torrance N, 2007, FAM PRACT, V24, P481, DOI 10.1093/fampra/cmm042; van der Most PJ, 2009, PROG NEUROBIOL, V88, P64, DOI 10.1016/j.pneurobio.2009.02.002; Waehre T, 2004, CIRCULATION, V109, P1966, DOI 10.1161/01.CIR.0000125700.33637.B1; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Warwick MJ, 2000, ATHEROSCLEROSIS, V151, P39; Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393; Wolf G, 2006, PAIN, V120, P315, DOI 10.1016/j.pain.2005.11.011; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Wu HT, 2010, J NEUROSURG, V113, P591, DOI 10.3171/2009.9.JNS09859; ZHANG J, 2009, FUNCTIONAL PAIN SYND, P319; Zhao SP, 2004, CLIN CHIM ACTA, V344, P195, DOI 10.1016/j.cccn.2004.03.003	63	55	59	2	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	MAY	2011	152	5					1033	1043		10.1016/j.pain.2011.01.006			11	Anesthesiology; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology	749YI	WOS:000289507500015	21414721				2022-02-06	
J	Wu, AG; Ying, Z; Schubert, D; Gomez-Pinilla, F				Wu, Aiguo; Ying, Zhe; Schubert, David; Gomez-Pinilla, Fernando			Brain and Spinal Cord Interaction: A Dietary Curcumin Derivative Counteracts Locomotor and Cognitive Deficits After Brain Trauma	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; hippocampus; learning; BDNF; curcumin derivative	CONTROLLED CORTICAL IMPACT; CENTRAL-NERVOUS-SYSTEM; NEUROTROPHIC FACTOR; SYNAPTIC PLASTICITY; OXIDATIVE STRESS; SYNAPSIN-I; INJURY; EXERCISE; RAT; MEMORY	Background. In addition to cognitive dysfunction, locomotor deficits are prevalent in traumatic brain injured (TBI) patients; however, it is unclear how a concussive injury can affect spinal cord centers. Moreover, there are no current efficient treatments that can counteract the broad pathology associated with TBI. Objective. The authors have investigated potential molecular basis for the disruptive effects of TBI on spinal cord and hippocampus and the neuroprotection of a curcumin derivative to reduce the effects of experimental TBI. Methods. The authors performed fluid percussion injury (FPI) and then rats were exposed to dietary supplementation of the curcumin derivative (CNB-001; 500 ppm). The curry spice curcumin has protective capacity in animal models of neurodegenerative diseases, and the curcumin derivative has enhanced brain absorption and biological activity. Results. The results show that FPI in rats, in addition to reducing learning ability, reduced locomotor performance. Behavioral deficits were accompanied by reductions in molecular systems important for synaptic plasticity underlying behavioral plasticity in the brain and spinal cord. The post-TBI dietary supplementation of the curcumin derivative normalized levels of BDNF, and its downstream effectors on synaptic plasticity (CREB, synapsin I) and neuronal signaling (CaMKII), as well as levels of oxidative stress-related molecules (SOD, Sir2). Conclusions. These studies define a mechanism by which TBI can compromise centers related to cognitive processing and locomotion. The findings also show the influence of the curcumin derivative on synaptic plasticity events in the brain and spinal cord and emphasize the therapeutic potential of this noninvasive dietary intervention for TBI.	[Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; [Schubert, David] Salk Inst Biol Studies, La Jolla, CA USA		Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Dept Physiol Sci, 621 Charles E Young Dr, Los Angeles, CA 90095 USA.	fgomezpi@ucla.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RC1 NS068473, R01 NS056413]; Craig H Neilsen Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056413, RC1NS068473] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research and/or authorship of this article: This study was supported by NIH award RC1 NS068473 and R01 NS056413 and Craig H Neilsen Foundation.	Aggarwal BB, 2007, ADV EXP MED BIOL, V595, P1; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Ashman TA, 2006, MT SINAI J MED, V73, P999; Bolton MM, 2000, PROG BRAIN RES, V128, P203; Bregman BS, 1997, EXP NEUROL, V148, P475, DOI 10.1006/exnr.1997.6705; BROCK TO, 1987, J NEUROSCI, V7, P931; Clough RW, 2007, NEUROSCIENCE, V147, P286, DOI 10.1016/j.neuroscience.2007.04.043; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Exo JL, 2009, J NEUROTRAUM, V26, P2403, DOI 10.1089/neu.2009.0980; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gomez-Pinilla F, 2007, NEUROSCIENCE, V148, P893, DOI 10.1016/j.neuroscience.2007.05.051; Gomez-Pinilla F, 2001, EUR J NEUROSCI, V13, P1078, DOI 10.1046/j.0953-816x.2001.01484.x; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Jakeman LB, 1998, EXP NEUROL, V154, P170, DOI 10.1006/exnr.1998.6924; Johnk K, 1999, RESTOR NEUROL NEUROS, V14, P143; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; Levine ES, 1998, P NATL ACAD SCI USA, V95, P10235, DOI 10.1073/pnas.95.17.10235; Liu YB, 2008, J NEUROCHEM, V105, P1336, DOI 10.1111/j.1471-4159.2008.05236.x; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Mu JS, 1999, BRAIN RES, V835, P259, DOI 10.1016/S0006-8993(99)01592-9; Niechwiej-Szwedo E, 2007, GAIT POSTURE, V25, P70, DOI 10.1016/j.gaitpost.2006.01.002; Piot-Grosjean O, 2001, NEUROBIOL DIS, V8, P1082, DOI 10.1006/nbdi.2001.0450; Sherwood NT, 1999, J NEUROSCI, V19, P7025, DOI 10.1523/JNEUROSCI.19-16-07025.1999; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Vaynman S, 2007, NEUROSCIENCE, V144, P825, DOI 10.1016/j.neuroscience.2006.10.005; Vaynman S, 2005, NEUROREHAB NEURAL RE, V19, P283, DOI 10.1177/1545968305280753; Venturi L, 2009, J NEUROTRAUM, V26, P1547, DOI [10.1089/neu.2008.0723, 10.1089/neu.2008-0723]; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; WANG T, 1995, J NEUROSCI, V15, P4796; Williams G, 2010, NEUROREHAB NEURAL RE, V24, P550, DOI 10.1177/1545968309357925; Wu A, 2008, NEUROSCIENCE, V155, P751, DOI 10.1016/j.neuroscience.2008.05.061; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Wu AG, 2006, EUR J NEUROSCI, V23, P2573, DOI 10.1111/j.1460-9568.2006.04807.x; Ying SW, 2002, J NEUROSCI, V22, P1532, DOI 10.1523/JNEUROSCI.22-05-01532.2002; Ying Z, 2008, NEUROSCIENCE, V155, P1070, DOI 10.1016/j.neuroscience.2008.06.057; Ying Z, 2005, EXP NEUROL, V193, P411, DOI 10.1016/j.expneurol.2005.01.015	50	55	57	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	MAY	2011	25	4					332	342		10.1177/1545968310397706			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	742KJ	WOS:000288940900004	21343524	Green Accepted			2022-02-06	
J	Akin, FW; Murnane, OD				Akin, Faith W.; Murnane, Owen D.			Head Injury and Blast Exposure: Vestibular Consequences	OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA			English	Article						Dizziness; Traumatic brain injury; Blast injuries; Vestibular function tests; Saccule and utricle; Postural balance; Vestibular labyrinth	TRAUMATIC BRAIN-INJURY; MILD HEAD; POSTURAL STABILITY; EVOKED-POTENTIALS; OTOLITH DISORDERS; DIZZINESS; EAR; IMPAIRMENT; VERTIGO; DUTY	Young adults are more likely to suffer blast injury and traumatic brain injury (TBI) than other age groups. This article reviews the literature on the vestibular consequences of blast exposure and TBI and concussion. In addition, the vestibular test findings obtained from 31 veterans with a history of blast exposure and/or mild TBI are presented. The authors discuss loss of horizontal semicircular canal function and postural instability related to head injury. Preliminary data suggest the novel theory that otolith organs are uniquely vulnerable to head injury and blast exposure.	[Akin, Faith W.; Murnane, Owen D.] E Tennessee State Univ, Dept Audiol & Speech Pathol, Johnson City, TN 37614 USA; [Akin, Faith W.; Murnane, Owen D.] Vet Affairs Med Ctr, Audiol Serv, Vestibular Balance Lab, Mountain Home, TN 37684 USA		Akin, FW (corresponding author), E Tennessee State Univ, Dept Audiol & Speech Pathol, Johnson City, TN 37614 USA.	faith.akin@va.gov			Auditory and Vestibular Dysfunction Research Enhancement Award Program; Merit Review grants; Rehabilitation Research and Development Service, Department of Veterans Affairs, Washington, DCUS Department of Veterans Affairs	This work was supported by the Merit Review grants and by the Auditory and Vestibular Dysfunction Research Enhancement Award Program. All funding was sponsored by the Rehabilitation Research and Development Service, Department of Veterans Affairs, Washington, DC.	BARANY R, 1967, NOBEL LECT PHYSL MED; BARBER H O, 1964, Laryngoscope, V74, P891; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Basta D, 2005, HUM MOVEMENT SCI, V24, P268, DOI 10.1016/j.humov.2005.04.002; Basta D, 2008, GAIT POSTURE, V28, P397, DOI 10.1016/j.gaitpost.2008.01.006; Bohmer A, 1999, J VESTIBUL RES-EQUIL, V9, P413; CAVENESS W F, 1961, N Y State J Med, V61, P871; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Clarke AH, 2001, ACTA OTO-LARYNGOL, P84; Cohen JT, 2002, ISRAEL MED ASSOC J, V4, P559; COLEBATCH JG, 1992, NEUROLOGY, V42, P1635, DOI 10.1212/WNL.42.8.1635; Colebatch JG, 2001, CURR OPIN NEUROL, V14, P21, DOI 10.1097/00019052-200102000-00004; DAVIES RA, 1995, J NEUROL, V242, P222, DOI 10.1007/BF00919595; de Waele C, 1999, AM J OTOL, V20, P223; *DEF VET BRAIN INJ, 2006, CLIN PRACT GUID REC; DIETERICH M, 1993, ANN NEUROL, V33, P292, DOI 10.1002/ana.410330311; Ernst A, 2005, OTOLARYNG HEAD NECK, V132, P554, DOI 10.1016/j.otohns.2004.09.034; GANNON RP, 1978, ARCH OTOLARYNGOL, V104, P404; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Gottshall KR, 2007, MIL MED, V172, P852, DOI 10.7205/MILMED.172.8.852; GRIFFITHS MV, 1979, J LARYNGOL OTOL, V93, P253, DOI 10.1017/S0022215100086990; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; HALMAGYI G, 2007, VESTIBULAR REHABILIT, P144; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Jantzen KJ, 2010, J HEAD TRAUMA REHAB, V25, P256, DOI 10.1097/HTR.0b013e3181e5477c; Jury MA, 2001, NEW ZEAL MED J, V114, P286; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; KERR AG, 1975, J LARYNGOL OTOL, V89, P131, DOI 10.1017/S002221510008018X; KERR AG, 1980, J LARYNGOL OTOL, V94, P107, DOI 10.1017/S0022215100088538; Kisilevski V, 2001, Int Tinnitus J, V7, P118; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Lachman J, 1955, ACTA MED ORIENT, V14, P44; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; PAHOR AL, 1981, J LARYNGOL OTOL, V95, P399, DOI 10.1017/S0022215100090873; PALOSKI WH, 1993, AM J OTOL, V14, P9; PROCTOR B, 1956, Laryngoscope, V66, P16; RUBIN AM, 1995, AM J OTOL, V16, P216; SANNA M, 1983, ORL J OTO-RHINO-LARY, V45, P216, DOI 10.1159/000275645; Scherer M, 2007, MIL MED, V172, P731, DOI 10.7205/MILMED.172.7.731; SCHUKNECHT HF, 1956, ARCHIV OTOLARYNGOL, V63, P513; SHUPAK A, 1993, ARCH OTOLARYNGOL, V119, P1362; Tanielian T., 2008, INVISIBLE WOUNDS WAR; TOGLIA JU, 1970, ARCHIV OTOLARYNGOL, V92, P485; TUOHIMAA P, 1978, ACTA OTO-LARYNGOL, P7; Van Campen L E, 1999, J Am Acad Audiol, V10, P467; WETZIG J, 1990, ACTA ASTRONAUT, V21, P519, DOI 10.1016/0094-5765(90)90070-2; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; YLIKOSKI J, 1982, AM J OTOL, V3, P343	51	55	56	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0030-6665			OTOLARYNG CLIN N AM	Otolaryngol. Clin. N. Am.	APR	2011	44	2					323	+		10.1016/j.otc.2011.01.005			13	Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED)	Otorhinolaryngology	757ZH	WOS:000290128000006	21474007				2022-02-06	
J	Heinemann, AW; Lai, JS; Magasi, S; Hammel, J; Corrigan, JD; Bogner, JA; Whiteneck, GG				Heinemann, Allen W.; Lai, Jin-Shei; Magasi, Susan; Hammel, Joy; Corrigan, John D.; Bogner, Jennifer A.; Whiteneck, Gale G.			Measuring Participation Enfranchisement	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Conference on the American-Psychological-Association-Division	APR 06, 2008	Tucson, AZ	Amer Psychol Assoc Div		Patient participation; Psychometrics; Rehabilitation	REHABILITATION; INTEGRATION; COMMUNITY; HANDICAP; PEOPLE	Heinemann AW, Lai J-S, Magasi S, Hammel J, Corrigan JD, Bogner JA, Whiteneck GG. Measuring participation enfranchisement. Arch Phys Med Rehabil 2011;92:564-71. Objective: To reflect the perspectives of rehabilitation stakeholders in a measure of participation enfranchisement that can be used by people with and without disabilities. Design: Survey. Setting: Community settings. Participants: We pilot-tested a draft instrument with 326 adults who had sustained stroke, spinal cord injury, traumatic brain injury, or other disabling condition, as well as a general population sample. We administered a revised version of the instrument to a statewide sample drawn from the 2006 Colorado Behavioral Risk Factors Surveillance System that included persons with (N=461) and without (N=451) self-identified activity limitations. Interventions: None. Main Outcome Measure: Participation enfranchisement. Results: We used multidimensional scaling, exploratory factor analysis (EFA) and confirmatory factor analysis (CFA), followed by rating scale analysis to evaluate the psychometric properties of the instrument. EFA identified 3 participation enfranchisement factors that describe perceived choice and control, contributing to one's community, and feeling valued; the factors were supported marginally by CFA. Rating scale analysis revealed marginal person separation and no misfitting items. Conclusions: Participation enfranchisement constitutes a new, previously unmeasured aspect of participation one that addresses subjective perceptions rather than objective performance with items that are clearly distinct from more generalized satisfaction with participation. The 19 enfranchisement items describe aspects of participation that may prove useful in characterizing longer-term rehabilitation outcomes.	[Heinemann, Allen W.] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Heinemann, Allen W.] Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Chicago, IL 60611 USA; [Lai, Jin-Shei; Magasi, Susan] Northwestern Univ, Dept Med Social Sci, Feinberg Sch Med, Chicago, IL 60611 USA; [Hammel, Joy] Univ Illinois, Chicago, IL USA; [Corrigan, John D.; Bogner, Jennifer A.] Ohio State Univ, Columbus, OH 43210 USA; [Whiteneck, Gale G.] Craig Hosp, Englewood, CO USA		Heinemann, AW (corresponding author), Rehabil Inst Chicago, 345 E Super St, Chicago, IL 60611 USA.	a-heinemann@northwestern.edu	Corrigan, John D./E-2921-2011; Bogner, Jennifer/E-2773-2011; Heinemann, Allen W./AAI-2790-2021; Heinemann, Allen W/K-6283-2012	Heinemann, Allen W./0000-0003-2782-7326; Heinemann, Allen W/0000-0003-2782-7326			Ader DN, 2007, MED CARE, V45, pS1, DOI 10.1097/01.mlr.0000260537.45076.74; *ASS CLASS EP GROU, 1999, INT CLASS FUNCT DIS; Bogner JA, 2011, ARCH PHYS MED REHAB, V92, P552, DOI 10.1016/j.apmr.2010.11.014; Cardol M, 1999, CLIN REHABIL, V13, P411, DOI 10.1191/026921599668601325; Cox MAA., 2001, MULTIDIMENSIONAL SCA; Field M.J., 2007, FUTURE DISABILITY AM; Gandek B, 2007, AM J PHYS MED REHAB, V86, P57, DOI 10.1097/01.PHM.0000233200.43822.21; Gray DB, 2006, ARCH PHYS MED REHAB, V87, P189, DOI 10.1016/j.apmr.2005.09.014; Haley SM, 2008, ARCH PHYS MED REHAB, V89, P275, DOI 10.1016/j.apmr.2007.08.150; Hammel J, 2008, DISABIL REHABIL, V30, P1445, DOI 10.1080/09638280701625534; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Magasi S, 2009, J REHABIL MED, V41, P936, DOI 10.2340/16501977-0450; Magasi SR, 2008, J SPINAL CORD MED, V31, P145, DOI 10.1080/10790268.2008.11760705; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; MUTHEN BO, 1987, ROBUST INFERENCE USI; Rasch, 1960, PROBABILISTIC MODELS; Townley G, 2009, J COMMUNITY PSYCHOL, V37, P362, DOI 10.1002/jcop.20301; *US BUR CENS, 2006 2008 AM COMM SU; van de Ven L, 2005, DISABIL SOC, V20, P311, DOI 10.1080/09687590500060778; Whiteneck G, 2009, ARCH PHYS MED REHAB, V90, pS22, DOI 10.1016/j.apmr.2009.06.009; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Willis G., 1994, 7 CDCP NAT CTR HLTH; World Health Organization, 2007, INT CLASS FUNCT DIS; Wright B., 1999, MEASUREMENT ESSENTIA, V2nd; 2000, MORB MORTAL WKLY REP, V49, P711	26	55	55	0	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2011	92	4					564	571		10.1016/j.apmr.2010.07.220			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	743VT	WOS:000289047500006	21367395				2022-02-06	
J	Li, J; Li, XY; Feng, DF; Gu, L				Li, Jia; Li, Xue-Yuan; Feng, Dong-Fu; Gu, Lei			Quantitative evaluation of microscopic injury with diffusion tensor imaging in a rat model of diffuse axonal injury	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						anisotropy; diffusivity; electron microscopy; immunohistochemistry; region of interest	TRAUMATIC BRAIN-INJURY; INTRAAXONAL NEUROFILAMENT COMPACTION; WHITE-MATTER INJURY; IN-VIVO; AMYLOID-BETA; OPTIC-NERVE; MOUSE MODEL; DAMAGE; ACCUMULATION; DIAGNOSIS	Diffuse axonal injury (DAI) is the predominant effect of severe traumatic brain injury and contributes significantly to neurological deficits. However, it is difficult to diagnose or characterize non-invasively with conventional imaging. Our study provides significant validation of a visual and statistical diffusion tensor imaging (DTI) technique as compared with pathological and electron microscopic study in a rat DAI model at multiple predilection sites and time points following trauma. Two DTI parameters, fractional anisotropy (FA) and axial diffusivity (AD), were significantly reduced from 12 h to 5 days post-trauma, corresponding to pathological axonal injury. At 7 days post-trauma, FA remained decreased, whereas AD pseudo-normalized and radial diffusivity increased. The temporal alterations in DTI parameters were observed in multiple predilection sites, and the extent of the changes in these parameters correlated significantly with the severity of histologically visualized axonal injury, as assessed by integrated optical density of immunochemically stained injured axons with quantitative stereology. Although anatomical T2-weighted magnetic resonance images showed no abnormal signals in microscopic lesions, we detected and characterized axonal injury directly by DTI at each time point. These results demonstrate that DTI has significant potential as a non-invasive tool with which to quantitatively diagnose and evaluate microstructural injury in the experimental and clinical assessment of DAI. This method can assist in accurate evaluation of the extent of axonal injury, detection of severe predilection foci, determination of approximate time of injury, and monitoring of the pathogenic condition at the early post-injury stage.	[Li, Jia; Li, Xue-Yuan; Feng, Dong-Fu; Gu, Lei] Shanghai Jiao Tong Univ, Sch Med, Dept Neurosurg, Peoples Hosp 3, Shanghai 201900, Peoples R China; [Feng, Dong-Fu] Shanghai Jiao Tong Univ, Sch Med, Inst Traumat Med, Shanghai 201900, Peoples R China		Feng, DF (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Neurosurg, Peoples Hosp 3, 280 Mo He Rd, Shanghai 201900, Peoples R China.	feng_df@yahoo.com			Shanghai Committee of Science and TechnologyShanghai Science & Technology Committee [064119639]; Shanghai Jiao Tong University School of Medicine [09XJ21072]; Shanghai Jiao Tong University [YG08PETMS19]	This study was supported by grants from the Shanghai Committee of Science and Technology (No. 064119639), the Shanghai Jiao Tong University School of Medicine (No. 09XJ21072) and the Medicine-Engineering Combination Project of Shanghai Jiao Tong University (No. YG08PETMS19).	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bockhorst KH, 2008, J NEUROSCI RES, V86, P1520, DOI 10.1002/jnr.21607; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Budde MD, 2008, NMR BIOMED, V21, P589, DOI 10.1002/nbm.1229; Budde MD, 2007, MAGN RESON MED, V57, P688, DOI 10.1002/mrm.21200; Chan KC, 2009, J MAGN RESON IMAGING, V29, P1013, DOI 10.1002/jmri.21736; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Chua CO, 2009, STROKE, V40, P3369, DOI 10.1161/STROKEAHA.109.549212; DASILVA AFM, 2003, NEUROSURG FOCUS, V15, P1; Deboy CA, 2007, BRAIN, V130, P2199, DOI 10.1093/brain/awm122; Dijkhuizen RM, 2003, J CEREBR BLOOD F MET, V23, P1383, DOI 10.1097/01.WCB.0000100341.78607.EB; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; Hannila I, 2009, OSTEOARTHR CARTILAGE, V17, P1570, DOI 10.1016/j.joca.2009.05.011; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Hortobagyi T, 2007, NEUROPATH APPL NEURO, V33, P226, DOI 10.1111/j.1365-2990.2006.00794.x; Hoshino S, 2003, NEUROL MED-CHIR, V43, P165, DOI 10.2176/nmc.43.165; Irving EA, 2001, ACTA NEUROPATHOL, V102, P627, DOI 10.1007/s004010100416; Jang SH, 2009, NEUROREHABILITATION, V25, P229, DOI 10.3233/NRE-2009-0519; Lespessailles E, 2007, CALCIFIED TISSUE INT, V80, P97, DOI 10.1007/s00223-006-0216-y; Li J, 2010, J TRAUMA, V69, P1610, DOI 10.1097/TA.0b013e3181f5a9ed; Li XY, 2010, NEUROSCIENCE, V169, P357, DOI 10.1016/j.neuroscience.2010.04.075; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Lima RR, 2008, INFLAMMATION, V31, P24, DOI 10.1007/s10753-007-9046-y; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Ma TG, 2001, ANAL BIOCHEM, V296, P18, DOI 10.1006/abio.2001.5208; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; MARMAROU A, 2007, NEUROSURG FOCUS, V15, P1; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; MCNAMARA G, 1995, MVPMATH PROGRAM IMAG; Ment LR, 2009, LANCET NEUROL, V8, P1042, DOI 10.1016/S1474-4422(09)70257-1; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Muller MJ, 2006, AM J NEURORADIOL, V27, P440; Paxinos G, 1996, RAT BRAIN STEREOTAXI; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; SKANDSEN T, 2009, J NEUROSURG, V23, P1; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Sun SW, 2006, NEUROIMAGE, V32, P1195, DOI 10.1016/j.neuroimage.2006.04.212; Sundgren PC, 2004, NEURORADIOLOGY, V46, P339, DOI 10.1007/s00234-003-1114-x; Sykova E, 2004, NEUROSCIENCE, V129, P861, DOI 10.1016/j.neuroscience.2004.06.077; Szaleczky E, 2000, ANAL CELL PATHOL, V20, P131, DOI 10.1155/2000/830906; Thomalla G, 2004, NEUROIMAGE, V22, P1767, DOI 10.1016/j.neuroimage.2004.03.041; Thuen M, 2009, J MAGN RESON IMAGING, V29, P39, DOI 10.1002/jmri.21606; vanderToorn A, 1996, MAGN RESON MED, V36, P52, DOI 10.1002/mrm.1910360110; Wang CJ, 2009, APPL IMMUNOHISTO M M, V17, P530, DOI 10.1097/PAI.0b013e3181a13bf2; Wang S, 2009, AM J NEURORADIOL, V30, P1907, DOI 10.3174/ajnr.A1697; Wang SL, 2008, STROKE, V39, P2348, DOI 10.1161/STROKEAHA.107.509927; Wang-Tilz Y, 2006, EPILEPSIA, V47, P233, DOI 10.1111/j.1528-1167.2006.00414.x; Wexler EJ, 2002, J NEUROSCI METH, V113, P51, DOI 10.1016/S0165-0270(01)00476-9; Wood RI, 1999, J NEUROBIOL, V39, P359, DOI 10.1002/(SICI)1097-4695(19990605)39:3<359::AID-NEU3>3.0.CO;2-W; Xavier LL, 2005, BRAIN RES PROTOC, V16, P58, DOI 10.1016/j.brainresprot.2005.10.002; Xie MQ, 2010, J NEUROPATH EXP NEUR, V69, P704, DOI 10.1097/NEN.0b013e3181e3de90; Zhao M, 2003, NEUROBIOL DIS, V14, P391, DOI 10.1016/j.nbd.2003.07.006	62	55	61	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	MAR	2011	33	5					933	945		10.1111/j.1460-9568.2010.07573.x			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	727MN	WOS:000287804500013	21385236				2022-02-06	
J	Gill, CJ; Sander, AM; Robins, N; Mazzei, DK; Struchen, MA				Gill, Carol J.; Sander, Angelle M.; Robins, Nina; Mazzei, Diana K.; Struchen, Margaret A.			Exploring Experiences of Intimacy From the Viewpoint of Individuals With Traumatic Brain Injury and Their Partners	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						craniocerebral trauma; intimacy; relationships; sexuality; traumatic brain injury	BLUNT HEAD-INJURY; CAREGIVERS; DISTRESS; TBI; SATISFACTION; PREDICTORS; ADJUSTMENT; STABILITY; ABILITIES; SYMPTOMS	Objective: To explore qualitatively the experience of intimacy from the viewpoint of persons with traumatic brain injury (TBI) and their intimate partners. Design: Qualitative interview study. Setting: Outpatient community. Participants: Eighteen persons with TBI and their intimate partners at a mean length of 4.78 years postinjury. Main measures: Open-ended, semistructured, in-depth interviews regarding participants' experience of intimacy, factors impacting intimacy, and need for services. Results: Factors that were perceived as helping relationships remain strong included unconditional commitment, spending time together, open communication, a strong preinjury relationship, bonding through surviving the injury together, social support, family bonds, spirituality, experience with overcoming hardship, and coping skills. Factors that were perceived as barriers to intimacy included injury-related changes, emotional reactions to changes, sexual difficulties, role conflict and strain, family issues, social isolation, and communication issues. Conclusions and Implications: Education regarding the impact of TBI on intimacy should be integrated into rehabilitation. Health professionals should be sensitized as to the needs that persons with TBI and their partners have regarding intimacy and how to make appropriate referrals to assist them.	[Gill, Carol J.; Robins, Nina] Univ Illinois, Dept Disabil & Human Dev, Chicago, IL 60680 USA; [Sander, Angelle M.; Struchen, Margaret A.] Harris Cty Hosp Dist, Dept Phys Med & Rehabil, Baylor Coll Med, Houston, TX USA; [Mazzei, Diana K.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX USA		Gill, CJ (corresponding author), Univ Illinois, Dept Disabil & Human Dev, Chicago, IL 60680 USA.				National Institute on Disability and Rehabilitation Research, US Department of Education (Rehabilitation Research and Training Center on Community Integration of Persons With Traumatic Brain Injury)US Department of Education [H133B031117]; National Institute on Disability and Rehabilitation Research, US Department of Education (Rehabilitation Research and Training Center on Developing Strategies to Foster Community Integration and Participation for Individuals With Traumatic Brain Injury) [H133B090023]; National Institute on Disability and Rehabilitation Research, US Department of Education (Texas Traumatic Brain Injury Model System of TIRR)US Department of Education [H133A70015]	This work was supported by grants from the National Institute on Disability and Rehabilitation Research, US Department of Education (grants H133B031117, Rehabilitation Research and Training Center on Community Integration of Persons With Traumatic Brain Injury; H133B090023, Rehabilitation Research and Training Center on Developing Strategies to Foster Community Integration and Participation for Individuals With Traumatic Brain Injury; and H133A70015, Texas Traumatic Brain Injury Model System of TIRR). The authors thank the individuals with traumatic brain injury and their partners who trusted us enough to share intimate details of their relationships with us. We hope that the information published here will be a first step toward increasing the services available to couples to improve intimacy after traumatic brain injury.	ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/0090-5550.39.1.29; Aloni A, 1999, BRAIN INJURY, V13, P89, DOI 10.1080/026990599121755; Aloni R, 2003, SEXUAL DIFFICULTIES; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Anderson-Parente JK., 1990, COGN REHABIL, V8, P22; BERGLAND MM, 1991, REHABIL COUNS BULL, V35, P5; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Garden F. H., 1990, J HEAD TRAUMA REHAB, V5, P52, DOI DOI 10.1097/00001199-199005020-00009; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Gosling J, 1999, BRAIN INJURY, V13, P785; HARRICK L, 1994, BRAIN INJURY, V8, P439, DOI 10.3109/02699059409150995; Hibbard MR, 2000, NEUROREHABILITATION, V15, P109; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jeon YH, 2004, SCAND J CARING SCI, V18, P249, DOI 10.1111/j.1471-6712.2004.00287.x; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; KRAVETZ S, 1995, BRAIN INJURY, V9, P131, DOI 10.3109/02699059509008186; Kravetz S, 2001, REHABIL PSYCHOL, V46, P436; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; Kreutzer JS, 2007, NEUROREHABILITATION, V22, P53; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Lippert T, 2001, PERS RELATIONSHIP, V8, P283, DOI 10.1111/j.1475-6811.2001.tb00041.x; Marsh NV, 1991, NEUROPSYCHOLOGY, V5, P107, DOI 10.1037/0894-4105.5.2.107; McPherson KM, 2000, INT J REHABIL RES, V23, P295, DOI 10.1097/00004356-200023040-00005; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Panting A, 1972, REHABILITATION, V38, P33; Patton M.Q., 2001, QUALITATIVE RES EVAL, V3rd ed.; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Ponsford J, 2003, NEUROPSYCHOL REHABIL, V13, P275, DOI 10.1080/09602010244000363; Porter D, 1994, DISS ABSTR INT A, P55; Resnick C, 1992, DISS ABSTR INT A, P53; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; SANDEL ME, 2007, BRAIN INJURY MED PRI, P673; Seibert PS, 2002, BRAIN INJURY, V16, P837, DOI 10.1080/02699050210131939; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Tate DG, 2003, AM PSYCHOL, V58, P289, DOI 10.1037/0003-066X.58.4.289; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Wallace CA, 1998, BRAIN INJURY, V12, P483, DOI 10.1080/02699052.1998.11910751; Webster G, 1999, BRAIN INJURY, V13, P593; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	47	55	55	1	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2011	26	1					56	68		10.1097/HTR.0b013e3182048ee9			13	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	703GA	WOS:000285965200006	21209563				2022-02-06	
J	Dudley, RR; Aziz, I; Bonnici, A; Saluja, RS; Lamoureux, J; Kalmovitch, B; Gursahaney, A; Razek, T; Maleki, M; Marcoux, J				Dudley, Roy R.; Aziz, Ishtiaque; Bonnici, Andre; Saluja, Rajeet S.; Lamoureux, Julie; Kalmovitch, Boaz; Gursahaney, Ash; Razek, Tarek; Maleki, Mohammad; Marcoux, Judith			Early Venous Thromboembolic Event Prophylaxis in Traumatic Brain Injury with Low-Molecular-Weight Heparin: Risks and Benefits	JOURNAL OF NEUROTRAUMA			English	Article						dalteparin; enoxaparin; low-molecular-weight heparin; traumatic brain injury; venous thromboembolic event	DEEP-VEIN THROMBOSIS; SPINAL-CORD-INJURY; MAJOR TRAUMA; ENOXAPARIN; PREVENTION; DALTEPARIN; HEMORRHAGE	Traumatic brain injury (TBI) patients are known to be at high risk for venous thromboembolic events (VTEs). The Brain Trauma Foundation Guidelines (2007) state that low-molecular-weight heparin or unfractionated heparin should be used to prevent VTE complications, but suggest that there is an increased risk of expansion of intracranial hemorrhages (ICH) with VTE prophylaxis. In addition, it is unclear which treatment regimen (i.e., medication, dose, and timing) provides the best risk: benefit ratio in TBI patients. We reviewed all moderate-to-severe TBI patients admitted over a 5-year period to: (1) examine the occurrence of VTEs and their timing; (2) examine the symptomatic expansion of ICH while on VTE prophylaxis; and (3) compare the efficacy of two prophylactic agents: enoxaparin and dalteparin. Two-hundred eighty-seven patients were included. VTE prophylaxis was started 48-72 h post-trauma in all individuals who had no confounding coagulopathy, when two consecutive computed tomography (CT) scans revealed hemorrhage stability. VTEs occurred in 7.3% of treated patients, mostly within 2 weeks after trauma. Proximal VTEs occurred in 3.1% of treated patients. No significant difference in VTE rates was seen between enoxaparin (7.0%) and dalteparin (7.5%; p = 0.868). Moreover, the group treated with dalteparin was more severely injured (higher Injury Severity Score [p = 0.002]), had lower Glasgow Coma Scale (GCS) scores (p = 0.003), and had more inferior vena cava (IVC) filters placed (p = 0.007). The two groups did not show significant differences in the development of VTE when controlled for ISS and IVC filters (p = 0.819). Importantly, only one patient suffered a symptomatic expansion of ICH while on VTE prophylaxis, at 15 days post-trauma. These results suggest that current regimens of VTE prophylaxis used in our TBI population provide a relatively high level of protection against VTEs, and an extremely low risk of expanding ICH. They also suggest that there was no difference in VTE between dalteparin- and enoxaparin-treated patients.	[Maleki, Mohammad; Marcoux, Judith] McGill Univ, Ctr Hlth, Dept Neurosurg, Montreal, PQ H3G 1A4, Canada; [Aziz, Ishtiaque] McGill Univ, Fac Sci, Dept Biochem, Montreal, PQ H3G 1A4, Canada; [Bonnici, Andre] McGill Univ, Fac Pharm, Montreal, PQ H3G 1A4, Canada; [Dudley, Roy R.; Aziz, Ishtiaque; Saluja, Rajeet S.] McGill Univ, Ctr Hlth, Montreal Neurol Hosp, Montreal, PQ H3G 1A4, Canada; [Lamoureux, Julie] Univ Montreal, Montreal, PQ, Canada; [Kalmovitch, Boaz] Tel Aviv Univ, IL-69978 Tel Aviv, Israel; [Kalmovitch, Boaz] E Wolfson Med Ctr, Dept Surg, Holon, Israel; [Gursahaney, Ash] McGill Univ, Ctr Hlth, Clin Serv, Montreal, PQ H3G 1A4, Canada; [Gursahaney, Ash] McGill Univ, Div Crit Care, Dept Med, Montreal, PQ H3G 1A4, Canada; [Razek, Tarek] McGill Univ, Ctr Hlth, Trauma Program, Montreal, PQ H3G 1A4, Canada		Marcoux, J (corresponding author), McGill Univ, Ctr Hlth, Montreal Gen Hosp, Dept Neurosurg, 1650 Cedar Ave,Room L7-524, Montreal, PQ H3G 1A4, Canada.	judith.marcoux@mcgill.ca		Lamoureux, Julie/0000-0002-4986-2504			Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS32, DOI 10.1089/neu.2007.9991; Chiou-Tan FY, 2003, AM J PHYS MED REHAB, V82, P678, DOI 10.1097/01.PHM.0000083671.27501.47; Cothren CC, 2007, WORLD J SURG, V31, P98, DOI 10.1007/s00268-006-0304-1; Denson K, 2007, AM J SURG, V193, P380, DOI 10.1016/j.amjsurg.2006.12.004; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Gerlach R, 2003, NEUROSURGERY, V53, P1028, DOI 10.1227/01.NEU.0000088565.15719.22; Hess Dean R, 2004, Respir Care, V49, P1171; KAUFMAN HH, 1983, ANGIOLOGY, V34, P627, DOI 10.1177/000331978303401001; Kim KS, 2009, NEUROCRIT CARE, V11, P28, DOI 10.1007/s12028-009-9201-4; Kleindienst A, 2003, ACTA NEUROCHIR, V145, P1085, DOI 10.1007/s00701-003-0142-y; Nathens AB, 2007, J TRAUMA, V62, P557, DOI 10.1097/TA.0b013e318031b5f5; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; Slavik RS, 2007, J TRAUMA, V62, P1075, DOI 10.1097/TA.0b013e31804fa177; SMITH RM, 1994, INJURY, V25, P551, DOI 10.1016/0020-1383(94)90099-X; TEASDALE G, 1974, LANCET, V2, P81	19	55	58	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2010	27	12					2165	2172		10.1089/neu.2010.1366			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	691PN	WOS:000285093400006	20939698	Green Submitted			2022-02-06	
J	Hayward, NMEA; Immonen, R; Tuunanen, PI; Ndode-Ekane, XE; Grohn, O; Pitkanen, A				Hayward, Nick M. E. A.; Immonen, Riikka; Tuunanen, Pasi I.; Ndode-Ekane, Xavier Ekolle; Grohn, Olli; Pitkanen, Asla			Association of Chronic Vascular Changes with Functional Outcome after Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						cerebrovascular changes; functional outcome; MRI; seizure susceptibility; traumatic brain injury	CEREBRAL-BLOOD-FLOW; LATERAL FLUID-PERCUSSION; CLOSED-HEAD-INJURY; TECHNETIUM-99M-HMPAO SPECT; SEIZURE SUSCEPTIBILITY; IMMUNOHISTOCHEMICAL CHARACTERIZATION; POSTTRAUMATIC EPILEPSY; ELECTRICAL-STIMULATION; THALAMIC NUCLEI; VESSEL DENSITY	We tested the hypothesis that vascular remodeling in the cortex, hippocampus, and thalamus is associated with long-term functional recovery after traumatic brain injury (TBI). We induced TBI with lateral fluid-percussion (LFP) injury in adult rats. Animals were followed-up for 9 months, during which we tested motor performance using a neuroscore test, spatial learning and memory with a Morris water maze, and seizure susceptibility with a pentylenetetrazol (PTZ) test. At 8 months, they underwent structural MRI, and cerebral blood flow (CBF) was assessed by arterial spin labeling (ASL) MRI. Then, rats were perfused for histology to assess the density of blood vessels. In the perilesional cortex, the CBF decreased by 56% (p<0.01 compared to controls), and vessel density increased by 28% (p<0.01). There was a negative correlation between CBF in the perilesional cortex and vessel density (r = -0.75, p<0.01). However, in the hippocampus, we found a 13% decrease in CBF ipsilaterally (p<0.05) and 20% contralaterally (p<0.01), and no change in vessel number. In the ipsilateral thalamus, the increase in CBF (34%, p<0.01) was associated with a remarkable increase in vessel density (78%, p<0.01). Animals showed motor impairment that was not associated with vascular changes. Instead, poor performance in the Morris water maze correlated with enhanced thalamic vessel density (r = -0.81, p<0.01). Finally, enhanced seizure susceptibility was associated with reduced CBF in the ipsilateral hippocampus (r = 0.78, p<0.05) and increased vascular density in the thalamus (r = 0.69, p<0.05). There was little interaction between the behavioral measures. The present study demonstrates that each of the investigated brain areas has a unique pattern of vascular abnormalities. Chronic alterations in CBF could not be attributed to changes in vascular density. Association of thalamic hypervascularity to epileptogenesis warrants further studies. Finally, hippocampal hypoperfusion may predict later seizure susceptibility in the LFP injury model of TBI, which could be of value for pre-clinical antiepileptogenesis trials.	[Ndode-Ekane, Xavier Ekolle; Pitkanen, Asla] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Epilepsy Res Grp, Dept Neurobiol, FIN-70211 Kuopio, Finland; [Hayward, Nick M. E. A.; Immonen, Riikka; Tuunanen, Pasi I.; Grohn, Olli] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Biomed NMR Grp, Dept Neurobiol, FIN-70211 Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland		Pitkanen, A (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, Epilepsy Res Grp, Dept Neurobiol, POB 1627, FIN-70211 Kuopio, Finland.	asla.pitkanen@uef.fi		Hayward, Nick/0000-0001-9496-7332; Ndode-Ekane, Xavier Ekolle/0000-0001-5682-5632	Marie Curie Early Stage Trainee Research Fellowship [MEST-CT-2005-019217]; Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius Fundation	We thank Mrs. Maarit Pulkkinen and Mr. Jarmo Hartikainen for providing technical assistance. This study was funded by a Marie Curie Early Stage Trainee Research Fellowship MEST-CT-2005-019217 (N.H., X.E., O.G.), by The Academy of Finland (A.P., O.G.), and by The Sigrid Juselius Fundation (A.P.).	Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; Berg Jenny, 2004, Eur J Health Econ, V5 Suppl 1, pS43, DOI 10.1007/s10198-005-0288-z; Best PJ, 2001, ANNU REV NEUROSCI, V24, P459, DOI 10.1146/annurev.neuro.24.1.459; Blanco MM, 2009, EPILEPSIA, V50, P824, DOI 10.1111/j.1528-1167.2008.01797.x; Blumenfeld H, 2009, BRAIN, V132, P999, DOI 10.1093/brain/awp028; Bonilha L, 2004, ARCH NEUROL-CHICAGO, V61, P1379, DOI 10.1001/archneur.61.9.1379; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bratane BT, 2010, J CEREBR BLOOD F MET, V30, P336, DOI 10.1038/jcbfm.2009.218; Chen L, 2009, EXP MOL MED, V41, P849, DOI 10.3858/emm.2009.41.12.103; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; Dombrowski SM, 2008, NEUROSCIENCE, V152, P346, DOI 10.1016/j.neuroscience.2007.11.049; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; DUIJVESTIJN AM, 1992, LAB INVEST, V66, P459; Echegoyen J, 2009, EPILEPSY RES, V85, P123, DOI 10.1016/j.eplepsyres.2009.02.019; Ghabriel MN, 2010, ACTA NEUROCHIR SUPPL, V106, P239, DOI 10.1007/978-3-211-98811-4_45; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GOLDMAN H, 1992, EPILEPSY RES, V12, P227, DOI 10.1016/0920-1211(92)90077-7; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; GRAY BG, 1992, J NUCL MED, V33, P52; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; HAYWARD NM, 2010, J CEREB BLO IN PRESS; Hendrich KS, 2001, MAGNET RESON MED, V46, P202, DOI 10.1002/mrm.1178; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; Hiltunen M, 2009, NEUROBIOL DIS, V35, P103, DOI 10.1016/j.nbd.2009.04.009; Holley JE, 2010, NEUROSCI LETT, V470, P65, DOI 10.1016/j.neulet.2009.12.059; ICHISE M, 1994, J NUCL MED, V35, P217; Iltis I, 2005, J MAGN RESON IMAGING, V22, P242, DOI 10.1002/jmri.20352; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Inoue Y, 2005, J NEUROTRAUM, V22, P1411, DOI 10.1089/neu.2005.22.1411; Jacobs A, 1996, J NUCL MED, V37, P1605; Jejeli M, 2003, NEUROSCI RES, V47, P309, DOI 10.1016/S0168-0102(03)00224-4; Johnson V. E., 2010, NAT REV NEUROSCI; Karhunen H, 2003, EPILEPSY RES, V54, P1, DOI 10.1016/S0920-1211(03)00034-2; Katz DI, 1998, ARCH PHYS MED REHAB, V79, P488, DOI 10.1016/S0003-9993(98)90060-0; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; LEWIS DA, 1986, J COMP NEUROL, V248, P1, DOI 10.1002/cne.902480102; Lim YM, 2008, EPILEPSY RES, V82, P183, DOI 10.1016/j.eplepsyres.2008.08.001; Lin TN, 2002, STROKE, V33, P2985, DOI 10.1161/01.STR.0000037675.97888.9D; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; Madri JA, 2009, J PHYSIOL PHARMACOL, V60, P95; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mora GN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005759; Ndode-Ekane XE, 2010, NEUROSCIENCE, V166, P312, DOI 10.1016/j.neuroscience.2009.12.002; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pitkanen A, 2009, EPILEPSY BEHAV, V14, P16, DOI 10.1016/j.yebeh.2008.09.023; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; PRAYER L, 1993, ACTA RADIOL, V34, P593; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Rougier A, 1999, J NEUROSURG, V90, P282, DOI 10.3171/jns.1999.90.2.0282; Schwartz TH, 2006, EPILEPSIA, V47, P567, DOI 10.1111/j.1528-1167.2006.00469.x; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; Stamatakis EA, 2002, J NUCL MED, V43, P476; Tetrault S, 2008, EUR J NEUROSCI, V28, P1330, DOI 10.1111/j.1460-9568.2008.06443.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; VEZZANI A, 1994, BRAIN RES, V660, P138, DOI 10.1016/0006-8993(94)90847-8; Vogel J, 2004, J CEREBR BLOOD F MET, V24, P849, DOI 10.1097/01.WCB.0000126564.89011.11; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; Zaharchuk G, 2000, J CEREBR BLOOD F MET, V20, P1341, DOI 10.1097/00004647-200009000-00009; Zhang C, 2005, J NEUROTRAUM, V22, P1456, DOI 10.1089/neu.2005.22.1456	84	55	55	1	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2010	27	12					2203	2219		10.1089/neu.2010.1448			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	691PN	WOS:000285093400010	20839948				2022-02-06	
J	Schneider, KJ; Emery, CA; Kang, JA; Schneider, GM; Meeuwisse, WH				Schneider, Kathryn J.; Emery, Carolyn A.; Kang, Jian; Schneider, Geoff M.; Meeuwisse, Willem H.			Examining Sport Concussion Assessment Tool ratings for male and female youth hockey players with and without a history of concussion	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							INTERNATIONAL-CONFERENCE; RISK-FACTORS; STATEMENT; INJURY	Background Concussion is one of the most commonly occurring injuries in sport today. The Sport Concussion Assessment Tool (SCAT) is a commonly used paper neurocognitive tool. To date, little is known about SCAT baseline normative values in youth athletes. Objective The purpose of this study was to determine normative values on the SCAT for male and female youth hockey players. Methods This is a secondary data analysis of pooled data from three prospective cohort studies examining the risk of injury in paediatric ice hockey players aged 9-17 years. A preseason baseline demographic and injury history questionnaire was completed by each player. Results A total of 4193 players completed SCATs at baseline and were included in the analysis. 781 players (18.6%) reported a previous history of concussion. Fatigue and low energy followed by headache were the most commonly reported symptoms in all players. The majority of youth players could recite all five words immediately but only three words when delayed. A smaller proportion of the males were able to report the months of the year in reverse order compared with females of a similar age. The median number of digits recited in reverse order was 4. Conclusions Youth ratings varied between age groups, gender and from previously reported ratings of varsity athletes, possibly reflecting developmental and gender differences. An understanding of these differences in youth athletes is important to ensure appropriate performance expectations on the SCAT and when making clinical decisions following a concussion.	[Schneider, Kathryn J.; Emery, Carolyn A.; Kang, Jian; Meeuwisse, Willem H.] Univ Calgary, Sport Injury Prevent Res Ctr, Fac Kinesiol, Calgary, AB T2N 1N4, Canada; [Emery, Carolyn A.; Meeuwisse, Willem H.] Univ Calgary, Dept Community Hlth Sci, Fac Med, Calgary, AB T2N 1N4, Canada; [Emery, Carolyn A.] Univ Calgary, Res Inst Child & Maternal Hlth, Fac Med, Alberta Childrens Hosp, Calgary, AB T2N 1N4, Canada; [Schneider, Geoff M.] Univ Calgary, Dept Med Sci, Fac Med, Calgary, AB T2N 1N4, Canada		Schneider, KJ (corresponding author), Univ Calgary, Sport Injury Prevent Res Ctr, Fac Kinesiol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	kjschnei@ucalgary.ca	Emery, Carolyn/AAI-2761-2020	Schneider, Kathryn/0000-0002-5951-5899	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Max Bell Foundation; Alberta Centre for Child, Family and Community Research; Alberta Heritage Foundation for Medical ResearchAlberta Heritage Foundation for Medical ResearchGeneral Electric; Children's Hospital Foundation through the Alberta Children's Hospital Research Institute for Child and Maternal Health	These studies were funded by the Canadian Institutes of Health Research, Max Bell Foundation and Alberta Centre for Child, Family and Community Research. KJS is funded by an Alberta Heritage Foundation for Medical Research Doctoral Award. CAE is funded by a Canadian Institutes of Health Research New Investigator Award, Alberta Heritage Foundation for Medical Research Population Health Investigator Award and a Professorship in Pediatric Rehabilitation funded by the Children's Hospital Foundation through the Alberta Children's Hospital Research Institute for Child and Maternal Health.	Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; Cohen JS, 2009, CURR OPIN PEDIATR, V21, P288, DOI 10.1097/MOP.0b013e32832b1195; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Decloe M, 2009, CLIN J SPORT MED, V19, P247; Emery C, 2009, J SCI MED SPORT, V12, P180; Emery C, 2009, CLIN J SPORT MED, V19, P245; Emery CA, 2005, AM J SPORT MED, V33, P1882, DOI 10.1177/0363546505279576; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Sullivan SJ, 2009, CLIN J SPORT MED, V19, P228, DOI 10.1097/JSM.0b013e3181a41e43	19	55	55	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	DEC	2010	44	15					1112	1117		10.1136/bjsm.2009.071266			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	696CW	WOS:000285420500008	20966034				2022-02-06	
J	Liu, YR; Cardamone, L; Hogan, RE; Gregoire, MC; Williams, JP; Hicks, RJ; Binns, D; Koe, A; Jones, NC; Myers, DE; O'Brien, TJ; Bouilleret, V				Liu, Ying R.; Cardamone, Lisa; Hogan, R. Edward; Gregoire, Marie-Claude; Williams, John P.; Hicks, Rod J.; Binns, David; Koe, Amelia; Jones, Nigel C.; Myers, Damian E.; O'Brien, Terence J.; Bouilleret, Viviane			Progressive Metabolic and Structural Cerebral Perturbations After Traumatic Brain Injury: An In Vivo Imaging Study in the Rat	JOURNAL OF NUCLEAR MEDICINE			English	Article						traumatic brain injury; rat; F-18-FDG PET; MRI; anxiety	TEMPORAL-LOBE EPILEPSY; TIME-COURSE; MRI; HIPPOCAMPUS; PET; MODEL; DIFFUSION	Traumatic brain injury (TBI) has a high incidence of long-term neurologic and neuropsychiatric morbidity. Metabolic and structural changes in rat brains were assessed after TBI using serial F-18-FDG PET and 3-dimensional MRI in vivo. Methods: Rats underwent lateral fluid percussion injury (FPI; n = 16) or a sham procedure (n = 11). PET and MR images were acquired at 1 wk and at 1, 3, and 6 mo after injury. Morphologic changes were assessed using MRI-based regions of interest, and hippocampal shape changes were assessed with large-deformation high-dimensional mapping. Metabolic changes were assessed using region-of-interest analysis and statistical parametric mapping with the flexible factorial analysis. Anxiety-like behavior and learning were assessed at 1, 3, and 6 mo after injury. Results: PET analyses showed widespread hypometabolism in injured rats, in particular involving the ipsilateral cortex, hippocampus, and amygdalae, present at 1 wk after FPI, most prominent at 1 mo, and then decreasing. Compared with the sham group, rats in the FPI group had decreased structural volume which progressively increased over 3-6 mo, occurring in the ipsilateral cortex, hippocampus, and ventricles after FPI (P < 0.05). Large-deformation high-dimensional mapping showed evolving hippocampal shape changes across the 6 mo after FPI. Injured rats displayed increased anxiety-like behavior (P < 0.05), but there were no direct correlations between the severity of the behavior abnormalities and functional or structural imaging changes. Conclusion: In selected brain structures, FPI induces early hypometabolism and delayed progressive atrophic changes that are dynamic and continue to evolve for months. These findings have implications for the understanding of the pathophysiology and evolution of long-term neurologic morbidity following TBI, and indicate an extended window for targeted neuroprotective interventions.	[Bouilleret, Viviane] UNCE, CHU Bicetre, AP HP, Dept Neurophysiol & Epilepsy, F-94275 Le Kremlin Bicetre, France; [Liu, Ying R.; Cardamone, Lisa; Koe, Amelia; Jones, Nigel C.; Myers, Damian E.; O'Brien, Terence J.; Bouilleret, Viviane] Univ Melbourne, Dept Med, Royal Melbourne Hosp, Melbourne, Vic 3010, Australia; [Hogan, R. Edward] Washington Univ, Dept Neurol, St Louis, MO USA		Bouilleret, V (corresponding author), UNCE, CHU Bicetre, AP HP, Dept Neurophysiol & Epilepsy, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.	viviane.bouilleret@bct.aphp.fr	Bouilleret, viviane/AAQ-5878-2021; Myers, Damian E/L-5302-2013; Jones, Nigel C/K-7773-2012; O'Brien, Terence/AAU-5525-2021; O'Brien, Terence/L-8102-2013	Jones, Nigel/0000-0002-1080-8439; O'Brien, Terence/0000-0002-7198-8621; Hicks, Rodney/0000-0002-0758-0824; Hogan, Robert/0000-0003-2272-5005; Myers, Damian/0000-0002-7569-9907	Victorian Government Transport Accident Commission (TAC) [DP0023]; Australian NHMRCNational Health and Medical Research Council of Australia [400088]	We thank Prof. Gary Egan and the staff of the Small Animal MRI Facility, Howard Florey Institute, for assistance with MRI scanning. We also thank the radiochemistry staff of the Peter MacCallum Cancer Centre for assistance with <SUP>18</SUP>F-FDG PET. This work was supported by the Victorian Government Transport Accident Commission (TAC) in the form of a Victorian Neurotrauma Initiative Project grant (DP0023) and a project grant from the Australian NHMRC (400088).	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bernasconi N, 2003, BRAIN, V126, P462, DOI 10.1093/brain/awg034; Bouilleret V, 2009, J NEUROTRAUM, V26, P1999, DOI 10.1089/neu.2009.0943; Bouilleret V, 2009, NEUROIMAGE, V45, P267, DOI 10.1016/j.neuroimage.2008.12.019; Carobrez AP, 2005, NEUROSCI BIOBEHAV R, V29, P1193, DOI 10.1016/j.neubiorev.2005.04.017; Casteels C, 2006, J NUCL MED, V47, P1858; Cavada C, 2000, CEREB CORTEX, V10, P220, DOI 10.1093/cercor/10.3.220; Chassoux F, 2004, BRAIN, V127, P164, DOI 10.1093/brain/awh014; Csernansky JG, 1998, P NATL ACAD SCI USA, V95, P11406, DOI 10.1073/pnas.95.19.11406; Etkin A, 2009, ARCH GEN PSYCHIAT, V66, P1361, DOI 10.1001/archgenpsychiatry.2009.104; Hogan RE, 2008, J NEUROL NEUROSUR PS, V79, P636, DOI 10.1136/jnnp.2007.123406; Hogan RE, 2006, AM J NEURORADIOL, V27, P2149; Hogan RE, 2009, J MAGN RESON IMAGING, V29, P1027, DOI 10.1002/jmri.21766; Hogan RE, 2004, BRAIN, V127, P1731, DOI 10.1093/brain/awh197; IGARDNER R, 2005, CLIN ANAT, V18, P481; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; Jones NC, 2009, BEHAV BRAIN RES, V203, P81, DOI 10.1016/j.bbr.2009.04.023; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Jupp B, 2007, EPILEPSIA, V48, P82, DOI 10.1111/j.1528-1167.2007.01245.x; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; LOBKR H, 2006, Carr Alzheimer Res, V3, P327; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Posener JA, 2003, AM J PSYCHIAT, V160, P83, DOI 10.1176/appi.ajp.160.1.83; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Ryvlin P, 1998, BRAIN, V121, P2067, DOI 10.1093/brain/121.11.2067; Soto-Montenegro M, 2009, MOL IMAGING BIOL, V11, P94, DOI 10.1007/s11307-008-0179-7; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; van Kuyck K, 2007, NEUROIMAGE, V35, P214, DOI 10.1016/j.neuroimage.2006.12.009; YARNAKI T, 1996, J TRAUMA, V40, P50; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	38	55	57	0	11	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	NOV	2010	51	11					1788	1795		10.2967/jnumed.110.078626			8	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	674RQ	WOS:000283766000047	21051651	Bronze			2022-02-06	
J	Thurmond, VA; Hicks, R; Gleason, T; Miller, AC; Szuflita, N; Orman, J; Schwab, K				Thurmond, Veronica A.; Hicks, Ramona; Gleason, Theresa; Miller, A. Cate; Szuflita, Nicholas; Orman, Jean; Schwab, Karen			Advancing Integrated Research in Psychological Health and Traumatic Brain Injury: Common Data Elements	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Analysis, demographics; Biomarkers; Brain injuries, traumatic; Outcome measures; Rehabilitation; Stress disorders, posttraumatic	IRAQ	In civilian, military, and veteran populations, there is increased recognition of the interrelationship between traumatic brain injury (TBI) and some psychological health (PH) disorders and the need to better understand the relationships by integrating research for these topics. The use of different measures to assess similar study variables and/or assess outcomes may limit important advances in PH and TBI research. Without a set of common data elements (CDEs; to include variable definitions and recommended measures for the purpose of this discussion), comparison of findings across studies is challenging. The federal agencies involved in PH and TBI research, the National Institute of Neurological Disorders and Stroke, Department of Veterans Affairs, National Institute on Disability and Rehabilitation Research, Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury, and Defense and Veterans Brain Injury Center, therefore cosponsored a scientific initiative to develop CDEs for PH and TBI research. Scientific experts were invited to participate in 1 of 8 working groups to develop recommendations for specific topic-driven CDEs. Draft recommendations were presented and discussed in the workshop "Advancing Integrated Research in Psychological Health and Traumatic Brain Injury: Common Data Elements (CDE)" held on March 23-24, 2009, in Silver Spring, MD. The overall process leading to the workshop and subsequent recommendations by the working groups are presented in this article. Topic-driven recommendations for CDEs are presented in individual reports in this edition.	[Hicks, Ramona] Natl Inst Neurol Disorders & Stroke, Bethesda, MD USA; [Gleason, Theresa; Orman, Jean] Dept Vet Affairs, Washington, DC USA; [Miller, A. Cate] Natl Inst Disabil & Rehabil Res, US Dept Educ, Washington, DC USA; [Schwab, Karen] Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA; [Thurmond, Veronica A.; Szuflita, Nicholas] Def Ctr Excellence PH TBI, Silver Spring, MD 20910 USA		Thurmond, VA (corresponding author), Def Ctr Excellence PH TBI, 1335 East West Highway, Silver Spring, MD 20910 USA.	veronica.thurmond@us.anny.mil					Alexander MS, 2009, SPINAL CORD, V47, P582, DOI 10.1038/sc.2009.18; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kupersmith J, 2009, J REHABIL RES DEV, V46, pVII, DOI 10.1682/JRRD.2009.06.0079; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519	7	55	55	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2010	91	11					1633	1636		10.1016/j.apmr.2010.06.034			4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	681UQ	WOS:000284346400001	21044705				2022-02-06	
J	Oni, MB; Wilde, EA; Bigler, ED; McCauley, SR; Wu, TC; Yallampalli, R; Chu, ZL; Li, XQ; Hunter, JV; Vasquez, AC; Levin, HS				Oni, Margaret B.; Wilde, Elisabeth A.; Bigler, Erin D.; McCauley, Stephen R.; Wu, Trevor C.; Yallampalli, Ragini; Chu, Zili; Li, Xiaoqi; Hunter, Jill V.; Vasquez, Ana C.; Levin, Harvey S.			Diffusion Tensor Imaging Analysis of Frontal Lobes in Pediatric Traumatic Brain Injury	JOURNAL OF CHILD NEUROLOGY			English	Article						frontal lobe; traumatic brain injury; diffusion tensor imaging; outcome; Glasgow Coma Scale; Glasgow Outcome Scale	AXONAL INJURY; PRACTICAL SCALE; HEAD-INJURY; CHILDREN; MODERATE; PREDICTORS; DISABILITY; EXPERIENCE; CHILDHOOD; SEVERITY	This study examined the use of diffusion tensor imaging in detecting white matter changes in the frontal lobes following pediatric traumatic brain injury. A total of 46 children (ages 8-16 years) with moderate to severe traumatic brain injury and 47 children with orthopedic injury underwent 1.5 Tesla magnetic resonance imaging (MRI) at 3 months postinjury. Conventional MRI studies were obtained along with diffusion tensor imaging. Diffusion tensor imaging metrics, including fractional anisotropy, apparent diffusion coefficient, and radial diffusivity, were compared between the groups. Significant group differences were identified, implicating frontal white matter alterations in the injury group that were predictive of later Glasgow Outcome Scale ratings; however, focal lesions were not related to the Glasgow Outcome Scale ratings. Injury severity was also significantly associated with diffusion tensor imaging metrics. Diffusion tensor imaging holds great promise as an index of white matter integrity in traumatic brain injury and as a potential biomarker reflective of outcome.	[Wilde, Elisabeth A.; McCauley, Stephen R.; Yallampalli, Ragini; Li, Xiaoqi; Vasquez, Ana C.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Chu, Zili; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [McCauley, Stephen R.] Baylor Coll Med, Dept Pediat Hematol & Oncol, Houston, TX 77030 USA; [Bigler, Erin D.; Wu, Trevor C.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Inst Brain, Salt Lake City, UT USA; [Wilde, Elisabeth A.; Chu, Zili; Hunter, Jill V.] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA		Wilde, EA (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Ste 725, Houston, TX 77030 USA.	ewilde@bcm.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS021889]; TIRR Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	Dr Oni and Dr Wilde are both first authors and contributed equally to this work. We would like to acknowledge the generous support by Mission Connect of the TIRR Foundation. We acknowledge the contribution of Stacey K. Martin for assistance in manuscript preparation. We also wish to thank Ms Lori Cook and Drs Sandra B. Chapman and Gillian Hotz. We would also like to thank the patients and their families for their involvement in this study. Participants in this study were recruited from Children's Medical Center Dallas (Dallas, Texas), Parkland Memorial Hospital (Dallas, Texas), Cook Children's Medical Center (Fort Worth, Texas), Baylor Institute for Rehabilitation (Dallas, Texas), Our Children's House at Baylor (Dallas, Texas), Texas Children's Hospital (Houston, Texas), Jackson Memorial Hospital (Miami, Florida), and Miami Children's Hospital (Miami, Florida). Imaging was performed at the Texas Children's Hospital (Houston, Texas) and the Mary Nell and Ralph B. Rogers Magnetic Resonance Center at the University of Texas Southwestern Medical Center (Dallas, Texas) and Miami Children's Hospital (Miami, Florida). Image analysis was performed at the Baylor College of Medicine/Texas Children's Hospital Diagnostic Imaging Laboratory in Houston, Texas. Portions of this study were presented at the 2009 International Neuropsychological Society meeting, Atlanta, Georgia.; The authors disclosed receipt of the following financial support for the research and/or authorship of this article: this research was supported by grant NS021889 awarded to Harvey S. Levin by the National Institutes of Health.	Akpinar E, 2007, J COMPUT ASSIST TOMO, V31, P657, DOI 10.1097/RCT.0b013e318033df1a; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; Bigler ED, 2006, AM J PHYS MED REHAB, V85, P793, DOI 10.1097/01.phm.0000237873.26250.e1; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Carli P, 2004, LANCET, V363, P584, DOI 10.1016/S0140-6736(04)15626-2; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; *COMM INJ SCAL, 1990, ABBR INJ SCAL; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; JENNETT B, 1975, LANCET, V1, P480; Ker K, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a865; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; Lazar M, 2006, AM J NEURORADIOL, V27, P1258; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Netsch T, 2004, IEEE T MED IMAGING, V23, P789, DOI 10.1109/TMI.2004.827479; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Riggio S, 2009, MT SINAI J MED, V76, P163, DOI 10.1002/msj.20097; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; TEASDALE G, 1974, LANCET, V2, P81; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wang SL, 2009, CANCER RES, V69, P1190, DOI 10.1158/0008-5472.CAN-08-2661; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698; Yung A, 2007, PEDIATR RES, V61, P732, DOI 10.1203/pdr.0b013e31805365db	49	55	55	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	AUG	2010	25	8					976	984		10.1177/0883073809356034			9	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	625PS	WOS:000279908100006	20332386	Green Accepted			2022-02-06	
J	Yang, L; Afroz, S; Michelson, HB; Goodman, JH; Valsamis, HA; Ling, DSF				Yang, Lie; Afroz, Sonia; Michelson, Hillary B.; Goodman, Jeffrey H.; Valsamis, Helen A.; Ling, Douglas S. F.			Spontaneous Epileptiform Activity in Rat Neocortex after Controlled Cortical Impact Injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; epileptogenesis; ictal; interictal; traumatic brain injury	TRAUMATIC BRAIN-INJURY; FLUID PERCUSSION INJURY; NEURONS IN-VIVO; POSTTRAUMATIC EPILEPSY; SEIZURE ACTIVITY; EPILEPTOGENESIS; VITRO; INHIBITION; MICE; MECHANISMS	A hallmark of severe traumatic brain injury (TBI) is the development of post-traumatic epilepsy (PTE). However, the mechanisms underlying PTE remain poorly understood. In this study, we used a controlled cortical impact (CCI) model in rats to examine post-traumatic changes in neocortical excitability. Neocortical slices were prepared from rats at 7-9 days (week 1) and 14-16 days (week 2) after CCI injury. By week 2, we observed a substantial gray matter lesion with a cavity that extended to the hippocampal structure. Fluoro-Jade B staining of slices revealed active neuronal degeneration during weeks 1 and 2. Intracellular and extracellular recordings obtained from layer V revealed evoked and spontaneous epileptiform discharges in neocortices of CCI-injured rats. At week 1, intracellular recordings from pyramidal cells revealed evoked epileptiform firing that was synchronized with population events recorded extracellularly, suggestive of increased excitability. This activity was characterized by bursts of action potentials that were followed by recurrent, repetitive after-discharges. At week 2, both spontaneous and evoked epileptiform firing were recorded in slices from injured rats. The evoked discharges resembled those observed at week 1, but with longer burst durations. Spontaneous activity included prolonged, ictal-like discharges lasting up to 8-10 sec, and briefer interictal-like burst events (<1 sec). These results indicate that during the first 2 weeks following severe CCI injury, there is a progressive development of neocortical hyperexcitability that ultimately leads to spontaneous epileptiform firing, suggesting a rapid epileptogenic process.	[Yang, Lie; Afroz, Sonia; Michelson, Hillary B.; Goodman, Jeffrey H.; Ling, Douglas S. F.] SUNY Downstate Med Ctr, Dept Physiol & Pharmacol, Brooklyn, NY 11203 USA; [Michelson, Hillary B.; Goodman, Jeffrey H.; Ling, Douglas S. F.] SUNY Downstate Med Ctr, Program Neural & Behav Sci, Brooklyn, NY 11203 USA; [Yang, Lie; Michelson, Hillary B.; Goodman, Jeffrey H.; Valsamis, Helen A.; Ling, Douglas S. F.] SUNY Downstate Med Ctr, Robert F Furchgott Ctr Neural & Behav Sci, Brooklyn, NY 11203 USA; [Goodman, Jeffrey H.] New York State Inst Basic Res Dev Disabil, Dept Dev Neurobiol, Staten Isl, NY 10314 USA; [Valsamis, Helen A.] Kings Cty Hosp, Neurol Serv, Brooklyn, NY USA		Ling, DSF (corresponding author), SUNY Downstate Med Ctr, Dept Physiol & Pharmacol, 450 Clarkson Ave,Box 29, Brooklyn, NY 11203 USA.	douglas.ling@downstate.edu	Goodman, Jeffrey/AAG-8734-2020		Research Foundation of SUNY Principal Investigator Incentive program	The authors wish to thank Dr. Robert K.S. Wong for helpful comments and suggestions in the preparation of this manuscript, and Dr. David Brody and Katherine Schwetye for generously providing training and instruction in the CCI technique. This work was supported by funds from the Research Foundation of SUNY Principal Investigator Incentive program (to D.S.F.L).	Abdelmalik PA, 2005, EPILEPSIA, V46, P356, DOI 10.1111/j.0013-9580.2005.34204.x; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Avramescu S, 2009, J NEUROTRAUM, V26, P799, DOI 10.1089/neu.2008.0739; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V61, P747, DOI 10.1152/jn.1989.61.4.747; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Antuono M, 2010, EPILEPSIA, V51, P423, DOI 10.1111/j.1528-1167.2009.02273.x; Destexhe A, 2003, NAT REV NEUROSCI, V4, P739, DOI 10.1038/nrn1198; Destexhe A, 1999, J NEUROPHYSIOL, V81, P1531, DOI 10.1152/jn.1999.81.4.1531; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Fuortes MG, 2008, EPILEPSY RES, V82, P38, DOI 10.1016/j.eplepsyres.2008.07.002; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HAMMOND EJ, 1980, EPILEPSIA, V21, P3, DOI 10.1111/j.1528-1157.1980.tb04039.x; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762, DOI 10.1152/jn.1994.71.5.1762; Hudak AM, 2004, J HEAD TRAUMA REHAB, V19, P290, DOI 10.1097/00001199-200407000-00003; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kohling R, 2000, J NEUROSCI, V20, P6820, DOI 10.1523/JNEUROSCI.20-18-06820.2000; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Ling DSF, 1995, J NEUROPHYSIOL, V74, P2329, DOI 10.1152/jn.1995.74.6.2329; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; PRINCE DA, 1984, ANN NEUROL, V16, pS59, DOI 10.1002/ana.410160710; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276, DOI 10.1152/jn.1993.69.4.1276; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; RACINE RJ, 1975, ELECTROEN CLIN NEURO, V38, P1, DOI 10.1016/0013-4694(75)90204-7; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Somjen GG, 2002, NEUROSCIENTIST, V8, P254, DOI 10.1177/1073858402008003011; Timofeev I, 2010, NEUROSCIENTIST, V16, P19, DOI 10.1177/1073858409333545; Traub RD, 1996, EPILEPSIA, V37, P879, DOI 10.1111/j.1528-1157.1996.tb00042.x; YABLON SA, 2007, BRAIN INJURY MED PRI, P443; Yang L, 1997, J NEUROPHYSIOL, V78, P2804, DOI 10.1152/jn.1997.78.5.2804; Yang L, 2007, J NEUROPHYSIOL, V97, P178, DOI 10.1152/jn.01374.2005	42	55	58	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2010	27	8					1541	1548		10.1089/neu.2009.1244			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	639OU	WOS:000280984900017	20504156				2022-02-06	
J	Santiago, PN; Wilk, JE; Milliken, CS; Castro, CA; Engel, CC; Hoge, CW				Santiago, Patcho N.; Wilk, Joshua E.; Milliken, Charles S.; Castro, Carl A.; Engel, Charles C.; Hoge, Charles W.			Screening for Alcohol Misuse and Alcohol-Related Behaviors Among Combat Veterans	PSYCHIATRIC SERVICES			English	Article							TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; PRIMARY-CARE; MILITARY; IRAQ; DISORDERS; PERSONNEL; PTSD; DUTY	Objective: The U.S. military conducts health screenings of service members three to six months after they return from combat deployments. This population health program includes a modified version of the Two-Item Conjoint Screen (TICS), which is widely used in primary care to screen for alcohol misuse. Rates of referral in the military for alcohol treatment are very low, and the utility of these screening questions in predicting serious alcohol-related behaviors is unknown. Methods: Anonymous surveys were collected from 6,527 U. S. Army soldiers who were screened three to four months after returning from deployment to Iraq. Positive responses on the TICS alcohol screen were correlated with alcohol-related behaviors. Odds ratios (ORs) were calculated using logistic regression, after adjusting for gender, rank, race, and military component (active or reserve). Results: Twenty-seven percent of soldiers screened positive for alcohol misuse. Compared with soldiers who screened negative, those who screened positive were more likely to have recently engaged in the following behaviors: drinking and driving (OR=4.99, 95% confidence interval [CI]=4.31-5.76), riding with a driver who had been drinking (OR=5.87, CI=4.99-6.91), reporting late or missing work because of a hangover (OR=9.24, CI=6.73-12.68), using illicit drugs (OR=4.97, CI=3.68-6.71), being referred to alcohol rehabilitation (OR=7.15, CI=4.84-10.58), and being convicted of driving under the influence (OR=4.84, CI=3.04-7.67). Conclusions: Positive responses to a two-item alcohol screening tool were strongly associated with serious alcohol-related behaviors. This study highlights the need to improve screening and access to care for alcohol-related problems among service members returning from combat deployments. (Psychiatric Services 61:575-581, 2010)	[Santiago, Patcho N.; Engel, Charles C.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA; [Wilk, Joshua E.; Milliken, Charles S.; Castro, Carl A.; Hoge, Charles W.] Walter Reed Army Inst Res, Div Psychiat & Neurosci, Silver Spring, MD USA		Santiago, PN (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Psychiat, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	psantiago@usuhs.mil		Santiago, Patcho/0000-0003-0805-4313; Engel, Charles/0000-0002-9232-3389			Ames GM, 2007, J STUD ALCOHOL DRUGS, V68, P336, DOI 10.15288/jsad.2007.68.336; Bell N S, 2001, Inj Prev, V7, P4, DOI 10.1136/ip.7.1.4; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bliese P., 2005, POSTDEPLOYMENT PSYCH, V3; Bray RM, 2007, ADDICTION, V102, P1092, DOI 10.1111/j.1360-0443.2007.01841.x; Brown R L, 2001, J Am Board Fam Pract, V14, P95; Browne T, 2008, OCCUP ENVIRON MED, V65, P628, DOI 10.1136/oem.2007.036830; Day Andrew, 2003, Crim Behav Ment Health, V13, P45, DOI 10.1002/cbm.530; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hoge CW, 2005, AM J PSYCHIAT, V162, P585, DOI 10.1176/appi.ajp.162.3.585; Hosmer D, 1989, APPL LOGISTIC REGRES; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; MAXFIELD BD, 2005, ARMY PROFILE FY 05; McFarlane AC, 1998, ADDICT BEHAV, V23, P813, DOI 10.1016/S0306-4603(98)00098-7; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Solberg LI, 2008, AM J PREV MED, V34, P143, DOI 10.1016/j.amepre.2007.09.035; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Taft CT, 2007, J ABNORM PSYCHOL, V116, P498, DOI 10.1037/0021-843X.116.3.498; Wynd CA, 1998, MIL MED, V163, P283, DOI 10.1093/milmed/163.5.283	21	55	55	0	13	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	1075-2730			PSYCHIAT SERV	Psychiatr. Serv.	JUN	2010	61	6					575	581					7	Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry	602UT	WOS:000278165100008	20513680				2022-02-06	
J	Mans, RA; Chowdhury, N; Cao, D; McMahon, LL; Li, L				Mans, R. A.; Chowdhury, N.; Cao, D.; McMahon, L. L.; Li, L.			SIMVASTATIN ENHANCES HIPPOCAMPAL LONG-TERM POTENTIATION IN C57BL/6 MICE	NEUROSCIENCE			English	Article						statins; synaptic plasticity; learning and memory; cognitive function; protein phosphorylation; Alzheimer's disease	COA REDUCTASE INHIBITOR; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; PHOSPHATIDYLINOSITOL 3-KINASE; CORTICAL-NEURONS; INDUCED INCREASE; CONTROLLED TRIAL; AMYLOID PEPTIDE; STATINS; ATORVASTATIN	Statins inhibit 3-hydroxy-3-methylglutaryl CoA reductase, the rate-limiting enzyme in the cholesterol biosynthetic pathway, and they are widely used to control plasma cholesterol levels and prevent cardiovascular disease. However, emerging evidence indicates that the beneficial effects of statins extend to the CNS. Statins have been shown to improve the outcome of stroke and traumatic brain injury, and statin use has been associated with a reduced prevalence of Alzheimer's disease (AD) and dementia. However, prospective studies with statins in AD have produced mixed results. Recently, we reported that simvastatin, a widely used statin in humans, enhances learning and memory in non-transgenic mice as well as in transgenic mice with AD-like pathology on a mixed genetic background. However, the cellular and molecular mechanisms underlying the beneficial effects of simvastatin on learning and memory remain elusive. The present study was undertaken to investigate the effect of acute simvastatin treatment on hippocampal long-term potentiation (LTP), a cellular model of learning and memory, in brain slices from C57BL/6 mice. Our results demonstrate that a prolonged in vitro simvastatin treatment for 2-4 h, but not a short-term 20-min exposure, significantly increases the magnitude of LTP at CA3-CA1 synapses without altering basal synaptic transmission or the paired-pulse facilitation ratio in hippocampal slices. Furthermore, we show that phosphorylation of Akt (protein kinase B) is increased significantly in the CA1 region following 2-hour treatment with simvastatin, and that inhibition of Akt phosphorylation suppresses the simvastatin-induced enhancement of LTP. These findings suggest activation of Akt as a molecular pathway for augmented hippocampal LTP by simvastatin treatment, and implicate enhancement of hippocampal LTP as a potential cellular mechanism underlying the beneficial effects of simvastatin on cognitive function. (C) 2010 IBRO. Published by Elsevier Ltd. All rights reserved.	[Mans, R. A.; Chowdhury, N.; Cao, D.; Li, L.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Mans, R. A.; McMahon, L. L.; Li, L.] Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL 35294 USA; [McMahon, L. L.] Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA		Li, L (corresponding author), Univ Alabama Birmingham, Dept Med, 1808 7th Ave S,BDB 658, Birmingham, AL 35294 USA.	lili@uab.edu	McMahon, Lori/C-2922-2009	Li, Ling/0000-0002-9245-7387	National Institutes of Health NIA AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG-031846]; Neurobiology of Cognition and Cognitive Disorders Training [T32 NS-061788]; Neuroscience Blueprint Core [NS-57098]; anonymous philanthropic foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS061788, P30NS057098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG031846] Funding Source: NIH RePORTER	We thank Drs. Caroline Smith and Portia McCoy and Hailin Lu for technical support. This work was supported by the National Institutes of Health NIA Award AG-031846 to L. Li, the Neurobiology of Cognition and Cognitive Disorders Training Grant T32 NS-061788, Neuroscience Blueprint Core Grant NS-57098, and a grant from an anonymous philanthropic foundation to L. Li.	Balduini W, 2003, STROKE, V34, P2007, DOI 10.1161/01.STR.0000080677.24419.88; Bosel J, 2005, J NEUROCHEM, V92, P1386, DOI 10.1111/j.1471-4159.2004.02980.x; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Buxbaum JD, 2002, FRONT BIOSCI, V7, pA50, DOI 10.2741/buxbaum; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Clarke RM, 2008, J BIOL CHEM, V283, P1808, DOI 10.1074/jbc.M707442200; Clarke RM, 2007, NEUROPHARMACOLOGY, V52, P136, DOI 10.1016/j.neuropharm.2006.07.031; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Cordle A, 2005, J NEUROSCI, V25, P299, DOI 10.1523/JNEUROSCI.2544-04.2005; Costa ACS, 2005, NEUROSCI LETT, V382, P317, DOI 10.1016/j.neulet.2005.03.031; Endo A, 2004, ATHEROSCLEROSIS SUPP, V5, P67, DOI 10.1016/j.atherosclerosissup.2004.08.026; Esteban JA, 2003, NAT NEUROSCI, V6, P136, DOI 10.1038/nn997; Fassbender K, 2002, NEUROLOGY, V59, P1257, DOI 10.1212/WNL.59.8.1257; Hoffman DA, 2002, P NATL ACAD SCI USA, V99, P7740, DOI 10.1073/pnas.092157999; Hoglund K, 2005, EXP BRAIN RES, V164, P205, DOI 10.1007/s00221-005-2243-8; Hoglund K, 2004, ARCH NEUROL-CHICAGO, V61, P333, DOI 10.1001/archneur.61.3.333; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Jones PH, 2003, CLIN CARDIOL, V26, pI15; Kotti T, 2008, P NATL ACAD SCI USA, V105, P11394, DOI 10.1073/pnas.0805556105; Kotti TJ, 2006, P NATL ACAD SCI USA, V103, P3869, DOI 10.1073/pnas.0600316103; Kuenzi FM, 2000, J NEUROSCI METH, V100, P117, DOI 10.1016/S0165-0270(00)00239-9; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Li L, 2006, ANN NEUROL, V60, P729, DOI 10.1002/ana.21053; Liao JK, 2002, J CLIN INVEST, V110, P285, DOI 10.1172/JCI200216421; Lisman J, 2003, PHILOS T ROY SOC B, V358, P829, DOI 10.1098/rstb.2002.1242; Lu CB, 2001, EXP NEUROL, V170, P180, DOI 10.1006/exnr.2001.7686; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu Y, 2007, EMBO J, V26, P4879, DOI 10.1038/sj.emboj.7601884; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Nakao T, 2007, J PHARMACOL SCI, V105, P334, DOI 10.1254/jphs.FP0070682; Opazo P, 2003, J NEUROSCI, V23, P3679; Pooler AM, 2006, J NEUROCHEM, V97, P716, DOI 10.1111/j.1471-4159.2006.03763.x; Sanna PP, 2002, J NEUROSCI, V22, P3359; SAWADA M, 1975, ANN NY ACAD SCI, V243, P337, DOI 10.1111/j.1749-6632.1975.tb25375.x; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; Simons M, 2002, ANN NEUROL, V52, P346, DOI 10.1002/ana.10292; Sjogren M, 2003, DEMENT GERIATR COGN, V16, P25, DOI 10.1159/000069989; Skaletz-Rorowski A, 2003, CARDIOVASC RES, V57, P253, DOI 10.1016/S0008-6363(02)00618-1; Smith CC, 2006, J NEUROSCI, V26, P8517, DOI 10.1523/JNEUROSCI.5279-05.2006; Smith CC, 2005, J NEUROSCI, V25, P7780, DOI 10.1523/JNEUROSCI.0762-05.2005; Sparks DL, 2005, ARCH NEUROL-CHICAGO, V62, P753, DOI 10.1001/archneur.62.5.753; Tsvyetlynska NA, 2005, J NEUROPHYSIOL, V94, P3951, DOI 10.1152/jn.00201.2005; Vaughan CJ, 2003, AM J CARDIOL, V91, p23B, DOI 10.1016/S0002-9149(02)03270-8; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Wolozin B, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-20; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Yasuda H, 2003, NAT NEUROSCI, V6, P15, DOI 10.1038/nn985; Zacco A, 2003, J NEUROSCI, V23, P11104	48	55	56	1	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAR 17	2010	166	2					435	444		10.1016/j.neuroscience.2009.12.062			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	560PJ	WOS:000274914300011	20040368	Green Accepted			2022-02-06	
J	McIntosh, AS; McCrory, P; Finch, CF; Wolfe, R				McIntosh, A. S.; McCrory, P.; Finch, C. F.; Wolfe, R.			Head, face and neck injury in youth rugby: incidence and risk factors	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; PROSPECTIVE COHORT; DESCRIPTIVE EPIDEMIOLOGY; SURVEILLANCE SYSTEM; PERFORMANCE PROJECT; FOOTBALL PLAYERS; SPINAL-CORD; UNION; CONCUSSION; SPORTS	Objectives: In this study, the incidence of head, neck and facial injuries in youth rugby was determined, and the associated risk factors were assessed. Design: Data were extracted from a cluster randomised controlled trial of headgear with the football teams as the unit of randomisation. No effect was observed for headgear use on injury rates, and the data were pooled. Setting: General school and club-based community competitive youth rugby in the 2002 and 2003 seasons. Participants: Young male rugby union football players participating in under-13, under 15, under 18 and under 21 years competitions. Eighty-two teams participated in year 1 and 87 in year 2. Main outcome measures: Injury rates for all body regions combined, head, neck and face calculated for game and missed game injuries. Results: 554 head, face and neck injuries were recorded within a total of 28 902 h of rugby game exposure. Level of play and player position were related to injury risk. Younger players had the lowest rates of injury; forwards, especially the front row had the highest rate of neck injury; and inside backs had the highest rate of injuries causing the player to miss a game. Contact events, including the scrum and tackle, were the main events leading to injury. Conclusion: Injury prevention must focus on the tackle and scrum elements of a youth rugby game.	[McIntosh, A. S.] Univ New S Wales, Sch Risk & Safety Sci, Sydney, NSW 2052, Australia; [McCrory, P.] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia; [Finch, C. F.] Univ Ballarat, Sch Human Movement & Sport Sci, Ballarat, Vic, Australia; [Wolfe, R.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia		McIntosh, AS (corresponding author), Univ New S Wales, Sch Risk & Safety Sci, Sydney, NSW 2052, Australia.	a.mcintosh@unsw.edu.au	McCrory, Paul/Q-8688-2019	Wolfe, Rory/0000-0002-2126-1045; McCrory, Paul/0000-0003-4850-0568	International Rugby Board (IRB); NHMRCNational Health and Medical Research Council of Australia	This project was funded by the International Rugby Board (IRB). CF was funded by an NHMRC Principal Research Fellowship. The investigators were solely responsible for decisions regarding the design and conduct of the study, as well as collection, management, analysis and interpretation of the data. The authors prepared this manuscript, and it was sent to the IRB for approval. All authors and researchers are independent of the International Rugby Board, and the project was conducted independently. Statistical analyses were conducted in part by Dr Rory Wolfe from Monash University. Dr J P Best and Associate Professor D Chalmers were investigators on the randomised controlled trial of headgear. The authors would like to thank the following research assistants on the project: Ms M Romiti, Dr D Twomey, Mr C French and Mr T Savage. Thanks go to Mr John Searl from the Australian Rugby Union who liaised with the ARU and rugby clubs. Many other people contributed to the execution of the project-for example, primary data collectors, club/school personnel, team staff and medical personnel. We gratefully acknowledge their contributions.	Agel J, 2007, J ATHL TRAINING, V42, P270; Agel J, 2007, J ATHL TRAINING, V42, P241; Bahr R, 2005, BRIT J SPORT MED, V39, P324, DOI 10.1136/bjsm.2005.018341; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; Best JP, 2005, BRIT J SPORT MED, V39, P812, DOI 10.1136/bjsm.2004.016402; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Boufous S, 2004, AUST NZ J PUBL HEAL, V28, P482, DOI 10.1111/j.1467-842X.2004.tb00032.x; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Browne GJ, 2006, BRIT J SPORT MED, V40, P68, DOI 10.1136/bjsm.2005.020636; Carmody DJ, 2005, MED J AUSTRALIA, V182, P561, DOI 10.5694/j.1326-5377.2005.tb06814.x; Checkoway H, 2004, RES METHODS OCCUPATI; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; DURIE RM, 2000, NZ J SPORTS MED, V28, P84; Finch CF, 1997, SPORTS MED, V24, P157, DOI 10.2165/00007256-199724030-00002; Fuller CW, 2007, BRIT J SPORT MED, V41, P862, DOI 10.1136/bjsm.2007.037499; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2007, CLIN J SPORT MED, V17, P10, DOI 10.1097/JSM.0b013e31802e9c28; GARRAWAY M, 1995, LANCET, V345, P1485; Hagglund M, 2005, BRIT J SPORT MED, V39, P340, DOI 10.1136/bjsm.2005.018267; Junge A, 2004, BRIT J SPORT MED, V38, P168, DOI 10.1136/bjsm.2002.003020; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McIntosh Andrew S, 2005, Med Sport Sci, V49, P120, DOI 10.1159/000085394; McIntosh AS, 2005, BRIT J SPORT MED, V39, P314, DOI 10.1136/bjsm.2005.018200; MCINTOSH AS, 2004, 7 WORLD C INJ PREV S; MCINTOSH AS, 2005, P AUSTR C SCI MED SP; Murray D. M., 1998, DESIGN ANAL GROUP RA; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Quarrie KL, 2002, SPORTS MED, V32, P633, DOI 10.2165/00007256-200232100-00003; Quarrie KL, 2001, BRIT J SPORT MED, V35, P157, DOI 10.1136/bjsm.35.3.157; Sparks J P, 1981, Br J Sports Med, V15, P30	33	55	55	0	36	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	MAR	2010	44	3					188	193		10.1136/bjsm.2007.041400			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	569IR	WOS:000275590300007	18385188	Bronze			2022-02-06	
J	Holmes, MD; Tucker, DM; Quiring, JM; Hakimian, S; Miller, JW; Ojemann, JG				Holmes, Mark D.; Tucker, Don M.; Quiring, Jason M.; Hakimian, Shahin; Miller, John W.; Ojemann, Jeffrey G.			Comparing Noninvasive Dense Array and Intracranial Electroencephalography for Localization of Seizures	NEUROSURGERY			English	Article						Dense array electroencephalography; Epilepsy surgery; Intracranial electroencephalography; Refractory seizures; Source localization	SCALP EEG; DISCHARGES	OBJECTIVE: To compare the localization of the seizure onset zone estimated from ictal recordings with high spatial resolution, 256-channel scalp dense array electroencephalographic video long-term monitoring (LTM) with the aid of source analysis with that obtained from subsequent intracranial ictal recordings. METHODS: Ten patients with medically refractory epilepsy, all surgical candidates, underwent intracranial LTM after standard noninvasive evaluation failed to provide adequate localizing information regarding ictal origins. Before invasive studies, all patients underwent dense array electroencephalographic LTM in which habitual clinical seizures were recorded for each patient. Source analysis was applied to ictal onsets. Intracranial electrode placement followed conventional guidelines, although the neurosurgeon was aware of the dense array electroencephalographic results. Patients ranged in age from 10 to 49 years (mean age, 24 y); 7 were male. Identified risk factors included closed head injury in 1 patient and childhood meningitis in another. No focal neurological signs were found in any patient. Magnetic resonance imaging findings were normal in 6 patients; 1 patient had cerebellar hypoplasia, 1 had right frontoparietal dysplasia, 1 had bilateral nonspecific white matter abnormalities, and 1 had bilateral cavernous angiomas. RESULTS: Ictal onsets, based on invasive recordings, were in the mesiotemporal lobe (3 patients), lateroparietal (2 patients), mesioparietal (1 patient), laterofrontal (1 patient), superolateral frontocentral (11 patient), frontopolar (1 patient), and posteroinferior temporo-occipital neocortex (1 patient). Dense array electroencephalography localized ictal onsets to the same region as intracranial monitoring in 8 of 10 cases; invasive studies disclosed an additional ictal focus in 2 of these patients. Surgical resections were based only on intracranial electroencephalographic findings. CONCLUSION: Dense array electroencephalography has the potential to assist in the noninvasive localization of epileptic seizures and to guide the placement of invasive electrodes for localizing seizure onset.	[Holmes, Mark D.] Univ Washington, Harborview Med Ctr, Reg Epilepsy Ctr, Dept Neurol, Seattle, WA 98104 USA; [Miller, John W.; Ojemann, Jeffrey G.] Univ Washington, Dept Neurol Surg, Reg Epilepsy Ctr, Seattle, WA 98104 USA; [Tucker, Don M.; Quiring, Jason M.] Univ Oregon, Dept Psychol, Eugene, OR 97403 USA; [Tucker, Don M.; Quiring, Jason M.] Elect Geodes Inc, Eugene, OR USA		Holmes, MD (corresponding author), Univ Washington, Harborview Med Ctr, Reg Epilepsy Ctr, Dept Neurol, 325 9th Ave, Seattle, WA 98104 USA.	mdholmes@u.washington.edu		Ojemann, Jeffrey/0000-0001-7580-8934; Hakimian, Shahin/0000-0002-1310-2773			Engel J, 1996, NEW ENGL J MED, V334, P647, DOI 10.1056/NEJM199603073341008; Engel Jerome Jr., 1993, P609; Ferree TC, 2001, CLIN NEUROPHYSIOL, V112, P536, DOI 10.1016/S1388-2457(00)00533-2; Freeman WJ, 2006, CLIN NEUROPHYSIOL, V117, P1228, DOI 10.1016/j.clinph.2006.03.012; Freeman WJ, 2003, CLIN NEUROPHYSIOL, V114, P1053, DOI 10.1016/S1388-2457(03)00045-2; Holmes M, 2006, EPILEPSY SURG PRINCI, P247; Holmes MD, 2005, EPILEPSIA, V46, P136; Holmes MD, 2004, EPILEPSIA, V45, P1568, DOI 10.1111/j.0013-9580.2004.23204.x; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Lantz G, 2003, CLIN NEUROPHYSIOL, V114, P63, DOI 10.1016/S1388-2457(02)00337-1; Liu AK, 2002, HUM BRAIN MAPP, V16, P47, DOI 10.1002/hbm.10024; LUU P, 2008, EEG SENSOR ELECT ATT; Menendez RGD, 2004, NEUROIMAGE, V21, P527, DOI 10.1016/j.neuroimage.2003.09.051; Michel CM, 2001, BRAIN RES REV, V36, P108, DOI 10.1016/S0165-0173(01)00086-8; Michel CM, 2004, CLIN NEUROPHYSIOL, V115, P2195, DOI 10.1016/j.clinph.2004.06.001; Miller JW, 2007, NEUROIMAGE, V35, P583, DOI 10.1016/j.neuroimage.2006.12.018; MORRELL F, 1989, J NEUROSURG, V70, P231, DOI 10.3171/jns.1989.70.2.0231; Nunez P. L., 2006, ELECT FIELDS BRAIN N; PERRIN F, 1987, ELECTROEN CLIN NEURO, V66, P75, DOI 10.1016/0013-4694(87)90141-6; Plummer C, 2008, EPILEPSIA, V49, P201, DOI 10.1111/j.1528-1167.2007.01381.x; RAMON C, 2007, AM EP ANN M NOV 30 D; Russell GS, 2005, CLIN NEUROPHYSIOL, V116, P1130, DOI 10.1016/j.clinph.2004.12.022; Thompson Paul, 2008, Am J Electroneurodiagnostic Technol, V48, P93; Tucker D. M., 1994, HUMAN BRAIN MAPPING, V1, P134, DOI DOI 10.1002/HBM.460010206; Tucker DM, 2004, EPILEPSIA, V45, P71; Tucker DM, 2007, EPILEPSY BEHAV, V11, P546, DOI 10.1016/j.yebeh.2007.04.023; Vanhatalo S, 2003, NEUROLOGY, V60, P1098, DOI 10.1212/01.WNL.0000052993.37621.CC; Worrell GA, 2004, BRAIN, V127, P1496, DOI 10.1093/brain/awh149	28	55	56	1	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2010	66	2					354	362		10.1227/01.NEU.0000363721.06177.07			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	546RV	WOS:000273829400036	20087136				2022-02-06	
J	Reinhard, M; Neunhoeffer, F; Gerds, TA; Niesen, WD; Buttler, KJ; Timmer, J; Schmidt, B; Czosnyka, M; Weiller, C; Hetzel, A				Reinhard, Matthias; Neunhoeffer, Florian; Gerds, Thomas A.; Niesen, Wolf-Dirk; Buttler, Klaus-Juergen; Timmer, Jens; Schmidt, Bernhard; Czosnyka, Marek; Weiller, Cornelius; Hetzel, Andreas			Secondary decline of cerebral autoregulation is associated with worse outcome after intracerebral hemorrhage	INTENSIVE CARE MEDICINE			English	Article						Cerebral autoregulation; Spontaneous intracerebral hemorrhage; Transcranial Doppler sonography	ACUTE ISCHEMIC-STROKE; TRAUMATIC BRAIN-INJURY; CEREBROVASCULAR AUTOREGULATION; BLOOD-FLOW; PERFUSION-PRESSURE; TRIAL; FLUCTUATIONS; VALIDATION	Blood pressure management in acute intracerebral hemorrhage (ICH) relies on functioning cerebral autoregulation. The time course of autoregulation in acute ICH and its relation with clinical outcome are not known. Twenty-six patients with spontaneous ICH were studied on days 1, 3 and 5 after ictus. Autoregulation was noninvasively measured from spontaneous fluctuations of blood pressure and middle cerebral artery flow velocity (assessed by transcranial Doppler) using the correlation coefficient index Mx. From the same signals, non-invasive cerebral perfusion pressure was calculated. Results were compared with 55 healthy controls and related with clinical and radiological factors and 90-day outcome (modified Rankin scale). Average Mx values of all patients did not differ across days or from controls. Higher Mx (i.e., poorer autoregulation) on day 5 was significantly related with lower Glasgow coma score, ventricular hemorrhage (both sides) and lower noninvasive cerebral perfusion pressure (ipsilateral). Increasing ipsilateral Mx between days 3 and 5 was related with lower Glasgow coma score and ventricular hemorrhage. In a multivariate analysis controlling for other hemodynamic factors, higher ipsilateral Mx on day 5 (p = 0.013) was a significant predictor for poor 90-day outcome. Cerebral autoregulation is primarily preserved in acute ICH, but a secondary decline mainly ipsilateral to the ICH can occur. This is associated with poor clinical status, ventricular hemorrhage, lower cerebral perfusion pressure and worse clinical outcome.	[Reinhard, Matthias; Neunhoeffer, Florian; Niesen, Wolf-Dirk; Weiller, Cornelius; Hetzel, Andreas] Univ Freiburg, Dept Neurol, Neuroctr, D-79106 Freiburg, Germany; [Buttler, Klaus-Juergen] Univ Freiburg, Dept Neurosurg, Neuroctr, D-79106 Freiburg, Germany; [Gerds, Thomas A.] Univ Copenhagen, Dept Biostat, Copenhagen, Denmark; [Timmer, Jens] Univ Freiburg, Ctr Data Anal & Modeling, Freiburg, Germany; [Timmer, Jens] Univ Freiburg, Freiburg Inst Adv Studies FRIAS, Freiburg, Germany; [Schmidt, Bernhard] Med Ctr Chemnitz, Dept Neurol, Chemnitz, Germany; [Czosnyka, Marek] Univ Cambridge, Dept Neurosci, Acad Neurosurg Unit, Cambridge, England		Reinhard, M (corresponding author), Univ Freiburg, Dept Neurol, Neuroctr, Breisacherstr 64, D-79106 Freiburg, Germany.	matthias.reinhard@uniklinik-freiburg.de		Gerds, Thomas Alexander/0000-0002-5955-816X	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [He 1949/4-1, Ti 315/4-2]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G0001237, G9439390] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	M. R. acknowledges support from the Deutsche Forschungsgemeinschaft (He 1949/4-1 and Ti 315/4-2).	Anderson CS, 2008, LANCET NEUROL, V7, P391, DOI 10.1016/S1474-4422(08)70069-3; Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; Brady KM, 2008, STROKE, V39, P2531, DOI 10.1161/STROKEAHA.108.514877; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Bruder N, 1998, ANESTH ANALG, V86, P320, DOI 10.1097/00000539-199802000-00020; Christ M, 2007, INTENS CARE MED, V33, P246, DOI 10.1007/s00134-006-0451-8; Cipolla MJ, 2002, STROKE, V33, P2094, DOI 10.1161/01.STR.0000020712.84444.8D; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Dawson SL, 2000, CEREBROVASC DIS, V10, P126, DOI 10.1159/000016041; Diedler J, 2009, STROKE, V40, P815, DOI 10.1161/STROKEAHA.108.531020; Dohmen C, 2007, STROKE, V38, P56, DOI 10.1161/01.STR.0000251642.18522.b6; FitzMaurice E, 2008, STROKE, V39, P2151, DOI 10.1161/STROKEAHA.107.508861; Huttner HB, 2006, STROKE, V37, P404, DOI 10.1161/01.STR.0000198806.67472.5c; KANEKO T, 1983, J CEREB BLOOD FLO S1, V5, pS51; KLINGELHOFER J, 1992, STROKE, V23, P962, DOI 10.1161/01.STR.23.7.962; Kuwata N, 1995, NEUROSURG REV, V18, P237, DOI 10.1007/BF00383874; Lang EW, 2003, J NEUROTRAUM, V20, P69, DOI 10.1089/08977150360517191; Lang EW, 2002, J NEUROL NEUROSUR PS, V72, P583, DOI 10.1136/jnnp.72.5.583; Mendelow AD, 2005, LANCET, V365, P387; Merino JG, 2005, STROKE, V36, P232, DOI 10.1161/01.STR.0000153055.43138.2f; Powers WJ, 2001, NEUROLOGY, V57, P18, DOI 10.1212/WNL.57.1.18; Reinhard M, 2005, STROKE, V36, P1684, DOI 10.1161/01.STR.0000173183.36331.ee; Reinhard M, 2008, CEREBROVASC DIS, V26, P147, DOI 10.1159/000139662; Schmidt B, 2003, STROKE, V34, P84, DOI 10.1161/01.STR.0000047849.01376.AE; Soehle M, 2004, ANESTH ANALG, V98, P1133, DOI 10.1213/01.ANE.0000111101.41190.99; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steiner T, 2006, CEREBROVASC DIS, V22, P294, DOI 10.1159/000094831; STRANDGAARD S, 1976, CIRCULATION, V53, P720, DOI 10.1161/01.CIR.53.4.720; Tseng MY, 2005, STROKE, V36, P1627, DOI 10.1161/01.STR.0000176743.67564.5d; von Helden A, 1993, Acta Neurochir Suppl (Wien), V59, P102; Wang J, 2007, J CEREBR BLOOD F MET, V27, P894, DOI 10.1038/sj.jcbfm.9600403	31	55	59	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	FEB	2010	36	2					264	271		10.1007/s00134-009-1698-7			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546KU	WOS:000273810500012	19838669				2022-02-06	
J	Gerrard-Morris, A; Taylor, HG; Yeates, KO; Walz, NC; Stancin, T; Minich, N; Wade, SL				Gerrard-Morris, Aimee; Taylor, H. Gerry; Yeates, Keith Owen; Walz, Nicolay Chertkoff; Stancin, Terry; Minich, Nori; Wade, Shari L.			Cognitive development after traumatic brain injury in young children	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Head injuries; outcomes; Child development; Child; Preschool; Brain injuries; Neurobehavioral manifestations; Recovery of function	CLOSED-HEAD-INJURY; OUTCOME 30 MONTHS; EARLY-CHILDHOOD; LONGITUDINAL OUTCOMES; SOCIOECONOMIC-STATUS; EXECUTIVE FUNCTIONS; SOCIAL COMPETENCE; SHORT-TERM; FULL-TERM; RECOVERY	The primary aims of this study were to examine post-injury cognitive development in young Children with traumatic brain injury (TBI) and to investigate the role of the proximal family environment in predicting Cognitive Outcomes. Age at injury, was 3-6 years, and TBI was classified as severe (n = 23), moderate (n = 21), and complicated mild (n = 43). A comparison group of children who Sustained orthopedic injuries (OI, n = 117) was also recruited. Child cognitive assessments were administered at a post-acute baseline evaluation and repeated at 6, 12, and 18 months post-injury. Assessment of the family environment consisted of baseline measures of learning support and stimulation in the home and of parenting characteristics observed during videotaped parent-child interactions. Relative to the OI group, children with severe TBI group had generalized cognitive deficiencies and those with less severe TBI had weaknesses in Visual memory and executive function. Although deficits persisted or emerged across follow-up, more optimal family environments were associated with higher scores for all injury groups. The findings confirm other reports of poor recovery of cognitive skills following early childhood TBI and suggest environmental influences on outcomes. (JINS, 2010, 16, 157-168.)	[Gerrard-Morris, Aimee; Taylor, H. Gerry; Minich, Nori] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Gerrard-Morris, Aimee; Taylor, H. Gerry; Minich, Nori] Univ Hosp Case Med Ctr, Cleveland, OH USA; [Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA; [Walz, Nicolay Chertkoff] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH USA; [Walz, Nicolay Chertkoff; Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Pediat, Cleveland, OH USA; [Stancin, Terry] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Dept Rehabil, Cincinnati, OH USA		Taylor, HG (corresponding author), Div Dev Behav Pediat & Psychol, WO Walker Bldg,Suite 3150,10524 Euclid Ave, Cleveland, OH 44106 USA.	hgt2@case.edu	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD42729]; USPHS NIHUnited States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA [M01 RR 08084]; State of Ohio Emergency Medical Services; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039834, K02HD044099] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR008084] Funding Source: NIH RePORTER	Supported by grant R01 HD42729 to Dr. Wade from NICHD, in part by USPHS NIH grant no. M01 RR 08084, and by Trauma Research grants from the State of Ohio Emergency Medical Services. The authors wish to acknowledge the contributions of Christine Abraham. Andrea Beebe, Lori Bernard, Anne Birnbaum, Belli Bishop, Tammy Matecun, Karen Oberjohn, Elizabeth Roth, and Elizabeth Shaver in data collection and coding. The Cincinnati Children's Medical Center Trauma Registry. Rainbow Pediatric Trauma Center at Rainbow Babies & Children's Hospital, Nationwide Children's Hospital Trauma Program, and MetroHealth Center Department of Pediatrics and Trauma Registry provided assistance with recruitment.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson VA, 2000, BRAIN INJURY, V14, P679; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Barnes MA, 2001, BRAIN LANG, V76, P253, DOI 10.1006/brln.2000.2385; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Blair C, 2006, BEHAV BRAIN SCI, V29, P109; Bradley RH, 2002, ANNU REV PSYCHOL, V53, P371, DOI 10.1146/annurev.psych.53.100901.135233; BRADLEY RH, 1989, DEV PSYCHOL, V25, P217, DOI 10.1037/0012-1649.25.2.217; Bradley RH, 2000, J RES ADOLESCENCE, V10, P247, DOI 10.1207/SJRA1003_1; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Breslau N, 2001, AM J EPIDEMIOL, V154, P711, DOI 10.1093/aje/154.8.711; Burchinal MR, 2000, DEV PSYCHOL, V36, P793, DOI 10.1037//0012-1649.36.6.793; CALDWELL BM, 2000, HOME INVENTORY ADM M; Carrow-Woolfolk E, 2000, COMPREHENSIVE ASSESS; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Cohen J., 2013, STAT POWER ANAL BEHA; Collins WA, 2000, AM PSYCHOL, V55, P218, DOI 10.1037/0003-066X.55.2.218; Conger RD, 2007, ANNU REV PSYCHOL, V58, P175, DOI 10.1146/annurev.psych.58.110405.085551; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; DENNIS M, 1988, MASTER LECT SERIES C, P89; Donders J, 2005, J INT NEUROPSYCH SOC, V11, P386, DOI 10.1017/S1355617705050435; Elliott C. D., 1990, DIFFERENTIAL ABILITY; Espy KA, 1997, DEV NEUROPSYCHOL, V13, P495, DOI 10.1080/87565649709540690; Espy KA, 2001, MERRILL PALMER QUART, V47, P42, DOI 10.1353/mpq.2001.0001; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; Eyberg S., 1988, CHILD FAMILY BEHAV T, V10, P33, DOI [10.1300/J019v10n01_04, DOI 10.1300/J019V10N01_04]; Farah MJ, 2006, BRAIN RES, V1110, P166, DOI 10.1016/j.brainres.2006.06.072; Fiese B. H., 2001, ENV EFFECTS COGNITIV, P39; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; Kemp, 1998, NEPSY DEV NEUROPSYCH; LANDRY SH, 1990, CHILD DEV, V61, P1605, DOI 10.2307/1130768; Landry SH, 1998, CHILD DEV, V69, P105, DOI 10.1111/j.1467-8624.1998.tb06137.x; Landry SH, 1997, DEV PSYCHOL, V33, P1040, DOI 10.1037/0012-1649.33.6.1040; Landry SH, 2006, DEV PSYCHOL, V42, P627, DOI 10.1037/0012-1649.42.4.627; Landry SH, 1996, MERRILL PALMER QUART, V42, P177; Landry SH, 2003, DEV NEUROPSYCHOL, V24, P559, DOI 10.1207/S15326942DN242&3_04; Landry SH, 2002, DEV NEUROPSYCHOL, V21, P15, DOI 10.1207/S15326942DN2101_2; Landry SH, 2001, DEV PSYCHOL, V37, P387, DOI 10.1037//0012-1649.37.3.387; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; McLoyd VC, 1998, AM PSYCHOL, V53, P185, DOI 10.1037/0003-066X.53.2.185; Murray AD, 1997, DEV PSYCHOPATHOL, V9, P507, DOI 10.1017/S0954579497001272; Noble KG, 2005, DEVELOPMENTAL SCI, V8, P74, DOI 10.1111/j.1467-7687.2005.00394.x; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Rutter M, 2001, PSYCHOL BULL, V127, P291, DOI 10.1037//0033-2909.127.3.291; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Singer JD, 1998, J EDUC BEHAV STAT, V23, P323; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Smith KE, 2000, J SCHOOL PSYCHOL, V38, P27, DOI 10.1016/S0022-4405(99)00035-7; Stiles J, 2005, TRENDS COGN SCI, V9, P136, DOI 10.1016/j.tics.2005.01.002; Taylor HG, 2004, J INT NEUROPSYCH SOC, V10, P149, DOI 10.1017/S1355617704102038; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Taylor HG, 2000, NEUROPSYCHOLOGY, V14, P509, DOI 10.1037/0894-4105.14.4.509; TAYLOR HG, 1997, J INT NEUROPSYCH SOC, V3, P1; Taylor JH, 2008, AFR J AGR RES, V3, P1; TEASDALE G, 1974, LANCET, V2, P81; Verger K, 2000, BRAIN INJURY, V14, P495; Wade SL, 2008, REHABIL PSYCHOL, V53, P180, DOI 10.1037/0090-5550.53.2.180; Wade SL, 2009, J HEAD TRAUMA REHAB, V24, P239, DOI 10.1097/HTR.0b013e3181ad6680; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Woodcock R. W., 2001, WOODCOCKJOHNSON 3 TE; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	88	55	55	3	28	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2010	16	1					157	168		10.1017/S1355617709991135			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	543LR	WOS:000273579600017	19849883	Green Accepted			2022-02-06	
J	Nelson, NW; Hoelzle, JB; Sweet, JJ; Arbisi, PA; Demakis, GJ				Nelson, Nathaniel W.; Hoelzle, James B.; Sweet, Jerry J.; Arbisi, Paul A.; Demakis, George J.			[image omitted] Updated meta-analysis of the MMPI-2 symptom validity scale (FBS): verified utility in forensic practice	CLINICAL NEUROPSYCHOLOGIST			English	Article						Minnesota Multiphasic Personality Inventory-2; MMPI-2; Response validity assessment; Forensic neuropsychology	FAKE-BAD-SCALE; POSTTRAUMATIC-STRESS-DISORDER; MALINGERED NEUROCOGNITIVE DYSFUNCTION; PERSONAL-INJURY LITIGANTS; TRAUMATIC BRAIN-INJURY; HENRY-HEILBRONNER INDEX; LEES-HALEY; CLASSIFICATION ACCURACY; CONSTRUCT-VALIDITY; MCMI-II	Clinical research interest in the symptom reporting validity scale currently known as the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) Symptom Validity Scale (FBS) has continued to be strong, with multiple new publications annually in peer-reviewed journals that publish psychological and neuropsychological assessment research. Related to this growth in relevant literature, the present study was conducted to update the Nelson, Sweet, and Demakis (2006b) FBS meta-analysis. A total of 83 FBS studies (43 new studies) were identified, and 32 (38.5%) met inclusion criteria. Analyses were conducted on a pooled sample of 2218 over-reporting and 3123 comparison participants. Large omnibus effect sizes were observed for FBS, Obvious-Subtle (O-S), and the Dissimulation Scale-Revised (Dsr2) scales. Moderate effect sizes were observed for the following scales: Back Infrequency (Fb), Gough's F-K, Infrequency (F), Infrequency Psychopathology (Fp), and Dissimulation (Ds2). Moderator analyses illustrate that relative to the F-family scales, FBS exhibited larger effect sizes when (1) effort is known to be insufficient and (2) evaluation is conducted in the context of traumatic brain injury. Overall, current results summarize an extensive literature that continues to support use of FBS in forensic neuropsychology practice.	[Nelson, Nathaniel W.; Hoelzle, James B.; Arbisi, Paul A.] Minneapolis VA Med Ctr, Minneapolis, MN 55417 USA; [Nelson, Nathaniel W.; Arbisi, Paul A.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; [Sweet, Jerry J.] Northshore Univ Hlth Syst, Evanston, IL USA; [Sweet, Jerry J.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA; [Demakis, George J.] Univ N Carolina, Charlotte, NC USA		Nelson, NW (corresponding author), Minneapolis VA Med Ctr, Minneapolis, MN 55417 USA.	nels5363@umn.edu					Arbisi P. A., 2006, PSYCHOL SERV, V3, P249, DOI DOI 10.1037/1541-1559.3.4.249; Arbisi PA, 1995, PSYCHOL ASSESSMENT, V7, P424, DOI 10.1037/1040-3590.7.4.424; Arbisi PA, 2004, CLIN J PAIN, V20, P383, DOI 10.1097/00002508-200411000-00002; Arbisi PA, 2004, ARCH CLIN NEUROPSYCH, V19, P341, DOI 10.1016/j.acn.2003.12.003; Arbisi PA, 2002, PSYCHOL ASSESSMENT, V14, P3, DOI 10.1037//1040-3590.14.1.3; ARNOLD G, 2005, 33 ANN M INT NEUR SO; Bagby RM, 2000, ASSESSMENT, V7, P55, DOI 10.1177/107319110000700104; Ben-Porath Y. S., 2008, MINNESOTA MULTIPHASI; Ben-Porath YS, 2009, PSYCHOL INJ LAW, V2, P62, DOI 10.1007/s12207-009-9037-4; Berry D. T. R., 2007, ASSESSMENT MALINGERE, P226; Bianchini KJ, 2008, ASSESSMENT, V15, P435, DOI 10.1177/1073191108317341; Bianchini KJ, 2006, CLIN NEUROPSYCHOL, V20, P831, DOI 10.1080/13854040600875203; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Bianchini KJ, 2003, J OCCUP ENVIRON MED, V45, P1087, DOI 10.1097/01.jom.0000085886.18136.7d; Binder LM, 2006, CLIN NEUROPSYCHOL, V20, P848, DOI 10.1080/13854040500246927; Blanchard DD, 2003, J PERS ASSESS, V80, P197, DOI 10.1207/S15327752JPA8002_08; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; Burandt C. A., 2006, DISS ABSTR INT, V67, P2216; Bury AS, 2002, PSYCHOL ASSESSMENT, V14, P472, DOI 10.1037//1040-3590.14.4.472; Butcher J., 2008, PERSONALITY ASSESSME; Butcher JN, 2008, PSYCHOL INJ LAW, V1, P191, DOI 10.1007/s12207-007-9002-z; Butcher JN, 2003, ARCH CLIN NEUROPSYCH, V18, P473, DOI 10.1016/S0887-6177(02)00142-7; BUTCHER JN, 1989, MANUAL ADM SCORING T; CHARLES T, 1999, DISS ABSTR INT, V60, P5221; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cramer KM, 1995, J CLIN PSYCHOL, V51, P831, DOI 10.1002/1097-4679(199511)51:6<831::AID-JCLP2270510616>3.0.CO;2-O; Crawford EF, 2006, J PERS ASSESS, V86, P217, DOI 10.1207/s15327752jpa8602_11; CRAWFORD EF, 2004, DISS ABSTR INT, V65, P2090; CRESPO GS, 2007, REV PSICOLOGIA GEN A, V60, P299; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Dean AC, 2008, CLIN NEUROPSYCHOL, V22, P1054, DOI 10.1080/13854040701750891; Dearth CS, 2005, ARCH CLIN NEUROPSYCH, V20, P95, DOI 10.1016/j.acn.2004.03.004; Demakis GJ, 2008, CLIN NEUROPSYCHOL, V22, P879, DOI 10.1080/13854040701564482; Demakis GJ, 2003, NEUROPSYCHOLOGY, V17, P255, DOI 10.1037/0894-4105.17.2.255; Downing SK, 2008, CLIN NEUROPSYCHOL, V22, P680, DOI 10.1080/13854040701562825; DUKARM PD, 2006, DISS ABSTR INT, V67, P3447; Efendov AA, 2008, PSYCHOL ASSESSMENT, V20, P317, DOI 10.1037/a0013870; Elhai JD, 2000, J PERS ASSESS, V75, P449, DOI 10.1207/S15327752JPA7503_06; Elhai JD, 2001, ASSESSMENT, V8, P221, DOI 10.1177/107319110100800210; Eyler VA, 2000, ARCH CLIN NEUROPSYCH, V15, P834, DOI 10.1016/S0887-6177(00)80334-0; FOX DD, 1995, J CLIN PSYCHOL, V51, P42, DOI 10.1002/1097-4679(199501)51:1<42::AID-JCLP2270510108>3.0.CO;2-Z; Frueh BC, 1997, J PERS ASSESS, V68, P369, DOI 10.1207/s15327752jpa6802_8; GERVAIS R, 2005, ANN M NAT AC NEUR TA; Gervais RO, 2007, ARCH CLIN NEUROPSYCH, V22, P873; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; Gough H.G., 1950, J CONSULT PSYCHOL, V14, P408, DOI [10.1037/h0054506, DOI 10.1037/H0054506]; Gough HG, 1957, CALIFORNIA PSYCHOL I; GOUGH HG, 1954, J CONSULT PSYCHOL, V18, P287; Greene R. L, 1991, MMPI 2 MMPI INTERPRE; Greiffenstein M.F., 2007, ASSESSMENT FEIGNED C, P210; Greiffenstein MF, 2008, CLIN NEUROPSYCHOL, V22, P565, DOI 10.1080/13854040701377810; Greiffenstein MF, 2004, CLIN NEUROPSYCHOL, V18, P573, DOI 10.1080/13854040490888512; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greiffenstein MF, 2002, J CLIN PSYCHOL, V58, P1591, DOI 10.1002/jclp.10077; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 1996, AM PSYCHOL LAW SOC N; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P337, DOI 10.1016/j.acn.2003.12.005; GRILLO J, 1994, J CLIN PSYCHOL, V50, P651, DOI 10.1002/1097-4679(199407)50:4<651::AID-JCLP2270500424>3.0.CO;2-C; Guez M, 2005, J CLIN EXP NEUROPSYC, V27, P151, DOI 10.1080/13803390490515487; Hedges LV., 1981, J EDUC STAT, V6, P107, DOI [10.3102/10769986006002107, DOI 10.2307/1164588]; Henry GK, 2008, CLIN NEUROPSYCHOL, V22, P919, DOI 10.1080/13854040701625853; Henry GK, 2006, CLIN NEUROPSYCHOL, V20, P786, DOI 10.1080/13854040500287749; HINOJOSA L, 1993, DISS ABSTR INT, V54, P2203; Horwitz JE, 2006, ARCH CLIN NEUROPSYCH, V21, P551; Iverson GL, 2002, PSYCHOL REP, V90, P131, DOI 10.2466/PR0.90.1.131-136; IVERSON GL, 1995, PSYCHOL ASSESSMENT, V7, P118, DOI 10.1037/1040-3590.7.1.118; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; IVERSON GL, 2006, PSYCHOL INJURIES FOR; Lamberty G. J., 2008, UNDERSTANDING SOMATI; Lanyon RI, 2002, J AM ACAD PSYCHIATRY, V30, P400; Larrabee, 1997, Semin Clin Neuropsychiatry, V2, P196; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; LARRABEE GJ, 2007, ASSESSMENT MALINGERE, P264; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Lees-Haley PR, 2004, ARCH CLIN NEUROPSYCH, V19, P333, DOI 10.1016/j.acn.2003.12.004; Lees-Haley PR, 2002, J FORENSIC NEUROPSYC, V3, P167, DOI DOI 10.1300/J151V03N01_01; LeesHaley PR, 1997, J CLIN PSYCHOL, V53, P745, DOI 10.1002/(SICI)1097-4679(199711)53:7<745::AID-JCLP13>3.3.CO;2-7; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 1992, J CLIN PSYCHOL, V48, P681, DOI 10.1002/1097-4679(199209)48:5<681::AID-JCLP2270480516>3.0.CO;2-Q; LEESHALEY PR, 1994, J CLIN PSYCHOL, V50, P252, DOI 10.1002/1097-4679(199403)50:2<252::AID-JCLP2270500217>3.0.CO;2-T; Lipsey M.W., 2001, PRACTICAL META ANAL; LIPSEY MW, 1993, AM PSYCHOL, V48, P1181, DOI 10.1037/0003-066X.48.12.1181; Martin William F, 2005, Nutr Metab (Lond), V2, P25, DOI 10.1186/1743-7075-2-25; MCCARTHY J, 2005, 33 ANN M INT NEUR SO; MCCARTHY JR, 2004, DISS ABSTR INT, V65, P3171; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Millis SR., 2001, J FORENSIC NEUROPSYC, V2, P1, DOI [10.1300/J151v02n01_01, DOI 10.1300/J151V02N01_]; MILLIS SR, 1995, 30 ANN S REC DEV US; MITCHELL CA, 2008, DISS ABSTR INT, V68, P6975; Nelson NW, 2007, J INT NEUROPSYCH SOC, V13, P440, DOI 10.1017/S1355617707070373; Nelson NW, 2007, J CLIN EXP NEUROPSYC, V29, P67, DOI 10.1080/13803390500488546; Nelson NW, 2006, CLIN NEUROPSYCHOL, V20, P39, DOI 10.1080/13854040500459322; Nelson NW, 2006, J CLIN EXP NEUROPSYC, V28, P1, DOI 10.1080/13803390490919272; NELSON NW, 2005, AM AC CLIN NEUR MINN; Posthuma AB, 1998, PROF PSYCHOL-RES PR, V29, P437; Rawls KR, 2008, ARCH CLIN NEUROPSYCH, V23, P749; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; Rogers R., 1995, ASSESSMENT, V2, P81, DOI DOI 10.1177/1073191195002001008; Rogers R., 1994, ASSESSMENT, V1, P227, DOI DOI 10.1177/107319119400100302; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; Rosenthal R., 1994, HDB RES SYNTHESIS, P231, DOI DOI 10.7758/9781610441377.20; Ross SR, 2004, J CLIN EXP NEUROPSYC, V26, P115, DOI 10.1076/jcen.26.1.115.23933; SCHMIDT FL, 2003, HDB PSYCHOL, V12; Sellers S, 2006, PSYCHIAT PSYCHOL LAW, V13, P91; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; SHEA C, 2006, DISS ABSTR INT, V67, P560; SISUNG JRJ, 2006, DISS ABSTR INT, V66, P6330; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Soetaert DK, 2008, ARCH CLIN NEUROPSYCH, V23, P711; Staudenmayer H, 2007, J PSYCHOSOM RES, V62, P61, DOI 10.1016/j.jpsychores.2006.01.013; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Sweet JJ, 2006, CLIN NEUROPSYCHOL, V20, P541, DOI 10.1080/13854040590967135; Sweet JJ, 2006, CLIN NEUROPSYCHOL, V20, P206; Thomas ML, 2009, CLIN NEUROPSYCHOL, V23, P1067, DOI 10.1080/13854040902795000; Tsushima WT, 2001, ASSESSMENT, V8, P205, DOI 10.1177/107319110100800208; Van Gaasbeek JK, 2001, ARCH CLIN NEUROPSYCH, V16, P813; Vanderslice-Barr J, 2008, ARCH CLIN NEUROPSYCH, V23, P706; WEMAN TJ, 2005, 33 ANN M INT NEUR SO; Whitney KA, 2008, ARCH CLIN NEUROPSYCH, V23, P777, DOI 10.1016/j.acn.2008.09.001; WIENER DN, 1948, J CONSULT PSYCHOL, V12, P164, DOI 10.1037/h0055594; Wilkinson L, 1999, AM PSYCHOL, V54, P594, DOI 10.1037/0003-066X.54.8.594; Williams CL, 2009, PSYCHOL INJ LAW, V2, P182, DOI 10.1007/s12207-009-9046-3; WYGANT DB, 2008, DISS ABSTR INT, V68, P6975; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027	134	55	55	3	21	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2010	24	4					701	724	PII 922247870	10.1080/13854040903482863			24	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	597LR	WOS:000277759300175	20473828				2022-02-06	
J	Classen, S; Levy, C; McCarthy, D; Mann, WC; Lanford, D; Waid-Ebbs, JK				Classen, Sherrilene; Levy, Charles; McCarthy, Dennis; Mann, William C.; Lanford, Desiree; Waid-Ebbs, J. Kay			Traumatic Brain Injury and Driving Assessment: An Evidence-Based Literature Review	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						automobile driving; brain injuries; psychological tests; risk assessment; reproducibility of results	ABILITY; RETURN; FITNESS; TESTS; TBI	OBJECTIVE. We conducted a literature review of assessment tools predicting driving performance for people with traumatic brain injury (TBI). METHOD. Data sources were Web of Science, EBSCOhost, PubMed, and recently published literature from experts and team members not yet catalogued in the databases. We used the American Academy of Neurology's classification criteria to extract data from 13 studies, and we assigned a class (I-IV, with I being the highest level of evidence) to each study. We grouped primary studies into categories of driving assessment (neuropsychological; simulator; off-road; self-report, other report, and postinjury disability status; and comprehensive driving evaluation) and synthesized the predictability of these tools as it relates to driving performance for people with TBI. CONCLUSIONS. To assist clinicians and researchers in making decisions regarding testing the driving performance of people with TBI, we provide recommendations for neuropsychological tests; off-road tests; self-report, other report, and postinjury disability status; and comprehensive driving evaluation.	[Classen, Sherrilene; Mann, William C.; Lanford, Desiree] Univ Florida, Inst Mobil Act & Participat, Coll Publ Hlth & Hlth Profess, Gainesville, FL 32611 USA; [Classen, Sherrilene; Mann, William C.; Lanford, Desiree] Univ Florida, Dept Occupat Therapy, Coll Publ Hlth & Hlth Profess, Gainesville, FL 32611 USA; [Levy, Charles] N Florida S Georgia Vet Hlth Syst, Phys Med & Rehabil Serv, Gainesville, FL USA; [Levy, Charles] N Florida S Georgia Vet Hlth Syst, TBI PTSD, Gainesville, FL USA; [McCarthy, Dennis] Florida Int Univ, Dept Occupat Therapy, Coll Nursing & Hlth Sci, Miami, FL 33199 USA; [Mann, William C.; Waid-Ebbs, J. Kay] Univ Florida, Rehabil Sci Doctoral Program, Coll Publ Hlth & Hlth Profess, Gainesville, FL 32611 USA; [Waid-Ebbs, J. Kay] N Florida S Georgia Vet Hlth Syst, Brain Rehabil Res Ctr, Gainesville, FL USA		Classen, S (corresponding author), Univ Florida, Inst Mobil Act & Participat, Coll Publ Hlth & Hlth Profess, POB 100164, Gainesville, FL 32611 USA.	sclassen@phhp.ufl.edu					American Occupational Therapy Association, 2002, AM J OCCUPATIONAL TH, V62, P625; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; Cote Murray J, 2007, Health Care Manag Sci, V10, P253, DOI 10.1007/s10729-007-9018-7; Crooks Carol Y, 2007, Phys Med Rehabil Clin N Am, V18, P681, DOI 10.1016/j.pmr.2007.06.005; Fisk GD, 2002, J HEAD TRAUMA REHAB, V17, P16, DOI 10.1097/00001199-200202000-00004; Fisk GD, 1998, BRAIN INJURY, V12, P683; Franklin G., 2004, CLIN PRACTICE GUIDEL; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; Hedges LV., 1994, HDB RES SYNTHESIS; Heegaard W, 2007, EMERG MED CLIN N AM, V25, P655, DOI 10.1016/j.emc.2007.07.001; Innes CRH, 2007, J NEUROL SCI, V260, P188, DOI 10.1016/j.jns.2007.04.052; INNES CR, 2005, 27 ANN INT C IEEE EN; Korner-Bitensky N, 1994, Can J Occup Ther, V61, P141; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Leon-Carrion J, 2005, BRAIN INJURY, V19, P213, DOI 10.1080/02699050400017205; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; Marshall SC, 1999, CAN MED ASSOC J, V160, P1701; McMahon Brian T, 2005, Work, V25, P67; Meyers J E, 1999, Appl Neuropsychol, V6, P154, DOI 10.1207/s15324826an0603_3; Novack TA, 2006, BRAIN INJURY, V20, P455, DOI 10.1080/02699050600664541; ODENHEIMER GL, 1994, J GERONTOL, V49, P153, DOI DOI 10.1093/GERONJ/49.4.M153; Pietrapiana P, 2005, BRAIN INJURY, V19, P197, DOI 10.1080/02699050400017197; Rapport L, 2006, J HEAD TRAUMA REHAB, V21, P34, DOI 10.1097/00001199-200601000-00004; Richardson W. S., 2000, EVIDENCE BASED MED P, V2nd; Rizzo M, 1996, NEUROLOGIST, V2, P150; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; Schneider JJ, 2005, APPL NEUROPSYCHOL, V12, P138, DOI 10.1207/S15324826AN1203_3; Schultheis MT, 2003, REHABIL PSYCHOL, V48, P275, DOI 10.1037/0090-5550.48.4.275; Schultz SM, 2002, J WILDLIFE DIS, V38, P47, DOI 10.7589/0090-3558-38.1.47; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; Sundstrom A, 2008, TRANSPORT RES F-TRAF, V11, P1, DOI 10.1016/j.trf.2007.05.002; Tamietto M, 2006, NEUROREHABILITATION, V21, P81; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Yale Steven H, 2003, Clin Med Res, V1, P177	40	55	56	1	8	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490			AM J OCCUP THER	Am. J. Occup. Ther.	SEP-OCT	2009	63	5					580	591		10.5014/ajot.63.5.580			12	Rehabilitation	Social Science Citation Index (SSCI)	Rehabilitation	493SG	WOS:000269757700008	19785257				2022-02-06	
J	Huang, TT; Solano, J; He, DS; Loutfi, M; Dietrich, WD; Kuluz, JW				Huang, Tingting; Solano, Juan; He, Dansha; Loutfi, Maher; Dietrich, W. Dalton; Kuluz, John W.			Traumatic Injury Activates MAP Kinases in Astrocytes: Mechanisms of Hypothermia and Hyperthermia	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; astrocyte; hyperthermia; hypothermia; MAPKs; SP60025; traumatic brain injury	TRANSIENT FOREBRAIN ISCHEMIA; PERCUSSION BRAIN-INJURY; SPINAL-CORD-INJURY; PROTEIN-KINASE; REACTIVE ASTROCYTES; IN-VITRO; CULTURED ASTROCYTES; SIGNALING CASCADES; ENDOTHELIAL-CELLS; REGULATED KINASE	Hyperthermia is common following traumatic brain injury (TBI) and has been associated with poor neurologic outcome, and hypothermia has emerged as a potentially effective therapy for TBI, although its mechanism is still unclear. In this study we investigated the effects of temperature modulations on astrocyte survival following traumatic injury and the involved MAPK pathways. Trauma was produced by scratch injury of a monolayer of confluent astrocytes in culture, followed by incubation at hypothermia (30 degrees C), normothermia (37 degrees C), or hyperthermia (39 degrees C). The activation of MAPK pathways including extracellular signal-regulated protein kinase (ERK), c-Jun NH(2)-terminal kinase (JNK), and p38 MAPK were measured at 0, 15, 30, 60, and 120 min after traumatic injury followed by temperature modulation. Apoptosis of astrocytes was assessed by quantitation of cleaved caspase-3 expression 24 h after injury. Our findings showed that only JNK activation at 15 min after trauma was reduced by hypothermia, and this was associated with a marked reduction in apoptosis. Hyperthermia activated both ERK and JNK and increased apoptosis. The specific JNK inhibitor, SP60025, markedly reduced JNK-induced apoptosis at normothermia and hyperthermia, and showed a dose-dependent effect. In conclusion, the JNK pathway appears to mediate traumatic injury-induced apoptosis in astrocytes. Prolonged hyperthermia as a secondary insult worsens apoptosis by increasing JNK activation. Hypothermia protects against traumatic injury via early suppression on JNK activation and subsequent prevention of apoptosis. Manipulation of the JNK pathway in astrocytes may represent a therapeutic target for ameliorating the devastating progression of tissue injury and cell death after TBI.	[Huang, Tingting; Solano, Juan; He, Dansha; Kuluz, John W.] Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33101 USA; [Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33101 USA; [Loutfi, Maher] Univ S Alabama, Coll Med, Dept Neurol, Mobile, AL USA		Kuluz, JW (corresponding author), Univ Miami, Sch Med, POB 016960, Miami, FL 33101 USA.	jkuluz@bellsouth.net			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS089443, R01 NS042133] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, R01NS089443] Funding Source: NIH RePORTER		Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; ASCHNER M, 1991, NEUROTOXICOLOGY, V12, P505; Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Chen SH, 2008, TOXICOL SCI, V102, P138, DOI 10.1093/toxsci/kfm292; Cui W, 2001, GLIA, V34, P272, DOI 10.1002/glia.1061; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; Dihne M, 2001, BRAIN RES, V902, P178, DOI 10.1016/S0006-8993(01)02378-2; Dringen R, 2000, EUR J BIOCHEM, V267, P4912, DOI 10.1046/j.1432-1327.2000.01597.x; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fritz HG, 2004, J NEUROSURG ANESTH, V16, P43, DOI 10.1097/00008506-200401000-00009; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Haseloff RF, 2005, CELL MOL NEUROBIOL, V25, P25, DOI 10.1007/s10571-004-1375-x; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1089, DOI 10.1097/00004647-200007000-00008; Ikeda H, 2004, J NEUROSCI, V24, P9888, DOI 10.1523/JNEUROSCI.2608-04.2004; Jayakumar AR, 2008, J NEUROPATH EXP NEUR, V67, P417, DOI 10.1097/NEN.0b013e31816fc9d4; Katano H, 2001, NEUROSCI LETT, V306, P101, DOI 10.1016/S0304-3940(01)01832-8; Krum JM, 2008, EXP NEUROL, V212, P108, DOI 10.1016/j.expneurol.2008.03.019; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; Liu LP, 2007, FRONT BIOSCI-LANDMRK, V12, P816, DOI 10.2741/2104; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Moon C, 2004, BRAIN RES, V1028, P238, DOI 10.1016/j.brainres.2004.09.022; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Neary JT, 2005, IUBMB LIFE, V57, P711, DOI 10.1080/15216540500319143; Otani N, 2003, ACT NEUR S, V86, P287; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Rostworowski M, 1997, J NEUROSCI, V17, P3664; Siddharthan V, 2007, BRAIN RES, V1147, P39, DOI 10.1016/j.brainres.2007.02.029; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; Tanaka J, 1999, GLIA, V28, P85, DOI 10.1002/(SICI)1098-1136(199911)28:2<85::AID-GLIA1>3.0.CO;2-Y; VandeVord PJ, 2008, NEUROSCI LETT, V434, P247, DOI 10.1016/j.neulet.2008.01.056; Wanner IB, 2008, GLIA, V56, P1691, DOI 10.1002/glia.20721; Wilson JX, 1997, CAN J PHYSIOL PHARM, V75, P1149, DOI 10.1139/cjpp-75-10-11-1149; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306; YU ACH, 1989, J CEREBR BLOOD F MET, V9, P20, DOI 10.1038/jcbfm.1989.3; Yu CG, 2001, NEUROSURGERY, V49, P152, DOI 10.1097/00006123-200107000-00023	52	55	64	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1535	1545		10.1089/neu.2008.0743			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200010	19331517	Green Published			2022-02-06	
J	Katz-Leurer, M; Rotem, H; Keren, O; Meyer, S				Katz-Leurer, Michal; Rotem, Hemda; Keren, Ofer; Meyer, Shirley			The effects of a 'home-based' task-oriented exercise programme on motor and balance performance in children with spastic cerebral palsy and severe traumatic brain injury	CLINICAL REHABILITATION			English	Article							RESISTANCE EXERCISE; REHABILITATION; STAND; RELIABILITY	Objectives: To evaluate the feasibility and the ability to recruit and retain children with severe traumatic brain injury or cerebral palsy, and their families, to a simple home-based exercise programme and to assess the immediate and short-term effects of such intervention on reducing impairment and improving function. Study design: Randomized clinical trial. Participants: Twenty children aged 7-13 years, with traumatic brain injury (N = 10) or cerebral palsy (N = 10) who were independent ambulators. Five children from each group were randomly assigned to a control group - regular daily activities, or to an experimental group - regular daily activities plus a home-based task-oriented exercise programme of sit-to-stand and step-up exercise, for six weeks. Outcome measures: Feasibility: The number of participants who completed the programme protocol. Efficacy: Timed Up and Go Test and Functional Reach Test were used as functional balance tests. Maximal isometric strength was assessed by using a hand-held dynamometer; walking performance was assessed by the 10 m walk test, 2-minute walk test and Energy Expenditure Index. Results: Nine children completed all parts of the training programme. At the end of the intervention period an increase of 3 - 4 cm in the mean Functional Reach Test and a reduction of 1.6 +/- 2.1 seconds in the Timed Up and Go Test were noted (P < 0.01) in the experimental group while no changes were noted in the control group. In all other outcomes assessed no significant differences were noted between groups. The positive change in balance performance in the experimental group was maintained during a six-week follow-up period. Conclusions: A home-based task-oriented exercise programme can improve balance performance in children with spastic cerebral palsy or severe traumatic brain injury.	[Katz-Leurer, Michal] Tel Aviv Univ, Sackler Fac Med, Phys Therapy Dept, Sch Hlth Profess, IL-69978 Ramat Aviv, Israel; [Katz-Leurer, Michal; Rotem, Hemda; Keren, Ofer; Meyer, Shirley] Alyn Hosp, Pediat & Adolescent Rehabil Ctr, Jerusalem, Israel		Katz-Leurer, M (corresponding author), Tel Aviv Univ, Sackler Fac Med, Phys Therapy Dept, Sch Hlth Profess, IL-69978 Ramat Aviv, Israel.	michalkz@post.tau.ac.il					Baxter RE, 2003, J ORTHOP SPORT PHYS, V33, P40, DOI 10.2519/jospt.2003.33.1.40; Bodkin Amy Winter, 2003, Pediatr Phys Ther, V15, P247, DOI 10.1097/01.PEP.0000096384.19136.02; Brown DA, 1998, PHYS THER, V78, P934, DOI 10.1093/ptj/78.9.934; Byerly P N, 1994, J Athl Train, V29, P352; Carr J. H., 1998, NEUROLOGICAL REHABIL; DAMIANO DL, 1995, DEV MED CHILD NEUROL, V37, P731, DOI 10.1111/j.1469-8749.1995.tb15019.x; Dite W, 2002, ARCH PHYS MED REHAB, V83, P1566, DOI 10.1053/apmr.2002.35469; Dodd KJ, 2003, DEV MED CHILD NEUROL, V45, P652, DOI 10.1017/S0012162203001221; Donahoe B, 1994, PEDIAT PHYSICAL THER, V6, P189, DOI DOI 10.1097/00001577-199400640-00004; FISHER AC, 1988, PHYSICIAN SPORTSMED, V16, P47, DOI 10.1080/00913847.1988.11709551; Fragala-Pinkham MA, 2005, PHYS THER, V85, P1182, DOI 10.1093/ptj/85.11.1182; Greenwood E, 2003, NAT REV CANCER, V3, P7, DOI 10.1038/nrc978; Henry KD, 1999, PHYS THER, V79, P270, DOI 10.1093/ptj/79.3.270; Katz-Leurer M, 2008, PHYSIOTHERAPY, V94, P71, DOI 10.1016/j.physio.2007.04.003; Katz-Leurer Michal, 2008, Pediatr Phys Ther, V20, P254, DOI 10.1097/PEP.0b013e3181820dd8; Katz-Leurer Michal, 2008, Pediatr Phys Ther, V20, P259, DOI 10.1097/PEP.0b013e3181824782; Kosak M, 2005, J REHABIL RES DEV, V42, P103, DOI 10.1682/JRRD.2003.11.0171; Kraemer WJ, 2002, MED SCI SPORT EXER, V34, P364, DOI 10.1097/00005768-200202000-00027; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Liao HF, 2007, ARCH PHYS MED REHAB, V88, P25, DOI 10.1016/j.apmr.2006.10.006; Lin MR, 2004, J AM GERIATR SOC, V52, P1343, DOI 10.1111/j.1532-5415.2004.52366.x; Livingstone MBE, 2000, MED SCI SPORT EXER, V32, P1513, DOI 10.1097/00005768-200008000-00022; Lowes LP, 1996, PEDIATR PHYS THER, V8, P176; MATHIOWETZ V, 1985, OCCUP THER J RES, V5, P24, DOI 10.1177/153944928500500102; Mossberg KA, 2003, AM J PHYS MED REHAB, V82, P385, DOI 10.1097/01.PHM.0000052589.96202.BE; NICHOLAS F, 2004, PHYSIOTHERAPY, V90, P57; PAI YC, 1991, ARCH PHYS MED REHAB, V72, P881, DOI 10.1016/0003-9993(91)90004-3; RAYNOR DK, 1998, ADHERENCE TREATMENT, P83; RIDDLE DL, 1989, PHYS THER, V69, P182, DOI 10.1093/ptj/69.3.182; RIOLO L, 1993, PHYS THER, V73, P784, DOI 10.1093/ptj/73.11.784; Rivera JE, 2010, J SPORT REHABIL, V3, DOI 10.1123/jsr.3.2.154; Robertson RJ, 2006, MED SCI SPORT EXER, V38, P158, DOI 10.1249/01.mss.0000190595.03402.66; Schneiders AG, 1998, MAN THER, V3, P147, DOI DOI 10.1016/S1356-689X(98)80005-2; Seven YB, 2008, HUM MOVEMENT SCI, V27, P65, DOI 10.1016/j.humov.2007.11.001; SHUMWAYCOOK A, 1995, MOTOR CONTROL THEORY, P4; TEASDALE G, 1974, LANCET, V2, P81	36	55	59	1	31	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	AUG	2009	23	8					714	724		10.1177/0269215509335293			11	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	475UV	WOS:000268388200006	19506005				2022-02-06	
J	Prins, ML; Hovda, DA				Prins, Mayumi L.; Hovda, David A.			The Effects of Age and Ketogenic Diet on Local Cerebral Metabolic Rates of Glucose after Controlled Cortical Impact Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						age; metabolism; pediatric brain injury; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; BLOOD-FLOW; EMISSION-TOMOGRAPHY; FLUID PERCUSSION; LUMPED CONSTANT; ADULT RATS; CONTUSION; HYPERGLYCEMIA; MICRODIALYSIS	Previous studies from our laboratory have shown the neuroprotective potential of ketones after TBI in the juvenile brain. It is our premise that acutely after TBI, glucose may not be the optimum fuel and decreasing metabolism of glucose in the presence of an alternative substrate will improve cellular metabolism and recovery. The current study addresses whether TBI will induce age-related differences in the cerebral metabolic rates for glucose (CMRglc) after cortical controlled impact (CCI) and whether ketone metabolism will further decrease CMRglc after injury. Postnatal day 35 (PND35; n-48) and PND70 (n-42) rats were given either sham or CCI injury and placed on either a standard or a ketogenic (KG) diet. CMRglc studies using C-14-2deoxy-d-glucose autoradiography were conducted on days 1, 3, or 7 post-injury. PND35 and PND70 standard-fed CCI-injured rats exhibited no significant neocortical differences in CMRglc magnitude or time course compared to controls. Measurement of contusion volume also indicated no age differences in response to TBI. However, PND35 subcortical structures showed earlier metabolic recovery compared to controls than PND70. Ketosis induced by the KG diet was shown to affect CMRglc in an age-dependent manner after TBI. The presence of ketones after injury further reduced CMRglc in PND35 and normalized CMRglc in PND70 rats at 7 days bilaterally after injury. The changes in CMRglc seen in PND35 TBI rats on the KG diet were associated with decreased contusion volume. These results suggest that conditions of reduced glucose utilization and increased alternative substrate metabolism may be preferable acutely after TBI in the younger rat.	[Prins, Mayumi L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA		Prins, ML (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Brain Injury Res Ctr, Semel Room 18-228,Box 957039, Los Angeles, CA 90095 USA.	mprins@mednet.ucla.edu	Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	 [NS052406];  [NS27544];  [NS37363]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, R01NS037363, R01NS052406] Funding Source: NIH RePORTER	This work was supported by NS052406, NS27544, and NS37363.	Abo M, 2001, NEUROREPORT, V12, P1543, DOI 10.1097/00001756-200105250-00048; Alessandri B, 2000, ACTA NEUROCHIR SUPPL, V76, P425; AlMudallal AS, 1995, NEUROLOGY, V45, P2261, DOI 10.1212/WNL.45.12.2261; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; ANDERSEN BJ, 1989, INTRACRANIAL PRESSUR, V7, P575; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bartolucci EJ, 2007, IEEE IND APPL MAG, V13, P24, DOI 10.1109/MIA.2007.322272; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; CHEREL Y, 1988, METABOLISM, V37, P1033, DOI 10.1016/0026-0495(88)90063-7; Cherian L, 2004, J NEUROTRAUM, V21, P1196; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; CORDDRY DH, 1982, J NEUROCHEM, V38, P1637, DOI 10.1111/j.1471-4159.1982.tb06644.x; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; FEISE G, 1977, BRAIN RES, V126, P263, DOI 10.1016/0006-8993(77)90725-9; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GOODMAN JC, 1999, CRIT CARE MED, V27, P2063; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HIRT D, 2007, BRAIN B, V51; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; Jablonka J, 2006, ACTA NEUROBIOL EXP, V66, P261; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; MILLER AL, 1986, METAB BRAIN DIS, V1, P53, DOI 10.1007/BF00998477; NEDERGAARD M, 1988, J CEREBR BLOOD F MET, V8, P100, DOI 10.1038/jcbfm.1988.13; NEHLIG A, 1988, J NEUROSCI, V8, P2321; O'Connell MT, 2005, ACTA NEUROCHIR SUPPL, V95, P165; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Passineau MJ, 2000, AM J PHYSIOL-HEART C, V279, pH924, DOI 10.1152/ajpheart.2000.279.3.H924; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Randle P J, 1966, Recent Prog Horm Res, V22, P1; Richards HK, 2001, J CEREBR BLOOD F MET, V21, P779, DOI 10.1097/00004647-200107000-00002; Ritter AM, 1996, J NEUROTRAUM, V13, P473, DOI 10.1089/neu.1996.13.473; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; RUDERMAN NB, 1974, BIOCHEM J, V138, P1; SCHUIER F, 1990, J CEREBR BLOOD F MET, V10, P765, DOI 10.1038/jcbfm.1990.134; Scremin OU, 2007, BRAIN RES, V1141, P235, DOI 10.1016/j.brainres.2007.01.006; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SUTTON RL, 1994, ACTA NEUROCHIR, P446; TAKEI H, 1986, J NEUROCHEM, V46, P931, DOI 10.1111/j.1471-4159.1986.tb13059.x; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; VESPA P, 2006, CRIT CARE MED, V34, P400; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812	51	55	55	1	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2009	26	7					1083	1093		10.1089/neu.2008.0769			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	470HJ	WOS:000267965500014	19226210	Green Published			2022-02-06	
J	Yang, H; Cheng, XP; Li, JW; Yao, Q; Ju, G				Yang, Hao; Cheng, Xi-Ping; Li, Jing-Wen; Yao, Qin; Ju, Gong			De-differentiation Response of Cultured Astrocytes to Injury Induced by Scratch or Conditioned Culture Medium of Scratch-Insulted Astrocytes	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Astrocyte; De-differentiation; Rat; Nestin; GFAP	NEURAL STEM-CELLS; FIBROBLAST-GROWTH-FACTOR; TRAUMATIC BRAIN-INJURY; RAT SPINAL-CORD; RADIAL-GLIA; NERVOUS-SYSTEM; SUBVENTRICULAR ZONE; REACTIVE ASTROCYTES; PROGENITOR CELLS; MULLER CELLS	Our previous reports indicated that astrocytes (ASTs) in injured adult rat spinal cord underwent a process of de-differentiation, and may acquire the potential of neural stem cells (NSCs). However, the AST de-differentiation and transitional rejuvenation process following injury is still largely unclear. The aim of the present study was to determine whether injured in vitro ASTs can re-enter the multipotential-like stem cell pool and regain NSC characteristics, and to further understand the mechanism of AST de-differentiation. We used an in vitro scratch-wound model to evoke astrocytic response to mechanical injury. GFAP and nestin double-labeled indirect immunofluorescence were carried out to characterize these scratched cells at various periods. Western-blot analysis was used to determine the changes of GFAP and nestin expression following injury. Furthermore, the rate of proliferation was determined by immunocytochemical detection of BrdU incorporating cells. These scratch-wound ASTs were cultured with stem cells medium to explore their ability to generate neurospheres and examine the self-renewal and multi-potency of such neurospheres. Moreover, scratched AST culture supernatant as conditioned cultured medium (ACM) was used to investigate if some diffusible factors derived from injured ASTs could induce de-differentiation of AST. The results showed: (1) the nestin positivity first appeared in GFAP-positive cells at the edge of the scratch, subsequently, disseminated into un-insulted zone. The expression of nestin in AST was increased with longer culture, while that of GFAP was decreased. Furthermore, these nestin-immunoreactive ASTs could generate neurospheres, which showed self-renewal and could be differentiated into neurons, ASTs and oligodendrocytes. (2) Scratched ASTs culture supernatant can induce astrocytic proliferation and de-differentiation. These results reveal that the in vitro injured ASTs can de-differentiate into nestin-positive stem/precursor cells, the process of de-differentiation may arise from direct injury or some diffusible factors released from injured ASTs.	[Yang, Hao; Cheng, Xi-Ping; Li, Jing-Wen; Yao, Qin; Ju, Gong] Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Shaanxi, Peoples R China		Ju, G (corresponding author), Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Shaanxi, Peoples R China.	jugong@fmmu.edu.cn			National Basic Research Program of ChinaNational Basic Research Program of China [2003CB515301]; Chinese PLA national scientific technological project [06G089]	We thank Dr. Gautam Hebbar and Dr. Zhe Liang from Emory University for critical reading of the manuscript. This work was supported by the National Basic Research Program of China (2003CB515301) and Chinese PLA national scientific technological project (06G089).	AUBERT I, 1995, CURR OPIN NEUROBIOL, V5, P625, DOI 10.1016/0959-4388(95)80068-9; Barker Roger A, 2004, NeuroRx, V1, P472, DOI 10.1007/BF03206631; Bonfanti L, 2007, PROG NEUROBIOL, V83, P24, DOI 10.1016/j.pneurobio.2006.11.002; Bottai D, 2003, J HEMATOTH STEM CELL, V12, P655, DOI 10.1089/15258160360732687; Brawley C, 2004, SCIENCE, V304, P1331, DOI 10.1126/science.1097676; ChalmersRedman RME, 1997, NEUROSCIENCE, V76, P1121, DOI 10.1016/S0306-4522(96)00386-7; Chang ML, 2007, J ANAT, V210, P54, DOI 10.1111/j.1469-7580.2006.00671.x; Chen J, 2005, EUR J NEUROSCI, V22, P1895, DOI 10.1111/j.1460-9568.2005.04348.x; Diez del Corral R, 2003, NEURON, V40, P65; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; DRAGUNOW M, 1995, MOL BRAIN RES, V32, P279, DOI 10.1016/0169-328X(95)00088-A; Duggal N, 1997, BRAIN RES, V768, P1, DOI 10.1016/S0006-8993(97)00588-X; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Fischer AJ, 2002, J NEUROSCI, V22, P9387; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; Hung CH, 2006, BIOMATERIALS, V27, P5901, DOI 10.1016/j.biomaterials.2006.08.009; HUNTER KE, 1995, P NATL ACAD SCI USA, V92, P2061, DOI 10.1073/pnas.92.6.2061; ISHIKAWA R, 1991, NEUROSCI LETT, V127, P70, DOI 10.1016/0304-3940(91)90897-3; Itoh T, 2006, NEUROCHEM RES, V31, P1381, DOI 10.1007/s11064-006-9186-8; Kaya SS, 1999, BRAIN RES, V840, P153, DOI 10.1016/S0006-8993(99)01757-6; Kohno H, 2006, GRAEF ARCH CLIN EXP, V244, P90, DOI 10.1007/s00417-005-0030-7; Lang B, 2004, NEUROSCIENCE, V128, P775, DOI 10.1016/j.neuroscience.2004.06.033; Laywell ED, 2000, P NATL ACAD SCI USA, V97, P13883, DOI 10.1073/pnas.250471697; Leavitt BR, 1999, EXP NEUROL, V157, P43, DOI 10.1006/exnr.1999.6982; Lee J, 2003, DEV BIOL, V253, P84, DOI 10.1006/dbio.2002.0868; Lepore AC, 2006, NEUROSCIENCE, V142, P285, DOI 10.1016/j.neuroscience.2005.12.068; Liu Y, 2004, BIOL CELL, V96, P279, DOI 10.1016/j.biolcel.2004.02.001; MALHOTRA SK, 1990, CYTOBIOS, V61, P133; MartinezSerrano A, 1997, TRENDS NEUROSCI, V20, P530, DOI 10.1016/S0166-2236(97)01119-3; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Monnin J, 2007, NEUROSCI LETT, V421, P22, DOI 10.1016/j.neulet.2007.04.073; MORGANTIKOSSMANN MC, 1992, J NEUROIMMUNOL, V39, P163, DOI 10.1016/0165-5728(92)90185-N; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; Mori T, 2005, CURR TOP DEV BIOL, V69, P67, DOI 10.1016/S0070-2153(05)69004-7; Novitch BG, 2003, NEURON, V40, P81, DOI 10.1016/j.neuron.2003.08.006; Ooto S, 2004, P NATL ACAD SCI USA, V101, P13654, DOI 10.1073/pnas.0402129101; PHIFER CB, 1986, PHYSIOL BEHAV, V38, P887, DOI 10.1016/0031-9384(86)90058-2; Pillai R, 2006, EXP CELL RES, V312, P2336, DOI 10.1016/j.yexcr.2006.03.031; Rao MS, 1999, ANAT RECORD, V257, P137; Raymond PA, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-36; Rowitch DH, 2002, TRENDS NEUROSCI, V25, P417, DOI 10.1016/S0166-2236(02)02201-4; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; Schmid RS, 2003, P NATL ACAD SCI USA, V100, P4251, DOI 10.1073/pnas.0630496100; Sergent-Tanguy S, 2003, J NEUROSCI METH, V129, P73, DOI 10.1016/S0165-0270(03)00210-3; Sergent-Tanguy S, 2006, J NEUROSCI RES, V83, P1515, DOI 10.1002/jnr.20846; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Steindler DA, 2003, GLIA, V43, P62, DOI 10.1002/glia.10242; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Timiras PS, 2005, MECH AGEING DEV, V126, P3, DOI 10.1016/j.mad.2004.09.020; Yang H, 2006, CYTOTECHNOLOGY, V52, P87, DOI 10.1007/s10616-006-9033-4; Yu T, 2006, J CELL BIOCHEM, V99, P1096, DOI 10.1002/jcb.20979; Zhou RX, 2001, BRAIN RES BULL, V56, P37, DOI 10.1016/S0361-9230(01)00591-3	53	55	57	1	13	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	JUN	2009	29	4					455	473		10.1007/s10571-008-9337-3			19	Cell Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Neurosciences & Neurology	457IH	WOS:000266921200005	19130217				2022-02-06	
J	Chaiwat, O; Sharma, D; Udomphorn, Y; Armstead, WM; Vavilala, MS				Chaiwat, Onuma; Sharma, Deepak; Udomphorn, Yuthana; Armstead, William M.; Vavilala, Monica S.			Cerebral Hemodynamic Predictors of Poor 6-Month Glasgow Outcome Score in Severe Pediatric Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral autoregulation; outcome; pediatric; traumatic brain injury	SEVERE HEAD-INJURIES; BLOOD-FLOW; PERFUSION-PRESSURE; CHILDREN; AUTOREGULATION; HYPOTENSION; METABOLISM; AGE; SURVIVAL; MODERATE	Little is known regarding the cerebral autoregulation in pediatric traumatic brain injury (TBI). We examined the relationship between cerebral hemodynamic predictors, including cerebral autoregulation, and long-term outcome after severe pediatric TBI. After Institutional Review Board (IRB) approval, a retrospective analysis of prospectively collected data (May 2002 to October 2007) for children age <= 16 years with severe TBI (admission Glasgow Coma Scale [GCS] score < 9) was performed. Cerebral autoregulation was assessed within 72 h after TBI. Cerebral hemodynamic predictors (intracranial pressure [ICP], systolic blood pressure [SBP], and cerebral perfusion pressure [CPP]) through the first 72 h after TBI were abstracted. Univariate and multivariate analyses examined the relationship between impaired cerebral autoregulation (autoregulatory index <0.4), intracranial hypertension (ICP >20mmHg), and hypotension (SBP <5(th) percentile and CPP < 40 mm Hg). Six-month Glasgow Outcome Scale (GOS) score of <4 defined poor outcome. Ten (28%) of the 36 children examined (9.1 +/- 5.3 [0.8-16] years; 74% male) had poor outcome. Univariate factors associated with poor outcome were impaired cerebral autoregulation (p = 0.005), SBP < 5(th) percentile for age and gender ( p = 0.02), and low middle cerebral artery flow velocity (< 2 SD for age and gender; p = 0.04). Independent risk factors for poor 6-month GOS were impaired cerebral autoregulation (adjusted odds ratio [aOR] 12.0; 95% confidence interval [CI] 1.4-99.4) and hypotension (SBP <5(th) percentile; aOR 8.8; 95% CI 1.1-70.5), respectively. Previous studies of TBI describing poor outcome with hemodynamics did not consider the status of cerebral autoregulation. In this study, both impaired cerebral autoregulation and SBP < 5(th) percentile were independent risk factors for poor 6-month GOS.	[Vavilala, Monica S.] Univ Washington, Dept Anesthesiol, Harborview Med Ctr, Seattle, WA 98104 USA; [Chaiwat, Onuma; Udomphorn, Yuthana] Univ Washington, Harborview Anesthesiol Res Ctr, Seattle, WA 98104 USA; [Vavilala, Monica S.] Univ Washington, Dept Pediat, Seattle, WA 98104 USA; [Vavilala, Monica S.] Univ Washington, Dept Neurol Surg, Seattle, WA 98104 USA; [Vavilala, Monica S.] Harborview Injury Prevent & Res Ctr, Seattle, WA USA; [Armstead, William M.] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA		Vavilala, MS (corresponding author), Univ Washington, Dept Anesthesiol, Harborview Med Ctr, 325 Ninth Ave,Box 359724,7EH-77, Seattle, WA 98104 USA.	vavilala@u.washington.edu					Adelson P David, 2003, Pediatr Crit Care Med, V4, pS31; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS12; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; BODE H, 1988, APPL PEDIAT TRANSCRA; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; ELIASJONES AC, 1992, ARCH DIS CHILD, V67, P1430, DOI 10.1136/adc.67.12.1430; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Langlois JA, 2001, TRAUMATIC BRAIN INJU; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; NAKAYAMA DK, 1991, J TRAUMA, V31, P1521, DOI 10.1097/00005373-199111000-00010; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Puppo C, 2007, ACTA NEUROCHIR, V149, P139, DOI 10.1007/s00701-006-1074-0; Samant UB, 2008, J NEUROTRAUM, V25, P495, DOI 10.1089/neu.2007.0491; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; Tontisirin N, 2007, CHILD NERV SYST, V23, P1163, DOI 10.1007/s00381-007-0339-0; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vavilala MS, 2008, NEUROCRIT CARE, V9, P45, DOI 10.1007/s12028-007-9036-9; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003	29	55	59	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2009	26	5					657	663		10.1089/neu.2008.0770			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	452XM	WOS:000266574500002	19292656	Green Published			2022-02-06	
J	Bee, TK; Magnotti, LJ; Croce, MA; Maish, GO; Minard, G; Schroeppel, TJ; Zarzaur, BL; Fabian, TC				Bee, Tiffany K.; Magnotti, Louis J.; Croce, Martin A.; Maish, George O.; Minard, Gayle; Schroeppel, Thomas J.; Zarzaur, Ben L.; Fabian, Timothy C.			Necessity of Repeat Head CT and ICU Monitoring in Patients With Minimal Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Minimal brain injury; Repeat head CT; Traumatic head injury; Brain trauma; Intensive care monitoring; Traumatic brain injury	COMPUTED-TOMOGRAPHY; EXTRADURAL HEMATOMA; MANAGEMENT; ADMISSION; UTILITY	Background: Recent publications have dismissed the need for routine repeat computed tomography (CT) scans in patients with minimal brain injury (MBI) (Glasgow Coma Scale score 13-15 with positive initial CT) unless physical examination changes. In an attempt to better allocate scarce resources, we hypothesized that not only was repeat head CT unnecessary but also routine intensive care unit (ICU) monitoring of these patients with MBI and stable examinations were unnecessary. Methods: All blunt injured patients admitted to a level I trauma center from January 2005 through December 2007 who met our criteria for MBI (Glasgow Coma Scale score 14-15 with positive initial CT) were reviewed. All patients had ICU monitoring and repeat CT done (at 12-24 hours) regardless of clinical examination. Patients with skull fractures, facial fractures needing urgent repair, those requiring immediate neurosurgical intervention and those with other injuries requiring ICU monitoring were excluded. Data including demographics, initial brain injury, follow-up CT scan results, changes in clinical examination, neurosurgical interventions, and ICU days were recorded. Results: Two hundred seven patients met criteria. Fifty-eight patients (28%) developed worsening findings on follow-up CT or examination. Eighteen required invasive neurosurgicai intervention (6 intracranial pressure [ICP] monitors, 12 craniotomies) and I died (stroke). Those requiring ICP monitors had worsening intracranial hemorrhages (IPHs) with clinical examination changes or examination changes only, whereas those requiring craniotomy had worsening subaralmoid hemorrhage (2 patient), epidural hematoma (1 patient), and subdural hematoma (8 patients). Five of the subdural hematoma patients remained asymptomatic before craniotomy. ICU days were significantly increased in those patients with worsening CT findings who did not require neurosurgical intervention compared with those patients with unchanged or improved CT scans (5 days vs. 2.7 days, p <= 0002). Conclusions Routine follow-up CT scans are beneficial in those patients with MBI and may lead to higher levels of medical management or neurosurgical intervention in patients with worsening CT findings. These patients should be kept in an ICU setting until head CT has stabilized. With these dissimilar results from previous studies, a prospectively randomized multicentered trial would be beneficial.	[Bee, Tiffany K.; Magnotti, Louis J.; Croce, Martin A.; Maish, George O.; Minard, Gayle; Schroeppel, Thomas J.; Zarzaur, Ben L.; Fabian, Timothy C.] Univ Tennessee, Dept Gen Surg, Crit Care Trauma Div, Memphis, TN 38163 USA		Bee, TK (corresponding author), Univ Tennessee, Dept Gen Surg, Crit Care Trauma Div, Memphis, TN 38163 USA.	tbee@utmem.edu	Zarzaur, Ben/S-6572-2019	Zarzaur, Ben/0000-0001-9988-9572; Schroeppel, Thomas/0000-0001-9164-5004			BOROVICH B, 1985, J NEUROSURG, V63, P30, DOI 10.3171/jns.1985.63.1.0030; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; KRAUPS KL, 2004, J TRAUMA, V56, P475; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; MENDELOW AD, 1979, BRIT MED J, V1, P1240, DOI 10.1136/bmj.1.6173.1240; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Stein SC, 2008, J TRAUMA, V65, P66, DOI 10.1097/TA.0b013e318068d75f; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d	11	55	55	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2009	66	4					1015	1018		10.1097/TA.0b013e31819adbc8			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	431KI	WOS:000265059800013	19359908				2022-02-06	
J	Hanrieder, J; Wetterhall, M; Enblad, P; Hillered, L; Bergquist, J				Hanrieder, Jorg; Wetterhall, Magnus; Enblad, Per; Hillered, Lars; Bergquist, Jonas			Temporally resolved differential proteomic analysis of human ventricular CSF for monitoring traumatic brain injury biomarker candidates	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Traumatic brain injury (TBI); Ventricular cerebrospinal fluid (CSF); Shotgun proteomics; Protein quantification; Isobaric tag labeling; Matrix assisted laser desorption/ionization time of flight tandem mass spectrometry (MALDI TOF MS/MS)	NEURON-SPECIFIC ENOLASE; CEREBROSPINAL-FLUID; MASS-SPECTROMETRY; OUTCOME PREDICTION; SERUM MARKERS; PROTEIN; DAMAGE; ACCUMULATION; STRATEGIES; DISCOVERY	A shotgun proteomic approach based on nanoflow liquid chromatography (nanoLC) in conjunction with matrix assisted laser desorption/ionization time of flight tandem mass spectrometry (MALDI TOF MS/MS) was utilized to quantitatively analyze the protein content of consecutive ventricular cerebrospinal fluid (CSF) samples of severe traumatic brain injury (TBI) patients on an individual basis. CSF was acquired from the lateral ventricle 1-9 days after the TBI incident by canula drain to investigate temporally resolved protein changes in three patients that required intracranial pressure monitoring during neurointensive care. The samples were subjected to at once tryptic digestion followed by isobaric tag labeling before multiplexed peptide separation and MS analysis. By using this approach, we were able to follow characteristic changes in protein concentrations over time allowing new conclusions to be drawn about ongoing pathological processes during TBI. Certain suggested protein-biomarker candidates for TBI, like acute phase reactants (APRs), fibrinogens (FIB), cystatin C (CC) or more brain specific proteins like glial fibrillary acid protein (GFAP) and neuron-specific enolase (NSE) were found to be significantly up-regulated which is in strong consistence with previously reported results. This methodology appears to be a promising tool for studying candidate biomarkers of neurovascular and traumatic brain injuries in the neurointensive care setting. (C) 2008 Elsevier B.V. All rights reserved.	[Hanrieder, Jorg; Wetterhall, Magnus; Bergquist, Jonas] Uppsala Univ, Dept Phys & Analyt Chem Analyt Chem, SE-75124 Uppsala, Sweden; [Enblad, Per; Hillered, Lars] Univ Uppsala Hosp, Dept Neurosci Neurosurg, Uppsala, Sweden		Bergquist, J (corresponding author), Uppsala Univ, Dept Phys & Analyt Chem Analyt Chem, POB 599, SE-75124 Uppsala, Sweden.	jonas.bergquist@kemi.uu.se	Bergquist, Jonas/C-5894-2015; Hanrieder, Jorg/E-9706-2011	Bergquist, Jonas/0000-0002-4597-041X; Hillered, Lars/0000-0002-2808-9292	Swedish Agency for Innovation SystemsVinnova; Ahlen Foundation; Uppsala University Hospital; Swedish Research Counci; Swedish Research CouncilSwedish Research CouncilEuropean Commission [621-2005-5379, 342-2004-3944, 629-2002-6821, 2004-6210, 2007-3254 LH]	This research was supported by the Uppsala Berzelii Technology Center for Neurodiagnostics, with financing from the Swedish Agency for Innovation Systems, the Ahlen Foundation, Uppsala University Hospital and the Swedish Research Council. The Swedish Research Council (Grants 621-2005-5379, 342-2004-3944 and 629-2002-6821 (JB) 2004-6210 and 2007-3254 LH) is gratefully acknowledged for financial support.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; BERGER RP, 2002, PEDIATRICS, P109; Bergquist J, 2002, MASS SPECTROM REV, V21, P2, DOI 10.1002/mas.10016; Brancia FL, 2006, CURR ANAL CHEM, V2, P1, DOI 10.2174/157341106775197367; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Calvo KR, 2005, BIOSCIENCE REP, V25, P107, DOI 10.1007/s10540-005-2851-3; Conti A, 2004, J NEUROTRAUM, V21, P854, DOI 10.1089/0897715041526212; DAUBERSCHMIDT R, 1983, CLIN CHIM ACTA, V131, P165, DOI 10.1016/0009-8981(83)90085-2; Denslow N, 2003, J NEUROTRAUM, V20, P401, DOI 10.1089/089771503765355487; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Gygi SP, 2000, CURR OPIN CHEM BIOL, V4, P489, DOI 10.1016/S1367-5931(00)00121-6; Gygi SP, 2000, P NATL ACAD SCI USA, V97, P9390, DOI 10.1073/pnas.160270797; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; HORN M, 1995, STROKE, V26, P290, DOI 10.1161/01.STR.26.2.290; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; KAISER E, 1989, CLIN CHIM ACTA, V183, P13, DOI 10.1016/0009-8981(89)90268-4; Kay AD, 2003, J NEUROTRAUM, V20, P243, DOI 10.1089/089771503321532824; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Levy Efrat, 2008, Expert Rev Neurother, V8, P687, DOI 10.1586/14737175.8.5.687; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Mirgorodskaya E, 2005, PROTEOMICS, V5, P399, DOI 10.1002/pmic.200400984; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Ottens AK, 2005, ANAL CHEM, V77, P4836, DOI 10.1021/ac050478r; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Smith RD, 2000, NAT BIOTECHNOL, V18, P1041, DOI 10.1038/80226; Sundelof J, 2008, NEUROLOGY, V71, P1072, DOI 10.1212/01.wnl.0000326894.40353.93; Wang KKW, 2004, INT REV NEUROBIOL, V61, P215; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6	44	55	55	0	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	MAR 15	2009	177	2					469	478		10.1016/j.jneumeth.2008.10.038			10	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	407VV	WOS:000263393300027	19263575				2022-02-06	
J	Frechede, B; McIntosh, AS				Frechede, Bertrand; McIntosh, Andrew S.			Numerical Reconstruction of Real-Life Concussive Football Impacts	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						HEAD; RIGID BODY; MODEL; CONCUSSION; INJURY; TOLERANCE	RISK COMPENSATION; HEAD IMPACTS; INJURY; BIOMECHANICS; SPORT; SIDE	FRECHEDE, B., and A. S. MCINTOSH. Numerical Reconstruction of Real-Life Concussive Football Impacts. Med. Sci. Sports Exerc., Vol. 41, No. 2, pp. 390-398, 2009. Purpose: To present a protocol of numerical reconstructions of concussive events in football using MADYMO. To refine the knowledge of the dynamics associated with these events. Methods: Twenty-seven cases of concussive head impacts involving unhelmeted Australian football and rugby players were simulated Using MADYMO. The cases had been previously analyzed using a video analysis protocol and were fully reconstructed for the purpose of this study. The reliability of these reconstructions had been previously assessed using a sensitivity analysis of the influence of several independent variables on the dynamical outputs. The use of a complete human model enabled consideration for morphometry, initial movements of the players, and an accurate estimate of the effective masses involved in the impacts. Results: Mean peak values for concussion were found to be 103g for the head center of gravity linear acceleration, 8022 rad.s(-2) for the head angular acceleration, and 359 for the head impact criterion. An estimate of the average effective energy transferred to the head was 47 J. With the severity grading used in this study, the head impact power was found to be the best predictor of concussion severity. Conclusions: These biomechanical results compare well with other studies. They should contribute to the identification of the energy levels at which concussive impacts occur in football for the purpose of a better evaluation of protective devices in these sports.	[Frechede, Bertrand; McIntosh, Andrew S.] Univ New S Wales, Sch Risk & Safety Sci, Sydney, NSW 2052, Australia		Frechede, B (corresponding author), Univ New S Wales, Sch Risk & Safety Sci, Sydney, NSW 2052, Australia.	b.frechede@unsw.edu.au	FRECHEDE, Bertrand/H-3091-2018	FRECHEDE, Bertrand/0000-0002-9292-3544			ABEL J, 1978, P 22 STAPP CAR CRASH, V33; BAUMGARTNER D, 2001, P 2001 INT IRCOBI C, P353; BEUSENBERG M, 2001, P 2001 IRCOBI C BIOM, P295; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; Cheng HM, 1996, PROCEEDINGS OF THE 1996 FIFTEENTH SOUTHERN BIOMEDICAL ENGINEERING CONFERENCE, P251, DOI 10.1109/SBEC.1996.493162; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; FRECHEDE B, 2007, P 21 ESV C 2007 JUN, P1; Gennarelli TA, 1972, P 16 STAPP CAR CRASH, P296; Gilchrist A, 1996, ACCIDENT ANAL PREV, V28, P525, DOI 10.1016/0001-4575(96)00030-9; Gurdjian E S, 1972, Clin Neurosurg, V19, P1; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hodgson V.R., 1969, P 13 STAPP CAR CRASH, P18; King A. I., 2003, IRCOBI C LISB PORT; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 1998, SPORTS NEUROLOGY, P441; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2005, BRIT J SPORT MED, V39, P314, DOI 10.1136/bjsm.2005.018200; McIntosh AS, 2005, BRIT J SPORT MED, V39, P2, DOI 10.1136/bjsm.2004.016188; MILLER RT, 1998, P 42 STAPP CAR CRASH, P155; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; NEWMAN JA, 2000, P INT RES C BIOM IMP, P223; NEWMAN JA, 2000, STAPP CAR CRASH J, V44, P362; O'Riordain K, 2003, CLIN BIOMECH, V18, P590, DOI 10.1016/S0268-0033(03)00111-6; ONO K, 1980, P 24 STAPP CAR CRASH, P379; ONO K, 2002, P IRCOBI C 2002 SEP, P235; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Pincemaille Y, 1989, P 33 STAPP CAR CRASH, P177; Ruan JS, 1993, SAE TECHNICAL PAPERS, DOI [10. 4271/933114, DOI 10.4271/933114]; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI26, DOI 10.1136/bjsm.2005.019042; *TNO, 2005, MADYMO HUM MOD MAN V, P219; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; Withnall C, 2005, BRIT J SPORT MED, V39, pI49, DOI 10.1136/bjsm.2005.019182; ZHANG L, 2003, P IRCOBI C 2003 SEP, P27; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	40	55	55	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	FEB	2009	41	2					390	398		10.1249/MSS.0b013e318186b1c5			9	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	396OO	WOS:000262601200018	19127185				2022-02-06	
J	Stahel, PF; Flierl, MA; Morgan, BP; Persigehl, I; Stoll, C; Conrad, C; Touban, BM; Smith, WR; Beauchamp, K; Schmidt, OI; Ertel, W; Leinhase, I				Stahel, Philip F.; Flierl, Michael A.; Morgan, B. Paul; Persigehl, Ivonne; Stoll, Christiane; Conrad, Claudia; Touban, Basel M.; Smith, Wade R.; Beauchamp, Kathryn; Schmidt, Oliver I.; Ertel, Wolfgang; Leinhase, Iris			Absence of the complement regulatory molecule CD59a leads to exacerbated neuropathology after traumatic brain injury in mice	JOURNAL OF NEUROINFLAMMATION			English	Article							MEMBRANE ATTACK COMPLEX; CLOSED-HEAD INJURY; NEURONAL CELL-DEATH; NERVOUS-SYSTEM; ALTERNATIVE PATHWAY; BARRIER DYSFUNCTION; AXONAL INJURY; ACTIVATION; DEFICIENCY; INHIBITION	Background: Complement represents a crucial mediator of neuroinflammation and neurodegeneration after traumatic brain injury. The role of the terminal complement activation pathway, leading to generation of the membrane attack complex (MAC), has not been thoroughly investigated. CD59 is the major regulator of MAC formation and represents an essential protector from homologous cell injury after complement activation in the injured brain. Methods: Mice deleted in the Cd59a gene (CD59a(-/-)) and wild-type littermates (n = 60) were subjected to focal closed head injury. Sham-operated (n = 60) and normal untreated mice (n = 14) served as negative controls. The posttraumatic neurological impairment was assessed for up to one week after trauma, using a standardized Neurological Severity Score (NSS). The extent of neuronal cell death was determined by serum levels of neuron-specific enolase (NSE) and by staining of brain tissue sections in TUNEL technique. The expression profiles of pro-apoptotic (Fas, FasL, Bax) and anti-apoptotic (Bcl-2) mediators were determined at the gene and protein level by real-time RT-PCR and Western blot, respectively. Results: Clinically, the brain-injured CD59a(-/-) mice showed a significantly impaired neurological outcome within 7 days, as determined by a higher NSS, compared to wild-type controls. The NSE serum levels, an indirect marker of neuronal cell death, were significantly elevated in CD59a(-/-) mice at 4 h and 24 h after trauma, compared to wild-type littermates. At the tissue level, increased neuronal cell death and brain tissue destruction was detected by TUNEL histochemistry in CD59a(-/-) mice within 24 hours to 7 days after head trauma. The analysis of brain homogenates for potential mediators and regulators of cell death other than the complement MAC (Fas, FasL, Bax, Bcl-2) revealed no difference in gene expression and protein levels between CD59a(-/-) and wild-type mice. Conclusion: These data emphasize an important role of CD59 in mediating protection from secondary neuronal cell death and further underscore the key role of the terminal complement pathway in the pathophysiology of traumatic brain injury. The exact mechanisms of complement MAC-induced secondary neuronal cell death after head injury require further investigation.	[Stahel, Philip F.; Flierl, Michael A.; Touban, Basel M.; Smith, Wade R.] Univ Colorado, Sch Med, Dept Orthoped Surg, Denver Hlth Med Ctr, Denver, CO 80204 USA; [Schmidt, Oliver I.] Dept Trauma Surg & Orthopaed, Trauma Ctr St Georg, D-04129 Leipzig, Germany; [Beauchamp, Kathryn] Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Surg,Div Neurosurg, Denver, CO 80204 USA; [Persigehl, Ivonne; Stoll, Christiane; Conrad, Claudia; Ertel, Wolfgang; Leinhase, Iris] Charite Univ Med Ctr, Dept Trauma & Reconstruct Surg, D-12207 Berlin, Germany; [Morgan, B. Paul] Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales		Stahel, PF (corresponding author), Univ Colorado, Sch Med, Dept Orthoped Surg, Denver Hlth Med Ctr, Denver, CO 80204 USA.	philip.stahel@dhha.org; michael.flierl@dhha.org; morganbp@cardiff.ac.uk; ivonne.persigehl@charite.de; christiane.stoll@charite.de; claudia.conrad@charite.de; bmtouba@hotmail.com; wade.smith@dhha.org; kathryn.beauchamp@dhha.org; oliver.schmidt@sanktgeorg.de; wolfgang.ertel@charite.de; irisleinhase@freenet.de		Morgan, Paul/0000-0003-4075-7676	German Research FoundationGerman Research Foundation (DFG) [STA 635/2-1, STA 635/2-2]	This study was supported by the German Research Foundation (DFG) grants No. STA 635/2-1 and STA 635/2-2 to PFS, OIS, and WE. The project has been previously presented at the "11th European Meeting on Complement in Human Diseases" in Cardiff, Wales, UK, September 8-11, 2007. Parts of this work have been published in abstract form in the proceedings of this scientific meeting.	Baalasubramanian S, 2004, J IMMUNOL, V173, P3684, DOI 10.4049/jimmunol.173.6.3684; Barnum SR, 1999, MOL MED, V5, P569, DOI 10.1007/BF03402070; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Casarsa C, 2003, EUR J IMMUNOL, V33, P1260, DOI 10.1002/eji.200323574; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cole DS, 2006, MOL IMMUNOL, V43, P1953, DOI 10.1016/j.molimm.2005.11.015; Donev RM, 2008, MOL IMMUNOL, V45, P534, DOI 10.1016/j.molimm.2007.05.011; Farkas I, 1998, NEUROSCIENCE, V86, P903, DOI 10.1016/S0306-4522(98)00108-0; Holers VM, 2004, MOL IMMUNOL, V41, P147, DOI 10.1016/j.molimm.2004.03.012; Holt DS, 2001, BLOOD, V98, P442, DOI 10.1182/blood.V98.2.442; Huang YX, 2005, J BIOL CHEM, V280, P34073, DOI 10.1074/jbc.M504922200; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kimberley FC, 2007, MOL IMMUNOL, V44, P73, DOI 10.1016/j.molimm.2006.06.019; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Lindsberg PJ, 1996, ANN NEUROL, V40, P587, DOI 10.1002/ana.410400408; Mead RJ, 2004, LAB INVEST, V84, P21, DOI 10.1038/labinvest.3700015; Mead RJ, 2002, J IMMUNOL, V168, P458, DOI 10.4049/jimmunol.168.1.458; Morgan BP, 1999, CRIT REV IMMUNOL, V19, P173; Morgan BP, 2003, MOL IMMUNOL, V40, P159, DOI 10.1016/S0161-5890(03)00111-1; Morgan BP, 1997, EXP CLIN IMMUNOGENET, V14, P19; MULLEREBERHARD HJ, 1985, J INVEST DERMATOL, V85, pS47; Niculescu T, 2003, ANN NY ACAD SCI, V1010, P530, DOI 10.1196/annals.1299.098; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Sahu A, 2000, IMMUNOPHARMACOLOGY, V49, P133, DOI 10.1016/S0162-3109(00)80299-4; Singhrao SK, 1999, LAB INVEST, V79, P1247; Singhrao SK, 2000, AM J PATHOL, V157, P905, DOI 10.1016/S0002-9440(10)64604-4; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel Philip F, 2006, Expert Rev Clin Immunol, V2, P445, DOI 10.1586/1744666X.2.3.445; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Turnberg D, 2004, AM J PATHOL, V165, P825, DOI 10.1016/S0002-9440(10)63345-7; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; Xiong ZQ, 2003, J NEUROSCI, V23, P955; Yager PH, 2008, J CEREBR BLOOD F MET, V28, P1030, DOI 10.1038/sj.jcbfm.9600605; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497	42	55	55	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JAN 8	2009	6								2	10.1186/1742-2094-6-2			11	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	409WJ	WOS:000263536200001	19133139	Green Published, gold, Green Accepted			2022-02-06	
J	Colantonio, A; Croxford, R; Farooq, S; Laporte, A; Coyte, PC				Colantonio, Angela; Croxford, Ruth; Farooq, Samina; Laporte, Audrey; Coyte, Peter C.			Trends in Hospitalization Associated With Traumatic Brain Injury in a Publicly Insured Population, 1992-2002	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Epidemiology; Hospitalization; Age; Gender	LICENSE; DRIVERS	Background., Traumatic brain injury (TBI) is a leading cause of death and disability in developed countries. We document trends in TBI-related hospitalizations in Ontario, Canada, between April 1992 and March 2002, focusing on relationships between inpatient hospitalization rates, age, sex, cause of injury, severity level, and in-hospital mortality. Methods: Information on all acute hospital separations in Ontario with a diagnosis of TBI was analyzed using logistic regression. Results: Hospitalization rates fell steeply among children and young adults but remained stable among adults aged 66 and older. The proportion of TBI hospitalizations with mild injuries decreased from 75% to 54%, whereas the proportion with moderate injuries increased from 19% to 37%. Adjusting for other risk factors, in-hospital deaths were higher for injuries because of motor vehicle crashes than those because of falls. In-hospital death rates were stable for patients with moderate or severe injuries, but increased over time among those whose injuries were classified as mild, suggesting a trend toward more serious injury within the "mild" classification. Conclusions: Hospitalizations for TBI involve fewer mild injuries over time and are highest in the oldest segment of the population.	[Colantonio, Angela] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto Rehabil Inst, Toronto, ON M5G 1V7, Canada; [Croxford, Ruth] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Farooq, Samina] Univ Toronto, Dept Rehabil Sci, Toronto, ON M5G 1V7, Canada; [Laporte, Audrey; Coyte, Peter C.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON M5G 1V7, Canada; [Coyte, Peter C.] CHSRF CIHR Hlth Serv, Toronto, ON, Canada		Colantonio, A (corresponding author), Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto Rehabil Inst, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca		Colantonio, Angela/0000-0003-2094-4765	Ontario Neurotrauma Foundation; Toronto Rehabilitation Institute Foundation; Ontario Ministry of Health and Long-term careMinistry of Health and Long-Term Care, Ontario	This research was funded by the Ontario Neurotrauma Foundation and the Toronto Rehabilitation Institute Foundation. The Institute for Clinical Evaluative Sciences and the Toronto Rehabilitation Institute receives funding from the Ontario Ministry of Health and Long-term care.	ASBRIDGE M, DRUGS ED PR IN PRESS; Baldo V, 2003, EUR J EPIDEMIOL, V18, P1059, DOI 10.1023/A:1026192020963; *CAN I HLTH INF, 2003, HOSP INJ ADM ONT 200; Centers for Disease Control and Prevention, NAT CTR INJ PREV CON; FRAKEL JE, 2006, ARCH PHYS MED REHAB, V87, P57; KINGMA J, 1994, PERCEPT MOTOR SKILL, V78, P915, DOI 10.2466/pms.1994.78.3.915; MACPHERSON AK, 2008, PEDIATRICS, V110, P1; Mann RE, 2002, CAN J PUBLIC HEALTH, V93, P176, DOI 10.1007/BF03404995; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Peloso PM, 2004, J REHABIL MED, V36, P22, DOI 10.1080/16501960410023714; Pickett W, 2001, CAN MED ASSOC J, V165, P288; Pickett William, 2004, Chronic Dis Can, V25, P32; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; World Health Organization, 1978, INT CLASS DIS; Zhao JH, 2006, ACCIDENT ANAL PREV, V38, P35, DOI 10.1016/j.aap.2005.06.019; Zygun DA, 2005, CAN J NEUROL SCI, V32, P87, DOI 10.1017/S0317167100016930	16	55	56	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2009	66	1					179	183		10.1097/TA.0b013e3181715d66			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	395SJ	WOS:000262543500024	19131822				2022-02-06	
J	Kocsis, JD; Tessler, A				Kocsis, Jeffery D.; Tessler, Alan			Pathology of blast-related brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						barotrauma; blast injury; blast overpressure; blast-related; brain injury; blast underpressure; central nervous system; closed head injury; improvised explosive devices; neuropathology; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; INDUCED NEUROTRAUMA; INVOLVEMENT	Blasts are responsible for about two-thirds of the combat injuries in Operation Iraqi Freedom and Operation Enduring Freedom, which include at least 1,200 traumatic brain injuries. Blasts inflict damage to the brain directly and by causing injuries to other organs, resulting in air emboli, hypoxia, and shock. Direct injuries to the brain result from rapid shifts in air pressure (primary blast injury), from impacts with munitions fragments and other objects propelled by the explosion (secondary blast injury), and from collisions with objects and rapid acceleration of individuals propelled by the explosion (tertiary blast injury). Tertiary injury can occur from a building or other structure collapsing and from an individual being thrown by the blast wind. The pathological consequences of secondary and tertiary blast injuries are very likely to be similar to those of other types of mechanical trauma seen in civilian life. The damage attributable to the specific effects of a blast, however, has received little study, although it has been assumed to include the focal and diffuse lesions characteristic of closed head injuries. Available clinical studies of blast injuries show focal damage similar to that found in other types of closed head injuries but have not determined whether diffuse axonal injury also occurs. In this article, we will try to reach a better understanding of the specific pathology of blast-related brain injury by reviewing the available experimental studies and the autopsy reports of victims of terrorist attacks and military casualties dating back to World War I.	[Kocsis, Jeffery D.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; [Kocsis, Jeffery D.] Yale Univ, Sch Med, Ctr Neurosci & Regenerat Res, New Haven, CT 06510 USA; [Kocsis, Jeffery D.] Dept Vet Affairs VA Connecticut Healthcare Syst, Rehabil Res Ctr, West Haven, CT USA; [Tessler, Alan] Philadelphia VA Med Ctr, Dept Neurol, Philadelphia, PA USA		Kocsis, JD (corresponding author), Yale Univ, Sch Med, Neurosci Res Ctr 127A, VA CT Healthcare Syst, West Haven, CT 06516 USA.	jeffery.kocsis@yale.edu			Department of Veterans AffairsUS Department of Veterans Affairs	This material was supported by the Department of Veterans Affairs.	Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; CLEMEDSON CJ, 1956, PHYSIOL REV, V36, P336, DOI 10.1152/physrev.1956.36.3.336; COHEN H, 1946, ARCH PATHOL, V42, P12; CRAMER F, 1949, ARCH NEURO PSYCHIATR, V61, P1; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296, DOI 10.1152/physrev.1945.25.2.296; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; FABING HD, 1947, ARCH NEURO PSYCHIATR, V57, P14, DOI 10.1001/archneurpsyc.1947.02300240030002; Guy R J, 2000, J R Nav Med Serv, V86, P27; HIRSCH AE, 1972, J NEUROSURG, V37, P95, DOI 10.3171/jns.1972.37.1.0095; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Knudsen SK, 2003, NEUROSCI RES, V46, P377, DOI 10.1016/S0168-0102(03)00101-9; Macleod AD, 2004, J ROY SOC MED, V97, P86, DOI 10.1258/jrsm.97.2.86; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Mott FW, 1916, LANCET, V1, P441; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; MURTHY JMK, 1979, J NEUROSURG, V50, P260, DOI 10.3171/jns.1979.50.2.0260; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; *WAR OFF COMM ENQ, 1922, REP WAR OFF COMM ENQ; Wightman JM, 2001, ANN EMERG MED, V37, P664, DOI 10.1067/mem.2001.114906; Yilmaz S, 2007, AM J EMERG MED, V25, P97, DOI 10.1016/j.ajem.2006.04.014	24	55	57	0	10	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2009	46	6					667	671		10.1682/JRRD.2008.08.0100			5	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	531BQ	WOS:000272638100004	20104396	Bronze			2022-02-06	
J	Muscara, F; Catroppa, C; Eren, S; Anderson, V				Muscara, Frank; Catroppa, Cathy; Eren, Senem; Anderson, Vicki			The impact of injury severity on long-term social outcome following paediatric traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							CLOSED-HEAD-INJURY; EARLY-CHILDHOOD; CHILDREN; RECOVERY; BEHAVIOR; FAMILY; ADOLESCENCE; INTEGRATION; COMPETENCE; PREDICTORS	Despite suggestions that paediatric traumatic brain injury (TBI) disrupts social skill development, few studies have investigated long-term social outcome following the transition into adulthood. The current study aimed to investigate long-term social outcome, in a sample of 36 survivors who suffered a mild, moderate or severe TBI between 8 and 12 years of age. At 7-10 years post-injury, the age of participants ranged between 16 and 22 years. Social outcome was assessed using a number of self-rated and parent-rated questionnaires, in order to obtain self-and other-rated accounts of the groups' current social functioning. Predictors of long-term social outcome were also explored, with findings suggesting that young people who suffered mild TBI during childhood tended to be functioning at a higher level on some measures of social functioning, compared to those that suffered a moderate and severe injury. Further, results suggested that pre-injury adaptive functioning and socio-economic status predicted long-term functioning for some measures of social outcome. Finally, social problem-solving skills predicted the success of social reintegration post-TBI. These preliminary findings indicate that there is a risk of social difficulties following paediatric TBI continuing into adulthood, and that a number of demographic, social, and neuropsychological variables continue to predict social outcome even at this late stage post-injury.	[Muscara, Frank; Catroppa, Cathy; Eren, Senem; Anderson, Vicki] Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki] Royal Childrens Hosp, Melbourne, Vic, Australia; [Muscara, Frank; Catroppa, Cathy; Eren, Senem; Anderson, Vicki] Univ Melbourne, Melbourne, Vic 3010, Australia		Muscara, F (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	frank.muscara@mcri.edu.au	Catroppa, Cathy/AAX-9458-2021	Catroppa, Cathy/0000-0002-9750-0436			Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Bohnert AM, 1997, DEV NEUROPSYCHOL, V13, P477, DOI 10.1080/87565649709540688; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Ciccetti D., 1984, VINELAND ADAPTIVE BE; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; Daniel A., 1983, POWER PRIVILEGE PRES; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; DZURILLA TJ, 1998, MANUAL SOCIAL PROBLE; Gioia GA IP, 2000, BEHAV RATING INVENTO; Gresham FM., 1990, SOCIAL SKILLS RATING; Harrison P. L., 2003, ADAPTIVE BEHAV ASSES, V2nd; Hessen E, 2008, BRAIN INJURY, V22, P39, DOI 10.1080/02699050701846179; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Jonsson CA, 2004, BRAIN INJURY, V18, P921, DOI 10.1080/02699050410001671900; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; McGann W, 1997, BRAIN INJURY, V11, P621, DOI 10.1080/026990597123179; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Noller P., 1988, ICPS FAMILY FUNCTION; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; Rath JF, 2003, REHABIL PSYCHOL, V48, P137, DOI 10.1037/0090-5550.48.3.137; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Tabachnick B.G., 2001, USING MULTIVARIATE S; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Taylor HG, 2000, CHILD DEV, V71, P1495, DOI 10.1111/1467-8624.00242; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Warschausky S, 1997, Pediatr Rehabil, V1, P77; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; [No title captured]; [No title captured]	48	55	55	0	13	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2009	19	4					541	561		10.1080/09602010802365223			21	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	539EJ	WOS:000273236100003	18839384				2022-02-06	
J	Stovner, LJ; Schrader, H; Mickeviciene, D; Surkiene, D; Sand, T				Stovner, L. J.; Schrader, H.; Mickeviciene, D.; Surkiene, D.; Sand, T.			Headache after concussion	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						cohort study; concussion; headache; migraine; prognosis	LATE WHIPLASH SYNDROME; FREQUENT HEADACHE; MILD HEAD; INJURY; EPIDEMIOLOGY; EXPECTATION; PREVALENCE; PAIN; MIGRAINE; COHORT	Chronic post-traumatic headache attributed to mild head injury is a somewhat disputed headache diagnosis. A main object of this study was to assess the validity of this diagnosis by studying the headache pattern of concussed patients that participated in one historic (n = 131) and one prospective cohort (n = 217) study. Head injury patients were recruited from two hospitals in Kaunas, Lithuania. Controls were recruited amongst patients with minor orthopaedic traumas not involving the head and neck. When data from the two studies were pooled, no difference in any headache category (diagnosis, attack frequency, symptoms) was found one or more years after the trauma, except that photophobia was somewhat more prevalent amongst the concussed patients. In both injury groups, the existence of pre-traumatic headache was a predictor of post-traumatic headache, although pre-traumatic headache seems to have been underreported amongst the concussed patients. There was a significant negative correlation between the duration of unconsciousness and the headache. This negative correlation, and the lack of specificity indicates that headache occurring 3 months or more after concussion is not caused by the head or brain injury. Rather it may represent an episode of one of the primary headaches, possibly induced by the stress of the situation.	[Stovner, L. J.; Schrader, H.] Norwegian Univ Sci & Technol, Norwegian Natl Headache Ctr, Dept Neurosci, N-7034 Trondheim, Norway; [Stovner, L. J.; Schrader, H.; Sand, T.] St Olavs Hosp, Dept Neurol & Clin Neurophysiol, Trondheim, Norway; [Mickeviciene, D.; Surkiene, D.] Kaunas Univ Med, Dept Neurol, Kaunas, Lithuania		Stovner, LJ (corresponding author), Univ Trondheim Hosp, Norwegian Natl Headache Ctr, N-7006 Trondheim, Norway.	lars.stovner@ntnu.no	Stovner, Lars Jacob/D-5025-2014	Schrader, Harald/0000-0001-9975-1960			ALVES WM, 1990, NEUROLOGICAL SURG, P2219; Boardman HF, 2003, CEPHALALGIA, V23, P129, DOI 10.1046/j.1468-2982.2003.00468.x; Castillo J, 1999, HEADACHE, V39, P190, DOI 10.1046/j.1526-4610.1999.3903190.x; Castro WHM, 2001, INT J LEGAL MED, V114, P316, DOI 10.1007/s004140000193; Couch JR, 2007, NEUROLOGY, V69, P1169, DOI 10.1212/01.wnl.0000276985.07981.0a; De Benedittis G, 1983, J Neurosurg Sci, V27, P177; DROTTNING M, 1995, NORD J PSYCHIAT, V49, P293, DOI 10.3109/08039489509011919; Ferrari R, 2001, J NEUROL NEUROSUR PS, V70, P722, DOI 10.1136/jnnp.70.6.722; Ferrari R, 2001, CLIN NEUROL NEUROSUR, V103, P184, DOI 10.1016/S0303-8467(01)00143-3; Ferrari Robert, 2002, Med Sci Monit, V8, pCR728; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Haas DC, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-17; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Hagen K, 2002, CEPHALALGIA, V22, P672, DOI 10.1046/j.1468-2982.2002.00413.x; Hasvold T, 1996, SCAND J PRIM HEALTH, V14, P92, DOI 10.3109/02813439608997077; KATSARAVA ZK, 2008, 17 INT HEAD RES SEM; Keidel M, 1997, NERVENARZT, V68, P769, DOI 10.1007/s001150050193; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LACHIN JM, 1981, CONTROL CLIN TRIALS, V2, P93, DOI 10.1016/0197-2456(81)90001-5; Long C J, 1983, Psychiatr Med, V1, P35; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Obelieniene D, 1999, J NEUROL NEUROSUR PS, V66, P279, DOI 10.1136/jnnp.66.3.279; PAVLIC GO, 2008, 17 INT HEAD RES SEM; RASMUSSEN BK, 1995, CEPHALALGIA, V15, P45; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P115; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Scher AI, 1998, HEADACHE, V38, P497, DOI 10.1046/j.1526-4610.1998.3807497.x; Schrader H, 2006, EUR J NEUROL, V13, P1226, DOI 10.1111/j.1468-1331.2006.01481.x; Schrader H, 1996, LANCET, V347, P1207, DOI 10.1016/S0140-6736(96)90733-3; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; Stovner LJ, 2005, HEADACHES, V3rd, P17	35	55	57	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	JAN	2009	16	1					112	120		10.1111/j.1468-1331.2008.02363.x			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	381GG	WOS:000261523100029	19087157				2022-02-06	
J	Theodoros, D; Hill, A; Russell, T; Ward, E; Wootton, R				Theodoros, Deborah; Hill, Anne; Russell, Trevor; Ward, Elizabeth; Wootton, Richard			Assessing acquired language disorders in adults via the internet	TELEMEDICINE JOURNAL AND E-HEALTH			English	Article							TELEREHABILITATION; SPEECH	Aphasia, a language disturbance, frequently occurs following acquired brain impairment in adults. Because management of aphasia is often long-term, provision of ongoing and equitable access to treatment creates a significant challenge to speech-language pathologists (SLPs). This study aimed to determine the validity and reliability of assessing aphasia using standardized language assessments via an Internet-based videoconferencing system using a bandwidth of 128 kbits/sec. Thirty-two participants with aphasia due to stroke or traumatic brain injury were assessed simultaneously in either a face-to-face or online-led environment by two SLPs. Short forms of the Boston Diagnostic Aphasia Examination (BDAE-3) and the Boston Naming Test (BNT, 2nd edition) were administered. An eight-item participant satisfaction questionnaire was completed by 15 participants assigned to the online-led assessment. Results failed to identify any significant differences between the 24 subtest scores of the BDAE-3 and the BNT scores obtained in the online and face-to-face test environments (p > 0.01). Weighted kappa statistics indicated moderate to very good agreement (0.59-1.00) between the two assessors for the 24 subtests and eight rating scales of the BDAE-3, the BNT, and for aphasia diagnosis. Good to very good inter- and intra-rater reliability for the online assessment was found across the majority of assessment tasks. Participants reported high overall satisfaction, comfort level, and audio and visual quality in the online environment. This study supports the validity and reliability of delivering standardized assessments of aphasia online and provides a basis for ongoing development of telerehabilitation as an alternate mode of service delivery to persons with aphasia.	[Theodoros, Deborah; Hill, Anne; Ward, Elizabeth] Univ Queensland, Sch Hlth & Rehabil Sci, Div Speech Pathol, Brisbane, Qld 4072, Australia; [Russell, Trevor] Univ Queensland, Sch Hlth & Rehabil Sci, Div Physiotherapy, Brisbane, Qld 4072, Australia; [Wootton, Richard] Univ Queensland, Ctr Online Hlth, Brisbane, Qld 4072, Australia		Theodoros, D (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Div Speech Pathol, Brisbane, Qld 4072, Australia.	d.theodoros@uq.edu.au	Theodoros, Deborah/F-1362-2010; Wootton, Richard/F-7609-2014; Russell, Trevor/F-6888-2010; Ward, Elizabeth/F-9652-2010; Hill, Anne/F-4106-2010; Russell, Trevor/AAS-2590-2020	Wootton, Richard/0000-0002-2666-3596; Russell, Trevor/0000-0002-9732-6167; Ward, Elizabeth/0000-0002-2680-8978; Hill, Anne/0000-0003-3907-8369; Russell, Trevor/0000-0002-9732-6167	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [401604]; National Health and Medical Research Council of Australia Public Health Postgraduate ScholarshipNational Health and Medical Research Council of Australia [ID: 351649]	This research was made possible with funding from the National Health and Medical Research Council of Australia Project Grant No. 401604, and a National Health and Medical Research Council of Australia Public Health Postgraduate Scholarship ID: 351649. The authors acknowledge the assistance of Roy Andersen in the software development of the assessment application, Monique Waite in data collection, and the Princess Alexandra Hospital, The Royal Brisbane and Womens' Hospital, Queen Elizabeth II Jubilee Hospital, the School of Health and Rehabilitation Sciences Clinic, and the University of Queensland Aphasia Registry for assistance in participant recruitment.	American Heart Association, HEART DIS STROK STAT; BIDDLE A, 2002, AHRQ PUBLICATION; BOROD J C, 1980, Journal of Clinical Neuropsychology, V2, P209, DOI 10.1080/01688638008403793; Brennan DM, 2004, TELEMED J E-HEALTH, V10, P147, DOI 10.1089/1530562041641237; BROOKSHIRE RH, 2007, INTRO NEUROGENIC COM, P445; Duffy JR, 1997, MAYO CLIN PROC, V72, P1116, DOI 10.4065/72.12.1116; DUFFY JR, 2005, MOTOR SPEECH DISORDE, P3; ENDERBY P., 1995, DOES SPEECH LANGUAGE; FINLAYSON MAJ, 1994, BRAIN INJURY REHABIL, P3; Fleiss J.L., 1981, STAT METHODS RATES P; Georgeadis AC, 2004, APHASIOLOGY, V18, P639, DOI 10.1080/02687030444000075; Goodglass H., 2001, BOSTON DIAGNOSTIC AP; HAYES JM, MICROSOFT NETMEETING; Kaplan E., 2001, BOSTON NAMING TEST; Kraus JF, 1993, HEAD INJURY, P1; LANDIS JR, 1977, BIOMETRICS, V33, P174; Mair F, 2000, BMJ-BRIT MED J, V320, P1517, DOI 10.1136/bmj.320.7248.1517; Naugle RI, 1990, TRAUMATIC BRAIN INJU, P69; Palsbo SE, 2007, J TELEMED TELECARE, V13, P40, DOI 10.1258/135763307779701121; Pickering M, 1998, AM J SPEECH-LANG PAT, V7, P5, DOI 10.1044/1058-0360.0704.05; Savard L, 2003, NEUROREHABILITATION, V18, P93; Worrall L, 2000, NEUROGENIC COMMUNICA	22	55	60	0	19	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1530-5627			TELEMED J E-HEALTH	Telemed. J. e-Health	AUG	2008	14	6					552	559		10.1089/tmj.2007.0091			8	Health Care Sciences & Services	Science Citation Index Expanded (SCI-EXPANDED)	Health Care Sciences & Services	347GN	WOS:000259128700044	18729754				2022-02-06	
J	Wong, DY; Leveque, JC; Brumblay, H; Krebsbach, PH; Hollister, SJ; LaMarca, F				Wong, Darice Y.; Leveque, Jean-Christophe; Brumblay, Hunter; Krebsbach, Paul H.; Hollister, Scott J.; LaMarca, Frank			Macro-architectures in spinal cord scaffold implants influence regeneration	JOURNAL OF NEUROTRAUMA			English	Article						immunohistochemistry; in vivo studies; neural injury; polycaprolactone; regeneration; scaffold architecture; traumatic spinal cord injury	PERIPHERAL-NERVE GRAFTS; NEURAL STEM-CELLS; AXONAL REGENERATION; GUIDANCE CHANNELS; POLY(2-HYDROXYETHYL METHACRYLATE); FUNCTIONAL RECOVERY; BRAIN-STEM; INJURY; TRANSECTION; REPAIR	Biomaterial scaffold architecture has not been investigated as a tunable source of influence on spinal cord regeneration. This study compared regeneration in a transected spinal cord within various designed-macro-architecture scaffolds to determine if these architectures alone could enhance regeneration. Three-dimensional (3D) designs were created and molds were built on a 3-D printer. Salt-leached porous poly(epsilon-caprolactone) was cast in five different macro-architectures: cylinder, tube, channel, open-path with core, and open-path without core. The two open-path designs were created in this experiment to compare different supportive aspects of architecture provided by scaffolds and their influence on regeneration. Rats received T8 transections and implanted scaffolds for 1 and 3 months. Overall morphology and orientation of sections were characterized by H&E, luxol fast blue, and cresyl violet staining. Borders between intact gray matter and non-regenerated defect were observed from GFAP immunolabeling. Nerve fibers and regenerating axons were identified with Tuj-1 immunolabeling. The open-path designs allowed extension of myelinated fibers along the length of the defect both exterior to and inside the scaffolds and maintained their original defect length up to 3 months. In contrast, the cylinder, tube, and channel implants had a doubling of defect length from secondary damage and large scar and cyst formation with no neural tissue bridging. The open-path scaffold architectures enhanced spinal cord regeneration compared to the three other designs without the use of biological factors.	[Leveque, Jean-Christophe; Brumblay, Hunter; Hollister, Scott J.; LaMarca, Frank] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA; [Wong, Darice Y.; Krebsbach, Paul H.; Hollister, Scott J.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA		Hollister, SJ (corresponding author), Univ Michigan, Dept Neurosurg, 1101 Beal Ave,2149 LBME, Ann Arbor, MI 48109 USA.	scottho@umich.edu	Krebsbach, Paul H./AAC-4765-2021; Leveque, Jean-Christophe/L-6367-2017; Hollister, Scott/ABH-3463-2021	Leveque, Jean-Christophe/0000-0003-2465-444X; Hollister, Scott/0000-0001-7625-892X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 DE-007057-31]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [T32DE007057] Funding Source: NIH RePORTER	Thanks go to Alex Garnepudi for all his assistance. Funding was provided by NIH (training grant T32 DE-007057-31 to D.Y.W.).	Bakshi A, 2004, J NEUROSURG-SPINE, V1, P322, DOI 10.3171/spi.2004.1.3.0322; Barnett SC, 2007, NAT CLIN PRACT NEURO, V3, P152, DOI 10.1038/ncpneuro0447; Barritt AW, 2006, J NEUROSCI, V26, P10856, DOI 10.1523/JNEUROSCI.2980-06.2006; Busch SA, 2007, CURR OPIN NEUROBIOL, V17, P120, DOI 10.1016/j.conb.2006.09.004; Carone TW, 2006, J BIOMED MATER RES B, V78B, P274, DOI 10.1002/jbm.b.30483; CLARK P, 1990, DEVELOPMENT, V108, P635; CLARK P, 1991, J CELL SCI, V99, P73; Dinh P, 2007, SPINE, V32, P943, DOI 10.1097/01.brs.0000261408.61303.77; El Maarouf A, 2006, P NATL ACAD SCI USA, V103, P16989, DOI 10.1073/pnas.0608036103; Flynn L, 2003, BIOMATERIALS, V24, P4265, DOI 10.1016/S0142-9612(03)00334-X; Friedman JA, 2002, NEUROSURGERY, V51, P742, DOI 10.1097/00006123-200209000-00024; Fukunaga S, 2004, J ORTHOP SCI, V9, P605, DOI 10.1007/s00776-004-0833-0; Gelain F, 2007, J NANOSCI NANOTECHNO, V7, P424, DOI 10.1166/jnn.2007.154; Goldner JS, 2006, BIOMATERIALS, V27, P460, DOI 10.1016/j.biomaterials.2005.06.035; Hadlock T, 2006, EXPERT OPIN BIOL TH, V6, P1105, DOI 10.1517/14712598.6.11.1105; Horn EM, 2007, J NEUROSURG-SPINE, V6, P133, DOI 10.3171/spi.2007.6.2.133; HOULE JD, 1994, J NEURAL TRANSP PLAS, V5, P115, DOI 10.1155/NP.1994.115; Houle JD, 2006, J NEUROSCI, V26, P7405, DOI 10.1523/JNEUROSCI.1166-06.2006; Huang YC, 2005, J BIOMED MATER RES B, V74B, P659, DOI 10.1002/jbm.b.30267; Hurtado A, 2006, BIOMATERIALS, V27, P430, DOI 10.1016/j.biomaterials.2005.07.014; Ito Y, 1999, BIOMATERIALS, V20, P2333, DOI 10.1016/S0142-9612(99)00162-3; Jones LL, 2003, J NEUROSCI, V23, P9276; Kaegi S, 2002, EUR J NEUROSCI, V16, P249, DOI 10.1046/j.1460-9568.2002.02076.x; Kuo HS, 2007, BIOCHEM BIOPH RES CO, V357, P1, DOI 10.1016/j.bbrc.2007.02.167; Levi ADO, 2002, J NEUROSURG, V96, P197, DOI 10.3171/spi.2002.96.2.0197; Li XG, 2006, PROG NAT SCI-MATER, V16, P1051; Maier IC, 2006, PHILOS T R SOC B, V361, P1611, DOI 10.1098/rstb.2006.1890; Miller C, 2002, TISSUE ENG, V8, P367, DOI 10.1089/107632702760184646; MORI S, 1992, BRAIN DEV-JPN, V14, pS109; NOGA BR, 1991, J NEUROSCI, V11, P1691; Nomura H, 2006, J NEUROTRAUM, V23, P496, DOI 10.1089/neu.2006.23.496; Nomura H, 2006, NEUROSURGERY, V59, P183, DOI 10.1227/01.NEU.0000219859.35349.EF; Novikova LN, 2003, CURR OPIN NEUROL, V16, P711, DOI 10.1097/00019052-200312000-00011; Oudega M, 2001, BIOMATERIALS, V22, P1125, DOI 10.1016/S0142-9612(00)00346-X; Oudega M, 1999, EUR J NEUROSCI, V11, P2453, DOI 10.1046/j.1460-9568.1999.00666.x; Patist CM, 2004, BIOMATERIALS, V25, P1569, DOI 10.1016/S0142-9612(03)00503-9; Schucht P, 2002, EXP NEUROL, V176, P143, DOI 10.1006/exnr.2002.7909; Schwab JM, 2006, PROG NEUROBIOL, V78, P91, DOI 10.1016/j.pneurobio.2005.12.004; Schwab ME, 2002, SCIENCE, V295, P1029, DOI 10.1126/science.1067840; Stokols S, 2006, TISSUE ENG, V12, P2777, DOI 10.1089/ten.2006.12.2777; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; Tsai EC, 2006, BIOMATERIALS, V27, P519, DOI 10.1016/j.biomaterials.2005.07.025; Tsai EC, 2004, J NEUROTRAUM, V21, P789, DOI 10.1089/0897715041269687; Wong DY, 2007, TISSUE ENG, V13, P2515, DOI 10.1089/ten.2006.0440; Yoshii S, 2004, J BIOMED MATER RES A, V70A, P569, DOI 10.1002/jbm.a.30120; Yoshii S, 2003, SPINE, V28, P2346, DOI 10.1097/01.BRS.0000085302.95413.16; Zhang N, 2005, BRAIN RES REV, V49, P48, DOI 10.1016/j.brainresrev.2004.11.002	49	55	58	0	24	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2008	25	8					1027	1037		10.1089/neu.2007.0473			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	343ZT	WOS:000258895700009	18721107	Green Submitted, Green Published			2022-02-06	
J	Kelly, P; Farrant, B				Kelly, Patrick; Farrant, Bridget			Shaken baby syndrome in New Zealand, 2000-2002	JOURNAL OF PAEDIATRICS AND CHILD HEALTH			English	Article						child abuse; shaken baby syndrome; subdural hematoma; traumatic brain injury	TRAUMATIC BRAIN-INJURY; NONACCIDENTAL HEAD-INJURY; YOUNG-CHILDREN; SUBDURAL HEMATOMAS; IMPACT SYNDROME; RISK-FACTORS; INFANT; NEUROPATHOLOGY; HEMORRHAGES; PATTERNS	Aim: To describe the epidemiology of subdural haemorrhage (SDH) in New Zealand infants. Methods: Prospective enrolment of all cases of infantile SDH from 2000 to 2002. Retrospective analysis of national discharge and death data for the same period. Results: Seventy-seven cases of infantile SDH were identified prospectively, and a further 49 cases retrospectively. Of these 126 cases, 92 resulted from non-birth-related trauma. Forty-eight of these were attributed to abuse and 28 to accidental injury. Sixteen cases were undetermined. The 'minimum' annual incidence of inflicted infantile SDH in New Zealand is 14.7 per 100 000 (95% confidence interval(CI) 10.8-19.4), and the 'maximum' 19.6 per 100 000 (95% CI 15.1-25.0). Among Maori, the 'minimum' is 32.5 per 100 000 (95% CI 21.4-47.3), and the 'maximum' 38.5 per 100 000 (95% CI 26.3-54.4). Conclusions: The epidemiology of infantile subdural haemorrhage in New Zealand is similar to that described elsewhere. Non-accidental head injury is a significant child health issue in New Zealand, and the incidence is particularly high among Maori.	[Kelly, Patrick] Starship Childrens Hosp, Child Abuse Assessment Unit, Auckland 1, New Zealand; [Farrant, Bridget] Univ Auckland, Dept Paediat, Auckland, New Zealand		Kelly, P (corresponding author), Starship Childrens Hosp, Child Abuse Assessment Unit, Pk Rd,Private Bag 92024, Auckland 1, New Zealand.	patrickk@adhb.govt.nz					AOKI N, 1984, J NEUROSURG, V61, P273, DOI 10.3171/jns.1984.61.2.0273; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; BECROFT DMO, 1989, NEW ZEAL MED J, V102, P207; Biron D, 2005, CHILD ABUSE NEGLECT, V29, P1347, DOI 10.1016/j.chiabu.2005.05.003; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; BROWN JK, 1993, DEV MED CHILD NEUROL, V35, P849; Campbell-Stokes PL, 2005, DIABETOLOGIA, V48, P643, DOI 10.1007/s00125-005-1697-3; CRAIG E, 2005, HLTH STATUS CHILDREN, P94; Dias MS, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1896; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Feldman KW, 2001, PEDIATRICS, V108, P636, DOI 10.1542/peds.108.3.636; FRASIER LD, 1997, EC CONSEQUENCES SHAK; FROMM S, 2001, PREVENT CHILD ABUSE; Geddes JF, 2004, BMJ-BRIT MED J, V328, P719, DOI 10.1136/bmj.328.7442.719; Geddes JF, 2003, NEUROPATH APPL NEURO, V29, P14, DOI 10.1046/j.1365-2990.2003.00434.x; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gilliland MGF, 1996, J FORENSIC SCI, V41, P114; GOULD MS, 1995, CHILD MALTREATMENT C; Harding B, 2004, BMJ-BRIT MED J, V328, P720, DOI 10.1136/bmj.328.7442.720; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Hobbs C, 2005, ARCH DIS CHILD, V90, P952, DOI 10.1136/adc.2003.037739; HOWARD MA, 1993, BRIT J NEUROSURG, V7, P355, DOI 10.3109/02688699309103489; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kelly Patrick, 2004, N Z Med J, V117, pU1047; King WJ, 2003, CAN MED ASSOC J, V168, P155; LANTZ PE, 2002, BMJ-BRIT MED J, V328, P754; LENTNER C, 1984, GEIGY SCI TABLES, V2; Makaroff KL, 2003, DEV MED CHILD NEUROL, V45, P497, DOI 10.1017/S0012162203000926; *MIN HLTH, 1998, OUR CHILDR HLTH KEY, P151; *MIN HLTH, 1998, FAM VIOL GUID HLTH S; Minns RA, 2004, BRIT MED J, V328, P766, DOI 10.1136/bmj.328.7442.766; Overpeck MD, 1998, NEW ENGL J MED, V339, P1211, DOI 10.1056/NEJM199810223391706; Punt J, 2004, Pediatr Rehabil, V7, P173, DOI 10.1080/13638490410001711515; Reijneveld SA, 2004, LANCET, V364, P1340, DOI 10.1016/S0140-6736(04)17191-2; Rubin DM, 2003, PEDIATRICS, V111, P1382, DOI 10.1542/peds.111.6.1382; Schnitzer PG, 2005, PEDIATRICS, V116, pE687, DOI 10.1542/peds.2005-0296; Sinal SH, 2000, CHILD ABUSE NEGLECT, V24, P1241, DOI 10.1016/S0145-2134(00)00177-0; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; Theodore AD, 2005, PEDIATRICS, V115, pE331, DOI 10.1542/peds.2004-1033; Tzioumi D, 1998, CHILD ABUSE NEGLECT, V22, P1105, DOI 10.1016/S0145-2134(98)00093-3	46	55	55	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1034-4810	1440-1754		J PAEDIATR CHILD H	J. Paediatr. Child Health	MAR	2008	44	3					99	107		10.1111/j.1440-1754.2007.01234.x			9	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	269DJ	WOS:000253629400004	18086144				2022-02-06	
J	Newton, A; Ratchford, A; Khan, I				Newton, Alastair; Ratchford, Andrew; Khan, Ifly			Incidence of adverse events during prehospital rapid sequence intubation: A review of one year on the London helicopter emergency medical service	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	3rd Mediterranean Emergency Medicine Congress	SEP 01-05, 2005	Nice, FRANCE			prehospital; rapid sequence intubation; complications; airway; hypoxia; hypotension	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; ENDOTRACHEAL INTUBATION; HYPOXIA; HYPOTENSION; INDUCTION; FIELD	Background To establish the incidence of hypoxemia and hypotension during prehospital rapid sequence intubation (RSI) in trauma patients attended by the London Helicopter Emergency Medical Service (HEMS) and to compare it with historical control data from published studies of both hospital and prehospital RSI. Methods: A retrospective observational study during a 12-month period of London HEMS. All mission reports from the period March 1, 2003 to February 28, 2004 were reviewed and all intubations involving the use of drugs were included in the analysis. Measurements of oxygen saturation (SPO2) and systolic blood pressure (SBP) were obtained from the printed record produced by the portable monitor. Results: During the 12-month period 244 RSIs were performed. Completed SpO(2), data were available on 175 patients (71.7%), and of those 32 (18.3%) experienced hypoxemia (SpO(2), < 90%, or > 10% fall if initial SpO(2), < 90%). Completed SBP data were available for 192 patients (79.1%), and of those 25 (13%) experienced hypotension (SBP < 90 mm Hg or > 10 mm. Hg fall if initial SBP < 90 mm Hg). No patients developed both hypoxemia and hypotension. Conclusions. Rates of hypoxemia and hypotension during prehospital RSI performed by London HEMS are relatively low. They are less than that found in previous studies of prehospital RSI and are similar to those reported in studies of in-hospital emergency RSI undertaken in the emergency department or ward setting. We therefore conclude that prehospital RSI has an acceptably low complication rate when performed by appropriately trained personnel.	[Newton, Alastair] St Thomas Hosp, Emergency Dept, London SE1 7EH, England; [Ratchford, Andrew] Mona Vale Hosp, Emergency Dept, Sydney, NSW, Australia; [Khan, Ifly] Royal London Hosp, London E1 1BB, England		Newton, A (corresponding author), St Thomas Hosp, Emergency Dept, London SE1 7EH, England.	alastair.newton@gstt.nhs.uk					Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CORMACK RS, 1984, ANAESTHESIA, V39, P1105, DOI 10.1111/j.1365-2044.1984.tb08932.x; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Graham CA, 2004, J TRAUMA, V56, P1123, DOI 10.1097/01.TA.0000109066.62811.8A; Graham CA, 1997, J ACCID EMERG MED, V14, P219; Mackay CA, 2001, EMERG MED J, V18, P20, DOI 10.1136/emj.18.1.20; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Omert L, 2001, J TRAUMA, V51, P1065, DOI 10.1097/00005373-200112000-00007; Reid C, 2004, EMERG MED J, V21, P296, DOI 10.1136/emj.2003.007344; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Wang H E, 2001, Prehosp Emerg Care, V5, P40, DOI 10.1080/10903120190940317; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wang HE, 2002, ANN EMERG MED, V40, P168, DOI 10.1067/mem.2002.126370; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	17	55	56	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2008	64	2					487	492		10.1097/TA.0b013e31802e7476			6	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	264KV	WOS:000253287100047	18301219				2022-02-06	
J	Frye, CA; Walf, AA				Frye, Cheryl A.; Walf, Alicia A.			Effects of progesterone administration and APPswe+PSEN1 Delta e9 mutation for cognitive performance of mid-aged mice	NEUROBIOLOGY OF LEARNING AND MEMORY			English	Article						Alzheimer's disease; allopregnanolone; hippocampus; cortex; learning and memory; neurosteroids	TRAUMATIC BRAIN-INJURY; FAMILIAL ALZHEIMERS-DISEASE; HORMONE REPLACEMENT THERAPY; WILD-TYPE MICE; FEMALE RATS; AMYLOID DEPOSITION; PREFRONTAL CORTEX; INDUCED SEIZURES; KAINIC ACID; CELL-DEATH	Progesterone (P-4) and its metabolite, 5 alpha-pregnan-3 alpha-ol-20-one (3 alpha,5 alpha-THP) have trophic effects and may improve cognitive function. We investigated the role of progestins in a murine model of Alzheimer's Disease (AD) in which transgenic mice co-overexpress a mutant form of amyloid precursor protein (APPswe) and a deletion in presenilin 1 Delta exon 9 (APPswe+PSEN1 Delta e9). We hypothesized that: (1) mice with the APPswe+PSEN1 Delta e9 mutation would have performance deficits compared to wildtype mice and (2) long-term administration of P-4 would enhance cognitive performance and increase brain progestin levels over placebo. Mice were ovariectomized at 6 months of age and administered placebo or P-4 via subcutaneously implanted pellets. Mice were tested between 9 and 12 months of age for cognitive performance in the object placement, water maze, object recognition, and T-maze tasks and for motor behavior in an activity monitor and then tissues were collected for steroid measurement. P-4 administration increased progestin levels in cortex, diencephalon, midbrain, and cerebellum of wildtype and mutant mice, but increases in 3 alpha,5 alpha-THP levels in the hippocampus of APPswe+PSEN1 Delta e9 mutant mice were attenuated compared to that observed in wildtype mice. APPswe+PSEN1 Delta e9 mice showed poorer performance in hippocampus measures (object placement and water maze tasks). In the object recognition and T-maze task, which are mediated by the cortex and hippocampus, P-4 administration improved performance-in both wildtype and APPswe+PSEN1 Delta e9 mutant mice compared to placebo administration. Thus, APPswe+PSEN1 Delta 9, mice have deficits in hippocampal performance and capacity to form 3 alpha,5 alpha-THP in the hippocampus and both wildtype and APPswe+PSEN1 Delta 9 mice show beneficial effects of P-4 in cortical function and similar capacity to form 3 alpha,5 alpha-THP in the cortex. (C) 2007 Elsevier Inc. All rights reserved.	[Frye, Cheryl A.; Walf, Alicia A.] SUNY Albany, Dept Psychol, Albany, NY 12222 USA; [Frye, Cheryl A.] SUNY Albany, Dept Biol Sci, Albany, NY 12222 USA; [Frye, Cheryl A.] SUNY Albany, Ctr Res Neurosci, Albany, NY 12222 USA; [Frye, Cheryl A.; Walf, Alicia A.] SUNY Albany, Ctr Life Sci Res, Albany, NY 12222 USA		Frye, CA (corresponding author), SUNY Albany, Dept Psychol, Life Sci Res Bldg 01058,1400 Washington Ave, Albany, NY 12222 USA.	cafrye@albany.edu					Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; Bernardi F, 2000, EUR J ENDOCRINOL, V142, P466, DOI 10.1530/eje.0.1420466; Borchelt DR, 1996, GENET ANAL-BIOMOL E, V13, P159, DOI 10.1016/S1050-3862(96)00167-2; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BROOKMEYER R, 1998, PROJECTIONS ALZHEIME; Buckwalter JG, 1999, PSYCHONEUROENDOCRINO, V24, P69; Burgess BL, 2006, NEUROBIOL DIS, V24, P114, DOI 10.1016/j.nbd.2006.06.007; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Charalampopoulos I, 2006, ANN NY ACAD SCI, V1088, P139, DOI 10.1196/annals.1366.003; CHENG YJ, 1973, ENDOCRINOLOGY, V93, P1157, DOI 10.1210/endo-93-5-1157; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Crawley JN, 2007, NEUROPEPTIDES, V41, P145, DOI 10.1016/j.npep.2007.02.002; de Wit H, 2001, PSYCHONEUROENDOCRINO, V26, P697, DOI 10.1016/S0306-4530(01)00024-5; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; DOHANICH GP, 1994, BEHAV NEUROSCI, V108, P988, DOI 10.1037/0735-7044.108.5.988; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Fillit HM, 2002, ARCH INTERN MED, V162, P1934, DOI 10.1001/archinte.162.17.1934; Frick KM, 2003, LEARN MEMORY, V10, P187, DOI 10.1101/lm.50703; Frye CA, 2006, PSYCHOPHARMACOLOGY, V186, P312, DOI 10.1007/s00213-006-0309-3; Frye CA, 2000, PSYCHONEUROENDOCRINO, V25, P407, DOI 10.1016/S0306-4530(99)00068-2; Frye CA, 1999, J NEUROENDOCRINOL, V11, P839; Frye CA, 2000, BRAIN RES, V881, P98, DOI 10.1016/S0006-8993(00)02897-3; Frye CA, 1999, PHARMACOL BIOCHEM BE, V62, P315, DOI 10.1016/S0091-3057(98)00182-8; Frye CA, 1998, J NEUROENDOCRINOL, V10, P291, DOI 10.1046/j.1365-2826.1998.00202.x; Frye CA, 2004, BRAIN RES, V1004, P116, DOI 10.1016/j.brainres.2004.01.020; Frye CA, 2002, EPILEPSIA, V43, P14, DOI 10.1046/j.1528-1157.43.s.5.19.x; Frye CA, 2001, BRAIN RES, V911, P146, DOI 10.1016/S0006-8993(01)02560-4; FRYE CA, 1995, NEUROBIOL LEARN MEM, V64, P83, DOI 10.1006/nlme.1995.1046; FRYE CA, 1995, BRAIN RES, V696, P113, DOI 10.1016/0006-8993(95)00793-P; Frye CA, 2000, PSYCHOBIOLOGY, V28, P550; Frye CA, 2005, PHARMACOL BIOCHEM BE, V81, P907, DOI 10.1016/j.pbb.2005.06.016; Frye CA, 2007, NEUROBIOL LEARN MEM, V88, P208, DOI 10.1016/j.nlm.2007.04.003; Gao S, 1998, ARCH GEN PSYCHIAT, V55, P809, DOI 10.1001/archpsyc.55.9.809; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Heikkinen T, 2004, EXP NEUROL, V187, P105, DOI 10.1016/j.expneurol.2004.01.015; Hughes RN, 2004, NEUROSCI BIOBEHAV R, V28, P497, DOI 10.1016/j.neubiorev.2004.06.006; Jankowsky JL, 2004, HUM MOL GENET, V13, P159, DOI 10.1093/hmg/ddh019; Lalonde R, 2004, NEUROSCI LETT, V369, P156, DOI 10.1016/j.neulet.2004.07.069; Leonelli E, 2007, NEUROSCIENCE, V144, P1293, DOI 10.1016/j.neuroscience.2006.11.014; Leskiewicz M, 1997, POL J PHARMACOL, V49, P411; Levin-Allerhand JA, 2002, J ALZHEIMERS DIS, V4, P449; Lonsdale D, 2003, EPILEPSIA, V44, P1494, DOI 10.1111/j.0013-9580.2003.59402.x; Luine VN, 2003, ENDOCRINOLOGY, V144, P2836, DOI 10.1210/en.2003-0004; MALENDOWICZ LK, 1976, ENDOKRINOLOGIE, V67, P26; Marx CE, 2006, BIOL PSYCHIAT, V60, P1287, DOI 10.1016/j.biopsych.2006.06.017; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; Payami H, 1996, NEUROLOGY, V46, P126, DOI 10.1212/WNL.46.1.126; PENNING TM, 1985, J BIOL CHEM, V260, P5266; PHILLIPS SM, 1992, PSYCHONEUROENDOCRINO, V17, P497, DOI 10.1016/0306-4530(92)90008-U; POSER CM, 1986, ACTA NEUROL SCAND, V73, P39, DOI 10.1111/j.1600-0404.1986.tb03239.x; Reddy DS, 2001, EPILEPSIA, V42, P337, DOI 10.1046/j.1528-1157.2001.10200.x; Reiserer RS, 2007, GENES BRAIN BEHAV, V6, P54, DOI 10.1111/j.1601-183X.2006.00221.x; RESKO JA, 1986, BIOL REPROD, V34, P870, DOI 10.1095/biolreprod34.5.870; Rhodes ME, 2004, PHARMACOL BIOCHEM BE, V78, P551, DOI 10.1016/j.pbb.2004.03.025; Rhodes ME, 2004, PHARMACOL BIOCHEM BE, V78, P505, DOI 10.1016/j.pbb.2004.04.021; RODBARD D, 1974, S RAD REL PROC MED N, P209; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Sandstrom NJ, 2001, BEHAV NEUROSCI, V115, P384, DOI 10.1037//0735-7044.115.2.384; Sato T, 2004, BEHAV BRAIN RES, V150, P33, DOI 10.1016/S0166-4328(03)00249-3; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Smith CD, 2006, PSYCHOPHARMACOLOGY, V186, P481, DOI 10.1007/s00213-005-0186-1; Smith SS, 1998, J NEUROSCI, V18, P5275, DOI 10.1523/JNEUROSCI.18-14-05275.1998; Solis-Ortiz S, 2004, PSYCHONEUROENDOCRINO, V29, P1047, DOI 10.1016/j.psyneuen.2003.10.007; Spowart-Manning L, 2004, BEHAV BRAIN RES, V151, P37, DOI 10.1016/j.bbr.2003.08.004; Vongher JM, 1999, PHARMACOL BIOCHEM BE, V64, P777, DOI 10.1016/S0091-3057(99)00140-9; Walf AA, 2006, NEUROBIOL LEARN MEM, V86, P35, DOI 10.1016/j.nlm.2006.01.004; Zandi PP, 2002, JAMA-J AM MED ASSOC, V288, P2123, DOI 10.1001/jama.288.17.2123; Zhang C, 2007, EXP NEUROL, V204, P77, DOI 10.1016/j.expneurol.2006.09.018; Zheng H, 2002, J NEUROCHEM, V80, P191, DOI 10.1046/j.0022-3042.2001.00690.x	75	55	55	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1074-7427	1095-9564		NEUROBIOL LEARN MEM	Neurobiol. Learn. Mem.	JAN	2008	89	1					17	26		10.1016/j.nlm.2007.09.008			10	Behavioral Sciences; Neurosciences; Psychology; Psychology, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	246YL	WOS:000252044200002	17988898				2022-02-06	
J	King, NS				King, Nigel S.			PTSD and traumatic brain injury: Folklore and fact?	BRAIN INJURY			English	Article						post-traumatic stress disorder; traumatic brain injury; dual diagnosis	POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; SYMPTOMS; IMPAIRMENT; AMNESIA	A number of contraversies and debates have arisen over the years surrounding the dual diagnosis of post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI). Many of these have centred around the around the degree of protection provided by TBI against developing the disorder. The following is brief review of the literature in this area to help resolve some of these issues and to address a number of specific challenges which arise when working with this patient group.	[King, Nigel S.] Camborne Ctr, Community Head Injury Serv, Aylesbury HP21 7ET, Bucks, England; [King, Nigel S.] Univ Oxford, Warneford Hosp, Oxford Doctoral Course Clin Psychol, Oxford, England		King, NS (corresponding author), Camborne Ctr, Community Head Injury Serv, Jansel Sq, Aylesbury HP21 7ET, Bucks, England.	nigel.king@hmc.ox.ac.uk					Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Bisson J, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003388.pub2; Blake D. D., 1990, BEHAV THER, V13, P187, DOI DOI 10.1007/BF02105408; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant RA, 2001, CURR OPIN PSYCHIATR, V14, P119, DOI 10.1097/00001504-200103000-00004; CLARK DM, 1999, COGNITIVE BEHAV TREA; Eisendrath SJ, 1995, NEUROLOGY, V45, pS26, DOI 10.1212/WNL.45.12_Suppl_9.S26; GIL G, 2005, AM J PSYCHIAT, V162, P936; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 2001, J TRAUMA STRESS, V14, P277, DOI 10.1023/A:1011108816888; HORTON AM, 1993, PERCEPT MOTOR SKILL, V76, P243, DOI 10.2466/pms.1993.76.1.243; Jobe PC, 2005, EPILEPSY BEHAV, V7, P602, DOI 10.1016/j.yebeh.2005.07.014; King NS, 1997, J NEUROL NEUROSUR PS, V62, P82, DOI 10.1136/jnnp.62.1.82; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; King NS, 2002, BRAIN INJURY, V16, P65, DOI 10.1080/02699050110088263; KING NS, 2008, IN PRESS PSYCHOL APP; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; Macleod AD, 1999, AUST NZ J PSYCHIAT, V33, P102, DOI 10.1046/j.1440-1614.1999.00514.x; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; McGrath J, 1997, NEUROPSYCHOL REHABIL, V7, P231, DOI 10.1080/713755532; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; McMillan TM, 2003, NEUROPSYCHOL REHABIL, V13, P149, DOI 10.1080/09602010244000453; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; *NAT I CLIN EX, 2005, CLIN GUID POST STRES; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; REITHER AM, 1988, SOUTH MED J, V81, P568; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Sharp TJ, 2001, CLIN PSYCHOL REV, V21, P857, DOI 10.1016/S0272-7358(00)00071-4; Sumpter RE, 2005, BRIT J PSYCHIAT, V186, P423, DOI 10.1192/bjp.186.5.423; TAYLOR ST, 2001, J CONSULT CLIN PSYCH, V67, P13; Williams W H, 2003, Cogn Neuropsychiatry, V8, P1, DOI 10.1080/713752238; Williams WH, 2002, BRAIN INJURY, V16, P673, DOI 10.1080/02699050210128861	38	55	55	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	1					1	5		10.1080/02699050701829696			5	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	250QF	WOS:000252314400001	18183503				2022-02-06	
J	Yeo, JE; Kim, JH; Kang, SK				Yeo, Jee Eun; Kim, Jeong Hwan; Kang, Soo Kyung			Selenium attenuates ROS-mediated apoptotic cell death of injured spinal cord through prevention of mitochondria dysfunction; in vitro and in vivo study	CELLULAR PHYSIOLOGY AND BIOCHEMISTRY			English	Article						apoptotic cell death function recovery; inflammation; myelination; neuroprotection; selenium; spinal cord injury	MAMMALIAN THIOREDOXIN REDUCTASE; TRAUMATIC BRAIN-INJURY; NERVOUS-SYSTEM INJURY; OXIDATIVE STRESS; PARKINSONS-DISEASE; LIPID-PEROXIDATION; RADICAL HYPOTHESIS; CYTOCHROME-C; RELEASE; BCL-2	The primary objective of this study was to determine the possible apoptotic cell death preventive effects of the antioxidant selenium using an experimental rat spinal cord injury (SCI) model and cultured spinal cord-derived neural progenitor cells (NPCs). Sodium selenite treatment exerted a profound preventive effect on apoptotic cell death, including p-P38, pSAPK/JNK, caspases, and PARP activity, and ameliorated astrogliosis and hypomyelination, which occurs in regions of active cell death in the spinal cords of SCI rats. The foremost protective effect of selenite in SCI would therefore be manifested in the suppression of acute secondary apoptotic cell death. However, selenite does not appear to exert an anti-inflammatory function associated with active microglia and macrophage propagation or infiltration into the lesion site. Selenite-mediated neuroprotection has been linked to selenite's attenuation or inhibition of p38 mitogen-activated protein kinase, pSAPK/JNK, and Bax activation in in vitro and in vivo SCI lesion sites. Selenite also attenuated cell death via the prevention of cytochrome c release, caspase activation, and ROS accumulation in the cytosol. Also, our study showed that selenite administered immediately after SCI significantly diminishes functional deficits. The selenite-treated group recovered hind limb reflexes more rapidly, and a higher percentage of these rats regained responses to a greater degree than was seen in the untreated injured rats. Our data indicate that the therapeutic outcome of selenite is most likely the consequence of its comprehensive apoptotic cell death blocking effects, resulting in the protection of white matter, oligodendrocytes, and neurons, and the inhibition of astrogliosis. The finding that the administration of selenite prevents secondary pathological events in traumatic spinal cord injuries, and promotes the recovery of motor function in an animal model. Its efficacy may facilitate the development of novel drug targets for the treatment of SCI. Copyright (c) 2008 S. Karger AG, Basel.	[Yeo, Jee Eun; Kim, Jeong Hwan; Kang, Soo Kyung] Pusan Natl Univ, Coll Med, Dept Physiol, Pusan 602739, South Korea		Kang, SK (corresponding author), Pusan Natl Univ, Coll Med, Dept Physiol, Pusan 602739, South Korea.	skkang@pusan.ac.kr					BELLAVITE P, 1988, FREE RADICAL BIO MED, V4, P225, DOI 10.1016/0891-5849(88)90044-5; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; Bruce-Keller AJ, 1998, J NEUROCHEM, V70, P31; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Cornett CR, 1998, NEUROTOXICOLOGY, V19, P339; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; Facchinetti F, 1998, CELL MOL NEUROBIOL, V18, P667, DOI 10.1023/A:1020221919154; GIULIAN D, 1993, J NEUROSCI, V13, P29; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; HARMAN D, 1993, FREE RADICALS AGING, P205; HOLSTEGE G, 1991, PROGR BRAIN RES, V87, P307; Imam SZ, 1999, BRAIN RES, V818, P575, DOI 10.1016/S0006-8993(98)01311-0; ITOH N, 1993, J IMMUNOL, V151, P621; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Jurynec MJ, 2003, MOL CELL NEUROSCI, V23, P69, DOI 10.1016/S1044-7431(03)00019-8; Kang SK, 2006, PROTEOMICS, V6, P2797, DOI 10.1002/pmic.200500621; Kim TS, 2002, BIOCHEM BIOPH RES CO, V294, P1130, DOI 10.1016/S0006-291X(02)00612-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Le Belle JE, 2002, BIODRUGS, V16, P389, DOI 10.2165/00063030-200216060-00001; Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797; Limke TL, 2003, J HEMATOTH STEM CELL, V12, P615, DOI 10.1089/15258160360732641; Limoli CL, 2004, RADIAT RES, V161, P17, DOI 10.1667/RR3112; LIU X, 1996, CELL, V86, P145; Marcocci L, 1997, BIOFACTORS, V6, P351, DOI 10.1002/biof.5520060305; Murphy MP, 2000, ADV DRUG DELIVER REV, V41, P235, DOI 10.1016/S0169-409X(99)00069-1; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; OLANOW CW, 1992, ANN NEUROL, V32, pS2, DOI 10.1002/ana.410320703; Ragusa RJ, 1997, NEUROMUSCULAR DISORD, V7, P379, DOI 10.1016/S0960-8966(97)00096-5; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RICHTER C, 1993, TOXICOL LETT, V67, P119, DOI 10.1016/0378-4274(93)90050-8; RICHTER C, 1991, CHEM-BIOL INTERACT, V77, P1, DOI 10.1016/0009-2797(91)90002-O; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; Sagara Y, 1998, NEUROTOXICOLOGY, V19, P339; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Skaper SD, 2003, ANN NY ACAD SCI, V993, P217, DOI 10.1111/j.1749-6632.2003.tb07532.x; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; TAN S, 1995, J NEUROCHEM, V71, P95; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Whalen MJ, 2000, ACT NEUR S, V76, P61; YU BP, 1994, PHYSIOL REV, V74, P139, DOI 10.1152/physrev.1994.74.1.139	45	55	58	0	8	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1015-8987	1421-9778		CELL PHYSIOL BIOCHEM	Cell. Physiol. Biochem.		2008	21	1-3					225	238		10.1159/000113764			14	Cell Biology; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Physiology	254ME	WOS:000252589900023	18209489	Bronze			2022-02-06	
J	Zehtabchi, S; Soghoian, S; Liu, YJ; Carmody, K; Shah, L; Whittaker, B; Sinert, R				Zehtabchi, Shahriar; Soghoian, Samara; Liu, Yiju; Carmody, Kristin; Shah, Lekha; Whittaker, Brian; Sinert, Richard			The association of coagulopathy and traumatic brain injury in patients with isolated head injury	RESUSCITATION			English	Article						coagulation; brain injury; international normalized ratio; trauma	ACTIVATED FACTOR-VII; MORTALITY PREDICTION; COAGULATION; SCORE	The emergence of prothrombotic agents (e.g. activated factor VII) to treat traumatic brain injury (TBI) requires a better understanding of the association of coagulopathy with isolated head injury (IHI). Objective: To investigate the association of IHI and coagulopathy. Methods: Prospective, observational study in an urban level I trauma center. Inclusion criteria: Adult (>= 13 years of age) patients with IHI. Exclusion criteria: patients with known coagulopathies or on anticoagulant therapy. Predictor Variables: TBI (head abbreviated injury severity score >2, or brain hematoma on CT scan), age, gender, mechanism of injury, Glasgow Coma Score (GCS), and loss of consciousness (LOC). Outcome variables: coagulopathy defined as etevated International Normalized Ratio (INR>1.3) or activated partial thromboplastin time (PTT) greater than 34s. We divided IHI subjects into two groups of patients with and without TBI. Statistical Analysis: Fisher's exact test and Mann-Whitney U were used to compare data where appropriate (alpha: 0.05, two-tailed). Results: From July 2005 to December 2006, 276 patients with IHI were studied. The median age was 35 years (interquartile range: 25-52) with a 79% male predominance and 88% blunt trauma. Eight percent (95% Cl, 5-12%) of patients had coagulopathy. The rate of coagulopathy in TBI patients (17%) was significantly higher than non-TBI patients (6%) (11% difference, 95% Cl, 3-20%]. The relative risk of coagutopathy in TBI patients was 2.9 (95% Cl, 1.3-6.6). Conclusion: Coagulopathy as defined by elevated INR and/or PTT is associated with TBI after isolated head injury. (c) 2007 Elsevier Ireland Ltd. All rights reserved.	[Zehtabchi, Shahriar; Soghoian, Samara; Liu, Yiju; Carmody, Kristin; Shah, Lekha; Whittaker, Brian; Sinert, Richard] Suny Downstate Med Ctr, Dept Emergency Med, Brooklyn, NY 11203 USA		Zehtabchi, S (corresponding author), Suny Downstate Med Ctr, Dept Emergency Med, Box 1228,450 Clarkson Ave, Brooklyn, NY 11203 USA.	szehtabchi@yahoo.com		Soghoian, Samara/0000-0002-8767-6681; Carmody, Kristin/0000-0003-1223-5280; zehtabchi, shahriar/0000-0002-6427-986X			Alvarez M, 1998, CRIT CARE MED, V26, P142, DOI 10.1097/00003246-199801000-00030; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Becker S, 1999, EUR J PEDIATR, V158, pS197, DOI 10.1007/PL00014355; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Dutton RP, 2004, J TRAUMA, V57, P709, DOI 10.1097/01.TA.0000140646.66852.AB; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; KUMURA E, 1987, ACTA NEUROCHIR, V85, P23, DOI 10.1007/BF01402365; May AK, 1997, AM SURGEON, V63, P233; Morenski JD, 2003, J NEUROSURG, V98, P611, DOI 10.3171/jns.2003.98.3.0611; Murshid WR, 2002, BRIT J NEUROSURG, V16, P362, DOI 10.1080/0268869021000007597; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Park P, 2003, NEUROSURGERY, V53, P34, DOI 10.1227/01.NEU.0000068830.54968.A8; Pondaag W, 1979, Acta Neurochir Suppl (Wien), V28, P98; Schurr MJ, 2004, J TRAUMA, V57, P718; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; 1999, WHO TECH REP SER, V889, P64	20	55	63	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572	1873-1570		RESUSCITATION	Resuscitation	JAN	2008	76	1					52	56		10.1016/j.resuscitation.2007.06.024			5	Critical Care Medicine; Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine	263GB	WOS:000253204500011	17706857				2022-02-06	
J	Hare, GMT; Mazer, CD; Hutchison, JS; McLaren, AT; Liu, E; Rassouli, A; Ai, J; Shaye, RE; Lockwood, JA; Hawkins, CE; Sikich, N; To, K; Baker, AJ				Hare, Gregory M. T.; Mazer, C. David; Hutchison, James S.; McLaren, Anya T.; Liu, Elaine; Rassouli, Alipasha; Ai, Jinglu; Shaye, Rachel E.; Lockwood, Julia A.; Hawkins, Cynthia E.; Sikich, Nancy; To, Kevin; Baker, Andrew J.			Severe hemodilutional anemia increases cerebral tissue injury following acute neurotrauma	JOURNAL OF APPLIED PHYSIOLOGY			English	Article; Proceedings Paper	21st Annual National-Neurotrauma-Society Symposium	NOV 06-07, 2003	BILOXI, MS	Natl Neurotrauma Soc			FLUID PERCUSSION INJURY; TRAUMATIC BRAIN INJURY; OXYGEN-TENSION; CARDIOPULMONARY BYPASS; HEMORRHAGIC-SHOCK; BLOOD-FLOW; HYPOXIA; RAT; EXPRESSION; HYPOXEMIA	Anemia may worsen neurological outcomes following traumatic brain injury (TBI) by undefined mechanisms. We hypothesized that hemodilutional anemia accentuates hypoxic cerebral injury following TBI. Anesthetized rats underwent unilateral TBI or sham injury (n >= 7). Target hemoglobin concentrations between 50 and 70 g/ l were achieved by exchanging 40-50% of the blood volume (1: 1) with pentastarch. The effect of TBI, anemia, and TBI-anemia was assessed by measuring brain tissue oxygen tension (PbrO(2)), regional cerebral blood flow (rCBF), jugular venous oxygen saturation (SjvO(2)), cerebral contusion area, and nuclear staining for programmed cell death. Baseline postinjury PbrO2 values in the TBI and TBI-anemia groups (9.3 +/- 1.3 and 11.3 +/- 4.1 Torr, respectively) were lower than the uninjured controls (18.2 +/- 5.2 Torr, P < 0.05 for both). Hemodilution caused a further reduction in PbrO2 in the TBI-anemia group relative to the TBI group without anemia (7.8 +/- 2.7 vs. 14.8 +/- 3.9 Torr, P < 0.05). The rCBF remained stable after TBI and increased comparably after hemodilution in both anemia and TBI-anemia groups. The SjvO(2) was elevated after TBI (87.4 +/- 8.9%, P < 0.05) and increased further following hemodilution (95.0 +/- 1.6%, P < 0.05). Cerebral contusion area and nuclear counts for programmed cell death were increased following TBI-anemia (4.1 +/- 3.0 mm2 and 686 +/- 192, respectively) relative to TBI alone (1.3 +/- 0.3 mm2 and 404 +/- 133, respectively, P < 0.05 for both). Hemodilutional anemia reduced cerebral PbrO(2) and oxygen extraction and increased cell death following TBI. These results support our hypothesis that acute anemia accentuated hypoxic cerebral injury after neurotrauma.	Univ Toronto, St Michaels Hosp, Dept Anesthesia,Keenan Res Ctr Li Ka Shing Knowle, Cara Phelan Ctr Trauma Res, Toronto, ON M5B 1W8, Canada; Univ Toronto, Dept Physiol, Toronto, ON, Canada; Hosp Sick Children, Dept Crit Care Med & Paediat, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Neurosci & Mental Hlth Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Fac Med, Interdept Div Crit Care, Toronto, ON, Canada; Hosp Sick Children, Div Neuropathol, Dept Lab Med, Toronto, ON M5G 1X8, Canada		Hare, GMT (corresponding author), Univ Toronto, St Michaels Hosp, Dept Anesthesia,Keenan Res Ctr Li Ka Shing Knowle, Cara Phelan Ctr Trauma Res, 30 Bond St, Toronto, ON M5B 1W8, Canada.	hareg@smh.toronto.on.ca	Hare, Greg/AAM-5599-2021; Hawkins, Cynthia/M-2571-2019	Mazer, Cyril David/0000-0003-2566-4308; AI, JINGLU/0000-0001-7414-0207			Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Bauman RA, 2000, J NEUROTRAUM, V17, P679, DOI 10.1089/089771500415427; BAXT WG, 1987, J TRAUMA, V27, P602, DOI 10.1097/00005373-198706000-00003; BROWN MM, 1985, BRAIN, V108, P81, DOI 10.1093/brain/108.1.81; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Dunn JF, 1999, ADV EXP MED BIOL, V471, P43; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Habib RH, 2003, J THORAC CARDIOV SUR, V125, P1438, DOI 10.1016/S0022-5223(02)73291-1; Hare GMT, 2004, ANESTH ANALG, V99, P528, DOI 10.1213/01.ANE.0000136769.65960.D1; Hare GMT, 2003, CAN J ANAESTH, V50, P1061, DOI 10.1007/BF03018375; Hare GMT, 2003, J NEUROTRAUM, V20, P1134; Hare GMT, 2003, J APPL PHYSIOL, V94, P2058, DOI 10.1152/japplphysiol.00931.2002; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Homi HM, 2004, ANESTH ANALG, V99, P974, DOI 10.1213/01.ane.0000131504.90754.d0; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HUDAK ML, 1986, AM J PHYSIOL, V251, pH63, DOI 10.1152/ajpheart.1986.251.1.H63; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Jonas RA, 2003, J THORAC CARDIOV SUR, V126, P1765, DOI 10.1016/j.jtcvs.2003.04.003; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Kramer MS, 1996, NEUROSURGERY, V38, P355, DOI 10.1097/00006123-199602000-00024; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; MAZZONI MC, 1994, AM J PHYSIOL-HEART C, V267, pH1928, DOI 10.1152/ajpheart.1994.267.5.H1928; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; McLaren AT, 2007, AM J PHYSIOL-REG I, V292, pR403, DOI 10.1152/ajpregu.00403.2006; Mikrogianakis A, 2007, J NEUROTRAUM, V24, P338, DOI 10.1089/neu.2006.003615; Morimoto Y, 2001, J NEUROSURG ANESTH, V13, P33, DOI 10.1097/00008506-200101000-00006; Murkin JM, 2007, ANESTH ANALG, V104, P51, DOI 10.1213/01.ane.0000246814.29362.f4; Nwaigwe CI, 2000, BRAIN RES, V868, P150, DOI 10.1016/S0006-8993(00)02321-0; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Rebel A, 2001, AM J PHYSIOL-HEART C, V280, pH2591, DOI 10.1152/ajpheart.2001.280.6.H2591; Shen H, 2002, ANESTHESIOLOGY, V96, P142, DOI 10.1097/00000542-200201000-00027; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; TODD MM, 1994, AM J PHYSIOL-HEART C, V267, pH2025, DOI 10.1152/ajpheart.1994.267.5.H2025; Tsai AG, 2001, TRANSFUSION, V41, P1290, DOI 10.1046/j.1537-2995.2001.41101290.x; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van Bommel J, 2002, ANESTHESIOLOGY, V97, P660, DOI 10.1097/00000542-200209000-00021; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018	50	55	58	0	6	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587	1522-1601		J APPL PHYSIOL	J. Appl. Physiol.	SEP	2007	103	3					1021	1029		10.1152/japplphysiol.01315.2006			9	Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Physiology; Sport Sciences	204OU	WOS:000249054700040	17556499				2022-02-06	
J	Hollingworth, W; Vavilala, MS; Jarvik, JG; Chaudhry, S; Johnston, BD; Layman, S; Tontisirin, N; Muangman, SL; Wang, MC				Hollingworth, William; Vavilala, Monica S.; Jarvik, Jeffrey G.; Chaudhry, Sidhartha; Johnston, Brian D.; Layman, Sarah; Tontisirin, Nuj; Muangman, Saipin L.; Wang, Marjorie C.			The use of repeated head computed tomography in pediatric blunt head trauma: Factors predicting new and worsening brain injury	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						traumatic brain injuries; radiograph computed tomography; pediatrics; critical care; intracranial pressure; traumatic brain hemorrhage	GLASGOW COMA SCALE; CHILDREN; CT; PROGRESSION; HEMORRHAGE; MORTALITY; HEMATOMA; MODERATE; SCORE	Objective: Opinion is divided on the value of repeat head computed tomography for guiding clinical management of pediatric patients with blunt head trauma. This study describes the prevalence of worsening brain injury on repeat computed tomography, predictors of worsening computed tomography findings, and the frequency of neurosurgical intervention after the repeat computed tomography. Design: Retrospective cohort study. Setting: All patients were admitted to a level I pediatric trauma center between 1994 and 2003. Patients: Children < 15 yrs old with two or more head computed tomographies following hospital admission for blunt head trauma. Interventions: None. Measurements and Main Results: We reviewed the imaging reports to determine injury progression. Potential predictors of worsening computed tomography findings and neurosurgical intervention were recorded by chart review. Logistic regression and recursive partitioning were used to identify predictors. Twenty percent (50 of 257) of patients with mild head injury had worsening computed tomography findings, and three patients (1%) had subsequent neurosurgical intervention. Patients with moderate and severe head injuries were more likely to have worsening computed tomography findings (107 of 248; 43%) and to have neurosurgical intervention (15 of 248; 6%). In most surgical patients, repeat computed tomography was preceded by rapid decline in neurologic status or elevated intracranial pressure. Stratification based on four clinical factors (initial head injury severity, any intraparenchymal finding on initial computed tomography, normal findings on initial computed tomography, coagulopathy) identified 100% of the surgical patients and 89% of patents with worsening brain injuries on the repeat computed tomography. Conclusions: Repeat head computed tomography imaging is frequently used. About 30% of repeated computed tomographies showed new or worsening brain injury. However, worsening brain injury on repeat computed tomography rarely resulted in neurosurgical intervention. Patients with moderate or severe head injury and intraparenchymal injuries were more likely to show worsening brain injury and undergo neurosurgical intervention.	Univ Washington, Dept Radiol, Sch Publ Hlth, Seattle, WA 98195 USA; Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA		Hollingworth, W (corresponding author), Univ Washington, Dept Radiol, Sch Publ Hlth, Seattle, WA 98195 USA.	willh@u.washington.edu	Jarvik, Jeffrey/AAL-4292-2021	Hollingworth, William/0000-0002-0840-6254			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS12; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS45; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS28; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Boone JM, 2003, RADIOLOGY, V228, P352, DOI 10.1148/radiol.2282020471; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Chung CY, 2006, PEDIATR NEUROL, V34, P379, DOI 10.1016/j.pediatrneurol.2005.10.012; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; COOK EF, 1984, J CHRON DIS, V37, P721, DOI 10.1016/0021-9681(84)90041-9; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; DOMENICUCCI M, 1995, NEUROSURG REV, V18, P109, DOI 10.1007/BF00417668; FARINGER PD, 1993, J TRAUMA, V34, P481, DOI 10.1097/00005373-199304000-00002; Figg RE, 2006, PEDIATR SURG INT, V22, P215, DOI 10.1007/s00383-005-1560-0; Givner A, 2002, J PEDIATR SURG, V37, P381, DOI 10.1053/jpsu.2002.30825; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; Holmes JF, 2001, PEDIATR EMERG CARE, V17, P324, DOI 10.1097/00006565-200110000-00002; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Ostir GV, 2000, AM J PHYS MED REHAB, V79, P565, DOI 10.1097/00002060-200011000-00017; Paterson A, 2001, AM J ROENTGENOL, V176, P297, DOI 10.2214/ajr.176.2.1760297; Shafi S, 2005, J TRAUMA, V59, P1081, DOI 10.1097/01.ta.0000188647.03665.fd; Slovis TL, 2002, RADIOLOGY, V223, P5, DOI 10.1148/radiol.2231012100; SNOEY ER, 1994, ANN EMERG MED, V23, P1127, DOI 10.1016/S0196-0644(94)70115-6; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003; WANG MC, IN PRESS J TRAUMA	37	55	55	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JUL	2007	8	4					348	356		10.1097/01.PCC.0000270837.66217.3B			9	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	190MK	WOS:000248062800006	17545925				2022-02-06	
J	Mossberg, KA; Ayala, D; Baker, T; Heard, J; Masel, B				Mossberg, Kurt A.; Ayala, Danielle; Baker, Tracey; Heard, Justin; Masel, Brent			Aerobic capacity after traumatic brain injury: Comparison with a nondisabled cohort	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Combined Sections Meeting of the American-Physical-Therapy-Association	FEB 01-05, 2006	San Diego, CA	Amer Phys Therapy Assoc		brain injuries; head injuries, closed; physical endurance; rehabilitation	PEAK CARDIORESPIRATORY RESPONSES; PHYSICAL-ACTIVITY; MAXIMAL TREADMILL; OXYGEN UPTAKE; EXERCISE; REHABILITATION; PREVENTION; OUTCOMES; RELIABILITY; EFFICIENCY	Objective: To compare aerobic capacity of people recovering from traumatic brain injury (TBI) with an age- and sex-matched group of nondisabled sedentary people. Design: Descriptive comparative study of peak and submaximal physiologic responses. Setting: Residential postacute treatment center. Participants: Convenience sample of 13 people with TBI and 13 age- and sex-matched nondisabled subjects. All subjects could walk 5.3kph (3.3mph), follow 2-step commands, and comply with testing using the gas collection apparatus. Interventions: Not applicable. Main Outcome Measures: Subjects performed a graded maximal treadmill test during which heart rate, minute ventilation (V-E), oxygen consumption (Vo(2)), carbon dioxide production, and respiratory exchange ratio (RER) were measured every minute until exhaustion. Ventilatory equivalents for oxygen (V-E/Vo(2)) and oxygen pulse were calculated. Results: Subjects recovering from TBI had significantly lower peak responses for heart rate, Vo(2,) V-E, and oxygen pulse TBI (P <.01). Peak RER and V-E/Vo(2) were similar. There were significant differences in subinaximal responses for V-E/Vo(2) and oxygen pulse. Conclusions: Patients with TBI were significantly more deconditioned than a comparable group of sedentary people without disability. Participation in cardiorespiratory fitness programs after TBI should be encouraged to prevent secondary disability.	Univ Texas, Med Branch, Dept Phys Therapy, Galveston, TX 77555 USA; Transit Learning Ctr, Galveston, TX USA		Mossberg, KA (corresponding author), Univ Texas, Med Branch, Dept Phys Therapy, 301 Univ Blvd, Galveston, TX 77555 USA.	kmossber@utmb.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046570] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD046570] Funding Source: Medline		ASTRAND P, 2003, TXB WORK PHYSLK PHYS; BALKE B, 1959, U S Armed Forces Med J, V10, P675; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; BECKER E, 1978, SCAND J REHABIL MED, V10, P47; Bhambhani Y, 2005, ARCH PHYS MED REHAB, V86, P268, DOI 10.1016/j.apmr.2004.04.022; Bhambhani Y, 2003, ARCH PHYS MED REHAB, V84, P1629, DOI 10.1053/S0003-9993(03)00343-5; Booth FW, 2000, J APPL PHYSIOL, V88, P774, DOI 10.1152/jappl.2000.88.2.774; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; *CDC, TRAUM BRAIN INJ; Chakravarthy MV, 2003, EXERCISE; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Etnier JL, 1997, J SPORT EXERCISE PSY, V19, P249, DOI 10.1123/jsep.19.3.249; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; HERMANSE.L, 1969, J APPL PHYSIOL, V26, P31, DOI 10.1152/jappl.1969.26.1.31; Hillier SL, 1997, BRAIN INJURY, V11, P661; HUNTER M, 1990, PHYS THER, V70, P363, DOI 10.1093/ptj/70.6.363; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; *JOINT NAT COMM PR, 1997, DHHS PUBL; Kinne S, 2004, AM J PUBLIC HEALTH, V94, P443, DOI 10.2105/AJPH.94.3.443; LaPier TLK, 1998, PHYS THER, V78, P417, DOI 10.1093/ptj/78.4.417; LUKASKI HC, 1989, J SPORT MED PHYS FIT, V29, P223; McTiernan A, 2004, CANCER INVEST, V22, P68, DOI 10.1081/CNV-120027581; MORAN AJ, 1972, MED J AUSTRALIA, V2, P782, DOI 10.5694/j.1326-5377.1972.tb103537.x; MORAN AJ, 1976, MED J AUSTRALIA, V1, P396, DOI 10.5694/j.1326-5377.1976.tb140699.x; Mossberg KA, 2005, AM J PHYS MED REHAB, V84, P492, DOI 10.1097/01.phm.0000166883.97562.cd; Mossberg KA, 2002, BRAIN INJURY, V16, P789, DOI 10.1080/02699050210131894; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; POLLOCK ML, 1976, AM HEART J, V92, P39, DOI 10.1016/S0002-8703(76)80401-2; Pollock ML, 1990, EXERCISE HLTH DIS; SALTIN B, 1967, J APPL PHYSIOL, V23, P353, DOI 10.1152/jappl.1967.23.3.353; SULLIVAN S J, 1990, Brain Injury, V4, P407, DOI 10.3109/02699059009026194; Taaffe DR, 2000, J REHABIL RES DEV, V37, P245; TAYLOR HL, 1955, J APPL PHYSIOL, V8, P73, DOI 10.1152/jappl.1955.8.1.73; Thompson PD, 2003, CIRCULATION, V107, P3109, DOI 10.1161/01.CIR.0000075572.40158.77; Whaley MH, 2006, ACSMS GUIDELINES EXE	35	55	55	0	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2007	88	3					315	320		10.1016/j.apmr.2006.12.006			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	142AU	WOS:000244621600008	17321823				2022-02-06	
J	Maegele, M; Engel, D; Bouillon, B; Lefering, R; Fach, H; Raum, M; Buchheister, B; Schaefer, U; Klug, N; Neugebauer, E				Maegele, M.; Engel, D.; Bouillon, B.; Lefering, R.; Fach, H.; Raum, M.; Buchheister, B.; Schaefer, U.; Klug, N.; Neugebauer, E.			Incidence and outcome of traumatic brain injury in an urban area in western Europe over 10 years	EUROPEAN SURGICAL RESEARCH			English	Article						traumatic brain injury; incidence; traumatic brain injury, outcome; urban area in western Europe	SEVERE HEAD-INJURY; GLASGOW COMA SCALE; FINNISH PATIENTS 5; UNITED-STATES; PRACTICAL SCALE; DATA-BANK; SCORE; MORTALITY; MANAGEMENT; MODERATE	Introduction: Valid epidemiological data on incidence and outcome of traumatic brain injury (TBI) show great variability. A study on incidence, severity and outcome of TBI was conducted in an urban area of one million inhabitants. Materials and Methods: 130,000 prehospital emergencies were screened for TBI. Inclusion criteria: Glasgow Coma Scale (GCS) score <= 8 and/or Abbreviated Injury Scale for head injuries (AIS head) score 6 2 with confirmed TBI via appropriate diagnostics. Results: Annual incidence was 7.3/100,000. Overall mortality rate was 45.8%: 182 (28%) were prehospital deaths, 116 (17.8%) patients died in hospital. Two hundred and fourteen of 352 (60.8%) surviving patients were sufficiently rehabilitated at discharge [Glasgow Outcome Scale (GOS) score = 1], but 138 patients (39.2%) survived with persisting deficits. GOS was associated with initial GCS and AIS head. Conclusion: The incidence of TBI was lower compared to the literature. The overall mortality was high, especially prehospital and early in-hospital mortality rates. Copyright (c) 2007 S. Karger AG, Basel.	Univ Witten Herdecke, Inst Res Operat Med, Cologne Merheim Med Ctr, Dept Traumatol & Orthoped Surg, D-51109 Cologne, Germany; Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Surg, D-51109 Cologne, Germany; Univ Cologne, Inst Med Stat Informat & Epidemiol, Cologne, Germany; Univ Cologne, Dept Neurosurg, Cologne, Germany; Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands		Maegele, M (corresponding author), Univ Witten Herdecke, Inst Res Operat Med, Cologne Merheim Med Ctr, Dept Traumatol & Orthoped Surg, Ostmerheimerstr 200, D-51109 Cologne, Germany.	Marc.Maegele@t-online.de					ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; ANNONI JM, 1991, SCHWEIZ MED WSCHR, V121, P207; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Asikainen I, 1999, EUR J NEUROL, V6, P179, DOI 10.1111/j.1468-1331.1999.tb00011.x; BOUILLON B, 1990, THEOR SURG, V5, P36; Bouillon B, 1997, J TRAUMA, V42, P652, DOI 10.1097/00005373-199704000-00012; Bouillon B, 1999, RESTOR NEUROL NEUROS, V14, P85; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; *BTF, 2000, J NEUROTRAUM, V17, P457; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; Demetriades D, 2004, ARCH SURG-CHICAGO, V139, P1066, DOI 10.1001/archsurg.139.10.1066; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Engberg A, 1995, Acta Neurol Scand Suppl, V164, P1; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; FEARNSIDE FR, 1997, HEAD INJURY; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; HARTWIG E, 1993, UNFALLCHIRURG, V96, P564; Hoffmann B, 2002, ACT NEUR S, V79, P33; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; Klemen P, 2006, ACTA ANAESTH SCAND, V50, P1250, DOI 10.1111/J.1399-6576.2006.01039.X; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1992, HEAD INJURY, P1; Lehr D, 1997, J TRAUMA, V42, pS71, DOI 10.1097/00005373-199705001-00015; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; MacKenzie E J, 1989, Md Med J, V38, P725; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; Meixensberger J, 1998, LANGENBECK ARCH SURG, V383, P214, DOI 10.1007/s004230050121; MOECKE H, 1994, ANASTH INTENSIVMED, V31, P96; Mullins RJ, 1996, J TRAUMA, V40, P536, DOI 10.1097/00005373-199604000-00004; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; Poggi G, 2003, BRAIN INJURY, V17, P835, DOI 10.1080/0269905031000088612; Prough DS, 1997, J TRAUMA, V42, pS10, DOI 10.1097/00005373-199705001-00003; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROY PD, 1987, CAN J SURG, V30, P17; Rudehill A, 2002, J NEUROTRAUM, V19, P855, DOI 10.1089/08977150260190447; SAMPALIS JS, 1995, J TRAUMA, V39, P232, DOI 10.1097/00005373-199508000-00008; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sundstrom T, 2007, J NEUROTRAUM, V24, P147, DOI 10.1089/neu.2006.0099; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; TEASDALE G, 1974, LANCET, V2, P81; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; WALDER AD, 1995, INTENS CARE MED, V21, P606, DOI 10.1007/BF01700170; Watts Dorraine D, 2004, Prehosp Emerg Care, V8, P254; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	73	55	57	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0014-312X	1421-9921		EUR SURG RES	Eur. Surg. Res.		2007	39	6					372	379		10.1159/000107097			8	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	214FW	WOS:000249722400007	17690556				2022-02-06	
J	Suh, M; Basu, S; Kolster, R; Sarkar, R; McCandliss, B; Ghajar, J				Suh, Minah; Basu, Sambrita; Kolster, Rachel; Sarkar, Ranjeeta; McCandliss, Bruce; Ghajar, Jamshid			Increased oculomotor deficits during target blanking as an indicator of mild traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						mild TBI; diffuse axonal injury (DAI); predictive smooth pursuit eye movement; variability; cognitive deficits	SMOOTH-PURSUIT; INTRAINDIVIDUAL VARIABILITY; TRANSIENT DISAPPEARANCE; COGNITIVE PERFORMANCE; EYE-MOVEMENT; OLDER-ADULTS; HEAD-INJURY; ATTENTION; PREDICTION	Given the susceptibility of cerebellar-cortical tracts to shearing injury from traumatic brain injury (TBI), we investigated impairment in the generation of predictive eye movements and its relationship to cognitive deficits in mild TBI patients using a smooth pursuit target-blanking paradigm. Compared to a target-tracking paradigm without blanking, this paradigm more greatly necessitates the generation of predictive eye movements, which are subserved by brain regions involved in cognitive processing. Mild TBI patients showed impaired prediction of target trajectories during target blanking, demonstrated by generation of saccades at earlier and more variable time points, as well as greater and more variable oculomotor error compared to controls. In addition, California Verbal Learning Test (CVLT-II) scores related to working memory, learning, and executive function were more highly correlated with oculomotor variability during target blanking than during target tracking. Our results suggest that a disruption of cerebellar-cortical connections in TBI may account for both oculomotor and cognitive impairment, and that measures of predictive eye movements during target blanking may be a sensitive metric of cognitive deficits after mild TBI. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Weill Cornell Med Coll, Dept Neurol Surg, New York, NY 10021 USA; Brain Trauma Fdn, New York, NY 10021 USA; Weill Cornell Med Coll, Dept Psychiat, Sackler Inst, New York, NY 10021 USA		Suh, M (corresponding author), Weill Cornell Med Coll, Dept Neurol Surg, New York, NY 10021 USA.	mis2032@med.cornell.edu					Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Barnes GR, 2005, EXP BRAIN RES, V160, P10, DOI 10.1007/s00221-004-1981-3; BECKER W, 1985, EXP BRAIN RES, V57, P562; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; Chen Y, 2002, PROG BRAIN RES, V140, P255; Courchesne E, 1997, LEARN MEMORY, V4, P1, DOI 10.1101/lm.4.1.1; de Xivry JJO, 2006, J NEUROPHYSIOL, V95, P418, DOI 10.1152/jn.00596.2005; Delis D.C., 2000, CALIFORNIA VERBAL LE; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hultsch DF, 2000, NEUROPSYCHOLOGY, V14, P588, DOI 10.1037/0894-4105.14.4.588; Hutton SB, 2005, EXP BRAIN RES, V163, P306, DOI 10.1007/s00221-004-2171-z; Kalashnikova L A, 2005, Neurosci Behav Physiol, V35, P773, DOI 10.1007/s11055-005-0123-0; KHURANA B, 1987, VISION RES, V27, P1603, DOI 10.1016/0042-6989(87)90168-4; KOWLER E, 1989, VISION RES, V29, P1049, DOI 10.1016/0042-6989(89)90052-7; Leth-Steensen C, 2000, ACTA PSYCHOL, V104, P167, DOI 10.1016/S0001-6918(00)00019-6; Machner B, 2005, NEUROREPORT, V16, P1507, DOI 10.1097/01.wnr.0000177015.75096.b6; Madelain L, 2003, J NEUROPHYSIOL, V90, P972, DOI 10.1152/jn.00869.2002; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; Middleton FA, 2001, J NEUROSCI, V21, P700, DOI 10.1523/JNEUROSCI.21-02-00700.2001; MISSAL M, 2004, J NEUROPHYS, V92; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Murtha S, 2002, J INT NEUROPSYCH SOC, V8, P360, DOI 10.1017/S1355617702813170; MUSHIAKE H, 1993, J NEUROPHYSIOL, V70, P2660, DOI 10.1152/jn.1993.70.6.2660; Nagel M, 2006, NEUROIMAGE, V29, P1319, DOI 10.1016/j.neuroimage.2005.08.050; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; POSNER MI, 1984, J NEUROSCI, V4, P1863; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Roche RAP, 2004, NEUROSCI LETT, V362, P1, DOI 10.1016/j.neulet.2003.11.064; Rosenberg DR, 1997, PSYCHIAT RES, V66, P121, DOI 10.1016/S0165-1781(96)02975-7; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Strauss E, 2002, J INT NEUROPSYCH SOC, V8, P893, DOI 10.1017/S1355617702870035; Stuss D., 2002, PR FRONTAL LOBE FUNC, P392, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0025; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Suchoff I B, 1999, J Am Optom Assoc, V70, P301; Suh M, 2000, J NEUROPHYSIOL, V84, P1835, DOI 10.1152/jn.2000.84.4.1835; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; Theoret H, 2001, NEUROSCI LETT, V306, P29, DOI 10.1016/S0304-3940(01)01860-2; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925	42	55	55	0	13	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	DEC 27	2006	410	3					203	207		10.1016/j.neulet.2006.10.001			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	120NR	WOS:000243092200011	17055156				2022-02-06	
J	Williams, AJ; Ling, GSF; Tortella, FC				Williams, Anthony J.; Ling, Geoffrey S. F.; Tortella, Frank C.			Severity level and injury track determine outcome following a penetrating ballistic-like brain injury in the rat	NEUROSCIENCE LETTERS			English	Article						traumatic brain injury; ballistic; penetrating; gunshot wound; rat	CRANIOCEREBRAL GUNSHOT WOUNDS; COMBAT CASUALTY CARE; HEAD-INJURY; MULTIVARIATE-ANALYSIS; WARFARE	Penetrating ballistic brain injury (PBBI) is a high-energy transfer wound causing direct damage to the cerebrum. Outcome is directly related to the ballistic's anatomical path and degree of energy transfer. In this study we evaluated differences in outcome induced by altering the 'projectile' paths and severity levels of a simulated bullet wound using a newly characterized rat model of PBBI. Severity levels (5, 10, and 15%) were compared across three distinct injury paths: (1) unilateral 'frontal', (2) 'bilateral' hemispheric, and (3) unilateral 'caudal' (including cerebellum/midbrain). Outcome was assessed by differences in mortality rate and motor dysfunction (e.g. neurological and balance beam deficits). Results indicated that outcome was dependent not only on the severity level of PBBI (P < 0.00 1, r = 0.535) but also brain regions injured (P < 0.00 1, r = 0.398). A unilateral caudal injury was associated with the highest degree of mortality (up to 100%) and motor dysfunction (64-100% disability). Bilateral hemispheric injuries were also potentially fatal, while the best outcomes were associated with a unilateral frontal injury (no mortality and 14-39% motor disability). These data closely resemble clinical reports of ballistic wounds to the head and further validate the rat PBBI model with the ultimate intent to investigate novel therapeutic approaches for diagnosis and treatment of the neuropathological damage associated with PBBI. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Walter Reed Army Inst Res, Dept Appl Neurobiol, Silver Spring, MD 20910 USA; Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA		Williams, AJ (corresponding author), Walter Reed Army Inst Res, Dept Appl Neurobiol, 503 Robert Grant Ave,Bldg 503,Room 2A40, Silver Spring, MD 20910 USA.	anthony.williams@na.amedd.army.mil					BELLAMY RF, 1984, MIL MED, V149, P55; CAREY ME, 1989, J NEUROSURG, V71, P754, DOI 10.3171/jns.1989.71.5.0754; Hinsley DE, 2005, BRIT J SURG, V92, P637, DOI 10.1002/bjs.4911; Holcomb JB, 2005, J TRAUMA, V59, P990, DOI 10.1097/01.ta.0000188010.65920.26; Hotz GA, 2000, BRAIN INJURY, V14, P649; KAUFMAN HH, 1995, NEUROSURG CLIN N AM, V6, P701, DOI 10.1016/s1042-3680(18)30426-1; Martins RS, 2003, SURG NEUROL, V60, P98, DOI 10.1016/S0090-3019(03)00302-1; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; POLIN RS, 1995, NEUROSURG CLIN N AM, V6, P689; RAIMONDI AJ, 1970, J NEUROSURG, V32, P647, DOI 10.3171/jns.1970.32.6.0647; Sapsford W, 2003, J R Army Med Corps, V149, P5; SELDEN BS, 1988, ANN EMERG MED, V17, P247, DOI 10.1016/S0196-0644(88)80117-3; SHAFFREY ME, 1992, J NEUROTRAUM, V9, pS279; Vajkoczy P, 1999, CLIN NEUROL NEUROSUR, V101, P175, DOI 10.1016/S0303-8467(99)00033-5; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Xydakis MS, 2005, OTOLARYNG HEAD NECK, V133, P497, DOI 10.1016/j.otohns.2005.07.003; Zafonte RD, 2001, NEUROL RES, V23, P219, DOI 10.1179/016164101101198370; Zafonte RD, 2001, ARCH PHYS MED REHAB, V82, P306, DOI 10.1053/apmr.2001.18226	18	55	56	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	NOV 20	2006	408	3					183	188		10.1016/j.neulet.2006.08.086			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	104LB	WOS:000241958800006	17030434				2022-02-06	
J	Nishio, Y; Koda, M; Kamada, T; Someya, Y; Yoshinaga, K; Okada, S; Harada, H; Okawa, A; Moriya, H; Yamazaki, M				Nishio, Yutaka; Koda, Masao; Kamada, Takahito; Someya, Yukio; Yoshinaga, Katsunori; Okada, Seiji; Harada, Hideki; Okawa, Akihiko; Moriya, Hideshige; Yamazaki, Masashi			The use of hemopoietic stem cells derived from human umbilical cord blood to promote restoration of spinal cord tissue and recovery of hindlimb function in adult rats	JOURNAL OF NEUROSURGERY-SPINE			English	Article						spinal cord injury; human umbilical cord blood; hemopoiesis; stem cell; transplantation; rat	MARROW STROMAL CELL; TRAUMATIC BRAIN-INJURY; PROGENITOR CELLS; TRANSPLANTATION; EXPRESSION; STROKE; MODEL; DIFFERENTIATION; NEUROGENESIS; REGENERATION	Object. The use of human umbilical cord blood (HUCB) cells has been reported to improve functional recovery in cases of central nervous system injuries such as stroke, traumatic brain injury, and spinal cord injury (SCI). The authors investigated the effects of hemopoietic stem cells that were derived from HUCB and transplanted into the injured spinal cords of rats. Methods. One week after injury, an HUCB fraction enriched in CD34-positive cells was transplanted into the experimental group. In control animals, vehicle (Matrigel) was transplanted. Recovery of motor functions was assessed using the Basso-Beattie-Bresnahan Locomotor Scale, and immunohistochemical examinations were performed. Cells from HUCB that were CD34 positive improved functional recovery, reduced the area of the cystic cavity at the site of injury, increased the volume of residual white matter, and promoted the regeneration or sparing of axons in the injured spinal cord. Immunohistochemical examination revealed that transplanted CD34-positive cells survived in the host spinal cord for at least 3 weeks after transplantation but had disappeared by 5 weeks. The transplanted cells were not positive for neural markers, but they were positive for hemopoietic markers. There was no evidence of an immune reaction at the site of injury in either group. Conclusions. These results suggest that transplantation of a CD34-positive fraction from HUCB may have therapeutic effects for SCI. The results of this study provide important preclinical data regarding HUCB stem cell-based therapy for SCI.	Chiba Univ, Dept Orthopaed Surg, Grad Sch Med, Tougane Chiba Prefecture Hosp, Chiba, Japan; Narashino Daiiti Hosp, Chiba, Japan; Chiba Univ Hosp, Div Rehabl Med, Chiba, Japan; Kumamoto Univ, Div Hemopoiesis, Ctr Acquired Immunodeficiency Syndrome Res, Kumamoto, Japan		Yamazaki, M (corresponding author), Chiba Univ, Dept Orthopaed Surg, Grad Sch Med, Tougane Chiba Prefecture Hosp, Chiba, Japan.	masashiy@faculty.Chiba-u.jp					Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; BANIK NL, 1980, J NEUROPATH EXP NEUR, V39, P232, DOI 10.1097/00005072-198005000-00002; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Broxmeyer H E, 1996, Cancer Treat Res, V84, P139; BROXMEYER HE, 1989, P NATL ACAD SCI USA, V86, P3828, DOI 10.1073/pnas.86.10.3828; Buzanska L, 2002, J CELL SCI, V115, P2131; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Chung K, 2001, BRAIN RES, V895, P204, DOI 10.1016/S0006-8993(01)02092-3; Ha Y, 2001, NEUROREPORT, V12, P3523, DOI 10.1097/00001756-200111160-00030; Joshi SS, 2000, CLIN CANCER RES, V6, P4351; Kamada T, 2005, J NEUROPATH EXP NEUR, V64, P37, DOI 10.1093/jnen/64.1.37; Koda M, 2005, NEUROREPORT, V16, P1763, DOI 10.1097/01.wnr.0000183329.05994.d7; Koshizuka S, 2004, J NEUROPATH EXP NEUR, V63, P64, DOI 10.1093/jnen/63.1.64; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Massengale M, 2005, J EXP MED, V201, P1579, DOI 10.1084/jem.20050030; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Nakamura M, 2003, EXP NEUROL, V184, P313, DOI 10.1016/S0014-4886(03)00361-3; Nakamura M, 2001, EXP NEUROL, V169, P407, DOI 10.1006/exnr.2001.7670; Newman MB, 2004, EXPERT OPIN BIOL TH, V4, P121, DOI 10.1517/14712598.4.8.1351; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Ohta M, 2004, EXP NEUROL, V187, P266, DOI 10.1016/j.expneurol.2004.01.021; PAHWA RN, 1994, P NATL ACAD SCI USA, V91, P4485, DOI 10.1073/pnas.91.10.4485; Saporta S, 2003, J HEMATOTH STEM CELL, V12, P271, DOI 10.1089/152581603322023007; Sribnick EA, 2005, J NEUROSCI RES, V82, P283, DOI 10.1002/jnr.20622; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Takami T, 2002, J NEUROSCI, V22, P6670; Walczak P, 2004, J NEUROSCI RES, V76, P244, DOI 10.1002/jnr.20042; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Willing AE, 2003, J NEUROSCI RES, V73, P296, DOI 10.1002/jnr.10659; Wu SF, 2003, J NEUROSCI RES, V72, P343, DOI 10.1002/jnr.10587; Young W, 1996, SCIENCE, V273, P451, DOI 10.1126/science.273.5274.451; Zhao ZM, 2004, CELL TRANSPLANT, V13, P113, DOI 10.3727/000000004773301780; Zhao Zong-mao, 2003, Zhonghua Xue Ye Xue Za Zhi, V24, P484	36	55	73	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	NOV	2006	5	5					424	433		10.3171/spi.2006.5.5.424			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	100OO	WOS:000241678600007	17120892				2022-02-06	
